{
  "cells": [
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "PIyoZFtZJ0zv",
        "outputId": "008e9a08-f700-4b45-e7d9-9628bfab98ca"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Collecting PyPDF2\n",
            "  Downloading pypdf2-3.0.1-py3-none-any.whl.metadata (6.8 kB)\n",
            "Downloading pypdf2-3.0.1-py3-none-any.whl (232 kB)\n",
            "Installing collected packages: PyPDF2\n",
            "Successfully installed PyPDF2-3.0.1\n",
            "Note: you may need to restart the kernel to use updated packages.\n"
          ]
        }
      ],
      "source": [
        "pip install PyPDF2"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 1,
      "metadata": {
        "id": "5LMFme6UJVwl"
      },
      "outputs": [],
      "source": [
        "# Data read/write\n",
        "import PyPDF2\n",
        "import numpy as np\n",
        "import pandas as pd\n",
        "from PyPDF2 import PdfReader\n",
        "\n",
        "# Data Visualization\n",
        "from wordcloud import WordCloud\n",
        "import matplotlib.pyplot as plt\n",
        "from collections import Counter"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {},
      "source": [
        "Read pdf file by through PyPDF2 package"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 3,
      "metadata": {
        "id": "oaAuF8c6K1Ks"
      },
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "1874\n"
          ]
        }
      ],
      "source": [
        "\n",
        "path = r\"C:\\\\Users\\\\HP\\\\OneDrive\\\\Desktop\\\\Diagnosis\\\\2022, CURRENT Medical Diagnosis and Treatment- Original.pdf\"\n",
        "text_file = open( path ,\"rb\")\n",
        "# open file and read it through PyPDF2 packages\n",
        "reader = PdfReader(text_file)\n",
        "total_page = len(reader.pages)\n",
        "print(total_page)\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 13,
      "metadata": {},
      "outputs": [],
      "source": [
        "def extract_articles_from_pdf(reader, start_page, end_page):\n",
        "    article_text = \"\"\n",
        "    for page_num in range(start_page, end_page):\n",
        "        pageObj = reader.pages[page_num]\n",
        "        extract = pageObj.extract_text().split(\"\\n\")\n",
        "        article_text += ' '.join(extract)\n",
        "        list_from_pdf.append(extract)\n",
        "    return article_text\n",
        "\n",
        "list_from_pdf = []\n",
        "\n",
        "# Extracting each article\n",
        "article1 = extract_articles_from_pdf(reader, 1632, 1696)\n",
        "article2 = extract_articles_from_pdf(reader, 1232, 1276)\n",
        "article3 = extract_articles_from_pdf(reader, 998, 1074)\n",
        "article4 = extract_articles_from_pdf(reader, 932, 972)\n",
        "article5 = extract_articles_from_pdf(reader, 463, 522)\n",
        "article6 = extract_articles_from_pdf(reader, 187, 221)\n",
        "\n",
        "# Creating a DataFrame\n",
        "articles = [article1, article2, article3, article4, article5, article6]\n",
        "df = pd.DataFrame(articles, columns=['string_values'])\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 8,
      "metadata": {},
      "outputs": [],
      "source": [
        "article= article1 + \" \" + article2 + \" \" + article3 + \" \" + article4  + \" \" +article5 + \" \" + article6 \n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 14,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 638
        },
        "id": "hsovYBWZS-vJ",
        "outputId": "49140c66-d454-41b4-e7ac-bffc4918bcb6"
      },
      "outputs": [
        {
          "data": {
            "image/png": "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",
            "text/plain": [
              "<Figure size 1500x1000 with 1 Axes>"
            ]
          },
          "metadata": {},
          "output_type": "display_data"
        }
      ],
      "source": [
        "\n",
        "word_cloud2 = WordCloud(collocations = False, background_color = 'white').generate(article)\n",
        "plt.figure(figsize=(15,10))\n",
        "plt.imshow(word_cloud2, interpolation='bilinear')\n",
        "plt.axis(\"off\")\n",
        "plt.show()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 15,
      "metadata": {},
      "outputs": [],
      "source": [
        "def get_freq_word(TEXT_list):\n",
        "    \"\"\"This method get count the frequency of each word in the passed parameter\"\"\"\n",
        "    Vocab_list = ' '.join(TEXT_list)\n",
        "    temp_dict = Counter(Vocab_list.split()).items()\n",
        "    freq_df = pd.DataFrame(temp_dict)\n",
        "    freq_df = freq_df.sort_values(1, ascending = False)\n",
        "    return freq_df"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 17,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 591
        },
        "id": "Zb2Psb8BTnDs",
        "outputId": "67a344c7-e797-48d3-be06-1f865c976ed4"
      },
      "outputs": [
        {
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "c:\\Users\\HP\\anaconda3\\envs\\diagnosis\\Lib\\site-packages\\IPython\\core\\pylabtools.py:170: UserWarning: Glyph 57403 (\\ue03b) missing from font(s) DejaVu Sans.\n",
            "  fig.canvas.print_figure(bytes_io, **kw)\n"
          ]
        },
        {
          "data": {
            "image/png": "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",
            "text/plain": [
              "<Figure size 1500x1000 with 1 Axes>"
            ]
          },
          "metadata": {},
          "output_type": "display_data"
        }
      ],
      "source": [
        "\n",
        "freq_words = get_freq_word(df.string_values)\n",
        "freq_words.columns = ['WORD', 'COUNT']\n",
        "\n",
        "plt.figure(figsize=(15,10))\n",
        "plt.bar(freq_words.WORD[:40], freq_words.COUNT[:40], color ='#ceeffa',\n",
        "        width = 0.4)\n",
        "plt.xticks(rotation=90 ,fontsize = 15)\n",
        "plt.yticks(fontsize = 15)\n",
        "plt.xlabel(\"Words\" , fontsize = 25)\n",
        "plt.ylabel(\"Repetition\", fontsize = 25)\n",
        "plt.title(\"Most Frequent Word\", fontsize = 30)\n",
        "plt.show();"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 18,
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "showing info https://raw.githubusercontent.com/nltk/nltk_data/gh-pages/index.xml\n"
          ]
        },
        {
          "data": {
            "text/plain": [
              "True"
            ]
          },
          "execution_count": 18,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "import nltk\n",
        "nltk.download()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "W-WLulpYJdLE",
        "outputId": "d729fc87-962f-455f-d979-b4c22cca3231"
      },
      "outputs": [
        {
          "name": "stderr",
          "output_type": "stream",
          "text": [
            "[nltk_data] Downloading package punkt to\n",
            "[nltk_data]     C:\\Users\\HP\\AppData\\Roaming\\nltk_data...\n",
            "[nltk_data]   Package punkt is already up-to-date!\n",
            "[nltk_data] Downloading package stopwords to\n",
            "[nltk_data]     C:\\Users\\HP\\AppData\\Roaming\\nltk_data...\n",
            "[nltk_data]   Unzipping corpora\\stopwords.zip.\n",
            "[nltk_data] Downloading package wordnet to\n",
            "[nltk_data]     C:\\Users\\HP\\AppData\\Roaming\\nltk_data...\n",
            "[nltk_data]   Package wordnet is already up-to-date!\n"
          ]
        }
      ],
      "source": [
        "import ssl\n",
        "from nltk.tokenize import sent_tokenize\n",
        "from nltk.tokenize import word_tokenize\n",
        "ssl._create_default_https_context = ssl._create_unverified_context\n",
        "\n",
        "import nltk\n",
        "nltk.download('punkt')\n",
        "nltk.download('stopwords')\n",
        "nltk.download('wordnet')\n",
        "\n",
        "# Import WordNetLemmatizer, and stopwords\n",
        "from nltk.stem import WordNetLemmatizer\n",
        "from nltk.corpus import stopwords\n",
        "\n",
        "# import spcay framework\n",
        "import spacy\n",
        "nlp = spacy.load('en_core_web_sm')\n",
        "from spacy.symbols import amod\n",
        "# Import Counter\n",
        "from collections import Counter\n",
        "nltk.download('punkt_tab')\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 27,
      "metadata": {},
      "outputs": [],
      "source": [
        "df['spacy_doc'] = list(nlp.pipe(df.string_values))"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 73,
      "metadata": {},
      "outputs": [],
      "source": [
        "# Create an empty list to store the processed docs\n",
        "processed_docs = []\n",
        "\n",
        "# Process each text and split long ones\n",
        "for text in df['string_values']:\n",
        "        processed_docs.append(nlp(text))\n",
        "\n",
        "\n",
        "\n",
        "# Assign the processed docs back to the DataFrame\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 74,
      "metadata": {},
      "outputs": [],
      "source": [
        "df['spacy_doc'] = processed_docs"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 75,
      "metadata": {},
      "outputs": [
        {
          "data": {
            "application/vnd.microsoft.datawrangler.viewer.v0+json": {
              "columns": [
                {
                  "name": "index",
                  "rawType": "int64",
                  "type": "integer"
                },
                {
                  "name": "string_values",
                  "rawType": "object",
                  "type": "string"
                },
                {
                  "name": "spacy_doc",
                  "rawType": "object",
                  "type": "unknown"
                }
              ],
              "conversionMethod": "pd.DataFrame",
              "ref": "7180a854-08e1-4e8e-b658-686eb61565fc",
              "rows": [
                [
                  "0",
                  "CANCER1613 CMDT 2022Office  of Disease Prevention and Health Promotion. Healthy People 2030. Tobacco use objectives: reduce tobacco use in adults. https://health.gov/healthypeople/objectives-and-data/ browse-objectives/tobacco-use/reduce-current-tobacco- use-adults-tu-01Table 391. Estimated 10 most common cancer cases in the United States in males and females (all races).R ankMales Females Total Cases [N] = 970,250 (100 percent)Total Cases [N] = 927,910 (100 percent) 1 Prostate 248,530 (26)Breast 281,550 (30) 2 Lung and bronchus 119,100 (12)Lung and bronchus 116,660 (13) 3 Colon and rectum 79,520 (8)Colon and rectum 69,980 (8) 4 Urinary bladder 64,280 (7)Uterine corpus 66,570 (7) 5 Melanoma 62,260 (6)Melanoma 43,850 (5) 6 Kidney and renal pelvis 48,780 (5)Non-Hodgkin lymphoma 35,930 (4) 7 Non-Hodgkin lymphoma 45,630 (5)Thyroid 32,130 (3) 8 Oral cavity and pharynx 38,800 (4)Pancreas 28,480 (3) 9 Leukemia 35,530 (4)Kidney and renal pelvis 27,300 (3) 10 Pancreas 31,950 (3)Leukemia 25,560 (3) Other sites 195,870 (20)Other sites 199,900 (21) Data from the American Cancer Society, 2021.Klein WMP et al. Alcohol and cancer risk: clinical and research implications. JAMA. 2020;323:23. [PMID: 31834355] Siegel RL et al. Cancer statistics, 2021. CA Cancer J Clin. 2021; 71:7. [PMID: 33433946] StagingThe  TNM system is the commonly used classification to stage cancer. Staging is important not only because it cor- relates with the patients long-term survival but also because it is used to determine which patients should receive adjuvant or neoadjuvant therapy. Certain characteristics of cancers, not reflected in the TNM stage, may be used to indicate prognosis and guide treat- ment. Pathologic features seen on routine histologic examina- tion for some cancers are very important; examples include the Gleason score for prostate cancer, human papillomavirus (HPV) status of oropharyngeal cancer, and grade of sarcomas. Cancer specimens should also be sent for molecular diagnostic testing and programmed death-ligand 1 (PD-L1) expression testing when appropriate. Some examples of targeted molecu- lar testing include HER2 in breast and gastric cancer, K-ras and BRAF mutations in colorectal cancer and melanoma, and epidermal growth factor receptor (EGFR) and fusion genes (ALK andROS1 ) in lung cancer.Machczys ki P et al. A review of the 8th edition of the AJCC staging system for oropharyngeal cancer according to HPV status. Eur Arch Otorhinolaryngol. 2020;277:2407. [PMID: 32342197] TreatmentSee  Primary Cancer Treatment section below. Table 392 outlines treatment choices by cancer type for those respon- sive to systemic agents, and Table 393 provides a listing of common chemotherapeutic agents. Table 392. Treatment choices for cancers responsive to systemic agents.Diagnosis Initial Treatment Acute lymphoblastic leukemia (ALL)Induction combination cemoterapy (Piladelpia cromosomepositive): Cyclophosphamide, vincristine, doxorubicin/daunorubicin, dexamethasone (hyper-CVAD) alternating with cytarabine, methotrexate; add imatinib or dasatinib or nilotinib Induction combination cemoterapy (Piladelpia cromosomenegative): Daunorubicin, vincristine, prednisone, pegaspargase, cyclophosphamide; or hyper-CVAD alternating with methotrexate and cytarabine Maintenance cemoterapy: Methotrexate, 6-mercaptopurine, vincristine, prednisone Acute myeloid leukemia (AML) Induction combination cemoterapy: Cytarabine with daunorubicin or idarubicin, with gemtuzumab ozogamicin (CD33-positive), or with midostaurin ( FLT3-mutated), or with fludarabine Alternative cemoterapy for  60 years old: Azacitidine, decitabine, or low-dose cytarabine with or without venetoclax; or Liposomal encapsulation of cytarabine and daunorubicin (therapy-related or myelodysplasia-related changes) Ivosidenib ( IDH1 mutation); or Enasidenib ( IDH2 mutation) (continued )CMDT22_Ch39_p1612-p1675.indd  1613 02/07/21 2:44 PMChAPTER 391614 CMDT 2022T able 392. Treatment choices for cancers responsive to systemic agents.Diagnosis Initial Treatment Chronic myeloid leukemia (CML)Nilotinib or dasatinib or imatinib or bosutinib Chronic lymphocytic leukemia (CLL)Venetoclax with obinutuzumab, or acalabrutinib with or without obinutuzumab, or ibrutinib Hairy cell leukemia Cladribine with or without rituximab1or pentostatin Hodgkin lymphoma Combination cemoterapy: Doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD), or Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone (BEACOPP) Non-Hodgkin lymphoma (intermediate and high grade)Combination cemoterapy: Cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab1 (CHOP-R), or Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab1(dose-adjusted R-EPOCH) (for double-/triple-hit) Non-Hodgkin lymphoma (low grade)Combination cemoterapy: Bendamustine plus obinutuzumab or rituximab1, or Cyclophosphamide, vincristine, doxorubicin, prednisone, rituximab1(CHOP-R), or Cyclophosphamide, vincristine, prednisone, rituximab1(CVP-R), or Lenalidomide, rituximab1Plasma  cell myeloma Combination cemoterapy (transplant candidates): Bortezomib, dexamethasone, cyclophosphamide, or Bortezomib, dexamethasone, lenalidomide Followed by autologous or mini-allogeneic stem cell transplantation Combination cemoterapy (non-transplant candidates): Bortezomib, lenalidomide, dexamethasone, or Daratumumab, lenalidomide, dexamethasone, or Lenalidomide, dexamethasone, or Bortezomib, cyclophosphamide, dexamethasone Waldenstrm macroglobulinemiaPlasmaperesis alone or followed by combination cemoterapy: Ibrutinib with or without rituximab1Bortezomib,  dexamethasone, rituximab1, or Cyclophosphamide, dexamethasone, rituximab1, or Bendamustine, rituximab1Poly cythemia vera Phlebotomy or hydroxyurea or aspirin Nonsmall cell lung cancer Combination terapy: Cisplatin, etoposide, or Paclitaxel, carboplatin, or Cisplatin, gemcitabine or docetaxel (squamous histology), or Cisplatin, pemetrexed (nonsquamous histology), or Carboplatin, albumin-bound paclitaxel, or Dabrafenib/trametinib ( BRAF V600F mutation), or Carboplatin or cisplatin/pemetrexed/pembrolizumab (nonsquamous); carboplatin/paclitaxel or albumin-bound paclitaxel/pembrolizumab (squamous) Single-agent terapy: Erlotinib, gefitinib, osimertinib, afatinib, or dacomitinib ( EGFR mutation positive) Crizotinib, alectinib, ceritinib, or brigatinib ( ALKmutation positive) Ceritinib, crizotinib, or entrectinib ( ROS1 rearrangement) Larotrectinib or entrectinib ( NTRK gene fusion positive) Pembrolizumab (PD-L1  1%) or atezolizumab (PD-L1  50%) Small cell lung cancer Combination terapy: Cisplatin, etoposide (limited stage), or Cisplatin, etoposide, durvalumab (extensive stage), or Carboplatin, etoposide, atezolizumab or durvalumab (extensive stage) Mesothelioma Combination terapy: Cisplatin or carboplatin/pemetrexed with or without bevacizumab, or Nivolumab/ipilimumab (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1614 02/07/21 2:44 PMCANCER1615 CMDT 2022T able 392. Treatment choices for cancers responsive to systemic agents.Diagnosis Initial Treatment Head and neck cancer Cisplatin with radiation therapy, or Carboplatin with 5-fluorouracil with radiation therapy, or Docetaxel, cisplatin, 5-fluorouracil, or Cisplatin or carboplatin/5-fluorouracil/cetuximab, or Pembrolizumab (PD-L1  1%), or Pembrolizumab/cisplatin or carboplatin/5-fluorouracil Esophageal and esophagogastric junction cancerCombination terapy: Cisplatin, 5-fluorouracil or capecitabine, or Paclitaxel, carboplatin, or Oxaliplatin, 5-fluorouracil or capecitabine, or 5-Fluorouracil, leucovorin, oxaliplatin, docetaxel (FLOT) Add trastuzumab for HER2 -overexpressing metastatic adenocarcinoma Uterine cancer hormone terapy: Progestins, tamoxifen, aromatase inhibitors, or fulvestrant Combination cemoterapy: Carboplatin, paclitaxel Carboplatin, paclitaxel, trastuzumab ( HER2 positive) Ovarian cancer Combination cemoterapy: Paclitaxel, carboplatin, with or without bevacizumab, or 5-Fluorouracil/leucovorin or capecitabine, oxaliplatin Cervical cancer Wit radiation: Cisplatin or carboplatin Combination cemoterapy: Cisplatin or carboplatin, paclitaxel with or without bevacizumab Breast cancer Adjuvant ormone terapy: Premenopausal: Tamoxifen Postmenopausal: Aromatase inhibitors (anastrozole, letrozole, exemestane) Adjuvant cemoterapy ( HER2 negative): Doxorubicin, cyclophosphamide, followed by paclitaxel, or Docetaxel, cyclophosphamide Adjuvant cemoterapy ( HER2 positive): Doxorubicin, cyclophosphamide, followed by paclitaxel, trastuzumab with or without pertuzumab, or Docetaxel, carboplatin, trastuzumab with or without pertuzumab, or Paclitaxel, trastuzumab Gestational trophoblastic neoplasiaSingle-agent cemoterapy: Methotrexate or dactinomycin for low-risk disease Combination cemoterapy: Etoposide, methotrexate, dactinomycin, cyclophosphamide, vincristine (EMA-CO) for high-risk disease Testicular cancer Combination cemoterapy: Cisplatin, etoposide (EP), or Bleomycin, etoposide, cisplatin (BEP), or Etoposide, mesna, ifosfamide, cisplatin (VIP) Kidney (renal cell) cancer Clear cell istology: Axitinib plus pembrolizumab, ipilimumab plus nivolumab, pazopanib, sunitinib, or cabozantinib Nonclear cell istology: Sunitinib Bladder cancer Combination cemoterapy: Gemcitabine, cisplatin, or Methotrexate, vinblastine, doxorubicin, cisplatin (MVAC), or Atezolizumab, or pembrolizumab, or gemcitabine plus carboplatin (cisplatin ineligible) Prostate cancer hormone terapy: Luteinizing hormonereleasing agonist (leuprolide, goserelin, triptorelin, histrelin), or degarelix with or without an antiandrogen (flutamide, bicalutamide, nilutamide, enzalutamide, apalutamide) or abiraterone Cemoterapy: Docetaxel or cabazitaxel or mitoxantrone with corticosteroid Brain cancer (anaplastic astro- cytoma and glioblastoma multiforme)Single-agent cemoterapy wit radiation terapy: Temozolomide Neuroblastoma Combination cemoterapy: Cyclophosphamide, doxorubicin, cisplatin, etoposide Thyroid cancer Single-agent terapy: Radioiodine (131I) or sorafenib, lenvatinib, vandetanib (medullary thyroid cancer) or cabozantinib (medullary thyroid cancer) Adrenal cancer Cisplatin or carboplatin with etoposide, with or without doxorubicin, with or without mitotane (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1615 02/07/21 2:44 PMChAPTER 391616 CMDT 2022T able 392. Treatment choices for cancers responsive to systemic agents.Diagnosis Initial Treatment Stomach (gastric) cancer Combination cemoterapy: 5-Fluorouracil, leucovorin, oxaliplatin, docetaxel (FLOT) (perioperative) 5-Fluorouracil or capecitabine with oxaliplatin or cisplatin Add trastuzumab for HER2 -overexpressing adenocarcinomas Pancreatic cancer Combination cemoterapy: Gemcitabine, nab-paclitaxel, or 5-Fluorouracil, leucovorin, irinotecan, oxaliplatin (FOLFIRINOX), or Gemcitabine, capecitabine, or Gemcitabine, cisplatin (for BRCA1/2 orPALB2 mutation) Single-agent cemoterapy: Gemcitabine Colon cancer Combination cemoterapy: 5-Fluorouracil, leucovorin, oxaliplatin (FOLFOX) with or without bevacizumab, or Capecitabine, oxaliplatin (CAPEOX) with or without bevacizumab, or 5-Fluorouracil, leucovorin, irinotecan (FOLFIRI) with or without bevacizumab 5-Fluorouracil, leucovorin, oxaliplatin, irinotecan (FOLFOXIRI) with or without bevacizumab Cetuximab or panitumumab added to FOLFOX or FOLFIRI for KRAS/NRAS/BRAF wild-type and left-sided tumors Capecitabine or 5-fluorouracil/leucovorin with or without bevacizumab Single-agent terapy: Nivolumab or pembrolizumab (deficient mismatch repair [dMMR]/high-level microsatellite instability [MSI-H]) Rectal cancer 5-Fluorouracil or capecitabine or FOLFOX or CAPEOX Anal cancer Mitomycin with 5-fluorouracil or capecitabine with radiation Carboplatin, paclitaxel with or without radiation therapy Carcinoid Octreotide LAR or lanreotide or everolimus or lutetium Lu 177-dotatate Osteosarcoma Combination cemoterapy: Cisplatin, doxorubicin, or Methotrexate, doxorubicin, cisplatin (MAP) Soft tissue sarcomas Combination cemoterapy: Doxorubicin, dacarbazine (AD), or Doxorubicin, ifosfamide, mesna (AIM), or Ifosfamide, epirubicin, mesna Single-agent terapy: Imatinib or sunitinib or regorafenib (gastrointestinal stromal tumors) Doxorubicin or epirubicin or liposomal doxorubicin Melanoma Pembrolizumab or nivolumab or nivolumab/ipilimumab (non- BRAF mutation) Dabrafenib/trametinib or vemurafenib/cobimetinib or encorafenib/binimetinib ( BRAF mutation) Hepatocellular cancer Sorafenib or lenvatinib or atezolizumab with bevacizumab Kaposi sarcoma Liposomal doxorubicin1 In patients with past hepatitis B virus (HBV) infection, rituximab should be used with anti-HBV agent (eg, entecavir) prophylax is since HBV reactivation, fulminant hepatitis, and, rarely, death can occur otherwise.T able 393. Common cancer therapeutic agents.Cemoterapeutic Agent Usual Adult Dosage Adverse Effects Alkylating AgentsNitrogen Mustards Bendamustine (Treanda) 100120 mg/m2intravenously every 34 weeks Acute: hypersensitivity, nausea, vomiting Delayed: myelosuppression, rash, pyrexia, fatigue Cyclophosphamide (Cytoxan)5001000 mg/m2intravenously every 3 weeks; 100 mg/m2/day orally for 14 days every 4 weeks; various dosesAcute: nausea and vomiting Delayed: myelosuppression, alopecia, hemorrhagic cystitis, cardiotoxicity (high dose) Ifosfamide (Ifex) 1200 mg/m2intravenously daily for 5 days every 3 weeks; various dosesAcute: nausea and vomiting Delayed: alopecia, myelosuppression, hemorrhagic cystitis, neurotoxicity (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1616 02/07/21 2:44 PMCANCER1617 CMDT 2022T able 393. Common cancer therapeutic agents.Cemoterapeutic Agent Usual Adult Dosage Adverse Effects Alkylating AgentsPlatinum Analogs Carboplatin (Paraplatin) Area under the curve (AUC)based dosing use Calvert equation [Dose (mg) = AUC  (GFR + 25)] AUC = 27 mg/mL/min every 24 weeksAcute: nausea and vomiting Delayed: myelosuppression, electrolyte disturbances, peripheral neuropathy, nephrotoxicity, hypersensitivity Cisplatin (Platinol) 50100 mg/m2intravenously every 34 weeks; 20 mg/m2/day intravenously for 5 days every 3 weeks; various dosesAcute: nausea and vomiting Delayed: nephrotoxicity, ototoxicity, neurotoxicity, myelosuppression, electrolyte disturbances Oxaliplatin (Eloxatin) 85130 mg/m2intravenously every 23 weeks Acute: peripheral neuropathy exacerbated by cold, nausea, vomiting, diarrhea Delayed: myelosuppression, elevated transaminases Alkylating AgentsTriazenes Dacarbazine (DTIC-Dome) 375 mg/m2intravenously on days 1 and 15 every 4 weeks; 9001000 mg/m2intrave- nously over 3 to 4 days; various dosesAcute: nausea, vomiting, photosensitivity Delayed: myelosuppression, anorexia, hypotension, flu-like syndrome Procarbazine (Matulane) 60100 mg/m2orally for 14 days every 4 weeks; various dosesAcute: nausea and vomiting Delayed: myelosuppression, disulfiram-like reaction, MAO inhibition, rash Temozolomide (Temodar) 75 mg/m2orally daily during radiation for 42 days; 150200 mg/m2orally for 5 days every 4 weeksAcute: nausea, vomiting, constipation Delayed: myelosuppression, fatigue AntimetabolitesFolate Antagonists Methotrexate (MTX; Trexall)Intratecal: 12 mg hig dose: 100012,000 mg/m2intravenously every 23 weeksAcute: nausea, vomiting, mucositis Delayed: myelosuppression, nephrotoxicity, hepatotoxicity, neurotoxicity, photosensitivity, pulmonary toxicity Pemetrexed (Alimta) 500 mg/m2intravenously every 3 weeks Acute: nausea, vomiting, diarrhea, rash Delayed: myelosuppression, fatigue, mucositis AntimetabolitesPurine Analogs Fludarabine (Fludara) 25 mg/m2intravenously for 5 days every 4 weeksAcute: fever, nausea, vomiting Delayed: asthenia, myelosuppression, immunosuppression, neurotoxicity, anorexia Mercaptopurine (6-MP; Purinethol)Induction: 2.55 mg/kg/day orally Maintenance: 1.52.5 mg/kg/day orallyAcute: nausea, vomiting, diarrhea, rash Delayed: myelosuppression, immunosuppression, hepatotoxicity, mucositis AntimetabolitesPyrimidine Analogs Azacitidine (Vidaza) 75100 mg/m2subcutaneously or intravenously for 7 days every 4 weeksAcute: injection site reaction (subcutaneously), nausea, diarrhea, fever Delayed: myelosuppression, dyspnea, arthralgia Capecitabine (Xeloda) 10001250 mg/m2orally twice a day for 14 days every 3 weeksAcute: nausea, vomiting, diarrhea Delayed: hand-foot syndrome, mucositis, hyperbilirubinemia, myelosuppression Cytarabine (Ara-C, Cytosar U)Standard dose: 100 mg/m2/day intravenously via continuous infusion for 7 days hig dose: 10003000 mg/m2intravenously every 12 hours for 26 daysAcute: nausea, vomiting, rash, flu-like syndrome Delayed: myelosuppression High-dose: neurotoxicity, ocular toxicities Decitabine (Dacogen) 15 mg/m2intravenously every 8 hours for 3 days every 8 weeks; 20 mg/m2intravenously daily for 5 daysAcute: nausea, vomiting, hyperglycemia Delayed: myelosuppression, fever, fatigue, cough Fluorouracil (Adrucil) 400 mg/m2intravenous bolus followed by 2400 mg/m2intravenously over 46 hours every 2 weeks; 1000 mg/m2intravenously via continuous infusion for 45 days every 34 weeks; various dosesAcute: nausea, vomiting, diarrhea Delayed: myelosuppression, hand-foot syndrome, mucositis, photosensitivity, cardiotoxicity (rare) (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1617 02/07/21 2:44 PMChAPTER 391618 CMDT 2022T able 393. Common cancer therapeutic agents.Cemoterapeutic Agent Usual Adult Dosage Adverse Effects AntimetabolitesPyrimidine Analogs (cont.) Gemcitabine (Gemzar) 10001250 mg/m2intravenously on days 1 and 8 every 3 weeks or days 1, 8, 15 every 4 weeksAcute: nausea, vomiting, rash, flu-like symptoms, fever, diarrhea Delayed: myelosuppression, edema, elevated transaminases AntimicrotubulesVinca Alkaloids Vinblastine (Velban) 6 mg/m2intravenously on days 1 and 15 every 4 weeks; various dosesAcute: constipation Delayed: myelosuppression, alopecia, bone pain, malaise Vincristine (Oncovin) 0.51.4 mg/m2intravenously every 3 weeks; various doses; maximum single dose usually limited to 2 mgAcute: constipation, nausea Delayed: peripheral neuropathy, alopecia AntimicrotubulesTaxanes Docetaxel (Taxotere) 60100 mg/m2intravenously every 3 weeks Acute: nausea, vomiting, diarrhea, hypersensitivity, rash Delayed: myelosuppression, asthenia, peripheral neuropathy, alopecia, edema, mucositis Paclitaxel (Taxol) 135175 mg/m2intravenously every 3 weeks; 5080 mg/m2intravenously weekly; various dosesAcute: diarrhea, nausea, vomiting, hypersensitivity Delayed: myelosuppression, peripheral neuropathy, alopecia, mucositis, arthralgia Paclitaxel protein-bound (Abraxane)100125 mg/m2on days 1, 8, 15 every 34 weeks; 260 mg/m2intravenously every 3 weeksAcute: nausea, vomiting, diarrhea Delayed: myelosuppression, peripheral neuropathy, alopecia, asthenia Enzyme InibitorsAntracyclines Daunorubicin (Cerubidine) 3060 mg/m2intravenously for 3 days Acute: nausea, vomiting, diarrhea, red/orange discoloration of urine, infusion-related reactions (liposomal products) Delayed: myelosuppression, mucositis, alopecia, hand-foot syndrome (liposomal doxorubicin), cardiotoxicity (dose related) Doxorubicin (Adriamycin) 4575 mg/m2intravenously every 3 weeks; various doses Epirubicin (Ellence) 60120 mg/m2intravenously every 34 weeks Idarubicin (Idamycin) 1012 mg/m2intravenously for 3 days Liposomal doxorubicin (Doxil, Lipodox)2050 mg/m2intravenously every 34 weeks Enzyme InibitorsTopoisomerase Inibitors Etoposide (Vepesid) 50100 mg/m2intravenously for 35 days every 3 weeksAcute: nausea, vomiting, diarrhea, hypersensitivity, fever, hypotension Delayed: myelosuppression, alopecia, fatigue Irinotecan (Camptosar) 180 mg/m2intravenously every other week; various dosesAcute: diarrhea, cholinergic syndrome, nausea, vomiting Delayed: myelosuppression, alopecia, asthenia Targeted TerapyMonoclonal Antibodies Atezolizumab (Tecentriq) 1200 mg intravenously every 3 weeks Acute: infusion-related reaction Delayed: immune-mediated reactions, fatigue, decreased appetite Bevacizumab (Avastin) 515 mg/kg intravenously every 23 weeks Acute: infusion-related reaction Delayed: hypertension, proteinuria, wound healing compli- cations, gastrointestinal perforation, hemorrhage Cetuximab (Erbitux) Loading dose 400 mg/m2intravenously, maintenance dose 250 mg/m2intravenously weeklyAcute: infusion-related reaction, nausea, diarrhea Delayed: acneiform skin rash, hypomagnesemia, asthenia, paronychial inflammation, dyspnea Daratumumab (Darzalex) 16 mg/kg intravenously weekly for weeks 18, every 2 weeks for weeks 924, and every 4 weeks from week 25 until disease progressionAcute: infusion-related reaction, nausea Delayed: myelosuppression, fatigue, upper respiratory tract infection (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1618 02/07/21 2:44 PMCANCER1619 CMDT 2022T able 393. Common cancer therapeutic agents.Cemoterapeutic Agent Usual Adult Dosage Adverse Effects Targeted TerapyMonoclonal Antibodies (cont.) Ipilimumab (Yervoy) 110 mg/kg intravenously every 3 weeks for a total of four dosesAcute: infusion-related reaction Delayed: immune-related reactions, fatigue Nivolumab (Opdivo) 240 mg intravenously every 2 weeks or 480 mg every 4 weeksAcute: vomiting Delayed: fatigue, musculoskeletal pain, rash, pruritus, cough, elevated transaminases Obinutuzumab (Gazyva) Cycle 1: 100 mg intravenously on day 1, 900 mg on day 2, 1000 mg on days 8 and 15 of a 28-day cycle; cycles 26: 1000 mg intrave- nously on day 1Acute: infusion-related reaction, tumor lysis syndrome Delayed: myelosuppression, pyrexia, cough, musculoskeletal disorder, potential hepatitis B reactivation Panitumumab (Vectibix) 6 mg/kg intravenously every 2 weeks Acute: infusion-related reaction, nausea Delayed: acneiform skin rash, hypomagnesemia, asthenia, paronychia, fatigue, dyspnea Pembrolizumab (Keytruda) 200 mg intravenously every 3 weeks or 400 mg every 6 weeksAcute: infusion-related reaction, nausea Delayed: immune-mediated reactions, fatigue, cough Pertuzumab (Perjeta) 840 mg intravenously once followed by 420 mg intravenously every 3 weeksAcute: infusion-related reaction, diarrhea, nausea Delayed: fatigue, alopecia, neutropenia, rash, peripheral neuropathy, cardiomyopathy Rituximab (Rituxan) 375 mg/m2intravenously weekly for 4 weeks, or every 34 weeksAcute: infusion-related reaction, tumor lysis syndrome Delayed: lymphopenia, asthenia, rash, potential hepatitis B reactivation Trastuzumab (Herceptin) Initial dose 4 mg/kg intravenously, then 2 mg/kg intravenously weekly; or initial dose 8 mg/kg, then 6 mg/kg, intravenously every 3 weeksAcute: headache, nausea, diarrhea, infusion-related reaction Delayed: myelosuppression, pyrexia, cardiomyopathy, pulmonary toxicity (rare) Targeted TerapyKinase Inibitors Acalabrutinib 100 mg orally twice daily Acute: diarrhea Delayed: myelosuppression, upper respiratory infection, musculoskeletal pain Afatinib (Gilotrif) 40 mg orally once daily without food Acute: diarrhea Delayed: acneiform rash, stomatitis, paronychia Alectinib (Alecensa) 600 mg orally twice daily with food Acute: none Delayed: myelosuppression, fatigue, edema, myalgia, dyspnea, elevated transaminases Axitinib (Inlyta) 510 mg orally twice daily Acute: diarrhea, nausea, vomiting Delayed: hypertension, fatigue, dysphonia, hand-foot syndrome, elevated transaminases Bosutinib (Bosulif) 500600 mg orally once daily with food Acute: diarrhea, nausea, vomiting Delayed: myelosuppression, rash, abdominal pain, hepatotoxicity, fluid retention Ceritinib (Zykadia) 740 mg orally once daily Acute: diarrhea, nausea, vomiting Delayed: elevated transaminases, abdominal pain, fatigue, decreased appetite Cobimetinib (Cotellic) 60 mg orally once daily on days 121 of a 28-day cycleAcute: diarrhea, photosensitivity reaction, nausea, vomiting Delayed: myelosuppression, hepatotoxicity, rash, cardiomyopathy (with vemurafenib) Crizotinib (Xalkori) 250 mg orally twice daily Acute: nausea, vomiting, diarrhea, constipation Delayed: vision disorder, edema, elevated transaminases, fatigue Dabrafenib (Tafinlar) 150 mg orally twice daily without food Acute: headache Delayed: hyperkeratosis, fever, hand-foot syndrome, hyperglycemia, hypophosphatemia Dacomitinib (Vizimpro) 45 mg orally once daily Acute: diarrhea Delayed: rash, paronychia, mucositis, cough, interstitial lung disease (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1619 02/07/21 2:44 PMChAPTER 391620 CMDT 2022T able 393. Common cancer therapeutic agents.Cemoterapeutic Agent Usual Adult Dosage Adverse Effects Targeted TerapyKinase Inibitors (cont.) Dasatinib (Sprycel) 100180 mg orally once daily Acute: diarrhea, nausea, vomiting Delayed: myelosuppression, fluid retention, fatigue, dyspnea, musculoskeletal pain, rash Entrectinib (Rozlytrek) 600 mg orally daily Acute: nausea, vomiting, diarrhea Delayed: fatigue, cognitive impairment, heart failure, potential for birth defects, hepatotoxicity, vision disorder, prolonged QT interval (rare) Erlotinib (Tarceva) 100 or 150 mg orally once daily without food Acute: diarrhea, nausea, vomiting Delayed: acneiform skin rash, fatigue, anorexia, dyspnea Gefitinib (Iressa) 250 mg orally once daily Acute: diarrhea Delayed: acneiform skin rash Ibrutinib (Imbruvica) 420 or 560 mg orally once daily Acute: diarrhea, nausea Delayed: myelosuppression, fatigue, edema, rash, elevated serum creatinine, hemorrhage Imatinib (Gleevec) 100800 mg orally once daily with food Acute: nausea, vomiting, diarrhea Delayed: edema, muscle cramps, rash, myelosuppression, hepatotoxicity Larotrectinib (Vitrakvi) 100 mg orally twice daily Acute: nausea, vomiting, diarrhea Delayed: fatigue, cognitive impairment, potential for birth defects, hepatotoxicity Lenvatinib (Lenvima) 24 mg orally daily Acute: hypertension, nausea, vomiting, diarrhea Delayed: fatigue, arthralgia/myalgia, stomatitis, hand-foot syndrome Nilotinib (Tasigna) 300 or 400 mg orally twice daily without food Acute: nausea, vomiting, diarrhea Delayed: rash, fatigue, myelosuppression, prolonged QT interval (rare) Osimertinib (Tagrisso) 80 mg orally once daily Acute: diarrhea Delayed: myelosuppression, rash, dry skin, nail toxicity, cardiomyopathy (rare), QTc interval prolongation (rare) Pazopanib (Votrient) 800 mg orally once daily without food Acute: diarrhea, nausea, vomiting Delayed: hypertension, hair color changes, hepatotoxicity, hemorrhage Regorafenib (Stivarga) 160 mg orally once daily with food (low-fat breakfast)Acute: diarrhea Delayed: asthenia, hand-foot syndrome, anorexia, hyperten- sion, mucositis, myelosuppression, hepatotoxicity Sorafenib (Nexavar) 400 mg orally twice daily without food Acute: diarrhea and nausea Delayed: fatigue, hand-foot syndrome, rash, hypertension, hemorrhage Sunitinib (Sutent) 50 mg orally once daily for 4 weeks followed by 2 weeks rest; 37.5 mg orally dailyAcute: diarrhea and nausea Delayed: hypertension, hand-foot syndrome, rash, yellow discoloration of skin, fatigue, hypothyroidism, mucositis, left ventricular dysfunction, bleeding, hepatotoxicity Trametinib (Mekinist) 2 mg orally once daily without food Acute: rash, diarrhea Delayed: elevated transaminases, lymphedema, cardiomyopathy Vemurafenib (Zelboraf) 960 mg orally twice daily Acute: nausea, hypersensitivity (rare) Delayed: photosensitivity, rash, arthralgia, alopecia, fatigue, prolonged QT interval, cutaneous squamous cell carcinoma (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1620 02/07/21 2:44 PMCANCER1621 CMDT 2022T able 393. Common cancer therapeutic agents.Cemoterapeutic Agent Usual Adult Dosage Adverse Effects Miscellaneous Agents Abiraterone (Zytiga) 1000 mg orally once daily Acute: diarrhea, edema Delayed: adrenal insufficiency, hepatotoxicity, joint pain, hypokalemia Bleomycin (Blenoxane) 10 units/m2intravenously on days 1 and 15 every 28 days; 30 units intravenously on days 2, 9, and 16 every 21 daysAcute: hypersensitivity, fever Delayed: skin reaction (rash, hyperpigmentation of skin, striae), mucositis, pneumonitis Bortezomib (Velcade) 1.3 mg/m2intravenous bolus or subcutaneously on days 1, 4, 8, 11 followed by a 10-day rest, or weekly for 4 weeks followed by 13-day restAcute: nausea, vomiting, diarrhea Delayed: peripheral neuropathy, fatigue, myelosuppression Hydroxyurea (Hydrea) 2030 mg/kg orally daily Acute: none Delayed: myelosuppression Lenalidomide (Revlimid) 525 mg orally once daily on days 121 of 28-day cycle; or continuouslyAcute: diarrhea, rash Delayed: myelosuppression, fatigue, venous thromboembolism, potential for birth defects Mitomycin (Mutamycin) 1020 mg/m2intravenously every 48 weeks; 2040 mg intravesicallyAcute: cystitis (intravesically), nausea, vomiting Delayed: myelosuppression, mucositis, anorexia Pegaspargase (Oncaspar) 20002500 international units/m2intramuscu- larly every 14 daysAcute: hypersensitivity Delayed: febrile neutropenia, coagulation abnormalities, hepatotoxicity, pancreatitis Venetoclax (Venclexta) 20 mg orally daily during week 1; 50 mg daily during week 2; 100 mg daily during week 3; 200 mg daily during week 4; then 400 mg orally daily thereafterAcute: diarrhea, nausea, vomiting, tumor lysis syndrome Delayed: myelosuppression, upper respiratory infections, fatigue Antiandrogens Apalutamide (Erleada) 240 mg orally daily Acute: fatigue, diarrhea Delayed: arthralgia, hot flashes, falls, peripheral edema, seizure (rare) Bicalutamide (Casodex) 50 mg orally once daily Acute: none Delayed: hot flashes, back pain, asthenia Enzalutamide (Xtandi) 160 mg orally once daily Acute: asthenia, diarrhea Delayed: hot flashes, arthralgia, peripheral edema, seizure (rare) Flutamide (Eulexin) 250 mg orally every 8 hours Acute: diarrhea Delayed: hot flashes, hepatotoxicity Nilutamide (Nilandron) 300 mg orally for 30 days, then 150 mg orally once dailyAcute: none Delayed: visual disturbances (impaired adaptation to dark), hot flashes, disulfiram-like reaction Selective Estrogen Receptor Modulators Tamoxifen (Nolvadex) 2040 mg orally once daily Acute: none Delayed: hot flashes, vaginal discharge, menstrual irregularities, arthralgia Aromatase Inibitors Anastrozole (Arimidex) 1 mg orally once daily Acute: nausea Delayed: hot flashes, peripheral edema, asthenia, hypercholesterolemia, arthralgia/myalgia, osteoporosis Exemestane (Aromasin) 25 mg orally once daily Letrozole (Femara) 2.5 mg orally once daily (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1621 02/07/21 2:44 PMChAPTER 391622 CMDT 2022T able 393. Common cancer therapeutic agents.Cemoterapeutic Agent Usual Adult Dosage Adverse Effects Pure Estrogen Receptor Antagonist Fulvestrant (Faslodex) 500 mg intramuscularly on days 1, 15, 29, then monthlyAcute: injection site reaction, nausea Delayed: hot flashes, bone pain, elevated transaminases LhRh Analogs Goserelin acetate (Zoladex)3.6 mg subcutaneously every month; 10.8 mg subcutaneously every 3 monthsAcute: injection site discomfort Delayed: hot flashes, tumor flare, edema, decreased libido, erectile dysfunction, osteoporosis Leuprolide (Lupron) 7.5 mg intramuscularly or subcutaneously every month; 22.5 mg intramuscularly or subcuta- neously every 3 months; 30 mg intramuscu- larly or subcutaneously every 4 months; 45 mg intramuscularly or subcutaneously every 6 months Triptorelin pamoate (Trelstar)3.75 mg intramuscularly every 4 weeks; 11.25 mg intramuscularly every 12 weeks; 22.5 mg intramuscularly every 24 weeks LhRh Antagonist Degarelix (Firmagon) 240 mg subcutaneously once, then 80 mg subcutaneously every 28 daysAcute: injection site reaction Delayed: hot flashes, weight gain, elevated transaminases, QT prolongation AV, atrioventricular; GFR, glomerular filtration rate; LHRH, luteinizing hormonereleasing hormone; MAO, monoamine oxidase; MCV , mean corpuscular volume. TYPES OF CANCER LUNG CANCER Sunny Wang, MD BRONCHOGENIC CARCINOMAE S S E N T I A L S  O F  D I A G N O S I S New cough or change in chronic cough. Dyspnea, hemoptysis, anorexia, weight loss. Enlarging lung nodule or mass; persistent opacity, atelectasis, or pleural effusion on chest radiograph or CT scan. Cytologic or histologic findings of lung cancer in sputum, pleural fluid, or biopsy specimen. General ConsiderationsLung  cancer is the leading cause of cancer deaths in both men and women. The American Cancer Society estimates 228,820 new diagnoses and 135,720 deaths from lung can- cer in the United States in 2020, accounting for approxi- mately 13% of new cancer diagnoses and 22% of all cancer deaths. More Americans die of lung cancer than of colorec- tal, breast, and prostate cancers combined.Cigarette smoking causes 8590% of cases of lung cancer. The causal connection between cigarettes and lung cancer is established not only epidemiologically but also through identification of carcinogens in tobacco smoke and analysis of the effect of these carcinogens on specific oncogenes expressed in lung cancer. Other environmental risk factors for the development of lung cancer include exposure to environmental tobacco smoke, radon, asbestos, diesel exhaust, ionizing radiation, metals (arsenic, chromium, nickel, iron oxide), and indus- trial carcinogens. A familial predisposition to lung cancer is recognized. Certain diseases are associated with an increased risk of lung cancer, including pulmonary fibrosis, chronic obstructive pulmonary disease, and sarcoidosis. The median age at diagnosis of lung cancer in the United States is 70; it is unusual under the age of 40. The combined relative 5-year survival rate for all stages of lung cancer is currently 21%. There are five main histologic categories of broncho- genic carcinoma. Squamous cell carcinomas (23% of cases, based on US SEER data 20132017) arise from the bronchial epithelium and often present as intraluminal masses. They are usually centrally located and can present with hemoptysis. Adenocarcinomas (50% of cases) arise from mucous glands or from any epithelial cell within or distal to the terminal bronchioles. They usually present as peripheral nodules or masses. Adenocarcinomas in situ (formerly bronchioloalveolar cell carcinomas) spread along preexisting alveolar structures (lepidic growth) with- out evidence of invasion. Large cell carcinomas (1.3% of(continued)CMDT22_Ch39_p1612-p1675.indd  1622 02/07/21 2:44 PMCANCER1623 CMDT 2022cases)  are a heterogeneous group of undifferentiated can- cers that share large cells and do not fit into other catego- ries. Large cell carcinomas are typically aggressive and have rapid doubling times. They present as central or peripheral masses. Cancers that are not better differentiated on patho- logic review other than nonsmall cell carcinomas (NSCLC) or carcinomas not otherwise specified make up about 13% of cases. Small cell carcinomas (13% of cases) are tumors of bronchial origin that typically begin cen- trally, infiltrating submucosally to cause narrowing of the bronchus without a discrete luminal mass. They are aggres- sive cancers that often involve regional or distant metastasis on presentation. For purposes of staging and treatment, bronchogenic carcinomas are divided into small cell lung cancer (SCLC) and the other four types, labeled NSCLC. This practical classification reflects different natural histories and differ- ent treatment. SCLC is prone to early hematogenous spread and has a more aggressive course with a median survival (untreated) of 618 weeks. Clinical FindingsLun g cancer is symptomatic at diagnosis in a majority of patients. The clinical presentation depends on the type and location of the primary tumor, the extent of local spread, and the presence of distant metastases and any paraneo- plastic syndromes.A.  Symptoms and SignsAnor exia, weight loss, or asthenia occurs in 5590% of patients presenting with a new diagnosis of lung cancer. Up to 60% of patients have a new cough or a change in a chronic cough; 631% have hemoptysis; and 2540% com- plain of pain, either nonspecific chest pain or pain from bony metastases to the vertebrae, ribs, or pelvis. Local spread may cause endobronchial obstruction with atelectasis and postobstructive pneumonia, pleural effusion (1233%), change in voice (compromise of the recurrent laryngeal nerve), superior vena cava syndrome (obstruc- tion of the superior vena cava with supraclavicular venous engorgement), and Horner syndrome (ipsilateral ptosis, miosis, and anhidrosis from involvement of the inferior cervical ganglion and the paravertebral sympathetic chain). Distant metastases to the liver are associated with asthenia and weight loss. Brain metastases (10% in NSCLC, more common in adenocarcinoma, and 2030% in SCLC) may present with headache, nausea, vomiting, seizures, dizzi- ness, or altered mental status. Paraneoplastic syndromes are patterns of organ dys- function related to immune-mediated or secretory effects of neoplasms. These syndromes occur in 1020% of lung cancer patients. They may precede, accompany, or follow the diagnosis of lung cancer. In patients with small cell carcinoma, the syndrome of inappropriate antidiuretic hormone (SIADH) can develop in 1015%; in those with squamous cell carcinoma, hypercalcemia can develop in 10%. Digital clubbing is seen in up to 20% of patients at diagnosis (see Figure 642). Other common paraneoplastic syndromes include increased ACTH production, anemia,hypercoagulability, peripheral neuropathy, and the Lambert- Eaton myasthenic syndrome. Their recognition is important because treatment of the primary tumor may improve or resolve symptoms even when the cancer is not curable.B.  Laboratory FindingsThe diagnosis of lu ng cancer rests on examination of a tis- sue or cytology specimen. Sputum cytology is highly spe- cific but insensitive; the yield is highest when there are lesions in the central airways. While the diagnostic yield of CT-guided biopsy of peripheral nodules approaches 8090%, the rates of pneumothorax are significant (1530%), especially in those with emphysema. Thoracentesis (sensi- tivity 5065%) can be used to establish a diagnosis of lung cancer in patients with malignant pleural effusions. Fine-needle aspiration (FNA) of palpable supraclavicular or cervical lymph nodes is frequently diagnostic. Fiberoptic bronchoscopy allows visualization of the major airways, cytology brushing of visible lesions or lavage of lung segments with cytologic evaluation of speci- mens, direct biopsy of endobronchial abnormalities, blind transbronchial biopsy of the pulmonary parenchyma or peripheral nodules, and FNA biopsy of mediastinal lymph nodes. The use of fluorescence bronchoscopy improves the ability to identify early endobronchial lesions, and endo- bronchial and transesophageal endoscopic ultrasound enhance the direction and yield of FNA of mediastinal nodes. Electromagnetic navigational bronchoscopy allows bronchoscopic approaches to small peripheral nodules. Mediastinoscopy, video-assisted thoracoscopic surgery (VATS), and thoracotomy may be necessary in cases where less invasive techniques fail to yield a diagnosis.C.  ImagingNear ly all patients with lung cancer have abnormal find- ings on chest radiography or CT scan (Figure 391). These findings are rarely specific for a particular diagnosis. Inter- pretation of characteristic findings in isolated nodules is described in Chapter 9.D . Special Examinations1. Staging  Accurate staging is crucial (1) to provide the clinician with information to guide treatment, (2) to pro- vide the patient with accurate information regarding prog- nosis, and (3) to standardize entry criteria for clinical trials to allow interpretation of results. Staging of NSCLC uses two integrated systems and is continuously updated with the eighth edition of the AJCC/ Union for International Cancer Control (UICC) stage classification for lung cancer in effect since January 2018. TheAJCC TNM international staging system attempts a physical description of the neoplasm: T describes the size and location of the primary tumor; N describes the pres- ence and location of nodal metastases; and M refers to the presence or absence of distant metastases. These TNM stages are grouped into summary stages IIV , and these are used to guide therapy. Many patients with stage I and stage II disease are cured through surgery. Patients with stage IIIB and stage IV disease do not benefit from surgeryCMDT22_Ch39_p1612-p1675.indd  1623 02/07/21 2:44 PMChAPTER 391624 CMDT 2022 Figure 391. Squamous cell carcinoma of the right lung on chest radiograph (A)and CT scan (B).(Repro- duced, with permission, from Elsayes KM, Oldham SA. Introduction to Diagnostic Radiology. McGraw-Hill, 2014.) A B(T able 394). Patients with stage IIIA disease have locally invasive disease that may benefit from surgery in selected cases as part of multimodality therapy. SCLC is traditionally divided into two categories: limited disease (30%), when the tumor is limited to the unilateral hemithorax (including contralateral mediastinal nodes); or extensive disease (70%), when the tumor extends beyond the hemithorax (including pleural effu- sion). It is also recommended to stage SCLC according to the TNM staging system. For both SCLC and NSCLC, a complete examination is essential to exclude obvious metastatic disease to lymph nodes, skin, and bone. A detailed history is essential because the patients performance status is a powerful pre- dictor of disease course. All patients should have measure- ment of a complete blood count (CBC), serum electrolytes, calcium, creatinine, liver biochemical tests, lactate dehy- drogenase, and albumin.NSCLC patients being considered for surgery require meticulous evaluation to identify those with resectable disease. CT imaging is key for staging candidates for resec- tion. The sensitivity and specificity of CT imaging for identifying lung cancer metastatic to the mediastinal lymph nodes are 57% (4966%) and 82% (7786%), respectively. Therefore, chest CT imaging alone does not provide definitive staging information. CT imaging helps determine where to biopsy, and how the mediastinum should be sampled. Positron emission tomography (PET) using 2-[18F] fluoro-2-deoxyglucose (FDG) is an important modality for identifying metastatic foci in the mediastinum or distant sites. The sensitivity and specificity of PET for detecting mediastinal spread of primary lung cancer depend on the size of mediastinal nodes or masses. When mediastinal lymph nodes smaller than 1 cm are present, the sensitivity and specificity of PET for tumor involvement of nodes are 74% and 96%, respectively. When CT shows lymph nodes larger than 1 cm, the sensitivity and specificity are 95% and 76%, respectively. The combination of PET and CT imaging has improved preoperative staging compared with CT or PET alone. Whole body fusion PET-CT imaging is most useful toTable 394. Five-year survival rates for nonsmall cell lung cancer, based on TNM staging.Stage TNM Subset5-Year Survival for Clinical TNM5-Year Survival for Pato- logic TNM 0 Carcinoma in situ 1A1 T1aN0M0 92% 90% 1A2 T1bN0M0 83% 85% IA3 T1cN0M0 77% 80% IB T2aN0M0 68% 73% IIA T2bN0M0 60% 65% IIB T1/T2, N1M0 T3N0M053% 56% IIIA T1/T2, N2M0 T3N1M0 T4, N0/N1, M036% 41% IIIB T1/T2, N3M0 T3/T4, N2M026% 24% IIIC T3/T4, N3M0 13% 12% IVA Any T, Any N, M1a/M1b10%  IVB Any T, Any N, M1c 0%  Data from multiple sources. Modified and reproduced, with per- mission, from Detterbeck FC et al. The Eighth Edition Lung Cancer Stage Classification. Chest. 2017;151:193. Copyright  Elsevier; and data from Goldstraw P et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2015;11:39.CMDT22_Ch39_p1612-p1675.indd  1624 02/07/21 2:44 PMCANCER1625 CMDT 2022confirm  lack of regional or metastatic disease in NSCLC patients who are candidates for surgical resection. Obtaining an MRI of the brain is important to rule out brain metastases in patients with SCLC and in patients with NSCLC with at least stage II disease or poorly differ- entiated histologies. 2. Preoperative assessment See Chapter 3. 3. Pulmonary function testing Many patients with NSCLC have moderate to severe chronic lung disease that increases the risk of perioperative complications as well as long-term pulmonary insufficiency following lung resec- tion. All patients considered for surgery require spirome- try. In the absence of other comorbidities, patients with good lung function (preoperative FEV12 L or more) are at low risk for complications from lobectomy or pneumonec- tomy. High-risk patients include those with a predicted postoperative FEV1less than 700 mL (or less than 40% of predicted FEV1). 4. Screening Screening with low-dose helical CT scans has been shown to improve mortality rates for lung cancer. The National Lung Screening Trial, a multicenter random- ized US trial involving over 53,000 current and former heavy smokers, showed that screening annually with low- dose helical CT for 3 years yielded a 20% relative reduction in lung cancer mortality and 6.7% reduction in all-cause mortality compared to chest radiography. Given these find- ings, US professional organizations have recommended annual screening with low-dose helical CT for lung cancer. The 2021 US Preventive Services Task Force (USPSTF) recommends annual low-dose CT for smokers aged 5080 who have at least a 20 pack-year smoking history and who either currently smoke or have quit within the last 15 years. Smoking cessation policies and efforts should be integrated with any screening program. TreatmentA.  NonSmall Cell Lung CarcinomaSurgic al resection offers the best chance for cure of NSCLC. Clinical features that preclude complete surgical resection include extrathoracic metastases or a malignant pleural effusion; or tumor involving the heart, pericar- dium, great vessels, esophagus, recurrent laryngeal or phrenic nerves, trachea, main carina, or contralateral mediastinal lymph nodes. Accordingly, stage I and stage II patients are treated with surgical resection where possible. Stage II and select cases of stage IB are additionally recom- mended to receive adjuvant chemotherapy. Stage IIIA patients have poor outcomes if treated with resection alone. They should undergo multimodality treatment that includes chemotherapy or radiotherapy, or both. Inopera- ble stage IIIA and stage IIIB patients treated with concur- rent chemotherapy and radiation therapy have improved survival. Stage IV patients are treated with systemic ther- apy (targeted therapy, chemotherapy, or immunotherapy) or symptom-based palliative therapy, or both. Surgical approach affects outcome. In 1994, the North American Lung Cancer Study Group conducted a prospec- tive trial of stage IA patients randomized to lobectomyversus limited resection. They reported a threefold increased rate of local recurrence in the limited resection group (P= 0.008) and a trend toward an increase in overall death rate (increase of 30%, P= 0.08) and increase in cancer- related death rate (increase of 50%, P= 0.09), compared with patients receiving lobectomy. However, for patients who cannot tolerate lobectomy, a sublobar resection (wedge resection or segmentectomy) may be considered. Patients with clinical stage I primary NSCLC, who are not candidates for surgery because of significant comor- bidity or other surgical contraindication, are candidates for stereotactic body radiotherapy. Stereotactic body radio- therapy, which is composed of multiple non-parallel radia- tion beams that converge, allows the delivery of a relatively large dose of radiation to a small, well-defined target. For clinical stage I NSCLC, 3-year local control rates with ste- reotactic body radiotherapy exceed 90%, and large meta- analyses of nonrandomized data have shown 2-year survival of 70% and 5-year survival of 40%. Patients with locally advanced disease (stages IIIA and IIIB) who are not surgical candidates have improved survival when treated with concurrent chemotherapy and radiation therapy com- pared with no therapy, radiation alone, or even sequential chemotherapy and radiation. Neoadjuvant chemotherapy consists of giving antineo- plastic drugs in advance of surgery or radiation therapy. Neoadjuvant therapy can be used in select patients with stage IIIA or stage IIIB disease. Some studies suggest a survival advantage. Adjuvant chemotherapy consists of administering antineoplastic drugs following surgery or radiation ther- apy. Cisplatin-containing regimens have been shown to confer an overall survival benefit in at least stage II disease and a subset of stage IB disease where primary tumor size exceeds 4 cm. The Lung Adjuvant Cisplatin Evaluation Collaborative Group, a meta-analysis of the five largest cisplatin-based adjuvant trials, reported a 5% absolute ben- efit in 5-year overall survival with a cisplatin-containing doublet regimen following surgery ( P= 0.005) in patients with at least stage II disease. For stage IIIB and stage IV NSCLC, options for therapy include targeted therapy, cytotoxic chemotherapy, and immunotherapy (checkpoint inhibitors) (Tables 392 and 393). The approach to therapy is individualized based on molecular profiling and PD-L1 testing. Molecular profiling is offered as next-generation sequencing multi-gene assays. The key driver mutations in lung cancer currently include EGFR, ALK, BRAF, ROS1, NTRK ,MET, and RET muta- tions, but only a minority of all lung cancer cases harbor these mutations. K-ras mutation is more commonly found among smokers. Difficulties in testing may arise when only small fine-needle aspirate biopsies are obtained; to have sufficient tissue for analysis, it is recommended that clini- cians obtain core biopsies. PD-L1 expression is a flawed but actively used biomarker to assess possible response to checkpoint inhibitor therapy (specifically, programmed death-1 [PD-1] inhibitors). Targeted therapy has played a pivotal role in advanced NSCLC (Tables 392 and 393). Activating EGFR muta- tions are found in approximately 1020% of the WhiteCMDT22_Ch39_p1612-p1675.indd  1625 02/07/21 2:44 PMChAPTER 391626 CMDT 2022popula tion and 3048% of the Asian population and are usually found among nonsmokers to light smokers, females, and persons with nonsquamous histologies (particularly adenocarcinomas). For patients with EGFR mutations, an EGFR tyrosine kinase inhibitor (osimertinib, erlotinib, gefi- tinib, afatinib, or dacomitinib) rather than platinum-based chemotherapy is the first-line treatment. Response rates with EGFR tyrosine kinase inhibitors in patients with EGFR mutation are at least 70%, and median overall survival is estimated to be 2133 months. Osimertinib (a third-gener- ation irreversible EGFR tyrosine kinase inhibitor) is recom- mended as first-line treatment of EGFR -mutated lung cancers. Phase 3 data show that osimertinib leads to a lon- ger duration of response, longer progression-free survival, and lower rates of severe adverse events compared to earlier generation EGFR tyrosine kinase inhibitors. Approximately 5% of all patients with NSCLC carry translocations of ALK resulting in novel fusion gene prod- ucts with oncogenic activity. For patients with ALK- rearranged lung cancers, ALK tyrosine kinase inhibitors (alectinib, ceritinib, crizotinib, brigatinib, and lorlatinib) are recommended therapeutic agents. Alectinib and briga- tinib are recommended as first-line agents in ALK - rearranged lung cancers with response rates ranging from 74% to 83%. For patients who have developed resistance to either first- or second-generation ALK inhibitors, lorlati- nib (a third-generation ALK and ROS1 tyrosine kinase inhibitor) has shown a response rate of 47%. Approxi- mately 12% of NSCLC harbor ROS1 rearrangements and they are usually lung adenocarcinomas found among non- smokers or light smokers. ROS1 -rearranged lung cancers respond to crizotinib ( ALK,cMET , and ROS1 tyrosine kinase inhibitor) and entrectinib (multikinase inhibitor, including ROS-1) with response rates over 70%. MET exon 14 (METex14) skipping mutations are found in 3% of lung adenocarcinomas. Capmatinib (MET inhibitor) is recom- mended as first-line treatment for patients with METex14 skipping mutation. BRAF mutations have been found in 2% of NSCLC patients. The combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) has shown response rates of over 60% in patients with BRAF V600E mutations. Treatment with larotrectinib (TRKA/ B/C inhibitor) or entrectinib (multikinase inhibitor, including TRKA/B/C) is recommended for patients whose tumors reveal NTRK 1/2/3 gene fusion. Selpercatinib and pralsetinib (RET inhibitors) are recommended first-line treatments for RET fusionpositive NSCLC. Finally, K-ras mutations are found among 30% of patients with adenocar- cinomas, are associated with smoking, and indicate a poor prognosis. Early clinical trials are already under way evalu- ating the role of novel K-ras inhibitors, sotorasib (AMG 510) and adagrasib (MRTX849), in treating K-ras G12C mutated lung cancers. Immune checkpoint inhibition using PD-1 or PD-L1 inhibitors (nivolumab, pembrolizumab, atezolizumab, and durvalumab) has an important role in the treatment of NSCLC (Tables 392 and 393). Checkpoint inhibitors release T cells from the inhibitory signals they receive from tumor cells via the PD-1 pathway, restoring antitumor immunity. For patients with tumors staining greater than50% for PDL-1, pembrolizumab outperforms first-line platinum-based chemotherapy, with response rates of 45% vs 28% and median progression-free survival of 10 months vs 6 months. Phase 3 trials have shown improved survival outcomes with adding pembrolizumab to platinum- doublet chemotherapy as first-line therapy for patients with advanced NSCLC regardless of PD-L1 status. If patients received chemotherapy alone as first-line treatment, PD-1 inhibitors are recommended as second-line treatment of NSCLC, regardless of PD-L1 staining intensity. However, significant side effects and toxicity have been reported with checkpoint inhibitors, especially autoimmune manifesta- tions such as hepatitis, thyroiditis, hypophysitis, colitis, pneumonitis, and type 1 diabetes mellitus. Recently, a ran- domized phase 3 trial has shown improved survival out- comes by adding durvalumab as consolidation therapy post-definitive chemoradiation for stage III NSCLCs. If no targetable mutations are found and there is inad- equate PD-L1 expression on tumor cells, patients are either offered combination immunotherapy with cytotoxic che- motherapy or cytotoxic chemotherapy alone (Table 392). Although not curative, chemotherapy has been shown in multiple clinical trials to provide a modest increase in over- all survival in patients with stage IIIB and stage IV NSCLC compared with supportive care alone, with the median survival increased from 5 months to a range of 812 months and 1-year survival rate of 3040%. Palliative chemother- apy also leads to improved quality of life and symptom control, with first-line therapy involving a platinum-based regimen.B.  Small Cell Lung CarcinomaResponse  rates of SCLC to cisplatin and etoposide (Table 392) are excellent with 8090% response in limited-stage disease (5060% complete response), and 6080% response in extensive-stage disease (1520% complete response). However, remissions tend to be short-lived with a median duration of 68 months. Once the disease has recurred, median survival is 34 months. Overall 2-year survival is 2040% in limited-stage disease and 5% in extensive-stage disease (Table 395). Modest improvement in survival has been achieved with the addition of a checkpoint inhibitor (atezolizumab or durvalumab) to cisplatin or carboplatin and etoposide therapy in extensive stage disease. Thoracic radiation therapy improves survival in patients with lim- ited SCLC and is given concurrently with chemotherapy. There is a high rate of brain metastasis in patients with SCLC, even following a good response to chemotherapy. Table 395. Median survival for small cell lung carci- noma following treatment.Stage Mean 2-Year Survival Median Survival Limited 2040% 1520 months Extensive 5% 813 months Data from multiple sources, including Van Meerbeeck JP et al. Small-cell lung cancer. Lancet. 2011;378:1741.CMDT22_Ch39_p1612-p1675.indd  1626 02/07/21 2:44 PMCANCER1627 CMDT 2022Pro phylactic cranial irradiation may be considered for patients with limited-stage disease who respond to chemo- therapy and in a subset of patients with extensive-stage disease who have had an excellent response to chemotherapy.C.  Palliative TherapyPhoto resection with the Nd:YAG laser is sometimes per- formed on central tumors to relieve endobronchial obstruc- tion, improve dyspnea, and control hemoptysis. External beam radiation therapy is also used to control dyspnea, hemoptysis, endobronchial obstruction, pain from bony metastases, obstruction from superior vena cava syn- drome, and symptomatic brain metastases. Resection of a solitary brain metastasis improves quality of life and sur- vival when combined with radiation therapy if there is no evidence of other metastatic disease. Stereotactic radia- tion therapy is offered for limited brain metastases. Repeated thoracenteses, pleurodesis, and PleurX catheter tube placement are key interventions for palliation of symptomatic malignant pleural effusions. Pain is very common in advanced disease. Meticulous efforts at pain control are essential (see Chapter 5). In addition to standard oncologic care, early referral to a palliative care specialist is recommended in advanced disease to aid in pain and other symptom management. Such palliative care can modestly improve survival. PrognosisThe  overall 5-year survival rate for lung cancer is approxi- mately 20%. Predictors of survival include the tumor type (SCLC versus NSCLC), molecular profiling, and stage, and the patients performance status and weight loss in the prior 6 months. Patients with targetable mutations have better overall survival when compared with those without muta- tions due to superior efficacy of targeted drug therapy.Camidg e DR et al. Brigatinib versus crizotinib in advanced ALK inhibitor-nave ALK-positive non-small cell lung cancer: sec- ond interim analysis of the phase III ALTA-1L trial. J Clin Oncol. 2020;38:3592. [PMID: 32780660] Drilon A et al. Entrectinib in ROS1 fusion-positive non-small- cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21:262. [PMID: 31838015] Ghimessy A et al. Current therapy of KRAS -mutant lung cancer. Cancer Metastasis Rev. 2020;39:1159. [PMID: 32548736] Ramalingam SS et al; FLAURA Investigators. Overall survival with osimertinib in untreated EGFR -mutated advanced NSCLC. N Engl J Med. 2020;382:41. [PMID: 31751012] Siegel RL et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7. [PMID: 33433946] US Preventive Services Task Force. Screening for lung cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325:962. [PMID: 33687470]PU LMONARY METASTASISPulmonary metastasis  results from the spread of an extra- pulmonary malignant tumor through vascular or lym- phatic channels or by direct extension. Metastases usually occur via the pulmonary artery and typically present asmultiple nodules or masses on chest radiography. The radiographic differential diagnosis of multiple pulmonary nodules also includes pulmonary arteriovenous malforma- tion, infections (including abscesses, septic emboli, and atypical infections), sarcoidosis, rheumatoid nodules, and granulomatosis with polyangiitis. Metastases to the lungs are found in 2055% of patients with various metastatic malignancies. Carcinomas of the kidney, breast, rectum, colon, and cervix and malignant melanoma are the most likely primary tumors. Lymphangitic carcinomatosis denotes diffuse involve- ment of the pulmonary lymphatic network by primary or metastatic lung cancer, probably a result of extension of tumor from lung capillaries to the lymphatics. Tumor embolization from extrapulmonary cancer (renal cell car- cinoma, hepatocellular carcinoma, choriocarcinoma) is an uncommon route for tumor spread to the lungs. Metastatic cancer may also present as a malignant pleural effusion. Clinical FindingsA.  Symptoms and SignsSymp toms are uncommon but include cough, hemoptysis and, in advanced cases, dyspnea and hypoxemia. Symp- toms are more often referable to the site of the primary tumor.B.  Laboratory FindingsThe  diagnosis of metastatic cancer involving the lungs is usually established by identifying a primary tumor. Appro- priate studies should be ordered if there is a suspicion of any primary cancer, such as breast, thyroid, testis, colorec- tal, or prostate, for which specific treatment is available. If the history, physical examination, and initial studies fail to reveal the site of the primary tumor, attention is better focused on the lung, where tissue samples obtained by bronchoscopy, percutaneous needle biopsy, video-assisted thoracoscopic surgery (V ATS), or thoracotomy may estab- lish the histologic diagnosis and suggest the most likely primary cancer. Occasionally, cytologic studies of pleural fluid or pleural biopsy reveals the diagnosis.C.  ImagingChest  radiographs usually show multiple spherical densi- ties with sharp margins. The lesions are usually bilateral, pleural, or subpleural in location, and more common in lower lung zones. Lymphangitic spread and solitary pul- monary nodule are less common radiographic presenta- tions of pulmonary metastasis. CT imaging of the chest, abdomen, and pelvis may reveal the site of a primary tumor and will help determine feasibility of surgical resection of the metastatic lung tumors. FDG PET-CT scan is helpful in identifying the site of a primary cancer and identifying other areas of extrathoracic metastasis. TreatmentOnce  the diagnosis has been established, management consists of treatment of the primary neoplasm and any pulmonary complications. Surgical resection of a solitaryCMDT22_Ch39_p1612-p1675.indd  1627 02/07/21 2:44 PMChAPTER 391628 CMDT 2022pulmona ry nodule is often prudent in the patient with known current or previous extrapulmonary cancer. Local resection of one or more pulmonary metastases is feasible in a few carefully selected patients with various sarcomas and carcinomas (such as testis, colorectal, and kidney). About 1525% of metastatic solid tumor patients have metastases limited to the lungs and are surgical candidates. Surgical resection should be considered only if (1) the pri- mary tumor is under control, (2) the patient has adequate cardiopulmonary reserve to tolerate resection, (3) all meta- static tumor can be resected, (4) effective nonsurgical approaches are not available, and (5) there is no evidence of extrathoracic metastases that are not controlled. Unfa- vorable prognostic factors also include shorter disease-free interval from primary tumor treatment to presentation of metastases and a larger number of metastases. Retrospec- tive data from the International Registry of Lung Metasta- ses report an overall 5-year survival rate of 36% and 10-year survival rate of 26% after complete resection of pulmonary metastases. Patients who are not surgical can- didates but have solitary or limited metastatic disease to the lungs may be candidates for stereotactic radiotherapy, radioablation, or cryotherapy. For patients with unresect- able progressive disease, chemotherapy tailored to the pri- mary tumor can be offered, and diligent attention to palliative care is essential (see Chapter 5).Ha ndy JR et al. Expert consensus document on pulmonary metastasectomy. Ann Thorac Surg. 2019;107:631. [PMID: 30476477] Sudarshan M et al. Current indications for pulmonary metasta- sectomy. Surg Oncol Clin N Am. 2020;29:673. [PMID: 32883466]ME SOTHELIOMAE S S E N T I A L S  O F  D I A G N O S I S Unilateral, nonpleuritic chest pain and dyspnea. Distant (> 20 years earlier) history of exposure to asbestos. Pleural effusion or pleural thickening or both on chest radiographs. Malignant cells in pleural fluid or tissue biopsy. General ConsiderationsMeso theliomas are primary tumors arising from the sur- face lining of the pleura (80% of cases) or peritoneum (20% of cases). Numerous studies have confirmed the associa- tion of malignant pleural mesothelioma with exposure to asbestos. The lifetime risk to asbestos workers of develop- ing malignant pleural mesothelioma is as high as 10%. The latent period between exposure and onset of symptoms ranges from 20 to 40 years. The clinician should inquire about asbestos exposure through mining, milling, manu- facturing, shipyard work, insulation, brake linings,building construction and demolition, roofing materials, and other asbestos products (pipes, textiles, paints, tiles, gaskets, panels). Clinical FindingsA.  Symptoms and SignsThe  average interval between onset of symptoms and diagnosis is 23 months; the median age at diagnosis is 7274 years in Western countries. Symptoms include the insidious onset of shortness of breath, nonpleuritic chest pain, and weight loss. Physical findings include dullness to percussion, diminished breath sounds and, in some cases, digital clubbing.B.  Laboratory FindingsPleural  fluid is exudative and often hemorrhagic. Cytologic tests of pleural fluid are often negative. VATS biopsy is usu- ally necessary to obtain an adequate specimen for histo- logic diagnosis. The histologic variants of malignant pleural mesothelioma are epithelial (5060%), sarcomatoid (10%), and biphasic (3040%). Since distinction from benign inflammatory conditions and metastatic adenocar- cinoma may be difficult, immunohistochemical stains are important to confirm the diagnosis.C.  ImagingRadiographic  abnormalities consist of nodular, irregular, unilateral pleural thickening and varying degrees of unilat- eral pleural effusion. Sixty percent of patients have right- sided disease, while only 5% have bilateral involvement. CT scans demonstrate the extent of pleural involvement. PET-CT is used to help differentiate benign from malig- nant pleural disease, improve staging accuracy, and iden- tify candidates for aggressive surgical approaches. ComplicationsMalignan t pleural mesothelioma progresses rapidly as the tumor spreads along the pleural surface to involve the peri- cardium, mediastinum, and contralateral pleura. The tumor may eventually extend beyond the thorax to involve abdominal lymph nodes and organs. Progressive pain and dyspnea are characteristic. Local invasion of thoracic struc- tures may cause superior vena cava syndrome, hoarseness, Horner syndrome, arrhythmias, and dysphagia. TreatmentChemothera py is the mainstay of treatment (Tables 392 and 393), with cytoreductive surgery included in multi- modality treatment only if there is localized disease that is amenable to complete macroscopic surgical resection. The optimal surgical approach is still under debate. For local- ized disease, surgical options include pleurectomy and decortication (surgical stripping of the pleura and pericar- dium from apex of the lung to diaphragm) or extrapleural pneumonectomy (a radical surgical procedure involving removal of the ipsilateral lung, parietal and visceral pleura,CMDT22_Ch39_p1612-p1675.indd  1628 02/07/21 2:44 PMCANCER1629 CMDT 2022pericardium,  and most of the hemidiaphragm). Surgical cytoreduction alone is not sufficient, and either chemo- therapy or radiation therapy (or both) should be included in a multimodality approach. In advanced unresectable disease, palliative chemotherapy with cisplatin and peme- trexed can achieve response rates of 3040%, can extend median overall survival to 12 months, and can improve quality of life. Adding bevacizumab (a monoclonal anti- body to vascular endothelial growth factor [VEGF]) to cisplatin and pemetrexed has been shown to further improve overall survival. Nivolumab and ipilimumab (checkpoint inhibition therapy) can also be offered as first- line treatment, with improved outcomes among those with nonepithelioid tumors. Drainage of pleural effusions, pleurodesis, radiation therapy, and even surgical resection may offer palliative benefit to some patients. PrognosisMos t patients die of respiratory failure and complications of local extension. Median survival time from diagnosis ranges from 7 months to 17 months. Five-year survival is 510%. Tumors that are predominantly sarcomatoid are more resistant to therapy and have a worse prognosis, with median survivals less than 1 year. Poor prognostic features include poor performance status, non-epithelioid histol- ogy, male gender, nodal involvement, elevated lactate dehy- drogenase, high white blood cell count, low hemoglobin, and high platelet count.Sch erpereel A et al; French Cooperative Thoracic Intergroup. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019;20:239. [PMID: 30660609] Scherpereel A et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020;55:1900953. [PMID: 32451346] Waller DA et al. Divided by an ocean of water but united in an ocean of uncertainty: a transatlantic review of mesothelioma surgery guidelines. J Thorac Cardiovasc Surg. 2020;S0022-5223 (20)32986-X . [PMID: 33223192]hE PATOBILIARY CANCERS Lawrence S. Friedman, MD HEPATOCELLULAR CARCINOMAE S S E N T I A L S  O F  D I A G N O S I S Usually a complication of cirrhosis. Characteristic CT and MRI features may obviate the need for a confirmatory biopsy. General ConsiderationsMalignan t neoplasms of the liver that arise from parenchy- mal cells are called hepatocellular carcinomas (accountingfor 85% of liver cancers); those that originate in the ductu- lar cells are called cholangiocarcinomas (15% or less). Rare tumors of the liver include angiosarcoma and lymphoma. Worldwide, hepatocellular carcinomas are the fourth most common cause of cancer-related deaths and the sixth most common in incidence. They are associated with cir- rhosis in 85% of cases. In Africa and most of Asia, hepatitis B virus (HBV) infection (including occult HBV infection; see Chapter 16) is a major etiologic factor, and a family history of hepatocellular carcinoma increases the risk syn- ergistically. In the United States and other Western coun- tries, incidence rates rose over twofold after 1978, with slowing of the rate increase after 2006 except in men ages 5564, presumably because of the increasing prevalence of cirrhosis caused by chronic hepatitis C virus (HCV) infec- tion and nonalcoholic fatty liver disease (NAFLD). Rates appear to have plateaued since 2010 because of improved treatment of viral hepatitis. In Western countries, risk fac- tors for hepatocellular carcinoma in patients known to have cirrhosis are male gender, age greater than 55 years (although there has been an increase in the number of younger cases), Hispanic or Asian ethnicity, family history in a first-degree relative, overweight, obesity (especially in early adulthood), alcohol use (especially in combination with obesity), tobacco use, diabetes mellitus, hypothyroid- ism (in women), a prolonged prothrombin time, a low platelet count, and an elevated serum transferrin satura- tion. The risk of hepatocellular carcinoma is higher in persons with a viral rather than nonviral cause of cirrhosis and may be increased in persons with autoimmune dis- eases. Other associations include high levels of HBV repli- cation; HBV genotype C; hepatitis D coinfection; elevated serum ALT levels in persons with chronic hepatitis B (in whom antiviral therapy to suppress HBV replication appears to reduce the risk); HCV genotypes 1b and 3; lack of response to antiviral therapy for HCV infection; hemo- chromatosis (and possibly the C282Y carrier state); afla- toxin exposure (associated with mutation of the TP53 gene); alpha-1-antiprotease (alpha-1-antitrypsin) defi- ciency; tyrosinemia; and radiation exposure. In patients with the metabolic syndrome and NAFLD, hepatocellular carcinoma may rarely arise from nonalcoholic steatohepa- titis in the absence of cirrhosis. Hepatocellular adenoma may be a precursor for hepatocellular carcinoma (see Chapter 16). Evidence for an association with long-term use of oral contraceptives is inconclusive. Whereas sulfo- nylurea and insulin use may increase the risk of hepatocel- lular carcinoma, consumption of coffee, vegetables, white meat, fish, and n-3 polyunsaturated fatty acids; use of aspirin; and use of lipophilic HMG-CoA reductase inhibi- tors (statins) (eg, atorvastatin, simvastatin) and, in diabetic patients, metformin appear to be protective. The fibrolamellar variant of hepatocellular carcinoma generally occurs in young women and is characterized by a distinctive histologic picture, absence of risk factors, unique genomic profiles, and indolent course. Vinyl chlo- ride exposure is associated with angiosarcoma of the liver. Hepatoblastoma, the most common malignant liver cancer in infants and young children, rarely occurs in adults.CMDT22_Ch39_p1612-p1675.indd  1629 02/07/21 2:44 PMChAPTER 391630 CMDT 2022 Clinical FindingsA.  Symptoms and SignsThe pr esence of a hepatocellular carcinoma may be unsus- pected until there is deterioration in the condition of a cirrhotic patient who was formerly stable. Cachexia, weak- ness, and weight loss are associated symptoms. The sudden appearance of ascites, which may be bloody, suggests portal or hepatic vein thrombosis by cancer or bleeding from a necrotic cancer. Physical examination may show tender enlargement of the liver, occasionally with a palpable mass. In Africa, the typical presentation in young patients is a rapidly expand- ing abdominal mass. Auscultation may reveal a bruit over the tumor or a friction rub when the tumor has extended to the surface of the liver.B.  Laboratory FindingsLabora tory tests may reveal leukocytosis, as opposed to the leukopenia that is frequently encountered in cirrhotic patients. Anemia is common, but a normal or elevated hematocrit value may be found in up to one-third of patients owing to elaboration of erythropoietin by the tumor. Sudden and sustained elevation of the serum alka- line phosphatase in a patient who was formerly stable is a common finding. HBsAg is present in a majority of cases in endemic areas, whereas in the United States anti-HCV is found in up to 40% of cases. Serum alpha-fetoprotein (AFP) levels are elevated in up to 70% of patients with hepa- tocellular carcinoma in Western countries (although the sensitivity is lower in Blacks and levels are not elevated in patients with fibrolamellar hepatocellular carcinoma); how- ever, mild elevations (10200 ng/mL [10200 mcg/L]) are also often seen in patients with chronic hepatitis. Serum levels of des-gamma-carboxy prothrombin are elevated in up to 90% of patients with hepatocellular carcinoma, but they may also be elevated in patients with vitamin K defi- ciency, chronic hepatitis, and metastatic cancer. Cytologic study of ascitic fluid rarely reveals malignant cells.C.  ImagingM ultiphasic helical CT and MRI with contrast enhance- ment are the preferred imaging studies for determining the location and vascularity of the tumor; MRI may be more sensitive than CT, and imaging with gadoxetic acid increases sensitivity. Lesions smaller than 1 cm may be dif- ficult to characterize. Based on stringent criteria developed by the American College of Radiology through its Liver Imaging Reporting and Data System, the Organ Procure- ment and Transplantation Network, and the American Association for the Study of Liver Diseases, arterial phase enhancement of a lesion that is greater than or equal to 1 cm in diameter followed by delayed hypointensity (washout) has a 90% specificity for hepatocellular carci- noma. Ultrasonography is less sensitive and more operator dependent but is used to screen for hepatic nodules in high-risk patients. Contrast-enhanced ultrasonography has a sensitivity and specificity approaching those of arterial phase helical CT but, unlike CT and MRI, cannot image theentire liver during the short duration of the arterial phase and is thus associated with false-positive results. In selected cases, endoscopic ultrasonography (EUS) may be useful. PET is under study and appears to improve detection of extrahepatic metastases.D . Liver Biopsy and StagingLiver  biopsy is diagnostic, although seeding of the needle tract by cancer is a potential risk (13%). For lesions smaller than 1 cm, ultrasonography may be repeated every 3 months followed by further investigation of enlarging lesions. For lesions 1 cm or larger, biopsy can be deferred when characteristic arterial hypervascularity and delayed washout are demonstrated on either multiphasic helical CT or MRI with contrast enhancement (or both) in a patient with cirrhosis or if surgical resection is planned. The TNM system is the commonly used classification to stage hepatocellular carcinoma. Staging is important not only because it correlates with the patients long-term sur- vival but also because it is used to determine which patients should receive adjuvant or neoadjuvant therapy. The Barcelona Clinic Liver Cancer (BCLC) staging system is preferred and includes the Child-Pugh class, tumor stage, and liver function and has the advantage of linking overall stage with preferred treatment modalities and with an estimation of life expectancy. Screening & PreventionSurveillance (screening) fo r the development of hepatocel- lular carcinoma is recommended in patients with chronic hepatitis B (beginning as early as age 20 in Africans, age 40 in Asian males or Asians with a family history of hepatocel- lular carcinoma, and age 50 in others) or cirrhosis caused by HCV , HBV , or alcohol. There is some evidence that screening for hepatocellular carcinoma leads to a survival advantage over clinical diagnosis, but only a minority of cases are detected by screening. The standard screening approach is performing ultrasonography and obtaining serum AFP level every 6 months, although AFP testing has low sensitivity. A serum AFP level of 20 ng/mL (20 mcg/L) is generally the cutoff value that should trigger further evaluation. CT and MRI are considered too expensive for screening. The sensitivity of ultrasonography for detecting early hepatocellular carcinoma is only 63%. The risk of hepatocellular carcinoma developing in a patient with cirrhosis is 35% a year. Among patients with cirrhosis, over 60% of nodules smaller than 2 cm in diam- eter detected on a screening ultrasonography prove to be hepatocellular carcinoma. Patients with cancers detected by surveillance have a less advanced stage on average and greater likelihood that treatment will prolong survival than those whose cancers were not detected by surveillance. However, controversy persists about whether surveillance reduces cancer-related mortality. Mass vaccination programs against HBV in developing countries are leading to reduced rates of hepatocellular carcinoma. Successful treatment of hepatitis B and of hepatitis C in patients with cirrhosis also reduces the subsequent risk of hepatocellular carcinoma, and thusCMDT22_Ch39_p1612-p1675.indd  1630 02/07/21 2:44 PMCANCER1631 CMDT 2022hepatocellular carcino ma is considered a preventable neo- plasm. However, hepatocellular carcinoma may still occur after clearance of hepatitis B surface antigen or cure of HCV infection, thereby reducing the benefit of treatment for HBV and HCV infection. TreatmentSurgical  resection of a solitary hepatocellular carcinoma may result in cure if liver function is preserved (Child- Pugh class A or possibly B) and portal vein thrombosis is not present. Laparoscopic liver resection has been per- formed in selected cases. Treatment of underlying chronic viral hepatitis, adjuvant chemotherapy, and adaptive immunotherapy may lower postsurgical recurrence rates. Liver transplantation may be appropriate for small unre- sectable tumors in a patient with advanced cirrhosis, with reported 5-year survival rates of up to 75%. The recurrence- free survival may be better for liver transplantation than for resection in patients with well-compensated cirrhosis and small tumors (one tumor less than 5 cm or three or fewer tumors each less than 3 cm in diameter [Milan criteria]) and in those with expanded (University of California, San Francisco) criteria of one tumor less than or equal to 6.5 cm or three or fewer tumors less than or equal to 4.5 cm (or a combined tumor diameter of 8.5 cm) without vascular invasion. The Extended Toronto criteria include tumor dif- ferentiation, cancer-related symptoms, confinement of tumor to the liver, and absence of vascular invasion, without regard to tumor number or size, to determine candidacy for liver transplantation and appear to predict outcomes as well as the Milan criteria. After 6 months on the waiting list, patients with stage 2 hepatocellular carcinoma meeting the Milan criteria are awarded a fixed score of 3 points lower than the median Model for End-Stage Liver Disease (MELD) score for patients transplanted in the area where the candidate is listed (see Chapter 16), thereby increasing their chances of undergoing transplantation. However, orthotopic liver transplantation is often impractical because of donor organ shortage, so living donor liver transplanta- tion may be considered in these cases. Patients with larger tumors (35 cm), a serum AFP level of 1000 ng/mL (1000 mcg/L) or higher, or a MELD score of 20 or higher have poor posttransplantation survival. In patients with a serum AFP level greater than 1000 ng/mL (1000 mcg/L), down- staging by locoregional therapy to an AFP level less than 500 ng/mL (500 mcg/L) improves survival following subse- quent liver transplantation. Chemotherapy, hormonal therapy with tamoxifen, and long-acting octreotide have not been shown to prolong life, but transarterial chemoembolization (TACE), TACE with drug-eluting beads, transarterial chemoinfusion (TACI), and transarterial radioembolization (TARE) via the hepatic artery are not only palliative but may also prolong survival in patients with a large or multifocal tumor in the absence of extrahepatic spread. TACI and TARE are suitable for patients with portal vein thrombosis. TARE with yttrium-90 has been shown to result in a longer time to progression than TACE. Microwave ablation, radiofrequency ablation, cryotherapy, or injection of absolute ethanol into tumors smaller than 2 cm may prolong survival in patients who arenot candidates for resection and have tumors that are accessible; these interventions, as well as stereotactic body radiation therapy, may also provide a bridge to liver transplantation. Microwave ablation is becoming the pre- ferred approach because it allows shorter treatment times and, like radiofrequency ablation, can be performed after TACE in select cases. Cryoablation may result in slower tumor progression than radiofrequency ablation for tumors that are 3.14 cm in diameter. Stereotactic body radiation therapy is also being used to treat unresectable hepatocel- lular carcinoma and may be effective in treating lesions larger than those treated with ablation techniques. Sorafenib (an oral multikinase inhibitor of Raf kinase, the VEGF receptor, and the platelet-derived growth factor receptor [and others]) prolongs median survival as well as the time to radiologic progression by 3 months in patients with advanced hepatocellular carcinoma and until recently was the standard care in these patients. Lenvatinib is another oral multikinase inhibitor that is FDA approved for the same indications as sorafenib. However, the combi- nation of atezolizumab, an immune checkpoint inhibitor, and bevacizumab, an antibody to the VEGF receptor, has been shown to be superior to sorafenib and has become standard first-line therapy. Regorafenib is an oral multiki- nase inhibitor that provides a survival benefit for patients whose disease progresses despite sorafenib therapy, and nivolumab and pembrolizumab are immune checkpoint inhibitors that have been approved for advanced hepatocel- lular carcinoma. The combination of nivolumab and ipili- mumab has been recommended as second-line therapy after failure of sorafenib. Cabozantinib, another multiki- nase inhibitor, has been approved by the FDA for the treat- ment of hepatocellular carcinoma after prior treatment with sorafenib, as has ramucirumab, an antibody to the VEGF receptor, which is approved for patients with an AFP level greater than or equal to 400 ng/mL (400 mcg/L) and previous treatment with sorafenib. The modified Response Evaluation Criteria in Solid Tumors (mRECIST) are used to assess treatment response based on tumor shrinkage and viability after locoregional and antiangiogenic treatment. Meticulous efforts at palliative care are essential for patients in whom disease progresses despite treatment or in whom advanced tumors, vascular invasion, or extrahepatic spread are present. Severe pain may develop in such patients due to expansion of the liver capsule by the tumor and requires concerted efforts at pain management, including the use of opioids (see Chapter 5). PrognosisIn  the United States, overall 1- and 5-year survival rates for patients with hepatocellular carcinoma are 23% and 5%, respectively. Five-year survival rates rise to 56% for patients with localized resectable disease (T1, T2, selected T3 and T4; N0; M0) but are virtually nil for those with locally unresectable or advanced disease. In patients with HCV- related hepatocellular carcinoma, the serum AFP level at the time of diagnosis of cancer has been reported to be an independent predictor of mortality. A serum AFP level greater than or equal to 200 ng/mL (200 mcg/L) or increases of greater than 15 ng/mL/month predict worseCMDT22_Ch39_p1612-p1675.indd  1631 02/07/21 2:44 PMChAPTER 391632 CMDT 2022outco mes in patients awaiting liver transplantation. In patients who are not eligible for surgery, an elevated serum C-reactive protein level is associated with poor survival. Contrary to traditional opinion, the fibrolamellar variant does not have a better prognosis than conventional hepato- cellular carcinoma without cirrhosis. When to ReferAll  patients with hepatocellular carcinoma should be referred to a specialist. When to Admit Complications of cirrhosis. Severe pain. For surgery and other interventions.Bangaru  S et al. Review article: new therapeutic interventions for advanced hepatocellular carcinoma. Aliment Pharmacol Ther. 2020;51:78. [PMID: 31747082] Bruix J et al (editors). The growing burden of liver cancer. Semin Liver Dis. 2020;40:101. [Full issue] Fanwal F et al. Surveillance for hepatocellular carcinoma: cur- rent best practice and future direction. Gastroenterology. 2019;157:54. [PMID: 30986389] Shiels MS et al. Recent decline in hepatocellular carcinoma rates in the United States. Gastroenterology. 2020;158:1503. [PMID: 31962125] Simon TG et al. Association of aspirin with hepatocellular carci- noma and liver-related mortality. N Engl J Med. 2020;382:1018. [PMID: 32160663]CA RCINOMA OF THE BILIARY TRACTE S S E N T I A L S  O F  D I A G N O S I S Presents with obstructive jaundice, usually pain- less, often with dilated biliary tract. Pain is more common in gallbladder carcinoma than cholangiocarcinoma. A dilated gallbladder may be palpable (Cour- voisier sign). Diagnosis by cholangiography with biopsy and brushings for cytology. General ConsiderationsCarcino ma of the gallbladder occurs in approximately 2% of all people operated on for biliary tract disease; the inci- dence, like that of carcinoma of the bile ducts, had been decreasing in the United States but may be increasing again in some Western countries because of lifestyle changes. It is notoriously insidious, and the diagnosis is often made unexpectedly at surgery. Cholelithiasis (often large, symp- tomatic stones) is usually present. Other risk factors are chronic infection of the gallbladder with Salmonella typhi , adenomatous gallbladder polyps over 1 cm in diameter (particularly with hypoechoic foci on EUS), mucosalcalcification of the gallbladder (porcelain gallbladder), anomalous pancreaticobiliary ductal junction, high parity in women, and aflatoxin exposure. Genetic factors include K-ras andTP53 mutations. Spread of the cancerby direct extension into the liver or to the peritoneal surfacemay be seen on initial presentation. Carcinoma of the bile ducts (cholangiocarcinoma) accounts for 1025% of all hepatobiliary malignancies and 3% of all cancer deaths in the United States. It is more prevalent in persons aged 5070, with a slight male pre- dominance, and more common in Asia. About 50% arise at the confluence of the hepatic ducts (perihilar, or so-called Klatskin, tumors), and 40% arise in the distal extrahepatic bile duct (the incidence of which has risen since 1990); the remainder are intrahepatic (the incidence of which rose dramatically from the 1970s to the early 2000s). Mortality from intrahepatic cholangiocarcinoma has been increas- ing. The frequency of carcinoma in persons with a chole- dochal cyst has been reported to be over 14% at 20 years, and surgical excision is recommended. Most cases of chol- angiocarcinoma are sporadic. There is an increased inci- dence of cholangiocarcinoma in patients with bile duct adenoma; Caroli disease; a biliary-enteric anastomosis; ulcerative colitis, especially those with primary sclerosing cholangitis; biliary cirrhosis; diabetes mellitus; hyperthy- roidism; chronic pancreatitis; heavy alcohol consumption; smoking; and past exposure to Thorotrast, a contrast agent. Premalignant lesions of the bile duct include biliary intraepithelial neoplasia and intraductal papillary neopla- sia of the biliary system (biliary papillomatosis). Aspirin use and statin use are associated with a reduced risk of cholangiocarcinoma, and in diabetic patients, metformin use is associated with a reduced risk of intrahepatic cholan- giocarcinoma. In Southeast Asia, hepatolithiasis, chronic typhoid carriage, and infection of the bile ducts with hel- minths (Clonorchis sinensis, Opisthorchis viverrini) are associated with an increased risk of cholangiocarcinoma. Hepatitis C virus (and possibly hepatitis B virus) infection, cirrhosis, HIV infection, nonalcoholic fatty liver disease, diabetes mellitus, obesity, and tobacco smoking are risk factors for intrahepatic cholangiocarcinoma. The TNM system is the commonly used classification to stage carcinoma of the biliary tract, including gallblad- der carcinomas and perihilar and intrahepatic cholangio- carcinomas. Staging is important not only because it correlates with the patients long-term survival but also because it is used to determine which patients should receive adjuvant or neoadjuvant therapy. Other staging systems consider the patients age, perfor- mance status, tumor extent and form, perineural invasion, vascular encasement, hepatic lobe atrophy, underlying liver disease, and peritoneal metastasis. Clinical FindingsA.  Symptoms and SignsProgres sive jaundice is the most common and usually the first sign of obstruction of the extrahepatic biliary system. Pain in the right upper abdomen with radiation into the back is usually present early in the course of gallbladderCMDT22_Ch39_p1612-p1675.indd  1632 02/07/21 2:44 PMCANCER1633 CMDT 2022carcino ma but occurs later in the course of bile duct carci- noma. Anorexia and weight loss are common and may be associated with fever and chills due to cholangitis. Rarely, hematemesis or melena results from erosion of cancer into a blood vessel (hemobilia). Fistula formation between the bili- ary system and adjacent organs may also occur. The course is usually one of rapid deterioration, with death occurring within a few months. Physical examination reveals profound jaundice. Pruritus and skin excoriations are common. A palpable gallbladder with obstructive jaundice usually is said to signify malignant disease (Courvoisier sign); however, this clinical generaliza- tion has been proven to be accurate only about 50% of the time. Hepatomegaly due to hypertrophy of the unobstructed liver lobe is usually present and is associated with liver ten- derness. Ascites may occur with peritoneal implants.B.  Laboratory FindingsW ith biliary obstruction, laboratory examination reveals predominantly conjugated hyperbilirubinemia, with total serum bilirubin values ranging from 5 to 30 mg/dL. There is usually concomitant elevation of the alkaline phosphatase and serum cholesterol. AST is normal or minimally elevated. The serum CA 19-9 level is elevated in up to 85% of patients and may help distinguish cholangiocarcinoma from a benign biliary stricture (in the absence of cholangitis), but this test is neither sensitive nor specific.C.  ImagingUl trasonography and contrast-enhanced, triple-phase, heli- cal CT may show a gallbladder mass in gallbladder carci- noma and intrahepatic mass or biliary dilatation in carcinoma of the bile ducts. CT may also show involved regional lymph nodes and atrophy of a hepatic lobe because of vascular encasement with compensatory hypertrophy of the unaffected lobe. MRI with magnetic resonance cholan- giopancreatography (MRCP) and gadolinium enhancement permits visualization of the entire biliary tract and detection of vascular invasion and obviates the need for angiography and, in some cases, direct cholangiography; it is the imaging procedure of choice but may understage malignant hilar strictures. The sensitivity and image quality can be increased with use of ferumoxide enhancement. The features of intra- hepatic cholangiocarcinoma on MRI appear to differ from those of hepatocellular carcinoma, with contrast washout in the latter but not the former. In indeterminate cases, PET can detect cholangiocarcinomas as small as 1 cm and lymph node and distant metastases, but false-positive results occur. The most helpful diagnostic studies before surgery are either endoscopic retrograde cholangiography or percutaneous transhepatic cholangiography with biopsy and cytologic specimens, although false-negative biopsy and cytology results are common. Digital image analysis and fluorescent in situ hybridization of cytologic specimens for polysomy improve sensitivity. EUS with FNA of tumors, peroral chol- angioscopy, confocal laser endomicroscopy, and intraductal ultrasonography may confirm a diagnosis of cholangiocarci- noma in a patient with bile duct stricture and an otherwise indeterminate evaluation, but FNA can result in cancerseeding and should be avoided if the cancer is potentially resectable. TreatmentIn  young and fit patients, curative surgery for gallbladder carcinoma may be attempted if the cancer is well localized. The 5-year survival rate for carcinoma of the gallbladder invading the lamina propria or muscularis (stage 1, T1a or 1b, N0, M0) is as high as 85% with laparoscopic cholecys- tectomy but drops to 60%, even with a more extended open resection, if there is perimuscular invasion (T2). The role of radical surgery for T3 and T4 tumors is debatable. If the cancer is unresectable at laparotomy, biliary-enteric bypass (eg, Roux-en-Y hepaticojejunostomy) can be performed. Carcinoma of the bile ducts is curable by surgery in less than 10% of cases. If resection margins are negative, the 5-year survival rate may be as high as 47% for intrahepatic cholangiocarcinomas, 41% for hilar cholangiocarcinoma, and 37% for distal cholangiocarcinomas, but the perioper- ative mortality rate may be as high as 10%. Factors predicting shorter survival for intrahepatic cholangiocarcinoma include large cancer size, multiple cancers, lymph node metastasis, and vascular invasion. Adjuvant chemotherapy with capecitabine has been shown to result in superior overall survival compared with no adjuvant therapy. Pallia- tion can be achieved by placement of a self-expandable metal stent via an endoscopic or percutaneous transhepatic route. Covered metal stents may be more cost-effective than uncovered metal stents because of a longer duration of patency. However, they are associated with a higher rate of stent migration and cholecystitis due to occlusion of the cystic duct and are not associated with longer survival. For perihilar cancers, insertion of a unilateral stent rather than bilateral stents may suffice. Plastic stents are less expensive initially, but not in the long term, because they are more prone to occlude than metal ones; they may be considered in patients expected to survive only a few months. Photo- dynamic therapy in combination with stent placement prolongs survival when compared with stent placement alone in patients with nonresectable cholangiocarcinoma. Endoscopic retrograde cholangiopancreatography (ERCP) directed radiofrequency ablation, TACE, and TARE are additional emerging options. Radiotherapy may relieve pain and contribute to biliary decompression. There is limited response to chemotherapy with gemcitabine alone, but the combination of cisplatin and gemcitabine or capecitabine and gemcitabine prolongs survival in patients with locally advanced or metastatic cholangiocarcinoma. Few patients survive for more than 24 months. Although cholangiocarcinoma is generally considered to be a contra- indication to liver transplantation because of rapid cancer recurrence, a 5-year survival rate of 75% has been reported in patients with stage I and II perihilar cholangiocarcinoma undergoing chemoradiation and exploratory laparotomy followed by liver transplantation, and a 5-year survival rate of 67% has been reported in those with intrahepatic cholangiocarcinoma. For those patients whose disease progresses despite treatment, meticulous efforts at palliative care are essential (see Chapter 5).CMDT22_Ch39_p1612-p1675.indd  1633 02/07/21 2:44 PMChAPTER 391634 CMDT 2022 When to ReferAll  patients with carcinoma of the biliary tract should be referred to a specialist. When to Admit Biliary obstruction. Cholangitis.Bertuccio  P et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019;71:104. [PMID: 30910538] De Martin E et al. Analysis of liver resection versus liver trans- plantation on outcome of small intrahepatic cholangiocarci- noma and combined hepatocellular-cholangiocarcinoma in the setting of cirrhosis. Liver Transpl. 2020;26:785. [PMID: 32090444] Lavu S et al. Effect of statins on the risk of extrahepatic cholan- giocarcinoma. Hepatology. 2020;72:1298. [PMID: 32119126]CA RCINOMA OF THE PANCREAS & AMPULLA OF VATERE S S E N T I A L S  O F  D I A G N O S I S Obstructive jaundice (may be painless). Enlarged gallbladder (may be painful). Upper abdominal pain with radiation to back, weight loss, and thrombophlebitis are usually late manifestations. General ConsiderationsCarcino ma is the most common neoplasm of the pancreas. About 75% are in the head and 25% in the body and tail of the organ. Pancreatic carcinomas account for 2% of all cancers and 5% of cancer deaths. Ampullary carcinomas are much less common. Risk factors for pancreatic cancer include age, tobacco use (which is thought to cause 2025% of cases), heavy alcohol use, obesity, chronic pan- creatitis, diabetes mellitus, prior abdominal radiation, fam- ily history, and possibly gastric ulcer and exposure to arsenic and cadmium. New-onset diabetes mellitus after age 45 years occasionally heralds the onset of pancreatic cancer. In diabetic patients, metformin use and possibly aspirin use may reduce the risk of pancreatic cancer slightly, but insulin use and glucagon-like peptide-1based therapy (eg, sitagliptin) may increase the risk. About 7% of patients with pancreatic cancer have a family history of pancreatic cancer in a first-degree relative, compared with 0.6% of control subjects. The majority of pancreatic can- cers originate from pancreatic intraepithelial neoplasias, which measure less than 5 mm in diameter and can only be seen with a microscope. In 510% of cases, pancreatic cancer occurs as part of a hereditary syndrome, including familial breast cancer (car- riers of BRCA2 have a 7% lifetime risk of pancreatic can- cer), hereditary pancreatitis ( PSS1 mutation), familialatypical multiple mole melanoma ( p16/CDKN2A muta- tion), Peutz-Jeghers syndrome ( STK11 /LKB1 mutation), ataxia-telangiectasia ( ATM mutation), and Lynch syn- drome (hereditary nonpolyposis colorectal cancer [ MLH1 , MSH2 ,MSH6 mutations]). Neuroendocrine tumors account for 12% of pancreatic neoplasms and may be functional (producing gastrin, insu- lin, glucagon, vasoactive intestinal peptide, somatostatin, growth hormonereleasing hormone, adrenocorticotropic hormone, and others) or nonfunctional. Cystic neoplasms account for only 1% of pancreatic cancers, but they are important because pancreatic cysts are common and may be mistaken for pseudocysts. A cystic neoplasm should be suspected when a cystic lesion in the pancreas is found in the absence of a history of pancreatitis. At least 15% of all pancreatic cysts are neoplasms. Serous cystadenomas (which account for 3239% of cystic pancreatic neoplasms and also occur in patients with von Hippel-Lindau disease) are benign. However, mucinous cystic neoplasms (defined by the presence of ovarian stroma and accounting for 1045% of cystic pancreatic neoplasms), intraductal papil- lary mucinous neoplasms (2133% of cystic pancreatic neoplasms), solid pseudopapillary tumors (less than 5%, primarily in young women), and cystic islet cell tumors (35%) may be malignant. Their prognoses are better than the prognosis of pancreatic adenocarcinoma, unless the cystic neoplasm is at least locally advanced. Mucinous cystic neoplasms and intraductal papillary mucinous neoplasms account for 1530% of pancreatic cancers. Clinical FindingsA.  Symptoms and SignsPai n is present in over 70% of cases and is often vague, dif- fuse, and located in the epigastrium or, when the lesion is in the tail, located in the left upper quadrant of the abdo- men. Radiation of pain into the back is common and some- times predominates. Sitting up and leaning forward may afford some relief, and this usually indicates that the lesion has spread beyond the pancreas and is inoperable. Diar- rhea, perhaps due to maldigestion, is an occasional early symptom. Migratory thrombophlebitis is a rare sign. Weight loss is a common but late finding and may be asso- ciated with depression. Hyperglycemia and decreases in subcutaneous abdominal fat and serum lipid levels have been reported to precede a diagnosis of pancreatic cancer. Occasional patients (often aged 40 years or older) present with acute pancreatitis in the absence of an alternative cause. Jaundice is usually due to biliary obstruction by a cancer in the pancreatic head. A palpable gallbladder is also indicative of obstruction by a neoplasm (Courvoisier sign), but there are frequent exceptions. A hard, fixed, occasionally tender mass may be present. In advanced cases, a hard periumbilical (Sister Mary Josephs) nodule may be palpable.B.  Laboratory FindingsThere  may be mild anemia. Glycosuria, hyperglycemia, and impaired glucose tolerance or true diabetes mellitus are found in 1020% of cases. The serum amylase or lipaseCMDT22_Ch39_p1612-p1675.indd  1634 02/07/21 2:44 PMCANCER1635 CMDT 2022level  is occasionally elevated. Liver biochemical tests may suggest obstructive jaundice. Steatorrhea in the absence of jaundice is uncommon. Occult blood in the stool is sugges- tive of carcinoma of the ampulla of Vater (the combination of biliary obstruction and bleeding may give the stools a distinctive silver appearance). CA 19-9, with a sensitivity of 70% and a specificity of 87%, has not proven useful for early detection of pancreatic cancer; increased values are also found in acute and chronic pancreatitis and cholangi- tis. Plasma chromogranin A levels are elevated in 88100% of patients with pancreatic neuroendocrine tumors (NETs).C.  ImagingM ultiphase thin-cut helical CT is generally the initial diag- nostic procedure and detects a mass in over 80% of cases. CT identifies metastases, delineates the extent of the tumor, and allows percutaneous FNA for cytologic studies and tumor markers. MRI is an alternative to CT. Ultraso- nography is not reliable because of interference by intesti- nal gas. PET is a sensitive technique for detecting pancreatic cancer and metastases, but PET-CT is not a routine staging procedure. Selective celiac and superior mesenteric arteri- ography may demonstrate vessel invasion by cancer, a find- ing that would preclude attempts at surgical resection, but it is used uncommonly since the advent of multiphase helical CT. EUS is more sensitive than CT for detecting pancreatic cancer and is equivalent to CT for determining nodal involvement and resectability; contrast-enhanced EUS improves accuracy. A normal EUS excludes pancre- atic cancer. EUS may also be used to guide FNA or biopsy for tissue diagnosis, tumor markers, and DNA analysis. ERCP may clarify an ambiguous CT or MRI study by delineating the pancreatic duct system or confirming an ampullary or biliary neoplasm. MRCP appears to be at least as sensitive as ERCP in diagnosing pancreatic cancer. In some centers, pancreatoscopy or intraductal ultrasonog- raphy is used to evaluate filling defects in the pancreatic duct and assess resectability of intraductal papillary muci- nous cancers. With obstruction of the splenic vein, spleno- megaly or gastric varices are present, the latter detected by endoscopy, EUS, or angiography. Cystic neoplasms can be distinguished by their appear- ance on CT, EUS, and ERCP and features of the cyst fluid on gross, cytologic, and genetic analysis. For example, serous cystadenomas may have a central scar or honey- comb appearance; mucinous cystadenomas are unilocular or multilocular and contain mucin-rich fluid with high carcinoembryonic antigen levels (greater than 200 ng/mL [200 mcg/L]) and K-ras mutations; and intraductal papil- lary mucinous neoplasms are associated with a dilated pancreatic duct and extrusion of gelatinous material from the ampulla. StagingThe  TNM system is the commonly used classification to stage pancreatic cancer. Staging is important not only because it correlates with the patients long-term survival but also because it is used to determine which patients should receive adjuvant or neoadjuvant therapy.TreatmentAbdo minal exploration is usually necessary when cytologic diagnosis cannot be made or if resection is to be attempted (in up to 30% of patients with pancreatic carcinoma). In a patient with a localized mass in the head of the pancreas and without jaundice, laparoscopy may detect tiny perito- neal or liver metastases and thereby avoid resection in 413% of patients. Radical pancreaticoduodenal (Whipple) resection is indicated for cancers strictly limited to the head of the pancreas, periampullary area, and duodenum (T1, N0, M0). Five-year survival rates are 2025% in this group and as high as 40% in those with negative resection margins and without lymph node involvement. Preopera- tive endoscopic decompression of an obstructed bile duct is often achieved with a plastic stent or short metal stent but does not reduce operative mortality and is associated with complications. The best surgical results are achieved at centers that specialize in the multidisciplinary treatment of pancreatic cancer. Adjuvant chemotherapy with gemcitabine, 5-fluo- rouracil, or gemcitabine with capecitabine is superior to no adjuvant therapy. Gemcitabine with capecitabine and a modified FOLFIRINOX (5-fluorouracil, leucovorin, irino- tecan, oxaliplatin) regimen have been found to be superior to gemcitabine alone. The role of adjuvant chemoradiation is controversial but often used in the United States. Neoad- juvant chemotherapy with or without radiation is increas- ingly being used to downstage patients and in those with resectable cancer. Common chemotherapy regimens for this purpose include FOLFIRINOX and gemcitabine with nanoparticle albumin-bound (nab)-paclitaxel. Chemora- diotherapy downstages about 30% of patients with locally advanced disease to allow resection. When resection is not feasible, endoscopic stenting of the bile duct is performed to relieve jaundice. A plastic stent is generally placed if the patients anticipated survival is less than 6 months (or if surgery is planned). A metal stent is preferred when anticipated survival is 6 months or greater. Whether covered metal stents designed to prevent cancer ingrowth offer an advantage over uncovered stents is uncertain because covered stents are associated with higher rates of migration and acute cholecystitis due to occlusion of the cystic duct. Surgical biliary bypass may be considered in patients expected to survive at least 6 months. Surgical duodenal bypass may be considered in patients in whom duodenal obstruction is expected to develop; alternatively, endoscopic placement of a self- expandable duodenal stent may be feasible. Chemoradia- tion may be used for palliation of unresectable cancer confined to the pancreas. Chemotherapy has been disappointing in metastatic pancreatic cancer, although improved response rates have been reported with FOLFIRINOX and with the combination of gemcitabine and nab-paclitaxel. In patients who have received prior chemotherapy, a regimen of 5-fluorouracil and leucovorin in combination with nanoliposomal irinotecan has resulted in improved survival compared with 5-fluorouracil and leucovorin alone. Celiac plexus nerve block (under CT or endoscopic ultrasound guidance) or thoracoscopic splanchnicectomy may improve pain control.CMDT22_Ch39_p1612-p1675.indd  1635 02/07/21 2:44 PMChAPTER 391636 CMDT 2022Surgical  resection is the treatment of choice for NETs, when feasible. Lesions that are less than 1 cm in diameter and nonfunctioning without evidence of local invasion or metastasis may be followed expectantly. Metastatic disease may be controlled with long-acting somatostatin analogs, interferon, chemotherapy, peptide-receptor radionuclide therapy, and chemoembolization. There is a consensus that asymptomatic incidental pan- creatic cysts 2 cm or smaller are at low risk for harboring invasive carcinoma. The cysts may be monitored by imag- ing tests (MRI) in 1 year and then every 2 years for 5 years and probably longer if no changes are observed, with EUS and FNA performed if a cyst enlarges to 3 cm and another high-risk feature (dilated main pancreatic duct, presence of a solid component) develops. The optimal approach is uncertain, however, and other guidelines have been pro- posed. Surgical resection is indicated for mucinous cystic neoplasms, symptomatic serous cystadenomas, solid pseu- dopapillary tumors (which have a 15% risk of malignant transformation), and cystic tumors larger than 2 cm in diameter that remain undefined after helical CT, EUS, and diagnostic aspiration. All intraductal papillary mucinous neoplasms of the main pancreatic duct should be resected, but those of branch ducts may be monitored with serial imaging if they (1) are asymptomatic and exhibit benign features; (2) have a diameter less than 3 cm (some authori- ties recommend a diameter of 1.5 cm or smaller, but even lesions 3 cm or larger may be monitored in elderly persons with no other worrisome cyst features); and (3) lack non- enhancing mural nodules, or thick wall, or abrupt change in the caliber of the pancreatic duct with distal pancreatic atrophy, or possibly bile duct dilatation and gallbladder adenomyomatosis. Most lesions with such benign features remain stable on follow-up, but a risk of malignancy per- sists for more than 10 years. Moreover, the risk of pancre- atic ductal carcinoma and of nonpancreatic cancers is also increased in this group of patients. In the absence of locally advanced disease, survival is higher for malignant cystic neoplasms than for adenocarcinomas. The role of EUS- guided ablative treatment of potentially premalignant pancreatic cysts is under study. Endoscopic resection or ablation, with temporary placement of a pancreatic duct stent, may be feasible for ampullary adenomas, but patients must be followed for recurrence. PrognosisCarcino ma of the pancreas, especially in the body or tail, has a poor prognosis; 8085% of patients present with advanced unresectable disease, and reported 5-year sur- vival rates range from 2% to 5%. From 1980 to 2010, mor- tality from pancreatic cancer did not decrease, but it has since started to improve. Obesity may adversely affect mortality in Western countries. Metformin may improve survival in diabetic patients with pancreatic adenocarci- noma, and use of statins preceding a diagnosis of pancre- atic cancer may improve survival. Tumors of the ampulla have a better prognosis, with reported 5-year survival rates of 2040% after resection; jaundice and lymph node involvement are adverse prognostic factors. In carefully selected patients, resection of cancer of the pancreatic headis feasible and results in reasonable survival. In persons with a family history of pancreatic cancer in at least two first-degree relatives, or with a genetic syndrome associ- ated with an increased risk of pancreatic cancer, screening with EUS and helical CT or MRI/MRCP should be consid- ered beginning at age 50 (age 40 in CKDN2A orPRSS1 mutation carriers and age 35 in those with Peutz-Jeghers syndrome) or 10 years before the age at which pancreatic cancer was first diagnosed in a family member. For those patients whose disease progresses despite treatment, meticulous efforts at palliative care are essential (see Chapter 5). When to ReferAll pa tients with carcinoma involving the pancreas and the ampulla of Vater should be referred to a specialist. When to AdmitPatients  who require surgery and other interventions should be hospitalized.Aslanian  HR et al. AGA Clinical Practice Update on pancreas cancer screening in high-risk individuals: expert review. Gas- troenterology. 2020;159:358. [PMID: 32416142] Elta GH et al. ACG Clinical Guideline: diagnosis and manage- ment of pancreatic cysts. Am J Gastroenterol. 2018;113:464. [PMID: 29485131] US Preventive Services Task Force; Owens DK et al. Screening for pancreatic cancer: US Preventive Services Task Force reaf- firmation recommendation statement. JAMA. 2019;322:438. [PMID: 31386141]AL IMENTARY TRACT CANCERS Carling Ursem, MD Kenneth R. McQuaid, MD ESOPHAGEAL CANCERE S S E N T I A L S  O F  D I A G N O S I S Progressive dysphagia to solid food. Weight loss common. Endoscopy with biopsy establishes diagnosis. General ConsiderationsEsophageal cancer usually develo ps in persons between 50 and 70 years of age. There were an estimated 18,440 new cases of esophageal cancer in the United States in 2020. The overall ratio of men to women is 3:1. There are two histo- logic types: squamous cell carcinoma and adenocarcinoma, and their incidence has significant geographic variation. Squamous cell carcinoma is associated with smoking, alco- hol, poor nutritional status, and drinking hot beverages. It accounts for over 90% of cases of esophageal cancer inCMDT22_Ch39_p1612-p1675.indd  1636 02/07/21 2:44 PMCANCER1637 CMDT 2022Eastern  and Southeast Asia and sub-Saharan Africa. Ade- nocarcinoma is associated with obesity and gastroesopha- geal reflux disease, with the majority of cases developing as a complication of Barrett metaplasia due to chronic gastro- esophageal reflux. Adenocarcinomas make up the majority of new cases of esophageal cancer in North America and Northern and Western Europe. Clinical FindingsA.  Symptoms and SignsThe  majority (5060%) of patients with esophageal cancer present with advanced, incurable disease. While early symptoms are nonspecific and subtle, over 90% eventually have solid food dysphagia, which progresses over weeks to months. Odynophagia is sometimes present. Significant weight loss is common. Local tumor extension into the tracheobronchial tree may result in a tracheo-esophageal fistula, characterized by coughing on swallowing or by pneumonia. Chest or back pain suggests mediastinal exten- sion. Recurrent laryngeal nerve involvement may produce hoarseness. Physical examination is often unrevealing. The presence of supraclavicular or cervical lymphadenopathy or of hepatomegaly implies metastatic disease.B.  Laboratory FindingsLaborato ry findings are nonspecific. Anemia related to chronic disease or occult blood loss is common. Elevated aminotransferase or alkaline phosphatase concentrations suggest hepatic or bony metastases. Hypoalbuminemia may result from malnutrition.C.  ImagingA  barium esophagogram may be the first study obtained to evaluate dysphagia. The appearance of a polypoid, obstruc- tive, or ulcerative lesion is suggestive of carcinoma and requires endoscopic evaluation. However, even lesions believed to be benign by radiography warrant endoscopic evaluation. Chest radiographs may show adenopathy, a widened mediastinum, pulmonary or bony metastases, or signs of tracheo-esophageal fistula such as pneumonia.D . Upper EndoscopyEndoscopy  with biopsy establishes the diagnosis of esopha- geal carcinoma with a high degree of reliability. In some cases, significant submucosal spread of the tumor may yield nondiagnostic mucosal biopsies. Repeat biopsy may be necessary. StagingAfter  confirmation of the diagnosis of esophageal carci- noma, the stage of the disease should be determined since doing so influences the choice of therapy. Patients should undergo evaluation with contrast CT of the chest and abdomen to look for evidence of pulmonary or hepatic metastases, lymphadenopathy, and local tumor extension. If there is no evidence of distant metastases or extensive local spread on CT, then EUS with guided FNA biopsy of suspicious lymph nodes should be performed to evaluatethe locoregional stage. EUS is superior to CT in demon- strating the level of local mediastinal extension and local lymph node involvement. PET with fluorodeoxyglucose or integrated PET-CT imaging is indicated to look for regional or distant spread in patients thought to have localized dis- ease after other diagnostic studies, prior to invasive sur- gery. Bronchoscopy is sometimes required in esophageal cancers above the carina to exclude tracheobronchial extension. Laparoscopy to exclude occult peritoneal carci- nomatosis should be considered in patients with tumors at or near the gastroesophageal junction (see Gastric Adenocarcinoma). Differential DiagnosisEsophageal  carcinoma must be distinguished from other causes of progressive dysphagia, including peptic stricture, achalasia, and adenocarcinoma of the gastric cardia with esophageal involvement. Benign-appearing peptic stric- tures should be biopsied at presentation to exclude occult malignancy. TreatmentThe appr oach to esophageal cancer depends on the tumor stage, tumor location, patient preference and functional status, and the expertise of the gastroenterologists, sur- geons, oncologists, and radiation oncologists. It is helpful to classify patients into two general categories: those with early stage (curable) disease and those with advanced stage (incurable) disease.A.  Therapy for Curable DiseaseSuperficial  esophageal cancers confined to the epithelium (high-grade dysplasia or carcinoma in situ [Tis]), lamina propria (T1a), or submucosal (T1b) are increasingly recog- nized in endoscopic screening and surveillance programs. Esophagectomy achieves high cure rates for superficial tumors but is associated with mortality (2%) and morbid- ity. If performed by experienced clinicians, endoscopic mucosal resection of Tis and T1a cancers achieves equiva- lent long-term survival with less morbidity (see Barrett Esophagus, Chapter 15). Esophagectomy is recommended for superficial tumors that are invasive to the submucosa (T1b) because of higher rates of lymph node metastasis. 1. Surgery with or without neoadjuvant chemoradiation therapy There are multiple surgical approaches to the resection of invasive but potentially curable esophageal cancers (stage Ib, II, IIIA, or IIIB). Accepted techniques include en bloc transthoracic excision of the esophagus with extended lymph node dissection, transhiatal esopha- gogastrectomy (entailing laparotomy with cervical anasto- mosis), and minimally invasive esophagectomy techniques. Meta-analysis data suggest equivalent oncologic outcomes from minimally invasive esophagectomy and conventional open techniques, although there are fewer postoperative complications and shorter hospital stays with the laparo- scopic approach. Multiple meta-analyses have shown that regardless of surgery type, surgery at a high-volume hospi- tal is associated with decreased perioperative mortality.CMDT22_Ch39_p1612-p1675.indd  1637 02/07/21 2:44 PMChAPTER 391638 CMDT 2022Pa tients with stage I tumors have high cure rates with surgery alone and do not require radiation or chemother- apy. Whether radiation or chemotherapy or both are required in addition to surgery for T2N0 stage II tumors is a subject of ongoing debate. If regional lymph node metas- tases have occurred (stages IIB and III), the rate of cure with surgery alone is reduced to less than 20%. Meta- analysis of trials comparing neoadjuvant (preoperative) therapy followed by surgery with surgery alone suggests a 13% absolute improvement in 2-year survival with com- bined therapy. Preoperative (neoadjuvant) chemoradiation therapy is recommended for stage IIB and III tumors in fit patients. The preferred neoadjuvant chemotherapy regi- men used with radiation is weekly carboplatin plus pacli- taxel (Table 392). As an alternative, a combination of cisplatin plus 5-fluorouracil may be used along with radia- tion. When radiation therapy is considered, techniques that are less toxic such as intensity-modulated radiation therapy (IMRT) or proton beam therapy may be consid- ered. Perioperative chemotherapy without radiation may also be considered for tumors of the gastroesophageal junction based on the randomized, multicenter, phase III MAGIC trial. 2. Chemotherapy plus radiation therapy without surgery Combined treatment with chemotherapy and radiation achieves long-term survival rates in up to 25% of patients and is superior to radiation alone. Chemoradia- tion alone should be considered in patients with localized disease (stage II or IIIA) who are poor surgical candidates due to serious medical illness or poor functional status (Eastern Cooperative Oncology Group score greater than 2). Patients with cervical esophageal cancers, which appear similar biologically to head and neck cancers and in whom surgery is highly morbid and typically not recommended, also should be considered for chemoradiation. 3. Supportive care during definitive therapy Patients with significant tumor obstruction may require percutane- ous gastric or jejunal tube placement to maintain adequate hydration and nutrition during neoadjuvant chemoradia- tion or chemotherapy. Multidisciplinary consultation is required to determine the optimal procedure and to opti- mize perioperative nutrition.B.  Therapy for Incurable DiseaseMo re than half of patients have either locally extensive tumor spread (T4b) that is unresectable or distant metasta- ses (M1) at the time of diagnosis. Surgery is not warranted in these patients. Since prolonged survival can be achieved in few patients, the primary goal is to provide relief from dysphagia and pain, optimize quality of life, and minimize treatment side effects. The optimal palliative approach depends on the presence or absence of metastatic disease, expected survival, patient preference, and institutional experience. 1. Chemotherapy or chemoradiation Combined radia- tion therapy and chemotherapy may achieve palliation in two-thirds of patients but is associated with significant side effects. It should be considered for patients with locallyadvanced tumors without distant metastases who have good functional status and no significant medical prob- lems, in whom prolonged survival may be achieved. Com- bination chemotherapy may be considered in patients with metastatic disease who still have good functional status and expected survival of at least several months. The systemic therapy treatment options are the same for metastatic esophageal, gastroesophageal junction, and gastric cancers (Table 392). Choice of treatment is increas- ingly influenced by the results of molecular testing, includ- ing PD-L1 expression, mismatch repair/microsatellite instability (MSI) and, for adenocarcinomas, HER2 amplifi- cation testing. Because of the number of targetable altera- tions, a next generation sequencing panel should be considered. In patients with amplification of the HER2 gene (approximately 15% of cases), addition of the mono- clonal antibody trastuzumab (see Chapter 17) to chemo- therapy is associated with prolonged survival. For patients without HER2 amplification who have increased PD-L1 expression, the addition of a PD-1 or PD-L1 targeted anti- body to chemotherapy may improve overall survival. Immunotherapy with pembrolizumab should be consid- ered for tumors with either microsatellite instability-high (MSI-H) or deficient mismatch repair protein expression (dMMR). For patients with poor functional status, single- agent therapy with a fluoropyrimidine, a taxane, or irinote- can may be used. 2. Local therapy for esophageal obstruction Patients with advanced esophageal cancer often have a poor func- tional and nutritional status. Radiation therapy alone to the area of esophageal obstruction may afford short-term relief of pain and dysphagia. Rapid palliation of dysphagia may be achieved by peroral placement of permanent expand- able wire stents (alone or followed by radiation). However, placement of these stents is complicated by perforation, migration, or tumor ingrowth in up to 40% of cases. PrognosisThe ov erall 5-year survival rate of esophageal carcinoma is less than 20%. Apart from distant metastasis (M1b), the two most important predictors of poor survival are adja- cent mediastinal spread (T4) and lymph node involvement. Whereas cure may be achieved in patients with regional lymph node involvement (stages IIB and III), involvement of nodes outside the chest (M1a) is indicative of metastatic disease (stage IV) that is incurable. For those patients whose disease progresses despite chemotherapy, meticu- lous efforts at palliative care are essential (see Chapter 5). When to Refer Patients should be referred to a gastroenterologist for evaluation and staging (endoscopy with biopsy, EUS) and palliative endoscopic stenting. Patients with curable and resectable disease for whom neoadjuvant therapy may be appropriate (stage IIB or IIIA) should be referred to medical, radiation, and sur- gical oncologists for consideration of neoadjuvant che- motherapy, chemoradiotherapy, and surgical resection.CMDT22_Ch39_p1612-p1675.indd  1638 02/07/21 2:44 PMCANCER1639 CMDT 2022 Patients with metastatic disease should be referred to medical and radiation oncologists for consideration of palliative chemotherapy or chemoradiation. Patients with metastatic disease and obstructive tumors not amenable to or refractory to palliative radiation or stenting may require referral to an interventional radi- ologist, gastroenterologist, or surgeon for gastric or jejunal tube placement for liquid artificial nutrition. Early referral to palliative care services may improve symptom management in patients with advanced or metastatic disease. When to AdmitP atients with high-grade esophageal obstruction with inabil- ity to manage oral secretions or maintain hydration should be admitted. Acute complications such as perforation, bleeding, aspiration, or fistula also may require admission.Boku  N et al. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previ- ously untreated, unresectable, advanced, or recurrent gastric/ gastroesophageal junction cancer: interim results of a ran- domized, phase II trial (ATTRACTION-4). Ann Oncol. 2019;30:250. [PMID: 30566590] Gottlieb-Vedi E et al. Long-term survival in esophageal cancer after minimally invasive compared to open esophagectomy: a systematic review and meta-analysis. Ann Surg 2019;270:1005. [PMID: 30817355] Mariette C et al; Fdration de Recherche en Chirurgie (FRENCH) and French Eso-Gastric Tumors (FREGAT) Working Group. Hybrid minimally invasive esophagectomy for esophageal cancer. N Engl J Med. 2019;380:152. [PMID: 30625052] National Cancer Institute. SEER Cancer Statistics Factsheets: Esophageal Cancer, 2020. https://seer.cancer.gov/statfacts/ html/esoph.html National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Esophageal and esophagogastric junction cancers. Version5.2020. 2020 December 23. https:// www.nccn.org/professionals/physician_gls/pdf/esophageal. pdfGA STRIC ADENOCARCINOMAE S S E N T I A L S  O F  D I A G N O S I S Dyspeptic symptoms with weight loss in patients over age 40 years. Iron deficiency anemia: occult blood in stools. Abnormality detected on upper gastrointestinal series or endoscopy. General ConsiderationsGastric  adenocarcinoma is the third most common cause of cancer death worldwide. However, its incidence has declined rapidly over the last 70 years, especially in Western countries, which may be attributable to changes in diet (more fruits and vegetables), food refrigeration (allowingmore fresh foods and reduced salted, smoked, and pre- served foods), reduced toxic environmental exposures, and a decline in Helicobacter pylori infections. The incidence of gastric cancer remains high (62/100,000 males) in Japan and many developing regions, including eastern Asia, Eastern Europe, Chile, Colombia, and Central America. In the United States, there were an estimated 27,600 new cases and 11,010 deaths in 2020. The incidence is higher in Asian Americans, Hispanics, African Americans, and Native Americans (including Native Alaskans). There are two main histologic variants of gastric cancer: intestinal-type (which resembles intestinal cancers in forming glandular structures) and diffuse (which is poorly differentiated, has signet-ring cells, and lacks glan- dular formation). The incidence of intestinal-type gastric cancer has declined significantly, but it is still the more common type (7080%); it occurs twice as often in men as women, primarily affects older people (mean age 68 years), and is more strongly associated with environmental fac- tors. It is believed to arise through a gradual, multi-step progression from inflammation (most commonly due to H pylori ), to atrophic gastritis, to intestinal metaplasia, and finally to dysplasia and cancer. Chronic H pylori gastritis is the strongest risk factor for gastric carcinoma, increasing the relative risk 3.5- to 20-fold. It is estimated that 6090% of cases of gastric carcinomas may be attributable to H pylori. Other risk factors for intestinal-type gastric cancer include pernicious anemia, a history of partial gastric resection more than 15 years previously, smoking, and diets that are high in nitrates or salt and low in vitamin C. Diffuse gastric cancer accounts for 2030% of gastric can- cer cases. In contrast to intestinal-type cancer, it affects men and women equally, occurs more commonly in young people, is not as strongly related to H pylori infection, and has a worse prognosis than intestinal-type cancer due to early metastasis. Most diffuse gastric cancers are attribut- able to acquired or hereditary mutations in the genes regulating the E-cadherin cell adhesion protein. Hereditary diffuse gastric cancer accounts for 13% of gastric cancers. The cancer may arise at a young age, is often multifocal and infiltrating with signet ring cell histology, and confers poor prognosis. Many of these families have a germline muta- tion of E-cadherin CDH1, which is inherited in an autoso- mal dominant pattern and carries a greater than 60% lifetime risk of gastric cancer. Prophylactic gastrectomy should be considered in patients known to carry this mutation. Most gastric cancers arise in the body and antrum. These may occur in a variety of morphologic types: (1) polypoid or fungating intraluminal masses; (2) ulcerating masses; (3) diffusely spreading ( linitis plastica ), in which the tumor spreads through the submucosa, resulting in a rigid, atonic stomach with thickened folds (prognosis dis- mal); and (4) superficially spreading or early gastric cancerconfined to the mucosa or submucosa (with or without lymph node metastases) and associated with a favorable prognosis. HER2 amplification and overexpres- sion is seen in 1025% of gastric adenocarcinoma cases and is more commonly observed in intestinal histology and moderately differentiated disease. Testing for MSI,CMDT22_Ch39_p1612-p1675.indd  1639 02/07/21 2:44 PMChAPTER 391640 CMDT 2022defici ency in mismatch repair proteins (dMMR), and PD-L1 is recommended in advanced disease to identify tumors that may respond to immunotherapy. For gastric adenocarcinoma, MSI-H/dMMR is found in 816% of cases. In contrast to the dramatic decline in cancers of the distal stomach, a rise in incidence of tumors of the gastric cardia has been noted. These tumors have demographic and pathologic features that resemble Barrett-associated esoph- ageal adenocarcinomas (see Esophageal Cancer). Clinical FindingsA.  Symptoms and SignsGastri c carcinoma is generally asymptomatic until the dis- ease is quite advanced. Symptoms are nonspecific and are determined in part by the location of the tumor. Dyspepsia, vague epigastric pain, anorexia, early satiety, and weight loss are the presenting symptoms in most patients. Patients may derive initial symptomatic relief from over-the-counter rem- edies, further delaying diagnosis. Ulcerating lesions can lead to acute gastrointestinal bleeding with hematemesis or melena. Pyloric obstruction results in postprandial vomiting. Lower esophageal obstruction causes progressive dysphagia. Physical examination is rarely helpful. Stools may be guaiac positive.B.  Laboratory FindingsIr on deficiency anemia due to chronic blood loss or anemia of chronic disease is common. Circulating tumor markers do not have established clinical validity in screening or diagnosis of gastric cancer. However, when checked serially, tumor markers can assist in monitoring treatment response.C.  EndoscopyU pper endoscopy should be obtained in all patients over age 60 years with new onset of epigastric symptoms (dyspepsia) and young patients with alarm symptoms (dysphagia, recur- rent vomiting, significant weight loss), especially in immi- grants from countries with a high prevalence of gastric cancer. Endoscopy with biopsies of suspicious lesions is highly sensi- tive for detecting gastric carcinoma. It can be difficult to obtain adequate biopsy specimens in diffuse type gastric cancer.D . ImagingOnce  a gastric cancer is diagnosed, preoperative evaluation with contrast CT of chest, abdomen, and pelvis and EUS is indicated to delineate the local extent of the primary tumor as well as to evaluate for nodal or distant metastases. EUS is superior to CT in determining the depth of tumor pen- etration and is useful for evaluation of early gastric cancers that may be removed by endoscopic mucosal resection. PET or combined PET-CT imaging is recommended for detection of distant metastasis. ScreeningBecause  of its unproven efficacy and cost-effectiveness, screening for H pylori infection and treating it to preventgastric cancer is not recommended for asymptomatic adults in the general population but may be considered in patients who have immigrated from regions with a high incidence of gastric cancer or who have a family history of gastric cancer. Because of the high incidence of gastric carcinoma in Japan, screening upper endoscopy is per- formed there to detect early gastric carcinoma. Approxi- mately 40% of tumors detected by screening are early, with a 5-year survival rate of almost 90%. Screening is not rec- ommended in the United States. StagingThe  TNM system is the commonly used classification to stage gastric adenocarcinoma. Staging is important not only because it correlates with the patients long-term sur- vival but also because it is used to determine which patients should receive adjuvant or neoadjuvant therapy. A staging laparoscopy prior to definitive surgery to exclude peritoneal carcinomatosis should be considered in patients with stage T1b or greater disease without radio- graphic evidence of distant metastases. Pathologic review should include (1) grade of tumor, (2) histologic subtype, (3) depth of invasion, (4) whether lymphatic or vascular inva- sion is present, and (5) if there is known metastatic disease, the status of HER2 protein expression by immunohisto- chemistry or fluorescent in situ hybridization or both, along with MMR or MSI testing and PD-L1 protein expression. Differential DiagnosisUlce rating gastric adenocarcinomas are distinguished from benign gastric ulcers by biopsies. Approximately 3% of gastric ulcers initially believed to be benign later prove to be malignant. All gastric ulcers identified at endoscopy should be biopsied to exclude malignancy. Ulcers that are suspicious for malignancy to the endoscopist or that have atypia or dysplasia on histologic examination warrant repeat endoscopy in 23 months to verify healing and exclude malignancy. Nonhealing ulcers should be consid- ered for resection. Infiltrative carcinoma with thickened gastric folds must be distinguished from lymphoma and other hypertrophic gastropathies. TreatmentA.  Curative Surgical ResectionSurgical resecti on is the only therapy with curative poten- tial. Laparoscopic techniques achieve similar outcomes and lower overall complication rates as open gastrectomy. In Japan and in specialized centers in the United States, endo- scopic mucosal resection is performed in select patients with small (less than 12 cm), early (intramucosal or T1aN0) gastric cancers after careful staging with EUS. Approximately 25% of patients undergoing surgery will be found to have locally unresectable tumors or peritoneal, hepatic, or distant lymph node metastases that are incur- able. The remaining patients with confirmed localized disease should undergo radical surgical resection. For adenocarcinoma localized to the distal two-thirds of the stomach, a subtotal gastrectomy should be performed. ForCMDT22_Ch39_p1612-p1675.indd  1640 02/07/21 2:44 PMCANCER1641 CMDT 2022pro ximal gastric cancer or diffusely infiltrating disease, total gastrectomy is necessary. The ultimate goal of surgery is obtaining negative surgical margins. Vitamin B12supple- mentation is required after gastrectomy. For patients with localized gastric cancer that is resectable, current National Comprehensive Cancer Network (NCCN) treatment guidelines recommend gastrectomy with extended (D1), or modified regional (D2), lymph node dissection and sam- pling of 15 or more lymph nodes. D2 lymphadenectomy has been shown to improve disease-specific survival but is associated with increased postoperative mortality.B.  Perioperative Chemotherapy or ChemoradiationThe  use of perioperative chemotherapy or adjuvant chemo- radiation is associated with improved survival in patients with localized or locoregional gastric adenocarcinoma who undergo surgical resection. The choice of treatment depends on the location and extent of tumor, type of sur- gery, patient comorbidities and performance status, and institutional experience. Tumors arising in the gastro- esophageal junction are treated following algorithms for esophageal primary tumors. Multidisciplinary treatment decision making involving the surgeon, radiation oncolo- gist, and medical oncologist is imperative.C.  Palliative ModalitiesMan y patients will be found either preoperatively or at the time of surgical exploration to have advanced disease that is not amenable to curative intent surgery due to peritoneal or distant metastases or local invasion of other organs. In some of these cases, palliative resection of the tumor none- theless may be indicated to alleviate pain, bleeding, or obstruction. For patients with unresectable disease, a surgi- cal diversion with gastrojejunostomy may be indicated to prevent obstruction. Alternatively, unresected tumors may be treated with endoscopic stent therapy, radiation therapy, or angiographic embolization to relieve bleeding or obstruction. Systemic therapy may be considered in patients with metastatic disease who still have good func- tional status and expected survival of at least several months. The regimens used are the same as those for esophageal and gastroesophageal junction tumors dis- cussed above (Table 392). PrognosisThe  5-year survival for gastric cancer varies greatly by stage, location, and histologic features. The 5-year survival is approximately 90% for early-stage cancer (T1b or less), 80% for stage II after curative intent treatment, but less than 20% for stage IIIC. Even with apparently localized disease, proxi- mal tumors have a 5-year survival of less than 15%. For those whose disease progresses despite therapy, meticulous efforts at palliative care are essential (see Chapter 5). When to Refer Patients with dysphagia, weight loss, protracted vomit- ing, iron deficiency anemia, melena, or new-onset dys- pepsia (especially if aged 60 years or older or associatedwith other alarm symptoms) in whom gastric cancer is suspected should be referred for endoscopy. Patients should be referred to a surgeon for attempt at curative resection in stage I, II, or III cancer, including staging laparoscopy if indicated. Prior to surgery, patients should be referred to an oncolo- gist to determine the role for perioperative chemother- apy or adjuvant chemoradiation or chemotherapy. Patients who have undergone gastrectomy require con- sultation with a nutritionist due to propensity for mal- nutrition and complications, such as dumping syndrome and vitamin B12deficiency, postoperatively. Patients with unresectable or metastatic disease should be referred to an oncologist for consideration of pallia- tive chemotherapy or chemoradiation. Early referral to palliative care services may also be considered for symptom management in patients with advanced and metastatic disease. When to AdmitPa tients with acute bleeding, protracted vomiting, or inabil- ity to maintain hydration or nutrition.Ja ng S et al. Superiority of gastrojejunostomy over endoscopic stenting for palliation of malignant gastric outlet obstruction. Clin Gastroenterol Hepatol. 2019;17:1295. [PMID: 30391433] Katai H et al. Survival outcomes after laparoscopy-assisted distal gastrectomy versus open-distal gastrectomy with nodal dis- section for clinical stage IA or IB gastric cancer: a multicentre, non-inferiority, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2020;5:142. [PMID: 31757656] National Cancer Institute. SEER Cancer Stat Facts: Stomach Cancer, 2020. https://seer.cancer.gov/statfacts/html/stomach. html National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Gastric Cancer. Version 4.2020. 2020 December 23. https://www.nccn.org/professionals/physician_ gls/pdf/gastric.pdfGA STRIC LYMPHOMAE S S E N T I A L S  O F  D I A G N O S I S Symptoms of dyspepsia, weight loss, or anemia. Variable abnormalities on upper gastrointestinal series or endoscopy including thickened folds, ulcer, mass, or infiltrating lesions; diagnosis estab- lished by endoscopic biopsy. Abdominal CT and EUS required for staging. General ConsiderationsGastric lympho mas may be primary (arising from the gas- tric mucosa) or may represent a site of secondary involve- ment in patients with nodal lymphomas. Distinguishing advanced primary gastric lymphoma with adjacent nodal spread from advanced nodal lymphoma with secondaryCMDT22_Ch39_p1612-p1675.indd  1641 02/07/21 2:44 PMChAPTER 391642 CMDT 2022gastric spread is essential  because the prognosis and treat- ment of primary and secondary gastric lymphomas are different. Primary gastric lymphoma is the second most common gastric malignancy, accounting for 35% of gas- tric cancers. More than 95% of these are non-Hodgkin B-cell lymphomas mainly consisting of either mucosa- associated lymphoid tissue (MALT)-type lymphoma and diffuse large B-cell lymphoma. Over 90% of low-grade primary gastric MALT-type lymphomas are associated with H pylori infection. Gastric T-cell lymphoma, which is associated with HTLV-1 infection, is rare and makes up 7% of primary gastric lymphomas. Clinical Findings & StagingThe  clinical presentation and endoscopic appearance of gastric lymphoma are similar to those of adenocarcinoma. Most patients have abdominal pain, weight loss, or bleed- ing. Patients with diffuse large B-cell lymphoma are more likely to have systemic symptoms and advanced tumor stage. At endoscopy, lymphoma may appear as an ulcer, mass, or diffusely infiltrating lesion. It tends to have hori- zontal infiltration as opposed to the vertical extension seen in adenocarcinoma. The diagnosis is established with endoscopic biopsy; FNA is not adequate. Since the disease can be multifocal, biopsies of both suspicious and normal- appearing areas are recommended. Biopsy specimens should be tested for H pylori and, if positive, for t(11;18) via PCR or FISH. EUS is the most sensitive test for determin- ing the level of invasion and presence of perigastric lymph- adenopathy and should be performed for accurate staging, if available. All patients should undergo staging with CT scanning of chest, abdomen, and pelvis. For gastric MALT lymphomas, the Lugano staging system is most frequently used. Stage I is confined to the gastrointestinal tract, stage II involves local or regional lymph nodes, stage IIE has invasion of adjacent organs or tissues, and stage IV has distant metastases. There is no stage III. For patients with diffuse large B-cell lymphomas involving the stomach, combination PET-CT imaging, bone marrow biopsy with aspirate, tumor lysis laboratory tests, and hepatitis B and HIV serologies also may be required for staging and treat- ment planning (see Chapter 13). TreatmentT reatment of primary gastric lymphomas depends on the tumor histology, grade, and stage. Marginal B-cell lympho- mas of the MALT type that are low-grade and localized to the stomach wall (stage I) or perigastric lymph nodes (stage IIE1) have an excellent prognosis. Patients with pri- mary gastric MALT-lymphoma should be tested for H pylori infection and treated if positive. Complete lym- phoma regression after successful H pylori eradication occurs in approximately 75% of cases of stage I and approx- imately 55% with stage IIE low-grade lymphoma. However, 95% of cancers positive for t(11;18) do not respond to antibiotics. Remission may take as long as a year, and relapse occurs in about 2% of cases per year. Many patients with minimal disease after successful H pylori eradication may be observed closely without further therapy. Restagingwith endoscopy and biopsy is recommended 3 months after antibiotic treatment and 36 months following radia- tion therapy. Ultimately, endoscopic surveillance after treatment is recommended every 36 months for 5 years to evaluate for recurrence. In patients whose tumors harbor specific gene translo- cations, including t(11;18) (API2-MALT1), t(1;14), or t(14;18), rates of remission after H pylori eradication are lower, and treatment with radiation is often required. The long-term survival of low-grade MALT lymphoma for stage I is over 90% and for stage II is 3565%. Surgical resection is not recommended. Diffuse large B-cell or other higher-grade lymphomas with secondary gastrointestinal involvement usually present at an advanced stage with widely disseminated disease and are treated according to stage and subtype of lymphoma (see Chapter 13).A vils A et al. Primary gastric diffuse large B-cell lymphoma: the role of dose-dense chemotherapy. J Oncol Pharm Pract. 2019; 25:1682. [PMID: 30370804] Jurez-Salcedo LM et al. Primary gastric lymphoma, epidemiol- ogy, clinical diagnosis, and treatment. Cancer Control. 2018;25: 1073274818778256. [PMID: 29779412] Lin JL et al. Dynamic prediction of long-term survival in patients with primary gastric diffuse large B-cell lymphoma: a SEER population-based study. BMC Cancer. 2019;19:873. [PMID: 31481021] National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. B-Cell Lymphomas. Version 1.2020. https://www.nccn.org/professionals/physician_gls/pdf/b-cell. pdf https://www.nccn.org/professionals/physician_gls/pdf/b- cell.pdf Tian C et al. A retrospective analysis of primary gastrointestinal non-Hodgkin lymphomas: clinical features, prognostic fac- tors and treatment outcomes. Onco Targets Ther. 2020;13: 5345. [PMID: 32606752]GA STRIC NEUROENDOCRINE TUMORSGastric  NETs make up less than 1% of gastric neoplasms. They may occur sporadically or secondary to chronic hypergastrinemia that results in hyperplasia and transfor- mation of enterochromaffin cells in the gastric fundus. The majority of NETs are caused by hypergastrinemia and occur in association with either pernicious anemia (75%) (type 1) or Zollinger-Ellison syndrome (5%) (type 2). Type 1 tumors are associated with chronic atrophic gastritis, gas- tric achlorhydria, and secondary hypergastrinemia. Initial diagnostic workup includes serum gastrin level, upper endoscopy, and EUS. Gastrin level should be obtained 1 week after the patient has stopped taking protein pump inhibitors. For low-grade tumors (Ki-67 less than 3% or less than 2 mitoses/10 high-power fields [HPF]), soma- tostatin receptorbased imaging (somatostatin receptor scintigraphy or gallium-68 dotatate PET/CT) should be performed. For high-grade tumors (Ki-67 greater than 20% or greater than 20 mitoses/10 HPF), FDG-PET/CT is pre- ferred to evaluate the extent of disease. For patients with hypergastrinemia (suspected of type 1 or type 2 carcinoid), serum vitamin B12and intrinsic factor antibody levels should be obtained to exclude pernicious anemia. Gastric NETs associated with Zollinger-EllisonCMDT22_Ch39_p1612-p1675.indd  1642 02/07/21 2:44 PMCANCER1643 CMDT 2022syndrom e occur almost exclusively in patients with multi- ple endocrine neoplasia type 1 (MEN 1), in which chromo- somal loss of 11q13 has been reported. Gastric NETs caused by hypergastrinemia tend to be multifocal, be smaller than 1 cm, have a low potential for metastatic spread, and thus are unlikely to cause development of the carcinoid syn- drome. Small lesions may be successfully treated with endo- scopic resection followed by endoscopic surveillance every 612 months, or with observation. Antrectomy reduces serum gastrin levels and may lead to regression of small tumors. It can be considered in patients with type 1 gastric NETs to reduce recurrence risk and frequency of post- therapy monitoring. Octreotide therapy may be appropriate for patients with underlying gastrinoma and Zollinger- Ellison syndrome. Patients with tumors larger than 2 cm should undergo endoscopic or surgical resection (see Small Intestinal Adenocarcinomas below). Type 3 gastric NETs arise sporadically, independent of gastrin production, and account for up to 20% of gastric NETs. Most sporadic gastric NETs are solitary, larger than 2 cm, and have a strong propensity for hepatic or pulmo- nary metastases and thus the carcinoid syndrome at initial presentation. CT or MRI should be obtained to evaluate for metastatic disease. Localized sporadic NETs should be treated with partial or total gastrectomy and regional lymphadenectomy. Advanced, low-grade gastric NETs can be monitored with serial scans, if asymptomatic. Soma- tostatin analogs may provide symptomatic relief for patients with functional gastric NETs. Advanced high- grade gastric neuroendocrine carcinomas are treated in a fashion similar to SCLCs.Algashaam y K et al. Multifocal G1-G2 gastric neuroendocrine tumors: differentiating between type I, II and III, a clinico- pathologic review. World J Clin Cases. 2019;7:2413. [PMID: 31559277] National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Neuroendocrine and Adrenal Tumors. Version 2.2020. 2020 July 24. https://www.nccn.org/ professionals/physician_gls/pdf/neuroendocrine.pdfGA STROINTESTINAL MESENCHYMAL TUMORS Pathobiology & DiagnosisGastroin testinal mesenchymal tumors (which include stro- mal tumors, leiomyomas, and schwannomas) derive from mesenchymal stem cells and have an epithelioid or spindle cell histologic pattern, resembling smooth muscle. The most common stromal tumors are gastrointestinal stromal tumors (GISTs), which originate from interstitial cells of Cajal. GISTs occur throughout the gastrointestinal tract, but most commonly in the stomach (60%) and small intes- tine (30%). Approximately 80% of GISTs have mutations in KIT. A percentage of the KIT wild type tumors have a mutation in PDGFRA , and only a minority of patients are wild type for both genes. Mesenchymal tumors may be discovered incidentally on imaging studies or endoscopy or may cause symptoms (most commonly bleeding, pain, or obstruction). At endoscopy, they appear as a submucosalmass that may have central umbilication or ulceration. EUS with guided FNA biopsy is the optimal study for diagnos- ing gastric mesenchymal tumors and distinguishing them from other submucosal lesions. Percutaneous biopsy may confer risk of bleeding or intra-abdominal seeding. CT of the abdomen and pelvis with contrast, MRI, and PET imaging are useful in the diagnosis and staging. PET imaging also may be useful to monitor response to treatment. While almost all GISTs have malignant potential, the risk of developing metastasis is increased with tumor size greater than 2 cm, nongastric location, and mitotic index greater than 5 mitoses per 50 HPF. It is difficult to distinguish benign from malignant tumors by EUS appearance or by FNA. But, in general, lesions are more likely benign if they are smaller than 2 cm, have a smooth border, and have a homogeneous echo pattern on EUS. Resection settles the issue. TreatmentA.  Localized TreatmentSu rgery is recommended for all patients with tumors that are 2 cm or larger, increasing in size, have an EUS appearance suspicious for malignancy, or are symptomatic. The man- agement of asymptomatic gastric lesions 2 cm or smaller in size depends on the EUS features. Tumors with high-risk EUS features can be surgically resected. If no high-risk fea- tures are noted, endoscopic surveillance can be performed. Because of the low but real long-term risk of malignancy, surgical resection should be considered in younger, other- wise healthy patients. However, other patients may be moni- tored with serial endoscopic ultrasonographic examinations or, in select cases, endoscopic resections. After complete surgical resection, the risk of GIST recurrence can be calcu- lated based on tumor location, size, and mitotic index. The majority of recurrences occur within the first 3 years.B.  Systemic TreatmentBecause  the majority of GISTs are driven by mutations in KIT orPDGFRA , the tyrosine kinase inhibitor, imatinib, which blocks signaling through this pathway, is used across disease stages. Neoadjuvant therapy with imatinib may be considered for patients with localized GIST tumors who are deemed to be at high risk for resection because of comorbidities, tumor size, or tumor location. A biopsy is required to confirm the diagnosis of GIST prior to initia- tion of neoadjuvant imatinib. Adjuvant therapy with ima- tinib delays recurrence and prolongs survival, but it is not likely to be curative. Untreated metastatic GIST tumors are aggressive and carry a poor prognosis. However, imatinib induces disease control in up to 85% of patients with metastatic disease with a progression-free survival of 2024 months and median overall survival of almost 5 years. Additionally, imatinib is associated with long-term survival in some patients. One study reported that 18% of patients contin- ued treatment after a median follow-up of 9 years. For patients with imatinib-resistant cancers, high-dose imatinib or other approved tyrosine kinase inhibitors (eg, sunitinib or regorafenib) are options.CMDT22_Ch39_p1612-p1675.indd  1643 02/07/21 2:44 PMChAPTER 391644 CMDT 2022H einrich MC et al. Avapritinib in advanced PDGFRA D842V- mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol. 2020;21: 935. [PMID: 32615108] Patel DJ et al. Adjuvant systemic therapy for intermediate and large gastric gastrointestinal stromal tumors (GISTs): is there a survival benefit following margin negative surgical resection? Am J Surg. 2020;219:436. [PMID: 31679654] von Mehren M et al. Gastrointestinal stromal tumors. J Clin Oncol. 2018;36:136. [PMID: 29220298] Wang C et al. Safety and efficiency of endoscopic resection versus laparoscopic resection in gastrointestinal stromal tumours: a systematic review and meta-analysis. Eur J Surg Oncol. 2020; 46:667. [PMID: 31864827]MA LIGNANCIES OF THE SMALL INTESTINEThe  frequency of different tumor types varies by location within the small intestine. Adenocarcinomas are most common in the duodenum and jejunum and neuroendo- crine tumors, in the ileum. Lymphomas and sarcomas each have similar incidences in the various segments of the small intestine.1.  Small Intestinal AdenocarcinomasThese  tumors often present with nonspecific symptoms such as abdominal pain and nausea. The incidence is rare, with 11,110 new diagnoses estimated in 2020 in the United States. These adenocarcinomas are most often diag- nosed at stage III or IV , but their prognosis is slightly worse than for similar stage colon adenocarcinoma. The duode- num is the most common site of small bowel adenocarci- noma, specifically in the periampullary region. Ampullary carcinoma may present with jaundice due to bile duct obstruction or bleeding. Surgical resection of early lesions is curative in up to 40% of patients. The management of nonampullary small intestinal adenocarcinoma is extrapolated from data available for the management of colon adenocarcinoma.2.  Small Intestinal LympomasL ymphomas may arise primarily in the gastrointestinal tract or may involve it secondarily in patients with dissemi- nated disease. In Western countries, primary gastrointesti- nal lymphomas account for 5% of lymphomas and 20% of small bowel malignancies. There is an increased incidence of small intestinal lymphomas in patients with AIDS, Crohn disease, and those receiving immunosuppressive therapy. The most common histologic subtype is non- Hodgkin extranodal marginal zone (MALT) B-cell lymphoma. That said, enteropathy-associated T-cell lym- phomas appear to be increasing in incidence in the United States. They are associated with the diagnosis of celiac disease. In the Middle East, lymphomas may arise in the setting of immunoproliferative small intestinal disease. Other types of intestinal lymphomas include primary intestinal follicular cell lymphoma, mantle cell lymphoma, and Burkitt lymphoma (see Chapter 13). Presenting symptoms or signs of primary small bowel lymphoma include abdominal pain, weight loss, nausea and vomiting, distention, anemia, and occult blood in thestool. Fevers are unusual. Protein-losing enteropathy may result in hypoalbuminemia, but other signs of malabsorption are unusual. Barium radiography or CT enterography helps localize the site of the lesion. The diagnosis requires endo- scopic, percutaneous, or laparoscopic biopsy. Imaging and possibly bone marrow biopsy are required to determine stage. Treatment depends on the tumor histologic subtype and stage of disease (see Chapter 13). If feasible, surgical resec- tion of primary intestinal lymphoma, may be appropriate for localized tumors. In patients with limited disease (stage IE) in whom resection is performed with negative margins, the role of adjuvant chemotherapy is unclear. Locoregional radiation should be considered if surgical margins are posi- tive. Patients with more extensive disease generally are treated according to the tumor histology.3.  Intestinal Neuroendocrine TumorsE S S E N T I A L S  O F  D I A G N O S I S Majority are asymptomatic and discovered inci- dentally at endoscopy or surgery. Carcinoid syndrome occurs in < 10%; hepatic metastases are generally present. Risk of metastasis is related to tumor size and location. General ConsiderationsNeur oendocrine tumors are the most common type of tumor arising in the small bowel. Gastrointestinal NETs (also called carcinoids) most commonly occur in the small intestine (45%) but are also found in the rectum (20%), appendix (17%), and colon (11%), with the remainder occurring in the stomach (less than 10%; see Gastric Neu- roendocrine Tumors above). Carcinoid tumors are well- differentiated neuroendocrine tumors that may secrete a variety of hormones, including serotonin, somatostatin, gastrin, and substance P . Small intestinal carcinoids most commonly arise in the distal ileum within 60 cm of the ileocecal valve. Up to 30% are multicentric. The risk of metastatic spread increases when the tumor is 1 cm or larger and when it is larger than 2 cm with invasion beyond the muscularis propria. Appen- diceal carcinoids are identified in 0.3% of appendectomies, usually as an incidental finding. Almost 80% of these tumors are smaller than 1 cm, and 90% are smaller than 2 cm. However, in patients with appendiceal carcinoid tumors larger than 2 cm, approximately 90% develop nodal and distant metastases; right hemicolectomy is recom- mended in these cases. Rectal carcinoids are usually detected incidentally as submucosal nodules during proctoscopic examination and often locally excised by biopsy or snare polypectomy before the histologic diagnosis is known. Rectal carcinoids smaller than 1 cm virtually never metastasize and are treated effec- tively with local endoscopic or transanal excision. Larger tumors are associated with the development of metastasisCMDT22_Ch39_p1612-p1675.indd  1644 02/07/21 2:44 PMCANCER1645 CMDT 2022in  10%. Hence, a more extensive cancer resection operation is warranted in fit patients with rectal carcinoid tumors larger than 12 cm or with high-risk features (such as inva- sion of muscularis propria or evidence of nodal involve- ment), or both. Clinical FindingsA.  Symptoms and SignsMos t lesions smaller than 12 cm are asymptomatic and difficult to detect by endoscopy or imaging studies. Small intestinal carcinoids may present with intermittent abdom- inal pain, bowel obstruction, bleeding, or bowel infarction. Appendiceal and rectal carcinoids usually are small and asymptomatic, but large lesions can cause bleeding, obstruction, or altered bowel habits. Carcinoid syndrome occurs in less than 10% of patients. More than 90% of patients with carcinoid syndrome have hepatic metastases, usually from carcinoids of small bowel origin. About 10% of patients with carcinoid syndrome have primary bron- chial or ovarian tumors without hepatic metastases. Carci- noid syndrome is caused by tumor secretion of hormonal mediators. The manifestations include facial flushing, edema of the head and neck (especially with bronchial carcinoid), abdominal cramps and diarrhea, broncho- spasm, cardiac lesions (pulmonary or tricuspid stenosis or regurgitation in 1030%), and telangiectases.B.  Laboratory FindingsSerum  chromogranin A is elevated in the majority of NETs, although its sensitivity for small, localized carcinoid tumors is unknown. Serum chromogranin A is elevated in almost 90% of patients with advanced small bowel carcinoid. Urinary 5-hydroxyindoleacetic acid (5-HIAA) and platelet serotonin levels are also elevated in patients with metastatic carcinoid; however, these tests are less sensitive than serum chromogranin A. There is increased urinary 5-HIAA in carcinoid syndrome; symptomatic patients usually excrete more than 25 mg of 5-HIAA per day in the urine. Because certain foods and medications can interfere with 5-HIAA levels, these should be withheld for 48 hours prior to a 24-hour urine collection.C.  ImagingAbdo minal CT may demonstrate a mesenteric mass with tethering of the bowel, lymphadenopathy, and hepatic metastasis. Abdominal CT or enterography may reveal kinking of the bowel, but because the lesion is extralumi- nal, the diagnosis may be overlooked for several years. Gallium Ga-68 DOTATATE PET scan has replaced soma- tostatin receptor scintigraphy as the standard of care for staging; however, both may help identify disease that may benefit from treatment with somatostatin analogs or pep- tide receptor radionuclide therapy (PRRT). Treatment & OutcomesSmall  intestinal carcinoids generally are indolent tumors with slow spread. Patients with disease confined to the small intestine should be treated with surgical excision.There is no proven role for adjuvant therapy after complete resection. Five-year survival rates for patients with stage I and II disease are 96% and 87%, respectively. In patients with resectable disease who have lymph node involvement (stage III), the 5-year survival rate is 74%; however, by 25 years, less than 25% remain disease free. Across stages, prognosis is strongly associated with histologic differentia- tion and grade. Patients with grade 1 disease may not require treatment for many years even with metastatic disease. However, patients with a grade 3 neuroendocrine tumor may have a clinical course more similar to a high- grade neuroendocrine carcinoma. In patients with advanced disease, therapy historically has been deferred until the patient is symptomatic. Con- ventional cytotoxic chemotherapy agents do not achieve significant responses in carcinoid tumors and have not been associated with improved outcomes. For patients who are symptomatic either from tumor bulk or carcinoid syn- drome, the cornerstone of therapy is typically a long-acting somatostatin analog, which inhibits hormone secretion from the carcinoid tumor. In 90% of patients, this results in dramatic relief of symptoms of carcinoid syndrome, includ- ing diarrhea or flushing, and may also control tumor growth for a median period of 1 year. Options at disease progression include octreotide dose escalation, or addition of everolimus, a mammalian target of rapamycin (mTOR) inhibitor. For patients with somatostatin receptorpositive disease based on imaging, another option after progression is treatment with PRRT. PRRT consists of a somatostatin analog conjugated to a radioactive isotope such as yttrium-90 or lutetium-177. Studies of anti-angiogenic kinase inhibitors have shown some benefit; currently, suni- tinib is approved in the United States for pancreatic neuro- endocrine tumors. In selected patients with hepatic-dominant disease, resection of hepatic metastases may provide dramatic improvement in carcinoid syndrome symptoms. Tumor debulking with liver-directed chemoembolization or radio- embolization may also provide symptomatic improvement in some of these patients. Patients with advanced, poorly differentiated intestinal NETs are treated in a similar fashion to those with small cell carcinomas. They have a poor prognosis.4.  Small Intestine SarcomaSarco mas constitute approximately 10% of small bowel neoplasms and are commonly found in the jejunum and ileum (and in a Meckel diverticulum, if present). Most arise from stromal tumors (GISTs) that stain positive for CD117; a minority arise from smooth muscle tumors (leiomyosar- comas) (see Gastrointestinal Mesenchymal Tumors above). Common symptoms of small intestine sarcoma include pain, weight loss, bleeding, and perforation. As the lesions tend to enlarge extraluminally, obstruction is rare. Kaposi sarcoma was at one time a common complica- tion in AIDS, but the incidence is declining with antiretro- viral therapy. It can also occur in the setting of immunosuppression after organ transplantation. It is caused by infection with human herpesvirus 8 (HHV8). Lesions may be present anywhere in the intestinal tract.CMDT22_Ch39_p1612-p1675.indd  1645 02/07/21 2:44 PMChAPTER 391646 CMDT 2022V isceral involvement usually is associated with cutaneous disease. Most lesions are clinically silent; however, large lesions may be symptomatic. Widespread involvement may be best treated by systemic chemotherapy using single- agent therapy or combinations of pegylated-doxorubicin, paclitaxel, vincristine, bleomycin, or etoposide. Surgery or radiation may be indicated for isolated high-risk lesions.Akce  M et al. Clinical outcomes of small bowel adenocarcinoma. Clin Colorectal Cancer. 2019;18:257. [PMID: 31606297] Bonds M et al. Neuroendocrine tumors of the pancreaticobiliary and gastrointestinal tracts. Surg Clin North Am. 2020;100:635. [PMID: 32402306] Lee MR et al. Incidence trends of gastroenteropancreatic neuro- endocrine tumors in the United States. Clin Gastroenterol Hepatol. 2019;17:2212. [PMID: 30580091] National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Small Bowel Adenocarcinoma. Ver- sion 2.2020. 2020 May 6. https://www.nccn.org/professionals/ physician_gls/pdf/small_bowel.pdf Scott AT et al. Management of small bowel neuroendocrine tumors. J Oncol Pract. 2018;14:471. [PMID: 30096273]COLOR ECTAL CANCERE S S E N T I A L S  O F  D I A G N O S I S Personal or family history of adenomatous or ser- rated polyps or colorectal cancer are important risk factors. Symptoms or signs depend on tumor location. Proximal colon: fecal occult blood, anemia. Distal colon: change in bowel habits, hematochezia. Diagnosis established with colonoscopy. General ConsiderationsColor ectal cancer is the second leading cause of death due to malignancy in the United States. Colorectal cancer will develop in approximately 4.2% of Americans and has a 5-year survival rate of 65%. In 2020, there were an estimated 147,950 new cases of colorectal cancer in the United States, with an estimated 53,200 deaths. Between 1996 and 2010, its mortality rate decreased by 46%. A 2015 National Health Interview Survey estimated that 62% of US adults have undergone recommended screening. On average, new cases have been falling 3.2% each year over the last 10 years. Colorectal cancers are almost all adenocarcinomas, which tend to form bulky exophytic masses or annular constricting lesions. The majority of colorectal cancers are thought to arise from malignant transformation of an adenomatous polyp (tubular, tubulovillous, or villous ade- noma) or serrated polyp (hyperplastic polyp, traditional serrated adenoma, or sessile serrated adenoma). Polyps that are advanced (ie, polyps at least 1 cm in size, adeno- mas with villous features or high-grade dysplasia, or ser- rated polyps with dysplasia) are associated with a greaterrisk of cancer. Approximately 85% of sporadic colorectal cancers arise from adenomatous polyps. They have loss of function of one or more tumor suppressor genes (eg, p53, APC, orDCC ) due to a combination of spontaneous muta- tion of one allele combined with chromosomal instability and aneuploidy (abnormal DNA content) that leads to dele- tion and loss of heterozygosity of the other allele (eg, 5q, 17q, or 18p deletion). Activation of oncogenes such as KRAS and BRAF is present in a subset of colorectal cancers with prog- nostic and therapeutic implications discussed further below. Approximately 1020% of colorectal cancers arise from serrated polyps, most of which have hypermethylation of CpG-rich promoter regions that leads to inactivation of the DNA mismatch repair gene MLH1, resulting in MSI, and activation of mutations of the BRAF gene. Serrated colon cancers have distinct clinical and pathologic characteris- tics, including diploid DNA content, predominance in the proximal colon, poor differentiation, and more favorable prognosis. Up to 5% of colorectal cancers are caused by inherited germline mutations resulting in polyposis syndromes (eg, familial adenomatous polyposis) or hereditary nonpolypo- sis colorectal cancer (HNPCC or Lynch syndrome). These conditions are discussed further in Chapter 15. Risk FactorsA n umber of factors increase the risk of developing colorec- tal cancer. Some of these factors include smoking, consump- tion of red and processed meats, alcohol intake, diabetes mellitus, physical inactivity, obesity, and history of inflam- matory bowel disease. Recognition of these factors has had an impact on screening strategies. However, 75% of all cases occur in people with no known predisposing factors.A.  AgeThe  incidence of colorectal cancer rises sharply after age 45 years, and 90% of cases occur in persons over the age of 50 years. The median age at diagnosis is 68 for men and 72 for women. Over the past two decades there has been a 20% decrease in incidence among adults over age 50 (likely due to colorectal cancer screening programs) but a 50% increase in incidence among adults under age 50 (espe- cially in the distal colon and rectum). The incidence of young adultonset colorectal cancer is rising in all racial and ethnic groups but is highest in Blacks. In the United States, the colorectal cancer incidence rates in adults over age 50 is 40/100,000 and is 12.2/100,000 in adults younger than age 50. It is estimated that by 2030, 10% of colon cancer and 20% of rectal cancers will occur in patients under the age of 50. The reason for the increase in colorectal cancer incidence among adults under age 50 is uncertain.B.  Family History of NeoplasiaA family history of colorectal cancer is presen t in approxi- mately 20% of patients with colon cancer. Hereditary fac- tors are believed to contribute to 2030% of colorectal cancers; however, the genes responsible for most of these cases have not yet been identified. Hereditary cancerCMDT22_Ch39_p1612-p1675.indd  1646 02/07/21 2:44 PMCANCER1647 CMDT 2022syndromes  (Lynch syndrome or polyposis syndromes) account for approximately 34% of colorectal cancers in patients 50 years or older but 1015% of patients with young adultonset colorectal cancer (see Chapter 15). Approximately 6% of the Ashkenazi Jewish population has a missense mutation in the APC gene (APC I1307K) that confers a modestly increased lifetime risk of developing colorectal cancer (odds ratio [OR] 1.41.9) that phenotypi- cally resembles sporadic colorectal cancer rather than familial adenomatous polyposis. Genetic screening is avail- able, and patients harboring the mutation merit more intensive colorectal screening. A family history of colorectal cancer or adenomatous polyps is one of the most important risk factors for colorec- tal cancer. The risk of colon cancer is proportionate to the number and age of affected first-degree family members with colon neoplasia. People with one first-degree family member with colorectal cancer have an increased risk approximately two times that of the general population; however, the risk is almost four times if the family member was younger than 45 years when the cancer was diagnosed. Patients with two first-degree relatives have a fourfold increased, or 2530% lifetime, risk of developing colon can- cer. First-degree relatives of patients with adenomatous pol- yps also have a twofold increased risk for colorectal neoplasia, especially if they were younger than 60 years when the polyp was detected or if the polyp was 10 mm or larger.C.  Inflammatory Bowel DiseaseThe  risk of adenocarcinoma of the colon begins to rise 8 years after disease onset in patients with ulcerative colitis and Crohn colitis (see Chapter 15). For this reason, initia- tion of surveillance with colonoscopy is recommended at 810 years after onset of inflammatory bowel disease symptoms.D . Dietary and Lifestyle Factors and ChemopreventionIn  epidemiologic studies, diets rich in fats and red meat are associated with an increased risk of colorectal adenomas and cancer, whereas diets high in fruits, vegetables, and fiber are associated with a decreased risk. However, pro- spective studies have not shown a reduction in colon can- cer or recurrence of adenomatous polyps with diets that are low in fat; that are high in fiber, fruits or vegetables; or that include calcium, folate, beta-carotene, or vitamin A, C, D, or E supplements. Meta-analyses suggest that individuals with increased physical activity are up to 27% less likely to develop colon cancer. There also is a correlation between increasing body mass index and cancer risk, such that for each increase of 5 kg/m2in BMI, there is a 5% increased cancer risk. Patients with higher levels of pre- and post-diagnosis physical activ- ity experience reduced colorectal cancerspecific mortality and all-cause mortality. Maintaining a healthy body weight, a healthy diet, and a physically active lifestyle are recom- mended in colorectal cancer survivors. Low-dose aspirin has been associated with a reduced risk of colorectal adenomas and cancer in multiple studies.A 2016 USPSTF systematic review of controlled trials con- cluded that prolonged regular use of low-dose aspirin (81 mg/day) is associated with a 40% reduction in colorectal cancer incidence after 10 years and a 33% reduction in colorectal cancer mortality after 20 years. Because long- term aspirin use is associated with a low incidence of seri- ous complications (gastrointestinal hemorrhage, stroke), low-dose aspirin should not be routinely administered as a chemopreventive agent without other medical indications. Low-dose aspirin may also be considered in patients with a personal or family history of colorectal cancer or advanced adenomas; however, its administration does not obviate the need for colonoscopy screening and surveillance.E.  Other FactorsThe  overall incidence of colorectal cancer is similar in men and women; however, similar incidence rates are reached in women about 46 years later than in men. A higher proportion of cancers are located in the proximal colon in women (46%) than men (37%). The incidence and mortal- ity of colon adenocarcinoma is higher in Blacks and Native Americans than in Whites. It is unclear whether this is due to genetic or socioeconomic factors (eg, diet or reduced access to medical care). Clinical FindingsA.  Symptoms and SignsAdenocar cinomas grow slowly and may be present for several years before symptoms appear. However, some asymptomatic tumors may be detected by the presence of fecal occult blood (see Screening for Colorectal Neo- plasms, below). Symptoms depend on the location of the carcinoma. Chronic blood loss from right-sided colonic cancers may cause iron deficiency anemia, manifested by fatigue and weakness. Obstruction, however, is uncommon because of the large diameter of the right colon and the liquid consistency of the fecal material. Lesions of the left colon often involve the bowel circumferentially. Because the left colon has a smaller diameter and the fecal matter is solid, obstructive symptoms may develop with colicky abdominal pain and a change in bowel habits. Constipation may alternate with periods of increased frequency and loose stools. The stool may be streaked with blood, though marked bleeding is unusual. With rectal cancers, patients note tenesmus, urgency, and recurrent hematochezia. Physical examination is usually normal except in advanced disease. The liver should be examined for hepatomegaly, suggesting metastatic spread. For cancers of the distal rec- tum, digital examination is necessary to determine whether there is extension into the anal sphincter or fixation, sug- gesting extension to the pelvic floor.B.  Laboratory FindingsA  CBC should be obtained to look for anemia. Elevated liver biochemical tests raise suspicion of metastatic disease. The serum carcinoembryonic antigen (CEA) should be measured in all patients with proven colorectal cancer but is not appropriate for screening. The CEA is not elevated inCMDT22_Ch39_p1612-p1675.indd  1647 02/07/21 2:44 PMChAPTER 391648 CMDT 2022man y patients with confirmed colorectal cancer; con- versely, the CEA may be elevated in active smokers and those with a variety of other nonmalignant conditions. A preoperative CEA level greater than 5 ng/mL is a poor prognostic indicator. After complete surgical resection, CEA levels should normalize; persistently elevated levels suggest the presence of persistent disease and warrant fur- ther evaluation. CEA is routinely monitored at the time of adjuvant therapy and during postoperative surveillance for patients who had elevated levels before resection.C.  ColonoscopyColo noscopy is the required diagnostic procedure in patients with a clinical history suggestive of colorectal cancer or in patients with an abnormality suspicious for cancer detected on radiographic imaging. Colonoscopy and upper endos- copy should be considered in all adults with new-onset iron deficiency anemia. Colonoscopy permits biopsy for patho- logic confirmation of malignancy.D . ImagingChes t, abdominal, and pelvic CT scans with contrast are required for preoperative staging. CT scans may demon- strate distant metastases but are less accurate in the determi- nation of the level of local tumor extension (T stage) or lymphatic spread (N stage). Intraoperative assessment of the liver by direct palpation and ultrasonography can be per- formed to detect hepatic metastases (M stage). For rectal cancers (generally defined as tumors arising 12 cm or less proximal to the anal verge), pelvic MRI or endorectal ultra- sonography is required to determine the depth of penetra- tion of the cancer through the rectal wall (T stage) and perirectal lymph nodes (N stage), informing decisions about preoperative (neoadjuvant) chemoradiotherapy and opera- tive management. PET is not routinely used for staging or surveillance in colorectal cancers. StagingThe  TNM system is the commonly used classification to stage colorectal cancer. Staging is important not only because it correlates with the patients long-term survival but also because it is used to determine which patients should receive adjuvant or neoadjuvant therapy. Differential DiagnosisThe  nonspecific symptoms of colorectal cancer may be con- fused with those of irritable bowel syndrome, diverticular disease, ischemic colitis, inflammatory bowel disease, infec- tious colitis, and hemorrhoids. Neoplasm must be excluded in any patient over age 40 years who reports a change in bowel habits or hematochezia or who has an unexplained iron deficiency anemia or occult blood in stool samples. TreatmentA.  Colon CancerSurgical resection  of the colonic tumor is the treatment of choice for almost all patients. It may be curative in patientswith stage I, II, and III disease and even some patients with metastatic (stage IV) disease. Multiple studies demonstrate that minimally invasive, laparoscopically assisted colec- tomy results in similar outcomes and rates of recurrence to open colectomy. Regional dissection of at least 12 lymph nodes should be performed to determine staging, which guides decisions about adjuvant therapy. Following com- plete endoscopic removal of an adenomatous polyp (polyp- ectomy) that is found on pathologic review to contain a focus of cancer (malignant polyp), observation is a reason- able alternative to further surgical resection in carefully selected patients with invasion into the submucosa (T1 disease). Pathology review of colorectal cancers should include testing for mismatch repair proteins for all patients. Tumors of patients with metastatic colorectal cancer should also be tested for extended RAS andBRAF mutations. Following surgical resection, chemotherapy has been demonstrated to improve overall and tumor-free survival in select patients with colon cancer depending on stage (Table 392). 1. Stage I Because of the excellent 5-year survival rate (approximately 92%), no adjuvant therapy is recommended for stage I colon cancer. 2. Stage II node-negative disease The 5-year survival rate is approximately 87% for stage IIA disease and 63% for stage IIB disease. A significant survival benefit from adju- vant chemotherapy has not been demonstrated in most randomized clinical trials for stage II colon cancer (see discussion for stage III disease). However, otherwise healthy patients with stage II disease who are at higher risk for recurrence (perforation; obstruction; close or indeter- minate margins; poorly differentiated histology; lymphatic, vascular, or perineural invasion; T4 tumors; or fewer than 12 lymph nodes sampled) may benefit from adjuvant che- motherapy. Patients whose tumors reveal MSI have a more favorable prognosis and do not benefit from 5-fluorouracil- based adjuvant therapy. 3. Stage III node-positive disease With surgical resec- tion alone, the expected 5-year survival rate is 3050%. Postoperative adjuvant chemotherapy significantly increases disease-free survival as well as overall survival by up to 30% and is recommended for all fit patients (Table 392). Multiple large, well-designed studies of adjuvant therapy for stage III colorectal cancer have reported a higher rate of disease-free survival at 5 years for patients treated for 6 months postoperatively with a combination of oxalipla- tin, 5-fluorouracil, and leucovorin (FOLFOX) (73.3%) than with 5-fluorouracil and leucovorin (FL) alone (67.4%). Similar benefit was reported for patients treated with oxali- platin and capecitabine (orally active fluoropyrimidine). A large international randomized controlled trial com- paring 3 months with 6 months of adjuvant therapy for colon cancer found that 3 months of adjuvant therapy resulted in equivalent disease-free survival for patients with earlier stage T1, T2, or T3, and N1 disease but not with more advanced T4 or N2 disease. For patients with high-risk disease (T4 or N2), 6 months of adjuvant che- motherapy are still recommended. The addition of aCMDT22_Ch39_p1612-p1675.indd  1648 02/07/21 2:44 PMCANCER1649 CMDT 2022biologic  agent (bevacizumab or cetuximab) to adjuvant chemotherapy does not improve outcomes. 4. Stage IV metastatic disease Approximately 20% of patients have metastatic disease at the time of initial diag- nosis, and an additional 30% eventually develop metastasis. A subset of these patients has limited disease that is poten- tially curable with surgical resection. Surgery may also be warranted to provide palliation of tumor bleeding or obstruction. Resection of isolated liver metastases may result in long-term (over 5 years) survival in 3555% of cases. For those with unresectable hepatic metastases, local ablative techniques (cryosurgery, radiofrequency or micro- wave coagulation, embolization, hepatic intra-arterial che- motherapy) or radiation may provide long-term tumor control. A subset of patients who have isolated pulmonary metastases may undergo resection or radiation with poten- tial cure. In the absence of other treatment, the median survival is less than 12 months; however, with current therapies, median survival approaches 30 months. Primary cancer location has been found to have a potential prog- nostic importance: median survival times are 33.3 months for patients with left-sided colon cancers compared to 19.4 months for those with right-sided cancers. The goals of therapy for patients with metastatic colorectal cancer are to slow tumor progression while maintaining a reasonable quality of life for as long as pos- sible. Currently, either FOLFOX (the addition of oxalipla- tin to 5-fluorouracil and folinic acid) or FOLFIRI (the addition of irinotecan to 5-fluorouracil and folinic acid) is the preferred first-line treatment regimen for fit patients. For convenience, oral capecitabine (instead of intravenous 5-fluorouracil and leucovorin) can be used in combination with oxaliplatin since it has similar efficacy to 5-fluorouracil; however, combination with irinotecan is not recommended due to increased toxicity (diarrhea). Addition of a biologic agent to combination chemotherapy improves response rates and overall survival and is recommended in the first line of treatment in suitable patients. Bevacizumab is a monoclonal antibody targeting VEGF. Combination of bevacizumab with FOLFOX or FOLFIRI prolongs mean survival by 25 months compared with either regimen alone. Cetuximab and panitumumab are monoclonal anti- bodies targeting EGFR. Activating K-ras gene mutations downstream of EGFR are present in approximately 35% of patients with metastatic colorectal cancer and are a bio- marker for nonresponse to cetuximab and panitumumab, for which reason the use of these agents is restricted to patients with tumors wild-type for K-ras. Mutations in N-ras and BRAF are also predictive of nonresponse to EGFR inhibition alone. In stage IV patients with K-ras wild-type cancers, the addition of panitumumab or cetux- imab to FOLFOX or FOLFIRI prolongs survival by approx- imately 4 months. When disease progresses despite treatment either with FOLFOX or with FOLFIRI (often in conjunction with bevacizumab or an EGFR-targeted antibody), therapy is switched to the alternate regimen. Although the ideal sequence of agents is not known, patients do benefit from exposure to all available therapies. Clinical trial participa- tion should be considered for eligible patients who areintolerant of or ineligible for standard therapies or in whom disease has progressed.B.  Rectal CancerThe  treatment approach to rectal cancer is guided by clinical staging as determined by colonoscopy and endorectal ultrasound or MRI with endorectal coil. In carefully selected patients with small (less than 4 cm), mobile, well-differentiated T1 rectal cancers that are less than 8 cm from the anal verge, transanal endoscopic or surgical excision may be considered. All other patients with rectal cancer require either a low anterior resection with a colorectal anastomosis or an abdominoperineal resection with a colostomy, depending on how far above the anal verge the cancer is located and the extent of local tumor spread. For invasive rectal carcinoma, preoperative (neoadju- vant) therapy with radiation or chemoradiation, with or without postoperative (adjuvant) therapy with chemother- apy or chemoradiation, is generally recommended in all node-positive tumors and in T3 and greater tumors due to increased risk of local recurrence. The choice and timing of radiation and chemotherapy depend on a host of factors. Neoadjuvant chemoradiation has become the preferred standard in many centers because chemotherapy is more tolerable prior to surgery, leads to improved local control, and may result in improved long-term survival. For patients with clinical node-positive disease, a bulky primary cancer (T4), or a low-lying cancer that will require a permanent colostomy, giving all chemotherapy in the neoadjuvant set- ting (total neoadjuvant therapy) is now an option in NCCN guidelines. After neoadjuvant therapy, the operative approach (low anterior resection versus abdominoperineal resection with colostomy) depends on how far above the anal verge the cancer is located, its size and depth of penetration, and the patients overall condition. Careful dissection of the entire mesorectum by either open or laparoscopic surgery reduces local recurrence to 5%. Although low anterior resections obviate a colostomy, they are associated with increased immediate postsurgical complications (eg, leak, dehis- cence, stricture) and long-term defecatory complaints (eg, increased stool frequency, and incontinence). With unre- sectable rectal cancer, the patient may be palliated with a diverting colostomy. Follow-Up After SurgeryColorectal cancer p atients who have undergone resections for cure are monitored closely to look for evidence of symptomatic or asymptomatic tumor recurrence that may occasionally be amenable to curative resection. Patients should be evaluated every 36 months for 2 years and then every 6 months for a total of 5 years with history, physical examination, and laboratory surveillance, including serum CEA levels if baseline levels are elevated. The NCCN and ASCO guidelines recommend surveillance contrast CT scans of chest, abdomen, and pelvis up to every 612 months for up to 5 years post-resection in high-risk stage II and all stage III patients. Patients who had aCMDT22_Ch39_p1612-p1675.indd  1649 02/07/21 2:44 PMChAPTER 391650 CMDT 2022comple te preoperative colonoscopy should undergo another colonoscopy 1 year after surgical resection. Patients who did not undergo full colonoscopy preopera- tively also should undergo a full colonoscopy after comple- tion of all adjuvant therapy to exclude other synchronous colorectal neoplasms. If a colonoscopy does not detect new adenomatous polyps 1 year postoperatively, surveillance colonoscopy should be performed every 35 years thereaf- ter to look for metachronous polyps or cancer. New onset of symptoms or a rising CEA warrants investigation with chest, abdominal, and pelvic CT and colonoscopy to look for a new primary tumor or recurrence, or metachronous metastatic disease that may be amenable to curative or pal- liative therapy. The majority of colorectal cancer recur- rences occur within 3 years of the conclusion of treatment, and almost all (greater than 90%) occur within 5 years. PrognosisThe  stage of disease at presentation remains the most important determinant of 5-year survival in colorectal cancer, which is estimated in older registries as: stage I, greater than 90%; stage II, 7085%; stage III with fewer than 4 positive lymph nodes, 67%; stage III with more than 4 positive lymph nodes, 33%; and stage IV , 57%. Long- term registry follow-up data from the modern chemo- therapy era are not yet available. For each stage, rectal cancers have a worse prognosis. For those patients whose disease progresses despite therapy, meticulous efforts at palliative care are essential (see Chapter 5). Screening for Colorectal NeoplasmsColorectal can cer is ideal for screening because it is a com- mon disease that is fatal in almost 50% of cases and yet is curable if detected at an earlier stage. Furthermore, most cases arise from benign adenomatous or serrated polyps that progress over many years to cancer, and removal of these polyps has been shown to prevent the majority of cancers. Colorectal cancer screening is endorsed by the USPSTF, the Agency for Health Care Policy and Research, the American Cancer Society, and every professional gas- troenterology and colorectal surgery society. Although there is continued debate about the optimal cost-effective means of providing population screening, there is now almost unanimous consent that screening of some kind should be offered to all adults ages 4575 years. The 2018 American Cancer Society recommendations for screening and 2020 USPSTF draft recommendations for screening are listed in Table 396. Due to a rising incidence of colorectal cancer in adults younger than 50 years, the 2020 USPSTF and 2018 American Cancer Society guidelines both endorse consideration of screening in asymptomatic, average-risk adults beginning at age 45; however, the cost- effectiveness of this strategy is uncertain. It is important for primary care providers to understand the relative merits of various options and to discuss them with their patients. The potential for harm from screening must be weighed against the likelihood of benefit, especially in elderly patients with comorbid illnesses and shorter life expec- tancy. Although routine screening is not recommended inadults above age 75, it may be considered on a case-by-case basis in adults age 76 through 85 years who have excellent health and functional status. Patients with first-degree relatives with colorectal neo- plasms (cancer or adenomatous polyps) are at increased risk. Therefore, most guidelines recommend initiating screening at age 4050 years (or 10 years younger than the familial diagnosis) in individuals with first-degree relatives with colorectal cancer or with advanced adenomas. Rec- ommendations for screening in families with inherited cancer syndromes or inflammatory bowel disease are pro- vided in Chapter 15. Screening tests may be classified into two broad catego- ries: stool-based tests and examinations that visualize the structure of the colon by direct endoscopic inspection or radiographic imaging.A.  Stool-Based Tests1.  Fecal occult blood test Most colorectal cancers and some large adenomas result in increased chronic blood loss. A variety of tests for fecal occult blood are commer- cially available that have varying sensitivities and specifici- ties for colorectal neoplasia. These include guaiac-based fecal occult blood tests (gFOBT) (eg, Hemoccult I and II and Hemoccult SENSA) that detect the pseudoperoxidase activity of heme or hemoglobin and fecal immunochemical tests (FITs) that detect human globin. In clinical trials, FITsTable 396. Recommendations for colorectal cancer screening,1based on updated draft 2020 US Preventive Services Task Force and 2018 American Cancer Society recommendations.2Av erage-risk individuals  45 years old2 Annual fecal occult blood testing using higher sensitivity tests (Hemoccult SENSA) Annual fecal immunochemical test (FIT) Fecal DNA test (interval uncertain) Flexible sigmoidoscopy every 5 years Colonoscopy every 10 years CT colonography every 5 years Individuals wit a family istory of a first-degree member wit colorectal neoplasia3 Single first-degree relative wit colorectal cancer diagnosed at age 60 years or older: Begin screening at age 40. Screen- ing guidelines same as average-risk individual; however, preferred method is colonoscopy every 10 years. Single first-degree relative wit colorectal cancer or advanced adenoma diagnosed before age 60 years, or two first-degree relatives: Begin screening at age 40 or at age 10 years younger than age at diagnosis of the youngest affected relative, whichever is first in time. Recommended screening: colonoscopy every 5 years.1 For recommendations for families with inherited polyposis syn- dromes or hereditary nonpolyposis colon cancer, see Chapter 15.2 The American Cancer Society recommends screening of average- risk adults from age 45 to 75; the US Preventive Services Task Force recommends screening of all adults ages 5075 (Grade A recom- mendation) and ages 4559 (Grade B). Both recommend screen- ing in selected patients ages 7685 based on life expectancy, patient preferences, overall health, and prior screening results.CMDT22_Ch39_p1612-p1675.indd  1650 02/07/21 2:44 PMCANCER1651 CMDT 2022have  proven superior to gFOBT in sensitivity for detection of colorectal cancer and advanced adenomas with similar specificity. Because FITs are not affected by diet or medica- tions and have superior accuracy, the USMSTF now rec- ommends their use instead of gFOBT. In 19 clinical studies, the pooled sensitivity and specificity of FIT for colorectal cancer in average-risk patients were 79% and 94%, respectively. FIT testing is the preferred option for population-based screening in various European and Australian programs. In the United States, it is offered as the preferred option by many health care plans. For health care systems in which screening colonoscopy is readily available, FIT is a suitable option for patients seeking a noninvasive screening test who are willing to undertake annual fecal testing. The opti- mal interval (yearly or every 2 years) and number of stool samples (one or two) required for optimal FIT testing is as yet undetermined, but currently annual testing is recom- mended. Patients with a positive FIT test must undergo further evaluation with colonoscopy. 2. Multitarget DNA assay Stool DNA tests measure a variety of mutated genes and methylated gene markers from exfoliated tumor cells. A newer-generation assay (Cologuard) combines a fecal DNA panel with a FIT. In a prospective comparative trial conducted in persons at aver- age risk for colorectal cancer undergoing colonoscopy, the sensitivity for colorectal cancer for Cologuard was 92.3% vs 73.8% for FIT alone and the sensitivity for adenomas larger than 1 cm or serrated polyps for Cologuard was 42.4% vs 23.8% for FIT alone. A positive stool DNA test requires colonoscopy evaluation. Compared with FIT testing alone, FIT-fecal DNA testing has disadvantages including higher cost, lower specificity, lower cost-effectiveness, and cum- bersome requirements for stool collection and mailing.B.  Endoscopic Examinations of the Colon1.  Colonoscopy Colonoscopy permits examination of the entire colon. In addition to detecting early cancers, colo- noscopy allows removal of adenomatous polyps by biopsy or polypectomy, which is believed to reduce the risk of subsequent cancer. Over the past decade, there has been a dramatic increase in screening colonoscopy, with over 60% of US adults screened in the past 10 years. In asymptomatic individuals between 50 and 75 years of age undergoing screening colonoscopy, the prevalence of advanced colonic neoplasia is 411% and of colon cancer is 0.11%. Although colonoscopy is believed to be the most sensi- tive test for detecting adenomas and cancer, it has several disadvantages. Adequate visualization of the entire colonic mucosa requires thorough bowel cleansing the evening and morning prior to the examination. To alleviate discomfort during the procedure, intravenous sedation is used for most patients, necessitating a companion to transport the patient home post-procedure. Serious complications occur uncommonly; they include perforation (0.1%), bleeding (0.25%), and death (2.9/100,000). The skill of the operator has a major impact upon the quality of the colonoscopy examination. In several studies, the rate of colorectal cancer within 3 years of a screeningcolonoscopy was 0.70.9%, ie, approximately 1 in 110 patients. Population-based case-control and cohort studies suggest that colonoscopy is associated with greater reduc- tion in colorectal cancer incidence and mortality in the distal colon (80%) than the proximal colon (4060%). This may be attributable to incomplete examination of the proximal colon, and differences between the proximal and distal colon that include worse bowel preparation, subopti- mal colonoscopic technique, and a higher prevalence of serrated polyps and flat adenomas, which are more diffi- cult to identify than raised (sessile or pedunculated) polyps. To optimize diagnostic accuracy as well as patient safety and comfort, colonoscopy should be performed after optimal bowel preparation by a well-trained endoscopist who spends sufficient time (at least 7 minutes) carefully examining the colon (especially the proximal colon) while withdrawing the endoscope. 2. Flexible sigmoidoscopy Use of a 60-cm flexible sig- moidoscope permits visualization of the rectosigmoid and descending colon. Adenomatous polyps are identi- fied in 1020% and colorectal cancers in 1% of patients. The finding at sigmoidoscopy of an adenomatous polyp in the distal colon increases the likelihood at least twofold that an advanced neoplasm is present in the proximal colon. The chief disadvantage of screening with flexible sig- moidoscopy is that it requires some bowel cleansing, it may be associated with some discomfort (since intravenous sedation is not used), and it does not examine the proximal colon. The prevalence of proximal versus distal neoplasia is higher in persons older than age 65 years, in Blacks, and in women.C.  Radiographic and Other Imaging of the Colon1. CT colonograph y CT colonography requires a similar bowel cleansing regimen as colonoscopy as well as insuffla- tion of air into the colon through a rectal tube, which may be associated with discomfort. Using current imaging soft- ware with multidetector helical scanners, the sensitivity is greater than 95% for the detection of cancer and greater than 8492% for the detection of polyps 10 mm or larger. CT colonography is less sensitive than colonoscopy for the detection of polyps smaller than 1 cm, flat adenomas, and serrated polyps. The chief disadvantages of CT colonography are the need for a bowel preparation, limited availability in many health care systems, a possible increased risk of neoplasia due to radiation exposure, and the potential for finding incidental extracolonic findings that may lead to further evaluations. CT colonography is an excellent screening option in patients who do not wish to undergo or are unsuitable for colonoscopy and in patients in whom colo- noscopy could not be completed. 2. Capsule colonoscopy Imaging of the colon can be accomplished by oral ingestion of a capsule that captures video images of the colon. Compared with colonoscopy, the colon capsule has reduced sensitivity for polyps greater than 6 mm (64% vs 84%) and for colorectal cancers (74% vs 100%). At present, it is approved by the FDA forCMDT22_Ch39_p1612-p1675.indd  1651 02/07/21 2:44 PMChAPTER 391652 CMDT 2022evaluation  in patients who are not suitable candidates for colonoscopy or in whom colonoscopy could not evaluate the proximal colon. In addition to its suboptimal sensitivity for neoplasia, the main disadvantages of capsule colonos- copy are its cost, need for extensive bowel preparation, lack of reimbursement by most insurance carriers, and small risk of small bowel obstruction. When to Refer Patients with symptoms (change in bowel habits, hema- tochezia), signs (mass on abdominal examination or digital rectal examination), or laboratory tests (iron deficiency anemia) suggestive of colorectal neoplasia should be referred for colonoscopy. Patients with suspected colorectal cancer or adenoma- tous polyps of any size should be referred for colonoscopy. Virtually all patients with proven colorectal cancer should be referred to a surgeon for resection. Patients with clinical stage T3 or node-positive rectal tumors (or both) also should be referred to medical and radiation oncologists preoperatively for neoadjuvant therapy. Patients with stage II, III, or IV colorectal tumors should be referred to a medical oncologist. When to Admit Patients with complications of colorectal cancer (obstruction, acute bleeding) requiring urgent evalua- tion and intervention. Patients with advanced metastatic disease requiring palliative care.Biller LH et a l. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325:669. [PMID: 33591350] Ladabaum U et al. Strategies for colorectal cancer screening. Gastroenterology. 2020;158:418. [PMID: 31394083] National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Colon Cancer. Version 2.2021. 2021 Jan 21. https://www.nccn.org/professionals/physician_gls/ pdf/colon.pdf National Comprehensive Cancer Network. Clinical Practice Guide- lines in Oncology. Rectal Cancer. Version 1.2021. 2020 Dec 22. https://www.nccn.org/professionals/physician_gls/pdf/rectal. pdf National Institutes of Health. SEER Cancer Stat Facts: Colorectal Cancer, 2020. https://seer.cancer.gov/statfacts/html/colorect. html Petrelli F et al. Total neoadjuvant therapy in rectal cancer: a system- atic review and meta-analysis of treatment outcomes. Ann Surg. 2020;271:440. [PMID: 31318794] Ran T et al. Cost-effectiveness of colorectal cancer screening strategies: a systematic review. Clin Gastroenterol Hepatol. 2019; 17:1969. [PMID: 30659991] Stoffel EM et al. Epidemiology and mechanisms of the increasing incidence of colon and rectal cancers in young adults. Gastroen- terology. 2020;158:341. [PMID: 31394082] US Preventive Services Task Force. Colorectal Cancer: Screening 2021 May 18. https://www.uspreventiveservicestaskforce.org/ uspstf/recommendation/colorectal-cancer-screeningCARCINOMA OF THE ANUSThe an al canal is lined from its proximal to distal extent by columnar, transitional, and non-keratinized squamous epi- thelium, which merges at the anal verge with the keratin- ized perianal skin. Cancers arising from the mucosa of the anal canal are relatively rare, comprising only 12% of all cancers of the anus and large intestine. Squamous cancers make up the majority of anal cancers. Anal cancer is increased among people practicing receptive anal inter- course and those with a history of anorectal warts. In over 80% of cases, HPV may be detected, suggesting that this virus is a major causal factor. In a large controlled trial, HPV vaccination of healthy men (16 to 26 years old) who have sex with men decreased the incidence of anal intraepi- thelial neoplasia by 50%. Women with anal cancer are at increased risk for cervical cancer (which may be due to a field effect of oncogenic HPV infection) and require gyne- cologic screening and monitoring. Anal cancer is increased in HIV-infected individuals, possibly due to interaction with HPV . Nine-valent HPV (9vHPV) vaccine is recom- mended for boys and girls starting at age 11 or 12 and for individuals up to age 26 who have not been previously vac- cinated. Thereafter, shared clinical decision-making regard- ing HPV vaccination is recommended for some adults aged 27 through 45 years who are not adequately vaccinated. Bleeding, pain, and local mass are the most common symptoms. The lesion is often confused with hemorrhoids or other common anal disorders. These tumors tend to become annular, invade the sphincter, and spread upward via the lymphatics into the perirectal mesenteric lymphatic nodes. CT or MRI scans of the abdomen and pelvis are required to identify regional lymphadenopathy or meta- static disease at diagnosis. PET imaging may be used in conjunction. Treatment depends on the tumor location and histo- logic stage. Well-differentiated and small (less than 2 cm) superficial lesions of the perianal skin may be treated with wide local excision. Adenocarcinoma of the anal canal is treated in similar fashion to rectal cancer (see above), commonly by abdomi- noperineal resection with neoadjuvant chemoradiotherapy and adjuvant chemotherapy. The more common squa- mous cell cancer of the anal canal and large perianal tumors invading the sphincter or rectum are treated with combined-modality therapy that includes external radia- tion with simultaneous chemotherapy (5-fluorouracil plus mitomycin). Local control is achieved in approximately 80% of patients. Radical surgery (abdominoperineal resec- tion) is reserved for patients who fail chemotherapy and radiation therapy. Metastatic disease is generally treated with carboplatin and paclitaxel. The 5-year survival rate is 81% for localized tumors and approximately 30% for meta- static (stage IV) disease.Mahal  AR et al. An update to changing patterns of anal carci- noma in the United States. Am J Clin Oncol. 2020;42:887. [PMID: 31651454] National Cancer Institute. SEER Cancer Stat Facts: Anal Cancer, 2020. https://seer.cancer.gov/statfacts/html/anus.htmlCMDT22_Ch39_p1612-p1675.indd  1652 02/07/21 2:44 PMCANCER1653 CMDT 2022Na tional Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Anal Carcinoma. Version 2.2020. 2020 May 6. https://www.nccn.org/professionals/physician_ gls/pdf/anal.pdf Parwaiz I et al. A systematic review and meta-analysis of prog- nostic biomarkers in anal squamous cell carcinoma treated with primary chemoradiotherapy. Clin Oncol (R Coll Radiol). 2019;31:e1. [PMID: 31301958]CA NCERS OF ThE GENITOURINARY TRACT George R. Schade, MD PROSTATE CANCERE S S E N T I A L S  O F  D I A G N O S I S Prostatic induration on digital rectal examination (DRE) or elevation of PSA. Most often asymptomatic. Rarely: systemic symptoms (weight loss, bone pain). General ConsiderationsProsta te cancer is the most common noncutaneous cancer and the second leading cause of cancer-related death in American men with an estimated 191,930 new prostate cancer diagnoses and 33,330 prostate cancer deaths in 2020. The clinical incidence, however, does not match the prevalence of the disease. Autopsy studies have demon- strated that more than 40% of men over age 50 years have prostate cancer, and its prevalence increases with age with 30% of men aged 6069 years and 67% of men aged 8089 years harboring the disease at autopsy. Most of these occult cancers are small indolent organ-confined cancers with few representing regional or metastatic disease. Although the global prevalence of prostatic cancer at autopsy is relatively consistent, the clinical incidence varies consider- ably (high in North America and European countries, inter- mediate in South America, and low in the Far East). A 50-year-old American man has a lifetime risk of 40% for latent cancer, a 16% risk for developing clinically apparent cancer, and a 2.9% risk of death due to prostatic cancer. Black race, family history of prostatic cancer, and history of high dietary fat intake are risk factors for prostate cancer. Clinical FindingsA.  Symptoms and SignsPresen tly, most prostate cancers are asymptomatic and are diagnosed because of elevations in serum PSA. However, some men will be diagnosed based on discrete nodules or areas of induration within the prostate on a DRE. Obstruc- tive voiding symptoms are most often due to benign pros- tatic hyperplasia, which occurs in the same age group. Nevertheless, large or locally extensive prostatic cancers can cause obstructive voiding symptoms, including urinaryretention. Lymph node metastases can lead to lower extremity lymphedema. Because the axial skeleton is the most common site of metastases, patients may present with back pain, pathologic fractures, or rarely neurologic symp- toms from epidural metastases and cord compression.B.  Laboratory Findings1.  Serum tumor markers PSA is a glycoprotein produced only by prostatic cells, either benign or malignant. The serum level is typically low and correlates with the total volume of prostate tissue and tends to increase with age. Measurement of serum PSA is useful in detecting and stag- ing prostate cancer, monitoring response to treatment, and identifying recurrence before it becomes clinically evident. As a screening test, PSA is elevated (greater than 4.0 ng/mL [4.0 mcg/L]) in 1015% of men. Prostate cancer will be diagnosed in approximately 1830% of men with PSA 4.110 ng/mL (4.110 mcg/L) and 5070% of men with PSA greater than 10 ng/mL (10 mcg/L). However, no PSA threshold excludes the diagnosis of prostate cancer. In untreated patients with prostate cancer, the level of PSA correlates with the volume and stage of disease. Patients with PSA levels less than 10 ng/mL (10 mcg/L) usually have localized and therefore potentially curable cancers, while those with PSA levels in excess of 40 ng/mL (40 mcg/L) are more likely to have advanced disease (semi- nal vesicle invasion, lymph node involvement, or occult distant metastases). Approximately 98% of patients with metastatic prostate cancer will have an elevated PSA level. However, there are rare cancers that are localized despite substantial elevations in PSA. Therefore, initial treatment decisions cannot be made on the basis of PSA testing alone. A rising PSA after therapy is usually consistent with pro- gressive disease, either locally recurrent or metastatic. 2. Miscellaneous laboratory testing Patients with uri- nary retention or with ureteral obstruction due to loco- regionally advanced prostate cancers may present with elevations in blood urea nitrogen or serum creatinine. Patients with bony metastases may have elevations in serum alkaline phosphatase or calcium. Laboratory and clinical evidence of disseminated intravascular coagulation can occur in patients with advanced prostate cancers. 3. Prostate biopsy Transrectal ultrasound-guided biopsy is the standard method for detection of prostate cancer. The use of a spring-loaded, 18-gauge biopsy needle has allowed transrectal biopsy to be performed with minimal patient discomfort and morbidity. Local anesthesia is standard and increases the tolerability of the procedure. The specimen preserves glandular architecture and permits accurate grad- ing. Prostate biopsy specimens are taken from the apex, mid-portion, and base in men who have an abnormal DRE or an elevated serum PSA, or both. Extended-pattern biop- sies, including a total of at least 10 biopsies, are associated with improved cancer detection and risk stratification of patients with newly diagnosed disease. In addition, suspi- cious hypoechoic prostatic lesions seen on transrectal ultra- sound may be targeted for biopsy. Patients with abnormalities of the seminal vesicles can have these struc- tures specifically biopsied to identify local tumor invasion.CMDT22_Ch39_p1612-p1675.indd  1653 02/07/21 2:44 PMChAPTER 391654 CMDT 2022C.  ImagingU se of imaging for staging should be tailored to the likeli- hood of advanced disease in newly diagnosed cases. CTof the abdomen and pelvis and radionuclide (99-techne- tium) bone scans are generally the first-line staging studies performed, when indicated, to assess for nodal and bony metastases, respectively. MRI allows for evaluation of the prostate as well as regional lymph nodes. The positive predictive value for detec- tion of both capsular penetration and seminal vesicle invasion is similar for transrectal ultrasound and MRI, although newer multi-parametric MRI techniques may better stage patients considering treatment or, alternatively, active surveillance. Additionally, there is a growing role for multi-parametric MRI in prostate cancer diagnosis, particularly among men with previous negative prostate biopsies, to evaluate for suspi- cious prostatic lesions. Such lesions may then be sampled via MRI-guided needle biopsy or via MR Fusion (in which pros- tate MRI images are fused in real-time with images from an ultrasound-guided needle biopsy). Such an approach may improve not only overall cancer detection but discovery of clinically relevant disease, and its use in routine clinical prac- tice has increased and continues to evolve. Conventional radionuclide (99-technetium) bone scans are superior to conventional plain skeletal radio- graphs in detecting bony metastases. Prostate cancer bony metastases tend to be multiple and most commonly occur in the axial skeleton. Men with more advanced local lesions, symptoms of metastases (eg, bone pain), high- grade disease, or elevations in PSA greater than 20 ng/mL (20 mcg/L) should undergo radionuclide bone scan. PET (eg,18F-sodium fluoride [18F-NaF] PET ) and18F-NaF PET/CT hybrid imaging are more sensitive than con- ventional bone scans. However, a high frequency of abnormal scans with18F-NaF PET/CT resulting from degenerative joint disease has limited their usefulness. Fluciclovine (Axumin) PET imaging has been approved for suspected cancer recurrence based on elevated PSA after prior treatment. PSMA (prostate-specific membrane antigen) PET, using small-molecule radiotracers target- ing PSMA (eg,18F-DCFBC [N-[N-[(S)-1,3-dicarboxypro- pyl]carbamoyl]-4-18F-fluorobenzyl-L-cysteine]) has shown significant promise as a next-generation imaging method and may replace traditional imaging modalities in the future. Despite application of modern, sophisticated tech- niques, understaging of prostate cancer occurs in at least 20% of patients.D . Genetic TestingThe role of gene tics in prostate cancer diagnosis and man- agement is evolving. A family history of prostate cancer increases the risk of prostate cancer. Additionally, prostate cancer has been associated with several hereditary cancer syndromes (eg, Lynch syndrome, hereditary breast and ovarian cancer syndrome, etc.) with approximately 11% of prostate cancer patients with at least one additional primary cancer carrying germline mutations. Consequently, some patients with prostate cancer and their families may haveelevated risk for other cancers. Further, data suggest that some germline mutations, such as BRCA1/2 , are associated with lower PSA at diagnosis and increased risk of progres- sion and death; approximately 12% of patients with metastatic prostate cancer have germline mutations in homologous DNA repair genes. Finally, germline mutations in DNA repair genes can have implications for treatment and, as a result, play a role in personalized treatment. Patients with prostate cancer should have a thorough review of their family history and those with a concerning family history should be referred for genetic counselling and possible testing. Additionally, patients with high-risk disease or metastatic disease should undergo genetic evalu- ation as well. Screening for Prostate CancerThe  impact of prostate cancer screening on mortality remains controversial. The screening tests currently avail- able include DRE, PSA testing, and transrectal ultrasound. Prostate cancer detection rates using DRE alone vary from 1.5% to 7%, but unfortunately, most of these cancers are advanced (stage T3 or greater). Transrectal ultrasound should not be used as a first-line screening tool due to its expense, low specificity, and minimal improvement in detec- tion rate versus the combined use of DRE and PSA testing. PSA testing increases the detection rate of prostate can- cers compared with DRE. Approximately 22.5% of men older than 50 years of age will be found to have prostate cancer using PSA testing compared with a rate of approxi- mately 1.5% using DRE alone. The sensitivity, specificity, and positive predictive value of PSA and DRE are listed in Table 397. PSA-detected cancers are more likely to be localized compared with those detected by DRE alone. The Prostate Cancer Prevention Trial provided data demon- strating a significant risk of prostate cancer even in men with PSA less than 4.0 ng/mL (4.0 mcg/L) (Table 398) and a web-based calculator has been developed to estimate the risk of harboring both prostate cancer and high-grade cancer (http://riskcalc.org/PBCG). Table 397. Screening for prostatic cancer: test performance.T est Sensitivity SpecificityPositive Pre- dictive Value Abnormal PSA (> 4 ng/mL [mcg/L])0.67 0.97 0.43 Abnormal DRE 0.50 0.94 0.24 Abnormal PSA or DRE0.84 0.92 0.28 Abnormal PSA and DRE0.34 0.995 0.49 DRE, digital rectal examination; PSA, prostate-specific antigen. Modified, with permission, from Kramer BS et al. Prostate cancer screening: what we know and what we need to know. Ann Intern Med. 1993;119:914. Copyright  1993 American College of Physicians. All rights reserved.CMDT22_Ch39_p1612-p1675.indd  1654 02/07/21 2:44 PMCANCER1655 CMDT 2022T o improve the performance of PSA as a screening test, several investigators have developed alternative methods for its use. These include establishment of age- and race- specific reference ranges, measurement of free serum and protein-bound levels of PSA ( percent free PSA ), and cal- culation of changes in PSA over time ( PSA velocity ). Gen- erally, men with PSA free fractions exceeding 25% are unlikely to have prostate cancer, whereas those with free fractions less than 10% have an approximately 50% chance of having prostate cancer. Newer tests, including the Pros- tate Health Index (PHI) and 4kscore (https://4kscore.com), may better identify not only men at greater risk for prostate cancer but those with more aggressive disease. The frequency of PSA testing also remains a matter of debate. The traditional yearly screening approach may not be the most efficient; rather, earlier PSA testing at younger age may allow less frequent testing later as well as provide information regarding PSA velocity. Men with PSA above the age-based median when tested between 40 and 60 years are at significantly increased risk for subsequent cancer detection over 25 years. Men aged 4050 with PSA below 0.6 ng/mL (0.6 mcg/L) and aged 5060 with PSA below 0.71 ng/mL (0.71 mcg/L) may require less frequent PSA tests. In addition, men with PSA velocity greater than 0.35 ng/mL (0.35 mcg/L) per year measured 1015 years before diagnosis had significantly worse cancer-specific survival compared with those with lower PSA velocity. The NCCN guidelines (https://www.nccn.org/professionals/physician_ gls/f_guidelines.asp) for prostate cancer early detection incorporate many of these factors. The European Associa- tion of Urology (EAU) recommends offering PSA screening to men beginning at age 4050 years, dependent on risk factors, and subsequently initiating a risk-adapted strategy. Two large, randomized trials have evaluated the benefit of PSA screening for early detection of prostate cancer. In the US Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, no mortality benefit was observed after combined screening with PSA testing and DRE dur- ing 15-year follow-up. Although screening resulted in a 12% increase in prostate cancer detection, the cancer-specific mortality rate was similar in the screening and controlarms (2.55 and 2.44 deaths per 10,000 person-years, respectively). However, an estimated 86% of control patients received at least one screening PSA test and 46% of control patients received yearly PSA screening during the trial. Conversely, the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial demonstrated a significant 20% reduction in prostate cancer mortality with an absolute reduction of 1.75 deaths per 1000 men screened at 16 years. The number of men needed to be invited for screening to prevent one prostate cancer death was 570 at 16 years compared with 742 at 13 years, while the number of prostate cancers needing to be diagnosed to prevent one prostate cancer death was reduced from 26 to 18, underscoring the importance of adequate long-term follow-up for prostate cancer. In 2018, the USPSTF issued a revised (Grade C) recom- mendation for men aged 55 to 69 years that the decision to undergo periodic PSAbased screening should be an indi- vidual one. Before deciding about screening, men should discuss its potential benefits and harms with their clinician, incorporating their own values and preferences in the deci- sion. The revised recommendation acknowledges that, while screening offers some men a small potential benefit of reducing the chance of dying from prostate cancer, many other men will experience potential harms from screening. These include false-positive results that require additional testing and possible prostate biopsy; overdiagnosis and overtreatment; and treatment complications, such as incontinence and erectile dysfunction. In determining whether screening is appropriate in individual cases, the individual patients family history, race/ethnicity, comorbid medical conditions, values about the benefits and harms of screening and treatment-specific outcomes, and other health needs should be considered. Clinicians should not screen men who do not express a preference for screening. For men age 70 years and older, the USPSTF recommends against PSA-based screening (Grade D recommendation). StagingThe  majority of prostate cancers are adenocarcinomas. Most arise in the peripheral zone of the prostate, though a small percentage arise in the central (510%) and transi- tion zones (20%) of the gland. Pathologists utilize the Gleason grading system whereby a primary grade is applied to the architectural pattern of malignant glands occupying the largest area of the specimen and a second- ary grade is assigned to the next largest area of cancer. Grading is based on architectural rather than histologic criteria, and five grades are possible. Adding the score of the primary and secondary grades gives a Gleason score from 2 to 10. Gleason score correlates with tumor volume, pathologic stage, and prognosis. A simplified five-grade group system has been introduced by the International Society of Urological Pathologists. TreatmentA.  General MeasuresThe  optimal management of localized prostate cancer remains controversial owing to the plethora of treatmentTable 398. Risk of prostate cancer in men with PSA  4.0 ng/mL (or mcg/L).PSA  Level (ng/mL [or mcg/L])Percentage wit Prostate CancerPercentage wit hig-Grade1 Prostate Cancer  0.5 6.6 12.5 0.61.0 10.1 10.0 1.12.0 17.0 11.8 2.13.0 23.9 19.1 3.14.0 26.9 25.01 High-grade cancer was defined as Gleason score  7. Data from Thompson IM et al. Prevalence of prostate cancer among men with a prostate-specific antigen level  4.0 ng per milliliter. N Engl J Med. 2004;350:2239.CMDT22_Ch39_p1612-p1675.indd  1655 02/07/21 2:44 PMChAPTER 391656 CMDT 2022optio ns, side effects of the various options, and indolent nature of many prostate cancers. These factors have contrib- uted to uncertainty regarding a definitive survival benefit of treating localized prostate cancer. To help guide treatment decision making, patients are risk stratified according to their PSA level at diagnosis, DRE, and prostate cancer grade (Gleason score). Additionally, patients should have an assessment of life expectancy prior to treatment decision- making since all patients with low-risk disease and many with intermediate-risk disease with less than 10-year life expectancy will not benefit from treatment.B.  Active SurveillanceThe g oal of active surveillance is to avoid treatment in men who may never require it while recognizing and definitively treating men harboring higher-risk disease in order to bal- ance cancer risk with the morbidity of treatment. Treatment decisions are made based on stage, PSA, and cancer grade (Gleason score) as well as the age and health of the patient. Active surveillance alone may be effective management for appropriately selected patients, typically those with low PSA, small volume, well-differentiated cancers, and life expectancy less than 1015 years. For such patients, active surveillance involves serial PSA levels, DREs, and periodic prostate biopsies to reassess grade and extent of cancer. Endpoints for intervention in patients on active surveil- lance, particularly PSA changes, have not been clearly defined and surveillance regimens remain an active area of research. Nonetheless, they are increasingly accepted by patients and clinicians with contemporary series demon- strating freedom from definitive treatment in greater than half of patients at 5 years, and risk of developing metastases and suffering cancer-specific death in less than 3% and 2%, respectively, at 10 years. Active surveillance, which is distin- guished from mere observation (watchful waiting), is fea- tured prominently in the NCCN and EAU guidelines and is the preferred management in most men with very low risk prostate cancer. This approach is increasingly accepted and incorporated in routine clinical practice.C.  Radical ProstatectomyDuring  radical prostatectomy, the seminal vesicles, prostate, and ampullae of the vas deferens are removed. Refinements in technique have allowed preservation of urinary conti- nence in most patients and erectile function in selected patients. Radical prostatectomy can be performed via open retropubic, transperineal, or laparoscopic (with or without robotic assistance) surgery. Local recurrence is uncommon after radical prostatectomy and related to pathologic stage. Organ-confined cancers rarely recur; however, cancers with adverse pathologic features (capsular penetration, seminal vesicle invasion) are associated with higher local (1025%) and distant (2050%) relapse rates. Ideal candidates for radical prostatectomy include healthy patients with stages T1 and T2 prostate cancers. Patients with advanced local tumors (T4) or lymph node metastases are rarely candidates for prostatectomy alone, although surgery is sometimes used in combination with hormonal therapy and postoperative radiation therapy for select high-risk patients.D. Radiation TherapyRadiatio n can be delivered by a variety of techniques to the prostate and, when clinically indicated, to the pelvic lymph nodes. Conformal techniques, including three-dimensional conformal radiation, intensity modulated radiotherapy, and image-guided radiotherapy, have become the standard of care for external photon-based radiotherapy, while proton beam therapy has gained acceptance as an alternative exter- nal beam therapy that theoretically may reduce toxicities. Additionally, hypofractionated and ultra-hypofractionated (ie, stereotactic radiotherapy) regimens have shown prom- ising short- and intermediate-term outcomes vs conven- tionally dosed regimens. Brachytherapythe implantation of permanent or temporary radioactive sources (palladium, iodine, or iridium) into the prostatecan be used as mono- therapy in those with low-grade or low-volume malignan- cies or combined with external beam radiation in patients with higher-grade or higher-volume disease. The PSA may rise after brachytherapy because of prostate inflammation and necrosis. This transient elevation (PSA bounce) should not be mistaken for recurrence and may occur up to 20 months after treatment. Patients with intermediate- and high-risk disease benefit from concomitant androgen deprivation therapy. As with surgery, the likelihood of local failure fol- lowing radiation correlates with technique and cancer char- acteristics. The likelihood of a positive prostate biopsy more than 18 months after radiation varies between 20% and 60%. Patients with local recurrence are at an increased risk of cancer progression and cancer death compared with those who have negative biopsies. Survival of patients with localized cancers (T1, T2, and selected T3) approaches 65% at 10 years. Ambiguous target definitions, inadequate radia- tion doses, and understaging of the cancer may be respon- sible for the failure noted in some series.E.  Focal TherapyT o reduce the morbidity of localized prostate cancer treat- ment, there has been a growing interest in focal therapy. Focal therapy delivers energy to the prostate, destroying the tumor(s) and a margin of normal prostate tissue while avoiding collateral damage to the neurovascular bundles, external urinary sphincter, bladder, and rectum. To date, several energy sources (cryotherapy, high intensity focused ultrasound, lasers, etc) have been evaluated and several others are under development. The multifocal nature and the difficulty of localizing the prostate cancer with contem- porary imaging techniques combined with the prolonged disease course, lack of clearly defined endpoints, and ran- domized prospective data have limited the widespread adoption of focal therapies as well as a clear understanding of which are the ideal candidates.F . Localized DiseaseAlthough  selected patients may be candidates for active surveillance based on age or health and evidence of small- volume or well-differentiated cancers, most men with an anticipated life expectancy of longer than 10 years should be considered for treatment. Newly introduced genomic tests may provide important information to help guideCMDT22_Ch39_p1612-p1675.indd  1656 02/07/21 2:44 PMCANCER1657 CMDT 2022tr eatment decisions. Both radiation therapy and radical pros- tatectomy result in acceptable levels of local control. A large, prospective, randomized trial compared watchful waiting with radical prostatectomy in 695 men with clinically local- ized and well-differentiated to moderately differentiated cancers. Radical prostatectomy significantly reduced disease- specific mortality, overall mortality, and risks of metastasis and local progression. The relative reduction in the risk of death at 23 years was 0.56 in the prostatectomy group, with the number needed to treat to avert one death (NNT) = 8 patients; the benefit was largest in men younger than age 65 years (relative risk [RR] = 0.45) and with intermediate- risk prostate cancer (RR = 0.38). Surgery also reduced the risk of metastases in older men (RR = 0.68).G.  Locally and Regionally Advanced DiseasePa tients with advanced pathologic stage or positive surgical margins are at an increased risk for local and distant tumor relapse. Due to these risks, such patients have been consid- ered for adjuvant therapy (radiation for positive margins and seminal vesicle invasion or androgen deprivation and/ or radiation for lymph node metastases). Two randomized clinical trials (EORTC 22911 and SWOG 8794) demon- strated improved progression-free and metastasis-free sur- vival with early radiotherapy in these men, and subsequent analysis of SWOG 8794 showed improved overall survival in men receiving adjuvant radiation therapy. However, the publication of two trials comparing adjuvant radiotherapy with early-salvage therapy using contemporary radiother- apy techniques (GETUG-AFU17 and RAVES) demon- strated no difference in 5-year biochemical progression-free survival casting doubt on the benefit of adjuvant radio- therapy in the contemporary era.H.  Metastatic DiseaseSince death due to prosta te carcinoma is almost invariably the result of failure to control metastatic disease, research has emphasized efforts to improve control of distant dis- ease. Most prostate carcinomas are hormone dependent and approximately 7080% of men with metastatic prostate carcinoma will respond to various forms of androgen deprivation. Androgen deprivation therapy may be effec- tive at several levels along the pituitarygonadal axis using a variety of methods or agents (Table 399). Use of lutein- izing hormone-releasing hormone (LHRH) agonists (leup- rolide, goserelin) achieves medical castration without orchiectomy and is the most common method of reducing testosterone levels. A single LHRH antagonist (degarelix) is FDA approved and has no short-term testosterone flare associated with LHRH agonists. Because of its rapid onset of action, ketoconazole should be considered in patients with advanced prostate cancer who present with spinal cord compression, bilateral ureteral obstruction, or dis- seminated intravascular coagulation. Although testoster- one is the major circulating androgen, the adrenal gland secretes the androgens dehydroepiandrosterone, dehy- droepiandrosterone sulfate, and androstenedione. This led to the development of abiraterone acetate (an inhibi- tor of CYP17, a key enzyme in androgen synthesis) to block both testicular and adrenal androgens. Nonsteroidalantiandrogen agents act by competitively binding the receptor for dihydrotestosterone, the intracellular andro- gen responsible for prostate cell growth and development. In addition to immediate side effects of androgen depriva- tion (sexual dysfunction and hot flashes), the chronic sup- pression of testosterone leads to osteoporosis and risk of fractures, cardiovascular disease and diabetes mellitus, and decreased muscle and increased fat. Bisphosphonates can prevent osteoporosis associated with androgen depriva- tion, decrease bone pain from metastases, and reduce skeletal-related events. Denosumab , a RANK ligand inhib- itor, is approved for the prevention of skeletal-related events in patients with bone metastases from prostate cancer and also appears to delay the development of these metastases in patients with castration-resistant prostate cancer. In addition, enzalutamide definitively improves metastasis-free survival in men with nonmetastatic castrate- resistant prostate cancer and rapidly rising PSAs. The management of advanced prostate cancer is rapidly evolving. Contemporary management consists of initiating androgen deprivation therapy with orchiectomy, LHRH agonist, or LHRH antagonist. A meta-analysis compared using an LHRH agonist or orchiectomy alone with an LHRH agonist or orchiectomy plus an antiandrogen agent; results showed little benefit of combination therapy. However, patients at risk for disease-related symptoms (bone pain, obstructive voiding symptoms) should receive concurrent antiandrogens due to the initial elevation of serum testoster- one that accompanies LHRH agonists. For patients with elevated PSAs only (indicating recurrent, but nonmetastatic, cancer), nonsteroidal antiandrogen agents may be useful. Further androgen manipulations, initiation of cytotoxic chemotherapy, and local therapy (eg, radiation) is defined by the cancers androgen sensitivity status. For patients with hormone-sensitive metastatic prostate cancer, the addition of systemic cytotoxic chemotherapy with docetaxol to androgen deprivation therapy results in improved survival compared to androgen deprivation therapy alone. Similarly, the addition, of abiraterone acetate plus prednisone to androgen deprivation therapy, results in superior survival compared to androgen deprivation therapy alone. Patients with castrate-resistant disease or prostate can- cer that demonstrates rising PSA or progression of disease despite castrate levels of serum testosterone (less than 50 ng/dL) should continue their LHRH agonist/antagonist regimen. Additional treatment options are stratified based on the presence of metastatic disease. Patients with non- metastatic castrate-resistant disease and long PSA doubling time (longer than10 months) can simply be observed due to their relatively indolent disease. Conversely, nonmeta- static castrate-resistant patients with short doubling times (10 months or less) have demonstrated improved metastasis- free survival with the addition of the potent nonsteroidal androgen receptor antagonists enzalutamide ,apalu- tamide , and darolutamide to androgen deprivation therapy. For patients with metastatic castrate-resistant prostate cancer, docetaxol was the first cytotoxic chemo- therapy agent to improve survival. Enzalutamide and abiraterone improve overall survival in men with meta- static castrate prostate cancer in both the docetaxol nave and non-nave setting. Cabazitaxel is a second-line taxaneCMDT22_Ch39_p1612-p1675.indd  1657 02/07/21 2:44 PMChAPTER 391658 CMDT 2022chemothera py that improves overall survival in men who have received docetaxel. Sipuleucel-T, an autologous cel- lular immunotherapy, is FDA approved in asymptomatic or minimally symptomatic men with metastatic castration- resistant prostate cancer. Radium-223 dichloride is approved for the treatment of men with castration-resistant, symptomatic bone metastases, with significant improve- ments in both overall survival and time to skeletal-related events (eg, fractures and spinal cord compression). Finally, patients who have undergone a genetics evaluation and are found to have specific germline or somatic mutations may benefit from personalized treatment strategies. PrognosisTh e likelihood of success of active surveillance or treatment can be predicted using risk assessment tools that usuallyTable 399. Androgen deprivation for prostatic cancer.Lev el Agent Dose Sequelae Pituitary, hypothalamus Diethylstilbestrol 13 mg orally daily Gynecomastia, hot flushes, thromboembolic disease, erectile dysfunction LhRh agonists Leuprolide Goserelin Triptorelin HistrelinDaily subcutaneous injection Monthly to quarterly depot injection Monthly depot injection Annual subcutaneous implantErectile dysfunction, hot flushes, gynecomastia, rarely anemia LhRh antagonist Degarelix 240 mg subcutaneously initial dose, then 80 mg subcutaneously monthlyHot flushes, weight gain, erectile dysfunction, increased liver tests Adrenal Ketoconazole 400 mg three times orally daily Adrenal insufficiency, nausea, rash, ataxia Aminoglutethimide 250 mg four times orally daily Adrenal insufficiency, nausea, rash, ataxia Corticosteroid Prednisone 2040 mg orally daily Gastrointestinal bleeding, fluid retention CYP17a1 inibitor Abiraterone 1000 mg orally daily (with predni- sone 5 mg orally twice daily)Weight gain, fluid retention, hypokalemia, hypertension Testis Orchiectomy  Gynecomastia, hot flushes, erectile dysfunction Prostate cell Antiandrogens Flutamide 250 mg three times orally daily No erectile dysfunction when used alone; nausea, diarrhea Bicalutamide 50 mg orally daily Liver, cardiac, and pulmonary toxicity Enzalutamide 160 mg orally daily Seizures, dizziness, asthenia Apalutamide 240 mg orally daily Fatigue, leukopenia, hyperlipidemia, hyperglycemia, hyperkalemia, seizures (rare) Doralutamide 600 mg orally twice daily Fatigue, extremity pain, rash Cytotoxic cemotera- peutic agentsBone marrow, skin, pulmonary, cardiac, gastrointestinal, hepatic toxicities possible Docetaxel 75 mg/m2intravenously once on day 1 of 21-day cycle (with prednisone 10 mg orally daily) Cabazitaxel 20 mg/m2intravenously once on day 1 of 21-day cycle (with prednisone 10 mg orally daily) LHRH, luteinizing hormone-releasing hormone.co mbine stage, grade, PSA level, and number and extent of positive prostate biopsies. Several web-based tools are avail- able (eg, https://www.mskcc.org/nomograms/prostate). Widely used nomograms include the Kattan nomogram and theCAPRA nomogram. CAPRA uses serum PSA, Gleason score, clinical stage, percent positive biopsies, and patient age in a point system to risk stratify and predict the likelihood of PSA recurrence 3 and 5 years after radical prostatectomy (Tables 3910 and 3911) as well as metastasis and prostate cancer-specific and overall survival. The CAPRA nomogram has been validated on large multicenter and international radical prostatectomy and radiation-treated cohorts. The patterns of prostate cancer progression have been well defined. Small and well-differentiated cancers (Gleason grade 3) are usually confined within the prostate, whereas large-volume (greater than 4 mL) or poorly differentiatedCMDT22_Ch39_p1612-p1675.indd  1658 02/07/21 2:44 PMCANCER1659 CMDT 2022T able 3911. CAPRA: Probability of freedom from PSA recurrence after radical prostatectomy by CAPRA point total.CA PRA Score3-Year Recurrence-Free Survival (%) (95% CI)5-Year Recurrence-Free Survival (%) (95% CI) 01 91 (8595) 85 (7392) 2 89 (8394) 81 (6989) 3 81 (7387) 66 (5476) 4 81 (6989) 59 (4074) 5 69 (5182) 60 (3777) 6 54 (2775) 34 (1257) 7+ 24 (943) 8 (028) PSA, prostate-specific antigen. Source: https://urology.ucsf.edu/research/cancer/prostate-cancer- risk-assessment-and-the-ucsf-capra-score.Table 3910. The UCSF Cancer of the Prostate Risk Assessment (CAPRA).V ariable Level Points PSA (ng/mL [or mcg/L]) at diagnosis 06 0 6.110 1 10.120 2 20.130 3 > 30 4 Gleason grade, primary/secondary 13/13 0 13/45 1 45/15 3 T stage T1 or T2 0 T3a 1 % positive biopsies (biopsy cores posi- tive divided by the number of biop- sies obtained)< 34% 0  34% 1 Age < 50 years 0  50 years 1 Source: https://urology.ucsf.edu/research/cancer/prostate- cancer-risk-assessment-and-the-ucsf-capra-score.(G leason grades 4 and 5) cancers are more often locally exten- sive or metastatic to regional lymph nodes or bone. Penetra- tion of the prostate capsule by cancer is common and occurs along perineural spaces. Seminal vesicle invasion is associ- ated with a high likelihood of regional or distant disease and disease recurrence. The most common sites of lymph node metastases are the obturator and internal iliac lymph node chains and of distant metastases, the axial skeleton.When to Refer Refer all patients to a urologist for management of localized disease or for active surveillance. For metastatic disease, medical oncology should be consulted for consideration of systemic treatments. Active surveillance may be appropriate in selected patients with very low-volume, low-grade prostate cancer. Localized disease may be managed by active surveil- lance, surgery, or radiation therapy. Locally extensive, regionally advanced, and metastatic disease often require multimodal treatment strategies.Bill-Ax elson A et al. Radical prostatectomy or watchful waiting in prostate cancer29-year follow-up. N Engl J Med. 2018;379: 2319. [PMID: 30575473] Gourd E. New advances in prostate cancer screening and moni- toring. Lancet Oncol. 2020;21:887. [PMID: 32534632] Hoffman KE et al. Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA. 2020;323:149. [PMID: 31935027] Hugosson J et al; ERSPC investigators. A 16-yr follow-up of the European Randomized Study of Screening for Prostate Cancer. Eur Urol. 2019;76:43. [PMID: 30824296] Hussain M et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018; 378:2465. [PMID: 29949494] Kneebone A et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ ANZUP RAVES): a randomised, controlled, phase 3, non- inferiority trial. Lancet Oncol. 2020;21:1331. [PMID: 33002437] Parker CC et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a ran- domised controlled phase 3 trial. Lancet. 2018;392:2353. [PMID: 30355464] Sargos P et al. Adjuvant radiotherapy versus early salvage radio- therapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol. 2020;21:1341. [PMID: 33002438] Shoag JE et al. Reconsidering the trade-offs of prostate cancer screening. N Engl J Med. 2020;382:2465. [PMID: 32558473]BL ADDER CANCERE S S E N T I A L S  O F  D I A G N O S I S Gross or microscopic hematuria. Irritative voiding symptoms. Positive urinary cytology in most patients. Filling defect within bladder noted on imaging. General ConsiderationsBladder  cancer is the second most common urologic can- cer; it occurs more commonly in men than women (3.1:1), and the mean age at diagnosis is 73 years. Cigarette smok- ing and exposure to industrial dyes or solvents are risk factors for the disease and account for approximately 60%CMDT22_Ch39_p1612-p1675.indd  1659 02/07/21 2:44 PMChAPTER 391660 CMDT 2022and  15% of new cases, respectively. In the United States, almost all primary bladder cancers (98%) are epithelial malignancies, usually urothelial cell carcinomas (90%). Adenocarcinomas and squamous cell cancers account for approximately 2% and 7%, respectively. The latter is often associated with schistosomiasis, vesical calculi, or pro- longed catheter use. Clinical FindingsA.  Symptoms and SignsH ematuriagross or microscopic, chronic or intermittent is the presenting symptom in 8590% of patients with bladder cancer. Irritative voiding symptoms (urinary fre- quency and urgency) occur in a small percentage of patients as a result of the location or size of the cancer. Most patients with bladder cancer do not have signs of the disease because of its superficial nature. Abdominal masses detected on bimanual examination may be present in patients with large-volume or deeply infiltrating cancers. Hepatomegaly or palpable lymphadenopathy may be pres- ent in patients with metastatic disease, and lymphedema of the lower extremities results from locally advanced cancers or metastases to pelvic lymph nodes.B.  Laboratory FindingsU rinalysis reveals microscopic or gross hematuria in the majority of cases. On occasion, hematuria is accompanied by pyuria. Azotemia may be present in a small number of cases associated with ureteral obstruction. Anemia may occasionally be due to chronic blood loss or to bone mar- row metastases. Exfoliated cells from normal and abnormal urothelium can be readily detected in voided urine speci- mens. Cytology can be useful to detect the disease initially or to detect its recurrence. Cytology is sensitive in detect- ing cancers of higher grade and stage (8090%), but less so in detecting superficial or well-differentiated lesions (50%). There are numerous urinary tumor markers under investi- gation for screening or assessing recurrence, progression, prognosis, or response to therapy.C.  ImagingBladder  cancers may be identified as masses within the bladder using ultrasound, CT, or MRI. However, the pres- ence of cancer is confirmed by cystoscopy and biopsy, with imaging primarily used to evaluate the upper urinary tract and to stage more advanced lesions.D . Cystourethroscopy and BiopsyThe  diagnosis and staging of bladder cancers are made by cystoscopy and transurethral resection. If cystoscopy usually performed under local anesthesiaconfirms the presence of a bladder tumor, the patient is scheduled for transurethral resection under general or regional anesthe- sia. Random bladder and transurethral prostate biopsies are occasionally performed to detect occult disease and potentially identify patients at greater risk for cancer recur- rence and progression.Pathology & StagingGrading  is based on cellular features: size, pleomorphism, mitotic rate, and hyperchromatism. Bladder cancer staging is based on the extent (depth) of bladder wall penetration and the presence of regional or distant metastases. Both cancer grade and stage influence the natural history of bladder cancer including local recurrence within the blad- der and progression to higher-stage disease. TreatmentPa tients with superficial nonmuscle invasive cancers (Tis, Ta, T1) are treated with complete transurethral resection with selective use of a single dose intravesical chemother- apy immediately following resection. The subset of patients with carcinoma in situ (Tis) and those undergoing resec- tion of large, high-grade, recurrent Ta lesions or T1 cancers (or both) are good candidates for additional intravesical therapy. Patients with muscle invasive (T2+) but still localized cancers are at risk for both nodal metastases and progres- sion and require more aggressive treatment. The gold standard treatment is neoadjuvant chemotherapy followed by radical cystectomy, which confers a survival advantage versus cystectomy alone. This is particularly important for higher-stage or bulky tumors to improve their surgical resectability. Trimodal bladder preservation therapy con- sisting of complete transurethral resection, sensitizing sys- temic chemotherapy, and external beam radiotherapy can offer similar outcomes in optimally selected patients.A.  Intravesical TherapyImm unotherapeutic or chemotherapeutic agents delivered directly into the bladder via a urethral catheter can reduce the likelihood of recurrence in those who have undergone complete transurethral resection. Most agents are adminis- tered weekly for 612 weeks. Efficacy may be increased by prolonging contact time to 2 hours. The use of main- tenance therapy after the initial induction regimen is beneficial. Common agents include gemcitabine, mito- mycin, doxorubicin, valrubicin, and bacillus Calmette Gurin (BCG), with the last being the only agent effective in reducing disease progression. Side effects of intravesical chemotherapy include irritative voiding symptoms and hemorrhagic cystitis. Patients in whom symptoms or infection develop from BCG may require antituberculous therapy.B.  Surgical TreatmentAlthough  transurethral resection is the initial form of treatment for all bladder tumors (since it is diagnostic, allows for proper staging, and controls superficial cancers), muscle-invasive cancers require more aggressive treat- ment. Partial cystectomy can be considered in selected patients with solitary lesions at the bladder dome or those with cancer in a bladder diverticulum. Radical cystectomy in men entails removal of the bladder, prostate, seminal vesicles, and surrounding fat and peritoneal attachments and in women removal of the bladder, uterus, cervix,CMDT22_Ch39_p1612-p1675.indd  1660 02/07/21 2:44 PMCANCER1661 CMDT 2022urethra,  anterior vaginal vault, and usually the ovaries. In women with anterior tumors, vaginal and reproductive organ-sparing surgery can be considered. Bilateral pelvic lymph node dissection is performed in all patients. Urinary diversion is performed in all. In most patients, it uses a conduit of ileum or colon. However, continent forms of diversion avoid the necessity of an external appliance; it can be considered in a significant percentage of patients.C.  RadiotherapyExternal  beam radiotherapy delivered in fractions over a 6- to 8-week period is generally well tolerated, but approxi- mately 1015% of patients will develop bladder, bowel, or rectal complications. Local recurrence is common after radiotherapy alone (3070%) and it is therefore combined with radiosensitizing systemic chemotherapy to improve complete response and to decrease recurrence rates. Bladder- preserving chemoradiation can be offered to those patients seeking to keep their bladder and is best suited for those with solitary T2 or limited T3 tumors without ureteral obstruction. Radiation with or without chemotherapy can be offered to patients with localized cancers and to patients who are poor candidates for radical cystectomy or to patients with metastatic disease seeking palliation of local symptoms.D . ChemotherapyMetas tatic disease is present in 15% of patients with newly diagnosed bladder cancer. Furthermore, metastases develop in up to 40% of patients within 2 years of cystec- tomy, including those patients who were believed to have localized disease at the time of treatment. Cisplatin-based combination chemotherapy results in partial or complete responses in 1545% of patients (see Table 392) and is the preferred approach. Combination chemotherapy has been used to decrease recurrence rates in patients treated both with surgery and with radiotherapy. Neoadjuvant chemotherapy appears to benefit all patients with muscle-invasive disease prior to planned cystectomy. Chemotherapy should also be consid- ered before surgery in those with bulky lesions or those in whom regional metastases are suspected. Alternatively, adjuvant chemotherapy has been used after cystectomy in patients at high risk for recurrence, such as those who have lymph node involvement or extravesical local invasion.E.  ImmunotherapyThe  FDA has now approved several checkpoint inhibitors as immunotherapy for metastatic urothelial cancer. Approved antiPDL-1 inhibitors include atezolizumab, durvalumab , and avelumab (Table 392). Approved anti- PD1 inhibitors include nivolumab andpembrolizumab. All are approved for second-line treatment of locally advanced or metastatic urothelial cancer that progressed during or after platinum-based chemotherapy. Addition- ally, atezolizumab and pembrolizumab are approved as first-line therapy in cisplatin-ineligible patients whose tumors express PD-L1 or in patients ineligible for any platinum-based chemotherapy regardless of PD-L1expression status. Overall response rates of these agents are similar and range from 17% to 25% in locally advanced and metastatic urothelial bladder cancer. PrognosisThe  frequency of recurrence and progression are correlated with grade. Whereas progression may be noted in few low- grade cancers (1937%), it is common with poorly differ- entiated lesions (3367%). Carcinoma in situ is most often found in association with papillary bladder cancers. Its presence identifies patients at increased risk for recurrence and progression. At initial presentation, approximately 5080% of blad- der cancers are superficial: stage Ta, Tis, or T1. When properly treated, lymph node metastases and progression are uncommon in such patients and survival is excellent (81%). Five-year survival of patients with T2 and T3 dis- ease ranges from 50% to 75% after radical cystectomy. Long-term survival for patients with metastatic disease at presentation is rare. When to Refer Refer all patients to a urologist. Hematuria often deserves evaluation with both upper urinary tract imaging and cystoscopy, particularly in a high-risk group (eg, older men). Refer when histologic diagnosis and staging require endoscopic resection of cancer. Metastatic urothelial cancer should be managed by a medical oncologist.Babjuk  M et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)2019 update. Eur Urol. 2019;76:639. [PMID: 31443960] Faba OR et al. Update of the ICUD-SIU International Consulta- tion on Bladder Cancer 2018: urinary diversion. World J Urol. 2019;37:85. [PMID: 30238399] Flaig TW et al. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18:329. [PMID: 32135513] Hussain SA et al. From clinical trials to real-life clinical practice: the role of immunotherapy with PD-1/PD-L1 inhibitors in advanced urothelial carcinoma. Eur Urol Oncol. 2018;1:486. [PMID: 31158093] Nadal R et al. Management of metastatic bladder cancer. Cancer Treat Rev. 2019;76:10. [PMID: 31030123]C ANCERS OF THE URETER & RENAL PELVISCancers  of the ureter and renal pelvis are rare and occur more commonly in patients who have bladder cancer, Bal- kan nephropathy, or Lynch syndrome, who smoke, or who have a long history of analgesic abuse. The majority are urothelial cell carcinomas. Gross or microscopic hematuria is present in most patients; flank pain secondary to bleed- ing and obstruction occurs less commonly. As with bladder cancers, urinary cytology is often positive in high-grade cancers. The most common signs identified at the time of CT or intravenous urography include an intraluminal fill- ing defect, unilateral nonvisualization of the collectingCMDT22_Ch39_p1612-p1675.indd  1661 02/07/21 2:44 PMChAPTER 391662 CMDT 2022system,  and hydronephrosis. Ureteral and renal pelvic tumors must be differentiated from calculi, blood clots, papillary necrosis, or inflammatory and infectious lesions. On occasion, upper urinary tract lesions are accessible for biopsy, fulguration, or resection using a ureteroscope. Treatment is based on the site, size, grade, depth of pene- tration, and number of cancers present. Most are excised with laparoscopic or open nephroureterectomy (renal pel- vic and upper ureteral lesions) or segmental excision of the ureter (distal ureteral lesions). Endoscopic resection may be indicated in patients with limited renal function or focal, low-grade, cancers. Similar to urothelial bladder cancers, use of chemotherapy prior to surgery may improve outcomes.Kim  HS et al. Immune checkpoint inhibitors for urothelial carci- noma. Investig Clin Urol. 2018;59:285. [PMID: 30182073] Leow JJ et al. Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: a 2020 systematic review and meta-analysis, and future perspectives on systemic therapy. Eur Urol. 2021;79:635. [PMID: 32798146] Scotland KB et al. Long term outcomes of ureteroscopic man- agement of upper tract urothelial carcinoma. Urol Oncol. 2020;38:850.e17. [PMID: 32773230]RE NAL CELL CARCINOMAE S S E N T I A L S  O F  D I A G N O S I S Gross or microscopic hematuria. Flank pain or mass in some patients. Systemic symptoms such as fever, weight loss may be prominent. Solid renal mass on imaging. General ConsiderationsKidney  (renal cell) and renal pelvis carcinomas account for 3.8% of all adult cancers. In 2019 in the United States, it is estimated that approximately 73,820 cases of renal cell car- cinoma will be diagnosed and 14,770 deaths will result. Renal cell carcinoma has a peak incidence in the sixth decade of life and a male-to-female ratio of 2:1. It may be associated with a number of paraneoplastic syndromes. Risk factors include physical inactivity, obesity, and diabetes mellitus. Cigarette smoking is the only known significant environmental risk factor. Familial causes of renal cell carcinoma have been identified (von Hippel Lindau syndrome, hereditary papillary renal cell carci- noma, hereditary leiomyoma-renal cell carcinoma, and Birt-Hogg-Dub syndrome). There is an association with dialysis-related acquired cystic disease and specific genetic aberrations (eg, Xp11.2 translocation). But sporadic carci- nomas are far more common. Renal cell carcinoma originates from the proximal tubule cells. Various histologic cell types are recognized (clear cell, papillary, chromophobe, collecting duct, and sarcomatoid).Clinical FindingsA.  Symptoms and SignsHisto rically, 60% of patients presented with gross or micro- scopic hematuria. Flank pain or an abdominal mass was detected in approximately 30% of cases. The triad of flank pain, hematuria, and mass, found in only 10% of patients, is often a sign of advanced disease. Fever can occur as a paraneoplastic symptom. Symptoms of metastatic disease (cough, bone pain) occur in 2030% of patients at presenta- tion. Due to the widespread use of ultrasound and cross- sectional imaging, renal tumors are frequently detected incidentally in individuals with no urologic symptoms. Consequently, there has been profound stage migration toward lower stages of disease over the last 20 years. How- ever, population mortality rates have remained stable.B.  Laboratory FindingsCon temporary studies suggest hematuria is present in less than 50% of patients. Erythrocytosis from increased eryth- ropoietin production occurs in 5%, though anemia is more common; hypercalcemia may be present in up to 10% of patients. Stauffer syndrome is a reversible syndrome of hepatic dysfunction (with elevated liver tests) in the absence of metastatic disease.C.  ImagingSolid  renal masses are often first identified by abdominal ultrasonography or CT. CT and MRI scanning are the most valuable imaging tests for renal cell carcinoma. These scans confirm the character of the mass and provide valuable stag- ing information with respect to regional lymph nodes, renal vein or vena cava tumor thrombus, and adrenal or liver metastases. CT and MRI also provide valuable information regarding the contralateral kidney (function, bilaterality of neoplasm). Chest radiographs or CT exclude pulmonary metastases. Bone scans should be performed for large tumors and in patients with bone pain or elevated serum alkaline phosphatase levels. Brain imaging should be obtained in patients with high metastatic burden or in those with neurologic deficits. Differential DiagnosisSolid  renal masses are renal cell carcinoma until proven otherwise. Other solid masses include renal angiomyoli- pomas (fat density usually detectable by CT), renal pelvis urothelial cancers (more central location, involvement of the collecting system, positive urinary cytology), renal oncocytomas (indistinguishable from renal cell carcinoma preoperatively), renal abscesses, and adrenal tumors (superoanterior to the kidney). TreatmentSu rgical extirpation is the primary treatment for localized renal cell carcinoma. Patients with a single kidney, bilateral lesions, or significant medical renal disease should be con- sidered for partial nephrectomy. Patients harboring a small tumor with a normal contralateral kidney and good kidneyCMDT22_Ch39_p1612-p1675.indd  1662 02/07/21 2:44 PMCANCER1663 CMDT 2022funct ion are also candidates for partial nephrectomy, while radical nephrectomy is indicated in patients with cancers larger than 7 cm and those in whom partial nephrectomy is not technically feasible. Radiofrequency and cryosurgical ablation are alternative options instead of surgery in select patients with tumors less than 34 cm with similar risk of metastatic progression but higher risk of local recurrence. Active surveillance is warranted in select patients (signifi- cant comorbidity, short life expectancy) and appears safe with low risk of 5-year systemic progression. Percutaneous biopsy can provide tumor histology and grade to help guide treatment decisions. Cytotoxic chemotherapy has no role in the treatment of metastatic renal cell carcinoma. Historically, cytokine-based immunotherapies, such as interferon-alpha and interleukin-2, produced partial response rates of 1520% and 1535%, respectively (Table 392). Responders tended to have lower tumor burden, metastatic disease confined to the lung, and a high-performance status. Two randomized trials demonstrat- ing a survival benefit of cytoreductive nephrectomy followed by systemic interferon-alpha compared with the use of sys- temic therapy alone led to the widespread adoption of cytore- ductive nephrectomy. Patients most likely to benefit from cytoreduction were those with good performance status, lung only metastases, and good prognostic features. Presently, management strategies are based on tumor histology and patient risk (favorable, intermediate, or poor). Several targeted medications, specifically VEGF, Raf- kinase, and mTOR inhibitors, are effective (4060% response rates) in patients with advanced kidney cancer (Table 392). These oral agents, which include sunitinib, pazopanib, cabozantinib, axitinib, and sorafenib, are generally well tolerated and particularly active for clear cell carcinoma. The optimal timing and combination of these agents remain to be determined. Sunitinib is approved for adjuvant use after complete surgical resection in patients with adverse pathologic features. The mTOR inhibitors everolimus and temsirolimus are approved for use in patients with prior anti-VEGF therapy, as is the combina- tion of lenvatinib and everolimus. Nivolumab is an approved anti-PD-1 immunotherapy for treating metastatic disease that has progressed despite antiangiogenic therapy. Nivolumab in combination with the anti-CTLA4 immuno- therapy ipilimumab and pembrolizumab (anti-PD-1) in combination with the VEGF inhibitor axitinib have proved superior to sunitinib in previously untreated intermediate- and poor-risk metastatic clear cell renal cell carcinoma and are considered the standard first-line treatment for this patient population (Table 392). The utilization of cytoreductive nephrectomy in combi- nation with contemporary agents has decreased in response to the results of CARMENA and adoption of combination immunotherapy regimens (nivolumab plus ipilimumab, pembrolizumab plus axitinib). Still, there remains a role for cytoreductive surgery in select patients with intermediate- risk disease. PrognosisAfter  radical or partial nephrectomy, tumors confined to the renal capsule (T1T2) demonstrate 5-year disease-freesurvivals of 90100%. Tumors extending beyond the renal capsule (T3 or T4) and node-positive tumors have 5-year disease-free survivals of 5060% and 015%, respectively. One subgroup of patients with nonlocalized disease has reasonable long-term survival, namely, those with solitary resectable metastases. In this setting, radical nephrectomy with resection of the solitary metastasis results in 5-year disease-free survival rates of 1530%. When to Refer Refer patients with solid renal masses or complex cysts to a urologist for further evaluation. Refer patients with renal cell carcinoma to a urologic surgeon for surgical excision. Refer patients with metastatic disease to an oncologist and urologist.Lalani AA et  al. Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: current paradigms, use of immuno- therapy, and future directions. Eur Urol. 2019;75:100. [PMID: 30327274] Motzer RJ et al; CheckMate 214 Investigators. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277. [PMID: 29562145] Rini BI et al; KEYNOTE-426 Investigators. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1116. [PMID: 30779529] Sanchez A et al. Current management of small renal masses, including patient selection, renal tumor biopsy, active surveil- lance, and thermal ablation. J Clin Oncol. 2018;36:3591. [PMID: 30372390]OTH ER PRIMARY TUMORS OF THE KIDNEYOncocytomas  account for 35% of renal tumors, are usu- ally benign, and are indistinguishable from renal cell carci- noma on preoperative imaging. These tumors are seen in other organs, including the adrenals, salivary glands, and thyroid and parathyroid glands. Angiomyolipomas are rare benign tumors composed of fat, smooth muscle, and blood vessels. They are most com- monly seen in patients with tuberous sclerosis (often mul- tiple and bilateral) or in young to middle-aged women. CT scanning may identify the fat component, which is diagnos- tic for angiomyolipoma. Asymptomatic lesions less than 5 cm in diameter usually do not require intervention; large lesions can spontaneously bleed. Acute bleeding can be treated by angiographic embolization or, in rare cases, nephrectomy. Lesions over 5 cm are often prophylacti- cally treated with angioembolization to reduce the risk of bleeding.SE CONDARY CANCERS OF THE KIDNEYThe kidney is not an infrequent site fo r metastatic disease. Of the solid tumors, lung cancer is the most common (20%), followed by breast (10%), stomach (10%), and the contralateral kidney (10%). Lymphoma, both Hodgkin and non-Hodgkin, may also involve the kidney, although it tends to appear as a diffusely infiltrative process resulting in renal enlargement rather than a discrete mass.CMDT22_Ch39_p1612-p1675.indd  1663 02/07/21 2:44 PMChAPTER 391664 CMDT 2022TE STICULAR CANCERS (Germ Cell Tumors)E S S E N T I A L S  O F  D I A G N O S I S Most common neoplasm in men aged 2035 years. Patient typically discovers a painless nodule. Orchiectomy necessary for diagnosis. General ConsiderationsMalignan t tumors of the testis are rare, with approximately five to six cases per 100,000 males reported in the United States each year. Ninety to 95 percent of all primary testicu- lar tumors are germ cell tumors and can be divided into two major categories: nonseminomas, including embryo- nal cell carcinoma (20%), teratoma (5%), choriocarcinoma (less than 1%), and mixed cell types (40%); and semino- mas (35%). The lifetime probability of developing testicu- lar cancer is 0.3% for an American male. Approximately 5% of testicular cancers develop in a patient with a history of cryptorchism, with seminoma being the most common. However, 510% of these tumors occur in the contralateral, normally descended testis. The relative risk of development of malignancy is higher for the intra- abdominal testis (1:20) and lower for the inguinal testis (1:80). Placement of the cryptorchid testis into the scrotum (orchidopexy) does not alter its malignant potential but does facilitate routine examination and cancer detection. Testicular cancer is slightly more common on the right than the left, paralleling the increased incidence of cryptor- chidism on the right side. One to 2 percent of primary tes- ticular cancers are bilateral and up to 50% of these men have a history of unilateral or bilateral cryptorchidism. Primary bilateral testicular cancers may occur synchronously or asynchronously but tend to be of the same histology. Semi- noma is the most common histologic finding in bilateral primary testicular cancers, while malignant lymphoma is the most common bilateral testicular tumor overall. Clinical FindingsA.  Symptoms and SignsThe  most common symptom of testicular cancer is painless enlargement of the testis. Sensations of heaviness are not unusual. Patients are usually the first to recognize an abnormality, yet often delay in seeking medical attention ranges from 3 to 6 months. Acute testicular pain resulting from intratesticular hemorrhage occurs in approximately 10% of cases. Ten percent of patients are asymptomatic at presentation, and 10% manifest symptoms relating to metastatic disease such as back pain (retroperitoneal metastases), cough (pulmonary metastases), or lower extremity edema (vena cava obstruction). A discrete mass or diffuse testicular enlargement is noted in most cases. Secondary hydroceles may be present in 510% of cases. In advanced disease, supraclavicular adenop- athy may be present, and abdominal examination may reveal a mass. Gynecomastia is seen in 5% of germ cell tumors.B. Laboratory FindingsSeveral  serum markers are important in the diagnosis and monitoring of testicular carcinoma, including human cho- rionic gonadotropin (hCG), alpha-fetoprotein, and lactate dehydrogenase. Alpha-fetoprotein is never elevated with pure seminomas, and while hCG is occasionally elevated in seminomas, levels tend to be lower than those seen with nonseminomas. Lactate dehydrogenase may be elevated with either type of tumor and is a marker for disease bur- den. Liver tests may be elevated in the presence of hepatic metastases, and anemia may be present in advanced disease.C.  ImagingScrotal  ultrasound can readily determine whether a mass is intratesticular or extratesticular. Once the diagnosis of testicular cancer has been established by inguinal orchiec- tomy, clinical staging of the disease is accomplished by chest, abdominal, and pelvic CT scanning. StagingT esticular cancer is staged using the TNM system created based on extent of cancer in the testis, status of regional lymph nodes, the presence of metastases in distant lymph nodes or other viscera, and serum levels of tumor markers. Based on these features, germ cell tumors can be grouped to assign an overall stage: stage I lesion is confined to the testis; stage II demonstrates regional lymph node involve- ment in the retroperitoneum; and stage III indicates distant metastasis. Differential DiagnosisAn  incorrect diagnosis is made at the initial examination in up to 25% of patients with testicular tumors. Scrotal ultra- sonography should be performed if any uncertainty exists with respect to the diagnosis. Although most intratesticu- lar masses are malignant, a benign lesionepidermoid cystmay rarely be seen. Epidermoid cysts are usually very small benign nodules located just underneath the tunica albuginea; occasionally, however, they can be large. Testicular lymphoma is discussed below. TreatmentIn guinal exploration with early vascular control of the sper- matic cord structures is the initial intervention. If cancer cannot be excluded by examination of the testis, radical orchiectomy is warranted. Scrotal approaches and open tes- ticular biopsies should be avoided. Further therapy depends on the histology of the tumor as well as the clinical stage. Patients with clinical stage I seminomas are candidates for surveillance (preferred), single-agent carboplatin, or adjuvant radiotherapy. Stage IIa and IIb seminomas (retro- peritoneal disease less than 2 cm diameter in IIa and 25 cm in IIb) are treated by radical orchiectomy plus retroperito- neal irradiation or primary systemic chemotherapy (etoposide and cisplatin or cisplatin, etoposide, and bleo- mycin) (Table 392). Seminomas of stage IIc (greater than 5-cm-diameter retroperitoneal nodes) and stage III receiveCMDT22_Ch39_p1612-p1675.indd  1664 02/07/21 2:44 PMCANCER1665 CMDT 2022primary systemic chemotherap y. After chemotherapy, sur- gical resection of residual retroperitoneal nodes is war- ranted if the node is greater than 3 cm in diameter and positive on PET scan, since 40% will harbor residual carcinoma. Up to 75% of clinical stage I nonseminomas are cured by orchiectomy alone. Selected patients without specific risk factors have low-risk of recurrence and are generally offered surveillance after orchiectomy. These criteria include (1) cancer is confined within the tunica albuginea; (2) cancer does not demonstrate vascular invasion; (3) tumor markers normalize after orchiectomy; (4) radio- graphic imaging of the chest and abdomen shows no evi- dence of disease; and (5) the patient is reliable. Patients most likely to experience relapse on a surveillance regimen include those with predominantly embryonal cancer and those with vascular or lymphatic invasion identified in the orchiectomy specimen. Alternatives to surveillance for clinical stage I nonseminomas include adjuvant chemo- therapy (bleomycin, etoposide, cisplatin) (see Table 392) or retroperitoneal lymph node dissection. Following orchiectomy, patients with bulky retroperito- neal disease (greater than 5-cm nodes) or metastatic non- seminomas are treated with combination chemotherapy (cisplatin and etoposide or cisplatin, etoposide, and bleo- mycin) (Table 392). If tumor markers normalize and a residual mass greater than 1 cm persists on imaging stud- ies, it is resected because 1520% will harbor residual cancer and 40% will harbor teratomas. Even if patients have a complete response to chemotherapy, some clinicians advocate retroperitoneal lymphadenectomy since 10% of patients may harbor residual carcinoma and 10%, retro- peritoneal teratoma. If tumor markers fail to normalize following primary chemotherapy, salvage chemotherapy is required (cisplatin, etoposide, and ifosfamide). Postoperative active surveillance by the clinician and patient means patients are followed up every 26 months for the first 2 years and every 46 months in the third year. For nonseminomas, tumor markers are obtained at each visit, and chest radiographs and abdominal and pelvic CT scans are obtained every 46 months. For seminomas, serum tumor markers may be obtained (optional), chest imaging is obtained only as clinically indicated, and abdominal and pelvic CT scans are performed every 36 months. Follow-up continues beyond the initial 3 years; however, 80% of relapses will occur within the first 2 years. With rare exceptions, patients who relapse can be cured by chemotherapy or surgery. PrognosisThe  5-year disease-free survival rates for stage I and IIa seminomas (retroperitoneal disease less than 2 cm in diameter) treated by radical orchiectomy and retroperito- neal irradiation are 98% and 9294%, respectively. Ninety- five percent of patients with stage III disease attain a complete response following orchiectomy and chemother- apy. The 5-year disease-free survival for patients with stage I nonseminomas (includes all treatments) ranges from 96% to 100%. For low-volume stage II disease, a 5-year disease- free survival of 90% is expected. Patients withbulky retroperitoneal or disseminated disease treated with primary chemotherapy followed by surgery have a 5-year disease-free survival rate of 5580%. When to ReferRef er all patients with solid masses of the testis to a urologist and a medical oncologist if metastatic disease is suspected.Goldber g H et al. Germ cell testicular tumorscontemporary diagnosis, staging and management of localized and advanced disease. Urology. 2019;125:8. [PMID: 30597167] King J et al. Management of residual disease after chemotherapy in germ cell tumors. Curr Opin Oncol. 2020;32:250. [PMID: 32168037] Pierorazio PM et al. Performance characteristics of clinical stag- ing modalities for early stage testicular germ cell tumors: a systematic review. J Urol. 2020;203:894. [PMID: 31609176]SE CONDARY CANCERS OF THE TESTISSecondary  cancers of the testis are rare. In men over the age of 50 years, lymphoma is the most common. Overall, it is the most common secondary neoplasm of the testis, accounting for 5% of all testicular cancers. It may be seen in three clinical settings: (1) late manifestation of wide- spread lymphoma, (2) the initial presentation of clinically occult disease, and (3) primary extranodal disease. Radical orchiectomy is indicated to make the diagnosis. Prognosis is related to the stage of disease. Metastasis to the testis is rare. The most common pri- mary site of origin is the prostate, followed by the lung, gastrointestinal tract, melanoma, and kidney.CA NCER COMPLICATIONS & EMERGENCIESSunny  Wang, MD Tiffany O. Dea, PharmD, BCOPSP INAL CORD COMPRESSIONE S S E N T I A L S  O F  D I A G N O S I S Complication of metastatic solid tumor, lym- phoma, or plasma cell myeloma. Back pain is most common presenting symptom. Prompt diagnosis is essential because once a severe neurologic deficit develops, it is often irreversible. Emergent treatment may prevent or potentially reverse paresis and urinary and bowel incontinence. General ConsiderationsCancers  that cause spinal cord compression most com- monly metastasize to the vertebral bodies, resulting in physical damage to the spinal cord from edema, hemorrhage,CMDT22_Ch39_p1612-p1675.indd  1665 02/07/21 2:44 PMChAPTER 391666 CMDT 2022and  pressure-induced ischemia to its vasculature. Persis- tent compression can result in irreversible changes to the myelin sheaths resulting in permanent neurologic impairment. Prompt diagnosis and therapeutic intervention are essential, since the probability of reversing neurologic symptoms largely depends on the duration of symptoms. Patients who are treated promptly after symptoms appear may have partial or complete return of function and, depending on tumor sensitivity to specific treatment, may respond favorably to subsequent anticancer therapy. Clinical FindingsA.  Symptoms and SignsBack  pain at the level of the tumor mass occurs in over 80% of cases and may be aggravated by lying down, weight bear- ing, sneezing, or coughing; it usually precedes the develop- ment of neurologic symptoms or signs. Since involvement is usually epidural, a mixture of nerve root and spinal cord symptoms often develops. Progressive weakness and sen- sory changes commonly occur. Bowel and bladder symp- toms progressing to incontinence are late findings. The initial findings of impending cord compression may be quite subtle, and there should be a high index of suspicion when back pain or weakness of the lower extrem- ities develops in a cancer patient.B.  ImagingMRI is usually the initial imaging procedure o f choice in a cancer patient with new-onset back pain. If the back pain symptom is nonspecific, a whole-body PET-CT scan with18 F-2-deoxyglucose may be a useful screening procedure. Bone radiographs are neither sensitive nor specific for the evaluation of a cancer patient with back pain. When neu- rologic findings suggest spinal cord compression, an emer- gent MRI should be obtained; the MRI should survey the entire spine to define all areas of tumor involvement for treatment planning purposes. MRI has a sensitivity of 93% and a specificity of 97% for diagnosis of metastatic spinal cord compression. TreatmentPa tients with a known cancer diagnosis found to have epi- dural impingement of the spinal cord should be given corticosteroids immediately. The initial dexamethasone dose is 10 mg intravenously followed by 46 mg every 6 hours intravenously or orally. Patients without a known diagnosis of cancer should have emergent surgery to relieve the impingement and obtain a pathologic speci- men; preoperative corticosteroids should not be given since they might compromise the pathology results. Patients with solid tumors who have a single area of com- pression and who are considered candidates for surgery are best treated first with surgical decompression followed by radiation therapy. Better outcomes (ie, improved ability to ambulate and improved bladder and bowel function) occur in patients who undergo surgery followed byradiation therapy than in those who receive radiation alone. If multiple vertebral body levels are involved with cancer, fractionated radiation therapy is the preferred treatment option. Corticosteroids are generally tapered toward the end of radiation therapy. A scoring system exists for patients presenting with spinal cord metastases to identify those with poor survival times who would be best managed with supportive care or single fraction palliative radiation.Boussios S et  al. Metastatic spinal cord compression: unraveling the diagnostic and therapeutic challenges. Anticancer Res. 2018;38:4987. [PMID: 30194142] Hoskin PJ et al. Effect of single-fraction vs multifraction radio- therapy on ambulatory status among patients with spinal canal compression from metastatic cancer: the SCORAD randomized clinical trial. JAMA. 2019;322:2084. [PMID: 31794625] Lawton AJ et al. Assessment and management of patients with metastatic spinal cord compression: a multidisciplinary review. J Clin Oncol. 2019;37:61. [PMID: 30395488]MA LIGNANT EFFUSIONSE S S E N T I A L S  O F  D I A G N O S I S Occur in pleural, pericardial, and peritoneal spaces. Caused by direct neoplastic involvement of serous surface or obstruction of lymphatic drainage. Half of undiagnosed effusions in patients not known to have cancer are malignant. General ConsiderationsThe developme nt of an effusion in the pleural, pericardial, or peritoneal space may be the initial finding in a patient with cancer, or an effusion may appear during the course of disease progression. Direct involvement of the serous sur- face with tumor is the most frequent initiating cause of the accumulation of fluid. The most common malignancies causing pleural and pericardial effusions are lung and breast cancers; the most common malignancies associated with malignant ascites are ovarian, colorectal, stomach, and pancreatic cancers. Clinical FindingsA.  Symptoms and SignsPa tients with pleural and pericardial effusions complain of shortness of breath and orthopnea. Patients with ascites complain of abdominal distention and discomfort. Cardiac tamponade causing pressure equalization in the chambers impairs both filling and cardiac output and can be life- threatening. Signs of tamponade include tachycardia, muf- fled heart sounds, pulsus paradoxus, and hypotension. Signs of pleural effusions include decreased breath sounds, egophony, and percussion dullness.CMDT22_Ch39_p1612-p1675.indd  1666 02/07/21 2:44 PMCANCER1667 CMDT 2022B.  Laboratory FindingsMalignancy is confirmed  as the cause of an effusion when analysis of the fluid specimen shows malignant cells in either the cytology or cell block specimen.C.  ImagingThe  presence of effusions can be confirmed with radio- graphic studies or ultrasonography. Differential DiagnosisThe  differential diagnosis of a malignant pleural or pericar- dial effusion includes nonmalignant processes, such as infection, pulmonary embolism, heart failure, and trauma. The differential diagnosis of malignant ascites includes similar benign processes, such as heart failure, cirrhosis, peritonitis, and pancreatic ascites. Bloody effusions are usually due to cancer, but a bloody pleural effusion can also be due to pulmonary embolism, trauma and, occasionally, infection. Chylous pleural or ascitic fluid is generally asso- ciated with obstruction of lymphatic drainage as might occur in lymphoma. TreatmentThe  development of a malignant effusion is a late-stage manifestation of the cancer. Treatment is tailored to the underlying cancer, whether with targeted therapy, chemo- therapy, or immunotherapy, depending on tumor testing results. Effective systemic treatment can lead to regression of the effusion. Acute symptoms related to the effusion often require urgent intervention with drainage of the effu- sion. Decisions regarding palliative management of malig- nant effusion are in large part dictated by the patients symptoms and goals of care.A.  Pleural EffusionA  pleural effusion that is symptomatic may be managed initially with a large volume thoracentesis. In some patients, the effusion slowly reaccumulates, which allows for periodic thoracentesis when the patient becomes symp- tomatic. However, in many patients, the effusion reaccu- mulates quickly, causing rapid return of shortness of breath. For those patients, two other management options exist: pleurodesis or indwelling pleural catheter (eg, PleurX). Chest tube drainage followed by pleurodesis involves placement of a chest tube that is connected to closed water seal drainage. After lung expansion is con- firmed on a chest radiograph, a sclerosing agent (such as talc slurry or doxycycline) is injected into the catheter. Patients should be premedicated with analgesics. Pleurode- sis will not be successful if the lung cannot be reexpanded. These patients are better managed with placement of an indwelling catheter that can be drained by a family mem- ber or a visiting nurse. This procedure is often preferable for patients with short life expectancies or for those who do not respond to pleurodesis. In a meta-analysis of random- ized controlled trials comparing indwelling pleural cathe- ter with pleurodesis, indwelling pleural catheters resultedin shorter hospital stays and fewer repeat pleural interven- tions, but increased rates of cellulitis.B.  Pericardial EffusionFluid  may be removed by a needle aspiration or by place- ment of a catheter for more thorough drainage. As with pleural effusions, most pericardial effusions will reaccu- mulate. Management options for recurrent, symptomatic effusions include prolonged catheter drainage (for several days until drainage has decreased to 2030 mL/day) or surgical intervention such as a pericardiotomy or pericardiectomy.C.  Malignant AscitesPa tients with malignant ascites not responsive to chemo- therapy are generally treated with repeated large-volume paracenteses. Since the frequency of drainage to maintain comfort can compromise the patients quality of life, other alternatives include placement of a catheter or port so that the patient, family member, or visiting nurse can drain fluid as needed at home. For patients with portal hyper- tension from large hepatic masses, diuretics (such as spi- ronolactone 100 mg with furosemide 2040 mg orally daily) may be useful to decrease the need for repeated paracentesis.As ciak R et al. Malignant pleural effusion: from diagnostics to therapeutics. Clin Chest Med. 2018;39:181. [PMID: 29433714] Feller-Kopman DJ et al. Management of malignant pleural effu- sions. An official ATS/STS/STR clinical practice guideline. Am J Respir Crit Care Med. 2018;198:839. [PMID: 30272503] Iyer NP et al. Indwelling pleural catheter versus pleurodesis for malignant pleural effusions. A systematic review and meta- analysis. Ann Am Thorac Soc. 2019;16:124. [PMID: 30272486] Walker S et al. Malignant pleural effusion management: keeping the flood gates shut. Lancet Respir Med. 2020;8:609. [PMID: 31669226]HYP ERCALCEMIAE S S E N T I A L S  O F  D I A G N O S I S Most common paraneoplastic endocrine syndrome. Usually symptomatic and severe ( 15 mg/dL [3.75 mmol/L]); accounts for most inpatients with hypercalcemia. The neoplasm is clinically apparent in nearly all cases when hypercalcemia is detected. General ConsiderationsH ypercalcemia affects 2030% of cancer patients at some point during their illness. The most common cancers causing hypercalcemia are myeloma, breast carcinoma, and NSCLC. Hypercalcemia is caused by one of three mechanisms: sys- temic effects of tumor-released proteins, direct osteolysis of bone by tumor, or vitamin Dmediated osteoabsorption.CMDT22_Ch39_p1612-p1675.indd  1667 02/07/21 2:44 PMChAPTER 391668 CMDT 2022 Clinical FindingsA.  Symptoms and SignsSy mptoms and signs of hypercalcemia can be subtle; more severe symptoms occur with higher levels of hypercalcemia and with a rapidly rising calcium level. Early symptoms typi- cally include anorexia, nausea, fatigue, constipation, and polyuria; later findings may include muscular weakness and hyporeflexia, confusion, psychosis, tremor, and lethargy.B.  Laboratory FindingsSym ptoms and signs are caused by free calcium; as calcium is bound by protein in the serum, the measured serum calcium will underestimate the free or ionized calcium in patients with low albumin levels. Free ionized calcium can be measured. When the corrected serum calcium rises above 12 mg/dL (3 mmol/L), especially if the rise occurs rapidly, sudden death due to cardiac arrhythmia or asystole may occur. Initial work-up for hypercalcemia includes obtaining serum PTH, PTHrP , and calcitriol levels. The presence of hypercalcemia does not invariably indicate a dismal prognosis, especially in patients with breast cancer, myeloma, or lymphoma.C.  ECGElectrocardiograph y in hypercalcemia often shows a short- ening of the QT interval. TreatmentEme rgency management should begin with the initiation of intravenous fluids with 0.9% saline at 100300 mL/h to ensure rehydration with brisk urinary output of the often volume-depleted patient. If kidney function is normal or only marginally impaired, a bisphosphonate should be given. Choices include pamidronate, 6090 mg intravenously over 24 hours, or zoledronic acid, 4 mg intravenously over 15 minutes. Zoledronic acid is more potent than pamidro- nate and has the advantage of a shorter administration time as well as a longer duration of effect. Once hypercalcemia is controlled, treatment directed at the cancer should be initi- ated if possible. In the event that the hypercalcemia becomes refractory to repeated doses of bisphosphonates, other agents that can help control hypercalcemia (at least temporarily) include calcitonin and denosumab; corticosteroids can be useful in patients with myeloma and lymphoma. Salmon calcitonin, 48 international units/kg given subcutaneously or intramuscularly every 12 hours, can be used in patients with severe, symptomatic hypercalcemia; its onset of action is within hours but its hypocalcemic effect wanes in 23 days. Denosumab, 120 mg given subcutaneously weekly for 4 weeks followed by monthly administration, is a choice for long-term management of bisphosphonate-refractory hyper- calcemia or for patients with kidney dysfunction that pre- cludes use of a bisphosphonate.Asoni tis N et al. Diagnosis, pathophysiology, and management of hypercalcemia in malignancy: a review of the literature. Horm Metab Res. 2019;51:770. [PMID: 31826272]Zagzag J et al. Hypercalcemia and cancer: differential diagnosis and treatment. CA Cancer J Clin. 2018;68:377. [PMID: 30240520]HYP ERURICEMIA & TUMOR LYSIS SYNDROMEE S S E N T I A L S  O F  D I A G N O S I S Complication of treatment-associated tumor lysis of hematologic and rapidly proliferating malignancies. May be worsened by thiazide diuretics. Rapid increase in serum uric acid can cause acute urate nephropathy from uric acid crystallization. Reducing pre-chemotherapy serum uric acid is fundamental to preventing urate nephropathy. General ConsiderationsT umor lysis syndrome (TLS) is seen most commonly fol- lowing treatment of hematologic malignancies, such as acute lymphoblastic leukemia and Burkitt lymphoma. However, TLS can develop from any tumor highly sensitive to chemotherapy. TLS is caused by the massive release of cellular material including nucleic acids, proteins, phos- phorus, and potassium. If both the metabolism and excre- tion of these breakdown products are impaired, hyperuricemia, hyperphosphatemia, and hyperkalemia will develop abruptly. Acute kidney injury may then develop from the crystallization and deposition of uric acid and calcium phosphate within the renal tubules, further exacerbating the hyperphosphatemia and hyperkalemia. Clinical FindingsA.  Symptoms and SignsSymp toms of hyperphosphatemia include nausea, vomit- ing, anorexia, muscle cramps, tetany, and seizures. High levels of phosphorus and co-precipitation with calcium can cause renal tubule blockage, further exacerbating the kid- ney injury. Hyperkalemia, due to release of intracellular potassium and impaired kidney excretion, can cause arrhythmias and sudden death.B.  Laboratory FindingsThe laborat ory diagnosis of TLS include at least two of the following criteria observed within a 24-hour period: uric acid 8 mg/dL or higher (476 mcmol/L or higher), phos- phate 4.5 mg/dL or higher (1.45 mmol/L or higher), potas- sium 6.0 mEq/L or more (6 mmol/L or more) (or a 25% increase from baseline for these parameters), and corrected serum calcium 7 mg/dL or lower (1.75 mmol/L or lower). A clinical diagnosis of TLS includes meeting the laboratory criteria and at least one clinical criterion: acute kidney injury (creatinine greater than or equal to 1.5  upper limit of normal or increase greater than 0.3 g/dL or urinaryCMDT22_Ch39_p1612-p1675.indd  1668 02/07/21 2:44 PMCANCER1669 CMDT 2022out put greater than 0.5 mL/kg/h for 6 hours) or cardiac arrhythmia, sudden cardiac death, or seizure. TreatmentPreven tion is the most important factor in the manage- ment of TLS. Aggressive hydration at least 24 hours prior to chemotherapy as well as 2448 hours after chemotherapy completion helps keep urine flowing and facilitates excre- tion of uric acid and phosphorus. It is recommended to maintain a urinary output of at least 100 mL/h, and a daily urine volume of at least 3 L/day. If evidence of volume over- load or inadequate urinary output develops, loop diuretics can be used. Thiazide diuretics are contraindicated because they increase uric acid levels and can interact with allopuri- nol. For patients at moderate risk of developing TLS, eg, those with intermediate-grade lymphomas and acute leuke- mias, allopurinol should be given before starting chemo- therapy with dose reductions for impaired kidney function. Rasburicase is given intravenously to patients at high risk for developing TLS, eg, those with high-grade lymphomas or acute leukemias with markedly elevated white blood cell counts. Rasburicase may also be considered for patients with baseline elevated uric acid who are being treated with venetoclax (Bcl-2 inhibitor) for chronic lymphocytic leuke- mia or in any patient in whom uric acid levels reach levels greater than 8 mg/dL despite treatment with allopurinol. Rasburicase cannot be given to patients with known glucose 6-phosphate dehydrogenase (G6PD) deficiency nor can it be given to pregnant or lactating women. When to ReferShould  urinary output drop, serum creatinine or potas- sium levels rise, or hyperphosphatemia persist, a nephrolo- gist should be immediately consulted to evaluate the need for dialysis.Durani  U et al. Emergencies in haematology: tumor lysis syn- drome. Br J Haematol. 2020;188:494. [PMID: 31774551] Matuszkiewicz-Rowinska J et al. Prevention and treatment of tumor lysis syndrome in the era of onco-nephrology progress. Kidney Blood Press Res. 2020;45:645. [PMID: 32998135]IN FECTIONSChapt ers 30 and 31 provide more detailed discussions of infections in the immunocompromised patient.E S S E N T I A L S  O F  D I A G N O S I S In patients with neutropenia, infection is a medi- cal emergency. Although sometimes attributable to other causes, the presence of fever, defined as a single tempera- ture > 38.3C (101F) or a temperature of > 38C (100.4F) for > 1 hour, must be assumed to be due to an infection.General ConsiderationsMa ny patients with disseminated neoplasms have increased susceptibility to infection. In some patients, this results from impaired defense mechanisms (eg, acute leukemia, Hodgkin lymphoma, plasma cell myeloma, chronic lymphocytic leu- kemia); in others, it results from the myelosuppressive and immunosuppressive effects of cancer chemotherapy or a combination of these factors. Complicating impaired defense mechanisms are the frequent presence of indwelling cathe- ters, impaired mucosal surfaces, and colonization with more virulent hospital-acquired pathogens. The source of a neutropenic febrile episode is deter- mined in about 30% of cases through blood, urine, or sputum cultures. The bacterial organisms accounting for the majority of infections in cancer patients include gram- positive bacteria (coagulase-negative Staphylococcus, Staphylococcus aureus, Streptococcus pneumoniae, Coryne- bacterium, and streptococci) and gram-negative bacteria (Escherichia coli, Klebsiella, Pseudomonas, Enterobacter ). Gram-positive organism infections are more common, but gram-negative infections are more serious and life- threatening. The risk of bacterial infections rises when the neutrophil count is below 500/mcL (0.5  109/L); the risk markedly increases when the count falls below 100/mcL (0.1  109/L) or when there is a prolonged duration of neu- tropenia, typically greater than 7 days. Clinical FindingsA  thorough physical examination should be performed. Appropriate cultures (eg, blood, sputum, urine and, if indi- cated, cerebrospinal fluid) should always be obtained. Two sets of blood cultures should be drawn before starting antibiotics; if the patient has an indwelling catheter, one of the cultures should be drawn from the line. A chest radio- graph should also be obtained. TreatmentEmpiric  antibiotic therapy needs to be initiated within 1 hour of presentation and following the collection of blood cultures in the febrile neutropenic patient. The choice of antibiotics depends on a number of different factors includ- ing the patients clinical status and any localizing source of infection. If the patient is clinically well, monotherapy with an intravenous beta-lactam with anti- Pseudomonas activity (cefepime, ceftazidime, imipenem/cilastatin, piperacillin/ tazobactam) should be started (see Infections in the Immu- nocompromised Patient, Chapter 30). If the patient is clini- cally ill with hypotension or hypoxia, an intravenous aminoglycoside or fluoroquinolone should be added for double gram-negative bacteria coverage. If there is a strong suspicion of a gram-positive organism, such as from aS aureus catheter infection, intravenous vancomycin can be given empirically. Low-risk patients may be treated with oral antibiotics in the outpatient setting. Antibiotics should be continued until the neutrophil count is rising and greater than 500/mcL (0.5  109/L) for at least 1 day and the patient has been afebrile for 2 days. If an organism is identified through the cultures, theCMDT22_Ch39_p1612-p1675.indd  1669 02/07/21 2:44 PMChAPTER 391670 CMDT 2022antib iotics should be adjusted to the antibiotic sensitivities of the isolate; treatment should be continued for the appro- priate period of time and at least until the neutrophil count recovers and fever resolves. For the neutropenic patient who is persistently febrile despite broad-spectrum antibiotics, an empiric antifungal drug should be added (amphotericin B, caspofungin, itra- conazole, voriconazole, or liposomal amphotericin B).Braga  CC et al. Clinical implications of febrile neutropenia guidelines in the cancer patient population. J Clin Oncol. 2019;15:25. [PMID: 30629901] Taplitz A et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. J Clin Oncol. 2018;36:1443. [PMID: 29461916] PRIMARY CANCER TREATMENTSunny  Wang, MD Tiffany O. Dea, PharmD, BCOPSYS TEMIC CANCER THERAPYDetailed  guidelines from the NCCN for cancer treatment can be found at www.nccn.org. Use of cytotoxic drugs, hormones, antihormones, and biologic agents has become a highly specialized and increasingly effective means of treating cancer, with therapyadministered and monitored by a medical oncologist or hematologist. Selection of specific drugs or protocols for various types of cancer is usually based on results of clini- cal trials. Increasingly, newer agents are being identified that target specific molecular pathways. Yet both initial and acquired drug resistance remains a challenge. Described mechanisms of drug resistance include impaired mem- brane transport of drugs, enhanced drug metabolism, mutated target proteins, and blockage of apoptosis due to mutations in cellular proteins (see Table 392 for suggested agents for various cancers).TOXI CITY & DOSE MODIFICATION OF CHEMOTHERAPEUTIC AGENTSU se of chemotherapy to treat cancer is generally guided by results from clinical trials in individual tumor types. The complexity of treating cancer has increased over the last decade as more drugs, including those with targeted mechanisms of action, have been approved by the US Food and Drug Administration (FDA) and introduced into gen- eral practice. Drug side effects and toxicities must be anticipated and carefully monitored. The short- and long- term toxicities of individual drugs are listed in Tables 393 and 3912. Decisions on dose modifications for toxicities should be guided by the intent of therapy. In the palliative setting where the aim of therapy is to improve symptoms and quality of life, lowering doses to minimize toxicity is commonly done. However, when the goal of treatment is cure, dosing frequency and intensity should be maintained whenever possible. Table 3912. Commonly used supportive care agents.1Agent Indication Usual Dose Adverse Effects Allopurinol (Xyloprim) Prevent hyperuricemia from tumor lysis syndrome600800 mg/day orally Acute: none Delayed: rash Dexrazoxane (Zinecard) Prevent cardiomyopathy second- ary to doxorubicin; anthracy- cline-induced injection site extravasation10 times the doxorubicin dose intravenously before doxorubi- cin; 1000 mg/m2intravenously on days 1 and 2, then 500 mg/m2 intravenously on day 3Acute: nausea Delayed: myelosuppression, elevated transaminases Leucovorin Rescue after high-dose metho- trexate; in combination with 5-fluorouracil for colon cancer10 mg/m2intravenously or orally every 6 hours; 20 mg/m2or 200 500 mg/m2intravenously before 5-fluorouracil; various dosesAcute: nausea, vomiting, diarrhea Delayed: stomatitis, fatigue Mesna (Mesnex) Prevent ifosfamide-induced hemorrhagic cystitis20% of ifosfamide dose intrave- nously at 0, 4, and 8 hours; various dosesAcute: nausea, vomiting Delayed: fatigue Palifermin (Kepivance) Prevent mucositis following chemotherapy60 mcg/kg/day intravenously for 3 days before and 3 days after chemotherapyAcute: none Delayed: rash, fever, elevated serum amylase, erythema, edema Radium (Ra)-223 dichloride (Xofigo)Symptomatic bone metastases 50 kilobecquerel/kg (1.35 microCurie/kg) intrave- nously every 4 weeks for 6 cyclesAcute: nausea, vomiting, diarrhea, peripheral edema Delayed: myelosuppression Rasburicase (Elitek) Prevent hyperuricemia from tumor lysis syndrome36 mg intravenously once Acute: hypersensitivity, nausea, vomiting, diarrhea, fever, headache Delayed: rash, peripheral edema (continued )CMDT22_Ch39_p1612-p1675.indd  1670 02/07/21 2:44 PMCANCER1671 CMDT 2022T able 3912. Commonly used supportive care agents.1Agent Indication Usual Dose Adverse Effects Bone-Modifying Agents Denosumab (Xgeva) Osteolytic bone metastasis 120 mg subcutaneously every 4 weeksAcute: nausea Delayed: hypocalcemia, hypophos- phatemia, fatigue, osteonecrosis of the jaw Pamidronate (Aredia) Osteolytic bone metastasis, hypercalcemia of malignancy90 mg intravenously every 34 weeks; 6090 mg intrave- nously, may repeat after 7 daysAcute: nausea Delayed: dyspnea, arthralgia, bone pain, osteonecrosis of the jaw, nephrotoxicity, hypocalcemia Zoledronic acid (Zometa) Osteolytic bone metastasis, hypercalcemia of malignancy4 mg intravenously every 34 weeks; 4 mg intravenously once, may repeat after 7 days Growt Factors Darbepoetin alfa (Aranesp)Chemotherapy-induced anemia 2.25 mcg/kg subcutaneously weekly; 500 mcg subcutaneously every 3 weeks Epoetin alfa (Epogen, Procrit)Chemotherapy-induced anemia 40,000 units subcutaneously once weekly; 150 units/kg subcutane- ously three times a weekAcute: injection site reaction Delayed: hypertension, thromboem- bolic events, increased risk of tumor progression or recurrence Filgrastim (Neupogen) Febrile neutropenia prophylaxis, mobilization of peripheral stem cells510 mcg/kg/day subcutaneously or intravenously once daily, treat past nadirAcute: injection site reaction Delayed: bone pain Pegfilgrastim (Neulasta) Febrile neutropenia prophylaxis 6 mg subcutaneously once per chemotherapy cycle Sargramostim (Leukine) Myeloid reconstitution following bone marrow transplant, mobilization of peripheral blood stem cells250 mcg/m2intravenously daily until the absolute neutrophil count is > 1500 cells/mcL (1.5  109/L) for 3 consecutive daysAcute: fever, rash, pruritus, nausea, vomiting, diarrhea, injection site reaction, dyspnea Delayed: asthenia, bone pain, mucositis, edema, arrhythmia1 For amifostine, levoleucovorin, pilocarpine, samarium, strontium, filgrastim-sndz, and tbo-filgrastim, see Table 3912 in CMDT Online at www.accessmedicine.com.A  CBC including a differential count, with absolute neutrophil count and platelet count, and liver and kid- ney tests should be obtained before the initiation of chemotherapy. In patients with good performance sta- tus, normal CBCs, as well as normal liver and kidney function, drugs are started at their full dose. When the intent of chemotherapy is cure, including treatment in the adjuvant setting, every attempt should be made to schedule chemotherapy on time and at full dose. A CBC with differential may be checked at mid cycle (to determine the nadir of the absolute neutrophil and platelet counts), and liver and kidney function tests should be obtained immediately before the next cycle of chemotherapy. Dose reductions may be necessary for patients with impaired kidney or liver function depending on the clear- ance mechanism of the drug. For patients receiving chemo- therapy for palliation, bone marrow toxicity can be managed with dose reductions or delaying the next treat- ment cycle. A schema for dose modification is shown in Table 3913.1. Bone Marrow ToxicityA.  NeutropeniaGra nulocyte colony-stimulating factor (G-CSF), given as either daily subcutaneous injections (eg, filgrastim, 300 mcg Table 3913. A common scheme for dose modifica- tion of cancer chemotherapeutic agents.Granulocyte Count Platelet CountSuggested Drug Dosage (% of Full Dose) > 2000 cells/mcL (2  109/L)> 100,000/mcL (100  109/L)100% 10002000 cells/mcL (12  109/L)75,000100,000/ mcL (75100  109/L)50% < 1000 cells/mcL (1  109/L)< 50,000/mcL (50  109/L)0%(continued)CMDT22_Ch39_p1612-p1675.indd  1671 02/07/21 2:44 PMChAPTER 391672 CMDT 2022or  480 mcg) or as a one-time dose (pegfilgrastim, 6 mg) beginning 24 hours after cytotoxic chemotherapy is com- pleted, reduces the duration and severity of granulocytope- nia following cytotoxic chemotherapy (Table 3912). The American Society of Clinical Oncology and NCCN guide- lines recommend primary prophylaxis with G-CSF when there is at least a 20% risk of febrile neutropenia or when age, medical history, and disease characteristics put the patient at high risk for complications related to myelosuppression.B.  AnemiaErythropoiesis-stimulatin g agents (ESAs) ameliorate the anemia and its associated symptoms caused by cancer che- motherapy but these drugs have untoward effects, includ- ing an increased risk of thromboembolism, and possibly a decreased survival due to cancer-related deaths as well as a shortened time to tumor progression. The FDA recom- mends that these drugs should not be used when the intent of chemotherapy is curative. Administration of red blood cell transfusions is an alternative for managing symptom- atic anemia in chemotherapy patients. ESAs can be an option in cancer patients with symptom- atic anemia undergoing palliative treatment; patient prefer- ence is important in determining when to use ESAs or transfusions. When using ESAs, treatment should not be initiated until the hemoglobin is less than 10 g/dL (100 g/L) and the ESA held when the hemoglobin is greater than 12 g/dL (120 g/L). Epoetin alfa can be given subcutaneously at a dose of 40,000 units weekly or 150 units/kg three times weekly with a target hemoglobin of 1112 g/dL (110120 g/L). Darbepoetin alfa is given subcutaneously at a dose of 300500 mcg every 3 weeks or 2.25 mcg weekly with the same target hemoglobin (see Table 3912). To have maxi- mum therapeutic effect, patients need to be iron replete. Uncontrolled hypertension is a contraindication to the use of ESAs; blood pressure must be controlled prior to initia- tion of this therapy.C.  ThrombocytopeniaDrug  management of chemotherapy-induced thrombocyto- penia is more limited. Two drugs that activate the thrombo- poietin receptor, romiplostim and eltrombopag, are FDA approved for use in idiopathic thrombocytopenia, thrombo- cytopenia related to interferon therapy of hepatitis C, and thrombocytopenia in aplastic anemia. While these agents have been used in selected cases of refractory chemotherapy- related thrombocytopenia with some reports of success, trials to date have not demonstrated convincing efficacy in patients with chemotherapy-induced thrombocytopenia and neither agent is FDA approved for this indication.2.  Cemoterapy-Induced Nausea & VomitingA numbe r of cytotoxic anticancer drugs can induce nau- sea and vomiting, which can be the most anticipated and stressful side effects for patients. Chemotherapy-induced nausea and vomiting is mediated in part by the stimulation of at least two central nervous system receptors, 5-hydroxy- tryptamine subtype 3 (5HT3) and neurokinin subtype 1 (NK1). Chemotherapy-induced nausea and vomiting can beanticipatory, occurring even before chemotherapy adminis- tration; acute, occurring within minutes to hours of chemo- therapy administration; or delayed, lasting up to 7 days. Chemotherapy drugs are classified into high, moderate, low, and minimal likelihoods of causing emesis (90%, 3090%, 1030%, less than 10%, respectively). Highly emetogenic chemotherapy drugs include carmustine, cisplatin, cyclo- phosphamide (at doses over 1.5 g/m2), dacarbazine, and streptozocin, or a combination of regularly dosed anthracy- clines and cyclophosphamide. Moderately emetogenic che- motherapy drugs include azacitadine, bendamustine, carboplatin, crizotinib, cyclophosphamide, cytarabine, doxo- rubicin, epirubicin, ifosfamide, irinotecan, oxaliplatin, and temozolomide. Low emetogenic drugs include bortezomib, capecitabine, dabrafenib, dasatinib, docetaxel, erlotinib, eto- poside, 5-fluorouracil, gemcitabine, hydroxyurea, lenalido- mide, methotrexate, mitomycin, paclitaxel, pemetrexed, pomalidomide, and topotecan. Drugs with minimal risk of emesis include bevacizumab, bleomycin, cetuximab, decitabine, panitumumab, rituximab, trastuzumab, and vincristine. Major advances have occurred in the development of highly effective antiemetic drugs. Antagonists to the 5HT3-receptor include alosetron, dolasetron, granisetron, ondansetron, and palonosetron, as well as ramosetron and tropisetron (neither yet available in the United States). Ondansetron can be given either intravenously (8 mg or 0.15 mg/kg) or orally (24 mg once before highly emeto- genic chemotherapy, 8 mg twice daily for moderately emetogenic chemotherapy). Doses of 8 mg can be repeated parenterally or orally every 8 hours. Dosing of granisetron is 1 mg or 0.01 mg/kg intravenously or 12 mg orally. Dola- setron is given once as an oral 100-mg dose. Palonosetron, a long-acting 5HT3-receptor antagonist with high affinity for the receptor, is given once at a dose of 0.25 mg intravenously, both for acute and delayed emesis. As a class of drugs, the 5HT3-receptor antagonists have the potential to cause elec- trocardiogram changes, including QT prolongation. Antagonists to the NK1-receptor are aprepitant, fosa- prepitant, and netupitant. Aprepitant is given as a 125-mg oral dose followed by an 80-mg dose on the second and third day along with a 5HT3-receptor antagonist and dexa- methasone to increase its immediate and delayed protective effect for highly emetogenic chemotherapy. Fosaprepitant, the intravenous formulation of the prodrug to aprepitant, can be given at a dose of 115 mg if followed by 2 days of aprepitant or at a dose of 150 mg if given alone. NEPA is a single-dose capsule consisting of a combination of netupitant and palonosetron. For highly emetogenic chemotherapy (eg, cisplatin), patients should be offered a four-drug regimen (a 5HT3- antagonist, dexamethasone, NK1-receptor antagonist, and olanzapine), all given on the first day (and if used, aprepi- tant given again on the second and third days with dexa- methasone and olanzapine continued on days 24. For moderately emetogenic chemotherapy, standard regimens include both three-drug regimens (an NK1-antagonist, a 5HT3-antagonist, and dexamethasone) or a two-drug combination (5HT3-antagonist and dexamethasone). Palonosetron is the preferred 5HT3-blocker due to its greaterCMDT22_Ch39_p1612-p1675.indd  1672 02/07/21 2:44 PMCANCER1673 CMDT 2022affinity  for the 5HT3-receptor and its longer half-life. For low emetogenic chemotherapy drugs, a single agent such as a 5HT3-antagonist or prochlorperazine or dexamethasone can be given. A 25-mg suppository form of prochlorpera- zine may be used for patients unable to swallow oral medi- cations. Another medication that is helpful for anticipatory or refractory nausea and vomiting is olanzapine, 10 mg given orally once. The importance of treating chemotherapy-induced nau- sea and vomiting expectantly and aggressively beginning with the first course of chemotherapy cannot be overem- phasized. Patients being treated in the clinic setting should always be given antiemetics for home use with written instructions as well as contact numbers to call for advice.3.  Gastrointestinal ToxicityU ntoward effects of cancer chemotherapy include damage to the more rapidly growing cells of the body such as the mucosal lining from the mouth through the gastrointesti- nal tract. Oral symptoms range from mild mouth soreness to frank ulcerations. Not uncommonly, mouth ulcerations will have superimposed candida or herpes simplex infec- tions. In addition to receiving cytotoxic chemotherapy, a significant risk factor for development of oral mucositis is poor oral hygiene and existing caries or periodontal dis- ease. Toxicity in the gastrointestinal tract usually manifests as diarrhea. Gastrointestinal symptoms can range from mild symptoms of loose stools to life-threatening diar- rhea leading to dehydration and electrolyte imbalances. Drugs most commonly associated with causing mucositis in the mouth and the gastrointestinal tract are cytarabine, 5-fluorouracil, and methotrexate. Patients undergoing treatment for head and neck can- cer with concurrent chemotherapy and radiation therapy have a very high risk of developing severe mucositis. Preventive strategies for oral mucositis include pretreat- ment dental care, particularly for all head and neck cancer patients and any cancer patient with poor dental hygiene who will be receiving chemotherapy. For patients receiving 5-fluorouracil, simple measures such as ice chips in the mouth for 30 minutes during infusion can reduce the inci- dence and severity of mucositis. Once mucositis is encoun- tered, superimposed fungal infections should be treated with topical antifungal medications (oral nystatin mouth suspensions, or clotrimazole troches) or systemic therapy (fluconazole 100400 mg orally daily). Suspected herpetic infections can be treated with acyclovir (up to 800 mg orally five times daily) or valacyclovir (1 g orally twice daily). Mucositis may also be managed with mouthwashes; it is also important to provide adequate pain medication. Another strategy for prevention of oral mucositis is the use of palifermin, the recombinant keratinocyte growth factor inhibitor. Prophylaxis with intravenous palifermin (60 mcg/kg/day) for patients receiving high-dose chemo- therapy can reduce the incidence and duration of mucositis (Table 3912). Diarrhea is most associated with 5-fluorouracil, capecitabine, and irinotecan as well as the tyrosine kinase inhibitors (dasatinib, imatinib, nilotinib, regorafenib, sorafenib, sunitinib) and epithelial growth factor inhibitors(cetuximab, erlotinib, panitumumab). Mild to moderate diarrhea can be managed with oral antidiarrheal medica- tion (loperamide, 4 mg initially followed by 2 mg every 24 hours until bowel movements are formed). Occasion- ally, severe diarrhea will cause dehydration, electrolyte imbalances, and acute kidney injury; these patients require inpatient management with aggressive intravenous hydra- tion and electrolyte replacement. Octreotide, 100150 mcg subcutaneously three times daily, can be useful.4.  Skin ToxicityDerm atologic complications from cancer chemotherapy can include hyperpigmentation (busulfan, hydroxyurea, liposomal doxorubicin), alopecia, photosensitivity, nail changes, acral erythema, and generalized rashes. Acral erythema (hand-foot syndrome), most commonly associ- ated with administration of capecitabine, 5-fluorouracil, and liposomal doxorubicin, manifests as painful palms or soles accompanied by erythema, progressing to blistering, desquamation, and ulceration in its worst forms. Strate- gies for prevention of acral erythema include oral pyri- doxine, 200 mg daily, and applying cold packs to the extremities during chemotherapy administration. Agents targeting the epidermal growth factor pathway can cause an acne-like rash; the development of the rash may iden- tify those who will respond to the drug. Inhibitors of the tyrosine kinase pathway are also associated with a high incidence of dermatologic complications, such as rash and acral erythema.5.  Miscellaneous Drug-Specific ToxicitiesThe  toxicities of individual drugs are summarized in Tables 393 and 3912; however, several of these toxicities war- rant additional mention, since they occur with frequently administered agents, and special measures are often indicated.A.  Hemorrhagic Cystitis Induced by Cyclophosphamide or IfosfamidePa tients receiving cyclophosphamide must maintain a high fluid intake prior to and following the administration of the drug and be counseled to empty their bladders fre- quently. Early symptoms suggesting bladder toxicity include dysuria and increased frequency of urination. Should microscopic hematuria develop, it is advisable to stop the drug temporarily or switch to a different alkylating agent, to increase fluid intake, and to administer a urinary analgesic such as phenazopyridine. The neutralizing agent, mesna, can be used for patients in whom cystitis develops. With severe cystitis, large segments of bladder mucosa may be shed, resulting in prolonged gross hematuria. Such patients should be observed for signs of urinary obstruc- tion and may require cystoscopy for removal of obstructing blood clots. The cyclophosphamide analog ifosfamide can cause severe hemorrhagic cystitis when used alone. How- ever, when its use is followed by a series of doses of the neutralizing agent mesna, bladder toxicity can be pre- vented (Table 3912).CMDT22_Ch39_p1612-p1675.indd  1673 02/07/21 2:44 PMChAPTER 391674 CMDT 2022B.  Neuropathy Due to Vinca Alkaloids and Other Chemotherapy DrugsNeur opathy is caused by a number of different chemo- therapy drugs, the most common being vincristine. The peripheral neuropathy can be sensory, motor, autonomic, or a combination of these types. In its mildest form, it con- sists of paresthesias of the fingers and toes. Occasionally, acute jaw or throat pain can develop as a form of trigeminal or glossopharyngeal neuralgia. With continued vincristine therapy, the paresthesias extend to the proximal interpha- langeal joints, hyporeflexia appears in the lower extremi- ties, and significant weakness can develop. Other drugs in the vinca alkaloid class as well as the taxane drugs (docetaxel and paclitaxel) and agents to treat myeloma (bortezomib and thalidomide) cause similar toxicity. Constipation is the most common symptom of auto- nomic neuropathy associated with the vinca alkaloids. Patients receiving these drugs should be started on mild cathartics and other agents (Table 154); otherwise, severe impaction may result from an atonic bowel. More serious autonomic involvement can lead to acute intestinal obstruction with signs indistinguishable from those of an acute abdomen. Bladder neuropathies are uncommon but may be severe. These two complications are absolute con- traindications to continued vincristine therapy.C.  Methotrexate ToxicityMethotr exate, a folate antagonist, is a commonly used component of regimens to treat patients with leptomenin- geal disease, acute lymphoblastic leukemia, and sarcomas. Methotrexate is almost entirely eliminated by the kidney. Methotrexate toxicity affects cells with rapid turnover, including the bone marrow and mucosa resulting in myelosuppression and mucositis. Methotrexate can also damage the liver and kidney manifesting as elevated serum liver enzymes and creatinine. High-dose methotrexate, usually defined as a dose of 500 mg/m2or more given over 436 hours, would be lethal without rescue of the normal tissues. Leucovorin, a form of folate, will reverse the toxic effects of methotrexate and is given until serum methotrex- ate levels are in the safe range (less than 0.05 mmol/L). It is crucial that high-dose methotrexate and leucovorin are given precisely according to protocol as deviations of the timing of methotrexate delivery or delay in rescue can result in death. In a patient with kidney disease or an effu- sion, prolonged rescue with leucovorin is necessary. Vigorous hydration and bicarbonate loading can help prevent crystallization of high-dose methotrexate in the renal tubular epithelium and consequent nephrotoxicity. Daily monitoring of the serum creatinine is mandatory. If possible, drugs impairing methotrexate excretion, such as aspirin, nonsteroidal anti-inflammatory drugs, amio- darone, omeprazole, penicillin, phenytoin, and sulfa, should be stopped before methotrexate administration.D . Cardiotoxicity from Anthracyclines and Other Chemotherapy DrugsA  number of cancer chemotherapy drugs are associated with cardiovascular complications including traditionaldrugs such as anthracyclines as well as new targeted agents. The anthracycline drugs, including doxorubicin, daunomycin, epirubicin, and idarubicin, can produce acute (during administration), subacute (days to months following administration), and delayed (years following administration) cardiac toxicity. The most feared compli- cation is the delayed development of heart failure. Risk factors for this debilitating toxicity include the anthracy- cline cumulative dose, age over 70, previous or concurrent irradiation of the chest, preexisting cardiac disease, and concurrent administration of chemotherapy drugs such as trastuzumab. The problem is greatest with doxorubicin because it is the most commonly administered anthracy- cline due to its major role in the treatment of lymphomas, sarcomas, breast cancer, and certain other solid tumors. Patients receiving anthracyclines should have an assessment of left ventricular ejection fraction (LVEF). If the LVEF is greater than 50%, anthracyclines can be administered; if the LVEF is less than 30%, these drugs should not be given. For patients with intermediate values, anthracyclines can be cautiously given, if necessary, at lower doses with LVEF monitoring between doses. In general, patients should not receive doses in excess of 450 mg/m2; the dose should be lower if prior chest radiotherapy has been given. Unfortu- nately, toxicity may be irreversible and frequently fatal at total dosage levels above 550 mg/m2. At lower doses (eg, 350 mg/m2), the symptoms and signs of cardiac failure gen- erally respond well to medical therapy and discontinuation of the anthracycline. Doxorubicin and daunomycin have been formulated as liposomal products; these drugs, approved for use in patients with Kaposi sarcoma and sometimes in other cancers as a substitute for the conventional anthracy- clines, appear to have less potential for cardiac toxicity. As molecular mechanisms for cancer have been increas- ingly delineated, therapies have been developed that better target these mechanisms. Therapies targeting oncogenic pathways include (1) HER2 inhibitors (lapatinib, pertu- zumab, trastuzumab, ado-trastuzumab emtansine); (2) VEGF signaling pathway inhibitors (afilbercept, axitinib, bevacizumab, cabozantinib, lenvatinib, pazopanib, ramuci- rumab, regorafenib, sorafenib, sunitinib, vandetanib); (3) multitargeted tyrosine kinase inhibitors (dasatinib, nilo- tinib, ponatinib); (4) proteasome inhibitors (bortezomib, carfilzomib); and (5) immune checkpoint inhibitors (atezolizumab, durvalumab, ipilimumab, nivolumab, pem- brolizumab). Many of the pathways targeted by these drugs share a common biologic pathway in cardiac tissue. Untow- ard cardiac events are being increasingly reported with these agents, including arrhythmias, cardiac ischemia, myocarditis, thrombosis, and heart failure.E.  Cisplatin Nephrotoxicity and NeurotoxicityCispla tin is effective in treating testicular, bladder, head and neck, lung, and ovarian cancers. With cisplatin, the serious side effects of nephrotoxicity and neurotoxicity must be anticipated and aggressively managed. Patients must be vigorously hydrated prior to, during, and after cis- platin administration. Both kidney function and electro- lytes must be monitored. Low serum magnesium, potassium, and sodium levels can develop. The neurotoxicity is usuallyCMDT22_Ch39_p1612-p1675.indd  1674 02/07/21 2:44 PMCANCER1675 CMDT 2022mani fested as a peripheral neuropathy of mixed sensorimo- tor type and may be associated with painful paresthesias. Development of neuropathy typically occurs after cumula- tive doses of 300 mg/m2. Ototoxicity is a potentially serious manifestation of neurotoxicity and can progress to deafness. The second-generation platinum analog, carboplatin, is non-nephrotoxic, although it is myelosuppressive. In the setting of preexisting kidney disease or neuropathy, carbo- platin is occasionally substituted for cisplatin.F . Bleomycin ToxicitySee online text at www .accessmedicine.com/cmdt.PR OGNOSISPa tients receiving chemotherapy for curative intent will often tolerate side effects with the knowledge that the treat- ment may result in eradication of their cancer. Patients receiving therapy for palliative intent often have their therapy tailored to improve quality of life while minimizingmajor side effects. A valuable sign of clinical improvement is the general well-being of the patient. Although general well-being is a combination of subjective factors (possibly partly a placebo effect) and objective factors, it nonetheless serves as a sign of clinical improvement along with improved appetite and weight gain and increased performance status (eg, ambulatory versus bedridden). Evaluation of factors such as activity status enables the clinician to judge whether the net effect of chemotherapy is worthwhile pal- liation (see Chapter 5).Babiker  HM et al. Cardiotoxic effects of chemotherapy: a review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system. Crit Rev Oncol Hematol. 2018;126:186. [PMID: 29759560] Okada Y et al. One-day versus three-day dexamethasone in combination with palonosetron for the prevention of chemo- therapy-induced nausea and vomiting: a systematic review and individual patient data-based meta-analysis. Oncologist. 2019;24:1593. [PMID: 31217343]CMDT22_Ch39_p1612-p1675.indd  1675 02/07/21 2:44 PM1676 CMDT 2022ACU TE INTERMITTENT PORPHYRIAE S S E N T I A L S  O F  D I A G N O S I S Unexplained abdominal crisis, generally in young women. Acute peripheral or central nervous system dys- function; recurrent psychiatric illnesses. Hyponatremia. Porphobilinogen in the urine during an attack. General ConsiderationsTho ugh there are several different types of porphyrias, the one with the most serious consequences and the one that usually presents in adulthood is acute intermittent porphyria (AIP), which is inherited as an autosomal dominant condi- tion, though it remains clinically silent in most patients who carry a mutation in HMBS . Clinical illness usually develops in women. Symptoms begin in the teens or 20s, but onset can begin after menopause in rare cases. The disorder is caused by partial deficiency of hydroxymethylbilane synthase activ- ity, leading to increased excretion of aminolevulinic acid and porphobilinogen in the urine. The diagnosis may be elusive if not specifically considered. The characteristic abdominal pain may be due to abnormalities in autonomic innervation in the gut. In contrast to other forms of porphyria, cutaneous photosensitivity is absent in AIP . Attacks are precipitated by numerous factors, including drugs and intercurrent infec- tions. Harmful and relatively safe drugs for use in treatment are listed in Table 401. Hyponatremia may be seen, due in part to inappropriate release of antidiuretic hormone, although gastrointestinal loss of sodium in some patients may be a contributing factor. Clinical FindingsA.  Symptoms and SignsPa tients show intermittent abdominal pain of varying severity, and in some instances, it may so simulate an acuteabdomen as to lead to exploratory laparotomy. Because the origin of the abdominal pain is neurologic, there is an absence of fever and leukocytosis. Complete recovery between attacks is usual. Any part of the nervous system may be involved, with evidence for autonomic and periph- eral neuropathy. Peripheral neuropathy may be symmetric or asymmetric and mild or profound; in the latter instance, it can even lead to quadriplegia with respiratory paralysis. Other central nervous system manifestations include sei- zures, altered consciousness, psychosis, and abnormalities of the basal ganglia. Hyponatremia may further cause or exacerbate central nervous system manifestations.B.  Laboratory FindingsOften  there is profound hyponatremia. The diagnosis can be confirmed by demonstrating an increased amount of porphobilinogen in the urine during an acute attack. Freshly voided urine is of normal color but may turn dark upon standing in light and air. Most families have different mutations in HMBS caus- ing AIP . Mutations can be detected in 90% of patients and used for presymptomatic and prenatal diagnosis. PreventionA voidance of factors known to precipitate attacks of AIP especially drugscan reduce morbidity. Sulfonamides and barbiturates are the most common culprits; others are listed in Table 401 and on the Internet (www.drugs- porphyria.org). Starvation diets and prolonged fasting also cause attacks and so must be avoided. Hormonal changes during pregnancy can precipitate crises. TreatmentT reatment with a high-carbohydrate diet diminishes the number of attacks in some patients and is a reasonable empiric gesture considering its benignity. Acute attacks may be life-threatening and require prompt diagnosis, withdrawal of the inciting agent (if possible), and treat- ment with analgesics and intravenous glucose in saline and hematin. A minimum of 300 g of carbohydrate per day should be provided orally or intravenously. Electrolyte40Reed E. Pyeritz, MD, PhDGenetic & Genomic DisordersCMDT22_Ch40_p1676-p1684.indd  1676 02/07/21 2:45 PM",
                  "CANCER1613 CMDT 2022Office  of Disease Prevention and Health Promotion. Healthy People 2030. Tobacco use objectives: reduce tobacco use in adults. https://health.gov/healthypeople/objectives-and-data/ browse-objectives/tobacco-use/reduce-current-tobacco- use-adults-tu-01Table 391. Estimated 10 most common cancer cases in the United States in males and females (all races).R ankMales Females Total Cases [N] = 970,250 (100 percent)Total Cases [N] = 927,910 (100 percent) 1 Prostate 248,530 (26)Breast 281,550 (30) 2 Lung and bronchus 119,100 (12)Lung and bronchus 116,660 (13) 3 Colon and rectum 79,520 (8)Colon and rectum 69,980 (8) 4 Urinary bladder 64,280 (7)Uterine corpus 66,570 (7) 5 Melanoma 62,260 (6)Melanoma 43,850 (5) 6 Kidney and renal pelvis 48,780 (5)Non-Hodgkin lymphoma 35,930 (4) 7 Non-Hodgkin lymphoma 45,630 (5)Thyroid 32,130 (3) 8 Oral cavity and pharynx 38,800 (4)Pancreas 28,480 (3) 9 Leukemia 35,530 (4)Kidney and renal pelvis 27,300 (3) 10 Pancreas 31,950 (3)Leukemia 25,560 (3) Other sites 195,870 (20)Other sites 199,900 (21) Data from the American Cancer Society, 2021.Klein WMP et al. Alcohol and cancer risk: clinical and research implications. JAMA. 2020;323:23. [PMID: 31834355] Siegel RL et al. Cancer statistics, 2021. CA Cancer J Clin. 2021; 71:7. [PMID: 33433946] StagingThe  TNM system is the commonly used classification to stage cancer. Staging is important not only because it cor- relates with the patients long-term survival but also because it is used to determine which patients should receive adjuvant or neoadjuvant therapy. Certain characteristics of cancers, not reflected in the TNM stage, may be used to indicate prognosis and guide treat- ment. Pathologic features seen on routine histologic examina- tion for some cancers are very important; examples include the Gleason score for prostate cancer, human papillomavirus (HPV) status of oropharyngeal cancer, and grade of sarcomas. Cancer specimens should also be sent for molecular diagnostic testing and programmed death-ligand 1 (PD-L1) expression testing when appropriate. Some examples of targeted molecu- lar testing include HER2 in breast and gastric cancer, K-ras and BRAF mutations in colorectal cancer and melanoma, and epidermal growth factor receptor (EGFR) and fusion genes (ALK andROS1 ) in lung cancer.Machczys ki P et al. A review of the 8th edition of the AJCC staging system for oropharyngeal cancer according to HPV status. Eur Arch Otorhinolaryngol. 2020;277:2407. [PMID: 32342197] TreatmentSee  Primary Cancer Treatment section below. Table 392 outlines treatment choices by cancer type for those respon- sive to systemic agents, and Table 393 provides a listing of common chemotherapeutic agents. Table 392. Treatment choices for cancers responsive to systemic agents.Diagnosis Initial Treatment Acute lymphoblastic leukemia (ALL)Induction combination cemoterapy (Piladelpia cromosomepositive): Cyclophosphamide, vincristine, doxorubicin/daunorubicin, dexamethasone (hyper-CVAD) alternating with cytarabine, methotrexate; add imatinib or dasatinib or nilotinib Induction combination cemoterapy (Piladelpia cromosomenegative): Daunorubicin, vincristine, prednisone, pegaspargase, cyclophosphamide; or hyper-CVAD alternating with methotrexate and cytarabine Maintenance cemoterapy: Methotrexate, 6-mercaptopurine, vincristine, prednisone Acute myeloid leukemia (AML) Induction combination cemoterapy: Cytarabine with daunorubicin or idarubicin, with gemtuzumab ozogamicin (CD33-positive), or with midostaurin ( FLT3-mutated), or with fludarabine Alternative cemoterapy for  60 years old: Azacitidine, decitabine, or low-dose cytarabine with or without venetoclax; or Liposomal encapsulation of cytarabine and daunorubicin (therapy-related or myelodysplasia-related changes) Ivosidenib ( IDH1 mutation); or Enasidenib ( IDH2 mutation) (continued )CMDT22_Ch39_p1612-p1675.indd  1613 02/07/21 2:44 PMChAPTER 391614 CMDT 2022T able 392. Treatment choices for cancers responsive to systemic agents.Diagnosis Initial Treatment Chronic myeloid leukemia (CML)Nilotinib or dasatinib or imatinib or bosutinib Chronic lymphocytic leukemia (CLL)Venetoclax with obinutuzumab, or acalabrutinib with or without obinutuzumab, or ibrutinib Hairy cell leukemia Cladribine with or without rituximab1or pentostatin Hodgkin lymphoma Combination cemoterapy: Doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD), or Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone (BEACOPP) Non-Hodgkin lymphoma (intermediate and high grade)Combination cemoterapy: Cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab1 (CHOP-R), or Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab1(dose-adjusted R-EPOCH) (for double-/triple-hit) Non-Hodgkin lymphoma (low grade)Combination cemoterapy: Bendamustine plus obinutuzumab or rituximab1, or Cyclophosphamide, vincristine, doxorubicin, prednisone, rituximab1(CHOP-R), or Cyclophosphamide, vincristine, prednisone, rituximab1(CVP-R), or Lenalidomide, rituximab1Plasma  cell myeloma Combination cemoterapy (transplant candidates): Bortezomib, dexamethasone, cyclophosphamide, or Bortezomib, dexamethasone, lenalidomide Followed by autologous or mini-allogeneic stem cell transplantation Combination cemoterapy (non-transplant candidates): Bortezomib, lenalidomide, dexamethasone, or Daratumumab, lenalidomide, dexamethasone, or Lenalidomide, dexamethasone, or Bortezomib, cyclophosphamide, dexamethasone Waldenstrm macroglobulinemiaPlasmaperesis alone or followed by combination cemoterapy: Ibrutinib with or without rituximab1Bortezomib,  dexamethasone, rituximab1, or Cyclophosphamide, dexamethasone, rituximab1, or Bendamustine, rituximab1Poly cythemia vera Phlebotomy or hydroxyurea or aspirin Nonsmall cell lung cancer Combination terapy: Cisplatin, etoposide, or Paclitaxel, carboplatin, or Cisplatin, gemcitabine or docetaxel (squamous histology), or Cisplatin, pemetrexed (nonsquamous histology), or Carboplatin, albumin-bound paclitaxel, or Dabrafenib/trametinib ( BRAF V600F mutation), or Carboplatin or cisplatin/pemetrexed/pembrolizumab (nonsquamous); carboplatin/paclitaxel or albumin-bound paclitaxel/pembrolizumab (squamous) Single-agent terapy: Erlotinib, gefitinib, osimertinib, afatinib, or dacomitinib ( EGFR mutation positive) Crizotinib, alectinib, ceritinib, or brigatinib ( ALKmutation positive) Ceritinib, crizotinib, or entrectinib ( ROS1 rearrangement) Larotrectinib or entrectinib ( NTRK gene fusion positive) Pembrolizumab (PD-L1  1%) or atezolizumab (PD-L1  50%) Small cell lung cancer Combination terapy: Cisplatin, etoposide (limited stage), or Cisplatin, etoposide, durvalumab (extensive stage), or Carboplatin, etoposide, atezolizumab or durvalumab (extensive stage) Mesothelioma Combination terapy: Cisplatin or carboplatin/pemetrexed with or without bevacizumab, or Nivolumab/ipilimumab (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1614 02/07/21 2:44 PMCANCER1615 CMDT 2022T able 392. Treatment choices for cancers responsive to systemic agents.Diagnosis Initial Treatment Head and neck cancer Cisplatin with radiation therapy, or Carboplatin with 5-fluorouracil with radiation therapy, or Docetaxel, cisplatin, 5-fluorouracil, or Cisplatin or carboplatin/5-fluorouracil/cetuximab, or Pembrolizumab (PD-L1  1%), or Pembrolizumab/cisplatin or carboplatin/5-fluorouracil Esophageal and esophagogastric junction cancerCombination terapy: Cisplatin, 5-fluorouracil or capecitabine, or Paclitaxel, carboplatin, or Oxaliplatin, 5-fluorouracil or capecitabine, or 5-Fluorouracil, leucovorin, oxaliplatin, docetaxel (FLOT) Add trastuzumab for HER2 -overexpressing metastatic adenocarcinoma Uterine cancer hormone terapy: Progestins, tamoxifen, aromatase inhibitors, or fulvestrant Combination cemoterapy: Carboplatin, paclitaxel Carboplatin, paclitaxel, trastuzumab ( HER2 positive) Ovarian cancer Combination cemoterapy: Paclitaxel, carboplatin, with or without bevacizumab, or 5-Fluorouracil/leucovorin or capecitabine, oxaliplatin Cervical cancer Wit radiation: Cisplatin or carboplatin Combination cemoterapy: Cisplatin or carboplatin, paclitaxel with or without bevacizumab Breast cancer Adjuvant ormone terapy: Premenopausal: Tamoxifen Postmenopausal: Aromatase inhibitors (anastrozole, letrozole, exemestane) Adjuvant cemoterapy ( HER2 negative): Doxorubicin, cyclophosphamide, followed by paclitaxel, or Docetaxel, cyclophosphamide Adjuvant cemoterapy ( HER2 positive): Doxorubicin, cyclophosphamide, followed by paclitaxel, trastuzumab with or without pertuzumab, or Docetaxel, carboplatin, trastuzumab with or without pertuzumab, or Paclitaxel, trastuzumab Gestational trophoblastic neoplasiaSingle-agent cemoterapy: Methotrexate or dactinomycin for low-risk disease Combination cemoterapy: Etoposide, methotrexate, dactinomycin, cyclophosphamide, vincristine (EMA-CO) for high-risk disease Testicular cancer Combination cemoterapy: Cisplatin, etoposide (EP), or Bleomycin, etoposide, cisplatin (BEP), or Etoposide, mesna, ifosfamide, cisplatin (VIP) Kidney (renal cell) cancer Clear cell istology: Axitinib plus pembrolizumab, ipilimumab plus nivolumab, pazopanib, sunitinib, or cabozantinib Nonclear cell istology: Sunitinib Bladder cancer Combination cemoterapy: Gemcitabine, cisplatin, or Methotrexate, vinblastine, doxorubicin, cisplatin (MVAC), or Atezolizumab, or pembrolizumab, or gemcitabine plus carboplatin (cisplatin ineligible) Prostate cancer hormone terapy: Luteinizing hormonereleasing agonist (leuprolide, goserelin, triptorelin, histrelin), or degarelix with or without an antiandrogen (flutamide, bicalutamide, nilutamide, enzalutamide, apalutamide) or abiraterone Cemoterapy: Docetaxel or cabazitaxel or mitoxantrone with corticosteroid Brain cancer (anaplastic astro- cytoma and glioblastoma multiforme)Single-agent cemoterapy wit radiation terapy: Temozolomide Neuroblastoma Combination cemoterapy: Cyclophosphamide, doxorubicin, cisplatin, etoposide Thyroid cancer Single-agent terapy: Radioiodine (131I) or sorafenib, lenvatinib, vandetanib (medullary thyroid cancer) or cabozantinib (medullary thyroid cancer) Adrenal cancer Cisplatin or carboplatin with etoposide, with or without doxorubicin, with or without mitotane (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1615 02/07/21 2:44 PMChAPTER 391616 CMDT 2022T able 392. Treatment choices for cancers responsive to systemic agents.Diagnosis Initial Treatment Stomach (gastric) cancer Combination cemoterapy: 5-Fluorouracil, leucovorin, oxaliplatin, docetaxel (FLOT) (perioperative) 5-Fluorouracil or capecitabine with oxaliplatin or cisplatin Add trastuzumab for HER2 -overexpressing adenocarcinomas Pancreatic cancer Combination cemoterapy: Gemcitabine, nab-paclitaxel, or 5-Fluorouracil, leucovorin, irinotecan, oxaliplatin (FOLFIRINOX), or Gemcitabine, capecitabine, or Gemcitabine, cisplatin (for BRCA1/2 orPALB2 mutation) Single-agent cemoterapy: Gemcitabine Colon cancer Combination cemoterapy: 5-Fluorouracil, leucovorin, oxaliplatin (FOLFOX) with or without bevacizumab, or Capecitabine, oxaliplatin (CAPEOX) with or without bevacizumab, or 5-Fluorouracil, leucovorin, irinotecan (FOLFIRI) with or without bevacizumab 5-Fluorouracil, leucovorin, oxaliplatin, irinotecan (FOLFOXIRI) with or without bevacizumab Cetuximab or panitumumab added to FOLFOX or FOLFIRI for KRAS/NRAS/BRAF wild-type and left-sided tumors Capecitabine or 5-fluorouracil/leucovorin with or without bevacizumab Single-agent terapy: Nivolumab or pembrolizumab (deficient mismatch repair [dMMR]/high-level microsatellite instability [MSI-H]) Rectal cancer 5-Fluorouracil or capecitabine or FOLFOX or CAPEOX Anal cancer Mitomycin with 5-fluorouracil or capecitabine with radiation Carboplatin, paclitaxel with or without radiation therapy Carcinoid Octreotide LAR or lanreotide or everolimus or lutetium Lu 177-dotatate Osteosarcoma Combination cemoterapy: Cisplatin, doxorubicin, or Methotrexate, doxorubicin, cisplatin (MAP) Soft tissue sarcomas Combination cemoterapy: Doxorubicin, dacarbazine (AD), or Doxorubicin, ifosfamide, mesna (AIM), or Ifosfamide, epirubicin, mesna Single-agent terapy: Imatinib or sunitinib or regorafenib (gastrointestinal stromal tumors) Doxorubicin or epirubicin or liposomal doxorubicin Melanoma Pembrolizumab or nivolumab or nivolumab/ipilimumab (non- BRAF mutation) Dabrafenib/trametinib or vemurafenib/cobimetinib or encorafenib/binimetinib ( BRAF mutation) Hepatocellular cancer Sorafenib or lenvatinib or atezolizumab with bevacizumab Kaposi sarcoma Liposomal doxorubicin1 In patients with past hepatitis B virus (HBV) infection, rituximab should be used with anti-HBV agent (eg, entecavir) prophylax is since HBV reactivation, fulminant hepatitis, and, rarely, death can occur otherwise.T able 393. Common cancer therapeutic agents.Cemoterapeutic Agent Usual Adult Dosage Adverse Effects Alkylating AgentsNitrogen Mustards Bendamustine (Treanda) 100120 mg/m2intravenously every 34 weeks Acute: hypersensitivity, nausea, vomiting Delayed: myelosuppression, rash, pyrexia, fatigue Cyclophosphamide (Cytoxan)5001000 mg/m2intravenously every 3 weeks; 100 mg/m2/day orally for 14 days every 4 weeks; various dosesAcute: nausea and vomiting Delayed: myelosuppression, alopecia, hemorrhagic cystitis, cardiotoxicity (high dose) Ifosfamide (Ifex) 1200 mg/m2intravenously daily for 5 days every 3 weeks; various dosesAcute: nausea and vomiting Delayed: alopecia, myelosuppression, hemorrhagic cystitis, neurotoxicity (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1616 02/07/21 2:44 PMCANCER1617 CMDT 2022T able 393. Common cancer therapeutic agents.Cemoterapeutic Agent Usual Adult Dosage Adverse Effects Alkylating AgentsPlatinum Analogs Carboplatin (Paraplatin) Area under the curve (AUC)based dosing use Calvert equation [Dose (mg) = AUC  (GFR + 25)] AUC = 27 mg/mL/min every 24 weeksAcute: nausea and vomiting Delayed: myelosuppression, electrolyte disturbances, peripheral neuropathy, nephrotoxicity, hypersensitivity Cisplatin (Platinol) 50100 mg/m2intravenously every 34 weeks; 20 mg/m2/day intravenously for 5 days every 3 weeks; various dosesAcute: nausea and vomiting Delayed: nephrotoxicity, ototoxicity, neurotoxicity, myelosuppression, electrolyte disturbances Oxaliplatin (Eloxatin) 85130 mg/m2intravenously every 23 weeks Acute: peripheral neuropathy exacerbated by cold, nausea, vomiting, diarrhea Delayed: myelosuppression, elevated transaminases Alkylating AgentsTriazenes Dacarbazine (DTIC-Dome) 375 mg/m2intravenously on days 1 and 15 every 4 weeks; 9001000 mg/m2intrave- nously over 3 to 4 days; various dosesAcute: nausea, vomiting, photosensitivity Delayed: myelosuppression, anorexia, hypotension, flu-like syndrome Procarbazine (Matulane) 60100 mg/m2orally for 14 days every 4 weeks; various dosesAcute: nausea and vomiting Delayed: myelosuppression, disulfiram-like reaction, MAO inhibition, rash Temozolomide (Temodar) 75 mg/m2orally daily during radiation for 42 days; 150200 mg/m2orally for 5 days every 4 weeksAcute: nausea, vomiting, constipation Delayed: myelosuppression, fatigue AntimetabolitesFolate Antagonists Methotrexate (MTX; Trexall)Intratecal: 12 mg hig dose: 100012,000 mg/m2intravenously every 23 weeksAcute: nausea, vomiting, mucositis Delayed: myelosuppression, nephrotoxicity, hepatotoxicity, neurotoxicity, photosensitivity, pulmonary toxicity Pemetrexed (Alimta) 500 mg/m2intravenously every 3 weeks Acute: nausea, vomiting, diarrhea, rash Delayed: myelosuppression, fatigue, mucositis AntimetabolitesPurine Analogs Fludarabine (Fludara) 25 mg/m2intravenously for 5 days every 4 weeksAcute: fever, nausea, vomiting Delayed: asthenia, myelosuppression, immunosuppression, neurotoxicity, anorexia Mercaptopurine (6-MP; Purinethol)Induction: 2.55 mg/kg/day orally Maintenance: 1.52.5 mg/kg/day orallyAcute: nausea, vomiting, diarrhea, rash Delayed: myelosuppression, immunosuppression, hepatotoxicity, mucositis AntimetabolitesPyrimidine Analogs Azacitidine (Vidaza) 75100 mg/m2subcutaneously or intravenously for 7 days every 4 weeksAcute: injection site reaction (subcutaneously), nausea, diarrhea, fever Delayed: myelosuppression, dyspnea, arthralgia Capecitabine (Xeloda) 10001250 mg/m2orally twice a day for 14 days every 3 weeksAcute: nausea, vomiting, diarrhea Delayed: hand-foot syndrome, mucositis, hyperbilirubinemia, myelosuppression Cytarabine (Ara-C, Cytosar U)Standard dose: 100 mg/m2/day intravenously via continuous infusion for 7 days hig dose: 10003000 mg/m2intravenously every 12 hours for 26 daysAcute: nausea, vomiting, rash, flu-like syndrome Delayed: myelosuppression High-dose: neurotoxicity, ocular toxicities Decitabine (Dacogen) 15 mg/m2intravenously every 8 hours for 3 days every 8 weeks; 20 mg/m2intravenously daily for 5 daysAcute: nausea, vomiting, hyperglycemia Delayed: myelosuppression, fever, fatigue, cough Fluorouracil (Adrucil) 400 mg/m2intravenous bolus followed by 2400 mg/m2intravenously over 46 hours every 2 weeks; 1000 mg/m2intravenously via continuous infusion for 45 days every 34 weeks; various dosesAcute: nausea, vomiting, diarrhea Delayed: myelosuppression, hand-foot syndrome, mucositis, photosensitivity, cardiotoxicity (rare) (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1617 02/07/21 2:44 PMChAPTER 391618 CMDT 2022T able 393. Common cancer therapeutic agents.Cemoterapeutic Agent Usual Adult Dosage Adverse Effects AntimetabolitesPyrimidine Analogs (cont.) Gemcitabine (Gemzar) 10001250 mg/m2intravenously on days 1 and 8 every 3 weeks or days 1, 8, 15 every 4 weeksAcute: nausea, vomiting, rash, flu-like symptoms, fever, diarrhea Delayed: myelosuppression, edema, elevated transaminases AntimicrotubulesVinca Alkaloids Vinblastine (Velban) 6 mg/m2intravenously on days 1 and 15 every 4 weeks; various dosesAcute: constipation Delayed: myelosuppression, alopecia, bone pain, malaise Vincristine (Oncovin) 0.51.4 mg/m2intravenously every 3 weeks; various doses; maximum single dose usually limited to 2 mgAcute: constipation, nausea Delayed: peripheral neuropathy, alopecia AntimicrotubulesTaxanes Docetaxel (Taxotere) 60100 mg/m2intravenously every 3 weeks Acute: nausea, vomiting, diarrhea, hypersensitivity, rash Delayed: myelosuppression, asthenia, peripheral neuropathy, alopecia, edema, mucositis Paclitaxel (Taxol) 135175 mg/m2intravenously every 3 weeks; 5080 mg/m2intravenously weekly; various dosesAcute: diarrhea, nausea, vomiting, hypersensitivity Delayed: myelosuppression, peripheral neuropathy, alopecia, mucositis, arthralgia Paclitaxel protein-bound (Abraxane)100125 mg/m2on days 1, 8, 15 every 34 weeks; 260 mg/m2intravenously every 3 weeksAcute: nausea, vomiting, diarrhea Delayed: myelosuppression, peripheral neuropathy, alopecia, asthenia Enzyme InibitorsAntracyclines Daunorubicin (Cerubidine) 3060 mg/m2intravenously for 3 days Acute: nausea, vomiting, diarrhea, red/orange discoloration of urine, infusion-related reactions (liposomal products) Delayed: myelosuppression, mucositis, alopecia, hand-foot syndrome (liposomal doxorubicin), cardiotoxicity (dose related) Doxorubicin (Adriamycin) 4575 mg/m2intravenously every 3 weeks; various doses Epirubicin (Ellence) 60120 mg/m2intravenously every 34 weeks Idarubicin (Idamycin) 1012 mg/m2intravenously for 3 days Liposomal doxorubicin (Doxil, Lipodox)2050 mg/m2intravenously every 34 weeks Enzyme InibitorsTopoisomerase Inibitors Etoposide (Vepesid) 50100 mg/m2intravenously for 35 days every 3 weeksAcute: nausea, vomiting, diarrhea, hypersensitivity, fever, hypotension Delayed: myelosuppression, alopecia, fatigue Irinotecan (Camptosar) 180 mg/m2intravenously every other week; various dosesAcute: diarrhea, cholinergic syndrome, nausea, vomiting Delayed: myelosuppression, alopecia, asthenia Targeted TerapyMonoclonal Antibodies Atezolizumab (Tecentriq) 1200 mg intravenously every 3 weeks Acute: infusion-related reaction Delayed: immune-mediated reactions, fatigue, decreased appetite Bevacizumab (Avastin) 515 mg/kg intravenously every 23 weeks Acute: infusion-related reaction Delayed: hypertension, proteinuria, wound healing compli- cations, gastrointestinal perforation, hemorrhage Cetuximab (Erbitux) Loading dose 400 mg/m2intravenously, maintenance dose 250 mg/m2intravenously weeklyAcute: infusion-related reaction, nausea, diarrhea Delayed: acneiform skin rash, hypomagnesemia, asthenia, paronychial inflammation, dyspnea Daratumumab (Darzalex) 16 mg/kg intravenously weekly for weeks 18, every 2 weeks for weeks 924, and every 4 weeks from week 25 until disease progressionAcute: infusion-related reaction, nausea Delayed: myelosuppression, fatigue, upper respiratory tract infection (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1618 02/07/21 2:44 PMCANCER1619 CMDT 2022T able 393. Common cancer therapeutic agents.Cemoterapeutic Agent Usual Adult Dosage Adverse Effects Targeted TerapyMonoclonal Antibodies (cont.) Ipilimumab (Yervoy) 110 mg/kg intravenously every 3 weeks for a total of four dosesAcute: infusion-related reaction Delayed: immune-related reactions, fatigue Nivolumab (Opdivo) 240 mg intravenously every 2 weeks or 480 mg every 4 weeksAcute: vomiting Delayed: fatigue, musculoskeletal pain, rash, pruritus, cough, elevated transaminases Obinutuzumab (Gazyva) Cycle 1: 100 mg intravenously on day 1, 900 mg on day 2, 1000 mg on days 8 and 15 of a 28-day cycle; cycles 26: 1000 mg intrave- nously on day 1Acute: infusion-related reaction, tumor lysis syndrome Delayed: myelosuppression, pyrexia, cough, musculoskeletal disorder, potential hepatitis B reactivation Panitumumab (Vectibix) 6 mg/kg intravenously every 2 weeks Acute: infusion-related reaction, nausea Delayed: acneiform skin rash, hypomagnesemia, asthenia, paronychia, fatigue, dyspnea Pembrolizumab (Keytruda) 200 mg intravenously every 3 weeks or 400 mg every 6 weeksAcute: infusion-related reaction, nausea Delayed: immune-mediated reactions, fatigue, cough Pertuzumab (Perjeta) 840 mg intravenously once followed by 420 mg intravenously every 3 weeksAcute: infusion-related reaction, diarrhea, nausea Delayed: fatigue, alopecia, neutropenia, rash, peripheral neuropathy, cardiomyopathy Rituximab (Rituxan) 375 mg/m2intravenously weekly for 4 weeks, or every 34 weeksAcute: infusion-related reaction, tumor lysis syndrome Delayed: lymphopenia, asthenia, rash, potential hepatitis B reactivation Trastuzumab (Herceptin) Initial dose 4 mg/kg intravenously, then 2 mg/kg intravenously weekly; or initial dose 8 mg/kg, then 6 mg/kg, intravenously every 3 weeksAcute: headache, nausea, diarrhea, infusion-related reaction Delayed: myelosuppression, pyrexia, cardiomyopathy, pulmonary toxicity (rare) Targeted TerapyKinase Inibitors Acalabrutinib 100 mg orally twice daily Acute: diarrhea Delayed: myelosuppression, upper respiratory infection, musculoskeletal pain Afatinib (Gilotrif) 40 mg orally once daily without food Acute: diarrhea Delayed: acneiform rash, stomatitis, paronychia Alectinib (Alecensa) 600 mg orally twice daily with food Acute: none Delayed: myelosuppression, fatigue, edema, myalgia, dyspnea, elevated transaminases Axitinib (Inlyta) 510 mg orally twice daily Acute: diarrhea, nausea, vomiting Delayed: hypertension, fatigue, dysphonia, hand-foot syndrome, elevated transaminases Bosutinib (Bosulif) 500600 mg orally once daily with food Acute: diarrhea, nausea, vomiting Delayed: myelosuppression, rash, abdominal pain, hepatotoxicity, fluid retention Ceritinib (Zykadia) 740 mg orally once daily Acute: diarrhea, nausea, vomiting Delayed: elevated transaminases, abdominal pain, fatigue, decreased appetite Cobimetinib (Cotellic) 60 mg orally once daily on days 121 of a 28-day cycleAcute: diarrhea, photosensitivity reaction, nausea, vomiting Delayed: myelosuppression, hepatotoxicity, rash, cardiomyopathy (with vemurafenib) Crizotinib (Xalkori) 250 mg orally twice daily Acute: nausea, vomiting, diarrhea, constipation Delayed: vision disorder, edema, elevated transaminases, fatigue Dabrafenib (Tafinlar) 150 mg orally twice daily without food Acute: headache Delayed: hyperkeratosis, fever, hand-foot syndrome, hyperglycemia, hypophosphatemia Dacomitinib (Vizimpro) 45 mg orally once daily Acute: diarrhea Delayed: rash, paronychia, mucositis, cough, interstitial lung disease (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1619 02/07/21 2:44 PMChAPTER 391620 CMDT 2022T able 393. Common cancer therapeutic agents.Cemoterapeutic Agent Usual Adult Dosage Adverse Effects Targeted TerapyKinase Inibitors (cont.) Dasatinib (Sprycel) 100180 mg orally once daily Acute: diarrhea, nausea, vomiting Delayed: myelosuppression, fluid retention, fatigue, dyspnea, musculoskeletal pain, rash Entrectinib (Rozlytrek) 600 mg orally daily Acute: nausea, vomiting, diarrhea Delayed: fatigue, cognitive impairment, heart failure, potential for birth defects, hepatotoxicity, vision disorder, prolonged QT interval (rare) Erlotinib (Tarceva) 100 or 150 mg orally once daily without food Acute: diarrhea, nausea, vomiting Delayed: acneiform skin rash, fatigue, anorexia, dyspnea Gefitinib (Iressa) 250 mg orally once daily Acute: diarrhea Delayed: acneiform skin rash Ibrutinib (Imbruvica) 420 or 560 mg orally once daily Acute: diarrhea, nausea Delayed: myelosuppression, fatigue, edema, rash, elevated serum creatinine, hemorrhage Imatinib (Gleevec) 100800 mg orally once daily with food Acute: nausea, vomiting, diarrhea Delayed: edema, muscle cramps, rash, myelosuppression, hepatotoxicity Larotrectinib (Vitrakvi) 100 mg orally twice daily Acute: nausea, vomiting, diarrhea Delayed: fatigue, cognitive impairment, potential for birth defects, hepatotoxicity Lenvatinib (Lenvima) 24 mg orally daily Acute: hypertension, nausea, vomiting, diarrhea Delayed: fatigue, arthralgia/myalgia, stomatitis, hand-foot syndrome Nilotinib (Tasigna) 300 or 400 mg orally twice daily without food Acute: nausea, vomiting, diarrhea Delayed: rash, fatigue, myelosuppression, prolonged QT interval (rare) Osimertinib (Tagrisso) 80 mg orally once daily Acute: diarrhea Delayed: myelosuppression, rash, dry skin, nail toxicity, cardiomyopathy (rare), QTc interval prolongation (rare) Pazopanib (Votrient) 800 mg orally once daily without food Acute: diarrhea, nausea, vomiting Delayed: hypertension, hair color changes, hepatotoxicity, hemorrhage Regorafenib (Stivarga) 160 mg orally once daily with food (low-fat breakfast)Acute: diarrhea Delayed: asthenia, hand-foot syndrome, anorexia, hyperten- sion, mucositis, myelosuppression, hepatotoxicity Sorafenib (Nexavar) 400 mg orally twice daily without food Acute: diarrhea and nausea Delayed: fatigue, hand-foot syndrome, rash, hypertension, hemorrhage Sunitinib (Sutent) 50 mg orally once daily for 4 weeks followed by 2 weeks rest; 37.5 mg orally dailyAcute: diarrhea and nausea Delayed: hypertension, hand-foot syndrome, rash, yellow discoloration of skin, fatigue, hypothyroidism, mucositis, left ventricular dysfunction, bleeding, hepatotoxicity Trametinib (Mekinist) 2 mg orally once daily without food Acute: rash, diarrhea Delayed: elevated transaminases, lymphedema, cardiomyopathy Vemurafenib (Zelboraf) 960 mg orally twice daily Acute: nausea, hypersensitivity (rare) Delayed: photosensitivity, rash, arthralgia, alopecia, fatigue, prolonged QT interval, cutaneous squamous cell carcinoma (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1620 02/07/21 2:44 PMCANCER1621 CMDT 2022T able 393. Common cancer therapeutic agents.Cemoterapeutic Agent Usual Adult Dosage Adverse Effects Miscellaneous Agents Abiraterone (Zytiga) 1000 mg orally once daily Acute: diarrhea, edema Delayed: adrenal insufficiency, hepatotoxicity, joint pain, hypokalemia Bleomycin (Blenoxane) 10 units/m2intravenously on days 1 and 15 every 28 days; 30 units intravenously on days 2, 9, and 16 every 21 daysAcute: hypersensitivity, fever Delayed: skin reaction (rash, hyperpigmentation of skin, striae), mucositis, pneumonitis Bortezomib (Velcade) 1.3 mg/m2intravenous bolus or subcutaneously on days 1, 4, 8, 11 followed by a 10-day rest, or weekly for 4 weeks followed by 13-day restAcute: nausea, vomiting, diarrhea Delayed: peripheral neuropathy, fatigue, myelosuppression Hydroxyurea (Hydrea) 2030 mg/kg orally daily Acute: none Delayed: myelosuppression Lenalidomide (Revlimid) 525 mg orally once daily on days 121 of 28-day cycle; or continuouslyAcute: diarrhea, rash Delayed: myelosuppression, fatigue, venous thromboembolism, potential for birth defects Mitomycin (Mutamycin) 1020 mg/m2intravenously every 48 weeks; 2040 mg intravesicallyAcute: cystitis (intravesically), nausea, vomiting Delayed: myelosuppression, mucositis, anorexia Pegaspargase (Oncaspar) 20002500 international units/m2intramuscu- larly every 14 daysAcute: hypersensitivity Delayed: febrile neutropenia, coagulation abnormalities, hepatotoxicity, pancreatitis Venetoclax (Venclexta) 20 mg orally daily during week 1; 50 mg daily during week 2; 100 mg daily during week 3; 200 mg daily during week 4; then 400 mg orally daily thereafterAcute: diarrhea, nausea, vomiting, tumor lysis syndrome Delayed: myelosuppression, upper respiratory infections, fatigue Antiandrogens Apalutamide (Erleada) 240 mg orally daily Acute: fatigue, diarrhea Delayed: arthralgia, hot flashes, falls, peripheral edema, seizure (rare) Bicalutamide (Casodex) 50 mg orally once daily Acute: none Delayed: hot flashes, back pain, asthenia Enzalutamide (Xtandi) 160 mg orally once daily Acute: asthenia, diarrhea Delayed: hot flashes, arthralgia, peripheral edema, seizure (rare) Flutamide (Eulexin) 250 mg orally every 8 hours Acute: diarrhea Delayed: hot flashes, hepatotoxicity Nilutamide (Nilandron) 300 mg orally for 30 days, then 150 mg orally once dailyAcute: none Delayed: visual disturbances (impaired adaptation to dark), hot flashes, disulfiram-like reaction Selective Estrogen Receptor Modulators Tamoxifen (Nolvadex) 2040 mg orally once daily Acute: none Delayed: hot flashes, vaginal discharge, menstrual irregularities, arthralgia Aromatase Inibitors Anastrozole (Arimidex) 1 mg orally once daily Acute: nausea Delayed: hot flashes, peripheral edema, asthenia, hypercholesterolemia, arthralgia/myalgia, osteoporosis Exemestane (Aromasin) 25 mg orally once daily Letrozole (Femara) 2.5 mg orally once daily (continued )(continued)CMDT22_Ch39_p1612-p1675.indd  1621 02/07/21 2:44 PMChAPTER 391622 CMDT 2022T able 393. Common cancer therapeutic agents.Cemoterapeutic Agent Usual Adult Dosage Adverse Effects Pure Estrogen Receptor Antagonist Fulvestrant (Faslodex) 500 mg intramuscularly on days 1, 15, 29, then monthlyAcute: injection site reaction, nausea Delayed: hot flashes, bone pain, elevated transaminases LhRh Analogs Goserelin acetate (Zoladex)3.6 mg subcutaneously every month; 10.8 mg subcutaneously every 3 monthsAcute: injection site discomfort Delayed: hot flashes, tumor flare, edema, decreased libido, erectile dysfunction, osteoporosis Leuprolide (Lupron) 7.5 mg intramuscularly or subcutaneously every month; 22.5 mg intramuscularly or subcuta- neously every 3 months; 30 mg intramuscu- larly or subcutaneously every 4 months; 45 mg intramuscularly or subcutaneously every 6 months Triptorelin pamoate (Trelstar)3.75 mg intramuscularly every 4 weeks; 11.25 mg intramuscularly every 12 weeks; 22.5 mg intramuscularly every 24 weeks LhRh Antagonist Degarelix (Firmagon) 240 mg subcutaneously once, then 80 mg subcutaneously every 28 daysAcute: injection site reaction Delayed: hot flashes, weight gain, elevated transaminases, QT prolongation AV, atrioventricular; GFR, glomerular filtration rate; LHRH, luteinizing hormonereleasing hormone; MAO, monoamine oxidase; MCV , mean corpuscular volume. TYPES OF CANCER LUNG CANCER Sunny Wang, MD BRONCHOGENIC CARCINOMAE S S E N T I A L S  O F  D I A G N O S I S New cough or change in chronic cough. Dyspnea, hemoptysis, anorexia, weight loss. Enlarging lung nodule or mass; persistent opacity, atelectasis, or pleural effusion on chest radiograph or CT scan. Cytologic or histologic findings of lung cancer in sputum, pleural fluid, or biopsy specimen. General ConsiderationsLung  cancer is the leading cause of cancer deaths in both men and women. The American Cancer Society estimates 228,820 new diagnoses and 135,720 deaths from lung can- cer in the United States in 2020, accounting for approxi- mately 13% of new cancer diagnoses and 22% of all cancer deaths. More Americans die of lung cancer than of colorec- tal, breast, and prostate cancers combined.Cigarette smoking causes 8590% of cases of lung cancer. The causal connection between cigarettes and lung cancer is established not only epidemiologically but also through identification of carcinogens in tobacco smoke and analysis of the effect of these carcinogens on specific oncogenes expressed in lung cancer. Other environmental risk factors for the development of lung cancer include exposure to environmental tobacco smoke, radon, asbestos, diesel exhaust, ionizing radiation, metals (arsenic, chromium, nickel, iron oxide), and indus- trial carcinogens. A familial predisposition to lung cancer is recognized. Certain diseases are associated with an increased risk of lung cancer, including pulmonary fibrosis, chronic obstructive pulmonary disease, and sarcoidosis. The median age at diagnosis of lung cancer in the United States is 70; it is unusual under the age of 40. The combined relative 5-year survival rate for all stages of lung cancer is currently 21%. There are five main histologic categories of broncho- genic carcinoma. Squamous cell carcinomas (23% of cases, based on US SEER data 20132017) arise from the bronchial epithelium and often present as intraluminal masses. They are usually centrally located and can present with hemoptysis. Adenocarcinomas (50% of cases) arise from mucous glands or from any epithelial cell within or distal to the terminal bronchioles. They usually present as peripheral nodules or masses. Adenocarcinomas in situ (formerly bronchioloalveolar cell carcinomas) spread along preexisting alveolar structures (lepidic growth) with- out evidence of invasion. Large cell carcinomas (1.3% of(continued)CMDT22_Ch39_p1612-p1675.indd  1622 02/07/21 2:44 PMCANCER1623 CMDT 2022cases)  are a heterogeneous group of undifferentiated can- cers that share large cells and do not fit into other catego- ries. Large cell carcinomas are typically aggressive and have rapid doubling times. They present as central or peripheral masses. Cancers that are not better differentiated on patho- logic review other than nonsmall cell carcinomas (NSCLC) or carcinomas not otherwise specified make up about 13% of cases. Small cell carcinomas (13% of cases) are tumors of bronchial origin that typically begin cen- trally, infiltrating submucosally to cause narrowing of the bronchus without a discrete luminal mass. They are aggres- sive cancers that often involve regional or distant metastasis on presentation. For purposes of staging and treatment, bronchogenic carcinomas are divided into small cell lung cancer (SCLC) and the other four types, labeled NSCLC. This practical classification reflects different natural histories and differ- ent treatment. SCLC is prone to early hematogenous spread and has a more aggressive course with a median survival (untreated) of 618 weeks. Clinical FindingsLun g cancer is symptomatic at diagnosis in a majority of patients. The clinical presentation depends on the type and location of the primary tumor, the extent of local spread, and the presence of distant metastases and any paraneo- plastic syndromes.A.  Symptoms and SignsAnor exia, weight loss, or asthenia occurs in 5590% of patients presenting with a new diagnosis of lung cancer. Up to 60% of patients have a new cough or a change in a chronic cough; 631% have hemoptysis; and 2540% com- plain of pain, either nonspecific chest pain or pain from bony metastases to the vertebrae, ribs, or pelvis. Local spread may cause endobronchial obstruction with atelectasis and postobstructive pneumonia, pleural effusion (1233%), change in voice (compromise of the recurrent laryngeal nerve), superior vena cava syndrome (obstruc- tion of the superior vena cava with supraclavicular venous engorgement), and Horner syndrome (ipsilateral ptosis, miosis, and anhidrosis from involvement of the inferior cervical ganglion and the paravertebral sympathetic chain). Distant metastases to the liver are associated with asthenia and weight loss. Brain metastases (10% in NSCLC, more common in adenocarcinoma, and 2030% in SCLC) may present with headache, nausea, vomiting, seizures, dizzi- ness, or altered mental status. Paraneoplastic syndromes are patterns of organ dys- function related to immune-mediated or secretory effects of neoplasms. These syndromes occur in 1020% of lung cancer patients. They may precede, accompany, or follow the diagnosis of lung cancer. In patients with small cell carcinoma, the syndrome of inappropriate antidiuretic hormone (SIADH) can develop in 1015%; in those with squamous cell carcinoma, hypercalcemia can develop in 10%. Digital clubbing is seen in up to 20% of patients at diagnosis (see Figure 642). Other common paraneoplastic syndromes include increased ACTH production, anemia,hypercoagulability, peripheral neuropathy, and the Lambert- Eaton myasthenic syndrome. Their recognition is important because treatment of the primary tumor may improve or resolve symptoms even when the cancer is not curable.B.  Laboratory FindingsThe diagnosis of lu ng cancer rests on examination of a tis- sue or cytology specimen. Sputum cytology is highly spe- cific but insensitive; the yield is highest when there are lesions in the central airways. While the diagnostic yield of CT-guided biopsy of peripheral nodules approaches 8090%, the rates of pneumothorax are significant (1530%), especially in those with emphysema. Thoracentesis (sensi- tivity 5065%) can be used to establish a diagnosis of lung cancer in patients with malignant pleural effusions. Fine-needle aspiration (FNA) of palpable supraclavicular or cervical lymph nodes is frequently diagnostic. Fiberoptic bronchoscopy allows visualization of the major airways, cytology brushing of visible lesions or lavage of lung segments with cytologic evaluation of speci- mens, direct biopsy of endobronchial abnormalities, blind transbronchial biopsy of the pulmonary parenchyma or peripheral nodules, and FNA biopsy of mediastinal lymph nodes. The use of fluorescence bronchoscopy improves the ability to identify early endobronchial lesions, and endo- bronchial and transesophageal endoscopic ultrasound enhance the direction and yield of FNA of mediastinal nodes. Electromagnetic navigational bronchoscopy allows bronchoscopic approaches to small peripheral nodules. Mediastinoscopy, video-assisted thoracoscopic surgery (VATS), and thoracotomy may be necessary in cases where less invasive techniques fail to yield a diagnosis.C.  ImagingNear ly all patients with lung cancer have abnormal find- ings on chest radiography or CT scan (Figure 391). These findings are rarely specific for a particular diagnosis. Inter- pretation of characteristic findings in isolated nodules is described in Chapter 9.D . Special Examinations1. Staging  Accurate staging is crucial (1) to provide the clinician with information to guide treatment, (2) to pro- vide the patient with accurate information regarding prog- nosis, and (3) to standardize entry criteria for clinical trials to allow interpretation of results. Staging of NSCLC uses two integrated systems and is continuously updated with the eighth edition of the AJCC/ Union for International Cancer Control (UICC) stage classification for lung cancer in effect since January 2018. TheAJCC TNM international staging system attempts a physical description of the neoplasm: T describes the size and location of the primary tumor; N describes the pres- ence and location of nodal metastases; and M refers to the presence or absence of distant metastases. These TNM stages are grouped into summary stages IIV , and these are used to guide therapy. Many patients with stage I and stage II disease are cured through surgery. Patients with stage IIIB and stage IV disease do not benefit from surgeryCMDT22_Ch39_p1612-p1675.indd  1623 02/07/21 2:44 PMChAPTER 391624 CMDT 2022 Figure 391. Squamous cell carcinoma of the right lung on chest radiograph (A)and CT scan (B).(Repro- duced, with permission, from Elsayes KM, Oldham SA. Introduction to Diagnostic Radiology. McGraw-Hill, 2014.) A B(T able 394). Patients with stage IIIA disease have locally invasive disease that may benefit from surgery in selected cases as part of multimodality therapy. SCLC is traditionally divided into two categories: limited disease (30%), when the tumor is limited to the unilateral hemithorax (including contralateral mediastinal nodes); or extensive disease (70%), when the tumor extends beyond the hemithorax (including pleural effu- sion). It is also recommended to stage SCLC according to the TNM staging system. For both SCLC and NSCLC, a complete examination is essential to exclude obvious metastatic disease to lymph nodes, skin, and bone. A detailed history is essential because the patients performance status is a powerful pre- dictor of disease course. All patients should have measure- ment of a complete blood count (CBC), serum electrolytes, calcium, creatinine, liver biochemical tests, lactate dehy- drogenase, and albumin.NSCLC patients being considered for surgery require meticulous evaluation to identify those with resectable disease. CT imaging is key for staging candidates for resec- tion. The sensitivity and specificity of CT imaging for identifying lung cancer metastatic to the mediastinal lymph nodes are 57% (4966%) and 82% (7786%), respectively. Therefore, chest CT imaging alone does not provide definitive staging information. CT imaging helps determine where to biopsy, and how the mediastinum should be sampled. Positron emission tomography (PET) using 2-[18F] fluoro-2-deoxyglucose (FDG) is an important modality for identifying metastatic foci in the mediastinum or distant sites. The sensitivity and specificity of PET for detecting mediastinal spread of primary lung cancer depend on the size of mediastinal nodes or masses. When mediastinal lymph nodes smaller than 1 cm are present, the sensitivity and specificity of PET for tumor involvement of nodes are 74% and 96%, respectively. When CT shows lymph nodes larger than 1 cm, the sensitivity and specificity are 95% and 76%, respectively. The combination of PET and CT imaging has improved preoperative staging compared with CT or PET alone. Whole body fusion PET-CT imaging is most useful toTable 394. Five-year survival rates for nonsmall cell lung cancer, based on TNM staging.Stage TNM Subset5-Year Survival for Clinical TNM5-Year Survival for Pato- logic TNM 0 Carcinoma in situ 1A1 T1aN0M0 92% 90% 1A2 T1bN0M0 83% 85% IA3 T1cN0M0 77% 80% IB T2aN0M0 68% 73% IIA T2bN0M0 60% 65% IIB T1/T2, N1M0 T3N0M053% 56% IIIA T1/T2, N2M0 T3N1M0 T4, N0/N1, M036% 41% IIIB T1/T2, N3M0 T3/T4, N2M026% 24% IIIC T3/T4, N3M0 13% 12% IVA Any T, Any N, M1a/M1b10%  IVB Any T, Any N, M1c 0%  Data from multiple sources. Modified and reproduced, with per- mission, from Detterbeck FC et al. The Eighth Edition Lung Cancer Stage Classification. Chest. 2017;151:193. Copyright  Elsevier; and data from Goldstraw P et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2015;11:39.CMDT22_Ch39_p1612-p1675.indd  1624 02/07/21 2:44 PMCANCER1625 CMDT 2022confirm  lack of regional or metastatic disease in NSCLC patients who are candidates for surgical resection. Obtaining an MRI of the brain is important to rule out brain metastases in patients with SCLC and in patients with NSCLC with at least stage II disease or poorly differ- entiated histologies. 2. Preoperative assessment See Chapter 3. 3. Pulmonary function testing Many patients with NSCLC have moderate to severe chronic lung disease that increases the risk of perioperative complications as well as long-term pulmonary insufficiency following lung resec- tion. All patients considered for surgery require spirome- try. In the absence of other comorbidities, patients with good lung function (preoperative FEV12 L or more) are at low risk for complications from lobectomy or pneumonec- tomy. High-risk patients include those with a predicted postoperative FEV1less than 700 mL (or less than 40% of predicted FEV1). 4. Screening Screening with low-dose helical CT scans has been shown to improve mortality rates for lung cancer. The National Lung Screening Trial, a multicenter random- ized US trial involving over 53,000 current and former heavy smokers, showed that screening annually with low- dose helical CT for 3 years yielded a 20% relative reduction in lung cancer mortality and 6.7% reduction in all-cause mortality compared to chest radiography. Given these find- ings, US professional organizations have recommended annual screening with low-dose helical CT for lung cancer. The 2021 US Preventive Services Task Force (USPSTF) recommends annual low-dose CT for smokers aged 5080 who have at least a 20 pack-year smoking history and who either currently smoke or have quit within the last 15 years. Smoking cessation policies and efforts should be integrated with any screening program. TreatmentA.  NonSmall Cell Lung CarcinomaSurgic al resection offers the best chance for cure of NSCLC. Clinical features that preclude complete surgical resection include extrathoracic metastases or a malignant pleural effusion; or tumor involving the heart, pericar- dium, great vessels, esophagus, recurrent laryngeal or phrenic nerves, trachea, main carina, or contralateral mediastinal lymph nodes. Accordingly, stage I and stage II patients are treated with surgical resection where possible. Stage II and select cases of stage IB are additionally recom- mended to receive adjuvant chemotherapy. Stage IIIA patients have poor outcomes if treated with resection alone. They should undergo multimodality treatment that includes chemotherapy or radiotherapy, or both. Inopera- ble stage IIIA and stage IIIB patients treated with concur- rent chemotherapy and radiation therapy have improved survival. Stage IV patients are treated with systemic ther- apy (targeted therapy, chemotherapy, or immunotherapy) or symptom-based palliative therapy, or both. Surgical approach affects outcome. In 1994, the North American Lung Cancer Study Group conducted a prospec- tive trial of stage IA patients randomized to lobectomyversus limited resection. They reported a threefold increased rate of local recurrence in the limited resection group (P= 0.008) and a trend toward an increase in overall death rate (increase of 30%, P= 0.08) and increase in cancer- related death rate (increase of 50%, P= 0.09), compared with patients receiving lobectomy. However, for patients who cannot tolerate lobectomy, a sublobar resection (wedge resection or segmentectomy) may be considered. Patients with clinical stage I primary NSCLC, who are not candidates for surgery because of significant comor- bidity or other surgical contraindication, are candidates for stereotactic body radiotherapy. Stereotactic body radio- therapy, which is composed of multiple non-parallel radia- tion beams that converge, allows the delivery of a relatively large dose of radiation to a small, well-defined target. For clinical stage I NSCLC, 3-year local control rates with ste- reotactic body radiotherapy exceed 90%, and large meta- analyses of nonrandomized data have shown 2-year survival of 70% and 5-year survival of 40%. Patients with locally advanced disease (stages IIIA and IIIB) who are not surgical candidates have improved survival when treated with concurrent chemotherapy and radiation therapy com- pared with no therapy, radiation alone, or even sequential chemotherapy and radiation. Neoadjuvant chemotherapy consists of giving antineo- plastic drugs in advance of surgery or radiation therapy. Neoadjuvant therapy can be used in select patients with stage IIIA or stage IIIB disease. Some studies suggest a survival advantage. Adjuvant chemotherapy consists of administering antineoplastic drugs following surgery or radiation ther- apy. Cisplatin-containing regimens have been shown to confer an overall survival benefit in at least stage II disease and a subset of stage IB disease where primary tumor size exceeds 4 cm. The Lung Adjuvant Cisplatin Evaluation Collaborative Group, a meta-analysis of the five largest cisplatin-based adjuvant trials, reported a 5% absolute ben- efit in 5-year overall survival with a cisplatin-containing doublet regimen following surgery ( P= 0.005) in patients with at least stage II disease. For stage IIIB and stage IV NSCLC, options for therapy include targeted therapy, cytotoxic chemotherapy, and immunotherapy (checkpoint inhibitors) (Tables 392 and 393). The approach to therapy is individualized based on molecular profiling and PD-L1 testing. Molecular profiling is offered as next-generation sequencing multi-gene assays. The key driver mutations in lung cancer currently include EGFR, ALK, BRAF, ROS1, NTRK ,MET, and RET muta- tions, but only a minority of all lung cancer cases harbor these mutations. K-ras mutation is more commonly found among smokers. Difficulties in testing may arise when only small fine-needle aspirate biopsies are obtained; to have sufficient tissue for analysis, it is recommended that clini- cians obtain core biopsies. PD-L1 expression is a flawed but actively used biomarker to assess possible response to checkpoint inhibitor therapy (specifically, programmed death-1 [PD-1] inhibitors). Targeted therapy has played a pivotal role in advanced NSCLC (Tables 392 and 393). Activating EGFR muta- tions are found in approximately 1020% of the WhiteCMDT22_Ch39_p1612-p1675.indd  1625 02/07/21 2:44 PMChAPTER 391626 CMDT 2022popula tion and 3048% of the Asian population and are usually found among nonsmokers to light smokers, females, and persons with nonsquamous histologies (particularly adenocarcinomas). For patients with EGFR mutations, an EGFR tyrosine kinase inhibitor (osimertinib, erlotinib, gefi- tinib, afatinib, or dacomitinib) rather than platinum-based chemotherapy is the first-line treatment. Response rates with EGFR tyrosine kinase inhibitors in patients with EGFR mutation are at least 70%, and median overall survival is estimated to be 2133 months. Osimertinib (a third-gener- ation irreversible EGFR tyrosine kinase inhibitor) is recom- mended as first-line treatment of EGFR -mutated lung cancers. Phase 3 data show that osimertinib leads to a lon- ger duration of response, longer progression-free survival, and lower rates of severe adverse events compared to earlier generation EGFR tyrosine kinase inhibitors. Approximately 5% of all patients with NSCLC carry translocations of ALK resulting in novel fusion gene prod- ucts with oncogenic activity. For patients with ALK- rearranged lung cancers, ALK tyrosine kinase inhibitors (alectinib, ceritinib, crizotinib, brigatinib, and lorlatinib) are recommended therapeutic agents. Alectinib and briga- tinib are recommended as first-line agents in ALK - rearranged lung cancers with response rates ranging from 74% to 83%. For patients who have developed resistance to either first- or second-generation ALK inhibitors, lorlati- nib (a third-generation ALK and ROS1 tyrosine kinase inhibitor) has shown a response rate of 47%. Approxi- mately 12% of NSCLC harbor ROS1 rearrangements and they are usually lung adenocarcinomas found among non- smokers or light smokers. ROS1 -rearranged lung cancers respond to crizotinib ( ALK,cMET , and ROS1 tyrosine kinase inhibitor) and entrectinib (multikinase inhibitor, including ROS-1) with response rates over 70%. MET exon 14 (METex14) skipping mutations are found in 3% of lung adenocarcinomas. Capmatinib (MET inhibitor) is recom- mended as first-line treatment for patients with METex14 skipping mutation. BRAF mutations have been found in 2% of NSCLC patients. The combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) has shown response rates of over 60% in patients with BRAF V600E mutations. Treatment with larotrectinib (TRKA/ B/C inhibitor) or entrectinib (multikinase inhibitor, including TRKA/B/C) is recommended for patients whose tumors reveal NTRK 1/2/3 gene fusion. Selpercatinib and pralsetinib (RET inhibitors) are recommended first-line treatments for RET fusionpositive NSCLC. Finally, K-ras mutations are found among 30% of patients with adenocar- cinomas, are associated with smoking, and indicate a poor prognosis. Early clinical trials are already under way evalu- ating the role of novel K-ras inhibitors, sotorasib (AMG 510) and adagrasib (MRTX849), in treating K-ras G12C mutated lung cancers. Immune checkpoint inhibition using PD-1 or PD-L1 inhibitors (nivolumab, pembrolizumab, atezolizumab, and durvalumab) has an important role in the treatment of NSCLC (Tables 392 and 393). Checkpoint inhibitors release T cells from the inhibitory signals they receive from tumor cells via the PD-1 pathway, restoring antitumor immunity. For patients with tumors staining greater than50% for PDL-1, pembrolizumab outperforms first-line platinum-based chemotherapy, with response rates of 45% vs 28% and median progression-free survival of 10 months vs 6 months. Phase 3 trials have shown improved survival outcomes with adding pembrolizumab to platinum- doublet chemotherapy as first-line therapy for patients with advanced NSCLC regardless of PD-L1 status. If patients received chemotherapy alone as first-line treatment, PD-1 inhibitors are recommended as second-line treatment of NSCLC, regardless of PD-L1 staining intensity. However, significant side effects and toxicity have been reported with checkpoint inhibitors, especially autoimmune manifesta- tions such as hepatitis, thyroiditis, hypophysitis, colitis, pneumonitis, and type 1 diabetes mellitus. Recently, a ran- domized phase 3 trial has shown improved survival out- comes by adding durvalumab as consolidation therapy post-definitive chemoradiation for stage III NSCLCs. If no targetable mutations are found and there is inad- equate PD-L1 expression on tumor cells, patients are either offered combination immunotherapy with cytotoxic che- motherapy or cytotoxic chemotherapy alone (Table 392). Although not curative, chemotherapy has been shown in multiple clinical trials to provide a modest increase in over- all survival in patients with stage IIIB and stage IV NSCLC compared with supportive care alone, with the median survival increased from 5 months to a range of 812 months and 1-year survival rate of 3040%. Palliative chemother- apy also leads to improved quality of life and symptom control, with first-line therapy involving a platinum-based regimen.B.  Small Cell Lung CarcinomaResponse  rates of SCLC to cisplatin and etoposide (Table 392) are excellent with 8090% response in limited-stage disease (5060% complete response), and 6080% response in extensive-stage disease (1520% complete response). However, remissions tend to be short-lived with a median duration of 68 months. Once the disease has recurred, median survival is 34 months. Overall 2-year survival is 2040% in limited-stage disease and 5% in extensive-stage disease (Table 395). Modest improvement in survival has been achieved with the addition of a checkpoint inhibitor (atezolizumab or durvalumab) to cisplatin or carboplatin and etoposide therapy in extensive stage disease. Thoracic radiation therapy improves survival in patients with lim- ited SCLC and is given concurrently with chemotherapy. There is a high rate of brain metastasis in patients with SCLC, even following a good response to chemotherapy. Table 395. Median survival for small cell lung carci- noma following treatment.Stage Mean 2-Year Survival Median Survival Limited 2040% 1520 months Extensive 5% 813 months Data from multiple sources, including Van Meerbeeck JP et al. Small-cell lung cancer. Lancet. 2011;378:1741.CMDT22_Ch39_p1612-p1675.indd  1626 02/07/21 2:44 PMCANCER1627 CMDT 2022Pro phylactic cranial irradiation may be considered for patients with limited-stage disease who respond to chemo- therapy and in a subset of patients with extensive-stage disease who have had an excellent response to chemotherapy.C.  Palliative TherapyPhoto resection with the Nd:YAG laser is sometimes per- formed on central tumors to relieve endobronchial obstruc- tion, improve dyspnea, and control hemoptysis. External beam radiation therapy is also used to control dyspnea, hemoptysis, endobronchial obstruction, pain from bony metastases, obstruction from superior vena cava syn- drome, and symptomatic brain metastases. Resection of a solitary brain metastasis improves quality of life and sur- vival when combined with radiation therapy if there is no evidence of other metastatic disease. Stereotactic radia- tion therapy is offered for limited brain metastases. Repeated thoracenteses, pleurodesis, and PleurX catheter tube placement are key interventions for palliation of symptomatic malignant pleural effusions. Pain is very common in advanced disease. Meticulous efforts at pain control are essential (see Chapter 5). In addition to standard oncologic care, early referral to a palliative care specialist is recommended in advanced disease to aid in pain and other symptom management. Such palliative care can modestly improve survival. PrognosisThe  overall 5-year survival rate for lung cancer is approxi- mately 20%. Predictors of survival include the tumor type (SCLC versus NSCLC), molecular profiling, and stage, and the patients performance status and weight loss in the prior 6 months. Patients with targetable mutations have better overall survival when compared with those without muta- tions due to superior efficacy of targeted drug therapy.Camidg e DR et al. Brigatinib versus crizotinib in advanced ALK inhibitor-nave ALK-positive non-small cell lung cancer: sec- ond interim analysis of the phase III ALTA-1L trial. J Clin Oncol. 2020;38:3592. [PMID: 32780660] Drilon A et al. Entrectinib in ROS1 fusion-positive non-small- cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21:262. [PMID: 31838015] Ghimessy A et al. Current therapy of KRAS -mutant lung cancer. Cancer Metastasis Rev. 2020;39:1159. [PMID: 32548736] Ramalingam SS et al; FLAURA Investigators. Overall survival with osimertinib in untreated EGFR -mutated advanced NSCLC. N Engl J Med. 2020;382:41. [PMID: 31751012] Siegel RL et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7. [PMID: 33433946] US Preventive Services Task Force. Screening for lung cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325:962. [PMID: 33687470]PU LMONARY METASTASISPulmonary metastasis  results from the spread of an extra- pulmonary malignant tumor through vascular or lym- phatic channels or by direct extension. Metastases usually occur via the pulmonary artery and typically present asmultiple nodules or masses on chest radiography. The radiographic differential diagnosis of multiple pulmonary nodules also includes pulmonary arteriovenous malforma- tion, infections (including abscesses, septic emboli, and atypical infections), sarcoidosis, rheumatoid nodules, and granulomatosis with polyangiitis. Metastases to the lungs are found in 2055% of patients with various metastatic malignancies. Carcinomas of the kidney, breast, rectum, colon, and cervix and malignant melanoma are the most likely primary tumors. Lymphangitic carcinomatosis denotes diffuse involve- ment of the pulmonary lymphatic network by primary or metastatic lung cancer, probably a result of extension of tumor from lung capillaries to the lymphatics. Tumor embolization from extrapulmonary cancer (renal cell car- cinoma, hepatocellular carcinoma, choriocarcinoma) is an uncommon route for tumor spread to the lungs. Metastatic cancer may also present as a malignant pleural effusion. Clinical FindingsA.  Symptoms and SignsSymp toms are uncommon but include cough, hemoptysis and, in advanced cases, dyspnea and hypoxemia. Symp- toms are more often referable to the site of the primary tumor.B.  Laboratory FindingsThe  diagnosis of metastatic cancer involving the lungs is usually established by identifying a primary tumor. Appro- priate studies should be ordered if there is a suspicion of any primary cancer, such as breast, thyroid, testis, colorec- tal, or prostate, for which specific treatment is available. If the history, physical examination, and initial studies fail to reveal the site of the primary tumor, attention is better focused on the lung, where tissue samples obtained by bronchoscopy, percutaneous needle biopsy, video-assisted thoracoscopic surgery (V ATS), or thoracotomy may estab- lish the histologic diagnosis and suggest the most likely primary cancer. Occasionally, cytologic studies of pleural fluid or pleural biopsy reveals the diagnosis.C.  ImagingChest  radiographs usually show multiple spherical densi- ties with sharp margins. The lesions are usually bilateral, pleural, or subpleural in location, and more common in lower lung zones. Lymphangitic spread and solitary pul- monary nodule are less common radiographic presenta- tions of pulmonary metastasis. CT imaging of the chest, abdomen, and pelvis may reveal the site of a primary tumor and will help determine feasibility of surgical resection of the metastatic lung tumors. FDG PET-CT scan is helpful in identifying the site of a primary cancer and identifying other areas of extrathoracic metastasis. TreatmentOnce  the diagnosis has been established, management consists of treatment of the primary neoplasm and any pulmonary complications. Surgical resection of a solitaryCMDT22_Ch39_p1612-p1675.indd  1627 02/07/21 2:44 PMChAPTER 391628 CMDT 2022pulmona ry nodule is often prudent in the patient with known current or previous extrapulmonary cancer. Local resection of one or more pulmonary metastases is feasible in a few carefully selected patients with various sarcomas and carcinomas (such as testis, colorectal, and kidney). About 1525% of metastatic solid tumor patients have metastases limited to the lungs and are surgical candidates. Surgical resection should be considered only if (1) the pri- mary tumor is under control, (2) the patient has adequate cardiopulmonary reserve to tolerate resection, (3) all meta- static tumor can be resected, (4) effective nonsurgical approaches are not available, and (5) there is no evidence of extrathoracic metastases that are not controlled. Unfa- vorable prognostic factors also include shorter disease-free interval from primary tumor treatment to presentation of metastases and a larger number of metastases. Retrospec- tive data from the International Registry of Lung Metasta- ses report an overall 5-year survival rate of 36% and 10-year survival rate of 26% after complete resection of pulmonary metastases. Patients who are not surgical can- didates but have solitary or limited metastatic disease to the lungs may be candidates for stereotactic radiotherapy, radioablation, or cryotherapy. For patients with unresect- able progressive disease, chemotherapy tailored to the pri- mary tumor can be offered, and diligent attention to palliative care is essential (see Chapter 5).Ha ndy JR et al. Expert consensus document on pulmonary metastasectomy. Ann Thorac Surg. 2019;107:631. [PMID: 30476477] Sudarshan M et al. Current indications for pulmonary metasta- sectomy. Surg Oncol Clin N Am. 2020;29:673. [PMID: 32883466]ME SOTHELIOMAE S S E N T I A L S  O F  D I A G N O S I S Unilateral, nonpleuritic chest pain and dyspnea. Distant (> 20 years earlier) history of exposure to asbestos. Pleural effusion or pleural thickening or both on chest radiographs. Malignant cells in pleural fluid or tissue biopsy. General ConsiderationsMeso theliomas are primary tumors arising from the sur- face lining of the pleura (80% of cases) or peritoneum (20% of cases). Numerous studies have confirmed the associa- tion of malignant pleural mesothelioma with exposure to asbestos. The lifetime risk to asbestos workers of develop- ing malignant pleural mesothelioma is as high as 10%. The latent period between exposure and onset of symptoms ranges from 20 to 40 years. The clinician should inquire about asbestos exposure through mining, milling, manu- facturing, shipyard work, insulation, brake linings,building construction and demolition, roofing materials, and other asbestos products (pipes, textiles, paints, tiles, gaskets, panels). Clinical FindingsA.  Symptoms and SignsThe  average interval between onset of symptoms and diagnosis is 23 months; the median age at diagnosis is 7274 years in Western countries. Symptoms include the insidious onset of shortness of breath, nonpleuritic chest pain, and weight loss. Physical findings include dullness to percussion, diminished breath sounds and, in some cases, digital clubbing.B.  Laboratory FindingsPleural  fluid is exudative and often hemorrhagic. Cytologic tests of pleural fluid are often negative. VATS biopsy is usu- ally necessary to obtain an adequate specimen for histo- logic diagnosis. The histologic variants of malignant pleural mesothelioma are epithelial (5060%), sarcomatoid (10%), and biphasic (3040%). Since distinction from benign inflammatory conditions and metastatic adenocar- cinoma may be difficult, immunohistochemical stains are important to confirm the diagnosis.C.  ImagingRadiographic  abnormalities consist of nodular, irregular, unilateral pleural thickening and varying degrees of unilat- eral pleural effusion. Sixty percent of patients have right- sided disease, while only 5% have bilateral involvement. CT scans demonstrate the extent of pleural involvement. PET-CT is used to help differentiate benign from malig- nant pleural disease, improve staging accuracy, and iden- tify candidates for aggressive surgical approaches. ComplicationsMalignan t pleural mesothelioma progresses rapidly as the tumor spreads along the pleural surface to involve the peri- cardium, mediastinum, and contralateral pleura. The tumor may eventually extend beyond the thorax to involve abdominal lymph nodes and organs. Progressive pain and dyspnea are characteristic. Local invasion of thoracic struc- tures may cause superior vena cava syndrome, hoarseness, Horner syndrome, arrhythmias, and dysphagia. TreatmentChemothera py is the mainstay of treatment (Tables 392 and 393), with cytoreductive surgery included in multi- modality treatment only if there is localized disease that is amenable to complete macroscopic surgical resection. The optimal surgical approach is still under debate. For local- ized disease, surgical options include pleurectomy and decortication (surgical stripping of the pleura and pericar- dium from apex of the lung to diaphragm) or extrapleural pneumonectomy (a radical surgical procedure involving removal of the ipsilateral lung, parietal and visceral pleura,CMDT22_Ch39_p1612-p1675.indd  1628 02/07/21 2:44 PMCANCER1629 CMDT 2022pericardium,  and most of the hemidiaphragm). Surgical cytoreduction alone is not sufficient, and either chemo- therapy or radiation therapy (or both) should be included in a multimodality approach. In advanced unresectable disease, palliative chemotherapy with cisplatin and peme- trexed can achieve response rates of 3040%, can extend median overall survival to 12 months, and can improve quality of life. Adding bevacizumab (a monoclonal anti- body to vascular endothelial growth factor [VEGF]) to cisplatin and pemetrexed has been shown to further improve overall survival. Nivolumab and ipilimumab (checkpoint inhibition therapy) can also be offered as first- line treatment, with improved outcomes among those with nonepithelioid tumors. Drainage of pleural effusions, pleurodesis, radiation therapy, and even surgical resection may offer palliative benefit to some patients. PrognosisMos t patients die of respiratory failure and complications of local extension. Median survival time from diagnosis ranges from 7 months to 17 months. Five-year survival is 510%. Tumors that are predominantly sarcomatoid are more resistant to therapy and have a worse prognosis, with median survivals less than 1 year. Poor prognostic features include poor performance status, non-epithelioid histol- ogy, male gender, nodal involvement, elevated lactate dehy- drogenase, high white blood cell count, low hemoglobin, and high platelet count.Sch erpereel A et al; French Cooperative Thoracic Intergroup. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019;20:239. [PMID: 30660609] Scherpereel A et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020;55:1900953. [PMID: 32451346] Waller DA et al. Divided by an ocean of water but united in an ocean of uncertainty: a transatlantic review of mesothelioma surgery guidelines. J Thorac Cardiovasc Surg. 2020;S0022-5223 (20)32986-X . [PMID: 33223192]hE PATOBILIARY CANCERS Lawrence S. Friedman, MD HEPATOCELLULAR CARCINOMAE S S E N T I A L S  O F  D I A G N O S I S Usually a complication of cirrhosis. Characteristic CT and MRI features may obviate the need for a confirmatory biopsy. General ConsiderationsMalignan t neoplasms of the liver that arise from parenchy- mal cells are called hepatocellular carcinomas (accountingfor 85% of liver cancers); those that originate in the ductu- lar cells are called cholangiocarcinomas (15% or less). Rare tumors of the liver include angiosarcoma and lymphoma. Worldwide, hepatocellular carcinomas are the fourth most common cause of cancer-related deaths and the sixth most common in incidence. They are associated with cir- rhosis in 85% of cases. In Africa and most of Asia, hepatitis B virus (HBV) infection (including occult HBV infection; see Chapter 16) is a major etiologic factor, and a family history of hepatocellular carcinoma increases the risk syn- ergistically. In the United States and other Western coun- tries, incidence rates rose over twofold after 1978, with slowing of the rate increase after 2006 except in men ages 5564, presumably because of the increasing prevalence of cirrhosis caused by chronic hepatitis C virus (HCV) infec- tion and nonalcoholic fatty liver disease (NAFLD). Rates appear to have plateaued since 2010 because of improved treatment of viral hepatitis. In Western countries, risk fac- tors for hepatocellular carcinoma in patients known to have cirrhosis are male gender, age greater than 55 years (although there has been an increase in the number of younger cases), Hispanic or Asian ethnicity, family history in a first-degree relative, overweight, obesity (especially in early adulthood), alcohol use (especially in combination with obesity), tobacco use, diabetes mellitus, hypothyroid- ism (in women), a prolonged prothrombin time, a low platelet count, and an elevated serum transferrin satura- tion. The risk of hepatocellular carcinoma is higher in persons with a viral rather than nonviral cause of cirrhosis and may be increased in persons with autoimmune dis- eases. Other associations include high levels of HBV repli- cation; HBV genotype C; hepatitis D coinfection; elevated serum ALT levels in persons with chronic hepatitis B (in whom antiviral therapy to suppress HBV replication appears to reduce the risk); HCV genotypes 1b and 3; lack of response to antiviral therapy for HCV infection; hemo- chromatosis (and possibly the C282Y carrier state); afla- toxin exposure (associated with mutation of the TP53 gene); alpha-1-antiprotease (alpha-1-antitrypsin) defi- ciency; tyrosinemia; and radiation exposure. In patients with the metabolic syndrome and NAFLD, hepatocellular carcinoma may rarely arise from nonalcoholic steatohepa- titis in the absence of cirrhosis. Hepatocellular adenoma may be a precursor for hepatocellular carcinoma (see Chapter 16). Evidence for an association with long-term use of oral contraceptives is inconclusive. Whereas sulfo- nylurea and insulin use may increase the risk of hepatocel- lular carcinoma, consumption of coffee, vegetables, white meat, fish, and n-3 polyunsaturated fatty acids; use of aspirin; and use of lipophilic HMG-CoA reductase inhibi- tors (statins) (eg, atorvastatin, simvastatin) and, in diabetic patients, metformin appear to be protective. The fibrolamellar variant of hepatocellular carcinoma generally occurs in young women and is characterized by a distinctive histologic picture, absence of risk factors, unique genomic profiles, and indolent course. Vinyl chlo- ride exposure is associated with angiosarcoma of the liver. Hepatoblastoma, the most common malignant liver cancer in infants and young children, rarely occurs in adults.CMDT22_Ch39_p1612-p1675.indd  1629 02/07/21 2:44 PMChAPTER 391630 CMDT 2022 Clinical FindingsA.  Symptoms and SignsThe pr esence of a hepatocellular carcinoma may be unsus- pected until there is deterioration in the condition of a cirrhotic patient who was formerly stable. Cachexia, weak- ness, and weight loss are associated symptoms. The sudden appearance of ascites, which may be bloody, suggests portal or hepatic vein thrombosis by cancer or bleeding from a necrotic cancer. Physical examination may show tender enlargement of the liver, occasionally with a palpable mass. In Africa, the typical presentation in young patients is a rapidly expand- ing abdominal mass. Auscultation may reveal a bruit over the tumor or a friction rub when the tumor has extended to the surface of the liver.B.  Laboratory FindingsLabora tory tests may reveal leukocytosis, as opposed to the leukopenia that is frequently encountered in cirrhotic patients. Anemia is common, but a normal or elevated hematocrit value may be found in up to one-third of patients owing to elaboration of erythropoietin by the tumor. Sudden and sustained elevation of the serum alka- line phosphatase in a patient who was formerly stable is a common finding. HBsAg is present in a majority of cases in endemic areas, whereas in the United States anti-HCV is found in up to 40% of cases. Serum alpha-fetoprotein (AFP) levels are elevated in up to 70% of patients with hepa- tocellular carcinoma in Western countries (although the sensitivity is lower in Blacks and levels are not elevated in patients with fibrolamellar hepatocellular carcinoma); how- ever, mild elevations (10200 ng/mL [10200 mcg/L]) are also often seen in patients with chronic hepatitis. Serum levels of des-gamma-carboxy prothrombin are elevated in up to 90% of patients with hepatocellular carcinoma, but they may also be elevated in patients with vitamin K defi- ciency, chronic hepatitis, and metastatic cancer. Cytologic study of ascitic fluid rarely reveals malignant cells.C.  ImagingM ultiphasic helical CT and MRI with contrast enhance- ment are the preferred imaging studies for determining the location and vascularity of the tumor; MRI may be more sensitive than CT, and imaging with gadoxetic acid increases sensitivity. Lesions smaller than 1 cm may be dif- ficult to characterize. Based on stringent criteria developed by the American College of Radiology through its Liver Imaging Reporting and Data System, the Organ Procure- ment and Transplantation Network, and the American Association for the Study of Liver Diseases, arterial phase enhancement of a lesion that is greater than or equal to 1 cm in diameter followed by delayed hypointensity (washout) has a 90% specificity for hepatocellular carci- noma. Ultrasonography is less sensitive and more operator dependent but is used to screen for hepatic nodules in high-risk patients. Contrast-enhanced ultrasonography has a sensitivity and specificity approaching those of arterial phase helical CT but, unlike CT and MRI, cannot image theentire liver during the short duration of the arterial phase and is thus associated with false-positive results. In selected cases, endoscopic ultrasonography (EUS) may be useful. PET is under study and appears to improve detection of extrahepatic metastases.D . Liver Biopsy and StagingLiver  biopsy is diagnostic, although seeding of the needle tract by cancer is a potential risk (13%). For lesions smaller than 1 cm, ultrasonography may be repeated every 3 months followed by further investigation of enlarging lesions. For lesions 1 cm or larger, biopsy can be deferred when characteristic arterial hypervascularity and delayed washout are demonstrated on either multiphasic helical CT or MRI with contrast enhancement (or both) in a patient with cirrhosis or if surgical resection is planned. The TNM system is the commonly used classification to stage hepatocellular carcinoma. Staging is important not only because it correlates with the patients long-term sur- vival but also because it is used to determine which patients should receive adjuvant or neoadjuvant therapy. The Barcelona Clinic Liver Cancer (BCLC) staging system is preferred and includes the Child-Pugh class, tumor stage, and liver function and has the advantage of linking overall stage with preferred treatment modalities and with an estimation of life expectancy. Screening & PreventionSurveillance (screening) fo r the development of hepatocel- lular carcinoma is recommended in patients with chronic hepatitis B (beginning as early as age 20 in Africans, age 40 in Asian males or Asians with a family history of hepatocel- lular carcinoma, and age 50 in others) or cirrhosis caused by HCV , HBV , or alcohol. There is some evidence that screening for hepatocellular carcinoma leads to a survival advantage over clinical diagnosis, but only a minority of cases are detected by screening. The standard screening approach is performing ultrasonography and obtaining serum AFP level every 6 months, although AFP testing has low sensitivity. A serum AFP level of 20 ng/mL (20 mcg/L) is generally the cutoff value that should trigger further evaluation. CT and MRI are considered too expensive for screening. The sensitivity of ultrasonography for detecting early hepatocellular carcinoma is only 63%. The risk of hepatocellular carcinoma developing in a patient with cirrhosis is 35% a year. Among patients with cirrhosis, over 60% of nodules smaller than 2 cm in diam- eter detected on a screening ultrasonography prove to be hepatocellular carcinoma. Patients with cancers detected by surveillance have a less advanced stage on average and greater likelihood that treatment will prolong survival than those whose cancers were not detected by surveillance. However, controversy persists about whether surveillance reduces cancer-related mortality. Mass vaccination programs against HBV in developing countries are leading to reduced rates of hepatocellular carcinoma. Successful treatment of hepatitis B and of hepatitis C in patients with cirrhosis also reduces the subsequent risk of hepatocellular carcinoma, and thusCMDT22_Ch39_p1612-p1675.indd  1630 02/07/21 2:44 PMCANCER1631 CMDT 2022hepatocellular carcino ma is considered a preventable neo- plasm. However, hepatocellular carcinoma may still occur after clearance of hepatitis B surface antigen or cure of HCV infection, thereby reducing the benefit of treatment for HBV and HCV infection. TreatmentSurgical  resection of a solitary hepatocellular carcinoma may result in cure if liver function is preserved (Child- Pugh class A or possibly B) and portal vein thrombosis is not present. Laparoscopic liver resection has been per- formed in selected cases. Treatment of underlying chronic viral hepatitis, adjuvant chemotherapy, and adaptive immunotherapy may lower postsurgical recurrence rates. Liver transplantation may be appropriate for small unre- sectable tumors in a patient with advanced cirrhosis, with reported 5-year survival rates of up to 75%. The recurrence- free survival may be better for liver transplantation than for resection in patients with well-compensated cirrhosis and small tumors (one tumor less than 5 cm or three or fewer tumors each less than 3 cm in diameter [Milan criteria]) and in those with expanded (University of California, San Francisco) criteria of one tumor less than or equal to 6.5 cm or three or fewer tumors less than or equal to 4.5 cm (or a combined tumor diameter of 8.5 cm) without vascular invasion. The Extended Toronto criteria include tumor dif- ferentiation, cancer-related symptoms, confinement of tumor to the liver, and absence of vascular invasion, without regard to tumor number or size, to determine candidacy for liver transplantation and appear to predict outcomes as well as the Milan criteria. After 6 months on the waiting list, patients with stage 2 hepatocellular carcinoma meeting the Milan criteria are awarded a fixed score of 3 points lower than the median Model for End-Stage Liver Disease (MELD) score for patients transplanted in the area where the candidate is listed (see Chapter 16), thereby increasing their chances of undergoing transplantation. However, orthotopic liver transplantation is often impractical because of donor organ shortage, so living donor liver transplanta- tion may be considered in these cases. Patients with larger tumors (35 cm), a serum AFP level of 1000 ng/mL (1000 mcg/L) or higher, or a MELD score of 20 or higher have poor posttransplantation survival. In patients with a serum AFP level greater than 1000 ng/mL (1000 mcg/L), down- staging by locoregional therapy to an AFP level less than 500 ng/mL (500 mcg/L) improves survival following subse- quent liver transplantation. Chemotherapy, hormonal therapy with tamoxifen, and long-acting octreotide have not been shown to prolong life, but transarterial chemoembolization (TACE), TACE with drug-eluting beads, transarterial chemoinfusion (TACI), and transarterial radioembolization (TARE) via the hepatic artery are not only palliative but may also prolong survival in patients with a large or multifocal tumor in the absence of extrahepatic spread. TACI and TARE are suitable for patients with portal vein thrombosis. TARE with yttrium-90 has been shown to result in a longer time to progression than TACE. Microwave ablation, radiofrequency ablation, cryotherapy, or injection of absolute ethanol into tumors smaller than 2 cm may prolong survival in patients who arenot candidates for resection and have tumors that are accessible; these interventions, as well as stereotactic body radiation therapy, may also provide a bridge to liver transplantation. Microwave ablation is becoming the pre- ferred approach because it allows shorter treatment times and, like radiofrequency ablation, can be performed after TACE in select cases. Cryoablation may result in slower tumor progression than radiofrequency ablation for tumors that are 3.14 cm in diameter. Stereotactic body radiation therapy is also being used to treat unresectable hepatocel- lular carcinoma and may be effective in treating lesions larger than those treated with ablation techniques. Sorafenib (an oral multikinase inhibitor of Raf kinase, the VEGF receptor, and the platelet-derived growth factor receptor [and others]) prolongs median survival as well as the time to radiologic progression by 3 months in patients with advanced hepatocellular carcinoma and until recently was the standard care in these patients. Lenvatinib is another oral multikinase inhibitor that is FDA approved for the same indications as sorafenib. However, the combi- nation of atezolizumab, an immune checkpoint inhibitor, and bevacizumab, an antibody to the VEGF receptor, has been shown to be superior to sorafenib and has become standard first-line therapy. Regorafenib is an oral multiki- nase inhibitor that provides a survival benefit for patients whose disease progresses despite sorafenib therapy, and nivolumab and pembrolizumab are immune checkpoint inhibitors that have been approved for advanced hepatocel- lular carcinoma. The combination of nivolumab and ipili- mumab has been recommended as second-line therapy after failure of sorafenib. Cabozantinib, another multiki- nase inhibitor, has been approved by the FDA for the treat- ment of hepatocellular carcinoma after prior treatment with sorafenib, as has ramucirumab, an antibody to the VEGF receptor, which is approved for patients with an AFP level greater than or equal to 400 ng/mL (400 mcg/L) and previous treatment with sorafenib. The modified Response Evaluation Criteria in Solid Tumors (mRECIST) are used to assess treatment response based on tumor shrinkage and viability after locoregional and antiangiogenic treatment. Meticulous efforts at palliative care are essential for patients in whom disease progresses despite treatment or in whom advanced tumors, vascular invasion, or extrahepatic spread are present. Severe pain may develop in such patients due to expansion of the liver capsule by the tumor and requires concerted efforts at pain management, including the use of opioids (see Chapter 5). PrognosisIn  the United States, overall 1- and 5-year survival rates for patients with hepatocellular carcinoma are 23% and 5%, respectively. Five-year survival rates rise to 56% for patients with localized resectable disease (T1, T2, selected T3 and T4; N0; M0) but are virtually nil for those with locally unresectable or advanced disease. In patients with HCV- related hepatocellular carcinoma, the serum AFP level at the time of diagnosis of cancer has been reported to be an independent predictor of mortality. A serum AFP level greater than or equal to 200 ng/mL (200 mcg/L) or increases of greater than 15 ng/mL/month predict worseCMDT22_Ch39_p1612-p1675.indd  1631 02/07/21 2:44 PMChAPTER 391632 CMDT 2022outco mes in patients awaiting liver transplantation. In patients who are not eligible for surgery, an elevated serum C-reactive protein level is associated with poor survival. Contrary to traditional opinion, the fibrolamellar variant does not have a better prognosis than conventional hepato- cellular carcinoma without cirrhosis. When to ReferAll  patients with hepatocellular carcinoma should be referred to a specialist. When to Admit Complications of cirrhosis. Severe pain. For surgery and other interventions.Bangaru  S et al. Review article: new therapeutic interventions for advanced hepatocellular carcinoma. Aliment Pharmacol Ther. 2020;51:78. [PMID: 31747082] Bruix J et al (editors). The growing burden of liver cancer. Semin Liver Dis. 2020;40:101. [Full issue] Fanwal F et al. Surveillance for hepatocellular carcinoma: cur- rent best practice and future direction. Gastroenterology. 2019;157:54. [PMID: 30986389] Shiels MS et al. Recent decline in hepatocellular carcinoma rates in the United States. Gastroenterology. 2020;158:1503. [PMID: 31962125] Simon TG et al. Association of aspirin with hepatocellular carci- noma and liver-related mortality. N Engl J Med. 2020;382:1018. [PMID: 32160663]CA RCINOMA OF THE BILIARY TRACTE S S E N T I A L S  O F  D I A G N O S I S Presents with obstructive jaundice, usually pain- less, often with dilated biliary tract. Pain is more common in gallbladder carcinoma than cholangiocarcinoma. A dilated gallbladder may be palpable (Cour- voisier sign). Diagnosis by cholangiography with biopsy and brushings for cytology. General ConsiderationsCarcino ma of the gallbladder occurs in approximately 2% of all people operated on for biliary tract disease; the inci- dence, like that of carcinoma of the bile ducts, had been decreasing in the United States but may be increasing again in some Western countries because of lifestyle changes. It is notoriously insidious, and the diagnosis is often made unexpectedly at surgery. Cholelithiasis (often large, symp- tomatic stones) is usually present. Other risk factors are chronic infection of the gallbladder with Salmonella typhi , adenomatous gallbladder polyps over 1 cm in diameter (particularly with hypoechoic foci on EUS), mucosalcalcification of the gallbladder (porcelain gallbladder), anomalous pancreaticobiliary ductal junction, high parity in women, and aflatoxin exposure. Genetic factors include K-ras andTP53 mutations. Spread of the cancerby direct extension into the liver or to the peritoneal surfacemay be seen on initial presentation. Carcinoma of the bile ducts (cholangiocarcinoma) accounts for 1025% of all hepatobiliary malignancies and 3% of all cancer deaths in the United States. It is more prevalent in persons aged 5070, with a slight male pre- dominance, and more common in Asia. About 50% arise at the confluence of the hepatic ducts (perihilar, or so-called Klatskin, tumors), and 40% arise in the distal extrahepatic bile duct (the incidence of which has risen since 1990); the remainder are intrahepatic (the incidence of which rose dramatically from the 1970s to the early 2000s). Mortality from intrahepatic cholangiocarcinoma has been increas- ing. The frequency of carcinoma in persons with a chole- dochal cyst has been reported to be over 14% at 20 years, and surgical excision is recommended. Most cases of chol- angiocarcinoma are sporadic. There is an increased inci- dence of cholangiocarcinoma in patients with bile duct adenoma; Caroli disease; a biliary-enteric anastomosis; ulcerative colitis, especially those with primary sclerosing cholangitis; biliary cirrhosis; diabetes mellitus; hyperthy- roidism; chronic pancreatitis; heavy alcohol consumption; smoking; and past exposure to Thorotrast, a contrast agent. Premalignant lesions of the bile duct include biliary intraepithelial neoplasia and intraductal papillary neopla- sia of the biliary system (biliary papillomatosis). Aspirin use and statin use are associated with a reduced risk of cholangiocarcinoma, and in diabetic patients, metformin use is associated with a reduced risk of intrahepatic cholan- giocarcinoma. In Southeast Asia, hepatolithiasis, chronic typhoid carriage, and infection of the bile ducts with hel- minths (Clonorchis sinensis, Opisthorchis viverrini) are associated with an increased risk of cholangiocarcinoma. Hepatitis C virus (and possibly hepatitis B virus) infection, cirrhosis, HIV infection, nonalcoholic fatty liver disease, diabetes mellitus, obesity, and tobacco smoking are risk factors for intrahepatic cholangiocarcinoma. The TNM system is the commonly used classification to stage carcinoma of the biliary tract, including gallblad- der carcinomas and perihilar and intrahepatic cholangio- carcinomas. Staging is important not only because it correlates with the patients long-term survival but also because it is used to determine which patients should receive adjuvant or neoadjuvant therapy. Other staging systems consider the patients age, perfor- mance status, tumor extent and form, perineural invasion, vascular encasement, hepatic lobe atrophy, underlying liver disease, and peritoneal metastasis. Clinical FindingsA.  Symptoms and SignsProgres sive jaundice is the most common and usually the first sign of obstruction of the extrahepatic biliary system. Pain in the right upper abdomen with radiation into the back is usually present early in the course of gallbladderCMDT22_Ch39_p1612-p1675.indd  1632 02/07/21 2:44 PMCANCER1633 CMDT 2022carcino ma but occurs later in the course of bile duct carci- noma. Anorexia and weight loss are common and may be associated with fever and chills due to cholangitis. Rarely, hematemesis or melena results from erosion of cancer into a blood vessel (hemobilia). Fistula formation between the bili- ary system and adjacent organs may also occur. The course is usually one of rapid deterioration, with death occurring within a few months. Physical examination reveals profound jaundice. Pruritus and skin excoriations are common. A palpable gallbladder with obstructive jaundice usually is said to signify malignant disease (Courvoisier sign); however, this clinical generaliza- tion has been proven to be accurate only about 50% of the time. Hepatomegaly due to hypertrophy of the unobstructed liver lobe is usually present and is associated with liver ten- derness. Ascites may occur with peritoneal implants.B.  Laboratory FindingsW ith biliary obstruction, laboratory examination reveals predominantly conjugated hyperbilirubinemia, with total serum bilirubin values ranging from 5 to 30 mg/dL. There is usually concomitant elevation of the alkaline phosphatase and serum cholesterol. AST is normal or minimally elevated. The serum CA 19-9 level is elevated in up to 85% of patients and may help distinguish cholangiocarcinoma from a benign biliary stricture (in the absence of cholangitis), but this test is neither sensitive nor specific.C.  ImagingUl trasonography and contrast-enhanced, triple-phase, heli- cal CT may show a gallbladder mass in gallbladder carci- noma and intrahepatic mass or biliary dilatation in carcinoma of the bile ducts. CT may also show involved regional lymph nodes and atrophy of a hepatic lobe because of vascular encasement with compensatory hypertrophy of the unaffected lobe. MRI with magnetic resonance cholan- giopancreatography (MRCP) and gadolinium enhancement permits visualization of the entire biliary tract and detection of vascular invasion and obviates the need for angiography and, in some cases, direct cholangiography; it is the imaging procedure of choice but may understage malignant hilar strictures. The sensitivity and image quality can be increased with use of ferumoxide enhancement. The features of intra- hepatic cholangiocarcinoma on MRI appear to differ from those of hepatocellular carcinoma, with contrast washout in the latter but not the former. In indeterminate cases, PET can detect cholangiocarcinomas as small as 1 cm and lymph node and distant metastases, but false-positive results occur. The most helpful diagnostic studies before surgery are either endoscopic retrograde cholangiography or percutaneous transhepatic cholangiography with biopsy and cytologic specimens, although false-negative biopsy and cytology results are common. Digital image analysis and fluorescent in situ hybridization of cytologic specimens for polysomy improve sensitivity. EUS with FNA of tumors, peroral chol- angioscopy, confocal laser endomicroscopy, and intraductal ultrasonography may confirm a diagnosis of cholangiocarci- noma in a patient with bile duct stricture and an otherwise indeterminate evaluation, but FNA can result in cancerseeding and should be avoided if the cancer is potentially resectable. TreatmentIn  young and fit patients, curative surgery for gallbladder carcinoma may be attempted if the cancer is well localized. The 5-year survival rate for carcinoma of the gallbladder invading the lamina propria or muscularis (stage 1, T1a or 1b, N0, M0) is as high as 85% with laparoscopic cholecys- tectomy but drops to 60%, even with a more extended open resection, if there is perimuscular invasion (T2). The role of radical surgery for T3 and T4 tumors is debatable. If the cancer is unresectable at laparotomy, biliary-enteric bypass (eg, Roux-en-Y hepaticojejunostomy) can be performed. Carcinoma of the bile ducts is curable by surgery in less than 10% of cases. If resection margins are negative, the 5-year survival rate may be as high as 47% for intrahepatic cholangiocarcinomas, 41% for hilar cholangiocarcinoma, and 37% for distal cholangiocarcinomas, but the perioper- ative mortality rate may be as high as 10%. Factors predicting shorter survival for intrahepatic cholangiocarcinoma include large cancer size, multiple cancers, lymph node metastasis, and vascular invasion. Adjuvant chemotherapy with capecitabine has been shown to result in superior overall survival compared with no adjuvant therapy. Pallia- tion can be achieved by placement of a self-expandable metal stent via an endoscopic or percutaneous transhepatic route. Covered metal stents may be more cost-effective than uncovered metal stents because of a longer duration of patency. However, they are associated with a higher rate of stent migration and cholecystitis due to occlusion of the cystic duct and are not associated with longer survival. For perihilar cancers, insertion of a unilateral stent rather than bilateral stents may suffice. Plastic stents are less expensive initially, but not in the long term, because they are more prone to occlude than metal ones; they may be considered in patients expected to survive only a few months. Photo- dynamic therapy in combination with stent placement prolongs survival when compared with stent placement alone in patients with nonresectable cholangiocarcinoma. Endoscopic retrograde cholangiopancreatography (ERCP) directed radiofrequency ablation, TACE, and TARE are additional emerging options. Radiotherapy may relieve pain and contribute to biliary decompression. There is limited response to chemotherapy with gemcitabine alone, but the combination of cisplatin and gemcitabine or capecitabine and gemcitabine prolongs survival in patients with locally advanced or metastatic cholangiocarcinoma. Few patients survive for more than 24 months. Although cholangiocarcinoma is generally considered to be a contra- indication to liver transplantation because of rapid cancer recurrence, a 5-year survival rate of 75% has been reported in patients with stage I and II perihilar cholangiocarcinoma undergoing chemoradiation and exploratory laparotomy followed by liver transplantation, and a 5-year survival rate of 67% has been reported in those with intrahepatic cholangiocarcinoma. For those patients whose disease progresses despite treatment, meticulous efforts at palliative care are essential (see Chapter 5).CMDT22_Ch39_p1612-p1675.indd  1633 02/07/21 2:44 PMChAPTER 391634 CMDT 2022 When to ReferAll  patients with carcinoma of the biliary tract should be referred to a specialist. When to Admit Biliary obstruction. Cholangitis.Bertuccio  P et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019;71:104. [PMID: 30910538] De Martin E et al. Analysis of liver resection versus liver trans- plantation on outcome of small intrahepatic cholangiocarci- noma and combined hepatocellular-cholangiocarcinoma in the setting of cirrhosis. Liver Transpl. 2020;26:785. [PMID: 32090444] Lavu S et al. Effect of statins on the risk of extrahepatic cholan- giocarcinoma. Hepatology. 2020;72:1298. [PMID: 32119126]CA RCINOMA OF THE PANCREAS & AMPULLA OF VATERE S S E N T I A L S  O F  D I A G N O S I S Obstructive jaundice (may be painless). Enlarged gallbladder (may be painful). Upper abdominal pain with radiation to back, weight loss, and thrombophlebitis are usually late manifestations. General ConsiderationsCarcino ma is the most common neoplasm of the pancreas. About 75% are in the head and 25% in the body and tail of the organ. Pancreatic carcinomas account for 2% of all cancers and 5% of cancer deaths. Ampullary carcinomas are much less common. Risk factors for pancreatic cancer include age, tobacco use (which is thought to cause 2025% of cases), heavy alcohol use, obesity, chronic pan- creatitis, diabetes mellitus, prior abdominal radiation, fam- ily history, and possibly gastric ulcer and exposure to arsenic and cadmium. New-onset diabetes mellitus after age 45 years occasionally heralds the onset of pancreatic cancer. In diabetic patients, metformin use and possibly aspirin use may reduce the risk of pancreatic cancer slightly, but insulin use and glucagon-like peptide-1based therapy (eg, sitagliptin) may increase the risk. About 7% of patients with pancreatic cancer have a family history of pancreatic cancer in a first-degree relative, compared with 0.6% of control subjects. The majority of pancreatic can- cers originate from pancreatic intraepithelial neoplasias, which measure less than 5 mm in diameter and can only be seen with a microscope. In 510% of cases, pancreatic cancer occurs as part of a hereditary syndrome, including familial breast cancer (car- riers of BRCA2 have a 7% lifetime risk of pancreatic can- cer), hereditary pancreatitis ( PSS1 mutation), familialatypical multiple mole melanoma ( p16/CDKN2A muta- tion), Peutz-Jeghers syndrome ( STK11 /LKB1 mutation), ataxia-telangiectasia ( ATM mutation), and Lynch syn- drome (hereditary nonpolyposis colorectal cancer [ MLH1 , MSH2 ,MSH6 mutations]). Neuroendocrine tumors account for 12% of pancreatic neoplasms and may be functional (producing gastrin, insu- lin, glucagon, vasoactive intestinal peptide, somatostatin, growth hormonereleasing hormone, adrenocorticotropic hormone, and others) or nonfunctional. Cystic neoplasms account for only 1% of pancreatic cancers, but they are important because pancreatic cysts are common and may be mistaken for pseudocysts. A cystic neoplasm should be suspected when a cystic lesion in the pancreas is found in the absence of a history of pancreatitis. At least 15% of all pancreatic cysts are neoplasms. Serous cystadenomas (which account for 3239% of cystic pancreatic neoplasms and also occur in patients with von Hippel-Lindau disease) are benign. However, mucinous cystic neoplasms (defined by the presence of ovarian stroma and accounting for 1045% of cystic pancreatic neoplasms), intraductal papil- lary mucinous neoplasms (2133% of cystic pancreatic neoplasms), solid pseudopapillary tumors (less than 5%, primarily in young women), and cystic islet cell tumors (35%) may be malignant. Their prognoses are better than the prognosis of pancreatic adenocarcinoma, unless the cystic neoplasm is at least locally advanced. Mucinous cystic neoplasms and intraductal papillary mucinous neoplasms account for 1530% of pancreatic cancers. Clinical FindingsA.  Symptoms and SignsPai n is present in over 70% of cases and is often vague, dif- fuse, and located in the epigastrium or, when the lesion is in the tail, located in the left upper quadrant of the abdo- men. Radiation of pain into the back is common and some- times predominates. Sitting up and leaning forward may afford some relief, and this usually indicates that the lesion has spread beyond the pancreas and is inoperable. Diar- rhea, perhaps due to maldigestion, is an occasional early symptom. Migratory thrombophlebitis is a rare sign. Weight loss is a common but late finding and may be asso- ciated with depression. Hyperglycemia and decreases in subcutaneous abdominal fat and serum lipid levels have been reported to precede a diagnosis of pancreatic cancer. Occasional patients (often aged 40 years or older) present with acute pancreatitis in the absence of an alternative cause. Jaundice is usually due to biliary obstruction by a cancer in the pancreatic head. A palpable gallbladder is also indicative of obstruction by a neoplasm (Courvoisier sign), but there are frequent exceptions. A hard, fixed, occasionally tender mass may be present. In advanced cases, a hard periumbilical (Sister Mary Josephs) nodule may be palpable.B.  Laboratory FindingsThere  may be mild anemia. Glycosuria, hyperglycemia, and impaired glucose tolerance or true diabetes mellitus are found in 1020% of cases. The serum amylase or lipaseCMDT22_Ch39_p1612-p1675.indd  1634 02/07/21 2:44 PMCANCER1635 CMDT 2022level  is occasionally elevated. Liver biochemical tests may suggest obstructive jaundice. Steatorrhea in the absence of jaundice is uncommon. Occult blood in the stool is sugges- tive of carcinoma of the ampulla of Vater (the combination of biliary obstruction and bleeding may give the stools a distinctive silver appearance). CA 19-9, with a sensitivity of 70% and a specificity of 87%, has not proven useful for early detection of pancreatic cancer; increased values are also found in acute and chronic pancreatitis and cholangi- tis. Plasma chromogranin A levels are elevated in 88100% of patients with pancreatic neuroendocrine tumors (NETs).C.  ImagingM ultiphase thin-cut helical CT is generally the initial diag- nostic procedure and detects a mass in over 80% of cases. CT identifies metastases, delineates the extent of the tumor, and allows percutaneous FNA for cytologic studies and tumor markers. MRI is an alternative to CT. Ultraso- nography is not reliable because of interference by intesti- nal gas. PET is a sensitive technique for detecting pancreatic cancer and metastases, but PET-CT is not a routine staging procedure. Selective celiac and superior mesenteric arteri- ography may demonstrate vessel invasion by cancer, a find- ing that would preclude attempts at surgical resection, but it is used uncommonly since the advent of multiphase helical CT. EUS is more sensitive than CT for detecting pancreatic cancer and is equivalent to CT for determining nodal involvement and resectability; contrast-enhanced EUS improves accuracy. A normal EUS excludes pancre- atic cancer. EUS may also be used to guide FNA or biopsy for tissue diagnosis, tumor markers, and DNA analysis. ERCP may clarify an ambiguous CT or MRI study by delineating the pancreatic duct system or confirming an ampullary or biliary neoplasm. MRCP appears to be at least as sensitive as ERCP in diagnosing pancreatic cancer. In some centers, pancreatoscopy or intraductal ultrasonog- raphy is used to evaluate filling defects in the pancreatic duct and assess resectability of intraductal papillary muci- nous cancers. With obstruction of the splenic vein, spleno- megaly or gastric varices are present, the latter detected by endoscopy, EUS, or angiography. Cystic neoplasms can be distinguished by their appear- ance on CT, EUS, and ERCP and features of the cyst fluid on gross, cytologic, and genetic analysis. For example, serous cystadenomas may have a central scar or honey- comb appearance; mucinous cystadenomas are unilocular or multilocular and contain mucin-rich fluid with high carcinoembryonic antigen levels (greater than 200 ng/mL [200 mcg/L]) and K-ras mutations; and intraductal papil- lary mucinous neoplasms are associated with a dilated pancreatic duct and extrusion of gelatinous material from the ampulla. StagingThe  TNM system is the commonly used classification to stage pancreatic cancer. Staging is important not only because it correlates with the patients long-term survival but also because it is used to determine which patients should receive adjuvant or neoadjuvant therapy.TreatmentAbdo minal exploration is usually necessary when cytologic diagnosis cannot be made or if resection is to be attempted (in up to 30% of patients with pancreatic carcinoma). In a patient with a localized mass in the head of the pancreas and without jaundice, laparoscopy may detect tiny perito- neal or liver metastases and thereby avoid resection in 413% of patients. Radical pancreaticoduodenal (Whipple) resection is indicated for cancers strictly limited to the head of the pancreas, periampullary area, and duodenum (T1, N0, M0). Five-year survival rates are 2025% in this group and as high as 40% in those with negative resection margins and without lymph node involvement. Preopera- tive endoscopic decompression of an obstructed bile duct is often achieved with a plastic stent or short metal stent but does not reduce operative mortality and is associated with complications. The best surgical results are achieved at centers that specialize in the multidisciplinary treatment of pancreatic cancer. Adjuvant chemotherapy with gemcitabine, 5-fluo- rouracil, or gemcitabine with capecitabine is superior to no adjuvant therapy. Gemcitabine with capecitabine and a modified FOLFIRINOX (5-fluorouracil, leucovorin, irino- tecan, oxaliplatin) regimen have been found to be superior to gemcitabine alone. The role of adjuvant chemoradiation is controversial but often used in the United States. Neoad- juvant chemotherapy with or without radiation is increas- ingly being used to downstage patients and in those with resectable cancer. Common chemotherapy regimens for this purpose include FOLFIRINOX and gemcitabine with nanoparticle albumin-bound (nab)-paclitaxel. Chemora- diotherapy downstages about 30% of patients with locally advanced disease to allow resection. When resection is not feasible, endoscopic stenting of the bile duct is performed to relieve jaundice. A plastic stent is generally placed if the patients anticipated survival is less than 6 months (or if surgery is planned). A metal stent is preferred when anticipated survival is 6 months or greater. Whether covered metal stents designed to prevent cancer ingrowth offer an advantage over uncovered stents is uncertain because covered stents are associated with higher rates of migration and acute cholecystitis due to occlusion of the cystic duct. Surgical biliary bypass may be considered in patients expected to survive at least 6 months. Surgical duodenal bypass may be considered in patients in whom duodenal obstruction is expected to develop; alternatively, endoscopic placement of a self- expandable duodenal stent may be feasible. Chemoradia- tion may be used for palliation of unresectable cancer confined to the pancreas. Chemotherapy has been disappointing in metastatic pancreatic cancer, although improved response rates have been reported with FOLFIRINOX and with the combination of gemcitabine and nab-paclitaxel. In patients who have received prior chemotherapy, a regimen of 5-fluorouracil and leucovorin in combination with nanoliposomal irinotecan has resulted in improved survival compared with 5-fluorouracil and leucovorin alone. Celiac plexus nerve block (under CT or endoscopic ultrasound guidance) or thoracoscopic splanchnicectomy may improve pain control.CMDT22_Ch39_p1612-p1675.indd  1635 02/07/21 2:44 PMChAPTER 391636 CMDT 2022Surgical  resection is the treatment of choice for NETs, when feasible. Lesions that are less than 1 cm in diameter and nonfunctioning without evidence of local invasion or metastasis may be followed expectantly. Metastatic disease may be controlled with long-acting somatostatin analogs, interferon, chemotherapy, peptide-receptor radionuclide therapy, and chemoembolization. There is a consensus that asymptomatic incidental pan- creatic cysts 2 cm or smaller are at low risk for harboring invasive carcinoma. The cysts may be monitored by imag- ing tests (MRI) in 1 year and then every 2 years for 5 years and probably longer if no changes are observed, with EUS and FNA performed if a cyst enlarges to 3 cm and another high-risk feature (dilated main pancreatic duct, presence of a solid component) develops. The optimal approach is uncertain, however, and other guidelines have been pro- posed. Surgical resection is indicated for mucinous cystic neoplasms, symptomatic serous cystadenomas, solid pseu- dopapillary tumors (which have a 15% risk of malignant transformation), and cystic tumors larger than 2 cm in diameter that remain undefined after helical CT, EUS, and diagnostic aspiration. All intraductal papillary mucinous neoplasms of the main pancreatic duct should be resected, but those of branch ducts may be monitored with serial imaging if they (1) are asymptomatic and exhibit benign features; (2) have a diameter less than 3 cm (some authori- ties recommend a diameter of 1.5 cm or smaller, but even lesions 3 cm or larger may be monitored in elderly persons with no other worrisome cyst features); and (3) lack non- enhancing mural nodules, or thick wall, or abrupt change in the caliber of the pancreatic duct with distal pancreatic atrophy, or possibly bile duct dilatation and gallbladder adenomyomatosis. Most lesions with such benign features remain stable on follow-up, but a risk of malignancy per- sists for more than 10 years. Moreover, the risk of pancre- atic ductal carcinoma and of nonpancreatic cancers is also increased in this group of patients. In the absence of locally advanced disease, survival is higher for malignant cystic neoplasms than for adenocarcinomas. The role of EUS- guided ablative treatment of potentially premalignant pancreatic cysts is under study. Endoscopic resection or ablation, with temporary placement of a pancreatic duct stent, may be feasible for ampullary adenomas, but patients must be followed for recurrence. PrognosisCarcino ma of the pancreas, especially in the body or tail, has a poor prognosis; 8085% of patients present with advanced unresectable disease, and reported 5-year sur- vival rates range from 2% to 5%. From 1980 to 2010, mor- tality from pancreatic cancer did not decrease, but it has since started to improve. Obesity may adversely affect mortality in Western countries. Metformin may improve survival in diabetic patients with pancreatic adenocarci- noma, and use of statins preceding a diagnosis of pancre- atic cancer may improve survival. Tumors of the ampulla have a better prognosis, with reported 5-year survival rates of 2040% after resection; jaundice and lymph node involvement are adverse prognostic factors. In carefully selected patients, resection of cancer of the pancreatic headis feasible and results in reasonable survival. In persons with a family history of pancreatic cancer in at least two first-degree relatives, or with a genetic syndrome associ- ated with an increased risk of pancreatic cancer, screening with EUS and helical CT or MRI/MRCP should be consid- ered beginning at age 50 (age 40 in CKDN2A orPRSS1 mutation carriers and age 35 in those with Peutz-Jeghers syndrome) or 10 years before the age at which pancreatic cancer was first diagnosed in a family member. For those patients whose disease progresses despite treatment, meticulous efforts at palliative care are essential (see Chapter 5). When to ReferAll pa tients with carcinoma involving the pancreas and the ampulla of Vater should be referred to a specialist. When to AdmitPatients  who require surgery and other interventions should be hospitalized.Aslanian  HR et al. AGA Clinical Practice Update on pancreas cancer screening in high-risk individuals: expert review. Gas- troenterology. 2020;159:358. [PMID: 32416142] Elta GH et al. ACG Clinical Guideline: diagnosis and manage- ment of pancreatic cysts. Am J Gastroenterol. 2018;113:464. [PMID: 29485131] US Preventive Services Task Force; Owens DK et al. Screening for pancreatic cancer: US Preventive Services Task Force reaf- firmation recommendation statement. JAMA. 2019;322:438. [PMID: 31386141]AL IMENTARY TRACT CANCERS Carling Ursem, MD Kenneth R. McQuaid, MD ESOPHAGEAL CANCERE S S E N T I A L S  O F  D I A G N O S I S Progressive dysphagia to solid food. Weight loss common. Endoscopy with biopsy establishes diagnosis. General ConsiderationsEsophageal cancer usually develo ps in persons between 50 and 70 years of age. There were an estimated 18,440 new cases of esophageal cancer in the United States in 2020. The overall ratio of men to women is 3:1. There are two histo- logic types: squamous cell carcinoma and adenocarcinoma, and their incidence has significant geographic variation. Squamous cell carcinoma is associated with smoking, alco- hol, poor nutritional status, and drinking hot beverages. It accounts for over 90% of cases of esophageal cancer inCMDT22_Ch39_p1612-p1675.indd  1636 02/07/21 2:44 PMCANCER1637 CMDT 2022Eastern  and Southeast Asia and sub-Saharan Africa. Ade- nocarcinoma is associated with obesity and gastroesopha- geal reflux disease, with the majority of cases developing as a complication of Barrett metaplasia due to chronic gastro- esophageal reflux. Adenocarcinomas make up the majority of new cases of esophageal cancer in North America and Northern and Western Europe. Clinical FindingsA.  Symptoms and SignsThe  majority (5060%) of patients with esophageal cancer present with advanced, incurable disease. While early symptoms are nonspecific and subtle, over 90% eventually have solid food dysphagia, which progresses over weeks to months. Odynophagia is sometimes present. Significant weight loss is common. Local tumor extension into the tracheobronchial tree may result in a tracheo-esophageal fistula, characterized by coughing on swallowing or by pneumonia. Chest or back pain suggests mediastinal exten- sion. Recurrent laryngeal nerve involvement may produce hoarseness. Physical examination is often unrevealing. The presence of supraclavicular or cervical lymphadenopathy or of hepatomegaly implies metastatic disease.B.  Laboratory FindingsLaborato ry findings are nonspecific. Anemia related to chronic disease or occult blood loss is common. Elevated aminotransferase or alkaline phosphatase concentrations suggest hepatic or bony metastases. Hypoalbuminemia may result from malnutrition.C.  ImagingA  barium esophagogram may be the first study obtained to evaluate dysphagia. The appearance of a polypoid, obstruc- tive, or ulcerative lesion is suggestive of carcinoma and requires endoscopic evaluation. However, even lesions believed to be benign by radiography warrant endoscopic evaluation. Chest radiographs may show adenopathy, a widened mediastinum, pulmonary or bony metastases, or signs of tracheo-esophageal fistula such as pneumonia.D . Upper EndoscopyEndoscopy  with biopsy establishes the diagnosis of esopha- geal carcinoma with a high degree of reliability. In some cases, significant submucosal spread of the tumor may yield nondiagnostic mucosal biopsies. Repeat biopsy may be necessary. StagingAfter  confirmation of the diagnosis of esophageal carci- noma, the stage of the disease should be determined since doing so influences the choice of therapy. Patients should undergo evaluation with contrast CT of the chest and abdomen to look for evidence of pulmonary or hepatic metastases, lymphadenopathy, and local tumor extension. If there is no evidence of distant metastases or extensive local spread on CT, then EUS with guided FNA biopsy of suspicious lymph nodes should be performed to evaluatethe locoregional stage. EUS is superior to CT in demon- strating the level of local mediastinal extension and local lymph node involvement. PET with fluorodeoxyglucose or integrated PET-CT imaging is indicated to look for regional or distant spread in patients thought to have localized dis- ease after other diagnostic studies, prior to invasive sur- gery. Bronchoscopy is sometimes required in esophageal cancers above the carina to exclude tracheobronchial extension. Laparoscopy to exclude occult peritoneal carci- nomatosis should be considered in patients with tumors at or near the gastroesophageal junction (see Gastric Adenocarcinoma). Differential DiagnosisEsophageal  carcinoma must be distinguished from other causes of progressive dysphagia, including peptic stricture, achalasia, and adenocarcinoma of the gastric cardia with esophageal involvement. Benign-appearing peptic stric- tures should be biopsied at presentation to exclude occult malignancy. TreatmentThe appr oach to esophageal cancer depends on the tumor stage, tumor location, patient preference and functional status, and the expertise of the gastroenterologists, sur- geons, oncologists, and radiation oncologists. It is helpful to classify patients into two general categories: those with early stage (curable) disease and those with advanced stage (incurable) disease.A.  Therapy for Curable DiseaseSuperficial  esophageal cancers confined to the epithelium (high-grade dysplasia or carcinoma in situ [Tis]), lamina propria (T1a), or submucosal (T1b) are increasingly recog- nized in endoscopic screening and surveillance programs. Esophagectomy achieves high cure rates for superficial tumors but is associated with mortality (2%) and morbid- ity. If performed by experienced clinicians, endoscopic mucosal resection of Tis and T1a cancers achieves equiva- lent long-term survival with less morbidity (see Barrett Esophagus, Chapter 15). Esophagectomy is recommended for superficial tumors that are invasive to the submucosa (T1b) because of higher rates of lymph node metastasis. 1. Surgery with or without neoadjuvant chemoradiation therapy There are multiple surgical approaches to the resection of invasive but potentially curable esophageal cancers (stage Ib, II, IIIA, or IIIB). Accepted techniques include en bloc transthoracic excision of the esophagus with extended lymph node dissection, transhiatal esopha- gogastrectomy (entailing laparotomy with cervical anasto- mosis), and minimally invasive esophagectomy techniques. Meta-analysis data suggest equivalent oncologic outcomes from minimally invasive esophagectomy and conventional open techniques, although there are fewer postoperative complications and shorter hospital stays with the laparo- scopic approach. Multiple meta-analyses have shown that regardless of surgery type, surgery at a high-volume hospi- tal is associated with decreased perioperative mortality.CMDT22_Ch39_p1612-p1675.indd  1637 02/07/21 2:44 PMChAPTER 391638 CMDT 2022Pa tients with stage I tumors have high cure rates with surgery alone and do not require radiation or chemother- apy. Whether radiation or chemotherapy or both are required in addition to surgery for T2N0 stage II tumors is a subject of ongoing debate. If regional lymph node metas- tases have occurred (stages IIB and III), the rate of cure with surgery alone is reduced to less than 20%. Meta- analysis of trials comparing neoadjuvant (preoperative) therapy followed by surgery with surgery alone suggests a 13% absolute improvement in 2-year survival with com- bined therapy. Preoperative (neoadjuvant) chemoradiation therapy is recommended for stage IIB and III tumors in fit patients. The preferred neoadjuvant chemotherapy regi- men used with radiation is weekly carboplatin plus pacli- taxel (Table 392). As an alternative, a combination of cisplatin plus 5-fluorouracil may be used along with radia- tion. When radiation therapy is considered, techniques that are less toxic such as intensity-modulated radiation therapy (IMRT) or proton beam therapy may be consid- ered. Perioperative chemotherapy without radiation may also be considered for tumors of the gastroesophageal junction based on the randomized, multicenter, phase III MAGIC trial. 2. Chemotherapy plus radiation therapy without surgery Combined treatment with chemotherapy and radiation achieves long-term survival rates in up to 25% of patients and is superior to radiation alone. Chemoradia- tion alone should be considered in patients with localized disease (stage II or IIIA) who are poor surgical candidates due to serious medical illness or poor functional status (Eastern Cooperative Oncology Group score greater than 2). Patients with cervical esophageal cancers, which appear similar biologically to head and neck cancers and in whom surgery is highly morbid and typically not recommended, also should be considered for chemoradiation. 3. Supportive care during definitive therapy Patients with significant tumor obstruction may require percutane- ous gastric or jejunal tube placement to maintain adequate hydration and nutrition during neoadjuvant chemoradia- tion or chemotherapy. Multidisciplinary consultation is required to determine the optimal procedure and to opti- mize perioperative nutrition.B.  Therapy for Incurable DiseaseMo re than half of patients have either locally extensive tumor spread (T4b) that is unresectable or distant metasta- ses (M1) at the time of diagnosis. Surgery is not warranted in these patients. Since prolonged survival can be achieved in few patients, the primary goal is to provide relief from dysphagia and pain, optimize quality of life, and minimize treatment side effects. The optimal palliative approach depends on the presence or absence of metastatic disease, expected survival, patient preference, and institutional experience. 1. Chemotherapy or chemoradiation Combined radia- tion therapy and chemotherapy may achieve palliation in two-thirds of patients but is associated with significant side effects. It should be considered for patients with locallyadvanced tumors without distant metastases who have good functional status and no significant medical prob- lems, in whom prolonged survival may be achieved. Com- bination chemotherapy may be considered in patients with metastatic disease who still have good functional status and expected survival of at least several months. The systemic therapy treatment options are the same for metastatic esophageal, gastroesophageal junction, and gastric cancers (Table 392). Choice of treatment is increas- ingly influenced by the results of molecular testing, includ- ing PD-L1 expression, mismatch repair/microsatellite instability (MSI) and, for adenocarcinomas, HER2 amplifi- cation testing. Because of the number of targetable altera- tions, a next generation sequencing panel should be considered. In patients with amplification of the HER2 gene (approximately 15% of cases), addition of the mono- clonal antibody trastuzumab (see Chapter 17) to chemo- therapy is associated with prolonged survival. For patients without HER2 amplification who have increased PD-L1 expression, the addition of a PD-1 or PD-L1 targeted anti- body to chemotherapy may improve overall survival. Immunotherapy with pembrolizumab should be consid- ered for tumors with either microsatellite instability-high (MSI-H) or deficient mismatch repair protein expression (dMMR). For patients with poor functional status, single- agent therapy with a fluoropyrimidine, a taxane, or irinote- can may be used. 2. Local therapy for esophageal obstruction Patients with advanced esophageal cancer often have a poor func- tional and nutritional status. Radiation therapy alone to the area of esophageal obstruction may afford short-term relief of pain and dysphagia. Rapid palliation of dysphagia may be achieved by peroral placement of permanent expand- able wire stents (alone or followed by radiation). However, placement of these stents is complicated by perforation, migration, or tumor ingrowth in up to 40% of cases. PrognosisThe ov erall 5-year survival rate of esophageal carcinoma is less than 20%. Apart from distant metastasis (M1b), the two most important predictors of poor survival are adja- cent mediastinal spread (T4) and lymph node involvement. Whereas cure may be achieved in patients with regional lymph node involvement (stages IIB and III), involvement of nodes outside the chest (M1a) is indicative of metastatic disease (stage IV) that is incurable. For those patients whose disease progresses despite chemotherapy, meticu- lous efforts at palliative care are essential (see Chapter 5). When to Refer Patients should be referred to a gastroenterologist for evaluation and staging (endoscopy with biopsy, EUS) and palliative endoscopic stenting. Patients with curable and resectable disease for whom neoadjuvant therapy may be appropriate (stage IIB or IIIA) should be referred to medical, radiation, and sur- gical oncologists for consideration of neoadjuvant che- motherapy, chemoradiotherapy, and surgical resection.CMDT22_Ch39_p1612-p1675.indd  1638 02/07/21 2:44 PMCANCER1639 CMDT 2022 Patients with metastatic disease should be referred to medical and radiation oncologists for consideration of palliative chemotherapy or chemoradiation. Patients with metastatic disease and obstructive tumors not amenable to or refractory to palliative radiation or stenting may require referral to an interventional radi- ologist, gastroenterologist, or surgeon for gastric or jejunal tube placement for liquid artificial nutrition. Early referral to palliative care services may improve symptom management in patients with advanced or metastatic disease. When to AdmitP atients with high-grade esophageal obstruction with inabil- ity to manage oral secretions or maintain hydration should be admitted. Acute complications such as perforation, bleeding, aspiration, or fistula also may require admission.Boku  N et al. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previ- ously untreated, unresectable, advanced, or recurrent gastric/ gastroesophageal junction cancer: interim results of a ran- domized, phase II trial (ATTRACTION-4). Ann Oncol. 2019;30:250. [PMID: 30566590] Gottlieb-Vedi E et al. Long-term survival in esophageal cancer after minimally invasive compared to open esophagectomy: a systematic review and meta-analysis. Ann Surg 2019;270:1005. [PMID: 30817355] Mariette C et al; Fdration de Recherche en Chirurgie (FRENCH) and French Eso-Gastric Tumors (FREGAT) Working Group. Hybrid minimally invasive esophagectomy for esophageal cancer. N Engl J Med. 2019;380:152. [PMID: 30625052] National Cancer Institute. SEER Cancer Statistics Factsheets: Esophageal Cancer, 2020. https://seer.cancer.gov/statfacts/ html/esoph.html National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Esophageal and esophagogastric junction cancers. Version5.2020. 2020 December 23. https:// www.nccn.org/professionals/physician_gls/pdf/esophageal. pdfGA STRIC ADENOCARCINOMAE S S E N T I A L S  O F  D I A G N O S I S Dyspeptic symptoms with weight loss in patients over age 40 years. Iron deficiency anemia: occult blood in stools. Abnormality detected on upper gastrointestinal series or endoscopy. General ConsiderationsGastric  adenocarcinoma is the third most common cause of cancer death worldwide. However, its incidence has declined rapidly over the last 70 years, especially in Western countries, which may be attributable to changes in diet (more fruits and vegetables), food refrigeration (allowingmore fresh foods and reduced salted, smoked, and pre- served foods), reduced toxic environmental exposures, and a decline in Helicobacter pylori infections. The incidence of gastric cancer remains high (62/100,000 males) in Japan and many developing regions, including eastern Asia, Eastern Europe, Chile, Colombia, and Central America. In the United States, there were an estimated 27,600 new cases and 11,010 deaths in 2020. The incidence is higher in Asian Americans, Hispanics, African Americans, and Native Americans (including Native Alaskans). There are two main histologic variants of gastric cancer: intestinal-type (which resembles intestinal cancers in forming glandular structures) and diffuse (which is poorly differentiated, has signet-ring cells, and lacks glan- dular formation). The incidence of intestinal-type gastric cancer has declined significantly, but it is still the more common type (7080%); it occurs twice as often in men as women, primarily affects older people (mean age 68 years), and is more strongly associated with environmental fac- tors. It is believed to arise through a gradual, multi-step progression from inflammation (most commonly due to H pylori ), to atrophic gastritis, to intestinal metaplasia, and finally to dysplasia and cancer. Chronic H pylori gastritis is the strongest risk factor for gastric carcinoma, increasing the relative risk 3.5- to 20-fold. It is estimated that 6090% of cases of gastric carcinomas may be attributable to H pylori. Other risk factors for intestinal-type gastric cancer include pernicious anemia, a history of partial gastric resection more than 15 years previously, smoking, and diets that are high in nitrates or salt and low in vitamin C. Diffuse gastric cancer accounts for 2030% of gastric can- cer cases. In contrast to intestinal-type cancer, it affects men and women equally, occurs more commonly in young people, is not as strongly related to H pylori infection, and has a worse prognosis than intestinal-type cancer due to early metastasis. Most diffuse gastric cancers are attribut- able to acquired or hereditary mutations in the genes regulating the E-cadherin cell adhesion protein. Hereditary diffuse gastric cancer accounts for 13% of gastric cancers. The cancer may arise at a young age, is often multifocal and infiltrating with signet ring cell histology, and confers poor prognosis. Many of these families have a germline muta- tion of E-cadherin CDH1, which is inherited in an autoso- mal dominant pattern and carries a greater than 60% lifetime risk of gastric cancer. Prophylactic gastrectomy should be considered in patients known to carry this mutation. Most gastric cancers arise in the body and antrum. These may occur in a variety of morphologic types: (1) polypoid or fungating intraluminal masses; (2) ulcerating masses; (3) diffusely spreading ( linitis plastica ), in which the tumor spreads through the submucosa, resulting in a rigid, atonic stomach with thickened folds (prognosis dis- mal); and (4) superficially spreading or early gastric cancerconfined to the mucosa or submucosa (with or without lymph node metastases) and associated with a favorable prognosis. HER2 amplification and overexpres- sion is seen in 1025% of gastric adenocarcinoma cases and is more commonly observed in intestinal histology and moderately differentiated disease. Testing for MSI,CMDT22_Ch39_p1612-p1675.indd  1639 02/07/21 2:44 PMChAPTER 391640 CMDT 2022defici ency in mismatch repair proteins (dMMR), and PD-L1 is recommended in advanced disease to identify tumors that may respond to immunotherapy. For gastric adenocarcinoma, MSI-H/dMMR is found in 816% of cases. In contrast to the dramatic decline in cancers of the distal stomach, a rise in incidence of tumors of the gastric cardia has been noted. These tumors have demographic and pathologic features that resemble Barrett-associated esoph- ageal adenocarcinomas (see Esophageal Cancer). Clinical FindingsA.  Symptoms and SignsGastri c carcinoma is generally asymptomatic until the dis- ease is quite advanced. Symptoms are nonspecific and are determined in part by the location of the tumor. Dyspepsia, vague epigastric pain, anorexia, early satiety, and weight loss are the presenting symptoms in most patients. Patients may derive initial symptomatic relief from over-the-counter rem- edies, further delaying diagnosis. Ulcerating lesions can lead to acute gastrointestinal bleeding with hematemesis or melena. Pyloric obstruction results in postprandial vomiting. Lower esophageal obstruction causes progressive dysphagia. Physical examination is rarely helpful. Stools may be guaiac positive.B.  Laboratory FindingsIr on deficiency anemia due to chronic blood loss or anemia of chronic disease is common. Circulating tumor markers do not have established clinical validity in screening or diagnosis of gastric cancer. However, when checked serially, tumor markers can assist in monitoring treatment response.C.  EndoscopyU pper endoscopy should be obtained in all patients over age 60 years with new onset of epigastric symptoms (dyspepsia) and young patients with alarm symptoms (dysphagia, recur- rent vomiting, significant weight loss), especially in immi- grants from countries with a high prevalence of gastric cancer. Endoscopy with biopsies of suspicious lesions is highly sensi- tive for detecting gastric carcinoma. It can be difficult to obtain adequate biopsy specimens in diffuse type gastric cancer.D . ImagingOnce  a gastric cancer is diagnosed, preoperative evaluation with contrast CT of chest, abdomen, and pelvis and EUS is indicated to delineate the local extent of the primary tumor as well as to evaluate for nodal or distant metastases. EUS is superior to CT in determining the depth of tumor pen- etration and is useful for evaluation of early gastric cancers that may be removed by endoscopic mucosal resection. PET or combined PET-CT imaging is recommended for detection of distant metastasis. ScreeningBecause  of its unproven efficacy and cost-effectiveness, screening for H pylori infection and treating it to preventgastric cancer is not recommended for asymptomatic adults in the general population but may be considered in patients who have immigrated from regions with a high incidence of gastric cancer or who have a family history of gastric cancer. Because of the high incidence of gastric carcinoma in Japan, screening upper endoscopy is per- formed there to detect early gastric carcinoma. Approxi- mately 40% of tumors detected by screening are early, with a 5-year survival rate of almost 90%. Screening is not rec- ommended in the United States. StagingThe  TNM system is the commonly used classification to stage gastric adenocarcinoma. Staging is important not only because it correlates with the patients long-term sur- vival but also because it is used to determine which patients should receive adjuvant or neoadjuvant therapy. A staging laparoscopy prior to definitive surgery to exclude peritoneal carcinomatosis should be considered in patients with stage T1b or greater disease without radio- graphic evidence of distant metastases. Pathologic review should include (1) grade of tumor, (2) histologic subtype, (3) depth of invasion, (4) whether lymphatic or vascular inva- sion is present, and (5) if there is known metastatic disease, the status of HER2 protein expression by immunohisto- chemistry or fluorescent in situ hybridization or both, along with MMR or MSI testing and PD-L1 protein expression. Differential DiagnosisUlce rating gastric adenocarcinomas are distinguished from benign gastric ulcers by biopsies. Approximately 3% of gastric ulcers initially believed to be benign later prove to be malignant. All gastric ulcers identified at endoscopy should be biopsied to exclude malignancy. Ulcers that are suspicious for malignancy to the endoscopist or that have atypia or dysplasia on histologic examination warrant repeat endoscopy in 23 months to verify healing and exclude malignancy. Nonhealing ulcers should be consid- ered for resection. Infiltrative carcinoma with thickened gastric folds must be distinguished from lymphoma and other hypertrophic gastropathies. TreatmentA.  Curative Surgical ResectionSurgical resecti on is the only therapy with curative poten- tial. Laparoscopic techniques achieve similar outcomes and lower overall complication rates as open gastrectomy. In Japan and in specialized centers in the United States, endo- scopic mucosal resection is performed in select patients with small (less than 12 cm), early (intramucosal or T1aN0) gastric cancers after careful staging with EUS. Approximately 25% of patients undergoing surgery will be found to have locally unresectable tumors or peritoneal, hepatic, or distant lymph node metastases that are incur- able. The remaining patients with confirmed localized disease should undergo radical surgical resection. For adenocarcinoma localized to the distal two-thirds of the stomach, a subtotal gastrectomy should be performed. ForCMDT22_Ch39_p1612-p1675.indd  1640 02/07/21 2:44 PMCANCER1641 CMDT 2022pro ximal gastric cancer or diffusely infiltrating disease, total gastrectomy is necessary. The ultimate goal of surgery is obtaining negative surgical margins. Vitamin B12supple- mentation is required after gastrectomy. For patients with localized gastric cancer that is resectable, current National Comprehensive Cancer Network (NCCN) treatment guidelines recommend gastrectomy with extended (D1), or modified regional (D2), lymph node dissection and sam- pling of 15 or more lymph nodes. D2 lymphadenectomy has been shown to improve disease-specific survival but is associated with increased postoperative mortality.B.  Perioperative Chemotherapy or ChemoradiationThe  use of perioperative chemotherapy or adjuvant chemo- radiation is associated with improved survival in patients with localized or locoregional gastric adenocarcinoma who undergo surgical resection. The choice of treatment depends on the location and extent of tumor, type of sur- gery, patient comorbidities and performance status, and institutional experience. Tumors arising in the gastro- esophageal junction are treated following algorithms for esophageal primary tumors. Multidisciplinary treatment decision making involving the surgeon, radiation oncolo- gist, and medical oncologist is imperative.C.  Palliative ModalitiesMan y patients will be found either preoperatively or at the time of surgical exploration to have advanced disease that is not amenable to curative intent surgery due to peritoneal or distant metastases or local invasion of other organs. In some of these cases, palliative resection of the tumor none- theless may be indicated to alleviate pain, bleeding, or obstruction. For patients with unresectable disease, a surgi- cal diversion with gastrojejunostomy may be indicated to prevent obstruction. Alternatively, unresected tumors may be treated with endoscopic stent therapy, radiation therapy, or angiographic embolization to relieve bleeding or obstruction. Systemic therapy may be considered in patients with metastatic disease who still have good func- tional status and expected survival of at least several months. The regimens used are the same as those for esophageal and gastroesophageal junction tumors dis- cussed above (Table 392). PrognosisThe  5-year survival for gastric cancer varies greatly by stage, location, and histologic features. The 5-year survival is approximately 90% for early-stage cancer (T1b or less), 80% for stage II after curative intent treatment, but less than 20% for stage IIIC. Even with apparently localized disease, proxi- mal tumors have a 5-year survival of less than 15%. For those whose disease progresses despite therapy, meticulous efforts at palliative care are essential (see Chapter 5). When to Refer Patients with dysphagia, weight loss, protracted vomit- ing, iron deficiency anemia, melena, or new-onset dys- pepsia (especially if aged 60 years or older or associatedwith other alarm symptoms) in whom gastric cancer is suspected should be referred for endoscopy. Patients should be referred to a surgeon for attempt at curative resection in stage I, II, or III cancer, including staging laparoscopy if indicated. Prior to surgery, patients should be referred to an oncolo- gist to determine the role for perioperative chemother- apy or adjuvant chemoradiation or chemotherapy. Patients who have undergone gastrectomy require con- sultation with a nutritionist due to propensity for mal- nutrition and complications, such as dumping syndrome and vitamin B12deficiency, postoperatively. Patients with unresectable or metastatic disease should be referred to an oncologist for consideration of pallia- tive chemotherapy or chemoradiation. Early referral to palliative care services may also be considered for symptom management in patients with advanced and metastatic disease. When to AdmitPa tients with acute bleeding, protracted vomiting, or inabil- ity to maintain hydration or nutrition.Ja ng S et al. Superiority of gastrojejunostomy over endoscopic stenting for palliation of malignant gastric outlet obstruction. Clin Gastroenterol Hepatol. 2019;17:1295. [PMID: 30391433] Katai H et al. Survival outcomes after laparoscopy-assisted distal gastrectomy versus open-distal gastrectomy with nodal dis- section for clinical stage IA or IB gastric cancer: a multicentre, non-inferiority, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2020;5:142. [PMID: 31757656] National Cancer Institute. SEER Cancer Stat Facts: Stomach Cancer, 2020. https://seer.cancer.gov/statfacts/html/stomach. html National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Gastric Cancer. Version 4.2020. 2020 December 23. https://www.nccn.org/professionals/physician_ gls/pdf/gastric.pdfGA STRIC LYMPHOMAE S S E N T I A L S  O F  D I A G N O S I S Symptoms of dyspepsia, weight loss, or anemia. Variable abnormalities on upper gastrointestinal series or endoscopy including thickened folds, ulcer, mass, or infiltrating lesions; diagnosis estab- lished by endoscopic biopsy. Abdominal CT and EUS required for staging. General ConsiderationsGastric lympho mas may be primary (arising from the gas- tric mucosa) or may represent a site of secondary involve- ment in patients with nodal lymphomas. Distinguishing advanced primary gastric lymphoma with adjacent nodal spread from advanced nodal lymphoma with secondaryCMDT22_Ch39_p1612-p1675.indd  1641 02/07/21 2:44 PMChAPTER 391642 CMDT 2022gastric spread is essential  because the prognosis and treat- ment of primary and secondary gastric lymphomas are different. Primary gastric lymphoma is the second most common gastric malignancy, accounting for 35% of gas- tric cancers. More than 95% of these are non-Hodgkin B-cell lymphomas mainly consisting of either mucosa- associated lymphoid tissue (MALT)-type lymphoma and diffuse large B-cell lymphoma. Over 90% of low-grade primary gastric MALT-type lymphomas are associated with H pylori infection. Gastric T-cell lymphoma, which is associated with HTLV-1 infection, is rare and makes up 7% of primary gastric lymphomas. Clinical Findings & StagingThe  clinical presentation and endoscopic appearance of gastric lymphoma are similar to those of adenocarcinoma. Most patients have abdominal pain, weight loss, or bleed- ing. Patients with diffuse large B-cell lymphoma are more likely to have systemic symptoms and advanced tumor stage. At endoscopy, lymphoma may appear as an ulcer, mass, or diffusely infiltrating lesion. It tends to have hori- zontal infiltration as opposed to the vertical extension seen in adenocarcinoma. The diagnosis is established with endoscopic biopsy; FNA is not adequate. Since the disease can be multifocal, biopsies of both suspicious and normal- appearing areas are recommended. Biopsy specimens should be tested for H pylori and, if positive, for t(11;18) via PCR or FISH. EUS is the most sensitive test for determin- ing the level of invasion and presence of perigastric lymph- adenopathy and should be performed for accurate staging, if available. All patients should undergo staging with CT scanning of chest, abdomen, and pelvis. For gastric MALT lymphomas, the Lugano staging system is most frequently used. Stage I is confined to the gastrointestinal tract, stage II involves local or regional lymph nodes, stage IIE has invasion of adjacent organs or tissues, and stage IV has distant metastases. There is no stage III. For patients with diffuse large B-cell lymphomas involving the stomach, combination PET-CT imaging, bone marrow biopsy with aspirate, tumor lysis laboratory tests, and hepatitis B and HIV serologies also may be required for staging and treat- ment planning (see Chapter 13). TreatmentT reatment of primary gastric lymphomas depends on the tumor histology, grade, and stage. Marginal B-cell lympho- mas of the MALT type that are low-grade and localized to the stomach wall (stage I) or perigastric lymph nodes (stage IIE1) have an excellent prognosis. Patients with pri- mary gastric MALT-lymphoma should be tested for H pylori infection and treated if positive. Complete lym- phoma regression after successful H pylori eradication occurs in approximately 75% of cases of stage I and approx- imately 55% with stage IIE low-grade lymphoma. However, 95% of cancers positive for t(11;18) do not respond to antibiotics. Remission may take as long as a year, and relapse occurs in about 2% of cases per year. Many patients with minimal disease after successful H pylori eradication may be observed closely without further therapy. Restagingwith endoscopy and biopsy is recommended 3 months after antibiotic treatment and 36 months following radia- tion therapy. Ultimately, endoscopic surveillance after treatment is recommended every 36 months for 5 years to evaluate for recurrence. In patients whose tumors harbor specific gene translo- cations, including t(11;18) (API2-MALT1), t(1;14), or t(14;18), rates of remission after H pylori eradication are lower, and treatment with radiation is often required. The long-term survival of low-grade MALT lymphoma for stage I is over 90% and for stage II is 3565%. Surgical resection is not recommended. Diffuse large B-cell or other higher-grade lymphomas with secondary gastrointestinal involvement usually present at an advanced stage with widely disseminated disease and are treated according to stage and subtype of lymphoma (see Chapter 13).A vils A et al. Primary gastric diffuse large B-cell lymphoma: the role of dose-dense chemotherapy. J Oncol Pharm Pract. 2019; 25:1682. [PMID: 30370804] Jurez-Salcedo LM et al. Primary gastric lymphoma, epidemiol- ogy, clinical diagnosis, and treatment. Cancer Control. 2018;25: 1073274818778256. [PMID: 29779412] Lin JL et al. Dynamic prediction of long-term survival in patients with primary gastric diffuse large B-cell lymphoma: a SEER population-based study. BMC Cancer. 2019;19:873. [PMID: 31481021] National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. B-Cell Lymphomas. Version 1.2020. https://www.nccn.org/professionals/physician_gls/pdf/b-cell. pdf https://www.nccn.org/professionals/physician_gls/pdf/b- cell.pdf Tian C et al. A retrospective analysis of primary gastrointestinal non-Hodgkin lymphomas: clinical features, prognostic fac- tors and treatment outcomes. Onco Targets Ther. 2020;13: 5345. [PMID: 32606752]GA STRIC NEUROENDOCRINE TUMORSGastric  NETs make up less than 1% of gastric neoplasms. They may occur sporadically or secondary to chronic hypergastrinemia that results in hyperplasia and transfor- mation of enterochromaffin cells in the gastric fundus. The majority of NETs are caused by hypergastrinemia and occur in association with either pernicious anemia (75%) (type 1) or Zollinger-Ellison syndrome (5%) (type 2). Type 1 tumors are associated with chronic atrophic gastritis, gas- tric achlorhydria, and secondary hypergastrinemia. Initial diagnostic workup includes serum gastrin level, upper endoscopy, and EUS. Gastrin level should be obtained 1 week after the patient has stopped taking protein pump inhibitors. For low-grade tumors (Ki-67 less than 3% or less than 2 mitoses/10 high-power fields [HPF]), soma- tostatin receptorbased imaging (somatostatin receptor scintigraphy or gallium-68 dotatate PET/CT) should be performed. For high-grade tumors (Ki-67 greater than 20% or greater than 20 mitoses/10 HPF), FDG-PET/CT is pre- ferred to evaluate the extent of disease. For patients with hypergastrinemia (suspected of type 1 or type 2 carcinoid), serum vitamin B12and intrinsic factor antibody levels should be obtained to exclude pernicious anemia. Gastric NETs associated with Zollinger-EllisonCMDT22_Ch39_p1612-p1675.indd  1642 02/07/21 2:44 PMCANCER1643 CMDT 2022syndrom e occur almost exclusively in patients with multi- ple endocrine neoplasia type 1 (MEN 1), in which chromo- somal loss of 11q13 has been reported. Gastric NETs caused by hypergastrinemia tend to be multifocal, be smaller than 1 cm, have a low potential for metastatic spread, and thus are unlikely to cause development of the carcinoid syn- drome. Small lesions may be successfully treated with endo- scopic resection followed by endoscopic surveillance every 612 months, or with observation. Antrectomy reduces serum gastrin levels and may lead to regression of small tumors. It can be considered in patients with type 1 gastric NETs to reduce recurrence risk and frequency of post- therapy monitoring. Octreotide therapy may be appropriate for patients with underlying gastrinoma and Zollinger- Ellison syndrome. Patients with tumors larger than 2 cm should undergo endoscopic or surgical resection (see Small Intestinal Adenocarcinomas below). Type 3 gastric NETs arise sporadically, independent of gastrin production, and account for up to 20% of gastric NETs. Most sporadic gastric NETs are solitary, larger than 2 cm, and have a strong propensity for hepatic or pulmo- nary metastases and thus the carcinoid syndrome at initial presentation. CT or MRI should be obtained to evaluate for metastatic disease. Localized sporadic NETs should be treated with partial or total gastrectomy and regional lymphadenectomy. Advanced, low-grade gastric NETs can be monitored with serial scans, if asymptomatic. Soma- tostatin analogs may provide symptomatic relief for patients with functional gastric NETs. Advanced high- grade gastric neuroendocrine carcinomas are treated in a fashion similar to SCLCs.Algashaam y K et al. Multifocal G1-G2 gastric neuroendocrine tumors: differentiating between type I, II and III, a clinico- pathologic review. World J Clin Cases. 2019;7:2413. [PMID: 31559277] National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Neuroendocrine and Adrenal Tumors. Version 2.2020. 2020 July 24. https://www.nccn.org/ professionals/physician_gls/pdf/neuroendocrine.pdfGA STROINTESTINAL MESENCHYMAL TUMORS Pathobiology & DiagnosisGastroin testinal mesenchymal tumors (which include stro- mal tumors, leiomyomas, and schwannomas) derive from mesenchymal stem cells and have an epithelioid or spindle cell histologic pattern, resembling smooth muscle. The most common stromal tumors are gastrointestinal stromal tumors (GISTs), which originate from interstitial cells of Cajal. GISTs occur throughout the gastrointestinal tract, but most commonly in the stomach (60%) and small intes- tine (30%). Approximately 80% of GISTs have mutations in KIT. A percentage of the KIT wild type tumors have a mutation in PDGFRA , and only a minority of patients are wild type for both genes. Mesenchymal tumors may be discovered incidentally on imaging studies or endoscopy or may cause symptoms (most commonly bleeding, pain, or obstruction). At endoscopy, they appear as a submucosalmass that may have central umbilication or ulceration. EUS with guided FNA biopsy is the optimal study for diagnos- ing gastric mesenchymal tumors and distinguishing them from other submucosal lesions. Percutaneous biopsy may confer risk of bleeding or intra-abdominal seeding. CT of the abdomen and pelvis with contrast, MRI, and PET imaging are useful in the diagnosis and staging. PET imaging also may be useful to monitor response to treatment. While almost all GISTs have malignant potential, the risk of developing metastasis is increased with tumor size greater than 2 cm, nongastric location, and mitotic index greater than 5 mitoses per 50 HPF. It is difficult to distinguish benign from malignant tumors by EUS appearance or by FNA. But, in general, lesions are more likely benign if they are smaller than 2 cm, have a smooth border, and have a homogeneous echo pattern on EUS. Resection settles the issue. TreatmentA.  Localized TreatmentSu rgery is recommended for all patients with tumors that are 2 cm or larger, increasing in size, have an EUS appearance suspicious for malignancy, or are symptomatic. The man- agement of asymptomatic gastric lesions 2 cm or smaller in size depends on the EUS features. Tumors with high-risk EUS features can be surgically resected. If no high-risk fea- tures are noted, endoscopic surveillance can be performed. Because of the low but real long-term risk of malignancy, surgical resection should be considered in younger, other- wise healthy patients. However, other patients may be moni- tored with serial endoscopic ultrasonographic examinations or, in select cases, endoscopic resections. After complete surgical resection, the risk of GIST recurrence can be calcu- lated based on tumor location, size, and mitotic index. The majority of recurrences occur within the first 3 years.B.  Systemic TreatmentBecause  the majority of GISTs are driven by mutations in KIT orPDGFRA , the tyrosine kinase inhibitor, imatinib, which blocks signaling through this pathway, is used across disease stages. Neoadjuvant therapy with imatinib may be considered for patients with localized GIST tumors who are deemed to be at high risk for resection because of comorbidities, tumor size, or tumor location. A biopsy is required to confirm the diagnosis of GIST prior to initia- tion of neoadjuvant imatinib. Adjuvant therapy with ima- tinib delays recurrence and prolongs survival, but it is not likely to be curative. Untreated metastatic GIST tumors are aggressive and carry a poor prognosis. However, imatinib induces disease control in up to 85% of patients with metastatic disease with a progression-free survival of 2024 months and median overall survival of almost 5 years. Additionally, imatinib is associated with long-term survival in some patients. One study reported that 18% of patients contin- ued treatment after a median follow-up of 9 years. For patients with imatinib-resistant cancers, high-dose imatinib or other approved tyrosine kinase inhibitors (eg, sunitinib or regorafenib) are options.CMDT22_Ch39_p1612-p1675.indd  1643 02/07/21 2:44 PMChAPTER 391644 CMDT 2022H einrich MC et al. Avapritinib in advanced PDGFRA D842V- mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol. 2020;21: 935. [PMID: 32615108] Patel DJ et al. Adjuvant systemic therapy for intermediate and large gastric gastrointestinal stromal tumors (GISTs): is there a survival benefit following margin negative surgical resection? Am J Surg. 2020;219:436. [PMID: 31679654] von Mehren M et al. Gastrointestinal stromal tumors. J Clin Oncol. 2018;36:136. [PMID: 29220298] Wang C et al. Safety and efficiency of endoscopic resection versus laparoscopic resection in gastrointestinal stromal tumours: a systematic review and meta-analysis. Eur J Surg Oncol. 2020; 46:667. [PMID: 31864827]MA LIGNANCIES OF THE SMALL INTESTINEThe  frequency of different tumor types varies by location within the small intestine. Adenocarcinomas are most common in the duodenum and jejunum and neuroendo- crine tumors, in the ileum. Lymphomas and sarcomas each have similar incidences in the various segments of the small intestine.1.  Small Intestinal AdenocarcinomasThese  tumors often present with nonspecific symptoms such as abdominal pain and nausea. The incidence is rare, with 11,110 new diagnoses estimated in 2020 in the United States. These adenocarcinomas are most often diag- nosed at stage III or IV , but their prognosis is slightly worse than for similar stage colon adenocarcinoma. The duode- num is the most common site of small bowel adenocarci- noma, specifically in the periampullary region. Ampullary carcinoma may present with jaundice due to bile duct obstruction or bleeding. Surgical resection of early lesions is curative in up to 40% of patients. The management of nonampullary small intestinal adenocarcinoma is extrapolated from data available for the management of colon adenocarcinoma.2.  Small Intestinal LympomasL ymphomas may arise primarily in the gastrointestinal tract or may involve it secondarily in patients with dissemi- nated disease. In Western countries, primary gastrointesti- nal lymphomas account for 5% of lymphomas and 20% of small bowel malignancies. There is an increased incidence of small intestinal lymphomas in patients with AIDS, Crohn disease, and those receiving immunosuppressive therapy. The most common histologic subtype is non- Hodgkin extranodal marginal zone (MALT) B-cell lymphoma. That said, enteropathy-associated T-cell lym- phomas appear to be increasing in incidence in the United States. They are associated with the diagnosis of celiac disease. In the Middle East, lymphomas may arise in the setting of immunoproliferative small intestinal disease. Other types of intestinal lymphomas include primary intestinal follicular cell lymphoma, mantle cell lymphoma, and Burkitt lymphoma (see Chapter 13). Presenting symptoms or signs of primary small bowel lymphoma include abdominal pain, weight loss, nausea and vomiting, distention, anemia, and occult blood in thestool. Fevers are unusual. Protein-losing enteropathy may result in hypoalbuminemia, but other signs of malabsorption are unusual. Barium radiography or CT enterography helps localize the site of the lesion. The diagnosis requires endo- scopic, percutaneous, or laparoscopic biopsy. Imaging and possibly bone marrow biopsy are required to determine stage. Treatment depends on the tumor histologic subtype and stage of disease (see Chapter 13). If feasible, surgical resec- tion of primary intestinal lymphoma, may be appropriate for localized tumors. In patients with limited disease (stage IE) in whom resection is performed with negative margins, the role of adjuvant chemotherapy is unclear. Locoregional radiation should be considered if surgical margins are posi- tive. Patients with more extensive disease generally are treated according to the tumor histology.3.  Intestinal Neuroendocrine TumorsE S S E N T I A L S  O F  D I A G N O S I S Majority are asymptomatic and discovered inci- dentally at endoscopy or surgery. Carcinoid syndrome occurs in < 10%; hepatic metastases are generally present. Risk of metastasis is related to tumor size and location. General ConsiderationsNeur oendocrine tumors are the most common type of tumor arising in the small bowel. Gastrointestinal NETs (also called carcinoids) most commonly occur in the small intestine (45%) but are also found in the rectum (20%), appendix (17%), and colon (11%), with the remainder occurring in the stomach (less than 10%; see Gastric Neu- roendocrine Tumors above). Carcinoid tumors are well- differentiated neuroendocrine tumors that may secrete a variety of hormones, including serotonin, somatostatin, gastrin, and substance P . Small intestinal carcinoids most commonly arise in the distal ileum within 60 cm of the ileocecal valve. Up to 30% are multicentric. The risk of metastatic spread increases when the tumor is 1 cm or larger and when it is larger than 2 cm with invasion beyond the muscularis propria. Appen- diceal carcinoids are identified in 0.3% of appendectomies, usually as an incidental finding. Almost 80% of these tumors are smaller than 1 cm, and 90% are smaller than 2 cm. However, in patients with appendiceal carcinoid tumors larger than 2 cm, approximately 90% develop nodal and distant metastases; right hemicolectomy is recom- mended in these cases. Rectal carcinoids are usually detected incidentally as submucosal nodules during proctoscopic examination and often locally excised by biopsy or snare polypectomy before the histologic diagnosis is known. Rectal carcinoids smaller than 1 cm virtually never metastasize and are treated effec- tively with local endoscopic or transanal excision. Larger tumors are associated with the development of metastasisCMDT22_Ch39_p1612-p1675.indd  1644 02/07/21 2:44 PMCANCER1645 CMDT 2022in  10%. Hence, a more extensive cancer resection operation is warranted in fit patients with rectal carcinoid tumors larger than 12 cm or with high-risk features (such as inva- sion of muscularis propria or evidence of nodal involve- ment), or both. Clinical FindingsA.  Symptoms and SignsMos t lesions smaller than 12 cm are asymptomatic and difficult to detect by endoscopy or imaging studies. Small intestinal carcinoids may present with intermittent abdom- inal pain, bowel obstruction, bleeding, or bowel infarction. Appendiceal and rectal carcinoids usually are small and asymptomatic, but large lesions can cause bleeding, obstruction, or altered bowel habits. Carcinoid syndrome occurs in less than 10% of patients. More than 90% of patients with carcinoid syndrome have hepatic metastases, usually from carcinoids of small bowel origin. About 10% of patients with carcinoid syndrome have primary bron- chial or ovarian tumors without hepatic metastases. Carci- noid syndrome is caused by tumor secretion of hormonal mediators. The manifestations include facial flushing, edema of the head and neck (especially with bronchial carcinoid), abdominal cramps and diarrhea, broncho- spasm, cardiac lesions (pulmonary or tricuspid stenosis or regurgitation in 1030%), and telangiectases.B.  Laboratory FindingsSerum  chromogranin A is elevated in the majority of NETs, although its sensitivity for small, localized carcinoid tumors is unknown. Serum chromogranin A is elevated in almost 90% of patients with advanced small bowel carcinoid. Urinary 5-hydroxyindoleacetic acid (5-HIAA) and platelet serotonin levels are also elevated in patients with metastatic carcinoid; however, these tests are less sensitive than serum chromogranin A. There is increased urinary 5-HIAA in carcinoid syndrome; symptomatic patients usually excrete more than 25 mg of 5-HIAA per day in the urine. Because certain foods and medications can interfere with 5-HIAA levels, these should be withheld for 48 hours prior to a 24-hour urine collection.C.  ImagingAbdo minal CT may demonstrate a mesenteric mass with tethering of the bowel, lymphadenopathy, and hepatic metastasis. Abdominal CT or enterography may reveal kinking of the bowel, but because the lesion is extralumi- nal, the diagnosis may be overlooked for several years. Gallium Ga-68 DOTATATE PET scan has replaced soma- tostatin receptor scintigraphy as the standard of care for staging; however, both may help identify disease that may benefit from treatment with somatostatin analogs or pep- tide receptor radionuclide therapy (PRRT). Treatment & OutcomesSmall  intestinal carcinoids generally are indolent tumors with slow spread. Patients with disease confined to the small intestine should be treated with surgical excision.There is no proven role for adjuvant therapy after complete resection. Five-year survival rates for patients with stage I and II disease are 96% and 87%, respectively. In patients with resectable disease who have lymph node involvement (stage III), the 5-year survival rate is 74%; however, by 25 years, less than 25% remain disease free. Across stages, prognosis is strongly associated with histologic differentia- tion and grade. Patients with grade 1 disease may not require treatment for many years even with metastatic disease. However, patients with a grade 3 neuroendocrine tumor may have a clinical course more similar to a high- grade neuroendocrine carcinoma. In patients with advanced disease, therapy historically has been deferred until the patient is symptomatic. Con- ventional cytotoxic chemotherapy agents do not achieve significant responses in carcinoid tumors and have not been associated with improved outcomes. For patients who are symptomatic either from tumor bulk or carcinoid syn- drome, the cornerstone of therapy is typically a long-acting somatostatin analog, which inhibits hormone secretion from the carcinoid tumor. In 90% of patients, this results in dramatic relief of symptoms of carcinoid syndrome, includ- ing diarrhea or flushing, and may also control tumor growth for a median period of 1 year. Options at disease progression include octreotide dose escalation, or addition of everolimus, a mammalian target of rapamycin (mTOR) inhibitor. For patients with somatostatin receptorpositive disease based on imaging, another option after progression is treatment with PRRT. PRRT consists of a somatostatin analog conjugated to a radioactive isotope such as yttrium-90 or lutetium-177. Studies of anti-angiogenic kinase inhibitors have shown some benefit; currently, suni- tinib is approved in the United States for pancreatic neuro- endocrine tumors. In selected patients with hepatic-dominant disease, resection of hepatic metastases may provide dramatic improvement in carcinoid syndrome symptoms. Tumor debulking with liver-directed chemoembolization or radio- embolization may also provide symptomatic improvement in some of these patients. Patients with advanced, poorly differentiated intestinal NETs are treated in a similar fashion to those with small cell carcinomas. They have a poor prognosis.4.  Small Intestine SarcomaSarco mas constitute approximately 10% of small bowel neoplasms and are commonly found in the jejunum and ileum (and in a Meckel diverticulum, if present). Most arise from stromal tumors (GISTs) that stain positive for CD117; a minority arise from smooth muscle tumors (leiomyosar- comas) (see Gastrointestinal Mesenchymal Tumors above). Common symptoms of small intestine sarcoma include pain, weight loss, bleeding, and perforation. As the lesions tend to enlarge extraluminally, obstruction is rare. Kaposi sarcoma was at one time a common complica- tion in AIDS, but the incidence is declining with antiretro- viral therapy. It can also occur in the setting of immunosuppression after organ transplantation. It is caused by infection with human herpesvirus 8 (HHV8). Lesions may be present anywhere in the intestinal tract.CMDT22_Ch39_p1612-p1675.indd  1645 02/07/21 2:44 PMChAPTER 391646 CMDT 2022V isceral involvement usually is associated with cutaneous disease. Most lesions are clinically silent; however, large lesions may be symptomatic. Widespread involvement may be best treated by systemic chemotherapy using single- agent therapy or combinations of pegylated-doxorubicin, paclitaxel, vincristine, bleomycin, or etoposide. Surgery or radiation may be indicated for isolated high-risk lesions.Akce  M et al. Clinical outcomes of small bowel adenocarcinoma. Clin Colorectal Cancer. 2019;18:257. [PMID: 31606297] Bonds M et al. Neuroendocrine tumors of the pancreaticobiliary and gastrointestinal tracts. Surg Clin North Am. 2020;100:635. [PMID: 32402306] Lee MR et al. Incidence trends of gastroenteropancreatic neuro- endocrine tumors in the United States. Clin Gastroenterol Hepatol. 2019;17:2212. [PMID: 30580091] National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Small Bowel Adenocarcinoma. Ver- sion 2.2020. 2020 May 6. https://www.nccn.org/professionals/ physician_gls/pdf/small_bowel.pdf Scott AT et al. Management of small bowel neuroendocrine tumors. J Oncol Pract. 2018;14:471. [PMID: 30096273]COLOR ECTAL CANCERE S S E N T I A L S  O F  D I A G N O S I S Personal or family history of adenomatous or ser- rated polyps or colorectal cancer are important risk factors. Symptoms or signs depend on tumor location. Proximal colon: fecal occult blood, anemia. Distal colon: change in bowel habits, hematochezia. Diagnosis established with colonoscopy. General ConsiderationsColor ectal cancer is the second leading cause of death due to malignancy in the United States. Colorectal cancer will develop in approximately 4.2% of Americans and has a 5-year survival rate of 65%. In 2020, there were an estimated 147,950 new cases of colorectal cancer in the United States, with an estimated 53,200 deaths. Between 1996 and 2010, its mortality rate decreased by 46%. A 2015 National Health Interview Survey estimated that 62% of US adults have undergone recommended screening. On average, new cases have been falling 3.2% each year over the last 10 years. Colorectal cancers are almost all adenocarcinomas, which tend to form bulky exophytic masses or annular constricting lesions. The majority of colorectal cancers are thought to arise from malignant transformation of an adenomatous polyp (tubular, tubulovillous, or villous ade- noma) or serrated polyp (hyperplastic polyp, traditional serrated adenoma, or sessile serrated adenoma). Polyps that are advanced (ie, polyps at least 1 cm in size, adeno- mas with villous features or high-grade dysplasia, or ser- rated polyps with dysplasia) are associated with a greaterrisk of cancer. Approximately 85% of sporadic colorectal cancers arise from adenomatous polyps. They have loss of function of one or more tumor suppressor genes (eg, p53, APC, orDCC ) due to a combination of spontaneous muta- tion of one allele combined with chromosomal instability and aneuploidy (abnormal DNA content) that leads to dele- tion and loss of heterozygosity of the other allele (eg, 5q, 17q, or 18p deletion). Activation of oncogenes such as KRAS and BRAF is present in a subset of colorectal cancers with prog- nostic and therapeutic implications discussed further below. Approximately 1020% of colorectal cancers arise from serrated polyps, most of which have hypermethylation of CpG-rich promoter regions that leads to inactivation of the DNA mismatch repair gene MLH1, resulting in MSI, and activation of mutations of the BRAF gene. Serrated colon cancers have distinct clinical and pathologic characteris- tics, including diploid DNA content, predominance in the proximal colon, poor differentiation, and more favorable prognosis. Up to 5% of colorectal cancers are caused by inherited germline mutations resulting in polyposis syndromes (eg, familial adenomatous polyposis) or hereditary nonpolypo- sis colorectal cancer (HNPCC or Lynch syndrome). These conditions are discussed further in Chapter 15. Risk FactorsA n umber of factors increase the risk of developing colorec- tal cancer. Some of these factors include smoking, consump- tion of red and processed meats, alcohol intake, diabetes mellitus, physical inactivity, obesity, and history of inflam- matory bowel disease. Recognition of these factors has had an impact on screening strategies. However, 75% of all cases occur in people with no known predisposing factors.A.  AgeThe  incidence of colorectal cancer rises sharply after age 45 years, and 90% of cases occur in persons over the age of 50 years. The median age at diagnosis is 68 for men and 72 for women. Over the past two decades there has been a 20% decrease in incidence among adults over age 50 (likely due to colorectal cancer screening programs) but a 50% increase in incidence among adults under age 50 (espe- cially in the distal colon and rectum). The incidence of young adultonset colorectal cancer is rising in all racial and ethnic groups but is highest in Blacks. In the United States, the colorectal cancer incidence rates in adults over age 50 is 40/100,000 and is 12.2/100,000 in adults younger than age 50. It is estimated that by 2030, 10% of colon cancer and 20% of rectal cancers will occur in patients under the age of 50. The reason for the increase in colorectal cancer incidence among adults under age 50 is uncertain.B.  Family History of NeoplasiaA family history of colorectal cancer is presen t in approxi- mately 20% of patients with colon cancer. Hereditary fac- tors are believed to contribute to 2030% of colorectal cancers; however, the genes responsible for most of these cases have not yet been identified. Hereditary cancerCMDT22_Ch39_p1612-p1675.indd  1646 02/07/21 2:44 PMCANCER1647 CMDT 2022syndromes  (Lynch syndrome or polyposis syndromes) account for approximately 34% of colorectal cancers in patients 50 years or older but 1015% of patients with young adultonset colorectal cancer (see Chapter 15). Approximately 6% of the Ashkenazi Jewish population has a missense mutation in the APC gene (APC I1307K) that confers a modestly increased lifetime risk of developing colorectal cancer (odds ratio [OR] 1.41.9) that phenotypi- cally resembles sporadic colorectal cancer rather than familial adenomatous polyposis. Genetic screening is avail- able, and patients harboring the mutation merit more intensive colorectal screening. A family history of colorectal cancer or adenomatous polyps is one of the most important risk factors for colorec- tal cancer. The risk of colon cancer is proportionate to the number and age of affected first-degree family members with colon neoplasia. People with one first-degree family member with colorectal cancer have an increased risk approximately two times that of the general population; however, the risk is almost four times if the family member was younger than 45 years when the cancer was diagnosed. Patients with two first-degree relatives have a fourfold increased, or 2530% lifetime, risk of developing colon can- cer. First-degree relatives of patients with adenomatous pol- yps also have a twofold increased risk for colorectal neoplasia, especially if they were younger than 60 years when the polyp was detected or if the polyp was 10 mm or larger.C.  Inflammatory Bowel DiseaseThe  risk of adenocarcinoma of the colon begins to rise 8 years after disease onset in patients with ulcerative colitis and Crohn colitis (see Chapter 15). For this reason, initia- tion of surveillance with colonoscopy is recommended at 810 years after onset of inflammatory bowel disease symptoms.D . Dietary and Lifestyle Factors and ChemopreventionIn  epidemiologic studies, diets rich in fats and red meat are associated with an increased risk of colorectal adenomas and cancer, whereas diets high in fruits, vegetables, and fiber are associated with a decreased risk. However, pro- spective studies have not shown a reduction in colon can- cer or recurrence of adenomatous polyps with diets that are low in fat; that are high in fiber, fruits or vegetables; or that include calcium, folate, beta-carotene, or vitamin A, C, D, or E supplements. Meta-analyses suggest that individuals with increased physical activity are up to 27% less likely to develop colon cancer. There also is a correlation between increasing body mass index and cancer risk, such that for each increase of 5 kg/m2in BMI, there is a 5% increased cancer risk. Patients with higher levels of pre- and post-diagnosis physical activ- ity experience reduced colorectal cancerspecific mortality and all-cause mortality. Maintaining a healthy body weight, a healthy diet, and a physically active lifestyle are recom- mended in colorectal cancer survivors. Low-dose aspirin has been associated with a reduced risk of colorectal adenomas and cancer in multiple studies.A 2016 USPSTF systematic review of controlled trials con- cluded that prolonged regular use of low-dose aspirin (81 mg/day) is associated with a 40% reduction in colorectal cancer incidence after 10 years and a 33% reduction in colorectal cancer mortality after 20 years. Because long- term aspirin use is associated with a low incidence of seri- ous complications (gastrointestinal hemorrhage, stroke), low-dose aspirin should not be routinely administered as a chemopreventive agent without other medical indications. Low-dose aspirin may also be considered in patients with a personal or family history of colorectal cancer or advanced adenomas; however, its administration does not obviate the need for colonoscopy screening and surveillance.E.  Other FactorsThe  overall incidence of colorectal cancer is similar in men and women; however, similar incidence rates are reached in women about 46 years later than in men. A higher proportion of cancers are located in the proximal colon in women (46%) than men (37%). The incidence and mortal- ity of colon adenocarcinoma is higher in Blacks and Native Americans than in Whites. It is unclear whether this is due to genetic or socioeconomic factors (eg, diet or reduced access to medical care). Clinical FindingsA.  Symptoms and SignsAdenocar cinomas grow slowly and may be present for several years before symptoms appear. However, some asymptomatic tumors may be detected by the presence of fecal occult blood (see Screening for Colorectal Neo- plasms, below). Symptoms depend on the location of the carcinoma. Chronic blood loss from right-sided colonic cancers may cause iron deficiency anemia, manifested by fatigue and weakness. Obstruction, however, is uncommon because of the large diameter of the right colon and the liquid consistency of the fecal material. Lesions of the left colon often involve the bowel circumferentially. Because the left colon has a smaller diameter and the fecal matter is solid, obstructive symptoms may develop with colicky abdominal pain and a change in bowel habits. Constipation may alternate with periods of increased frequency and loose stools. The stool may be streaked with blood, though marked bleeding is unusual. With rectal cancers, patients note tenesmus, urgency, and recurrent hematochezia. Physical examination is usually normal except in advanced disease. The liver should be examined for hepatomegaly, suggesting metastatic spread. For cancers of the distal rec- tum, digital examination is necessary to determine whether there is extension into the anal sphincter or fixation, sug- gesting extension to the pelvic floor.B.  Laboratory FindingsA  CBC should be obtained to look for anemia. Elevated liver biochemical tests raise suspicion of metastatic disease. The serum carcinoembryonic antigen (CEA) should be measured in all patients with proven colorectal cancer but is not appropriate for screening. The CEA is not elevated inCMDT22_Ch39_p1612-p1675.indd  1647 02/07/21 2:44 PMChAPTER 391648 CMDT 2022man y patients with confirmed colorectal cancer; con- versely, the CEA may be elevated in active smokers and those with a variety of other nonmalignant conditions. A preoperative CEA level greater than 5 ng/mL is a poor prognostic indicator. After complete surgical resection, CEA levels should normalize; persistently elevated levels suggest the presence of persistent disease and warrant fur- ther evaluation. CEA is routinely monitored at the time of adjuvant therapy and during postoperative surveillance for patients who had elevated levels before resection.C.  ColonoscopyColo noscopy is the required diagnostic procedure in patients with a clinical history suggestive of colorectal cancer or in patients with an abnormality suspicious for cancer detected on radiographic imaging. Colonoscopy and upper endos- copy should be considered in all adults with new-onset iron deficiency anemia. Colonoscopy permits biopsy for patho- logic confirmation of malignancy.D . ImagingChes t, abdominal, and pelvic CT scans with contrast are required for preoperative staging. CT scans may demon- strate distant metastases but are less accurate in the determi- nation of the level of local tumor extension (T stage) or lymphatic spread (N stage). Intraoperative assessment of the liver by direct palpation and ultrasonography can be per- formed to detect hepatic metastases (M stage). For rectal cancers (generally defined as tumors arising 12 cm or less proximal to the anal verge), pelvic MRI or endorectal ultra- sonography is required to determine the depth of penetra- tion of the cancer through the rectal wall (T stage) and perirectal lymph nodes (N stage), informing decisions about preoperative (neoadjuvant) chemoradiotherapy and opera- tive management. PET is not routinely used for staging or surveillance in colorectal cancers. StagingThe  TNM system is the commonly used classification to stage colorectal cancer. Staging is important not only because it correlates with the patients long-term survival but also because it is used to determine which patients should receive adjuvant or neoadjuvant therapy. Differential DiagnosisThe  nonspecific symptoms of colorectal cancer may be con- fused with those of irritable bowel syndrome, diverticular disease, ischemic colitis, inflammatory bowel disease, infec- tious colitis, and hemorrhoids. Neoplasm must be excluded in any patient over age 40 years who reports a change in bowel habits or hematochezia or who has an unexplained iron deficiency anemia or occult blood in stool samples. TreatmentA.  Colon CancerSurgical resection  of the colonic tumor is the treatment of choice for almost all patients. It may be curative in patientswith stage I, II, and III disease and even some patients with metastatic (stage IV) disease. Multiple studies demonstrate that minimally invasive, laparoscopically assisted colec- tomy results in similar outcomes and rates of recurrence to open colectomy. Regional dissection of at least 12 lymph nodes should be performed to determine staging, which guides decisions about adjuvant therapy. Following com- plete endoscopic removal of an adenomatous polyp (polyp- ectomy) that is found on pathologic review to contain a focus of cancer (malignant polyp), observation is a reason- able alternative to further surgical resection in carefully selected patients with invasion into the submucosa (T1 disease). Pathology review of colorectal cancers should include testing for mismatch repair proteins for all patients. Tumors of patients with metastatic colorectal cancer should also be tested for extended RAS andBRAF mutations. Following surgical resection, chemotherapy has been demonstrated to improve overall and tumor-free survival in select patients with colon cancer depending on stage (Table 392). 1. Stage I Because of the excellent 5-year survival rate (approximately 92%), no adjuvant therapy is recommended for stage I colon cancer. 2. Stage II node-negative disease The 5-year survival rate is approximately 87% for stage IIA disease and 63% for stage IIB disease. A significant survival benefit from adju- vant chemotherapy has not been demonstrated in most randomized clinical trials for stage II colon cancer (see discussion for stage III disease). However, otherwise healthy patients with stage II disease who are at higher risk for recurrence (perforation; obstruction; close or indeter- minate margins; poorly differentiated histology; lymphatic, vascular, or perineural invasion; T4 tumors; or fewer than 12 lymph nodes sampled) may benefit from adjuvant che- motherapy. Patients whose tumors reveal MSI have a more favorable prognosis and do not benefit from 5-fluorouracil- based adjuvant therapy. 3. Stage III node-positive disease With surgical resec- tion alone, the expected 5-year survival rate is 3050%. Postoperative adjuvant chemotherapy significantly increases disease-free survival as well as overall survival by up to 30% and is recommended for all fit patients (Table 392). Multiple large, well-designed studies of adjuvant therapy for stage III colorectal cancer have reported a higher rate of disease-free survival at 5 years for patients treated for 6 months postoperatively with a combination of oxalipla- tin, 5-fluorouracil, and leucovorin (FOLFOX) (73.3%) than with 5-fluorouracil and leucovorin (FL) alone (67.4%). Similar benefit was reported for patients treated with oxali- platin and capecitabine (orally active fluoropyrimidine). A large international randomized controlled trial com- paring 3 months with 6 months of adjuvant therapy for colon cancer found that 3 months of adjuvant therapy resulted in equivalent disease-free survival for patients with earlier stage T1, T2, or T3, and N1 disease but not with more advanced T4 or N2 disease. For patients with high-risk disease (T4 or N2), 6 months of adjuvant che- motherapy are still recommended. The addition of aCMDT22_Ch39_p1612-p1675.indd  1648 02/07/21 2:44 PMCANCER1649 CMDT 2022biologic  agent (bevacizumab or cetuximab) to adjuvant chemotherapy does not improve outcomes. 4. Stage IV metastatic disease Approximately 20% of patients have metastatic disease at the time of initial diag- nosis, and an additional 30% eventually develop metastasis. A subset of these patients has limited disease that is poten- tially curable with surgical resection. Surgery may also be warranted to provide palliation of tumor bleeding or obstruction. Resection of isolated liver metastases may result in long-term (over 5 years) survival in 3555% of cases. For those with unresectable hepatic metastases, local ablative techniques (cryosurgery, radiofrequency or micro- wave coagulation, embolization, hepatic intra-arterial che- motherapy) or radiation may provide long-term tumor control. A subset of patients who have isolated pulmonary metastases may undergo resection or radiation with poten- tial cure. In the absence of other treatment, the median survival is less than 12 months; however, with current therapies, median survival approaches 30 months. Primary cancer location has been found to have a potential prog- nostic importance: median survival times are 33.3 months for patients with left-sided colon cancers compared to 19.4 months for those with right-sided cancers. The goals of therapy for patients with metastatic colorectal cancer are to slow tumor progression while maintaining a reasonable quality of life for as long as pos- sible. Currently, either FOLFOX (the addition of oxalipla- tin to 5-fluorouracil and folinic acid) or FOLFIRI (the addition of irinotecan to 5-fluorouracil and folinic acid) is the preferred first-line treatment regimen for fit patients. For convenience, oral capecitabine (instead of intravenous 5-fluorouracil and leucovorin) can be used in combination with oxaliplatin since it has similar efficacy to 5-fluorouracil; however, combination with irinotecan is not recommended due to increased toxicity (diarrhea). Addition of a biologic agent to combination chemotherapy improves response rates and overall survival and is recommended in the first line of treatment in suitable patients. Bevacizumab is a monoclonal antibody targeting VEGF. Combination of bevacizumab with FOLFOX or FOLFIRI prolongs mean survival by 25 months compared with either regimen alone. Cetuximab and panitumumab are monoclonal anti- bodies targeting EGFR. Activating K-ras gene mutations downstream of EGFR are present in approximately 35% of patients with metastatic colorectal cancer and are a bio- marker for nonresponse to cetuximab and panitumumab, for which reason the use of these agents is restricted to patients with tumors wild-type for K-ras. Mutations in N-ras and BRAF are also predictive of nonresponse to EGFR inhibition alone. In stage IV patients with K-ras wild-type cancers, the addition of panitumumab or cetux- imab to FOLFOX or FOLFIRI prolongs survival by approx- imately 4 months. When disease progresses despite treatment either with FOLFOX or with FOLFIRI (often in conjunction with bevacizumab or an EGFR-targeted antibody), therapy is switched to the alternate regimen. Although the ideal sequence of agents is not known, patients do benefit from exposure to all available therapies. Clinical trial participa- tion should be considered for eligible patients who areintolerant of or ineligible for standard therapies or in whom disease has progressed.B.  Rectal CancerThe  treatment approach to rectal cancer is guided by clinical staging as determined by colonoscopy and endorectal ultrasound or MRI with endorectal coil. In carefully selected patients with small (less than 4 cm), mobile, well-differentiated T1 rectal cancers that are less than 8 cm from the anal verge, transanal endoscopic or surgical excision may be considered. All other patients with rectal cancer require either a low anterior resection with a colorectal anastomosis or an abdominoperineal resection with a colostomy, depending on how far above the anal verge the cancer is located and the extent of local tumor spread. For invasive rectal carcinoma, preoperative (neoadju- vant) therapy with radiation or chemoradiation, with or without postoperative (adjuvant) therapy with chemother- apy or chemoradiation, is generally recommended in all node-positive tumors and in T3 and greater tumors due to increased risk of local recurrence. The choice and timing of radiation and chemotherapy depend on a host of factors. Neoadjuvant chemoradiation has become the preferred standard in many centers because chemotherapy is more tolerable prior to surgery, leads to improved local control, and may result in improved long-term survival. For patients with clinical node-positive disease, a bulky primary cancer (T4), or a low-lying cancer that will require a permanent colostomy, giving all chemotherapy in the neoadjuvant set- ting (total neoadjuvant therapy) is now an option in NCCN guidelines. After neoadjuvant therapy, the operative approach (low anterior resection versus abdominoperineal resection with colostomy) depends on how far above the anal verge the cancer is located, its size and depth of penetration, and the patients overall condition. Careful dissection of the entire mesorectum by either open or laparoscopic surgery reduces local recurrence to 5%. Although low anterior resections obviate a colostomy, they are associated with increased immediate postsurgical complications (eg, leak, dehis- cence, stricture) and long-term defecatory complaints (eg, increased stool frequency, and incontinence). With unre- sectable rectal cancer, the patient may be palliated with a diverting colostomy. Follow-Up After SurgeryColorectal cancer p atients who have undergone resections for cure are monitored closely to look for evidence of symptomatic or asymptomatic tumor recurrence that may occasionally be amenable to curative resection. Patients should be evaluated every 36 months for 2 years and then every 6 months for a total of 5 years with history, physical examination, and laboratory surveillance, including serum CEA levels if baseline levels are elevated. The NCCN and ASCO guidelines recommend surveillance contrast CT scans of chest, abdomen, and pelvis up to every 612 months for up to 5 years post-resection in high-risk stage II and all stage III patients. Patients who had aCMDT22_Ch39_p1612-p1675.indd  1649 02/07/21 2:44 PMChAPTER 391650 CMDT 2022comple te preoperative colonoscopy should undergo another colonoscopy 1 year after surgical resection. Patients who did not undergo full colonoscopy preopera- tively also should undergo a full colonoscopy after comple- tion of all adjuvant therapy to exclude other synchronous colorectal neoplasms. If a colonoscopy does not detect new adenomatous polyps 1 year postoperatively, surveillance colonoscopy should be performed every 35 years thereaf- ter to look for metachronous polyps or cancer. New onset of symptoms or a rising CEA warrants investigation with chest, abdominal, and pelvic CT and colonoscopy to look for a new primary tumor or recurrence, or metachronous metastatic disease that may be amenable to curative or pal- liative therapy. The majority of colorectal cancer recur- rences occur within 3 years of the conclusion of treatment, and almost all (greater than 90%) occur within 5 years. PrognosisThe  stage of disease at presentation remains the most important determinant of 5-year survival in colorectal cancer, which is estimated in older registries as: stage I, greater than 90%; stage II, 7085%; stage III with fewer than 4 positive lymph nodes, 67%; stage III with more than 4 positive lymph nodes, 33%; and stage IV , 57%. Long- term registry follow-up data from the modern chemo- therapy era are not yet available. For each stage, rectal cancers have a worse prognosis. For those patients whose disease progresses despite therapy, meticulous efforts at palliative care are essential (see Chapter 5). Screening for Colorectal NeoplasmsColorectal can cer is ideal for screening because it is a com- mon disease that is fatal in almost 50% of cases and yet is curable if detected at an earlier stage. Furthermore, most cases arise from benign adenomatous or serrated polyps that progress over many years to cancer, and removal of these polyps has been shown to prevent the majority of cancers. Colorectal cancer screening is endorsed by the USPSTF, the Agency for Health Care Policy and Research, the American Cancer Society, and every professional gas- troenterology and colorectal surgery society. Although there is continued debate about the optimal cost-effective means of providing population screening, there is now almost unanimous consent that screening of some kind should be offered to all adults ages 4575 years. The 2018 American Cancer Society recommendations for screening and 2020 USPSTF draft recommendations for screening are listed in Table 396. Due to a rising incidence of colorectal cancer in adults younger than 50 years, the 2020 USPSTF and 2018 American Cancer Society guidelines both endorse consideration of screening in asymptomatic, average-risk adults beginning at age 45; however, the cost- effectiveness of this strategy is uncertain. It is important for primary care providers to understand the relative merits of various options and to discuss them with their patients. The potential for harm from screening must be weighed against the likelihood of benefit, especially in elderly patients with comorbid illnesses and shorter life expec- tancy. Although routine screening is not recommended inadults above age 75, it may be considered on a case-by-case basis in adults age 76 through 85 years who have excellent health and functional status. Patients with first-degree relatives with colorectal neo- plasms (cancer or adenomatous polyps) are at increased risk. Therefore, most guidelines recommend initiating screening at age 4050 years (or 10 years younger than the familial diagnosis) in individuals with first-degree relatives with colorectal cancer or with advanced adenomas. Rec- ommendations for screening in families with inherited cancer syndromes or inflammatory bowel disease are pro- vided in Chapter 15. Screening tests may be classified into two broad catego- ries: stool-based tests and examinations that visualize the structure of the colon by direct endoscopic inspection or radiographic imaging.A.  Stool-Based Tests1.  Fecal occult blood test Most colorectal cancers and some large adenomas result in increased chronic blood loss. A variety of tests for fecal occult blood are commer- cially available that have varying sensitivities and specifici- ties for colorectal neoplasia. These include guaiac-based fecal occult blood tests (gFOBT) (eg, Hemoccult I and II and Hemoccult SENSA) that detect the pseudoperoxidase activity of heme or hemoglobin and fecal immunochemical tests (FITs) that detect human globin. In clinical trials, FITsTable 396. Recommendations for colorectal cancer screening,1based on updated draft 2020 US Preventive Services Task Force and 2018 American Cancer Society recommendations.2Av erage-risk individuals  45 years old2 Annual fecal occult blood testing using higher sensitivity tests (Hemoccult SENSA) Annual fecal immunochemical test (FIT) Fecal DNA test (interval uncertain) Flexible sigmoidoscopy every 5 years Colonoscopy every 10 years CT colonography every 5 years Individuals wit a family istory of a first-degree member wit colorectal neoplasia3 Single first-degree relative wit colorectal cancer diagnosed at age 60 years or older: Begin screening at age 40. Screen- ing guidelines same as average-risk individual; however, preferred method is colonoscopy every 10 years. Single first-degree relative wit colorectal cancer or advanced adenoma diagnosed before age 60 years, or two first-degree relatives: Begin screening at age 40 or at age 10 years younger than age at diagnosis of the youngest affected relative, whichever is first in time. Recommended screening: colonoscopy every 5 years.1 For recommendations for families with inherited polyposis syn- dromes or hereditary nonpolyposis colon cancer, see Chapter 15.2 The American Cancer Society recommends screening of average- risk adults from age 45 to 75; the US Preventive Services Task Force recommends screening of all adults ages 5075 (Grade A recom- mendation) and ages 4559 (Grade B). Both recommend screen- ing in selected patients ages 7685 based on life expectancy, patient preferences, overall health, and prior screening results.CMDT22_Ch39_p1612-p1675.indd  1650 02/07/21 2:44 PMCANCER1651 CMDT 2022have  proven superior to gFOBT in sensitivity for detection of colorectal cancer and advanced adenomas with similar specificity. Because FITs are not affected by diet or medica- tions and have superior accuracy, the USMSTF now rec- ommends their use instead of gFOBT. In 19 clinical studies, the pooled sensitivity and specificity of FIT for colorectal cancer in average-risk patients were 79% and 94%, respectively. FIT testing is the preferred option for population-based screening in various European and Australian programs. In the United States, it is offered as the preferred option by many health care plans. For health care systems in which screening colonoscopy is readily available, FIT is a suitable option for patients seeking a noninvasive screening test who are willing to undertake annual fecal testing. The opti- mal interval (yearly or every 2 years) and number of stool samples (one or two) required for optimal FIT testing is as yet undetermined, but currently annual testing is recom- mended. Patients with a positive FIT test must undergo further evaluation with colonoscopy. 2. Multitarget DNA assay Stool DNA tests measure a variety of mutated genes and methylated gene markers from exfoliated tumor cells. A newer-generation assay (Cologuard) combines a fecal DNA panel with a FIT. In a prospective comparative trial conducted in persons at aver- age risk for colorectal cancer undergoing colonoscopy, the sensitivity for colorectal cancer for Cologuard was 92.3% vs 73.8% for FIT alone and the sensitivity for adenomas larger than 1 cm or serrated polyps for Cologuard was 42.4% vs 23.8% for FIT alone. A positive stool DNA test requires colonoscopy evaluation. Compared with FIT testing alone, FIT-fecal DNA testing has disadvantages including higher cost, lower specificity, lower cost-effectiveness, and cum- bersome requirements for stool collection and mailing.B.  Endoscopic Examinations of the Colon1.  Colonoscopy Colonoscopy permits examination of the entire colon. In addition to detecting early cancers, colo- noscopy allows removal of adenomatous polyps by biopsy or polypectomy, which is believed to reduce the risk of subsequent cancer. Over the past decade, there has been a dramatic increase in screening colonoscopy, with over 60% of US adults screened in the past 10 years. In asymptomatic individuals between 50 and 75 years of age undergoing screening colonoscopy, the prevalence of advanced colonic neoplasia is 411% and of colon cancer is 0.11%. Although colonoscopy is believed to be the most sensi- tive test for detecting adenomas and cancer, it has several disadvantages. Adequate visualization of the entire colonic mucosa requires thorough bowel cleansing the evening and morning prior to the examination. To alleviate discomfort during the procedure, intravenous sedation is used for most patients, necessitating a companion to transport the patient home post-procedure. Serious complications occur uncommonly; they include perforation (0.1%), bleeding (0.25%), and death (2.9/100,000). The skill of the operator has a major impact upon the quality of the colonoscopy examination. In several studies, the rate of colorectal cancer within 3 years of a screeningcolonoscopy was 0.70.9%, ie, approximately 1 in 110 patients. Population-based case-control and cohort studies suggest that colonoscopy is associated with greater reduc- tion in colorectal cancer incidence and mortality in the distal colon (80%) than the proximal colon (4060%). This may be attributable to incomplete examination of the proximal colon, and differences between the proximal and distal colon that include worse bowel preparation, subopti- mal colonoscopic technique, and a higher prevalence of serrated polyps and flat adenomas, which are more diffi- cult to identify than raised (sessile or pedunculated) polyps. To optimize diagnostic accuracy as well as patient safety and comfort, colonoscopy should be performed after optimal bowel preparation by a well-trained endoscopist who spends sufficient time (at least 7 minutes) carefully examining the colon (especially the proximal colon) while withdrawing the endoscope. 2. Flexible sigmoidoscopy Use of a 60-cm flexible sig- moidoscope permits visualization of the rectosigmoid and descending colon. Adenomatous polyps are identi- fied in 1020% and colorectal cancers in 1% of patients. The finding at sigmoidoscopy of an adenomatous polyp in the distal colon increases the likelihood at least twofold that an advanced neoplasm is present in the proximal colon. The chief disadvantage of screening with flexible sig- moidoscopy is that it requires some bowel cleansing, it may be associated with some discomfort (since intravenous sedation is not used), and it does not examine the proximal colon. The prevalence of proximal versus distal neoplasia is higher in persons older than age 65 years, in Blacks, and in women.C.  Radiographic and Other Imaging of the Colon1. CT colonograph y CT colonography requires a similar bowel cleansing regimen as colonoscopy as well as insuffla- tion of air into the colon through a rectal tube, which may be associated with discomfort. Using current imaging soft- ware with multidetector helical scanners, the sensitivity is greater than 95% for the detection of cancer and greater than 8492% for the detection of polyps 10 mm or larger. CT colonography is less sensitive than colonoscopy for the detection of polyps smaller than 1 cm, flat adenomas, and serrated polyps. The chief disadvantages of CT colonography are the need for a bowel preparation, limited availability in many health care systems, a possible increased risk of neoplasia due to radiation exposure, and the potential for finding incidental extracolonic findings that may lead to further evaluations. CT colonography is an excellent screening option in patients who do not wish to undergo or are unsuitable for colonoscopy and in patients in whom colo- noscopy could not be completed. 2. Capsule colonoscopy Imaging of the colon can be accomplished by oral ingestion of a capsule that captures video images of the colon. Compared with colonoscopy, the colon capsule has reduced sensitivity for polyps greater than 6 mm (64% vs 84%) and for colorectal cancers (74% vs 100%). At present, it is approved by the FDA forCMDT22_Ch39_p1612-p1675.indd  1651 02/07/21 2:44 PMChAPTER 391652 CMDT 2022evaluation  in patients who are not suitable candidates for colonoscopy or in whom colonoscopy could not evaluate the proximal colon. In addition to its suboptimal sensitivity for neoplasia, the main disadvantages of capsule colonos- copy are its cost, need for extensive bowel preparation, lack of reimbursement by most insurance carriers, and small risk of small bowel obstruction. When to Refer Patients with symptoms (change in bowel habits, hema- tochezia), signs (mass on abdominal examination or digital rectal examination), or laboratory tests (iron deficiency anemia) suggestive of colorectal neoplasia should be referred for colonoscopy. Patients with suspected colorectal cancer or adenoma- tous polyps of any size should be referred for colonoscopy. Virtually all patients with proven colorectal cancer should be referred to a surgeon for resection. Patients with clinical stage T3 or node-positive rectal tumors (or both) also should be referred to medical and radiation oncologists preoperatively for neoadjuvant therapy. Patients with stage II, III, or IV colorectal tumors should be referred to a medical oncologist. When to Admit Patients with complications of colorectal cancer (obstruction, acute bleeding) requiring urgent evalua- tion and intervention. Patients with advanced metastatic disease requiring palliative care.Biller LH et a l. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325:669. [PMID: 33591350] Ladabaum U et al. Strategies for colorectal cancer screening. Gastroenterology. 2020;158:418. [PMID: 31394083] National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Colon Cancer. Version 2.2021. 2021 Jan 21. https://www.nccn.org/professionals/physician_gls/ pdf/colon.pdf National Comprehensive Cancer Network. Clinical Practice Guide- lines in Oncology. Rectal Cancer. Version 1.2021. 2020 Dec 22. https://www.nccn.org/professionals/physician_gls/pdf/rectal. pdf National Institutes of Health. SEER Cancer Stat Facts: Colorectal Cancer, 2020. https://seer.cancer.gov/statfacts/html/colorect. html Petrelli F et al. Total neoadjuvant therapy in rectal cancer: a system- atic review and meta-analysis of treatment outcomes. Ann Surg. 2020;271:440. [PMID: 31318794] Ran T et al. Cost-effectiveness of colorectal cancer screening strategies: a systematic review. Clin Gastroenterol Hepatol. 2019; 17:1969. [PMID: 30659991] Stoffel EM et al. Epidemiology and mechanisms of the increasing incidence of colon and rectal cancers in young adults. Gastroen- terology. 2020;158:341. [PMID: 31394082] US Preventive Services Task Force. Colorectal Cancer: Screening 2021 May 18. https://www.uspreventiveservicestaskforce.org/ uspstf/recommendation/colorectal-cancer-screeningCARCINOMA OF THE ANUSThe an al canal is lined from its proximal to distal extent by columnar, transitional, and non-keratinized squamous epi- thelium, which merges at the anal verge with the keratin- ized perianal skin. Cancers arising from the mucosa of the anal canal are relatively rare, comprising only 12% of all cancers of the anus and large intestine. Squamous cancers make up the majority of anal cancers. Anal cancer is increased among people practicing receptive anal inter- course and those with a history of anorectal warts. In over 80% of cases, HPV may be detected, suggesting that this virus is a major causal factor. In a large controlled trial, HPV vaccination of healthy men (16 to 26 years old) who have sex with men decreased the incidence of anal intraepi- thelial neoplasia by 50%. Women with anal cancer are at increased risk for cervical cancer (which may be due to a field effect of oncogenic HPV infection) and require gyne- cologic screening and monitoring. Anal cancer is increased in HIV-infected individuals, possibly due to interaction with HPV . Nine-valent HPV (9vHPV) vaccine is recom- mended for boys and girls starting at age 11 or 12 and for individuals up to age 26 who have not been previously vac- cinated. Thereafter, shared clinical decision-making regard- ing HPV vaccination is recommended for some adults aged 27 through 45 years who are not adequately vaccinated. Bleeding, pain, and local mass are the most common symptoms. The lesion is often confused with hemorrhoids or other common anal disorders. These tumors tend to become annular, invade the sphincter, and spread upward via the lymphatics into the perirectal mesenteric lymphatic nodes. CT or MRI scans of the abdomen and pelvis are required to identify regional lymphadenopathy or meta- static disease at diagnosis. PET imaging may be used in conjunction. Treatment depends on the tumor location and histo- logic stage. Well-differentiated and small (less than 2 cm) superficial lesions of the perianal skin may be treated with wide local excision. Adenocarcinoma of the anal canal is treated in similar fashion to rectal cancer (see above), commonly by abdomi- noperineal resection with neoadjuvant chemoradiotherapy and adjuvant chemotherapy. The more common squa- mous cell cancer of the anal canal and large perianal tumors invading the sphincter or rectum are treated with combined-modality therapy that includes external radia- tion with simultaneous chemotherapy (5-fluorouracil plus mitomycin). Local control is achieved in approximately 80% of patients. Radical surgery (abdominoperineal resec- tion) is reserved for patients who fail chemotherapy and radiation therapy. Metastatic disease is generally treated with carboplatin and paclitaxel. The 5-year survival rate is 81% for localized tumors and approximately 30% for meta- static (stage IV) disease.Mahal  AR et al. An update to changing patterns of anal carci- noma in the United States. Am J Clin Oncol. 2020;42:887. [PMID: 31651454] National Cancer Institute. SEER Cancer Stat Facts: Anal Cancer, 2020. https://seer.cancer.gov/statfacts/html/anus.htmlCMDT22_Ch39_p1612-p1675.indd  1652 02/07/21 2:44 PMCANCER1653 CMDT 2022Na tional Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Anal Carcinoma. Version 2.2020. 2020 May 6. https://www.nccn.org/professionals/physician_ gls/pdf/anal.pdf Parwaiz I et al. A systematic review and meta-analysis of prog- nostic biomarkers in anal squamous cell carcinoma treated with primary chemoradiotherapy. Clin Oncol (R Coll Radiol). 2019;31:e1. [PMID: 31301958]CA NCERS OF ThE GENITOURINARY TRACT George R. Schade, MD PROSTATE CANCERE S S E N T I A L S  O F  D I A G N O S I S Prostatic induration on digital rectal examination (DRE) or elevation of PSA. Most often asymptomatic. Rarely: systemic symptoms (weight loss, bone pain). General ConsiderationsProsta te cancer is the most common noncutaneous cancer and the second leading cause of cancer-related death in American men with an estimated 191,930 new prostate cancer diagnoses and 33,330 prostate cancer deaths in 2020. The clinical incidence, however, does not match the prevalence of the disease. Autopsy studies have demon- strated that more than 40% of men over age 50 years have prostate cancer, and its prevalence increases with age with 30% of men aged 6069 years and 67% of men aged 8089 years harboring the disease at autopsy. Most of these occult cancers are small indolent organ-confined cancers with few representing regional or metastatic disease. Although the global prevalence of prostatic cancer at autopsy is relatively consistent, the clinical incidence varies consider- ably (high in North America and European countries, inter- mediate in South America, and low in the Far East). A 50-year-old American man has a lifetime risk of 40% for latent cancer, a 16% risk for developing clinically apparent cancer, and a 2.9% risk of death due to prostatic cancer. Black race, family history of prostatic cancer, and history of high dietary fat intake are risk factors for prostate cancer. Clinical FindingsA.  Symptoms and SignsPresen tly, most prostate cancers are asymptomatic and are diagnosed because of elevations in serum PSA. However, some men will be diagnosed based on discrete nodules or areas of induration within the prostate on a DRE. Obstruc- tive voiding symptoms are most often due to benign pros- tatic hyperplasia, which occurs in the same age group. Nevertheless, large or locally extensive prostatic cancers can cause obstructive voiding symptoms, including urinaryretention. Lymph node metastases can lead to lower extremity lymphedema. Because the axial skeleton is the most common site of metastases, patients may present with back pain, pathologic fractures, or rarely neurologic symp- toms from epidural metastases and cord compression.B.  Laboratory Findings1.  Serum tumor markers PSA is a glycoprotein produced only by prostatic cells, either benign or malignant. The serum level is typically low and correlates with the total volume of prostate tissue and tends to increase with age. Measurement of serum PSA is useful in detecting and stag- ing prostate cancer, monitoring response to treatment, and identifying recurrence before it becomes clinically evident. As a screening test, PSA is elevated (greater than 4.0 ng/mL [4.0 mcg/L]) in 1015% of men. Prostate cancer will be diagnosed in approximately 1830% of men with PSA 4.110 ng/mL (4.110 mcg/L) and 5070% of men with PSA greater than 10 ng/mL (10 mcg/L). However, no PSA threshold excludes the diagnosis of prostate cancer. In untreated patients with prostate cancer, the level of PSA correlates with the volume and stage of disease. Patients with PSA levels less than 10 ng/mL (10 mcg/L) usually have localized and therefore potentially curable cancers, while those with PSA levels in excess of 40 ng/mL (40 mcg/L) are more likely to have advanced disease (semi- nal vesicle invasion, lymph node involvement, or occult distant metastases). Approximately 98% of patients with metastatic prostate cancer will have an elevated PSA level. However, there are rare cancers that are localized despite substantial elevations in PSA. Therefore, initial treatment decisions cannot be made on the basis of PSA testing alone. A rising PSA after therapy is usually consistent with pro- gressive disease, either locally recurrent or metastatic. 2. Miscellaneous laboratory testing Patients with uri- nary retention or with ureteral obstruction due to loco- regionally advanced prostate cancers may present with elevations in blood urea nitrogen or serum creatinine. Patients with bony metastases may have elevations in serum alkaline phosphatase or calcium. Laboratory and clinical evidence of disseminated intravascular coagulation can occur in patients with advanced prostate cancers. 3. Prostate biopsy Transrectal ultrasound-guided biopsy is the standard method for detection of prostate cancer. The use of a spring-loaded, 18-gauge biopsy needle has allowed transrectal biopsy to be performed with minimal patient discomfort and morbidity. Local anesthesia is standard and increases the tolerability of the procedure. The specimen preserves glandular architecture and permits accurate grad- ing. Prostate biopsy specimens are taken from the apex, mid-portion, and base in men who have an abnormal DRE or an elevated serum PSA, or both. Extended-pattern biop- sies, including a total of at least 10 biopsies, are associated with improved cancer detection and risk stratification of patients with newly diagnosed disease. In addition, suspi- cious hypoechoic prostatic lesions seen on transrectal ultra- sound may be targeted for biopsy. Patients with abnormalities of the seminal vesicles can have these struc- tures specifically biopsied to identify local tumor invasion.CMDT22_Ch39_p1612-p1675.indd  1653 02/07/21 2:44 PMChAPTER 391654 CMDT 2022C.  ImagingU se of imaging for staging should be tailored to the likeli- hood of advanced disease in newly diagnosed cases. CTof the abdomen and pelvis and radionuclide (99-techne- tium) bone scans are generally the first-line staging studies performed, when indicated, to assess for nodal and bony metastases, respectively. MRI allows for evaluation of the prostate as well as regional lymph nodes. The positive predictive value for detec- tion of both capsular penetration and seminal vesicle invasion is similar for transrectal ultrasound and MRI, although newer multi-parametric MRI techniques may better stage patients considering treatment or, alternatively, active surveillance. Additionally, there is a growing role for multi-parametric MRI in prostate cancer diagnosis, particularly among men with previous negative prostate biopsies, to evaluate for suspi- cious prostatic lesions. Such lesions may then be sampled via MRI-guided needle biopsy or via MR Fusion (in which pros- tate MRI images are fused in real-time with images from an ultrasound-guided needle biopsy). Such an approach may improve not only overall cancer detection but discovery of clinically relevant disease, and its use in routine clinical prac- tice has increased and continues to evolve. Conventional radionuclide (99-technetium) bone scans are superior to conventional plain skeletal radio- graphs in detecting bony metastases. Prostate cancer bony metastases tend to be multiple and most commonly occur in the axial skeleton. Men with more advanced local lesions, symptoms of metastases (eg, bone pain), high- grade disease, or elevations in PSA greater than 20 ng/mL (20 mcg/L) should undergo radionuclide bone scan. PET (eg,18F-sodium fluoride [18F-NaF] PET ) and18F-NaF PET/CT hybrid imaging are more sensitive than con- ventional bone scans. However, a high frequency of abnormal scans with18F-NaF PET/CT resulting from degenerative joint disease has limited their usefulness. Fluciclovine (Axumin) PET imaging has been approved for suspected cancer recurrence based on elevated PSA after prior treatment. PSMA (prostate-specific membrane antigen) PET, using small-molecule radiotracers target- ing PSMA (eg,18F-DCFBC [N-[N-[(S)-1,3-dicarboxypro- pyl]carbamoyl]-4-18F-fluorobenzyl-L-cysteine]) has shown significant promise as a next-generation imaging method and may replace traditional imaging modalities in the future. Despite application of modern, sophisticated tech- niques, understaging of prostate cancer occurs in at least 20% of patients.D . Genetic TestingThe role of gene tics in prostate cancer diagnosis and man- agement is evolving. A family history of prostate cancer increases the risk of prostate cancer. Additionally, prostate cancer has been associated with several hereditary cancer syndromes (eg, Lynch syndrome, hereditary breast and ovarian cancer syndrome, etc.) with approximately 11% of prostate cancer patients with at least one additional primary cancer carrying germline mutations. Consequently, some patients with prostate cancer and their families may haveelevated risk for other cancers. Further, data suggest that some germline mutations, such as BRCA1/2 , are associated with lower PSA at diagnosis and increased risk of progres- sion and death; approximately 12% of patients with metastatic prostate cancer have germline mutations in homologous DNA repair genes. Finally, germline mutations in DNA repair genes can have implications for treatment and, as a result, play a role in personalized treatment. Patients with prostate cancer should have a thorough review of their family history and those with a concerning family history should be referred for genetic counselling and possible testing. Additionally, patients with high-risk disease or metastatic disease should undergo genetic evalu- ation as well. Screening for Prostate CancerThe  impact of prostate cancer screening on mortality remains controversial. The screening tests currently avail- able include DRE, PSA testing, and transrectal ultrasound. Prostate cancer detection rates using DRE alone vary from 1.5% to 7%, but unfortunately, most of these cancers are advanced (stage T3 or greater). Transrectal ultrasound should not be used as a first-line screening tool due to its expense, low specificity, and minimal improvement in detec- tion rate versus the combined use of DRE and PSA testing. PSA testing increases the detection rate of prostate can- cers compared with DRE. Approximately 22.5% of men older than 50 years of age will be found to have prostate cancer using PSA testing compared with a rate of approxi- mately 1.5% using DRE alone. The sensitivity, specificity, and positive predictive value of PSA and DRE are listed in Table 397. PSA-detected cancers are more likely to be localized compared with those detected by DRE alone. The Prostate Cancer Prevention Trial provided data demon- strating a significant risk of prostate cancer even in men with PSA less than 4.0 ng/mL (4.0 mcg/L) (Table 398) and a web-based calculator has been developed to estimate the risk of harboring both prostate cancer and high-grade cancer (http://riskcalc.org/PBCG). Table 397. Screening for prostatic cancer: test performance.T est Sensitivity SpecificityPositive Pre- dictive Value Abnormal PSA (> 4 ng/mL [mcg/L])0.67 0.97 0.43 Abnormal DRE 0.50 0.94 0.24 Abnormal PSA or DRE0.84 0.92 0.28 Abnormal PSA and DRE0.34 0.995 0.49 DRE, digital rectal examination; PSA, prostate-specific antigen. Modified, with permission, from Kramer BS et al. Prostate cancer screening: what we know and what we need to know. Ann Intern Med. 1993;119:914. Copyright  1993 American College of Physicians. All rights reserved.CMDT22_Ch39_p1612-p1675.indd  1654 02/07/21 2:44 PMCANCER1655 CMDT 2022T o improve the performance of PSA as a screening test, several investigators have developed alternative methods for its use. These include establishment of age- and race- specific reference ranges, measurement of free serum and protein-bound levels of PSA ( percent free PSA ), and cal- culation of changes in PSA over time ( PSA velocity ). Gen- erally, men with PSA free fractions exceeding 25% are unlikely to have prostate cancer, whereas those with free fractions less than 10% have an approximately 50% chance of having prostate cancer. Newer tests, including the Pros- tate Health Index (PHI) and 4kscore (https://4kscore.com), may better identify not only men at greater risk for prostate cancer but those with more aggressive disease. The frequency of PSA testing also remains a matter of debate. The traditional yearly screening approach may not be the most efficient; rather, earlier PSA testing at younger age may allow less frequent testing later as well as provide information regarding PSA velocity. Men with PSA above the age-based median when tested between 40 and 60 years are at significantly increased risk for subsequent cancer detection over 25 years. Men aged 4050 with PSA below 0.6 ng/mL (0.6 mcg/L) and aged 5060 with PSA below 0.71 ng/mL (0.71 mcg/L) may require less frequent PSA tests. In addition, men with PSA velocity greater than 0.35 ng/mL (0.35 mcg/L) per year measured 1015 years before diagnosis had significantly worse cancer-specific survival compared with those with lower PSA velocity. The NCCN guidelines (https://www.nccn.org/professionals/physician_ gls/f_guidelines.asp) for prostate cancer early detection incorporate many of these factors. The European Associa- tion of Urology (EAU) recommends offering PSA screening to men beginning at age 4050 years, dependent on risk factors, and subsequently initiating a risk-adapted strategy. Two large, randomized trials have evaluated the benefit of PSA screening for early detection of prostate cancer. In the US Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, no mortality benefit was observed after combined screening with PSA testing and DRE dur- ing 15-year follow-up. Although screening resulted in a 12% increase in prostate cancer detection, the cancer-specific mortality rate was similar in the screening and controlarms (2.55 and 2.44 deaths per 10,000 person-years, respectively). However, an estimated 86% of control patients received at least one screening PSA test and 46% of control patients received yearly PSA screening during the trial. Conversely, the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial demonstrated a significant 20% reduction in prostate cancer mortality with an absolute reduction of 1.75 deaths per 1000 men screened at 16 years. The number of men needed to be invited for screening to prevent one prostate cancer death was 570 at 16 years compared with 742 at 13 years, while the number of prostate cancers needing to be diagnosed to prevent one prostate cancer death was reduced from 26 to 18, underscoring the importance of adequate long-term follow-up for prostate cancer. In 2018, the USPSTF issued a revised (Grade C) recom- mendation for men aged 55 to 69 years that the decision to undergo periodic PSAbased screening should be an indi- vidual one. Before deciding about screening, men should discuss its potential benefits and harms with their clinician, incorporating their own values and preferences in the deci- sion. The revised recommendation acknowledges that, while screening offers some men a small potential benefit of reducing the chance of dying from prostate cancer, many other men will experience potential harms from screening. These include false-positive results that require additional testing and possible prostate biopsy; overdiagnosis and overtreatment; and treatment complications, such as incontinence and erectile dysfunction. In determining whether screening is appropriate in individual cases, the individual patients family history, race/ethnicity, comorbid medical conditions, values about the benefits and harms of screening and treatment-specific outcomes, and other health needs should be considered. Clinicians should not screen men who do not express a preference for screening. For men age 70 years and older, the USPSTF recommends against PSA-based screening (Grade D recommendation). StagingThe  majority of prostate cancers are adenocarcinomas. Most arise in the peripheral zone of the prostate, though a small percentage arise in the central (510%) and transi- tion zones (20%) of the gland. Pathologists utilize the Gleason grading system whereby a primary grade is applied to the architectural pattern of malignant glands occupying the largest area of the specimen and a second- ary grade is assigned to the next largest area of cancer. Grading is based on architectural rather than histologic criteria, and five grades are possible. Adding the score of the primary and secondary grades gives a Gleason score from 2 to 10. Gleason score correlates with tumor volume, pathologic stage, and prognosis. A simplified five-grade group system has been introduced by the International Society of Urological Pathologists. TreatmentA.  General MeasuresThe  optimal management of localized prostate cancer remains controversial owing to the plethora of treatmentTable 398. Risk of prostate cancer in men with PSA  4.0 ng/mL (or mcg/L).PSA  Level (ng/mL [or mcg/L])Percentage wit Prostate CancerPercentage wit hig-Grade1 Prostate Cancer  0.5 6.6 12.5 0.61.0 10.1 10.0 1.12.0 17.0 11.8 2.13.0 23.9 19.1 3.14.0 26.9 25.01 High-grade cancer was defined as Gleason score  7. Data from Thompson IM et al. Prevalence of prostate cancer among men with a prostate-specific antigen level  4.0 ng per milliliter. N Engl J Med. 2004;350:2239.CMDT22_Ch39_p1612-p1675.indd  1655 02/07/21 2:44 PMChAPTER 391656 CMDT 2022optio ns, side effects of the various options, and indolent nature of many prostate cancers. These factors have contrib- uted to uncertainty regarding a definitive survival benefit of treating localized prostate cancer. To help guide treatment decision making, patients are risk stratified according to their PSA level at diagnosis, DRE, and prostate cancer grade (Gleason score). Additionally, patients should have an assessment of life expectancy prior to treatment decision- making since all patients with low-risk disease and many with intermediate-risk disease with less than 10-year life expectancy will not benefit from treatment.B.  Active SurveillanceThe g oal of active surveillance is to avoid treatment in men who may never require it while recognizing and definitively treating men harboring higher-risk disease in order to bal- ance cancer risk with the morbidity of treatment. Treatment decisions are made based on stage, PSA, and cancer grade (Gleason score) as well as the age and health of the patient. Active surveillance alone may be effective management for appropriately selected patients, typically those with low PSA, small volume, well-differentiated cancers, and life expectancy less than 1015 years. For such patients, active surveillance involves serial PSA levels, DREs, and periodic prostate biopsies to reassess grade and extent of cancer. Endpoints for intervention in patients on active surveil- lance, particularly PSA changes, have not been clearly defined and surveillance regimens remain an active area of research. Nonetheless, they are increasingly accepted by patients and clinicians with contemporary series demon- strating freedom from definitive treatment in greater than half of patients at 5 years, and risk of developing metastases and suffering cancer-specific death in less than 3% and 2%, respectively, at 10 years. Active surveillance, which is distin- guished from mere observation (watchful waiting), is fea- tured prominently in the NCCN and EAU guidelines and is the preferred management in most men with very low risk prostate cancer. This approach is increasingly accepted and incorporated in routine clinical practice.C.  Radical ProstatectomyDuring  radical prostatectomy, the seminal vesicles, prostate, and ampullae of the vas deferens are removed. Refinements in technique have allowed preservation of urinary conti- nence in most patients and erectile function in selected patients. Radical prostatectomy can be performed via open retropubic, transperineal, or laparoscopic (with or without robotic assistance) surgery. Local recurrence is uncommon after radical prostatectomy and related to pathologic stage. Organ-confined cancers rarely recur; however, cancers with adverse pathologic features (capsular penetration, seminal vesicle invasion) are associated with higher local (1025%) and distant (2050%) relapse rates. Ideal candidates for radical prostatectomy include healthy patients with stages T1 and T2 prostate cancers. Patients with advanced local tumors (T4) or lymph node metastases are rarely candidates for prostatectomy alone, although surgery is sometimes used in combination with hormonal therapy and postoperative radiation therapy for select high-risk patients.D. Radiation TherapyRadiatio n can be delivered by a variety of techniques to the prostate and, when clinically indicated, to the pelvic lymph nodes. Conformal techniques, including three-dimensional conformal radiation, intensity modulated radiotherapy, and image-guided radiotherapy, have become the standard of care for external photon-based radiotherapy, while proton beam therapy has gained acceptance as an alternative exter- nal beam therapy that theoretically may reduce toxicities. Additionally, hypofractionated and ultra-hypofractionated (ie, stereotactic radiotherapy) regimens have shown prom- ising short- and intermediate-term outcomes vs conven- tionally dosed regimens. Brachytherapythe implantation of permanent or temporary radioactive sources (palladium, iodine, or iridium) into the prostatecan be used as mono- therapy in those with low-grade or low-volume malignan- cies or combined with external beam radiation in patients with higher-grade or higher-volume disease. The PSA may rise after brachytherapy because of prostate inflammation and necrosis. This transient elevation (PSA bounce) should not be mistaken for recurrence and may occur up to 20 months after treatment. Patients with intermediate- and high-risk disease benefit from concomitant androgen deprivation therapy. As with surgery, the likelihood of local failure fol- lowing radiation correlates with technique and cancer char- acteristics. The likelihood of a positive prostate biopsy more than 18 months after radiation varies between 20% and 60%. Patients with local recurrence are at an increased risk of cancer progression and cancer death compared with those who have negative biopsies. Survival of patients with localized cancers (T1, T2, and selected T3) approaches 65% at 10 years. Ambiguous target definitions, inadequate radia- tion doses, and understaging of the cancer may be respon- sible for the failure noted in some series.E.  Focal TherapyT o reduce the morbidity of localized prostate cancer treat- ment, there has been a growing interest in focal therapy. Focal therapy delivers energy to the prostate, destroying the tumor(s) and a margin of normal prostate tissue while avoiding collateral damage to the neurovascular bundles, external urinary sphincter, bladder, and rectum. To date, several energy sources (cryotherapy, high intensity focused ultrasound, lasers, etc) have been evaluated and several others are under development. The multifocal nature and the difficulty of localizing the prostate cancer with contem- porary imaging techniques combined with the prolonged disease course, lack of clearly defined endpoints, and ran- domized prospective data have limited the widespread adoption of focal therapies as well as a clear understanding of which are the ideal candidates.F . Localized DiseaseAlthough  selected patients may be candidates for active surveillance based on age or health and evidence of small- volume or well-differentiated cancers, most men with an anticipated life expectancy of longer than 10 years should be considered for treatment. Newly introduced genomic tests may provide important information to help guideCMDT22_Ch39_p1612-p1675.indd  1656 02/07/21 2:44 PMCANCER1657 CMDT 2022tr eatment decisions. Both radiation therapy and radical pros- tatectomy result in acceptable levels of local control. A large, prospective, randomized trial compared watchful waiting with radical prostatectomy in 695 men with clinically local- ized and well-differentiated to moderately differentiated cancers. Radical prostatectomy significantly reduced disease- specific mortality, overall mortality, and risks of metastasis and local progression. The relative reduction in the risk of death at 23 years was 0.56 in the prostatectomy group, with the number needed to treat to avert one death (NNT) = 8 patients; the benefit was largest in men younger than age 65 years (relative risk [RR] = 0.45) and with intermediate- risk prostate cancer (RR = 0.38). Surgery also reduced the risk of metastases in older men (RR = 0.68).G.  Locally and Regionally Advanced DiseasePa tients with advanced pathologic stage or positive surgical margins are at an increased risk for local and distant tumor relapse. Due to these risks, such patients have been consid- ered for adjuvant therapy (radiation for positive margins and seminal vesicle invasion or androgen deprivation and/ or radiation for lymph node metastases). Two randomized clinical trials (EORTC 22911 and SWOG 8794) demon- strated improved progression-free and metastasis-free sur- vival with early radiotherapy in these men, and subsequent analysis of SWOG 8794 showed improved overall survival in men receiving adjuvant radiation therapy. However, the publication of two trials comparing adjuvant radiotherapy with early-salvage therapy using contemporary radiother- apy techniques (GETUG-AFU17 and RAVES) demon- strated no difference in 5-year biochemical progression-free survival casting doubt on the benefit of adjuvant radio- therapy in the contemporary era.H.  Metastatic DiseaseSince death due to prosta te carcinoma is almost invariably the result of failure to control metastatic disease, research has emphasized efforts to improve control of distant dis- ease. Most prostate carcinomas are hormone dependent and approximately 7080% of men with metastatic prostate carcinoma will respond to various forms of androgen deprivation. Androgen deprivation therapy may be effec- tive at several levels along the pituitarygonadal axis using a variety of methods or agents (Table 399). Use of lutein- izing hormone-releasing hormone (LHRH) agonists (leup- rolide, goserelin) achieves medical castration without orchiectomy and is the most common method of reducing testosterone levels. A single LHRH antagonist (degarelix) is FDA approved and has no short-term testosterone flare associated with LHRH agonists. Because of its rapid onset of action, ketoconazole should be considered in patients with advanced prostate cancer who present with spinal cord compression, bilateral ureteral obstruction, or dis- seminated intravascular coagulation. Although testoster- one is the major circulating androgen, the adrenal gland secretes the androgens dehydroepiandrosterone, dehy- droepiandrosterone sulfate, and androstenedione. This led to the development of abiraterone acetate (an inhibi- tor of CYP17, a key enzyme in androgen synthesis) to block both testicular and adrenal androgens. Nonsteroidalantiandrogen agents act by competitively binding the receptor for dihydrotestosterone, the intracellular andro- gen responsible for prostate cell growth and development. In addition to immediate side effects of androgen depriva- tion (sexual dysfunction and hot flashes), the chronic sup- pression of testosterone leads to osteoporosis and risk of fractures, cardiovascular disease and diabetes mellitus, and decreased muscle and increased fat. Bisphosphonates can prevent osteoporosis associated with androgen depriva- tion, decrease bone pain from metastases, and reduce skeletal-related events. Denosumab , a RANK ligand inhib- itor, is approved for the prevention of skeletal-related events in patients with bone metastases from prostate cancer and also appears to delay the development of these metastases in patients with castration-resistant prostate cancer. In addition, enzalutamide definitively improves metastasis-free survival in men with nonmetastatic castrate- resistant prostate cancer and rapidly rising PSAs. The management of advanced prostate cancer is rapidly evolving. Contemporary management consists of initiating androgen deprivation therapy with orchiectomy, LHRH agonist, or LHRH antagonist. A meta-analysis compared using an LHRH agonist or orchiectomy alone with an LHRH agonist or orchiectomy plus an antiandrogen agent; results showed little benefit of combination therapy. However, patients at risk for disease-related symptoms (bone pain, obstructive voiding symptoms) should receive concurrent antiandrogens due to the initial elevation of serum testoster- one that accompanies LHRH agonists. For patients with elevated PSAs only (indicating recurrent, but nonmetastatic, cancer), nonsteroidal antiandrogen agents may be useful. Further androgen manipulations, initiation of cytotoxic chemotherapy, and local therapy (eg, radiation) is defined by the cancers androgen sensitivity status. For patients with hormone-sensitive metastatic prostate cancer, the addition of systemic cytotoxic chemotherapy with docetaxol to androgen deprivation therapy results in improved survival compared to androgen deprivation therapy alone. Similarly, the addition, of abiraterone acetate plus prednisone to androgen deprivation therapy, results in superior survival compared to androgen deprivation therapy alone. Patients with castrate-resistant disease or prostate can- cer that demonstrates rising PSA or progression of disease despite castrate levels of serum testosterone (less than 50 ng/dL) should continue their LHRH agonist/antagonist regimen. Additional treatment options are stratified based on the presence of metastatic disease. Patients with non- metastatic castrate-resistant disease and long PSA doubling time (longer than10 months) can simply be observed due to their relatively indolent disease. Conversely, nonmeta- static castrate-resistant patients with short doubling times (10 months or less) have demonstrated improved metastasis- free survival with the addition of the potent nonsteroidal androgen receptor antagonists enzalutamide ,apalu- tamide , and darolutamide to androgen deprivation therapy. For patients with metastatic castrate-resistant prostate cancer, docetaxol was the first cytotoxic chemo- therapy agent to improve survival. Enzalutamide and abiraterone improve overall survival in men with meta- static castrate prostate cancer in both the docetaxol nave and non-nave setting. Cabazitaxel is a second-line taxaneCMDT22_Ch39_p1612-p1675.indd  1657 02/07/21 2:44 PMChAPTER 391658 CMDT 2022chemothera py that improves overall survival in men who have received docetaxel. Sipuleucel-T, an autologous cel- lular immunotherapy, is FDA approved in asymptomatic or minimally symptomatic men with metastatic castration- resistant prostate cancer. Radium-223 dichloride is approved for the treatment of men with castration-resistant, symptomatic bone metastases, with significant improve- ments in both overall survival and time to skeletal-related events (eg, fractures and spinal cord compression). Finally, patients who have undergone a genetics evaluation and are found to have specific germline or somatic mutations may benefit from personalized treatment strategies. PrognosisTh e likelihood of success of active surveillance or treatment can be predicted using risk assessment tools that usuallyTable 399. Androgen deprivation for prostatic cancer.Lev el Agent Dose Sequelae Pituitary, hypothalamus Diethylstilbestrol 13 mg orally daily Gynecomastia, hot flushes, thromboembolic disease, erectile dysfunction LhRh agonists Leuprolide Goserelin Triptorelin HistrelinDaily subcutaneous injection Monthly to quarterly depot injection Monthly depot injection Annual subcutaneous implantErectile dysfunction, hot flushes, gynecomastia, rarely anemia LhRh antagonist Degarelix 240 mg subcutaneously initial dose, then 80 mg subcutaneously monthlyHot flushes, weight gain, erectile dysfunction, increased liver tests Adrenal Ketoconazole 400 mg three times orally daily Adrenal insufficiency, nausea, rash, ataxia Aminoglutethimide 250 mg four times orally daily Adrenal insufficiency, nausea, rash, ataxia Corticosteroid Prednisone 2040 mg orally daily Gastrointestinal bleeding, fluid retention CYP17a1 inibitor Abiraterone 1000 mg orally daily (with predni- sone 5 mg orally twice daily)Weight gain, fluid retention, hypokalemia, hypertension Testis Orchiectomy  Gynecomastia, hot flushes, erectile dysfunction Prostate cell Antiandrogens Flutamide 250 mg three times orally daily No erectile dysfunction when used alone; nausea, diarrhea Bicalutamide 50 mg orally daily Liver, cardiac, and pulmonary toxicity Enzalutamide 160 mg orally daily Seizures, dizziness, asthenia Apalutamide 240 mg orally daily Fatigue, leukopenia, hyperlipidemia, hyperglycemia, hyperkalemia, seizures (rare) Doralutamide 600 mg orally twice daily Fatigue, extremity pain, rash Cytotoxic cemotera- peutic agentsBone marrow, skin, pulmonary, cardiac, gastrointestinal, hepatic toxicities possible Docetaxel 75 mg/m2intravenously once on day 1 of 21-day cycle (with prednisone 10 mg orally daily) Cabazitaxel 20 mg/m2intravenously once on day 1 of 21-day cycle (with prednisone 10 mg orally daily) LHRH, luteinizing hormone-releasing hormone.co mbine stage, grade, PSA level, and number and extent of positive prostate biopsies. Several web-based tools are avail- able (eg, https://www.mskcc.org/nomograms/prostate). Widely used nomograms include the Kattan nomogram and theCAPRA nomogram. CAPRA uses serum PSA, Gleason score, clinical stage, percent positive biopsies, and patient age in a point system to risk stratify and predict the likelihood of PSA recurrence 3 and 5 years after radical prostatectomy (Tables 3910 and 3911) as well as metastasis and prostate cancer-specific and overall survival. The CAPRA nomogram has been validated on large multicenter and international radical prostatectomy and radiation-treated cohorts. The patterns of prostate cancer progression have been well defined. Small and well-differentiated cancers (Gleason grade 3) are usually confined within the prostate, whereas large-volume (greater than 4 mL) or poorly differentiatedCMDT22_Ch39_p1612-p1675.indd  1658 02/07/21 2:44 PMCANCER1659 CMDT 2022T able 3911. CAPRA: Probability of freedom from PSA recurrence after radical prostatectomy by CAPRA point total.CA PRA Score3-Year Recurrence-Free Survival (%) (95% CI)5-Year Recurrence-Free Survival (%) (95% CI) 01 91 (8595) 85 (7392) 2 89 (8394) 81 (6989) 3 81 (7387) 66 (5476) 4 81 (6989) 59 (4074) 5 69 (5182) 60 (3777) 6 54 (2775) 34 (1257) 7+ 24 (943) 8 (028) PSA, prostate-specific antigen. Source: https://urology.ucsf.edu/research/cancer/prostate-cancer- risk-assessment-and-the-ucsf-capra-score.Table 3910. The UCSF Cancer of the Prostate Risk Assessment (CAPRA).V ariable Level Points PSA (ng/mL [or mcg/L]) at diagnosis 06 0 6.110 1 10.120 2 20.130 3 > 30 4 Gleason grade, primary/secondary 13/13 0 13/45 1 45/15 3 T stage T1 or T2 0 T3a 1 % positive biopsies (biopsy cores posi- tive divided by the number of biop- sies obtained)< 34% 0  34% 1 Age < 50 years 0  50 years 1 Source: https://urology.ucsf.edu/research/cancer/prostate- cancer-risk-assessment-and-the-ucsf-capra-score.(G leason grades 4 and 5) cancers are more often locally exten- sive or metastatic to regional lymph nodes or bone. Penetra- tion of the prostate capsule by cancer is common and occurs along perineural spaces. Seminal vesicle invasion is associ- ated with a high likelihood of regional or distant disease and disease recurrence. The most common sites of lymph node metastases are the obturator and internal iliac lymph node chains and of distant metastases, the axial skeleton.When to Refer Refer all patients to a urologist for management of localized disease or for active surveillance. For metastatic disease, medical oncology should be consulted for consideration of systemic treatments. Active surveillance may be appropriate in selected patients with very low-volume, low-grade prostate cancer. Localized disease may be managed by active surveil- lance, surgery, or radiation therapy. Locally extensive, regionally advanced, and metastatic disease often require multimodal treatment strategies.Bill-Ax elson A et al. Radical prostatectomy or watchful waiting in prostate cancer29-year follow-up. N Engl J Med. 2018;379: 2319. [PMID: 30575473] Gourd E. New advances in prostate cancer screening and moni- toring. Lancet Oncol. 2020;21:887. [PMID: 32534632] Hoffman KE et al. Patient-reported outcomes through 5 years for active surveillance, surgery, brachytherapy, or external beam radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA. 2020;323:149. [PMID: 31935027] Hugosson J et al; ERSPC investigators. A 16-yr follow-up of the European Randomized Study of Screening for Prostate Cancer. Eur Urol. 2019;76:43. [PMID: 30824296] Hussain M et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018; 378:2465. [PMID: 29949494] Kneebone A et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ ANZUP RAVES): a randomised, controlled, phase 3, non- inferiority trial. Lancet Oncol. 2020;21:1331. [PMID: 33002437] Parker CC et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a ran- domised controlled phase 3 trial. Lancet. 2018;392:2353. [PMID: 30355464] Sargos P et al. Adjuvant radiotherapy versus early salvage radio- therapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol. 2020;21:1341. [PMID: 33002438] Shoag JE et al. Reconsidering the trade-offs of prostate cancer screening. N Engl J Med. 2020;382:2465. [PMID: 32558473]BL ADDER CANCERE S S E N T I A L S  O F  D I A G N O S I S Gross or microscopic hematuria. Irritative voiding symptoms. Positive urinary cytology in most patients. Filling defect within bladder noted on imaging. General ConsiderationsBladder  cancer is the second most common urologic can- cer; it occurs more commonly in men than women (3.1:1), and the mean age at diagnosis is 73 years. Cigarette smok- ing and exposure to industrial dyes or solvents are risk factors for the disease and account for approximately 60%CMDT22_Ch39_p1612-p1675.indd  1659 02/07/21 2:44 PMChAPTER 391660 CMDT 2022and  15% of new cases, respectively. In the United States, almost all primary bladder cancers (98%) are epithelial malignancies, usually urothelial cell carcinomas (90%). Adenocarcinomas and squamous cell cancers account for approximately 2% and 7%, respectively. The latter is often associated with schistosomiasis, vesical calculi, or pro- longed catheter use. Clinical FindingsA.  Symptoms and SignsH ematuriagross or microscopic, chronic or intermittent is the presenting symptom in 8590% of patients with bladder cancer. Irritative voiding symptoms (urinary fre- quency and urgency) occur in a small percentage of patients as a result of the location or size of the cancer. Most patients with bladder cancer do not have signs of the disease because of its superficial nature. Abdominal masses detected on bimanual examination may be present in patients with large-volume or deeply infiltrating cancers. Hepatomegaly or palpable lymphadenopathy may be pres- ent in patients with metastatic disease, and lymphedema of the lower extremities results from locally advanced cancers or metastases to pelvic lymph nodes.B.  Laboratory FindingsU rinalysis reveals microscopic or gross hematuria in the majority of cases. On occasion, hematuria is accompanied by pyuria. Azotemia may be present in a small number of cases associated with ureteral obstruction. Anemia may occasionally be due to chronic blood loss or to bone mar- row metastases. Exfoliated cells from normal and abnormal urothelium can be readily detected in voided urine speci- mens. Cytology can be useful to detect the disease initially or to detect its recurrence. Cytology is sensitive in detect- ing cancers of higher grade and stage (8090%), but less so in detecting superficial or well-differentiated lesions (50%). There are numerous urinary tumor markers under investi- gation for screening or assessing recurrence, progression, prognosis, or response to therapy.C.  ImagingBladder  cancers may be identified as masses within the bladder using ultrasound, CT, or MRI. However, the pres- ence of cancer is confirmed by cystoscopy and biopsy, with imaging primarily used to evaluate the upper urinary tract and to stage more advanced lesions.D . Cystourethroscopy and BiopsyThe  diagnosis and staging of bladder cancers are made by cystoscopy and transurethral resection. If cystoscopy usually performed under local anesthesiaconfirms the presence of a bladder tumor, the patient is scheduled for transurethral resection under general or regional anesthe- sia. Random bladder and transurethral prostate biopsies are occasionally performed to detect occult disease and potentially identify patients at greater risk for cancer recur- rence and progression.Pathology & StagingGrading  is based on cellular features: size, pleomorphism, mitotic rate, and hyperchromatism. Bladder cancer staging is based on the extent (depth) of bladder wall penetration and the presence of regional or distant metastases. Both cancer grade and stage influence the natural history of bladder cancer including local recurrence within the blad- der and progression to higher-stage disease. TreatmentPa tients with superficial nonmuscle invasive cancers (Tis, Ta, T1) are treated with complete transurethral resection with selective use of a single dose intravesical chemother- apy immediately following resection. The subset of patients with carcinoma in situ (Tis) and those undergoing resec- tion of large, high-grade, recurrent Ta lesions or T1 cancers (or both) are good candidates for additional intravesical therapy. Patients with muscle invasive (T2+) but still localized cancers are at risk for both nodal metastases and progres- sion and require more aggressive treatment. The gold standard treatment is neoadjuvant chemotherapy followed by radical cystectomy, which confers a survival advantage versus cystectomy alone. This is particularly important for higher-stage or bulky tumors to improve their surgical resectability. Trimodal bladder preservation therapy con- sisting of complete transurethral resection, sensitizing sys- temic chemotherapy, and external beam radiotherapy can offer similar outcomes in optimally selected patients.A.  Intravesical TherapyImm unotherapeutic or chemotherapeutic agents delivered directly into the bladder via a urethral catheter can reduce the likelihood of recurrence in those who have undergone complete transurethral resection. Most agents are adminis- tered weekly for 612 weeks. Efficacy may be increased by prolonging contact time to 2 hours. The use of main- tenance therapy after the initial induction regimen is beneficial. Common agents include gemcitabine, mito- mycin, doxorubicin, valrubicin, and bacillus Calmette Gurin (BCG), with the last being the only agent effective in reducing disease progression. Side effects of intravesical chemotherapy include irritative voiding symptoms and hemorrhagic cystitis. Patients in whom symptoms or infection develop from BCG may require antituberculous therapy.B.  Surgical TreatmentAlthough  transurethral resection is the initial form of treatment for all bladder tumors (since it is diagnostic, allows for proper staging, and controls superficial cancers), muscle-invasive cancers require more aggressive treat- ment. Partial cystectomy can be considered in selected patients with solitary lesions at the bladder dome or those with cancer in a bladder diverticulum. Radical cystectomy in men entails removal of the bladder, prostate, seminal vesicles, and surrounding fat and peritoneal attachments and in women removal of the bladder, uterus, cervix,CMDT22_Ch39_p1612-p1675.indd  1660 02/07/21 2:44 PMCANCER1661 CMDT 2022urethra,  anterior vaginal vault, and usually the ovaries. In women with anterior tumors, vaginal and reproductive organ-sparing surgery can be considered. Bilateral pelvic lymph node dissection is performed in all patients. Urinary diversion is performed in all. In most patients, it uses a conduit of ileum or colon. However, continent forms of diversion avoid the necessity of an external appliance; it can be considered in a significant percentage of patients.C.  RadiotherapyExternal  beam radiotherapy delivered in fractions over a 6- to 8-week period is generally well tolerated, but approxi- mately 1015% of patients will develop bladder, bowel, or rectal complications. Local recurrence is common after radiotherapy alone (3070%) and it is therefore combined with radiosensitizing systemic chemotherapy to improve complete response and to decrease recurrence rates. Bladder- preserving chemoradiation can be offered to those patients seeking to keep their bladder and is best suited for those with solitary T2 or limited T3 tumors without ureteral obstruction. Radiation with or without chemotherapy can be offered to patients with localized cancers and to patients who are poor candidates for radical cystectomy or to patients with metastatic disease seeking palliation of local symptoms.D . ChemotherapyMetas tatic disease is present in 15% of patients with newly diagnosed bladder cancer. Furthermore, metastases develop in up to 40% of patients within 2 years of cystec- tomy, including those patients who were believed to have localized disease at the time of treatment. Cisplatin-based combination chemotherapy results in partial or complete responses in 1545% of patients (see Table 392) and is the preferred approach. Combination chemotherapy has been used to decrease recurrence rates in patients treated both with surgery and with radiotherapy. Neoadjuvant chemotherapy appears to benefit all patients with muscle-invasive disease prior to planned cystectomy. Chemotherapy should also be consid- ered before surgery in those with bulky lesions or those in whom regional metastases are suspected. Alternatively, adjuvant chemotherapy has been used after cystectomy in patients at high risk for recurrence, such as those who have lymph node involvement or extravesical local invasion.E.  ImmunotherapyThe  FDA has now approved several checkpoint inhibitors as immunotherapy for metastatic urothelial cancer. Approved antiPDL-1 inhibitors include atezolizumab, durvalumab , and avelumab (Table 392). Approved anti- PD1 inhibitors include nivolumab andpembrolizumab. All are approved for second-line treatment of locally advanced or metastatic urothelial cancer that progressed during or after platinum-based chemotherapy. Addition- ally, atezolizumab and pembrolizumab are approved as first-line therapy in cisplatin-ineligible patients whose tumors express PD-L1 or in patients ineligible for any platinum-based chemotherapy regardless of PD-L1expression status. Overall response rates of these agents are similar and range from 17% to 25% in locally advanced and metastatic urothelial bladder cancer. PrognosisThe  frequency of recurrence and progression are correlated with grade. Whereas progression may be noted in few low- grade cancers (1937%), it is common with poorly differ- entiated lesions (3367%). Carcinoma in situ is most often found in association with papillary bladder cancers. Its presence identifies patients at increased risk for recurrence and progression. At initial presentation, approximately 5080% of blad- der cancers are superficial: stage Ta, Tis, or T1. When properly treated, lymph node metastases and progression are uncommon in such patients and survival is excellent (81%). Five-year survival of patients with T2 and T3 dis- ease ranges from 50% to 75% after radical cystectomy. Long-term survival for patients with metastatic disease at presentation is rare. When to Refer Refer all patients to a urologist. Hematuria often deserves evaluation with both upper urinary tract imaging and cystoscopy, particularly in a high-risk group (eg, older men). Refer when histologic diagnosis and staging require endoscopic resection of cancer. Metastatic urothelial cancer should be managed by a medical oncologist.Babjuk  M et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)2019 update. Eur Urol. 2019;76:639. [PMID: 31443960] Faba OR et al. Update of the ICUD-SIU International Consulta- tion on Bladder Cancer 2018: urinary diversion. World J Urol. 2019;37:85. [PMID: 30238399] Flaig TW et al. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18:329. [PMID: 32135513] Hussain SA et al. From clinical trials to real-life clinical practice: the role of immunotherapy with PD-1/PD-L1 inhibitors in advanced urothelial carcinoma. Eur Urol Oncol. 2018;1:486. [PMID: 31158093] Nadal R et al. Management of metastatic bladder cancer. Cancer Treat Rev. 2019;76:10. [PMID: 31030123]C ANCERS OF THE URETER & RENAL PELVISCancers  of the ureter and renal pelvis are rare and occur more commonly in patients who have bladder cancer, Bal- kan nephropathy, or Lynch syndrome, who smoke, or who have a long history of analgesic abuse. The majority are urothelial cell carcinomas. Gross or microscopic hematuria is present in most patients; flank pain secondary to bleed- ing and obstruction occurs less commonly. As with bladder cancers, urinary cytology is often positive in high-grade cancers. The most common signs identified at the time of CT or intravenous urography include an intraluminal fill- ing defect, unilateral nonvisualization of the collectingCMDT22_Ch39_p1612-p1675.indd  1661 02/07/21 2:44 PMChAPTER 391662 CMDT 2022system,  and hydronephrosis. Ureteral and renal pelvic tumors must be differentiated from calculi, blood clots, papillary necrosis, or inflammatory and infectious lesions. On occasion, upper urinary tract lesions are accessible for biopsy, fulguration, or resection using a ureteroscope. Treatment is based on the site, size, grade, depth of pene- tration, and number of cancers present. Most are excised with laparoscopic or open nephroureterectomy (renal pel- vic and upper ureteral lesions) or segmental excision of the ureter (distal ureteral lesions). Endoscopic resection may be indicated in patients with limited renal function or focal, low-grade, cancers. Similar to urothelial bladder cancers, use of chemotherapy prior to surgery may improve outcomes.Kim  HS et al. Immune checkpoint inhibitors for urothelial carci- noma. Investig Clin Urol. 2018;59:285. [PMID: 30182073] Leow JJ et al. Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: a 2020 systematic review and meta-analysis, and future perspectives on systemic therapy. Eur Urol. 2021;79:635. [PMID: 32798146] Scotland KB et al. Long term outcomes of ureteroscopic man- agement of upper tract urothelial carcinoma. Urol Oncol. 2020;38:850.e17. [PMID: 32773230]RE NAL CELL CARCINOMAE S S E N T I A L S  O F  D I A G N O S I S Gross or microscopic hematuria. Flank pain or mass in some patients. Systemic symptoms such as fever, weight loss may be prominent. Solid renal mass on imaging. General ConsiderationsKidney  (renal cell) and renal pelvis carcinomas account for 3.8% of all adult cancers. In 2019 in the United States, it is estimated that approximately 73,820 cases of renal cell car- cinoma will be diagnosed and 14,770 deaths will result. Renal cell carcinoma has a peak incidence in the sixth decade of life and a male-to-female ratio of 2:1. It may be associated with a number of paraneoplastic syndromes. Risk factors include physical inactivity, obesity, and diabetes mellitus. Cigarette smoking is the only known significant environmental risk factor. Familial causes of renal cell carcinoma have been identified (von Hippel Lindau syndrome, hereditary papillary renal cell carci- noma, hereditary leiomyoma-renal cell carcinoma, and Birt-Hogg-Dub syndrome). There is an association with dialysis-related acquired cystic disease and specific genetic aberrations (eg, Xp11.2 translocation). But sporadic carci- nomas are far more common. Renal cell carcinoma originates from the proximal tubule cells. Various histologic cell types are recognized (clear cell, papillary, chromophobe, collecting duct, and sarcomatoid).Clinical FindingsA.  Symptoms and SignsHisto rically, 60% of patients presented with gross or micro- scopic hematuria. Flank pain or an abdominal mass was detected in approximately 30% of cases. The triad of flank pain, hematuria, and mass, found in only 10% of patients, is often a sign of advanced disease. Fever can occur as a paraneoplastic symptom. Symptoms of metastatic disease (cough, bone pain) occur in 2030% of patients at presenta- tion. Due to the widespread use of ultrasound and cross- sectional imaging, renal tumors are frequently detected incidentally in individuals with no urologic symptoms. Consequently, there has been profound stage migration toward lower stages of disease over the last 20 years. How- ever, population mortality rates have remained stable.B.  Laboratory FindingsCon temporary studies suggest hematuria is present in less than 50% of patients. Erythrocytosis from increased eryth- ropoietin production occurs in 5%, though anemia is more common; hypercalcemia may be present in up to 10% of patients. Stauffer syndrome is a reversible syndrome of hepatic dysfunction (with elevated liver tests) in the absence of metastatic disease.C.  ImagingSolid  renal masses are often first identified by abdominal ultrasonography or CT. CT and MRI scanning are the most valuable imaging tests for renal cell carcinoma. These scans confirm the character of the mass and provide valuable stag- ing information with respect to regional lymph nodes, renal vein or vena cava tumor thrombus, and adrenal or liver metastases. CT and MRI also provide valuable information regarding the contralateral kidney (function, bilaterality of neoplasm). Chest radiographs or CT exclude pulmonary metastases. Bone scans should be performed for large tumors and in patients with bone pain or elevated serum alkaline phosphatase levels. Brain imaging should be obtained in patients with high metastatic burden or in those with neurologic deficits. Differential DiagnosisSolid  renal masses are renal cell carcinoma until proven otherwise. Other solid masses include renal angiomyoli- pomas (fat density usually detectable by CT), renal pelvis urothelial cancers (more central location, involvement of the collecting system, positive urinary cytology), renal oncocytomas (indistinguishable from renal cell carcinoma preoperatively), renal abscesses, and adrenal tumors (superoanterior to the kidney). TreatmentSu rgical extirpation is the primary treatment for localized renal cell carcinoma. Patients with a single kidney, bilateral lesions, or significant medical renal disease should be con- sidered for partial nephrectomy. Patients harboring a small tumor with a normal contralateral kidney and good kidneyCMDT22_Ch39_p1612-p1675.indd  1662 02/07/21 2:44 PMCANCER1663 CMDT 2022funct ion are also candidates for partial nephrectomy, while radical nephrectomy is indicated in patients with cancers larger than 7 cm and those in whom partial nephrectomy is not technically feasible. Radiofrequency and cryosurgical ablation are alternative options instead of surgery in select patients with tumors less than 34 cm with similar risk of metastatic progression but higher risk of local recurrence. Active surveillance is warranted in select patients (signifi- cant comorbidity, short life expectancy) and appears safe with low risk of 5-year systemic progression. Percutaneous biopsy can provide tumor histology and grade to help guide treatment decisions. Cytotoxic chemotherapy has no role in the treatment of metastatic renal cell carcinoma. Historically, cytokine-based immunotherapies, such as interferon-alpha and interleukin-2, produced partial response rates of 1520% and 1535%, respectively (Table 392). Responders tended to have lower tumor burden, metastatic disease confined to the lung, and a high-performance status. Two randomized trials demonstrat- ing a survival benefit of cytoreductive nephrectomy followed by systemic interferon-alpha compared with the use of sys- temic therapy alone led to the widespread adoption of cytore- ductive nephrectomy. Patients most likely to benefit from cytoreduction were those with good performance status, lung only metastases, and good prognostic features. Presently, management strategies are based on tumor histology and patient risk (favorable, intermediate, or poor). Several targeted medications, specifically VEGF, Raf- kinase, and mTOR inhibitors, are effective (4060% response rates) in patients with advanced kidney cancer (Table 392). These oral agents, which include sunitinib, pazopanib, cabozantinib, axitinib, and sorafenib, are generally well tolerated and particularly active for clear cell carcinoma. The optimal timing and combination of these agents remain to be determined. Sunitinib is approved for adjuvant use after complete surgical resection in patients with adverse pathologic features. The mTOR inhibitors everolimus and temsirolimus are approved for use in patients with prior anti-VEGF therapy, as is the combina- tion of lenvatinib and everolimus. Nivolumab is an approved anti-PD-1 immunotherapy for treating metastatic disease that has progressed despite antiangiogenic therapy. Nivolumab in combination with the anti-CTLA4 immuno- therapy ipilimumab and pembrolizumab (anti-PD-1) in combination with the VEGF inhibitor axitinib have proved superior to sunitinib in previously untreated intermediate- and poor-risk metastatic clear cell renal cell carcinoma and are considered the standard first-line treatment for this patient population (Table 392). The utilization of cytoreductive nephrectomy in combi- nation with contemporary agents has decreased in response to the results of CARMENA and adoption of combination immunotherapy regimens (nivolumab plus ipilimumab, pembrolizumab plus axitinib). Still, there remains a role for cytoreductive surgery in select patients with intermediate- risk disease. PrognosisAfter  radical or partial nephrectomy, tumors confined to the renal capsule (T1T2) demonstrate 5-year disease-freesurvivals of 90100%. Tumors extending beyond the renal capsule (T3 or T4) and node-positive tumors have 5-year disease-free survivals of 5060% and 015%, respectively. One subgroup of patients with nonlocalized disease has reasonable long-term survival, namely, those with solitary resectable metastases. In this setting, radical nephrectomy with resection of the solitary metastasis results in 5-year disease-free survival rates of 1530%. When to Refer Refer patients with solid renal masses or complex cysts to a urologist for further evaluation. Refer patients with renal cell carcinoma to a urologic surgeon for surgical excision. Refer patients with metastatic disease to an oncologist and urologist.Lalani AA et  al. Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: current paradigms, use of immuno- therapy, and future directions. Eur Urol. 2019;75:100. [PMID: 30327274] Motzer RJ et al; CheckMate 214 Investigators. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277. [PMID: 29562145] Rini BI et al; KEYNOTE-426 Investigators. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1116. [PMID: 30779529] Sanchez A et al. Current management of small renal masses, including patient selection, renal tumor biopsy, active surveil- lance, and thermal ablation. J Clin Oncol. 2018;36:3591. [PMID: 30372390]OTH ER PRIMARY TUMORS OF THE KIDNEYOncocytomas  account for 35% of renal tumors, are usu- ally benign, and are indistinguishable from renal cell carci- noma on preoperative imaging. These tumors are seen in other organs, including the adrenals, salivary glands, and thyroid and parathyroid glands. Angiomyolipomas are rare benign tumors composed of fat, smooth muscle, and blood vessels. They are most com- monly seen in patients with tuberous sclerosis (often mul- tiple and bilateral) or in young to middle-aged women. CT scanning may identify the fat component, which is diagnos- tic for angiomyolipoma. Asymptomatic lesions less than 5 cm in diameter usually do not require intervention; large lesions can spontaneously bleed. Acute bleeding can be treated by angiographic embolization or, in rare cases, nephrectomy. Lesions over 5 cm are often prophylacti- cally treated with angioembolization to reduce the risk of bleeding.SE CONDARY CANCERS OF THE KIDNEYThe kidney is not an infrequent site fo r metastatic disease. Of the solid tumors, lung cancer is the most common (20%), followed by breast (10%), stomach (10%), and the contralateral kidney (10%). Lymphoma, both Hodgkin and non-Hodgkin, may also involve the kidney, although it tends to appear as a diffusely infiltrative process resulting in renal enlargement rather than a discrete mass.CMDT22_Ch39_p1612-p1675.indd  1663 02/07/21 2:44 PMChAPTER 391664 CMDT 2022TE STICULAR CANCERS (Germ Cell Tumors)E S S E N T I A L S  O F  D I A G N O S I S Most common neoplasm in men aged 2035 years. Patient typically discovers a painless nodule. Orchiectomy necessary for diagnosis. General ConsiderationsMalignan t tumors of the testis are rare, with approximately five to six cases per 100,000 males reported in the United States each year. Ninety to 95 percent of all primary testicu- lar tumors are germ cell tumors and can be divided into two major categories: nonseminomas, including embryo- nal cell carcinoma (20%), teratoma (5%), choriocarcinoma (less than 1%), and mixed cell types (40%); and semino- mas (35%). The lifetime probability of developing testicu- lar cancer is 0.3% for an American male. Approximately 5% of testicular cancers develop in a patient with a history of cryptorchism, with seminoma being the most common. However, 510% of these tumors occur in the contralateral, normally descended testis. The relative risk of development of malignancy is higher for the intra- abdominal testis (1:20) and lower for the inguinal testis (1:80). Placement of the cryptorchid testis into the scrotum (orchidopexy) does not alter its malignant potential but does facilitate routine examination and cancer detection. Testicular cancer is slightly more common on the right than the left, paralleling the increased incidence of cryptor- chidism on the right side. One to 2 percent of primary tes- ticular cancers are bilateral and up to 50% of these men have a history of unilateral or bilateral cryptorchidism. Primary bilateral testicular cancers may occur synchronously or asynchronously but tend to be of the same histology. Semi- noma is the most common histologic finding in bilateral primary testicular cancers, while malignant lymphoma is the most common bilateral testicular tumor overall. Clinical FindingsA.  Symptoms and SignsThe  most common symptom of testicular cancer is painless enlargement of the testis. Sensations of heaviness are not unusual. Patients are usually the first to recognize an abnormality, yet often delay in seeking medical attention ranges from 3 to 6 months. Acute testicular pain resulting from intratesticular hemorrhage occurs in approximately 10% of cases. Ten percent of patients are asymptomatic at presentation, and 10% manifest symptoms relating to metastatic disease such as back pain (retroperitoneal metastases), cough (pulmonary metastases), or lower extremity edema (vena cava obstruction). A discrete mass or diffuse testicular enlargement is noted in most cases. Secondary hydroceles may be present in 510% of cases. In advanced disease, supraclavicular adenop- athy may be present, and abdominal examination may reveal a mass. Gynecomastia is seen in 5% of germ cell tumors.B. Laboratory FindingsSeveral  serum markers are important in the diagnosis and monitoring of testicular carcinoma, including human cho- rionic gonadotropin (hCG), alpha-fetoprotein, and lactate dehydrogenase. Alpha-fetoprotein is never elevated with pure seminomas, and while hCG is occasionally elevated in seminomas, levels tend to be lower than those seen with nonseminomas. Lactate dehydrogenase may be elevated with either type of tumor and is a marker for disease bur- den. Liver tests may be elevated in the presence of hepatic metastases, and anemia may be present in advanced disease.C.  ImagingScrotal  ultrasound can readily determine whether a mass is intratesticular or extratesticular. Once the diagnosis of testicular cancer has been established by inguinal orchiec- tomy, clinical staging of the disease is accomplished by chest, abdominal, and pelvic CT scanning. StagingT esticular cancer is staged using the TNM system created based on extent of cancer in the testis, status of regional lymph nodes, the presence of metastases in distant lymph nodes or other viscera, and serum levels of tumor markers. Based on these features, germ cell tumors can be grouped to assign an overall stage: stage I lesion is confined to the testis; stage II demonstrates regional lymph node involve- ment in the retroperitoneum; and stage III indicates distant metastasis. Differential DiagnosisAn  incorrect diagnosis is made at the initial examination in up to 25% of patients with testicular tumors. Scrotal ultra- sonography should be performed if any uncertainty exists with respect to the diagnosis. Although most intratesticu- lar masses are malignant, a benign lesionepidermoid cystmay rarely be seen. Epidermoid cysts are usually very small benign nodules located just underneath the tunica albuginea; occasionally, however, they can be large. Testicular lymphoma is discussed below. TreatmentIn guinal exploration with early vascular control of the sper- matic cord structures is the initial intervention. If cancer cannot be excluded by examination of the testis, radical orchiectomy is warranted. Scrotal approaches and open tes- ticular biopsies should be avoided. Further therapy depends on the histology of the tumor as well as the clinical stage. Patients with clinical stage I seminomas are candidates for surveillance (preferred), single-agent carboplatin, or adjuvant radiotherapy. Stage IIa and IIb seminomas (retro- peritoneal disease less than 2 cm diameter in IIa and 25 cm in IIb) are treated by radical orchiectomy plus retroperito- neal irradiation or primary systemic chemotherapy (etoposide and cisplatin or cisplatin, etoposide, and bleo- mycin) (Table 392). Seminomas of stage IIc (greater than 5-cm-diameter retroperitoneal nodes) and stage III receiveCMDT22_Ch39_p1612-p1675.indd  1664 02/07/21 2:44 PMCANCER1665 CMDT 2022primary systemic chemotherap y. After chemotherapy, sur- gical resection of residual retroperitoneal nodes is war- ranted if the node is greater than 3 cm in diameter and positive on PET scan, since 40% will harbor residual carcinoma. Up to 75% of clinical stage I nonseminomas are cured by orchiectomy alone. Selected patients without specific risk factors have low-risk of recurrence and are generally offered surveillance after orchiectomy. These criteria include (1) cancer is confined within the tunica albuginea; (2) cancer does not demonstrate vascular invasion; (3) tumor markers normalize after orchiectomy; (4) radio- graphic imaging of the chest and abdomen shows no evi- dence of disease; and (5) the patient is reliable. Patients most likely to experience relapse on a surveillance regimen include those with predominantly embryonal cancer and those with vascular or lymphatic invasion identified in the orchiectomy specimen. Alternatives to surveillance for clinical stage I nonseminomas include adjuvant chemo- therapy (bleomycin, etoposide, cisplatin) (see Table 392) or retroperitoneal lymph node dissection. Following orchiectomy, patients with bulky retroperito- neal disease (greater than 5-cm nodes) or metastatic non- seminomas are treated with combination chemotherapy (cisplatin and etoposide or cisplatin, etoposide, and bleo- mycin) (Table 392). If tumor markers normalize and a residual mass greater than 1 cm persists on imaging stud- ies, it is resected because 1520% will harbor residual cancer and 40% will harbor teratomas. Even if patients have a complete response to chemotherapy, some clinicians advocate retroperitoneal lymphadenectomy since 10% of patients may harbor residual carcinoma and 10%, retro- peritoneal teratoma. If tumor markers fail to normalize following primary chemotherapy, salvage chemotherapy is required (cisplatin, etoposide, and ifosfamide). Postoperative active surveillance by the clinician and patient means patients are followed up every 26 months for the first 2 years and every 46 months in the third year. For nonseminomas, tumor markers are obtained at each visit, and chest radiographs and abdominal and pelvic CT scans are obtained every 46 months. For seminomas, serum tumor markers may be obtained (optional), chest imaging is obtained only as clinically indicated, and abdominal and pelvic CT scans are performed every 36 months. Follow-up continues beyond the initial 3 years; however, 80% of relapses will occur within the first 2 years. With rare exceptions, patients who relapse can be cured by chemotherapy or surgery. PrognosisThe  5-year disease-free survival rates for stage I and IIa seminomas (retroperitoneal disease less than 2 cm in diameter) treated by radical orchiectomy and retroperito- neal irradiation are 98% and 9294%, respectively. Ninety- five percent of patients with stage III disease attain a complete response following orchiectomy and chemother- apy. The 5-year disease-free survival for patients with stage I nonseminomas (includes all treatments) ranges from 96% to 100%. For low-volume stage II disease, a 5-year disease- free survival of 90% is expected. Patients withbulky retroperitoneal or disseminated disease treated with primary chemotherapy followed by surgery have a 5-year disease-free survival rate of 5580%. When to ReferRef er all patients with solid masses of the testis to a urologist and a medical oncologist if metastatic disease is suspected.Goldber g H et al. Germ cell testicular tumorscontemporary diagnosis, staging and management of localized and advanced disease. Urology. 2019;125:8. [PMID: 30597167] King J et al. Management of residual disease after chemotherapy in germ cell tumors. Curr Opin Oncol. 2020;32:250. [PMID: 32168037] Pierorazio PM et al. Performance characteristics of clinical stag- ing modalities for early stage testicular germ cell tumors: a systematic review. J Urol. 2020;203:894. [PMID: 31609176]SE CONDARY CANCERS OF THE TESTISSecondary  cancers of the testis are rare. In men over the age of 50 years, lymphoma is the most common. Overall, it is the most common secondary neoplasm of the testis, accounting for 5% of all testicular cancers. It may be seen in three clinical settings: (1) late manifestation of wide- spread lymphoma, (2) the initial presentation of clinically occult disease, and (3) primary extranodal disease. Radical orchiectomy is indicated to make the diagnosis. Prognosis is related to the stage of disease. Metastasis to the testis is rare. The most common pri- mary site of origin is the prostate, followed by the lung, gastrointestinal tract, melanoma, and kidney.CA NCER COMPLICATIONS & EMERGENCIESSunny  Wang, MD Tiffany O. Dea, PharmD, BCOPSP INAL CORD COMPRESSIONE S S E N T I A L S  O F  D I A G N O S I S Complication of metastatic solid tumor, lym- phoma, or plasma cell myeloma. Back pain is most common presenting symptom. Prompt diagnosis is essential because once a severe neurologic deficit develops, it is often irreversible. Emergent treatment may prevent or potentially reverse paresis and urinary and bowel incontinence. General ConsiderationsCancers  that cause spinal cord compression most com- monly metastasize to the vertebral bodies, resulting in physical damage to the spinal cord from edema, hemorrhage,CMDT22_Ch39_p1612-p1675.indd  1665 02/07/21 2:44 PMChAPTER 391666 CMDT 2022and  pressure-induced ischemia to its vasculature. Persis- tent compression can result in irreversible changes to the myelin sheaths resulting in permanent neurologic impairment. Prompt diagnosis and therapeutic intervention are essential, since the probability of reversing neurologic symptoms largely depends on the duration of symptoms. Patients who are treated promptly after symptoms appear may have partial or complete return of function and, depending on tumor sensitivity to specific treatment, may respond favorably to subsequent anticancer therapy. Clinical FindingsA.  Symptoms and SignsBack  pain at the level of the tumor mass occurs in over 80% of cases and may be aggravated by lying down, weight bear- ing, sneezing, or coughing; it usually precedes the develop- ment of neurologic symptoms or signs. Since involvement is usually epidural, a mixture of nerve root and spinal cord symptoms often develops. Progressive weakness and sen- sory changes commonly occur. Bowel and bladder symp- toms progressing to incontinence are late findings. The initial findings of impending cord compression may be quite subtle, and there should be a high index of suspicion when back pain or weakness of the lower extrem- ities develops in a cancer patient.B.  ImagingMRI is usually the initial imaging procedure o f choice in a cancer patient with new-onset back pain. If the back pain symptom is nonspecific, a whole-body PET-CT scan with18 F-2-deoxyglucose may be a useful screening procedure. Bone radiographs are neither sensitive nor specific for the evaluation of a cancer patient with back pain. When neu- rologic findings suggest spinal cord compression, an emer- gent MRI should be obtained; the MRI should survey the entire spine to define all areas of tumor involvement for treatment planning purposes. MRI has a sensitivity of 93% and a specificity of 97% for diagnosis of metastatic spinal cord compression. TreatmentPa tients with a known cancer diagnosis found to have epi- dural impingement of the spinal cord should be given corticosteroids immediately. The initial dexamethasone dose is 10 mg intravenously followed by 46 mg every 6 hours intravenously or orally. Patients without a known diagnosis of cancer should have emergent surgery to relieve the impingement and obtain a pathologic speci- men; preoperative corticosteroids should not be given since they might compromise the pathology results. Patients with solid tumors who have a single area of com- pression and who are considered candidates for surgery are best treated first with surgical decompression followed by radiation therapy. Better outcomes (ie, improved ability to ambulate and improved bladder and bowel function) occur in patients who undergo surgery followed byradiation therapy than in those who receive radiation alone. If multiple vertebral body levels are involved with cancer, fractionated radiation therapy is the preferred treatment option. Corticosteroids are generally tapered toward the end of radiation therapy. A scoring system exists for patients presenting with spinal cord metastases to identify those with poor survival times who would be best managed with supportive care or single fraction palliative radiation.Boussios S et  al. Metastatic spinal cord compression: unraveling the diagnostic and therapeutic challenges. Anticancer Res. 2018;38:4987. [PMID: 30194142] Hoskin PJ et al. Effect of single-fraction vs multifraction radio- therapy on ambulatory status among patients with spinal canal compression from metastatic cancer: the SCORAD randomized clinical trial. JAMA. 2019;322:2084. [PMID: 31794625] Lawton AJ et al. Assessment and management of patients with metastatic spinal cord compression: a multidisciplinary review. J Clin Oncol. 2019;37:61. [PMID: 30395488]MA LIGNANT EFFUSIONSE S S E N T I A L S  O F  D I A G N O S I S Occur in pleural, pericardial, and peritoneal spaces. Caused by direct neoplastic involvement of serous surface or obstruction of lymphatic drainage. Half of undiagnosed effusions in patients not known to have cancer are malignant. General ConsiderationsThe developme nt of an effusion in the pleural, pericardial, or peritoneal space may be the initial finding in a patient with cancer, or an effusion may appear during the course of disease progression. Direct involvement of the serous sur- face with tumor is the most frequent initiating cause of the accumulation of fluid. The most common malignancies causing pleural and pericardial effusions are lung and breast cancers; the most common malignancies associated with malignant ascites are ovarian, colorectal, stomach, and pancreatic cancers. Clinical FindingsA.  Symptoms and SignsPa tients with pleural and pericardial effusions complain of shortness of breath and orthopnea. Patients with ascites complain of abdominal distention and discomfort. Cardiac tamponade causing pressure equalization in the chambers impairs both filling and cardiac output and can be life- threatening. Signs of tamponade include tachycardia, muf- fled heart sounds, pulsus paradoxus, and hypotension. Signs of pleural effusions include decreased breath sounds, egophony, and percussion dullness.CMDT22_Ch39_p1612-p1675.indd  1666 02/07/21 2:44 PMCANCER1667 CMDT 2022B.  Laboratory FindingsMalignancy is confirmed  as the cause of an effusion when analysis of the fluid specimen shows malignant cells in either the cytology or cell block specimen.C.  ImagingThe  presence of effusions can be confirmed with radio- graphic studies or ultrasonography. Differential DiagnosisThe  differential diagnosis of a malignant pleural or pericar- dial effusion includes nonmalignant processes, such as infection, pulmonary embolism, heart failure, and trauma. The differential diagnosis of malignant ascites includes similar benign processes, such as heart failure, cirrhosis, peritonitis, and pancreatic ascites. Bloody effusions are usually due to cancer, but a bloody pleural effusion can also be due to pulmonary embolism, trauma and, occasionally, infection. Chylous pleural or ascitic fluid is generally asso- ciated with obstruction of lymphatic drainage as might occur in lymphoma. TreatmentThe  development of a malignant effusion is a late-stage manifestation of the cancer. Treatment is tailored to the underlying cancer, whether with targeted therapy, chemo- therapy, or immunotherapy, depending on tumor testing results. Effective systemic treatment can lead to regression of the effusion. Acute symptoms related to the effusion often require urgent intervention with drainage of the effu- sion. Decisions regarding palliative management of malig- nant effusion are in large part dictated by the patients symptoms and goals of care.A.  Pleural EffusionA  pleural effusion that is symptomatic may be managed initially with a large volume thoracentesis. In some patients, the effusion slowly reaccumulates, which allows for periodic thoracentesis when the patient becomes symp- tomatic. However, in many patients, the effusion reaccu- mulates quickly, causing rapid return of shortness of breath. For those patients, two other management options exist: pleurodesis or indwelling pleural catheter (eg, PleurX). Chest tube drainage followed by pleurodesis involves placement of a chest tube that is connected to closed water seal drainage. After lung expansion is con- firmed on a chest radiograph, a sclerosing agent (such as talc slurry or doxycycline) is injected into the catheter. Patients should be premedicated with analgesics. Pleurode- sis will not be successful if the lung cannot be reexpanded. These patients are better managed with placement of an indwelling catheter that can be drained by a family mem- ber or a visiting nurse. This procedure is often preferable for patients with short life expectancies or for those who do not respond to pleurodesis. In a meta-analysis of random- ized controlled trials comparing indwelling pleural cathe- ter with pleurodesis, indwelling pleural catheters resultedin shorter hospital stays and fewer repeat pleural interven- tions, but increased rates of cellulitis.B.  Pericardial EffusionFluid  may be removed by a needle aspiration or by place- ment of a catheter for more thorough drainage. As with pleural effusions, most pericardial effusions will reaccu- mulate. Management options for recurrent, symptomatic effusions include prolonged catheter drainage (for several days until drainage has decreased to 2030 mL/day) or surgical intervention such as a pericardiotomy or pericardiectomy.C.  Malignant AscitesPa tients with malignant ascites not responsive to chemo- therapy are generally treated with repeated large-volume paracenteses. Since the frequency of drainage to maintain comfort can compromise the patients quality of life, other alternatives include placement of a catheter or port so that the patient, family member, or visiting nurse can drain fluid as needed at home. For patients with portal hyper- tension from large hepatic masses, diuretics (such as spi- ronolactone 100 mg with furosemide 2040 mg orally daily) may be useful to decrease the need for repeated paracentesis.As ciak R et al. Malignant pleural effusion: from diagnostics to therapeutics. Clin Chest Med. 2018;39:181. [PMID: 29433714] Feller-Kopman DJ et al. Management of malignant pleural effu- sions. An official ATS/STS/STR clinical practice guideline. Am J Respir Crit Care Med. 2018;198:839. [PMID: 30272503] Iyer NP et al. Indwelling pleural catheter versus pleurodesis for malignant pleural effusions. A systematic review and meta- analysis. Ann Am Thorac Soc. 2019;16:124. [PMID: 30272486] Walker S et al. Malignant pleural effusion management: keeping the flood gates shut. Lancet Respir Med. 2020;8:609. [PMID: 31669226]HYP ERCALCEMIAE S S E N T I A L S  O F  D I A G N O S I S Most common paraneoplastic endocrine syndrome. Usually symptomatic and severe ( 15 mg/dL [3.75 mmol/L]); accounts for most inpatients with hypercalcemia. The neoplasm is clinically apparent in nearly all cases when hypercalcemia is detected. General ConsiderationsH ypercalcemia affects 2030% of cancer patients at some point during their illness. The most common cancers causing hypercalcemia are myeloma, breast carcinoma, and NSCLC. Hypercalcemia is caused by one of three mechanisms: sys- temic effects of tumor-released proteins, direct osteolysis of bone by tumor, or vitamin Dmediated osteoabsorption.CMDT22_Ch39_p1612-p1675.indd  1667 02/07/21 2:44 PMChAPTER 391668 CMDT 2022 Clinical FindingsA.  Symptoms and SignsSy mptoms and signs of hypercalcemia can be subtle; more severe symptoms occur with higher levels of hypercalcemia and with a rapidly rising calcium level. Early symptoms typi- cally include anorexia, nausea, fatigue, constipation, and polyuria; later findings may include muscular weakness and hyporeflexia, confusion, psychosis, tremor, and lethargy.B.  Laboratory FindingsSym ptoms and signs are caused by free calcium; as calcium is bound by protein in the serum, the measured serum calcium will underestimate the free or ionized calcium in patients with low albumin levels. Free ionized calcium can be measured. When the corrected serum calcium rises above 12 mg/dL (3 mmol/L), especially if the rise occurs rapidly, sudden death due to cardiac arrhythmia or asystole may occur. Initial work-up for hypercalcemia includes obtaining serum PTH, PTHrP , and calcitriol levels. The presence of hypercalcemia does not invariably indicate a dismal prognosis, especially in patients with breast cancer, myeloma, or lymphoma.C.  ECGElectrocardiograph y in hypercalcemia often shows a short- ening of the QT interval. TreatmentEme rgency management should begin with the initiation of intravenous fluids with 0.9% saline at 100300 mL/h to ensure rehydration with brisk urinary output of the often volume-depleted patient. If kidney function is normal or only marginally impaired, a bisphosphonate should be given. Choices include pamidronate, 6090 mg intravenously over 24 hours, or zoledronic acid, 4 mg intravenously over 15 minutes. Zoledronic acid is more potent than pamidro- nate and has the advantage of a shorter administration time as well as a longer duration of effect. Once hypercalcemia is controlled, treatment directed at the cancer should be initi- ated if possible. In the event that the hypercalcemia becomes refractory to repeated doses of bisphosphonates, other agents that can help control hypercalcemia (at least temporarily) include calcitonin and denosumab; corticosteroids can be useful in patients with myeloma and lymphoma. Salmon calcitonin, 48 international units/kg given subcutaneously or intramuscularly every 12 hours, can be used in patients with severe, symptomatic hypercalcemia; its onset of action is within hours but its hypocalcemic effect wanes in 23 days. Denosumab, 120 mg given subcutaneously weekly for 4 weeks followed by monthly administration, is a choice for long-term management of bisphosphonate-refractory hyper- calcemia or for patients with kidney dysfunction that pre- cludes use of a bisphosphonate.Asoni tis N et al. Diagnosis, pathophysiology, and management of hypercalcemia in malignancy: a review of the literature. Horm Metab Res. 2019;51:770. [PMID: 31826272]Zagzag J et al. Hypercalcemia and cancer: differential diagnosis and treatment. CA Cancer J Clin. 2018;68:377. [PMID: 30240520]HYP ERURICEMIA & TUMOR LYSIS SYNDROMEE S S E N T I A L S  O F  D I A G N O S I S Complication of treatment-associated tumor lysis of hematologic and rapidly proliferating malignancies. May be worsened by thiazide diuretics. Rapid increase in serum uric acid can cause acute urate nephropathy from uric acid crystallization. Reducing pre-chemotherapy serum uric acid is fundamental to preventing urate nephropathy. General ConsiderationsT umor lysis syndrome (TLS) is seen most commonly fol- lowing treatment of hematologic malignancies, such as acute lymphoblastic leukemia and Burkitt lymphoma. However, TLS can develop from any tumor highly sensitive to chemotherapy. TLS is caused by the massive release of cellular material including nucleic acids, proteins, phos- phorus, and potassium. If both the metabolism and excre- tion of these breakdown products are impaired, hyperuricemia, hyperphosphatemia, and hyperkalemia will develop abruptly. Acute kidney injury may then develop from the crystallization and deposition of uric acid and calcium phosphate within the renal tubules, further exacerbating the hyperphosphatemia and hyperkalemia. Clinical FindingsA.  Symptoms and SignsSymp toms of hyperphosphatemia include nausea, vomit- ing, anorexia, muscle cramps, tetany, and seizures. High levels of phosphorus and co-precipitation with calcium can cause renal tubule blockage, further exacerbating the kid- ney injury. Hyperkalemia, due to release of intracellular potassium and impaired kidney excretion, can cause arrhythmias and sudden death.B.  Laboratory FindingsThe laborat ory diagnosis of TLS include at least two of the following criteria observed within a 24-hour period: uric acid 8 mg/dL or higher (476 mcmol/L or higher), phos- phate 4.5 mg/dL or higher (1.45 mmol/L or higher), potas- sium 6.0 mEq/L or more (6 mmol/L or more) (or a 25% increase from baseline for these parameters), and corrected serum calcium 7 mg/dL or lower (1.75 mmol/L or lower). A clinical diagnosis of TLS includes meeting the laboratory criteria and at least one clinical criterion: acute kidney injury (creatinine greater than or equal to 1.5  upper limit of normal or increase greater than 0.3 g/dL or urinaryCMDT22_Ch39_p1612-p1675.indd  1668 02/07/21 2:44 PMCANCER1669 CMDT 2022out put greater than 0.5 mL/kg/h for 6 hours) or cardiac arrhythmia, sudden cardiac death, or seizure. TreatmentPreven tion is the most important factor in the manage- ment of TLS. Aggressive hydration at least 24 hours prior to chemotherapy as well as 2448 hours after chemotherapy completion helps keep urine flowing and facilitates excre- tion of uric acid and phosphorus. It is recommended to maintain a urinary output of at least 100 mL/h, and a daily urine volume of at least 3 L/day. If evidence of volume over- load or inadequate urinary output develops, loop diuretics can be used. Thiazide diuretics are contraindicated because they increase uric acid levels and can interact with allopuri- nol. For patients at moderate risk of developing TLS, eg, those with intermediate-grade lymphomas and acute leuke- mias, allopurinol should be given before starting chemo- therapy with dose reductions for impaired kidney function. Rasburicase is given intravenously to patients at high risk for developing TLS, eg, those with high-grade lymphomas or acute leukemias with markedly elevated white blood cell counts. Rasburicase may also be considered for patients with baseline elevated uric acid who are being treated with venetoclax (Bcl-2 inhibitor) for chronic lymphocytic leuke- mia or in any patient in whom uric acid levels reach levels greater than 8 mg/dL despite treatment with allopurinol. Rasburicase cannot be given to patients with known glucose 6-phosphate dehydrogenase (G6PD) deficiency nor can it be given to pregnant or lactating women. When to ReferShould  urinary output drop, serum creatinine or potas- sium levels rise, or hyperphosphatemia persist, a nephrolo- gist should be immediately consulted to evaluate the need for dialysis.Durani  U et al. Emergencies in haematology: tumor lysis syn- drome. Br J Haematol. 2020;188:494. [PMID: 31774551] Matuszkiewicz-Rowinska J et al. Prevention and treatment of tumor lysis syndrome in the era of onco-nephrology progress. Kidney Blood Press Res. 2020;45:645. [PMID: 32998135]IN FECTIONSChapt ers 30 and 31 provide more detailed discussions of infections in the immunocompromised patient.E S S E N T I A L S  O F  D I A G N O S I S In patients with neutropenia, infection is a medi- cal emergency. Although sometimes attributable to other causes, the presence of fever, defined as a single tempera- ture > 38.3C (101F) or a temperature of > 38C (100.4F) for > 1 hour, must be assumed to be due to an infection.General ConsiderationsMa ny patients with disseminated neoplasms have increased susceptibility to infection. In some patients, this results from impaired defense mechanisms (eg, acute leukemia, Hodgkin lymphoma, plasma cell myeloma, chronic lymphocytic leu- kemia); in others, it results from the myelosuppressive and immunosuppressive effects of cancer chemotherapy or a combination of these factors. Complicating impaired defense mechanisms are the frequent presence of indwelling cathe- ters, impaired mucosal surfaces, and colonization with more virulent hospital-acquired pathogens. The source of a neutropenic febrile episode is deter- mined in about 30% of cases through blood, urine, or sputum cultures. The bacterial organisms accounting for the majority of infections in cancer patients include gram- positive bacteria (coagulase-negative Staphylococcus, Staphylococcus aureus, Streptococcus pneumoniae, Coryne- bacterium, and streptococci) and gram-negative bacteria (Escherichia coli, Klebsiella, Pseudomonas, Enterobacter ). Gram-positive organism infections are more common, but gram-negative infections are more serious and life- threatening. The risk of bacterial infections rises when the neutrophil count is below 500/mcL (0.5  109/L); the risk markedly increases when the count falls below 100/mcL (0.1  109/L) or when there is a prolonged duration of neu- tropenia, typically greater than 7 days. Clinical FindingsA  thorough physical examination should be performed. Appropriate cultures (eg, blood, sputum, urine and, if indi- cated, cerebrospinal fluid) should always be obtained. Two sets of blood cultures should be drawn before starting antibiotics; if the patient has an indwelling catheter, one of the cultures should be drawn from the line. A chest radio- graph should also be obtained. TreatmentEmpiric  antibiotic therapy needs to be initiated within 1 hour of presentation and following the collection of blood cultures in the febrile neutropenic patient. The choice of antibiotics depends on a number of different factors includ- ing the patients clinical status and any localizing source of infection. If the patient is clinically well, monotherapy with an intravenous beta-lactam with anti- Pseudomonas activity (cefepime, ceftazidime, imipenem/cilastatin, piperacillin/ tazobactam) should be started (see Infections in the Immu- nocompromised Patient, Chapter 30). If the patient is clini- cally ill with hypotension or hypoxia, an intravenous aminoglycoside or fluoroquinolone should be added for double gram-negative bacteria coverage. If there is a strong suspicion of a gram-positive organism, such as from aS aureus catheter infection, intravenous vancomycin can be given empirically. Low-risk patients may be treated with oral antibiotics in the outpatient setting. Antibiotics should be continued until the neutrophil count is rising and greater than 500/mcL (0.5  109/L) for at least 1 day and the patient has been afebrile for 2 days. If an organism is identified through the cultures, theCMDT22_Ch39_p1612-p1675.indd  1669 02/07/21 2:44 PMChAPTER 391670 CMDT 2022antib iotics should be adjusted to the antibiotic sensitivities of the isolate; treatment should be continued for the appro- priate period of time and at least until the neutrophil count recovers and fever resolves. For the neutropenic patient who is persistently febrile despite broad-spectrum antibiotics, an empiric antifungal drug should be added (amphotericin B, caspofungin, itra- conazole, voriconazole, or liposomal amphotericin B).Braga  CC et al. Clinical implications of febrile neutropenia guidelines in the cancer patient population. J Clin Oncol. 2019;15:25. [PMID: 30629901] Taplitz A et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. J Clin Oncol. 2018;36:1443. [PMID: 29461916] PRIMARY CANCER TREATMENTSunny  Wang, MD Tiffany O. Dea, PharmD, BCOPSYS TEMIC CANCER THERAPYDetailed  guidelines from the NCCN for cancer treatment can be found at www.nccn.org. Use of cytotoxic drugs, hormones, antihormones, and biologic agents has become a highly specialized and increasingly effective means of treating cancer, with therapyadministered and monitored by a medical oncologist or hematologist. Selection of specific drugs or protocols for various types of cancer is usually based on results of clini- cal trials. Increasingly, newer agents are being identified that target specific molecular pathways. Yet both initial and acquired drug resistance remains a challenge. Described mechanisms of drug resistance include impaired mem- brane transport of drugs, enhanced drug metabolism, mutated target proteins, and blockage of apoptosis due to mutations in cellular proteins (see Table 392 for suggested agents for various cancers).TOXI CITY & DOSE MODIFICATION OF CHEMOTHERAPEUTIC AGENTSU se of chemotherapy to treat cancer is generally guided by results from clinical trials in individual tumor types. The complexity of treating cancer has increased over the last decade as more drugs, including those with targeted mechanisms of action, have been approved by the US Food and Drug Administration (FDA) and introduced into gen- eral practice. Drug side effects and toxicities must be anticipated and carefully monitored. The short- and long- term toxicities of individual drugs are listed in Tables 393 and 3912. Decisions on dose modifications for toxicities should be guided by the intent of therapy. In the palliative setting where the aim of therapy is to improve symptoms and quality of life, lowering doses to minimize toxicity is commonly done. However, when the goal of treatment is cure, dosing frequency and intensity should be maintained whenever possible. Table 3912. Commonly used supportive care agents.1Agent Indication Usual Dose Adverse Effects Allopurinol (Xyloprim) Prevent hyperuricemia from tumor lysis syndrome600800 mg/day orally Acute: none Delayed: rash Dexrazoxane (Zinecard) Prevent cardiomyopathy second- ary to doxorubicin; anthracy- cline-induced injection site extravasation10 times the doxorubicin dose intravenously before doxorubi- cin; 1000 mg/m2intravenously on days 1 and 2, then 500 mg/m2 intravenously on day 3Acute: nausea Delayed: myelosuppression, elevated transaminases Leucovorin Rescue after high-dose metho- trexate; in combination with 5-fluorouracil for colon cancer10 mg/m2intravenously or orally every 6 hours; 20 mg/m2or 200 500 mg/m2intravenously before 5-fluorouracil; various dosesAcute: nausea, vomiting, diarrhea Delayed: stomatitis, fatigue Mesna (Mesnex) Prevent ifosfamide-induced hemorrhagic cystitis20% of ifosfamide dose intrave- nously at 0, 4, and 8 hours; various dosesAcute: nausea, vomiting Delayed: fatigue Palifermin (Kepivance) Prevent mucositis following chemotherapy60 mcg/kg/day intravenously for 3 days before and 3 days after chemotherapyAcute: none Delayed: rash, fever, elevated serum amylase, erythema, edema Radium (Ra)-223 dichloride (Xofigo)Symptomatic bone metastases 50 kilobecquerel/kg (1.35 microCurie/kg) intrave- nously every 4 weeks for 6 cyclesAcute: nausea, vomiting, diarrhea, peripheral edema Delayed: myelosuppression Rasburicase (Elitek) Prevent hyperuricemia from tumor lysis syndrome36 mg intravenously once Acute: hypersensitivity, nausea, vomiting, diarrhea, fever, headache Delayed: rash, peripheral edema (continued )CMDT22_Ch39_p1612-p1675.indd  1670 02/07/21 2:44 PMCANCER1671 CMDT 2022T able 3912. Commonly used supportive care agents.1Agent Indication Usual Dose Adverse Effects Bone-Modifying Agents Denosumab (Xgeva) Osteolytic bone metastasis 120 mg subcutaneously every 4 weeksAcute: nausea Delayed: hypocalcemia, hypophos- phatemia, fatigue, osteonecrosis of the jaw Pamidronate (Aredia) Osteolytic bone metastasis, hypercalcemia of malignancy90 mg intravenously every 34 weeks; 6090 mg intrave- nously, may repeat after 7 daysAcute: nausea Delayed: dyspnea, arthralgia, bone pain, osteonecrosis of the jaw, nephrotoxicity, hypocalcemia Zoledronic acid (Zometa) Osteolytic bone metastasis, hypercalcemia of malignancy4 mg intravenously every 34 weeks; 4 mg intravenously once, may repeat after 7 days Growt Factors Darbepoetin alfa (Aranesp)Chemotherapy-induced anemia 2.25 mcg/kg subcutaneously weekly; 500 mcg subcutaneously every 3 weeks Epoetin alfa (Epogen, Procrit)Chemotherapy-induced anemia 40,000 units subcutaneously once weekly; 150 units/kg subcutane- ously three times a weekAcute: injection site reaction Delayed: hypertension, thromboem- bolic events, increased risk of tumor progression or recurrence Filgrastim (Neupogen) Febrile neutropenia prophylaxis, mobilization of peripheral stem cells510 mcg/kg/day subcutaneously or intravenously once daily, treat past nadirAcute: injection site reaction Delayed: bone pain Pegfilgrastim (Neulasta) Febrile neutropenia prophylaxis 6 mg subcutaneously once per chemotherapy cycle Sargramostim (Leukine) Myeloid reconstitution following bone marrow transplant, mobilization of peripheral blood stem cells250 mcg/m2intravenously daily until the absolute neutrophil count is > 1500 cells/mcL (1.5  109/L) for 3 consecutive daysAcute: fever, rash, pruritus, nausea, vomiting, diarrhea, injection site reaction, dyspnea Delayed: asthenia, bone pain, mucositis, edema, arrhythmia1 For amifostine, levoleucovorin, pilocarpine, samarium, strontium, filgrastim-sndz, and tbo-filgrastim, see Table 3912 in CMDT Online at www.accessmedicine.com.A  CBC including a differential count, with absolute neutrophil count and platelet count, and liver and kid- ney tests should be obtained before the initiation of chemotherapy. In patients with good performance sta- tus, normal CBCs, as well as normal liver and kidney function, drugs are started at their full dose. When the intent of chemotherapy is cure, including treatment in the adjuvant setting, every attempt should be made to schedule chemotherapy on time and at full dose. A CBC with differential may be checked at mid cycle (to determine the nadir of the absolute neutrophil and platelet counts), and liver and kidney function tests should be obtained immediately before the next cycle of chemotherapy. Dose reductions may be necessary for patients with impaired kidney or liver function depending on the clear- ance mechanism of the drug. For patients receiving chemo- therapy for palliation, bone marrow toxicity can be managed with dose reductions or delaying the next treat- ment cycle. A schema for dose modification is shown in Table 3913.1. Bone Marrow ToxicityA.  NeutropeniaGra nulocyte colony-stimulating factor (G-CSF), given as either daily subcutaneous injections (eg, filgrastim, 300 mcg Table 3913. A common scheme for dose modifica- tion of cancer chemotherapeutic agents.Granulocyte Count Platelet CountSuggested Drug Dosage (% of Full Dose) > 2000 cells/mcL (2  109/L)> 100,000/mcL (100  109/L)100% 10002000 cells/mcL (12  109/L)75,000100,000/ mcL (75100  109/L)50% < 1000 cells/mcL (1  109/L)< 50,000/mcL (50  109/L)0%(continued)CMDT22_Ch39_p1612-p1675.indd  1671 02/07/21 2:44 PMChAPTER 391672 CMDT 2022or  480 mcg) or as a one-time dose (pegfilgrastim, 6 mg) beginning 24 hours after cytotoxic chemotherapy is com- pleted, reduces the duration and severity of granulocytope- nia following cytotoxic chemotherapy (Table 3912). The American Society of Clinical Oncology and NCCN guide- lines recommend primary prophylaxis with G-CSF when there is at least a 20% risk of febrile neutropenia or when age, medical history, and disease characteristics put the patient at high risk for complications related to myelosuppression.B.  AnemiaErythropoiesis-stimulatin g agents (ESAs) ameliorate the anemia and its associated symptoms caused by cancer che- motherapy but these drugs have untoward effects, includ- ing an increased risk of thromboembolism, and possibly a decreased survival due to cancer-related deaths as well as a shortened time to tumor progression. The FDA recom- mends that these drugs should not be used when the intent of chemotherapy is curative. Administration of red blood cell transfusions is an alternative for managing symptom- atic anemia in chemotherapy patients. ESAs can be an option in cancer patients with symptom- atic anemia undergoing palliative treatment; patient prefer- ence is important in determining when to use ESAs or transfusions. When using ESAs, treatment should not be initiated until the hemoglobin is less than 10 g/dL (100 g/L) and the ESA held when the hemoglobin is greater than 12 g/dL (120 g/L). Epoetin alfa can be given subcutaneously at a dose of 40,000 units weekly or 150 units/kg three times weekly with a target hemoglobin of 1112 g/dL (110120 g/L). Darbepoetin alfa is given subcutaneously at a dose of 300500 mcg every 3 weeks or 2.25 mcg weekly with the same target hemoglobin (see Table 3912). To have maxi- mum therapeutic effect, patients need to be iron replete. Uncontrolled hypertension is a contraindication to the use of ESAs; blood pressure must be controlled prior to initia- tion of this therapy.C.  ThrombocytopeniaDrug  management of chemotherapy-induced thrombocyto- penia is more limited. Two drugs that activate the thrombo- poietin receptor, romiplostim and eltrombopag, are FDA approved for use in idiopathic thrombocytopenia, thrombo- cytopenia related to interferon therapy of hepatitis C, and thrombocytopenia in aplastic anemia. While these agents have been used in selected cases of refractory chemotherapy- related thrombocytopenia with some reports of success, trials to date have not demonstrated convincing efficacy in patients with chemotherapy-induced thrombocytopenia and neither agent is FDA approved for this indication.2.  Cemoterapy-Induced Nausea & VomitingA numbe r of cytotoxic anticancer drugs can induce nau- sea and vomiting, which can be the most anticipated and stressful side effects for patients. Chemotherapy-induced nausea and vomiting is mediated in part by the stimulation of at least two central nervous system receptors, 5-hydroxy- tryptamine subtype 3 (5HT3) and neurokinin subtype 1 (NK1). Chemotherapy-induced nausea and vomiting can beanticipatory, occurring even before chemotherapy adminis- tration; acute, occurring within minutes to hours of chemo- therapy administration; or delayed, lasting up to 7 days. Chemotherapy drugs are classified into high, moderate, low, and minimal likelihoods of causing emesis (90%, 3090%, 1030%, less than 10%, respectively). Highly emetogenic chemotherapy drugs include carmustine, cisplatin, cyclo- phosphamide (at doses over 1.5 g/m2), dacarbazine, and streptozocin, or a combination of regularly dosed anthracy- clines and cyclophosphamide. Moderately emetogenic che- motherapy drugs include azacitadine, bendamustine, carboplatin, crizotinib, cyclophosphamide, cytarabine, doxo- rubicin, epirubicin, ifosfamide, irinotecan, oxaliplatin, and temozolomide. Low emetogenic drugs include bortezomib, capecitabine, dabrafenib, dasatinib, docetaxel, erlotinib, eto- poside, 5-fluorouracil, gemcitabine, hydroxyurea, lenalido- mide, methotrexate, mitomycin, paclitaxel, pemetrexed, pomalidomide, and topotecan. Drugs with minimal risk of emesis include bevacizumab, bleomycin, cetuximab, decitabine, panitumumab, rituximab, trastuzumab, and vincristine. Major advances have occurred in the development of highly effective antiemetic drugs. Antagonists to the 5HT3-receptor include alosetron, dolasetron, granisetron, ondansetron, and palonosetron, as well as ramosetron and tropisetron (neither yet available in the United States). Ondansetron can be given either intravenously (8 mg or 0.15 mg/kg) or orally (24 mg once before highly emeto- genic chemotherapy, 8 mg twice daily for moderately emetogenic chemotherapy). Doses of 8 mg can be repeated parenterally or orally every 8 hours. Dosing of granisetron is 1 mg or 0.01 mg/kg intravenously or 12 mg orally. Dola- setron is given once as an oral 100-mg dose. Palonosetron, a long-acting 5HT3-receptor antagonist with high affinity for the receptor, is given once at a dose of 0.25 mg intravenously, both for acute and delayed emesis. As a class of drugs, the 5HT3-receptor antagonists have the potential to cause elec- trocardiogram changes, including QT prolongation. Antagonists to the NK1-receptor are aprepitant, fosa- prepitant, and netupitant. Aprepitant is given as a 125-mg oral dose followed by an 80-mg dose on the second and third day along with a 5HT3-receptor antagonist and dexa- methasone to increase its immediate and delayed protective effect for highly emetogenic chemotherapy. Fosaprepitant, the intravenous formulation of the prodrug to aprepitant, can be given at a dose of 115 mg if followed by 2 days of aprepitant or at a dose of 150 mg if given alone. NEPA is a single-dose capsule consisting of a combination of netupitant and palonosetron. For highly emetogenic chemotherapy (eg, cisplatin), patients should be offered a four-drug regimen (a 5HT3- antagonist, dexamethasone, NK1-receptor antagonist, and olanzapine), all given on the first day (and if used, aprepi- tant given again on the second and third days with dexa- methasone and olanzapine continued on days 24. For moderately emetogenic chemotherapy, standard regimens include both three-drug regimens (an NK1-antagonist, a 5HT3-antagonist, and dexamethasone) or a two-drug combination (5HT3-antagonist and dexamethasone). Palonosetron is the preferred 5HT3-blocker due to its greaterCMDT22_Ch39_p1612-p1675.indd  1672 02/07/21 2:44 PMCANCER1673 CMDT 2022affinity  for the 5HT3-receptor and its longer half-life. For low emetogenic chemotherapy drugs, a single agent such as a 5HT3-antagonist or prochlorperazine or dexamethasone can be given. A 25-mg suppository form of prochlorpera- zine may be used for patients unable to swallow oral medi- cations. Another medication that is helpful for anticipatory or refractory nausea and vomiting is olanzapine, 10 mg given orally once. The importance of treating chemotherapy-induced nau- sea and vomiting expectantly and aggressively beginning with the first course of chemotherapy cannot be overem- phasized. Patients being treated in the clinic setting should always be given antiemetics for home use with written instructions as well as contact numbers to call for advice.3.  Gastrointestinal ToxicityU ntoward effects of cancer chemotherapy include damage to the more rapidly growing cells of the body such as the mucosal lining from the mouth through the gastrointesti- nal tract. Oral symptoms range from mild mouth soreness to frank ulcerations. Not uncommonly, mouth ulcerations will have superimposed candida or herpes simplex infec- tions. In addition to receiving cytotoxic chemotherapy, a significant risk factor for development of oral mucositis is poor oral hygiene and existing caries or periodontal dis- ease. Toxicity in the gastrointestinal tract usually manifests as diarrhea. Gastrointestinal symptoms can range from mild symptoms of loose stools to life-threatening diar- rhea leading to dehydration and electrolyte imbalances. Drugs most commonly associated with causing mucositis in the mouth and the gastrointestinal tract are cytarabine, 5-fluorouracil, and methotrexate. Patients undergoing treatment for head and neck can- cer with concurrent chemotherapy and radiation therapy have a very high risk of developing severe mucositis. Preventive strategies for oral mucositis include pretreat- ment dental care, particularly for all head and neck cancer patients and any cancer patient with poor dental hygiene who will be receiving chemotherapy. For patients receiving 5-fluorouracil, simple measures such as ice chips in the mouth for 30 minutes during infusion can reduce the inci- dence and severity of mucositis. Once mucositis is encoun- tered, superimposed fungal infections should be treated with topical antifungal medications (oral nystatin mouth suspensions, or clotrimazole troches) or systemic therapy (fluconazole 100400 mg orally daily). Suspected herpetic infections can be treated with acyclovir (up to 800 mg orally five times daily) or valacyclovir (1 g orally twice daily). Mucositis may also be managed with mouthwashes; it is also important to provide adequate pain medication. Another strategy for prevention of oral mucositis is the use of palifermin, the recombinant keratinocyte growth factor inhibitor. Prophylaxis with intravenous palifermin (60 mcg/kg/day) for patients receiving high-dose chemo- therapy can reduce the incidence and duration of mucositis (Table 3912). Diarrhea is most associated with 5-fluorouracil, capecitabine, and irinotecan as well as the tyrosine kinase inhibitors (dasatinib, imatinib, nilotinib, regorafenib, sorafenib, sunitinib) and epithelial growth factor inhibitors(cetuximab, erlotinib, panitumumab). Mild to moderate diarrhea can be managed with oral antidiarrheal medica- tion (loperamide, 4 mg initially followed by 2 mg every 24 hours until bowel movements are formed). Occasion- ally, severe diarrhea will cause dehydration, electrolyte imbalances, and acute kidney injury; these patients require inpatient management with aggressive intravenous hydra- tion and electrolyte replacement. Octreotide, 100150 mcg subcutaneously three times daily, can be useful.4.  Skin ToxicityDerm atologic complications from cancer chemotherapy can include hyperpigmentation (busulfan, hydroxyurea, liposomal doxorubicin), alopecia, photosensitivity, nail changes, acral erythema, and generalized rashes. Acral erythema (hand-foot syndrome), most commonly associ- ated with administration of capecitabine, 5-fluorouracil, and liposomal doxorubicin, manifests as painful palms or soles accompanied by erythema, progressing to blistering, desquamation, and ulceration in its worst forms. Strate- gies for prevention of acral erythema include oral pyri- doxine, 200 mg daily, and applying cold packs to the extremities during chemotherapy administration. Agents targeting the epidermal growth factor pathway can cause an acne-like rash; the development of the rash may iden- tify those who will respond to the drug. Inhibitors of the tyrosine kinase pathway are also associated with a high incidence of dermatologic complications, such as rash and acral erythema.5.  Miscellaneous Drug-Specific ToxicitiesThe  toxicities of individual drugs are summarized in Tables 393 and 3912; however, several of these toxicities war- rant additional mention, since they occur with frequently administered agents, and special measures are often indicated.A.  Hemorrhagic Cystitis Induced by Cyclophosphamide or IfosfamidePa tients receiving cyclophosphamide must maintain a high fluid intake prior to and following the administration of the drug and be counseled to empty their bladders fre- quently. Early symptoms suggesting bladder toxicity include dysuria and increased frequency of urination. Should microscopic hematuria develop, it is advisable to stop the drug temporarily or switch to a different alkylating agent, to increase fluid intake, and to administer a urinary analgesic such as phenazopyridine. The neutralizing agent, mesna, can be used for patients in whom cystitis develops. With severe cystitis, large segments of bladder mucosa may be shed, resulting in prolonged gross hematuria. Such patients should be observed for signs of urinary obstruc- tion and may require cystoscopy for removal of obstructing blood clots. The cyclophosphamide analog ifosfamide can cause severe hemorrhagic cystitis when used alone. How- ever, when its use is followed by a series of doses of the neutralizing agent mesna, bladder toxicity can be pre- vented (Table 3912).CMDT22_Ch39_p1612-p1675.indd  1673 02/07/21 2:44 PMChAPTER 391674 CMDT 2022B.  Neuropathy Due to Vinca Alkaloids and Other Chemotherapy DrugsNeur opathy is caused by a number of different chemo- therapy drugs, the most common being vincristine. The peripheral neuropathy can be sensory, motor, autonomic, or a combination of these types. In its mildest form, it con- sists of paresthesias of the fingers and toes. Occasionally, acute jaw or throat pain can develop as a form of trigeminal or glossopharyngeal neuralgia. With continued vincristine therapy, the paresthesias extend to the proximal interpha- langeal joints, hyporeflexia appears in the lower extremi- ties, and significant weakness can develop. Other drugs in the vinca alkaloid class as well as the taxane drugs (docetaxel and paclitaxel) and agents to treat myeloma (bortezomib and thalidomide) cause similar toxicity. Constipation is the most common symptom of auto- nomic neuropathy associated with the vinca alkaloids. Patients receiving these drugs should be started on mild cathartics and other agents (Table 154); otherwise, severe impaction may result from an atonic bowel. More serious autonomic involvement can lead to acute intestinal obstruction with signs indistinguishable from those of an acute abdomen. Bladder neuropathies are uncommon but may be severe. These two complications are absolute con- traindications to continued vincristine therapy.C.  Methotrexate ToxicityMethotr exate, a folate antagonist, is a commonly used component of regimens to treat patients with leptomenin- geal disease, acute lymphoblastic leukemia, and sarcomas. Methotrexate is almost entirely eliminated by the kidney. Methotrexate toxicity affects cells with rapid turnover, including the bone marrow and mucosa resulting in myelosuppression and mucositis. Methotrexate can also damage the liver and kidney manifesting as elevated serum liver enzymes and creatinine. High-dose methotrexate, usually defined as a dose of 500 mg/m2or more given over 436 hours, would be lethal without rescue of the normal tissues. Leucovorin, a form of folate, will reverse the toxic effects of methotrexate and is given until serum methotrex- ate levels are in the safe range (less than 0.05 mmol/L). It is crucial that high-dose methotrexate and leucovorin are given precisely according to protocol as deviations of the timing of methotrexate delivery or delay in rescue can result in death. In a patient with kidney disease or an effu- sion, prolonged rescue with leucovorin is necessary. Vigorous hydration and bicarbonate loading can help prevent crystallization of high-dose methotrexate in the renal tubular epithelium and consequent nephrotoxicity. Daily monitoring of the serum creatinine is mandatory. If possible, drugs impairing methotrexate excretion, such as aspirin, nonsteroidal anti-inflammatory drugs, amio- darone, omeprazole, penicillin, phenytoin, and sulfa, should be stopped before methotrexate administration.D . Cardiotoxicity from Anthracyclines and Other Chemotherapy DrugsA  number of cancer chemotherapy drugs are associated with cardiovascular complications including traditionaldrugs such as anthracyclines as well as new targeted agents. The anthracycline drugs, including doxorubicin, daunomycin, epirubicin, and idarubicin, can produce acute (during administration), subacute (days to months following administration), and delayed (years following administration) cardiac toxicity. The most feared compli- cation is the delayed development of heart failure. Risk factors for this debilitating toxicity include the anthracy- cline cumulative dose, age over 70, previous or concurrent irradiation of the chest, preexisting cardiac disease, and concurrent administration of chemotherapy drugs such as trastuzumab. The problem is greatest with doxorubicin because it is the most commonly administered anthracy- cline due to its major role in the treatment of lymphomas, sarcomas, breast cancer, and certain other solid tumors. Patients receiving anthracyclines should have an assessment of left ventricular ejection fraction (LVEF). If the LVEF is greater than 50%, anthracyclines can be administered; if the LVEF is less than 30%, these drugs should not be given. For patients with intermediate values, anthracyclines can be cautiously given, if necessary, at lower doses with LVEF monitoring between doses. In general, patients should not receive doses in excess of 450 mg/m2; the dose should be lower if prior chest radiotherapy has been given. Unfortu- nately, toxicity may be irreversible and frequently fatal at total dosage levels above 550 mg/m2. At lower doses (eg, 350 mg/m2), the symptoms and signs of cardiac failure gen- erally respond well to medical therapy and discontinuation of the anthracycline. Doxorubicin and daunomycin have been formulated as liposomal products; these drugs, approved for use in patients with Kaposi sarcoma and sometimes in other cancers as a substitute for the conventional anthracy- clines, appear to have less potential for cardiac toxicity. As molecular mechanisms for cancer have been increas- ingly delineated, therapies have been developed that better target these mechanisms. Therapies targeting oncogenic pathways include (1) HER2 inhibitors (lapatinib, pertu- zumab, trastuzumab, ado-trastuzumab emtansine); (2) VEGF signaling pathway inhibitors (afilbercept, axitinib, bevacizumab, cabozantinib, lenvatinib, pazopanib, ramuci- rumab, regorafenib, sorafenib, sunitinib, vandetanib); (3) multitargeted tyrosine kinase inhibitors (dasatinib, nilo- tinib, ponatinib); (4) proteasome inhibitors (bortezomib, carfilzomib); and (5) immune checkpoint inhibitors (atezolizumab, durvalumab, ipilimumab, nivolumab, pem- brolizumab). Many of the pathways targeted by these drugs share a common biologic pathway in cardiac tissue. Untow- ard cardiac events are being increasingly reported with these agents, including arrhythmias, cardiac ischemia, myocarditis, thrombosis, and heart failure.E.  Cisplatin Nephrotoxicity and NeurotoxicityCispla tin is effective in treating testicular, bladder, head and neck, lung, and ovarian cancers. With cisplatin, the serious side effects of nephrotoxicity and neurotoxicity must be anticipated and aggressively managed. Patients must be vigorously hydrated prior to, during, and after cis- platin administration. Both kidney function and electro- lytes must be monitored. Low serum magnesium, potassium, and sodium levels can develop. The neurotoxicity is usuallyCMDT22_Ch39_p1612-p1675.indd  1674 02/07/21 2:44 PMCANCER1675 CMDT 2022mani fested as a peripheral neuropathy of mixed sensorimo- tor type and may be associated with painful paresthesias. Development of neuropathy typically occurs after cumula- tive doses of 300 mg/m2. Ototoxicity is a potentially serious manifestation of neurotoxicity and can progress to deafness. The second-generation platinum analog, carboplatin, is non-nephrotoxic, although it is myelosuppressive. In the setting of preexisting kidney disease or neuropathy, carbo- platin is occasionally substituted for cisplatin.F . Bleomycin ToxicitySee online text at www .accessmedicine.com/cmdt.PR OGNOSISPa tients receiving chemotherapy for curative intent will often tolerate side effects with the knowledge that the treat- ment may result in eradication of their cancer. Patients receiving therapy for palliative intent often have their therapy tailored to improve quality of life while minimizingmajor side effects. A valuable sign of clinical improvement is the general well-being of the patient. Although general well-being is a combination of subjective factors (possibly partly a placebo effect) and objective factors, it nonetheless serves as a sign of clinical improvement along with improved appetite and weight gain and increased performance status (eg, ambulatory versus bedridden). Evaluation of factors such as activity status enables the clinician to judge whether the net effect of chemotherapy is worthwhile pal- liation (see Chapter 5).Babiker  HM et al. Cardiotoxic effects of chemotherapy: a review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system. Crit Rev Oncol Hematol. 2018;126:186. [PMID: 29759560] Okada Y et al. One-day versus three-day dexamethasone in combination with palonosetron for the prevention of chemo- therapy-induced nausea and vomiting: a systematic review and individual patient data-based meta-analysis. Oncologist. 2019;24:1593. [PMID: 31217343]CMDT22_Ch39_p1612-p1675.indd  1675 02/07/21 2:44 PM1676 CMDT 2022ACU TE INTERMITTENT PORPHYRIAE S S E N T I A L S  O F  D I A G N O S I S Unexplained abdominal crisis, generally in young women. Acute peripheral or central nervous system dys- function; recurrent psychiatric illnesses. Hyponatremia. Porphobilinogen in the urine during an attack. General ConsiderationsTho ugh there are several different types of porphyrias, the one with the most serious consequences and the one that usually presents in adulthood is acute intermittent porphyria (AIP), which is inherited as an autosomal dominant condi- tion, though it remains clinically silent in most patients who carry a mutation in HMBS . Clinical illness usually develops in women. Symptoms begin in the teens or 20s, but onset can begin after menopause in rare cases. The disorder is caused by partial deficiency of hydroxymethylbilane synthase activ- ity, leading to increased excretion of aminolevulinic acid and porphobilinogen in the urine. The diagnosis may be elusive if not specifically considered. The characteristic abdominal pain may be due to abnormalities in autonomic innervation in the gut. In contrast to other forms of porphyria, cutaneous photosensitivity is absent in AIP . Attacks are precipitated by numerous factors, including drugs and intercurrent infec- tions. Harmful and relatively safe drugs for use in treatment are listed in Table 401. Hyponatremia may be seen, due in part to inappropriate release of antidiuretic hormone, although gastrointestinal loss of sodium in some patients may be a contributing factor. Clinical FindingsA.  Symptoms and SignsPa tients show intermittent abdominal pain of varying severity, and in some instances, it may so simulate an acuteabdomen as to lead to exploratory laparotomy. Because the origin of the abdominal pain is neurologic, there is an absence of fever and leukocytosis. Complete recovery between attacks is usual. Any part of the nervous system may be involved, with evidence for autonomic and periph- eral neuropathy. Peripheral neuropathy may be symmetric or asymmetric and mild or profound; in the latter instance, it can even lead to quadriplegia with respiratory paralysis. Other central nervous system manifestations include sei- zures, altered consciousness, psychosis, and abnormalities of the basal ganglia. Hyponatremia may further cause or exacerbate central nervous system manifestations.B.  Laboratory FindingsOften  there is profound hyponatremia. The diagnosis can be confirmed by demonstrating an increased amount of porphobilinogen in the urine during an acute attack. Freshly voided urine is of normal color but may turn dark upon standing in light and air. Most families have different mutations in HMBS caus- ing AIP . Mutations can be detected in 90% of patients and used for presymptomatic and prenatal diagnosis. PreventionA voidance of factors known to precipitate attacks of AIP especially drugscan reduce morbidity. Sulfonamides and barbiturates are the most common culprits; others are listed in Table 401 and on the Internet (www.drugs- porphyria.org). Starvation diets and prolonged fasting also cause attacks and so must be avoided. Hormonal changes during pregnancy can precipitate crises. TreatmentT reatment with a high-carbohydrate diet diminishes the number of attacks in some patients and is a reasonable empiric gesture considering its benignity. Acute attacks may be life-threatening and require prompt diagnosis, withdrawal of the inciting agent (if possible), and treat- ment with analgesics and intravenous glucose in saline and hematin. A minimum of 300 g of carbohydrate per day should be provided orally or intravenously. Electrolyte40Reed E. Pyeritz, MD, PhDGenetic & Genomic DisordersCMDT22_Ch40_p1676-p1684.indd  1676 02/07/21 2:45 PM"
                ],
                [
                  "1",
                  "DIABETES MELLITUS & HYPOGLYCEMIA1213 CMDT 2022Whih  envirnentl ftr is respnsible fr the inresed risk is nt knwn. Brestfeeding in the first 6 nths f life ppers t be prtetive. There is uu- lting evidene tht iprveents in publi helth nd redued infetins (espeilly prsiti) led t iune syste dysregultin nd develpent f utiune disrders suh s sth nd type 1 dibetes. Chek pint inhibitr iuntherpies fr dvned lignnies, suh s nivlub, pebrlizub, nd ipiliub, n preipitte utiune disrders, inlud- ing type 1 dibetes. The nset f dibetes n be rpid nd the ptients frequently hve dibeti ketidsis t pre- senttin. Autntibdies ginst islet ntigens re nly present in but 50% f ptients. Ptients reeiving these drugs shuld be refully nitred fr the develpent f dibetes. Apprxitely 5% f subjets hve n evidene f pn- reti B ell utiunity t explin their insulinpeni nd ketidsis. This subgrup hs been lssified s idipthi type 1 dibetes nd designted s type 1B.  Althugh nly  inrity f ptients with type 1 dibetes fll int this grup, st f these individuls re f Asin r Afrin rigin. Abut 4% f the West Afrins with ketsis-prne dibetes re hzygus fr  uttin in PAX-4 (Arg133Trp ) trnsriptin ftr tht is essentil fr the develpent f pnreti islets.B.  Type 2 Diabetes MellitusT ype 2 dibetes is due t nn-iune uses f pnreti B ell lss with vrible degree f tissue insensitivity t insulin, tht is, insulin resistne. The residul bet ell funtin is suffiient t prevent ketidsis but is inde- qute t prevent the hyperglyei. This fr f dibetes used t ur predinntly in dults, but it is nw re frequently enuntered in hildren nd dlesents.Geneti nd envirnentl ftrs bine t use bth the bet ell lss nd the insulin resistne. Mst epi- deilgi dt indite strng geneti influenes, sine in nzygti twins ver 40 yers f ge, nrdne develps in ver 70% f ses within  yer whenever type 2 dibetes develps in ne twin. Gene wide ssitin studies hve identified 143 risk vrints nd puttive regu- ltr ehniss fr type 2 dibetes. A signifint nuber f the identified li pper t de fr prteins tht hve  rle in bet ell funtin r develpent. One f the geneti li with the lrgest risk effet is TCF7L2 . This gene des fr  trnsriptin ftr invlved in the WNT sig- nling pthwy tht is required fr nrl pnreti develpent. Obesity is the most important environmental factor causing insulin resistance. The degree nd prevlene f besity vries ng different ril grups with type 2 dibetes. While besity is pprent in n re thn 30% f Chinese nd Jpnese ptients with type 2, it is fund in 6070% f Nrth Aerins, Eurpens, r Afrins with type 2 nd pprhes 100% f ptients with type 2 ng Pi Indins r Pifi Islnders fr Nuru r S. Viserl besity, due t uultin f ft in the entl nd esenteri regins, rreltes with insulin resistne; subutneus bdinl ft sees t hve less f n ssitin with insulin insensitivity. There re ny ptients with type 2 dibetes wh, while nt vertly bese, hve inresed viserl ft; they re tered the etbli- lly bese.  Exerise y ffet the depsitin f viserl ft s suggested by CT sns f Jpnese wrestlers, whse extree besity is predinntly subutneus. Their dily vigrus exerise prgr prevents uultin f viserl ft, nd they hve nrl seru lipids nd eugly- ei despite dily intkes f 50007000 kl nd develp- ent f ssive subutneus besity.C.  Other Specific Types of Diabetes Mellitus1.  Maturityonset diabetes of the young (MODY) This subgrup f ngeni disrders is hrterized by nn- insulin requiring dibetes with utsl dinnt inher- itne nd n ge t nset f 25 yers r yunger. Ptients re nnbese, nd their hyperglyei is due t ipired gluse-indued seretin f insulin. Six types f MODY hve been desribed (Tble 271). Exept fr MODY 2, in whih  glukinse gene is defetive, ll ther types invlve uttins f  nuler trnsriptin ftr tht regultes islet gene expressin. Ptients yunger thn 30 yers with endgenus insulin prdutin (urinry C-peptide/retinine rti f 0.2 nl/l r higher) nd negtive utntibdies re ndidtes fr geneti sreening fr MODY. The enzye glukinse is  rte- liiting step in glylysis nd deterines the rte f de- nsine triphsphte (ATP) prdutin fr gluse nd the insulin seretry respnse in the bet ell. MODY 2, due t glukinse uttins, is usully quite ild, ssi- ted with nly slight fsting hyperglyei nd few if ny irvsulr dibeti plitins. MODY 3, due t uttins in hepti nuler ftr 1 lph, is the st n fr, unting fr tw-thirds f ll MODY ses. Initilly, ptients with MODY 3 re respnsive tTable 271. Other specific types of diabetes mellitus.Genetic  defects of pancreatic B cell function MODY 1 (HNF-4alpha); rare MODY 2 (glucokinase); less rare MODY 3 (HNF-1alpha); accounts for two-thirds of all MODY MODY 4 (PDX1); very rare MODY 5 (HNF-1beta); very rare MODY 6 (neuroD1); very rare Mitochondrial DNA Wolfram syndrome Genetic defects in insulin action Type A insulin resistance Leprechaunism Rabson-Mendenhall syndrome Lipoatrophic diabetes Diseases of the exocrine pancreas Endocrinopathies Drug- or chemical-induced diabetes Other genetic syndromes (Down, Klinefelter, Turner, others) sometimes associated with diabetes HNF, hepatic nuclear factor; MODY, maturity-onset diabetes of the young; PDX1, pancreatic duodenal homeobox 1.CMDT22_Ch27_p1212-p1255.indd  1213 29/06/21 8:53 PMCHAPTEr 271214 CMDT 2022sulfn ylure therpy but the linil urse is f prgres- sive bet ell filure nd eventul need fr insulin therpy. Muttins in bth lleles f glukinse present with re severe nentl dibetes. Muttin in ne llele f the pn- reti dudenl hebx 1 (PDX1) uses dibetes usu- lly t  lter ge (~ 35 yers) thn ther frs f MODY; uttins in bth lleles f PDX1 use pnreti genesis. 2. Diabetes mellitus associated with a mutation of mito chondrial DNA Sine sper d nt ntin ithn- dri, nly the ther trnsits ithndril genes t her ffspring. Dibetes due t uttins f ithndril DNA urs in less thn 2% f ptients with dibetes. The st n use is the A3243G uttin in the gene ding fr the tRNA (Leu, UUR). Dibetes usully devel- ps in these ptients in their lte 30s, nd hrteristilly, they ls hve hering lss (ternlly inherited dibetes nd defness [MIDD]). 3. Wolfram syndrome Wlfr syndre is n uts- l reessive neurdegenertive disrder first evident in hildhd. It nsists f dibetes insipidus, dibetes elli- tus, pti trphy, nd defness, hene the rny DID- MOAD. It is due t uttins in  gene ned WFS1 , whih endes  100.3 KD trnsebrne prtein ll- ized in the endplsi retiulu. Crnil dibetes insipi- dus nd sensrineurl defness develp during the send dede in 6075% f ptients. Ureterhydrnephrsis, neurgeni bldder, erebellr txi, peripherl neurp- thy, nd psyhitri illness develp lter in ny ptients. 4. Autosomal recessive syndromes Hzygus ut- tins in  nuber f pnreti trnsriptin ftrs, NEU- ROG3, PTF1A, RFX6 , nd GLI-similar 3 (GLIS3) , use nentl r hildhd dibetes. Hzygus PTF1A uttins result in bsent pnres nd erebellr trphy; NEUROG3 uttins use severe lbsrptin nd dibetes befre puberty. Hzygus uttins in RFX6 use the Mithell-Riley syndre hrterized by bsene f ll islet ell types prt fr pnreti ply- peptide ells, hypplsi f the pnres nd gllbldder, nd intestinl tresi. GLIS3 gene plys  rle in trnsrip- tin f insulin gene, nd hzygus uttins use nentl dibetes nd ngenitl hypthyridis. The gene EIF2AK3 endes PKR-like ER kinse (PERK), whih ntrls ne f the pthwys f the unflded prtein respnse. Absene f PERK leds t indequte respnse t ER stress nd elerted bet ell pptsis. Ptients with uttin in this gene hve nentl dibetes, epiphysel dysplsi, develpentl dely, nd liver nd kidney dys- funtin (Wltt-Rllisn syndre). 5. Diabetes mellitus secondary to other causes End- rine turs sereting grwth hrne, glurtiids, tehlines, glugn, r ststtin n use glu- se intlerne (Tble 272). In the first fur f these situ- tins, peripherl respnsiveness t insulin is ipired. With exess f glurtiids, tehlines, r glu- gn, inresed hepti utput f gluse is  ntributry ftr; in the se f tehlines, deresed insulin relese is n dditinl ftr in prduing rbhydrteintlerne, nd with ststtin, inhibitin f insulin seretin is the jr ftr. Dibetes inly urs in individuls with underlying defets in insulin seretin, nd hyperglyei typilly reslves when the hrne exess is reslved. High-titer nti-insulin reeptr ntibdies tht inhibit insulin binding use  linil syndre hrterized by severe insulin resistne, gluse intlerne r dibetes ellitus, nd nthsis nigrins. These ptients usully hve ther utiune disrders. There re reprts f spntneus reissin r reissin with yttxi therpy. Mny drugs re ssited with rbhydrte intler- ne r frnk dibetes (Tble 272). The drugs t by deresing insulin seretin r by inresing insulin resis- tne r bth. Cylsprine nd trlius ipir insulin seretin; sirlius priniplly inreses insulin resistne. These gents ntribute t the develpent f new-nset dibetes fter trnsplnttin. Crtisterids inrese insulin resistne but y ls hve n effet n bet ell funtin; in  se ntrl study nd  lrge ppultin hrt study, rl rtisterids dubled the risk fr develpent f dibetes. Thizide diuretis nd bet- blkers destly inrese the risk fr dibetes. Treting the hypklei due t thizides y reverse the hyper- glyei. Atypil ntipsyhtis, prtiulrly lnzpine nd lzpine, re ssited with inresed risk f gluse intlerne. These drugs use weight gin nd insulin resistne but y ls ipir bet ell funtin; n inrese in rtes f dibeti ketidsis (DKA) hs been reprted. Alpelisib is  phsphtidylinsitl-3-kinse (PI3K) inhibitr nd is pprved fr use in bintin with fulvestrnt fr hrne reeptrpsitive, HER2- negtive, PIK3CA -utted brest ner. PI3K is  p- nent f the insulin signling pthwy, nd hyperglyei is  n side effet f lpelisib tretent. Chrni pnretitis r subttl pnretety redues the nuber f funtining B ells nd n result in  etbli derngeent very siilr t tht f geneti type 1 dibetes exept tht  nitnt redu- tin in pnreti A ells y redue glugn seretin s tht reltively lwer dses f insulin repleent re needed.Table 272. Secondary causes of hyperglycemia.Hypeglycemia  due to tissue insensitivity to insulin Medications (corticosteroids, sympathomimetic drugs, niacin, alpelisib, sirolimus) Hormonal tumors (acromegaly, Cushing syndrome, glucagonoma, pheochromocytoma) Liver disease (cirrhosis, hemochromatosis) Muscle disorders (myotonic dystrophy) Adipose tissue disorders (lipodystrophy, truncal obesity) Hypeglycemia due to educed insulin secetion Medications (thiazide diuretics, phenytoin, pentamidine, calcineurin inhibitors, atypical antipsychotics) Hormonal tumors (somatostatinoma, pheochromocytoma) Pancreatic disorders (pancreatitis, hemosiderosis, hemochromatosis)CMDT22_Ch27_p1212-p1255.indd  1214 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1215 CMDT 2022 Metabolic Syndrome (Insulin Resistance Syndrome)The  ter etbli syndre hs been dvted t iden- tify individuls wh were t higher risk fr develpent f dibetes nd rdivsulr disese. Criteri inluded wist iruferene, gluse levels, bld pressure, trigly- erides, nd HDL hlesterl. There is, hwever, n unify- ing pthphysilgi bsis fr the syndre, nd in 2010,  WHO expert ittee reprted tht the syndre lked utility s  dignsti r ngeent tl. They bserved tht there ws nly dest ssitin between etbli syndre nd rdivsulr disese, nd the definitin ws utperfred by trditinl rdivsulr risk preditin lgriths suh s the Fringh risk sre. Siilrly, fsting gluse nveys  greter risk f inident dibetes thn the etbli syndre. There is ls n evidene tht hyperinsulinei nd insulin resis- tne ply  diret rle in these etbli bnrlities. Clinical Trials about Optimum Diabetic Glucose ControlFindings  f the Dibetes Cntrl nd Cplitins Tril nd f the United Kingd Prspetive Dibetes Study hve nfired the benefiil effets f iprved glyei ntrl in bth type 1 nd type 2 dibetes.A.  Type 1 DiabetesThe Dia betes Control and Complications Trial (DCCT),  lng-ter therpeuti study invlving 1441 ptients with type 1 dibetes ellitus, reprted tht ner nrliz- tin f bld gluse resulted in  dely in the nset nd  jr slwing f the prgressin f estblished irvs- ulr nd neurpthi plitins f dibetes. In hlf f the ptients,  en heglbin A1f 7.2% (nrl: less thn 6%) nd  en bld gluse f 155 g/dL (8.6 l/L) were hieved using intensive therpy, while in the nventinlly treted grup, HbA1 verged 8.9% with n verge bld gluse f 225 g/dL (12.5 l/L). Over the study perid, whih verged 7 yers, there ws n pprxitely 60% redutin in risk between the tw grups in regrd t dibeti retinpthy, nephrpthy, nd neurpthy. The intensively treted grup ls hd  nnsignifint redutin in the risk f rvsulr disese f 41% (95% CI, 10% t 68%). Intensively treted ptients hd  threefld greter risk f serius hypglyei s well s  greter tendeny twrd weight gin. Hwever, there were n deths definitely ttributble t hypglyei in ny persns in the DCCT study, nd n evidene f psthypglyei gnitive dge ws deteted. Prtiipnts in the DCCT study were subsequently enrlled in  fllw-up bservtinl study, the Epideil- gy f Dibetes Interventins nd Cplitins (EDIC) study. Even thugh the between-grup differenes in en HbA1nrrwed ver 4 yers, the grup ssigned t inten- sive therpy hd  lwer risk f retinpthy t 4 yers, irlbuinuri t 78 yers, nd ipired GFR (less thn 60 L/in/1.73 2) t 22 yers f ntinued studyfllw-up. Mrever, by the end f the 11-yer fllw-up perid, the intensive therpy grup hd signifintly redued their risk f ny rdivsulr disese events by 42% (95% CI, 9% t 23%; P= 0.02). Thus, it sees tht the benefits f gd gluse ntrl persist even if ntrl deterirtes t  lter dte. The generl nsensus f the ADA is tht intensive insulin therpy ssited with prehensive self- ngeent trining shuld be stndrd therpy in ptients with type 1 dibetes ellitus fter the ge f puberty. Exeptins inlude thse with dvned hrni kidney disese nd lder dults sine the detrientl risks f hypglyei utweigh the benefits f tight glyei ntrl in these grups.B.  Type 2 DiabetesThe  United Kingdom Prospective Diabetes Study (UKPDS),  ultienter study, ws designed t estblish whether the risk f rvsulr r irvsulr - plitins uld be redued by intensive bld gluse ntrl with rl hypglyei gents r insulin nd whether ny prtiulr therpy ws re benefiil thn the ther in type 2 dibeti ptients. Intensive tretent with either sulfnylures, etfr- in, bintins f thse tw, r insulin hieved en HbA1levels f 7%. This level f glyei ntrl deresed the risk f irvsulr plitins (retinpthy nd nephrpthy) in prisn with nventinl therpy (stly diet lne), whih hieved en levels f HbA1 f 7.9%. Weight gin urred in intensively treted ptients exept when etfrin ws used s ntherpy. N dverse rdivsulr utes were nted regrdless f the therpeuti gent. In the verweight r bese sub- grup, etfrin therpy ws re benefiil thn diet lne in reduing the nuber f ptients wh suffered yrdil infrtins nd strkes. Hypglyei re- tins urred in the intensive tretent grups, but nly ne deth fr hypglyei ws duented during 27,000 ptient-yers f intensive therpy. Tight ntrl f bld pressure (edin vlue 144/82  Hg vs 154/87  Hg) substntilly redued the risk f irvsulr disese nd strke but nt y- rdil infrtin. In ft, reduing bld pressure by this unt hd substntilly greter ipt n irvsulr utes thn tht hieved by lwering HbA1fr 7.9% t 7%. An epideilgi nlysis f the UKPDS dt shwed tht every 10  Hg derese in en systli bld pressure ws ssited with 11% redutin in risk fr yrdil infrtin. Mre thn hlf f the ptients needed tw r re editins fr dequte therpy f their hypertensin, nd there ws n denstrble dvn- tge f ngitensin-nverting enzye (ACE) inhibitr therpy ver therpy with bet-blkers with regrd t dibetes end pints. Use f  liu hnnel blker dded t bth tretent grups ppered t be sfe ver the lng ter in this dibeti ppultin despite se ntrversy in the literture but its sfety in ptients with dibetes. Like the DCCT trilists, the UKPDS reserhers per- fred pst-tril nitring t deterine whether thereCMDT22_Ch27_p1212-p1255.indd  1215 29/06/21 8:53 PMCHAPTEr 271216 CMDT 2022were  lng-ter benefits f hving been in the intensively treted gluse nd bld pressure rs f the study. The intensively treted grup hd signifintly redued risk f yrdil infrtin (15%, P= 0.01) nd deth fr ny use (13%, P= 0.007) during the fllw-up perid. The subgrup f verweight r bese subjets wh were ini- tilly rndized t etfrin therpy shwed sustined redutin in risk f yrdil infrtin nd deth fr ny use in the fllw-up perid. Unlike the sustined benefits seen with gluse ntrl, there were n sustined benefits fr hving been in the re tightly ntrlled bld pressure grup. Bth bld pressure grups were t siilr risk fr irvsulr events nd dibetes-relted end pints during the fllw-up perid. Thus, the fllw-up f the UKPDS type 2 dibetes hrt shwed tht, s in type 1 dibetes, the benefits f gd gluse ntrl persist even if ntrl deterirtes t  lter dte. Bld pressure benefits, hwever, lst nly s lng s the bld pressure is well ntrlled. Diabetes Prevention TrialsA.  Prevention of Type 1 DiabetesAt  the tie f dignsis f type 1 dibetes, there reins signifint B ell pnreti funtin. This explins why sn fter dignsis, the dibetes ges int prtil linil reissin nd little r n insulin is required (hneyn). The linil reissin is shrt- lived, hwever, nd eventully ptients lse ll B ell fun- tin nd hve re lbile gluse ntrl. Studies hve been perfred t prlng this prtil linil reissin using iundultry gents. The CD3 plex is the jr signl-trnsduing eleent f the T ell reep- tr, nd the nti-CD3 ntibdies re believed t dulte the utiune respnse by seletively inhibiting the pthgeni T ells r by induing regultry T ells. Phse 1/2 nd 2/3 linil trils f hunized nlnl nti- bdies ginst CD3, hOKT3g (Al-Al) (tepli- zub), nd ChAglyCD3 (telixizub) delyed but did nt pletely rrest the deline in insulin prdutin in ptients with newly dignsed type 1 dibetes. A siilr phse 2 linil tril using teplizub ws undertken in nndibeti reltives f ptients with type 1 dibetes wh hd tw r re dibetes-relted ntibdies nd gluse intlerne. In the 5 yers fter rndiztin, 43% f the ptients reeiving teplizub nd 72% f the pleb grup develped dibetes.B.  Prevention of Type 2 DiabetesThe  Dibetes Preventin Prgr studied whether tret- ent with either diet nd exerise r etfrin uld prevent the nset f type 2 dibetes in verweight en nd wen ged 2585 yers wh hd ipired gluse tler- ne. Interventin with  lw-ft diet nd 150 inutes f derte exerise (equivlent t  brisk wlk) per week redued the risk f prgressin t type 2 dibetes by 71%. Prtiipnts wh tk etfrin 850 g twie dily redued their risk f develping type 2 dibetes by 31%, but this interventin ws reltively ineffetive in thse wh were either less bese r in the lder ge grup.Eighty-eight perent f the persns in the Dibetes Preven- tin Prgr eleted t ntinue fllw up in the Dibetes Preventin Prgr Oute Study. At 15 yers f fllw up, the uultive inidene f dibetes ws 55% in the lifestyle grup nd 62% in the ntrl grup. Clinical FindingsA.  Symptoms and Signs1.  Type 1 diabetes A hrteristi sypt plex f hypersllity nd hyperketnei fr the uul- tin f irulting gluse nd ftty ids typilly presents in ptients with type 1 dibetes. When bslute insulin defiieny is f ute nset, there is brupt inrese in uri- ntin, thirst, blurred visin, weight lss, presthesis, nd ltered level f nsiusness. Ketidsis exerbtes the dehydrtin nd hypersllity by prduing nrexi nd nuse nd viting, interfering with rl fluid repleent. a. Increased urination and thirst These sypts re nsequenes f sti diuresis sendry t sus- tined hyperglyei. The diuresis results in  lss f glu- se s well s free wter nd eletrlytes in the urine. b. Blurred vision As the lenses re expsed t hyper- slr fluids, blurred visin ften develps. c. Weight loss Despite nrl r inresed ppetite, weight lss is  n feture f type 1 when it develps subutely. The weight lss is initilly due t depletin f wter, glygen, nd triglyerides; therefter, redued us- le ss urs s in ids re diverted t fr gluse nd ketne bdies. Lss f subutneus ft nd usle wsting re fetures f re slwly develping insulin defiieny. Lwered pls vlue prdues sypts f psturl hyptensin, whih is  serius prgnsti sign. Ttl bdy ptssiu lss nd the generl tblis f usle prtein ntribute t the wekness. d. Paresthesias Presthesis y be present t the tie f dignsis, prtiulrly when the nset is subute. They reflet  teprry dysfuntin f peripherl sensry nerves, whih lers s insulin repleent restres glye- i levels lser t nrl, suggesting neurtxiity fr sustined hyperglyei. e. The level of consciousness shown by the patient The ptients level f nsiusness n vry depending n the degree f hypersllity. When insulin defiieny develps reltively slwly nd suffiient wter intke is intined, ptients rein reltively lert nd physil findings y be inil. When viting urs in respnse t wrsening ketidsis, dehydrtin pr- gresses nd penstry ehniss bee indequte t keep seru sllity belw 320330 Os/L. Under these irustnes, stupr r even  y ur. The fruity breth dr f etne further suggests the dignsis f DKA. 2. Type 2 diabetes While inresed urintin nd thirst y be presenting sypts in se ptients with type 2 dibetes, ny ther ptients hve n insidius nset fCMDT22_Ch27_p1212-p1255.indd  1216 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1217 CMDT 2022hypergly ei nd re syptti initilly. This is pr- tiulrly true in bese ptients, whse dibetes y be deteted nly fter glysuri r hyperglyei is nted during rutine lbrtry studies. Osinlly, when the disese hs been ult fr se tie, ptients y hve evidene f neurpthi r rdivsulr plitins t the tie f presenttin. Hyperglyei hyperslr  n ls be present when the seru sllity exeeds 320330 Os/L; in these ses, ptients re pr- fundly dehydrted, hyptensive, lethrgi, r tse but withut the Kussul respirtins f ketidsis. a. Skin manifestations Chrni skin infetins re n. Generlized pruritus nd sypts f vginitis re frequently the initil plints f wen. Dibetes shuld be suspeted in wen with hrni ndidl vul- vvginitis. Blnpsthitis (infltin f the freskin nd glns in uniruised les) y ur. Other skin findings inlude nthsis nigrins. whih is ssited with signifint insulin resistne. The skin in the xill, grin, nd bk f nek is hyperpigented nd hyperkertti (Figure 271). Eruptive xnths n the flexr surfe f the libs nd n the buttks nd lipei retinlis due t hyperhylirnei n ur in ptients with unntrlled type 2 dibetes wh ls hve  filil fr f hypertriglyeridei. b. Body habitus Overweight r bese ptients fre- quently hve type 2 dibetes. Even thse wh re nt sig- nifintly bese ften hve hrteristi lliztin f ft depsits n the upper segent f the bdy (prtiulrly the bden, hest, nek, nd fe) nd reltively less ft n the ppendges, whih y be quite usulr. This en- tripetl ft distributin is hrterized by  high wist iruferene;  wist iruferene lrger thn 40 inhes (102 ) in en nd 35 inhes (88 ) in wen is ssi- ted with n inresed risk f dibetes. Mild hypertensin is ften present in bese ptients with dibetes. c. Obstetrical complications Type 2 dibetes shuld be nsidered in wen wh hve delivered bbieslrger thn 9 lb (4.1 kg) r hve hd plyhydrnis, pre- elpsi, r unexplined fetl lsses.B.  Laboratory Findings1. Urine  glucose A nvenient ethd t detet glus- uri is the pper strip ipregnted with gluse xidse nd  hrgen syste (Clinistix, Distix), whih is sen- sitive t s little s 100 g/dL (5.5 l) gluse in urine. A nrl renl threshld fr gluse s well s relible bldder eptying is essentil fr interprettin. Nndibeti glysuri (renl glysuri) is  benign syptti nditin wherein gluse ppers in the urine despite  nrl unt f gluse in the bld, either bslly r during  gluse tlerne test. Its use y vry fr uttins in the SGLT2 gene ding fr sdiu-gluse trnsprter 2 (filil renl glysuri) t ne ssited with dysfuntin f the prxil renl tubule (Fnni syndre, hrni kidney disese), r it y erely be  nsequene f the inresed ld f glu- se presented t the tubules by the elevted glerulr filtrtin rte (GFR) during pregnny. As ny s 50% f pregnnt wen nrlly hve denstrble sugr in the urine, espeilly during the third nd furth nths. This sugr is prtilly lwys gluse exept during the lte weeks f pregnny, when ltse y be present. 2. Urine and blood ketones Qulittive detetin f ketne bdies n be plished by nitrprusside tests (Aetest r Ketstix). Althugh these tests d nt detet bet-hydrxybutyri id, whih lks  ketne grup, the seiquntittive estitin f ketnuri thus btined is nnetheless usully dequte fr linil purpses. Mny lbrtries esure bet-hydrxybutyri id, nd there re eters vilble (Preisin Xtr; Nv Mx Plus) fr ptient use tht esures bet-hydrxybutyri id levels in pillry gluse sples. Bet-hydrxybutyrte levels greter thn 0.6 l/L require evlutin. Ptients with levels greter thn 3.0 l/L, equivlent t very lrge urinry ketnes, require hspitliztin. 3. Plasma or serum glucose The gluse nentrtin is 1015% higher in pls r seru thn in whle bld beuse struturl pnents f bld ells re bsent. A pls gluse level f 126 g/dL (7 l/L) r higher n re thn ne sin fter t lest 8 hurs f fsting is dignsti f dibetes ellitus (Tble 273). Fsting pls gluse levels f 100125 g/dL (5.66.9 l/L) re ssited with inresed risk f dibetes (ipired fsting gluse tlerne). 4. Oral glucose tolerance test If the fsting pls glu- se level is less thn 126 g/dL (7 l/L) when dibetes is nnetheless suspeted, then  stndrdized rl gluse tlerne test y be dne (Tble 273). In rder t pti- ize insulin seretin nd effetiveness, espeilly when ptients hve been n  lw-rbhydrte diet,  iniu f 150200 g f rbhydrte per dy shuld be inluded in the diet fr 3 dys preeding the test. The ptient shuld et nthing fter idnight prir t the test dy. On the rn- ing f the test, ptients re then given 75 g f gluse in 300 L f wter. The gluse ld is nsued within Figure 271. Acanthosis nigricans of the nape of the neck, with typical dark and velvety appearance. (Used, with permission, from Umesh Masharani, MB, BS, MRCP [UK].)CMDT22_Ch27_p1212-p1255.indd  1217 29/06/21 8:53 PMCHAPTEr 271218 CMDT 20225  inutes. The test is perfred in the rning beuse f diurnl vritin in rl gluse tlerne; ptients shuld nt ske r be tive during the test. Bld sples fr pls gluse re btined t 0 nd 120 inutes fter ingestin f gluse. Tble 273 pr- vides dignsti riteri fr dibetes ellitus bsed n the rl gluse tlerne test. An rl gluse tlerne test is nrl if the fsting venus pls gluse vlue is less thn 100 g/dL (5.6 l/L) nd the 2-hur vlue flls belw 140 g/dL (7.8 l/L). A fsting vlue f 126 g/dL (7 l/L) r higher r  2-hur vlue f greter thn 200 g/dL (11.1 l/L) is dignsti f di- betes ellitus. Ptients with  2-hur vlue f 140199 g/dL (7.811.1 l/L) hve ipired gluse tlerne. Flse- psitive results y ur in ptients wh re lnurished, bedridden, r fflited with n infetin r severe etinl stress. 5. Glycated hemoglobin (hemoglobin A1) measure ments Heglbin bees glyted by ketine retins between gluse nd ther sugrs nd the free in grups n the lph nd bet hins. Only glytin f the N-terinl vline f the bet hin iprts suffi- ient negtive hrge t the heglbin leule t llw seprtin by hrge dependent tehniques. These hrge- seprted heglbins re lletively referred t s heglbin A1(HbA1). The jr fr f HbA1is he- glbin A1(HbA1) where gluse is the rbhydrte. HbA1prises 46% f ttl heglbin A. Sine HbA1irultes within red bld ells whse life spn lsts up t 120 dys, it generlly reflets the stte f glyei ver the preeding 812 weeks, thereby prviding n iprved ethd f ssessing dibeti ntrl. The HbA1vlue, hwever, is weighted t re reent gluse levels (previus nth) nd this explins why signifint hnges in HbA1re bserved with shrt-ter (1 nth) hnges in en pls gluse levels. Mesureents shuld be de in ptients with either type f dibetes ellitus t 3- t 4-nth intervls. In ptients nitring their wn bld gluse levels, HbA1vlues prvide  vluble hek n the ury f nitring. In ptientswh d nt nitr their wn bld gluse levels, HbA1 vlues re essentil fr djusting therpy. The A1Derived Averge Gluse Study reprted tht the reltinship between verge gluse in the previus 3 nths nd HbA1ws (28.7  HbA1)  46.7. There is, hwever, sub- stntil individul vribility; fr HbA1vlues between 6.9% nd 7.1%, the gluse levels rnge fr 125 g/dL t 205 g/dL (6.911.4 l/L; 95% CIs). Fr HbA1f 6%, the en gluse levels rnge fr 100 g/dL t 152 g/dL (5.58.5 l/L); nd fr 8% they rnge fr 147 g/dL t 217 g/dL (8.112.1 l/L). Fr this resn, utin shuld be exerised in estiting verge gluse levels fr esured HbA1. The ury f HbA1vlues n be ffeted by he- glbin vrints r trits. In ptients with high levels f he- glbin F, iunssys give flsely lw vlues f HbA1. The Ntinl Glyheglbin Stndrdiztin Prgr web- site (www.ngsp.rg) hs infrtin n the ipt f fre- quently enuntered heglbin vrints nd trits n the results btined with the nly used HbA1ssys. Any nditin tht shrtens erythryte survivl r dereses en erythryte ge (eg, revery fr ute bld lss, helyti nei) will flsely lwer HbA1, irrespetive f the ssy ethd used beuse f the extended tie tht it tkes irulting heglbin t be glysylted. Intrvenus irn nd erythrpietin therpy fr tretent f nei in hrni kidney disese ls flsely lwer HbA1levels. Alterntive ethds suh s frutsine (see belw) shuld be nsidered fr these ptients. Vitins C nd E re reprted t flsely lwer test results pssibly by inhibiting glytin f heglbin. Cnditins tht inrese erythryte survivl suh s sple- nety fr hereditry spherytsis will flsely rise HbA1levels. Irn defiieny nei is ls ssited with higher HbA1levels. HbA1is endrsed by the ADA s  dignsti test fr type 1 nd type 2 dibetes (Tble 273). A utff vlue f 6.5% (48 l/l) ws hsen beuse the risk fr reti- npthy inreses substntilly bve this vlue. The advantages of using the HbA1cto diagnose diabetes is that there is no need to fast; it hs lwer intrindividul vri- bility thn the fsting gluse test nd the rl gluse tlerne test; nd it prvides n estite f gluse n- trl fr the preeding 23 nths. Peple with HbA1lev- els f 5.76.4% (3946 l/l) shuld be nsidered t high risk fr develping dibetes (predibetes). This test is nt pprprite t use in ppultins with high prevlene f heglbinpthies r in nditins with inresed red ell turnver. 6. Serum fructosamine Seru frutsine is fred by nnenzyti glysyltin f seru prteins (pre- dinntly lbuin). Sine seru lbuin hs  uh shrter hlf-life thn heglbin, seru frutsine generlly reflets the stte f glyei ntrl fr nly the preeding 12 weeks. Redutins in seru lbuin (eg, nephrti stte, prtein-lsing enterpthy, r hepti dis- ese) will lwer the seru frutsine vlue. When bnrl heglbins r helyti sttes ffet the inter- prettin f glyheglbin r when  nrrwer tieTable 273. Criteria for the diagnosis of diabetes. Nomal Glucose Toleance1Impaied Glucose Toleance1Diabetes Mellitus2F asting plasma glucose mg/dL (mmol/L)< 100 (5.6) 100125 (5.66.9) 126 (7.0) 2 hours after glucose load mg/dL (mmol/L)< 140 (7.8)  140199 (7.811.0) 200 (11.1) HbA1c(%) < 5.7 5.76.4  6.51 See text for the oral glucose tolerance test protocol.2 A fasting plasma glucose  126 mg/dL (7.0 mmol) is diagnostic of diabetes if confirmed by repeat testing. A fasting plasma glucose  126 mg/dL (7.0 mmol) and HbA1c 6.5% on the same sample is also diagnostic of diabetes.CMDT22_Ch27_p1212-p1255.indd  1218 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1219 CMDT 2022fre  is required, suh s fr sertining glyei ntrl t the tie f neptin in  dibeti wn wh hs reently bee pregnnt, seru frutsine ssys ffer se dvntge. Nrl vlues vry in reltin t the seru lbuin nentrtin nd re 200285 l/L when the seru lbuin level is 5 g/dL. HbA1vlues nd seru frutsine re highly rrelted. Seru fruts- ine levels f 300, 367, nd 430 l/L pprxite t HbA1vlues f 7%, 8%, nd 9%, respetively. Substntil individul vribility exists, thugh, when estiting the likely HbA1vlue fr the frutsine esureent. 7. Selfmonitoring of blood glucose Cpillry bld gluse esureents perfred by ptients theselves, s utptients, re extreely useful. A lrge nuber f bld gluse eters re vilble. All re urte, but they vry with regrd t speed, nveniene, size f bld sples required, reprting pbility, nd st. Ppulr dels inlude thse nuftured by LifeSn (One Tuh), Byer Crprtin (Cntur), Rhe Dignstis (Au-Chek), nd Abbtt Lbrtries (Preisin, Free- Style). These bld gluse eters re reltively inexpen- sive, rnging fr $20 t $80 eh. Test strips rein  jr expense, sting but $0.25 t $1.50 piee. Eh gluse eter ls es with  lnet devie nd disps- ble 26- t 33-guge lnets. Mst eters n stre fr 100 t 1000 gluse vlues in their eries nd hve pbilities t dwnld the vlues int  puter r srtphne. Se eters re designed t unite with  speifi insulin pup. Cntur Next Link eter, fr exple, unites with the MiniMed Medtrni pup. The ury f dt btined by he gluse nitring des require edutin f the ptient in s- pling nd esuring predures. The liniin shuld be wre f the liittins f the self-nitring gluse systes. The strips hve liited lifespns nd iprper strge (high teperture; pen vil) n ffet their funtin. Ptients shuld ls be dvised nt t use expired strips. Inreses r dereses in hetrit n derese r inrese the esured glu- se vlues. Meters nd the test strips re librted ver the gluse nentrtins rnging fr 60 g/dL (3.3 l/L) t 160 g/dL (8.9 l/L) nd the ury is nt s gd fr higher nd lwer gluse levels. When the gluse is less thn 60 g/dL (3.3 l/L), the differ- ene between the eter nd the lbrtry vlue y be s uh s 20%. Gluse xidsebsed peretri sys- tes underestite gluse levels in the presene f high xygen tensin. This y be iprtnt in the ritilly ill wh re reeiving suppleentl xygen; under these ir- ustnes,  gluse dehydrgensebsed syste y be preferble. Gluse-dehydrgense pyrrlquin- line quinne (GDH-PQQ) systes y reprt flsely high gluse levels in ptients wh re reeiving prenterl prduts ntining nngluse sugrs suh s ltse, gltse, r xylse r their etblites. Se eters re pprved fr esuring gluse in bld sples btined t lterntive sites suh s the frer nd thigh. There is, hwever,  5- t 20-inute lg in the gluse respnse n the r with respet t the gluse respnse n the finger.Frer bld gluse esureents uld therefre result in  dely in detetin f rpidly develping hypgly- ei. Ipired irultin t the fingers (fr exple, in ptients with Rynud disese) will rtifiilly lwer fingerstik gluse esureents (pseudhypglyei). 8. Continuous glucose monitoring systems A gluse xidsebsed syste t esure gluse nentrtins in the interstitil fluid is used by ptients wh re inres- ingly using ntinuus gluse nitring systes. These systes, nuftured by Medtrni MiniMed, DexC systes, nd Abbtt Dignstis, invlve inserting  sub- utneus sensr (rther like  sll wire) tht esures gluse nentrtins ntinuusly in the interstitil fluid fr 714 dys. The DexC nd MiniMed systes trns- it gluse dt wirelessly t srtphnes r t the sreens f insulin pups. Diretinl rrws indite rte nd diretin f hnge f gluse levels, nd lerts n be set fr dngerusly lw r high gluse vlues. The werer ls gins insight int hw prtiulr fds nd tivities ffet their gluse level. The FreeStyle Libre (Abbtt Dig- nstis) sensr syste requires the ptient t hld  red- ing devie r  srtphne lse t the sensr pth fr but  send t see the rel tie gluse vlue. The MiniMed syste requires librtin with peridi finger- stik gluse levels, whih is nt neessry fr the Dex nd Freestyle Libre systes. The ftry librted systes use  librtin funtin tht uttilly rrets fr sensr drift ver the subsequent 1014 dys. A 6-nth rndized ntrlled study f ptients with type 1 dibe- tes shwed tht dults (25 yers nd lder) using these ntinuus gluse nitring systes hd iprved glyei ntrl withut n inrese in the inidene f hypglyei. A rndized ntrlled study f ntinu- us gluse nitring during pregnny shwed iprved glyei ntrl in the third triester, lwer birth weight, nd redued risk f rsi. Suries f the ntinuus gluse nitring dt lleted ver 212 weeks n be very helpful. The perentge f tie in rnge (gluse levels 70180 g/dy [3.910 l/L]), gluse levels tht re lw r high, nd their vribility n be ssessed. There is  strng rreltin between gluse levels tht re 70% tie in rnge nd n HbA1f pprx- itely 7%. Mny f these systes re vered by insurne. The initil st is but $800 t $1000, nd the sensr, whih hs t be hnged every 7 t 14 dys, sts $35 t $60; the ut-f-pket expense is but $4000 nnully. 9. Lipoprotein abnormalities in diabetes Cirulting lipprteins re just s dependent n insulin s is the pls gluse. In type 1 dibetes, dertely defiient ntrl f hyperglyei is ssited with nly  slight elevtin f LDL hlesterl nd seru triglyerides nd little if ny hnge in HDL hlesterl. One the hypergly- ei is rreted, lipprtein levels re generlly nrl. Hwever, in ptients with type 2 dibetes,  distint dibeti dyslipidei is hrteristi f the insulin resistne syndre. Its fetures re  high seru tri- glyeride level (300400 g/dL [3.44.5 l/L]),  lwCMDT22_Ch27_p1212-p1255.indd  1219 29/06/21 8:53 PMCHAPTEr 271220 CMDT 2022HDL h lesterl (less thn 30 g/dL [0.8 l/L]), nd  qulittive hnge in LDL prtiles, prduing  sller dense prtile whse ebrne rries suprnrl unts f free hlesterl. These sller dense LDL pr- tiles re re suseptible t xidtin, whih renders the re thergeni. Mesures designed t rret the besity nd hyperglyei, suh s exerise, diet, nd hypglyei therpy, re the tretent f hie fr di- beti dyslipidei, nd in sinl ptients in wh nrl weight ws hieved, ll fetures f the lipprtein bnrlities lered. Sine priry disrders f lipid etblis y exist with dibetes, persistene f lipid bnrlities fter restrtin f nrl weight nd bld gluse shuld prpt  dignsti wrkup nd pssible phrtherpy f the lipid disrder. Chpter 28 dis- usses these tters in detil.Aerin  Dibetes Assitin. 6. Glyei Trgets: Standards of Medical Care in Diabetes 2021. Dibetes Cre. 2021;44:S73. [PMID: 33298417] TreatmentA.  DietA  well-blned, nutritius diet reins  fundentl eleent f therpy. There is n speifi reendtin n the perentge f lries tht shuld e fr rb- hydrte, prtein, nd ft. The rnutrient prprtins shuld be individulized bsed n the ptients eting pt- terns, preferenes, nd etbli gls. In generl, st ptients with dibetes nsue but 45% f their ttl dily lries in the fr f rbhydrtes, 2535% in the fr f ft, nd 1035% in the fr f prtein. In ptients with type 2 dibetes, liiting the rbhydrte intke nd substituting se f the lries with nunsturted fts, suh s live il, rpeseed (nl) il, r the ils in nuts nd vds, n lwer triglyerides nd inrese HDL hles- terl. A Mediterrnen-style eting pttern ( diet supple- ented with wlnuts, lnds, hzelnuts, nd live il) hs been shwn t iprve glyei ntrl nd lwer - bined endpints fr rdivsulr events nd strke. In thse ptients with besity nd type 2 dibetes, weight redutin by lri restritin is n iprtnt gl f the diet (see Chpter 29). Ptients with type 1 dibetes r type 2 dibetes wh tke insulin shuld be tught rbhydrte unting,  s they n dinister their insulin blus fr eh el bsed n its rbhydrte ntent. The urrent reendtins fr sturted fts nd dietry hlesterl intke fr peple with dibetes re the se s fr the generl ppultin. Sturted fts shuld be liited t less thn 10% f dily lries nd dietry h- lesterl intke shuld be less thn 300 g/dy. Fr thse ptients with kidney disese, dietry prtein shuld be intined t the reended dily llwne f 0.8 g/kg/dy. Exhnge lists fr el plnning n be btined fr the Aerin Dibetes Assitin nd its ffilite ssitins r fr the Aerin Dieteti Ass- itin (http://www.etright.rg), 216 W . Jksn Blvd., Chig, IL 60606 (312-899-0040).1. Dietary fiber Plnt pnents suh s ellulse, gu, nd petin re indigestible by huns nd re tered dietry fiber.  Insluble fibers suh s ellulse r hei- ellulse, s fund in brn, tend t inrese intestinl trn- sit nd y hve benefiil effets n lni funtin. In ntrst, sluble fibers suh s gus nd petins, s fund in bens, tel, r pple skin, tend t retrd nutrient bsrptin rtes s tht gluse bsrptin is slwer nd hyperglyei y be slightly diinished. Althugh its reendtins d nt inlude insluble fiber supple- ents suh s dded brn, the ADA reends fd suh s tel, erels, nd bens with reltively high sluble fiber ntent s stple pnents f the diet in dibetis. High sluble fiber ntent in the diet y ls hve  fvrble effet n bld hlesterl levels. 2. Glycemic index The glyei index f  rbhy- drte ntining fd is deterined by pring the gluse exursins fter nsuing 50 g f test fd with gluse exursins fter nsuing 50 g f referene fd (white bred): Glycemic indexBlood glucose area under the curve (3h) for test food Blood glucose area under the curve (3h) for reference food100 =   Eting lw glyei index fds results in lwer glu- se levels fter els. Lw glyei index fds hve vlues f 55 r less nd inlude ny fruits, vegetbles, griny breds, pst, nd legues. High glyei index fds hve vlues f 70 r greter nd inlude bked ptt, white bred, nd white rie. Glyei index is lw- ered by the presene f fts nd prtein when fd is n- sued in  ixed el. Even thugh it y nt be pssible t urtely predit the glyei index f  prtiulr fd in the ntext f  el, it is resnble t hse fds with lw glyei index. 3. Artificial and other sweeteners Shrin (Sweet N Lw), surlse (Splend), esulfe ptssiu (Sweet One), nd rebin (Truvi) re rtifiil sweeteners tht n be used in king nd bking. Asprte (NutrSweet) lks het stbility, s it nnt be used in king. Nne f these sweeteners rise bld gluse levels. Frutse represents  nturl sugr substne tht is  highly effetive sweetener, indues nly slight inreses in pls gluse levels, nd des nt require insulin fr its etblis. Hwever, beuse f ptentil dverse effets f lrge unts f frutse n rising seru hlesterl, triglyerides, nd LDL hlesterl, it des nt hve ny dvntge s  sweetening gent in the dibeti diet. This des nt prelude, hwever, ingestin f frutse-ntining fruits nd vegetbles r frutse-sweetened fds in dertin. Sugr lhls, ls knwn s plyls r plylhl, re nly used s sweeteners nd bulking gents. They ur nturlly in  vriety f fruits nd vegetbles but re ls erilly de fr surse, gluse, nd strh.CMDT22_Ch27_p1212-p1255.indd  1220 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1221 CMDT 2022Exp les re srbitl, xylitl, nnitl, ltitl, islt, ltitl, nd hydrgented strh hydrlystes (HSH). They re nt s esily bsrbed s sugr, s they d nt rise bld gluse levels s uh. Therefre, sugr l- hls re ften used in fd prduts tht re lbeled s sugr free,  suh s hewing gu, lzenges, hrd ndy, nd sugr-free ie re. Hwever, if nsued in lrge quntities, they will rise bld gluse nd n use blting nd dirrhe.B.  Medications for Treating HyperglycemiaThe  editins fr treting type 2 dibetes re listed in Tble 274. 1. Medications that primarily stimulate insulin secretion by binding to the sulfonylurea receptor on the beta cell a. Sulfonylureas The priry ehnis f tin f the sulfnylures is t stiulte insulin relese fr pn- reti B ells. Sulfnylures re used in ptients with type 2 but nt type 1 dibetes, sine these editins require funtin- ing pnreti B ells t prdue their effet n bld gluse. Sulfnylures re etblized by the liver nd prt fr ethexide, whse etblite is re tive thn the prent pund, the etblites f ll the ther sulfnylures re wekly tive r intive. The etblites re exreted by the kidney nd, in the se f the send-genertin sulfnylures, prtly exreted in the bile. Hypglyei is  n dverse retin with the sulfnylures. Weight gin is ls n, espeilly in the first yer f use. The ehniss f the weight gin inlude iprved gluse ntrl nd inresed fd intke in respnse t hypglyei. Idisynrti retins re rre, with skin rshes r hetlgi txiity (leukpeni, thrbytpeni) urring in less thn 0.1% f users. (1) First-generation oral sulfonylureas (tolbutamide, tolazamide, acetohexamide, chlorpropamide) Tlbut- ide is prbbly best dinistered in divided dses (eg, 500 g befre eh el nd t bedtie); hwever, se ptients require nly ne r tw tblets dily with  xi- u dse f 3000 g/dy. Beuse f its shrt durtin f tin (but 610 hurs, whih is independent f kidney funtin), tlbutide is reltively sfe t use in kidney disese. Prlnged hypgly- ei hs been reprted rrely with tlbutide, stly in ptients reeiving ntibteril sulfnides (sulfisx- zle), phenylbutzne fr rthrlgis, r the rl zle ntifungl editins t tret ndidisis. Tlzide, ethexide, nd hlrprpide re rrely used. Chlrprpide hs  prlnged bilgi effet, nd severe hypglyei n ur espeilly in lder dults s their renl lerne delines with ging. Its ther side effets inlude lhl-indued flushing nd hypntrei due t its effet n vspressin seretin nd tin. (2) Second-generation sulfonylureas (glyburide, glipizide, gliclazide, glimepiride) Glyburide, glipizide, glilzide, nd gliepiride re 100200 ties re ptentthn tlbutide. These editins shuld be used with utin in ptients with rdivsulr disese r in elderly ptients, in wh prlnged hypglyei wuld be espe- illy dngerus. The usul strting dse f glyburide is 2.5 g/dy, nd the verge intenne dse is 510 g/dy given s  single rning dse; intenne dses higher thn 20 g/dy re nt reended. Se reprts suggest tht 10 g is  xiu dily therpeuti dse, with 1520 g hving n dditinl benefit in pr respnders nd dses ver 20 g tully wrsening hyperglyei. A Press Tb frultin f irnized glyburideesy t divide in hlf with slight pressure if neessryis vil- ble. Glyburide is etblized in the liver nd the et- bli prduts f glyburide hve hypglyei tivity. This prbbly explins why ssys speifi fr the une- tblized pund suggest  pls hlf-life f nly 12 hurs, yet the bilgi effets f glyburide re lerly persistent 24 hurs fter  single rning dse in dibeti ptients. Glyburide hs few dverse effets ther thn its pten- til fr using hypglyei, whih t ties n be pr- lnged. Flushing hs rrely been reprted fter ethnl ingestin. It des nt use wter retentin, s hlrprp- ide des, but rther slightly enhnes free wter ler- ne. Glyburide shuld nt be used in ptients with liver filure nd hrni kidney disese beuse f the risk f hypglyei. Elderly ptients re t prtiulr risk fr hypglyei even with reltively sll dily dses. The reended strting dse f glipizide is 5 g/dy, with up t 15 g/dy given s  single dily dse befre brekfst. When higher dily dses re required, they shuld be divided nd given befre els. The xiu dse reended by the nufturer is 40 g/d, lthugh dses bve 1015 g prbbly prvide little dditinl benefit in pr respnders nd y even be less effetive thn sller dses. Fr xi- u effet in reduing pstprndil hyperglyei, glipizide shuld be ingested 30 inutes befre els, sine rpid bsrptin is delyed when the editin is tken with fd. At lest 90% f glipizide is etblized in the liver t intive prduts, nd 10% is exreted unhnged in the urine. Glipizide therpy shuld therefre nt be used in ptients with liver filure. Beuse f its lwer pteny nd shrter durtin f tin, it is preferble t glyburide in elderly ptients nd fr thse ptients with kidney disese. Glutrl-XL prvides extended relese f glipizide during trnsit thrugh the gstrintestinl trt with greter effe- tiveness in lwering prebrekfst hyperglyei thn the shrter-durtin iedite-relese stndrd glipizide tb- lets. Hwever, this frultin ppers t hve srified its lwer prpensity fr severe hypglyei pred with lnger-ting glyburide withut shwing ny den- strble therpeuti dvntges ver glyburide. Gliclazide (nt vilble in the United Sttes) is nther interedite durtin sulfnylure with  durtin f tin f but 12 hurs. The reended strting dse is 4080 g/dy with  xiu dse f 320 g. Dses f 160 g nd bve re given s divided dses befreCMDT22_Ch27_p1212-p1255.indd  1221 29/06/21 8:53 PMCHAPTEr 271222 CMDT 2022T able 274. Medications for treatment of type 2 diabetes mellitus (oral doses unless otherwise noted).Dug Tablet Size Daily DoseDuation of Action Sulfonylueas Acetohexamide (Dymelor) (not available in United States)250 and 500 mg 0.251.5 g as single dose or in two divided doses 824 hours Chlorpropamide (Diabinese) 100 and 250 mg 0.10.5 g as single dose 2472 hours Gliclazide (not available in United States) 80 mg 4080 mg as single dose; 160320 mg as divided dose 12 hours Glimepiride (Amaryl) 1, 2, and 4 mg Usual dose: 14 mg once daily Maximal dose: 8 mg once dailyUp to 24 hours Glipizide (Glucotrol) 5 and 10 mg Usual dose: 2.510 mg twice daily 30 minutes before meals Maximal dose: 20 mg twice daily612 hours (Glucotrol XL) 2.5, 5, and 10 mg Usual dose: 2.510 mg once daily Maximal dose: 20 mg once dailyUp to 24 hours Glyburide (Dia Beta, Micronase) 1.25, 2.5, and 5 mg 1.2520 mg as single dose or in two divided doses Up to 24 hours (Glynase) 1.5, 3, and 6 mg 1.512 mg as single dose or in two divided doses Up to 24 hours Tolazamide (Tolinase) 100, 250, and 500 mg 0.11 g as single dose or in two divided doses Up to 24 hours Tolbutamide (Orinase) 250 and 500 mg 0.52 g in two or three divided doses 610 hours Meglitinide Analogs Mitiglinide (available in Japan) 5 and 10 mg 5 or 10 mg three times daily before meals 2 hours Repaglinide (Prandin) 0.5, 1, and 2 mg Usual dose: 0.5 to 4 mg three times daily 15 minutes before meals Maximal dose: 16 mg daily3 hoursd -Phenylalanine Deivative Nateglinide (Starlix) 60 and 120 mg 60 or 120 mg three times daily before meals 4 hours Biguanides Metformin (Glucophage) 500, 850, and 1000 mg 500850 mg with meals two or three times daily; 8501000 mg with breakfast and dinner4 hours Metformin, extended release (Glucophage XR)1500, 750, and 1000 mg 5002000 mg once daily Up to 24 hours Thiazolidinediones Pioglitazone (Actos) 15, 30, and 45 mg 1545 mg daily Up to 24 hours Rosiglitazone (Avandia) 2, 4, and 8 mg 48 mg daily (can be divided) Up to 24 hours Alpha-Glucosidase Inhibitos Acarbose (Precose) 25, 50, and 100 mg 25100 mg three times daily just before meals 4 hours Miglitol (Glyset) 25, 50, and 100 mg 25100 mg three times daily just before meals 4 hours Voglibose (not available in United States) 0.2 and 0.3 mg 0.20.3 mg three times daily just before meals 4 hours GLP-1 recepto Agonists Dulaglutide (Trulicity) 0.75-, 1.5-mg single- dose pen or pre- filled syringeUsual dose: 0.75 mg subcutaneously once weekly Maximal dose: 1.5 mg subcutaneously once weekly1 week Exenatide (Byetta) 1.2 mL and 2.4 mL prefilled pens deliv- ering 5 mcg and 10 mcg doses5 mcg subcutaneously twice daily within 1 hour of breakfast and dinner. Increase to 10 mcg subcuta- neously twice daily after about a month. AVOID if eGFR < 30 mL/min/1.73 m26 hours Exenatide, long-acting release (Byetta LAR, Bydureon)2 mg (powder) Suspend in provided diluent and inject subcutaneously.1 week (continued )CMDT22_Ch27_p1212-p1255.indd  1222 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1223 CMDT 2022T able 274. Medications for treatment of type 2 diabetes mellitus (oral doses unless otherwise noted).Dug Tablet Size Daily DoseDuation of Action Liraglutide (Victoza) Prefilled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, or 1.8 mgInitial dose: 0.6 mg subcutaneously once daily. Increase to 1.2 mg after a week if no adverse reactions. Maximal dose: 1.8 mg subcutaneously once daily24 hours Lixisenatide (Adlyxin, Lyxumia) 3-mL prefilled pens delivering 10- or 20-mcg dosesInitial dose: 10 mcg daily. Increase to 20 mcg daily after 2 weeks.24 hours Semaglutide (Ozempic, Rybelsus) Prefilled pens deliver- ing 0.25 mg or 0.5 mg 1-, 3-,7-, and 14-mg tabletsInitial dose: 0.25 mg weekly for 1 month and increase to 0.5 mg weekly if no adverse reactions. Maximal dose: 1 mg weekly Initial dose: 3 mg for 1 month and then increase to 7 mg. Take fasting daily with water and wait 30 min to eat. Maximal dose: 14 mg1 week Daily DPP-4 Inhibitos Alogliptin (Nesina) 6.25, 12.5, and 25 mg 25 mg once daily if eGFR  60 mL/min/1.73 m2; 12.5 mg daily if eGFR 3059 mL/min/1.73 m2; 6.25 mg daily if eGFR < 30 mL/min/1.73 m224 hours Linagliptin (Tradjenta) 5 mg 5 mg daily 24 hours Saxagliptin (Onglyza) 2.5 and 5 mg 2.5 mg or 5 mg once daily if eGFR > 50 mL/min/1.73 m2. 2.5 mg daily if eGFR  50 mL/min/1.73 m2or if also taking drugs that are strong CYP3A4/5 inhibitors such as ketoconazole24 hours Sitagliptin (Januvia) 25, 50, and 100 mg 100 mg once daily if eGFR > 50 mL/min/1.73 m2; 50 mg once daily if eGFR 3050 mL/min/1.73 m2; 25 mg once daily if eGFR < 30 mL/min/1.73 m224 hours Vildagliptin (Galvus) (not available in United States)50 mg 50 mg once or twice daily. AVOID if eGFR  60 mL/min/1.73 m2or AST/ALT three times upper limit of normal24 hours SGLT2 Inhibitos Canagliflozin (Invokana) 100 and 300 mg Usual dose: 100 mg daily. 300 mg can be used if normal eGFR, resulting in lowering the HbA1can additional ~ 0.10.25%. AVOID if eGFR < 45 mL/min/1.73 m2.24 hours Dapagliflozin (Farxiga) 5 and 10 mg 10 mg daily 24 hours Empagliflozin (Jardiance) 10 and 25 mg Usual dose: 10 mg daily Maximal dose: 25 mg24 hours Ertugliflozin (Steglatro) 5 and 15 mg Usual dose: 5 mg daily Maximal dose: 15 mg24 hours Othes Bromocriptine (Cycloset) 0.8 mg 0.8 mg daily. Increase weekly by 1 tablet until maxi- mal tolerated dose of 1.64.8 mg daily.24 hours Colesevelam (Welchol) 625 mg 3 tablets twice daily 24 hours Pramlintide (Symlin) 5-mL vial containing 0.6 mg/mL; also available as pre- filled pens. Symlin pen 60 or Symlin pen 120For insulin-treated type 2 patients, start at 60-mcg dose subcutaneously three times daily (10 units on U100 insulin syringe). Increase to 120 mcg three times daily (20 units on U100 insulin syringe) if no nausea for 37 days. Give immediately before meal. For type 1 patients, start at 15 mcg three times daily (2.5 units on U100 insulin syringe) and increase by increments of 15 mcg to a maximum of 60 mcg three times daily, as tolerated. To avoid hypoglycemia, lower insulin dose by 50% on initiation of therapy.2 hours AST/ALT, aspartate aminotransferase/alanine aminotransferase; eGFR, estimated glomerular filtration rate.(continued)CMDT22_Ch27_p1212-p1255.indd  1223 29/06/21 8:53 PMCHAPTEr 271224 CMDT 2022brekfst  nd dinner. The editin is etblized by the liver; the etblites nd njugtes hve n hypglyei effet. An extended-relese preprtin is vilble. Glimepiride hs  lng durtin f effet with  hlf- life f 5 hurs llwing ne r twie dily dsing. Gliepiride hieves bld gluse lwering with the lw- est dse f ny sulfnylure pund. A single dily dse f 1 g/dy hs been shwn t be effetive, nd the xi- l reended dse is 8 g. It is pletely etb- lized by the liver t reltively intive etbli prduts. b. Meglitinide analogs Repglinide is struturlly siilr t glyburide but lks the sulfni id-ure iety. It ts by binding t the sulfnylure reeptr nd lsing the densine triphsphte (ATP)-sensitive ptssiu hnnel. It is rpidly bsrbed fr the intestine nd then underges plete etblis in the liver t intive biliry prduts, giving it  pls hlf-life f less thn 1 hur. The editin therefre uses  brief but rpid pulse f insulin. The strting dse is 0.5 g three ties  dy 15 inutes befre eh el. The dse n be titrted t  xiu dily dse f 16 g. Like the sulfnylures, repglinide n be used in bintin with etfrin. Hypglyei is the in side effet. Like the sulfnyl- ures, repglinide uses weight gin. Metblis is by ythre P450 3A4 isenzye, nd ther editins tht indue r inhibit this isenzye y inrese r inhibit (respetively) the etblis f repglinide. The editin y be useful in ptients with kidney ipir- ent r in lder dults. Mitiglinide is  benzylsuini id derivtive tht binds t the sulfnylure reeptr nd is siilr t rep- glinide in its linil effets. It is pprved fr use in Jpn. c. D-phenylalanine derivative Nteglinide stiu- ltes insulin seretin by binding t the sulfnylure reep- tr nd lsing the ATP-sensitive ptssiu hnnel. It is rpidly bsrbed fr the intestine, rehing pek pls levels within 1 hur. It is etblized in the liver nd hs  pls hlf-life f but 1.5 hurs. Like repglinide, it uses  brief rpid pulse f insulin, nd when given befre  el it redues the pstprndil rise in bld gluse. Fr st ptients, the reended strting nd intenne dse is 120 g three ties  dy befre els. Use 60 g in ptients wh hve ild elevtins in HbA1. Like the ther insulin seretggues, its in side effets re hyp- glyei nd weight gin. 2. Medications that primarily lower glucose levels by their actions on the liver, muscle, and adipose tissue a. Metformin Metfrin is the first-line therpy fr ptients with type 2 dibetes. It n be used lne r in njuntin with ther rl gents r insulin in the tret- ent f ptients with type 2 dibetes. It is ineffetive in ptients with type 1 dibetes. Metfrins therpeuti effets pririly derive fr the inresing hepti densine nphsphte-tivted pr- tein kinse tivity, whih redues hepti glunegenesis nd lipgenesis. Metfrin hs  hlf-life f 1.53 hurs nd is nt bund t pls prteins r etblized, being exreted unhnged by the kidneys.The urrent reendtin is t strt etfrin t dignsis. A side benefit f etfrin therpy is its ten- deny t iprve bth fsting nd pstprndil hypergly- ei nd hypertriglyeridei in bese ptients with dibetes withut the weight gin ssited with insulin r sulfnylure therpy. Ptients with hrni kidney disese shuld nt be given this editin beuse filure t exrete it wuld prdue high bld nd tissue levels f etfrin tht uld stiulte lti id verprdutin. In the United Sttes, etfrin use is nt reended t r bve  seru retinine level f 1.4 g/dL in wen nd 1.5 g/dL in en. In the United Kingd, the re- endtins re t review etfrin use when the seru retinine exeeds 130 l/L (1.5 g/dL) r the esti- ted glerulr filtrtin rte (eGFR) flls belw 45 L/ in/1.73 2. The editin shuld be stpped if the seru retinine exeeds 150 l/L (1.7 g/dL) r the eGFR is belw 30 L/in/1.73 2. Ptients with liver fil- ure r persns with exessive lhl intke shuld nt reeive this editin beuse f the risk f lti idsis. The xiu dsge f etfrin is 2550 g, lthugh little benefit is seen bve  ttl dse f 2000 g. It is iprtnt t begin with  lw dse nd inrese the dsge very grdully in divided dsestken with elst redue inr gstrintestinl upsets (nrexi, nuse, viting, bdinl disfrt, dirrhe), whih ur in up t 20% f ptients. A n shedule wuld be ne 500-g tblet three ties  dy with els r ne 850- r 1000-g tblet twie dily t brekfst nd dinner. Up t 2000 g f the extended-relese preprtin n be given ne  dy. Lwer dses shuld be used in ptients with eGFRs between 30 nd 45 L/in/1.73 2nd in the elderly wh re t higher risk fr ute kidney injury fr redued renl funtinl reserve. The gstrintestinl side effets re dse-relted, tend t ur t nset f therpy, nd ften re trnsient. Hw- ever, in 35% f ptients, therpy y hve t be disntin- ued beuse f persistent dirrhel disfrt. Ptients swithing fr iedite-relese etfrin t pr- ble dse f extended-relese etfrin y experiene fewer gstrintestinl side effets. Hypglyei des nt ur with therpeuti dses f etfrin, whih perits its desriptin s  euglyei r ntihyperglyei editin rther thn n rl hypglyei gent. Dertlgi r hetlgi txiity is rre. Metfrin interferes with the liu dependent bsrptin f vitin B12-intrinsi plex in the terinl ileu; vitin B12defiieny n ur fter ny yers f etfrin use. Peridi sreening with vitin B12levels shuld be nsidered, espeilly in ptients with peripherl neurpthy (whih y be errneusly ttributed t di- beti neurpthy) r if  ryti nei develps. Inresed intke f dietry liu y prevent the et- frin-indued B12lbrptin. Lti idsis hs been reprted s  side effet but is unn with etfrin in ntrst t phenfrin. Alst ll reprted ses hve invlved persns with ssited risk ftrs tht shuld hve ntrindited its use (kidney, liver, r rdirespirtry insuffiieny ndCMDT22_Ch27_p1212-p1255.indd  1224 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1225 CMDT 2022lhlis).  Aute kidney injury n ur rrely in er- tin ptients tking etfrin wh reeive rdintrst gents. Metfrin therpy shuld therefre be teprrily hlted n the dy f rdintrst dinistrtin nd restrted  dy r tw lter fter nfirtin tht kidney funtin hs nt deterirted. b. Thiazolidinediones Tw editins f this lss, rsiglitzne nd piglitzne, re vilble fr linil use. These editins sensitize peripherl tissues t insulin. They bind the nuler reeptr perxise prlifertr- tivted reeptr g (PPAR-g) nd ffet the expressin f  nuber f genes. Like the bigunides, this lss f editins des nt use hypglyei. Bth rsiglitzne nd piglitzne re effetive s ntherpy nd in bintin with sulfnylures r etfrin r insulin, lwering HbA1by 12%. When used in bintin with insulin, they n result in  3050% redutin in insulin dsge, nd se ptients n e ff insulin pletely. The rl dsge f rsigli- tzne is 48 g dily nd f piglitzne, 1545 g dily; the editins d nt hve t be tken with fd. Rsigli- tzne is pririly etblized by the CYP 2C8 isen- zye nd piglitzne is etblized by CYP 2C8 nd CYP 3A4. The bintin f  thizlidinedine nd etfr- in hs the dvntge f nt using hypglyei. Ptients indequtely nged n sulfnylures n d well n  bintin f sulfnylure nd rsiglitzne r piglitzne. These editins hve se dditinl effets prt fr gluse lwering. Rsiglitzne therpy is ssited with inreses in ttl hlesterl, LDL hlesterl (15%), nd HDL hlesterl (10%). There is  redutin in free ftty ids f but 815%. The hnges in triglyerides re generlly nt different fr pleb. Piglitzne in lini- l trils lwered triglyerides (9%) nd inresed HDL hlesterl (15%) but did nt use  nsistent hnge in ttl hlesterl nd LDL hlesterl levels. A prspetive rndized prisn f the etbli effets f pigli- tzne nd rsiglitzne shwed siilr effets n HbA1 nd weight gin. Sll prspetive studies hve den- strted tht tretent with these editins leds t iprveents in the biheil nd histlgi fetures f nnlhli ftty liver disese. The thizlidinedines ls y liit vsulr sth usle prlifertin fter injury, nd there re reprts tht piglitzne n redue neintil prlifertin fter rnry stent pleent. In ne duble-blind, pleb-ntrlled study, rsiglitzne ws shwn t be ssited with  derese in the rti f urinry lbuin t retinine exretin. Safety concerns nd se trublese side effets liit the use f this lss f editin. Rsiglitzne use delined when  et-nlysis f 42 rndized linil trils suggested tht this editin inreses the risk f ngin petris r yrdil infrtin; the Eurpen Mediines Ageny suspended the use f rsiglitzne in Eurpe. In the United Sttes, the FDA estblished  restrited distributin prgr. A subsequent lrge pr- spetive linil tril (the RECORD study) filed tnfir the et-nlysis finding nd the restritins were lifted in the United Sttes. Ede urs in but 34% f ptients reeiving ntherpy with rsiglitzne r piglitzne. The ede urs re frequently (1015%) in ptients reeiv- ing nitnt insulin therpy nd y result in hert filure. The editins re ntrindited in dibeti individuls with New Yrk Hert Assitin lss III nd IV rdi sttus. Thizlidinedines hve ls been reprted s being ssited with new nset r wrsening ulr ede. Apprently, this is  rre side effet, nd st f these ptients ls hd peripherl ede. The ulr ede reslved r iprved ne the editin ws disntinued. Trglitzne, the first editin in this lss, ws with- drwn fr linil use beuse f editin-ssited ftl liver filure. Althugh rsiglitzne nd piglitzne hve nt been reprted t use liver injury, the FDA re- ends tht they shuld nt be used in ptients with linil evidene f tive liver disese r pretretent elevtin f the lnine intrnsferse (ALT) level tht is 2.5 ties greter thn the upper liit f nrl. Liver biheil tests shuld be perfred n ll ptients prir t inititin f tretent nd peridilly therefter. An inrese in frture risk in wen (but nt en) hs been reprted with bth rsiglitzne nd pigli- tzne. The frture risk is in the rnge f 1.9 per 100 ptient-yers with the thizlidinedine s ppsed t 1.1 per 100 ptient-yers n prisn tretent. In t lest ne study f rsiglitzne, the frture risk ws inresed in preenpusl s well s pstenpusl wen. Other side effets inlude nei, whih urs in 4% f ptients treted with these editins; it y be due t  dilutinl effet f inresed pls vlue rther thn  redutin in red ell ss. Weight gin urs, espeilly when the editin is bined with  sulfnylure r insulin. Se f the weight gin is fluid retentin, but there is ls n inrese in ttl ft ss. Clinil studies hve reprted nfliting results regrding n ssitin f bldder ner with piglitzne use. A 10-yer bserv- tinl hrt study f ptients tking piglitzne filed t find n ssitin with bldder ner. A lrge ultippu- ltin pled nlysis (1.01 illin persns ver 5.9 illin persn-yers) ls filed t find n ssitin between uultive expsure f piglitzne r rsiglitzne nd inidene f bldder ner. Anther ppultin-bsed study, hwever, generting 689,616 persn-yers f fllw- up did find tht piglitzne but nt rsiglitzne ws ssited with n inresed risk f bldder ner. 3. Medications that affect absorption of glucose Alph- glusidse inhibitrs petitively inhibit the lph- glusidse enzyes in the gut tht digest dietry strh nd surse. Tw f these editinsrbse nd iglitlre vilble fr linil use in the United Sttes. Vglibse, nther lph-glusidse inhibitr is vilble in Jpn, Kre, nd Indi. Arbse nd iglitl re ptent inhibitrs f gluylse, lph-ylse, nd surse but hve less effet n isltse nd hrdly ny n trehlse nd ltse.CMDT22_Ch27_p1212-p1255.indd  1225 29/06/21 8:53 PMCHAPTEr 271226 CMDT 2022a.  Acarbose The reended strting dse f r- bse is 50 g rlly twie dily, grdully inresing t 100 g three ties dily. Fr xil benefit n pstprn- dil hyperglyei, rbse shuld be given with the first uthful f fd ingested. In dibeti ptients, it redues pstprndil hyperglyei by 3050%, nd its verll effet is t lwer the HbA1by 0.51%. The prinipl dverse effet, seen in 2030% f ptients, is fltulene. This is used by undigested rbhydrte rehing the lwer bwel, where gses re prdued by bteril flr. In 3% f ses, trublese dirrhe urs. This gstrintestinl disfrt tends t disur- ge exessive rbhydrte nsuptin nd prtes iprved pline f type 2 ptients with their diet presriptins. When rbse is given lne, there is n risk f hypglyei. Hwever, if bined with insulin r sulfnylures, it ight inrese the risk f hypglyei fr these gents. A slight rise in hepti intrnsfer- ses hs been nted in linil trils with rbse (5% vs 2% in pleb ntrls, nd prtiulrly with dses greter thn 300 g/dy). The levels generlly return t nrl n stpping the editin. b. Miglitol Miglitl is siilr t rbse in ters f its linil effets. It is indited fr use in diet- r sulfnyl- ure-treted ptients with type 2 dibetes. Therpy is initi- ted t the lwest effetive dsge f 25 g rlly three ties  dy. The usul intenne dse is 50 g three ties  dy, lthugh se ptients y benefit fr inresing the dse t 100 g three ties  dy. Gstrin- testinl side effets ur s with rbse. The editin is nt etblized nd is exreted unhnged by the kidney. Miglitl shuld nt be used in end-stge hrni kidney disese, when its lerne wuld be ipired. 4. Incretins Orl gluse prvkes  threefld t furfld higher insulin respnse thn n equivlent dse f gluse given intrvenusly. This is beuse the rl gluse uses  relese f gut hrnes, priniplly glugn-like pep- tide 1 (GLP-1) nd gluse-dependent insulintrpi ply- peptide (GIP1), tht plify the gluse-indued insulin relese. This inretin effet f GLP-1 seretin (but nt GIP1 seretin) is redued in ptients with type 2 dibetes; when GLP-1 is infused in ptients with type 2 dibetes, it stiultes insulin seretin nd lwers gluse levels. GLP-1, unlike the sulfnylures, hs nly  dest insulin stiul- try effet t nrglyei nentrtins. This ens tht GLP-1 hs  lwer risk fr hypglyei thn the sulfnylures. In dditin t its insulin stiultry effet, GLP-1 ls hs  nuber f ther pnreti nd extrpnreti effets. It suppresses glugn seretin nd s y e- lirte the hyperglugnei tht is present in peple with dibetes nd iprve pstprndil hyperglyei. GLP-1 ts n the sth delying gstri eptying; the iprtne f this effet n gluse lwering is illustrted by the bservtin tht ntgnizing the deelertin f gstri eptying rkedly redues the gluse lwering effet f GLP-1. GLP-1 reeptrs re present in the entrl nervus syste nd y ply  rle in the nreti effet f the drugs. Type 2 dibeti ptients underging GLP-1infusin re less hungry; it is unler whether this is inly due t  deelertin f gstri eptying r whether there is  entrl nervus syste effet s well. a. GLP-1 receptor agonists GLP-1s hlf-life is nly 12 inutes. It is rpidly prtelyzed by dipeptidyl pepti- dse 4 (DPP-4) nd by ther enzyes, suh s endpepti- dse 24.11, nd is ls lered quikly by the kidney. The ntive peptide, therefre, nnt be used therpeutilly. Five GLP-1 reeptr gnists with lnger hlf-lives, exen- tide, lirglutide, dulglutide, lixisentide, nd seglutide, re vilble fr linil use. Exenatide (Exendin 4) is  GLP-1 reeptr gnist is- lted fr the sliv f the Gil nster ( venus lizrd) tht is re resistnt t DPP-4 tin nd lered by the kidney. Its hlf-life is 2.4 hurs, nd its gluse lwering effet is but 6 hurs. Exentide is dispensed s tw fixed-dse pens (5 g nd 10 g). It is injeted 60 inutes befre brekfst nd befre dinner. Ptients with type 2 dibetes shuld be presribed the 5 g pen fr the first nth nd, if tlerted, the dse n then be inresed t 10 g twie  dy. The editin is nt reended in ptients with eGFR less thn 30 L/in/1.73 2. In linil trils, dding exentide therpy t ptients with type 2 dibetes lredy tking etfrin r  sulfnylure, r bth, further lwered the HbA1vlue by 0.4% t 0.6% ver  30-week perid. These ptients ls experiened  weight lss f 36 punds. Exentide LAR is  ne-weekly preprtin tht is dispensed s  pwder (2 g). It is suspended in the prvided diluent just prir t injetin. In prtive linil trils, the lng- ting drug lwers the HbA1level  little re thn the twie dily drug. Lw-titer ntibdies ginst exentide develp in ver ne-third (38%) f ptients, but the linil effets re nt ttenuted. High-titer ntibdies develp in  subset f ptients (~6%), nd in but hlf f these ses, n ttenu- tin f glyei respnse hs been seen. Liraglutide is  sluble ftty id ylted GLP-1 n- lg. The hlf-life is pprxitely 12 hurs, llwing the editin t be injeted ne  dy. The dsing is initi- ted t 0.6 g dily, inresed fter 1 week t 1.2 g dily. Se ptients y benefit fr inresing the dse t 1.8 g. In linil trils lsting 26 nd 52 weeks, dding lirglutide t the therpeuti regien (etfrin, sulf- nylure, thizlidinedine) f ptients with type 2 dibetes further lwered the HbA1vlue. Depending n the dse nd design f the study, the HbA1deline ws in the rnge f 0.6% t 1.5%. The ptients hd sustined weight lss f 16 punds. Lirglutide t  dse f 3 g dily hs been pprved fr weight lss. In  pstrketing ultintinl study f 9340 ptients with type 2 dibetes with knwn rdivsulr disese, the dditin f lirglutide ws ssited with  lwer priry psite ute f deth fr rdivsulr uses, nnftl yrdil infrtin, r nnftl strke (hzrd rti 0.87, P= 0.01). Ptients tking lirglutide hd lwer HbA1levels, weight lss f 2.3 kg, lwer systli bld pres- sure, nd fewer episdes f severe hypglyei. Dulaglutide nsists f tw GLP-1 nlg leules vlently linked t n F frgent f hun IgG4. The GLP-1 leule hs in id substitutins tht resistCMDT22_Ch27_p1212-p1255.indd  1226 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1227 CMDT 2022DPP -4 tin. The hlf-life f dulglutide is but 5 dys. The usul dse is 0.75 g weekly by subutneus inje- tin. The xiu reended dse is 1.5 g weekly. Dulglutide ntherpy nd bintin therpy lwers HbA1by but 0.7% t 1.6%. Weight lss rnged fr 2 punds t 7 punds. Lixisenatide is  syntheti nlg f exendin 4 (deletin f  prline nd dditin f 6 lysines t the C-terinl regin) with  hlf-life f 3 hurs. It is dispensed s tw fixed-dse pens (10 g nd 20 g). The 10-g dse is injeted ne dily befre brekfst fr the first 2 weeks, nd if tlerted, the dse is then inresed t 20 g dily. Its linil effet is but the se s exentide with HbA1 lwering in the 0.40.6% rnge. Weight lss rnges fr 2 punds t 6 punds. Antibdies t lixisentide ur frequently (70%) nd ~2.4% with the highest ntibdy titers hve ttenuted glyei respnse. Semaglutide is  syntheti nlg f GLP-1 with  drug hlf-life f but 1 week. It hs n lph-inisbutyri id substitutin t psitin 8 tht kes the leule resistnt t DPP4 tin nd  C-18 ftty di-id hin tthed t lysine t psitin 26 tht binds t lbuin, whih unts fr the drugs lng hlf-life. Seglutide is dispensed either subutneusly r rlly. There re tw pens fr subutneus injetin: ne pen delivers  0.25-g r 0.5-g dse nd the ther pen delivers  1-g dse. The reended dsing is 0.25 g weekly fr 4 weeks nd if tlerted the dse is then inresed t 0.5 g per week. The 1-g per week dse n prvide dditinl gluse lwering effet. Seglutide ntherpy nd bin- tin therpy lwers HbA1fr 1.5% t 1.8%. The ptient ust tke rl seglutide fsting with  glss f wter nd then wit hlf n hur befre eting, drinking, r tking ther ediines. The reended strting dse is 3 g dily fr the first nth, with the dse inresed t 714 g dily s tlerted nd s needed fr gluse ntrl. Side effects The st frequent dverse retins f the GLP-1 reeptr gnists re nuse (1140%), vit- ing (413%), nd dirrhe (917%). The retins re re frequent t the higher dses. In linil trils but 15% f prtiipnts withdrew fr the studies beuse f the gstrintestinl sypts. The GLP-1 reeptr gnists hve been ssited with inresed risk f pnretitis. The pnretitis ws severe (herrhgi r nertizing) in 6 instnes, nd 2 f these ptients died. In the lirglutide nd dulglutide linil trils, there were 13 nd 5 ses f pnretitis in the drug- treted grups versus 1 nd 1 se in the prtr grups, respetively. This trnsltes t but 1.42.2 vs 0.60.9 ses f pnretitis per 1000 ptient-yers. Patients taking GLP-1 receptor agonists should be advised to seek immediate medical care if they experience unexplained per- sistent severe abdominal pain . There hve been rre reprts f ute kidney injury in ptients tking exentide. Se f these ptients hd pre- existing kidney disese, nd thers hd ne r re risk ftrs fr kidney disese. A nuber f the ptients reprted nuse, viting, nd dirrhe, nd it is ps- sible tht these side effets used vlue depletin ndntributed t the develpent f the kidney injury. Lir- glutide, seglutide, nd dulglutide re etblized by prtelysis nd re preferred hies in ptients with kid- ney filure. GLP-1 reeptr gnists stiulte C-ell neplsi nd use edullry thyrid rin in rts. Hun C-ells express very few GLP-1 reeptrs, nd the relevne t hun therpy is unler. The editins, hwever, shuld nt be used in ptients with persnl r fily his- try f edullry thyrid rin r ultiple endrine neplsi (MEN) syndre type 2. b. DPP-4 inhibitors An lternte pprh t the use f GLP-1 reeptr gnists is t inhibit the enzye DPP-4 nd prlng the tin f endgenusly relesed GLP-1 nd GIP . Fur rl DPP-4 inhibitrs, sitgliptin, sx- gliptin, lingliptin, nd lgliptin, re vilble in the United Sttes fr the tretent f type 2 dibetes. An ddi- tinl DPP-4 inhibitr, vildgliptin, is vilble in Eurpe. Other DPP-4 inhibitrsgeigliptin, ngliptin, teneligliptin, trelgliptin, rigliptin, evgliptin, nd gsgliptinhve been pprved utside the United Sttes nd Eurpen Unin (Kre, Indi, Thilnd, Jpn, Russi, nd severl Suth Aerin untries). Sitagliptin, when used lne r in bintin with ther dibetes editins, lwers HbA1by pprxi- tely 0.5%. The usul dse f sitgliptin is 100 g ne dily, but the dse is redued t 50 g dily if the lu- lted retinine lerne is 3050 L/in nd t 25 g fr lernes less thn 30 L/in. Sxgliptin, when dded t the therpeuti regien (etfrin, sulfnyl- ure, thizlidinedine) f ptients with type 2 dibetes, further lwered the HbA1vlue by but 0.70.9%. The dse is 2.5 g r 5 g rlly ne  dy. The 2.5-g dse shuld be used in ptients with eGFR less thn 50 L/in/ 1.73 2. Alogliptin lwers HbA1by but 0.50.6% when dded t etfrin, sulfnylure, r piglitzne. The usul dse is 25 g rlly dily. The 12.5-g dse is used in ptients with eGFR f 3060 L/in/1.73 2; nd 6.25 g fr lerne less thn 30 L/in/1.73 2. Lin- gliptin lwers HbA1by but 0.40.6% when dded t etfrin, sulfnylure, r piglitzne. The dse is 5 g rlly dily, nd sine, it is pririly exreted unetblized vi the bile, n dse djustent is needed in ptients with kidney disese. Vildgliptin lwers HbA1by but 0.51% when dded t the ther- peuti regien f ptients with type 2 dibetes. The dse is 50 g ne r twie dily. Side effects The in dverse effet f DPP-4 inhibi- trs ppers t be  predispsitin t nsphryngitis r upper respirtry trt infetin. Hypersensitivity re- tins, inluding nphylxis, ngiede, nd exflitive skin nditins (suh s Stevens-Jhnsn syndre), hve been reprted. There hve ls been reprts f pnretitis, but the frequeny f the event is unler. Cses f liver filure hve been reprted with the use f lgliptin, but it is unertin if lgliptin ws the use. The editin, hwever, shuld be disntinued in the event f liver fil- ure. Rre ses f hepti dysfuntin, inluding heptitis,CMDT22_Ch27_p1212-p1255.indd  1227 29/06/21 8:53 PMCHAPTEr 271228 CMDT 2022hve  been reprted with the use f vildgliptin; nd liver biheil testing is reended qurterly during the first yer f use nd peridilly therefter. Sxgliptin y inrese the risk f hert filure. In  pst-rketing study f 16,492 ptients with type 2 dibetes, hert filure urred in 3.5% in the sxgliptin grup nd 2.8% in the pleb grup (hzrd rti 1.27). Ptients with the highest risk f hert filure were thse wh hd  histry f hert filure r hd elevted levels f N-terinl f the prhr- ne B-type ntriureti peptide (NT-pBNP) r hd kidney ipirent. In  lrge pst-rketing study, lgliptin, like sxgliptin, ws ssited with  slightly inresed rte f hert filure. The FDA hs issued  wrning tht the DPP-4 inhibitrs n sinlly use jint pins tht reslve fter stpping the drug. 5. Sodiumglucose cotransporter 2 inhibitors Gluse is freely filtered by the kidney gleruli nd is rebsrbed in the prxil tubules by the tin f sdiu-gluse -trnsprters (SGLT). Sdiu-gluse -trnsprter 2 (SGLT2) unts fr but 90% f gluse rebsrptin nd its inhibitin uses glysuri in peple with dibetes, lwering pls gluse levels. The rl SGLT2 inhibitrs ngliflzin, dpgliflzin, epgliflzin, nd ertugli- flzin re pprved fr linil use in the United Sttes. These gents redue the threshld fr glysuri fr  pls gluse threshld f but  180 g/dL t but 40 g/dL; nd lwer HbA1by 0.51% when used lne r in bintin with ther rl gents r insulin. The effi- y is higher t higher HbA1levels when re gluse is exreted s  result f SGLT2 inhibitin. The lss f l- ries results in dest weight lss f 25 kg. Cngliflzin is dsed t 100 g dily but up t 300 g dily n be used in ptients with nrl kidney funtin. The dse f dpgliflzin is 10 g dily but 5 g dily is the reended initil dse in ptients with hepti fil- ure. The usul dsge f epgliflzin is 10 g dily but  higher dse f 25 g dily n be used. The reended strting dse f ertugliflzin is 5 g, but the dse n be inresed t 15 g dily if dditinl gluse lwering is needed. Empagliflozin ws evluted in  ultintinl study f 7020 ptients with type 2 dibetes with knwn rdi- vsulr disese; the dditin f epgliflzin ws ssi- ted with  lwer priry psite ute f deth fr rdivsulr uses, nnftl yrdil infr- tin, r nnftl strke (hzrd rti 0.86, P= 0.04). The ehniss regrding the benefit rein unler. Weight lss, lwer bld pressure, nd diuresis y hve plyed  rle sine there were fewer deths fr hert filure in the treted grup wheres the rtes f yrdil infrtin were unltered. A siilr ultintinl study ws per- fred with the dditin f ngliflzin. This ws  study f 10,142 ptients with type 2 dibetes with knwn r t inresed risk fr rdivsulr disese. The ngliflzin treted grup hd  lwer priry psite ute f deth fr rdivsulr uses, nnftl yrdil infrtin, r nnftl strke (hzrd rti 0.86, P= 0.02). In  2019 hert filure study f 4744 ptients with NYHA lss II, III, r IV hert filure nd ejetin frtin f less40%, dpgliflzin redued the uultive inidene f wrsening hert filure r rdivsulr deth (hzrd rti 0.74, P< 0.001). Frty-tw perent f the ptients hd dibetes; the findings in ptients with nd withut dibetes were the se. Bth epgliflzin nd ngliflzin shw benefit in ters f prgressin f lbuinuri nd kidney injury, pssibly by lwering glerulr hyperfiltrtin. In  2019 ultintinl study f 4401 ptients with type 2 dibetes nd lbuinuri hrni kidney disese (eGFR 3089 L/in/1.73 2with lbuin [g] t retinine [g] rti > 300 t 5000) nd tking n ACE inhibitr r ngitensin reeptr blker, ngliflzin redued the risk f end-stge kidney disese, the dubling f seru reti- nine, nd f renl deth. In  2020 ultintinl study f 4304 ptients with hrni kidney disese, dpgliflzin redued the risk f end-stge kidney disese r deth fr renl nd rdivsulr uses. A third f the ptients in the study did nt hve dibetes nd hd benefit. Side effects As ight be expeted, the effiy f the SGLT2 inhibitrs is redued in hrni kidney disese. They n ls inrese retinine nd derese eGFR, espe- illy in ptients with kidney ipirent. Their use is generlly nt reended in ptients with eGFR less thn 45 L/in/1.73 2nd re ntrindited in ptients with eGFR less thn 30 L/in/1.73 2. The study f dpgliflzin in hrni kidney disese, hwever, nted tht the drug is sfe nd benefiil in ptients with eGFR s lw s 25 L/in/1.73 2. The in side effets re inresed inidene f genitl yti infetins nd urinry trt infetins ffeting ~89% f ptients. Cses f nertizing fsiitis f the perineu (Furnier gn- grene) hve been reprted. There hve ls been reprts f ses f pyelnephritis nd septiei requiring hspitl- iztin. The glysuri n use intrvsulr vlue ntrtin nd hyptensin. One ultintinl study with ngliflzin shwed n inresed risk f puttins, espeilly f the tes (hzrd rti 1.97). This finding hs nt been bserved in ther studies using this drug r with the ther SGLT2 inhibitrs. Cngliflzin hs been reprted t use  derese in bne inerl density t the lubr spine nd the hip. In  pled nlysis f eight linil trils (en durtin 68 weeks),  30% inrese in frtures ws bserved in ptients tking ngliflzin. It is likely tht the effet n the bnes is  lss effet nd nt restrited t n- gliflzin. All the SGLT2 inhibitrs use  dest inrese in LDL hlesterl levels (38%). Als, in linil trils, ptients tking dpgliflzin hd higher rtes f brest ner (nine ses vs nne in prtr rs) nd bld- der ner (10 ses vs 1 in pleb r). These ner rtes exeeded the expeted rtes in ge-thed referene dibetes ppultin. Cses f DKA hve been reprted with ff-lbel use f SGLT2 inhibitrs in ptients with type 1 dibetes. Type 1 ptients re tught t give less insulin if their gluse levels re nt elevted. SGLT2 inhibitrs lwer gluse levels by hnging the renl threshld nd nt by insulin tin. Type 1 ptients tking n SGLT2 inhibitr, beuse the gluse levels re nt elevted, y either withhld rCMDT22_Ch27_p1212-p1255.indd  1228 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1229 CMDT 2022redue  their insulin dses t suh  degree s t indue ketidsis. SGLT2 inhibitors should not be used in patients with type 1 diabetes and in those patients labeled as having type 2 diabetes but who are very insulin deficient and ketosis-prone. 6. Others Prlintide is  syntheti nlg f islet y- lid plypeptide (IAPP r ylin). When given subutne- usly, it delys gstri eptying, suppresses glugn seretin, nd dereses ppetite. It is pprved fr use bth in type 1 dibetes nd in insulin-treted type 2 dibe- tes. In 6-nth linil studies with type 1 nd insulin- treted type 2 ptients, thse tking the editin hd n pprxitely 0.4% redutin in HbA1nd but 1.7 kg weight lss pred with pleb. The HbA1redutin ws sustined fr 2 yers but se f the weight ws regined. The editin is given by injetin ieditely befre the el. Hypglyei n ur, nd it is re- ended tht the shrt-ting r preixed insulin dses be redued by 50% when the editin is strted. Sine the editin slws gstri eptying, revery fr hyp- glyei n be  prble beuse f dely in bsrptin f fst-ting rbhydrtes. Nuse is the ther in side effet, ffeting 3050% f persns, but tends t iprve with tie. In ptients with type 1 dibetes, the initil dse f prlintide is 15 g befre eh el nd titrted up by 15-g inreents t  intenne dse f 30 g r 60 g befre eh el. In ptients with type 2 dibetes, the strting dse is 60 g preels inresed t 120 g in 3 t 7 dys if n signifint nuse urs. Brriptine,  dpine 2 reeptr gnist, hs been shwn t destly lwer HbA1by 0.10.5% when pred t bseline nd 0.40.5% pred t pleb. Cn side effets re nuse, viting, dizziness, nd hedhe. Clesevel, the bile id sequestrnt, when dded t etfrin r sulfnylure r insulin, lwered HbA10.3 0.4% when pred t bseline nd 0.50.6% pred t pleb. HbA1lwering, hwever, ws nt bserved in  single ntherpy linil tril pring lesevel t pleb. Clesevel use is ssited with ~20% inrese in triglyeride levels. Other dverse effets inlude nstiptin nd dyspepsi.With their modest glucose lowering and significant side effects, using bromocriptine or colesevelam to treat diabetes is not recommended. 7. Medication combinations Severl editin bi- ntins re vilble in different dse sizes, inluding glyburide nd etfrin (Gluvne); glipizide nd et- frin (Metglip); repglinide nd etfrin (Prndi-Met); rsiglitzne nd etfrin (Avndet); piglitzne nd etfrin (ACTOplusMet); rsiglitzne nd gliepiride (Avndryl); piglitzne nd gliepiride (Duett); sitgliptin nd etfrin (Jnuet); sx- gliptin nd etfrin XR (Kbiglyze XR); lingliptin nd etfrin (Jentduet); lgliptin nd etfrin (Kzn); lgliptin nd piglitzne (Oseni); dp- gliflzin nd etfrin (Xigdu); ngliflzin nd et- frin (Invket); epgliflzin nd etfrin (Synjrdy); epgliflzin nd lingliptin (Glyxbi); epgliflzin, lingliptin, nd etfrin (Trijrdy); ertugliflzin nd etfrin (Segluret); ertugliflzin nd sitgliptin (Steglujn); insulin deglude nd lirglutide (Xultphy); nd insulin glrgine nd lixisentide (Sliqu). These editin bintins, hwever, liit the lini- ins bility t ptilly djust dsge f the individul editins nd fr tht resn re nt reended.C.  InsulinInsulin is indi ted fr type 1 dibetes s well s fr type 2 dibeti ptients with insulinpeni whse hyperglyei des nt respnd t diet therpy either lne r bined with ther hypglyei editins. 1. Characteristics of available insulin preparations Hun insulin is dispensed s either regulr (R) r NPH (N) frultins. Six nlgs f hun insulinthree rpidly ting (insulin lispr, insulin sprt, insulin gluli- sine) nd three lng-ting (insulin glrgine, insulin deteir, nd insulin deglude)re vilble fr linil use. Insulin preprtins differ with respet t the tie f nset nd durtin f their bilgi tin (Tble 275). All urrently vilble insulins ntin less thn 10 pp f prinsulin nd re lbeled s purified.  These purified insulins preserve their pteny, s tht refrigertin Table 275. Summary of bioavailability characteristics of the insulins.Insulin  Pepaations1Onset of Action Peak Action Effective Duation Insulins lispro, aspart,2,3glulisine 515 minutes 11.5 hours 34 hours Human regular 3060 minutes 2 hours 68 hours Human NPH 24 hours 67 hours 1020 hours Insulin glargine 0.51 hour Flat ~24 hours Insulin detemir 0.51 hour Flat 17 hours Insulin degludec 0.51.5 hours Flat More than 42 hours Technosphere inhaled insulin 515 minutes 1 hour 3 hours1 Insulin administered subcutaneously unless otherwise noted.2 Insulin aspart formulated with niacinamide (FiAsp has an ~10-minute faster onset of action).3 Insulin lispro formulated with treprostinil and citrate (Lyumjev has an 11-minute faster onset of action).CMDT22_Ch27_p1212-p1255.indd  1229 29/06/21 8:53 PMCHAPTEr 271230 CMDT 2022is  reended but nt ruil. During trvel, reserve supplies f insulin n be redily trnsprted fr weeks withut lsing pteny if prteted fr extrees f het r ld. All the insulins in the United Sttes re vilble in  nentrtin f 100 units/L (U100) nd dispensed in 10-L vils r 0.3-L rtridges r prefilled dispsble pens. Severl insulins re vilble t higher nentr- tins: insulin glrgine, 300 units/L (U300); insulin deglude, 200 units/L (U200); insulin lispr, 200 units/L (U200); nd regulr insulin, 500 units/L (U500). 2. Insulin preparations See Tble 276. The rpidly t- ing insulin nlgs nd the lng-ting insulins re designed fr subutneus dinistrtin, while regulr insulin nd insulin sprt n ls be given intrvenusly. a. Short-acting insulin preparations (1) Regular insulin Regulr insulin is  shrt-ting sluble rystlline zin insulin whse effet ppers within 30 inutes fter subutneus injetin nd lsts 57 hurs when usul quntities re dinistered. Intrvenus infu- sins f regulr insulin re prtiulrly useful in the tret- ent f DKA nd during the peripertive ngeent f ptients with dibetes wh require insulin. Fr rkedly insulin-resistnt persns wh wuld therwise require lrge vlues f insulin slutin,  U500 preprtin f hun regulr insulin is vilble bth in  vil fr nd  dispsble pen. A U500 insulin syringe shuld be used if the vil fr is dispensed. U500 regulr insulin is uh re expensive thn the U100 nentrtin nd is rrely needed.(2) Rapidly acting insulin analogs Insulin lispr (Hulg, Adelg) is n insulin nlg where the pr- line t psitin B28 is reversed with the lysine t B29. Insulin sprt (Nvlg) is  single substitutin f prline by sprti id t psitin B28. In insulin glulisine (Apidr) the sprgine t psitin B3 is repled by lysine nd the lysine in psitin B29 by gluti id. These three n- lgs hve less f  tendeny t fr hexers, in ntrst t hun insulin. When injeted subutneusly, the n- lgs quikly dissite int ners nd re bsrbed very rpidly, rehing pek seru vlues in s sn s 1 hurin ntrst t regulr hun insulin, whse hex- ers require nsiderbly re tie t dissite nd bee bsrbed. The in id hnges in these nlgs d nt interfere with their binding t the insulin reeptr, with the irulting hlf-life, r with their iungeniity, whih re ll identil with thse f hun regulr insulin. An insulin sprt frultin (FiAsp) tht ntins niin- ide (vitin B3) hs  re rpid initil bsrptin nd its nset f tin is but 10 inutes fster thn the stndrd insulin sprt frultin. Beuse f this re rpid nset f tin, the 1-hur (but nt 2-hur) pstprndil gluse exursins re lwer pred t the stndrd frultin. Siilrly, n insulin lispr frultin (Lyujev) ntin- ing trepstinil t indue ll vsdiltin nd itrte t inrese vsulr perebility hs 11 inutes fster nset f tin nd lwer 1- nd 2-hur pstprndil gluse exur- sins pred t the stndrd insulin lispr frultin. Clinil trils hve denstrted tht the ptil ties f preprndil subutneus injetin f prble dses f the rpidly ting insulin nlgs nd f regulr hun insulin re 20 inutes nd 60 inutes, respetively, befre the el. The quiker nset f tin with the rpidly t- ing insulin nlgs llws the ptient t injet insulin just befre eting rther thn wit fr 60 inutes s needed fr regulr insulin. Anther desirble feture f rpidly ting insulin nlgs is tht their durtin f tin reins t but 4 hurs fr st nly used dsges. This n- trsts with regulr insulin, whse durtin f tin is sig- nifintly prlnged when lrger dses re used. The rpidly ting nlgs re nly used in pups. In  duble-blind rssver study pring insu- lin lispr with regulr insulin in insulin pups, persns using insulin lispr hd lwer HbA1vlues nd iprved pstprndil gluse ntrl with the se frequeny f hypglyei. In the event f pup filure, hwever, users f the rpidly ting insulin nlgs will hve re rpid nset f hyperglyei nd ketsis. While insulin sprt hs been pprved fr intrvenus use (eg, in hyperglyei eergenies), there is n dvn- tge in using insulin sprt ver regulr insulin by this rute. A U200 nentrtin f insulin lispr is vilble in  dispsble prefilled pen. The nly dvntge f the U200 ver the U100 insulin lispr preprtin is tht it delivers the se dse in hlf the vlue. b. Long-acting insulin preparations (1) NPH (neutral protamine Hagedorn or isophane) insulin NPH is n interedite-ting insulin whse nset f tin is delyed t 24 hurs, nd its pekTable 276. Insulin preparations available in the United States.1rapidly  acting human insulin analogs Insulin lispro (Humalog, Lyumjev, Lilly; Admelog, Sanofi) Insulin aspart (Novolog, FiAsp, Novo Nordisk) Insulin glulisine (Apidra, Sanofi Aventis) Shot-acting egula insulin Regular insulin (Lilly, Novo Nordisk) Technosphere inhaled regular insulin (Afrezza) Intemediate-acting insulins NPH insulin (Lilly, Novo Nordisk) Pemixed insulins 70% NPH/30% regular (70/30 insulinLilly, Novo Nordisk) 70% NPL/25% insulin lispro (Humalog Mix 75/25Lilly) 50% NPL/50% insulin lispro (Humalog Mix 50/50Lilly) 70% insulin aspart protamine/30% insulin aspart (Novolog Mix 70/30Novo Nordisk) 70% insulin degludec/30 insulin aspart (Ryzodeg, Novo Nordisk) Long-acting human insulin analogs Insulin glargine (Lantus (U100), Toujeo (U300), Sanofi Aventis; Basaglar (U100), Lilly) Insulin detemir (Levemir, Novo Nordisk) Insulin degludec (Tresiba, Novo Nordisk)1 All insulins available in the United States are recombinant human or human insulin analog origin. All the above insulins are dis- pensed at U100 concentration. There is an additional U500 prepa- ration of regular insulin; U300 preparation of insulin glargine; U200 preparation of insulin lispro; U200 preparation of insulin degludec. NPH, neutral protamine Hagedorn.CMDT22_Ch27_p1212-p1255.indd  1230 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1231 CMDT 2022respn se is generlly rehed in but 67 hurs. The nset f tin is delyed by bining 2 prts sluble rystlline zin insulin with 1 prt prtine zin insulin. This prdues equivlent unts f insulin nd prt- ine, s tht neither is present in n unplexed fr (isphne). Beuse its durtin f tin is ften less thn 24 hurs (with  rnge f 1020 hurs), st ptients require t lest tw injetins dily t intin  sustined insulin effet. Osinl vils f NPH insulin hve tended t shw unusul luping f their ntents r frsting f the ntiner, with nsiderble lss f bitivity. This instbility is rre nd urs less frequently if NPH hun insulin is refrigerted when nt in use nd if bttles re disrded fter 1 nth f use. (2) Insulin glargine In this insulin, the sprgine t psitin 21 f the insulin A hin is repled by glyine nd tw rginines re dded t the rbxyl terinl f the B hin. The rginines rise the iseletri pint f the l- eule lser t neutrl king it re sluble in n idi envirnent. In ntrst, hun insulin hs n iseletri pint f pH 5.4. Insulin glrgine is  ler insulin, whih, when injeted int the neutrl pH envirnent f the sub- utneus tissue, frs irpreipittes tht slwly relese the insulin int the irultin. This insulin lsts fr but 24 hurs withut ny prnuned peks nd is given ne  dy t prvide bsl verge. This insulin nnt be ixed with the ther hun insulins beuse f its idi pH. When this insulin ws given s  single injetin t bedtie t type 1 ptients in linil trils, fsting hyper- glyei ws better ntrlled with less nturnl hyp- glyei when pred t NPH insulin. A re nentrted fr f insulin glrgine (U300) is vilble s n insulin pen. In linil trils in type 1 ptients, U300 use did nt result in better ntrl r redue the rtes f hypglyei. Althugh liited linil dt suggest tht insulin glrgine is sfe in pregnny, it is nt pprved fr this use. (3) Insulin detemir In this insulin nlg, the thre- nine t psitin B30 hs been reved nd  14-C ftty id hin (tetrdeni id) is tthed t the lysine t psitin 29 by yltin. Its prlnged tin is due t dihexeriztin nd binding f hexers nd diers t lbuin t the injetin site s well s binding f the ner vi its ftty id side hin t lbuin in the irultin. The ffinity f insulin deteir is furfld t fivefld lwer thn tht f hun sluble insulin nd therefre the U100 frultin f insulin deteir hs n insulin nentrtin f 2400 nl/L pred with 600 nl/L fr NPH. The durtin f tin fr insulin deteir is but 17 hurs t therpeutilly relevnt dses. It is reended tht the insulin be injeted ne r twie  dy t hieve  stble bsl verge. It hs been pprved fr use during pregnny. (4) Insulin degludec In this insulin nlg, the thre- nine t psitin B30 hs been reved, nd the lysine t psitin B29 is njugted t hexdeni id vi  g-L-glutyl sper. In the vil, in the presene f phenl nd zin, the insulin is in the fr f dihexers but when injeted subutneusly, it self ssites int lrge ultihexeri hins nsisting f thusnds fdihexers. The hins slwly disslve in the subutne- us tissue nd insulin ners re stedily relesed int the systei irultin. The hlf-life f insulin deglude is 25 hurs. Its nset f tin is in 3090 inutes nd its durtin f tin is re thn 42 hurs. It is re- ended tht the insulin be injeted ne r twie  dy t hieve  stble bsl verge. Insulin deglude is vil- ble in tw nentrtins, U100 nd U200, nd dispensed in prefilled dispsble pens. (5) Insulin icodec This is n insulin nlg tht is suit- ble fr ne weekly injetin nd is in phse 3 linil trils. c. Mixed insulin preparations Ptients with type 2 dibetes n seties hieve resnble gluse ntrl with just prebrekfst nd predinner injetins f ixtures f shrt ting nd NPH insulins. The regulr insulin r rpidly ting insulin nlg is withdrwn first, then the NPH insulin nd then injeted ieditely. Stble pre- ixed insulins (70% NPH nd 30% regulr) re vilble s  nveniene t ptients wh hve diffiulty ixing insu- lin beuse f visul prbles r ipirent f nul dexterity (Tble 276). Preixed preprtins f insulin lispr nd NPH insulins re unstble; stbility is hieved by repling the NPH insulin with NPL (neutrl prtine lispr). This insulin hs the se durtin f tin s NPH insulin. Preixed bintins f NPL nd insulin lispr (75% NPL/25% insulin lispr ixture [Hulg Mix 75/25] nd 50% NPL/50% insulin lispr ixture [Hulg Mix 50/50]) re vilble fr linil use. Sii- lrly,  70% insulin sprt prtine/30% insulin sprt (NvLg Mix 70/30) is vilble. The in dvntges f these ixtures re tht they n be given within 15 inutes f strting  el nd they re superir in ntrlling the pstprndil gluse rise fter  rbhydrte-rih el. These benefits hve nt trnslted int iprveents in HbA1levels when pred with the usul 70% NPH/30% regulr ixture. The lnger-ting insulin nlgs, insulin glrgine nd insulin deteir, nnt be ixed with either regulr insulin r the rpidly ting insulin nlgs. Insulin deglude, hwever, n be ixed nd is vilble s 70% insulin deglude/30% insulin sprt nd is injeted ne r twie  dy. 3. Methods of insulin administration a. Insulin syringes and needles Plsti dispsble syringes re vilble in 1-L, 0.5-L, nd 0.3-L sizes. Three lengths f needles re vilble: 6 , 8 , nd 12.7 . Lng needles re preferble in bese ptients t redue vribility f insulin bsrptin. The needles re f 28, 30, nd 31 guges. The 31-guge needles re lst pinless. Dispsble syringes y be reused until blunt- ing f the needle urs (usully fter three t five inje- tins). Sterility dequte t vid infetin with reuse ppers t be intined by repping syringes between uses. Clensing the needle with lhl y nt be desir- ble sine it n disslve the siline ting nd n inrese the pin f skin punturing. b. Sites of injection Any prt f the bdy vered by lse skin n be used, suh s the bden, thighs, upperCMDT22_Ch27_p1212-p1255.indd  1231 29/06/21 8:53 PMCHAPTEr 271232 CMDT 2022rs,  flnks, nd upper buttks. Preprtin with l- hl is nt required prir t injetin s lng s the skin is len. Rttin f sites is reended t vid delyed bsrptin when fibrsis r liphypertrphy urs fr repeted use f  single site. Regulr insulin is bsrbed re rpidly when injeted in the deltid r bden pred t thighs nd buttks. Exerise n inrese bsrptin when the injetin site is djent t the exer- ise usle. Fr st ptients, the bden is the re- end regin fr injetin beuse it prvides dequte re in whih t rtte sites. The effet f nti regins ppers t be uh less prnuned with the nlg insulins. c. Insulin pen injector devices Insulin pens (Nv Nrdisk, nd Owen Mufrd) eliinte the need fr r- rying insulin vils nd syringes. Srt pens (Cpnin Medil) tht re linked t ell phnes n be used t reind the user t tke their insulin befre els, lulte dses, nd keep trk f tiing f the dses. Crtridges f insulin lispr nd insulin sprt re vilble fr the reus- ble pens. Dispsble prefilled pens re ls vilble fr regulr insulin (U100 nd U500), insulin lispr, insulin sprt, insulin glulisine, insulin deteir, insulin glrgine, insulin deglude, NPH, 70% NPH/30% regulr, 75% NPL/25% insulin lispr, 50% NPL/50% insulin lispr, 70% insulin sprt prtine/30% insulin sprt, nd 70% insulin deglude/30% insulin sprt. Pen needles re vil- ble in 29, 31, nd 32 guges nd 4-, 5-, 6-, 8-, nd 12.7- lengths (Nvfine; BD). d. Insulin pumps In the United Sttes, Medtrni Mini- Med, Insulet, nd Tnde ke bttery perted ntinu- us subutneus insulin infusin (CSII) pups. These pups re sll (but the size f  pger) nd esy t prgr. They ffer ny fetures, inluding the bility t set  nuber f different bsl rtes thrughut the 24 hurs nd t djust the tie ver whih blus dses re given. They ls re ble t detet pressure build-up if the theter is kinked. The theter nneting the insulin reservir t the subutneus nnul n be disn- neted, llwing the ptient t reve the pup teprr- ily (eg, fr bthing). Oinpd (Insulet Crprtin) is n insulin infusin syste in whih the insulin reservir nd infusin set re integrted int ne unit (pd), s there is n theter (eletrni pth pup). The pd, pled n the skin, delivers subutneus bsl nd blus insulin bsed n wirelessly trnsitted instrutins fr  per- snl digitl ssistnt. The gret dvntge f ntinuus subutneus insulin infusin (CSII) is tht it llws fr estblishent f  bsl prfile tilred t the ptient llwing fr better vernight nd between els gluse ntrl. The bility t djust the bsl insulin infusin kes it esier fr the ptient t nge glyei exur- sins tht ur with exerise. The pups hve sftwre tht n ssist the ptient t lulte bluses bsed n gluse reding nd rbhydrtes t be nsued. They keep trk f the tie elpsed sine the lst insulin blus; the ptient is reinded f this when he r she ttepts t give dditinl rretin blus befre the effet f the previus blus hs wrn ff (insulin n brd feture).This feture redues the risk f verrreting nd subse- quent hypglyei. CSII therpy is pprprite fr ptients with type 1 dibetes wh re tivted, ehnilly inlined, edu- ted but dibetes (diet, insulin tin, tretent f hypglyei nd hyperglyei), nd willing t nitr their bld gluse fur t six ties  dy. Knwn pli- tins f CSII inlude ketidsis, whih n ur when insulin delivery is interrupted, nd skin infetins. Anther disdvntge is its st nd the tie needed f the liniin nd stff t initite therpy. Alst ll ptients use rpid- ting insulin nlgs in their pups. V-g (Vlerits) is  ehnil pth pup designed speifilly fr peple with type 2 dibetes wh use  bsl/ blus insulin regien. The devie is preset t deliver ne f three fixed nd flt bsl rtes (20, 30, r 40 units) fr 24 hurs (t whih pint it ust be repled) nd there is  buttn tht delivers tw units per press t help ver els. e. Closed loop systems Algriths hve been devised t use gluse dt fr the ntinuus gluse nitr- ing systes t uttilly deliver insulin by ntinuus subutneus insulin infusin pup. These lsed lp systes (rtifiil pnres) hve been shwn in linil studies t iprve nighttie gluse ntrl, destly lwer HbA1levels, nd redue the risk f nturnl hyp- glyei. The MiniMed 670 G nd the Tnde Cntrl- IQ, hve been pprved fr linil use. The MiniMed 670 G lsed lp syste uses gluse dt fr  sensr t uttilly djust bsl insulin dses every 5 inutes, trgeting  sensr gluse level f 120 g/dL (6.7 l/L). Insulin delivery is suspended when the sensr gluse level flls belw r is predited t fll belw trget level. The gluse trget n be djusted up t 150 g/dL (8.3 l/L) fr physil tivity. The Tnde Cntrl-IQ trgets  sen- sr gluse level f 112.5 g/dL (6.25 l/L). The ptient is still respnsible fr blusing insulin fr els nd snks. There re ls D-It-Yurself lsed lp sys- tes using free pen-sure sftwre. One suh syste, lled the Lp,  uses the Dex G6 sensr, the iPhne, nd the Onipd insulin pup. The Lp ntrller is dwnlded n t the iPhne, nd it uses the Dex G6 sensr gluse esureents (ls n the iPhne) t ut- tilly djust bsl insulin delivery n the Onipd pup. Inresing nubers f type 1 ptients use these D- It-Yurself systes, but they re nt pprved fr use by the FDA. Suessful use f these systes requires prfi- ieny t using bth the insulin pup nd ntinuus gluse nitr. The systes re expensive; the insulin pup, whih needs t be repled every 4 yers, sts but $6000 nd the pup supplies re $1500 per yer. The ntinuus gluse nitring syste sts pprxitely $4000 per yer. f. Inhaled insulin Tehnsphere insulin (Afrezz) is  dry-pwder frultin f rebinnt hun regulr insulin tht n be inhled. It nsists f 2- t 2.5- rystls f the exipient furyl diketpiperzine tht pr- vide  lrge surfe re fr dsrptin f prteins like insulin. The tehnsphere insulin is rpidly bsrbed with pek insulin levels rehed in 1215 inutes nd deliningCMDT22_Ch27_p1212-p1255.indd  1232 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1233 CMDT 2022t bseline  in 3 hurs; the edin tie t xiu effet with inhled insulin is pprxitely 1 hur nd delines t bseline by but 3 hurs. In ntrst, the edin tie t xiu effet with subutneus insulin lispr is but 2 hurs nd delines t bseline by 4 hurs. In lini- l trils, tehnsphere insulin bined with bsl insu- lin ws s effetive in gluse lwering s rpid-ting insulin nlgs bined with bsl insulin. It is fru- lted s  single-use, lr-ded rtridge delivering 4, 8, r 12 units ieditely befre the el. The nufturer prvides  dse nversin tble; ptients injeting up t 4 units f rpid-ting insulin nlg shuld use the 4-unit rtridge. Thse injeting 5 t 8 units shuld use the 8-unit rtridge. If the dse is 912 units f rpid-ting insulin preel then ne 4-unit rtridge nd ne 8-unit rtridge r ne 12-unit rtridge shuld be used. The inhler is but the size f  referees whistle. The st n dverse retin f the inhled insulin is  ugh, ffeting but 27% f ptients. A sll derese in pulnry funtin (fred expirtry vlue in 1 send [FEV1]) is seen in the first 3 nths f use, whih persists ver 2 yers f fllw-up. Inhled insulin is ntrindited in ptients wh ske nd in thse with hrni lung disese, suh s sth nd hrni bstru- tive pulnry disese. Spiretry shuld be perfred t identify ptentil lung disese prir t inititing therpy. During linil trils, there were tw ses f lung ner in ptients wh were tking inhled insulin nd nne in the prtr-treted ptients. All the ptients in wh lung ner develped hd  histry f prir igrette sking. Cses f lung ner were ls reprted in igrette sk- ers using  previusly vilble inhled insulin preprtin (Exuber). The inidene rte in the Exuber-treted grup ws 0.13 per 1000 ptient-yers, wheres it ws 0.03 per 1000 ptient-yers in the prtr-treted grup.D . Transplantation1. Pancreas transplan tation All ptients with end-stge kidney disese nd type 1 dibetes wh re ndidtes fr  kidney trnsplnt shuld be nsidered ptentil ndi- dtes fr  pnres trnsplnt. Eligibility riteri inlude ge yunger thn 55 nd inil rdivsulr risk. Cntrinditins inlude nnrretble rnry rtery disese, extensive peripherl vsulr disese, nd signifi- nt besity (weight greter thn 100 kg). The pnres trnsplnt y ur t the se tie s kidney trnsplnt r fter kidney trnsplnt. Ptients underging siultne- us pnres nd kidney trnsplnttin hve n 83% hne f pnreti grft survivl t 1 yer nd 69% t 5 yers. Slitry pnreti trnsplnttin in the bsene f  need fr kidney trnsplnttin is nsidered nly in thse rre ptients wh d nt respnd t ll ther insulin therpeuti pprhes nd wh hve frequent severe hypglyei, r wh hve life-thretening plitins relted t their lk f etbli ntrl. Slitry pnres trnsplnt grft survivl is 78% t 1 yer nd 54% t 5 yers. 2. Islet transplantation Ttl pnretety is urtive fr severe pin syndre ssited with hrni pnre- titis. The pnretety, hwever, results in surgildibetes. Hrvesting islets fr the reved pnres nd uttrnsplnting the int the liver (vi prtl vein) n prevent the develpent f dibetes r result in ild dibetes (prtil islet funtin) tht is esier t nge. Sine the islets re utlgus, n iunsuppressin is required. The nuber f islets trnsplnted is the in preditr f insulin independene. Peple with type 1 dibetes n bee insulin inde- pendent fter reeiving islets islted fr  dnr pn- res (llislet trnsplnt). The islets re infused int the prtl vein using  perutneus trnshepti pprh, nd they ldge in the liver relesing insulin in respnse t physilgi stiuli. Lng-ter iunsuppressin is neessry t prevent llgrft rejetin nd t suppress the utiune press tht led t the disese in the first ple. Insulin independene fr re thn 5 yers hs been denstrted in ptients wh gt nti-CD3 nti- bdy r nti-thyyte glbulin indutin iunsup- pressin nd lineurin inhibitrs, Tr inhibitrs, nd yphenlte fetil s intenne iunsuppres- sin. One jr liittin is the need fr re thn ne islet infusin t hieve insulin independene. This is beuse f signifint lss f islets during isltin nd the perid prir t engrftent. Widespred llislet trnsplnttin will depend n iprving insulin inde- pendene rtes with ne infusin nd ls denstrting tht the lng-ter utes re s gd s thse f pn- res trnsplnt lne.Kristensen  SL et l. Crdivsulr, rtlity, nd kidney ut- es with GLP-1 reeptr gnists in ptients with type 2 dibetes:  systeti review nd et-nlysis f rdivs- ulr ute trils. Lnet Dibetes Endrinl. 2019;7:776. [PMID: 31422062] Leelrthn L et l. Hybrid lsed-lp therpy: where re we in 2021? Dibetes Obes Metb. 2021;23:655. [PMID: 33269551] MGuire DK et l. Assitin f SGLT2 inhibitrs with rdi- vsulr nd kidney utes in ptients with type 2 dibe- tes:  et-nlysis. JAMA Crdil. 2021;6:148. [PMID: 33031522] Steps in the Management of DiabetesA.  Distinguishing the Types of DiabetesAn tt ept shuld be de t hrterize the dibetes s type 1 r type 2 r ther speifi types suh s MODY, bsed n the linil fetures present nd n whether r nt ketnuri pnies the glysuri. Fetures tht suggest end-rgn insulin insensitivity t insulin, suh s viserl besity, nthsis nigrins, r bth, ust be identified. The fily histry shuld duent nt nly the inidene f dibetes in ther ebers f the fily but ls the ge t nset, ssitin with besity, the need fr insulin, nd whether there were plitins. Fr the sinl ptient, esureent f GAD65, IAA, ICA 512, nd zin trnsprter 8 ntibdies n help distinguish between type 1 nd type 2 dibetes (Tble 277). Mny ptients with newly dignsed type 1 dibetes still hve signifint endgenus insulin prdutin, nd C peptide levels d nt relibly distinguish between type 1 nd type 2 dibetes.CMDT22_Ch27_p1212-p1255.indd  1233 29/06/21 8:53 PMCHAPTEr 271234 CMDT 2022B.  Patient Education (SelfManagement Training)Since  diabetes is a lifelong disorder, education of the patient and the family is probably the most important obligation of the clinician who provides care. The best persns t nge  disese tht is ffeted s rkedly by dily flututins in envirnentl stress, exerise, diet, nd infetins re the ptients theselves nd their fi- lies. The tehing urriulu shuld inlude expln- tins by the liniin r nurse f the nture f dibetes nd its ptentil ute nd hrni hzrds nd hw they n be regnized erly nd prevented r treted. Self- nitring f bld gluse shuld be ephsized, espe- illy in insulin-requiring dibeti ptients, nd instrutins ust be given n prper testing nd rerding f dt. Ptients tking insulin shuld hve n understnding f the tins f bsl nd blus insulins. They shuld be tught t deterine whether the bsl dse is pprprite nd hw t djust the rpidly ting insulin dse fr the rbhydrte ntent f  el. Ptients nd their filies nd friends shuld be tught t regnize signs nd syp- ts f hypglyei nd hw t tret lw gluse re- tins. Strenuus exerise n preipitte hypglyei, nd ptients ust therefre be tught t redue their insulin dsge in ntiiptin f strenuus tivity r t tke supple- entl rbhydrte. Injetin f insulin int  site frthest wy fr the usles st invlved in the exerise y help elirte exerise-indued hypglyei, sine insu- lin injeted in the prxiity f exerising usle y be re rpidly bilized. Exerise trining ls inreses the effetiveness f insulin, nd insulin dses shuld be djusted rdingly. Infetins n use insulin resistne, nd ptients shuld be instruted n hw t nge the hyper- glyei with suppleentl rpidly ting insulin. Advie n persnl hygiene, inluding detiled instru- tins n ft nd dentl re, shuld be prvided. All infe- tins (espeilly pygeni nes) prvke the relese f high levels f insulin ntgnists, suh s tehlines r glugn, nd thus bring but  rked inrese in insu- lin requireents. Ptients wh re tking rl gents y depenste nd teprrily require insulin. Ptients shuld be tld but unity genies, suh s Dibetes Assitin hpters, tht n serve s  ntinuing sure f instrutin.Finlly, vigrus effrts shuld be de t persude ptients with newly dignsed dibetes wh ske t give up the hbit, sine lrge vessel peripherl vsulr disese nd debilitting retinpthy re less n in nnsk- ing dibeti ptients.C.  MedicationsT retent ust be individulized n the bsis f the type f dibetes nd speifi needs f eh ptient. Hwever, ertin generl priniples f ngeent n be utlined fr hyperglyei sttes f different types. 1. Type 1 diabetes A bintin f rpidly ting insu- lin nlgs nd lng-ting insulin nlgs llws fr re physilgi insulin repleent. Tble 278 illustrtes  regien with  rpidly ting insulin nlg nd lng- ting bsl insulin tht ight be pprprite fr  70-kg persn with type 1 dibetes eting els prviding stn- drd rbhydrte intke nd derte t lw ft ntent. Insulin glrgine r insulin deglude is usully given ne in the evening t prvide 24-hur verge. There re sinl ptients in wh insulin glrgine des nt lst fr 24 hurs, nd in suh ses, it needs t be given twie  dy. Insulin deteir usully hs t be given twie  dy t get dequte 24-hur bsl verge. Altern- tively, sll dses f NPH (~34 units) n be given with eh el t prvide dytie bsl verge with  lrger dse t night. CSII by prtble bttery-perted pen lp devies llw the setting f different bsl rtes thrughut the 24 hurs nd perit blus dse djustents by s little s 0.05-unit inreents. The 24-hur bsl dsge is usully bsed n ge nd bdy weight. An dlesent ight need s uh s 0.4 unit/kg/dy;  yung dult (less thn 25 yers),Table 277. Diagnostic sensitivity and specificity of autoimmune markers in patients with newly diag- nosed type 1 diabetes mellitus. Sensitivity Specificity Islet cell antibodies (ICA) 44100% 96% Glutamic acid decarboxylase (GAD65)7090% 99% Insulin (IAA) 4070% 99% Tyrosine phosphatase (IA-2, ICA 512)5070% 99% Zinc transporter 8 (ZnT8) 5070% 99%T able 278. Examples of intensive insulin regimens using rapidly acting insulin analogs (insulin lispro, aspart, or glulisine) and long-acting insulin analogs (insulin detemir, or insulin glargine or degludec) in a 70-kg man with type 1 diabetes.13 Pe- beakfastPe- lunchPe- dinneAt Bedtime Rapidly acting insulin analog5 units 4 units 6 units Insulin detemir367 units  89 units OR Rapidly acting insulin analog5 units 4 units 6 units  Insulin glargine or degludec3  1516 units1 Assumes that patient is consuming approximately 75 g carbohy- drate at breakfast, 60 g at lunch, and 90 g at dinner.2 The dose of rapidly acting insulin can be raised by 1 or 2 units if extra carbohydrate (1530 g) is ingested or if premeal blood glu- cose is > 170 mg/dL (9.4 mmol/L).3 Insulin glargine or insulin detemir must be given as a separate injection.CMDT22_Ch27_p1212-p1255.indd  1234 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1235 CMDT 20220.35 unit p er/kg/dy; nd n lder dult, 0.25 unit/kg/dy. Fr exple,  70-kg, 30-yer-ld persn y require  bsl rte f 0.7 unit per hur thrughut the 24 hurs with the exeptin f 3 am t 8 am, when 0.8 unit per hur ight be pprprite (given the  dawn phenomenon  redued tissue sensitivity t insulin between 5 am nd 8 am). The el blus vries bsed n the tie f dy nd the persns ge. Adlesents nd yung dults usully require 1 unit fr but 10 g f rbhydrte. Older dults usully require but 1 unit fr 15 g f rbhydrte. The rretin ftrhw uh insulin is needed t lwer gluse levels by 50 g/dLn be lulted fr the insulin-t-rbhydrte rtis. Fr exple, if 1 unit is required fr 15 g f rbhydrte, then 1 unit will lwer gluse levels by 50 g/dL. If 1.5 units f insulin re required fr 15 g f rbhydrte (tht is, 1 unit fr 10 g rbhydrte), then 1.5 units f insulin will lwer gluse levels by 50 g/dL (tht is, 1 unit will lwer gluse level by 33 g/dL). Fr  70-kg 30-yer-ld persn, blus rtis f 1 unit fr 1215 g f rbhydrte plus 1 unit fr 50 g/dL f bld gluse ver  trget vlue f 120 g/dL wuld be resnble strting pint. Further djustents t bsl nd blus dsges wuld depend n the results f bld gluse nitring. One f the re diffiult ther- peuti prbles in nging ptients with type 1 dibetes is deterining the prper djustent f insulin dse when the prebrekfst bld gluse level is high. Osinlly, the prebrekfst hyperglyei is due t the Somogyi effect, in whih nturnl hypglyei leds t  surge f unterregultry hrnes t prdue high bld glu- se levels by 7 am. Hwever,  re n use fr prebrekfst hyperglyei is the wning f irulting insulin levels by the rning. The dignsis f the use f prebrekfst hyperglye- i n be filitted by self-nitring f bld gluse t 3 am in dditin t the usul bedtie nd 7 am e- sureents r by nlyzing dt fr the ntinuus glu- se nitr. This is required fr nly  few nights, nd when  prtiulr pttern eerges fr nitring bld gluse levels vernight, pprprite therpeuti esures n be tken. The Sgyi effet n be treted by lwer- ing the bsl insulin dse t bedtie r by eting  snk t bedtie. When  wning insulin level is the use, then either inresing the evening bsl insulin dse r shifting it fr dinnertie t bedtie (r bth) n be effetive. The urrently vilble lsed lp systes enble ptients t hieve lse t nrl gluse levels in the rning with  lw risk f nturnl hypglyei nd iprve verll gluse ntrl. All ptients with type 1 dibetes wh re skilled t using insulin pups shuld use these systes. 2. Type 2 diabetes Therpeuti reendtins re bsed n the reltive ntributins f bet ell insuffi- ieny nd insulin insensitivity in individul ptients. The pssibility tht the individul ptient hs  speifi eti- lgi use fr their dibetes shuld lwys be nsidered, espeilly when the ptient des nt hve  fily histry f type 2 dibetes r des nt hve ny evidene f entrl besity r insulin resistne. Suh ptients shuld be evlu- ted fr ther types f dibetes suh s LADA r MODY(Tble 271). Ptients with LADA shuld be presribed insulin when the disese is dignsed nd treted like ptients with type 1 dibetes. It is ls iprtnt t nte tht ny ptients with type 2 dibetes ellitus hve  prgressive lss f bet ell funtin nd will require ddi- tinl therpeuti interventins with tie. a. Weight reduction One f the priry des f therpy in the bese ptient with type 2 dibetes is weight redutin. Nrliztin f glyei n be hieved by weight lss nd iprveent in tissue sensitivity t insu- lin. A bintin f lri restritin, inresed exer- ise, nd behvir difitin is required if  weight redutin prgr is t be suessful. Understnding the risks ssited with the dignsis f dibetes y ti- vte the ptient t lse weight. Fr seleted ptients, edil r surgil ptins fr weight lss shuld be nsidered. Orlistt, phenterine/ tpirte, lrserin, nltrexne/extended-relese bupr- pin, nd high-dse lirglutide (3 g dily) re weight lss editins pprved fr use in bintin with diet nd exerise (see Chpter 29). Britri surgery (Rux-en-Y, gstri bnding, gstri sleeve, bilipnreti diversin/dudenl swith) typilly results in substntil weight lss nd iprveent in glu- se levels. A et-nlysis exining the ipt f br- itri surgery n ptients with dibetes nd BMI f 40 kg/2r greter nted tht 82% f ptients hd reslu- tin f linil nd lbrtry nifesttins f dibetes in the first 2 yers fter surgery nd 62% reined free f dibetes re thn 2 yers fter surgery. The iprveent ws st rked in the predure tht used the gretest weight lss (bilipnreti diversin/dudenl swith). There ws, hwever,  high ttritin f ptients vilble fr fllw-up, nd there ws little infrtin but differ- ent ethni types. Weight regin des ur fter britri surgery, nd it n be expeted tht 2025% f the lst weight will be regined ver 10 yers. The ipt f this weight gin n dibetes reurrene depends priniplly n the degree f bet ell dysfuntin. Nnbese ptients with type 2 dibetes frequently hve inresed viserl dipsitythe s-lled etblilly bese nrl weight ptient. There is less ephsis n weight lss, but exerise reins n iprtnt spet f tretent. b. Glucose-lowering agents Figure 272 utlines the tretent pprh bsed n the nsensus lgrith prpsed by the Aerin Dibetes Assitin nd the Eurpen Assitin fr the Study f Dibetes. The ur- rent reendtin is t strt etfrin therpy t dignsis nd nt wit t see whether the ptient n hieve trget glyei ntrl with weight ngeent nd exerise. See disussin f the individul editins, bve. When dibetes is nt well ntrlled with initil ther- py (usully etfrin), then  send gent shuld be dded. Presene f rdivsulr r kidney disese, r bth, will deterine the hie f the send gent. Lir- glutide, seglutide, epgliflzin, ngliflzin, nd dpgliflzin hve iprved rdivsulr utes.CMDT22_Ch27_p1212-p1255.indd  1235 29/06/21 8:53 PMCHAPTEr 271236 CMDT 2022The  SGLT2 inhibitrs re espeilly benefiil in ptients with hert filure r dibeti nephrpthy, r bth. The need fr weight lss shuld led t the use f GLP1- reeptr gnists in the bese ptient with r withut r- nry rtery disese. SGLT2 inhibitrs ls prte dest weight lss nd shuld be presribed in the ptient with hert filure r dibeti nephrpthy. Sulfnylures hve been vilble fr ny yers nd their use in bintin with etfrin is well estblished. They d, hwever, hve the prpensity f using hypglyei nd weight gin. In ptients wh experiene hyperglyei fter  rbhy- drte-rih el (suh s dinner),  shrt-ting seret- ggue (repglinide r nteglinide) befre els y suffie t get the gluse levels int the trget rnge. Ptients with severe insulin resistne y be ndidtes fr pigli- tzne. Piglitzne y ls redue the risk fr reurrent strke in ptients wh hve  histry f strke r trnsient ishei ttk. If tw gents re indequte, then  third gent is dded, lthugh dt regrding effiy f suh bined therpy re liited. When the bintin f rl gents (nd injetble GLP-1 reeptr gnists) fils t hieve euglyei in ptients with type 2 dibetes, then insulin tretent shuld be instituted. Vrius insulin regiens y be effetive. One prpsed regien is t ntinue the rl bintin therpy nd then siply dd  bedtie dse f NPH r lng-ting insulin nlg (insulin glrgine, deteir, r deglude) t redue exessive nturnl hepti gluse utput nd iprve fsting gluse levels. If the ptient des nt hieve trget gluse levels during the dy, then dytie insulin tretent n be initited. A nvenient insulin regien under these irustnes is  split dse f 70/30 NPH/regulr ixture (r Hulg Mix 75/25 r NvLgMix 70/30) befre brekfst nd befre dinner. If this regien fils t hieve stisftry glye- i gls r is ssited with uneptble frequeny f hypglyei episdes, then  re intensive regien f ultiple insulin injetins n be instituted s in ptients with type 1 dibetes. Metfrin priniplly redues hepti gluse utput, nd it is resnble t ntinue with this editin when insulin therpy is instituted. Piglitzne, whih iprves peripherl insulin sensitiv- ity, n be used tgether with insulin but this bintin is ssited with re weight gin nd peripherl ede. The sulfnylures, the GLP-1 reeptr gnists, the DPP-4 inhibitrs, nd the SGLT2 inhibitrs ls hve been shwn t be f ntinued benefit. Weight-reduing interventins shuld ntinue even fter inititin f insulin therpy nd y llw fr siplifitin f the therpeuti regi- en in the future.D . Acceptable Levels of Glycemic ControlA  resnble i f therpy is t pprh nrl glye- i exursins withut prvking severe r frequent hyp- glyei. Tble 279 surizes bld gluse nd HbA1 gls fr different ptient grups. The UKPDS study dem- onstrated that blood pressure control was as significant or more significant than glycemic control in patients with type 2 diabetes regarding the prevention of microvascular as well as macrovascular complications.Weight loss + exercise + metformin Metformin + another agent (noninsulin or insulin) Metformin + two other agents (noninsulin or insulin) Factors in Therapeutic Decision (single agent or combination)Seven main classes of agents  Metformin  Sulfonylureas (includes nateglinide, repaglinide)  Pioglitazone  GLP-1 receptor agonists  DPP-4 inhibitors  SGLT2 inhibitors  InsulinsIf HbA1ctarget not reached after ~ 3 months If HbA1ctarget not reached after ~ 3 months If HbA1ctarget not reache d after ~ 3 months Efficacy  DPP-4 inhibitors are of moderate efficacy  All other agents are of high efficacy Cost  All agents except metformin and sulfonylureas are expensive  Insulins are expensive if the additional cost of monitoring is taken into considerationCardiovascular and renal effects  Metformin, liraglutide, semaglutide, empagliflozin, and canagliflozin have know n cardiovascular benefits  SGLT2 inhibitors reduce the risk of ESKD, doubling of serum creatinine and renal death in patients with diabetic nephropathy Hypoglycemic risk  Sulfonylureas and insulins have increased risk of hypoglycemia Effect on weight  Metformin and DPP-4 inhibitors are weight neutral  GLP-1 receptor agonists and SGLT2 inhibitor s promote weight loss  Sulfonylureas, insulins, and pioglitazone ar e associated with weight gain Major side effects  Metformin: lactic acidosis  Pioglitazone: fluid retention, fracture risk, macular edema, possible bladder cancer  GLP-1 receptor agonists: nausea, vomiting and pancreatitis  DPP-4 inhibitors: possible pancreatitis  SGLT2 inhibitors: urinary tract infection; genital mycotic infections; dehydration; cannot use if eGFR < 30 mL/min/1.73 m2Metformin + insulin  other noninsulin agent Figure 272. Algorithm for the treatment of type 2 diabetes based on the 2018 recommendations of the consensus panel of the American Diabetes Association/ European Association for the Study of Diabetes.CMDT22_Ch27_p1212-p1255.indd  1236 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1237 CMDT 2022E.  Complications of Insulin Therapy1.  Hypoglycemia Hypglyei retins re the st n plitins tht ur in ptients with dibetes wh re treted with insulin. The signs nd sypts f hypglyei y be divided int thse resulting fr stiultin f the utni nervus syste nd thse fr neurglypeni (insuffiient gluse fr nrl entrl nervus syste funtin). When the bld gluse flls t rund 54 g/dL (3 l/L), the ptient strts t experiene bth syptheti (thyrdi, plpittins, sweting, treulusness) nd prsyptheti (nuse, hunger) nervus syste sypts. If these utni sypts re ignred nd the gluse levels fll further (t rund 50 g/dL [2.8 l/L]), then neurglypeni sypts pper, inluding irritbility, nfusin, blurred visin, tiredness, hedhe, nd diffiulty speking. A fur- ther deline in gluse n led t lss f nsiusness r even  seizure. With repeted episdes f hypglyei, there is dpttin, nd utni sypts d nt ur until the bld gluse levels re uh lwer nd s the first sypts re ften due t neurglypeni. This nditin is referred t s hypglyei unwreness.  It hs been shwn tht hypglyei unwreness n be reversed by keeping gluse levels high fr  perid f severl weeks. Exept fr sweting, st f the syptheti sypts f hypglyei re blunted in ptients reeiv- ing bet-blking gents. Thugh nt bslutely ntrin- dited, these editins ust be used with utin in ptients with dibetes wh require insulin, nd bet-1- seletive blking gents re preferred. Hypglyei n ur in  ptient tking sulfnyl- ures, repglinide, nd nteglinide, prtiulrly if the ptient is elderly, hs kidney r liver disese, r is tking ertin ther editins tht lter etblis f the sul- fnylures (eg, phenylbutzne, sulfnides, r wrf- rin). It urs re frequently with the use f lng-tingsulfnylures thn with shrter-ting gents. Otherwise, hypglyei in insulin-treted ptients urs s  nse- quene f three ftrs: behvirl issues, ipired un- terregultry systes, nd plitins f dibetes. Behvirl issues inlude injeting t uh insulin fr the unt f rbhydrtes ingested. Drinking lhl in exess, espeilly n n epty sth, n ls use hypglyei. In ptients with type 1 dibetes, hypglye- i n ur during r even severl hurs fter exerise, nd s gluse levels need t be nitred nd fd nd insulin djusted. Se ptients d nt like their gluse levels t be high, nd they tret every high gluse level ggressively. These individuls wh stk their insulin tht is, give nther dse f insulin befre the first injetin hs hd its full tinn develp hypglyei. Cunterregultry issues resulting in hypglyei inlude ipired glugn respnse, sypth-drenl respnses, nd rtisl defiieny. Ptients with dibetes f greter thn 5 yers in durtin lse their glugn respnse t hypglyei. As  result, they re t  signifi- nt disdvntge in prteting theselves ginst flling gluse levels. One the glugn respnse is lst, their sypth-drenl respnses tke n dded iprtne. Unfrtuntely, ging, utni neurpthy, r hypgly- ei unwreness due t repeted lw gluse levels fur- ther blunts the sypth-drenl respnses. Osinlly, Addisn disese develps in persns with type 1 dibetes ellitus; when this hppens, insulin requireents fll sig- nifintly, nd unless insulin dse is redued, reurrent hypglyei will develp. Cplitins f dibetes tht inrese the risk fr hypglyei inlude utni neurpthy, gstrpre- sis, nd end-stge hrni kidney disese. The syptheti nervus syste is n iprtnt syste lerting the indi- vidul tht the gluse level is flling by using sypts f thyrdi, plpittins, sweting, nd treulusness.Table 279. Glycemic targets for different groups of adults with diabetes. Blood Glucose Tagets (mg/dL [mmol/L]) HbA1cTaget (% [mmol/mol]) Nonpregnant healthy adults Premeal glucose 90130 (57.2) 1-hour peak < 180 (10) 2-hour peak < 150 (8.3)< 7 (53). Aim for < 6.5 (48) if it can be achieved without significant hypoglycemia or polypharmacy Pregnancy Premeal glucose  95 (5.3) 1-hour peak  140 (7.8) 2-hour peak  120 (6.7)66.5 (4248). Aim for < 6 (42) if possible without significant hypoglycemia Older adults Healthy Frail with limited life expectancyPremeal 90130 (57.2) Bedtime 90150 (58.3) Premeal 100180 (5.610) Bedtime 110200 (6.111.1)< 7.5 (58) < 8.5 (69) History of severe hypoglycemia Premeal 90150 (58.3) Bedtime 100180 (5.610)< 8 (64) Hospitalized patient 140180 (7.810)  Chronic kidney disease (CKD) Glycemic targets in CKD are the same as those without CKD. HbA1cand fructosamine values may not be accu- rate in end-stage kidney disease, and greater reliance should be placed on the home glucose measurementsCMDT22_Ch27_p1212-p1255.indd  1237 29/06/21 8:53 PMCHAPTEr 271238 CMDT 2022Fil ure f the sypth-drenl respnses inreses the risk f hypglyei. In dditin, in ptients with gstr- presis, if insulin is given befre  el, the pek f insulin tin y ur befre the fd is bsrbed using the gluse levels t fll. Finlly, in end-stge hrni kidney disese, hypglyei n ur presubly beuse f deresed insulin lerne s well s lss f renl ntri- butin t glunegenesis in the pstbsrptive stte. T prevent nd tret insulin-indued hypglyei, the dibeti ptient shuld rry gluse tblets r juie t ll ties. Fr st episdes, ingestin f 15 grs f rb- hydrte is suffiient t reverse the hypglyei. The ptient shuld be instruted t hek the bld gluse in 15 inutes nd tret gin if the gluse level is still lw. A prenterl (1 g) r nsl inhltin (3 g) glugn eergeny kit shuld be prvided t every ptient with dibetes wh is reeiving insulin therpy. Fily r friends shuld be instruted hw t injet it subutneusly r intrusulrly int the buttk, r, r thigh r din- ister  nsl dse in the event tht the ptient is unn- sius r refuses fd. The editin n sinlly use viting, nd the unnsius ptient shuld be turned n his r her side t prtet the irwy. Glugn bilizes glygen fr the liver, rising the bld gluse by but 36 g/dL (2 l/L) in but 15 inutes. After the ptient revers nsiusness, dditinl rl rb- hydrte shuld be given. Peple with dibetes reeiving hypglyei editin therpy shuld ls wer n identifitin MediAlert brelet r nekle r rry  rd in his r her wllet (1-800-ID-ALERT, www.edi- lert.rg). Medil persnnel treting severe hypglyei n give 50 L f 50% gluse slutin by rpid intrvenus infusin. If intrvenus ess is nt vilble, 1 g f glugn n be injeted intrusulrly r 3 g given by nsl spry. 2. Immunopathology of insulin therapy At lest five leulr lsses f insulin ntibdies re prdued dur- ing the urse f insulin therpy in dibetes, inluding IgA, IgD, IgE, IgG, nd IgM. With the swith t hun nd purified prk insulin, the vrius iunpthlgi syn- dres suh s insulin llergy, iune insulin resistne, nd liptrphy hve bee quite rre sine the titers nd vidity f these indued ntibdies re generlly quite lw. a. Insulin allergy Insulin llergy, r iedite-type hypersensitivity, is  rre nditin in whih ll r sys- tei urtiri is due t histine relese fr tissue st ells sensitized by dherene f nti-insulin IgE ntibdies. In severe ses, nphylxis results. When nly hun insulin hs been used fr the nset f insulin therpy, insulin llergy is exeedingly rre. Antihistines, rti- sterids, nd even desensitiztin y be required, espe- illy fr systei hypersensitivity. b. Immune insulin resistance A lw titer f irult- ing IgG nti-insulin ntibdies tht neutrlize the tin f insulin t  sll extent develps in st insulin-treted ptients. With the ld nil insulins,  high titer f iru- lting ntibdies seties develped, resulting inextreely high insulin requireentsften re thn 200 units dily. This is nw rrely seen with the swith t hun r highly purified prk insulins nd hs nt been reprted with the nlgs. c. Lipodystrophy Atrphy f subutneus ftty tissue leding t disfiguring exvtins nd depressed res y rrely ur t the site f injetin. This plitin results fr n iune retin, nd it hs bee rrer with the develpent f hun nd highly purified insu- lin preprtins. Liphypertrphy, n the ther hnd, is  nsequene f the phrlgi effets f insulin being depsited in the se ltin repetedly. It n ur with purified insulins s well. Rttin f injetin sites will prevent liphypertrphy.Rdriguez-Gutierrez  R et l. Benefits nd hrs f intensive glyei ntrl in ptients with type 2 dibetes. BMJ. 2019;367:l5887. [PMID: 31690574] Chronic Complications of DiabetesLte  linil nifesttins f dibetes ellitus inlude  nuber f pthlgi hnges tht invlve sll nd lrge bld vessels, rnil nd peripherl nerves, the skin, nd the lens f the eye. These lesins led t hypertensin, end- stge hrni kidney disese, blindness, utni nd peripherl neurpthy, puttins f the lwer extrei- ties, yrdil infrtin, nd erebrvsulr idents. These lte nifesttins rrelte with the durtin f the dibeti stte subsequent t the nset f puberty. In type 1 dibetes, end-stge hrni kidney disese develps in up t 40% f ptients, pred with less thn 20% f ptients with type 2 dibetes. Prlifertive retinpthy ultitely develps in bth types f dibetes but hs  slightly higher prevlene in type 1 ptients (25% fter 15 yers durtin). In ptients with type 1 dibetes, plitins fr end- stge hrni kidney disese re  jr use f deth, wheres ptients with type 2 dibetes re re likely t hve rvsulr diseses leding t yrdil infr- tin nd strke s the in uses f deth. Cigrette use dds signifintly t the risk f bth irvsulr nd rvsulr plitins in dibeti ptients.A.  Ocular Complications1.  Diabetic cataracts Preture trts ur in di- beti ptients nd see t rrelte with bth the durtin f dibetes nd the severity f hrni hyperglyei. Nnenzyti glysyltin f lens prtein is twie s high in dibeti ptients s in ge-thed nndibeti persns nd y ntribute t the preture urrene f trts. 2. Diabetic retinopathy The tw in tegries f di- beti retinpthy, nnprlifertive nd prlifertive, re disussed in Chpter 7. 3. Glaucoma Glu urs in pprxitely 6% f persns with dibetes. It is respnsive t the usul therpy fr pen-ngle disese. Nevsulriztin f the iris in ptients with dibetes n predispse t lsed-ngleCMDT22_Ch27_p1212-p1255.indd  1238 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1239 CMDT 2022glu,  but this is reltively unn exept fter trt extrtin, when grwth f new vessels hs been knwn t prgress rpidly, invlving the ngle f the iris nd bstruting utflw.B.  Diabetic NephropathyDibeti  nephrpthy is initilly nifested by lbuin- uri; subsequently, s kidney funtin delines, ure nd retinine uulte in the bld (see Chpter 22). An lbuin-retinine rti in n erly rning spt urine lleted upn wkening is the preferred ethd t ssess lbuin exretin. In the erly rning spt urine,  rti f lbuin (g/L) t retinine (g/L) f less thn 30 g/g retinine is nrl, nd  rti f 30300 g/g retinine suggests bnrl irlbuinuri. At lest tw erly rning spt urine lletins ver  3- t 6-nth perid shuld be bnrl befre  dignsis f irlbuinuri is justified. Shrt-ter hyperglyei, exerise, urinry trt infetins, hert filure, nd ute febrile illness n use trnsient lbuinuri nd s test- ing fr irlbuinuri shuld be pstpned until res- lutin f these prbles. Subsequent end-stge hrni kidney disese n be predited by persistent urinry lbuin exretin rtes exeeding 30 g/g retinine. Glyei ntrl s well s  prtein diet f ~0.8 g/kg/dy y redue bth the hyperfiltrtin nd the elevted irlbuinuri in ptients in the erly stges f dibetes nd thse with inipient dibeti nephrpthy. Antihypertensive therpy ls dereses irlbuinuri. Evidene fr se studies supprts  speifi rle fr ACE inhibitrs in redu- ing intrglerulr pressure in dditin t their lwering f systei hypertensin. An ACE inhibitr (ptpril, 50 g twie dily) in nrtensive dibeti ptients ipedes prgressin t prteinuri nd prevents the inrese in lbuin exretin rte. SGLT2 therpy shuld be instituted in ptients with type 2 dibetes wh hve prgressin f kidney disese despite tking ptil nti- hypertensive therpy, whih inludes n ACE inhibitr r ngitensin reeptr blker.C.  Diabetic NeuropathyDibeti  neurpthies re the st n plitins f dibetes, ffeting up t 50% f lder ptients with type 2 dibetes. 1. Peripheral neuropathy a. Distal symmetric polyneuropathy This is the st n fr f dibeti peripherl neurpthy where lss f funtin ppers in  stking-glve pttern nd is due t n xnl neurpthi press. Lnger nerves re espeilly vulnerble, hene the ipt n the ft. Bth tr nd sensry nerve ndutin is delyed in the peripherl nerves, nd nkle jerks y be bsent. Sensry invlveent usully urs first nd is gener- lly bilterl, syetri, nd ssited with dulled per- eptin f vibrtin, pin, nd teperture. The pin n rnge fr ild disfrt t severe inpitting syp- ts. The sensry defiit y eventully be f suffiientdegree t prevent ptients fr feeling pin. Ptients wh hve  sensry neurpthy shuld therefre be exined with  5.07 Sees-Weinstein filent nd thse wh nnt feel the filent ust be nsidered t risk fr unpereived neurpthi injury. The denervtin f the sll usles f the ft n result in lwing f the tes nd displeent f the sub- ettrsl ft pds nterirly. These hnges, tgether with the jint nd nnetive tissue hnges, lter the biehnis f the ft nd inrese plntr pressures. This bintin f deresed pin threshld, bnr- lly high ft pressures, nd repetitive stress (suh s fr wlking) n led t lluses nd ulertins in the high-pressure res suh s ver the ettrsl heds (Figure 273). Peripherl neurpthy, utni neu- rpthy, nd tru ls predispses t the develpent fCharcot arthropathy. An ute se f Chrt ft rthrpthy presents with pin nd swelling, nd if left untreted, leds t  rker btt defrity nd ulertin. The erly rdilgi hnges shw jint sub- luxtin nd perirtiulr frtures. As the press pr- gresses, there is frnk stelsti destrutin leding t dernged nd unstble jints prtiulrly in the idft. Nt surprisingly, the key issue fr the heling f neur- pthi ulers in  ft with gd vsulr supply is ehnil unlding. In dditin, ny infetin shuld be treted with debrideent nd pprprite ntibitis; heling durtin f 810 weeks is typil. Osinlly, when heling ppers refrtry, pltelet-derived grwth ftr (beplerin [Regrnex]) shuld be nsidered fr ll pplitin. One ulers re heled, therpeuti ftwer is key t preventing reurrenes. Cust lded shes re reserved fr ptients with signifint ft defrities. Other ptients with neurpthy y require dtive insles tht distribute the ld ver s wide n re s pssible. Ptients with ft defr- ities nd lss f their prtetive threshld shuld get regulr re fr  pditrist. Ptients shuld be edu- ted n pprprite ftwer nd thse with lss f their Figure 273. Diabetic foot ulcer over head of first metatarsal (arrow). (Used, with permission, from Dean SM, Satiani B, Abraham WT. Color Atlas and Synopsis of Vascular Diseases. McGraw-Hill, 2014.)CMDT22_Ch27_p1212-p1255.indd  1239 29/06/21 8:53 PMCHAPTEr 271240 CMDT 2022prtet ive threshld shuld be instruted t inspet their feet dily fr reddened res, blisters, brsins, r lertins. In se ptients, hypersensitivity t light tuh nd sinlly severe burning pin, prtiulrly t night, n bee physilly nd etinlly disbling. Nrtrip- tyline r desiprine in dses f 25150 g/dy rlly y prvide drti relief fr pin fr dibeti neu- rpthy, ften within 4872 hurs. Ptients ften ttribute the benefit t hving  full nights sleep. Mild t derte rning drwsiness is  side effet tht generlly iprves with tie r n be lessened by giving the editin sev- erl hurs befre bedtie. This editin shuld nt be ntinued if iprveent hs nt urred fter 5 dys f therpy. Aitriptyline, 2575 g rlly t bedtie, n ls be used but hs re ntihlinergi effets. Triyli ntidepressnts, in bintin with fluphenzine (3 g dily in three divided dses) hve been shwn in tw stud- ies t be effiius in pinful neurpthy, with benefits unrelted t relief f depressin. Gbpentin (9001800 g rlly dily in three divided dses) hs ls been shwn t be effetive in the tretent f pinful neurpthy nd shuld be tried if the triyli editins prve ineffe- tive. Pregblin,  ngener f gbpentin, hs been shwn in n 8-week study t be re effetive thn pleb in treting pinful dibeti peripherl neurpthy. Hwever, this editin ws nt pred with n tive ntrl. Als, beuse f its buse ptentil, it hs been tegrized s  shedule V ntrlled substne. Dulxetine (60120 g),  sertnin nd nrepinephrine reuptke inhibitr, is pprved fr the tretent f pinful dibeti neurpthy. Cpsiin,  tpil irritnt, is effetive in reduing ll nerve pin; it is dispensed s  re (Zstrix 0.025%, Zstrix-HP 0.075%) t be rubbed int the skin ver the pinful regin tw t fur ties dily. Glves shuld be used fr pplitin sine hnd ntintin uld result in disfrt if the re es in ntt with eyes r sensitive res suh s the genitli. Appli- tin f  5% lidine pth ver n re f xil pin hs been reprted t be f benefit. It is pprved fr tret- ent f pstherpeti neurlgi. Diabetic neuropathic cachexia is  syndre hr- terized by  syetri peripherl neurpthy ssited with prfund weight lss (up t 60% f ttl bdy weight) nd pinful dysesthesis ffeting the prxil lwer libs, the hnds, r the lwer trunk. Tretent is usully with insulin nd nlgesis. The prgnsis is generlly gd, nd ptients typilly rever their bseline weight with reslutin f the pinful sensry sypts within 1 yer. b. Isolated peripheral neuropathy Invlveent f the distributin f nly ne nerve (nneurpthy) r f severl nerves (nneurpthy ultiplex) is hr- terized by sudden nset with subsequent revery f ll r st f the funtin. This neurpthlgy hs been ttrib- uted t vsulr ishei r truti dge. Crnil nd ferl nerves re nly invlved, nd tr bnrlities predinte. The ptient with rnil nerve invlveent usully hs diplpi nd single third, furth, r sixth nerve wekness n exintin but the pupil isspred. A full revery f funtin urs in 612 weeks. Dibeti ytrphy presents with nset f severe pin in the frnt f the thigh. Within  few dys r weeks f the nset f pin, wekness nd wsting f the qudrieps develps. As the wekness ppers, the pin tends t iprve. Mngeent inludes nlgesi nd iprved dibetes ntrl. The sypts iprve ver 618 nths. 2. Autonomic neuropathy Neurpthy f the utni syste urs priniplly in ptients with dibetes f lng durtin. It ffets ny diverse viserl funtins inlud- ing bld pressure nd pulse, gstrintestinl tivity, bld- der funtin, nd eretile dysfuntin. Tretent is direted speifilly t eh bnrlity. Insulin neuritis r tretent-indued neurpthy f dibetes urs - sinlly in ptients with pr gluse ntrl nd whse gluse levels iprve rpidly in dys r  few weeks. Sypts inlude severe sensry neurpthi pins nd seties utni funtins. These sypts iprve ver  few nths. a. Gastrointestinal system Invlveent f the gs- trintestinl syste y be nifested by nuse, vit- ing, pstprndil fullness, reflux r dysphgi, nstiptin r dirrhe (r bth), nd fel inntinene. Gstrpre- sis shuld be nsidered in type 1 dibeti ptients in wh unexpeted flututins nd vribility in their bld gluse levels develps fter els. Metlpride hs been f se help in treting dibeti gstrpresis. It is given in  dse f 10 g rlly three r fur ties  dy, 30 inutes befre els nd t bedtie. Drwsiness, rest- lessness, ftigue, nd lssitude re n dverse effets. Trdive dyskinesi nd extrpyridl effets n ur, espeilly when used fr lnger thn 3 nths, nd the FDA hs utined ginst the lng-ter use f etlpride. Erythryin ppers t bind t tilin reeptrs in the sth nd hs been fund t iprve gstri epty- ing ver the shrt ter in dses f 250 g three ties dily, but its effetiveness sees t diinish ver tie. In seleted ptients, injetins f btulinu txin int the pylrus n redue pylrus sphinter resistne nd enhne gstri eptying. Gstri eletril stiultin hs been reprted t iprve sypts nd qulity f life indies in ptients with gstrpresis refrtry t phr- lgi therpy. Dirrhe ssited with utni neurpthy hs sinlly respnded t brd-spetru ntibiti ther- py (suh s rifxiin, etrnidzle, xiillin/lvul- nte, iprflxin, r dxyyline), lthugh it ften underges spntneus reissin. Refrtry dibeti dirrhe is ften ssited with ipired sphinter n- trl nd fel inntinene. Therpy with lperide, 48 g dily, r diphenxylte with trpine, tw tblets up t fur ties  dy, y prvide relief. In re severe ses, tinture f pregri r deine (60-g tblets) y be required t redue the frequeny f dirrhe nd iprve the nsisteny f the stls. Clnidine hs been reprted t lessen dibeti dirrhe; hwever, its usefulness is liited by its tendeny t lwer bld pressure in these ptients wh lredy hve utni neurpthy, resultingCMDT22_Ch27_p1212-p1255.indd  1240 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1241 CMDT 2022in  rthstti hyptensin. Cnstiptin usully respnds t stiulnt lxtives suh s senn. b. Genitourinary system Inplete eptying f the bldder n seties ur. Bethnehl in dses f 1050 g rlly three ties  dy hs sinlly iprved eptying f the tni urinry bldder. Ctheter depressin f the distended bldder hs been reprted t iprve its funtin, nd nsiderble benefit hs been reprted fter surgil severing f the internl vesile sphinter. Eretile dysfuntin n result fr neurlgi, psy- hlgil, r vsulr uses, r  bintin f these uses. The phsphdiesterse type 5 (PDE5) inhibitrs sildenfil (Vigr), vrdenfil (Levitr), nd tdlfil (Cilis) hve been shwn in pleb-ntrlled linil tri- ls t iprve eretins in respnse t sexul stiultin. The reended dse f sildenfil fr st ptients is ne 50-g tblet tken pprxitely 1 hur befre sexul tivity. The pek effet is t 1.52 hurs, with se effet persisting fr 4 hurs. Ptients with dibetes ellitus using sildenfil reprted 5060% iprveent in eretile fun- tin. The xiu reended dse is 100 g. The reended dse f bth vrdenfil nd tdlfil is 10 g. The dses y be inresed t 20 g r deresed t 5 g bsed n effiy nd side effets. Tdlfil hs been shwn t iprve eretile funtin fr up t 36 hurs fter dsing. Lw dses re vilble fr dily use. In linil trils, nly  few dverse effets hve been reprtedtrnsient ild hedhe, flushing, dyspepsi, nd se ltered lr visin. Pripis n ur with these editins, nd ptients shuld be dvised t seek iedite edil ttentin if n eretin persists fr lnger thn 4 hurs. The PDE5 inhibi- trs ptentite the hyptensive effets f nitrtes nd their use is ntrindited in ptients wh re nurrently using rgni nitrtes in ny fr. Cutin is dvised fr en wh hve suffered  hert ttk, strke, r life-thretening rrhythi within the previus 6 nths; en wh hve resting hyptensin r hypertensin; nd en wh hve  histry f hert filure r hve unstble ngin. Rrely,  derese in visin r pernent visul lss hs been reprted fter PDE5 inhibitr use. Intrrprel injetin f vstive editins uses penile engrgeent nd eretin. Meditins st nly used inlude ppverine lne, ppverine with phentline, nd lprstdil (prstglndin E1). Alprst- dil injetins re reltively pinless, but reful instrutin is essentil t prevent ll tru, pripis, nd fibrsis. Intrurethrl pellets f lprstdil vid the prble f injetin f the editin. Externl vuu therpy (Ere-Aid Syste) is  nnsur- gil tretent nsisting f  sutin hber perted by  hnd pup tht retes  vuu rund the penis. This drws bld int the penis t prdue n eretin tht is intined by  speilly designed tensin ring inserted rund the bse f the penis nd whih n be kept in ple fr up t 2030 inutes. While this ethd is generlly effetive, its uberse nture liits its ppel. Surgil iplnts f penile prstheses rein n ptin fr thse ptients in wh the nnsurgil pprhes re ineffetive.c. Orthostatic hypotension Use f Jbst fitted stkings, tilting the hed f the bed, nd rising slwly fr the supine psitin n be helpful in treting syp- ts f rthstti hyptensin. When suh esures re indequte, then tretent with fludrrtisne 0.10.2 g rlly dily n be nsidered. This editin, hwever, n result in supine hypertensin nd hypklei. The lph-gnist iddrine (10 g rlly three ties  dy) n ls be used.D . Cardiovascular Complications1.  Heart disease Mirngipthy urs in the hert f ptients with dibetes nd y explin the etilgy f n- gestive rdiypthies in thse wh d nt hve den- strble rnry rtery disese. Mre nly, hwever, hert disese in ptients with dibetes is due t rnry therslersis. Myrdil infrtin is three t five ties re n in dibeti ptients nd is the leding use f deth in ptients with type 2 dibetes. Crdivsulr disese risk is inresed in ptients with type 1 dibetes s well, lthugh the bslute risk is lwer thn in ptients with type 2 dibetes. Preenpusl wen wh nrlly hve lwer rtes f rnry rtery disese lse this prte- tin ne dibetes develps. The inresed risk in ptients with type 2 dibetes reflets the bintin f hypergly- ei, hyperlipidei, bnrlities f pltelet dhesive- ness, gultin ftrs, hypertensin, xidtive stress, nd infltin. Lrge interventin studies f risk ftr redutin in dibetes re lking, but it is resnble t ssue tht reduing these risk ftrs wuld hve  ben- efiil effet. Lwering LDL hlesterl redues first events in ptients withut knwn rnry disese nd sendry events in ptients with knwn rnry disese. These interventin studies inluded se ptients with dibetes, nd the benefits f LDL hlesterl lwering ws pprent in this grup. The Ntinl Chlesterl Edutin Pr- gr linil prtie guidelines hve designted dibetes s  rnry risk equivlent nd hve reended tht ptients with dibetes shuld hve n LDL hlesterl gl f less thn 100 g/dL (2.6 l/L). Lwering LDL h- lesterl t 70 g/dL (1.8 l/L) y hve dditinl benefit nd is  resnble trget fr st ptients with type 2 dibetes wh hve ultiple risk ftrs fr rdi- vsulr disese. Aspirin t  dse f 81325 g dily is effetive in reduing rdivsulr rbidity nd rtlity in ptients wh hve  histry f yrdil infrtin r strke (sendry preventin). Fr priry preventin,  2018 rndized study f 15,480 persns with dibetes but n evident rdivsulr disese bserved tht 100 g f spirin redued the first vsulr event f yrdil infrtin, strke r trnsient ishei ttk r deth fr vsulr event (exluding intrrnil herrhge) (rte rti 0.88; 95% nfidene intervl 0.79 t 0.97). There were, hwever, re jr bleeding events, espe- illy gstrintestinl, in the spirin grup (rte rti 1.29; 95% nfidene intervl 1.09 t 1.52). Thus, fr priry preventin, the use f spirin shuld nly be nsidered fr ptients with high rdivsulr risk nd lw bleeding risk nd generlly nt fr dults lder thn 70 yers. BsedCMDT22_Ch27_p1212-p1255.indd  1241 29/06/21 8:53 PMCHAPTEr 271242 CMDT 2022n  the Erly Tretent Dibeti Retinpthy Study (ETDRS), there des nt pper t be  ntrinditin t spirin use t hieve rdivsulr benefit in dibeti ptients wh hve prlifertive retinpthy. Aspirin ls des nt see t ffet the severity f vitreus/preretinl herrhges r their reslutin. 2. Hypertension The ADA reends lwering systli bld pressure t less thn 140  Hg nd distli pres- sure t less thn 90  Hg in ptients with dibetes. The systli trget f 130  Hg r less nd distli trget f 80  Hg r less re reended fr the yunger ptient if they n be hieved withut undue tretent burden. The Systli Bld Pressure Interventin Tril (SPRINT) reprted tht treting t  systli bld pressure f less thn 120  Hg redued rdivsulr events by 25% nd deth fr rdivsulr uses by 43% during 3.26 yers f fllw-up. Peple with dibetes, hwever, were exluded fr this study, nd it is unler if the results re pplible t this ppultin. Ptients with type 2 dibetes wh lredy hve rdivsulr disese r irlbuinuri shuld be nsidered fr tretent with n ACE inhibitr. Mre lini- l studies re needed t ddress the questin f whether ptients with type 2 dibetes wh d nt hve rdivsulr disese r irlbuinuri wuld speifilly benefit fr ACE inhibitr tretent. 3. Peripheral vascular disease Atherslersis is rk- edly elerted in the lrger rteries. It is ften diffuse, with llized enhneent in ertin res f turbulent bld flw, suh s t the bifurtin f the rt r ther lrge vessels. Clinil nifesttins f peripherl vsulr disese inlude ishei f the lwer extreities, eretile dysfuntin, nd intestinl ngin. The inidene f gangrene of the feet in ptients with dibetes is 30 ties tht in ge-thed ntrls. The f- trs respnsible fr its develpent, in dditin t periph- erl vsulr disese, re sll vessel disese, peripherl neurpthy with lss f bth pin senstin nd neur- geni infltry respnses, nd sendry infetin. In tw-thirds f ptients with ishei gngrene, pedl pulses re nt plpble. In the reining ne-third wh hve plpble pulses, redued bld flw thrugh these vessels n be denstrted by plethysgrphi r Dppler ultrsund exintin. Preventin f ft injury is ipertive. Agents tht redue peripherl bld flw suh s tb shuld be vided. Cntrl f ther risk ftrs suh s hypertensin is essentil. Bet-blkers re rel- tively ntrindited beuse f presued negtive peripherl hedyni nsequenes but dt tht sup- prt this re lking. Chlesterl-lwering gents re use- ful s djuntive therpy when erly ishei signs re deteted nd when dyslipidei is present. Ptients shuld be dvised t seek iedite edil re if  dibeti ft uler develps. Iprveent in peripherl bld flw with endrterety nd bypss pertins is pssible in er- tin ptients.E.  Skin and Mucous Membrane ComplicationsChrni  pygeni infetins f the skin y ur, espe- illy in prly ntrlled dibeti ptients. Cndidlinfetin n prdue erythe nd ede f intertrigi- nus res belw the brests, in the xills, nd between the fingers. It uses vulvvginitis in wen with hrnilly unntrlled dibetes wh hve persistent glusuri nd is  frequent use f pruritus. While ntifungl res ntining inzle r ltrizle ffer iedite relief f vulvvginitis, reurrene is frequent unless glu- suri is redued. In se ptients with type 2 dibetes, pr glyei ntrl n use severe hypertriglyei, whih n pres- ent s eruptive utneus xnths nd pnretitis. The skin lesins pper s yellw rbillifr eruptins 25  in dieter with erythetus rele. They ur n extensr surfes (elbws, knees, buttks) nd dispper fter triglyeride levels re redued. Nerbisis lipidi dibetiru is usully lted ver the nterir surfes f the legs r the drsl surfes f the nkles. They re vl r irregulrly shped plques with derted brders nd  glistening yellw surfe nd ur in wen tw t fur ties re frequently thn in en. Pthlgilly, the lesins shw degenertin f llgen, grnultus infltin f subutneus tissues nd bld vessels, pillry bseent ebrne thikening nd blitertin f vessel luin. The nditin is ssited with type 1 dibetes, lthugh it n ur in ptients with type 2 dibetes, nd ls in ptients withut dibetes. First-line therpy inludes tpil nd subutne- us rtisterids. Iprving glyei ntrl y help the nditin. Shin spts re nt unn in dults with dibetes. They re brwnish, runded, pinless trphi lesins f the skin in the pretibil re.F . Bone and Joint ComplicationsLng-stnding  dibetes n use prgressive stiffness f the hnd sendry t ntrture nd tightening f skin ver the jints (dibeti heirrthrpthy), frzen shul- der (dhesive psulitis), rpl tunnel syndre, nd Dupuytren ntrtures. These plitins re believed t be due t glysyltin f llgen nd perhps ther prteins in nnetive tissue. There y ls be n infl- try pnent. Dt n bne inerl density nd frture risk in peple with dibetes re ntrditry. Ptients with type 2 dibetes d pper t be t inresed risk fr nnvertebrl frtures. Wen with type 1 dibetes hve n inresed risk f fr- ture when pred with wen withut dibetes. Other ftrs, suh s durtin f dibetes, nd dibetes pli- tins, suh s neurpthy nd kidney disese, likely ffet bth the bne inerl density nd frture risk. Diffuse idipthi skeletl hyperstsis (DISH) is hr- terized by ssifitin f the nterir lngitudinl lig- ents f the spine nd vrius extrspinl ligents. It uses stiffness nd deresed rnge f spinl tin. The peripherl jints st nly ffeted re the etr- pphlngel jints, elbws, nd shulders. Dibetes, be- sity, hypertensin, nd dyslipidei re risk ftrs fr this nditin. Hyperuriei nd ute nd tpheus gut re re n in type 2 dibetes.CMDT22_Ch27_p1212-p1255.indd  1242 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1243 CMDT 2022Bursitis,  prtiulrly f the shulders nd hips, urs re frequently thn expeted in ptients with dibetes.ASCEND Study Cllbrtive Gr up et l. Effets f spirin fr priry preventin in persns with dibetes ellitus. N Engl J Med. 2018;379:1529. [PMID: 30146931] Grennn D. Dibeti ft ulers. JAMA. 2019;321:114. [PMID: 30620372] Hinhliffe RJ et l; Interntinl Wrking Grup n the Dibeti Ft (IWGDF). Guidelines n dignsis, prgnsis, nd n- geent f peripherl rtery disese in ptients with ft ulers nd dibetes (IWGDF 2019 updte). Dibetes Metb Res Rev. 2020;36:e3276. [PMID: 31958217] Selvrjh D et l. Dibeti peripherl neurpthy: dvnes in dignsis nd strtegies fr sreening nd erly interventin. Lnet Dibetes Endrinl. 2019;7:938. [PMID: 31624024] Shen JI et l. Evidene fr nd ginst ACC/AHA 2017 guideline fr trget systli bld pressure f < 130  Hg in persns with type 2 dibetes. Curr Crdil Rep. 2019;21:149. [PMID: 31760494] Special SituationsA.  Diabetes Management in the HospitalH spitlized ptients re generlly nt eting s usul nd they re ften fsting fr predures, whih kes it hl- lenging t use utptient rl r insulin regiens. There y be n inrese in the dverse retins f dibetes edi- ines (eg, thizlidinedines n use fluid retentin nd wrsen hert filure); etfrin shuld nt be used in ptients with signifint hrni kidney r liver disese r thse getting ntrst fr rdigrphi studies; nd SGLT2 inhibitrs y be ssited with inresed risk f dibeti ketidsis. The dt n the use f ntinuus gluse nitrs, insulin pups, nd hybrid lsed lp systes in hspitlized ptients re insuffiient. Whether ptients sty n these systes in the hspitl will depend n their severity f illness nd ess t speilist re. In generl, deisins regrding insulin dsing shuld be de bsed n pillry bld gluse esureents nd nt n the dt fr n- tinuus gluse nitrs. Ptients shuld be trnsitined t  nventinl bsl blus subutneus insulin regien if they re unble t nge their pup nd/r ntinuus gluse nitr beuse f their illness r if they refuse t fllw the institutinl guidelines n using the pup r ntinuus nitr (eg, giving theselves insulin bluses nd nt infring the linil stff). The systes hve t be reved if the ptient is getting n MRI. On the general medical and surgical inpatient ser- vices, st ptients re treted with subutneus insulin regiens. Liited rss-setinl nd prspetive studies suggest tht the best gluse ntrl is hieved n  - bintin f bsl nd blus regien with 50% f dily insulin needs prvided by interedite- r lng-ting insulins. Stndrdized rder sets n redue errrs, nd they ften inlude lgriths fr regnitin nd tret- ent f hypglyei (see http://usfinptientdibetes. pbwrks. fr exples). Orl ediines, espeilly etfrin nd sulfnylures, n be resued s the ptient is being prepred fr hspitl dishrge. In the intensive care units (ICUs), gluse levels re ntrlled st frequently using insulin infusins(http://usfinptientdibetes.pbwrks.). Ptients reeiv- ing ttl prenterl nutritin n hve insulin dded t the bg. Stndrd ttl prenterl nutritin ntins 25% dex- trse s n infusin rte f 50 L/h delivers 12.5 g f dextrse per hur. Bsed n the evidene vilble, ICU ptients with dibe- tes nd new-nset hyperglyei with bld gluse levels bve 180 g/dL (10 l/L) shuld be treted with insu- lin, iing fr trget gluse levels between 140 g/dL (7.8 l/L) nd 180 g/dL (10 l/L). In the ICU set- ting, iing fr bld gluse levels lse t 100 g/dL (5.6 l/L) is nt benefiil nd y even be hrful. When ptients leve the ICU, trget gluse vlues between 100 g/dL (5.6 l/L) nd 180 g/dL (10 l/L) y be pprprite, lthugh this view is bsed n linil bser- vtins rther thn nlusive evidene. Preoperative and perioperative diabetic management strtegies re disussed in Chpter 3. The rbidity nd rtlity in hspitlized dibeti ptients re twie thse f nndibeti ptients. Thse with new-nset hyperglyei (ie, thse withut  predis- sin dignsis f dibetes) hve even higher rtlity lst eightfld tht f nndibeti ptients in ne study. These bservtins hve led t the questin f whether tight glyei ntrl in the hspitl iprves utes.B.  Pregnancy and the Diabetic PatientSee Chpt er 19. Tight glyei ntrl with nrl HbA1 levels is very iprtnt during pregnny. Erly in preg- nny, pr ntrl inreses the risk f spntneus br- tin nd ngenitl lfrtins. Lte in pregnny, pr ntrl n result in plyhydrnis, preter lbr, stillbirth, nd fetl rsi with its ssited prb- les. Dibetes plitins n ipt bth ternl nd fetl helth. Dibeti retinpthy n first develp during pregnny r retinpthy tht is lredy present n wrsen. Dibeti wen with irlbuinuri n hve wrsening lbuinuri during pregnny nd re t higher risk fr preelpsi. Lw-dse (81 g) spirin n redue the risk f preelpsi nd shuld be presribed fter 12 weeks f gesttin. Ptients wh hve preexisting kidney filure (prepregnny retinine lerne less thn 80 L/in) re t high risk fr further deline in kidney funtin during the pregnny, nd this y nt reverse fter delivery. Dibeti gstrpresis n severely exer- bte the nuse nd viting f pregnny nd se ptients y require fluid nd nutritinl supprt. Althugh there is evidene tht glyburide is sfe during pregnny, the urrent prtie is t ntrl dibetes with insulin therpy. Every effrt shuld be de, utilizing ul- tiple injetins f insulin r  ntinuus infusin f insu- lin by pup, t intin ner-nrliztin f fsting nd preprndil bld gluse vlues while viding hypglyei. Regulr nd NPH insulin nd the insulin nlgs lispr, sprt, nd deteir re lbeled pregnny tegry B. Insu- lin glrgine, glulisine, nd deglude re lbeled tegry C beuse f lk f linil sfety dt. A sll study using insulin glrgine in 32 pregnnies did nt revel ny prbles.CMDT22_Ch27_p1212-p1255.indd  1243 29/06/21 8:53 PMCHAPTEr 271244 CMDT 2022U nless there re fetl r ternl plitins, dibeti wen shuld be ble t rry the pregnny t full-ter, delivering t 38 t 41 weeks. Indutin f lbr befre 39 weeks y be nsidered if there is nern but inresing fetl weight. See Chpter 19 fr further detils.Aerin  Dibetes Assitin. Mngeent f dibetes in pregnny: Standards of Medical Care in Diabetes2020 . Dibetes Cre. 2020;43:S183. [PMID: 31862757]DI ABETIC COMAC  y be due t uses nt diretly relted t dibetes. Dibeti  requires differentitin (Tble 2710): (1) Hypglyei  fr exessive insulin r rl hyp- glyei gents. (2) Hyperglyei  with either severe insulin defiieny (DKA) r ild t derte insu- lin defiieny (hyperglyei hyperslr stte). (3) Lti idsis, prtiulrly when ptients with dibetes hve severe infetins r rdivsulr llpse.DI ABETIC KETOACIDOSISE S S E N T I A L S  O F  D I A G N O S I S Hyperglycemia > than 250 mg/dL (13.9 mmol/L). Metabolic acidosis with blood pH < 7.3; serum bicarbonate < 15 mEq/L. Serum positive for ketones. General ConsiderationsDibeti  ketidsis (DKA) is  disrder pririly in ptients with type 1 dibetes but n ur in ptients with type 2 dibetes wh hve severe illness, suh s sepsis r tru. DKA y be the initil nifesttin f type 1dibetes r y result fr inresed insulin requireents in type 1 dibetes ptients during the urse f infetin, tru, yrdil infrtin, r surgery. It is  life-thret- ening edil eergeny. The Ntinl Dt Grup reprts n nnul inidene f five t eight episdes f DKA per 1000 dibeti persns. DKA is ne f the re n serius plitins f insulin pup therpy, urring in pprxitely 1 per 80 ptient-nths f tretent. Mny ptients wh nitr pillry bld gluse regulrly ignre urine ketne esureents, whih signls the pssibility f insulin lekge r pup filure befre serius illness develps. Pr pline, either fr psyhlgil resns r beuse f indequte edutin, is ne f the st n uses f reurrent DKA. Clinical FindingsA.  Symptoms and SignsThe  pperne f DKA is usully preeded by  dy r re f plyuri nd plydipsi ssited with rked ftigue, nuse, nd viting. If untreted, entl stupr ensues tht n prgress t . Drwsiness is firly n, but frnk  nly urs in but 10% f ptients. On physil exintin, evidene f dehydrtin in  stuprus ptient with rpid deep brething nd  fruity breth dr f etne strngly suggests the dignsis. Hyptensin with thy- rdi indites prfund fluid nd eletrlyte depletin, nd ild hyptheri is usully present. Abdinl pin nd even tenderness y be present in the bsene f bdinl disese. Cnversely, hleystitis r pnretitis y ur with inil sypts nd signs.B.  Laboratory FindingsT ypilly, the ptient with dertely severe DKA hs  pls gluse f 350900 g/dL (19.450 l/L), seru ketnes t  dilutin f 1:8 r greter rTable 2710. Laboratory diagnosis of coma in diabetic patients. Uine Glucose Uine Ketones Plasma Glucose Seum Bicabonate Seum Ketones related to Diabetes Hypoglycemia 010 or + Low Normal 0 Diabetic ketoacidosis ++++ ++++ High Low ++++ Hyperglycemic hyperosmolar state coma++++ 0 or + High Normal or slightly low 0 Lactic acidosis 0 or + 0 or + Normal or low or high Low 0 or + Unelated to Diabetes Alcohol or other toxic drugs 0 or + 0 or + May be low Normal or low20 or + Cerebrovascular accident or head trauma+ or 0 0 Often high Normal 0 Uremia 0 or + 0 High or normal Low 0 or +1 Leftover urine in bladder might still contain glucose from earlier hyperglycemia.2 Alcohol can elevate plasma lactate as well as keto acids to reduce pH.CMDT22_Ch27_p1212-p1255.indd  1244 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1245 CMDT 2022bet-hydr xybutyrte re thn 4 nl/L, hyperklei (seru ptssiu level f 58 Eq/L), ild hypntrei (seru sdiu f pprxitely 130 Eq/L), hyperphs- phtei (seru phsphte level f 67 g/dL [1.92.3 l/L]), nd elevted bld ure nitrgen nd seru retinine levels (Tble 2710). Aidsis y be severe (pH rnging fr 6.9 t 7.2 nd seru birbnte rnging fr 5 Eq/L t 15 Eq/L); Pco2is lw (1520  Hg) relted t penstry hyperventiltin. Fluid depletin is rked, typilly but 100 L/kg. In euglyei ketidsis, the ptient n hve severe id- sis nd fluid depletin but the pls gluse levels re nly destly elevted, usully less thn 250 g/dy (13.9 l/L). This nditin is seen in ptients in wh dibeti ketidsis develps while reeiving tretent with SGLT2 inhibitrs. Ketidsis with lwer gluse levels ls urs in pregnny nd y reflet the expnded pls vlue nd the inresed glerulr filtrtin rte. The differene between venus nd rteril pH is 0.02 t 0.15 pH units nd venus nd rteril birbnte is 1.88 Eq/L. These sll differenes will nt ffet either the dignsis r the ngeent f DKA, nd there is n need t llet rteril bld fr esuring the id-bse sttus. The hyperklei urs despite ttl bdy ptssiu depletin beuse f the shift f ptssiu fr the intr- ellulr t extrellulr spes tht urs in systei i- dsis. The verge ttl bdy ptssiu defiit resulting fr sti diuresis, idsis, nd gstrintestinl lsses is but 35 Eq/kg. Siilrly, despite the elevted seru phsphte, ttl bdy phsphte is generlly depleted. Seru sdiu is generlly redued due t lss f sdiu ins (710 Eq/kg) by plyuri nd viting nd beuse severe hyperglyei shifts intrellulr wter int the interstitil prtent. Fr every 100 g/dL f pls gluse, seru sdiu dereses by 1.6 Eq/L (5.56 l/L). The derese in seru sdiu y be greter when ptients hve re severe hyperglyei (greter thn 400 g/dL, 22.2 l/L) nd  rretin ftr f 2.4 Eq/L y be used. Hypertriglyeridei shuld be nsidered if the rreted sdiu is very lw. Seru sllity n be diretly esured by stndrd tests f freezing pint depressin r n be estited by lulting the lrity f sdiu, hlride, nd gluse in the seru. A nvenient ethd f estiting effetive seru sllity is s fllws (nrl vlues re 280300 Os/kg): mOsm/kg  2 [measured Na ]Glucose (mg/dL) 18=  ++These lulted esti tes re usully 1020 Os/kg lwer thn vlues esured by stndrd ryspi teh- niques. Centrl nervus syste depressin r  urs when the effetive seru sllity exeeds 320330 Os/L. C in  dibeti ptient with  lwer sllity shuld prpt  serh fr the use f  ther thn hypersllity (see Tble 2710 nd Chpter 24).Ketidei represents the effet f insulin lk t ultiple enzye li. Insulin lk ssited with elevted levels f grwth hrne, tehlines, nd glugn ntributes t inreses in liplysis fr dipse tissue nd in hepti ketgenesis. In dditin, redued ketlysis by insulin-defiient peripherl tissues ntributes t the ket- idei. The nly true ket id present in dibeti ketidsis is eteti id whih, lng with its by- prdut etne, is esured by nitrprusside regents (Aetest nd Ketstix). The sensitivity fr etne, hw- ever, is pr, requiring ver 10 l/L, whih is seld rehed in the pls f ketidti ptientslthugh this detetble nentrtin is redily hieved in urine. Thus, in the pls f ketti ptients, nly etette is esured by these regents. The re prevlent bet- hydrxybutyri id hs n ketne grup nd is therefre nt deteted by nventinl nitrprusside tests. This tkes n speil iprtne in the presene f irultry l- lpse during DKA, wherein n inrese in lti id n shift the redx stte t inrese bet-hydrxybutyri id t the expense f the redily detetble eteti id. Bed- side dignsti regents re then unrelible, suggesting n ketnei in ses where bet-hydrxybutyri id is  jr ftr in prduing the idsis. Cbined gluse nd ketne eters (Preisin Xtr, Nv Mx Plus) tht esure bld bet-hydrxybutyrte nentr- tin n pillry bld re vilble. Mny linil lbrtries ls ffer diret bld bet-hydrxybutyrte esureent. Nnspeifi elevtins f seru ylse nd lipse urs in but 1625% f ses f DKA, nd n iging study y be neessry if the dignsis f ute pnreti- tis is being seriusly nsidered. Leukytsis s high s 25,000/L (25  109/L) with  left shift y ur with r withut ssited infetin. The presene f n elevted r even  nrl teperture n suggest the presene f n infetin sine ptients with DKA re generlly hyp- theri if uninfeted. TreatmentP tients with mild DKA re lert nd hve pH levels between 7.25 nd 7.30 nd bet-hydrxybutyrte levels f 34 l/L; thse with moderate ketoacidosis re either lert r  little drwsy nd hve pH levels between 7.0 nd 7.24 nd bet-hydrxybutyrte levels f 48 l/L; nd thse with severe ketoacidosis re stuprse nd hve  pH < 7.0 nd bet-hydrxybutyrte levels f greter thn 8 l/L. Ptients with ild ketidsis n be treted in the eergeny deprtent, but thse with derte r severe ketidsis require dissin t the ICU r step- dwn unit. Therpeuti gls re t restre pls vlue nd tissue perfusin, redue bld gluse nd sllity twrd nrl, rret idsis, replenish eletrlyte lsses, nd identify nd tret preipitting ftrs. Gstri intubtin is reended in the tse ptient t prevent viting nd spirtin tht y ur s  result f gstri tny,  n plitin f DKA. An indwelling urinry theter y ls be neessry. In ptients with preexisting hert r kidney filure r thse in severe rdivsulr llpse,  entrl venus pressureCMDT22_Ch27_p1212-p1255.indd  1245 29/06/21 8:53 PMCHAPTEr 271246 CMDT 2022the ter shuld be inserted t evlute the degree f hypvlei nd t nitr subsequent fluid dinistrtin. A prehensive flw sheet tht inludes vitl signs, seril lbrtry dt, nd therpeuti interventins (eg, fluids, insulin) shuld be etiulusly intined by the liniin respnsible fr the ptients re. Pls gluse shuld be rerded hurly nd eletrlytes nd pH t lest every 23 hurs during the initil tretent perid. Bed- side gluse eters shuld be used t titrte the insulin therpy. The ptient shuld nt reeive sedtives r piids in rder t vid sking signs nd sypts f ipeding erebrl ede.A.  Fluid ReplacementIn  st ptients, the fluid defiit is 45 L. Initilly, 0.9% sline slutin is the slutin f hie t help reexpnd the ntrted vsulr vlue nd shuld be strted in the eergeny deprtent s sn s the dignsis is estblished. The sline shuld be infused rpidly t prvide 1 L/h ver the first 12 hurs. After the first 2 L f fluid hve been given, the intrvenus infusin shuld be t the rte f 300400 L/h. Use 0.9% (nrl) sline unless the seru sdiu is greter thn 150 Eq/L, when 0.45% (hlf nrl) sline slutin shuld be used. The vlue sttus shuld be refully nitred linilly. Filure t give enugh vlue repleent (t lest 34 L in 8 hurs) t restre nrl perfusin is ne f the st serius therpeuti shrtings dversely influening stisf- try revery. Exessive fluid repleent (re thn 5 L in 8 hurs) y ntribute t ute respirtry distress syndre r erebrl ede. When bld gluse flls t pprxitely 250 g/dL (13.9 l/L), the fluids shuld be hnged t  5% gluse-ntining slutin t in- tin seru gluse in the rnge f 250300 g/dL (13.916.7 l/L). This will prevent the develpent f hypglyei nd will ls redue the likelihd f ere- brl ede, whih uld result fr t rpid deline f bld gluse.B.  Insulin ReplacementIedi tely fter inititin f fluid repleent, regulr insulin n be given intrvenusly in  lding dse f 0.1 unit/kg s  blus t prie the tissue insulin reeptrs. Fllwing the initil blus, intrvenus dses f insulin s lw s 0.1 unit/kg/h re ntinuusly infused r given hurly s n intrusulr injetin; this is suffiient t reple the insulin defiit in st ptients. A prspetive rndized study shwed tht  blus dse is nt required if ptients re given hurly insulin infusin t 0.14 unit/kg. Repleent f insulin defiieny helps rret the id- sis by reduing the flux f ftty ids t the liver, reduing ketne prdutin by the liver, nd ls iprving revl f ketnes fr the bld. Insulin tretent redues the hypersllity by reduing the hyperglyei. It - plishes this by inresing revl f gluse thrugh peripherl utiliztin s well s by deresing prdutin f gluse by the liver. This ltter effet is plished by diret inhibitin f glunegenesis nd glygenlysis swell s by lwered in id flux fr usle t liver nd redued hyperglugnei. The insulin infusin shuld be piggy-bked int the fluid line s the rte f fluid repleent n be hnged withut ltering the insulin delivery rte. If the pls gluse level fils t fll t lest 10% in the first hur,  repet lding dse (0.1 r 0.14 unit/kg) is reended. Rrely,  ptient with iune insulin resistne is enun- tered, nd this requires dubling the insulin dse every 24 hurs if hyperglyei des nt iprve fter the first tw dses f insulin. The insulin dse shuld be djusted t lwer the gluse nentrtin by but 5070 g/dL/h (2.83.9 l/L). If linil irustnes prevent use f n insulin infusin, then the insulin n be given intrus- ulrly. An initil 0.15 unit/kg f regulr insulin is given intrvenusly, nd t the se tie, the se size dse is given intrusulrly. Subsequently, regulr insulin is given intrusulrly hurly t  dse f 0.1 unit/kg until the bld gluse flls t rund 250 g/dL, when the insulin n be given subutneusly. Ptients wh nrlly tke insulin glrgine r insulin deteir n be given their usul intenne dses during the initil tretent f their DKA. The ntinutin f their subutneus bsl insulins ens tht lwer dses f intrvenus insulin will be needed, nd there will be  sther trnsitin fr intr- venus insulin infusin t the subutneus regien.C.  PotassiumT tl bdy ptssiu lss fr plyuri nd viting y be s high s 200 Eq. Hwever, beuse f shifts f pts- siu fr ells int the extrellulr spe s  nse- quene f idsis, seru ptssiu is usully nrl t slightly elevted prir t institutin f tretent. As the idsis is rreted, ptssiu flws bk int the ells, nd hypklei n develp if ptssiu repleent is nt instituted. If the ptient is nt urei nd hs n de- qute urinry utput, ptssiu hlride in dses f 1030 Eq/h shuld be infused during the send nd third hurs fter beginning therpy s sn s the idsis strts t reslve. Repleent shuld be strted sner if the initil seru ptssiu is inpprpritely nrl r lw nd shuld be delyed if seru ptssiu fils t respnd t initil therpy nd reins bve 5 Eq/L, s in ses f hrni kidney disese. Osinlly,  ptient y present with  seru ptssiu level less thn 3.5 Eq/L, in whih se insulin therpy shuld be delyed until the ptssiu level is rreted t greter thn 3.5 Eq/L. An ECG n help nitr the ptients pts- siu sttus: High peked T wves re  sign f hyperkle- i, nd flttened T wves with U wves re  sign f hypklei. Fds high in ptssiu ntent shuld be presribed when the ptient hs revered suffiiently t tke fd rlly. Tt juie hs 14 Eq f ptssiu per 240 L, nd  ediu-sized bnn prvides but 10 Eq.D . Sodium BicarbonateThe  use f sdiu birbnte in the ngeent f DKA hs been questined sine linil benefit ws ntCMDT22_Ch27_p1212-p1255.indd  1246 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1247 CMDT 2022denstr ted in ne prspetive rndized tril nd beuse f the fllwing ptentilly hrful nsequenes: (1) develpent f hypklei fr rpid shift f pts- siu int ells if the idsis is verrreted; (2) tissue nxi fr redued dissitin f xygen fr he- glbin when idsis is rpidly reversed (leftwrd shift f the xygen dissitin urve); nd (3) erebrl idsis resulting fr lwering f erebrspinl fluid pH. It ust be ephsized, hwever, tht these nsidertins re less iprtnt when very severe idsis exists. Therefre, it is reended tht birbnte be dinistered in DKA if the rteril bld pH is 7.0 r less, with reful nitring t prevent verrretin. One r tw pules f sdiu birbnte (ne pule ntins 44 Eq/50 L) shuld be dded t 1 L f 0.45% sline with 20 Eq KCl r t 400 L f sterile wter with 20 Eq KCl nd infused ver 1 t 2 hurs. ( Note: Additin f sdiu birbnte t 0.9% sline wuld prdue  rkedly hypertni slutin tht uld ggrvte the hyperslr stte lredy pres- ent.) It n be repeted until the rteril pH rehes 7.1, but it should not be given if the pH is 7.1 or greater sine ddi- tinl birbnte wuld inrese the risk f rebund etbli lklsis s ketnes re etblized. Alklsis shifts ptssiu fr seru int ells, whih uld pre- ipitte  ftl rdi rrhythi.E.  PhosphatePh sphte repleent is seld required in treting DKA. Hwever, if severe hypphsphtei f less thn 1 g/dL (0.32 l/L) develps during insulin therpy,  sll unt f phsphte n be repled per hur s the pts- siu slt. Three rndized studies, thugh, in whih phsphte ws repled in ptients with DKA did nt shw ny pprent linil benefit fr phsphte dinistr- tin. Mrever, ttepts t use ptssiu phsphte s the sle ens f repling ptssiu hve led t  nuber f reprted ses f severe hyplei with tetny. T ini- ize the risk f induing tetny fr t-rpid repleent f phsphte, the verge defiit f 4050 l f phs- phte shuld be repled intrvenusly t  rte no greater than 34 mmol/h in  60- t 70-kg persn. A stk slutin (Abbtt) prvides  ixture f 1.12 g KH2PO4nd 1.18 g K2HPO4in  5-L single-dse vil (this equls 22 l f ptssiu nd 15 l f phsphte). One-hlf f this vil (2.5 L) shuld be dded t 1 L f either 0.45% sline r 5% dextrse in wter. Tw liters f this slutin, infused t  rte f 400 L/h, will rret the phsphte defiit t the ptil rte f 3 l/h while prviding 4.4 Eq f ptssiu per hur. (Additinl ptssiu shuld be dinistered s ptssiu hlride t prvide  ttl f 1030 Eq f pts- siu per hur, s nted bve.) If the seru phsphte reins belw 2.5 g/dL (0.8 l/L) fter this infusin,  repet 5-hur infusin n be given.F . Hyperchloremic Acidosis During TherapyBeuse  f the nsiderble lss f ket ids in the urine during the initil phse f therpy, substrte fr subsequent regenertin f birbnte is lst nd rretin f the ttl birbnte defiit is hpered. A prtin f thebirbnte defiit is repled with hlride ins infused in lrge unts s sline t rret the dehydrtin. In st ptients, s the ketidsis lers during insulin reple- ent,  hyperhlrei, lw-birbnte pttern eerges with  nrl nin gp. This is  reltively benign ndi- tin tht reverses itself ver the subsequent 1224 hurs ne intrvenus sline is n lnger being dinistered. Using  blned eletrlyte slutin with  pH f 7.4 nd 98 Eq/L hlride suh s Pls-lyte insted f nrl sline (pH ~5.5; hlride 154 Eq/L) hs been reprted t prevent the hyperhlrei idsis.G.  Treatment of Associated InfectionAntibi tis re presribed s indited (Tble 305). Ch- leystitis nd pyelnephritis y be prtiulrly severe in these ptients.H.  Transition to Subcutaneous Insulin RegimenOn e the DKA is ntrlled nd the ptient is wke nd ble t et, subutneus insulin therpy n be initited. The ptient with type 1 dibetes y hve persistent signifi- nt tissue insulin resistne nd y require  ttl dily insulin dse f pprxitely 0.6 unit/kg. The unt f insulin required in the previus 8 hurs n ls be helpful in estiting the initil insulin dses. Hlf the ttl dily dse n be given s  lng-ting bsl insulin nd the ther hlf s shrt-ting insulin preels. The ptient shuld reeive subutneus bsl insulin nd rpid-ting insulin nlg with the first el nd the insulin infusin disntin- ued n hur lter. The verlp f the subutneus insulin tin nd insulin infusin is neessry t prevent relpse f the DKA. In ptients with preexisting dibetes, giving their bsl insulin by subutneus injetin t inititin f tret- ent siplifies the trnsitin fr intrvenus t subut- neus regien. The inresed insulin resistne is nly present fr  few dys, nd it is iprtnt t redue bth the bsl nd blus insulins t vid hypglyei. A ptient with new-nset type 1 dibetes usully still hs signifint bet ell funtin nd y nt need ny bsl insulin nd nly very lw dses f rpid-ting insulin befre els fter revery fr the ketidsis. Ptients with type 2 dibetes nd DKA due t severe illness y initilly require insulin therpy but n ften trnsitin bk t rl gents during utptient fllw-up. Complications & PrognosisLw- dse insulin infusin nd fluid nd eletrlyte repleent bined with reful nitring f ptients linil nd lbrtry respnses t therpy hve drti- lly redued the rtlity rtes f DKA t less thn 5% in individuls under 40 yers f ge. Hwever, this pli- tin reins  signifint risk in the ged wh hve r- tlity rtes greter thn 20% nd in ptients in prfund  in wh tretent hs been delyed. Aute yr- dil infrtin nd infrtin f the bwel fllwing pr- lnged hyptensin wrsen the utlk. A serius prgnsti sign is end-stge hrni kidney disese, nd prir kidney dysfuntin wrsens the prgnsis nsider- bly beuse the kidney plys  key rle in penstingCMDT22_Ch27_p1212-p1255.indd  1247 29/06/21 8:53 PMCHAPTEr 271248 CMDT 2022f r ssive pH nd eletrlyte bnrlities. Syptti erebrl ede urs pririly in the peditri ppultin. Risk ftrs fr its develpent inlude severe bseline i- dsis, rpid rretin f hyperglyei, nd exess vlue dinistrtin in the first 4 hurs. Onset f hedhe r deterirtin in entl sttus during tretent shuld led t nsidertin f this plitin. Intrvenus nnitl t  dsge f 12 g/kg given ver 15 inutes is the insty f tretent. Exess rystllid infusin n preipitte pul- nry ede. Aute respirtry distress syndre is  rre plitin f tretent f DKA. After revery nd stbiliztin, ptients shuld be instruted n hw t regnize the erly sypts nd signs f ketidsis. Urine ketnes r pillry bld bet-hydrxybutyrte shuld be esured in ptients with signs f infetin r in insulin pup-treted ptients when pillry bld gluse reins unexpetedly nd persis- tently high. When hevy ketnuri nd glysuri persist n severl suessive exintins, suppleentl rpid- ting insulin shuld be dinistered nd liquid fds suh s lightly slted tt juie nd brth shuld be ingested t replenish fluids nd eletrlytes. The ptient shuld be instruted t ntt the liniin if ketnuri persists, nd espeilly if there is viting nd inbility t keep dwn fluids. Reurrent episdes f severe ketid- sis ften indite pr pline with the insulin regi- en, nd these ptients will require intensive unseling.F yfn M et l. Mngeent f hyperglyei rises: dibeti ketidsis nd hyperglyei hyperslr stte. Med Clin Nrth A. 2017;101:587. [PMID: 28372715] Isl T et l. Guidelines nd ntrversies in the ngeent f dibeti ketidsis ini-review. Wrld J Dibetes. 2018;9:226. [PMID: 30588284] Krsliglu Frenh E et l. Dibeti ketidsis nd hypers- lr hyperglyei syndre: review f ute depensted dibetes in dult ptients. BMJ. 2019;365:l114. [PMID: 31142480] Mdi A et l. Euglyei dibeti letidsis:  review. Curr Dibetes Rev. 2017;13:315. [PMID: 27097605]HYP ERGLYCEMIC HYPEROSMOLAR STATEE S S E N T I A L S  O F  D I A G N O S I S Hyperglycemia > 600 mg/dL (33.3 mmol/L). Serum osmolality > 310 mOsm/kg. No acidosis; blood pH > 7.3. Serum bicarbonate > 15 mEq/L. Normal anion gap (< 14 mEq/L). General ConsiderationsTh is send st n fr f hyperglyei  is hrterized by severe hyperglyei in the bsene f sig- nifint ketsis, with hypersllity nd dehydrtin. It urs in ptients with ild r ult dibetes, nd stptients re typilly iddle-ged t elderly. Aurte figures re nt vilble s t its true inidene, but fr dt n hspitl dishrges it is rrer thn DKA even in lder ge grups. Underlying hrni kidney disese r hert filure is n, nd the presene f either wrsens the prgnsis. A preipitting event suh s infetin, yrdil infrtin, strke, r reent pertin is ften present. Certin edi- tins suh s phenytin, dizxide, rtisterids, nd diuret- is hve been iplited in its pthgenesis, s hve predures ssited with gluse lding suh s peritnel dilysis. PathogenesisA prtil  r reltive insulin defiieny y initite the syn- dre by reduing gluse utiliztin f usle, ft, nd liver while induing hyperglugnei nd inresing hepti gluse utput. With ssive glysuri, bligtry wter lss ensues. If  ptient is unble t intin dequte fluid intke beuse f n ssited ute r hrni illness r hs suffered exessive fluid lss, rked dehydrtin results. As the pls vlue ntrts, kidney funtin bees ipired, liiting the urinry gluse lsses nd exerbting the hyperglyei. Severe hypersllity develps tht uses entl nfusin nd finlly . It is nt ler why ketsis is virtully bsent under these ndi- tins f insulin insuffiieny, lthugh redued levels f grwth hrne y be  ftr, lng with prtl vein insulin nentrtins suffiient t restrin ketgenesis. Clinical FindingsA.  Symptoms and SignsOnset  y be insidius ver  perid f dys r weeks, with wekness, plyuri, nd plydipsi. The lk f fe- tures f DKA (eg, viting, rpid deep brething, etne dr) y retrd regnitin f the syndre nd dely therpy until dehydrtin bees re prfund thn in ketidsis. Redued intke f fluid is nt n unn histril feture, due t either inpprprite lk f thirst, nuse, r inessibility f fluids t elderly, bedridden ptients. A histry f ingestin f lrge quntities f gluse-ntining fluids, suh s sft drinks r rnge juie, n sinlly be btined. Lethrgy nd nfu- sin develp s seru sllity exeeds 310 Os/kg, nd nvulsins nd  n ur if sllity exeeds 320330 Os/kg. Physil exintin nfirs the presene f prfund dehydrtin in  lethrgi r - tse ptient withut Kussul respirtins.B.  Laboratory FindingsSevere h yperglyei is present, with bld gluse vlues rnging fr 800 g/dL t 2400 g/dL (44.4 l/L t 133.2 l/L) (Tble 2710). In ild ses, where dehy- drtin is less severe, dilutinl hypntrei s well s urinry sdiu lsses y redue seru sdiu t 120125 Eq/L, whih prtets t se extent ginst extree hypersllity. Hwever, s dehydrtin pr- gresses, seru sdiu n exeed 140 Eq/L, prduing seru sllity redings f 330440 Os/kg. Ketsis nd idsis re usully bsent r ild. Prerenl zteiCMDT22_Ch27_p1212-p1255.indd  1248 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1249 CMDT 2022is  the rule, with seru ure nitrgen elevtins ver 100 g/dL (35.7 l/L) being typil. TreatmentA.  Fluid ReplacementFluid  repleent is f prunt iprtne in treting the nnketti hyperglyei stte. Fluid defiit y be s uh s 610 L. If hypvlei is present s evidened by hyptensin nd liguri, fluid therpy shuld be initited with 0.9% sline. In ll ther ses, 0.45% sline ppers t be prefer- ble s the initil repleent slutin beuse the bdy flu- ids f these ptients re rkedly hyperslr. As uh s 46 L f fluid y be required in the first 810 hurs. Cre- ful nitring f the ptient is required fr prper sdiu nd wter repleent. An iprtnt end pint f fluid therpy is t restre urinry utput t 50 L/h r re. One bld gluse rehes 250 g/dL (13.9 l/L), fluid repleent shuld inlude 5% dextrse in either wter, 0.45% sline slutin, r 0.9% sline slutin. The rte f dextrse infusin shuld be djusted t intin glyei levels f 250300 g/dL (13.916.7 l/L) in rder t redue the risk f erebrl ede.B.  InsulinLess  insulin y be required t redue the hyperglyei in nnketti ptients s pred t thse with dibeti ket- idti . In ft, fluid repleent lne n redue hyperglyei nsiderbly by rreting the hypvlei, whih then inreses bth glerulr filtrtin nd renl exretin f gluse. Insulin tretent shuld therefre be delyed unless the ptient hs signifint ketnei (bet- hydrxybutyrte re thn 1 l/L). Strt the insulin infusin rte t 0.05 unit/kg/h (blus is nt needed) nd titrte t lwer bld gluse levels by 5070 g/dL per hur (2.83.9 l/L/h). One the ptient hs stbilized nd the bld gluse flls t rund 250 g/dL (13.9 l/L), insulin n be given subutneusly.C.  PotassiumW ith the bsene f idsis, there y be n initil hyper- klei unless ssited end-stge hrni kidney disese is present. This results in less severe ttl ptssiu deple- tin thn in DKA, nd less ptssiu repleent is there- fre needed. Hwever, beuse initil seru ptssiu is usully nt elevted nd beuse it delines rpidly s  result f insulins effet n driving ptssiu intrellulrly, it is reended tht ptssiu repleent be initited erlier thn in ketti ptients, ssuing tht n hrni kidney disese r liguri is present. Ptssiu hlride (10 Eq/L) n be dded t the initil bttle f fluids din- istered if the ptients seru ptssiu is nt elevted.D . PhosphateIf  severe hypphsphtei (seru phsphte less thn 1 g/dL [0.32 l/L]) develps during insulin therpy, phsphte repleent n be given s desribed fr ket- idti ptients (t 3 l/h).Complications & PrognosisThe  severe dehydrtin nd lw utput stte y predis- pse the ptient t plitins suh s yrdil infrtin, strke, pulnry eblis, esenteri vein thrbsis, nd disseinted intrvsulr gultin. Fluid repleent reins the priry pprh t the preventin f these plitins. Lw-dse heprin pr- phylxis is resnble but benefits f rutine ntigul- tin rein dubtful. Rhbdylysis is  regnized plitin nd shuld be lked fr nd treted. The verll rtlity rte f hyperglyei hypers- lr stte  is re thn ten ties tht f DKA, hiefly beuse f its higher inidene in lder ptients, wh y hve prised rdivsulr systes r ssited jr illnesses nd whse dehydrtin is ften exessive beuse f delys in regnitin nd tretent. (When ptients re thed fr ge, the prgnses f these tw hyperglyei eergenies re resnbly pr- ble.) When prpt therpy is instituted, the rtlity rte n be redued fr nerly 50% t tht relted t the severity f existent disrders. After the ptient is stbilized, the pprprite fr f lng-ter ngeent f the dibetes ust be deter- ined. Insulin tretent shuld be ntinued fr  few weeks but ptients usully rever suffiient endgenus insulin seretin t ke  tril f diet r diet plus rl gents wrthwhile. When the episde urs in  ptient wh hs knwn dibetes, then edutin f the ptient nd regivers shuld be instituted. They shuld be tught hw t regnize situtins (nuse nd viting, infetin) tht predispse t reurrene f the hyperglyei, hyper- slr stte, s well s detiled infrtin n hw t prevent the eslting dehydrtin tht ulintes in hyperslr  (sll sips f sugr-free liquids, inrese in usul hypglyei therpy, r erly ntt with the liniin).F yfn M et l. Mngeent f hyperglyei rises: dibeti ketidsis nd hyperglyei hyperslr stte. Med Clin Nrth A. 2017;101:587. [PMID: 28372715] Stt AR; Jint British Dibetes Sieties (JBDS) fr Inptient Cre; JBDS hyperslr hyperglyei guidelines grup. Mngeent f hyperslr hyperglyei stte in dults with dibetes. Dibet Med. 2015;32:714. [PMID: 25980647]LAC TIC ACIDOSISE S S E N T I A L S  O F  D I A G N O S I S Severe metabolic acidosis with compensatory hyperventilation. Blood pH < 7.30. Serum bicarbonate < 15 mEq/L. Anion gap > 15 mEq/L. Absent serum ketones. Serum lactate > 5 mmol/L.CMDT22_Ch27_p1212-p1255.indd  1249 29/06/21 8:53 PMCHAPTEr 271250 CMDT 2022 General ConsiderationsL ti idsis is hrterized by uultin f exess lti id in the bld. Nrlly, the prinipl sures f this id re the erythrytes (whih lk enzyes fr erbi xidtin), skeletl usle, skin, nd brin. Cn- versin f lti id t gluse nd its xidtin prini- plly by the liver but ls by the kidneys represent the hief pthwys fr its revl. Hyperlttei nd i- dsis ur when ltte prdutin exeeds ltte n- suptin. Cuses inlude tissue hypxi (glbl r ll), disrders tht inrese epinephrine levels (severe sth with exess bet-drenergi gnist use, rdigeni r herrhgi shk, phehryt), nd drugs tht ipir xidtive phsphryltin (ntiretrvirl gents nd prpfl). Mst ses f etfrin-ssited lti idsis ur in ptients in wh there were ntrindi- tins t the use f etfrin, in prtiulr kidney filure. Metfrin levels re usully greter thn 5 g/L when etfrin is iplited s the use f lti id- sis. Other uses f lti idsis inlude severl inbrn errrs f etblis nd the MELAS syndre (it- hndril enephlpthy, lti idsis, nd strke-like episdes). D-lti idsis n ur in ptients with shrt bwel syndre when unbsrbed rbhydrtes re presented s substrte fr ferenttin by lni bteri. Clinical FindingsA.  Symptoms and SignsThe  in linil feture f lti idsis is rked hyperventiltin. When lti idsis is sendry t tissue hypxi r vsulr llpse, the linil present- tin is vrible, being tht f the previling tstrphi illness. Hwever, in the idipthi, r spntneus, vri- ety, the nset is rpid (usully ver  few hurs), bld pressure is nrl, peripherl irultin is gd, nd there is n ynsis.B.  Laboratory FindingsPl s birbnte nd bld pH re quite lw, indit- ing the presene f severe etbli idsis. Ketnes re usully bsent fr pls nd urine r t lest nt prinent. The first lue y be  high nin gp (seru sdiu inus the su f hlride nd birbn- te nins [in Eq/L] shuld be n greter thn 15). A higher vlue indites the existene f n bnrl - prtent f nins. If this nnt be linilly explined by n exess f ket ids (dibetes), inrgni ids (urei), r nins fr editin verdsge (sliy- ltes, ethyl lhl, ethylene glyl), then lti id- sis is prbbly the rret dignsis. (See ls Chpter 21.) In the bsene f ztei, hyperphsphtei y be  lue t the presene f lti idsis fr resns tht re nt ler. The dignsis is nfired by  pls lti id nentrtin f 5 l/L r higher (vlues s high s 30 l/L hve been reprted). Nrl pls vl- ues verge 1 l/L, with  nrl ltte/pyruvterti f 10:1. This rti is gretly exeeded in lti idsis.1 TreatmentAggressiv e tretent f the preipitting use f lti idsis is the in pnent f therpy, suh s ensur- ing dequte xygentin nd vsulr perfusin f tissues. Epiri ntibiti verge fr sepsis shuld be given fter ulture sples re btined in ny ptient in wh the use f the lti idsis is nt pprent (Tble 305). Alkliniztin with intrvenus sdiu birbnte t keep the pH bve 7.2 hs been reended by se in the eergeny tretent f lti idsis; s uh s 2000 Eq in 24 hurs hs been used. Hwever, there is n evidene tht the rtlity rte is fvrbly ffeted by dinistering birbnte, nd its use reins ntrver- sil. Hedilysis y be useful in ses where lrge sdiu lds re prly tlerted nd in ses ssited with etfrin txiity. PrognosisThe  rtlity rte f spntneus lti idsis is high. The prgnsis in st ses is tht f the priry disrder tht prdued the lti idsis.DeFr nz R et l. Metfrin-ssited lti idsis: urrent perspetives n uses nd risk. Metblis. 2016;65:20. [PMID: 26773926] THE HYPOGLYCEMIC STATESSpn tneus hypglyei in dults is f tw prinipl types: fsting nd pstprndil. Sypts begin t pls gluse levels in the rnge f 60 g/dL (3.3 l/L) nd ipirent f brin funtin t pprxitely 50 g/dL (2.8 l/L). Fsting hypglyei is ften subute r hrni nd usully presents with neurglypeni s its prinipl nifesttin; pstprndil hypglyei is rel- tively ute nd is ften herlded by sypts f neur- geni utni dishrge (sweting, plpittins, nxiety, treulusness). Differential Diagnosis (Table 2711)Fstin g hypglyei y ur in ertin endrine dis- rders, suh s hyppituitris, Addisn disese, r yx- ede; in disrders relted t liver lfuntin, suh s ute lhlis r liver filure; nd in instnes f end- stge hrni kidney disese, prtiulrly in ptients requiring dilysis. These nditins re usully bvius, with hypglyei being nly  sendry feture. When fsting hypglyei is  priry nifesttin develp- ing in dults withut pprent endrine disrders r inbrn etbli diseses fr hildhd, the prinipl1 In lleting sples, it is essentil t rpidly hill nd seprte the bld in rder t reve red ells, whse ntinued glylysis t r teperture is  n sure f errr in reprts f high pls ltte. Frzen pls reins stble fr subsequent ssy.CMDT22_Ch27_p1212-p1255.indd  1250 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1251 CMDT 2022dignsti pssibili ties inlude (1) hyperinsulinis, due t either pnreti B ell turs, itrgeni r surreptitius dinistrtin f insulin r sulfnylure; nd (2) hypgly- ei due t extrpnreti turs. Pstprndil (retive) hypglyei y ur fter gstrintestinl surgery nd is prtiulrly ssited with the duping syndre fter gstrety nd Rux-en-Y gstri bypss surgery. Oult dibetes very sinlly presents with pstprndil hypglyei. Rrely, it urs with islet ell hyperplsithe s-lled nninsulin pnretgenus hypglyei syndre. Alhl-relted hypglyei is due t hepti gly- gen depletin bined with lhl-edited inhibitin f glunegenesis. It is st n in lnurished individuls with exessive lhl intke but n ur in nyne wh is unble t ingest fd fter n ute lhli episde fllwed by gstritis nd viting. Iunpthlgi hypglyei is n extreely rre nditin in whih nti-insulin ntibdies r ntibdies t insulin reeptrs develp spntneusly.HYP OGLYCEMIA DUE TO PANCREATIC B CELL TUMORSE S S E N T I A L S  O F  D I A G N O S I S Hypoglycemic symptomsoften neuroglycopenic (confusion, blurred vision, anxiety, convulsions). Immediate recovery upon administration of glucose. Blood glucose < 45 mg/dL (2.5 mmol/L) with a serum insulin level of  6 microunits/mL. General ConsiderationsFsting  hypglyei in n therwise helthy, well- nurished dult is rre nd is st nly due t nden f the islets f Lngerhns. Ninety perent f suh turs re single nd benign, but ultiple dens n ur s well s lignnt turs with funtinl etstses. Adens y be filil, nd ultiple de- ns hve been fund in njuntin with turs f the prthyrids nd pituitry (MEN type 1 [MEN 1]). Abut 30% f sprdi insulin turs hve  sti ut- tin in the YY1 gene (T372R) tht endes the trnsrip- tinl repressr YY1. Over 99% f insulins re lted within the pnres nd less thn 1% in etpi pnreti tissue. Clinical FindingsA.  Symptoms and SignsThe st ip rtnt prerequisite t dignsing n insulin-  is siply t nsider it, prtiulrly in reltively helthy-ppering persns wh hve fsting hypglyei ssited with se degree f entrl nervus syste dysfuntin suh s nfusin r bnrl behvir. A dely in dignsis n result in unneessry tretent fr psyhtr epilepsy r psyhitri disrders nd y use irreversible brin dge. In lng-stnding ses, besity n result s  nsequene f vereting t relieve sypts. The s-lled Whipple trid is hrteristi f hyp- glyei regrdless f the use. It nsists f (1)  histry f hypglyei sypts, (2) n ssited lw pls gluse level (4050 g/dL), nd (3) relief f sypts upn ingesting fst-ting rbhydrtes in pprxitely 15 inutes. The hypglyei sypts in insulin ften develp in the erly rning r fter issing  el. Osinlly, they ur fter exerise. Ptients typilly plin f neurglypeni syp- ts suh s blurred visin r diplpi, hedhe, feelings f dethent, slurred speeh, nd wekness. Persnlity nd entl hnges vry fr nxiety t psyhti behv- ir, nd neurlgi deterirtin n result in nvulsins r . Hypglyei unwreness is very n nd drenergi sypts f plpittins nd sweting y be blunted. With the redy vilbility f he bld gluse nitring systes, ptients seties present with d- uented fingerstik bld gluse levels in 40s nd 50s t tie f sypts. Aess t sulfnylures r insulin shuld be explreddes  fily eber hve dibetes, r des the ptient r fily eber wrk in the edil field? Meditin-dispensing errrs shuld be exludedhs the ptients presriptin editin hnged in shpe r lr? Ptients with insulin r ftitius hypglyei usully hve  nrl physil exintin.B.  Laboratory FindingsB  ell dens d nt redue seretin f insulin in the presene f hypglyei, nd the ritil dignsti test is t denstrte inpprpritely elevted seru insulin, prinsulin, nd C-peptide levels, t  tie when pls gluse level is belw 45 g/dL. The dignsti riteri fr insulin fter  72-hur fst re listed in Tble 2712. Other uses f hyperinsulin- ei hypglyei inlude ftitius dinistrtin fTable 2711. Common causes of hypoglycemia in adults.1F asting hypoglycemia Pancreatic B cell tumor Surreptitious administration of insulin or sulfonylureas Extrapancreatic tumors Postpandial hypoglycemia Gastric surgery Occult diabetes mellitus Alcohol-elated hypoglycemia Immunopathologic hypoglycemia Idiopathic anti-insulin antibodies (which release their bound insulin) Antibodies to insulin receptors (which act as agonists) Dug-induced hypoglycemia1 In the absence of clinically obvious endocrine, kidney, or liver disorders and exclusive of diabetes mellitus treated with hypogly- cemic agents.CMDT22_Ch27_p1212-p1255.indd  1251 29/06/21 8:53 PMCHAPTEr 271252 CMDT 2022insulin  r sulfnylures. Ftitius use f insulin will result in suppressin f endgenus insulin seretin nd lw C-peptide levels. In ptients wh hve injeted insulin, the insulin/C-peptide rti (pl/L) will be greter thn 1. An elevted irulting prinsulin level in the presene f fst- ing hypglyei is hrteristi f st B ell dens nd des nt ur in ftitius hyperinsulinis. Thus, C-peptide levels (by iunheiluinetri ssys [ICMA]) f greter thn 200 pl/L nd prin- sulin levels (by rdiiunssy [RIA]) f greter thn 5 pl/L re hrteristi f insulins. In ptients with insulin, pls bet-hydrxybutyrte levels re suppressed t 2.7 l/L r less. N single hrne esureent (insulin, prinsulin, C-peptide) is 100% sensitive nd speifi fr the dignsis f insulin, nd insulin ses hve been reprted with insulin lev- els belw 3 irunits/L (ICMA ssy) r prinsulin level belw 5 pl/L. These hrnl ssys re ls nt stndrdized, nd there n be signifint vritin in the test results. Therefre, the dignsis shuld be bsed n ultiple biheil preters. In ptients with epigstri distress,  histry f renl luli, r enstrul r eretile dysfuntin,  seru l- iu, gstrin, r prltin level y be useful in sreening fr MEN 1 ssited with insulin.C.  Diagnostic TestsIf  the histry is nsistent with episdi spntneus hyp- glyei, ptients shuld be given  he bld gluse nitr nd dvised t nitr bld gluse levels t the tie f sypts nd befre nsuptin f rbhy- drtes, if this n be dne sfely. Ptients with insulins frequently reprt fingerstik bld gluse levels between 40 g/dL (2.2 l/L) nd 50 g/dL (2.8 l/L) t the tie f sypts. The dignsis, hwever, nnt be de bsed n  fingerstik bld gluse. It is neessry t hve  lw lbrtry gluse nitntly with ele- vted pls insulin, prinsulin, nd C-peptide levels nd  negtive sulfnylure sreen. When ptients give  his- try f sypts fter nly  shrt perid f fd with- drwl r with exerise, then n utptient ssessent nbe ttepted. The ptient shuld be brught by  fily eber t the ffie fter n vernight fst nd bserved in the ffie. Ativity suh s wlking shuld be enur- ged nd fingerstik bld gluse esured repetedly during bservtin. If sypts ur r fingerstik bld gluse is belw 50 g/dL (2.8 l/L), then sples fr pls gluse, insulin, C-peptide, prinsulin, sulfnyl- ure sreen, seru ketnes, nd ntibdies t insulin shuld be sent. If utptient bservtin des nt result in sypts r hypglyei nd if the linil suspiin reins high, then the ptient shuld underg n inptient supervised 72-hur fst. A suggested prtl fr the supervised fst is shwn in Tble 2713. In 30% f ptients with insulin, the bld gluse levels ften drp belw 45 g/dL (2.5 l/L) fter n vernight fst, but se ptients require up t 72 hurs t develp syptti hypglyei. Hwever, the ter 72-hur fst is tully  isner in st ses sine the fst shuld be ieditely terinted s sn s sypts pper nd lbrtry nfirtin f hypgly- ei is vilble. In nrl le subjets, the bld glu- se des nt fll belw 5560 g/dL (3.13.3 l/L) during  3-dy fst. In ntrst, in nrl preenpusl wen, the pls gluse n reh vlues s lw s 35 g/dL (1.9 l/L). In these ses, hwever, the wen re nt syptti, presubly wing t the develpent f suffiient ketnei t supply energy needs t the brin. Insulin ptients, n the ther hnd,Table 2712. Diagnostic criteria for insulinoma after a 72-hour fast.Laboatoy  Test result Plasma glucose < 45 mg/dL (2.5 mmol/L) Plasma insulin (RIA)  6 microunits/mL (36 pmol/L) Plasma insulin (ICMA)  3 microunits/mL (18 pmol/L) Plasma C-peptide  200 pmol/L (0.2 nmol/L, 0.6 ng/mL) Plasma proinsulin  5 pmol/L Beta-hydroxybutyrate  2.7 mmol/L Sulfonylurea screen (including repaglinide and nateglinide)Negative ICMA, immunochemiluminometric assays; RIA, radioimmunoassay.T able 2713. Suggested hospital protocol for super- vised fast in diagnosis of insulinoma.(1)  Place intravenous cannula and obtain baseline plasma glucose, insulin, proinsulin, beta-hydroxybutyrate, and C-peptide measurements at onset of fast. (2) Permit only calorie-free and caffeine-free fluids and encourage supervised activity (such as walking). (3) Obtain fingerstick glucose measurements every 4 hours until values < 60 mg/dL are obtained. Then increase the frequency of fingersticks to 12 hours, and when capillary glucose value is < 45 mg/dL send a venous blood sample to the laboratory for plasma glucose.1Check frequently for manifestations of neuroglycopenia. (4) At 48 hours into the fast, send a venous blood sample for plasma glucose, insulin, proinsulin, C-peptide, beta- hydroxybutyrate, and sulfonylurea measurement. (5) If symptoms of hypoglycemia occur oif a laboratory value of serum glucose is < 45 mg/dL, oif 72 hours have elapsed, conclude the fast with a final blood sample for plasma glucose,1insulin, proinsulin, C-peptide, beta-hydroxybutyrate, and sulfonylurea measurements. Then give oral fast-acting carbohydrate followed by a meal. If the patient is confused or unable to take oral agents, administer 50 mL of 50% dextrose intravenously over 35 minutes. Do not conclude a fast based simply on a capillary blood glucose measurementwait for the laboratory glucose valueunless the patient is very symptomatic and it would be dangerous to wait.1 Glucose sample should be collected in sodium fluoride contain- ing tube on ice to prevent glycolysis and the plasma separated immediately upon receipt at the laboratory. Arrange for the labora- tory to run the glucose samples stat.CMDT22_Ch27_p1212-p1255.indd  1252 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1253 CMDT 2022bee  syptti when pls gluse drps t sub- nrl levels, sine inpprprite insulin seretin restrits ketne frtin. Mrever, the denstrtin f  nn- suppressed insulin level f 3 irunits/L r re using n ICMA ssy (greter thn 6 irunits/L using n RIA ssy) in the presene f hypglyei suggests the dignsis f insulin. If hypglyei des nt develp in  le ptient fter fsting fr up t 72 hursnd pr- tiulrly when this prlnged fst is terinted with  perid f derte exeriseinsulin ust be nsid- ered n unlikely dignsis. An rl gluse tlerne test is f n vlue in the dig- nsis f insulin-sereting turs. HbA1levels y be lw but there is nsiderble verlp with nrl ptients nd n prtiulr vlue is dignsti.D . Preoperative Localization of B Cell TumorsAfter  the dignsis f insulin hs been unequivlly de by linil nd lbrtry findings, studies t llize the tur shuld be initited. Mst turs re in the pn- res, nd etpi ses re rre. Beuse f the sll size f these turs (verging 1.5  in dieter in ne lrge series), iging studies d nt neessrily identify ll f the. A pnreti dul phse helil CT sn with thin setin n identify 8294% f the lesins. MRI sns with gdliniu n be helpful in deteting  tur in 85% f ses. One se reprt suggests tht diffusin-weighted MRI n be useful fr deteting nd llizing sll insulins, espeilly fr thse with n hypervsulr pttern. PET/CT sns using glliu-lbeled ststtin nlgs suh s DOTA- 1-NI3-tretide (DOTA-NOC), whih hve  higher ffinity fr ststtin reeptr subtypes 2, 3, nd 5, hve been reprted t be useful in llizing the turs. Insuli- ns express GLP-1 reeptrs, nd rdilbeled GLP-1 reeptr gnists suh s Lys(40)(Ahx-hydrzinnitin- ide [HYNIC]-[(99)T)NH(2)]-exendin-4 fr SPECT/ CT hve ls been reprted t visulize the turs. If the iging study is nrl, then n endspi ultrsund shuld be perfred. In experiened hnds, but 8090% f turs n be deteted with this predure. Fine-needle spirtin f the identified lesin n be ttepted t n- fir the presene f  neurendrine tur. If the tur is nt identified r the iging result is equivl, then the ptient shuld underg seletive liu-stiulted ngi- grphy, whih hs been reprted t llize the tur t  prtiulr regin f the pnres pprxitely 90% f the tie. In this test, ngigrphy is bined with inje- tins f liu glunte int the gstrdudenl, spleni, nd superir esenteri rteries, nd insulin levels re esured in the hepti vein effluent. The predure is perfred fter n vernight fst. Cliu stiultes insulin relese fr insulins but nt nrl islets, nd s  step-up fr bseline in insulin levels (twfld r greter) reginlizes the sure f the hyperinsulinis t the hed f the pnres fr the gstrdudenl rtery, the uninte press fr the superir esenteri rtery, nd the bdy nd til f the pnres fr the spleni rtery liu infusins. These studies bined with reful intrper- tive ultrsngrphy nd plptin by  surgenexperiened in insulin surgery identifies up t 98% f turs. TreatmentThe  tretent f hie fr insulin-sereting turs is surgil resetin. While witing fr surgery, ptients shuld be given rl dizxide. Divided dses f 300400 g/dy usully suffie, lthugh n sinl ptient y require up t 800 g/dy. Side effets inlude ede due t sdiu retentin, gstri irrittin, nd ild hirsutis. Hydrhlrthizide, 2550 g dily, n be used t untert the sdiu retentin nd ede s well ptentite dizxides hyperglyei effet. In ptients with  single benign pnreti B ell de- n, 9095% hve  suessful ure t the first surgil ttept when intrpertive ultrsund is used by  skilled surgen. Dizxide shuld be dinistered n the dy f the surgery beuse it redues the risk f hypglyei during surgery. Typilly, it des nt sk the glyei rise inditive f surgil ure. Bld gluse shuld be nitred thrughut surgery, nd 5% r 10% dextrse infusin shuld be used t intin euglyei. In ses where the dignsis hs been estblished but n den is lted fter reful plptin nd use f intrpertive ultrsund, it is n lnger dvisble t blindly reset the bdy nd til f the pnres, sine  nnplpble tur issed by ultrsund is st likely ebedded within the fleshy hed f the pnres tht is left behind with subttl resetins. Mst surgens prefer t lse the inisin nd shedule  seletive rteril liu stiultin with hepti venus spling t lte the tur site prir t  repet pertin. Lprspy using ultrsund nd enu- letin hs been suessful with  single tur f the bdy r til f the pnres, but pen surgery reins neessry fr turs in the hed f the pnres. In ptients with inperble funtining islet ell ri- n with nd withut hepti etstsis nd in pprxi- tely 510% f MEN 1 ses when subttl revl f the pnres hs filed t prdue ure, the tretent pprh is the se s fr ther types f pnreti neu- rendrine turs (pNETs). Dizxide is the tretent f hie in preventing hypglyei. Frequent rbhy- drte feedings (every 23 hurs) n ls be helpful, lthugh weight gin n bee  prble. Ststtin nlgs, tretide r lnretide, shuld be nsidered if dizxide is ineffetive r if there is tur prgressin. Surgery r ebliztin (blnd, he- nd rdi-) r ther- l bltin (rdifrequeny, irwve, nd rybltin) n be used t redue tur burden nd ls prvide syp- tti relief. Chetherpy regiens tht n be nsid- ered inlude bintin f streptzin, 5-flururil, nd dxrubiin; peitbine nd xlipltin; nd peitbine nd tezlide (Tble 393). Trgeted therpies ginst ultiple steps in the PI3K/AKT/Tr pth- wy hve been shwn t be helpful. Everlius, n inhibi- tr f Tr, is pprved fr tretent f dvned pNETs. Sunitinib hs been shwn t slw grwth f pNETs. Tret- ent with rdiistpes (indiu-111 r yttriu-90 r lutetiu-177) linked t  ststtin nlg hs been reprted t shw benefit in  prprtin f ptients.CMDT22_Ch27_p1212-p1255.indd  1253 29/06/21 8:53 PMCHAPTEr 271254 CMDT 2022NO NISLET CELL TUMOR HYPOGLYCEMIAThese  rre uses f hypglyei inlude esenhyl turs suh s retrperitnel srs, heptellulr rins, drenrtil rins, nd isellneus epithelil-type turs. The turs re frequently lrge nd redily plpted r visulized n CT sns r MRI. In ny ses the hypglyei is due t the expres- sin nd relese f n inpletely pressed insulin-like grwth ftr 2 (IGF-2) by the tur. The dignsis is supprted by lbrtry duent- tin f seru insulin levels belw 5 irunit/L with pls gluse levels f 45 g/dL (2.5 l/L) r lwer. Vlues fr grwth hrne nd IGF-1 re ls deresed. Levels f IGF-2 y be inresed but ften re nrl in quntity, despite the presene f the iture, higher- leulr-weight fr f IGF-2, whih n be deteted nly by speil lbrtry tehniques. Nt ll the ptients with nnislet ell tur hypglye- i hve elevted pr-IGF-2. Etpi insulin prdutin hs been desribed in brnhil rin, vrin rin, nd sll ell rin f the ervix. Hypglyei due t IgF-1 relesed fr  etstti lrge ell rin f the lung hs ls been reprted. GLP-1sereting turs (vr- in nd pNETs) n ls use hypglyei by stiulting insulin relese fr nrl pnreti islets. The prgnsis fr these turs is generlly pr, nd surgil revl shuld be ttepted when fesible. Dietry ngeent f the hypglyei is the insty f edil tretent, sine dizxide is usully ineffetive.PO STPRANDIAL HYPOGLYCEMIA 1. Hypoglycemia Following Gastic SugeyH ypglyei seties develps in ptients wh hve undergne gstri surgery (eg, gstrety, vgty, pylrplsty, gstrjejunsty, Nissn fundplitin, Billrth II predure, nd Rux-en-Y), espeilly when they nsue fds ntining high levels f redily bsrbble rbhydrtes. This lte duping syndre urs but 13 hurs fter  el nd is  result f rpid delivery f high nentrtin f rbhydrtes in the prxil sll bwel nd rpid bsrptin f gluse. The hyperinsulinei respnse t the high rbhydrte ld uses hypglyei. Exessive relese f gstrintestinl hrnes suh s GLP-1 likely ply  rle in the hyperin- sulinei respnse. The sypts inlude lightheded- ness, sweting, nfusin nd even lss f nsiusness fter eting  high rbhydrte el. T duent hyp- glyei, the ptient shuld nsue  el tht leds t sypts during everydy life. An rl gluse tlerne test is nt reended beuse ny nrl persns hve flse-psitive test results. There hve been se reprts f insulin nd nninsulin pnretge- nus hypglyei syndre in ptients with hypglye- i pst Rux-en-Y surgery. It is unler hw ften this urs. A reful histry y identify ptients wh hve  histry f hypglyei with exerise r issed els, nd these individuls y require  frl 72-hur fst t rule ut n insulin.Tretent fr sendry duping inludes dietry difitin, but this y be diffiult t sustin. Ptients n try re frequent els with sller prtins f less rpidly digested rbhydrtes. Alph-glusidse therpy y be  useful djunt t  lw rbhydrte diet. Otre- tide 50 g dinistered subutneusly tw r three ties  dy 30 inutes prir t eh el hs been reprted t iprve sypts due t lte duping syndre. Tret- ent with exendin 9-39,  GLP-1 reeptr gnist, y prevent pst gstri bypss hypglyei. SGLT2 inhibitrs y elirte the pstprndil gluse rise, the subse- quent insulin respnse, nd hypglyei. There is  reprt f  ptient with Rux-en-Y surgery wh hd plete reslutin f bth hyperglyei nd hypglyei when she ws given ngliflzin. Vrius surgil predures t dely gstri eptying hve been reprted t iprve sypts but lng-ter effiy studies re lking.2.  Functional Alimentay HypoglycemiaP tients hve sypts suggestive f inresed syp- theti tivity, inluding nxiety, wekness, trer, swet- ing r plpittins fter els. Physil exintin nd lbrtry tests re nrl. It is nt reended tht ptients with sypts suggestive f inresed syp- theti tivity underg either  prlnged rl gluse tl- erne test r  ixed el test. Insted, the ptients shuld be given he bld gluse nitrs (with eries) nd instruted t nitr fingerstik gluse levels t the tie f sypts. Only ptients wh hve sypts when their fingerstik bld gluse is lw (less thn 50 g/dL) nd wh hve reslutin f sypts when the gluse is rised by eting rpidly relesed rb- hydrte need dditinl evlutin. Ptients wh d nt hve evidene fr lw gluse levels t tie f sypts re generlly ressured by their findings. Cunseling nd supprt shuld be the instys in therpy, with dietry nipultin nly n djunt.3.  Occult DiabetesThis  nditin is hrterized by  dely in erly insulin relese fr pnreti B ells, resulting in initil exgger- tin f hyperglyei during  gluse tlerne test. In respnse t this hyperglyei, n exggerted insulin relese prdues  lte hypglyei 45 hurs fter inges- tin f gluse. These ptients re ften bese nd fre- quently hve  fily histry f dibetes ellitus. Ptients with this type f pstprndil hypglyei ften respnd t redued intke f refined sugrs with ultiple, sped, sll feedings high in dietry fiber. In the bese, tretent is direted t weight redutin t hieve idel weight. These ptients shuld be nsidered t hve predibetes r erly dibetes (type 1 r 2) nd dvised t hve peridi edil evlutins.4.  Autoimmune HypoglycemiaP tients with utiune hypglyei hve erly pstprn- dil hyperglyei fllwed by hypglyei 34 hurs lter. The hypglyei is ttributed t  dissitin f insulin- ntibdy iune plexes, relesing free insulin.CMDT22_Ch27_p1212-p1255.indd  1254 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1255 CMDT 2022The  disrder is ssited with ethizle tretent fr Grves disese, lthugh it n ls ur in ptients treted with vrius ther sulfhydryl-ntining edi- tins (ptpril, peniilline) s well s ther drugs suh s hydrlzine, isnizid, nd prinide. In dditin, it hs been reprted in ptients with utiune disrders suh s rheutid rthritis, systei lupus erythetsus, nd plyysitis s well s in pls ell yel nd ther pls ell dysrsis where prprteins r ntibdies rss-ret with insulin. There is ls n ssitin with the HLA lss II lleles (DRB1*0406, DQA1*0301, nd DQB1*0302). These lleles re 10 t 20 ties re n in Jpnese nd Kren ppultins, whih explins why the disrder hs been reprted stly in Jpnese ptients. High titers f insulin utntibdies, usully IgG lss, n be deteted. Insulin, prinsulin, nd C-peptide levels y be elevted, but the results y be errneus beuse f the interferene f the insulin ntibdies with the iu- nssys fr these peptides. In st ses, the hypglyei is trnsient nd usully reslves spntneusly within 36 nths f dignsis, prtiulrly when the ffending editins re stpped. The st nsistent therpeuti benefit in ngeent f this syndre hs been hieved by dietry tretent with sll, frequent lw-rbhydrte els. Prednisne (3060 g rlly dily) hs been used t lwer the titer f insulin ntibdies.F ACTITIOUS HYPOGLYCEMIAF titius hypglyei y be diffiult t duent. A suspiin f self-indued hypglyei is supprted when the ptient is ssited with the helth prfessins r hs ess t dibeti editins tken by  dibeti eber f the fily. The trid f hypglyei, high iunretive insulin, nd suppressed pls C-peptide iunretivity is pthgnni f exgenus insulin dinistrtin. Insu- lin nd C-peptide re sereted in  1:1 lr rti. A lrge frtin f the endgenus insulin is lered by the liver, wheres C-peptide, whih is lered by the kidney, hs  lwer etbli lerne rte. Fr this resn, the lr rti f insulin nd C-peptide in  hypglyei ptient shuld be less thn 1.0 in ses f insulin nd is greter thn 1.0 in ses f exgenus insulin dinistrtin (see Hypglyei Due t Pnreti B Cell Turs, bve). When sulfnylures, repglinide, nd nteglinide re sus- peted s  use f ftitius hypglyei,  pls level f these editins t detet their presene y be required t distinguish lbrtry findings fr thse f insulin.HYP OGLYCEMIA DUE TO INSULIN RECEPTOR ANTIBODIESH ypglyei due t insulin reeptr utntibdies is n extreely rre syndre; st ses hve urred in wen ften with  histry f utiune disese. Alst ll f these ptients hve ls hd episdes f insulin- resistnt dibetes nd nthsis nigrins. Their hypglye- i y be either fsting r pstprndil nd is ften severend is ttributed t n gnisti tin f the ntibdy n the insulin reeptr. Blne between the ntgnisti nd g- nisti effets f the ntibdies deterines whether insulin- resistnt dibetes r hypglyei urs. Hypglyei ws fund t respnd t rtisterid therpy but nt t plspheresis r iunsuppressin.ME DICATION- & ETHANOL-INDUCED HYPOGLYCEMIAA  nuber f editins prt fr dibeti editins n sinlly use hypglyei. Cn ffenders inlude the flurquinlnes suh s gtiflxin nd lev- flxin, pentidine, quinine, ACE inhibitrs, sliyltes nd bet-drenergi blking gents. The flurquinlnes, prtiulrly gtiflxin, hve been ssited with bth hypglyei nd hyperglyei. It is thught tht the drug ts n the ATP sensitive ptssiu hnnels in the bet ell. Hypglyei is n erly event, nd hyperglyei urs severl dys int therpy. Intrvenus pentidine is yt- txi t bet ells nd uses ute hyperinsulinei nd hypglyei fllwed by insulinpeni nd hyperglyei. Fsting ptients tking nnrdiseletive bet-blkers n hve n exggerted hypglyei respnse t strvtin. The bet-blkde inhibits ftty ids nd glunegenesis substrte relese nd redues pls glugn respnse. Therpy with ACE inhibitrs inreses the risk f hypgly- ei in ptients wh re tking insulin r sulfnylures presubly beuse these drugs inrese sensitivity t iru- lting insulin by inresing bld flw t the usle. Se piids use hypglyei. Trdl use hs been ssi- ted with inresed risk f hspitliztin fr hypglyei. Methdne verdse hs ls been reprted t use hyp- glyei nd  rpid dse esltin f ethdne in ner ptients n lwer gluse levels. Ethnl-ssited hypglyei y be due t hepti lhl dehydrgense tivity depleting NAD. The resul- tnt hnge in the redx stteinrese in NADH t NAD+rtiuses  prtil blk t severl pints in the glunegeni pthwy. With prlnged strvtin, gly- gen reserves bee depleted within 1824 hurs nd hepti gluse utput bees ttlly dependent n glu- negenesis. Under these irustnes,  bld nen- trtin f ethnl s lw s 45 g/dL (9.8 l/L) n indue prfund hypglyei by blking glunegen- esis. Neurglypeni in  ptient whse breth sells f lhl y be istken fr lhli stupr. Preventin nsists f dequte fd intke during ethnl ingestin. Therpy nsists f gluse dinistrtin t replenish glygen stres until glunegenesis resues. When sugr-ntining sft drinks re used s ixers t dilute lhl in beverges (gin nd tni, ru nd l), there sees t be  greter insulin relese thn when the sft drink lne is ingested nd  tendeny fr re f  lte hypglyei verswing t ur 34 hurs lter. Preventin wuld nsist f viding sugr ixers while ingesting lhl nd ensuring suppleentry fd intke t prvide sustined bsrptin.CMDT22_Ch27_p1212-p1255.indd  1255 29/06/21 8:53 PM1256 CMDT 2022Lipid Disorders 28Michael J. Blaha, MD, MPHThe  Lipid Hypothesis of cardiovascular disease (CVD) stating that cholesterol is causal in the development of atherosclerotic cardiovascular disease (ASCVD) and that lowering of cholesterol is associated with lower cardiovas- cular event ratesis widely accepted throughout the medi- cal community. For patients with known CVD (secondary prevention), studies have shown that cholesterol lowering leads to a consistent reduction in total mortality and in recurrent cardiovascular events in men and women; other studies have documented lowered mortality and events in middle-aged and older patients. Among patients without CVD (primary prevention), the data are generally consis- tent, with rates of cardiovascular events, heart disease mortality, and all-cause mortality differing among studies. Treatment guidelines have been designed to assist clini- cians in selecting patients for cholesterol-lowering therapy based predominantly on their overall risk of developing CVD as well as their baseline cholesterol levels. There are several genetic disorders that provide insight into the pathogenesis of lipid-related diseases. Familial hypercholesterolemia, rare in the homozygous state (about one per million), causes markedly high low-density lipoprotein (LDL) levels and early CVD. The most common genetic defects involve absent or defective LDL receptors, resulting in unregulated LDL metabolism, genetic muta- tions of apolipoprotein B, or gain of function in proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that regulates breakdown of LDL receptors. Patients with two abnormal genes (homozygotes) have extremely high levelsup to eight times normaland present with ath- erosclerotic disease in childhood. Patients with two abnor- mal genes (homozygotes) may require liver transplantation or plasmapheresis to correct their severe lipid abnormali- ties; early treatment with statins appears to confer lifetime benefits in such patients. Those with one defective gene (heterozygotes) have LDL concentrations up to two or three times normal; persons with this condition may develop CVD in their 30s or 40s. Another rare condition is caused by an abnormality of lipoprotein lipase, the enzyme that enables peripheral tissues to take up triglyceride from chylomicrons and very- low-density lipoprotein (VLDL) particles. Patients with this condition, one cause of familial chylomicronemiasyndrome, have marked hypertriglyceridemia with recur- rent pancreatitis and hepatosplenomegaly in childhood. Numerous other genetic abnormalities of lipid metabo- lism are named for the abnormality noted when serum is electrophoresed (eg, dysbetalipoproteinemia, character- ized by elevated levels of remnant lipoproteins) or from polygenic combinations of lipid abnormalities in families (eg, familial combined hyperlipidemia). When to Refer Known genetic lipid disorders. Striking family history of hyperlipidemia or premature atherosclerosis. Extremely high serum LDL cholesterol or triglycerides, or extremely low serum high-density lipoprotein (HDL) cholesterol.Chyzh yk V et al. Familial chylomicronemia syndrome: a rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis. Trends Cardiovasc Med. 2020;30:80. [PMID: 31003756] Hegele RA et al. Rare dyslipidaemias, from phenotype to geno- type to management: a European Atherosclerosis Society task force consensus statement. Lancet Diabetes Endocrinol. 2020;8:50. [PMID: 31582260] Khera AV et al. What is familial hypercholesterolemia, and why does it matter? Circulation. 2020;141:1760. [PMID: 32479201] Mortensen MB et al. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary pre- vention cohort. Lancet. 2020;396:1644. [PMID: 33186534] Sniderman AD et al. Apolipoprotein B particles and cardiovas- cular disease: a narrative review. JAMA Cardiol. 2019;4:1287. [PMID: 31642874]LI PID FRACTIONS & THE RISK OF CORONARY HEART DISEASEIn  serum, cholesterol is carried primarily on three different lipoproteinsthe VLDL, LDL, and HDL molecules. Total cholesterol equals the sum of these three components: =  + +Total cholesterol  HDL cholesterol  VLDL cholesterol LDL cholesterolCMDT22_Ch28_p1256-p1266.indd  1256 29/06/21 8:55 PM",
                  "DIABETES MELLITUS & HYPOGLYCEMIA1213 CMDT 2022Whih  envirnentl ftr is respnsible fr the inresed risk is nt knwn. Brestfeeding in the first 6 nths f life ppers t be prtetive. There is uu- lting evidene tht iprveents in publi helth nd redued infetins (espeilly prsiti) led t iune syste dysregultin nd develpent f utiune disrders suh s sth nd type 1 dibetes. Chek pint inhibitr iuntherpies fr dvned lignnies, suh s nivlub, pebrlizub, nd ipiliub, n preipitte utiune disrders, inlud- ing type 1 dibetes. The nset f dibetes n be rpid nd the ptients frequently hve dibeti ketidsis t pre- senttin. Autntibdies ginst islet ntigens re nly present in but 50% f ptients. Ptients reeiving these drugs shuld be refully nitred fr the develpent f dibetes. Apprxitely 5% f subjets hve n evidene f pn- reti B ell utiunity t explin their insulinpeni nd ketidsis. This subgrup hs been lssified s idipthi type 1 dibetes nd designted s type 1B.  Althugh nly  inrity f ptients with type 1 dibetes fll int this grup, st f these individuls re f Asin r Afrin rigin. Abut 4% f the West Afrins with ketsis-prne dibetes re hzygus fr  uttin in PAX-4 (Arg133Trp ) trnsriptin ftr tht is essentil fr the develpent f pnreti islets.B.  Type 2 Diabetes MellitusT ype 2 dibetes is due t nn-iune uses f pnreti B ell lss with vrible degree f tissue insensitivity t insulin, tht is, insulin resistne. The residul bet ell funtin is suffiient t prevent ketidsis but is inde- qute t prevent the hyperglyei. This fr f dibetes used t ur predinntly in dults, but it is nw re frequently enuntered in hildren nd dlesents.Geneti nd envirnentl ftrs bine t use bth the bet ell lss nd the insulin resistne. Mst epi- deilgi dt indite strng geneti influenes, sine in nzygti twins ver 40 yers f ge, nrdne develps in ver 70% f ses within  yer whenever type 2 dibetes develps in ne twin. Gene wide ssitin studies hve identified 143 risk vrints nd puttive regu- ltr ehniss fr type 2 dibetes. A signifint nuber f the identified li pper t de fr prteins tht hve  rle in bet ell funtin r develpent. One f the geneti li with the lrgest risk effet is TCF7L2 . This gene des fr  trnsriptin ftr invlved in the WNT sig- nling pthwy tht is required fr nrl pnreti develpent. Obesity is the most important environmental factor causing insulin resistance. The degree nd prevlene f besity vries ng different ril grups with type 2 dibetes. While besity is pprent in n re thn 30% f Chinese nd Jpnese ptients with type 2, it is fund in 6070% f Nrth Aerins, Eurpens, r Afrins with type 2 nd pprhes 100% f ptients with type 2 ng Pi Indins r Pifi Islnders fr Nuru r S. Viserl besity, due t uultin f ft in the entl nd esenteri regins, rreltes with insulin resistne; subutneus bdinl ft sees t hve less f n ssitin with insulin insensitivity. There re ny ptients with type 2 dibetes wh, while nt vertly bese, hve inresed viserl ft; they re tered the etbli- lly bese.  Exerise y ffet the depsitin f viserl ft s suggested by CT sns f Jpnese wrestlers, whse extree besity is predinntly subutneus. Their dily vigrus exerise prgr prevents uultin f viserl ft, nd they hve nrl seru lipids nd eugly- ei despite dily intkes f 50007000 kl nd develp- ent f ssive subutneus besity.C.  Other Specific Types of Diabetes Mellitus1.  Maturityonset diabetes of the young (MODY) This subgrup f ngeni disrders is hrterized by nn- insulin requiring dibetes with utsl dinnt inher- itne nd n ge t nset f 25 yers r yunger. Ptients re nnbese, nd their hyperglyei is due t ipired gluse-indued seretin f insulin. Six types f MODY hve been desribed (Tble 271). Exept fr MODY 2, in whih  glukinse gene is defetive, ll ther types invlve uttins f  nuler trnsriptin ftr tht regultes islet gene expressin. Ptients yunger thn 30 yers with endgenus insulin prdutin (urinry C-peptide/retinine rti f 0.2 nl/l r higher) nd negtive utntibdies re ndidtes fr geneti sreening fr MODY. The enzye glukinse is  rte- liiting step in glylysis nd deterines the rte f de- nsine triphsphte (ATP) prdutin fr gluse nd the insulin seretry respnse in the bet ell. MODY 2, due t glukinse uttins, is usully quite ild, ssi- ted with nly slight fsting hyperglyei nd few if ny irvsulr dibeti plitins. MODY 3, due t uttins in hepti nuler ftr 1 lph, is the st n fr, unting fr tw-thirds f ll MODY ses. Initilly, ptients with MODY 3 re respnsive tTable 271. Other specific types of diabetes mellitus.Genetic  defects of pancreatic B cell function MODY 1 (HNF-4alpha); rare MODY 2 (glucokinase); less rare MODY 3 (HNF-1alpha); accounts for two-thirds of all MODY MODY 4 (PDX1); very rare MODY 5 (HNF-1beta); very rare MODY 6 (neuroD1); very rare Mitochondrial DNA Wolfram syndrome Genetic defects in insulin action Type A insulin resistance Leprechaunism Rabson-Mendenhall syndrome Lipoatrophic diabetes Diseases of the exocrine pancreas Endocrinopathies Drug- or chemical-induced diabetes Other genetic syndromes (Down, Klinefelter, Turner, others) sometimes associated with diabetes HNF, hepatic nuclear factor; MODY, maturity-onset diabetes of the young; PDX1, pancreatic duodenal homeobox 1.CMDT22_Ch27_p1212-p1255.indd  1213 29/06/21 8:53 PMCHAPTEr 271214 CMDT 2022sulfn ylure therpy but the linil urse is f prgres- sive bet ell filure nd eventul need fr insulin therpy. Muttins in bth lleles f glukinse present with re severe nentl dibetes. Muttin in ne llele f the pn- reti dudenl hebx 1 (PDX1) uses dibetes usu- lly t  lter ge (~ 35 yers) thn ther frs f MODY; uttins in bth lleles f PDX1 use pnreti genesis. 2. Diabetes mellitus associated with a mutation of mito chondrial DNA Sine sper d nt ntin ithn- dri, nly the ther trnsits ithndril genes t her ffspring. Dibetes due t uttins f ithndril DNA urs in less thn 2% f ptients with dibetes. The st n use is the A3243G uttin in the gene ding fr the tRNA (Leu, UUR). Dibetes usully devel- ps in these ptients in their lte 30s, nd hrteristilly, they ls hve hering lss (ternlly inherited dibetes nd defness [MIDD]). 3. Wolfram syndrome Wlfr syndre is n uts- l reessive neurdegenertive disrder first evident in hildhd. It nsists f dibetes insipidus, dibetes elli- tus, pti trphy, nd defness, hene the rny DID- MOAD. It is due t uttins in  gene ned WFS1 , whih endes  100.3 KD trnsebrne prtein ll- ized in the endplsi retiulu. Crnil dibetes insipi- dus nd sensrineurl defness develp during the send dede in 6075% f ptients. Ureterhydrnephrsis, neurgeni bldder, erebellr txi, peripherl neurp- thy, nd psyhitri illness develp lter in ny ptients. 4. Autosomal recessive syndromes Hzygus ut- tins in  nuber f pnreti trnsriptin ftrs, NEU- ROG3, PTF1A, RFX6 , nd GLI-similar 3 (GLIS3) , use nentl r hildhd dibetes. Hzygus PTF1A uttins result in bsent pnres nd erebellr trphy; NEUROG3 uttins use severe lbsrptin nd dibetes befre puberty. Hzygus uttins in RFX6 use the Mithell-Riley syndre hrterized by bsene f ll islet ell types prt fr pnreti ply- peptide ells, hypplsi f the pnres nd gllbldder, nd intestinl tresi. GLIS3 gene plys  rle in trnsrip- tin f insulin gene, nd hzygus uttins use nentl dibetes nd ngenitl hypthyridis. The gene EIF2AK3 endes PKR-like ER kinse (PERK), whih ntrls ne f the pthwys f the unflded prtein respnse. Absene f PERK leds t indequte respnse t ER stress nd elerted bet ell pptsis. Ptients with uttin in this gene hve nentl dibetes, epiphysel dysplsi, develpentl dely, nd liver nd kidney dys- funtin (Wltt-Rllisn syndre). 5. Diabetes mellitus secondary to other causes End- rine turs sereting grwth hrne, glurtiids, tehlines, glugn, r ststtin n use glu- se intlerne (Tble 272). In the first fur f these situ- tins, peripherl respnsiveness t insulin is ipired. With exess f glurtiids, tehlines, r glu- gn, inresed hepti utput f gluse is  ntributry ftr; in the se f tehlines, deresed insulin relese is n dditinl ftr in prduing rbhydrteintlerne, nd with ststtin, inhibitin f insulin seretin is the jr ftr. Dibetes inly urs in individuls with underlying defets in insulin seretin, nd hyperglyei typilly reslves when the hrne exess is reslved. High-titer nti-insulin reeptr ntibdies tht inhibit insulin binding use  linil syndre hrterized by severe insulin resistne, gluse intlerne r dibetes ellitus, nd nthsis nigrins. These ptients usully hve ther utiune disrders. There re reprts f spntneus reissin r reissin with yttxi therpy. Mny drugs re ssited with rbhydrte intler- ne r frnk dibetes (Tble 272). The drugs t by deresing insulin seretin r by inresing insulin resis- tne r bth. Cylsprine nd trlius ipir insulin seretin; sirlius priniplly inreses insulin resistne. These gents ntribute t the develpent f new-nset dibetes fter trnsplnttin. Crtisterids inrese insulin resistne but y ls hve n effet n bet ell funtin; in  se ntrl study nd  lrge ppultin hrt study, rl rtisterids dubled the risk fr develpent f dibetes. Thizide diuretis nd bet- blkers destly inrese the risk fr dibetes. Treting the hypklei due t thizides y reverse the hyper- glyei. Atypil ntipsyhtis, prtiulrly lnzpine nd lzpine, re ssited with inresed risk f gluse intlerne. These drugs use weight gin nd insulin resistne but y ls ipir bet ell funtin; n inrese in rtes f dibeti ketidsis (DKA) hs been reprted. Alpelisib is  phsphtidylinsitl-3-kinse (PI3K) inhibitr nd is pprved fr use in bintin with fulvestrnt fr hrne reeptrpsitive, HER2- negtive, PIK3CA -utted brest ner. PI3K is  p- nent f the insulin signling pthwy, nd hyperglyei is  n side effet f lpelisib tretent. Chrni pnretitis r subttl pnretety redues the nuber f funtining B ells nd n result in  etbli derngeent very siilr t tht f geneti type 1 dibetes exept tht  nitnt redu- tin in pnreti A ells y redue glugn seretin s tht reltively lwer dses f insulin repleent re needed.Table 272. Secondary causes of hyperglycemia.Hypeglycemia  due to tissue insensitivity to insulin Medications (corticosteroids, sympathomimetic drugs, niacin, alpelisib, sirolimus) Hormonal tumors (acromegaly, Cushing syndrome, glucagonoma, pheochromocytoma) Liver disease (cirrhosis, hemochromatosis) Muscle disorders (myotonic dystrophy) Adipose tissue disorders (lipodystrophy, truncal obesity) Hypeglycemia due to educed insulin secetion Medications (thiazide diuretics, phenytoin, pentamidine, calcineurin inhibitors, atypical antipsychotics) Hormonal tumors (somatostatinoma, pheochromocytoma) Pancreatic disorders (pancreatitis, hemosiderosis, hemochromatosis)CMDT22_Ch27_p1212-p1255.indd  1214 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1215 CMDT 2022 Metabolic Syndrome (Insulin Resistance Syndrome)The  ter etbli syndre hs been dvted t iden- tify individuls wh were t higher risk fr develpent f dibetes nd rdivsulr disese. Criteri inluded wist iruferene, gluse levels, bld pressure, trigly- erides, nd HDL hlesterl. There is, hwever, n unify- ing pthphysilgi bsis fr the syndre, nd in 2010,  WHO expert ittee reprted tht the syndre lked utility s  dignsti r ngeent tl. They bserved tht there ws nly dest ssitin between etbli syndre nd rdivsulr disese, nd the definitin ws utperfred by trditinl rdivsulr risk preditin lgriths suh s the Fringh risk sre. Siilrly, fsting gluse nveys  greter risk f inident dibetes thn the etbli syndre. There is ls n evidene tht hyperinsulinei nd insulin resis- tne ply  diret rle in these etbli bnrlities. Clinical Trials about Optimum Diabetic Glucose ControlFindings  f the Dibetes Cntrl nd Cplitins Tril nd f the United Kingd Prspetive Dibetes Study hve nfired the benefiil effets f iprved glyei ntrl in bth type 1 nd type 2 dibetes.A.  Type 1 DiabetesThe Dia betes Control and Complications Trial (DCCT),  lng-ter therpeuti study invlving 1441 ptients with type 1 dibetes ellitus, reprted tht ner nrliz- tin f bld gluse resulted in  dely in the nset nd  jr slwing f the prgressin f estblished irvs- ulr nd neurpthi plitins f dibetes. In hlf f the ptients,  en heglbin A1f 7.2% (nrl: less thn 6%) nd  en bld gluse f 155 g/dL (8.6 l/L) were hieved using intensive therpy, while in the nventinlly treted grup, HbA1 verged 8.9% with n verge bld gluse f 225 g/dL (12.5 l/L). Over the study perid, whih verged 7 yers, there ws n pprxitely 60% redutin in risk between the tw grups in regrd t dibeti retinpthy, nephrpthy, nd neurpthy. The intensively treted grup ls hd  nnsignifint redutin in the risk f rvsulr disese f 41% (95% CI, 10% t 68%). Intensively treted ptients hd  threefld greter risk f serius hypglyei s well s  greter tendeny twrd weight gin. Hwever, there were n deths definitely ttributble t hypglyei in ny persns in the DCCT study, nd n evidene f psthypglyei gnitive dge ws deteted. Prtiipnts in the DCCT study were subsequently enrlled in  fllw-up bservtinl study, the Epideil- gy f Dibetes Interventins nd Cplitins (EDIC) study. Even thugh the between-grup differenes in en HbA1nrrwed ver 4 yers, the grup ssigned t inten- sive therpy hd  lwer risk f retinpthy t 4 yers, irlbuinuri t 78 yers, nd ipired GFR (less thn 60 L/in/1.73 2) t 22 yers f ntinued studyfllw-up. Mrever, by the end f the 11-yer fllw-up perid, the intensive therpy grup hd signifintly redued their risk f ny rdivsulr disese events by 42% (95% CI, 9% t 23%; P= 0.02). Thus, it sees tht the benefits f gd gluse ntrl persist even if ntrl deterirtes t  lter dte. The generl nsensus f the ADA is tht intensive insulin therpy ssited with prehensive self- ngeent trining shuld be stndrd therpy in ptients with type 1 dibetes ellitus fter the ge f puberty. Exeptins inlude thse with dvned hrni kidney disese nd lder dults sine the detrientl risks f hypglyei utweigh the benefits f tight glyei ntrl in these grups.B.  Type 2 DiabetesThe  United Kingdom Prospective Diabetes Study (UKPDS),  ultienter study, ws designed t estblish whether the risk f rvsulr r irvsulr - plitins uld be redued by intensive bld gluse ntrl with rl hypglyei gents r insulin nd whether ny prtiulr therpy ws re benefiil thn the ther in type 2 dibeti ptients. Intensive tretent with either sulfnylures, etfr- in, bintins f thse tw, r insulin hieved en HbA1levels f 7%. This level f glyei ntrl deresed the risk f irvsulr plitins (retinpthy nd nephrpthy) in prisn with nventinl therpy (stly diet lne), whih hieved en levels f HbA1 f 7.9%. Weight gin urred in intensively treted ptients exept when etfrin ws used s ntherpy. N dverse rdivsulr utes were nted regrdless f the therpeuti gent. In the verweight r bese sub- grup, etfrin therpy ws re benefiil thn diet lne in reduing the nuber f ptients wh suffered yrdil infrtins nd strkes. Hypglyei re- tins urred in the intensive tretent grups, but nly ne deth fr hypglyei ws duented during 27,000 ptient-yers f intensive therpy. Tight ntrl f bld pressure (edin vlue 144/82  Hg vs 154/87  Hg) substntilly redued the risk f irvsulr disese nd strke but nt y- rdil infrtin. In ft, reduing bld pressure by this unt hd substntilly greter ipt n irvsulr utes thn tht hieved by lwering HbA1fr 7.9% t 7%. An epideilgi nlysis f the UKPDS dt shwed tht every 10  Hg derese in en systli bld pressure ws ssited with 11% redutin in risk fr yrdil infrtin. Mre thn hlf f the ptients needed tw r re editins fr dequte therpy f their hypertensin, nd there ws n denstrble dvn- tge f ngitensin-nverting enzye (ACE) inhibitr therpy ver therpy with bet-blkers with regrd t dibetes end pints. Use f  liu hnnel blker dded t bth tretent grups ppered t be sfe ver the lng ter in this dibeti ppultin despite se ntrversy in the literture but its sfety in ptients with dibetes. Like the DCCT trilists, the UKPDS reserhers per- fred pst-tril nitring t deterine whether thereCMDT22_Ch27_p1212-p1255.indd  1215 29/06/21 8:53 PMCHAPTEr 271216 CMDT 2022were  lng-ter benefits f hving been in the intensively treted gluse nd bld pressure rs f the study. The intensively treted grup hd signifintly redued risk f yrdil infrtin (15%, P= 0.01) nd deth fr ny use (13%, P= 0.007) during the fllw-up perid. The subgrup f verweight r bese subjets wh were ini- tilly rndized t etfrin therpy shwed sustined redutin in risk f yrdil infrtin nd deth fr ny use in the fllw-up perid. Unlike the sustined benefits seen with gluse ntrl, there were n sustined benefits fr hving been in the re tightly ntrlled bld pressure grup. Bth bld pressure grups were t siilr risk fr irvsulr events nd dibetes-relted end pints during the fllw-up perid. Thus, the fllw-up f the UKPDS type 2 dibetes hrt shwed tht, s in type 1 dibetes, the benefits f gd gluse ntrl persist even if ntrl deterirtes t  lter dte. Bld pressure benefits, hwever, lst nly s lng s the bld pressure is well ntrlled. Diabetes Prevention TrialsA.  Prevention of Type 1 DiabetesAt  the tie f dignsis f type 1 dibetes, there reins signifint B ell pnreti funtin. This explins why sn fter dignsis, the dibetes ges int prtil linil reissin nd little r n insulin is required (hneyn). The linil reissin is shrt- lived, hwever, nd eventully ptients lse ll B ell fun- tin nd hve re lbile gluse ntrl. Studies hve been perfred t prlng this prtil linil reissin using iundultry gents. The CD3 plex is the jr signl-trnsduing eleent f the T ell reep- tr, nd the nti-CD3 ntibdies re believed t dulte the utiune respnse by seletively inhibiting the pthgeni T ells r by induing regultry T ells. Phse 1/2 nd 2/3 linil trils f hunized nlnl nti- bdies ginst CD3, hOKT3g (Al-Al) (tepli- zub), nd ChAglyCD3 (telixizub) delyed but did nt pletely rrest the deline in insulin prdutin in ptients with newly dignsed type 1 dibetes. A siilr phse 2 linil tril using teplizub ws undertken in nndibeti reltives f ptients with type 1 dibetes wh hd tw r re dibetes-relted ntibdies nd gluse intlerne. In the 5 yers fter rndiztin, 43% f the ptients reeiving teplizub nd 72% f the pleb grup develped dibetes.B.  Prevention of Type 2 DiabetesThe  Dibetes Preventin Prgr studied whether tret- ent with either diet nd exerise r etfrin uld prevent the nset f type 2 dibetes in verweight en nd wen ged 2585 yers wh hd ipired gluse tler- ne. Interventin with  lw-ft diet nd 150 inutes f derte exerise (equivlent t  brisk wlk) per week redued the risk f prgressin t type 2 dibetes by 71%. Prtiipnts wh tk etfrin 850 g twie dily redued their risk f develping type 2 dibetes by 31%, but this interventin ws reltively ineffetive in thse wh were either less bese r in the lder ge grup.Eighty-eight perent f the persns in the Dibetes Preven- tin Prgr eleted t ntinue fllw up in the Dibetes Preventin Prgr Oute Study. At 15 yers f fllw up, the uultive inidene f dibetes ws 55% in the lifestyle grup nd 62% in the ntrl grup. Clinical FindingsA.  Symptoms and Signs1.  Type 1 diabetes A hrteristi sypt plex f hypersllity nd hyperketnei fr the uul- tin f irulting gluse nd ftty ids typilly presents in ptients with type 1 dibetes. When bslute insulin defiieny is f ute nset, there is brupt inrese in uri- ntin, thirst, blurred visin, weight lss, presthesis, nd ltered level f nsiusness. Ketidsis exerbtes the dehydrtin nd hypersllity by prduing nrexi nd nuse nd viting, interfering with rl fluid repleent. a. Increased urination and thirst These sypts re nsequenes f sti diuresis sendry t sus- tined hyperglyei. The diuresis results in  lss f glu- se s well s free wter nd eletrlytes in the urine. b. Blurred vision As the lenses re expsed t hyper- slr fluids, blurred visin ften develps. c. Weight loss Despite nrl r inresed ppetite, weight lss is  n feture f type 1 when it develps subutely. The weight lss is initilly due t depletin f wter, glygen, nd triglyerides; therefter, redued us- le ss urs s in ids re diverted t fr gluse nd ketne bdies. Lss f subutneus ft nd usle wsting re fetures f re slwly develping insulin defiieny. Lwered pls vlue prdues sypts f psturl hyptensin, whih is  serius prgnsti sign. Ttl bdy ptssiu lss nd the generl tblis f usle prtein ntribute t the wekness. d. Paresthesias Presthesis y be present t the tie f dignsis, prtiulrly when the nset is subute. They reflet  teprry dysfuntin f peripherl sensry nerves, whih lers s insulin repleent restres glye- i levels lser t nrl, suggesting neurtxiity fr sustined hyperglyei. e. The level of consciousness shown by the patient The ptients level f nsiusness n vry depending n the degree f hypersllity. When insulin defiieny develps reltively slwly nd suffiient wter intke is intined, ptients rein reltively lert nd physil findings y be inil. When viting urs in respnse t wrsening ketidsis, dehydrtin pr- gresses nd penstry ehniss bee indequte t keep seru sllity belw 320330 Os/L. Under these irustnes, stupr r even  y ur. The fruity breth dr f etne further suggests the dignsis f DKA. 2. Type 2 diabetes While inresed urintin nd thirst y be presenting sypts in se ptients with type 2 dibetes, ny ther ptients hve n insidius nset fCMDT22_Ch27_p1212-p1255.indd  1216 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1217 CMDT 2022hypergly ei nd re syptti initilly. This is pr- tiulrly true in bese ptients, whse dibetes y be deteted nly fter glysuri r hyperglyei is nted during rutine lbrtry studies. Osinlly, when the disese hs been ult fr se tie, ptients y hve evidene f neurpthi r rdivsulr plitins t the tie f presenttin. Hyperglyei hyperslr  n ls be present when the seru sllity exeeds 320330 Os/L; in these ses, ptients re pr- fundly dehydrted, hyptensive, lethrgi, r tse but withut the Kussul respirtins f ketidsis. a. Skin manifestations Chrni skin infetins re n. Generlized pruritus nd sypts f vginitis re frequently the initil plints f wen. Dibetes shuld be suspeted in wen with hrni ndidl vul- vvginitis. Blnpsthitis (infltin f the freskin nd glns in uniruised les) y ur. Other skin findings inlude nthsis nigrins. whih is ssited with signifint insulin resistne. The skin in the xill, grin, nd bk f nek is hyperpigented nd hyperkertti (Figure 271). Eruptive xnths n the flexr surfe f the libs nd n the buttks nd lipei retinlis due t hyperhylirnei n ur in ptients with unntrlled type 2 dibetes wh ls hve  filil fr f hypertriglyeridei. b. Body habitus Overweight r bese ptients fre- quently hve type 2 dibetes. Even thse wh re nt sig- nifintly bese ften hve hrteristi lliztin f ft depsits n the upper segent f the bdy (prtiulrly the bden, hest, nek, nd fe) nd reltively less ft n the ppendges, whih y be quite usulr. This en- tripetl ft distributin is hrterized by  high wist iruferene;  wist iruferene lrger thn 40 inhes (102 ) in en nd 35 inhes (88 ) in wen is ssi- ted with n inresed risk f dibetes. Mild hypertensin is ften present in bese ptients with dibetes. c. Obstetrical complications Type 2 dibetes shuld be nsidered in wen wh hve delivered bbieslrger thn 9 lb (4.1 kg) r hve hd plyhydrnis, pre- elpsi, r unexplined fetl lsses.B.  Laboratory Findings1. Urine  glucose A nvenient ethd t detet glus- uri is the pper strip ipregnted with gluse xidse nd  hrgen syste (Clinistix, Distix), whih is sen- sitive t s little s 100 g/dL (5.5 l) gluse in urine. A nrl renl threshld fr gluse s well s relible bldder eptying is essentil fr interprettin. Nndibeti glysuri (renl glysuri) is  benign syptti nditin wherein gluse ppers in the urine despite  nrl unt f gluse in the bld, either bslly r during  gluse tlerne test. Its use y vry fr uttins in the SGLT2 gene ding fr sdiu-gluse trnsprter 2 (filil renl glysuri) t ne ssited with dysfuntin f the prxil renl tubule (Fnni syndre, hrni kidney disese), r it y erely be  nsequene f the inresed ld f glu- se presented t the tubules by the elevted glerulr filtrtin rte (GFR) during pregnny. As ny s 50% f pregnnt wen nrlly hve denstrble sugr in the urine, espeilly during the third nd furth nths. This sugr is prtilly lwys gluse exept during the lte weeks f pregnny, when ltse y be present. 2. Urine and blood ketones Qulittive detetin f ketne bdies n be plished by nitrprusside tests (Aetest r Ketstix). Althugh these tests d nt detet bet-hydrxybutyri id, whih lks  ketne grup, the seiquntittive estitin f ketnuri thus btined is nnetheless usully dequte fr linil purpses. Mny lbrtries esure bet-hydrxybutyri id, nd there re eters vilble (Preisin Xtr; Nv Mx Plus) fr ptient use tht esures bet-hydrxybutyri id levels in pillry gluse sples. Bet-hydrxybutyrte levels greter thn 0.6 l/L require evlutin. Ptients with levels greter thn 3.0 l/L, equivlent t very lrge urinry ketnes, require hspitliztin. 3. Plasma or serum glucose The gluse nentrtin is 1015% higher in pls r seru thn in whle bld beuse struturl pnents f bld ells re bsent. A pls gluse level f 126 g/dL (7 l/L) r higher n re thn ne sin fter t lest 8 hurs f fsting is dignsti f dibetes ellitus (Tble 273). Fsting pls gluse levels f 100125 g/dL (5.66.9 l/L) re ssited with inresed risk f dibetes (ipired fsting gluse tlerne). 4. Oral glucose tolerance test If the fsting pls glu- se level is less thn 126 g/dL (7 l/L) when dibetes is nnetheless suspeted, then  stndrdized rl gluse tlerne test y be dne (Tble 273). In rder t pti- ize insulin seretin nd effetiveness, espeilly when ptients hve been n  lw-rbhydrte diet,  iniu f 150200 g f rbhydrte per dy shuld be inluded in the diet fr 3 dys preeding the test. The ptient shuld et nthing fter idnight prir t the test dy. On the rn- ing f the test, ptients re then given 75 g f gluse in 300 L f wter. The gluse ld is nsued within Figure 271. Acanthosis nigricans of the nape of the neck, with typical dark and velvety appearance. (Used, with permission, from Umesh Masharani, MB, BS, MRCP [UK].)CMDT22_Ch27_p1212-p1255.indd  1217 29/06/21 8:53 PMCHAPTEr 271218 CMDT 20225  inutes. The test is perfred in the rning beuse f diurnl vritin in rl gluse tlerne; ptients shuld nt ske r be tive during the test. Bld sples fr pls gluse re btined t 0 nd 120 inutes fter ingestin f gluse. Tble 273 pr- vides dignsti riteri fr dibetes ellitus bsed n the rl gluse tlerne test. An rl gluse tlerne test is nrl if the fsting venus pls gluse vlue is less thn 100 g/dL (5.6 l/L) nd the 2-hur vlue flls belw 140 g/dL (7.8 l/L). A fsting vlue f 126 g/dL (7 l/L) r higher r  2-hur vlue f greter thn 200 g/dL (11.1 l/L) is dignsti f di- betes ellitus. Ptients with  2-hur vlue f 140199 g/dL (7.811.1 l/L) hve ipired gluse tlerne. Flse- psitive results y ur in ptients wh re lnurished, bedridden, r fflited with n infetin r severe etinl stress. 5. Glycated hemoglobin (hemoglobin A1) measure ments Heglbin bees glyted by ketine retins between gluse nd ther sugrs nd the free in grups n the lph nd bet hins. Only glytin f the N-terinl vline f the bet hin iprts suffi- ient negtive hrge t the heglbin leule t llw seprtin by hrge dependent tehniques. These hrge- seprted heglbins re lletively referred t s heglbin A1(HbA1). The jr fr f HbA1is he- glbin A1(HbA1) where gluse is the rbhydrte. HbA1prises 46% f ttl heglbin A. Sine HbA1irultes within red bld ells whse life spn lsts up t 120 dys, it generlly reflets the stte f glyei ver the preeding 812 weeks, thereby prviding n iprved ethd f ssessing dibeti ntrl. The HbA1vlue, hwever, is weighted t re reent gluse levels (previus nth) nd this explins why signifint hnges in HbA1re bserved with shrt-ter (1 nth) hnges in en pls gluse levels. Mesureents shuld be de in ptients with either type f dibetes ellitus t 3- t 4-nth intervls. In ptients nitring their wn bld gluse levels, HbA1vlues prvide  vluble hek n the ury f nitring. In ptientswh d nt nitr their wn bld gluse levels, HbA1 vlues re essentil fr djusting therpy. The A1Derived Averge Gluse Study reprted tht the reltinship between verge gluse in the previus 3 nths nd HbA1ws (28.7  HbA1)  46.7. There is, hwever, sub- stntil individul vribility; fr HbA1vlues between 6.9% nd 7.1%, the gluse levels rnge fr 125 g/dL t 205 g/dL (6.911.4 l/L; 95% CIs). Fr HbA1f 6%, the en gluse levels rnge fr 100 g/dL t 152 g/dL (5.58.5 l/L); nd fr 8% they rnge fr 147 g/dL t 217 g/dL (8.112.1 l/L). Fr this resn, utin shuld be exerised in estiting verge gluse levels fr esured HbA1. The ury f HbA1vlues n be ffeted by he- glbin vrints r trits. In ptients with high levels f he- glbin F, iunssys give flsely lw vlues f HbA1. The Ntinl Glyheglbin Stndrdiztin Prgr web- site (www.ngsp.rg) hs infrtin n the ipt f fre- quently enuntered heglbin vrints nd trits n the results btined with the nly used HbA1ssys. Any nditin tht shrtens erythryte survivl r dereses en erythryte ge (eg, revery fr ute bld lss, helyti nei) will flsely lwer HbA1, irrespetive f the ssy ethd used beuse f the extended tie tht it tkes irulting heglbin t be glysylted. Intrvenus irn nd erythrpietin therpy fr tretent f nei in hrni kidney disese ls flsely lwer HbA1levels. Alterntive ethds suh s frutsine (see belw) shuld be nsidered fr these ptients. Vitins C nd E re reprted t flsely lwer test results pssibly by inhibiting glytin f heglbin. Cnditins tht inrese erythryte survivl suh s sple- nety fr hereditry spherytsis will flsely rise HbA1levels. Irn defiieny nei is ls ssited with higher HbA1levels. HbA1is endrsed by the ADA s  dignsti test fr type 1 nd type 2 dibetes (Tble 273). A utff vlue f 6.5% (48 l/l) ws hsen beuse the risk fr reti- npthy inreses substntilly bve this vlue. The advantages of using the HbA1cto diagnose diabetes is that there is no need to fast; it hs lwer intrindividul vri- bility thn the fsting gluse test nd the rl gluse tlerne test; nd it prvides n estite f gluse n- trl fr the preeding 23 nths. Peple with HbA1lev- els f 5.76.4% (3946 l/l) shuld be nsidered t high risk fr develping dibetes (predibetes). This test is nt pprprite t use in ppultins with high prevlene f heglbinpthies r in nditins with inresed red ell turnver. 6. Serum fructosamine Seru frutsine is fred by nnenzyti glysyltin f seru prteins (pre- dinntly lbuin). Sine seru lbuin hs  uh shrter hlf-life thn heglbin, seru frutsine generlly reflets the stte f glyei ntrl fr nly the preeding 12 weeks. Redutins in seru lbuin (eg, nephrti stte, prtein-lsing enterpthy, r hepti dis- ese) will lwer the seru frutsine vlue. When bnrl heglbins r helyti sttes ffet the inter- prettin f glyheglbin r when  nrrwer tieTable 273. Criteria for the diagnosis of diabetes. Nomal Glucose Toleance1Impaied Glucose Toleance1Diabetes Mellitus2F asting plasma glucose mg/dL (mmol/L)< 100 (5.6) 100125 (5.66.9) 126 (7.0) 2 hours after glucose load mg/dL (mmol/L)< 140 (7.8)  140199 (7.811.0) 200 (11.1) HbA1c(%) < 5.7 5.76.4  6.51 See text for the oral glucose tolerance test protocol.2 A fasting plasma glucose  126 mg/dL (7.0 mmol) is diagnostic of diabetes if confirmed by repeat testing. A fasting plasma glucose  126 mg/dL (7.0 mmol) and HbA1c 6.5% on the same sample is also diagnostic of diabetes.CMDT22_Ch27_p1212-p1255.indd  1218 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1219 CMDT 2022fre  is required, suh s fr sertining glyei ntrl t the tie f neptin in  dibeti wn wh hs reently bee pregnnt, seru frutsine ssys ffer se dvntge. Nrl vlues vry in reltin t the seru lbuin nentrtin nd re 200285 l/L when the seru lbuin level is 5 g/dL. HbA1vlues nd seru frutsine re highly rrelted. Seru fruts- ine levels f 300, 367, nd 430 l/L pprxite t HbA1vlues f 7%, 8%, nd 9%, respetively. Substntil individul vribility exists, thugh, when estiting the likely HbA1vlue fr the frutsine esureent. 7. Selfmonitoring of blood glucose Cpillry bld gluse esureents perfred by ptients theselves, s utptients, re extreely useful. A lrge nuber f bld gluse eters re vilble. All re urte, but they vry with regrd t speed, nveniene, size f bld sples required, reprting pbility, nd st. Ppulr dels inlude thse nuftured by LifeSn (One Tuh), Byer Crprtin (Cntur), Rhe Dignstis (Au-Chek), nd Abbtt Lbrtries (Preisin, Free- Style). These bld gluse eters re reltively inexpen- sive, rnging fr $20 t $80 eh. Test strips rein  jr expense, sting but $0.25 t $1.50 piee. Eh gluse eter ls es with  lnet devie nd disps- ble 26- t 33-guge lnets. Mst eters n stre fr 100 t 1000 gluse vlues in their eries nd hve pbilities t dwnld the vlues int  puter r srtphne. Se eters re designed t unite with  speifi insulin pup. Cntur Next Link eter, fr exple, unites with the MiniMed Medtrni pup. The ury f dt btined by he gluse nitring des require edutin f the ptient in s- pling nd esuring predures. The liniin shuld be wre f the liittins f the self-nitring gluse systes. The strips hve liited lifespns nd iprper strge (high teperture; pen vil) n ffet their funtin. Ptients shuld ls be dvised nt t use expired strips. Inreses r dereses in hetrit n derese r inrese the esured glu- se vlues. Meters nd the test strips re librted ver the gluse nentrtins rnging fr 60 g/dL (3.3 l/L) t 160 g/dL (8.9 l/L) nd the ury is nt s gd fr higher nd lwer gluse levels. When the gluse is less thn 60 g/dL (3.3 l/L), the differ- ene between the eter nd the lbrtry vlue y be s uh s 20%. Gluse xidsebsed peretri sys- tes underestite gluse levels in the presene f high xygen tensin. This y be iprtnt in the ritilly ill wh re reeiving suppleentl xygen; under these ir- ustnes,  gluse dehydrgensebsed syste y be preferble. Gluse-dehydrgense pyrrlquin- line quinne (GDH-PQQ) systes y reprt flsely high gluse levels in ptients wh re reeiving prenterl prduts ntining nngluse sugrs suh s ltse, gltse, r xylse r their etblites. Se eters re pprved fr esuring gluse in bld sples btined t lterntive sites suh s the frer nd thigh. There is, hwever,  5- t 20-inute lg in the gluse respnse n the r with respet t the gluse respnse n the finger.Frer bld gluse esureents uld therefre result in  dely in detetin f rpidly develping hypgly- ei. Ipired irultin t the fingers (fr exple, in ptients with Rynud disese) will rtifiilly lwer fingerstik gluse esureents (pseudhypglyei). 8. Continuous glucose monitoring systems A gluse xidsebsed syste t esure gluse nentrtins in the interstitil fluid is used by ptients wh re inres- ingly using ntinuus gluse nitring systes. These systes, nuftured by Medtrni MiniMed, DexC systes, nd Abbtt Dignstis, invlve inserting  sub- utneus sensr (rther like  sll wire) tht esures gluse nentrtins ntinuusly in the interstitil fluid fr 714 dys. The DexC nd MiniMed systes trns- it gluse dt wirelessly t srtphnes r t the sreens f insulin pups. Diretinl rrws indite rte nd diretin f hnge f gluse levels, nd lerts n be set fr dngerusly lw r high gluse vlues. The werer ls gins insight int hw prtiulr fds nd tivities ffet their gluse level. The FreeStyle Libre (Abbtt Dig- nstis) sensr syste requires the ptient t hld  red- ing devie r  srtphne lse t the sensr pth fr but  send t see the rel tie gluse vlue. The MiniMed syste requires librtin with peridi finger- stik gluse levels, whih is nt neessry fr the Dex nd Freestyle Libre systes. The ftry librted systes use  librtin funtin tht uttilly rrets fr sensr drift ver the subsequent 1014 dys. A 6-nth rndized ntrlled study f ptients with type 1 dibe- tes shwed tht dults (25 yers nd lder) using these ntinuus gluse nitring systes hd iprved glyei ntrl withut n inrese in the inidene f hypglyei. A rndized ntrlled study f ntinu- us gluse nitring during pregnny shwed iprved glyei ntrl in the third triester, lwer birth weight, nd redued risk f rsi. Suries f the ntinuus gluse nitring dt lleted ver 212 weeks n be very helpful. The perentge f tie in rnge (gluse levels 70180 g/dy [3.910 l/L]), gluse levels tht re lw r high, nd their vribility n be ssessed. There is  strng rreltin between gluse levels tht re 70% tie in rnge nd n HbA1f pprx- itely 7%. Mny f these systes re vered by insurne. The initil st is but $800 t $1000, nd the sensr, whih hs t be hnged every 7 t 14 dys, sts $35 t $60; the ut-f-pket expense is but $4000 nnully. 9. Lipoprotein abnormalities in diabetes Cirulting lipprteins re just s dependent n insulin s is the pls gluse. In type 1 dibetes, dertely defiient ntrl f hyperglyei is ssited with nly  slight elevtin f LDL hlesterl nd seru triglyerides nd little if ny hnge in HDL hlesterl. One the hypergly- ei is rreted, lipprtein levels re generlly nrl. Hwever, in ptients with type 2 dibetes,  distint dibeti dyslipidei is hrteristi f the insulin resistne syndre. Its fetures re  high seru tri- glyeride level (300400 g/dL [3.44.5 l/L]),  lwCMDT22_Ch27_p1212-p1255.indd  1219 29/06/21 8:53 PMCHAPTEr 271220 CMDT 2022HDL h lesterl (less thn 30 g/dL [0.8 l/L]), nd  qulittive hnge in LDL prtiles, prduing  sller dense prtile whse ebrne rries suprnrl unts f free hlesterl. These sller dense LDL pr- tiles re re suseptible t xidtin, whih renders the re thergeni. Mesures designed t rret the besity nd hyperglyei, suh s exerise, diet, nd hypglyei therpy, re the tretent f hie fr di- beti dyslipidei, nd in sinl ptients in wh nrl weight ws hieved, ll fetures f the lipprtein bnrlities lered. Sine priry disrders f lipid etblis y exist with dibetes, persistene f lipid bnrlities fter restrtin f nrl weight nd bld gluse shuld prpt  dignsti wrkup nd pssible phrtherpy f the lipid disrder. Chpter 28 dis- usses these tters in detil.Aerin  Dibetes Assitin. 6. Glyei Trgets: Standards of Medical Care in Diabetes 2021. Dibetes Cre. 2021;44:S73. [PMID: 33298417] TreatmentA.  DietA  well-blned, nutritius diet reins  fundentl eleent f therpy. There is n speifi reendtin n the perentge f lries tht shuld e fr rb- hydrte, prtein, nd ft. The rnutrient prprtins shuld be individulized bsed n the ptients eting pt- terns, preferenes, nd etbli gls. In generl, st ptients with dibetes nsue but 45% f their ttl dily lries in the fr f rbhydrtes, 2535% in the fr f ft, nd 1035% in the fr f prtein. In ptients with type 2 dibetes, liiting the rbhydrte intke nd substituting se f the lries with nunsturted fts, suh s live il, rpeseed (nl) il, r the ils in nuts nd vds, n lwer triglyerides nd inrese HDL hles- terl. A Mediterrnen-style eting pttern ( diet supple- ented with wlnuts, lnds, hzelnuts, nd live il) hs been shwn t iprve glyei ntrl nd lwer - bined endpints fr rdivsulr events nd strke. In thse ptients with besity nd type 2 dibetes, weight redutin by lri restritin is n iprtnt gl f the diet (see Chpter 29). Ptients with type 1 dibetes r type 2 dibetes wh tke insulin shuld be tught rbhydrte unting,  s they n dinister their insulin blus fr eh el bsed n its rbhydrte ntent. The urrent reendtins fr sturted fts nd dietry hlesterl intke fr peple with dibetes re the se s fr the generl ppultin. Sturted fts shuld be liited t less thn 10% f dily lries nd dietry h- lesterl intke shuld be less thn 300 g/dy. Fr thse ptients with kidney disese, dietry prtein shuld be intined t the reended dily llwne f 0.8 g/kg/dy. Exhnge lists fr el plnning n be btined fr the Aerin Dibetes Assitin nd its ffilite ssitins r fr the Aerin Dieteti Ass- itin (http://www.etright.rg), 216 W . Jksn Blvd., Chig, IL 60606 (312-899-0040).1. Dietary fiber Plnt pnents suh s ellulse, gu, nd petin re indigestible by huns nd re tered dietry fiber.  Insluble fibers suh s ellulse r hei- ellulse, s fund in brn, tend t inrese intestinl trn- sit nd y hve benefiil effets n lni funtin. In ntrst, sluble fibers suh s gus nd petins, s fund in bens, tel, r pple skin, tend t retrd nutrient bsrptin rtes s tht gluse bsrptin is slwer nd hyperglyei y be slightly diinished. Althugh its reendtins d nt inlude insluble fiber supple- ents suh s dded brn, the ADA reends fd suh s tel, erels, nd bens with reltively high sluble fiber ntent s stple pnents f the diet in dibetis. High sluble fiber ntent in the diet y ls hve  fvrble effet n bld hlesterl levels. 2. Glycemic index The glyei index f  rbhy- drte ntining fd is deterined by pring the gluse exursins fter nsuing 50 g f test fd with gluse exursins fter nsuing 50 g f referene fd (white bred): Glycemic indexBlood glucose area under the curve (3h) for test food Blood glucose area under the curve (3h) for reference food100 =   Eting lw glyei index fds results in lwer glu- se levels fter els. Lw glyei index fds hve vlues f 55 r less nd inlude ny fruits, vegetbles, griny breds, pst, nd legues. High glyei index fds hve vlues f 70 r greter nd inlude bked ptt, white bred, nd white rie. Glyei index is lw- ered by the presene f fts nd prtein when fd is n- sued in  ixed el. Even thugh it y nt be pssible t urtely predit the glyei index f  prtiulr fd in the ntext f  el, it is resnble t hse fds with lw glyei index. 3. Artificial and other sweeteners Shrin (Sweet N Lw), surlse (Splend), esulfe ptssiu (Sweet One), nd rebin (Truvi) re rtifiil sweeteners tht n be used in king nd bking. Asprte (NutrSweet) lks het stbility, s it nnt be used in king. Nne f these sweeteners rise bld gluse levels. Frutse represents  nturl sugr substne tht is  highly effetive sweetener, indues nly slight inreses in pls gluse levels, nd des nt require insulin fr its etblis. Hwever, beuse f ptentil dverse effets f lrge unts f frutse n rising seru hlesterl, triglyerides, nd LDL hlesterl, it des nt hve ny dvntge s  sweetening gent in the dibeti diet. This des nt prelude, hwever, ingestin f frutse-ntining fruits nd vegetbles r frutse-sweetened fds in dertin. Sugr lhls, ls knwn s plyls r plylhl, re nly used s sweeteners nd bulking gents. They ur nturlly in  vriety f fruits nd vegetbles but re ls erilly de fr surse, gluse, nd strh.CMDT22_Ch27_p1212-p1255.indd  1220 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1221 CMDT 2022Exp les re srbitl, xylitl, nnitl, ltitl, islt, ltitl, nd hydrgented strh hydrlystes (HSH). They re nt s esily bsrbed s sugr, s they d nt rise bld gluse levels s uh. Therefre, sugr l- hls re ften used in fd prduts tht re lbeled s sugr free,  suh s hewing gu, lzenges, hrd ndy, nd sugr-free ie re. Hwever, if nsued in lrge quntities, they will rise bld gluse nd n use blting nd dirrhe.B.  Medications for Treating HyperglycemiaThe  editins fr treting type 2 dibetes re listed in Tble 274. 1. Medications that primarily stimulate insulin secretion by binding to the sulfonylurea receptor on the beta cell a. Sulfonylureas The priry ehnis f tin f the sulfnylures is t stiulte insulin relese fr pn- reti B ells. Sulfnylures re used in ptients with type 2 but nt type 1 dibetes, sine these editins require funtin- ing pnreti B ells t prdue their effet n bld gluse. Sulfnylures re etblized by the liver nd prt fr ethexide, whse etblite is re tive thn the prent pund, the etblites f ll the ther sulfnylures re wekly tive r intive. The etblites re exreted by the kidney nd, in the se f the send-genertin sulfnylures, prtly exreted in the bile. Hypglyei is  n dverse retin with the sulfnylures. Weight gin is ls n, espeilly in the first yer f use. The ehniss f the weight gin inlude iprved gluse ntrl nd inresed fd intke in respnse t hypglyei. Idisynrti retins re rre, with skin rshes r hetlgi txiity (leukpeni, thrbytpeni) urring in less thn 0.1% f users. (1) First-generation oral sulfonylureas (tolbutamide, tolazamide, acetohexamide, chlorpropamide) Tlbut- ide is prbbly best dinistered in divided dses (eg, 500 g befre eh el nd t bedtie); hwever, se ptients require nly ne r tw tblets dily with  xi- u dse f 3000 g/dy. Beuse f its shrt durtin f tin (but 610 hurs, whih is independent f kidney funtin), tlbutide is reltively sfe t use in kidney disese. Prlnged hypgly- ei hs been reprted rrely with tlbutide, stly in ptients reeiving ntibteril sulfnides (sulfisx- zle), phenylbutzne fr rthrlgis, r the rl zle ntifungl editins t tret ndidisis. Tlzide, ethexide, nd hlrprpide re rrely used. Chlrprpide hs  prlnged bilgi effet, nd severe hypglyei n ur espeilly in lder dults s their renl lerne delines with ging. Its ther side effets inlude lhl-indued flushing nd hypntrei due t its effet n vspressin seretin nd tin. (2) Second-generation sulfonylureas (glyburide, glipizide, gliclazide, glimepiride) Glyburide, glipizide, glilzide, nd gliepiride re 100200 ties re ptentthn tlbutide. These editins shuld be used with utin in ptients with rdivsulr disese r in elderly ptients, in wh prlnged hypglyei wuld be espe- illy dngerus. The usul strting dse f glyburide is 2.5 g/dy, nd the verge intenne dse is 510 g/dy given s  single rning dse; intenne dses higher thn 20 g/dy re nt reended. Se reprts suggest tht 10 g is  xiu dily therpeuti dse, with 1520 g hving n dditinl benefit in pr respnders nd dses ver 20 g tully wrsening hyperglyei. A Press Tb frultin f irnized glyburideesy t divide in hlf with slight pressure if neessryis vil- ble. Glyburide is etblized in the liver nd the et- bli prduts f glyburide hve hypglyei tivity. This prbbly explins why ssys speifi fr the une- tblized pund suggest  pls hlf-life f nly 12 hurs, yet the bilgi effets f glyburide re lerly persistent 24 hurs fter  single rning dse in dibeti ptients. Glyburide hs few dverse effets ther thn its pten- til fr using hypglyei, whih t ties n be pr- lnged. Flushing hs rrely been reprted fter ethnl ingestin. It des nt use wter retentin, s hlrprp- ide des, but rther slightly enhnes free wter ler- ne. Glyburide shuld nt be used in ptients with liver filure nd hrni kidney disese beuse f the risk f hypglyei. Elderly ptients re t prtiulr risk fr hypglyei even with reltively sll dily dses. The reended strting dse f glipizide is 5 g/dy, with up t 15 g/dy given s  single dily dse befre brekfst. When higher dily dses re required, they shuld be divided nd given befre els. The xiu dse reended by the nufturer is 40 g/d, lthugh dses bve 1015 g prbbly prvide little dditinl benefit in pr respnders nd y even be less effetive thn sller dses. Fr xi- u effet in reduing pstprndil hyperglyei, glipizide shuld be ingested 30 inutes befre els, sine rpid bsrptin is delyed when the editin is tken with fd. At lest 90% f glipizide is etblized in the liver t intive prduts, nd 10% is exreted unhnged in the urine. Glipizide therpy shuld therefre nt be used in ptients with liver filure. Beuse f its lwer pteny nd shrter durtin f tin, it is preferble t glyburide in elderly ptients nd fr thse ptients with kidney disese. Glutrl-XL prvides extended relese f glipizide during trnsit thrugh the gstrintestinl trt with greter effe- tiveness in lwering prebrekfst hyperglyei thn the shrter-durtin iedite-relese stndrd glipizide tb- lets. Hwever, this frultin ppers t hve srified its lwer prpensity fr severe hypglyei pred with lnger-ting glyburide withut shwing ny den- strble therpeuti dvntges ver glyburide. Gliclazide (nt vilble in the United Sttes) is nther interedite durtin sulfnylure with  durtin f tin f but 12 hurs. The reended strting dse is 4080 g/dy with  xiu dse f 320 g. Dses f 160 g nd bve re given s divided dses befreCMDT22_Ch27_p1212-p1255.indd  1221 29/06/21 8:53 PMCHAPTEr 271222 CMDT 2022T able 274. Medications for treatment of type 2 diabetes mellitus (oral doses unless otherwise noted).Dug Tablet Size Daily DoseDuation of Action Sulfonylueas Acetohexamide (Dymelor) (not available in United States)250 and 500 mg 0.251.5 g as single dose or in two divided doses 824 hours Chlorpropamide (Diabinese) 100 and 250 mg 0.10.5 g as single dose 2472 hours Gliclazide (not available in United States) 80 mg 4080 mg as single dose; 160320 mg as divided dose 12 hours Glimepiride (Amaryl) 1, 2, and 4 mg Usual dose: 14 mg once daily Maximal dose: 8 mg once dailyUp to 24 hours Glipizide (Glucotrol) 5 and 10 mg Usual dose: 2.510 mg twice daily 30 minutes before meals Maximal dose: 20 mg twice daily612 hours (Glucotrol XL) 2.5, 5, and 10 mg Usual dose: 2.510 mg once daily Maximal dose: 20 mg once dailyUp to 24 hours Glyburide (Dia Beta, Micronase) 1.25, 2.5, and 5 mg 1.2520 mg as single dose or in two divided doses Up to 24 hours (Glynase) 1.5, 3, and 6 mg 1.512 mg as single dose or in two divided doses Up to 24 hours Tolazamide (Tolinase) 100, 250, and 500 mg 0.11 g as single dose or in two divided doses Up to 24 hours Tolbutamide (Orinase) 250 and 500 mg 0.52 g in two or three divided doses 610 hours Meglitinide Analogs Mitiglinide (available in Japan) 5 and 10 mg 5 or 10 mg three times daily before meals 2 hours Repaglinide (Prandin) 0.5, 1, and 2 mg Usual dose: 0.5 to 4 mg three times daily 15 minutes before meals Maximal dose: 16 mg daily3 hoursd -Phenylalanine Deivative Nateglinide (Starlix) 60 and 120 mg 60 or 120 mg three times daily before meals 4 hours Biguanides Metformin (Glucophage) 500, 850, and 1000 mg 500850 mg with meals two or three times daily; 8501000 mg with breakfast and dinner4 hours Metformin, extended release (Glucophage XR)1500, 750, and 1000 mg 5002000 mg once daily Up to 24 hours Thiazolidinediones Pioglitazone (Actos) 15, 30, and 45 mg 1545 mg daily Up to 24 hours Rosiglitazone (Avandia) 2, 4, and 8 mg 48 mg daily (can be divided) Up to 24 hours Alpha-Glucosidase Inhibitos Acarbose (Precose) 25, 50, and 100 mg 25100 mg three times daily just before meals 4 hours Miglitol (Glyset) 25, 50, and 100 mg 25100 mg three times daily just before meals 4 hours Voglibose (not available in United States) 0.2 and 0.3 mg 0.20.3 mg three times daily just before meals 4 hours GLP-1 recepto Agonists Dulaglutide (Trulicity) 0.75-, 1.5-mg single- dose pen or pre- filled syringeUsual dose: 0.75 mg subcutaneously once weekly Maximal dose: 1.5 mg subcutaneously once weekly1 week Exenatide (Byetta) 1.2 mL and 2.4 mL prefilled pens deliv- ering 5 mcg and 10 mcg doses5 mcg subcutaneously twice daily within 1 hour of breakfast and dinner. Increase to 10 mcg subcuta- neously twice daily after about a month. AVOID if eGFR < 30 mL/min/1.73 m26 hours Exenatide, long-acting release (Byetta LAR, Bydureon)2 mg (powder) Suspend in provided diluent and inject subcutaneously.1 week (continued )CMDT22_Ch27_p1212-p1255.indd  1222 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1223 CMDT 2022T able 274. Medications for treatment of type 2 diabetes mellitus (oral doses unless otherwise noted).Dug Tablet Size Daily DoseDuation of Action Liraglutide (Victoza) Prefilled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, or 1.8 mgInitial dose: 0.6 mg subcutaneously once daily. Increase to 1.2 mg after a week if no adverse reactions. Maximal dose: 1.8 mg subcutaneously once daily24 hours Lixisenatide (Adlyxin, Lyxumia) 3-mL prefilled pens delivering 10- or 20-mcg dosesInitial dose: 10 mcg daily. Increase to 20 mcg daily after 2 weeks.24 hours Semaglutide (Ozempic, Rybelsus) Prefilled pens deliver- ing 0.25 mg or 0.5 mg 1-, 3-,7-, and 14-mg tabletsInitial dose: 0.25 mg weekly for 1 month and increase to 0.5 mg weekly if no adverse reactions. Maximal dose: 1 mg weekly Initial dose: 3 mg for 1 month and then increase to 7 mg. Take fasting daily with water and wait 30 min to eat. Maximal dose: 14 mg1 week Daily DPP-4 Inhibitos Alogliptin (Nesina) 6.25, 12.5, and 25 mg 25 mg once daily if eGFR  60 mL/min/1.73 m2; 12.5 mg daily if eGFR 3059 mL/min/1.73 m2; 6.25 mg daily if eGFR < 30 mL/min/1.73 m224 hours Linagliptin (Tradjenta) 5 mg 5 mg daily 24 hours Saxagliptin (Onglyza) 2.5 and 5 mg 2.5 mg or 5 mg once daily if eGFR > 50 mL/min/1.73 m2. 2.5 mg daily if eGFR  50 mL/min/1.73 m2or if also taking drugs that are strong CYP3A4/5 inhibitors such as ketoconazole24 hours Sitagliptin (Januvia) 25, 50, and 100 mg 100 mg once daily if eGFR > 50 mL/min/1.73 m2; 50 mg once daily if eGFR 3050 mL/min/1.73 m2; 25 mg once daily if eGFR < 30 mL/min/1.73 m224 hours Vildagliptin (Galvus) (not available in United States)50 mg 50 mg once or twice daily. AVOID if eGFR  60 mL/min/1.73 m2or AST/ALT three times upper limit of normal24 hours SGLT2 Inhibitos Canagliflozin (Invokana) 100 and 300 mg Usual dose: 100 mg daily. 300 mg can be used if normal eGFR, resulting in lowering the HbA1can additional ~ 0.10.25%. AVOID if eGFR < 45 mL/min/1.73 m2.24 hours Dapagliflozin (Farxiga) 5 and 10 mg 10 mg daily 24 hours Empagliflozin (Jardiance) 10 and 25 mg Usual dose: 10 mg daily Maximal dose: 25 mg24 hours Ertugliflozin (Steglatro) 5 and 15 mg Usual dose: 5 mg daily Maximal dose: 15 mg24 hours Othes Bromocriptine (Cycloset) 0.8 mg 0.8 mg daily. Increase weekly by 1 tablet until maxi- mal tolerated dose of 1.64.8 mg daily.24 hours Colesevelam (Welchol) 625 mg 3 tablets twice daily 24 hours Pramlintide (Symlin) 5-mL vial containing 0.6 mg/mL; also available as pre- filled pens. Symlin pen 60 or Symlin pen 120For insulin-treated type 2 patients, start at 60-mcg dose subcutaneously three times daily (10 units on U100 insulin syringe). Increase to 120 mcg three times daily (20 units on U100 insulin syringe) if no nausea for 37 days. Give immediately before meal. For type 1 patients, start at 15 mcg three times daily (2.5 units on U100 insulin syringe) and increase by increments of 15 mcg to a maximum of 60 mcg three times daily, as tolerated. To avoid hypoglycemia, lower insulin dose by 50% on initiation of therapy.2 hours AST/ALT, aspartate aminotransferase/alanine aminotransferase; eGFR, estimated glomerular filtration rate.(continued)CMDT22_Ch27_p1212-p1255.indd  1223 29/06/21 8:53 PMCHAPTEr 271224 CMDT 2022brekfst  nd dinner. The editin is etblized by the liver; the etblites nd njugtes hve n hypglyei effet. An extended-relese preprtin is vilble. Glimepiride hs  lng durtin f effet with  hlf- life f 5 hurs llwing ne r twie dily dsing. Gliepiride hieves bld gluse lwering with the lw- est dse f ny sulfnylure pund. A single dily dse f 1 g/dy hs been shwn t be effetive, nd the xi- l reended dse is 8 g. It is pletely etb- lized by the liver t reltively intive etbli prduts. b. Meglitinide analogs Repglinide is struturlly siilr t glyburide but lks the sulfni id-ure iety. It ts by binding t the sulfnylure reeptr nd lsing the densine triphsphte (ATP)-sensitive ptssiu hnnel. It is rpidly bsrbed fr the intestine nd then underges plete etblis in the liver t intive biliry prduts, giving it  pls hlf-life f less thn 1 hur. The editin therefre uses  brief but rpid pulse f insulin. The strting dse is 0.5 g three ties  dy 15 inutes befre eh el. The dse n be titrted t  xiu dily dse f 16 g. Like the sulfnylures, repglinide n be used in bintin with etfrin. Hypglyei is the in side effet. Like the sulfnyl- ures, repglinide uses weight gin. Metblis is by ythre P450 3A4 isenzye, nd ther editins tht indue r inhibit this isenzye y inrese r inhibit (respetively) the etblis f repglinide. The editin y be useful in ptients with kidney ipir- ent r in lder dults. Mitiglinide is  benzylsuini id derivtive tht binds t the sulfnylure reeptr nd is siilr t rep- glinide in its linil effets. It is pprved fr use in Jpn. c. D-phenylalanine derivative Nteglinide stiu- ltes insulin seretin by binding t the sulfnylure reep- tr nd lsing the ATP-sensitive ptssiu hnnel. It is rpidly bsrbed fr the intestine, rehing pek pls levels within 1 hur. It is etblized in the liver nd hs  pls hlf-life f but 1.5 hurs. Like repglinide, it uses  brief rpid pulse f insulin, nd when given befre  el it redues the pstprndil rise in bld gluse. Fr st ptients, the reended strting nd intenne dse is 120 g three ties  dy befre els. Use 60 g in ptients wh hve ild elevtins in HbA1. Like the ther insulin seretggues, its in side effets re hyp- glyei nd weight gin. 2. Medications that primarily lower glucose levels by their actions on the liver, muscle, and adipose tissue a. Metformin Metfrin is the first-line therpy fr ptients with type 2 dibetes. It n be used lne r in njuntin with ther rl gents r insulin in the tret- ent f ptients with type 2 dibetes. It is ineffetive in ptients with type 1 dibetes. Metfrins therpeuti effets pririly derive fr the inresing hepti densine nphsphte-tivted pr- tein kinse tivity, whih redues hepti glunegenesis nd lipgenesis. Metfrin hs  hlf-life f 1.53 hurs nd is nt bund t pls prteins r etblized, being exreted unhnged by the kidneys.The urrent reendtin is t strt etfrin t dignsis. A side benefit f etfrin therpy is its ten- deny t iprve bth fsting nd pstprndil hypergly- ei nd hypertriglyeridei in bese ptients with dibetes withut the weight gin ssited with insulin r sulfnylure therpy. Ptients with hrni kidney disese shuld nt be given this editin beuse filure t exrete it wuld prdue high bld nd tissue levels f etfrin tht uld stiulte lti id verprdutin. In the United Sttes, etfrin use is nt reended t r bve  seru retinine level f 1.4 g/dL in wen nd 1.5 g/dL in en. In the United Kingd, the re- endtins re t review etfrin use when the seru retinine exeeds 130 l/L (1.5 g/dL) r the esti- ted glerulr filtrtin rte (eGFR) flls belw 45 L/ in/1.73 2. The editin shuld be stpped if the seru retinine exeeds 150 l/L (1.7 g/dL) r the eGFR is belw 30 L/in/1.73 2. Ptients with liver fil- ure r persns with exessive lhl intke shuld nt reeive this editin beuse f the risk f lti idsis. The xiu dsge f etfrin is 2550 g, lthugh little benefit is seen bve  ttl dse f 2000 g. It is iprtnt t begin with  lw dse nd inrese the dsge very grdully in divided dsestken with elst redue inr gstrintestinl upsets (nrexi, nuse, viting, bdinl disfrt, dirrhe), whih ur in up t 20% f ptients. A n shedule wuld be ne 500-g tblet three ties  dy with els r ne 850- r 1000-g tblet twie dily t brekfst nd dinner. Up t 2000 g f the extended-relese preprtin n be given ne  dy. Lwer dses shuld be used in ptients with eGFRs between 30 nd 45 L/in/1.73 2nd in the elderly wh re t higher risk fr ute kidney injury fr redued renl funtinl reserve. The gstrintestinl side effets re dse-relted, tend t ur t nset f therpy, nd ften re trnsient. Hw- ever, in 35% f ptients, therpy y hve t be disntin- ued beuse f persistent dirrhel disfrt. Ptients swithing fr iedite-relese etfrin t pr- ble dse f extended-relese etfrin y experiene fewer gstrintestinl side effets. Hypglyei des nt ur with therpeuti dses f etfrin, whih perits its desriptin s  euglyei r ntihyperglyei editin rther thn n rl hypglyei gent. Dertlgi r hetlgi txiity is rre. Metfrin interferes with the liu dependent bsrptin f vitin B12-intrinsi plex in the terinl ileu; vitin B12defiieny n ur fter ny yers f etfrin use. Peridi sreening with vitin B12levels shuld be nsidered, espeilly in ptients with peripherl neurpthy (whih y be errneusly ttributed t di- beti neurpthy) r if  ryti nei develps. Inresed intke f dietry liu y prevent the et- frin-indued B12lbrptin. Lti idsis hs been reprted s  side effet but is unn with etfrin in ntrst t phenfrin. Alst ll reprted ses hve invlved persns with ssited risk ftrs tht shuld hve ntrindited its use (kidney, liver, r rdirespirtry insuffiieny ndCMDT22_Ch27_p1212-p1255.indd  1224 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1225 CMDT 2022lhlis).  Aute kidney injury n ur rrely in er- tin ptients tking etfrin wh reeive rdintrst gents. Metfrin therpy shuld therefre be teprrily hlted n the dy f rdintrst dinistrtin nd restrted  dy r tw lter fter nfirtin tht kidney funtin hs nt deterirted. b. Thiazolidinediones Tw editins f this lss, rsiglitzne nd piglitzne, re vilble fr linil use. These editins sensitize peripherl tissues t insulin. They bind the nuler reeptr perxise prlifertr- tivted reeptr g (PPAR-g) nd ffet the expressin f  nuber f genes. Like the bigunides, this lss f editins des nt use hypglyei. Bth rsiglitzne nd piglitzne re effetive s ntherpy nd in bintin with sulfnylures r etfrin r insulin, lwering HbA1by 12%. When used in bintin with insulin, they n result in  3050% redutin in insulin dsge, nd se ptients n e ff insulin pletely. The rl dsge f rsigli- tzne is 48 g dily nd f piglitzne, 1545 g dily; the editins d nt hve t be tken with fd. Rsigli- tzne is pririly etblized by the CYP 2C8 isen- zye nd piglitzne is etblized by CYP 2C8 nd CYP 3A4. The bintin f  thizlidinedine nd etfr- in hs the dvntge f nt using hypglyei. Ptients indequtely nged n sulfnylures n d well n  bintin f sulfnylure nd rsiglitzne r piglitzne. These editins hve se dditinl effets prt fr gluse lwering. Rsiglitzne therpy is ssited with inreses in ttl hlesterl, LDL hlesterl (15%), nd HDL hlesterl (10%). There is  redutin in free ftty ids f but 815%. The hnges in triglyerides re generlly nt different fr pleb. Piglitzne in lini- l trils lwered triglyerides (9%) nd inresed HDL hlesterl (15%) but did nt use  nsistent hnge in ttl hlesterl nd LDL hlesterl levels. A prspetive rndized prisn f the etbli effets f pigli- tzne nd rsiglitzne shwed siilr effets n HbA1 nd weight gin. Sll prspetive studies hve den- strted tht tretent with these editins leds t iprveents in the biheil nd histlgi fetures f nnlhli ftty liver disese. The thizlidinedines ls y liit vsulr sth usle prlifertin fter injury, nd there re reprts tht piglitzne n redue neintil prlifertin fter rnry stent pleent. In ne duble-blind, pleb-ntrlled study, rsiglitzne ws shwn t be ssited with  derese in the rti f urinry lbuin t retinine exretin. Safety concerns nd se trublese side effets liit the use f this lss f editin. Rsiglitzne use delined when  et-nlysis f 42 rndized linil trils suggested tht this editin inreses the risk f ngin petris r yrdil infrtin; the Eurpen Mediines Ageny suspended the use f rsiglitzne in Eurpe. In the United Sttes, the FDA estblished  restrited distributin prgr. A subsequent lrge pr- spetive linil tril (the RECORD study) filed tnfir the et-nlysis finding nd the restritins were lifted in the United Sttes. Ede urs in but 34% f ptients reeiving ntherpy with rsiglitzne r piglitzne. The ede urs re frequently (1015%) in ptients reeiv- ing nitnt insulin therpy nd y result in hert filure. The editins re ntrindited in dibeti individuls with New Yrk Hert Assitin lss III nd IV rdi sttus. Thizlidinedines hve ls been reprted s being ssited with new nset r wrsening ulr ede. Apprently, this is  rre side effet, nd st f these ptients ls hd peripherl ede. The ulr ede reslved r iprved ne the editin ws disntinued. Trglitzne, the first editin in this lss, ws with- drwn fr linil use beuse f editin-ssited ftl liver filure. Althugh rsiglitzne nd piglitzne hve nt been reprted t use liver injury, the FDA re- ends tht they shuld nt be used in ptients with linil evidene f tive liver disese r pretretent elevtin f the lnine intrnsferse (ALT) level tht is 2.5 ties greter thn the upper liit f nrl. Liver biheil tests shuld be perfred n ll ptients prir t inititin f tretent nd peridilly therefter. An inrese in frture risk in wen (but nt en) hs been reprted with bth rsiglitzne nd pigli- tzne. The frture risk is in the rnge f 1.9 per 100 ptient-yers with the thizlidinedine s ppsed t 1.1 per 100 ptient-yers n prisn tretent. In t lest ne study f rsiglitzne, the frture risk ws inresed in preenpusl s well s pstenpusl wen. Other side effets inlude nei, whih urs in 4% f ptients treted with these editins; it y be due t  dilutinl effet f inresed pls vlue rther thn  redutin in red ell ss. Weight gin urs, espeilly when the editin is bined with  sulfnylure r insulin. Se f the weight gin is fluid retentin, but there is ls n inrese in ttl ft ss. Clinil studies hve reprted nfliting results regrding n ssitin f bldder ner with piglitzne use. A 10-yer bserv- tinl hrt study f ptients tking piglitzne filed t find n ssitin with bldder ner. A lrge ultippu- ltin pled nlysis (1.01 illin persns ver 5.9 illin persn-yers) ls filed t find n ssitin between uultive expsure f piglitzne r rsiglitzne nd inidene f bldder ner. Anther ppultin-bsed study, hwever, generting 689,616 persn-yers f fllw- up did find tht piglitzne but nt rsiglitzne ws ssited with n inresed risk f bldder ner. 3. Medications that affect absorption of glucose Alph- glusidse inhibitrs petitively inhibit the lph- glusidse enzyes in the gut tht digest dietry strh nd surse. Tw f these editinsrbse nd iglitlre vilble fr linil use in the United Sttes. Vglibse, nther lph-glusidse inhibitr is vilble in Jpn, Kre, nd Indi. Arbse nd iglitl re ptent inhibitrs f gluylse, lph-ylse, nd surse but hve less effet n isltse nd hrdly ny n trehlse nd ltse.CMDT22_Ch27_p1212-p1255.indd  1225 29/06/21 8:53 PMCHAPTEr 271226 CMDT 2022a.  Acarbose The reended strting dse f r- bse is 50 g rlly twie dily, grdully inresing t 100 g three ties dily. Fr xil benefit n pstprn- dil hyperglyei, rbse shuld be given with the first uthful f fd ingested. In dibeti ptients, it redues pstprndil hyperglyei by 3050%, nd its verll effet is t lwer the HbA1by 0.51%. The prinipl dverse effet, seen in 2030% f ptients, is fltulene. This is used by undigested rbhydrte rehing the lwer bwel, where gses re prdued by bteril flr. In 3% f ses, trublese dirrhe urs. This gstrintestinl disfrt tends t disur- ge exessive rbhydrte nsuptin nd prtes iprved pline f type 2 ptients with their diet presriptins. When rbse is given lne, there is n risk f hypglyei. Hwever, if bined with insulin r sulfnylures, it ight inrese the risk f hypglyei fr these gents. A slight rise in hepti intrnsfer- ses hs been nted in linil trils with rbse (5% vs 2% in pleb ntrls, nd prtiulrly with dses greter thn 300 g/dy). The levels generlly return t nrl n stpping the editin. b. Miglitol Miglitl is siilr t rbse in ters f its linil effets. It is indited fr use in diet- r sulfnyl- ure-treted ptients with type 2 dibetes. Therpy is initi- ted t the lwest effetive dsge f 25 g rlly three ties  dy. The usul intenne dse is 50 g three ties  dy, lthugh se ptients y benefit fr inresing the dse t 100 g three ties  dy. Gstrin- testinl side effets ur s with rbse. The editin is nt etblized nd is exreted unhnged by the kidney. Miglitl shuld nt be used in end-stge hrni kidney disese, when its lerne wuld be ipired. 4. Incretins Orl gluse prvkes  threefld t furfld higher insulin respnse thn n equivlent dse f gluse given intrvenusly. This is beuse the rl gluse uses  relese f gut hrnes, priniplly glugn-like pep- tide 1 (GLP-1) nd gluse-dependent insulintrpi ply- peptide (GIP1), tht plify the gluse-indued insulin relese. This inretin effet f GLP-1 seretin (but nt GIP1 seretin) is redued in ptients with type 2 dibetes; when GLP-1 is infused in ptients with type 2 dibetes, it stiultes insulin seretin nd lwers gluse levels. GLP-1, unlike the sulfnylures, hs nly  dest insulin stiul- try effet t nrglyei nentrtins. This ens tht GLP-1 hs  lwer risk fr hypglyei thn the sulfnylures. In dditin t its insulin stiultry effet, GLP-1 ls hs  nuber f ther pnreti nd extrpnreti effets. It suppresses glugn seretin nd s y e- lirte the hyperglugnei tht is present in peple with dibetes nd iprve pstprndil hyperglyei. GLP-1 ts n the sth delying gstri eptying; the iprtne f this effet n gluse lwering is illustrted by the bservtin tht ntgnizing the deelertin f gstri eptying rkedly redues the gluse lwering effet f GLP-1. GLP-1 reeptrs re present in the entrl nervus syste nd y ply  rle in the nreti effet f the drugs. Type 2 dibeti ptients underging GLP-1infusin re less hungry; it is unler whether this is inly due t  deelertin f gstri eptying r whether there is  entrl nervus syste effet s well. a. GLP-1 receptor agonists GLP-1s hlf-life is nly 12 inutes. It is rpidly prtelyzed by dipeptidyl pepti- dse 4 (DPP-4) nd by ther enzyes, suh s endpepti- dse 24.11, nd is ls lered quikly by the kidney. The ntive peptide, therefre, nnt be used therpeutilly. Five GLP-1 reeptr gnists with lnger hlf-lives, exen- tide, lirglutide, dulglutide, lixisentide, nd seglutide, re vilble fr linil use. Exenatide (Exendin 4) is  GLP-1 reeptr gnist is- lted fr the sliv f the Gil nster ( venus lizrd) tht is re resistnt t DPP-4 tin nd lered by the kidney. Its hlf-life is 2.4 hurs, nd its gluse lwering effet is but 6 hurs. Exentide is dispensed s tw fixed-dse pens (5 g nd 10 g). It is injeted 60 inutes befre brekfst nd befre dinner. Ptients with type 2 dibetes shuld be presribed the 5 g pen fr the first nth nd, if tlerted, the dse n then be inresed t 10 g twie  dy. The editin is nt reended in ptients with eGFR less thn 30 L/in/1.73 2. In linil trils, dding exentide therpy t ptients with type 2 dibetes lredy tking etfrin r  sulfnylure, r bth, further lwered the HbA1vlue by 0.4% t 0.6% ver  30-week perid. These ptients ls experiened  weight lss f 36 punds. Exentide LAR is  ne-weekly preprtin tht is dispensed s  pwder (2 g). It is suspended in the prvided diluent just prir t injetin. In prtive linil trils, the lng- ting drug lwers the HbA1level  little re thn the twie dily drug. Lw-titer ntibdies ginst exentide develp in ver ne-third (38%) f ptients, but the linil effets re nt ttenuted. High-titer ntibdies develp in  subset f ptients (~6%), nd in but hlf f these ses, n ttenu- tin f glyei respnse hs been seen. Liraglutide is  sluble ftty id ylted GLP-1 n- lg. The hlf-life is pprxitely 12 hurs, llwing the editin t be injeted ne  dy. The dsing is initi- ted t 0.6 g dily, inresed fter 1 week t 1.2 g dily. Se ptients y benefit fr inresing the dse t 1.8 g. In linil trils lsting 26 nd 52 weeks, dding lirglutide t the therpeuti regien (etfrin, sulf- nylure, thizlidinedine) f ptients with type 2 dibetes further lwered the HbA1vlue. Depending n the dse nd design f the study, the HbA1deline ws in the rnge f 0.6% t 1.5%. The ptients hd sustined weight lss f 16 punds. Lirglutide t  dse f 3 g dily hs been pprved fr weight lss. In  pstrketing ultintinl study f 9340 ptients with type 2 dibetes with knwn rdivsulr disese, the dditin f lirglutide ws ssited with  lwer priry psite ute f deth fr rdivsulr uses, nnftl yrdil infrtin, r nnftl strke (hzrd rti 0.87, P= 0.01). Ptients tking lirglutide hd lwer HbA1levels, weight lss f 2.3 kg, lwer systli bld pres- sure, nd fewer episdes f severe hypglyei. Dulaglutide nsists f tw GLP-1 nlg leules vlently linked t n F frgent f hun IgG4. The GLP-1 leule hs in id substitutins tht resistCMDT22_Ch27_p1212-p1255.indd  1226 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1227 CMDT 2022DPP -4 tin. The hlf-life f dulglutide is but 5 dys. The usul dse is 0.75 g weekly by subutneus inje- tin. The xiu reended dse is 1.5 g weekly. Dulglutide ntherpy nd bintin therpy lwers HbA1by but 0.7% t 1.6%. Weight lss rnged fr 2 punds t 7 punds. Lixisenatide is  syntheti nlg f exendin 4 (deletin f  prline nd dditin f 6 lysines t the C-terinl regin) with  hlf-life f 3 hurs. It is dispensed s tw fixed-dse pens (10 g nd 20 g). The 10-g dse is injeted ne dily befre brekfst fr the first 2 weeks, nd if tlerted, the dse is then inresed t 20 g dily. Its linil effet is but the se s exentide with HbA1 lwering in the 0.40.6% rnge. Weight lss rnges fr 2 punds t 6 punds. Antibdies t lixisentide ur frequently (70%) nd ~2.4% with the highest ntibdy titers hve ttenuted glyei respnse. Semaglutide is  syntheti nlg f GLP-1 with  drug hlf-life f but 1 week. It hs n lph-inisbutyri id substitutin t psitin 8 tht kes the leule resistnt t DPP4 tin nd  C-18 ftty di-id hin tthed t lysine t psitin 26 tht binds t lbuin, whih unts fr the drugs lng hlf-life. Seglutide is dispensed either subutneusly r rlly. There re tw pens fr subutneus injetin: ne pen delivers  0.25-g r 0.5-g dse nd the ther pen delivers  1-g dse. The reended dsing is 0.25 g weekly fr 4 weeks nd if tlerted the dse is then inresed t 0.5 g per week. The 1-g per week dse n prvide dditinl gluse lwering effet. Seglutide ntherpy nd bin- tin therpy lwers HbA1fr 1.5% t 1.8%. The ptient ust tke rl seglutide fsting with  glss f wter nd then wit hlf n hur befre eting, drinking, r tking ther ediines. The reended strting dse is 3 g dily fr the first nth, with the dse inresed t 714 g dily s tlerted nd s needed fr gluse ntrl. Side effects The st frequent dverse retins f the GLP-1 reeptr gnists re nuse (1140%), vit- ing (413%), nd dirrhe (917%). The retins re re frequent t the higher dses. In linil trils but 15% f prtiipnts withdrew fr the studies beuse f the gstrintestinl sypts. The GLP-1 reeptr gnists hve been ssited with inresed risk f pnretitis. The pnretitis ws severe (herrhgi r nertizing) in 6 instnes, nd 2 f these ptients died. In the lirglutide nd dulglutide linil trils, there were 13 nd 5 ses f pnretitis in the drug- treted grups versus 1 nd 1 se in the prtr grups, respetively. This trnsltes t but 1.42.2 vs 0.60.9 ses f pnretitis per 1000 ptient-yers. Patients taking GLP-1 receptor agonists should be advised to seek immediate medical care if they experience unexplained per- sistent severe abdominal pain . There hve been rre reprts f ute kidney injury in ptients tking exentide. Se f these ptients hd pre- existing kidney disese, nd thers hd ne r re risk ftrs fr kidney disese. A nuber f the ptients reprted nuse, viting, nd dirrhe, nd it is ps- sible tht these side effets used vlue depletin ndntributed t the develpent f the kidney injury. Lir- glutide, seglutide, nd dulglutide re etblized by prtelysis nd re preferred hies in ptients with kid- ney filure. GLP-1 reeptr gnists stiulte C-ell neplsi nd use edullry thyrid rin in rts. Hun C-ells express very few GLP-1 reeptrs, nd the relevne t hun therpy is unler. The editins, hwever, shuld nt be used in ptients with persnl r fily his- try f edullry thyrid rin r ultiple endrine neplsi (MEN) syndre type 2. b. DPP-4 inhibitors An lternte pprh t the use f GLP-1 reeptr gnists is t inhibit the enzye DPP-4 nd prlng the tin f endgenusly relesed GLP-1 nd GIP . Fur rl DPP-4 inhibitrs, sitgliptin, sx- gliptin, lingliptin, nd lgliptin, re vilble in the United Sttes fr the tretent f type 2 dibetes. An ddi- tinl DPP-4 inhibitr, vildgliptin, is vilble in Eurpe. Other DPP-4 inhibitrsgeigliptin, ngliptin, teneligliptin, trelgliptin, rigliptin, evgliptin, nd gsgliptinhve been pprved utside the United Sttes nd Eurpen Unin (Kre, Indi, Thilnd, Jpn, Russi, nd severl Suth Aerin untries). Sitagliptin, when used lne r in bintin with ther dibetes editins, lwers HbA1by pprxi- tely 0.5%. The usul dse f sitgliptin is 100 g ne dily, but the dse is redued t 50 g dily if the lu- lted retinine lerne is 3050 L/in nd t 25 g fr lernes less thn 30 L/in. Sxgliptin, when dded t the therpeuti regien (etfrin, sulfnyl- ure, thizlidinedine) f ptients with type 2 dibetes, further lwered the HbA1vlue by but 0.70.9%. The dse is 2.5 g r 5 g rlly ne  dy. The 2.5-g dse shuld be used in ptients with eGFR less thn 50 L/in/ 1.73 2. Alogliptin lwers HbA1by but 0.50.6% when dded t etfrin, sulfnylure, r piglitzne. The usul dse is 25 g rlly dily. The 12.5-g dse is used in ptients with eGFR f 3060 L/in/1.73 2; nd 6.25 g fr lerne less thn 30 L/in/1.73 2. Lin- gliptin lwers HbA1by but 0.40.6% when dded t etfrin, sulfnylure, r piglitzne. The dse is 5 g rlly dily, nd sine, it is pririly exreted unetblized vi the bile, n dse djustent is needed in ptients with kidney disese. Vildgliptin lwers HbA1by but 0.51% when dded t the ther- peuti regien f ptients with type 2 dibetes. The dse is 50 g ne r twie dily. Side effects The in dverse effet f DPP-4 inhibi- trs ppers t be  predispsitin t nsphryngitis r upper respirtry trt infetin. Hypersensitivity re- tins, inluding nphylxis, ngiede, nd exflitive skin nditins (suh s Stevens-Jhnsn syndre), hve been reprted. There hve ls been reprts f pnretitis, but the frequeny f the event is unler. Cses f liver filure hve been reprted with the use f lgliptin, but it is unertin if lgliptin ws the use. The editin, hwever, shuld be disntinued in the event f liver fil- ure. Rre ses f hepti dysfuntin, inluding heptitis,CMDT22_Ch27_p1212-p1255.indd  1227 29/06/21 8:53 PMCHAPTEr 271228 CMDT 2022hve  been reprted with the use f vildgliptin; nd liver biheil testing is reended qurterly during the first yer f use nd peridilly therefter. Sxgliptin y inrese the risk f hert filure. In  pst-rketing study f 16,492 ptients with type 2 dibetes, hert filure urred in 3.5% in the sxgliptin grup nd 2.8% in the pleb grup (hzrd rti 1.27). Ptients with the highest risk f hert filure were thse wh hd  histry f hert filure r hd elevted levels f N-terinl f the prhr- ne B-type ntriureti peptide (NT-pBNP) r hd kidney ipirent. In  lrge pst-rketing study, lgliptin, like sxgliptin, ws ssited with  slightly inresed rte f hert filure. The FDA hs issued  wrning tht the DPP-4 inhibitrs n sinlly use jint pins tht reslve fter stpping the drug. 5. Sodiumglucose cotransporter 2 inhibitors Gluse is freely filtered by the kidney gleruli nd is rebsrbed in the prxil tubules by the tin f sdiu-gluse -trnsprters (SGLT). Sdiu-gluse -trnsprter 2 (SGLT2) unts fr but 90% f gluse rebsrptin nd its inhibitin uses glysuri in peple with dibetes, lwering pls gluse levels. The rl SGLT2 inhibitrs ngliflzin, dpgliflzin, epgliflzin, nd ertugli- flzin re pprved fr linil use in the United Sttes. These gents redue the threshld fr glysuri fr  pls gluse threshld f but  180 g/dL t but 40 g/dL; nd lwer HbA1by 0.51% when used lne r in bintin with ther rl gents r insulin. The effi- y is higher t higher HbA1levels when re gluse is exreted s  result f SGLT2 inhibitin. The lss f l- ries results in dest weight lss f 25 kg. Cngliflzin is dsed t 100 g dily but up t 300 g dily n be used in ptients with nrl kidney funtin. The dse f dpgliflzin is 10 g dily but 5 g dily is the reended initil dse in ptients with hepti fil- ure. The usul dsge f epgliflzin is 10 g dily but  higher dse f 25 g dily n be used. The reended strting dse f ertugliflzin is 5 g, but the dse n be inresed t 15 g dily if dditinl gluse lwering is needed. Empagliflozin ws evluted in  ultintinl study f 7020 ptients with type 2 dibetes with knwn rdi- vsulr disese; the dditin f epgliflzin ws ssi- ted with  lwer priry psite ute f deth fr rdivsulr uses, nnftl yrdil infr- tin, r nnftl strke (hzrd rti 0.86, P= 0.04). The ehniss regrding the benefit rein unler. Weight lss, lwer bld pressure, nd diuresis y hve plyed  rle sine there were fewer deths fr hert filure in the treted grup wheres the rtes f yrdil infrtin were unltered. A siilr ultintinl study ws per- fred with the dditin f ngliflzin. This ws  study f 10,142 ptients with type 2 dibetes with knwn r t inresed risk fr rdivsulr disese. The ngliflzin treted grup hd  lwer priry psite ute f deth fr rdivsulr uses, nnftl yrdil infrtin, r nnftl strke (hzrd rti 0.86, P= 0.02). In  2019 hert filure study f 4744 ptients with NYHA lss II, III, r IV hert filure nd ejetin frtin f less40%, dpgliflzin redued the uultive inidene f wrsening hert filure r rdivsulr deth (hzrd rti 0.74, P< 0.001). Frty-tw perent f the ptients hd dibetes; the findings in ptients with nd withut dibetes were the se. Bth epgliflzin nd ngliflzin shw benefit in ters f prgressin f lbuinuri nd kidney injury, pssibly by lwering glerulr hyperfiltrtin. In  2019 ultintinl study f 4401 ptients with type 2 dibetes nd lbuinuri hrni kidney disese (eGFR 3089 L/in/1.73 2with lbuin [g] t retinine [g] rti > 300 t 5000) nd tking n ACE inhibitr r ngitensin reeptr blker, ngliflzin redued the risk f end-stge kidney disese, the dubling f seru reti- nine, nd f renl deth. In  2020 ultintinl study f 4304 ptients with hrni kidney disese, dpgliflzin redued the risk f end-stge kidney disese r deth fr renl nd rdivsulr uses. A third f the ptients in the study did nt hve dibetes nd hd benefit. Side effects As ight be expeted, the effiy f the SGLT2 inhibitrs is redued in hrni kidney disese. They n ls inrese retinine nd derese eGFR, espe- illy in ptients with kidney ipirent. Their use is generlly nt reended in ptients with eGFR less thn 45 L/in/1.73 2nd re ntrindited in ptients with eGFR less thn 30 L/in/1.73 2. The study f dpgliflzin in hrni kidney disese, hwever, nted tht the drug is sfe nd benefiil in ptients with eGFR s lw s 25 L/in/1.73 2. The in side effets re inresed inidene f genitl yti infetins nd urinry trt infetins ffeting ~89% f ptients. Cses f nertizing fsiitis f the perineu (Furnier gn- grene) hve been reprted. There hve ls been reprts f ses f pyelnephritis nd septiei requiring hspitl- iztin. The glysuri n use intrvsulr vlue ntrtin nd hyptensin. One ultintinl study with ngliflzin shwed n inresed risk f puttins, espeilly f the tes (hzrd rti 1.97). This finding hs nt been bserved in ther studies using this drug r with the ther SGLT2 inhibitrs. Cngliflzin hs been reprted t use  derese in bne inerl density t the lubr spine nd the hip. In  pled nlysis f eight linil trils (en durtin 68 weeks),  30% inrese in frtures ws bserved in ptients tking ngliflzin. It is likely tht the effet n the bnes is  lss effet nd nt restrited t n- gliflzin. All the SGLT2 inhibitrs use  dest inrese in LDL hlesterl levels (38%). Als, in linil trils, ptients tking dpgliflzin hd higher rtes f brest ner (nine ses vs nne in prtr rs) nd bld- der ner (10 ses vs 1 in pleb r). These ner rtes exeeded the expeted rtes in ge-thed referene dibetes ppultin. Cses f DKA hve been reprted with ff-lbel use f SGLT2 inhibitrs in ptients with type 1 dibetes. Type 1 ptients re tught t give less insulin if their gluse levels re nt elevted. SGLT2 inhibitrs lwer gluse levels by hnging the renl threshld nd nt by insulin tin. Type 1 ptients tking n SGLT2 inhibitr, beuse the gluse levels re nt elevted, y either withhld rCMDT22_Ch27_p1212-p1255.indd  1228 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1229 CMDT 2022redue  their insulin dses t suh  degree s t indue ketidsis. SGLT2 inhibitors should not be used in patients with type 1 diabetes and in those patients labeled as having type 2 diabetes but who are very insulin deficient and ketosis-prone. 6. Others Prlintide is  syntheti nlg f islet y- lid plypeptide (IAPP r ylin). When given subutne- usly, it delys gstri eptying, suppresses glugn seretin, nd dereses ppetite. It is pprved fr use bth in type 1 dibetes nd in insulin-treted type 2 dibe- tes. In 6-nth linil studies with type 1 nd insulin- treted type 2 ptients, thse tking the editin hd n pprxitely 0.4% redutin in HbA1nd but 1.7 kg weight lss pred with pleb. The HbA1redutin ws sustined fr 2 yers but se f the weight ws regined. The editin is given by injetin ieditely befre the el. Hypglyei n ur, nd it is re- ended tht the shrt-ting r preixed insulin dses be redued by 50% when the editin is strted. Sine the editin slws gstri eptying, revery fr hyp- glyei n be  prble beuse f dely in bsrptin f fst-ting rbhydrtes. Nuse is the ther in side effet, ffeting 3050% f persns, but tends t iprve with tie. In ptients with type 1 dibetes, the initil dse f prlintide is 15 g befre eh el nd titrted up by 15-g inreents t  intenne dse f 30 g r 60 g befre eh el. In ptients with type 2 dibetes, the strting dse is 60 g preels inresed t 120 g in 3 t 7 dys if n signifint nuse urs. Brriptine,  dpine 2 reeptr gnist, hs been shwn t destly lwer HbA1by 0.10.5% when pred t bseline nd 0.40.5% pred t pleb. Cn side effets re nuse, viting, dizziness, nd hedhe. Clesevel, the bile id sequestrnt, when dded t etfrin r sulfnylure r insulin, lwered HbA10.3 0.4% when pred t bseline nd 0.50.6% pred t pleb. HbA1lwering, hwever, ws nt bserved in  single ntherpy linil tril pring lesevel t pleb. Clesevel use is ssited with ~20% inrese in triglyeride levels. Other dverse effets inlude nstiptin nd dyspepsi.With their modest glucose lowering and significant side effects, using bromocriptine or colesevelam to treat diabetes is not recommended. 7. Medication combinations Severl editin bi- ntins re vilble in different dse sizes, inluding glyburide nd etfrin (Gluvne); glipizide nd et- frin (Metglip); repglinide nd etfrin (Prndi-Met); rsiglitzne nd etfrin (Avndet); piglitzne nd etfrin (ACTOplusMet); rsiglitzne nd gliepiride (Avndryl); piglitzne nd gliepiride (Duett); sitgliptin nd etfrin (Jnuet); sx- gliptin nd etfrin XR (Kbiglyze XR); lingliptin nd etfrin (Jentduet); lgliptin nd etfrin (Kzn); lgliptin nd piglitzne (Oseni); dp- gliflzin nd etfrin (Xigdu); ngliflzin nd et- frin (Invket); epgliflzin nd etfrin (Synjrdy); epgliflzin nd lingliptin (Glyxbi); epgliflzin, lingliptin, nd etfrin (Trijrdy); ertugliflzin nd etfrin (Segluret); ertugliflzin nd sitgliptin (Steglujn); insulin deglude nd lirglutide (Xultphy); nd insulin glrgine nd lixisentide (Sliqu). These editin bintins, hwever, liit the lini- ins bility t ptilly djust dsge f the individul editins nd fr tht resn re nt reended.C.  InsulinInsulin is indi ted fr type 1 dibetes s well s fr type 2 dibeti ptients with insulinpeni whse hyperglyei des nt respnd t diet therpy either lne r bined with ther hypglyei editins. 1. Characteristics of available insulin preparations Hun insulin is dispensed s either regulr (R) r NPH (N) frultins. Six nlgs f hun insulinthree rpidly ting (insulin lispr, insulin sprt, insulin gluli- sine) nd three lng-ting (insulin glrgine, insulin deteir, nd insulin deglude)re vilble fr linil use. Insulin preprtins differ with respet t the tie f nset nd durtin f their bilgi tin (Tble 275). All urrently vilble insulins ntin less thn 10 pp f prinsulin nd re lbeled s purified.  These purified insulins preserve their pteny, s tht refrigertin Table 275. Summary of bioavailability characteristics of the insulins.Insulin  Pepaations1Onset of Action Peak Action Effective Duation Insulins lispro, aspart,2,3glulisine 515 minutes 11.5 hours 34 hours Human regular 3060 minutes 2 hours 68 hours Human NPH 24 hours 67 hours 1020 hours Insulin glargine 0.51 hour Flat ~24 hours Insulin detemir 0.51 hour Flat 17 hours Insulin degludec 0.51.5 hours Flat More than 42 hours Technosphere inhaled insulin 515 minutes 1 hour 3 hours1 Insulin administered subcutaneously unless otherwise noted.2 Insulin aspart formulated with niacinamide (FiAsp has an ~10-minute faster onset of action).3 Insulin lispro formulated with treprostinil and citrate (Lyumjev has an 11-minute faster onset of action).CMDT22_Ch27_p1212-p1255.indd  1229 29/06/21 8:53 PMCHAPTEr 271230 CMDT 2022is  reended but nt ruil. During trvel, reserve supplies f insulin n be redily trnsprted fr weeks withut lsing pteny if prteted fr extrees f het r ld. All the insulins in the United Sttes re vilble in  nentrtin f 100 units/L (U100) nd dispensed in 10-L vils r 0.3-L rtridges r prefilled dispsble pens. Severl insulins re vilble t higher nentr- tins: insulin glrgine, 300 units/L (U300); insulin deglude, 200 units/L (U200); insulin lispr, 200 units/L (U200); nd regulr insulin, 500 units/L (U500). 2. Insulin preparations See Tble 276. The rpidly t- ing insulin nlgs nd the lng-ting insulins re designed fr subutneus dinistrtin, while regulr insulin nd insulin sprt n ls be given intrvenusly. a. Short-acting insulin preparations (1) Regular insulin Regulr insulin is  shrt-ting sluble rystlline zin insulin whse effet ppers within 30 inutes fter subutneus injetin nd lsts 57 hurs when usul quntities re dinistered. Intrvenus infu- sins f regulr insulin re prtiulrly useful in the tret- ent f DKA nd during the peripertive ngeent f ptients with dibetes wh require insulin. Fr rkedly insulin-resistnt persns wh wuld therwise require lrge vlues f insulin slutin,  U500 preprtin f hun regulr insulin is vilble bth in  vil fr nd  dispsble pen. A U500 insulin syringe shuld be used if the vil fr is dispensed. U500 regulr insulin is uh re expensive thn the U100 nentrtin nd is rrely needed.(2) Rapidly acting insulin analogs Insulin lispr (Hulg, Adelg) is n insulin nlg where the pr- line t psitin B28 is reversed with the lysine t B29. Insulin sprt (Nvlg) is  single substitutin f prline by sprti id t psitin B28. In insulin glulisine (Apidr) the sprgine t psitin B3 is repled by lysine nd the lysine in psitin B29 by gluti id. These three n- lgs hve less f  tendeny t fr hexers, in ntrst t hun insulin. When injeted subutneusly, the n- lgs quikly dissite int ners nd re bsrbed very rpidly, rehing pek seru vlues in s sn s 1 hurin ntrst t regulr hun insulin, whse hex- ers require nsiderbly re tie t dissite nd bee bsrbed. The in id hnges in these nlgs d nt interfere with their binding t the insulin reeptr, with the irulting hlf-life, r with their iungeniity, whih re ll identil with thse f hun regulr insulin. An insulin sprt frultin (FiAsp) tht ntins niin- ide (vitin B3) hs  re rpid initil bsrptin nd its nset f tin is but 10 inutes fster thn the stndrd insulin sprt frultin. Beuse f this re rpid nset f tin, the 1-hur (but nt 2-hur) pstprndil gluse exursins re lwer pred t the stndrd frultin. Siilrly, n insulin lispr frultin (Lyujev) ntin- ing trepstinil t indue ll vsdiltin nd itrte t inrese vsulr perebility hs 11 inutes fster nset f tin nd lwer 1- nd 2-hur pstprndil gluse exur- sins pred t the stndrd insulin lispr frultin. Clinil trils hve denstrted tht the ptil ties f preprndil subutneus injetin f prble dses f the rpidly ting insulin nlgs nd f regulr hun insulin re 20 inutes nd 60 inutes, respetively, befre the el. The quiker nset f tin with the rpidly t- ing insulin nlgs llws the ptient t injet insulin just befre eting rther thn wit fr 60 inutes s needed fr regulr insulin. Anther desirble feture f rpidly ting insulin nlgs is tht their durtin f tin reins t but 4 hurs fr st nly used dsges. This n- trsts with regulr insulin, whse durtin f tin is sig- nifintly prlnged when lrger dses re used. The rpidly ting nlgs re nly used in pups. In  duble-blind rssver study pring insu- lin lispr with regulr insulin in insulin pups, persns using insulin lispr hd lwer HbA1vlues nd iprved pstprndil gluse ntrl with the se frequeny f hypglyei. In the event f pup filure, hwever, users f the rpidly ting insulin nlgs will hve re rpid nset f hyperglyei nd ketsis. While insulin sprt hs been pprved fr intrvenus use (eg, in hyperglyei eergenies), there is n dvn- tge in using insulin sprt ver regulr insulin by this rute. A U200 nentrtin f insulin lispr is vilble in  dispsble prefilled pen. The nly dvntge f the U200 ver the U100 insulin lispr preprtin is tht it delivers the se dse in hlf the vlue. b. Long-acting insulin preparations (1) NPH (neutral protamine Hagedorn or isophane) insulin NPH is n interedite-ting insulin whse nset f tin is delyed t 24 hurs, nd its pekTable 276. Insulin preparations available in the United States.1rapidly  acting human insulin analogs Insulin lispro (Humalog, Lyumjev, Lilly; Admelog, Sanofi) Insulin aspart (Novolog, FiAsp, Novo Nordisk) Insulin glulisine (Apidra, Sanofi Aventis) Shot-acting egula insulin Regular insulin (Lilly, Novo Nordisk) Technosphere inhaled regular insulin (Afrezza) Intemediate-acting insulins NPH insulin (Lilly, Novo Nordisk) Pemixed insulins 70% NPH/30% regular (70/30 insulinLilly, Novo Nordisk) 70% NPL/25% insulin lispro (Humalog Mix 75/25Lilly) 50% NPL/50% insulin lispro (Humalog Mix 50/50Lilly) 70% insulin aspart protamine/30% insulin aspart (Novolog Mix 70/30Novo Nordisk) 70% insulin degludec/30 insulin aspart (Ryzodeg, Novo Nordisk) Long-acting human insulin analogs Insulin glargine (Lantus (U100), Toujeo (U300), Sanofi Aventis; Basaglar (U100), Lilly) Insulin detemir (Levemir, Novo Nordisk) Insulin degludec (Tresiba, Novo Nordisk)1 All insulins available in the United States are recombinant human or human insulin analog origin. All the above insulins are dis- pensed at U100 concentration. There is an additional U500 prepa- ration of regular insulin; U300 preparation of insulin glargine; U200 preparation of insulin lispro; U200 preparation of insulin degludec. NPH, neutral protamine Hagedorn.CMDT22_Ch27_p1212-p1255.indd  1230 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1231 CMDT 2022respn se is generlly rehed in but 67 hurs. The nset f tin is delyed by bining 2 prts sluble rystlline zin insulin with 1 prt prtine zin insulin. This prdues equivlent unts f insulin nd prt- ine, s tht neither is present in n unplexed fr (isphne). Beuse its durtin f tin is ften less thn 24 hurs (with  rnge f 1020 hurs), st ptients require t lest tw injetins dily t intin  sustined insulin effet. Osinl vils f NPH insulin hve tended t shw unusul luping f their ntents r frsting f the ntiner, with nsiderble lss f bitivity. This instbility is rre nd urs less frequently if NPH hun insulin is refrigerted when nt in use nd if bttles re disrded fter 1 nth f use. (2) Insulin glargine In this insulin, the sprgine t psitin 21 f the insulin A hin is repled by glyine nd tw rginines re dded t the rbxyl terinl f the B hin. The rginines rise the iseletri pint f the l- eule lser t neutrl king it re sluble in n idi envirnent. In ntrst, hun insulin hs n iseletri pint f pH 5.4. Insulin glrgine is  ler insulin, whih, when injeted int the neutrl pH envirnent f the sub- utneus tissue, frs irpreipittes tht slwly relese the insulin int the irultin. This insulin lsts fr but 24 hurs withut ny prnuned peks nd is given ne  dy t prvide bsl verge. This insulin nnt be ixed with the ther hun insulins beuse f its idi pH. When this insulin ws given s  single injetin t bedtie t type 1 ptients in linil trils, fsting hyper- glyei ws better ntrlled with less nturnl hyp- glyei when pred t NPH insulin. A re nentrted fr f insulin glrgine (U300) is vilble s n insulin pen. In linil trils in type 1 ptients, U300 use did nt result in better ntrl r redue the rtes f hypglyei. Althugh liited linil dt suggest tht insulin glrgine is sfe in pregnny, it is nt pprved fr this use. (3) Insulin detemir In this insulin nlg, the thre- nine t psitin B30 hs been reved nd  14-C ftty id hin (tetrdeni id) is tthed t the lysine t psitin 29 by yltin. Its prlnged tin is due t dihexeriztin nd binding f hexers nd diers t lbuin t the injetin site s well s binding f the ner vi its ftty id side hin t lbuin in the irultin. The ffinity f insulin deteir is furfld t fivefld lwer thn tht f hun sluble insulin nd therefre the U100 frultin f insulin deteir hs n insulin nentrtin f 2400 nl/L pred with 600 nl/L fr NPH. The durtin f tin fr insulin deteir is but 17 hurs t therpeutilly relevnt dses. It is reended tht the insulin be injeted ne r twie  dy t hieve  stble bsl verge. It hs been pprved fr use during pregnny. (4) Insulin degludec In this insulin nlg, the thre- nine t psitin B30 hs been reved, nd the lysine t psitin B29 is njugted t hexdeni id vi  g-L-glutyl sper. In the vil, in the presene f phenl nd zin, the insulin is in the fr f dihexers but when injeted subutneusly, it self ssites int lrge ultihexeri hins nsisting f thusnds fdihexers. The hins slwly disslve in the subutne- us tissue nd insulin ners re stedily relesed int the systei irultin. The hlf-life f insulin deglude is 25 hurs. Its nset f tin is in 3090 inutes nd its durtin f tin is re thn 42 hurs. It is re- ended tht the insulin be injeted ne r twie  dy t hieve  stble bsl verge. Insulin deglude is vil- ble in tw nentrtins, U100 nd U200, nd dispensed in prefilled dispsble pens. (5) Insulin icodec This is n insulin nlg tht is suit- ble fr ne weekly injetin nd is in phse 3 linil trils. c. Mixed insulin preparations Ptients with type 2 dibetes n seties hieve resnble gluse ntrl with just prebrekfst nd predinner injetins f ixtures f shrt ting nd NPH insulins. The regulr insulin r rpidly ting insulin nlg is withdrwn first, then the NPH insulin nd then injeted ieditely. Stble pre- ixed insulins (70% NPH nd 30% regulr) re vilble s  nveniene t ptients wh hve diffiulty ixing insu- lin beuse f visul prbles r ipirent f nul dexterity (Tble 276). Preixed preprtins f insulin lispr nd NPH insulins re unstble; stbility is hieved by repling the NPH insulin with NPL (neutrl prtine lispr). This insulin hs the se durtin f tin s NPH insulin. Preixed bintins f NPL nd insulin lispr (75% NPL/25% insulin lispr ixture [Hulg Mix 75/25] nd 50% NPL/50% insulin lispr ixture [Hulg Mix 50/50]) re vilble fr linil use. Sii- lrly,  70% insulin sprt prtine/30% insulin sprt (NvLg Mix 70/30) is vilble. The in dvntges f these ixtures re tht they n be given within 15 inutes f strting  el nd they re superir in ntrlling the pstprndil gluse rise fter  rbhydrte-rih el. These benefits hve nt trnslted int iprveents in HbA1levels when pred with the usul 70% NPH/30% regulr ixture. The lnger-ting insulin nlgs, insulin glrgine nd insulin deteir, nnt be ixed with either regulr insulin r the rpidly ting insulin nlgs. Insulin deglude, hwever, n be ixed nd is vilble s 70% insulin deglude/30% insulin sprt nd is injeted ne r twie  dy. 3. Methods of insulin administration a. Insulin syringes and needles Plsti dispsble syringes re vilble in 1-L, 0.5-L, nd 0.3-L sizes. Three lengths f needles re vilble: 6 , 8 , nd 12.7 . Lng needles re preferble in bese ptients t redue vribility f insulin bsrptin. The needles re f 28, 30, nd 31 guges. The 31-guge needles re lst pinless. Dispsble syringes y be reused until blunt- ing f the needle urs (usully fter three t five inje- tins). Sterility dequte t vid infetin with reuse ppers t be intined by repping syringes between uses. Clensing the needle with lhl y nt be desir- ble sine it n disslve the siline ting nd n inrese the pin f skin punturing. b. Sites of injection Any prt f the bdy vered by lse skin n be used, suh s the bden, thighs, upperCMDT22_Ch27_p1212-p1255.indd  1231 29/06/21 8:53 PMCHAPTEr 271232 CMDT 2022rs,  flnks, nd upper buttks. Preprtin with l- hl is nt required prir t injetin s lng s the skin is len. Rttin f sites is reended t vid delyed bsrptin when fibrsis r liphypertrphy urs fr repeted use f  single site. Regulr insulin is bsrbed re rpidly when injeted in the deltid r bden pred t thighs nd buttks. Exerise n inrese bsrptin when the injetin site is djent t the exer- ise usle. Fr st ptients, the bden is the re- end regin fr injetin beuse it prvides dequte re in whih t rtte sites. The effet f nti regins ppers t be uh less prnuned with the nlg insulins. c. Insulin pen injector devices Insulin pens (Nv Nrdisk, nd Owen Mufrd) eliinte the need fr r- rying insulin vils nd syringes. Srt pens (Cpnin Medil) tht re linked t ell phnes n be used t reind the user t tke their insulin befre els, lulte dses, nd keep trk f tiing f the dses. Crtridges f insulin lispr nd insulin sprt re vilble fr the reus- ble pens. Dispsble prefilled pens re ls vilble fr regulr insulin (U100 nd U500), insulin lispr, insulin sprt, insulin glulisine, insulin deteir, insulin glrgine, insulin deglude, NPH, 70% NPH/30% regulr, 75% NPL/25% insulin lispr, 50% NPL/50% insulin lispr, 70% insulin sprt prtine/30% insulin sprt, nd 70% insulin deglude/30% insulin sprt. Pen needles re vil- ble in 29, 31, nd 32 guges nd 4-, 5-, 6-, 8-, nd 12.7- lengths (Nvfine; BD). d. Insulin pumps In the United Sttes, Medtrni Mini- Med, Insulet, nd Tnde ke bttery perted ntinu- us subutneus insulin infusin (CSII) pups. These pups re sll (but the size f  pger) nd esy t prgr. They ffer ny fetures, inluding the bility t set  nuber f different bsl rtes thrughut the 24 hurs nd t djust the tie ver whih blus dses re given. They ls re ble t detet pressure build-up if the theter is kinked. The theter nneting the insulin reservir t the subutneus nnul n be disn- neted, llwing the ptient t reve the pup teprr- ily (eg, fr bthing). Oinpd (Insulet Crprtin) is n insulin infusin syste in whih the insulin reservir nd infusin set re integrted int ne unit (pd), s there is n theter (eletrni pth pup). The pd, pled n the skin, delivers subutneus bsl nd blus insulin bsed n wirelessly trnsitted instrutins fr  per- snl digitl ssistnt. The gret dvntge f ntinuus subutneus insulin infusin (CSII) is tht it llws fr estblishent f  bsl prfile tilred t the ptient llwing fr better vernight nd between els gluse ntrl. The bility t djust the bsl insulin infusin kes it esier fr the ptient t nge glyei exur- sins tht ur with exerise. The pups hve sftwre tht n ssist the ptient t lulte bluses bsed n gluse reding nd rbhydrtes t be nsued. They keep trk f the tie elpsed sine the lst insulin blus; the ptient is reinded f this when he r she ttepts t give dditinl rretin blus befre the effet f the previus blus hs wrn ff (insulin n brd feture).This feture redues the risk f verrreting nd subse- quent hypglyei. CSII therpy is pprprite fr ptients with type 1 dibetes wh re tivted, ehnilly inlined, edu- ted but dibetes (diet, insulin tin, tretent f hypglyei nd hyperglyei), nd willing t nitr their bld gluse fur t six ties  dy. Knwn pli- tins f CSII inlude ketidsis, whih n ur when insulin delivery is interrupted, nd skin infetins. Anther disdvntge is its st nd the tie needed f the liniin nd stff t initite therpy. Alst ll ptients use rpid- ting insulin nlgs in their pups. V-g (Vlerits) is  ehnil pth pup designed speifilly fr peple with type 2 dibetes wh use  bsl/ blus insulin regien. The devie is preset t deliver ne f three fixed nd flt bsl rtes (20, 30, r 40 units) fr 24 hurs (t whih pint it ust be repled) nd there is  buttn tht delivers tw units per press t help ver els. e. Closed loop systems Algriths hve been devised t use gluse dt fr the ntinuus gluse nitr- ing systes t uttilly deliver insulin by ntinuus subutneus insulin infusin pup. These lsed lp systes (rtifiil pnres) hve been shwn in linil studies t iprve nighttie gluse ntrl, destly lwer HbA1levels, nd redue the risk f nturnl hyp- glyei. The MiniMed 670 G nd the Tnde Cntrl- IQ, hve been pprved fr linil use. The MiniMed 670 G lsed lp syste uses gluse dt fr  sensr t uttilly djust bsl insulin dses every 5 inutes, trgeting  sensr gluse level f 120 g/dL (6.7 l/L). Insulin delivery is suspended when the sensr gluse level flls belw r is predited t fll belw trget level. The gluse trget n be djusted up t 150 g/dL (8.3 l/L) fr physil tivity. The Tnde Cntrl-IQ trgets  sen- sr gluse level f 112.5 g/dL (6.25 l/L). The ptient is still respnsible fr blusing insulin fr els nd snks. There re ls D-It-Yurself lsed lp sys- tes using free pen-sure sftwre. One suh syste, lled the Lp,  uses the Dex G6 sensr, the iPhne, nd the Onipd insulin pup. The Lp ntrller is dwnlded n t the iPhne, nd it uses the Dex G6 sensr gluse esureents (ls n the iPhne) t ut- tilly djust bsl insulin delivery n the Onipd pup. Inresing nubers f type 1 ptients use these D- It-Yurself systes, but they re nt pprved fr use by the FDA. Suessful use f these systes requires prfi- ieny t using bth the insulin pup nd ntinuus gluse nitr. The systes re expensive; the insulin pup, whih needs t be repled every 4 yers, sts but $6000 nd the pup supplies re $1500 per yer. The ntinuus gluse nitring syste sts pprxitely $4000 per yer. f. Inhaled insulin Tehnsphere insulin (Afrezz) is  dry-pwder frultin f rebinnt hun regulr insulin tht n be inhled. It nsists f 2- t 2.5- rystls f the exipient furyl diketpiperzine tht pr- vide  lrge surfe re fr dsrptin f prteins like insulin. The tehnsphere insulin is rpidly bsrbed with pek insulin levels rehed in 1215 inutes nd deliningCMDT22_Ch27_p1212-p1255.indd  1232 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1233 CMDT 2022t bseline  in 3 hurs; the edin tie t xiu effet with inhled insulin is pprxitely 1 hur nd delines t bseline by but 3 hurs. In ntrst, the edin tie t xiu effet with subutneus insulin lispr is but 2 hurs nd delines t bseline by 4 hurs. In lini- l trils, tehnsphere insulin bined with bsl insu- lin ws s effetive in gluse lwering s rpid-ting insulin nlgs bined with bsl insulin. It is fru- lted s  single-use, lr-ded rtridge delivering 4, 8, r 12 units ieditely befre the el. The nufturer prvides  dse nversin tble; ptients injeting up t 4 units f rpid-ting insulin nlg shuld use the 4-unit rtridge. Thse injeting 5 t 8 units shuld use the 8-unit rtridge. If the dse is 912 units f rpid-ting insulin preel then ne 4-unit rtridge nd ne 8-unit rtridge r ne 12-unit rtridge shuld be used. The inhler is but the size f  referees whistle. The st n dverse retin f the inhled insulin is  ugh, ffeting but 27% f ptients. A sll derese in pulnry funtin (fred expirtry vlue in 1 send [FEV1]) is seen in the first 3 nths f use, whih persists ver 2 yers f fllw-up. Inhled insulin is ntrindited in ptients wh ske nd in thse with hrni lung disese, suh s sth nd hrni bstru- tive pulnry disese. Spiretry shuld be perfred t identify ptentil lung disese prir t inititing therpy. During linil trils, there were tw ses f lung ner in ptients wh were tking inhled insulin nd nne in the prtr-treted ptients. All the ptients in wh lung ner develped hd  histry f prir igrette sking. Cses f lung ner were ls reprted in igrette sk- ers using  previusly vilble inhled insulin preprtin (Exuber). The inidene rte in the Exuber-treted grup ws 0.13 per 1000 ptient-yers, wheres it ws 0.03 per 1000 ptient-yers in the prtr-treted grup.D . Transplantation1. Pancreas transplan tation All ptients with end-stge kidney disese nd type 1 dibetes wh re ndidtes fr  kidney trnsplnt shuld be nsidered ptentil ndi- dtes fr  pnres trnsplnt. Eligibility riteri inlude ge yunger thn 55 nd inil rdivsulr risk. Cntrinditins inlude nnrretble rnry rtery disese, extensive peripherl vsulr disese, nd signifi- nt besity (weight greter thn 100 kg). The pnres trnsplnt y ur t the se tie s kidney trnsplnt r fter kidney trnsplnt. Ptients underging siultne- us pnres nd kidney trnsplnttin hve n 83% hne f pnreti grft survivl t 1 yer nd 69% t 5 yers. Slitry pnreti trnsplnttin in the bsene f  need fr kidney trnsplnttin is nsidered nly in thse rre ptients wh d nt respnd t ll ther insulin therpeuti pprhes nd wh hve frequent severe hypglyei, r wh hve life-thretening plitins relted t their lk f etbli ntrl. Slitry pnres trnsplnt grft survivl is 78% t 1 yer nd 54% t 5 yers. 2. Islet transplantation Ttl pnretety is urtive fr severe pin syndre ssited with hrni pnre- titis. The pnretety, hwever, results in surgildibetes. Hrvesting islets fr the reved pnres nd uttrnsplnting the int the liver (vi prtl vein) n prevent the develpent f dibetes r result in ild dibetes (prtil islet funtin) tht is esier t nge. Sine the islets re utlgus, n iunsuppressin is required. The nuber f islets trnsplnted is the in preditr f insulin independene. Peple with type 1 dibetes n bee insulin inde- pendent fter reeiving islets islted fr  dnr pn- res (llislet trnsplnt). The islets re infused int the prtl vein using  perutneus trnshepti pprh, nd they ldge in the liver relesing insulin in respnse t physilgi stiuli. Lng-ter iunsuppressin is neessry t prevent llgrft rejetin nd t suppress the utiune press tht led t the disese in the first ple. Insulin independene fr re thn 5 yers hs been denstrted in ptients wh gt nti-CD3 nti- bdy r nti-thyyte glbulin indutin iunsup- pressin nd lineurin inhibitrs, Tr inhibitrs, nd yphenlte fetil s intenne iunsuppres- sin. One jr liittin is the need fr re thn ne islet infusin t hieve insulin independene. This is beuse f signifint lss f islets during isltin nd the perid prir t engrftent. Widespred llislet trnsplnttin will depend n iprving insulin inde- pendene rtes with ne infusin nd ls denstrting tht the lng-ter utes re s gd s thse f pn- res trnsplnt lne.Kristensen  SL et l. Crdivsulr, rtlity, nd kidney ut- es with GLP-1 reeptr gnists in ptients with type 2 dibetes:  systeti review nd et-nlysis f rdivs- ulr ute trils. Lnet Dibetes Endrinl. 2019;7:776. [PMID: 31422062] Leelrthn L et l. Hybrid lsed-lp therpy: where re we in 2021? Dibetes Obes Metb. 2021;23:655. [PMID: 33269551] MGuire DK et l. Assitin f SGLT2 inhibitrs with rdi- vsulr nd kidney utes in ptients with type 2 dibe- tes:  et-nlysis. JAMA Crdil. 2021;6:148. [PMID: 33031522] Steps in the Management of DiabetesA.  Distinguishing the Types of DiabetesAn tt ept shuld be de t hrterize the dibetes s type 1 r type 2 r ther speifi types suh s MODY, bsed n the linil fetures present nd n whether r nt ketnuri pnies the glysuri. Fetures tht suggest end-rgn insulin insensitivity t insulin, suh s viserl besity, nthsis nigrins, r bth, ust be identified. The fily histry shuld duent nt nly the inidene f dibetes in ther ebers f the fily but ls the ge t nset, ssitin with besity, the need fr insulin, nd whether there were plitins. Fr the sinl ptient, esureent f GAD65, IAA, ICA 512, nd zin trnsprter 8 ntibdies n help distinguish between type 1 nd type 2 dibetes (Tble 277). Mny ptients with newly dignsed type 1 dibetes still hve signifint endgenus insulin prdutin, nd C peptide levels d nt relibly distinguish between type 1 nd type 2 dibetes.CMDT22_Ch27_p1212-p1255.indd  1233 29/06/21 8:53 PMCHAPTEr 271234 CMDT 2022B.  Patient Education (SelfManagement Training)Since  diabetes is a lifelong disorder, education of the patient and the family is probably the most important obligation of the clinician who provides care. The best persns t nge  disese tht is ffeted s rkedly by dily flututins in envirnentl stress, exerise, diet, nd infetins re the ptients theselves nd their fi- lies. The tehing urriulu shuld inlude expln- tins by the liniin r nurse f the nture f dibetes nd its ptentil ute nd hrni hzrds nd hw they n be regnized erly nd prevented r treted. Self- nitring f bld gluse shuld be ephsized, espe- illy in insulin-requiring dibeti ptients, nd instrutins ust be given n prper testing nd rerding f dt. Ptients tking insulin shuld hve n understnding f the tins f bsl nd blus insulins. They shuld be tught t deterine whether the bsl dse is pprprite nd hw t djust the rpidly ting insulin dse fr the rbhydrte ntent f  el. Ptients nd their filies nd friends shuld be tught t regnize signs nd syp- ts f hypglyei nd hw t tret lw gluse re- tins. Strenuus exerise n preipitte hypglyei, nd ptients ust therefre be tught t redue their insulin dsge in ntiiptin f strenuus tivity r t tke supple- entl rbhydrte. Injetin f insulin int  site frthest wy fr the usles st invlved in the exerise y help elirte exerise-indued hypglyei, sine insu- lin injeted in the prxiity f exerising usle y be re rpidly bilized. Exerise trining ls inreses the effetiveness f insulin, nd insulin dses shuld be djusted rdingly. Infetins n use insulin resistne, nd ptients shuld be instruted n hw t nge the hyper- glyei with suppleentl rpidly ting insulin. Advie n persnl hygiene, inluding detiled instru- tins n ft nd dentl re, shuld be prvided. All infe- tins (espeilly pygeni nes) prvke the relese f high levels f insulin ntgnists, suh s tehlines r glugn, nd thus bring but  rked inrese in insu- lin requireents. Ptients wh re tking rl gents y depenste nd teprrily require insulin. Ptients shuld be tld but unity genies, suh s Dibetes Assitin hpters, tht n serve s  ntinuing sure f instrutin.Finlly, vigrus effrts shuld be de t persude ptients with newly dignsed dibetes wh ske t give up the hbit, sine lrge vessel peripherl vsulr disese nd debilitting retinpthy re less n in nnsk- ing dibeti ptients.C.  MedicationsT retent ust be individulized n the bsis f the type f dibetes nd speifi needs f eh ptient. Hwever, ertin generl priniples f ngeent n be utlined fr hyperglyei sttes f different types. 1. Type 1 diabetes A bintin f rpidly ting insu- lin nlgs nd lng-ting insulin nlgs llws fr re physilgi insulin repleent. Tble 278 illustrtes  regien with  rpidly ting insulin nlg nd lng- ting bsl insulin tht ight be pprprite fr  70-kg persn with type 1 dibetes eting els prviding stn- drd rbhydrte intke nd derte t lw ft ntent. Insulin glrgine r insulin deglude is usully given ne in the evening t prvide 24-hur verge. There re sinl ptients in wh insulin glrgine des nt lst fr 24 hurs, nd in suh ses, it needs t be given twie  dy. Insulin deteir usully hs t be given twie  dy t get dequte 24-hur bsl verge. Altern- tively, sll dses f NPH (~34 units) n be given with eh el t prvide dytie bsl verge with  lrger dse t night. CSII by prtble bttery-perted pen lp devies llw the setting f different bsl rtes thrughut the 24 hurs nd perit blus dse djustents by s little s 0.05-unit inreents. The 24-hur bsl dsge is usully bsed n ge nd bdy weight. An dlesent ight need s uh s 0.4 unit/kg/dy;  yung dult (less thn 25 yers),Table 277. Diagnostic sensitivity and specificity of autoimmune markers in patients with newly diag- nosed type 1 diabetes mellitus. Sensitivity Specificity Islet cell antibodies (ICA) 44100% 96% Glutamic acid decarboxylase (GAD65)7090% 99% Insulin (IAA) 4070% 99% Tyrosine phosphatase (IA-2, ICA 512)5070% 99% Zinc transporter 8 (ZnT8) 5070% 99%T able 278. Examples of intensive insulin regimens using rapidly acting insulin analogs (insulin lispro, aspart, or glulisine) and long-acting insulin analogs (insulin detemir, or insulin glargine or degludec) in a 70-kg man with type 1 diabetes.13 Pe- beakfastPe- lunchPe- dinneAt Bedtime Rapidly acting insulin analog5 units 4 units 6 units Insulin detemir367 units  89 units OR Rapidly acting insulin analog5 units 4 units 6 units  Insulin glargine or degludec3  1516 units1 Assumes that patient is consuming approximately 75 g carbohy- drate at breakfast, 60 g at lunch, and 90 g at dinner.2 The dose of rapidly acting insulin can be raised by 1 or 2 units if extra carbohydrate (1530 g) is ingested or if premeal blood glu- cose is > 170 mg/dL (9.4 mmol/L).3 Insulin glargine or insulin detemir must be given as a separate injection.CMDT22_Ch27_p1212-p1255.indd  1234 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1235 CMDT 20220.35 unit p er/kg/dy; nd n lder dult, 0.25 unit/kg/dy. Fr exple,  70-kg, 30-yer-ld persn y require  bsl rte f 0.7 unit per hur thrughut the 24 hurs with the exeptin f 3 am t 8 am, when 0.8 unit per hur ight be pprprite (given the  dawn phenomenon  redued tissue sensitivity t insulin between 5 am nd 8 am). The el blus vries bsed n the tie f dy nd the persns ge. Adlesents nd yung dults usully require 1 unit fr but 10 g f rbhydrte. Older dults usully require but 1 unit fr 15 g f rbhydrte. The rretin ftrhw uh insulin is needed t lwer gluse levels by 50 g/dLn be lulted fr the insulin-t-rbhydrte rtis. Fr exple, if 1 unit is required fr 15 g f rbhydrte, then 1 unit will lwer gluse levels by 50 g/dL. If 1.5 units f insulin re required fr 15 g f rbhydrte (tht is, 1 unit fr 10 g rbhydrte), then 1.5 units f insulin will lwer gluse levels by 50 g/dL (tht is, 1 unit will lwer gluse level by 33 g/dL). Fr  70-kg 30-yer-ld persn, blus rtis f 1 unit fr 1215 g f rbhydrte plus 1 unit fr 50 g/dL f bld gluse ver  trget vlue f 120 g/dL wuld be resnble strting pint. Further djustents t bsl nd blus dsges wuld depend n the results f bld gluse nitring. One f the re diffiult ther- peuti prbles in nging ptients with type 1 dibetes is deterining the prper djustent f insulin dse when the prebrekfst bld gluse level is high. Osinlly, the prebrekfst hyperglyei is due t the Somogyi effect, in whih nturnl hypglyei leds t  surge f unterregultry hrnes t prdue high bld glu- se levels by 7 am. Hwever,  re n use fr prebrekfst hyperglyei is the wning f irulting insulin levels by the rning. The dignsis f the use f prebrekfst hyperglye- i n be filitted by self-nitring f bld gluse t 3 am in dditin t the usul bedtie nd 7 am e- sureents r by nlyzing dt fr the ntinuus glu- se nitr. This is required fr nly  few nights, nd when  prtiulr pttern eerges fr nitring bld gluse levels vernight, pprprite therpeuti esures n be tken. The Sgyi effet n be treted by lwer- ing the bsl insulin dse t bedtie r by eting  snk t bedtie. When  wning insulin level is the use, then either inresing the evening bsl insulin dse r shifting it fr dinnertie t bedtie (r bth) n be effetive. The urrently vilble lsed lp systes enble ptients t hieve lse t nrl gluse levels in the rning with  lw risk f nturnl hypglyei nd iprve verll gluse ntrl. All ptients with type 1 dibetes wh re skilled t using insulin pups shuld use these systes. 2. Type 2 diabetes Therpeuti reendtins re bsed n the reltive ntributins f bet ell insuffi- ieny nd insulin insensitivity in individul ptients. The pssibility tht the individul ptient hs  speifi eti- lgi use fr their dibetes shuld lwys be nsidered, espeilly when the ptient des nt hve  fily histry f type 2 dibetes r des nt hve ny evidene f entrl besity r insulin resistne. Suh ptients shuld be evlu- ted fr ther types f dibetes suh s LADA r MODY(Tble 271). Ptients with LADA shuld be presribed insulin when the disese is dignsed nd treted like ptients with type 1 dibetes. It is ls iprtnt t nte tht ny ptients with type 2 dibetes ellitus hve  prgressive lss f bet ell funtin nd will require ddi- tinl therpeuti interventins with tie. a. Weight reduction One f the priry des f therpy in the bese ptient with type 2 dibetes is weight redutin. Nrliztin f glyei n be hieved by weight lss nd iprveent in tissue sensitivity t insu- lin. A bintin f lri restritin, inresed exer- ise, nd behvir difitin is required if  weight redutin prgr is t be suessful. Understnding the risks ssited with the dignsis f dibetes y ti- vte the ptient t lse weight. Fr seleted ptients, edil r surgil ptins fr weight lss shuld be nsidered. Orlistt, phenterine/ tpirte, lrserin, nltrexne/extended-relese bupr- pin, nd high-dse lirglutide (3 g dily) re weight lss editins pprved fr use in bintin with diet nd exerise (see Chpter 29). Britri surgery (Rux-en-Y, gstri bnding, gstri sleeve, bilipnreti diversin/dudenl swith) typilly results in substntil weight lss nd iprveent in glu- se levels. A et-nlysis exining the ipt f br- itri surgery n ptients with dibetes nd BMI f 40 kg/2r greter nted tht 82% f ptients hd reslu- tin f linil nd lbrtry nifesttins f dibetes in the first 2 yers fter surgery nd 62% reined free f dibetes re thn 2 yers fter surgery. The iprveent ws st rked in the predure tht used the gretest weight lss (bilipnreti diversin/dudenl swith). There ws, hwever,  high ttritin f ptients vilble fr fllw-up, nd there ws little infrtin but differ- ent ethni types. Weight regin des ur fter britri surgery, nd it n be expeted tht 2025% f the lst weight will be regined ver 10 yers. The ipt f this weight gin n dibetes reurrene depends priniplly n the degree f bet ell dysfuntin. Nnbese ptients with type 2 dibetes frequently hve inresed viserl dipsitythe s-lled etblilly bese nrl weight ptient. There is less ephsis n weight lss, but exerise reins n iprtnt spet f tretent. b. Glucose-lowering agents Figure 272 utlines the tretent pprh bsed n the nsensus lgrith prpsed by the Aerin Dibetes Assitin nd the Eurpen Assitin fr the Study f Dibetes. The ur- rent reendtin is t strt etfrin therpy t dignsis nd nt wit t see whether the ptient n hieve trget glyei ntrl with weight ngeent nd exerise. See disussin f the individul editins, bve. When dibetes is nt well ntrlled with initil ther- py (usully etfrin), then  send gent shuld be dded. Presene f rdivsulr r kidney disese, r bth, will deterine the hie f the send gent. Lir- glutide, seglutide, epgliflzin, ngliflzin, nd dpgliflzin hve iprved rdivsulr utes.CMDT22_Ch27_p1212-p1255.indd  1235 29/06/21 8:53 PMCHAPTEr 271236 CMDT 2022The  SGLT2 inhibitrs re espeilly benefiil in ptients with hert filure r dibeti nephrpthy, r bth. The need fr weight lss shuld led t the use f GLP1- reeptr gnists in the bese ptient with r withut r- nry rtery disese. SGLT2 inhibitrs ls prte dest weight lss nd shuld be presribed in the ptient with hert filure r dibeti nephrpthy. Sulfnylures hve been vilble fr ny yers nd their use in bintin with etfrin is well estblished. They d, hwever, hve the prpensity f using hypglyei nd weight gin. In ptients wh experiene hyperglyei fter  rbhy- drte-rih el (suh s dinner),  shrt-ting seret- ggue (repglinide r nteglinide) befre els y suffie t get the gluse levels int the trget rnge. Ptients with severe insulin resistne y be ndidtes fr pigli- tzne. Piglitzne y ls redue the risk fr reurrent strke in ptients wh hve  histry f strke r trnsient ishei ttk. If tw gents re indequte, then  third gent is dded, lthugh dt regrding effiy f suh bined therpy re liited. When the bintin f rl gents (nd injetble GLP-1 reeptr gnists) fils t hieve euglyei in ptients with type 2 dibetes, then insulin tretent shuld be instituted. Vrius insulin regiens y be effetive. One prpsed regien is t ntinue the rl bintin therpy nd then siply dd  bedtie dse f NPH r lng-ting insulin nlg (insulin glrgine, deteir, r deglude) t redue exessive nturnl hepti gluse utput nd iprve fsting gluse levels. If the ptient des nt hieve trget gluse levels during the dy, then dytie insulin tretent n be initited. A nvenient insulin regien under these irustnes is  split dse f 70/30 NPH/regulr ixture (r Hulg Mix 75/25 r NvLgMix 70/30) befre brekfst nd befre dinner. If this regien fils t hieve stisftry glye- i gls r is ssited with uneptble frequeny f hypglyei episdes, then  re intensive regien f ultiple insulin injetins n be instituted s in ptients with type 1 dibetes. Metfrin priniplly redues hepti gluse utput, nd it is resnble t ntinue with this editin when insulin therpy is instituted. Piglitzne, whih iprves peripherl insulin sensitiv- ity, n be used tgether with insulin but this bintin is ssited with re weight gin nd peripherl ede. The sulfnylures, the GLP-1 reeptr gnists, the DPP-4 inhibitrs, nd the SGLT2 inhibitrs ls hve been shwn t be f ntinued benefit. Weight-reduing interventins shuld ntinue even fter inititin f insulin therpy nd y llw fr siplifitin f the therpeuti regi- en in the future.D . Acceptable Levels of Glycemic ControlA  resnble i f therpy is t pprh nrl glye- i exursins withut prvking severe r frequent hyp- glyei. Tble 279 surizes bld gluse nd HbA1 gls fr different ptient grups. The UKPDS study dem- onstrated that blood pressure control was as significant or more significant than glycemic control in patients with type 2 diabetes regarding the prevention of microvascular as well as macrovascular complications.Weight loss + exercise + metformin Metformin + another agent (noninsulin or insulin) Metformin + two other agents (noninsulin or insulin) Factors in Therapeutic Decision (single agent or combination)Seven main classes of agents  Metformin  Sulfonylureas (includes nateglinide, repaglinide)  Pioglitazone  GLP-1 receptor agonists  DPP-4 inhibitors  SGLT2 inhibitors  InsulinsIf HbA1ctarget not reached after ~ 3 months If HbA1ctarget not reached after ~ 3 months If HbA1ctarget not reache d after ~ 3 months Efficacy  DPP-4 inhibitors are of moderate efficacy  All other agents are of high efficacy Cost  All agents except metformin and sulfonylureas are expensive  Insulins are expensive if the additional cost of monitoring is taken into considerationCardiovascular and renal effects  Metformin, liraglutide, semaglutide, empagliflozin, and canagliflozin have know n cardiovascular benefits  SGLT2 inhibitors reduce the risk of ESKD, doubling of serum creatinine and renal death in patients with diabetic nephropathy Hypoglycemic risk  Sulfonylureas and insulins have increased risk of hypoglycemia Effect on weight  Metformin and DPP-4 inhibitors are weight neutral  GLP-1 receptor agonists and SGLT2 inhibitor s promote weight loss  Sulfonylureas, insulins, and pioglitazone ar e associated with weight gain Major side effects  Metformin: lactic acidosis  Pioglitazone: fluid retention, fracture risk, macular edema, possible bladder cancer  GLP-1 receptor agonists: nausea, vomiting and pancreatitis  DPP-4 inhibitors: possible pancreatitis  SGLT2 inhibitors: urinary tract infection; genital mycotic infections; dehydration; cannot use if eGFR < 30 mL/min/1.73 m2Metformin + insulin  other noninsulin agent Figure 272. Algorithm for the treatment of type 2 diabetes based on the 2018 recommendations of the consensus panel of the American Diabetes Association/ European Association for the Study of Diabetes.CMDT22_Ch27_p1212-p1255.indd  1236 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1237 CMDT 2022E.  Complications of Insulin Therapy1.  Hypoglycemia Hypglyei retins re the st n plitins tht ur in ptients with dibetes wh re treted with insulin. The signs nd sypts f hypglyei y be divided int thse resulting fr stiultin f the utni nervus syste nd thse fr neurglypeni (insuffiient gluse fr nrl entrl nervus syste funtin). When the bld gluse flls t rund 54 g/dL (3 l/L), the ptient strts t experiene bth syptheti (thyrdi, plpittins, sweting, treulusness) nd prsyptheti (nuse, hunger) nervus syste sypts. If these utni sypts re ignred nd the gluse levels fll further (t rund 50 g/dL [2.8 l/L]), then neurglypeni sypts pper, inluding irritbility, nfusin, blurred visin, tiredness, hedhe, nd diffiulty speking. A fur- ther deline in gluse n led t lss f nsiusness r even  seizure. With repeted episdes f hypglyei, there is dpttin, nd utni sypts d nt ur until the bld gluse levels re uh lwer nd s the first sypts re ften due t neurglypeni. This nditin is referred t s hypglyei unwreness.  It hs been shwn tht hypglyei unwreness n be reversed by keeping gluse levels high fr  perid f severl weeks. Exept fr sweting, st f the syptheti sypts f hypglyei re blunted in ptients reeiv- ing bet-blking gents. Thugh nt bslutely ntrin- dited, these editins ust be used with utin in ptients with dibetes wh require insulin, nd bet-1- seletive blking gents re preferred. Hypglyei n ur in  ptient tking sulfnyl- ures, repglinide, nd nteglinide, prtiulrly if the ptient is elderly, hs kidney r liver disese, r is tking ertin ther editins tht lter etblis f the sul- fnylures (eg, phenylbutzne, sulfnides, r wrf- rin). It urs re frequently with the use f lng-tingsulfnylures thn with shrter-ting gents. Otherwise, hypglyei in insulin-treted ptients urs s  nse- quene f three ftrs: behvirl issues, ipired un- terregultry systes, nd plitins f dibetes. Behvirl issues inlude injeting t uh insulin fr the unt f rbhydrtes ingested. Drinking lhl in exess, espeilly n n epty sth, n ls use hypglyei. In ptients with type 1 dibetes, hypglye- i n ur during r even severl hurs fter exerise, nd s gluse levels need t be nitred nd fd nd insulin djusted. Se ptients d nt like their gluse levels t be high, nd they tret every high gluse level ggressively. These individuls wh stk their insulin tht is, give nther dse f insulin befre the first injetin hs hd its full tinn develp hypglyei. Cunterregultry issues resulting in hypglyei inlude ipired glugn respnse, sypth-drenl respnses, nd rtisl defiieny. Ptients with dibetes f greter thn 5 yers in durtin lse their glugn respnse t hypglyei. As  result, they re t  signifi- nt disdvntge in prteting theselves ginst flling gluse levels. One the glugn respnse is lst, their sypth-drenl respnses tke n dded iprtne. Unfrtuntely, ging, utni neurpthy, r hypgly- ei unwreness due t repeted lw gluse levels fur- ther blunts the sypth-drenl respnses. Osinlly, Addisn disese develps in persns with type 1 dibetes ellitus; when this hppens, insulin requireents fll sig- nifintly, nd unless insulin dse is redued, reurrent hypglyei will develp. Cplitins f dibetes tht inrese the risk fr hypglyei inlude utni neurpthy, gstrpre- sis, nd end-stge hrni kidney disese. The syptheti nervus syste is n iprtnt syste lerting the indi- vidul tht the gluse level is flling by using sypts f thyrdi, plpittins, sweting, nd treulusness.Table 279. Glycemic targets for different groups of adults with diabetes. Blood Glucose Tagets (mg/dL [mmol/L]) HbA1cTaget (% [mmol/mol]) Nonpregnant healthy adults Premeal glucose 90130 (57.2) 1-hour peak < 180 (10) 2-hour peak < 150 (8.3)< 7 (53). Aim for < 6.5 (48) if it can be achieved without significant hypoglycemia or polypharmacy Pregnancy Premeal glucose  95 (5.3) 1-hour peak  140 (7.8) 2-hour peak  120 (6.7)66.5 (4248). Aim for < 6 (42) if possible without significant hypoglycemia Older adults Healthy Frail with limited life expectancyPremeal 90130 (57.2) Bedtime 90150 (58.3) Premeal 100180 (5.610) Bedtime 110200 (6.111.1)< 7.5 (58) < 8.5 (69) History of severe hypoglycemia Premeal 90150 (58.3) Bedtime 100180 (5.610)< 8 (64) Hospitalized patient 140180 (7.810)  Chronic kidney disease (CKD) Glycemic targets in CKD are the same as those without CKD. HbA1cand fructosamine values may not be accu- rate in end-stage kidney disease, and greater reliance should be placed on the home glucose measurementsCMDT22_Ch27_p1212-p1255.indd  1237 29/06/21 8:53 PMCHAPTEr 271238 CMDT 2022Fil ure f the sypth-drenl respnses inreses the risk f hypglyei. In dditin, in ptients with gstr- presis, if insulin is given befre  el, the pek f insulin tin y ur befre the fd is bsrbed using the gluse levels t fll. Finlly, in end-stge hrni kidney disese, hypglyei n ur presubly beuse f deresed insulin lerne s well s lss f renl ntri- butin t glunegenesis in the pstbsrptive stte. T prevent nd tret insulin-indued hypglyei, the dibeti ptient shuld rry gluse tblets r juie t ll ties. Fr st episdes, ingestin f 15 grs f rb- hydrte is suffiient t reverse the hypglyei. The ptient shuld be instruted t hek the bld gluse in 15 inutes nd tret gin if the gluse level is still lw. A prenterl (1 g) r nsl inhltin (3 g) glugn eergeny kit shuld be prvided t every ptient with dibetes wh is reeiving insulin therpy. Fily r friends shuld be instruted hw t injet it subutneusly r intrusulrly int the buttk, r, r thigh r din- ister  nsl dse in the event tht the ptient is unn- sius r refuses fd. The editin n sinlly use viting, nd the unnsius ptient shuld be turned n his r her side t prtet the irwy. Glugn bilizes glygen fr the liver, rising the bld gluse by but 36 g/dL (2 l/L) in but 15 inutes. After the ptient revers nsiusness, dditinl rl rb- hydrte shuld be given. Peple with dibetes reeiving hypglyei editin therpy shuld ls wer n identifitin MediAlert brelet r nekle r rry  rd in his r her wllet (1-800-ID-ALERT, www.edi- lert.rg). Medil persnnel treting severe hypglyei n give 50 L f 50% gluse slutin by rpid intrvenus infusin. If intrvenus ess is nt vilble, 1 g f glugn n be injeted intrusulrly r 3 g given by nsl spry. 2. Immunopathology of insulin therapy At lest five leulr lsses f insulin ntibdies re prdued dur- ing the urse f insulin therpy in dibetes, inluding IgA, IgD, IgE, IgG, nd IgM. With the swith t hun nd purified prk insulin, the vrius iunpthlgi syn- dres suh s insulin llergy, iune insulin resistne, nd liptrphy hve bee quite rre sine the titers nd vidity f these indued ntibdies re generlly quite lw. a. Insulin allergy Insulin llergy, r iedite-type hypersensitivity, is  rre nditin in whih ll r sys- tei urtiri is due t histine relese fr tissue st ells sensitized by dherene f nti-insulin IgE ntibdies. In severe ses, nphylxis results. When nly hun insulin hs been used fr the nset f insulin therpy, insulin llergy is exeedingly rre. Antihistines, rti- sterids, nd even desensitiztin y be required, espe- illy fr systei hypersensitivity. b. Immune insulin resistance A lw titer f irult- ing IgG nti-insulin ntibdies tht neutrlize the tin f insulin t  sll extent develps in st insulin-treted ptients. With the ld nil insulins,  high titer f iru- lting ntibdies seties develped, resulting inextreely high insulin requireentsften re thn 200 units dily. This is nw rrely seen with the swith t hun r highly purified prk insulins nd hs nt been reprted with the nlgs. c. Lipodystrophy Atrphy f subutneus ftty tissue leding t disfiguring exvtins nd depressed res y rrely ur t the site f injetin. This plitin results fr n iune retin, nd it hs bee rrer with the develpent f hun nd highly purified insu- lin preprtins. Liphypertrphy, n the ther hnd, is  nsequene f the phrlgi effets f insulin being depsited in the se ltin repetedly. It n ur with purified insulins s well. Rttin f injetin sites will prevent liphypertrphy.Rdriguez-Gutierrez  R et l. Benefits nd hrs f intensive glyei ntrl in ptients with type 2 dibetes. BMJ. 2019;367:l5887. [PMID: 31690574] Chronic Complications of DiabetesLte  linil nifesttins f dibetes ellitus inlude  nuber f pthlgi hnges tht invlve sll nd lrge bld vessels, rnil nd peripherl nerves, the skin, nd the lens f the eye. These lesins led t hypertensin, end- stge hrni kidney disese, blindness, utni nd peripherl neurpthy, puttins f the lwer extrei- ties, yrdil infrtin, nd erebrvsulr idents. These lte nifesttins rrelte with the durtin f the dibeti stte subsequent t the nset f puberty. In type 1 dibetes, end-stge hrni kidney disese develps in up t 40% f ptients, pred with less thn 20% f ptients with type 2 dibetes. Prlifertive retinpthy ultitely develps in bth types f dibetes but hs  slightly higher prevlene in type 1 ptients (25% fter 15 yers durtin). In ptients with type 1 dibetes, plitins fr end- stge hrni kidney disese re  jr use f deth, wheres ptients with type 2 dibetes re re likely t hve rvsulr diseses leding t yrdil infr- tin nd strke s the in uses f deth. Cigrette use dds signifintly t the risk f bth irvsulr nd rvsulr plitins in dibeti ptients.A.  Ocular Complications1.  Diabetic cataracts Preture trts ur in di- beti ptients nd see t rrelte with bth the durtin f dibetes nd the severity f hrni hyperglyei. Nnenzyti glysyltin f lens prtein is twie s high in dibeti ptients s in ge-thed nndibeti persns nd y ntribute t the preture urrene f trts. 2. Diabetic retinopathy The tw in tegries f di- beti retinpthy, nnprlifertive nd prlifertive, re disussed in Chpter 7. 3. Glaucoma Glu urs in pprxitely 6% f persns with dibetes. It is respnsive t the usul therpy fr pen-ngle disese. Nevsulriztin f the iris in ptients with dibetes n predispse t lsed-ngleCMDT22_Ch27_p1212-p1255.indd  1238 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1239 CMDT 2022glu,  but this is reltively unn exept fter trt extrtin, when grwth f new vessels hs been knwn t prgress rpidly, invlving the ngle f the iris nd bstruting utflw.B.  Diabetic NephropathyDibeti  nephrpthy is initilly nifested by lbuin- uri; subsequently, s kidney funtin delines, ure nd retinine uulte in the bld (see Chpter 22). An lbuin-retinine rti in n erly rning spt urine lleted upn wkening is the preferred ethd t ssess lbuin exretin. In the erly rning spt urine,  rti f lbuin (g/L) t retinine (g/L) f less thn 30 g/g retinine is nrl, nd  rti f 30300 g/g retinine suggests bnrl irlbuinuri. At lest tw erly rning spt urine lletins ver  3- t 6-nth perid shuld be bnrl befre  dignsis f irlbuinuri is justified. Shrt-ter hyperglyei, exerise, urinry trt infetins, hert filure, nd ute febrile illness n use trnsient lbuinuri nd s test- ing fr irlbuinuri shuld be pstpned until res- lutin f these prbles. Subsequent end-stge hrni kidney disese n be predited by persistent urinry lbuin exretin rtes exeeding 30 g/g retinine. Glyei ntrl s well s  prtein diet f ~0.8 g/kg/dy y redue bth the hyperfiltrtin nd the elevted irlbuinuri in ptients in the erly stges f dibetes nd thse with inipient dibeti nephrpthy. Antihypertensive therpy ls dereses irlbuinuri. Evidene fr se studies supprts  speifi rle fr ACE inhibitrs in redu- ing intrglerulr pressure in dditin t their lwering f systei hypertensin. An ACE inhibitr (ptpril, 50 g twie dily) in nrtensive dibeti ptients ipedes prgressin t prteinuri nd prevents the inrese in lbuin exretin rte. SGLT2 therpy shuld be instituted in ptients with type 2 dibetes wh hve prgressin f kidney disese despite tking ptil nti- hypertensive therpy, whih inludes n ACE inhibitr r ngitensin reeptr blker.C.  Diabetic NeuropathyDibeti  neurpthies re the st n plitins f dibetes, ffeting up t 50% f lder ptients with type 2 dibetes. 1. Peripheral neuropathy a. Distal symmetric polyneuropathy This is the st n fr f dibeti peripherl neurpthy where lss f funtin ppers in  stking-glve pttern nd is due t n xnl neurpthi press. Lnger nerves re espeilly vulnerble, hene the ipt n the ft. Bth tr nd sensry nerve ndutin is delyed in the peripherl nerves, nd nkle jerks y be bsent. Sensry invlveent usully urs first nd is gener- lly bilterl, syetri, nd ssited with dulled per- eptin f vibrtin, pin, nd teperture. The pin n rnge fr ild disfrt t severe inpitting syp- ts. The sensry defiit y eventully be f suffiientdegree t prevent ptients fr feeling pin. Ptients wh hve  sensry neurpthy shuld therefre be exined with  5.07 Sees-Weinstein filent nd thse wh nnt feel the filent ust be nsidered t risk fr unpereived neurpthi injury. The denervtin f the sll usles f the ft n result in lwing f the tes nd displeent f the sub- ettrsl ft pds nterirly. These hnges, tgether with the jint nd nnetive tissue hnges, lter the biehnis f the ft nd inrese plntr pressures. This bintin f deresed pin threshld, bnr- lly high ft pressures, nd repetitive stress (suh s fr wlking) n led t lluses nd ulertins in the high-pressure res suh s ver the ettrsl heds (Figure 273). Peripherl neurpthy, utni neu- rpthy, nd tru ls predispses t the develpent fCharcot arthropathy. An ute se f Chrt ft rthrpthy presents with pin nd swelling, nd if left untreted, leds t  rker btt defrity nd ulertin. The erly rdilgi hnges shw jint sub- luxtin nd perirtiulr frtures. As the press pr- gresses, there is frnk stelsti destrutin leding t dernged nd unstble jints prtiulrly in the idft. Nt surprisingly, the key issue fr the heling f neur- pthi ulers in  ft with gd vsulr supply is ehnil unlding. In dditin, ny infetin shuld be treted with debrideent nd pprprite ntibitis; heling durtin f 810 weeks is typil. Osinlly, when heling ppers refrtry, pltelet-derived grwth ftr (beplerin [Regrnex]) shuld be nsidered fr ll pplitin. One ulers re heled, therpeuti ftwer is key t preventing reurrenes. Cust lded shes re reserved fr ptients with signifint ft defrities. Other ptients with neurpthy y require dtive insles tht distribute the ld ver s wide n re s pssible. Ptients with ft defr- ities nd lss f their prtetive threshld shuld get regulr re fr  pditrist. Ptients shuld be edu- ted n pprprite ftwer nd thse with lss f their Figure 273. Diabetic foot ulcer over head of first metatarsal (arrow). (Used, with permission, from Dean SM, Satiani B, Abraham WT. Color Atlas and Synopsis of Vascular Diseases. McGraw-Hill, 2014.)CMDT22_Ch27_p1212-p1255.indd  1239 29/06/21 8:53 PMCHAPTEr 271240 CMDT 2022prtet ive threshld shuld be instruted t inspet their feet dily fr reddened res, blisters, brsins, r lertins. In se ptients, hypersensitivity t light tuh nd sinlly severe burning pin, prtiulrly t night, n bee physilly nd etinlly disbling. Nrtrip- tyline r desiprine in dses f 25150 g/dy rlly y prvide drti relief fr pin fr dibeti neu- rpthy, ften within 4872 hurs. Ptients ften ttribute the benefit t hving  full nights sleep. Mild t derte rning drwsiness is  side effet tht generlly iprves with tie r n be lessened by giving the editin sev- erl hurs befre bedtie. This editin shuld nt be ntinued if iprveent hs nt urred fter 5 dys f therpy. Aitriptyline, 2575 g rlly t bedtie, n ls be used but hs re ntihlinergi effets. Triyli ntidepressnts, in bintin with fluphenzine (3 g dily in three divided dses) hve been shwn in tw stud- ies t be effiius in pinful neurpthy, with benefits unrelted t relief f depressin. Gbpentin (9001800 g rlly dily in three divided dses) hs ls been shwn t be effetive in the tretent f pinful neurpthy nd shuld be tried if the triyli editins prve ineffe- tive. Pregblin,  ngener f gbpentin, hs been shwn in n 8-week study t be re effetive thn pleb in treting pinful dibeti peripherl neurpthy. Hwever, this editin ws nt pred with n tive ntrl. Als, beuse f its buse ptentil, it hs been tegrized s  shedule V ntrlled substne. Dulxetine (60120 g),  sertnin nd nrepinephrine reuptke inhibitr, is pprved fr the tretent f pinful dibeti neurpthy. Cpsiin,  tpil irritnt, is effetive in reduing ll nerve pin; it is dispensed s  re (Zstrix 0.025%, Zstrix-HP 0.075%) t be rubbed int the skin ver the pinful regin tw t fur ties dily. Glves shuld be used fr pplitin sine hnd ntintin uld result in disfrt if the re es in ntt with eyes r sensitive res suh s the genitli. Appli- tin f  5% lidine pth ver n re f xil pin hs been reprted t be f benefit. It is pprved fr tret- ent f pstherpeti neurlgi. Diabetic neuropathic cachexia is  syndre hr- terized by  syetri peripherl neurpthy ssited with prfund weight lss (up t 60% f ttl bdy weight) nd pinful dysesthesis ffeting the prxil lwer libs, the hnds, r the lwer trunk. Tretent is usully with insulin nd nlgesis. The prgnsis is generlly gd, nd ptients typilly rever their bseline weight with reslutin f the pinful sensry sypts within 1 yer. b. Isolated peripheral neuropathy Invlveent f the distributin f nly ne nerve (nneurpthy) r f severl nerves (nneurpthy ultiplex) is hr- terized by sudden nset with subsequent revery f ll r st f the funtin. This neurpthlgy hs been ttrib- uted t vsulr ishei r truti dge. Crnil nd ferl nerves re nly invlved, nd tr bnrlities predinte. The ptient with rnil nerve invlveent usully hs diplpi nd single third, furth, r sixth nerve wekness n exintin but the pupil isspred. A full revery f funtin urs in 612 weeks. Dibeti ytrphy presents with nset f severe pin in the frnt f the thigh. Within  few dys r weeks f the nset f pin, wekness nd wsting f the qudrieps develps. As the wekness ppers, the pin tends t iprve. Mngeent inludes nlgesi nd iprved dibetes ntrl. The sypts iprve ver 618 nths. 2. Autonomic neuropathy Neurpthy f the utni syste urs priniplly in ptients with dibetes f lng durtin. It ffets ny diverse viserl funtins inlud- ing bld pressure nd pulse, gstrintestinl tivity, bld- der funtin, nd eretile dysfuntin. Tretent is direted speifilly t eh bnrlity. Insulin neuritis r tretent-indued neurpthy f dibetes urs - sinlly in ptients with pr gluse ntrl nd whse gluse levels iprve rpidly in dys r  few weeks. Sypts inlude severe sensry neurpthi pins nd seties utni funtins. These sypts iprve ver  few nths. a. Gastrointestinal system Invlveent f the gs- trintestinl syste y be nifested by nuse, vit- ing, pstprndil fullness, reflux r dysphgi, nstiptin r dirrhe (r bth), nd fel inntinene. Gstrpre- sis shuld be nsidered in type 1 dibeti ptients in wh unexpeted flututins nd vribility in their bld gluse levels develps fter els. Metlpride hs been f se help in treting dibeti gstrpresis. It is given in  dse f 10 g rlly three r fur ties  dy, 30 inutes befre els nd t bedtie. Drwsiness, rest- lessness, ftigue, nd lssitude re n dverse effets. Trdive dyskinesi nd extrpyridl effets n ur, espeilly when used fr lnger thn 3 nths, nd the FDA hs utined ginst the lng-ter use f etlpride. Erythryin ppers t bind t tilin reeptrs in the sth nd hs been fund t iprve gstri epty- ing ver the shrt ter in dses f 250 g three ties dily, but its effetiveness sees t diinish ver tie. In seleted ptients, injetins f btulinu txin int the pylrus n redue pylrus sphinter resistne nd enhne gstri eptying. Gstri eletril stiultin hs been reprted t iprve sypts nd qulity f life indies in ptients with gstrpresis refrtry t phr- lgi therpy. Dirrhe ssited with utni neurpthy hs sinlly respnded t brd-spetru ntibiti ther- py (suh s rifxiin, etrnidzle, xiillin/lvul- nte, iprflxin, r dxyyline), lthugh it ften underges spntneus reissin. Refrtry dibeti dirrhe is ften ssited with ipired sphinter n- trl nd fel inntinene. Therpy with lperide, 48 g dily, r diphenxylte with trpine, tw tblets up t fur ties  dy, y prvide relief. In re severe ses, tinture f pregri r deine (60-g tblets) y be required t redue the frequeny f dirrhe nd iprve the nsisteny f the stls. Clnidine hs been reprted t lessen dibeti dirrhe; hwever, its usefulness is liited by its tendeny t lwer bld pressure in these ptients wh lredy hve utni neurpthy, resultingCMDT22_Ch27_p1212-p1255.indd  1240 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1241 CMDT 2022in  rthstti hyptensin. Cnstiptin usully respnds t stiulnt lxtives suh s senn. b. Genitourinary system Inplete eptying f the bldder n seties ur. Bethnehl in dses f 1050 g rlly three ties  dy hs sinlly iprved eptying f the tni urinry bldder. Ctheter depressin f the distended bldder hs been reprted t iprve its funtin, nd nsiderble benefit hs been reprted fter surgil severing f the internl vesile sphinter. Eretile dysfuntin n result fr neurlgi, psy- hlgil, r vsulr uses, r  bintin f these uses. The phsphdiesterse type 5 (PDE5) inhibitrs sildenfil (Vigr), vrdenfil (Levitr), nd tdlfil (Cilis) hve been shwn in pleb-ntrlled linil tri- ls t iprve eretins in respnse t sexul stiultin. The reended dse f sildenfil fr st ptients is ne 50-g tblet tken pprxitely 1 hur befre sexul tivity. The pek effet is t 1.52 hurs, with se effet persisting fr 4 hurs. Ptients with dibetes ellitus using sildenfil reprted 5060% iprveent in eretile fun- tin. The xiu reended dse is 100 g. The reended dse f bth vrdenfil nd tdlfil is 10 g. The dses y be inresed t 20 g r deresed t 5 g bsed n effiy nd side effets. Tdlfil hs been shwn t iprve eretile funtin fr up t 36 hurs fter dsing. Lw dses re vilble fr dily use. In linil trils, nly  few dverse effets hve been reprtedtrnsient ild hedhe, flushing, dyspepsi, nd se ltered lr visin. Pripis n ur with these editins, nd ptients shuld be dvised t seek iedite edil ttentin if n eretin persists fr lnger thn 4 hurs. The PDE5 inhibi- trs ptentite the hyptensive effets f nitrtes nd their use is ntrindited in ptients wh re nurrently using rgni nitrtes in ny fr. Cutin is dvised fr en wh hve suffered  hert ttk, strke, r life-thretening rrhythi within the previus 6 nths; en wh hve resting hyptensin r hypertensin; nd en wh hve  histry f hert filure r hve unstble ngin. Rrely,  derese in visin r pernent visul lss hs been reprted fter PDE5 inhibitr use. Intrrprel injetin f vstive editins uses penile engrgeent nd eretin. Meditins st nly used inlude ppverine lne, ppverine with phentline, nd lprstdil (prstglndin E1). Alprst- dil injetins re reltively pinless, but reful instrutin is essentil t prevent ll tru, pripis, nd fibrsis. Intrurethrl pellets f lprstdil vid the prble f injetin f the editin. Externl vuu therpy (Ere-Aid Syste) is  nnsur- gil tretent nsisting f  sutin hber perted by  hnd pup tht retes  vuu rund the penis. This drws bld int the penis t prdue n eretin tht is intined by  speilly designed tensin ring inserted rund the bse f the penis nd whih n be kept in ple fr up t 2030 inutes. While this ethd is generlly effetive, its uberse nture liits its ppel. Surgil iplnts f penile prstheses rein n ptin fr thse ptients in wh the nnsurgil pprhes re ineffetive.c. Orthostatic hypotension Use f Jbst fitted stkings, tilting the hed f the bed, nd rising slwly fr the supine psitin n be helpful in treting syp- ts f rthstti hyptensin. When suh esures re indequte, then tretent with fludrrtisne 0.10.2 g rlly dily n be nsidered. This editin, hwever, n result in supine hypertensin nd hypklei. The lph-gnist iddrine (10 g rlly three ties  dy) n ls be used.D . Cardiovascular Complications1.  Heart disease Mirngipthy urs in the hert f ptients with dibetes nd y explin the etilgy f n- gestive rdiypthies in thse wh d nt hve den- strble rnry rtery disese. Mre nly, hwever, hert disese in ptients with dibetes is due t rnry therslersis. Myrdil infrtin is three t five ties re n in dibeti ptients nd is the leding use f deth in ptients with type 2 dibetes. Crdivsulr disese risk is inresed in ptients with type 1 dibetes s well, lthugh the bslute risk is lwer thn in ptients with type 2 dibetes. Preenpusl wen wh nrlly hve lwer rtes f rnry rtery disese lse this prte- tin ne dibetes develps. The inresed risk in ptients with type 2 dibetes reflets the bintin f hypergly- ei, hyperlipidei, bnrlities f pltelet dhesive- ness, gultin ftrs, hypertensin, xidtive stress, nd infltin. Lrge interventin studies f risk ftr redutin in dibetes re lking, but it is resnble t ssue tht reduing these risk ftrs wuld hve  ben- efiil effet. Lwering LDL hlesterl redues first events in ptients withut knwn rnry disese nd sendry events in ptients with knwn rnry disese. These interventin studies inluded se ptients with dibetes, nd the benefits f LDL hlesterl lwering ws pprent in this grup. The Ntinl Chlesterl Edutin Pr- gr linil prtie guidelines hve designted dibetes s  rnry risk equivlent nd hve reended tht ptients with dibetes shuld hve n LDL hlesterl gl f less thn 100 g/dL (2.6 l/L). Lwering LDL h- lesterl t 70 g/dL (1.8 l/L) y hve dditinl benefit nd is  resnble trget fr st ptients with type 2 dibetes wh hve ultiple risk ftrs fr rdi- vsulr disese. Aspirin t  dse f 81325 g dily is effetive in reduing rdivsulr rbidity nd rtlity in ptients wh hve  histry f yrdil infrtin r strke (sendry preventin). Fr priry preventin,  2018 rndized study f 15,480 persns with dibetes but n evident rdivsulr disese bserved tht 100 g f spirin redued the first vsulr event f yrdil infrtin, strke r trnsient ishei ttk r deth fr vsulr event (exluding intrrnil herrhge) (rte rti 0.88; 95% nfidene intervl 0.79 t 0.97). There were, hwever, re jr bleeding events, espe- illy gstrintestinl, in the spirin grup (rte rti 1.29; 95% nfidene intervl 1.09 t 1.52). Thus, fr priry preventin, the use f spirin shuld nly be nsidered fr ptients with high rdivsulr risk nd lw bleeding risk nd generlly nt fr dults lder thn 70 yers. BsedCMDT22_Ch27_p1212-p1255.indd  1241 29/06/21 8:53 PMCHAPTEr 271242 CMDT 2022n  the Erly Tretent Dibeti Retinpthy Study (ETDRS), there des nt pper t be  ntrinditin t spirin use t hieve rdivsulr benefit in dibeti ptients wh hve prlifertive retinpthy. Aspirin ls des nt see t ffet the severity f vitreus/preretinl herrhges r their reslutin. 2. Hypertension The ADA reends lwering systli bld pressure t less thn 140  Hg nd distli pres- sure t less thn 90  Hg in ptients with dibetes. The systli trget f 130  Hg r less nd distli trget f 80  Hg r less re reended fr the yunger ptient if they n be hieved withut undue tretent burden. The Systli Bld Pressure Interventin Tril (SPRINT) reprted tht treting t  systli bld pressure f less thn 120  Hg redued rdivsulr events by 25% nd deth fr rdivsulr uses by 43% during 3.26 yers f fllw-up. Peple with dibetes, hwever, were exluded fr this study, nd it is unler if the results re pplible t this ppultin. Ptients with type 2 dibetes wh lredy hve rdivsulr disese r irlbuinuri shuld be nsidered fr tretent with n ACE inhibitr. Mre lini- l studies re needed t ddress the questin f whether ptients with type 2 dibetes wh d nt hve rdivsulr disese r irlbuinuri wuld speifilly benefit fr ACE inhibitr tretent. 3. Peripheral vascular disease Atherslersis is rk- edly elerted in the lrger rteries. It is ften diffuse, with llized enhneent in ertin res f turbulent bld flw, suh s t the bifurtin f the rt r ther lrge vessels. Clinil nifesttins f peripherl vsulr disese inlude ishei f the lwer extreities, eretile dysfuntin, nd intestinl ngin. The inidene f gangrene of the feet in ptients with dibetes is 30 ties tht in ge-thed ntrls. The f- trs respnsible fr its develpent, in dditin t periph- erl vsulr disese, re sll vessel disese, peripherl neurpthy with lss f bth pin senstin nd neur- geni infltry respnses, nd sendry infetin. In tw-thirds f ptients with ishei gngrene, pedl pulses re nt plpble. In the reining ne-third wh hve plpble pulses, redued bld flw thrugh these vessels n be denstrted by plethysgrphi r Dppler ultrsund exintin. Preventin f ft injury is ipertive. Agents tht redue peripherl bld flw suh s tb shuld be vided. Cntrl f ther risk ftrs suh s hypertensin is essentil. Bet-blkers re rel- tively ntrindited beuse f presued negtive peripherl hedyni nsequenes but dt tht sup- prt this re lking. Chlesterl-lwering gents re use- ful s djuntive therpy when erly ishei signs re deteted nd when dyslipidei is present. Ptients shuld be dvised t seek iedite edil re if  dibeti ft uler develps. Iprveent in peripherl bld flw with endrterety nd bypss pertins is pssible in er- tin ptients.E.  Skin and Mucous Membrane ComplicationsChrni  pygeni infetins f the skin y ur, espe- illy in prly ntrlled dibeti ptients. Cndidlinfetin n prdue erythe nd ede f intertrigi- nus res belw the brests, in the xills, nd between the fingers. It uses vulvvginitis in wen with hrnilly unntrlled dibetes wh hve persistent glusuri nd is  frequent use f pruritus. While ntifungl res ntining inzle r ltrizle ffer iedite relief f vulvvginitis, reurrene is frequent unless glu- suri is redued. In se ptients with type 2 dibetes, pr glyei ntrl n use severe hypertriglyei, whih n pres- ent s eruptive utneus xnths nd pnretitis. The skin lesins pper s yellw rbillifr eruptins 25  in dieter with erythetus rele. They ur n extensr surfes (elbws, knees, buttks) nd dispper fter triglyeride levels re redued. Nerbisis lipidi dibetiru is usully lted ver the nterir surfes f the legs r the drsl surfes f the nkles. They re vl r irregulrly shped plques with derted brders nd  glistening yellw surfe nd ur in wen tw t fur ties re frequently thn in en. Pthlgilly, the lesins shw degenertin f llgen, grnultus infltin f subutneus tissues nd bld vessels, pillry bseent ebrne thikening nd blitertin f vessel luin. The nditin is ssited with type 1 dibetes, lthugh it n ur in ptients with type 2 dibetes, nd ls in ptients withut dibetes. First-line therpy inludes tpil nd subutne- us rtisterids. Iprving glyei ntrl y help the nditin. Shin spts re nt unn in dults with dibetes. They re brwnish, runded, pinless trphi lesins f the skin in the pretibil re.F . Bone and Joint ComplicationsLng-stnding  dibetes n use prgressive stiffness f the hnd sendry t ntrture nd tightening f skin ver the jints (dibeti heirrthrpthy), frzen shul- der (dhesive psulitis), rpl tunnel syndre, nd Dupuytren ntrtures. These plitins re believed t be due t glysyltin f llgen nd perhps ther prteins in nnetive tissue. There y ls be n infl- try pnent. Dt n bne inerl density nd frture risk in peple with dibetes re ntrditry. Ptients with type 2 dibetes d pper t be t inresed risk fr nnvertebrl frtures. Wen with type 1 dibetes hve n inresed risk f fr- ture when pred with wen withut dibetes. Other ftrs, suh s durtin f dibetes, nd dibetes pli- tins, suh s neurpthy nd kidney disese, likely ffet bth the bne inerl density nd frture risk. Diffuse idipthi skeletl hyperstsis (DISH) is hr- terized by ssifitin f the nterir lngitudinl lig- ents f the spine nd vrius extrspinl ligents. It uses stiffness nd deresed rnge f spinl tin. The peripherl jints st nly ffeted re the etr- pphlngel jints, elbws, nd shulders. Dibetes, be- sity, hypertensin, nd dyslipidei re risk ftrs fr this nditin. Hyperuriei nd ute nd tpheus gut re re n in type 2 dibetes.CMDT22_Ch27_p1212-p1255.indd  1242 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1243 CMDT 2022Bursitis,  prtiulrly f the shulders nd hips, urs re frequently thn expeted in ptients with dibetes.ASCEND Study Cllbrtive Gr up et l. Effets f spirin fr priry preventin in persns with dibetes ellitus. N Engl J Med. 2018;379:1529. [PMID: 30146931] Grennn D. Dibeti ft ulers. JAMA. 2019;321:114. [PMID: 30620372] Hinhliffe RJ et l; Interntinl Wrking Grup n the Dibeti Ft (IWGDF). Guidelines n dignsis, prgnsis, nd n- geent f peripherl rtery disese in ptients with ft ulers nd dibetes (IWGDF 2019 updte). Dibetes Metb Res Rev. 2020;36:e3276. [PMID: 31958217] Selvrjh D et l. Dibeti peripherl neurpthy: dvnes in dignsis nd strtegies fr sreening nd erly interventin. Lnet Dibetes Endrinl. 2019;7:938. [PMID: 31624024] Shen JI et l. Evidene fr nd ginst ACC/AHA 2017 guideline fr trget systli bld pressure f < 130  Hg in persns with type 2 dibetes. Curr Crdil Rep. 2019;21:149. [PMID: 31760494] Special SituationsA.  Diabetes Management in the HospitalH spitlized ptients re generlly nt eting s usul nd they re ften fsting fr predures, whih kes it hl- lenging t use utptient rl r insulin regiens. There y be n inrese in the dverse retins f dibetes edi- ines (eg, thizlidinedines n use fluid retentin nd wrsen hert filure); etfrin shuld nt be used in ptients with signifint hrni kidney r liver disese r thse getting ntrst fr rdigrphi studies; nd SGLT2 inhibitrs y be ssited with inresed risk f dibeti ketidsis. The dt n the use f ntinuus gluse nitrs, insulin pups, nd hybrid lsed lp systes in hspitlized ptients re insuffiient. Whether ptients sty n these systes in the hspitl will depend n their severity f illness nd ess t speilist re. In generl, deisins regrding insulin dsing shuld be de bsed n pillry bld gluse esureents nd nt n the dt fr n- tinuus gluse nitrs. Ptients shuld be trnsitined t  nventinl bsl blus subutneus insulin regien if they re unble t nge their pup nd/r ntinuus gluse nitr beuse f their illness r if they refuse t fllw the institutinl guidelines n using the pup r ntinuus nitr (eg, giving theselves insulin bluses nd nt infring the linil stff). The systes hve t be reved if the ptient is getting n MRI. On the general medical and surgical inpatient ser- vices, st ptients re treted with subutneus insulin regiens. Liited rss-setinl nd prspetive studies suggest tht the best gluse ntrl is hieved n  - bintin f bsl nd blus regien with 50% f dily insulin needs prvided by interedite- r lng-ting insulins. Stndrdized rder sets n redue errrs, nd they ften inlude lgriths fr regnitin nd tret- ent f hypglyei (see http://usfinptientdibetes. pbwrks. fr exples). Orl ediines, espeilly etfrin nd sulfnylures, n be resued s the ptient is being prepred fr hspitl dishrge. In the intensive care units (ICUs), gluse levels re ntrlled st frequently using insulin infusins(http://usfinptientdibetes.pbwrks.). Ptients reeiv- ing ttl prenterl nutritin n hve insulin dded t the bg. Stndrd ttl prenterl nutritin ntins 25% dex- trse s n infusin rte f 50 L/h delivers 12.5 g f dextrse per hur. Bsed n the evidene vilble, ICU ptients with dibe- tes nd new-nset hyperglyei with bld gluse levels bve 180 g/dL (10 l/L) shuld be treted with insu- lin, iing fr trget gluse levels between 140 g/dL (7.8 l/L) nd 180 g/dL (10 l/L). In the ICU set- ting, iing fr bld gluse levels lse t 100 g/dL (5.6 l/L) is nt benefiil nd y even be hrful. When ptients leve the ICU, trget gluse vlues between 100 g/dL (5.6 l/L) nd 180 g/dL (10 l/L) y be pprprite, lthugh this view is bsed n linil bser- vtins rther thn nlusive evidene. Preoperative and perioperative diabetic management strtegies re disussed in Chpter 3. The rbidity nd rtlity in hspitlized dibeti ptients re twie thse f nndibeti ptients. Thse with new-nset hyperglyei (ie, thse withut  predis- sin dignsis f dibetes) hve even higher rtlity lst eightfld tht f nndibeti ptients in ne study. These bservtins hve led t the questin f whether tight glyei ntrl in the hspitl iprves utes.B.  Pregnancy and the Diabetic PatientSee Chpt er 19. Tight glyei ntrl with nrl HbA1 levels is very iprtnt during pregnny. Erly in preg- nny, pr ntrl inreses the risk f spntneus br- tin nd ngenitl lfrtins. Lte in pregnny, pr ntrl n result in plyhydrnis, preter lbr, stillbirth, nd fetl rsi with its ssited prb- les. Dibetes plitins n ipt bth ternl nd fetl helth. Dibeti retinpthy n first develp during pregnny r retinpthy tht is lredy present n wrsen. Dibeti wen with irlbuinuri n hve wrsening lbuinuri during pregnny nd re t higher risk fr preelpsi. Lw-dse (81 g) spirin n redue the risk f preelpsi nd shuld be presribed fter 12 weeks f gesttin. Ptients wh hve preexisting kidney filure (prepregnny retinine lerne less thn 80 L/in) re t high risk fr further deline in kidney funtin during the pregnny, nd this y nt reverse fter delivery. Dibeti gstrpresis n severely exer- bte the nuse nd viting f pregnny nd se ptients y require fluid nd nutritinl supprt. Althugh there is evidene tht glyburide is sfe during pregnny, the urrent prtie is t ntrl dibetes with insulin therpy. Every effrt shuld be de, utilizing ul- tiple injetins f insulin r  ntinuus infusin f insu- lin by pup, t intin ner-nrliztin f fsting nd preprndil bld gluse vlues while viding hypglyei. Regulr nd NPH insulin nd the insulin nlgs lispr, sprt, nd deteir re lbeled pregnny tegry B. Insu- lin glrgine, glulisine, nd deglude re lbeled tegry C beuse f lk f linil sfety dt. A sll study using insulin glrgine in 32 pregnnies did nt revel ny prbles.CMDT22_Ch27_p1212-p1255.indd  1243 29/06/21 8:53 PMCHAPTEr 271244 CMDT 2022U nless there re fetl r ternl plitins, dibeti wen shuld be ble t rry the pregnny t full-ter, delivering t 38 t 41 weeks. Indutin f lbr befre 39 weeks y be nsidered if there is nern but inresing fetl weight. See Chpter 19 fr further detils.Aerin  Dibetes Assitin. Mngeent f dibetes in pregnny: Standards of Medical Care in Diabetes2020 . Dibetes Cre. 2020;43:S183. [PMID: 31862757]DI ABETIC COMAC  y be due t uses nt diretly relted t dibetes. Dibeti  requires differentitin (Tble 2710): (1) Hypglyei  fr exessive insulin r rl hyp- glyei gents. (2) Hyperglyei  with either severe insulin defiieny (DKA) r ild t derte insu- lin defiieny (hyperglyei hyperslr stte). (3) Lti idsis, prtiulrly when ptients with dibetes hve severe infetins r rdivsulr llpse.DI ABETIC KETOACIDOSISE S S E N T I A L S  O F  D I A G N O S I S Hyperglycemia > than 250 mg/dL (13.9 mmol/L). Metabolic acidosis with blood pH < 7.3; serum bicarbonate < 15 mEq/L. Serum positive for ketones. General ConsiderationsDibeti  ketidsis (DKA) is  disrder pririly in ptients with type 1 dibetes but n ur in ptients with type 2 dibetes wh hve severe illness, suh s sepsis r tru. DKA y be the initil nifesttin f type 1dibetes r y result fr inresed insulin requireents in type 1 dibetes ptients during the urse f infetin, tru, yrdil infrtin, r surgery. It is  life-thret- ening edil eergeny. The Ntinl Dt Grup reprts n nnul inidene f five t eight episdes f DKA per 1000 dibeti persns. DKA is ne f the re n serius plitins f insulin pup therpy, urring in pprxitely 1 per 80 ptient-nths f tretent. Mny ptients wh nitr pillry bld gluse regulrly ignre urine ketne esureents, whih signls the pssibility f insulin lekge r pup filure befre serius illness develps. Pr pline, either fr psyhlgil resns r beuse f indequte edutin, is ne f the st n uses f reurrent DKA. Clinical FindingsA.  Symptoms and SignsThe  pperne f DKA is usully preeded by  dy r re f plyuri nd plydipsi ssited with rked ftigue, nuse, nd viting. If untreted, entl stupr ensues tht n prgress t . Drwsiness is firly n, but frnk  nly urs in but 10% f ptients. On physil exintin, evidene f dehydrtin in  stuprus ptient with rpid deep brething nd  fruity breth dr f etne strngly suggests the dignsis. Hyptensin with thy- rdi indites prfund fluid nd eletrlyte depletin, nd ild hyptheri is usully present. Abdinl pin nd even tenderness y be present in the bsene f bdinl disese. Cnversely, hleystitis r pnretitis y ur with inil sypts nd signs.B.  Laboratory FindingsT ypilly, the ptient with dertely severe DKA hs  pls gluse f 350900 g/dL (19.450 l/L), seru ketnes t  dilutin f 1:8 r greter rTable 2710. Laboratory diagnosis of coma in diabetic patients. Uine Glucose Uine Ketones Plasma Glucose Seum Bicabonate Seum Ketones related to Diabetes Hypoglycemia 010 or + Low Normal 0 Diabetic ketoacidosis ++++ ++++ High Low ++++ Hyperglycemic hyperosmolar state coma++++ 0 or + High Normal or slightly low 0 Lactic acidosis 0 or + 0 or + Normal or low or high Low 0 or + Unelated to Diabetes Alcohol or other toxic drugs 0 or + 0 or + May be low Normal or low20 or + Cerebrovascular accident or head trauma+ or 0 0 Often high Normal 0 Uremia 0 or + 0 High or normal Low 0 or +1 Leftover urine in bladder might still contain glucose from earlier hyperglycemia.2 Alcohol can elevate plasma lactate as well as keto acids to reduce pH.CMDT22_Ch27_p1212-p1255.indd  1244 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1245 CMDT 2022bet-hydr xybutyrte re thn 4 nl/L, hyperklei (seru ptssiu level f 58 Eq/L), ild hypntrei (seru sdiu f pprxitely 130 Eq/L), hyperphs- phtei (seru phsphte level f 67 g/dL [1.92.3 l/L]), nd elevted bld ure nitrgen nd seru retinine levels (Tble 2710). Aidsis y be severe (pH rnging fr 6.9 t 7.2 nd seru birbnte rnging fr 5 Eq/L t 15 Eq/L); Pco2is lw (1520  Hg) relted t penstry hyperventiltin. Fluid depletin is rked, typilly but 100 L/kg. In euglyei ketidsis, the ptient n hve severe id- sis nd fluid depletin but the pls gluse levels re nly destly elevted, usully less thn 250 g/dy (13.9 l/L). This nditin is seen in ptients in wh dibeti ketidsis develps while reeiving tretent with SGLT2 inhibitrs. Ketidsis with lwer gluse levels ls urs in pregnny nd y reflet the expnded pls vlue nd the inresed glerulr filtrtin rte. The differene between venus nd rteril pH is 0.02 t 0.15 pH units nd venus nd rteril birbnte is 1.88 Eq/L. These sll differenes will nt ffet either the dignsis r the ngeent f DKA, nd there is n need t llet rteril bld fr esuring the id-bse sttus. The hyperklei urs despite ttl bdy ptssiu depletin beuse f the shift f ptssiu fr the intr- ellulr t extrellulr spes tht urs in systei i- dsis. The verge ttl bdy ptssiu defiit resulting fr sti diuresis, idsis, nd gstrintestinl lsses is but 35 Eq/kg. Siilrly, despite the elevted seru phsphte, ttl bdy phsphte is generlly depleted. Seru sdiu is generlly redued due t lss f sdiu ins (710 Eq/kg) by plyuri nd viting nd beuse severe hyperglyei shifts intrellulr wter int the interstitil prtent. Fr every 100 g/dL f pls gluse, seru sdiu dereses by 1.6 Eq/L (5.56 l/L). The derese in seru sdiu y be greter when ptients hve re severe hyperglyei (greter thn 400 g/dL, 22.2 l/L) nd  rretin ftr f 2.4 Eq/L y be used. Hypertriglyeridei shuld be nsidered if the rreted sdiu is very lw. Seru sllity n be diretly esured by stndrd tests f freezing pint depressin r n be estited by lulting the lrity f sdiu, hlride, nd gluse in the seru. A nvenient ethd f estiting effetive seru sllity is s fllws (nrl vlues re 280300 Os/kg): mOsm/kg  2 [measured Na ]Glucose (mg/dL) 18=  ++These lulted esti tes re usully 1020 Os/kg lwer thn vlues esured by stndrd ryspi teh- niques. Centrl nervus syste depressin r  urs when the effetive seru sllity exeeds 320330 Os/L. C in  dibeti ptient with  lwer sllity shuld prpt  serh fr the use f  ther thn hypersllity (see Tble 2710 nd Chpter 24).Ketidei represents the effet f insulin lk t ultiple enzye li. Insulin lk ssited with elevted levels f grwth hrne, tehlines, nd glugn ntributes t inreses in liplysis fr dipse tissue nd in hepti ketgenesis. In dditin, redued ketlysis by insulin-defiient peripherl tissues ntributes t the ket- idei. The nly true ket id present in dibeti ketidsis is eteti id whih, lng with its by- prdut etne, is esured by nitrprusside regents (Aetest nd Ketstix). The sensitivity fr etne, hw- ever, is pr, requiring ver 10 l/L, whih is seld rehed in the pls f ketidti ptientslthugh this detetble nentrtin is redily hieved in urine. Thus, in the pls f ketti ptients, nly etette is esured by these regents. The re prevlent bet- hydrxybutyri id hs n ketne grup nd is therefre nt deteted by nventinl nitrprusside tests. This tkes n speil iprtne in the presene f irultry l- lpse during DKA, wherein n inrese in lti id n shift the redx stte t inrese bet-hydrxybutyri id t the expense f the redily detetble eteti id. Bed- side dignsti regents re then unrelible, suggesting n ketnei in ses where bet-hydrxybutyri id is  jr ftr in prduing the idsis. Cbined gluse nd ketne eters (Preisin Xtr, Nv Mx Plus) tht esure bld bet-hydrxybutyrte nentr- tin n pillry bld re vilble. Mny linil lbrtries ls ffer diret bld bet-hydrxybutyrte esureent. Nnspeifi elevtins f seru ylse nd lipse urs in but 1625% f ses f DKA, nd n iging study y be neessry if the dignsis f ute pnreti- tis is being seriusly nsidered. Leukytsis s high s 25,000/L (25  109/L) with  left shift y ur with r withut ssited infetin. The presene f n elevted r even  nrl teperture n suggest the presene f n infetin sine ptients with DKA re generlly hyp- theri if uninfeted. TreatmentP tients with mild DKA re lert nd hve pH levels between 7.25 nd 7.30 nd bet-hydrxybutyrte levels f 34 l/L; thse with moderate ketoacidosis re either lert r  little drwsy nd hve pH levels between 7.0 nd 7.24 nd bet-hydrxybutyrte levels f 48 l/L; nd thse with severe ketoacidosis re stuprse nd hve  pH < 7.0 nd bet-hydrxybutyrte levels f greter thn 8 l/L. Ptients with ild ketidsis n be treted in the eergeny deprtent, but thse with derte r severe ketidsis require dissin t the ICU r step- dwn unit. Therpeuti gls re t restre pls vlue nd tissue perfusin, redue bld gluse nd sllity twrd nrl, rret idsis, replenish eletrlyte lsses, nd identify nd tret preipitting ftrs. Gstri intubtin is reended in the tse ptient t prevent viting nd spirtin tht y ur s  result f gstri tny,  n plitin f DKA. An indwelling urinry theter y ls be neessry. In ptients with preexisting hert r kidney filure r thse in severe rdivsulr llpse,  entrl venus pressureCMDT22_Ch27_p1212-p1255.indd  1245 29/06/21 8:53 PMCHAPTEr 271246 CMDT 2022the ter shuld be inserted t evlute the degree f hypvlei nd t nitr subsequent fluid dinistrtin. A prehensive flw sheet tht inludes vitl signs, seril lbrtry dt, nd therpeuti interventins (eg, fluids, insulin) shuld be etiulusly intined by the liniin respnsible fr the ptients re. Pls gluse shuld be rerded hurly nd eletrlytes nd pH t lest every 23 hurs during the initil tretent perid. Bed- side gluse eters shuld be used t titrte the insulin therpy. The ptient shuld nt reeive sedtives r piids in rder t vid sking signs nd sypts f ipeding erebrl ede.A.  Fluid ReplacementIn  st ptients, the fluid defiit is 45 L. Initilly, 0.9% sline slutin is the slutin f hie t help reexpnd the ntrted vsulr vlue nd shuld be strted in the eergeny deprtent s sn s the dignsis is estblished. The sline shuld be infused rpidly t prvide 1 L/h ver the first 12 hurs. After the first 2 L f fluid hve been given, the intrvenus infusin shuld be t the rte f 300400 L/h. Use 0.9% (nrl) sline unless the seru sdiu is greter thn 150 Eq/L, when 0.45% (hlf nrl) sline slutin shuld be used. The vlue sttus shuld be refully nitred linilly. Filure t give enugh vlue repleent (t lest 34 L in 8 hurs) t restre nrl perfusin is ne f the st serius therpeuti shrtings dversely influening stisf- try revery. Exessive fluid repleent (re thn 5 L in 8 hurs) y ntribute t ute respirtry distress syndre r erebrl ede. When bld gluse flls t pprxitely 250 g/dL (13.9 l/L), the fluids shuld be hnged t  5% gluse-ntining slutin t in- tin seru gluse in the rnge f 250300 g/dL (13.916.7 l/L). This will prevent the develpent f hypglyei nd will ls redue the likelihd f ere- brl ede, whih uld result fr t rpid deline f bld gluse.B.  Insulin ReplacementIedi tely fter inititin f fluid repleent, regulr insulin n be given intrvenusly in  lding dse f 0.1 unit/kg s  blus t prie the tissue insulin reeptrs. Fllwing the initil blus, intrvenus dses f insulin s lw s 0.1 unit/kg/h re ntinuusly infused r given hurly s n intrusulr injetin; this is suffiient t reple the insulin defiit in st ptients. A prspetive rndized study shwed tht  blus dse is nt required if ptients re given hurly insulin infusin t 0.14 unit/kg. Repleent f insulin defiieny helps rret the id- sis by reduing the flux f ftty ids t the liver, reduing ketne prdutin by the liver, nd ls iprving revl f ketnes fr the bld. Insulin tretent redues the hypersllity by reduing the hyperglyei. It - plishes this by inresing revl f gluse thrugh peripherl utiliztin s well s by deresing prdutin f gluse by the liver. This ltter effet is plished by diret inhibitin f glunegenesis nd glygenlysis swell s by lwered in id flux fr usle t liver nd redued hyperglugnei. The insulin infusin shuld be piggy-bked int the fluid line s the rte f fluid repleent n be hnged withut ltering the insulin delivery rte. If the pls gluse level fils t fll t lest 10% in the first hur,  repet lding dse (0.1 r 0.14 unit/kg) is reended. Rrely,  ptient with iune insulin resistne is enun- tered, nd this requires dubling the insulin dse every 24 hurs if hyperglyei des nt iprve fter the first tw dses f insulin. The insulin dse shuld be djusted t lwer the gluse nentrtin by but 5070 g/dL/h (2.83.9 l/L). If linil irustnes prevent use f n insulin infusin, then the insulin n be given intrus- ulrly. An initil 0.15 unit/kg f regulr insulin is given intrvenusly, nd t the se tie, the se size dse is given intrusulrly. Subsequently, regulr insulin is given intrusulrly hurly t  dse f 0.1 unit/kg until the bld gluse flls t rund 250 g/dL, when the insulin n be given subutneusly. Ptients wh nrlly tke insulin glrgine r insulin deteir n be given their usul intenne dses during the initil tretent f their DKA. The ntinutin f their subutneus bsl insulins ens tht lwer dses f intrvenus insulin will be needed, nd there will be  sther trnsitin fr intr- venus insulin infusin t the subutneus regien.C.  PotassiumT tl bdy ptssiu lss fr plyuri nd viting y be s high s 200 Eq. Hwever, beuse f shifts f pts- siu fr ells int the extrellulr spe s  nse- quene f idsis, seru ptssiu is usully nrl t slightly elevted prir t institutin f tretent. As the idsis is rreted, ptssiu flws bk int the ells, nd hypklei n develp if ptssiu repleent is nt instituted. If the ptient is nt urei nd hs n de- qute urinry utput, ptssiu hlride in dses f 1030 Eq/h shuld be infused during the send nd third hurs fter beginning therpy s sn s the idsis strts t reslve. Repleent shuld be strted sner if the initil seru ptssiu is inpprpritely nrl r lw nd shuld be delyed if seru ptssiu fils t respnd t initil therpy nd reins bve 5 Eq/L, s in ses f hrni kidney disese. Osinlly,  ptient y present with  seru ptssiu level less thn 3.5 Eq/L, in whih se insulin therpy shuld be delyed until the ptssiu level is rreted t greter thn 3.5 Eq/L. An ECG n help nitr the ptients pts- siu sttus: High peked T wves re  sign f hyperkle- i, nd flttened T wves with U wves re  sign f hypklei. Fds high in ptssiu ntent shuld be presribed when the ptient hs revered suffiiently t tke fd rlly. Tt juie hs 14 Eq f ptssiu per 240 L, nd  ediu-sized bnn prvides but 10 Eq.D . Sodium BicarbonateThe  use f sdiu birbnte in the ngeent f DKA hs been questined sine linil benefit ws ntCMDT22_Ch27_p1212-p1255.indd  1246 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1247 CMDT 2022denstr ted in ne prspetive rndized tril nd beuse f the fllwing ptentilly hrful nsequenes: (1) develpent f hypklei fr rpid shift f pts- siu int ells if the idsis is verrreted; (2) tissue nxi fr redued dissitin f xygen fr he- glbin when idsis is rpidly reversed (leftwrd shift f the xygen dissitin urve); nd (3) erebrl idsis resulting fr lwering f erebrspinl fluid pH. It ust be ephsized, hwever, tht these nsidertins re less iprtnt when very severe idsis exists. Therefre, it is reended tht birbnte be dinistered in DKA if the rteril bld pH is 7.0 r less, with reful nitring t prevent verrretin. One r tw pules f sdiu birbnte (ne pule ntins 44 Eq/50 L) shuld be dded t 1 L f 0.45% sline with 20 Eq KCl r t 400 L f sterile wter with 20 Eq KCl nd infused ver 1 t 2 hurs. ( Note: Additin f sdiu birbnte t 0.9% sline wuld prdue  rkedly hypertni slutin tht uld ggrvte the hyperslr stte lredy pres- ent.) It n be repeted until the rteril pH rehes 7.1, but it should not be given if the pH is 7.1 or greater sine ddi- tinl birbnte wuld inrese the risk f rebund etbli lklsis s ketnes re etblized. Alklsis shifts ptssiu fr seru int ells, whih uld pre- ipitte  ftl rdi rrhythi.E.  PhosphatePh sphte repleent is seld required in treting DKA. Hwever, if severe hypphsphtei f less thn 1 g/dL (0.32 l/L) develps during insulin therpy,  sll unt f phsphte n be repled per hur s the pts- siu slt. Three rndized studies, thugh, in whih phsphte ws repled in ptients with DKA did nt shw ny pprent linil benefit fr phsphte dinistr- tin. Mrever, ttepts t use ptssiu phsphte s the sle ens f repling ptssiu hve led t  nuber f reprted ses f severe hyplei with tetny. T ini- ize the risk f induing tetny fr t-rpid repleent f phsphte, the verge defiit f 4050 l f phs- phte shuld be repled intrvenusly t  rte no greater than 34 mmol/h in  60- t 70-kg persn. A stk slutin (Abbtt) prvides  ixture f 1.12 g KH2PO4nd 1.18 g K2HPO4in  5-L single-dse vil (this equls 22 l f ptssiu nd 15 l f phsphte). One-hlf f this vil (2.5 L) shuld be dded t 1 L f either 0.45% sline r 5% dextrse in wter. Tw liters f this slutin, infused t  rte f 400 L/h, will rret the phsphte defiit t the ptil rte f 3 l/h while prviding 4.4 Eq f ptssiu per hur. (Additinl ptssiu shuld be dinistered s ptssiu hlride t prvide  ttl f 1030 Eq f pts- siu per hur, s nted bve.) If the seru phsphte reins belw 2.5 g/dL (0.8 l/L) fter this infusin,  repet 5-hur infusin n be given.F . Hyperchloremic Acidosis During TherapyBeuse  f the nsiderble lss f ket ids in the urine during the initil phse f therpy, substrte fr subsequent regenertin f birbnte is lst nd rretin f the ttl birbnte defiit is hpered. A prtin f thebirbnte defiit is repled with hlride ins infused in lrge unts s sline t rret the dehydrtin. In st ptients, s the ketidsis lers during insulin reple- ent,  hyperhlrei, lw-birbnte pttern eerges with  nrl nin gp. This is  reltively benign ndi- tin tht reverses itself ver the subsequent 1224 hurs ne intrvenus sline is n lnger being dinistered. Using  blned eletrlyte slutin with  pH f 7.4 nd 98 Eq/L hlride suh s Pls-lyte insted f nrl sline (pH ~5.5; hlride 154 Eq/L) hs been reprted t prevent the hyperhlrei idsis.G.  Treatment of Associated InfectionAntibi tis re presribed s indited (Tble 305). Ch- leystitis nd pyelnephritis y be prtiulrly severe in these ptients.H.  Transition to Subcutaneous Insulin RegimenOn e the DKA is ntrlled nd the ptient is wke nd ble t et, subutneus insulin therpy n be initited. The ptient with type 1 dibetes y hve persistent signifi- nt tissue insulin resistne nd y require  ttl dily insulin dse f pprxitely 0.6 unit/kg. The unt f insulin required in the previus 8 hurs n ls be helpful in estiting the initil insulin dses. Hlf the ttl dily dse n be given s  lng-ting bsl insulin nd the ther hlf s shrt-ting insulin preels. The ptient shuld reeive subutneus bsl insulin nd rpid-ting insulin nlg with the first el nd the insulin infusin disntin- ued n hur lter. The verlp f the subutneus insulin tin nd insulin infusin is neessry t prevent relpse f the DKA. In ptients with preexisting dibetes, giving their bsl insulin by subutneus injetin t inititin f tret- ent siplifies the trnsitin fr intrvenus t subut- neus regien. The inresed insulin resistne is nly present fr  few dys, nd it is iprtnt t redue bth the bsl nd blus insulins t vid hypglyei. A ptient with new-nset type 1 dibetes usully still hs signifint bet ell funtin nd y nt need ny bsl insulin nd nly very lw dses f rpid-ting insulin befre els fter revery fr the ketidsis. Ptients with type 2 dibetes nd DKA due t severe illness y initilly require insulin therpy but n ften trnsitin bk t rl gents during utptient fllw-up. Complications & PrognosisLw- dse insulin infusin nd fluid nd eletrlyte repleent bined with reful nitring f ptients linil nd lbrtry respnses t therpy hve drti- lly redued the rtlity rtes f DKA t less thn 5% in individuls under 40 yers f ge. Hwever, this pli- tin reins  signifint risk in the ged wh hve r- tlity rtes greter thn 20% nd in ptients in prfund  in wh tretent hs been delyed. Aute yr- dil infrtin nd infrtin f the bwel fllwing pr- lnged hyptensin wrsen the utlk. A serius prgnsti sign is end-stge hrni kidney disese, nd prir kidney dysfuntin wrsens the prgnsis nsider- bly beuse the kidney plys  key rle in penstingCMDT22_Ch27_p1212-p1255.indd  1247 29/06/21 8:53 PMCHAPTEr 271248 CMDT 2022f r ssive pH nd eletrlyte bnrlities. Syptti erebrl ede urs pririly in the peditri ppultin. Risk ftrs fr its develpent inlude severe bseline i- dsis, rpid rretin f hyperglyei, nd exess vlue dinistrtin in the first 4 hurs. Onset f hedhe r deterirtin in entl sttus during tretent shuld led t nsidertin f this plitin. Intrvenus nnitl t  dsge f 12 g/kg given ver 15 inutes is the insty f tretent. Exess rystllid infusin n preipitte pul- nry ede. Aute respirtry distress syndre is  rre plitin f tretent f DKA. After revery nd stbiliztin, ptients shuld be instruted n hw t regnize the erly sypts nd signs f ketidsis. Urine ketnes r pillry bld bet-hydrxybutyrte shuld be esured in ptients with signs f infetin r in insulin pup-treted ptients when pillry bld gluse reins unexpetedly nd persis- tently high. When hevy ketnuri nd glysuri persist n severl suessive exintins, suppleentl rpid- ting insulin shuld be dinistered nd liquid fds suh s lightly slted tt juie nd brth shuld be ingested t replenish fluids nd eletrlytes. The ptient shuld be instruted t ntt the liniin if ketnuri persists, nd espeilly if there is viting nd inbility t keep dwn fluids. Reurrent episdes f severe ketid- sis ften indite pr pline with the insulin regi- en, nd these ptients will require intensive unseling.F yfn M et l. Mngeent f hyperglyei rises: dibeti ketidsis nd hyperglyei hyperslr stte. Med Clin Nrth A. 2017;101:587. [PMID: 28372715] Isl T et l. Guidelines nd ntrversies in the ngeent f dibeti ketidsis ini-review. Wrld J Dibetes. 2018;9:226. [PMID: 30588284] Krsliglu Frenh E et l. Dibeti ketidsis nd hypers- lr hyperglyei syndre: review f ute depensted dibetes in dult ptients. BMJ. 2019;365:l114. [PMID: 31142480] Mdi A et l. Euglyei dibeti letidsis:  review. Curr Dibetes Rev. 2017;13:315. [PMID: 27097605]HYP ERGLYCEMIC HYPEROSMOLAR STATEE S S E N T I A L S  O F  D I A G N O S I S Hyperglycemia > 600 mg/dL (33.3 mmol/L). Serum osmolality > 310 mOsm/kg. No acidosis; blood pH > 7.3. Serum bicarbonate > 15 mEq/L. Normal anion gap (< 14 mEq/L). General ConsiderationsTh is send st n fr f hyperglyei  is hrterized by severe hyperglyei in the bsene f sig- nifint ketsis, with hypersllity nd dehydrtin. It urs in ptients with ild r ult dibetes, nd stptients re typilly iddle-ged t elderly. Aurte figures re nt vilble s t its true inidene, but fr dt n hspitl dishrges it is rrer thn DKA even in lder ge grups. Underlying hrni kidney disese r hert filure is n, nd the presene f either wrsens the prgnsis. A preipitting event suh s infetin, yrdil infrtin, strke, r reent pertin is ften present. Certin edi- tins suh s phenytin, dizxide, rtisterids, nd diuret- is hve been iplited in its pthgenesis, s hve predures ssited with gluse lding suh s peritnel dilysis. PathogenesisA prtil  r reltive insulin defiieny y initite the syn- dre by reduing gluse utiliztin f usle, ft, nd liver while induing hyperglugnei nd inresing hepti gluse utput. With ssive glysuri, bligtry wter lss ensues. If  ptient is unble t intin dequte fluid intke beuse f n ssited ute r hrni illness r hs suffered exessive fluid lss, rked dehydrtin results. As the pls vlue ntrts, kidney funtin bees ipired, liiting the urinry gluse lsses nd exerbting the hyperglyei. Severe hypersllity develps tht uses entl nfusin nd finlly . It is nt ler why ketsis is virtully bsent under these ndi- tins f insulin insuffiieny, lthugh redued levels f grwth hrne y be  ftr, lng with prtl vein insulin nentrtins suffiient t restrin ketgenesis. Clinical FindingsA.  Symptoms and SignsOnset  y be insidius ver  perid f dys r weeks, with wekness, plyuri, nd plydipsi. The lk f fe- tures f DKA (eg, viting, rpid deep brething, etne dr) y retrd regnitin f the syndre nd dely therpy until dehydrtin bees re prfund thn in ketidsis. Redued intke f fluid is nt n unn histril feture, due t either inpprprite lk f thirst, nuse, r inessibility f fluids t elderly, bedridden ptients. A histry f ingestin f lrge quntities f gluse-ntining fluids, suh s sft drinks r rnge juie, n sinlly be btined. Lethrgy nd nfu- sin develp s seru sllity exeeds 310 Os/kg, nd nvulsins nd  n ur if sllity exeeds 320330 Os/kg. Physil exintin nfirs the presene f prfund dehydrtin in  lethrgi r - tse ptient withut Kussul respirtins.B.  Laboratory FindingsSevere h yperglyei is present, with bld gluse vlues rnging fr 800 g/dL t 2400 g/dL (44.4 l/L t 133.2 l/L) (Tble 2710). In ild ses, where dehy- drtin is less severe, dilutinl hypntrei s well s urinry sdiu lsses y redue seru sdiu t 120125 Eq/L, whih prtets t se extent ginst extree hypersllity. Hwever, s dehydrtin pr- gresses, seru sdiu n exeed 140 Eq/L, prduing seru sllity redings f 330440 Os/kg. Ketsis nd idsis re usully bsent r ild. Prerenl zteiCMDT22_Ch27_p1212-p1255.indd  1248 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1249 CMDT 2022is  the rule, with seru ure nitrgen elevtins ver 100 g/dL (35.7 l/L) being typil. TreatmentA.  Fluid ReplacementFluid  repleent is f prunt iprtne in treting the nnketti hyperglyei stte. Fluid defiit y be s uh s 610 L. If hypvlei is present s evidened by hyptensin nd liguri, fluid therpy shuld be initited with 0.9% sline. In ll ther ses, 0.45% sline ppers t be prefer- ble s the initil repleent slutin beuse the bdy flu- ids f these ptients re rkedly hyperslr. As uh s 46 L f fluid y be required in the first 810 hurs. Cre- ful nitring f the ptient is required fr prper sdiu nd wter repleent. An iprtnt end pint f fluid therpy is t restre urinry utput t 50 L/h r re. One bld gluse rehes 250 g/dL (13.9 l/L), fluid repleent shuld inlude 5% dextrse in either wter, 0.45% sline slutin, r 0.9% sline slutin. The rte f dextrse infusin shuld be djusted t intin glyei levels f 250300 g/dL (13.916.7 l/L) in rder t redue the risk f erebrl ede.B.  InsulinLess  insulin y be required t redue the hyperglyei in nnketti ptients s pred t thse with dibeti ket- idti . In ft, fluid repleent lne n redue hyperglyei nsiderbly by rreting the hypvlei, whih then inreses bth glerulr filtrtin nd renl exretin f gluse. Insulin tretent shuld therefre be delyed unless the ptient hs signifint ketnei (bet- hydrxybutyrte re thn 1 l/L). Strt the insulin infusin rte t 0.05 unit/kg/h (blus is nt needed) nd titrte t lwer bld gluse levels by 5070 g/dL per hur (2.83.9 l/L/h). One the ptient hs stbilized nd the bld gluse flls t rund 250 g/dL (13.9 l/L), insulin n be given subutneusly.C.  PotassiumW ith the bsene f idsis, there y be n initil hyper- klei unless ssited end-stge hrni kidney disese is present. This results in less severe ttl ptssiu deple- tin thn in DKA, nd less ptssiu repleent is there- fre needed. Hwever, beuse initil seru ptssiu is usully nt elevted nd beuse it delines rpidly s  result f insulins effet n driving ptssiu intrellulrly, it is reended tht ptssiu repleent be initited erlier thn in ketti ptients, ssuing tht n hrni kidney disese r liguri is present. Ptssiu hlride (10 Eq/L) n be dded t the initil bttle f fluids din- istered if the ptients seru ptssiu is nt elevted.D . PhosphateIf  severe hypphsphtei (seru phsphte less thn 1 g/dL [0.32 l/L]) develps during insulin therpy, phsphte repleent n be given s desribed fr ket- idti ptients (t 3 l/h).Complications & PrognosisThe  severe dehydrtin nd lw utput stte y predis- pse the ptient t plitins suh s yrdil infrtin, strke, pulnry eblis, esenteri vein thrbsis, nd disseinted intrvsulr gultin. Fluid repleent reins the priry pprh t the preventin f these plitins. Lw-dse heprin pr- phylxis is resnble but benefits f rutine ntigul- tin rein dubtful. Rhbdylysis is  regnized plitin nd shuld be lked fr nd treted. The verll rtlity rte f hyperglyei hypers- lr stte  is re thn ten ties tht f DKA, hiefly beuse f its higher inidene in lder ptients, wh y hve prised rdivsulr systes r ssited jr illnesses nd whse dehydrtin is ften exessive beuse f delys in regnitin nd tretent. (When ptients re thed fr ge, the prgnses f these tw hyperglyei eergenies re resnbly pr- ble.) When prpt therpy is instituted, the rtlity rte n be redued fr nerly 50% t tht relted t the severity f existent disrders. After the ptient is stbilized, the pprprite fr f lng-ter ngeent f the dibetes ust be deter- ined. Insulin tretent shuld be ntinued fr  few weeks but ptients usully rever suffiient endgenus insulin seretin t ke  tril f diet r diet plus rl gents wrthwhile. When the episde urs in  ptient wh hs knwn dibetes, then edutin f the ptient nd regivers shuld be instituted. They shuld be tught hw t regnize situtins (nuse nd viting, infetin) tht predispse t reurrene f the hyperglyei, hyper- slr stte, s well s detiled infrtin n hw t prevent the eslting dehydrtin tht ulintes in hyperslr  (sll sips f sugr-free liquids, inrese in usul hypglyei therpy, r erly ntt with the liniin).F yfn M et l. Mngeent f hyperglyei rises: dibeti ketidsis nd hyperglyei hyperslr stte. Med Clin Nrth A. 2017;101:587. [PMID: 28372715] Stt AR; Jint British Dibetes Sieties (JBDS) fr Inptient Cre; JBDS hyperslr hyperglyei guidelines grup. Mngeent f hyperslr hyperglyei stte in dults with dibetes. Dibet Med. 2015;32:714. [PMID: 25980647]LAC TIC ACIDOSISE S S E N T I A L S  O F  D I A G N O S I S Severe metabolic acidosis with compensatory hyperventilation. Blood pH < 7.30. Serum bicarbonate < 15 mEq/L. Anion gap > 15 mEq/L. Absent serum ketones. Serum lactate > 5 mmol/L.CMDT22_Ch27_p1212-p1255.indd  1249 29/06/21 8:53 PMCHAPTEr 271250 CMDT 2022 General ConsiderationsL ti idsis is hrterized by uultin f exess lti id in the bld. Nrlly, the prinipl sures f this id re the erythrytes (whih lk enzyes fr erbi xidtin), skeletl usle, skin, nd brin. Cn- versin f lti id t gluse nd its xidtin prini- plly by the liver but ls by the kidneys represent the hief pthwys fr its revl. Hyperlttei nd i- dsis ur when ltte prdutin exeeds ltte n- suptin. Cuses inlude tissue hypxi (glbl r ll), disrders tht inrese epinephrine levels (severe sth with exess bet-drenergi gnist use, rdigeni r herrhgi shk, phehryt), nd drugs tht ipir xidtive phsphryltin (ntiretrvirl gents nd prpfl). Mst ses f etfrin-ssited lti idsis ur in ptients in wh there were ntrindi- tins t the use f etfrin, in prtiulr kidney filure. Metfrin levels re usully greter thn 5 g/L when etfrin is iplited s the use f lti id- sis. Other uses f lti idsis inlude severl inbrn errrs f etblis nd the MELAS syndre (it- hndril enephlpthy, lti idsis, nd strke-like episdes). D-lti idsis n ur in ptients with shrt bwel syndre when unbsrbed rbhydrtes re presented s substrte fr ferenttin by lni bteri. Clinical FindingsA.  Symptoms and SignsThe  in linil feture f lti idsis is rked hyperventiltin. When lti idsis is sendry t tissue hypxi r vsulr llpse, the linil present- tin is vrible, being tht f the previling tstrphi illness. Hwever, in the idipthi, r spntneus, vri- ety, the nset is rpid (usully ver  few hurs), bld pressure is nrl, peripherl irultin is gd, nd there is n ynsis.B.  Laboratory FindingsPl s birbnte nd bld pH re quite lw, indit- ing the presene f severe etbli idsis. Ketnes re usully bsent fr pls nd urine r t lest nt prinent. The first lue y be  high nin gp (seru sdiu inus the su f hlride nd birbn- te nins [in Eq/L] shuld be n greter thn 15). A higher vlue indites the existene f n bnrl - prtent f nins. If this nnt be linilly explined by n exess f ket ids (dibetes), inrgni ids (urei), r nins fr editin verdsge (sliy- ltes, ethyl lhl, ethylene glyl), then lti id- sis is prbbly the rret dignsis. (See ls Chpter 21.) In the bsene f ztei, hyperphsphtei y be  lue t the presene f lti idsis fr resns tht re nt ler. The dignsis is nfired by  pls lti id nentrtin f 5 l/L r higher (vlues s high s 30 l/L hve been reprted). Nrl pls vl- ues verge 1 l/L, with  nrl ltte/pyruvterti f 10:1. This rti is gretly exeeded in lti idsis.1 TreatmentAggressiv e tretent f the preipitting use f lti idsis is the in pnent f therpy, suh s ensur- ing dequte xygentin nd vsulr perfusin f tissues. Epiri ntibiti verge fr sepsis shuld be given fter ulture sples re btined in ny ptient in wh the use f the lti idsis is nt pprent (Tble 305). Alkliniztin with intrvenus sdiu birbnte t keep the pH bve 7.2 hs been reended by se in the eergeny tretent f lti idsis; s uh s 2000 Eq in 24 hurs hs been used. Hwever, there is n evidene tht the rtlity rte is fvrbly ffeted by dinistering birbnte, nd its use reins ntrver- sil. Hedilysis y be useful in ses where lrge sdiu lds re prly tlerted nd in ses ssited with etfrin txiity. PrognosisThe  rtlity rte f spntneus lti idsis is high. The prgnsis in st ses is tht f the priry disrder tht prdued the lti idsis.DeFr nz R et l. Metfrin-ssited lti idsis: urrent perspetives n uses nd risk. Metblis. 2016;65:20. [PMID: 26773926] THE HYPOGLYCEMIC STATESSpn tneus hypglyei in dults is f tw prinipl types: fsting nd pstprndil. Sypts begin t pls gluse levels in the rnge f 60 g/dL (3.3 l/L) nd ipirent f brin funtin t pprxitely 50 g/dL (2.8 l/L). Fsting hypglyei is ften subute r hrni nd usully presents with neurglypeni s its prinipl nifesttin; pstprndil hypglyei is rel- tively ute nd is ften herlded by sypts f neur- geni utni dishrge (sweting, plpittins, nxiety, treulusness). Differential Diagnosis (Table 2711)Fstin g hypglyei y ur in ertin endrine dis- rders, suh s hyppituitris, Addisn disese, r yx- ede; in disrders relted t liver lfuntin, suh s ute lhlis r liver filure; nd in instnes f end- stge hrni kidney disese, prtiulrly in ptients requiring dilysis. These nditins re usully bvius, with hypglyei being nly  sendry feture. When fsting hypglyei is  priry nifesttin develp- ing in dults withut pprent endrine disrders r inbrn etbli diseses fr hildhd, the prinipl1 In lleting sples, it is essentil t rpidly hill nd seprte the bld in rder t reve red ells, whse ntinued glylysis t r teperture is  n sure f errr in reprts f high pls ltte. Frzen pls reins stble fr subsequent ssy.CMDT22_Ch27_p1212-p1255.indd  1250 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1251 CMDT 2022dignsti pssibili ties inlude (1) hyperinsulinis, due t either pnreti B ell turs, itrgeni r surreptitius dinistrtin f insulin r sulfnylure; nd (2) hypgly- ei due t extrpnreti turs. Pstprndil (retive) hypglyei y ur fter gstrintestinl surgery nd is prtiulrly ssited with the duping syndre fter gstrety nd Rux-en-Y gstri bypss surgery. Oult dibetes very sinlly presents with pstprndil hypglyei. Rrely, it urs with islet ell hyperplsithe s-lled nninsulin pnretgenus hypglyei syndre. Alhl-relted hypglyei is due t hepti gly- gen depletin bined with lhl-edited inhibitin f glunegenesis. It is st n in lnurished individuls with exessive lhl intke but n ur in nyne wh is unble t ingest fd fter n ute lhli episde fllwed by gstritis nd viting. Iunpthlgi hypglyei is n extreely rre nditin in whih nti-insulin ntibdies r ntibdies t insulin reeptrs develp spntneusly.HYP OGLYCEMIA DUE TO PANCREATIC B CELL TUMORSE S S E N T I A L S  O F  D I A G N O S I S Hypoglycemic symptomsoften neuroglycopenic (confusion, blurred vision, anxiety, convulsions). Immediate recovery upon administration of glucose. Blood glucose < 45 mg/dL (2.5 mmol/L) with a serum insulin level of  6 microunits/mL. General ConsiderationsFsting  hypglyei in n therwise helthy, well- nurished dult is rre nd is st nly due t nden f the islets f Lngerhns. Ninety perent f suh turs re single nd benign, but ultiple dens n ur s well s lignnt turs with funtinl etstses. Adens y be filil, nd ultiple de- ns hve been fund in njuntin with turs f the prthyrids nd pituitry (MEN type 1 [MEN 1]). Abut 30% f sprdi insulin turs hve  sti ut- tin in the YY1 gene (T372R) tht endes the trnsrip- tinl repressr YY1. Over 99% f insulins re lted within the pnres nd less thn 1% in etpi pnreti tissue. Clinical FindingsA.  Symptoms and SignsThe st ip rtnt prerequisite t dignsing n insulin-  is siply t nsider it, prtiulrly in reltively helthy-ppering persns wh hve fsting hypglyei ssited with se degree f entrl nervus syste dysfuntin suh s nfusin r bnrl behvir. A dely in dignsis n result in unneessry tretent fr psyhtr epilepsy r psyhitri disrders nd y use irreversible brin dge. In lng-stnding ses, besity n result s  nsequene f vereting t relieve sypts. The s-lled Whipple trid is hrteristi f hyp- glyei regrdless f the use. It nsists f (1)  histry f hypglyei sypts, (2) n ssited lw pls gluse level (4050 g/dL), nd (3) relief f sypts upn ingesting fst-ting rbhydrtes in pprxitely 15 inutes. The hypglyei sypts in insulin ften develp in the erly rning r fter issing  el. Osinlly, they ur fter exerise. Ptients typilly plin f neurglypeni syp- ts suh s blurred visin r diplpi, hedhe, feelings f dethent, slurred speeh, nd wekness. Persnlity nd entl hnges vry fr nxiety t psyhti behv- ir, nd neurlgi deterirtin n result in nvulsins r . Hypglyei unwreness is very n nd drenergi sypts f plpittins nd sweting y be blunted. With the redy vilbility f he bld gluse nitring systes, ptients seties present with d- uented fingerstik bld gluse levels in 40s nd 50s t tie f sypts. Aess t sulfnylures r insulin shuld be explreddes  fily eber hve dibetes, r des the ptient r fily eber wrk in the edil field? Meditin-dispensing errrs shuld be exludedhs the ptients presriptin editin hnged in shpe r lr? Ptients with insulin r ftitius hypglyei usully hve  nrl physil exintin.B.  Laboratory FindingsB  ell dens d nt redue seretin f insulin in the presene f hypglyei, nd the ritil dignsti test is t denstrte inpprpritely elevted seru insulin, prinsulin, nd C-peptide levels, t  tie when pls gluse level is belw 45 g/dL. The dignsti riteri fr insulin fter  72-hur fst re listed in Tble 2712. Other uses f hyperinsulin- ei hypglyei inlude ftitius dinistrtin fTable 2711. Common causes of hypoglycemia in adults.1F asting hypoglycemia Pancreatic B cell tumor Surreptitious administration of insulin or sulfonylureas Extrapancreatic tumors Postpandial hypoglycemia Gastric surgery Occult diabetes mellitus Alcohol-elated hypoglycemia Immunopathologic hypoglycemia Idiopathic anti-insulin antibodies (which release their bound insulin) Antibodies to insulin receptors (which act as agonists) Dug-induced hypoglycemia1 In the absence of clinically obvious endocrine, kidney, or liver disorders and exclusive of diabetes mellitus treated with hypogly- cemic agents.CMDT22_Ch27_p1212-p1255.indd  1251 29/06/21 8:53 PMCHAPTEr 271252 CMDT 2022insulin  r sulfnylures. Ftitius use f insulin will result in suppressin f endgenus insulin seretin nd lw C-peptide levels. In ptients wh hve injeted insulin, the insulin/C-peptide rti (pl/L) will be greter thn 1. An elevted irulting prinsulin level in the presene f fst- ing hypglyei is hrteristi f st B ell dens nd des nt ur in ftitius hyperinsulinis. Thus, C-peptide levels (by iunheiluinetri ssys [ICMA]) f greter thn 200 pl/L nd prin- sulin levels (by rdiiunssy [RIA]) f greter thn 5 pl/L re hrteristi f insulins. In ptients with insulin, pls bet-hydrxybutyrte levels re suppressed t 2.7 l/L r less. N single hrne esureent (insulin, prinsulin, C-peptide) is 100% sensitive nd speifi fr the dignsis f insulin, nd insulin ses hve been reprted with insulin lev- els belw 3 irunits/L (ICMA ssy) r prinsulin level belw 5 pl/L. These hrnl ssys re ls nt stndrdized, nd there n be signifint vritin in the test results. Therefre, the dignsis shuld be bsed n ultiple biheil preters. In ptients with epigstri distress,  histry f renl luli, r enstrul r eretile dysfuntin,  seru l- iu, gstrin, r prltin level y be useful in sreening fr MEN 1 ssited with insulin.C.  Diagnostic TestsIf  the histry is nsistent with episdi spntneus hyp- glyei, ptients shuld be given  he bld gluse nitr nd dvised t nitr bld gluse levels t the tie f sypts nd befre nsuptin f rbhy- drtes, if this n be dne sfely. Ptients with insulins frequently reprt fingerstik bld gluse levels between 40 g/dL (2.2 l/L) nd 50 g/dL (2.8 l/L) t the tie f sypts. The dignsis, hwever, nnt be de bsed n  fingerstik bld gluse. It is neessry t hve  lw lbrtry gluse nitntly with ele- vted pls insulin, prinsulin, nd C-peptide levels nd  negtive sulfnylure sreen. When ptients give  his- try f sypts fter nly  shrt perid f fd with- drwl r with exerise, then n utptient ssessent nbe ttepted. The ptient shuld be brught by  fily eber t the ffie fter n vernight fst nd bserved in the ffie. Ativity suh s wlking shuld be enur- ged nd fingerstik bld gluse esured repetedly during bservtin. If sypts ur r fingerstik bld gluse is belw 50 g/dL (2.8 l/L), then sples fr pls gluse, insulin, C-peptide, prinsulin, sulfnyl- ure sreen, seru ketnes, nd ntibdies t insulin shuld be sent. If utptient bservtin des nt result in sypts r hypglyei nd if the linil suspiin reins high, then the ptient shuld underg n inptient supervised 72-hur fst. A suggested prtl fr the supervised fst is shwn in Tble 2713. In 30% f ptients with insulin, the bld gluse levels ften drp belw 45 g/dL (2.5 l/L) fter n vernight fst, but se ptients require up t 72 hurs t develp syptti hypglyei. Hwever, the ter 72-hur fst is tully  isner in st ses sine the fst shuld be ieditely terinted s sn s sypts pper nd lbrtry nfirtin f hypgly- ei is vilble. In nrl le subjets, the bld glu- se des nt fll belw 5560 g/dL (3.13.3 l/L) during  3-dy fst. In ntrst, in nrl preenpusl wen, the pls gluse n reh vlues s lw s 35 g/dL (1.9 l/L). In these ses, hwever, the wen re nt syptti, presubly wing t the develpent f suffiient ketnei t supply energy needs t the brin. Insulin ptients, n the ther hnd,Table 2712. Diagnostic criteria for insulinoma after a 72-hour fast.Laboatoy  Test result Plasma glucose < 45 mg/dL (2.5 mmol/L) Plasma insulin (RIA)  6 microunits/mL (36 pmol/L) Plasma insulin (ICMA)  3 microunits/mL (18 pmol/L) Plasma C-peptide  200 pmol/L (0.2 nmol/L, 0.6 ng/mL) Plasma proinsulin  5 pmol/L Beta-hydroxybutyrate  2.7 mmol/L Sulfonylurea screen (including repaglinide and nateglinide)Negative ICMA, immunochemiluminometric assays; RIA, radioimmunoassay.T able 2713. Suggested hospital protocol for super- vised fast in diagnosis of insulinoma.(1)  Place intravenous cannula and obtain baseline plasma glucose, insulin, proinsulin, beta-hydroxybutyrate, and C-peptide measurements at onset of fast. (2) Permit only calorie-free and caffeine-free fluids and encourage supervised activity (such as walking). (3) Obtain fingerstick glucose measurements every 4 hours until values < 60 mg/dL are obtained. Then increase the frequency of fingersticks to 12 hours, and when capillary glucose value is < 45 mg/dL send a venous blood sample to the laboratory for plasma glucose.1Check frequently for manifestations of neuroglycopenia. (4) At 48 hours into the fast, send a venous blood sample for plasma glucose, insulin, proinsulin, C-peptide, beta- hydroxybutyrate, and sulfonylurea measurement. (5) If symptoms of hypoglycemia occur oif a laboratory value of serum glucose is < 45 mg/dL, oif 72 hours have elapsed, conclude the fast with a final blood sample for plasma glucose,1insulin, proinsulin, C-peptide, beta-hydroxybutyrate, and sulfonylurea measurements. Then give oral fast-acting carbohydrate followed by a meal. If the patient is confused or unable to take oral agents, administer 50 mL of 50% dextrose intravenously over 35 minutes. Do not conclude a fast based simply on a capillary blood glucose measurementwait for the laboratory glucose valueunless the patient is very symptomatic and it would be dangerous to wait.1 Glucose sample should be collected in sodium fluoride contain- ing tube on ice to prevent glycolysis and the plasma separated immediately upon receipt at the laboratory. Arrange for the labora- tory to run the glucose samples stat.CMDT22_Ch27_p1212-p1255.indd  1252 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1253 CMDT 2022bee  syptti when pls gluse drps t sub- nrl levels, sine inpprprite insulin seretin restrits ketne frtin. Mrever, the denstrtin f  nn- suppressed insulin level f 3 irunits/L r re using n ICMA ssy (greter thn 6 irunits/L using n RIA ssy) in the presene f hypglyei suggests the dignsis f insulin. If hypglyei des nt develp in  le ptient fter fsting fr up t 72 hursnd pr- tiulrly when this prlnged fst is terinted with  perid f derte exeriseinsulin ust be nsid- ered n unlikely dignsis. An rl gluse tlerne test is f n vlue in the dig- nsis f insulin-sereting turs. HbA1levels y be lw but there is nsiderble verlp with nrl ptients nd n prtiulr vlue is dignsti.D . Preoperative Localization of B Cell TumorsAfter  the dignsis f insulin hs been unequivlly de by linil nd lbrtry findings, studies t llize the tur shuld be initited. Mst turs re in the pn- res, nd etpi ses re rre. Beuse f the sll size f these turs (verging 1.5  in dieter in ne lrge series), iging studies d nt neessrily identify ll f the. A pnreti dul phse helil CT sn with thin setin n identify 8294% f the lesins. MRI sns with gdliniu n be helpful in deteting  tur in 85% f ses. One se reprt suggests tht diffusin-weighted MRI n be useful fr deteting nd llizing sll insulins, espeilly fr thse with n hypervsulr pttern. PET/CT sns using glliu-lbeled ststtin nlgs suh s DOTA- 1-NI3-tretide (DOTA-NOC), whih hve  higher ffinity fr ststtin reeptr subtypes 2, 3, nd 5, hve been reprted t be useful in llizing the turs. Insuli- ns express GLP-1 reeptrs, nd rdilbeled GLP-1 reeptr gnists suh s Lys(40)(Ahx-hydrzinnitin- ide [HYNIC]-[(99)T)NH(2)]-exendin-4 fr SPECT/ CT hve ls been reprted t visulize the turs. If the iging study is nrl, then n endspi ultrsund shuld be perfred. In experiened hnds, but 8090% f turs n be deteted with this predure. Fine-needle spirtin f the identified lesin n be ttepted t n- fir the presene f  neurendrine tur. If the tur is nt identified r the iging result is equivl, then the ptient shuld underg seletive liu-stiulted ngi- grphy, whih hs been reprted t llize the tur t  prtiulr regin f the pnres pprxitely 90% f the tie. In this test, ngigrphy is bined with inje- tins f liu glunte int the gstrdudenl, spleni, nd superir esenteri rteries, nd insulin levels re esured in the hepti vein effluent. The predure is perfred fter n vernight fst. Cliu stiultes insulin relese fr insulins but nt nrl islets, nd s  step-up fr bseline in insulin levels (twfld r greter) reginlizes the sure f the hyperinsulinis t the hed f the pnres fr the gstrdudenl rtery, the uninte press fr the superir esenteri rtery, nd the bdy nd til f the pnres fr the spleni rtery liu infusins. These studies bined with reful intrper- tive ultrsngrphy nd plptin by  surgenexperiened in insulin surgery identifies up t 98% f turs. TreatmentThe  tretent f hie fr insulin-sereting turs is surgil resetin. While witing fr surgery, ptients shuld be given rl dizxide. Divided dses f 300400 g/dy usully suffie, lthugh n sinl ptient y require up t 800 g/dy. Side effets inlude ede due t sdiu retentin, gstri irrittin, nd ild hirsutis. Hydrhlrthizide, 2550 g dily, n be used t untert the sdiu retentin nd ede s well ptentite dizxides hyperglyei effet. In ptients with  single benign pnreti B ell de- n, 9095% hve  suessful ure t the first surgil ttept when intrpertive ultrsund is used by  skilled surgen. Dizxide shuld be dinistered n the dy f the surgery beuse it redues the risk f hypglyei during surgery. Typilly, it des nt sk the glyei rise inditive f surgil ure. Bld gluse shuld be nitred thrughut surgery, nd 5% r 10% dextrse infusin shuld be used t intin euglyei. In ses where the dignsis hs been estblished but n den is lted fter reful plptin nd use f intrpertive ultrsund, it is n lnger dvisble t blindly reset the bdy nd til f the pnres, sine  nnplpble tur issed by ultrsund is st likely ebedded within the fleshy hed f the pnres tht is left behind with subttl resetins. Mst surgens prefer t lse the inisin nd shedule  seletive rteril liu stiultin with hepti venus spling t lte the tur site prir t  repet pertin. Lprspy using ultrsund nd enu- letin hs been suessful with  single tur f the bdy r til f the pnres, but pen surgery reins neessry fr turs in the hed f the pnres. In ptients with inperble funtining islet ell ri- n with nd withut hepti etstsis nd in pprxi- tely 510% f MEN 1 ses when subttl revl f the pnres hs filed t prdue ure, the tretent pprh is the se s fr ther types f pnreti neu- rendrine turs (pNETs). Dizxide is the tretent f hie in preventing hypglyei. Frequent rbhy- drte feedings (every 23 hurs) n ls be helpful, lthugh weight gin n bee  prble. Ststtin nlgs, tretide r lnretide, shuld be nsidered if dizxide is ineffetive r if there is tur prgressin. Surgery r ebliztin (blnd, he- nd rdi-) r ther- l bltin (rdifrequeny, irwve, nd rybltin) n be used t redue tur burden nd ls prvide syp- tti relief. Chetherpy regiens tht n be nsid- ered inlude bintin f streptzin, 5-flururil, nd dxrubiin; peitbine nd xlipltin; nd peitbine nd tezlide (Tble 393). Trgeted therpies ginst ultiple steps in the PI3K/AKT/Tr pth- wy hve been shwn t be helpful. Everlius, n inhibi- tr f Tr, is pprved fr tretent f dvned pNETs. Sunitinib hs been shwn t slw grwth f pNETs. Tret- ent with rdiistpes (indiu-111 r yttriu-90 r lutetiu-177) linked t  ststtin nlg hs been reprted t shw benefit in  prprtin f ptients.CMDT22_Ch27_p1212-p1255.indd  1253 29/06/21 8:53 PMCHAPTEr 271254 CMDT 2022NO NISLET CELL TUMOR HYPOGLYCEMIAThese  rre uses f hypglyei inlude esenhyl turs suh s retrperitnel srs, heptellulr rins, drenrtil rins, nd isellneus epithelil-type turs. The turs re frequently lrge nd redily plpted r visulized n CT sns r MRI. In ny ses the hypglyei is due t the expres- sin nd relese f n inpletely pressed insulin-like grwth ftr 2 (IGF-2) by the tur. The dignsis is supprted by lbrtry duent- tin f seru insulin levels belw 5 irunit/L with pls gluse levels f 45 g/dL (2.5 l/L) r lwer. Vlues fr grwth hrne nd IGF-1 re ls deresed. Levels f IGF-2 y be inresed but ften re nrl in quntity, despite the presene f the iture, higher- leulr-weight fr f IGF-2, whih n be deteted nly by speil lbrtry tehniques. Nt ll the ptients with nnislet ell tur hypglye- i hve elevted pr-IGF-2. Etpi insulin prdutin hs been desribed in brnhil rin, vrin rin, nd sll ell rin f the ervix. Hypglyei due t IgF-1 relesed fr  etstti lrge ell rin f the lung hs ls been reprted. GLP-1sereting turs (vr- in nd pNETs) n ls use hypglyei by stiulting insulin relese fr nrl pnreti islets. The prgnsis fr these turs is generlly pr, nd surgil revl shuld be ttepted when fesible. Dietry ngeent f the hypglyei is the insty f edil tretent, sine dizxide is usully ineffetive.PO STPRANDIAL HYPOGLYCEMIA 1. Hypoglycemia Following Gastic SugeyH ypglyei seties develps in ptients wh hve undergne gstri surgery (eg, gstrety, vgty, pylrplsty, gstrjejunsty, Nissn fundplitin, Billrth II predure, nd Rux-en-Y), espeilly when they nsue fds ntining high levels f redily bsrbble rbhydrtes. This lte duping syndre urs but 13 hurs fter  el nd is  result f rpid delivery f high nentrtin f rbhydrtes in the prxil sll bwel nd rpid bsrptin f gluse. The hyperinsulinei respnse t the high rbhydrte ld uses hypglyei. Exessive relese f gstrintestinl hrnes suh s GLP-1 likely ply  rle in the hyperin- sulinei respnse. The sypts inlude lightheded- ness, sweting, nfusin nd even lss f nsiusness fter eting  high rbhydrte el. T duent hyp- glyei, the ptient shuld nsue  el tht leds t sypts during everydy life. An rl gluse tlerne test is nt reended beuse ny nrl persns hve flse-psitive test results. There hve been se reprts f insulin nd nninsulin pnretge- nus hypglyei syndre in ptients with hypglye- i pst Rux-en-Y surgery. It is unler hw ften this urs. A reful histry y identify ptients wh hve  histry f hypglyei with exerise r issed els, nd these individuls y require  frl 72-hur fst t rule ut n insulin.Tretent fr sendry duping inludes dietry difitin, but this y be diffiult t sustin. Ptients n try re frequent els with sller prtins f less rpidly digested rbhydrtes. Alph-glusidse therpy y be  useful djunt t  lw rbhydrte diet. Otre- tide 50 g dinistered subutneusly tw r three ties  dy 30 inutes prir t eh el hs been reprted t iprve sypts due t lte duping syndre. Tret- ent with exendin 9-39,  GLP-1 reeptr gnist, y prevent pst gstri bypss hypglyei. SGLT2 inhibitrs y elirte the pstprndil gluse rise, the subse- quent insulin respnse, nd hypglyei. There is  reprt f  ptient with Rux-en-Y surgery wh hd plete reslutin f bth hyperglyei nd hypglyei when she ws given ngliflzin. Vrius surgil predures t dely gstri eptying hve been reprted t iprve sypts but lng-ter effiy studies re lking.2.  Functional Alimentay HypoglycemiaP tients hve sypts suggestive f inresed syp- theti tivity, inluding nxiety, wekness, trer, swet- ing r plpittins fter els. Physil exintin nd lbrtry tests re nrl. It is nt reended tht ptients with sypts suggestive f inresed syp- theti tivity underg either  prlnged rl gluse tl- erne test r  ixed el test. Insted, the ptients shuld be given he bld gluse nitrs (with eries) nd instruted t nitr fingerstik gluse levels t the tie f sypts. Only ptients wh hve sypts when their fingerstik bld gluse is lw (less thn 50 g/dL) nd wh hve reslutin f sypts when the gluse is rised by eting rpidly relesed rb- hydrte need dditinl evlutin. Ptients wh d nt hve evidene fr lw gluse levels t tie f sypts re generlly ressured by their findings. Cunseling nd supprt shuld be the instys in therpy, with dietry nipultin nly n djunt.3.  Occult DiabetesThis  nditin is hrterized by  dely in erly insulin relese fr pnreti B ells, resulting in initil exgger- tin f hyperglyei during  gluse tlerne test. In respnse t this hyperglyei, n exggerted insulin relese prdues  lte hypglyei 45 hurs fter inges- tin f gluse. These ptients re ften bese nd fre- quently hve  fily histry f dibetes ellitus. Ptients with this type f pstprndil hypglyei ften respnd t redued intke f refined sugrs with ultiple, sped, sll feedings high in dietry fiber. In the bese, tretent is direted t weight redutin t hieve idel weight. These ptients shuld be nsidered t hve predibetes r erly dibetes (type 1 r 2) nd dvised t hve peridi edil evlutins.4.  Autoimmune HypoglycemiaP tients with utiune hypglyei hve erly pstprn- dil hyperglyei fllwed by hypglyei 34 hurs lter. The hypglyei is ttributed t  dissitin f insulin- ntibdy iune plexes, relesing free insulin.CMDT22_Ch27_p1212-p1255.indd  1254 29/06/21 8:53 PMDIABETES MELLITUS & HYPOGLYCEMIA1255 CMDT 2022The  disrder is ssited with ethizle tretent fr Grves disese, lthugh it n ls ur in ptients treted with vrius ther sulfhydryl-ntining edi- tins (ptpril, peniilline) s well s ther drugs suh s hydrlzine, isnizid, nd prinide. In dditin, it hs been reprted in ptients with utiune disrders suh s rheutid rthritis, systei lupus erythetsus, nd plyysitis s well s in pls ell yel nd ther pls ell dysrsis where prprteins r ntibdies rss-ret with insulin. There is ls n ssitin with the HLA lss II lleles (DRB1*0406, DQA1*0301, nd DQB1*0302). These lleles re 10 t 20 ties re n in Jpnese nd Kren ppultins, whih explins why the disrder hs been reprted stly in Jpnese ptients. High titers f insulin utntibdies, usully IgG lss, n be deteted. Insulin, prinsulin, nd C-peptide levels y be elevted, but the results y be errneus beuse f the interferene f the insulin ntibdies with the iu- nssys fr these peptides. In st ses, the hypglyei is trnsient nd usully reslves spntneusly within 36 nths f dignsis, prtiulrly when the ffending editins re stpped. The st nsistent therpeuti benefit in ngeent f this syndre hs been hieved by dietry tretent with sll, frequent lw-rbhydrte els. Prednisne (3060 g rlly dily) hs been used t lwer the titer f insulin ntibdies.F ACTITIOUS HYPOGLYCEMIAF titius hypglyei y be diffiult t duent. A suspiin f self-indued hypglyei is supprted when the ptient is ssited with the helth prfessins r hs ess t dibeti editins tken by  dibeti eber f the fily. The trid f hypglyei, high iunretive insulin, nd suppressed pls C-peptide iunretivity is pthgnni f exgenus insulin dinistrtin. Insu- lin nd C-peptide re sereted in  1:1 lr rti. A lrge frtin f the endgenus insulin is lered by the liver, wheres C-peptide, whih is lered by the kidney, hs  lwer etbli lerne rte. Fr this resn, the lr rti f insulin nd C-peptide in  hypglyei ptient shuld be less thn 1.0 in ses f insulin nd is greter thn 1.0 in ses f exgenus insulin dinistrtin (see Hypglyei Due t Pnreti B Cell Turs, bve). When sulfnylures, repglinide, nd nteglinide re sus- peted s  use f ftitius hypglyei,  pls level f these editins t detet their presene y be required t distinguish lbrtry findings fr thse f insulin.HYP OGLYCEMIA DUE TO INSULIN RECEPTOR ANTIBODIESH ypglyei due t insulin reeptr utntibdies is n extreely rre syndre; st ses hve urred in wen ften with  histry f utiune disese. Alst ll f these ptients hve ls hd episdes f insulin- resistnt dibetes nd nthsis nigrins. Their hypglye- i y be either fsting r pstprndil nd is ften severend is ttributed t n gnisti tin f the ntibdy n the insulin reeptr. Blne between the ntgnisti nd g- nisti effets f the ntibdies deterines whether insulin- resistnt dibetes r hypglyei urs. Hypglyei ws fund t respnd t rtisterid therpy but nt t plspheresis r iunsuppressin.ME DICATION- & ETHANOL-INDUCED HYPOGLYCEMIAA  nuber f editins prt fr dibeti editins n sinlly use hypglyei. Cn ffenders inlude the flurquinlnes suh s gtiflxin nd lev- flxin, pentidine, quinine, ACE inhibitrs, sliyltes nd bet-drenergi blking gents. The flurquinlnes, prtiulrly gtiflxin, hve been ssited with bth hypglyei nd hyperglyei. It is thught tht the drug ts n the ATP sensitive ptssiu hnnels in the bet ell. Hypglyei is n erly event, nd hyperglyei urs severl dys int therpy. Intrvenus pentidine is yt- txi t bet ells nd uses ute hyperinsulinei nd hypglyei fllwed by insulinpeni nd hyperglyei. Fsting ptients tking nnrdiseletive bet-blkers n hve n exggerted hypglyei respnse t strvtin. The bet-blkde inhibits ftty ids nd glunegenesis substrte relese nd redues pls glugn respnse. Therpy with ACE inhibitrs inreses the risk f hypgly- ei in ptients wh re tking insulin r sulfnylures presubly beuse these drugs inrese sensitivity t iru- lting insulin by inresing bld flw t the usle. Se piids use hypglyei. Trdl use hs been ssi- ted with inresed risk f hspitliztin fr hypglyei. Methdne verdse hs ls been reprted t use hyp- glyei nd  rpid dse esltin f ethdne in ner ptients n lwer gluse levels. Ethnl-ssited hypglyei y be due t hepti lhl dehydrgense tivity depleting NAD. The resul- tnt hnge in the redx stteinrese in NADH t NAD+rtiuses  prtil blk t severl pints in the glunegeni pthwy. With prlnged strvtin, gly- gen reserves bee depleted within 1824 hurs nd hepti gluse utput bees ttlly dependent n glu- negenesis. Under these irustnes,  bld nen- trtin f ethnl s lw s 45 g/dL (9.8 l/L) n indue prfund hypglyei by blking glunegen- esis. Neurglypeni in  ptient whse breth sells f lhl y be istken fr lhli stupr. Preventin nsists f dequte fd intke during ethnl ingestin. Therpy nsists f gluse dinistrtin t replenish glygen stres until glunegenesis resues. When sugr-ntining sft drinks re used s ixers t dilute lhl in beverges (gin nd tni, ru nd l), there sees t be  greter insulin relese thn when the sft drink lne is ingested nd  tendeny fr re f  lte hypglyei verswing t ur 34 hurs lter. Preventin wuld nsist f viding sugr ixers while ingesting lhl nd ensuring suppleentry fd intke t prvide sustined bsrptin.CMDT22_Ch27_p1212-p1255.indd  1255 29/06/21 8:53 PM1256 CMDT 2022Lipid Disorders 28Michael J. Blaha, MD, MPHThe  Lipid Hypothesis of cardiovascular disease (CVD) stating that cholesterol is causal in the development of atherosclerotic cardiovascular disease (ASCVD) and that lowering of cholesterol is associated with lower cardiovas- cular event ratesis widely accepted throughout the medi- cal community. For patients with known CVD (secondary prevention), studies have shown that cholesterol lowering leads to a consistent reduction in total mortality and in recurrent cardiovascular events in men and women; other studies have documented lowered mortality and events in middle-aged and older patients. Among patients without CVD (primary prevention), the data are generally consis- tent, with rates of cardiovascular events, heart disease mortality, and all-cause mortality differing among studies. Treatment guidelines have been designed to assist clini- cians in selecting patients for cholesterol-lowering therapy based predominantly on their overall risk of developing CVD as well as their baseline cholesterol levels. There are several genetic disorders that provide insight into the pathogenesis of lipid-related diseases. Familial hypercholesterolemia, rare in the homozygous state (about one per million), causes markedly high low-density lipoprotein (LDL) levels and early CVD. The most common genetic defects involve absent or defective LDL receptors, resulting in unregulated LDL metabolism, genetic muta- tions of apolipoprotein B, or gain of function in proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that regulates breakdown of LDL receptors. Patients with two abnormal genes (homozygotes) have extremely high levelsup to eight times normaland present with ath- erosclerotic disease in childhood. Patients with two abnor- mal genes (homozygotes) may require liver transplantation or plasmapheresis to correct their severe lipid abnormali- ties; early treatment with statins appears to confer lifetime benefits in such patients. Those with one defective gene (heterozygotes) have LDL concentrations up to two or three times normal; persons with this condition may develop CVD in their 30s or 40s. Another rare condition is caused by an abnormality of lipoprotein lipase, the enzyme that enables peripheral tissues to take up triglyceride from chylomicrons and very- low-density lipoprotein (VLDL) particles. Patients with this condition, one cause of familial chylomicronemiasyndrome, have marked hypertriglyceridemia with recur- rent pancreatitis and hepatosplenomegaly in childhood. Numerous other genetic abnormalities of lipid metabo- lism are named for the abnormality noted when serum is electrophoresed (eg, dysbetalipoproteinemia, character- ized by elevated levels of remnant lipoproteins) or from polygenic combinations of lipid abnormalities in families (eg, familial combined hyperlipidemia). When to Refer Known genetic lipid disorders. Striking family history of hyperlipidemia or premature atherosclerosis. Extremely high serum LDL cholesterol or triglycerides, or extremely low serum high-density lipoprotein (HDL) cholesterol.Chyzh yk V et al. Familial chylomicronemia syndrome: a rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis. Trends Cardiovasc Med. 2020;30:80. [PMID: 31003756] Hegele RA et al. Rare dyslipidaemias, from phenotype to geno- type to management: a European Atherosclerosis Society task force consensus statement. Lancet Diabetes Endocrinol. 2020;8:50. [PMID: 31582260] Khera AV et al. What is familial hypercholesterolemia, and why does it matter? Circulation. 2020;141:1760. [PMID: 32479201] Mortensen MB et al. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary pre- vention cohort. Lancet. 2020;396:1644. [PMID: 33186534] Sniderman AD et al. Apolipoprotein B particles and cardiovas- cular disease: a narrative review. JAMA Cardiol. 2019;4:1287. [PMID: 31642874]LI PID FRACTIONS & THE RISK OF CORONARY HEART DISEASEIn  serum, cholesterol is carried primarily on three different lipoproteinsthe VLDL, LDL, and HDL molecules. Total cholesterol equals the sum of these three components: =  + +Total cholesterol  HDL cholesterol  VLDL cholesterol LDL cholesterolCMDT22_Ch28_p1256-p1266.indd  1256 29/06/21 8:55 PM"
                ],
                [
                  "2",
                  "NERVOUS SYSTEM DISORDERS979 CMDT 2022alhli  beverages, bright lights, lud nise, menstrua- tin, r use f ral ntraeptives. An unmmn variant is migraine with brainstem aura, in whih blindness r visual disturbanes thrughut bth visual fields are ampanied r fllwed by dysar- thria, dysequilibrium, tinnitus, and periral and distal paresthesias and are smetimes fllwed by transient lss r impairment f nsiusness r by a nfusinal state. This, in turn, is fllwed by a thrbbing (usually ipital) headahe, ften with nausea and vmiting. Inrecurrent painful ophthalmoplegic neuropathy (previusly phthalmplegi migraine), lateralized pain ften abut the eyeis ampanied by nausea, vmiting, and diplpia due t transient external phthalmplegia. The phthalmplegia is due t third nerve palsy, smetimes with ampanying sixth nerve invlvement, and may ut- last the rbital pain by several days r even weeks. The phthalmi divisin f the fifth nerve has als been affeted in sme patients. The nditin is rare and a diagnsis f exlusin; mre mmn auses f a painful phthalmple- gia are internal artid artery aneurysms and diabetes. TreatmentMan agement f migraine nsists f avidane f any pre- ipitating fatrs, tgether with prphylati r symptm- ati pharmalgi treatment if neessary.A.  Symptomatic TherapyDuring  aute attaks, rest in a quiet, darkened rm may be helpful until symptms subside. A simple analgesi (eg, aspirin, aetaminphen, ibuprfen, r naprxen) taken immediately ften prvides relief, but presriptin media- tin is smetimes neessary. To prevent medication overuse, use of simple analgesics should be limited to 15 days or less per month, and combination analgesics should be limited to no more than 10 days per month . 1. Ergotamines Cafergt, a mbinatin f ergtamine tartrate (1 mg) and affeine (100 mg), is ften partiularly helpful; ne r tw tablets are taken at the nset f headahe r warning symptms, fllwed by ne tablet every 30 minutes, if neessary, up t six tablets per attak and n mre than 10 days per mnth. Cafergt given retally (ne- half t ne suppsitry ntaining 2 mg f ergtamine) r dihydrergtamine mesylate (0.51 mg intravenusly r 12 mg subutaneusly r intramusularly) may be useful when vmiting preludes use f ral mediatins. Ergta- mine-ntaining preparatins shuld be avided during pregnany, in patients with ardivasular disease r its risk fatrs, and in patients taking ptent CYP 3A4 inhibitrs. 2. Serotonin agonists Triptans are 5-HT1b/1dreeptr agnists that inhibit release f vasative neurpeptides. Sumatriptan is a rapidly effetive agent fr abrting attaks when given subutaneusly by an autinjetin devie (46 mg ne subutaneusly, may repeat ne after 2 hurs if needed; maximum dse 12 mg/24 h). Nasal and ral preparatins are available but may be less effetive due t slwer absrptin. Zlmitriptan is available in ral and nasal frmulatins. The dse is 5 mg rally r in ne nstrilne; this may be repeated ne after 2 hurs. The maxi- mum dse fr bth frmulatins is 10 mg/24 h. Other triptans are available, inluding rizatriptan (510 mg rally at nset, may repeat every 2 hurs twie [maximum dse 30 mg/24 h]); naratriptan (12.5 mg rally at nset, may repeat ne after 4 hurs [maximum dse 5 mg/24 h]); almtriptan (6.2512.5 mg rally at nset, may repeat dse ne after 2 hurs [maximum dse 25 mg/24 h]); frvatrip- tan (2.5 mg rally at nset, may repeat after 2 hurs ne [maximum dse 7.5 mg/24]); and eletriptan (2040 mg rally at nset; may repeat after 2 hurs ne [maximum dse 80 mg/24 h]). Eletriptan is useful fr immediate therapy, and frvatriptan, whih has a lnger half-life, may be wrthwhile fr patients with prlnged attaks r attaks prvked by menstrual perids. Patients ften experiene greater benefit when the triptan is mbined with naprxen (500 mg rally). Triptans may ause nausea and vmiting. They shuld prbably be avided in wmen wh are pregnant, and in patients with hemiplegi r basilar migraine, a histry f strke r transient ishemi attak (TIA), r unntrlled hypertensin. In patients whse hypertensin is ntrlled, triptans are mmnly used safely, althugh autin is advised. Triptans are ntraindiated in patients with r- nary r peripheral vasular disease and Prinzmetal angina. Lasmiditan (50200 mg taken ne at headahe nset; n mre than ne dse in 24 hurs) is a 5-HT1Freeptr agnist apprved fr use in the United States that laks the vasnstritive prperties f triptans and an be given safely t patients with ardivasular risk fatrs. Dizziness and smnlene are mmn side effets, and patients shuld nt drive within 8 hurs f administratin. 3. Calcitonin generelated peptide antagonists Rimegepant sulfate (75 mg rally disslved tablet taken ne at headahe nset; maximum dse 75 mg/24 h) and ubrgepant (50 r 100 mg rally at headahe nset, may repeat after 2 hurs ne [maximum dse 200 mg/24 h]) are bth alitnin generelated peptide antagnists that ahieve pain freedm in 20% and pain relief in 60% f patients within 2 hurs. Hypersensitivity reatins may ur immediately r several days after administratin with rimegepant. 4. Other agents Prhlrperazine is effetive and may be administered retally (25 mg suppsitry), intravenusly r intramusularly (510 mg), r rally (510 mg). Intrave- nus metlpramide (1020 mg) is als partiularly use- ful in the emergeny department setting. Varius butalbital-ntaining mbinatin ral analgesis risk veruse and dependene and shuld nly be used as a last resrt. Opiid analgesis shuld be avoided beause f high rates f rebund headahe and the tendeny t develp mediatin veruse headahe. 5. Neuromodulation Sham-ntrlled trials shw that single-pulse transranial magneti stimulatin abrts migraine with aura, and nninvasive vagus nerve stimula- tin, transutaneus trigeminal nerve stimulatin, and remte eletrial stimulatin applied t the upper arm abrt migraine with r withut aura. Transranial magneti stimulatin is ntraindiated in patients with epilepsy.CMDT22_Ch24_p0978-p1053.indd  979 29/06/21 8:50 PMChapTER 24980 CMDT 2022T able 241. Pharmacologic prophylaxis of migraine (listed in alphabetical order within classes).Mediction Usul adult Orl Dily Dose Selected Side Effects nd Comments antieiletic1T opiramate 100 mg (divided twice daily) Somnolence, nausea, dyspepsia, irritability, dizziness, ataxia, nystagmus, diplopia, glaucoma, renal calculi, weight loss, hypohidrosis, hyperthermia. Valproic acid2,35001000 mg (divided twice daily)Nausea, vomiting, diarrhea, drowsiness, alopecia, weight gain, hepatotoxic- ity, thrombocytopenia, tremor, pancreatitis. Crdiovsculr Candesartan3832 mg once daily Dizziness, cough, diarrhea, fatigue. Guanfacine 1 mg once daily Dry mouth, somnolence, dizziness, constipation, erectile dysfunction. Propranolol480240 mg (divided twice to four times daily)Fatigue, dizziness, hypotension, bradycardia, depression, insomnia, nausea, vomiting, constipation. Verapamil5120240 mg (divided three times daily)Headache, hypotension, flushing, edema, constipation. May aggravate atrioventricular nodal heart block and heart failure. antideressnt6Amitriptyline 710150 mg at bedtime Sedation, dry mouth, constipation, weight gain, blurred vision, edema, hypotension, urinary retention. Venlafaxine 37.5150 mg extended release once dailyNausea, somnolence, dry mouth, dizziness, diaphoresis, sexual dysfunction, anxiety, weight loss. Monoclonl ntibodies ginst clcitonin generelted etide Eptinezumab 100 mg intravenously every 3 monthsHypersensitivity reaction during infusion, nasopharyngitis. Erenumab 70140 mg subcutaneously once monthlyInjection site reactions, constipation, muscle cramps, antibody development. Fremanezumab 225 mg subcutaneously once monthlyInjection site reactions, antibody development. Galcanezumab 120 mg subcutaneously daily  2 doses, followed by 120 mg monthlyInjection site reactions, antibody development. Oter Acupuncture  More rapid pain relief and fewer side effects than pharmacologic treatment. Botulinum toxin A Intramuscular injection Injection site reaction, hypersensitivity, muscle weakness. Riboflavin 400 mg once daily Yellow-orange discoloration of urine. Transcutaneous supraor- bital neurostimulation20 minutes daily Transient paresthesia at site of stimulation.1 Gabapentin and possibly other antiepileptics have also been used successfully.2 Avoid during pregnancy.3 Not FDA-approved for this indication.4 Other beta-adrenergic antagonists such as atenolol, metoprolol, nadolol, and timolol are similarly effective.5 Other calcium channel antagonists (eg, nimodipine, nicardipine, and diltiazem) may also help.6 Depression is commonly comorbid with migraine disorder and may warrant separate treatment.7 Other tricyclic antidepressants (eg, nortriptyline and imipramine) may help similarly.B. Preventive TherapyPreven tive treatment may be neessary if migraine head- ahes ur more frequently than two or three times a month r signifiant disability is assiated with attaks. Avid- ane f triggers and maintenane f hmestasis with reg- ular sleep, meals, and hydratin shuld nt be negleted; a headahe diary may be useful t identify triggers. Sme mre mmn agents used fr prphylaxis are listed in Table 241. The mediatin hsen first will vary with theindividual patient, depending n fatrs suh as mrbid besity, depressin, anxiety, hypertensin, and patient preferene. Several mediatins may have t be tried in turn befre headahes are brught under ntrl. One a mediatin has been fund t help, it shuld be ntinued fr several mnths. If the patient remains headahe-free, the dse may be tapered and the mediatin eventually withdrawn. Transutaneus suprarbital neurstimulatin redued the number f migraine days per mnth in aCMDT22_Ch24_p0978-p1053.indd  980 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS981 CMDT 2022sham- ntrlled randmized trial and is apprved in the United States. In chronic migraine (at least 15 days per mnth with headahes lasting 4 hurs per day r lnger), aupunture is as effetive as prphylati pharmalgi treatment, and btulinum txin type A redues headahe frequeny. Certain neurstimulatin tehniques lk prmising as preventive treatment as well as having a rle in treatment f aute attaks. These inlude single-pulse transranial magneti stimulatin, vagus nerve stimula- trs, and implantable ipital nerve stimulatin, but riti- al appraisal is neessary.2.  Tension-Tye hedceThis is the mst mm n type f primary headahe disr- der. Patients frequently mplain f periranial tenderness, pr nentratin, and ther nnspeifi symptms, in additin t headahes that are ften vise-like r tight in quality but nt pulsatile. Headahes may be exaerbated by emtinal stress, fatigue, nise, r glare. The headahes are usually generalized, may be mst intense abut the nek r bak f the head, and are nt assiated with fal neur- lgi symptms. There is diagnsti verlap with migraine. The therapeuti apprah is similar t that in migraine, exept that triptans and ergtamines are notindiated. Triyli antidepressants, suh as amitriptyline, are sup- prted fr headahe prphylaxis by randmized trial evi- dene and ften are tried first. Treatment f mrbid anxiety r depressin is imprtant. Behaviral therapies that may be effetive inlude bifeedbak and relaxatin training.3.  Cluster hedceClus ter headahe affets predminantly middle-aged men. The pathphysilgy is unlear but may relate t ativatin f ells in the ipsilateral hypthalamus, triggering the tri- geminal autnmi vasular system. There is ften n fam- ily histry f headahe r migraine. Episdes f severe unilateral perirbital pain ur daily fr several weeks and are ften ampanied by ne r mre f the fllwing: ipsilateral nasal ngestin, rhinrrhea, larimatin, red- ness f the eye, and Hrner syndrme (ptsis, pupillary meisis, and faial anhidrsis r hyphidrsis). During attaks, patients are ften restless and agitated. Episdes typially ur at night, awaken the patient, and last between 15 minutes and 3 hurs. Spntaneus remissin then urs, and the patient remains well fr weeks r mnths befre anther but f lsely spaed attaks. Buts may last fr 4 t 8 weeks and may ur up t several times per year. During a but, many patients reprt alhl trig- gers an attak; thers reprt that stress, glare, r ingestin f speifi fds asinally preipitates attaks. In a- sinal patients, remissin des nt ur. This variant has been referred t as chronic cluster headache . In lngstand- ing ases, Hrner syndrme may persist between attaks. Cluster headahe is ne f the trigeminal autonomic cephalgias, whih inlude hemirania ntinua, parx- ysmal hemirania, and shrt-lasting neuralgifrm head- ahe attaks with njuntival injetin and tearing. Similar t luster headahe, the ther trigeminalautnmi ephalgias nsist f unilateral perirbital pain assiated with ipsilateral autnmi symptms; they are distinguished frm luster headahe by different attak duratin and frequeny and their exquisite respnsiveness t indmethain. Treatment f an individual attak with ral mediatins is generally unsatisfatry, but subutaneus (6 mg) r intranasal (20 mg/spray) sumatriptan r inhalatin f 100% xygen (1215 L/min fr 15 minutes via a nn-rebreather mask) may be effetive. Zlmitriptan (5- and 10-mg nasal spray) is als effetive. Dihydrergtamine (0.51 mg intra- musularly r intravenusly) r visus lidaine (1 mg f 46% slutin intranasally) is smetimes effetive. Varius prphylati agents inlude ral mediatins suh as lithium arbnate (start at 300 mg daily, titrating arding t serum levels and treatment respnse up t a typial ttal daily dse f 9001200 mg, divided three r fur times), verapamil (start at 240 mg daily, inrease by 80 mg every 2 weeks t 960 mg daily, with rutine ECG t mnitr the PR interval), tpiramate (100400 mg daily), and ivamide (nt available in the United States). As there is ften a delay befre these mediatins are effetive, tran- sitinal therapy is ften used. Prednisne (60 mg daily fr 5 days fllwed by gradual withdrawal ver 710 days) is effetive in 7080% f patients, and subipital rtiste- rid injetin abut the greater ipital nerve is effetive in 75%. Ergtamine tartrate an be given as retal suppsit- ries (0.51 mg at night r twie daily), by muth (2 mg daily), r by subutaneus injetin (0.25 mg three times daily fr 5 days per week). Eletrial stimulatin f the vagus nerve at headahe nset suessfully abrts pain in 3050% f attaks, and twie daily prphylati stimulatin redues attak number in hrni luster headahe; this treatment is apprved in the United States. In Eurpe, sphe- npalatine ganglin stimulatin is apprved fr treatment f luster headahe based n effiay in ne randmized sham-ntrlled study. Limited evidene suggests that eletrial stimulatin f the ipital nerve by an implant- able devie may be helpful, espeially in hrni luster headahe.4.  posttrumtic hedceA variety  f nnspeifi symptms may fllw lsed head injury, regardless f whether nsiusness is lst (see Head Injury). Headahe is ften a nspiuus feature. It usually appears within a day r s fllwing injury, may wrsen ver the ensuing weeks, and then gradually sub- sides. It is usually a nstant dull ahe, with superimpsed thrbbing that may be lalized, lateralized, r generalized. Headahes are smetimes ampanied by nausea, vmit- ing, r sintillating stmas and ften respnd t simple analgesis; severe headahes may neessitate preventive treatment as utlined fr migraine.5.  primry Coug hedceSevere  head pain may be prdued by ughing (and by straining, sneezing, and laughing) but, frtunately, usually lasts fr nly a few minutes r less. Intraranial lesins, usually in the psterir fssa (eg, Arnld-ChiariCMDT22_Ch24_p0978-p1053.indd  981 29/06/21 8:50 PMChapTER 24982 CMDT 2022malfrma tin), are present in abut 10% f ases, and brain tumrs r ther spae-upying lesins may present in this way. Ardingly, CT scanning or MRI should be undertaken in all patients. The disrder is usually self-limited, althugh it may persist fr several years. Fr unknwn reasns, symptms smetimes lear mpletely after lumbar punture. Ind- methain (75150 mg daily rally) may prvide relief. Similar ativity-triggered headahe syndrmes inlude primary exertinal headahe and primary headahe ass- iated with sexual ativity.6.  hedce Due to Gint Cell (Temorl or Crnil) arteritisThis tp i is disussed in Chapter 20.7.  hedce Due to Intrcrnil Mss LesionIn traranial mass lesins f all types may ause headahe wing t displaement f vasular strutures and ther pain-sensitive tissues. While pain and latin are nnspe- ifi, headahe may be wrse upn lying dwn, awaken the patient at night, r peak in the mrning after vernight reumbeny. The key feature prompting brain imaging is a new or worsening headache in middle or later life . Other features suggesting an intraranial lesin inlude signs r symptms f infetin r malignany suh as fever, night sweats, and weight lss; immunmprmise; r histry f malignany. Signs f fal r diffuse erebral dysfuntin r f inreased intraranial pressure (eg, papilledema) als neessitate investigatin.8.  Mediction Overuse (anlgesic Rebound) hedceIn  many patients with chronic daily headaches, media- tin veruse is respnsible. Patients have hrni pain r severe headahe unrespnsive t mediatin (typially defined as n effet after having been used regularly fr mre than 3 mnths). Ergtamines, triptans, mediatins ntaining butalbital, and piids ause mediatin ver- use headahe when taken n mre than 10 days per mnth; aetaminphen, aetylsaliyli aid, and nnsteridal anti- inflammatry drugs may als be ffenders if taken n mre than 15 days per mnth. Early initiatin f a migraine preventive therapy permits withdrawal f analgesis and eventual relief f headahe.9.  hedce Due to Oter Neurologic CusesCerebr vasular disease may be assiated with headahe, but the mehanism is unlear. Headahe may ur with internal artid artery lusin r artid dissetin and after artid endarteretmy. Aute severe headahe (thunderclap ) ampanies subarahnid hemrrhage, artid r vertebral artery dissetin, erebral venus thrmbsis, ishemi r hemrrhagi strke, reversible erebral vasnstritin syndrme, hypertensive risis, psterir reversible leukenephalpathy syndrme, pitu- itary applexy, spntaneus intraranial hyptensin, vas- ulitis, and meningeal infetins; ampanying falneurlgi signs, impairment f nsiusness, and signs f meningeal irritatin indiate the need fr further inves- tigatins. Headahes are als a feature f idipathi intra- ranial hypertensin (pseudtumr erebri). Dull r thrbbing headahe is a frequent sequela f lumbar punture and may last fr several days. It is aggra- vated by the eret psture and alleviated by reumbeny. The mehanism is unlear, but the headahe is mmnly attributed t leakage f erebrspinal fluid thrugh the dural punture site. Its inidene may be redued if an atraumati needle (instead f a beveled, utting needle) is used fr the lumbar punture. When to Refer Thunderlap nset. Inreasing headahe unrespnsive t simple measures. Histry f trauma, hypertensin, fever, visual hanges. Presene f neurlgi signs r f salp tenderness. When to AdmitSuspeted  subarahnid hemrrhage r ther strutural intraranial lesin.Ceriani  CEJ et al. Nvel mediatins fr the treatment f migraine. Headahe. 2019;59:1597. [PMID: 31559638] Vukvi-Cvetkvi V et al. Neurstimulatin fr the treatment f hrni migraine and luster headahe. Ata Neurl Sand. 2019;139:4. [PMID: 30291633]F ACIAL PAIN 1. Trigeminl NeurlgiE S S E N T I A L S  O F  D I A G N O S I S Brief episodes of stabbing facial pain. Pain is in the territory of the second and third divi- sion of the trigeminal nerve. Pain exacerbated by touch. General ConsiderationsT rigeminal neuralgia (ti dulureux) is mst mmn in middle and later life. It affets wmen mre frequently than men. Pain may be due t an anmalus artery r vein impinging n the trigeminal nerve. Clinical FindingsM mentary episdes f sudden laninating faial pain mmnly arise near ne side f the muth and sht tward the ipsilateral ear, eye, r nstril. The pain may be triggered by suh fatrs as tuh, mvement, drafts, and eating. In rder t lessen the likelihd f triggering fur- ther attaks, many patients try t hld the fae still while talking. Spntaneus remissins fr several mnths rCMDT22_Ch24_p0978-p1053.indd  982 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS983 CMDT 2022lnger  may ur. As the disrder prgresses, hwever, the episdes f pain beme mre frequent, remissins beme shrter and less mmn, and a dull ahe may persist between the episdes f stabbing pain. Symptms remain nfined t the distributin f the trigeminal nerve (usu- ally the send r third divisin) n ne side nly. Differential DiagnosisThe  harateristi features f the pain in trigeminal neural- gia usually distinguish it frm ther auses f faial pain. Neurlgi examinatin shws n abnrmality exept in a few patients in whm trigeminal neuralgia is symptmati f sme underlying lesin, suh as multiple slersis r a brainstem neplasm, in whih ase the finding will depend n the nature and site f the lesin. Multiple slersis mustbe suspeted in a patient yunger than 40 years in whm trigeminal neuralgia is the presenting symptm, even if there are n ther neurlgi signs. Bilateral symptms shuld als prmpt further investigatin. Brain MRI need nly be btained when a sendary ause is suspeted; it is usually nrmal in lassi trigeminal neuralgia. TreatmentThe m ediatins mst helpful fr treatment are xarbaze- pine (althugh nt apprved by the FDA fr this india- tin) r arbamazepine, with mnitring by serial bld unts and liver bihemial tests. If these mediatins are ineffetive r annt be tlerated, phenytin shuld be tried. (Dses and side effets f these mediatins are shwn in Table 242.) Balfen (1020 mg rally three r Table 242. Medication treatment for seizures in adults (in alphabetical order within classes).Mediction Usul adult Dily Orl DoseMinimum No. of Dily DosesTime to Stedy-Stte Mediction LevelsOtiml Medic- tion Level nd Lbortory Monitoring1Selected Side Effects nd Idiosyncrtic Rections Generlized or Focl Seizures Brivaracetam2,350100 mg 2 12 days CBC, liver biochemi- cal testsSomnolence, fatigue, ataxia, vertigo, psycho- sis, leukopenia, hypersensitivity (broncho- spasm and angioedema). Cannabidiol4520 mg/kg 2 1113 days Liver biochemical tests at baseline, 1, 3, and 6 monthsSomnolence, fatigue, anorexia, weight loss, anemia, diarrhea, rash, sleep disorder, infections. Elevation in liver enzymes may occur; reduce dose in hepatic impairment. Carbamazepine24001600 mg (immediate or extended release)2 34 days 48 mcg/mL CBC, liver biochemi- cal tests, BUN/CrNystagmus, dysarthria, diplopia, ataxia, drowsiness, nausea, blood dyscrasias, hepatotoxicity, hyponatremia, Stevens-Johnson syndrome.5My  excerbte myoclonic seizures. Cenobamate2,3200400 mg 1 14 days Liver biochemical tests, potassiumMultiorgan hypersensitivity, QT shortening, somnolence, dizziness, cognitive dysfunc- tion, blurred vision. Clobazam61040 mg 2 710 days  Lethargy and somnolence, ataxia, insomnia, dysarthria, aggression, constipation, fever, Stevens-Johnson syndrome. Clorazepate322.590 mg 2 10 days  Sedation, dizziness, confusion, ataxia, depres- sion, dependency/abuse. Eslicarbazepine2,34001200 mg 1 4 days Serum sodium and chloride; liver bio- chemical testsAs for carbamazepine. Ezogabine33001200 mg 3 23 days ECG to assess QT intervalDizziness, somnolence, confusion, vertigo, nausea, ataxia, psychiatric disturbances, prolonged QT interval, retinal abnormalities.7F elbamate2,3,6,812003600 mg 3 45 days CBC and reticulo- cytes, liver bio- chemical testsAnorexia, nausea, vomiting, headache, insom- nia, weight loss, dizziness, hepatotoxicity, fatal aplastic anemia. Reserved for refractory epilepsy. (continued )CMDT22_Ch24_p0978-p1053.indd  983 29/06/21 8:50 PMChapTER 24984 CMDT 2022T able 242. Medication treatment for seizures in adults (in alphabetical order within classes).Mediction Usul adult Dily Orl DoseMinimum No. of Dily DosesTime to Stedy-Stte Mediction LevelsOtiml Medic- tion Level nd Lbortory Monitoring1Selected Side Effects nd Idiosyncrtic Rections Gabapentin39003600 mg 3 1 day  Sedation, fatigue, ataxia, nystagmus, weight loss. Lacosamide2,3100400 mg 2 3 days ECG if known cardiac conduction problems or severe cardiac diseaseVertigo, diplopia, nausea, headache, fatigue, ataxia, tremor, anaphylactoid reactions, PR prolongation, cardiac dysrhythmia, suicidality. Lamotrigine3,6,9,10100500 mg 2 45 days  Sedation, skin rash, visual disturbances, dyspepsia, ataxia. Levetiracetam3,9,1110003000 mg 2 2 days  Somnolence, ataxia, headache, behavioral changes. Oxcarbazepine2,39001800 mg 2 23 days Serum sodium As for carbamazepine. Perampanel2,3,9412 mg 1 3 weeks  Dizziness, somnolence, irritability, weight gain, falls, ataxia, dysarthria, blurred vision. Phenobarbital2,12100200 mg 1 1421 days 1040 mcg/mL CBC, liver biochemi- cal tests, BUN/CrDrowsiness, nystagmus, ataxia, skin rashes, learning difficulties, hyperactivity. Phenytoin2,12200400 mg 1 510 days 1020 mcg/mL CBC, liver biochemi- cal tests, folateNystagmus, ataxia, dysarthria, sedation, con- fusion, gingival hyperplasia, hirsutism, megaloblastic anemia, blood dyscrasias, skin rashes, fever, systemic lupus erythema- tosus, lymphadenopathy, peripheral neu- ropathy, dyskinesias. My excerbte myoclonic seizures. Pregabalin3150300 mg 2 24 days  Somnolence, dizziness, poor concentration, weight gain, thrombocytopenia, skin rashes, anaphylactoid reactions. Primidone2,127501500 mg 3 47 days 512 mcg/mL CBCSedation, nystagmus, ataxia, vertigo, nausea, skin rashes, megaloblastic anemia, irritability. Rufinamide68003200 mg 2 2 days  Somnolence, headache, dizziness, suicidality, Stevens-Johnson syndrome, leukopenia, shortened QT interval, nausea, vomiting. Tiagabine33256 mg 2 2 days  Somnolence, anxiety, dizziness, poor concen- tration, tremor, diarrhea. Topiramate2,3,6,9,12200400 mg 2 4 days Serum bicarbonate, BUN/Cr in elderly patientsSomnolence, nausea, dyspepsia, irritability, dizziness, ataxia, nystagmus, diplopia, glau- coma, renal calculi, weight loss, hypohidro- sis, hyperthermia. Valproic acid2,3,13,1415002000 mg 23 24 days 50100 mcg/mL CBC, liver biochemi- cal testsNausea, vomiting, diarrhea, drowsiness, alope- cia, weight gain, hepatotoxicity, thrombo- cytopenia, tremor, pancreatitis. Tertogenic; void in women of cildber- ing ge. Vigabatrin3,153000 mg 2 2 days  Somnolence, anorexia, nausea, vomiting, agi- tation, hostility, confusion, suicidality, neu- tropenia, Stevens-Johnson syndrome, permanent visual field loss.7Zoni samide3200600 mg 1 14 days BUN/Cr, serum bicarbonateSomnolence, ataxia, anorexia, nausea, vomiting, rash, confusion, renal calculi. Do not use in patients with sulfonamide allergy. (continued )(continued )CMDT22_Ch24_p0978-p1053.indd  984 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS985 CMDT 2022T able 242. Medication treatment for seizures in adults (in alphabetical order within classes).Mediction Usul adult Dily Orl DoseMinimum No. of Dily DosesTime to Stedy-Stte Mediction LevelsOtiml Medic- tion Level nd Lbortory Monitoring1Selected Side Effects nd Idiosyncrtic Rections absence Seizures Clonaze- pam6,11,13,16,170.040.2 mg/kg 2 710 days 2080 ng/mL CBC, liver biochemical testsDrowsiness, ataxia, irritability, behavioral changes, exacerbation of tonic-clonic seizures. Ethosuximide135001500 mg 2 510 days 40100 mcg/mL CBC, liver biochemi- cal tests, urinalysisNausea, vomiting, anorexia, headache, lethargy, unsteadiness, blood dyscrasias, systemic lupus erythematosus, urticaria, pruritus. Valproic acid2,3,13,1415002000 mg 23 24 days See above Nausea, vomiting, diarrhea, drowsiness, alopecia, weight gain, hepatotoxicity, thrombocytopenia, tremor, pancreatitis. Myoclonic Seizures Clonaze- pam6,11,13,16,170.040.2 mg/kg 2 710 days See above Drowsiness, ataxia, irritability, behavioral changes, exacerbation of tonic-clonic seizures. Levetiracetam3,9,1110003000 mg 2 2 days  Somnolence, ataxia, headache, behavioral changes. Valproic acid2,3,13,1415002000 mg 23 24 days See above Nausea, vomiting, diarrhea, drowsiness, alopecia, weight gain, hepatotoxicity, thrombocytopenia, tremor, pancreatitis. BUN, blood urea nitrogen; CBC, complete blood count; Cr, creatinine; ECG, electrocardiogram. Note that many factors influence o ptimal dose of these drugs including age, tolerance, and concomitant medication.1 Patients starting treatment with any antiepileptic drug should be monitored for new or worsening depression or suicidal thought s, especially during the first weeks of therapy. Baseline measurement of creatinine clearance is advisable in renally metabolized drugs.2 Approved as monotherapy for focal-onset seizures.3 Approved as adjunctive therapy for focal-onset seizures.4 Approved for treatment of seizures in Lennox-Gastaut and Dravet syndrome in patients 2 years and older.5 Carriers of the HLA-B*1502 allele are at higher risk for Stevens-Johnson syndrome. Patients of Asian ancestry should be tested for this allele prior to initiation of therapy.6 Approved as adjunctive therapy for Lennox-Gastaut syndrome.7 Regular ophthalmologic examination is recommended.8 Not to be used as a first-line drug; when used, blood counts should be performed regularly (every 24 weeks). Should be used on ly in selected patients because of risk of aplastic anemia and hepatic failure. It is advisable to obtain written informed consent be fore use.9 Approved as adjunctive therapy for primary generalized tonic-clonic seizures.10 Approved as monotherapy (after conversion from another drug) in focal-onset seizures.11 Approved as adjunctive therapy for myoclonic seizures.12 Approved as initial monotherapy for primary generalized tonic-clonic seizures.13 Approved as monotherapy and adjunctive therapy for absence seizures.14 Approved as adjunctive therapy for patients with multiple seizure types including absence seizures.15 Approved as monotherapy for infantile spasms.16 Approved as monotherapy for Lennox-Gastaut syndrome.17 Approved as monotherapy for myoclonic seizures.f ur times daily), tpiramate (50 mg rally twie daily), r lamtrigine (400 mg rally daily) may als be helpful, either alne r in mbinatin with ne f these ther agents. Gabapentin may als relieve pain, espeially in patients wh d nt respnd t nventinal medial therapy and thse with multiple slersis. Depending n respnse and tler- ane, up t 3600 mg daily rally is given in divided dses. Fr neuralgia refratry t medial treatment, several surgial treatment ptins are available that prvide initial pain relief in at least 80% f patients. Mirvasularsurgial dempressin with separatin f the anmalus vessel (usually nt visible n CT sans, MRI, r arteri- grams) frm the nerve rt prdues lng-term relief f symptms in rughly 75% f patients. Three less invasive tehniques are based n destrutin f nieptive tri- geminal nerve fibers, whih auses sensry lss in additin t symptm relief in half f patients: (1) radifrequeny rhiztmy prdues lng-term pain relief in 60% f patients, (2) perutaneus balln mpressin f the tri- geminal ganglin in 67%, and (3) steretati radisurgery(continued )CMDT22_Ch24_p0978-p1053.indd  985 29/06/21 8:50 PMChapTER 24986 CMDT 2022t  the trigeminal nerve rt in 45%. In elderly patients with a limited life expetany, radifrequeny rhiztmy and steretati radisurgery are smetimes preferred beause bth an be perfrmed withut general anesthesia and have few mpliatins. Surgial explratin is inapprpri- ate in patients with trigeminal neuralgia due t multiple slersis, but the less invasive tehniques are smetimes helpful.2.  atyicl Fcil pinFaial  pain withut the typial features f trigeminal neu- ralgia is generally a nstant, ften burning pain that may have a restrited distributin at its nset but sn spreads t the rest f the fae n the affeted side and smetimes invlves the ther side, the nek, r the bak f the head as well. The disrder is espeially mmn in middle-aged wmen, many f them depressed, but it is nt lear whether depressin is the ause f r a reatin t the pain. Simple analgesis shuld be given a trial, as shuld triyli antidepressants, arbamazepine, xarbazepine, and phenytin; the respnse is ften disappinting. Opiid analgesis pse a danger f additin. Attempts at surgial treatment are nt indiated.3.  Glossoryngel NeurlgiGlsspharyngeal  neuralgia is an unmmn disrder in whih pain similar in quality t that in trigeminal neural- gia urs in the thrat, abut the tnsillar fssa, and smetimes deep in the ear and at the bak f the tngue. The pain may be preipitated by swallwing, hewing, talk- ing, r yawning and is smetimes ampanied by syn- pe. In mst instanes, n underlying strutural abnrmality is present; multiple slersis is smetimes respnsible. Oxarbazepine and arbamazepine are the treatments f hie and shuld be tried befre any surgi- al predures are nsidered. Mirvasular dempres- sin is ften effetive and is generally preferred ver destrutive surgial predures suh as partial rhiztmy in medially refratry ases.4.  posteretic NeurlgiP stherpeti neuralgia develps in abut 15% f patients wh have herpes zster (shingles). This mpliatin seems espeially likely t ur in elderly r immunm- prmised persns, when the rash is severe, and when the first divisin f the trigeminal nerve is affeted. It als relates t the duratin f the rash befre treatment is insti- tuted. A histry f shingles and the presene f utaneus sarring resulting frm shingles aid in the diagnsis. Severe pain with shingles rrelates with the intensity f psther- peti symptms. Aylvir (800 mg five times daily) r valaylvir (1000 mg three times daily), when given within 72 hurs f rash nset, redues the inidene f pstherpeti neuralgia by almst half; systemi rtisterids d nothelp prevent pstherpeti neuralgia (see Chapter 6). Management f the established mpliatin is with simple analgesis. If they fail t help, a trial f a triyli antidepressant (eg, amitrip- tyline r nrtriptyline, up t 100150 mg daily rally) isften effetive. Other patients respnd t gabapentin (up t 3600 mg daily rally) r pregabalin (up t 600 mg/daily rally). Subutaneus injetin f btulinum txin A int the affeted regin prdued sustained pain relief in 87% f patients in a small plaeb-ntrlled trial. Tpial applia- tin f apsaiin ream may be helpful, as may tpial lidaine (5%). The administratin f recombinant zoster vaccine t patients ver the age f 50 years is imprtant in reduing the likelihd f herpes zster r reduing the severity f pstherpeti neuralgia shuld a reativatin ur.5.  Fcil pin Due to Oter CusesFa ial pain may be aused by temprmandibular jint dysfuntin in patients with mallusin, abnrmal bite, r faulty dentures. There may be tenderness f the mastia- try musles, and smetimes pain begins at the nset f hewing. This pattern differs frm that f jaw (mastiatry) laudiatin, a symptm f giant ell arteritis, in whih pain develps prgressively with mastiatin. Treatment f the underlying jint dysfuntin relieves symptms. A relatinship f faial pain t hewing r temperature hanges may suggest a dental disturbane. The ause is smetimes nt bvius, and diagnsis requires areful dental examinatin and radigraphs. Sinusitis and ear infetins ausing faial pain are usually regnized by a histry f respiratry trat infetin, fever, and, in sme instanes, nasal r aural disharge. There may be lalized tenderness. Radilgi evidene f sinus infetin r mas- tiditis is nfirmatry. Glauma is an imprtant ular ause f faial pain, usually lalized t the perirbital regin. On asin, pain in the jaw may be the prinipal mani- festatin f angina petris. Preipitatin by exertin and radiatin t mre typial areas suggests a ardia rigin. When to Refer Wrsening pain unrespnsive t simple measures. Cntinuing pain f unertain ause. Fr nsideratin f surgial treatment (trigeminal r glsspharyngeal neuralgia).Bendtsen  L et al. Advanes in diagnsis, lassifiatin, path- physilgy, and management f trigeminal neuralgia. Lanet Neurl. 2020;19:784. [PMID: 32822636]EP ILEPSYE S S E N T I A L S  O F  D I A G N O S I S Recurrent unprovoked seizures. Characteristic electroencephalographic changes accompany seizures. Mental status abnormalities or focal neurologic symptoms may persist for hours postictally.CMDT22_Ch24_p0978-p1053.indd  986 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS987 CMDT 2022 General ConsiderationsThe term  epilepsy dentes any disrder haraterized by recurrent unprovoked seizures. A seizure is a transient dis- turbane f erebral funtin due t an abnrmal parxys- mal neurnal disharge in the brain. Epilepsy is relatively mmn, affeting apprximately 0.5% f the ppulatin in the United States. Patients with reurrent seizures prvked by a readily reversible ause, suh as withdrawal frm alhl r drugs, hypglyemia, hyperglyemia, r uremia, are nt nsid- ered t have epilepsy. Classification of EpilepsyA rding t the Internatinal League Against Epilepsy lassifiatin system, reurrent seizures shuld be lassi- fied first by seizure type, send by epilepsy type, and third, if pssible, by epilepsy syndrme. The etilgy f reurrent seizures shuld be sught at eah stage f lassi- fiatin (see Etilgy f Epilepsy).A.  Seizure TypesThe  Internatinal League Against Epilepsy distinguishes seizures affeting nly part f the brain (fal seizures) frm thse that are generalized. 1. Focal onset seizures The initial linial and eletren- ephalgraphi manifestatins f fal (partial) seizures indiate that nly a restrited part f ne erebral hemi- sphere has been ativated. The ital manifestatins depend n the area f the brain invlved. Fal seizures are lassi- fied by mtr r nnmtr nset as well as by whether awareness is impaired. a. Motor versus nonmotor onset Seizures with mtr nset may be clonic, tonic, atonic, myoclonic, r hyperkinetic, r may manifest as automatisms repilep- tic spasms . The mst mmnly bserved fal mtr seizures nsist f lni jerking r autmatisms. Nnm- tr seizures may be manifested by sensry symptms (eg, paresthesias r tingling, gustatry, lfatry, visual r audi- try sensatins), behavir arrest, gnitive symptms (eg, speeh arrest, dj vu, jamais vu), emtinal symptms (eg, fear), r autnmi symptms r signs (eg, abnrmal epi- gastri sensatins, sweating, flushing, pupillary dilatin). Fal sensry and mtr seizures may spread (r marh) t different parts f the limb r bdy depending n their rtial representatin and were previusly alled simple partial seizures. b. Aware versus impaired awareness Awareness is defined as knwledge f self and envirnment and f events urring during a seizure. Impaired awareness may be preeded, ampanied, r fllwed by the varius mtr and nnmtr symptms mentined abve. Suh seizures were previusly alled mplex partial seizures. c. Focal to bilateral tonic-clonic Fal seizures smetimes invlve lss f awareness and evlve t bilateral tni-lni seizures, in a press previusly alled se- ndary generalizatin. 2. Generalized onset seizures Generalized seizures are thught t riginate in r rapidly spread t invlve bilateral rtial netwrks. In sme ases, the distintin between fal and generalized nset an nly be made by eletren- ephalgram (EEG). Generalized seizures are lassified int thse with mtr r nnmtr features. Awareness is typially lst with generalized seizures but may be retained partially in the briefest absene attaks and sme my- lni seizures. a. Nonmotor (absence) seizures These are harater- ized by impairment f nsiusness, smetimes with mild lni, tni, mylni, r atni mpnents (ie, redu- tin r lss f pstural tne), autnmi mpnents (eg, enuresis), r ampanying autmatisms. Onset and termi- natin f attaks are abrupt. If attaks ur during nver- satin, the patient may miss a few wrds r may break ff in midsentene fr a few sends. The impairment f external awareness is s brief that the patient is unaware f it. Absence (petit mal) seizures almst always begin in hildhd and frequently ease by the age f 20 years r are then replaed by ther frms f generalized seizure. Ele- trenephalgraphially, suh attaks are assiated with bursts f bilaterally synhrnus and symmetri 3-Hz spike-wave ativity. A nrmal bakgrund in the eletren- ephalgram and nrmal r abve-nrmal intelligene imply a gd prgnsis fr the ultimate essatin f these seizures. Atypical absence seizures may demnstrate mre marked hanges in tne, r attaks may have a mre gradual nset and terminatin than in typial absene seizures. They mmnly ur in patients with multiple seizure types, may be ampanied by develpmental delay r mental retardatin, and are assiated with slwer spike- wave disharges than thse in typial absene attaks. b. Motor seizures Types f generalized mtr seizures inlude tonic-clonic, clonic, tonic, myoclonic, myoclonic- tonic-clonic, myoclonic-atonic, atonic, and epileptic spasms. During tni-lni seizures there is sudden lss f nsiusness, the patient bemes rigid and falls t the grund, and respiratin is arrested. This tni phase, whih usually lasts fr under 1 minute, is fllwed by a lni phase in whih there is jerking f the bdy musulature that may last fr 2 r 3 minutes and is then fllwed by a stage f flaid ma. During the seizure, the tngue r lips may be bitten, urinary r feal inntinene may ur, and the patient may be injured. Immediately after the sei- zure, the patient may rever nsiusness, drift int sleep, have a further nvulsin withut revery f n- siusness between the attaks (status epilepticus), r after revering nsiusness have a further nvulsin (serial seizures). In ther ases, patients may behave in an abnrmal fashin in the immediate pstital perid, with- ut subsequent awareness r memry f events (postepi- leptic automatism) . Headahe, disrientatin, nfusin, drwsiness, nausea, sreness f the musles, r sme m- binatin f these symptms mmnly urs pstitally. Mylni seizures nsist f single r multiple mylni jerks. Atni seizures nsist f very brief (less than 2 sends) lss f musle tne and ften result in falls (epileptic drop attacks) .Epileptic spasms are sudden flexin rCMDT22_Ch24_p0978-p1053.indd  987 29/06/21 8:50 PMChapTER 24988 CMDT 2022extensin  f trunal musles; these seizures usually mani- fest during infany. 3. Unknown onset seizures In sme irumstanes, sei- zures annt be lassified beause f inmplete infrmatin r beause they d nt fit int any ategry. Generally, with additinal infrmatin frm the histry r frm vide-EEG telemetry, the seizure nset an be rretly lassified.B.  Epilepsy TypesThe  Internatinal League Against Epilepsy lassifies epi- lepsy by the seizure type. Thus, epilepsy may be focal , generalized, rcombined generalized and focal. The EEG may be helpful in failitating lassifiatin.C.  Epilepsy SyndromesEp ilepsy syndrmes are defined by nstellatins f seizure types, EEG findings, and imaging features, and ften als depend n age at nset and mrbidities. Nt every patient with epilepsy an be given a syndrmi diagnsis. Several well-knwn epilepsy syndrmes exist but are beynd the spe f this hapter. Etiology of EpilepsyIn  parallel t lassifying the seizure type, epilepsy type, and epilepsy syndrme (if appliable), the ause f the patients seizures shuld be sught. The Internatinal League Against Epilepsy lists six brad etilgi ategries; sme- times a patients seizures have mre than ne etilgy.A.  Structural Etiology1.  Pediatric age groups Cngenital abnrmalities and perinatal injuries may result in seizures presenting in infany r hildhd. 2. Mesial temporal sclerosis Hippampal slersis is a regnized ause f fal and sendarily generalized sei- zures f unertain etilgy. 3. Trauma Trauma is an imprtant ause f seizures at any age, but espeially in yung adults. Psttraumati epi- lepsy is mre likely t develp if the dura mater was pene- trated and generally bemes manifest within 2 years fllwing the injury. Seizures develping in the first week after head injury d nt neessarily imply that future attaks will ur. There is noevidene that prphylati antinvulsant mediatin treatment redues the inidene f psttraumati epilepsy. 4. Tumors and other spaceoccupying lesions Ne- plasms may lead t seizures at any age, but they are an espeially imprtant ause f seizures in middle and later life, when the inidene f neplasti disease inreases. Seizures are mmnly the initial symptms f the tumr and ften are fal in harater. They are mst likely t ur with strutural lesins invlving the frntal, parietal, r tempral regins. Tumors must be excluded by imaging studies (MRI preferred over CT) in all patients with onset of seizures after 20 years of age, focal seizures or signs, or a progressive seizure disorder.5. Vascular diseases Strke and ther vasular diseases beme inreasingly frequent auses f seizures with advaning age and are the mst mmn ause f seizures with nset at age 60 years r lder. 6. Degenerative disorders Alzheimer disease and ther degenerative disrders are a ause f seizures in later life.B.  Genetic EtiologyThis ategry enmpasses a  brad range f disrders, fr whih the age at nset ranges frm the nenatal perid t adlesene r even later in life. Mngeni disrders tend t exhibit an autsmal dminant pattern f inheritane, and where the mutatin is knwn, the respnsible gene ften endes a neurnal in hannel. A geneti etilgy may als underpin ertain epilepsies with a metabli r strutural basis.C.  Infectious EtiologyInfetius diseases must be nsider ed in all age grups as ptentially reversible auses f seizures. Seizures may ur with an aute infetive r inflammatry illness, suh as baterial meningitis r herpes enephalitis, r in patients with mre lngstanding r hrni disrders, suh as neu- rsyphilis r erebral ystiersis. In patients with AIDS, seizures may result frm entral nervus system txplas- msis, ryptal meningitis, sendary viral enephali- tis, r ther infetive mpliatins. Seizures are a mmn sequela f supratentrial brain absess, develping mst frequently in the first year after treatment.D . Metabolic EtiologyInbrn  errrs f metablism and ther inherited ndi- tins may ause epilepsy as ne f their manifestatins (eg, pyridxine defiieny, mithndrial disease); these disr- ders typially present during hildhd.E.  Immune EtiologyA utimmune diseases suh as systemi lupus erythemat- sus and autimmune limbi enephalitis may ause epi- lepsy; ften the epilepsy an be ured with immuntherapy and lifelng antiepilepti mediatin treatment is nt neessary.F . Unknown EtiologyIn  many ases, the ause f epilepsy annt be determined. Clinical FindingsA.  Symptoms and SignsN nspeifi hanges suh as headahe, md alteratins, lethargy, and mylni jerking alert sme patients t an impending seizure hurs befre it urs. These prodro- mal symptoms are distint frm the aura; the aura that may preede a generalized seizure by a few sends r minutes is itself a part f the seizure indiating fal nset frm a restrited part f the brain.CMDT22_Ch24_p0978-p1053.indd  988 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS989 CMDT 2022In  mst patients, seizures ur unpreditably at any time and withut any relatinship t psture r nging ativities. Oasinally, hwever, they ur at a partiu- lar time (eg, during sleep) r in relatin t external pre- ipitants suh as lak f sleep, missed meals, emtinal stress, menstruatin, alhl ingestin (r alhl with- drawal), r use f ertain rereatinal drugs. Fever and nnspeifi infetins may als preipitate seizures in patients with epilepsy. In a few patients, seizures are pr- vked by speifi stimuli suh as flashing lights r a flik- ering televisin set (photosensitive epilepsy), musi, r reading. Clinial examinatin between seizures shws n abnr- mality in patients with idipathi epilepsy, but in the immediate pstital perid, extensr plantar respnses may be seen. The presene f lateralized r fal signs pstitally suggests that seizures may have a fal rigin. In patients with symptmati epilepsy, the findings n exami- natin will reflet the underlying ause.B.  ImagingMRI  is indiated fr patients with fal neurlgi symp- tms r signs, fal seizures, r eletrenephalgraphi findings f a fal disturbane. It shuld als be perfrmed in patients with linial evidene f a prgressive disrder and in thse with new nset f seizures after the age f 20 years beause f the pssibility f an underlying ne- plasm. CT is generally less sensitive than MRI in deteting small strutural brain abnrmalities but may be used when MRI is ntraindiated r unavailable.C.  Laboratory StudiesInit ial investigatins after a first seizure shuld inlude mplete bld unt, serum gluse, eletrlytes, re- atinine, alium, magnesium, and liver bihemial tests t exlude varius auses f prvked seizures and t prvide a baseline fr subsequent mnitring f lng-term effets f treatment. Rutine labratry investigatins are notusually neessary after reurrent seizures in patients with knwn epilepsy. A lumbar punture may be neessary when any sign f infetin is present r in the evaluatin f new-nset seizures in the aute setting.D . ElectroencephalographyEletrenephalgraph y may supprt the linial diagnsis f epilepsy (by demnstrating parxysmal abnrmalities ntaining spikes r sharp waves), prvide a guide t prg- nsis, and help lassify the seizure disrder. Classifiatin f the disrder is imprtant fr determining the mst apprpriate antinvulsant mediatin with whih t start treatment. Fr example, absene and fal seizures with impaired awareness may be diffiult t distinguish lini- ally, but the eletrenephalgraphi findings and treat- ment f hie differ in these tw nditins. Finally, by lalizing the epileptgeni sure, the eletrenephal- graphi findings are imprtant in evaluating andidates fr surgial treatment.Differential DiagnosisThe  distintin between the varius disrders likely t be nfused with generalized seizures is usually made n the basis f the histry. The imprtane f btaining an eye- witness aunt f the attaks annt be veremphasized.A.  Differential Diagnosis of Focal Seizures1.  TIAs These are distinguished frm seizures by their lnger duratin, lak f spread, and negative (eg, weakness r numbness) rather than psitive (eg, nvulsive jerking r paresthesias) symptms. Level f nsiusness, whih is unaltered, des nt distinguish them. 2. Migraine aura Migraine aura may prdue psitive r negative symptms, tends t spread slwly frm ne part f the bdy t anther (ver minutes rather than sends), and is usually lnger in duratin (minutes t hurs). It is usually, but nt always, fllwed by a typial migraine headahe. 3. Panic attacks These may be hard t distinguish frm fal seizures unless there is evidene f an anxiety disr- der between attaks and the attaks have a lear relatin- ship t external irumstanes. 4. Rage attacks These are situatinal and lead t gal- direted aggressive behavir.B.  Differential Diagnosis of Generalized Seizures1.  Syncope Synpal episdes usually ur in relatin t pstural hange, emtinal stress, instrumentatin, pain, r straining. They are typially preeded by pallr, sweating, nausea, and malaise and lead t lss f nsiusness ampanied by flaidity; revery urs rapidly with reumbeny, and there is n pstital headahe r nfu- sin. In sme instanes, hwever, mtr ampaniments and urinary inntinene may simulate a seizure. 2. Cardiac disease Cerebral hypperfusin due t a dis- turbane f ardia rhythm shuld be suspeted in patients with knwn ardia r vasular disease r in elderly patients wh present with episdi lss f nsiusness. Prdrmal symptms are typially absent. Cardia rhythm mnitring may be neessary t establish the diagnsis; external event rerders r implantable lp rerders may be valuable if the disturbanes f nsiusness are rare. A relatinship f attaks t physial ativity and the finding f a systli murmur are suggestive f arti stensis. 3. Brainstem ischemia Lss f nsiusness is preeded r ampanied by ther brainstem signs. Basilar artery migraine and vertebrbasilar vasular disease are disussed elsewhere in this hapter. 4. Psychogenic nonepileptic seizure PNES Simulating an epilepti seizure, a PNES may ur due t a nversin disrder r malingering. Many patients als have epilepti seizures r a family histry f epilepsy. A histry f hild- hd physial r sexual abuse is mmn. Althugh a PNES tends t ur at times f emtinal stress, this may als be the ase with epilepti seizures.CMDT22_Ch24_p0978-p1053.indd  989 29/06/21 8:50 PMChapTER 24990 CMDT 2022Clini ally, the attaks superfiially resemble tni-lni seizures, but there may be bvius preparatin befre a PNES. Mrever, there is usually n tni phase; instead, there may be an asynhrnus thrashing f the limbs and the attak rarely leads t injury. Eyes are ften fribly lsed during PNES, unlike epilepti seizures, in whih they are typially pen. Cnsiusness may be nrmal r lst,  but in the latter ntext the urrene f gal-direted behavir r f shuting, swearing, et, indiates that it is feigned. Pstitally, there are n hanges in behavir r neurlgi findings. Often, linial bservatin is insuffiient t disriminate epilepti frm nnepilepti seizures and video electroen- cephalographic monitoring is required. Elevatin f serum prlatin level t at least twie the upper limit f nrmal an be seen between 10 and 20 minutes after a seizure r syn- pal event but nt after a PNES. Hwever, prlatin measure- ment has limited linial utility beause levels are nrmal after an epilepti seizure in rughly half f patients and a baseline prlatin must be drawn 6 hurs after the attak. TreatmentA.  General MeasuresF r patients with epilepsy, mediatin is presribed with the gal f preventing further attaks and is usually ntinued until there have been n seizures fr at least 2 years. Patients shuld be advised t avid situatins that uld be danger- us r life-threatening if further seizures shuld ur. Legislatin may require liniians t reprt t the state authrities any patients with seizures r ther episdi dis- turbanes f nsiusness; driving cessation for 6 months r as legislated is apprpriate fllwing an unprvked seizure. 1. Choice of medication Mediatin seletin depends n seizure type (Table 242). The dse f the seleted anti- nvulsant is gradually inreased until seizures are n- trlled r side effets prevent further inreases. If seizures ntinue despite treatment at the maximal tlerated dse, a send mediatin is added and the dse inreased depending n tlerane; the first mediatin is then gradu- ally withdrawn. In mst patients with seizures f a single type, satisfatry ntrl an be ahieved with a single antinvulsant. Treatment with tw mediatins may fur- ther redue seizure frequeny r severity but usually nly at the st f greater txiity. Treatment with mre than tw mediatins is almst always unhelpful unless the patient is having seizures f different types. Other fatrs t nsider in seleting an antinvulsant inlude likely side effets, teratgeniity, interatins with ther media- tins and ral ntraeptives, and rute f metablism. All antiepileptis are ptentially teratgeni, althugh the teratgeniity f the newer antiseizure mediatins is less lear. Nevertheless, antiepilepti mediatin must be given t pregnant wmen with epilepsy t prevent seizures, whih an pse serius risk t the fetus frm trauma, hypxia, r ther fatrs. 2. Monitoring Individual differenes in drug metablism ause a given dse f a mediatin t prdue differentbld nentratins in different patients, and this will affet the therapeuti respnse. In general, the dose of an antiepileptic agent is increased, depending on tolerance, to achieve the desired clinical response regardless of the serum drug level. When a dse is reahed that either ntrls sei- zures r is the maximum tlerated, then a steady-state trugh drug level may be btained fr future referene; reheking this level may be apprpriate during pregnany, if a breakthrugh seizure urs, a dse hange urs, r anther (ptentially interating) mediatin is added t the regimen. A labratrys therapeuti range fr a mediatin is nly a guide; many patients ahieve gd seizure ntrl with n adverse effet at serum levels that exeed the stipu- lated range, and in these ases n dse adjustment is needed. The mst mmn ause f a lwer nentratin f mediatin than expeted fr the presribed dse is sub- ptimal patient adherene. Adherene an be imprved by limiting t a minimum the number f daily dses. Reur- rent seizures r status epileptius may result if mediatins are taken erratially, and in sme irumstanes nnadher- ent patients may be better ff withut any mediatin. All antinvulsants have side effets, and many require base- line and regular labratry mnitring (Table 242). 3. Discontinuance of medication Only when adult patients have been seizure-free fr 2 years shuld with- drawal f mediatin be nsidered. Unfrtunately, there is n way f prediting whih patients an be managed su- essfully withut treatment, althugh seizure reurrene is mre likely in (1) patients with a lnger duratin f epi- lepsy prir t remissin, (2) thse with a shrter duratin f remissin, (3) thse wh initially did nt respnd t therapy, (4) thse with seizures having fal features r f multiple types, (5) thse with nset during adulthd, and (6) thse with ntinuing eletrenephalgraphi abnr- malities. Dse redutin shuld be gradual (ver weeks r mnths), and mediatins shuld be withdrawn ne at a time. If seizures reur, treatment is reinstituted with the previusly effetive regimen. 4. Surgical treatment Patients with seizures refratry t tw r mre mediatins may be andidates fr perative treatment. Surgial resetin is mst effiaius when there is a single well-defined seizure fus, partiularly in the tempral lbe. Amng well-hsen patients, up t 70% remain seizure-free after extended fllw-up. Additinal surgial tehniques fr medially refratry epilepsy apprved in the United States inlude laser interstitial ther- mal therapy, deep brain stimulatin, respnsive rtial stimulatin, and vagus nerve stimulatin.B.  Special Circumstances1.  Solitary seizures In patients wh have had nly ne seizure r a flurry f seizures ver a brief perid f several hurs, investigatin as utlined earlier shuld exlude an underlying ause requiring speifi treatment. An eletr- enephalgram shuld be btained, preferably within 24 hurs after the seizure. Prphylati antinvulsant treat- ment is generally nt required unless further attaks ur r investigatins reveal underlying pathlgy. The risk f seizure reurrene varies in different series between abutCMDT22_Ch24_p0978-p1053.indd  990 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS991 CMDT 202230%  and 70%, with higher risk f reurrene in patients with strutural brain lesins r abnrmalities n eletren- ephalgram. Epilepsy shuld notbe diagnsed n the basis f a slitary seizure. If seizures ur in the ntext f transient, nnreurrent systemi disrders suh as hypna- tremia r hypglyemia, the diagnsis f epilepsy is ina- urate, and lng-term prphylati antinvulsant treatment is unneessary. 2. Alcohol withdrawal seizures The harateristi al- hl withdrawal seizure pattern is ne r mre generalized tni-lni seizures that may ur within 48 hurs r s f withdrawal frm alhl after a perid f high r pr- lnged intake. If the seizures have nsistently fal fea- tures, the pssibility f an assiated strutural abnrmality, ften traumati in rigin, must be nsidered. Treatment with antinvulsants is generally nt required fr alhl withdrawal seizures, sine they are self-limited. Benzdiaz- epines are effetive and safe fr preventing further seizures. Status epileptius may mpliate alhl withdrawal and is managed alng nventinal lines. Further attaks will nt ur if the patient abstains frm alhl. 3. Tonicclonic status epilepticus Pr adherene t the antinvulsant regimen is the mst mmn ause; hw- ever, any disrder that an ause a single seizure may be respnsible. The mrtality rate may be as high as 20%, and amng survivrs the inidene f neurlgi and gnitive sequelae is high. The prgnsis relates t the underlying ause as well as the length f time between nset f status epileptius and the start f effetive treatment. Status epilepticus is a medical emergency. Initial management inludes maintenane f the airway and 50% dextrse (2550 mL) intravenusly in ase hypglyemia is respnsible. If seizures ntinue, an intravenus blus f lrazepam, 4 mg, is given at a rate f 2 mg/min and repeated ne after 10 minutes if neessary; alternatively, 10 mg f midazlam is given intramusularly, and again after 10 minutes if neessary. Diazepam an als be given retally as a gel (0.2 mg/kg). These measures are usually effetive in halting seizures fr a brief perid. Respiratry depressin and hyptensin may mpliate the treatment and are treated as in ther irumstanes, inluding intuba- tin and mehanial ventilatin and admissin t an inten- sive are unit. Regardless f the respnse t lrazepam r midazlam, fsphenytin r phenytin shuld be administered intrave- nusly. Fsphenytin (1820 mg phenytin equivalents [PE]/kg) is rapidly and mpletely nverted t phenytin fllwing intravenus administratin and is preferred beause it is less likely t ause reatins at the infusin site, an be given with all mmn intravenus slutins, and may be administered at a faster rate (150 mg PE/min). When fsphenytin is nt available, phenytin (1820 mg/kg) is given intravenusly at a rate f 50 mg/min. Phenytin is best injeted diretly but an als be given in saline; it pre- ipitates, hwever, if injeted int gluse-ntaining slu- tins. Beause arrhythmias may develp during rapid administratin f fsphenytin r phenytin, eletrar- digraphi mnitring is prudent. Hyptensin may ur, espeially if diazepam has als been given. Alternatively radditinally, intravenus valprate (lading dse 2040 mg/ kg ver 15 min, maximum dse 3000 mg) r levetiraetam (lading dse 60 mg/kg ver 15 min, maximum dse 4500 mg) is used fr status epileptius. Althugh neither is apprved by the FDA fr this indiatin, bth were equiva- lent t fsphenytin in a randmized trial. Due t the teratgeniity f valprate, it shuld be avided in wmen wh may be pregnant. If seizures ntinue, phenbarbital is then given in a lading dse f 1020 mg/kg intravenusly by slw r intermittent injetin (50 mg/min). Respiratry depressin and hyptensin are espeially mmn with this therapy. If these measures fail, general anesthesia with ventila- try assistane may be required; sme experts rem- mend preeding diretly t general anesthesia if nvulsins d nt ease after the initial 1820 PE/kg fsphenytin lad. Intravenus midazlam may prvide ntrl f refratry status epileptius; the suggested lading dse is 0.2 mg/kg, fllwed by 0.050.2 mg/kg/h. Prpfl (12 mg/kg as an intravenus blus, fllwed by infusin at 215 mg/kg/h depending n respnse) may als be used, as may pentbarbital (515 mg/kg intrave- nusly, fllwed by 0.54 mg/kg/h). After status epileptius is ntrlled, an ral mediatin prgram fr the lng-term management f seizures is started, and investigatins int the ause f the disrder are pursued. 4. Nonconvulsive status epilepticus In sme ases, sta- tus epileptius presents nt with nvulsins, but with a flutuating abnrmal mental status, nfusin, impaired respnsiveness, and autmatism. Eletrenephalgraphy establishes the diagnsis. The treatment apprah utlined abve applies t any type f status epileptius, althugh intravenus anesthesia is usually nt neessary. The prg- nsis is a refletin f the underlying ause rather than f ntinuing seizures. When to Refer Behaviral episdes f unertain nature. Seizures are diffiult t ntrl with mntherapy. There is a prgressive neurlgi disrder. When to Admit Status epileptius. Frequent seizures requiring rapid mediatin titratin and eletrenephalgraphi mnitring. Fr inpatient mnitring when PNES is suspeted.Ahmad  S et al. Surgial treatments f epilepsy. Semin Neurl. 2020;40:696. [PMID: 33176368] Kanner AM et al. Pratie guideline update summary: effiay and tlerability f the new antiepilepti drugs I: treatment f new-nset epilepsy. Epilepsy Curr. 2018;18:260. [PMID: 30254527] Kapur J et al; NETT and PECARN Investigatrs. Randmized trial f three antinvulsant mediatins fr status epilepti- us. N Engl J Med. 2019;381:2103. [PMID: 31774955]CMDT22_Ch24_p0978-p1053.indd  991 29/06/21 8:50 PMChapTER 24992 CMDT 2022DYSAUTO NOMIAE S S E N T I A L S  O F  D I A G N O S I S Postural hypotension or abnormal heart rate regulation. Abnormalities of sweating, intestinal motility, sex- ual function, or sphincter control. Syncope may occur. Symptoms occur in isolation or any combination. General ConsiderationsDysautn mia may ur as a result f pathlgial pr- esses in the entral r peripheral nervus system. It is manifested by a variety f symptms related t abnrmali- ties f bld pressure regulatin, thermregulatry sweat- ing, gastrintestinal funtin, sphinter ntrl, sexual funtin, respiratin, and ular funtin. The differential diagnsis depends n the time urse f autnmi dys- funtin and whether dysautnmia is an islated symp- tm r assiated with entral r peripheral neurlgi symptms and signs.A.  Causes in the Central Nervous SystemDisease at  ertain sites, regardless f its nature, may lead t dysautnmi symptms. Postural hypotension, whih is usually the mst trublesme and disabling symptm, may result frm spinal rd transetin and ther myelpathies (eg, due t tumr r syringmyelia) abve the T6 level r frm brainstem lesins suh as syringbulbia and psterir fssa tumrs. Sphincter or sexual disturbances may result frm rd lesins at any level. Certain primary degenera- tive disrders are respnsible fr dysautnmia urring in islatin (pure autonomic failure) r in assiatin with mre widespread abnrmalities (multisystem atro- phy) that may inlude parkinsnism, pyramidal symp- tms, and erebellar defiits. Pstural hyptensin is als a prminent symptm f idipathi Parkinsn disease and dementia with Lewy bdies.B.  Causes in the Peripheral Nervous SystemA  pure autnmi neurpathy may ur autely r sub- autely after a viral infetin r as a paraneplasti disr- der related usually t small ell lung aner, partiularly in assiatin with ertain antibdies, suh as anti-Hu r thse direted at neurnal nitini ganglini aetylh- line reeptrs. Dysautnmia is ften nspiuus in patients with Guillain-Barr syndrme, manifesting with marked hyptensin r hypertensin r ardia arrhyth- mias that may have a fatal utme. It may als ur with diabeti, uremi, amylidti, and varius ther metabli r txi neurpathies; in assiatin with leprsy r Cha- gas disease; and as a feature f ertain hereditary neurpa- thies with autsmal dminant r reessive inheritane r an X-linked pattern. Autnmi symptms are prminentin the rises f hepati prphyria. Small fiber neurpathies may underlie sme ases f postural orthostatic tachycar- dia syndrome (POTS) due t impaired ntratility in denervated venules and resulting prelad failure (see belw). Patients with btulism r the Lambert-Eatn myastheni syndrme may have nstipatin, urinary retentin, and a sia syndrme as a result f impaired hlinergi funtin. Clinical FindingsA.  Symptoms and SignsDysautn mi symptms inlude synpe, pstural hyp- tensin, parxysmal hypertensin, persistent tahyardia withut ther ause, faial flushing, hyphidrsis r hyper- hidrsis, vmiting, nstipatin, diarrhea, dysphagia, abdminal distentin, disturbanes f mituritin r defe- atin, eretile dysfuntin, apnei episdes, and delining night visin. In synpe, prdrmal malaise, nausea, head- ahe, diaphresis, pallr, visual disturbane, lss f ps- tural tne, and a sense f weakness and impending lss f nsiusness are fllwed by atual lss f nsiusness. It is usually ampanied by hyptensin and bradyardia and may ur in respnse t emtinal stress, pstural hyptensin, vigrus exerise in a ht envirnment, bstruted venus return t the heart, aute pain r its antiipatin, fluid lss, and a variety f ther irum- stanes. Althugh the patient is usually flaid, sme mtr ativity is nt unmmn, and urinary (and rarely feal) inntinene may als ur, thereby simulating a seizure. Revery is rapid ne the patient bemes reum- bent, but headahe, nausea, and fatigue mmnly persist.B.  Evaluation of the PatientThe e xtent and severity f autnmi dysfuntin shuld be determined, and the presene f assiated neurlgi symptms and signs asertained. Bedside testing f aut- nmi funtin inludes examinatin f pupillary rea- tivity, examinatin f the skin fr areas f exessive r redued sweating and f the hands and feet fr lr r temperature hanges, as well as assessment f bld pres- sure and heart rate in the supine psitin and 2 minutes after standing. With dysautnmia, postural hypotension is not accompanied by a compensatory rise in heart rate. Speialized tests inlude the ardivasular respnse t the Valsalva maneuver and deep respiratin, tilt-table testing, the thermregulatry sweat test, the quantitative sudmtr axn reflex test, and the quantitative diret and indiret axn reflex test. Tests f gastrintestinal mtility and urdynamis may be helpful when symptms f dysmtility, inntinene, r urinary retentin are present. The neurlgi examinatin shuld fus n deteting signs f parkinsnism, erebellar dysfuntin, disrders f neurmusular transmissin, and peripheral neurpathy. All patients shuld be tested fr vitamin B12defiieny and diabetes. Patients with aute r subaute islated dysaut- nmia shuld underg testing fr ganglini aetylhline reeptr, anti-Hu, vltage-gated ptassium hannel m- plex, and vltage-gated alium hannel antibdies. Fr thse with evidene f peripheral neurpathy, nerveCMDT22_Ch24_p0978-p1053.indd  992 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS993 CMDT 2022ndu tin studies; eletrmygraphy; and testing fr HIV , amylidsis, Sjgren syndrme, and Fabry disease are indiated. If there is evidene f entral pathlgy, imag- ing studies will exlude a treatable strutural ause. If the neurlgi examinatin is nrmal, reversible, nnneur- lgi auses f symptms must be nsidered. Islated pstural hyptensin and synpe may relate t a redued ardia utput, parxysmal ardia dysrhythmias, vlume depletin, varius mediatins, and endrine and meta- bli disrders suh as Addisn disease, hypthyridism r hyperthyridism, phehrmytma, and arinid syndrme. TreatmentThe  mst disabling symptms are usually pstural hypten- sin and synpe. Abrupt pstural hange, prlnged reumbeny, heavy meals, and ther preipitants shuld be avided. Mediatins assiated with pstural hyptensin shuld be disntinued r redued in dse. Treatment may inlude wearing waist-high elasti hsiery, salt supplementa- tin, sleeping in a semieret psitin (whih minimizes the natriuresis and diuresis that ur during reumbeny), ingestin f 500 mL water 30 minutes befre arising, and fludrrtisne (0.10.5 mg rally daily). Vasnstritr agents may be helpful and inlude middrine (2.510 mg rally three times daily), drxidpa (100600 mg rally three times daily), and ephedrine (1530 mg rally three times daily). Other agents that have been used asinally r experimentally are dihydrergtamine, yhimbine, pyr- idstigmine, and lnidine; refratry ases may respnd t erythrpietin (epetin alfa) r desmpressin. Patients must be mnitred fr reumbent hypertensin. Pstprandial hyptensin is helped by affeine. There is n satisfatry treatment fr disturbanes f sweating, but an air-nditined envirnment is helpful in aviding extreme swings in bdy temperature. When to Refer When the diagnsis is unertain. When symptms persist despite nventinal treatment.Shiba  CA et al. Management f rthstati hyptensin, pst- prandial hyptensin, and supine hypertensin. Semin Neurl. 2020;40:515. [PMID: 33058087]PO STURAL ORTHOSTATIC TACHYCARDIA SYNDROME Clinical FindingsIn PO TS, rthstati symptms (tremulusness, lighthead- edness, palpitatins, visual disturbanes, weakness, fatigue, anxiety, hyperventilatin, nausea) develp with a signifiant tahyardia (an inrease f 30 beats/min r mre r a heart rate f 120 beats/min r mre) within 10 minutes f stand- ing, in the absene f pstural hyptensin r an autnmi neurpathy. POTS is mre mmn in wmen than menand in patients between 20 and 50 years f age. Other medi- al prblems ausing a tahyardia must be exluded. Its pathphysilgy is unertain but may invlve ar- dia denditining; impaired peripheral vasnstri- tin due t peripheral sympatheti denervatin, leading t venus pling in the legs n standing and a mpen- satry tahyardia ( neuropathic POTS ); r an exagger- ated sympatheti respnse t standing, with markedly elevated levels f plasma nrepinephrine ausing the tahyardia ( hyperadrenergic POTS ). Other pssible mehanisms inlude hypvlemia, pssibly frm impaired funtin f the renin-angitensin system (volume dysregulation POTS ) and exessive mast ell ativatin leading t inapprpriate release f histamine during physial ativity. Psyhlgial mehanisms have als been invked. POTS may be assiated with jint hypermbility syndrme and mitral valve prlapse, and it may fllw pregnany, surgery, trauma, hemtherapy, vainatins, r viral infetins. TreatmentMana gement may invlve vlume repletin, a high salt diet and pius fluids, pstural and psyhphysilgi train- ing, and a graduated exerise prgram. Mediatin treat- ment may inlude a beta-blking agent (eg, prpranll 1040 mg three times daily), phenbarbital (15 mg in the mrning, 60 mg at night) r lnidine (0.2 mg twie daily) fr patients with hyperadrenergi POTS; and mid- drine (2.510 mg three times daily) r fludrrtisne (0.10.2 mg daily) if the bld pressure is lw. The lng- term prgnsis is unlear but apprximately 50% f patients rever within 3 years.TR ANSIENT ISCHEMIC ATTACKSE S S E N T I A L S  O F  D I A G N O S I S Focal neurologic deficit of acute onset. Clinical deficit resolves completely within 24 hours. Risk factors for vascular disease often present. General ConsiderationsT ransient ishemi attaks (TIAs) are haraterized by focal ischemic cerebral neurologic deficits that last frless than 24 hours (usually less than 12 hurs). Abut 30% f patients with strke have a histry f TIAs and 510% f patients with TIAs will have a strke within 90 days. The natural his- try f attaks is variable. Sme patients will have a majr strke after nly a few attaks, whereas thers may have frequent attaks fr weeks r mnths withut having a strke. The risk f strke is high in the first 3 mnths after an attak, partiularly in the first mnth and espeially within the first 48 hurs. The strke risk is greater in patients lder than 60 years, in patients with diabetes, r after TIAs that last lnger than 10 minutes and with symptms r signsCMDT22_Ch24_p0978-p1053.indd  993 29/06/21 8:50 PMChapTER 24994 CMDT 2022f  weakness, speeh impairment, r gait disturbane. In general, artid ishemi attaks are mre liable than verte- brbasilar ishemi attaks t be fllwed by strke. Urgent interventin in TIA patients redues rates f subsequent strke, and the condition should be treated with a similar sense of urgency as unstable angina. EtiologyAn  imprtant ause f transient erebral ishemia is emblizatin. In many patients with these attaks, a sure is readily apparent in the heart r a majr extraranial artery t the head, and embli smetimes are visible in the retinal arteries. An embli phenmenn explains why separate attaks may affet different parts f the territry supplied by the same majr vessel. Cardia auses f embli ishemi attaks inlude atrial fibrillatin, heart failure, infetive and nnbaterial thrmbti endardi- tis, atrial myxma, and mural thrmbi mpliating my- ardial infartin. Atrial septal defets and patent framen vale may permit venus thrmbembli t reah the brain ( paradoxical emboli ). An ulerated plaque n a majr artery t the brain may serve as a sure f embli. In the anterir irulatin, atherslerti hanges ur mst mmnly in the regin f the artid bifuratin extraranially; these hanges may ause a bruit. Ather- slersis als affets the vertebrbasilar system and the majr intraranial vessels inluding the middle and ante- rir erebral arteries. Less mmn abnrmalities f bld vessels that may ause TIAs inlude fibrmusular dysplasia, whih affets partiularly the ervial internal artid artery; athersle- rsis f the arti arh; inflammatry arterial disrders suh as giant ell arteritis, plyarteritis, and granulma- tus angiitis; and meningvasular syphilis. Critial sten- sis f a majr extraranial r intraranial artery may ause TIA, espeially in the setting f hyptensin. Hematlgi auses f TIA inlude plyythemia, sikle ell disease, hypervissity syndrmes, and the antiphsphlipid antibdy syndrme. Severe anemia may als lead t transient fal neurlgi defiits in patients with preexisting erebral arterial disease. The subclavian steal syndrome may lead t transient vertebrbasilar ishemia. Symptms develp when there is lalized stensis r lusin f ne sublavian artery prximal t the sure f the vertebral artery, s that bld is stlen frm the vertebral artery t supply the arm. A bruit in the supralaviular fssa, unequal radial pulses, and a differene f 20 mm Hg r mre between the systli bld pressures in the arms shuld suggest the diagnsis in patients with vertebrbasilar TIAs. Clinical FindingsA.  Symptoms and SignsThe  symptms f TIAs vary markedly amng patients; hw- ever, the symptms in a given individual tend t be nstant in type. Onset is abrupt and withut warning, and revery usually urs rapidly, ften within a few minutes. The spe- ifi symptms depend n the arterial distributin affeted,as utlined in the subsequent setin n strke. Of nte, TIA rarely auses f lss f nsiusness r aute nfusin but is ften errneusly blamed fr suh symptms.B.  ImagingCT  r MRI san is indiated within 24 hurs f symptm nset, in part t exlude the pssibility f a small erebral hemrrhage r a erebral tumr masquerading as a TIA. MRI with diffusin-weighted sequenes is partiularly sen- sitive fr revealing aute r subaute infartin, whih is seen in up t ne-third f ases despite reslutin f linial symptms and indiates a high risk f subsequent strke. Nninvasive imaging f the ervial vasulature shuld als be perfrmed; artid duplex ultrasngraphy is useful fr deteting signifiant stensis f the internal artid artery, and MR r CT angigraphy permits brader visualizatin f ervial and intraranial vasulature.C.  Laboratory and Other StudiesClinial  and labratry evaluatin must inlude assessment fr hypertensin, heart disease, hematlgi disrders, dia- betes mellitus, hyperlipidemia, and peripheral vasular dis- ease. It shuld inlude mplete bld unt, fasting bld gluse and serum hlesterl determinatins, and may inlude serlgi tests fr syphilis and HIV infetin. An ECG shuld be btained. Ehardigraphy with agitated saline ntrast is perfrmed if a ardiembli sure is likely, and bld ultures are btained if endarditis is suspeted. Ambulatry ECG mnitring is indiated t detet parxysmal atrial fibrillatin and, if the ause f the TIA remains elusive, extended monitoring may detet parx- ysmal atrial fibrillatin in up t 20% f patients. Differential DiagnosisFal  seizures usually ause abnrmal mtr r sensry phenmena suh as lni limb mvements, paresthesias, r tingling, rather than weakness r lss f feeling. Symp- tms generally spread (marh) up the limb and may lead t a generalized tni-lni seizure. Classi migraine is easily regnized by the visual pre- mnitry symptms, fllwed by nausea, headahe, and phtphbia, but less typial ases may be hard t distin- guish. Patients with migraine are typially yunger, m- mnly have a histry f episdes sine adlesene, and reprt that ther family members have a similar disrder. Fal neurlgi defiits may ur during perids f hypglyemia in diabeti patients reeiving insulin r ral hypglyemi agent therapy. TreatmentA.  Medical MeasuresMedial  treatment is aimed at preventing further attaks and strke. Treat diabetes mellitus, hematlgi disrders, and hypertensin, preferably with an angitensin-nverting enzyme inhibitr r angitensin reeptr blker. ACMDT22_Ch24_p0978-p1053.indd  994 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS995 CMDT 2022stati n shuld be started regardless f the urrent lw- density lipprtein level (LDL), althugh this pratie is nly supprted by randmized trial data in patients with an LDL greater than 100 mg/dL. Cigarette smking shuld be stpped, and ardia sures f emblizatin shuld be treated apprpriately. Weight redutin and regular physial ativity shuld be enuraged when apprpriate. An antiplatelet r antiagulant shuld be started as sn as imaging has established the absene f hemrrhage. 1. Hospitalization Hspitalizatin shuld be nsid- ered fr patients seen within a week f the attak, when they are at inreased risk fr early reurrene. One m- mnly used methd t assess reurrene risk is the ABCD2score; pints are assigned fr eah f the fllw- ing riteria: age 60 years r lder (1 pint), bld pressure 140/90 mm Hg r higher (1 pint), linial symptms f fal weakness (2 pints) r speeh impairment withut weakness (1 pint), duratin f 60 minutes r lnger (2 pints) r 1059 minutes (1 pint), r diabetes mellitus (1 pint). An ABCD2sre f 4 r mre pints has been suggested as a threshld fr hspital admissin. The ABCD2I(with an additinal 3 pints fr any abnrmal diffusin-weighted MRI finding r any infart [new r ld] n nnntrast CT) has been prpsed as a better preditr f subsequent strke risk. Admissin is als advisable fr patients with resend attaks, symptm- ati artid stensis, r a knwn ardia sure f embli r hyperagulable state; suh hspitalizatin failitates early interventin fr any reurrene and rapid institu- tin f sendary preventin measures. 2. Anticoagulation The hief indiatin fr antiagula- tin after TIA is atrial fibrillatin. Patients with metal heart valves, left ventriular thrmbus, and the antiphs- phlipid antibdy syndrme shuld als reeive anti- agulatin therapy. Treatment is with warfarin (target INR 2.03.0); bridging warfarin with heparin is nt neessary, but sme experts advate treatment with aspirin until the INR bemes therapeuti. Fr lng-term antiagulatin in the setting f atrial fibrillatin, apixaban (2.55 mg rally twie daily), dabigatran (150 mg rally twie daily), edxa- ban (60 mg rally daily), and rivarxaban (20 mg rally daily) are ptins. Cmbinatin antiplatelet-antiagula- tin therapy is nly indiated in patients with mehanial heart valves r thse with a separate indiatin fr anti- platelet therapy suh as a ardia stent. In patients with ardimypathy and an ejetin fratin under 35% withut atrial fibrillatin, warfarin (target INR 2.03.0) redues ishemi strke risk mpared t aspirin but results in a rughly equivalent inrease in the risk f majr hemrrhage; treatment in this ppulatin shuld there- fre be individualized. 3. Antiplatelet therapy All patients in whm antiag- ulatin is nt indiated shuld be treated with shrt-term dual antiplatelet therapy and lng-term mntherapy t redue the frequeny f TIAs and the inidene f strke. Treatment shuld be initiated within 12 hurs after the TIA r minr strke (defined by a Natinal Institutes fHealth Strke Sale f 3 r less) with an ral lading dse f lpidgrel (300600 mg) fllwed by 75 mg/day rally plus aspirin (50325 mg daily rally) fr 21 days, fllwed by mntherapy with aspirin (81 mg daily rally), aspirin mbined with extended-release dipyridamle (200 mg twie daily rally), r lpidgrel (75 mg daily rally). Cilstazl (100 mg twie daily) had similar effiay as aspirin at lng-term strke preventin in an Asian ppu- latin with less risk f hemrrhage. Cmbining lpid- grel with aspirin beynd 90 days inreases the risk f hemrrhagi mpliatins and is notremmended.B. Surgic al or Endovascular Measures1. Car otid revascularization When arterigraphy reveals a surgially aessible high-grade stensis (7099% in lumi- nal diameter) n the side apprpriate t artid ishemi attaks, perative treatment ( carotid endarterectomy ) r endovascular intervention redues the risk f ipsilateral artid strke, espeially when TIAs are f reent nset (less than 1 mnth) and when the periperative mrbidity and mrtality risk is estimated t be less than 6%. Endvasular therapy arries a slightly higher predural strke risk than endarteretmy in patients lder than 70 years and is gener- ally reserved fr yunger patients whse nek anatmy is unfavrable fr surgery. Patients with symptmati artid stensis f 5069% derive mderate benefit frm interven- tin, but surgery is nt indiated fr mild stensis (less than 50%). 2. Closure of patent foramen ovale Carefully seleted patients with patent framen vale (PFO) and right-t- left shunt benefit frm PFO lsure and antiplatelet therapy. Patients shuld be nsidered fr PFO lsure if they are between 18 and 60 years ld; have had a rypt- geni strke r TIA; and d nt have unntrlled diabe- tes, hypertensin, r a speifi indiatin fr lng-term antiagulatin. A ryptgeni strke des nt have an identified mehanism, suh as large artery atherslersis (greater than r equal t 3050% stensis f the intrara- nial r ervial arteries r a plaque greater than r equal t 4mm thik in the arti arh), knwn ardiembli sure (eg, atrial fibrillatin), small vessel arterilsler- sis (eg, launar strke smaller than 1.5 m in diameter), hyperagulable state, r dissetin. Patients with mder- ate t large interatrial shunts r assiated atrial septal aneurysms appear t benefit mst frm PFO lsure. See als Chapter 10. When to ReferAll  patients shuld be referred fr urgent investigatin andtreatment to prevent stroke. When to AdmitIf s een within a week f a TIA, patients shuld be nsid- ered fr admissin when they have an ABCD2sre f 4 pints r mre, when utpatient evaluatin is impratial, r when there are multiple attaks, artid stensis f greater than 70%, r ther nern fr early reurrene r strke.CMDT22_Ch24_p0978-p1053.indd  995 29/06/21 8:50 PMChapTER 24996 CMDT 2022Pa n Y et al. Outmes assiated with lpidgrel-aspirin use in minr strke r transient ishemi attak: a pled analysis f Clpidgrel in High-Risk Patients With Aute Nn-Disabling Cerebrvasular Events (CHANCE) and Platelet-Oriented Inhibitin in New TIA and Minr Ishemi Strke (POINT) trials. JAMA Neurl. 2019;76:1466. [PMID: 31424481]ST ROKEE S S E N T I A L S  O F  D I A G N O S I S Sudden onset of neurologic deficit of cerebrovas- cular origin. Patient often has hypertension, diabetes mellitus, tobacco use, atrial fibrillation, or atherosclerosis. Distinctive neurologic signs reflect the region of the brain involved. General ConsiderationsIn  the United States, strke is the sixth leading ause f death and a leading ause f disability. Risk fatrs fr strke inlude hypertensin, diabetes mellitus, hyperlipid- emia, igarette smking, ardia disease, HIV infetin, trigeminal herpes zster, rereatinal drug abuse, heavy alhl nsumptin, and a family histry f strke. Strkes are subdivided pathlgially int infarcts and hemorrhages. The distintin may be diffiult linially; CT sanning is essential t larify the pathlgi basis (Table 243).1.  Lcunr InfrctionLa unar infarts are small lesins (usually less than 1.5 m in diameter) that ur in the distributin f shrt penetrating arteriles in the basal ganglia, pns, erebel- lum, internal apsule, thalamus, and, less mmnly, the deep erebral white matter (Table 243). Launar infarts are assiated with prly ntrlled hypertensin r diabetes and have been fund in several linial syn- drmes, inluding ntralateral pure mtr hemiparesis r pure hemisensry defiit, ipsilateral ataxia with hemi- paresis, and dysarthria with lumsiness f the hand. The neurlgi defiit may prgress ver 2436 hurs befre stabilizing. Early mrtality and risk f strke reurrene is higher fr patients with nnlaunar than launar infarts. The prgnsis fr revery frm the defiit prdued by a lau- nar infart is usually gd, with partial r mplete reslu- tin urring ver the fllwing 46 weeks in many instanes. Treatment is as desribed fr TIA and erebral infartin.2.  Cerebrl InfrctionThrm bti r embli lusin f a majr vessel leads t erebral infartin. Causes are idential t the disrders predispsing t TIAs. The resulting defiit depends n the partiular vessel invlved and the extent f any llateralirulatin. Cerebral ishemia leads t release f exitatry and ther neurpeptides that may augment alium flux int neurns, thereby leading t ell death and inreasing the neurlgi defiit. Clinical FindingsA.  Symptoms and SignsOnset  is usually abrupt, and there may then be very little prgressin exept that due t brain swelling. Clinial evaluatin shuld always inlude examinatin f the heart fr murmurs and rhythm irregularities. Ausultating ver the artid r sublavian vessels may reveal a bruit but is nt sensitive enugh t substitute fr vasular imaging. 1. Obstruction of carotid circulation Olusin f the anterior cerebral artery distal t its juntin with the ante- rir mmuniating artery auses weakness and rtial sensry lss in the ntralateral leg and smetimes mild weakness f the arm, espeially prximally. There may be a ntralateral grasp reflex, paratni rigidity, abulia (lak f initiative), r frank nfusin. Urinary inntinene is nt unmmn, partiularly if behaviral disturbanes are nspiuus. Bilateral anterir erebral infartin is espe- ially likely t ause marked behaviral hanges and memry disturbanes. Unilateral anterir erebral artery lusin prximal t the juntin with the anterir m- muniating artery is generally well tlerated beause f the llateral supply frm the ther side. Middle cerebral artery lusin leads t ntralateral hemiplegia, hemisensry lss, and hmnymus hemian- pia (ie, bilaterally symmetri lss f visin in half f the visual fields), with the eyes deviated t the side f the lesin. If the dminant hemisphere is invlved, glbal aphasia is als present. It may be impssible t distinguish this linially frm lusin f the internal artid artery. With lusin f either f these arteries, there may als be nsiderable swelling f the hemisphere during the first 72 hurs. Fr example, an infart invlving ne erebral hemisphere may lead t suh swelling that the funtin f the ther hemisphere r the rstral brainstem is disturbed and ma results. Olusins f different branhes f the middle erebral artery ause mre limited findings. Fr example, invlvement f the superir divisin in the dmi- nant hemisphere leads t a predminantly expressive (Broca ) aphasia and t ntralateral paralysis and lss f sensatins in the arm, the fae and, t a lesser extent, the leg. Inferir branh lusin in the dminant hemisphere prdues a reeptive ( Wernicke ) aphasia and a hmny- mus visual field defet. With invlvement f the nn- dminant hemisphere, speeh and mprehensin are preserved, but there may be a left hemispatial neglet syn- drme r nstrutinal and visuspatial defiits. Olusin f the ophthalmic or central retinal artery leads t sudden painless visual lss with retinal pallr and a maular herry red spt n fundspi examinatin. Sudden, transient visin lss in ne eye ( amaurosis fugax ) is a TIA in this arterial territry. Patients with a cilioretinal artery (apprximately 25%) may have maular sparing due t llateral bld supply.CMDT22_Ch24_p0978-p1053.indd  996 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS997 CMDT 20222. Obstruction of  vertebrobasilar circulation Olusin f the posterior cerebral artery may lead t a thalami syndrme in whih ntralateral hemisensry disturbane urs, fllwed by the develpment f spntaneus pain and hyperpathia. There is ften a maular-sparing hm- nymus hemianpia and smetimes a mild, usually tem- prary, hemiparesis. Depending n the site f the lesinand the llateral irulatin, the severity f these defiits varies and ther defiits may als ur, inluding invlun- tary mvements and alexia. Olusin f the main artery beynd the rigin f its penetrating branhes may lead slely t a maular-sparing hemianpia. Vertebral artery occlusion belw the rigin f the anterir spinal and psterir inferir erebellar arteriesTable 243. Features of the major stroke subtypes.Stro ke Tye nd Subtye Clinicl Fetures Dignosis Tretment Iscemic Stroke Lacunar infarct Small (< 1.5 cm) lesions in the basal ganglia, pons, cerebel- lum, or internal capsule; less often in deep cerebral white matter; prognosis generally good; clinical features depend on location, but may worsen over first 2436 hours.MRI with diffusion-weighted sequences usually defines the area of infarction; CT is insensitive acutely but can be used to exclude hemorrhage.Antiplatelet; control risk factors (hypertension, tobacco use, hyper- cholesterolemia, and diabetes mellitus). Carotid circulation obstructionSee textsigns vary depending on occluded vessel.Noncontrast CT to exclude hemorrhage but findings may be normal during first 624 hours of an ischemic stroke; diffusion-weighted MRI is gold stan- dard for identifying acute stroke; elec- trocardiography, carotid duplex studies, echocardiography, blood glucose, com- plete blood count, and tests for hyper- lipidemia are indicated; ambulatory ECG monitoring, including extended monitoring in selected instances; CTA, MRA, or conventional angiography in selected cases; tests for hypercoagula- ble states in selected cases.03 hours in United States: intrave- nous thrombolytics (approved in Europe for up to 4.5 hours). 06 hours: endovascular mechanical embolectomy. 624 hours: endovascular mechanical embolectomy in select cases. Secondary prevention: antiplatelet agent is first-line therapy; anticoag- ulation without heparin bridge for cardioembolic strokes due to atrial fibrillation and other select cases when no contraindications exist; control risk factors as above. Vertebrobasilar occlusionSee textsigns vary based on location of occluded vessel.As for carotid circulation obstruction. As for carotid circulation obstruction. hemorrgic Stroke Spontaneous intracerebral hemorrhageCommonly associated with hypertension; also with bleed- ing disorders, amyloid angiopathy. Hypertensive hemorrhage is located commonly in the basal ganglia, pons, thalamus, cere- bellum, and less commonly the cerebral white matter.Noncontrast CT is superior to MRI for detecting bleeds of < 48 hours dura- tion; laboratory tests to identify bleeding disorder: angiography may be indicated to exclude aneurysm or AVM in younger patients without hypertension. Do notperform lumbar puncture.Lower systolic blood pressure to 140 mm Hg; cerebellar bleeds or hematomas with gross mass effect may require urgent surgical evacuation. AVM: surgical resection indicated to prevent further bleeding; other modalities to treat nonoperable AVMs available at specialized centers. Subarachnoid hemorrhagePresent with sudden onset of worst headache of life, may lead rapidly to loss of con- sciousness; signs of meningeal irritation often present; etiol- ogy usually aneurysm or AVM, but 20% have no source identified.CT to confirm diagnosis, but may be normal in rare instances; if CT negative and suspicion high, perform lumbar puncture to look for red blood cells or xanthochromia; angiography to determine source of bleed in candidates for treatment.Lower systolic blood pressure to < 140 mm Hg immediately. Aneurysm: prevent further bleeding by clipping aneurysm or coil embo- lization; nimodipine helps prevent vasospasm; once aneurysm has been obliterated intravenous fluids and induced hypertension to pre- vent vasospasm; angioplasty may also reverse symptomatic vasospasm. AVM: as above. AVMs, arteriovenous malformations; CTA, computed tomography angiography; MRA, magnetic resonance angiography.CMDT22_Ch24_p0978-p1053.indd  997 29/06/21 8:50 PMChapTER 24998 CMDT 2022may  be linially silent beause the irulatin is main- tained by the ther vertebral artery. If the remaining verte- bral artery is ngenitally small r severely atherslerti, hwever, a defiit similar t that f basilar artery lusin is seen unless there is gd llateral irulatin frm the anterir irulatin thrugh the irle f Willis. An bstrutin f the posterior inferior cerebellar artery r an bstrutin f the vertebral artery just befre it branhes t this vessel leads t the lateral medullary syndrome, haraterized by vertig and nystagmus (vestibular nuleus), ipsilateral spinthalami sensry lss invlving the fae (trigeminal nuleus and trat), dysphagia (nuleus ambiguus), limb ataxia (inferir erebellar pedunle), and Hrner syndrme (desending sympatheti fibers), m- bined with ntralateral spinthalami sensry lss invlv- ing the limbs. Olusin f both vertebral arteries r the basilar artery leads t ma with pinpint pupils, flaid quadri- plegia and sensry lss, and variable ranial nerve abnr- malities. With partial basilar artery lusin, there may be diplpia, visual lss, vertig, dysarthria, ataxia, weakness r sensry disturbanes in sme r all f the limbs, and disrete ranial nerve palsies. In patients with hemiplegia f pntine rigin, the eyes are ften deviated t the para- lyzed side, whereas in patients with a hemispheri lesin, the eyes mmnly deviate frm the hemiplegi side. When the small paramedian arteries arising frm the basi- lar artery are luded, ntralateral hemiplegia and sen- sry defiit ur in assiatin with an ipsilateral ranial nerve palsy at the level f the lesin. Olusin f any f the majr cerebellar arteries pr- dues vertig, nausea, vmiting, nystagmus, and ipsilateral limb ataxia. Cntralateral spinthalami sensry lss in the limbs may als be present. Deafness due t hlear infar- tin may fllw lusin f the anterir inferir erebellar artery, whih may als ause ipsilateral faial spintha- lami sensry lss and weakness. Massive erebellar infar- tin may lead t bstrutive hydrephalus, ma, tnsillar herniatin, and death.B.  ImagingA  CT san f the head (withut ntrast) shuld be per- frmed immediately , befre the administratin f aspirin r ther antithrmbti agents, t exlude erebral hemr- rhage (Table 243). CT is relatively insensitive t aute ishemi strke within the first 612 hurs, and subse- quent MRI with diffusin-weighted sequenes helps define the distributin and extent f infartin as well as exlude tumr r ther differential nsideratins. CT angigraphy f the head and nek shuld be perfrmed t identify large vessel lusins amenable t endvasular therapy in patients presenting within 6 hurs f strke nset and shuld be nsidered in thse presenting between 6 and 24 hurs, tgether with CT perfusin studies. Regardless f timing f presentatin, imaging f the ervial vasulature is indiated as part f a searh t identify the sure f the strke. In patients with a PFO and therwise ryptgeni strke, the intraranial vasulature must be imaged t rule ut large vessel atherslersis befre PFO lsure an be nsidered.C. Laboratory and Other StudiesIn vestigatins shuld inlude a mplete bld unt, bld gluse determinatin, and fasting lipid panel. Ser- lgi tests fr syphilis and HIV infetin may be inluded depending n the irumstanes. Sreening fr antiphs- phlipid antibdies (lupus antiagulants, antiardilipin, and anti-beta2-glyprtein antibdies); the fatr V Leiden mutatin; abnrmalities f prtein C, prtein S, r antithrmbin; r a prthrmbin gene mutatin is indiated nly if a hyperagulable disrder is suspeted (eg, a yung patient withut apparent risk fatrs fr strke) r needs t be ruled ut if PFO lsure is under nsideratin. While elevated serum hmysteine is a risk fatr fr strke, lwering hmysteine levels with vitamin supplementa- tin has nt been shwn t derease strke risk, and there- fre, rutinely heking hmysteine is notremmended. Eletrardigraphy r ntinuus ardia mnitring fr at least 24 hurs will help exlude a reent myardial infartin r a ardia arrhythmia that might be a sure f emblizatin. While atrial fibrillatin will be disvered in apprximately 10% f patients with ishemi strke during their hspitalizatin, it is estimated that an arrhythmia will be fund in an additinal 10% with prlnged ambulatry ECG mnitring after disharge; this testing is indiated in ases where atrial fibrillatin is suspeted (eg, nnlaunar strke and left atrial enlargement n ehardigraphy r lak f intraranial r artid atherslersis) but has nt been demnstrated. Ehardigraphy (with agitated saline ntrast) shuld be perfrmed in ases f nnlau- nar strke t exlude valvular disease, right-t-left shunt- ing, and ardia thrmbus. Bld ultures shuld be perfrmed if endarditis is suspeted but are nt required rutinely. Examinatin f the erebrspinal fluid is nt always neessary but may be helpful if erebral vasulitis r anther inflammatry r infetius ause f strke is sus- peted, but it shuld be delayed until after CT r MRI t exlude any risk fr herniatin due t mass effet. TreatmentMana gement is divided int aute and hrni phases: the first is aimed at minimizing disability and the send at preventing reurrent strke. A mbinatin f thrmbly- sis and endvasular therapies is available t patients wh present within 24 hurs f strke nset, determined by when the patient was last nrmal. Intravenous thrombolytic therapy with rembinant tissue plasmingen ativatr (rtPA; 0.9 mg/kg t a maxi- mum f 90 mg, with 10% given as a blus ver 1 minute and the remainder ver 1 hur) imprves the hane f revery withut signifiant disability at 90 days frm 26% t 39% if given within 3 hurs frm strke nset; it is still effetive up t 4.5 hurs frm strke nset. Treatment shuld be initiated as sn as pssible; utme is diretly related t the time frm strke nset t treatment. Intrave- nus thrmblysis is apprved in Eurpe fr use up t 4.5 hurs frm strke nset but nly fr up t 3 hurs in the United States, althugh ff-label use during the 3- t 4.5-hur windw is standard. In patients with systli pressure greater than 185 mm Hg r diastli pressure greater thanCMDT22_Ch24_p0978-p1053.indd  998 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS999 CMDT 2022110  mm Hg, the bld pressure shuld be lwered t less than 185/110 mm Hg with intravenus labetall r niar- dipine t enable rtPA administratin. Due t the risk f hemrrhage, rtPA shuld nt be used beynd 4.5 hurs, r in ther situatins where it is medially ntraindiated, althugh sme evidene suggests patients with ishemi but nt infarted tissue identified by autmated perfusin imaging r MRI may be treated up t 9 hurs after nset r upn awakening with strke symptms. Several randmized trials have demnstrated an inreased likelihd f ahieving funtinal independene after endovascular mechanical embolectomy by stent retrievers as an adjunt t intravenus rtPA. Patients with large vessel lusin (abut 20% f patients with aute ishemi strke) in whm treatment an be initiated within 6 hurs f strke nset are eligible fr embletmy, as are patients wh present between 6 hurs and 24 hurs and als have a large ishemi penumbra identified by perfu- sin CT, perfusin MRI, r diffusin-weighted MRI. Early management f a mpleted strke therwise requires general supprtive measures. Management in a stroke care unit has been shwn t imprve utmes, likely due t early rehabilitatin and preventin f medial mpliatins. During the aute stage, there may be marked brain swelling and edema, with symptms and signs f inreasing intraranial pressure, an inreasing neurlgi defiit, r herniatin syndrme. Elevated intraranial pres- sure is managed by head elevatin and smti agents suh as mannitl. Maintenane f an adequate erebral perfusin pressure helps prevent further ishemia. Early dempres- sive hemiranietmy (within 48 hurs f strke nset) fr malignant middle erebral artery infartins redues mr- tality and imprves funtinal utme. Attempts t lwer the bld pressure f hypertensive patients during the aute phase (ie, within 72 hurs) f a strke shuld generally be avoided unless the purpse is t enable the safe administra- tin f rtPA, as there is lss f erebral autregulatin, and lwering the bld pressure may further mprmise ishemi areas. Hwever, if the systli pressure exeeds 220 mm Hg, it an be lwered using intravenus labetall r niardipine with ntinuus mnitring t 170200 mm Hg, and then after 72 hurs, it an be redued further t less than 140/90 mm Hg. Bld pressure augmentatin is usu- ally nt neessary in patients with relative hyptensin but maintenane f intravenus hydratin is imprtant. Prphylati and medial measures are disussed in the setin n TIAs and shuld guide management. One hemrrhage has been exluded by CT, aspirin (325 mg rally daily) is started immediately unless the patient reeived thrmblysis, in whih ase aspirin is initiated after a fllw-up CT has ruled ut thrmblyti-assiated hemrrhage at 24 hurs. Dual antiplatelet therapy shuld be used fr 21 days in patients with minr strke (Natinal Institutes f Health Strke Sale f 3 r less). Anticoagulant mediatins are started when indiated, as disussed in the setin n TIAs. There is generally noadvantage in delay, and the mmn fear f ausing hemrrhage int a previ- usly infarted area is misplaed, sine there is a far greater risk f further emblism t the erebral irulatin if treat- ment is withheld.Physical therapy has an imprtant rle in the manage- ment f patients with impaired mtr funtin. Passive mvements at an early stage will help prevent ntratures. As peratin inreases and sme revery begins, ative mvements will imprve strength and rdinatin. In all ases, early mbilizatin and ative rehabilitatin are impr- tant. Occupational therapy may imprve mrale and mtr skills, while speech therapy may help expressive aphasia r dysarthria. Beause f the risk fr dysphagia fllwing strke, aess t fd and drink is typially restrited until an appr- priate swallwing evaluatin; the head f the bed shuld be kept elevated t prevent aspiratin. Urinary atheters shuld notbe plaed and, if plaed, remved within 2448 hurs. PrognosisThe  prgnsis fr survival after erebral infartin is better than after erebral r subarahnid hemrrhage. Patients reeiving treatment with rtPA are at least 30% mre likely t have minimal r n disability at 3 mnths than thse nt treated by this means. Thse treated with mehanial embletmy are als at least 30% mre likely t ahieve funtinal independene. Lss f nsiusness after a erebral infart implies a prer prgnsis than therwise. The extent f the infart gverns the ptential fr rehabili- tatin. Patients wh have had a erebral infart are at risk fr additinal strkes and fr myardial infarts. The prphylati measures disussed earlier redue this risk. Antiplatelet therapy redues the reurrene rate by 30% amng patients withut a ardia ause fr the strke wh are nt andidates fr artid endarteretmy. Neverthe- less, the umulative risk f reurrene f nnardiembli strke is still 37% annually. Management is fused n palliative are when meaningful revery frm massive strkes is unlikely (see Chapter 5). When to ReferAll patients sh uld be referred. When to AdmitAll  patients shuld be hspitalized, preferably in a strke are unit.Albers  GW et al; DEFUSE 3 Investigatrs. Thrmbetmy fr strke at 6 t 16 hurs with seletin by perfusin imaging. N Engl J Med. 2018;378:708. [PMID: 29364767] Ngueira RG et al; DAWN Trial Investigatrs. Thrmbetmy 6 t 24 hurs after strke with a mismath between defiit and infart. N Engl J Med. 2018;378:11. [PMID: 29129157] Pwers WJ et al. Guidelines fr the early management f patients with aute ishemi strke: 2019 update t the 2018 guide- lines fr the early management f aute ishemi strke: a guideline fr healthare prfessinals frm the Amerian Heart Assiatin/Amerian Strke Assiatin. Strke. 2019;50:e344. [PMID: 31662037]3.  Intrcerebrl hemorrgeSpn taneus, nntraumati intraerebral hemrrhage in patients with n angigraphi evidene f an assiated vasular anmaly (eg, aneurysm r angima) is usually dueCMDT22_Ch24_p0978-p1053.indd  999 29/06/21 8:50 PMChapTER 241000 CMDT 2022t  hypertensin. The pathlgi basis fr hemrrhage is prbably the presene f miraneurysms that develp n perfrating vessels in hypertensive patients. Hypertensive intraerebral hemrrhage urs mst frequently in the basal ganglia, pns, thalamus, and erebellum, and less mmnly in the erebral white matter. Hemrrhage may extend int the ventriular system r subarahnid spae, and signs f meningeal irritatin are then fund. In lder adults, erebral amylid angipathy is anther imprtant and frequent ause f hemrrhage, whih is usually lbar in distributin, smetimes reurrent, and assiated with a better immediate prgnsis than hypertensive hemr- rhage. Arterivenus malfrmatins are an imprtant ause f intraerebral hemrrhage in yunger patients. Other auses f nntraumati intraerebral hemr- rhage inlude hematlgi and bleeding disrders (eg, leukemia, thrmbytpenia, hemphilia, r disseminated intravasular agulatin), antiagulant therapy, liver disease, high alhl intake, aine and methamphet- amine abuse, herpes simplex enephalitis, vasulitis, my- amya disease, reversible erebral vasnstritin syndrme, and primary r sendary brain tumrs. There is als an assiatin with advaning age and male sex. Bleeding is primarily int the subarahnid spae when it urs frm an intraranial aneurysm, but it may be partly intraparenhymal as well. Hemrrhage an als ur int arterial and venus erebral infarts. Clinical FindingsA.  Symptoms and SignsW ith hemrrhage int the erebral hemisphere, nsius- ness is initially lst r impaired in abut ne-half f patients. Vmiting urs very frequently at the nset f bleeding, and headahe is smetimes present. Fal symp- tms and signs then develp, depending n the site f the hemrrhage. With hypertensive hemrrhage, there is gen- erally a rapidly evlving neurlgi defiit with hemiplegia r hemiparesis. A hemisensry disturbane is als present with mre deeply plaed lesins. With lesins f the puta- men, lss f njugate lateral gaze may be nspiuus. With thalami hemrrhage, there may be a lss f upward gaze, dwnward r skew deviatin f the eyes, lateral gaze palsies, and pupillary inequalities. Cerebellar hemrrhage may present with sudden nset f nausea and vmiting, dysequilibrium, ataxia f gait, limbs, r trunk; headahe; and lss f nsiusness that may terminate fatally within 48 hurs. Pntine hemrrhage auses sme mbinatin f lateral njugate gaze palsies t the side f the lesin; small reative pupils; ntralateral hemiplegia; peripheral faial weakness; and peridi respi- ratin. These signs may be bilateral with larger pntine hemrrhage, and the patient may beme lked in, with quadriplegia and preserved nsiusness.B.  ImagingCT  sanning (withut ntrast) is imprtant nt nly in nfirming that hemrrhage has urred but als in determining the size and site f the hematma. MRI isequally sensitive when magneti suseptibility weighted sequenes (eg, gradient eh) are used. If the patients n- ditin permits further interventin, CT angigraphy, MR angigraphy, r erebral angigraphy may be undertaken t determine whether an aneurysm r arterivenus mal- frmatin is present. In patients under age 55 with lbar hemrrhage and n histry f hypertensin, a ntrast- enhaned MRI may indiate a nnhypertensive ause, suh as an underlying neplasm.C.  Laboratory and Other StudiesA  mplete bld unt, platelet unt, prthrmbin and partial thrmbplastin times, liver bihemial tests, and kidney funtin tests may reveal a predispsing ause fr the hemrrhage. Lumbar puncture is contraindicated beause it may preipitate a herniatin syndrme in patients with a large hematma, and CT sanning is supe- rir in deteting intraerebral hemrrhage. TreatmentPa tients shuld be admitted t an intensive are unit fr bservatin and supprtive are. The systli bld pres- sure shuld be lwered t 140 mm Hg with intravenus labetall r niardipine, althugh randmized trials target- ing systli bld pressures f less than 140 mm Hg and less than 180 mm Hg have nt shwn a differene in ut- mes. Thrmbytpenia shuld be treated with platelet transfusin; the speifi threshld fr treatment and the gal platelet unt after transfusin vary with patient har- ateristis and prvider experiene. Cagulpathies shuld be reversed using fresh frzen plasma, prthrmbin m- plex nentrates, vitamin K, r speifi reversal agents (eg, prtamine fr heparin; idaruizumab fr dabigatran; and andexanet alfa fr apixaban, betrixaban, edxaban, and rivarxaban). Hemstati therapy with rembinant ativated fatr VII in patients withut underlying agu- lpathy has nt imprved survival r funtinal utme. Intraranial pressure may require mnitring and smti therapy. Ventriular drainage may be required in patients with intraventriular hemrrhage and aute hydrephalus. Dempressin may be helpful when a superfiial hema- tma in erebral white matter is exerting a mass effet and ausing inipient herniatin. In patients with erebellar hemrrhage wh are deterirating neurlgially r wh have brainstem mpressin r hydrephalus, prmpt surgial evauatin f the hematma is apprpriate beause spntaneus unpreditable deteriratin may therwise lead t a fatal utme and beause perative treatment may lead t mplete reslutin f the linial defiit. The treatment f underlying strutural lesins r bleeding dis- rders depends n their nature. There is n speifi treatment fr erebral amylid angipathy. When to ReferAll patients sh uld be referred. When to AdmitAll patients sh uld be hspitalized.CMDT22_Ch24_p0978-p1053.indd  1000 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1001 CMDT 2022Hst ettler IC et al. Intraerebral hemrrhage: an update n diag- nsis and treatment. Expert Rev Neurther. 2019;19:679. [PMID: 31188036]4.  Sontneous Subrcnoid hemorrgeE S S E N T I A L S  O F  D I A G N O S I S Sudden (thunderclap) severe headache. Signs of meningeal irritation usually present. Obtundation is common. Focal deficits frequently absent. General ConsiderationsBetween  5% and 10% f strkes are due t subarahnid hemrrhage. Trauma is the mst mmn ause f sub- arahnid hemrrhage, the prgnsis f whih depends n the severity f the head injury. Spntaneus (nntrau- mati) subarahnid hemrrhage frequently results frm the rupture f an arterial saccular (berry) aneurysm r frm an arteriovenous malformation. Clinical FindingsA.  Symptoms and SignsSubarahn id hemrrhage has a harateristi linial pi- ture. Its nset is with sudden ( thunderclap ) headahe f a severity never experiened previusly by the patient. This may be fllwed by nausea and vmiting and by a lss r impairment f nsiusness that an either be transient r prgress inexrably t deepening ma and death. If n- siusness is regained, the patient is ften nfused and irritable and may shw ther symptms f an altered men- tal status. Neurlgi examinatin generally reveals nuhal rigidity and ther signs f meningeal irritatin, exept in deeply matse patients. Mst aneurysms are asymptmati until they rupture, but they may ause a fal neurlgi defiit by mpress- ing adjaent strutures. Oasinal patients with aneurysms have headahes, smetimes ampanied by nausea and nek stiffness, a few hurs r days befre massive subarah- nid hemrrhage urs. This has been attributed t warn- ing leaks f a small amunt f bld frm the aneurysm. A higher risk f subarahnid hemrrhage is assiated with lder age, female sex, nn-White ethniity, hyperten- sin, tba smking, high alhl nsumptin (exeed- ing 150 g per week), previus symptms, psterir irulatin aneurysms, and larger aneurysms. Fal neur- lgi signs are usually absent but, when present, may relate either t a fal intraerebral hematma (frm arterive- nus malfrmatins) r t ishemia in the territry f the vessel with a ruptured aneurysm.B.  ImagingA  CT san (preferably with CT angigraphy) shuld be perfrmed immediately t nfirm that hemrrhage hasurred and t searh fr lues regarding its sure. It is preferable t MRI beause it is faster and mre sensitive in deteting hemrrhage in the first 24 hurs. CT findings smetimes are nrmal in patients with suspeted hemr- rhage, and the erebrspinal fluid must then be examined fr the presene f bld r xanthhrmia befre the ps- sibility f subarahnid hemrrhage is disunted. Cerebral arterigraphy is undertaken t determine the sure f bleeding. In general, bilateral artid and verte- bral arterigraphy are neessary beause aneurysms are ften multiple, while arterivenus malfrmatins may be supplied frm several sures. The predure allws an interventinal radilgist t treat an underlying aneurysm r arterivenus malfrmatin by varius tehniques. If arterigrams shw n abnrmality, the examinatin shuld be repeated after 2 weeks beause vasspasm r thrmbus may have prevented detetin f an aneurysm r ther vasular anmaly during the initial study. CT r MR angi- graphy may als be revealing but is less sensitive than nventinal arterigraphy.C.  Laboratory and Other StudiesThe  erebrspinal fluid demnstrates an elevated red bld ell unt. Subarahnid hemrrhage an be differentiated frm a traumati lumbar punture by the lak f learing f red bld ells frm the first and furth tube f erebrspi- nal fluid r by the presene f xanthhrmia, whih urs due t lysis f red bld ells and takes at least 2 hurs t develp. The abslute red bld ell unt is als helpful: in the absene f xanthhrmia, a red bld ell unt f less than 2000  106/L is very unlikely t be due t subarahnid hemrrhage. Eletrardigraphi evidene f arrhythmias r myardial ishemia has been well desribed and prbably relates t exessive sympatheti ativity. Peripheral leukytsis and transient glysuria are als mmn findings. TreatmentAll p atients shuld be hspitalized and seen by a neurl- gist. The measures utlined belw in the setin n stupr and ma are applied t matse patients. Cnsius patients are nfined t bed, advised against any exertin r straining, treated symptmatially fr headahe and anxiety, and given laxatives r stl sfteners. The systli bld pressure shuld be lwered t 140 mm Hg until the aneurysm is treated definitively. Seizure prphylaxis is nt neessary unless a nvulsin has urred (see Table 242). Patients are generally hspitalized fr at least 14 days t mnitr, prevent, and treat vasspasm. The majr aim f treatment is t prevent further hem- rrhage. The risk f further hemrrhage frm a ruptured aneurysm is greatest within a few days f the first hemr- rhage; apprximately 20% f patients will have further bleeding within 2 weeks and 40% within 6 mnths. Defini- tive treatment, ideally within 2 days f the hemrrhage, requires surgial lipping f the aneurysm r endvasular treatment by il emblizatin; the latter is smetimes feasible even fr inperable aneurysms and has a lwer mrbidity than surgery.CMDT22_Ch24_p0978-p1053.indd  1001 29/06/21 8:50 PMChapTER 241002 CMDT 2022 ComplicationsSpntaneu s subarahnid hemrrhage may result in severe mpliatins, s mnitring is neessary, usually in an intensive are unit. Hemiplegia r ther fal defiit smetimes may fllw aneurysmal bleeding after a delay f 214 days due t fal arterial spasm. The etilgy f vaso- spasm is unertain and likely multifatrial, and it sme- times leads t signifiant erebral ishemia r infartin and may further aggravate any existing inrease in intra- ranial pressure. Transranial Dppler ultrasund may be used t sreen nninvasively fr vasspasm, but nven- tinal arterigraphy is required t dument and treat vasspasm when the linial suspiin is high. Nimdipine has been shwn t redue the inidene f ishemi defiits frm arterial spasm; a dse f 60 mg every 4 hurs rally fr 21 days is given prphylatially t all patients. After surgial bliteratin f all aneurysms, symptmati vas- spasm may als be treated by intravasular vlume expan- sin and indued hypertensin; transluminal balln angiplasty f invlved intraranial vessels is als helpful. Acute hydrocephalus, whih smetimes urs due t erebrspinal fluid utflw disruptin by the subarahnid bld, shuld be suspeted if the patient deterirates lini- ally; a repeat CT san shuld be btained. Aute hydr- ephalus frequently auses intraranial hypertensin severe enugh t require temprary, and less mmnly pr- lnged r permanent, intraventriular erebrspinal fluid shunting. Cerebral salt-wasting is anther mpliatin f subarahnid hemrrhage that may develp abruptly dur- ing the first several days f hspitalizatin. The resulting hypnatremia and erebral edema may exaerbate intra- ranial hypertensin and may require arefully titrated treatment with ral sdium hlride r intravenus hyper- smti sdium slutin. Daily measurement f the serum sdium level allws fr the early detetin f this mplia- tin. Hypopituitarism may ur as a late mpliatin f subarahnid hemrrhage.Etmina n N et al. Neurvasular disease, diagnsis, and therapy: subarahnid hemrrhage and erebral vasspasm. Handb Clin Neurl. 2021;176:135. [PMID: 33272393] Lindgren A et al. Endvasular iling versus neursurgial lip- ping fr peple with aneurysmal subarahnid hemrrhage. Chrane Database Syst Rev. 2018;8:CD003085. [PMID: 30110521]5.  Intrcrnil aneurysmE S S E N T I A L S  O F  D I A G N O S I S Subarachnoid hemorrhage or focal deficit. Abnormal imaging studies. General ConsiderationsSaular  aneurysms (berry aneurysms) tend t ur at arterial bifuratins, are frequently multiple (20% f ases), and are usually asymptmati. They are assiated withplyysti kidney disease, myamya disease, familial aldsternism type 1, and artatin f the arta. Risk fatrs fr aneurysm frmatin inlude igarette smking, hypertensin, and female sex. Mst aneurysms are lated n the anterir part f the irle f Willispartiularly n the anterir r psterir mmuniating arteries, at the bifuratin f the middle erebral artery, and at the bifur- atin f the internal artid artery. Myti aneurysms resulting frm septi emblism ur in mre distal vessels and ften at the rtial surfae. The mst signifiant m- pliatin f intraranial aneurysms is a subarahnid hem- rrhage, whih is disussed in the preeding setin. Clinical FindingsA.  Symptoms and SignsAneurysms  may ause a fal neurlgi defiit by m- pressing adjaent strutures. Hwever, mst are asymp- tmati r prdue nly nnspeifi symptms until they rupture, at whih time subarahnid hemrrhage results. Its manifestatins, mpliatins, and management were utlined in the preeding setin.B.  ImagingDefinitive evaluatin is  by digital subtratin angigraphy (bilateral artid and vertebral studies), whih generally indiates the size and site f the lesin, smetimes reveals multiple aneurysms, and may shw arterial spasm if rup- ture has urred. Visualizatin by CT r MR angigraphy is nt usually adequate if perative treatment is under nsideratin beause lesins may be multiple and small lesins are smetimes missed, but these mdalities an be used t sreen patients wh have tw r mre first-degree relatives with intraranial aneurysms. TreatmentThe m ajr aim f treatment is t prevent hemorrhage. Man- agement f ruptured aneurysms was desribed in the setin n subarahnid hemrrhage. Symptmati but unruptured aneurysms merit prmpt treatment, either surgially r by endvasular tehniques. The deisin t treat r mnitr asymptmati aneurysms disvered inidentally is mpli- ated and depends n aneurysm size, latin, risk fatrs fr rupture, and treatment-related mrbidity; risk sres t guide deisin-making are available. When to ReferAll patients sh uld be referred. When to Admit All patients with a subarahnid hemrrhage. All patients fr detailed imaging. All patients underging surgial r endvasular treatment.Hak enberg KAM et al. Neurvasular disease, diagnsis, and therapy: brain aneurysms. Handb Clin Neurl. 2021;176:121. [PMID: 33272392]CMDT22_Ch24_p0978-p1053.indd  1002 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1003 CMDT 20226.  arteriovenous MlformtionsE S S E N T I A L S  O F  D I A G N O S I S Sudden onset of subarachnoid and intracerebral hemorrhage. Distinctive neurologic signs reflect the region of the brain involved. Signs of meningeal irritation in patients present- ing with subarachnoid hemorrhage. Seizures or focal deficits may occur. General ConsiderationsArteriven us malfrmatins are ngenital vasular mal- frmatins that result frm a lalized maldevelpment f part f the primitive vasular plexus and nsist f abnr- mal arterivenus mmuniatins withut intervening apillaries. They vary in size, ranging frm massive lesins that are fed by multiple vessels and invlve a large part f the brain t lesins s small that they are hard t identify at arterigraphy, surgery, r autpsy. In apprximately 10% f ases, there is an assiated arterial aneurysm, while 12% f patients presenting with aneurysms have assi- ated arterivenus malfrmatins. Clinial presentatin may relate t hemrrhage frm the malfrmatin r an assiated aneurysm r may relate t erebral ishemia due t diversin f bld by the anmalus arterivenus shunt r due t venus stagnatin. Reginal maldevelp- ment f the brain, mpressin r distrtin f adjaent erebral tissue by enlarged anmalus vessels, and prgres- sive glisis due t mehanial and ishemi fatrs may als be ntributry. Clinical FindingsMs t erebral arterivenus malfrmatins are supratent- rial, usually lying in the territry f the middle erebral artery. Up t 70% bleed at sme pint in their natural his- try, mst mmnly befre the patient reahes the age f 40 years. Arterivenus malfrmatins that have bled ne are mre likely t bleed again, at an apprximate rate f 4.5% annually. A higher risk f bleeding is als bserved if there is an assiated aneurysm, deep venus drainage, r deep brain latin; size f the malfrmatin and sex are nt assiated with risk f hemrrhage.A.  Symptoms and SignsInitial  symptms nsist f hemrrhage in 3060% f ases, reurrent seizures in 2040%, headahe in 525%, and misellaneus mplaints (inluding fal defiits) in 1015%. Hemrrhage is mmnly intraerebral as well as int the subarahnid spae and is fatal in abut 10% f ases. Seizures are mre likely with frntal r parietal arte- rivenus malfrmatins. Headahes are espeially likely when the external artid arteries are invlved in the mal- frmatin. These smetimes simulate migraine, but mremmnly are nnspeifi in harater, with nthing abut them t suggest an underlying strutural lesin. Brainstem and erebellar arterivenus malfrmatins may ause bstrutive hydrephalus. In patients presenting with subarahnid hemrrhage, examinatin may reveal an abnrmal mental status and signs f meningeal irritatin. Additinal findings may help lalize the lesin and smetimes indiate that intraranial pressure is inreased. A ranial bruit always suggests the pssibility f a erebral arterivenus malfrmatin, but bruits may als be fund with aneurysms, meningimas, aquired arterivenus fistulas, and arterivenus malfr- matins invlving the salp, alvarium, r rbit. Bruits are best heard ver the ipsilateral eye r mastid regin and are f sme help in lateralizatin but f n help in lalizatin. Absene f a bruit does not exclude the pssibility f arte- rivenus malfrmatin.B.  ImagingIn patien ts with suspeted hemrrhage, CT sanning indi- ates whether subarahnid r intraerebral bleeding has reently urred, helps lalize its sure, and may reveal the arterivenus malfrmatin. When intraranial hem- rrhage is nfirmed but the sure f hemrrhage is nt evident n the CT san, arterigraphy is neessary t exlude aneurysm r arterivenus malfrmatin. MR and CT angigraphy are nt sensitive enugh fr this purpse. Even if the findings n CT san suggest arterivenus mal- frmatin, arterigraphy is required t establish the nature f the lesin with ertainty and t determine its anatmi features s that treatment an be planned. The examinatin must generally inlude bilateral paifiatin f the inter- nal and external artid arteries and the vertebral arteries. In patients presenting withut hemrrhage, CT san r MRI usually reveals the underlying abnrmality, and MRI frequently als shws evidene f ld r reent hemr- rhage that may have been asymptmati. The nature and detailed anatmy f any fal lesin identified by these means are delineated by angigraphy, espeially if pera- tive treatment is under nsideratin. TreatmentSurgial  treatment t prevent further hemrrhage is justi- fied in patients with arterivenus malfrmatins that have bled, prvided that the lesin is aessible and the patient has a reasnable life expetany. Surgial treatment is als apprpriate if intraranial pressure is inreased and t prevent further prgressin f a fal neurlgi defiit. In patients presenting slely with seizures, antinvulsant treatment is usually suffiient (Table 242), and perative treatment is unneessary unless seizures annt be n- trlled medially. Definitive perative treatment nsists f exisin f the arterivenus malfrmatin if it is surgially aessible. Steretati radisurgery is used t treat inperable ere- bral arterivenus malfrmatins. Arterivenus malfr- matins that are inperable beause f their latin are smetimes treated slely by emblizatin; althugh the risk f hemrrhage is nt redued, neurlgi defiits mayCMDT22_Ch24_p0978-p1053.indd  1003 29/06/21 8:50 PMChapTER 241004 CMDT 2022be  stabilized r even reversed by this predure. Embliza- tin is mre mmnly perfrmed as an adjunt t surgery r radisurgery; it is als used t treat aneurysms assi- ated with the arterivenus malfrmatins. When to ReferAll patients sh uld be referred. When to Admit All patients with a subarahnid r erebral hemrrhage. All patients fr detailed imaging. All patients underging surgial r endvasular treatment.Ru tledge C et al. Brain arterivenus malfrmatins. Handb Clin Neurl. 2021;176:171. [PMID: 33272394]7.  Intrcrnil Venous TrombosisIn traranial venus thrmbsis may ur in assiatin with intraranial r maxillfaial infetins, hyperagu- lable states, plyythemia, sikle ell disease, yanti ngenital heart disease, and in pregnany r during the puerperium. Geneti fatrs are als imprtant. The disr- der is haraterized by headahe, fal r generalized n- vulsins, drwsiness, nfusin, inreased intraranial pressure, and fal neurlgi defiitsand smetimes by evidene f meningeal irritatin. The diagnsis is n- firmed by CT r MR vengraphy r angigraphy. Treatment inludes antinvulsants if seizures have urred (Table 242) andif neessarymeasures t redue intraranial pressure. Antiagulatin with dse- adjusted intravenus heparin r weight-adjusted subuta- neus lw-mleular-weight heparin, fllwed by ral warfarin antiagulatin fr 6 mnths redues mrbidity and mrtality f venus sinus thrmbsis. Dabigatran shwed similar effiay t warfarin in ne randmized trial and may be an aeptable alternative. Cnmitant intra- ranial hemrrhage related t the venus thrmbsis des nt ntraindiate heparin therapy. In ases refratry t heparin, endvasular tehniques inluding atheter- direted thrmblyti therapy (urkinase) and thrmbe- tmy are smetimes helpful but may inrease the risk fr majr hemrrhage. When to ReferAll patients sh uld be referred. When to AdmitAll patients sh uld be hspitalized.Ferr  JM et al; RE-SPECT CVT Study Grup. Safety and effiay f dabigatran etexilate vs dse-adjusted warfarin in patients with erebral venus thrmbsis: a randmized linial trial. JAMA Neurl. 2019;76:1457. [PMID: 31479105]8. Sinl Cord Vsculr DisesesE S S E N T I A L S  O F  D I A G N O S I S Sudden onset of back or limb pain and neurologic deficit in limbs. Motor, sensory, or reflex changes in limbs depend- ing on level of lesion. Imaging studies distinguish between infarct and hematoma. Infarction of the Spinal CordInf artin f the spinal rd is rare. It typially urs in the territry f the anterior spinal artery beause this vessel, whih supplies the anterir tw-thirds f the rd, is itself supplied by nly a limited number f feeders. Infartin usu- ally results frm interrupted flw in ne r mre f these feeders, eg, with arti dissetin, arti aneurysm, artgra- phy, plyarteritis, severe hyptensin, r after surgial repair f the thrai r abdminal arta. The paired psterir spinal arteries, by ntrast, are supplied by numerus arteries at different levels f the rd. Spinal rd hypperfusin may lead t a entral rd syndrme with distal weakness f lwer mtr neurn type and lss f pain and temperature appre- iatin, with preserved psterir lumn funtin. Sine the anterir spinal artery reeives numerus feeders in the ervial regin, infarts almst always ur audally. Clinial presentatin is haraterized by aute nset f flaid, areflexive paraplegia that evlves after a few days r weeks int a spasti paraplegia with extensr plantar respnses. There is an ampanying dissiated sensry lss, with impairment f appreiatin f pain and temperature but pres- ervatin f sensatins f vibratin and jint psitin. The risk f spinal rd infartin in the setting f abdminal arti surgery and thrai endvasular repair may be redued by intraperative erebrspinal fluid drainage thrugh a atheter plaed in the lumbar subarah- nid spae t redue intraspinal pressure. If signs f infar- tin are nted after surgery, bld pressure augmentatin fr 2448 hurs in additin t lumbar drainage has been nted anedtally t imprve utmes. Treatment is th- erwise symptmati. Epidural or Subdural HemorrhageEp idural r subdural hemrrhage may lead t sudden severe bak pain fllwed by an aute mpressive myelp- athy neessitating urgent spinal MRI r myelgraphy and surgial evauatin. It may ur in patients with bleeding disrders r thse wh are taking antiagulants, sme- times fllwing trauma r lumbar punture. Epidural hemrrhage may als be related t a vasular malfrmatin r tumr depsit. Spinal Dural Arteriovenous FistulaeSpi nal dural arterivenus fistulae are ngenital lesins that present with spinal subarahnid hemrrhage rCMDT22_Ch24_p0978-p1053.indd  1004 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1005 CMDT 2022my elradiulpathy. Sine mst f these malfrmatins are lated in the thralumbar regin, they lead t mtr and sensry disturbanes in the legs and t sphinter disrders. Pain in the legs r bak is ften severe. Examinatin reveals an upper, lwer, r mixed mtr defiit in the legs; sensry defiits are als present and are usually extensive, althugh asinally they are nfined t a radiular distributin. Cervial spinal dural arterivenus fistulae lead als t symptms and signs in the arms. Spinal MRI may nt detet the spinal dural arterivenus fistula, althugh mst ases shw either T2 hyperintensity in the rd r perimedullary flw vids. Myelgraphy (perfrmed with the patient prne and supine) may detet serpiginus filling defets due t enlarged vessels. Seletive spinal arterigraphy is required t nfirm the diagnsis and plan treatment. Mst lesins are extramedullary, are psterir t the rd (lying either intradurally r extradurally), and an easily be treated by ligatin f feeding vessels and exisin f the fistulus anmaly r by emblizatin predures. Delay in treatment may lead t inreased and irreversible disability r t death frm reurrent subarahnid hemrrhage. When to ReferAll patients sh uld be referred. When to AdmitAll patients sh uld be hspitalized.Gyal A et  al. Outmes fllwing surgial versus endvasular treatment f spinal dural arterivenus fistula: a systemati review and meta-analysis. J Neurl Neursurg Psyhiatry. 2019;90:1139. [PMID: 31142659]IN TRACRANIAL & SPINAL MASS LESIONS 1. primry Intrcrnil TumorsE S S E N T I A L S  O F  D I A G N O S I S Generalized or focal disturbance of cerebral func- tion, or both. Increased intracranial pressure in some patients. Neuroradiologic evidence of space-occupying lesion. General ConsiderationsRughl y ne-third f all primary intraranial neplasms (Table 244) are meningimas, ne-quarter are glimas, and the remainder are pituitary adenmas (see Chapter 26), neurfibrmas, and ther tumrs. Certain tumrs, espe- ially neurfibrmas, hemangiblastmas, and retinblas- tmas, may have a familial basis, and ngenital fatrs bear n the develpment f ranipharyngimas. Tumrs may ur at any age, but ertain glimas shw partiular age prediletins.Clinical FindingsA.  Symptoms and SignsIn traranial tumrs typially present with headahe, sei- zures, r fal neurlgi defiits. New headahes r symp- tms f elevated intraranial pressure, suh as headahes awaking a patient frm sleep r wrsening with Valsalva maneuver, ugh, r reumbeny, are suggestive f brain tumr. Intraranial tumrs may als lead t a generalized disturbane f erebral funtin with persnality hanges, intelletual deline, emtinal lability, nausea, and malaise. 1. Frontal lobe lesions Tumrs f the frntal lbe ften lead t prgressive intelletual deline, slwing f mental ativity, persnality hanges, and ntralateral grasp reflexes. They may lead t expressive aphasia if the pste- rir part f the left inferir frntal gyrus is invlved. Ans- mia may als ur as a nsequene f pressure n the lfatry nerve. Preentral lesins may ause fal mtr seizures r ntralateral pyramidal defiits. 2. Temporal lobe lesions Tumrs f the uninate regin may be manifested by seizures with lfatry r gustatry halluinatins, mtr phenmena suh as liking r smaking f the lips, and sme impairment f external awareness withut atual lss f nsiusness. Tempral lbe lesins als lead t depersnalizatin, emtinal hanges, behaviral disturbanes, sensatins f dj vu r jamais vu, mirpsia r marpsia (bjets appear smaller r larger than they are), visual field defets (rssed upper quadrantanpia), and auditry illusins r halluinatins. Left-sided lesins may lead t dysnmia and reeptive aphasia, while right-sided invlvement smetimes disturbs the pereptin f musial ntes and meldies. 3. Parietal lobe lesions Tumrs in this latin hara- teristially ause ntralateral disturbanes f sensatin and may ause sensry seizures, sensry lss r inatten- tin, r sme mbinatin f these symptms. The sensry lss is rtial in type and invlves pstural sensibility and tatile disriminatin, s that the appreiatin f shape, size, weight, and texture is impaired. Objets plaed in the hand may nt be regnized (asteregnsis). Extensive parietal lbe lesins may prdue ntralateral hyper- pathia and spntaneus pain (thalami syndrme). Invlvement f the pti radiatin leads t a ntralateral hmnymus field defet that smetimes nsists slely f lwer quadrantanpia. Lesins f the left angular gyrus ause Gerstmann syndrome (a mbinatin f alexia, agraphia, aalulia, right-left nfusin, and finger agn- sia), whereas invlvement f the left submarginal gyrus auses ideatinal apraxia. Ansgnsia (the denial, neglet, r rejetin f a paralyzed limb) is seen in patients with lesins f the nndminant (right) hemisphere. Cnstru- tinal apraxia and dressing apraxia may als ur with right-sided lesins. 4. Occipital lobe lesions Tumrs f the ipital lbe harateristially prdue ntralateral hmnymus hemianpia r a partial field defet. With left-sided r bilateral lesins, there may be visual agnsia bth fr bjets and fr lrs, while irritative lesins n either sideCMDT22_Ch24_p0978-p1053.indd  1005 29/06/21 8:50 PMChapTER 241006 CMDT 2022T able 244. Primary intracranial tumors (listed by major histology grouping and by incidence within each group).T umor Clinicl Fetures Tretment nd prognosis Tumors of Meninges Meningioma Originates from the dura mater or arachnoid; compresses rather than invades adjacent neural structures. Increasingly common with advancing age. Tumor size varies greatly. Symptoms vary with tumor siteeg, unilateral proptosis (sphenoidal ridge); anosmia and optic nerve compression (olfactory groove). Tumor is usually benign and readily detected by CT scanning; may lead to calcification and bone erosion visible on plain radiographs of skull.Treatment is surgical. Tumor may recur if removal is incomplete. Tumors of Neuroeitelil Origin Glioblastoma multiformePresents commonly with nonspecific complaints and increased intracranial pressure. As it grows, focal deficits develop. O6-methylguanine-DNA methyltransferase pro- moter methylation positivity (seen in 40% of cases) and iso- citrate dehydrogenase 1/2 mutations (seen in 10% of cases) carry better prognosis.Course is rapidly progressive, with poor prognosis (< 20% survival at 2 years). Total surgical removal is usually not possible. Radiation therapy and temozolamide may prolong survival. Tumor treatment fields added to temozolamide after completion of radiation therapy prolong survival. Astrocytoma Presentation similar to glioblastoma multiforme but course more protracted, often over several years. Cerebellar astro- cytoma may have a more benign course. Isocitrate dehy- drogenase 1/2 mutations (seen in a majority of cases) carry better prognosis in grade II and III tumors.Prognosis is variable. By the time of diagnosis, total excision is usually impossible; tumor may be radio- sensitive and temozolamide is also helpful in grade II and III tumors. In cerebellar astrocytoma, total surgical removal is often possible. Ependymoma Glioma arising from the ependyma of a ventricle, especially the fourth ventricle; leads to early signs of increased intra- cranial pressure. Arises also from central canal of cord.Tumor is best treated surgically if possible. Radiation therapy may be used for residual tumor. Oligodendroglioma Slow-growing. Usually arises in cerebral hemisphere in adults. Calcification may be visible on skull radiograph. Co-deletion of 1p/19q and isocitrate dehydrogenase 1/2 mutation required for diagnosis.Treatment is surgical and usually successful. Radiation and chemotherapy (temozolamide or procarbazine, lomustine, and vincristine) are used in grade II and III tumors. Brainstem glioma Presents during childhood with cranial nerve palsies and then with long tract signs in the limbs. Signs of increased intra- cranial pressure occur late.Tumor is inoperable; treatment is by irradiation and shunt for increased intracranial pressure. Neuronal and mixed neuronal-glial tumorsSlow-growing; usually arise in cerebral hemispheres; often associated with seizures. Some are benign (eg, dysembryo- blastic neuroepithelial tumors) and some have malignant potential (eg, ganglioglioma).Resection is not always necessary for benign tumors unless seizures are medically refractory, but is indi- cated for those with malignant potential. Medulloblastoma Seen most frequently in children. Generally arises from roof of fourth ventricle and leads to increased intracranial pressure accompanied by brainstem and cerebellar signs. May seed subarachnoid space. Wingless activated tumors carry best prognosis (> 90% 5-year survival).Treatment consists of surgery combined with radia- tion therapy and chemotherapy; 5-year survival exceeds 70%. Wingless activated tumors may require less aggressive treatment. Pineal tumor Presents with increased intracranial pressure, sometimes asso- ciated with impaired upward gaze (Parinaud syndrome) and other deficits indicative of midbrain lesion.Ventricular decompression by shunting is followed by surgical approach to tumor; irradiation is indicated if tumor is malignant. Prognosis depends on histo- pathologic findings and extent of tumor. Tumors of te Sellr Region Pituitary adenoma Functioning adenomas present with symptoms of hormone secretion; nonfunctioning adenomas present with symp- toms of local mass effect (eg, bitemporal hemianopsia, hypopituitarism) or are found incidentally.Prolactin-secreting adenomas are treated with bro- mocriptine or cabergoline. Others are surgically resected. Pituitary hormone replacement may be required. Craniopharyngioma Originates from remnants of Rathke pouch above the sella, depressing the optic chiasm. May present at any age but usually in childhood, with endocrine dysfunction and bitemporal visual field defects.Treatment is surgical, but total removal may not be possible. Radiation may be used for residual tumor. (continued )CMDT22_Ch24_p0978-p1053.indd  1006 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1007 CMDT 2022an ause unfrmed visual halluinatin s. Bilateral ipi- tal lbe invlvement auses rtial blindness in whih there is preservatin f pupillary respnses t light and lak f awareness f the defet by the patient. There may als be lss f lr pereptin, prspagnsia (inability t identify a familiar fae), simultagnsia (inability t inte- grate and interpret a mpsite sene as ppsed t its individual elements), and Balint syndrme (failure t turn the eyes t a partiular pint in spae, despite preservatin f spntaneus and reflex eye mvements). The denial f blindness r a field defet nstitutes Antn syndrme. 5. Brainstem and cerebellar lesions Brainstem lesins lead t ranial nerve palsies, ataxia, inrdinatin, nystag- mus, and pyramidal and sensry defiits in the limbs n ne r bth sides. Intrinsi brainstem tumrs, suh as gli- mas, tend t prdue an inrease in intraranial pressure nly late in their urse. Cerebellar tumrs prdue marked ataxia f the trunk if the vermis erebelli is invlved and ipsilateral appendiular defiits (ataxia, in- rdinatin, and hyptnia f the limbs) if the erebellar hemispheres are affeted. 6. Herniation syndromes If the pressure is inreased in a partiular ranial mpartment, brain tissue may herniate int a mpartment with lwer pressure. The mst familiar syndrme is herniatin f the tempral lbe unus thrugh the tentrial hiatus, whih auses mpressin f the third ranial nerve, midbrain, and psterir erebral artery. The earliest sign f this is ipsilateral pupillary dilatin, fllwed by stupr, ma, deerebrate psturing, and respiratry arrest. Anther imprtant herniatin syndrme nsists fdisplaement f the erebellar tnsils thrugh the framen magnum, whih auses medullary mpressin leading t apnea, irulatry llapse, and death. 7. False localizing signs Tumrs may lead t neurlgi signs ther than by diret mpressin r infiltratin, thereby leading t errrs f linial lalizatin. These false lalizing signs inlude third r sixth nerve palsy and bilat- eral extensr plantar respnses prdued by herniatin syndrmes, and an extensr plantar respnse urring ipsilateral t a hemispheri tumr as a result f mpressin f the ppsite erebral pedunle against the tentrium.B.  ImagingMRI  with gadlinium enhanement is the preferred methd t detet the lesin and t define its latin, shape, and size; the extent t whih nrmal anatmy is distrted; and the degree f any assiated erebral edema r mass effet. CT sanning with radintrast enhanement uld be perfrmed; hwever, it is less helpful than MRI fr small lesins r tumrs in the psterir fssa. The harateristi appearane f meningimas n MRI r CT sanning is virtually diagnsti, ie, a lesin in a typial site (parasagittal and sylvian regins, lfatry grve, sphenidal ridge, tuberulum sellae) that appears as a hmgeneus area f inreased density in nnntrast sans and enhanes uni- frmly with ntrast. Additinal MRI sequenes that may be helpful in differentiating glimas frm ther intraranial pathlgy inlude perfusin imaging, magneti resnane spetrspy, and diffusin-weighted imaging, althugh nne are speifi enugh t bviate the need fr tissueTable 244. Primary intracranial tumors (listed by major histology grouping and by incidence within each group).T umor Clinicl Fetures Tretment nd prognosis Germ cell tumors (germinomas and nongerminoma- tous germ cell tumors)Two most common locations are pineal and suprasellar regions. The pineal region presentation is as described in pineal tumors, above. Suprasellar tumors present with hypothalamic and pituitary dysfunction such as diabetes insipidus, delayed or precocious puberty, or growth hor- mone deficiency.Germinomas are treated with radiation; prognosis is good for localized tumors. Chemotherapy is added for nongerminomatous germ cell tumors. Tumors of Crnil nd Sinl Nerves Acoustic neurinoma (also referred to as acoustic neuroma)Ipsilateral hearing loss is most common initial symptom. Sub- sequent symptoms may include tinnitus, headache, vertigo, facial weakness or numbness, and long tract signs. (May be familial and bilateral when related to neurofibromatosis.) Most sensitive screening tests are MRI and brainstem audi- tory evoked potential.Treatment is excision by translabyrinthine surgery, craniectomy, or a combined approach. Outcome is usually good. Lymoms Primary cerebral lymphomaAssociated with AIDS and other immunodeficient states. Pre- sentation may be with focal deficits or with disturbances of cognition and consciousness. May be indistinguishable from cerebral toxoplasmosis.Treatment is high-dose methotrexate and corticoste- roids followed by radiation therapy. Prognosis depends on CD4 count at diagnosis. Unclssified Cerebellar hemangioblas- tomaPresents with dysequilibrium, ataxia of trunk or limbs, and signs of increased intracranial pressure. Sometimes familial. May be associated with retinal and spinal vascular lesions, polycythemia, and renal cell carcinoma.Treatment is surgical. Radiation is used for residual tumor.(continued)CMDT22_Ch24_p0978-p1053.indd  1007 29/06/21 8:50 PMChapTER 241008 CMDT 2022samp ling. Arterigraphy is largely reserved fr presurgial emblizatin f highly vasular tumrs. In patients with nrmal hrmne levels and an intrasellar mass, angigra- phy is smetimes neessary t distinguish with nfidene between a pituitary adenma and an arterial aneurysm.C.  Laboratory and Other StudiesWhen  glial neplasms are suspeted, bipsy is neessary fr definitive histlgi diagnsis and mleular analysis. The Wrld Health Organizatin lassifies glial tumrs by bth histlgy and geneti harateristis. Lumbar pun- ture is rarely neessary; the findings are seldm diagnsti, and the predure arries the risk f ausing a herniatin syndrme. Suspeted intraranial germ ell tumrs are an exeptin. If lumbar punture an be perfrmed safely, ytlgy and determinatin f alpha-fetprtein and beta- human hrini gnadtrpin shuld be perfrmed in erebrspinal fluid; tumr markers shuld be examined in serum as well. TreatmentT reatment depends n the type and site f the tumr (Table 244) and the nditin f the patient. Sme benign tumrs, espeially meningimas disvered inidentally during brain imaging fr anther purpse, may be mni- tred with serial annual imaging. Fr symptmati tumrs, mplete surgial remval may be pssible if the tumr is extra-axial (eg, meningima, austi neurma) r is nt in a ritial r inaessible regin f the brain (eg, erebel- lar hemangiblastma). Surgery als permits the diagnsis t be verified and may be benefiial in reduing intrara- nial pressure and relieving symptms even if the neplasm annt be mpletely remved. Clinial defiits are sme- times due in part t bstrutive hydrephalus, in whih ase simple surgial shunting predures ften prdue dramati benefit. In patients with malignant glimas, sur- vival rrelates t the extent f initial resetin. Radiatin therapy inreases median survival rates regardless f any preeding surgery, and its mbinatin with hemtherapy prvides additinal benefit. India- tins fr irradiatin in the treatment f patients with ther primary intraranial neplasms depend n tumr type and aessibility and the feasibility f mplete surgial remval. Lng-term neurgnitive defiits may mpliate radia- tin therapy. Temzlmide is a mmnly used ral and intravenus hemtherapeuti fr glimas. In patients with gliblastma with methylated methylguanine-DNA meth- yltransferase (MGMT) prmter, mbinatin therapy with lmustine and temzlmide imprved median survival frm 31 t 48 mnths in a randmized ntrlled trial. The additin f lw-intensity, 200 kHz frequeny alternating eletri fields (tumr treatment fields) delivered extrarani- ally at least 18 hurs daily, imprves prgressin-free sur- vival by 2.7 mnths and median survival by 4.9 mnths mpared t temzlmide alne in gliblastma. Bevai- zumab is apprved in the United States but nt in Eurpe fr use in reurrent high-grade glima. Cmbinatin therapy with prarbazine, lmustine, and vinristine imprves median survival when given with radiatin tpatients with isitrate dehydrgenasemutant astry- tma and isitrate dehydrgenasemutant, p1/19q - deleted ligdendrglima. Crtisterids help redue erebral edema and are usu- ally started befre surgery. Herniatin is treated with intra- venus dexamethasne (1020 mg as a blus, fllwed by 4 mg every 6 hurs) and intravenus mannitl (20% slutin given in a dse f 1.5 g/kg ver abut 30 minutes). Antinvulsants are als mmnly administered in standard dses (see Table 242), but are nt indiated fr prphylaxis in patients wh have n histry f seizures. Fr thse patients with diffiult t treat symptms r thse needing help with advane are planning, speialty pallia- tive are nsultatin is apprpriate (see Chapter 5). When to ReferAll patients sh uld be referred. When to Admit All patients with inreased intraranial pressure. All patients requiring bipsy, surgial treatment, r shunting predures.Bell  EH et al. Cmprehensive genmi analysis in NRG nl- gy/RTOG 9802: a phase III trial f radiatin versus radiatin plus prarbazine, lmustine (CCNU), and vinristine in high-risk lw-grade glima. J Clin Onl. 2020;38:3407. [PMID: 32706640] Desjardins A et al. Reurrent gliblastma treated with rembi- nant plivirus. N Engl J Med. 2018;379:150. [PMID: 29943666] Herrlinger U et al; Neurnlgy Wrking Grup f the German Caner Siety. Lmustine-temzlmide mbinatin therapy versus standard temzlmide therapy in patients with newly diagnsed gliblastma with methylated MGMT prmter (CeTeG/NOA-09): a randmised, pen-label, phase 3 trial. Lanet. 2019;393:678. [PMID: 30782343]2.  Metsttic Intrcrnil TumorsA.  Cerebral MetastasesMetasta ti brain tumrs present in the same way as ther erebral neplasms, ie, with inreased intraranial pres- sure, with fal r diffuse disturbane f erebral funtin, r with bth f these manifestatins. Indeed, in patients with a single erebral lesin, the metastati nature f the lesin may beme evident nly n histpathlgi exami- natin. In ther patients, there is evidene f widespread metastati disease, r an islated erebral metastasis devel- ps during treatment f the primary neplasm. The most common source of intracranial metastasis is carcinoma of the lung; ther primary sites are the breast, kidney, skin (melanma), and gastrintestinal trat. Mst erebral metastases are lated supratentrially. Labratry and radilgi studies used t evaluate patients with metastases are thse desribed fr primary neplasms. They inlude MRI and CT sanning perfrmed bth with and withut ntrast. Lumbar punture is neessary nly in patients with suspeted arinmatus meningitis. In patients with verified erebral metastasis frm an unknwnCMDT22_Ch24_p0978-p1053.indd  1008 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1009 CMDT 2022primary , investigatin is guided by symptms and signs. In wmen, mammgraphy is indiated; in men under 50, germ ell rigin is sught. Treatment f brain metastases is rapidly evlving and a multidisiplinary apprah between neursurgery, radia- tin nlgy, and nlgy is neessary. In patients with nly a single, surgially aessible erebral metastasis wh are therwise well (ie, a high level f funtining and little r n evidene f extraranial disease), it may be pssible t remve the lesin and then treat with irradiatin; the latter may als be seleted as the sle treatment. Systemi immuntherapy may als be an aeptable initial ptin in selet ases. In patients with multiple metastases r wide- spread systemi disease, steretati radisurgery, whle- brain raditherapy, r bth may help in sme instanes; systemi hemtherapy r immuntherapy may be ptins in thers, but in many, treatment is palliative nly.Fuen tes R et al. Surgery versus steretati raditherapy fr peple with single r slitary brain metastasis. Chrane Database Syst Rev. 2018;8:CD012086. [PMID: 30125049] Tsa MN et al. Whle brain raditherapy fr the treatment f newly diagnsed multiple brain metastases. Chrane Data- base Syst Rev. 2018;1:CD003869. [PMID: 29365347]B.  Leptomeningeal Metastases Carcinomatous MeningitisThe  neoplasms metastasizing most commonly to the lepto- meninges are carcinoma of the breast and lung, lymphomas, and leukemia (see Chapter 39). Leptmeningeal metastases lead t multifal neurlgi defiits, whih may be assi- ated with infiltratin f ranial and spinal nerve rts, diret invasin f the brain r spinal rd, bstrutive r mmuniating hydrephalus, r sme mbinatin f these fatrs. The diagnsis is nfirmed by examinatin f the ere- brspinal fluid. Findings may inlude elevated erebr- spinal fluid pressure, pleytsis, inreased prtein nentratin, and dereased gluse nentratin. Cyt- lgi studies may indiate that malignant ells are present; if nt, lumbar punture shuld be repeated at least twie t btain further samples fr analysis. CT sans shwing ntrast enhanement in the basal isterns r shwing hydrephalus withut any evidene f a mass lesin supprt the diagnsis. Gadlinium-enhaned MRI is mre sensitive and frequently shws enhaning fi in the leptmeninges. Myelgraphy may shw depsits n multiple nerve rts. Treatment is by irradiatin t symptmati areas, m- bined with intratheal hemtherapy in selet patients. The lng-term prgnsis is prnly abut 10% f patients survive fr 1 yearand palliative are is therefre impr- tant (see Chapter 5).3.  Intrcrnil Mss Lesions in ptients wit aIDSPrimary  cerebral lymphoma is a mmn mpliatin in patients with AIDS. This leads t disturbanes in gni- tin r nsiusness, fal mtr r sensry defiits,aphasia, seizures, and ranial neurpathies. Similar linial disturbanes may result frm cerebral toxoplasmosis , whih is als a mmn mpliatin in patients with AIDS (see Chapters 31 and 35). Neither CT nr MRI find- ings distinguish these tw disrders and serlgi tests fr txplasmsis are unreliable in AIDS patients. Toxoplasma gondii DNA deteted by plymerase hain reatin in the spinal fluid is speifi but nt sensitive fr txplasmsis, and the finding f Epstein-Barr virus DNA suggests lym- phma but is nt speifi enugh t initiate treatment. Ardingly, fr neurlgially stable patients, a trial f treatment fr txplasmsis with pyrimethamine and sul- fadiazine is remmended fr 3 weeks; the imaging studies are then repeated, and if any lesin has imprved, the regi- men is ntinued indefinitely. If any lesin des nt imprve, erebral bipsy is neessary (see als Chapter 31). Primary erebral lymphma in patients with AIDS is treated with rtisterids, high-dse methtrexate, and antiretrviral therapy. Rituximab may be used in sme patients. Whle-brain irradiatin may nt be neessary. Cryptococcal meningitis is a mmn pprtunisti infetin in patients with AIDS. Clinially, it may resemble erebral txplasmsis r lymphma, but ranial CT sans are usually nrmal (see Chapter 36).4.  primry & Metsttic Sinl TumorsA pprximately 10% f spinal tumrs are intramedullary. Ependymma is the mst mmn type f intramedullary tumr; the remainder are ther types f glima. Extramed- ullary tumrs may be extradural r intradural in latin. Amng the primary extramedullary tumrs, neurfibr- mas and meningimas are relatively mmn, benign, and may be intradural r extradural. Carinmatus metasta- ses, lymphmatus r leukemi depsits, and myelma are usually extradural; in the ase f metastases, the prstate, breast, lung, and kidney are mmn primary sites. Tumrs may lead t spinal rd dysfuntin by diret mpressin, by ishemia sendary t arterial r venus bstrutin and, in the ase f intramedullary lesins, by invasive infiltratin. Clinical FindingsA.  Symptoms and SignsSymp tms usually develp insidiusly. Pain is ften n- spiuus with extradural lesins; is harateristially aggravated by ughing r straining; may be radiular, lalized t the bak, r felt diffusely in an extremity; and may be ampanied by mtr defiits, paresthesias, r numbness, espeially in the legs. Bladder, bwel, and sexual dysfuntin may ur. When sphinter disturbanes ur, they are usually partiularly disabling. Pain, hw- ever, ften preedes speifi neurlgi symptms frm epidural metastases. Examinatin may reveal lalized spinal tenderness. A segmental lwer mtr neurn defiit r dermatmal sen- sry hanges (r bth) are smetimes fund at the level f the lesin, while an upper mtr neurn defiit and sen- sry disturbane are fund belw it.CMDT22_Ch24_p0978-p1053.indd  1009 29/06/21 8:50 PMChapTER 241010 CMDT 2022B.  ImagingMRI  with ntrast r CT myelgraphy is used t identify and lalize the lesin. The mbinatin f knwn tumr elsewhere in the bdy, bak pain, and either abnrmal plain films f the spine r neurlgi signs f rd m- pressin is an indiatin t perfrm this n an urgent basis.C.  Laboratory FindingsThe  erebrspinal fluid is ften xanthhrmi and n- tains a greatly inreased prtein nentratin with nrmal ell ntent and gluse nentratin. TreatmentIn tramedullary tumrs are treated by dempressin and surgial exisin (when feasible) and by irradiatin. The prgnsis depends n the ause and severity f rd m- pressin befre it is relieved. Treatment f epidural spinal metastases nsists f surgial dempressin, radiatin, r bth. Dexametha- sne is als given in a high dsage (eg, 1096 mg ne intravenusly, fllwed by 425 mg fur times daily fr 3 days rally r intravenusly, fllwed by rapid tapering f the dsage, depending n initial dse and respnse) t redue rd swelling and relieve pain. Radiatin alne is ften all that is required in patients with radisensitive tumrs. Surgial dempressin is reserved fr patients with tumrs that are unrespnsive t irradiatin r wh have previusly been irradiated, fr thse with spinal instability, and fr patients in whm there is sme uner- tainty abut the diagnsis. The lng-term utlk is pr, but treatment may at least delay the nset f majr disability.Lawtn  AJ et al. Assessment and management f patients with metastati spinal rd mpressin: a multidisiplinary review. J Clin Onl. 2019;37:61. [PMID: 30395488]5.  Brin abscessE S S E N T I A L S  O F  D I A G N O S I S Signs of expanding intracranial mass. Signs of primary infection or congenital heart dis- ease are sometimes present. Fever may be absent. General ConsiderationsBrain  absess presents as an intraranial spae-upying lesin and arises as a sequela f disease f the ear r nse, may be a mpliatin f infetin elsewhere in the bdy, r may result frm infetin intrdued intraranially by trauma r surgial predures. The mst mmn infe- tive rganisms are strepti, staphyli, and anaer- bes; mixed infetins als ur.Clinical FindingsA.  Symptoms and SignsHeadahe,  drwsiness, inattentin, nfusin, and seizures are early symptms, fllwed by signs f inreasing intra- ranial pressure and then a fal neurlgi defiit. There may be little r n systemi evidene f infetin.B.  Imaging and Other InvestigationsA  CT san f the head harateristially shws an area f ntrast enhanement surrunding a lw-density re. Similar abnrmalities may be fund in patients with meta- stati neplasms. MRI findings ften permit earlier reg- nitin f fal erebritis r an absess. Steretati needle aspiratin may enable a speifi etilgi rganism t be identified. Examinatin f the erebrspinal fluid des nt help in diagnsis and may preipitate a herniatin syn- drme. Peripheral leukytsis is smetimes present. TreatmentT reatment nsists f intravenus antibitis mbined with surgial drainage (aspiratin r exisin), if neessary, t redue the mass effet r smetimes t establish the diagnsis. Absesses smaller than 2 m an ften be ured medially. Brad-spetrum antibitis, seleted based n risk fatrs and likely rganisms, are used if the infeting rganism is unknwn (see Chapter 33). An initial empiri multi-antibiti regimen typially inludes eftriaxne (2 g intravenusly every 12 hurs), metrnidazle (15 mg/kg intravenus lading dse, fllwed by 7.5 mg/kg intrave- nusly every 6 hurs), and vanmyin (1 g intravenusly every 12 hurs). The regimen is altered ne ulture and sensitivity data are available. Antimirbial treatment is usually ntinued parenterally fr 68 weeks and is fl- lwed by ral treatment fr ertain infetins, suh as nardisis, atinmysis, fungal infetins, and tuberu- lsis. The patient shuld be mnitred by serial CT sans r MRI every 2 weeks and at deteriratin. Dexametha- sne (425 mg fur times daily intravenusly r rally, depending n severity, fllwed by tapering f dse, depending n respnse) may redue any assiated edema, but intravenus mannitl is smetimes required.Chw  F. Brain and spinal epidural absess. Cntinuum (Min- neap Minn). 2018;24:1327. [PMID: 30273242]NO NMETASTATIC NEUROLOGIC COMPLICATIONS OF MALIGNANT DISEASEA  variety f nnmetastati neurlgi mpliatins f malignant disease an be regnized. Metabolic encepha- lopathy due t eletrlyte abnrmalities, infetins, drug verdse, r the failure f sme vital rgan may be refleted by drwsiness, lethargy, restlessness, insmnia, agitatin, nfusin, stupr, r ma. The mental hanges are usually assiated with tremr, asterixis, and multifal mylnus. The eletrenephalgram is generally diffusely slwed. Labratry studies are neessary t detet the ause f the enephalpathy, whih must then be treated apprpriately.CMDT22_Ch24_p0978-p1053.indd  1010 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1011 CMDT 2022Im mune suppression resulting frm either the malig- nant disease r its treatment (eg, by hemtherapy) predis- pses patients t brain absess, prgressive multifal leukenephalpathy, meningitis, herpes zster infetin, and ther pprtunisti infetius diseases. Mrever, an vert r ult erebrspinal fluid fistula, as urs with sme tumrs, may als inrease the risk f infetin. MRI r CT sanning aids in the early regnitin f a brain absess, but metastati brain tumrs may have a similar appearane. Examinatin f the erebrspinal fluid is essential in the evaluatin f patients with meningitis and enephalitis but is f n help in the diagnsis f brain absess. Cerebrovascular disorders that ause neurlgi m- pliatins in patients with systemi aner inlude nnbate- rial thrmbti endarditis and septi emblizatin. Cerebral, subarahnid, r subdural hemrrhages may ur in patients with myelgenus leukemia and may be fund in assiatin with metastati tumrs, espeially melanma. Spinal subdural hemrrhage smetimes urs after lumbar punture in patients with marked thrmbytpenia. Disseminated intravascular coagulation urs mst mmnly in patients with aute prmyelyti leukemia r with sme adenarinmas and is haraterized by a flutuating enephalpathy, ften with assiated seizures, that frequently prgresses t ma r death. There may be few ampanying neurlgi signs. Venous sinus throm- bosis, whih usually presents with nvulsins and head- ahes, may als ur in patients with leukemia r lymphma. Examinatin mmnly reveals papilledema and fal r diffuse neurlgi signs. Antinvulsants, antiagulants, and mediatins t lwer the intraranial pressure may be f value. Autoimmune paraneoplastic disorders ur when the immune system reats against neurnal antigens expressed by tumr ells. The linial manifestatins depend n the autantibdy. Symptms may preede thse due t the neplasm itself. Several distint syndrmes are mmn, eah assiated with speifi antibdies and tumrs (Table 245). Identifiatin f an antibdy is nt always pssible in a suspeted autimmune paraneplasti nditin, and a searh fr an underlying neplasm shuld be undertaken. Treatment f the neplasm ffers the best hpe fr stabilizatin r imprvement f the neurlgi symptms, whih ften are nt mpletely reversible. Spe- ifi treatment f the antibdy-mediated symptms by intravenus immunglbulin (IVIG) administratin, plas- mapheresis, rtisterids, r ther immunsuppressive regimens is frequently attempted despite limited evidene f effiay. Many f the disrders listed in Table 245 an ur either as paraneplasti phenmena r in islatin; when they ur in the absene f a tumr, the respnse t immuntherapy is typially mre favrable. Autimmune disrders may als be triggered as a result f aner immuntherapy; enephalitis, meningitis, trans- verse myelitis, aute and hrni inflammatry demyelin- ating plyneurpathy, autnmi neurpathy, myasthenia gravis, and mysitis have all been desribed.Rsenfeld MR et al. P araneplasti neurlgi syndrmes. Neu- rl Clin. 2018;36:675. [PMID: 30072076]IDIOPATHIC INTRACRANIAL HYPERTENSION (Pseudotumor Cerebri)E S S E N T I A L S  O F  D I A G N O S I S Headache, worse on straining. Visual obscurations or diplopia may occur. Examination reveals papilledema. Abducens palsy is commonly present. General ConsiderationsThere are man y auses f this disrder. Thrmbsis f the transverse venus sinus as a mpliatin f titis media r hrni mastiditis is ne ause, and sagittal sinus thrm- bsis may lead t a linially similar piture. Other auses inlude hrni pulmnary disease, systemi lupus erythe- matsus, uremia, endrine disturbanes suh as hyp- parathyridism, hypthyridism, r Addisn disease, vitamin A txiity, and the use f tetrayline r ral n- traeptives. Cases have als fllwed withdrawal f rti- sterids after lng-term use. In mst instanes, hwever, n speifi ause an be fund, and the disrder remits spntaneusly after several mnths. This idipathi variety urs mst mmnly amng verweight wmen aged 2044. In all ases, sreening fr a spae-upying lesin f the brain is imprtant. Clinical FindingsA.  Symptoms and SignsSymp tms nsist f headahe, diplpia, and ther visual disturbanes due t papilledema and abduens nerve dys- funtin. Pulse-synhrnus tinnitus may als ur. Examinatin reveals papilledema and sme enlargement f the blind spts, but patients therwise lk well.B.  ImagingIn vestigatins reveal n evidene f a spae-upying lesin. CT r MRI shws small r nrmal ventriles and an empty sella turia. MR vengraphy is imprtant in sreen- ing fr thrmbsis f the intraranial venus sinuses. In sme ases, stensis f ne r mre f the venus sinuses will be bserved.C.  Laboratory FindingsLum bar punture is neessary t nfirm the presene f intraranial hypertensin, but the erebrspinal fluid is nrmal. Labratry studies help exlude sme f the ther auses mentined earlier. TreatmentU ntreated intraranial hypertensin smetimes leads t sendary pti atrphy and permanent visual lss. Aet- azlamide (250500 mg rally three times daily, inreasing slwly t a maintenane dse f up t 4000 mg daily,CMDT22_Ch24_p0978-p1053.indd  1011 29/06/21 8:50 PMChapTER 241012 CMDT 2022T able 245. Autoimmune paraneoplastic disorders and their associated antibodies and tumors (listed in alphabetical order).Syndrome Clinicl Fetures associted antibodies Tyicl associted Tumors Anti-NMDA receptor associated encephalitisParanoia, delusions, behavioral disturbance, seizure, orofacial dyskinesias, athetosis, dysau- tonomia, hypoventilationNMDA receptor1Ovarian teratoma, lung, breast, ovary, testicle Autoimmune necrotizing myopathyWeakness SRP ,1HMGCR1Lung, breast, gastrointestinal, bladder Autonomic neuropathy Postural hypotension, gastroparesisHu, ganglionic AChR1 Cerebellar degeneration Ataxia, dysarthria, nystagmus GAD65,1KLHL11, mGluR1,1NIF,1Ri, Tr, VGCC,1YoLung, breast, thymus, ovary, testicle, Hodgkin lymphoma Dermatomyositis Weakness, heliotrope skin rash TIF-1 gamma Lung, breast, ovary, gastrointes- tinal, lymphoma Lambert-Eaton myasthenic syndromeFatiguable weakness, ptosis, dip- lopia, dry mouth, constipationVGCC1Lung Limbic encephalitis/ encephalomyelitisShort-term memory loss, halluci- nations, seizures, behavioral disturbance, encephalopathyAMPA receptor,1Caspr2,1CV2/CRMP5, DPPX,1GABAAreceptor,1GABAB receptor,1GAD65,1GFAP ,1Hu, LGI1,1 Ma2, mGluR5,1NIF,1thyroglobulin1/ thyroperoxidase1Lung, breast, thymus, ovary, testicle, Hodgkin lymphoma Myasthenia gravis Fatiguable weakness, ptosis, diplopiaAChR,1LRP4,1MuSK1Thymus Myelitis Paraparesis, bowel and bladder dysfunction; sensory levelAmphiphysin,1aquaporin 4,1CRMP-5, GFAP ,1Hu, MOG,1YoLung, breast, lymphoma, leukemia, thyroid, renal Opsoclonus/myoclonus Erratic, conjugate saccadic eye movements and limb myoclonusRi Lung, breast, ovary, testicle, neuroblastoma (children) Retinopathy Vision loss Anti-recoverin, anti-retinal bipolar cell Small cell lung, melanoma Sensorimotor neuropathy Numbness with or without weak- ness; may be mild and chronic or acute and severeHu, MAG Sensory neuronopathy Pain, numbness, sensory ataxia, hearing lossHu Small cell lung Stiff person syndrome Co-contraction of antagonist and agonist musclesAmphiphysin,1GAD65,1GlyR1Small cell lung, breast, thymus, lymphoma1 Can occur in absence of tumor. AChR, acetylcholine receptor; AMPA, alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid; Caspr2, contactin associated prot ein-like 2; CRMP , collapsin response-mediator protein; DPPX, dipeptidyl-peptidase-like protein-6; GABA, gamma-aminobutyric acid; GAD, gl utamic acid decarboxylase; GFAP , glial fibrillary acidic protein; GlyR, glycine receptor; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; KLHL11, kelch-like protein 11; LGI1, leucine rich glioma inactivated; LRP4, low-density lipoprotein receptor-related protein 4; mGluR, metabotropic glutamate receptor; MAG, myelin-associated glycoprotein; MOG, myelin oligodendrocyte glycoprotein; MuSK, Muscle- specific tyrosine kinase; NIF, neuronal intermediate filament; NMDA, N-methyl-D-aspartate; SRP , signal recognition particle; TI F-1, human transcription intermediary factor-1; VGCC, voltage-gated calcium channel.divided tw  t fur times daily) redues frmatin f ere- brspinal fluid. Like aetazlamide, the antiepilepti medi- atin tpiramate (Table 242) is a arbni anhydrase inhibitr and was shwn t be similarly effetive in an pen label study; tpiramate has the added benefit f aus- ing weight lss. Fursemide (2040 mg daily) may be help- ful as adjunt therapy. Crtisterids (eg, prednisne 6080 mg daily) are smetimes presribed, but side effets and the risk f relapse n withdrawal have disuragedtheir use. Obese patients shuld be advised t lse weight. Repeated lumbar punture t lwer the intraranial pres- sure by remval f erebrspinal fluid is effetive as a temprizing measure, but pharmalgi apprahes t treatment prvide better lng-term relief. Treatment is mnitred by heking visual auity and visual fields, fun- duspi appearane, and pressure f the erebrspinal fluid. The disrder may wrsen after a perid f stability, indiating the need fr lng-term fllw-up.CMDT22_Ch24_p0978-p1053.indd  1012 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1013 CMDT 2022If  medial treatment fails t ntrl the intraranial pressure, surgial plaement f a lumbperitneal r ven- triulperitneal shunt r pti nerve sheath fenestratin shuld be undertaken t preserve visin. Venus sinus stenting is an inreasingly aepted therapeuti ptin fr dural venus sinus stensis. In additin t the abve measures, any speifi ause f intraranial hypertensin requires apprpriate treatment. Thus, hrmne therapy shuld be initiated if there is an underlying endrine disturbane. Disntinuing the use f tetrayline, ral ntraeptives, r vitamin A will allw fr reslutin f intraranial hypertensin due t these agents. If rtisterid withdrawal is respnsible, the mediatin shuld be reintrdued and then tapered mre gradually. When to ReferAll patients sh uld be referred. When to AdmitAll  patients with wrsening visin requiring shunt plae- ment r pti nerve sheath fenestratin shuld be hspitalized.Kalyvas  A et al. A systemati review f surgial treatments f idipathi intraranial hypertensin (IIH). Neursurg Rev. 2021;44:773. [PMID: 32335853] Madriz Peralta G et al. An update f idipathi intraranial hypertensin. Curr Opin Ophthalml. 2018;29:495. [PMID: 30169466]SE LECTED NEUROCUTANEOUS DISEASESBeause  the nervus system develps frm the epithelial layer f the embry, a number f ngenital diseases inlude bth neurlgi and utaneus manifestatins. Amng these disrders, three are disussed belw, and vn Hippel-Lindau disease is disussed in Chapter 26.1.  Tuberous SclerosisT uberus slersis may ur spradially r n a familial basis with autsmal dminant inheritane. Neurlgi presentatin is with seizures and prgressive psyhmtr retardatin beginning in early hildhd. The utaneus abnrmality adenma sebaeum bemes manifest usually between 5 and 10 years f age and typially nsists f red- dened ndules n the fae (heeks, naslabial flds, sides f the nse, and hin) and smetimes n the frehead and nek. Other typial utaneus lesins inlude subungual fibrmas, shagreen pathes (leathery plaques f subepider- mal fibrsis, situated usually n the trunk), and leaf-shaped hyppigmented spts. Assiated abnrmalities inlude retinal lesins and tumrs, benign rhabdmymas f the heart, lung ysts, benign tumrs in the visera, and bne ysts. The disease is slwly prgressive and leads t inreasing mental deteriratin. Antinvulsants are indiated t ntrl seizures. Everlimus, a mammalian target frapamyin (mTOR) inhibitr, is apprved in the United States and Eurpe fr medially refratry epilepsy and subepen- dymal giant ell astrytmas due t tuberus slersis.2.  NeurofibromtosisNeur fibrmatsis may ur either spradially r n a familial basis with autsmal dminant inheritane. Tw distint frms are regnized: Type 1 (Recklinghausen disease) is haraterized by multiple hyperpigmented ma- ules, Lish ndules, and neurfibrmas, and results frm mutatins in the NF1 gene n hrmsme 17. Type 2 is haraterized by bilateral eighth nerve tumrs, ften ampanied by ther intraranial r intraspinal tumrs, and is assiated with mutatins in the NF2 (merlin) gene n hrmsme 22. Neurlgi presentatin is usually with symptms and signs f tumr. Multiple neurfibrmas harateristially are present and may invlve spinal r ranial nerves, espe- ially the eighth nerve. Examinatin f the superfiial utaneus nerves usually reveals palpable mbile ndules. In sme ases, there is marked vergrwth f subutaneus tissues (plexifrm neurmas), smetimes with an underly- ing bny abnrmality. Assiated utaneus lesins inlude axillary frekling and pathes f utaneus pigmentatin (caf au lait spots ). Malignant degeneratin f neurfibr- mas asinally urs and may lead t peripheral sar- mas. Meningimas, glimas (espeially pti nerve glimas), bne ysts, phehrmytmas, slisis, and bstrutive hydrephalus may als ur. Selumetinib (25 mg/m2rally twie daily), a mitgen-ativated prtein kinase inhibitr, auses plexifrm neurfibrmas t shrink by at least 20% in tw-thirds f patients and is apprved by the FDA fr treatment f inperable plexifrm neurfibr- mas in hildren 2 years f age and lder. Studies in adults are nging.3.  Sturge-Weber SyndromeSturg e-Weber syndrme nsists f a ngenital, usually unilateral, utaneus apillary angima invlving the upper fae, leptmeningeal angimatsis, and, in many patients, hridal angima. It has n sex prediletin and usually urs spradially. The utaneus angima sme- times has a mre extensive distributin ver the head and nek and is ften quite disfiguring, espeially if there is assiated vergrwth f nnetive tissue. Fal r gener- alized seizures are the usual neurlgi presentatin and may mmene at any age. There may be ntralateral hmnymus hemianpia, hemiparesis and hemisensry disturbane, ipsilateral glauma, and mental subnrmal- ity. Skull radigraphs taken after the first 2 years f life usually reveal gyrifrm (tramline) intraranial alifia- tin, espeially in the pariet-ipital regin, due t min- eral depsitin in the rtex beneath the intraranial angima. Treatment is aimed at ntrlling seizures pharma- lgially (Table 242), but surgial treatment may be ne- essary. Ophthalmlgi advie shuld be sught nerning the management f hridal angima and f inreased intraular pressure.CMDT22_Ch24_p0978-p1053.indd  1013 29/06/21 8:50 PMChapTER 241014 CMDT 2022MO VEMENT DISORDERS 1. Essentil (Fmilil) TremorE S S E N T I A L S  O F  D I A G N O S I S Postural tremor of hands, head, or voice. Family history common. May improve temporarily with alcohol. No abnormal findings other than tremor. General ConsiderationsThe  ause f essential tremr is unertain, but it is sme- times inherited in an autsmal dminant manner. Clinical FindingsT remr may begin at any age and is enhaned by emtinal stress. The tremr usually invlves ne r bth hands, the head, r the hands and head, while the legs tend t be spared. The tremr is nt present at rest, but emerges with atin. Examinatin reveals n ther abnrmalities. Inges- tin f a small quantity f alhl mmnly prvides remarkable but shrt-lived relief by an unknwn mehanism. The tremr typially bemes mre nspiuus with time. Oasinally, it interferes with manual skills and leads t impairment f handwriting. Speeh may als be affeted if the laryngeal musles are invlved. TreatmentT reatment is ften unneessary. When it is required beause f disability, prpranll (60240 mg daily rally) may be helpful. Lng-term therapy is typial; hwever, intermittent therapy is smetimes useful in patients whse tremr bemes exaerbated in speifi preditable situa- tins. Primidne may be helpful when prpranll is inef- fetive, but patients with essential tremr are ften very sensitive t it. Therefre, the starting dse is 50 mg daily rally, and the daily dse is inreased by 50 mg every 2 weeks depending n the patients respnse; a mainte- nane dse f 125 mg three times daily rally is mmnly effetive. Oasinal patients d nt respnd t these mea- sures but are helped by alprazlam (up t 3 mg daily rally in divided dses), tpiramate (titrated up t a dse f 400 mg daily rally in divided dses ver abut 8 weeks), r gabapentin (1800 mg daily rally in divided dses). Btulinum txin A may redue tremr, but adverse effets inlude dse-dependent weakness f the injeted musles. Disabling tremr unrespnsive t medial treatment may be helped by high-frequeny thalami stimulatin (deep brain stimulatin) n ne r bth sides, arding t the laterality f symptms. Fused transranial ultra- sund thalamtmy using MRI guidane is als effetive, as is steretati radisurgery fr unilateral upper extrem- ity tremr.When to Refer When refratry t first-line treatment with prpran- ll r primidne. When additinal neurlgi signs are present (ie, parkinsnism). When to AdmitPa tients requiring surgial treatment (deep brain stimula- tr plaement) shuld be hspitalized.Ha ubenberger D et al. Essential tremr. N Engl J Med. 2018;378: 1802. [PMID: 29742376]2.  prkinson DiseseE S S E N T I A L S  O F  D I A G N O S I S Any combination of tremor, rigidity, bradykinesia, and progressive postural instability (parkinsonism). Cognitive impairment is sometimes prominent. General ConsiderationsPar kinsnism is a relatively mmn disrder that urs in all ethni grups, with an apprximately equal sex distri- butin. The mst mmn variety, idipathi Parkinsn disease, begins mst ften between 45 and 65 years f age and is a prgressive disease. EtiologyPar kinsnism may rarely ur n a familial basis, and the parkinsnian phentype may result frm mutatins f several different genes. Pstenephaliti parkinsnism is beming inreasingly rare. Expsure t ertain txins (eg, manganese dust, arbn disulfide) and severe arbn mn- xide pisning may lead t parkinsnism. Reversible parkinsnism may develp in patients reeiving neurlep- ti mediatins (see Chapter 25), reserpine, r metl- pramide. Only rarely is hemiparkinsnism the presenting feature f a prgressive spae-upying lesin. In idipathi Parkinsn disease, dpamine depletin due t degeneratin f the dpaminergi nigrstriatal sys- tem leads t an imbalane f dpamine and aetylhline, whih are neurtransmitters nrmally present in the r- pus striatum. Treatment f the mtr disturbane is direted at redressing this imbalane by blking the effet f aetylhline with antihlinergi mediatins r by the administratin f levdpa, the preursr f dpamine. Prir use f ibuprfen is assiated with a decreased risk f develping Parkinsn disease; age, family histry, male sex, nging herbiide/pestiide expsure, and signifiant prir head trauma are risk fatrs. Clinical FindingsT remor, rigidity, bradykinesia, and postural instability are the ardinal mtr features f parkinsnism and mayCMDT22_Ch24_p0978-p1053.indd  1014 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1015 CMDT 2022be  present in any mbinatin. Nnmtr manifestatins inlude affetive disrders (depressin, anxiety, and apa- thy), psyhsis, gnitive hanges, fatigue, sleep disrders, ansmia, autnmi disturbanes, sensry mplaints r pain, and sebrrhei dermatitis. Dementia r mild gni- tive impairment will eventually develp in many patients. The tremr f abut fur t six yles per send is most conspicuous at rest , is enhaned by emtinal stress, and is ften less severe during vluntary ativity. Althugh it may ultimately be present in all limbs, the tremr is mmnly nfined t ne limb r t the limbs n ne side fr mnths r years befre it bemes mre generalized. In sme patients, tremr is absent. Rigidity (an inrease in resistane t passive mvement) is respnsible fr the harateristially flexed psture seen in many patients, but the mst disabling symptms f par- kinsnism are due t bradykinesia, manifested as a slwness f vluntary mvement and a redutin in autmati mve- ments suh as swinging f the arms while walking. Curi- usly, hwever, effetive vluntary ativity may briefly be regained during an emergeny (eg, the patient is able t leap aside t avid an nming mtr vehile). Clinial diagnsis f the well-develped syndrme is usually simple. The patient has a relatively immbile fae with widened palpebral fissures, infrequent blinking, and a fixity f faial expressin. Sebrrhea f the salp and fae is mmn. There is ften mild blepharlnus, and a tremr may be present abut the muth and lips. Repetitive tap- ping (abut twie per send) ver the bridge f the nse prdues a sustained blink respnse ( Myerson sign ). Other findings may inlude saliva drling frm the muth, per- haps due t impairment f swallwing; sft and prly mdulated vie; a variable rest tremr and rigidity in sme r all f the limbs; slwness f vluntary mvements; impairment f fine r rapidly alternating mvements; and mirgraphia. There is typially n musle weakness (pr- vided that suffiient time is allwed fr pwer t be devel- ped) and n alteratin in the tendn reflexes r plantar respnses. It is diffiult fr the patient t arise frm a sitting psitin and begin walking. The gait itself is haraterized by small shuffling steps and a lss f the nrmal autmati arm swing; there may be unsteadiness n turning, diffiulty in stpping, and a tendeny t fall. Differential DiagnosisDiagn sti prblems may ur in mild ases, espeially if tremr is minimal r absent. Fr example, mild hypkinesia r slight tremr is mmnly attributed t ld age. Depres- sin, with its assiated expressinless fae, prly mdu- lated vie, and redutin in vluntary ativity, an be diffiult t distinguish frm mild parkinsnism, espeially sine the tw disrders may exist. The family histry, the harater f the tremr, and lak f ther neurlgi signs shuld distinguish essential tremr frm parkinsnism. Wilsn disease an be distinguished by its early age at nset, the presene f ther abnrmal mvements, Kayser- Fleisher rings, and hrni hepatitis, and by inreased nentratins f pper in the tissues. Huntingtn disease presenting with rigidity and bradykinesia may be mistakenfr parkinsnism unless the family histry and ampany- ing dementia are regnized. In multisystem atrphy (pre- viusly alled the Shy-Drager syndrme), autnmi insuffiieny (leading t pstural hyptensin, anhidrsis, disturbanes f sphinter ntrl, eretile dysfuntin, et) may be ampanied by parkinsnism, pyramidal defiits, lwer mtr neurn signs, r erebellar dysfuntin. In prgressive supranulear palsy, bradykinesia and rigidity are ampanied by a supranulear disrder f eye mve- ments, pseudbulbar palsy, pseud-emtinal lability (pseudbulbar affet), and axial dystnia. Creutzfeldt-Jakb disease may be ampanied by features f parkinsnism, but prgressin is rapid, dementia is usual, mylni jerk- ing is mmn, ataxia and pyramidal signs may be n- spiuus, and the MRI and eletrenephalgraphi findings are usually harateristi. In rtibasal degener- atin, asymmetri parkinsnism is ampanied by n- spiuus signs f rtial dysfuntin (eg, apraxia, sensry inattentin, dementia, aphasia). Diffuse Lewy bdy disease is haraterized by prminent visual halluinatins and gnitive impairment that begin befre r within 1 year f nset f the mtr features f parkinsnism. TreatmentT reatment is symptmati. There is great interest in devel- ping disease-mdifying therapies, but trials f several putative neurprtetive agents have shwn n benefit. Tri- als f varius gene therapies have shwn limited r n benefit.A.  Medical MeasuresMe diatin is nt required early in the urse f Parkinsn disease, but the nature f the disrder and the availability f medial treatment fr use when neessary shuld be dis- ussed with the patient. 1. Amantadine Patients with mild symptms but n dis- ability may be helped by amantadine (100 mg rally tw t three times daily [immediate release] r ne daily [extended release]). This mediatin imprves all f the linial features f parkinsnism, but its mde f atin is unlear. Side effets are unmmn but may inlude rest- lessness, nfusin, depressin, skin rashes, edema, nausea, nstipatin, anrexia, pstural hyptensin, and distur- banes f ardia rhythm. It als amelirates dyskinesias resulting frm lng-term levdpa therapy. 2. Levodopa Levdpa, whih is nverted in the bdy t dpamine, imprves all f the majr features f parkinsn- ism, inluding bradykinesia, but does not stop progression f the disrder. The mst mmn early side effets f levdpa are nausea, vmiting, and hyptensin, but ar- dia arrhythmias may als ur. Dyskinesias, restlessness, nfusin, and ther behaviral hanges tend t ur smewhat later and beme mre mmn with time. Levodopa-induced dyskinesias may take any neivable frm, inluding hrea, athetsis, dystnia, tremr, tis, and mylnus. An even later mpliatin is the wearing off effect r the on-off phenomenon, in whih abrupt but transient flutuatins in the severity f parkinsnism urCMDT22_Ch24_p0978-p1053.indd  1015 29/06/21 8:50 PMChapTER 241016 CMDT 2022un preditably but frequently during the day. The off period of marked bradykinesia has been shwn t relate in sme instanes t falling plasma levels f levdpa. During the  onphase , dyskinesias are ften nspiuus but mbility is inreased. Hwever, suh respnse flutuatins may relate t advaning disease rather than t levdpa therapy itself. Carbidpa, whih inhibits the enzyme respnsible fr the breakdwn f levdpa t dpamine, des nt rss the bld-brain barrier. When levdpa is given in mbina- tin with arbidpa, the extraerebral breakdwn f levdpa is diminished. This redues the amunt f levdpa required daily fr benefiial effets, and it lwers the inidene f nausea, vmiting, hyptensin, and ardia irregularities. Suh a mbinatin des nt prevent the develpment f respnse flutuatins and the inidene f ther side effets (dyskinesias r psyhiatri mpliatins) may atually be inreased. Sinemet, a mmerially available preparatin that n- tains arbidpa and levdpa in a fixed rati (1:10 r 1:4), is generally used. Treatment is started with a small dse eg, ne tablet f Sinemet 25/100 (ntaining 25 mg f ar- bidpa and 100 mg f levdpa) three times dailyand gradually inreased depending n the respnse. Sinemet CR is a ntrlled-release frmulatin (ntaining 25 r 50 mg f arbidpa and 100 r 200 mg f levdpa). It is mainly useful when taken at bedtime t lessen mtr dis- ability upn awakening. A frmulatin f arbidpa/ levdpa (Rytary) ntaining bth immediate- and delayed- release beads prvides a smther respnse in patients with flutuatins. The mmerially available mbinatin f levdpa with bth arbidpa and entaapne (Stalev) may als be helpful in this ntext and is disussed in the fllwing setin n COMT inhibitrs. Respnse flutua- tins are als redued by keeping the daily intake f protein at the remmended minimum and taking the main prtein meal as the last meal f the day. A ntinuus infusin f a arbidpa-levdpa enteral suspensin thrugh a peruta- neus gastrjejunstmy tube by a prtable infusin pump redues ff time in patients with advaned Parkinsn disease. Levdpa an als be taken by inhalatin (Inbrija) as a resue mediatin fr patients develping severe akine- sia (ff perids). Benefit urs abut 10 minutes after inhalatin. Side effets inlude ugh, upper respiratry trat infetin, nausea, and dislred sputum. The dyskinesias and behaviral side effets f levdpa are dse-related, but redutin in dse may eliminate any therapeuti benefit. Levdpa-indued dyskinesias may als respnd t amantadine. Levdpa therapy is ntraindiated in patients with psyhti illness r narrw-angle glauma. It shuld nt be given t patients taking mnamine xidase A inhibitrs r within 2 weeks f their withdrawal, beause hypertensive rises may result. Sudden disntinuatin f levdpa an preipitate neurlepti malignant syndrme and shuld be avided. 3. Dopamine agonists Dpamine agnists, suh as pramipexle and rpinirle, at diretly n dpamine reeptrs, and their use in parkinsnism is assiated with a lwer inidene f the respnse flutuatins anddyskinesias that ur with lng-term levdpa therapy. They are effetive in bth early and advaned stages f Par- kinsn disease. They are ften given either befre the intr- dutin f levdpa r with a lw dse f Sinemet 25/100 (arbidpa 25 mg and levdpa 100 mg, ne tablet three times daily) when dpaminergi therapy is first intrdued; the dse f Sinemet is kept nstant, while the dse f the agnist is gradually inreased. Pramipexle is started at a dsage f 0.125 mg three times daily rally, and the dse is built up gradually t between 0.5 and 1.5 mg three times daily. Rpinirle is begun at 0.25 mg three times daily rally and gradually inreased; mst patients require between 2 and 8 mg three times daily fr benefit. Extended-release, ne-daily frmu- latins f pramipexle and rpinirle have similar effiay and tlerability as the immediate release versins. Rtig- tine is a dpamine agnist absrbed transdermally frm a skin path; it is started at 2 mg ne daily and inreased weekly by 2 mg daily until ahieving an ptimal respnse, up t a maximum f 8 mg daily. Adverse effets f these varius agnists inlude fatigue, smnlene, nausea, peripheral edema, dyskinesias, nfusin, and pstural hyptensin. Less mmnly, an irresistible urge t sleep may ur, smetimes in inapprpriate and hazardus ir- umstanes. Impulse ntrl disrders invlving gambling, shpping, r sexual ativity als ur. Lal skin reatins may ur with the rtigtine path. The dopamine ago- nist withdrawal syndrome develps asinally in patients in whm a dpamine agnist is tapered. It nsists f a mbinatin f distressing physial and psyhlgial symptms that are refratry t levdpa and ther dpa- minergi mediatins and may persist fr mnths r lnger. There is n effetive treatment. The dpamine agnist shuld be reintrdued and tapered mre gradually if pssible. 4. Selective monoamine oxidase inhibitors Rasagiline, a seletive mnamine xidase B inhibitr, has a lear symp- tmati benefit in sme patients at a daily ral dse f 1 mg, taken in the mrning; it may als be used fr adjuntive therapy in patients with respnse flutuatins t levdpa. Selegiline (5 mg rally with breakfast and lunh) and safin- amide (50 mg rally daily, inreased t 100 mg daily after 14 days) are als apprved as adjuntive treatments. By inhibiting the metabli breakdwn f dpamine, these mediatins may imprve flutuatins r delining respnse t levdpa. Studies have suggested (but failed t shw nlusively) that rasagiline may slw the prgressin f Parkinsn dis- ease, and it appears t delay the need fr ther symptmati therapies. Fr these reasns, rasagiline is ften started early, partiularly fr patients wh are yung r have mild dis- ease. Hwever, the FDA has rejeted an expansin f rasa- gilines indiatin t inlude disease mdifiatin. 5. COMT inhibitors Catehlamine- O-methyltransferase (COMT) inhibitrs redue the metablism f levdpa t 3-O-methyldpa and thereby alter the plasma pharmaki- netis f levdpa, leading t mre sustained plasma levels and mre nstant dpaminergi stimulatin f the brain. Treatment with entaapne r tlapne results in reduedCMDT22_Ch24_p0978-p1053.indd  1016 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1017 CMDT 2022res pnse flutuatins, with a greater perid f respnsive- ness t administered levdpa. Tlapne is given in a dsage f 100 mg r 200 mg three times daily rally, and entaapne is given as 200 mg with eah dse f Sinemet. Opiapne, a lng-ating, peripherally seletive COMT inhibitr, is taken ne daily (50 mg) at bedtime at least 1 hur befre and after eating. The dse f Sinemet taken nurrently may have t be redued by up t ne-third t avid side effets. Diarrhea is smetimes trublesme. Beause rare ases f fulminant hepati failure have fl- lwed its use, tlapne shuld be avided in patients with preexisting liver disease. Serial liver bihemial tests shuld be perfrmed at 2-week intervals fr the first year and at lnger intervals thereafter in patients reeiving the mediatinas remmended by the manufaturer. Seri- us hepattxiity has nt been reprted with entaapne r piapne. Stalev is the mmerial preparatin f levdpa m- bined with bth arbidpa and entaapne. It is best used in patients already stabilized n equivalent dses f arbi- dpa/levdpa and entaapne. It is pried at r belw the prie f the individual ingredients (ie, arbidpa/levdpa and entaapne) and has the added nveniene f requir- ing fewer tablets t be taken daily. It is available in three strengths: Stalev 50 (12.5 mg f arbidpa, 50 mg f levdpa, and 200 mg f entaapne), Stalev 100 (25 mg f arbidpa, 100 mg f levdpa, and 200 mg f entaa- pne), and Stalev 150 (37.5 mg f arbidpa, 150 mg f levdpa, and 200 mg f entaapne). 6. Istradefylline This adensine A2Areeptr antagnist (2040 mg rally ne daily) is given t patients taking levdpa r a dpamine agnist t redue ff time; ttal ff time is typially redued by less than 1 hur per day. 7. Anticholinergic medications Antihlinergis are mre helpful in alleviating tremr and rigidity than brady- kinesia. Trihexyphenidyl and benztrpine are mmnly used frmulatins. Treatment is started with a small dse and gradually inreased until benefit urs r side effets limit further inrements. If treatment is ineffetive, the mediatin is gradually withdrawn and anther prepara- tin then tried. Hwever, these mediatins are ften prly tlerated, espeially in lder adults. Side effets limit the rutine use f these mediatins, and inlude dryness f the muth, nausea, nstipatin, palpitatins, ardia arrhythmias, urinary retentin, n- fusin, agitatin, restlessness, drwsiness, mydriasis, inreased intraular pressure, and defetive ammda- tin. Antihlinergi mediatins are ntraindiated in patients with prstati hyperplasia, narrw-angle glau- ma, r bstrutive gastrintestinal disease and are ften tlerated prly by the elderly. They are best avided whenever gnitive impairment r a predispsitin t delirium exists. 8. Antipsychotics Cnfusin and psyhti symptms may ur as a side effet f dpaminergi therapy r as a part f the underlying illness. Pimavanserin (34 mg ne daily), a sertnin(2A) agnist, is apprved by the FDA speifially fr treating the psyhsis f Parkinsn disease. This may als respnd t the atypial antipsyhti agentslzapine and quetiapine, whih have few extrapyramidal side effets and d nt blk the effets f dpaminergi mediatin. Clzapine may rarely ause marrw suppres- sin, and weekly bld unts are therefre neessary fr patients taking it. The patient is started n 6.25 mg at bedtime and the dsage inreased t 25100 mg/day as needed. In lw dses, it may als imprve iatrgeni dyskinesias. Typical antipsychotic agents and the second- generation antipsychotic agents risperidone and olanzapine may cause worsening of motor symptoms and should be avoided .B.  General MeasuresPhysial  therapy r speeh therapy helps many patients. Cgnitive impairment and psyhiatri symptms may be helped by a hlinesterase inhibitr, suh as rivastigmine (312 mg rally daily r 4.6 r 9.5 mg/24 hurs transder- mally daily). The quality f life an ften be imprved by the prvisin f simple aids t daily living, eg, rails r ban- isters plaed strategially abut the hme, speial table utlery with large handles, nnslip rubber table mats, and devies t amplify the vie.C.  Stimulation and Ablative TreatmentsHigh-frequeny  stimulatin f the subthalami nulei r glbus pallidus internus may benefit many f the mtr features f the disease but des nt affet its natural histry. Eletrial stimulatin f the brain has the advantage ver ablative thalamtmy and pallidtmy predures f being reversible and f ausing minimal r n damage t the brain, and is therefre the preferred surgial apprah t treatment. It is reserved fr patients withut gnitive impairment r psyhiatri disrder wh have a gd respnse t levdpa, but in whm dyskinesias r respnse flutuatins are prblemati. It frequently takes 36 mnths after surgery t adjust stimulatr prgramming and t ahieve ptimal results. Side effets inlude depressin, apathy, impulsivity, exeutive dysfuntin, and dereased verbal flueny in a subset f patients. Fused ultrasund thalamtmy r steretati radisurgery may help patients with medially refratry tremr-predminant parkinsnism wh are relutant t underg surgery.D . Gene TherapyIn jetins f aden-assiated viruses ending varius human genes have been made int the subthalami nuleus r putamen in varius linial trials. These apprahes may be useful in the future but remain experimental. When to ReferAll patients sh uld be referred. When to AdmitPa tients requiring surgial treatment shuld be admitted.Mith ell KT et al. Surgial treatment f Parkinsn disease. Neu- rl Clin. 2020;38:293. [PMID: 32279711]CMDT22_Ch24_p0978-p1053.indd  1017 29/06/21 8:50 PMChapTER 241018 CMDT 2022Rugha ni A et al. Cngress f Neurlgial Surgens systemati review and evidene-based guideline n subthalami nuleus and glbus pallidus internus deep brain stimulatin fr the treatment f patients with Parkinsns disease: exeutive sum- mary. Neursurgery. 2018;82:753. [PMID: 29538685]3.  huntington DiseseE S S E N T I A L S  O F  D I A G N O S I S Gradual onset and progression of chorea and dementia or behavioral change. Family history of the disorder. Responsible gene identified on chromosome 4. General ConsiderationsHunt ingtn disease is haraterized by chorea and dementia. It is inherited in an autsmal dminant manner and urs thrughut the wrld, in all ethni grups, with a prevalene rate f abut 5 per 100,000. There is an expanded and unstable CAG trinuletide repeat in the huntingtin gene at 4p16.3; lnger repeat lengths rre- spnd t an earlier age f nset and faster disease prgressin. Clinical FindingsA.  Symptoms and SignsClinial  nset is usually between 30 and 50 years f age. The disease is prgressive and usually leads t a fatal ut- me within 1520 years. The initial symptms may n- sist f either abnrmal mvements r intelletual hanges, but ultimately bth ur. The earliest mental hanges are ften behaviral, with irritability, mdiness, antisial behavir, r a psyhiatri disturbane, but a mre bvius dementia subsequently develps. The dyskinesia may ini- tially be n mre than an apparent fidgetiness r restless- ness, but eventually hreifrm mvements and sme dystni psturing ur. A parkinsnian syndrme with prgressive rigidity and akinesia (rather than hrea) smetimes urs in assiatin with dementia, espeially in ases with hildhd nset. The diagnsis is established with a widely available geneti test, althugh suh testing shuld be pursued under the guidane f a liensed geneti unselr.B.  ImagingCT  sanning r MRI usually demnstrates erebral atrphy and atrphy f the audate nuleus in established ases. Psitrn emissin tmgraphy (PET) has shwn redued striatal metabli rate. Differential DiagnosisChre a develping with n family histry f hreathetsis shuld nt be attributed t Huntingtn disease, at least nt until ther auses f hrea have been exluded liniallyand by apprpriate labratry studies. Nngeneti auses f hrea inlude strke, systemi lupus erythematsus and antiphsphlipid antibdy syndrme, paraneplasti syn- drmes, infetin with HIV , and varius mediatins. In yunger patients, self-limiting Sydenham hrea develps after grup A streptal infetins n rare asins. If a patient presents slely with prgressive intelletual fail- ure, it may nt be pssible t distinguish Huntingtn dis- ease frm ther auses f dementia unless there is a harateristi family histry r a dyskinesia develps. Huntington diseaselike (HDL) disorders resemble Huntingtn disease but are aused by ther geneti muta- tins. A linially similar autsmal dminant disrder (dentatorubral-pallidoluysian atrophy), manifested by hrea, dementia, ataxia, and mylni epilepsy, is unmmn exept in persns f Japanese anestry. Treat- ment is as fr Huntingtn disease. TreatmentThere  is n ure fr Huntingtn disease; prgressin an- nt be halted; and treatment is purely symptmati, althugh studies f antisense lignuletides inhibiting prdutin f mutant huntingtin prtein are nging. The reprted bihemial hanges suggest a relative undera- tivity f neurns ntaining GABA and aetylhline r a relative verativity f dpaminergi neurns. Tetrabena- zine, a mediatin that interferes with the vesiular strage f bigeni amines, is widely used t treat the dyskinesia. The starting dse is 12.5 mg twie r three times daily rally, inreasing by 12.5 mg every 5 days depending n respnse and tlerane; the usual maintenane dse is 25 mg three times daily. Side effets inlude depressin, pstural hyptensin, drwsiness, and parkinsnian fea- tures; tetrabenazine shuld nt be given within 14 days f taking mnamine xidase inhibitrs and is nt indiated fr the treatment f levdpa-indued dyskinesias. Reser- pine is similar in depleting entral mnamines but has mre peripheral effets and a wrse side-effet prfile, making its use prblemati in Huntingtn disease; if utilized, the dse is built up gradually t between 2 mg and 5 mg rally daily, depending n the respnse. Deutetrabenazine is als effetive in reduing hrea in Huntingtn disease and may have fewer side effets than tetrabenazine but diret mparisns are laking. The starting dse is 6 mg ne daily rally, inreased t 6 mg twie daily after 1 week and by 6-mg inrements weekly thereafter, t a maximum f 24 mg twie daily. Treatment with mediatins blking dpamine reeptrs, suh as phenthiazines r halperidl, may ntrl the dyskinesia and any behaviral distur- banes. Halperidl treatment is usually begun with a dse f 1 mg ne r twie daily rally, whih is then inreased every 3 r 4 days depending n the respnse; alternatively, atypial antipsyhti agents suh as quetiapine (inreasing frm 25 mg daily rally up t 100 mg twie daily rally as tlerated) may be tried. Amantadine in a dse f 200 mg t 400 mg daily rally is smetimes helpful fr hrea. Deep brain stimulatin has been used suessfully t treat hrea in a small number f patients. Behaviral disturbanes may respnd t lzapine. Attempts t mpensate fr the rela- tive GABA defiieny by enhaning entral GABA ativityCMDT22_Ch24_p0978-p1053.indd  1018 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1019 CMDT 2022r t mpensat e fr the relative hlinergi underativity by giving hline hlride have nt been therapeutially helpful. Offspring shuld be ffered geneti unseling. Geneti testing permits presymptmati detetin and definitive diagnsis f the disease. When to ReferAll patients sh uld be referred.T abrizi SJ et al; Phase 12a IONIS-HTTRx Study Site Teams. Targeting huntingtin expressin in patients with Huntingtns disease. N Engl J Med. 2019;380:2307. [PMID: 31059641]4.  Idiotic Torsion DystoniE S S E N T I A L S  O F  D I A G N O S I S Dystonic movements and postures. Normal birth and developmental history. No other neurologic signs. Investigations (including CT scan or MRI) reveal no cause of dystonia. General ConsiderationsIdi pathi trsin dystnia may ur spradially r n a hereditary basis, with autsmal dminant, autsmal reessive, and X-linked reessive mdes f transmissin. Symptms may begin in hildhd r later and persist thrughut life. Clinical FindingsThe  disrder is haraterized by the nset f abnrmal mvements and pstures in a patient with a nrmal birth and develpmental histry, n relevant past medial ill- ness, and n ther neurlgi signs. Investigatins (inlud- ing CT san) reveal n ause fr the abnrmal mvements. Dystni mvements f the head and nek may take the frm f trtillis, blepharspasm, faial grimaing, r fred pening r lsing f the muth. The limbs may als adpt abnrmal but harateristi pstures. The age at nset influenes bth the linial findings and the prgn- sis. With nset in hildhd, there is usually a family his- try f the disrder, symptms mmnly mmene in the legs, and prgressin is likely until there is severe dis- ability frm generalized dystnia. In ntrast, when nset is later, a psitive family histry is unlikely, initial symp- tms are ften in the arms r axial strutures, and severe disability des nt usually ur, althugh generalized dystnia may ultimately develp in sme patients. If all ases are nsidered tgether, abut ne-third f patients eventually beme s severely disabled that they are n- fined t hair r bed, while anther ne-third are affeted nly mildly.Differential DiagnosisPe rinatal anxia, birth trauma, and kerniterus are m- mn auses f dystnia, but abnrmal mvements usually then develp befre the age f 5, the early develpment f the patient is usually abnrmal, and a histry f seizures is nt unusual. Mrever, examinatin may reveal signs f mental retardatin r pyramidal defiit in additin t the mvement disrder. Dystni psturing may als ur in Wilsn disease, Huntingtn disease, r parkinsnism; as a sequela f enephalitis lethargia r previus neurlepti mediatin therapy; and in ertain ther disrders. In these ases, diagnsis is based n the histry and ampa- nying linial manifestatins. TreatmentIdi pathi trsin dystnia usually respnds prly t mediatins. A distint variety f dminantly inherited dys- tnia is remarkably respnsive t levdpa; therefre, a levdpa trial is warranted in all patients. Failing this, diaze- pam, balfen, arbamazepine, amantadine, r antihliner- gi mediatin suh as trihexyphenidyl r benztrpine (in high dsage) is asinally helpful; if nt, a trial f treatment with tetrabenazine, phenthiazines, r halperidl may be wrthwhile. In eah ase, the dse has t be individualized, depending n respnse and tlerane. Hwever, the dses f these latter mediatins that are required fr benefit lead usually t mild parkinsnism. Pallidal deep brain stimulatin is helpful fr disabling generalized dystnia and has a lwer mrbidity than steretati thalamtmy, whih is sme- times helpful in patients with predminantly unilateral limb dystnia. Ptential adverse events f deep brain stimulatin inlude erebral infetin r hemrrhage, brken leads, affetive hanges, and dysarthria. When to ReferAll patients sh uld be referred. When to AdmitPa tients requiring surgial treatment shuld be admitted.R drigues FB et al. Deep brain stimulatin fr dystnia. Chrane Database Syst Rev. 2019;1:CD012405. [PMID: 30629283]5.  Focl Torsion DystoniA  number f the dystni manifestatins that ur in idipathi trsin dystnia may als ur as islated phe- nmena. They are best regarded as fal dystnias that either ur as frmes frustes f idipathi trsin dyst- nia in patients with a psitive family histry r represent a fal manifestatin f the adult-nset frm f that disrder when there is n family histry. Medial treatment is gen- erally unsatisfatry. A trial f the mediatins used in idipathi trsin dystnia is wrthwhile, hwever, sine a few patients d shw sme respnse. In additin, with restrited dystnias suh as blepharspasm r trtillis, lal injetin f btulinum A txin int the verativeCMDT22_Ch24_p0978-p1053.indd  1019 29/06/21 8:50 PMChapTER 241020 CMDT 2022musles  may prdue wrthwhile benefit fr several weeks r mnths and an be repeated as needed. Bth blepharospasm and oromandibular dystonia may ur as an islated fal dystnia. The frmer is har- aterized by spntaneus invluntary fred lsure f the eyelids fr a variable interval. Ormandibular dystnia is manifested by invluntary ntratin f the musles abut the muth ausing, fr example, invluntary pen- ing r lsing f the muth, rving r prtruding tngue mvements, and retratin f the platysma. Cervical dys- tonia (spasmdi trtillis), usually with nset between 25 and 50 years f age, is haraterized by a tendeny fr the nek t twist t ne side. This initially urs episdi- ally, but eventually the nek is held t the side. Sme patients have a sensry trik (geste antagniste) that lessens the dystni psture, eg, tuhing the side f the fae. Spntaneus reslutin may ur in the first year r s. The disrder is therwise usually lifelng. Lal inje- tin f btulinum A txin prvides benefit in mst ases. Deep brain stimulatin f the glbus pallidus interna is an ptin if medial treatment and btulinum txin injetin are unsuessful. Writers cramp is haraterized by dystni psturing f the hand and frearm when the hand is used fr writing and smetimes when it is used fr ther tasks, eg, playing the pian r using a srewdriver r eating utensils. Media- tin treatment is usually unrewarding, and patients are ften best advised t learn t use the ther hand fr ativi- ties requiring manual dexterity. Injetins f btulinum A txin are helpful in sme instanes.Rdrigues FB  et al. Btulinum txin type A therapy fr ervial dystnia. Chrane Database Syst Rev. 2020;11:CD003633. [PMID: 33180963]6.  MyoclonusOasi nal mylni jerks may ur in anyne, espeially when drifting int sleep. General or multifocal myoclonus is mmn in patients with idipathi epilepsy and is espe- ially prminent in ertain hereditary disrders harater- ized by seizures and prgressive intelletual deline, suh as the lipid strage diseases. It is als a feature f subaute slersing panenephalitis and Creutzfeldt-Jakb disease. Generalized mylni jerking may ampany uremi and ther metabli enephalpathies, result frm therapy with levdpa r triyli antidepressants, ur in alhl r drug withdrawal states, r fllw anxi brain damage. It als urs n a hereditary r spradi basis as an islated phenmenn in therwise healthy subjets. Segmental myoclonus is a rare manifestatin f a fal spinal rd lesin. It may als be the linial expressin f epilepsia partialis continua , a disrder in whih a repeti- tive fal epilepti disharge arises in the ntralateral sensrimtr rtex, smetimes frm an underlying stru- tural lesin. An eletrenephalgram is ften helpful in larifying the epilepti nature f the disrder, and CT r MRI san may reveal the ausal lesin. Mylnus may respnd t ertain antinvulsant mediatins, espeially valpri aid r levetiraetam, r tne f the benzdiazepines, partiularly lnazepam (see Table 242). It may als respnd t piraetam (up t 16.8 g daily; nt available in the United States). Mylnus fl- lwing anxi brain damage is ften respnsive t xitrip- tan (5-hydrxytryptphan), the preursr f sertnin, and smetimes t lnazepam. Oxitriptan is given in gradually inreasing dses up t 11.5 mg daily. In patients with segmental mylnus, a lalized lesin shuld be searhed fr and treated apprpriately.7.  Wilson DiseseIn th is metabli disrder, abnrmal mvement and ps- ture may ur with r withut existing signs f liver invlvement. Psyhiatri and neurpsyhlgial mani- festatins are mmn. Wilsn disease is disussed in Chapter 16.8.  Drug-Induced abnorml MovementsPhent hiazines, butyrphennes, and metlpramide may prdue a wide variety f abnrmal mvements, inluding parkinsnism, akathisia (ie, mtr restlessness), aute dystnia, hrea, and tardive dyskinesias r dystnia; several f these are als prdued by aripiprazle. These mpliatins are disussed in Chapter 25. Chrea may als develp in patients reeiving levdpa, brmriptine, antihlinergi mediatins, phenytin, arbamazepine, lithium, amphetamines, r ral ntraeptives, and it reslves with withdrawal f the ffending substane. Simi- larly, dystnia may be prdued by levdpa, brmrip- tine, lithium, r arbamazepine; and parkinsnism by reserpine and tetrabenazine. Pstural tremr may ur with a variety f mediatins, inluding epinephrine, is- prterenl, amidarne, thephylline, affeine, lithium, thyrid hrmne, triyli antidepressants, and valpri aid.9.  Restless Legs SyndromeThis  mmn disrder, affeting 15% f peple, may ur as a primary (idipathi) disrder r in relatin t Parkinsn disease, pregnany, irn defiieny anemia, r peripheral neurpathy (espeially uremi r diabeti). It may have a hereditary basis, and several geneti li have been assiated with the disrder. Restlessness and urius sensry disturbanes lead t an irresistible urge t mve the limbs, espeially during perids f relaxatin; mve- ment f the limbs prvides relief. The urge urs exlu- sively in the evening and at night r is wrse at night than during the day. Mst patients als have periodic limb movements of sleep and ne-third have peridi limb mvements during relaxed wakefulness; bth nsist f brief invluntary flexin at the ankle, knee, and hip. Dis- turbed nturnal sleep and exessive daytime smnlene may result. Ferritin levels shuld always be measured; treatment with ral irn sulfate in patients with ferritin levels less than r equal t 75 mg/L (13.4 mml/L) shuld be attempted prir t initiatin f ther pharma- therapies. Therapy is with nnergt dpamine agnists, suh as pramipexle (0.1250.5 mg rally ne daily),CMDT22_Ch24_p0978-p1053.indd  1020 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1021 CMDT 2022rp inirle (0.254 mg rally ne daily 2 t 3 hurs befre bedtime), r rtigtine (13 mg/24 h transdermal path ne daily), r with gabapentin enaarbil (3001200 mg rally eah evening). Gabapentin (starting with 300 mg rally daily, inreasing t apprximately 1800 mg daily depending n respnse and tlerane) and pregabalin (150300 mg rally divided twie t three times daily) are related mediatins that imprve symptms. Levdpa is helpful but may lead t an augmentatin f symptms, s its use is generally reserved fr thse wh d nt respnd t ther measures. Extended-release xydne-nalxne (2.55 mg t 510 mg rally twie daily) is useful in patients with severe symptms r thse wh are refratry t first-line therapies.Win kelmann J et al. Treatment f restless legs syndrme: evidene-based review and impliatins fr linial pratie. Mv Disrd. 2018;33:1077. [PMID: 29756335]10.  Gilles De L Tourette SyndromeE S S E N T I A L S  O F  D I A G N O S I S Multiple motor and phonic tics. Symptoms begin before age 18 years. Tics occur frequently for at least 1 year. Tics vary in number, frequency, and nature over time. Clinical FindingsSimple  tis ur transiently in up t 25% f hildren, remit within weeks t mnths, and d nt require treat- ment. Turette syndrme is a mre mplex disrder. Motor tics are the initial manifestatin in 80% f ases and mst mmnly invlve the fae, whereas in the remaining 20%, the initial symptms are phonic tics; ulti- mately a mbinatin f different mtr and phni tis develp in all patients. Tis are preeded by an urge that is relieved upn perfrmane f the mvement r valiza- tin; they an be temprarily suppressed but eventually the urge bemes verwhelming. These are nted first in hildhd, generally between the ages f 2 and 15. Mtr tis ur espeially abut the fae, head, and shulders (eg, sniffing, blinking, frwning, shulder shrugging, head thrusting, et). Phni tis mmnly nsist f grunts, barks, hisses, thrat-learing, ughs, et, but smetimes als f verbal utteranes inluding prlalia (bsene speeh). There may als be ehlalia (repetitin f the speeh f thers), ehpraxia (imitatin f thers mve- ments), and palilalia (repetitin f wrds r phrases). Sme tis may be self-mutilating in nature, suh as nail- biting, hair-pulling, r biting f the lips r tngue. The disrder is hrni, but the urse may be puntuated by relapses and remissins. Obsessive-mpulsive disrder (OCD) and attentin defiit hyperativity disrder (ADHD) are mmnly assiated and may be mre dis-abling than the tis themselves. A family histry is sme- times btained. Examinatin usually reveals n abnrmalities ther than the tis. In additin t OCD, psyhiatri disturbanes may ur beause f the assiated smeti and sial embarrassment. The diagnsis f the disrder is ften delayed fr years, the tis being interpreted as psyhiatri illness r sme ther frm f abnrmal mvement. Patients are thus ften subjeted t unneessary treatment befre the disrder is regnized. The ti-like harater f the abnrmal mvements and the absene f ther neurlgi signs shuld differentiate this disrder frm ther mve- ment disrders presenting in hildhd. Wilsn disease, hwever, an simulate the nditin and shuld be exluded. TreatmentT reatment is symptmati and may need t be ntinued indefinitely. Habit reversal training r ther frms f behaviral therapy an be effetive alne r in mbinatin with pharmatherapy. Alpha-adrenergi agnists, suh as lnidine (start 0.05 mg rally at bedtime, titrating t 0.30.4 mg rally daily, divided three t fur times per day) r guanfaine (start 0.5 mg rally at bedtime, titrating t a maximum f 34 mg rally daily, divided twie daily), are first-line therapies beause f a favrable side-effet prfile mpared with typial antipsyhtis, whih are the nly FDA-apprved therapies fr the disrder. They als have the advantage f imprving the symptms f nmitant ADHD. Many speialists favr the use f tetrabenazine. The atypial antipsyhti risperidne (16 mg daily rally) is mre effetive than plaeb in ntrlling tis and mre effetive than pimzide in imprving symptms f mrbid OCD and may be tried befre the typial anti- psyhti agents. When a typial antipsyhti is required in ases f severe tis, halperidl is generally regarded as the mediatin f hie. It is started in a lw dse (0.25 mg daily rally) that is gradually inreased (by 0.25 mg every 4 r 5 days) until there is maximum benefit with a minimum f side effets r until side effets limit further inrements. A ttal daily ral dse f between 2 mg and 8 mg is usually ptimal, but higher dses are sme- times neessary. Fluphenazine (115 mg rally daily) and pimzide (110 mg rally daily) are alternatives. Typial antipsyhtis an ause signifiant weight gain and arry a risk f tardive dyskinesias and ther lng-term, ptentially irreversible mtr side effets. Small ran- dmized trials r bservatinal studies have reprted benefit frm tpiramate, nitine, tetrahydrannabinl, balfen, and lnazepam. A number f ther media- tins, inluding deutetrabenazine, valbenazine, and e- pipam, are being studied fr the treatment f tis. Injetin f btulinum txin type A at the site f the mst distressing tis is smetimes wrthwhile and has fewer side effets than systemi antipsyhti therapy. Bilateral high-frequeny deep brain stimulatin at varius sites has been helpful in sme, therwise intratable, ases. When to ReferAll patients sh uld be referred.CMDT22_Ch24_p0978-p1053.indd  1021 29/06/21 8:50 PMChapTER 241022 CMDT 2022 When to AdmitPatients  underging surgial (deep brain stimulatin) treatment shuld be admitted.M artinez-Ramirez D et al. Effiay and safety f deep brain stimu- latin in Turette syndrme: the Internatinal Turette Syn- drme Deep Brain Stimulatin Publi Database and Registry. JAMA Neurl. 2018;75:353. [PMID: 29340590] Pringsheim T et al. Pratie guideline remmendatins summary: treatment f tis in peple with Turette syndrme and hrni ti disrders. Neurlgy. 2019;92:896. [PMID: 31061208]DE MENTIAE S S E N T I A L S  O F  D I A G N O S I S Progressive intellectual decline. Not due to delirium or psychiatric disease. Age is the main risk factor, followed by family his- tory and vascular disease risk factors.General ConsiderationsDementia  is a prgressive deline in intelletual funtin that is severe enugh t mprmise sial r upatinal funtining. Mild cognitive impairment desribes a deline that has notresulted in a hange in the level f funtin. Althugh a few patients identify a preipitating event, mst experiene an insidius nset and gradual prgressin f symptms. Dementia typially begins after age 60, and the preva- lene dubles apprximately every 5 years thereafter; in persns aged 85 and lder, arund half have dementia. The prevalene f Alzheimer dementia is predited t be 15 millin by 2060 in the United States. In mst ases, the ause f dementia is aquired, either as a spradi primary neurdegenerative disease r as the result f anther disr- der, suh as strke (Table 246). Other risk fatrs fr dementia inlude family histry, diabetes mellitus, iga- rette smking, hypertensin, besity, a histry f signifi- ant head injury, and hearing lss. Vitamin D defiieny and hrni sleep deprivatin may als inrease the risk f dementia. Dementia is mre prevalent amng wmen, but this may be aunted fr by their lnger life expetany. Table 246. Common causes of age-related dementia (listed by prevalence).Disorder ptology Clinicl Fetures Alzheimer disease Plaques containing beta-amyloid pep- tide, and neurofibrillary tangles con- taining tau protein, occur throughout the neocortex. Most common age-related neurodegenerative disease; incidence doubles every 5 years after age 60.  Short-term memory impairment is early and prominent in most cases.  Variable deficits of executive function, visuospatial function, and language. Vascular dementia Multifocal ischemic change.  Stepwise or progressive accumulation of cognitive deficits in association with repeated strokes.  Symptoms depend on localization of strokes. Dementia with Lewy bodiesHistologically indistinguishable from Parkinson disease: alpha-synuclein- containing Lewy bodies occur in the brainstem, midbrain, olfactory bulb, and neocortex. Alzheimer pathology may coexist. Cognitive dysfunction, with prominent visuospatial and executive deficits.  Psychiatric disturbance, with anxiety, visual hallucinations, and fluctuating delirium.  Parkinsonian motor deficits with or after other features.  Cholinesterase inhibitors lessen delirium; poor tolerance of neuroleptics and dopaminergics. Frontotemporal dementia (FTD)Neuropathology is variable and defined by the protein found in intraneuronal aggregates. Tau protein, TAR DNA- binding protein 43 (TDP-43), or fused-in-sarcoma (FUS) protein account for most cases. Peak incidence in the sixth decade; approximately equal to Alzheimer disease as a cause of dementia in patients under 60 years old.  Familial cases result from mutations in genes for tau, progranulin, or others. Beviorl vrint FTD  Deficits in empathy, social comportment, insight, abstract thought, and executive function.  Behavior is disinhibited, impulsive, and ritualistic, with prominent apathy and increased interest in sex or sweet/fatty foods.  Relative preservation of memory.  Focal right frontal atrophy.  Association with amyotrophic lateral sclerosis. Semntic vrint rimry rogressive si  Deficits in word-finding, single-word comprehension, object and category knowledge, and face recognition.  Behaviors may be similar to behavioral variant FTD.  Focal, asymmetric temporal pole atrophy. Nonfluent/grmmtic vrint rimry rogressive si  Speech is effortful with dysarthria, phonemic errors, sound distortions, and poor grammar.  Focal extrapyramidal signs and apraxia of the right arm and leg are common; overlaps with corticobasal degeneration.  Focal left frontal atrophy.CMDT22_Ch24_p0978-p1053.indd  1022 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1023 CMDT 2022Ph ysial ativity seems t be prtetive; eduatin, nging intelletual stimulatin, and sial engagement may als be prtetive, perhaps by prmting cognitive reserve, an imprved apaity t mpensate fr insidius neurdegeneratin. Dementia is distint frm delirium and psyhiatri dis- ease. Delirium is an aute nfusinal state that ften urs in respnse t an identifiable trigger, suh as drug r alhl intxiatin r withdrawal (eg, Wernike enepha- lpathy, desribed belw), mediatin side effets (espe- ially mediatins with antihlinergi prperties, antihistamines, benzdiazepines, sleeping aids, piids, neurleptis, rtisterids, and ther sedative r psyh- trpi agents), infetin (nsider ult urinary trat infetin r pneumnia in elderly patients), metabli dis- turbane (inluding an eletrlyte abnrmality; hypglye- mia r hyperglyemia; r a nutritinal, endrine, renal, r hepati disrder), sleep deprivatin, r ther neurlgi disease (seizure, inluding a pstital state, r strke). Delirium typially invlves fluctuating levels f arusal, inluding drwsiness r agitatin, and it imprves after remval r treatment f the preipitating fatr. Patients with dementia are espeially suseptible t episdes f delirium, but regnitin f dementia is nt pssible until delirium lifts. Fr this reasn, dementia is typially diag- nsed in utpatients wh are therwise medially stable, rather than in autely ill patients in the hspital. Psyhiatri disease smetimes leads t mplaints f impaired gnitin ( pseudodementia ). Impaired attentin is usually t blame, and in sme patients with depressin r anxiety, pr fus and nentratin may even be a pri- mary mplaint. The symptms shuld imprve with appr- priate psyhiatri treatment. Md disrders are mmnly seen in patients with neurdegenerative disease and in sme ases are an early symptm. There is sme evidene that a persistent, untreated md disrder may predispse t the develpment f an age-related dementia, and psyhiatri symptms an learly exaerbate gnitive impairment in patients wh already have dementia; therefre, suspiin f dementia shuld nt distrat frm apprpriate sreening fr and treatment f depressin r anxiety. Clinical FindingsA.  Symptoms and SignsSym ptms and signs f the mmn auses f dementia are detailed in Table 246. Cliniians shuld be aware that a patients insight int a gnitive hange may be vague r absent, and llateral histry is essential t a prper evalua- tin. As patients age, primary are liniians shuld inquire peridially abut the presene f any gnitive symptms. Symptms depend n the area f the brain affeted. Short-term memory loss , invlving the repeating f ques- tins r stries and a diminished ability t reall the details f reent nversatins r events, frequently results frm pathlgi hanges in the hippampus. Word-finding dif- ficulty ften invlves diffiulty realling the names f pe- ple, plaes, r bjets, with lw-frequeny wrds affeted first, eventually resulting in speeh laden with prnuns and irumlutins. This prblem is thught t arise frmpathlgy at the temprparietal juntin f the left hemi- sphere. Prblems with artiulatin, flueny, mprehensin, r wrd meaning are anatmially distint and less m- mn. Visuospatial dysfunction may result in pr naviga- tin and getting lst in familiar plaes, impaired regnitin f previusly familiar faes and buildings, r truble dis- erning an bjet against a bakgrund. The right parietal lbe is ne f the brain areas impliated in suh symptms. Executive dysfunction may manifest by easy distratibility, impulsivity, mental inflexibility, nrete thught, slwed pressing speed, pr planning and rganizatin, r impaired judgment. Lalizatin may vary and uld inlude the frntal lbes r subrtial areas like the basal ganglia r erebral white matter. Apathy r indifferene, separate frm depressin, is mmn and may have a simi- lar anatmy as exeutive dysfuntin. Apraxia , r the lss f learned mtr behavirs, may result frm dysfuntin f the frntal r parietal lbes, espeially the left parietal lbe. The time f symptm nset must be established, but subtle, early symptms are ften apparent nly in retr- spet. Anther event, suh as an illness r hspitalizatin, may lead t new regnitin f existing symptms. Symp- tms ften aumulate ver time, and the nature of the earliest symptom is most helpful in forming the differential diagnosis. The histry shuld establish risk fatrs fr dementia, inluding family histry, ther hrni illnesses, and vasular disease risk fatrs. Finally, it is imprtant t dument the patients urrent apaity t perfrm basic and instrumental activities of daily living (see Chapter 4) and t nte the extent f deline frm the premrbid level f funtin. Indeed, it is this funtinal assessment that defines the presene and severity f dementia. The physial examinatin is imprtant t identify any ult medial illness. In additin, eye mvement abnr- malities, parkinsnism, r ther mtr abnrmalities may help identify an underlying neurlgi nditin. The wrkup shuld priritize the exlusin f nditins that are reversible r require separate therapy. Sreening fr depressin is neessary, alng with imaging and labratry wrkup, as indiated belw.B.  Neuropsychological AssessmentBrief q uantifiatin f gnitive impairment is indiated in a patient mplaining f gnitive symptms r if aregiv- ers raise similar nerns. The Folstein Mini Mental State Exam (MMSE), Montreal Cognitive Assessment (MoCA), Mini-Cg, and ther similar tests are brief, bjetive, and widely used but have imprtant limitatins: they are insen- sitive t mild gnitive impairment, they may be biased negatively by the presene f language r attentin prb- lems, and they d nt rrelate with funtinal apaity. A neurpsyhiatri evaluatin by a trained neurpsy- hlgist r psyhmetriian may be apprpriate. The gal f suh testing is t enhane lalizatin by defining the gnitive dmains that are impaired as well as t quantify the degree f impairment. There is n standard battery f tests, but a variety f metris is mmnly used t assess the symptm types highlighted abve. Assessments are mst aurate when a patient is well rested, mfrtable, and therwise medially stable.CMDT22_Ch24_p0978-p1053.indd  1023 29/06/21 8:50 PMChapTER 241024 CMDT 2022C.  ImagingBra in imaging with MRI r CT withut ntrast is indiated in any patient with a new, prgressive gnitive mplaint. The gal is t exlude ult erebrvasular disease, tumr, r ther identifiable strutural abnrmality, rather than t prvide psitive evidene f a neurdegenerative disease. Glbal r fal brain atrphy may be wrse than expeted fr age and uld suggest a partiular neurde- generative press, but suh findings are rarely speifi. PET with flurdexygluse (FDG) des nt nfirm r exlude any speifi ause f dementia but may be useful as an element f the wrkup in speifi linial irum- stanes, suh as disriminating between Alzheimer disease and frnttempral dementia in a patient with sme symp- tms f eah. PET imaging with a radilabeled ligand fr beta-amylid, ne f the pathlgi prteins in Alzheimer disease, is highly sensitive t amylid pathlgy and may prvide psitive evidene fr Alzheimer disease in a patient with gnitive deline. Hwever, after age 60 r 70, amylid plaques an aumulate in the absene f gnitive impair- ment; thus, the speifiity f a psitive amylid san dimin- ishes with age. Single-phtn emissin mputed tmgraphy ffers similar infrmatin as FDG-PET but is less sensitive. PET imaging with radilabeled ligands fr tau, a pathgeni prtein in Alzheimer disease, prgressive supranulear palsy, and sme frms f frnttempral dementia, als may help refine premrtem diagnsti auray.D . Laboratory FindingsSerum  levels f vitamin B12, free T4, and thyrid-stimulat- ing hrmne shuld be measured fr any patient with gnitive symptms. A serum rapid plasma reagin (RPR) and testing fr HIV shuld be nsidered. Other testing shuld be driven by linial suspiin, and ften inludes a mplete bld unt, serum eletrlytes, gluse, and lipid prfile. Althugh the presene f ne r tw ApE epsiln-4 alleles indiates an inreased risk f Alzheimer disease and ApE gentyping is linially available, it is f limited clinical utility. Finding an ApE epsiln-4 allele in a yung patient with dementia might raise the index f suspiin fr Alzheimer disease, but btaining a gentype in an elderly patient is unlikely t be helpful, and ding s in an asymptmati patient as a marker f risk fr Alzheimer disease is inapprpriate until a preventive therapy bemes available. Spinal fluid prtein measurements are als avail- able and may supprt the diagnsis f Alzheimer disease in the apprpriate linial ntext; levels f beta-amylid derease and tau prtein inrease in Alzheimer disease, but this testing shares sme f the same nerns as amylid PET imaging. Differential DiagnosisIn  elderly patients with gradually prgressive gnitive symptms and n ther mplaint r sign, a neurde- generative disease is likely (Table 246). Deline begin- ning befre age 60, rapid prgressin, flutuating urse, unintended weight lss, systemi mplaints, r therunexplained symptms r signs raise suspiin fr a pr- ess ther than a neurdegenerative disease. In this ase, the differential is brad and inludes infetin r inflam- matry disease (nsider a lumbar punture t sreen fr ells r antibdies in the spinal fluid), neplasm r a para- neplasti nditin, endrine r metabli disease, drugs r txins, r ther nditins. Nrmal pressure hydrephalus is a diffiult diagnsis t establish. Symp- tms inlude gait apraxia (smetimes desribed as a mag- neti gait, as if the feet are stuk t the flr), urinary inntinene, and dementia. CT sanning r MRI f the brain reveals ventriles that are enlarged in bvius dispr- prtin t sulal widening and verall brain atrphy. TreatmentA.  Nonpharmacologic ApproachesAe robic exercise (30 minutes several days per week) may redue the rate f funtinal deline and derease the demented patients aregiving needs and may redue the risk f dementia in nrmal individuals. Maintaining as ative a rle in the family and mmunity as pratially pssible is likely t be f benefit, emphasizing ativities at whih the patient feels nfident. Patients with neurde- generative diseases have a limited apaity t regain lst skills; fr instane, memry drills in a patient with Alzheimer disease are mre likely t lead t frustratin than benefit and studies shw that mputerized gnitive training des not imprve gnitin r funtin in demented patients. Vitamin E (1000 internatinal units twie daily) appears t redue the rate f funtinal deline in patients with Alzheimer disease, but des nt affet gnitin r prevent the develpment f Alzheimer disease in patients with mild gnitive impairment.B.  Cognitive SymptomsCh olinesterase inhibitors are first-line therapy fr Alzheimer disease and dementia with Lewy bdies (Table 246). They prvide mdest, symptmati treat- ment fr gnitive dysfuntin and may prlng the apaity fr independene but d notprevent disease prgressin. Cmmnly used mediatins inlude dnepezil (start at 5 mg rally daily fr 4 weeks, then inrease t 10 mg daily; a 23 mg daily dse is apprved fr mderate t severe Alzheimer disease, althugh its very mdest additinal effiay ver the 10 mg dse is vershad- wed by an inreased risk f side effets); rivastigmine (start at 1.5 mg rally twie daily, then inreasing every 2 weeks by 1.5 mg twie daily t a gal f 36 mg twie daily; r 4.6, 9.5, r 13.3 mg/24 h transdermally daily); and galantamine (start at 4 mg rally twie daily, then inreasing every 4 weeks by 4 mg twie daily t a gal f 812 mg twie daily; a ne-daily extended-release frmulatin is als available). Chlinesterase inhibitrs are notgiven fr frn- ttempral dementia beause they may wrsen behaviral symptms. Nausea and diarrhea are mmn side effets; synpe and ardia dysrhythmia are unmmn but mre serius. An ECG is ften btained befre and after starting therapy, partiularly in a patient with ardia disease r a histry f synpe.CMDT22_Ch24_p0978-p1053.indd  1024 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1025 CMDT 2022Mema ntine (start at 5 mg rally daily, then inrease by 5 mg per week up t a target f 10 mg twie daily) is apprved fr the treatment f mderate t severe Alzheimer disease. In frnttempral dementia, memantine is ineffe- tive and may wrsen gnitin. There is sme evidene that memantine may imprve gnitin and behavir amng patients with dementia with Lewy bdies. Disease-mdifying mediatins are nt yet available fr Alzheimer disease.C.  Mood and Behavioral DisturbancesSeletive  sertnin reuptake inhibitrs are generally safe and well tlerated in elderly, gnitively impaired patients, and they may be effiaius fr the treatment f depres- sin, anxiety, r agitatin. There is evidene t supprt the use f italpram (1030 mg rally daily ) for agitation; side effets inlude QT prlngatin and wrsened gnitin at the highest dse. Parxetine shuld be avided beause it has antihlinergi effets; avid all triyli antidepres- sants fr the same reasn. Other antidepressant agents, suh as buprpin r venlafaxine, may be tried. Insmnia is mmn, and trazdne (2550 mg rally at bedtime as needed) an be safe and effetive. Over-the- unter antihistamine hypntis must be avided, alng with benzdiazepines, beause f their tendeny t wrsen gnitin and preipitate delirium. Other presriptin hypntis suh as zlpidem may result in similar adverse reatins. Fr agitatin, impulsivity, and ther behavirs that interfere with safe aregiving, auses f delirium (detailed abve) shuld first be nsidered. When n reversible trigger is identified, treatment shuld be apprahed in a staged manner. Behaviral interventins, suh as rerien- tatin and distratin frm anxiety-prvking stimuli, are first-line. Ensure that the patient is kept ative during the day with bth physial exerise and mentally stimulating ativities, and that there is adequate sleep at night. Reas- sess the level f aregiving, and nsider inreasing the time spent diretly with an attendant. Next, ensure that apprpriate pharmalgi treatment f gnitin and md is ptimized. Finally, as a last resrt, when ther measures prve insuffiient and the patients behavirs raise safety nerns, nsider pharmalgi therapy. Citalpram r lw dses f an atypial antipsyhti mediatin suh as quetiapine (start 25 mg rally daily as needed, inreasing t tw t three times daily as needed) an be tried; even thugh atypial agents ause extrapyra- midal side effets less frequently than typial antipsyht- is, they shuld be used with partiular autin in a patient at risk fr falls, espeially if parkinsnian signs are already present. Regularly sheduled dsing f antipsy- htis is nt remmended, and if implemented shuld be reassessed n a frequent basis (eg, weekly), with attempts t taper ff as tlerated. There is an FDA blak bx warning against the use f all antipsyhti media- tins in elderly demented patients beause f an increased risk of death; the reasn fr the inreased mrtality is unlear. The mbinatin f dextrmethrphan and quini- dine (up t 30/10 mg rally twie daily) has shwn prmise in early linial trials.Special CircumstancesA.  Rapidly Progressive DementiaWhen  dementia develps quikly, with bvius deline ver a few weeks t a few mnths, the syndrme may be lassified as a rapidly progressive dementia. The differen- tial diagnsis fr typial dementias is still relevant, but additinal etilgies must be nsidered, inluding prin disease; infetins; txins; neplasms; and autimmune and inflammatry diseases, inluding rtisterid- respnsive (Hashimt) enephalpathy and antibdy- mediated paraneplasti and nnparaneplasti enephalitis (Table 245). Wrkup shuld begin with brain MRI with ntrast and diffusin-weighted imaging, ru- tine labratry studies (serum vitamin B12, free T4, and thyrid-stimulating hrmne levels), serum RPR, HIV antibdy, Lyme serlgy, rheumatlgi tests (erythryte sedimentatin rate, C-reative prtein, and antinulear antibdy), anti-thyrglbulin and anti-thyrperxidase antibdy levels, paraneplasti and nnparaneplasti autimmune antibdies (Table 245), and erebrspinal fluid studies (ell unt and differential; prtein and glu- se levels; prtein eletrphresis fr liglnal bands; IgG index [spinal-fluid-t-serum-gamma-glbulin level] rati; and VDRL). Depending n the linial ntext, it may be neessary t exlude Wilsn disease (24-hur urine pper level); heavy metal intxiatin (urine heavy metal panel); and infetius enephalitis due t atypial bateria, viruses, fungi, and mybateria. Creutzfeldt-Jakob disease is a relatively mmn ause f rapidly prgressive dementia (see Chapter 32). Family histry is imprtant sine mutatins in PRNP , the gene fr the prin prtein, aunt fr arund 15% f ases. Diffu- sin-weighted MRI is the mst helpful diagnsti tl, lassially revealing rtial ribbning (a gyral pattern f hyperintensity) as well as restrited diffusin in the audate and anterir putamen. An eletrenephalgram ften shws peridi mplexes. Real time quaking indued nversin (RT-QuIC), in whih patient erebrspinal fluid is mixed with rembinant prin prtein and aggre- gatin f prin prtein is deteted, is a sensitive and spe- ifi diagnsti test. Refleting the high rate f neurnal death, erebrspinal fluid levels f the intraneurnal pr- teins tau, 14-3-3, and neurn-speifi enlase are ften elevated, althugh this finding is neither sensitive nr speifi.B.  Driving and DementiaI t is remmended that anypatient with mild dementia or worse should discontinue driving. Mst states have laws regulating driving amng gnitively impaired individuals, and many require the liniian t reprt the patients diag- nsis t the publi health department r department f mtr vehiles. There is n evidene that driving lasses help patients with neurdegenerative diseases. When to ReferAll  patients with new, unexplained gnitive deline shuld be referred.CMDT22_Ch24_p0978-p1053.indd  1025 29/06/21 8:50 PMChapTER 241026 CMDT 2022 When to AdmitAdmi ssin t the hspital shuld nly ur when essen- tial in patients with dementia due t inreased risk f develping hspital-aquired delirium.Arvanitakis  Z et al. Diagnsis and management f dementia: review. JAMA. 2019;322:1589. [PMID: 31638686] Law CK et al. Physial exerise attenuates gnitive deline and redues behaviral prblems in peple with mild gnitive impairment and dementia: a systemati review. J Physither. 2020;66:9. [PMID: 31843427]WE RNICKE ENCEPHALOPATHY & KORSAKOFF SYNDROMEW ernicke encephalopathy is haraterized by nfusin, ataxia, and nystagmus leading t phthalmplegia (lateral retus musle weakness, njugate gaze palsies); peripheral neurpathy may als be present. It is due to thiamine defi- ciency and in the United States urs mst mmnly in patients with alhlism. It may als ur in patients with AIDS r hyperemesis gravidarum, and after bariatri sur- gery. In suspeted ases, thiamine (100 mg) is given intra- venusly immediately and then intramusularly n a daily basis until a satisfatry diet an be ensured after whih the same dse is given rally. Sme guidelines remmend initial dses f 200500 mg intravenusly three times daily fr the first 57 days f treatment. Intravenus gluse given before thiamine may preipitate the syndrme r wrsen the symptms. The diagnsis is nfirmed by the respnse in 1 r 2 days t treatment, whih must nt be delayed while awaiting labratry nfirmatin f thia- mine defiieny frm a bld sample btained prir t thiamine administratin. Korsakoff syndrome urs in mre severe ases; it inludes antergrade and retrgrade amnesia and smetimes nfabulatin, and may nt be regnized until after the initial delirium has lifted.ST UPOR & COMAE S S E N T I A L S  O F  D I A G N O S I S Level of consciousness is depressed. Stuporous patients respond only to repeated vig- orous stimuli. Comatose patients are unarousable and unresponsive. General ConsiderationsThe pa tient wh is stuporous is unrespnsive exept when subjeted t repeated vigrus stimuli, while the comatose patient is unarusable and unable t respnd t external events r inner needs, althugh reflex mvements and psturing may be present. Cma is a majr mpliatin f serius entral nervus system disrders. It an result frm seizures,hypthermia, metabli disturbanes, r strutural lesins ausing bilateral erebral hemispheri dysfuntin r a disturbane f the brainstem retiular ativating system. A mass lesin invlving ne erebral hemisphere may ause ma by mpressin f the brainstem. Assessment & Emergency MeasuresThe  diagnsti wrkup f the matse patient must pr- eed nmitantly with management. Supprtive therapy fr respiratin r bld pressure is initiated; in hypther- mia, all vital signs may be absent and all suh patients shuld be rewarmed befre the prgnsis is assessed. The patient an be psitined n ne side with the nek partly extended, dentures remved, and seretins leared by sutin; if neessary, the pateny f the airways is main- tained with an rpharyngeal airway. Bld is drawn fr serum gluse, eletrlyte, and alium levels; arterial bld gases; liver bihemial and kidney funtin tests; and txilgi studies as indiated. Thiamine (100 mg), fllwed by dextrse 50% (25 g), and nalxne (0.41.2 mg) are given intravenusly withut delay. Further details are then btained frm attendants f the patients medial histry, the irumstanes surrunding the nset f ma, and the time urse f subsequent events. Abrupt nset f ma suggests subarahnid hemrrhage, brainstem strke, r intraerebral hemrrhage, whereas a slwer nset and prgressin ur with ther strutural r mass lesins. Urgent nnntrast CT sanning f the head is apprpriate if it an be btained diretly frm the emer- geny department, in rder t identify intraranial hemr- rhage, brain herniatin, r ther strutural lesin that may require immediate neursurgial interventin. A metabli ause is likely with a preeding intxiated state r agitated delirium. On examinatin, attentin is paid t the behav- iral respnse t painful stimuli, the pupils and their respnse t light, the respnse t tuhing the rnea with a wisp f sterile gauze, psitin f the eyes and their mve- ment in respnse t passive mvement f the head and ie-water alri stimulatin, and the respiratry pattern.A.  Response to Painful StimuliPurp seful limb withdrawal frm painful stimuli implies that sensry pathways frm and mtr pathways t the stimulated limb are funtinally intat. Unilateral absene f respnses despite appliatin f stimuli t bth sides f the bdy in turn implies a rtispinal lesin; bilateral absene f respnsiveness suggests brainstem invlvement, bilateral pyramidal trat lesins, r psyhgeni unrespnsiveness. Dertiate (flexr) psturing may ur with lesins f the internal apsule and rstral erebral pedunle and deere- brate (extensr) psturing with dysfuntin r destrutin f the midbrain and rstral pns. Deerebrate psturing urs in the arms ampanied by flaidity r slight flexr respnses in the legs in patients with extensive brainstem damage extending dwn t the pns at the trigeminal level.B.  Ocular Findings1.  Pupils Hypthalami disease presses may lead t unilateral Hrner syndrme, while bilateral dienephaliCMDT22_Ch24_p0978-p1053.indd  1026 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1027 CMDT 2022inv lvement r destrutive pntine lesins may lead t small but reative pupils. Ipsilateral pupillary dilatin with n diret r nsensual respnse t light urs with m- pressin f the third ranial nerve, eg, with unal hernia- tin. The pupils are slightly smaller than nrmal but respnsive t light in many metabli enephalpathies; hwever, they may be fixed and dilated fllwing verds- age with atrpine r splamine, and pinpint (but respnsive) with piids. 2. Corneal reflex Tuhing the rnea with a wisp f sterile gauze r ttn shuld eliit a blink reflex. The affer- ent limb f the ar is mediated by the fifth ranial nerve; the efferent limb by the seventh nerve. A unilateral absent rneal reflex implies damage t the ipsilateral pns r a trigeminal defiit. Bilateral lss an be seen with large pn- tine lesins r in deep pharmalgi ma. 3. Eye movements Cnjugate deviatin f the eyes t the side suggests the presene f an ipsilateral hemispheri lesin, a ntralateral pntine lesin, r nging seizures frm the ntralateral hemisphere. A mesenephali lesin leads t dwnward njugate deviatin. Dysnjugate u- lar deviatin in ma implies a strutural brainstem lesin unless there was preexisting strabismus. The ulmtr respnses t passive head turning and t alri stimulatin relate t eah ther and prvide m- plementary infrmatin. In respnse t brisk rtatin f the head frm side t side and t flexin and extensin f the head, nrmally nsius patients with pen eyes d nt exhibit ntraversive njugate eye deviatin ( oculocephalic reflex ) unless there is vluntary visual fixatin r bilateral frntal pathlgy. With rtial depressin in lightly ma- tse patients, a brisk ulephali reflex is seen. With brain- stem lesins, this ulephali reflex bemes impaired r lst, depending n the site f the lesin. Theoculovestibular reflex is tested by alri stimula- tin using irrigatin with ie water. In nrmal patients, jerk nystagmus is eliited fr abut 2 r 3 minutes, with the slw mpnent tward the irrigated ear. In unnsius patients with an intat brainstem, the fast mpnent f the nystagmus disappears, s that the eyes tnially deviate tward the irrigated side fr 23 minutes befre returning t their riginal psitin. With impairment f brainstem funtin, the respnse bemes abnrmal and finally dis- appears. In metabli ma, ulephali and ulves- tibular reflex respnses are preserved, at least initially.C.  Respiratory PatternsDiseases ausing ma may lead t resp iratry abnrmali- ties. Cheyne-Stokes respiration (in whih episdes f deep breathing alternate with perids f apnea) may ur with bihemispheri r dienephali disease r in metabli disrders. Central neurogenic hyperventilation urs with lesins f the brainstem tegmentum; apneustic breathing (in whih there are prminent end-inspiratry pauses) suggests damage at the pntine level (eg, due t basilar artery lusin); and ataxic breathing (a m- pletely irregular pattern f breathing with deep and shallw breaths urring randmly) is assiated with lesins f the lwer pntine tegmentum and medulla.1. Stuor & Com Due to Structurl LesionsSupra tentorial mass lesions tend t affet brain funtin in a systemati way. There may initially be signs f hemi- spheri dysfuntin, suh as hemiparesis. As ma devel- ps and deepens, erebral funtin bemes prgressively disturbed, prduing a preditable prgressin f neur- lgi signs that suggest rstraudal deteriratin. Thus, as a supratentrial mass lesin begins t impair the dienephaln, the patient bemes drwsy, then stu- prus, and finally matse. There may be Cheyne-Stkes respiratin; small but reative pupils r an ipsilateral third nerve palsy due t unal herniatin; nrmal ulephali respnses with side-t-side head mvements but sme- times an impairment f reflex upward gaze with brisk flexin f the head; tni ipsilateral deviatin f the eyes in respnse t vestibular stimulatin with ld water; and initially a psitive respnse t pain but subsequently nly dertiate psturing. With further prgressin, midbrain failure urs. Mtr dysfuntin prgresses frm derti- ate t bilateral deerebrate psturing in respnse t pain- ful stimuli; Cheyne-Stkes respiratin is gradually replaed by sustained entral hyperventilatin; the pupils beme middle-sized and fixed; and the ulephali and ul- vestibular reflex respnses beme impaired, abnrmal, r lst. As the pns and then the medulla fail, the pupils remain unrespnsive; ulvestibular respnses are unb- tainable; respiratin is rapid and shallw; and painful stimuli may lead nly t flexr respnses in the legs. Finally, respiratin bemes irregular and stps, the pupils ften then dilating widely. In ntrast, a subtentorial (ie, brainstem) lesion may lead t an early, smetimes abrupt disturbane f n- siusness withut any rderly rstraudal prgressin f neurlgi signs. Cmpressive lesins f the brainstem, espeially erebellar hemrrhage, may be linially indis- tinguishable frm intraparenhymal presses. A strutural lesin is suspeted if the findings suggest fality. In suh irumstanes, a CT san shuld be per- frmed befre, r instead f, a lumbar punture in rder t avid any risk f erebral herniatin. Further management is f the ausal lesin and is nsidered separately under the individual disrders.2.  Stuor & Com Due to Metbolic DisturbncesPa tients with a metabli ause f ma generally have signs f pathy, diffuse, and symmetri neurlgi invlve- ment that annt be explained by lss f funtin at any single level r in a sequential manner, althugh fal r lateralized defiits may ur in hypglyemia. Pupillary reativity is usually preserved. Cmatse patients with meningitis, enephalitis, r subarahnid hemrrhage may als exhibit little in the way f fal neurlgi signs, hw- ever, and linial evidene f meningeal irritatin is sme- times very subtle in matse patients. Examinatin f the erebrspinal fluid in suh patients is essential t establish the rret diagnsis. In patients with ma due t erebral ishemia and hypxia, the absene f pupillary light reflexes 24 hursCMDT22_Ch24_p0978-p1053.indd  1027 29/06/21 8:50 PMChapTER 241028 CMDT 2022after retu rn f spntaneus irulatin indiates that there is little hane f regaining independene; absent rneal reflexes r absent r extensr mtr respnses at 72 hurs als indiate a grim prgnsis. Physial findings are less reliable preditrs f utme amng thse treated with therapeuti hypthermia, althugh absent rneal r pupillary light reflexes at 72 hurs likely indiate a pr prgnsis, as d bilaterally absent rtial smatsensry evked ptentials in respnse t median nerve stimulatin after the patient has returned t nrmthermia. Treatment f metabli enephalpathy is f the under- lying disturbane and is nsidered in ther hapters. If the ause f the enephalpathy is bsure, all mediatins exept essential nes may have t be withdrawn in ase they are respnsible fr the altered mental status.3.  Brin DetBrain  death urs when there is mplete and irreversible essatin f all brain funtin; althugh the rgans an be maintained with mehanial ventilatin fr the purpses f dnatin, in mst untries the diagnsis f brain death is equivalent to a declaration of death. T diagnse brain death, the ause f ma must be established, be mpati- ble with a knwn ause f brain death, and be irreversible. Reversible ma simulating brain death may be seen with hypthermia (temperature lwer than 32C) and verds- age with entral nervus system depressant drugs. These nditins must be exluded by warming the patient and allwing enugh time fr all sedating mediatins t be metablized (ie, at least five half-lives) r by measuring serum levels. Severe bld pressure, eletrlyte, aid-base, and endrine derangements annt be present. Finally, a neurlgi examinatin must demnstrate that the patient is matse (ie, n eye pening and n respnse t entral r peripheral pain); has lst all brain- stem reflex respnses, inluding the pupillary, rneal, ulvestibular, ulephali, rpharyngeal, and ugh reflexes; and has n respiratry drive. The respnse t pain shuld be absent r nly nsist f spinal reflex mve- ments; deerebrate r dertiate psturing is nt nsis- tent with brain death. Absene f respiratry drive is demnstrated with an apnea test (absene f spntaneus respiratry ativity at a PAco2f at least 60 mm Hg r after a rise f 20 mm Hg frm baseline). Certain anillary tests may assist the determinatin f brain death if an apnea test annt be perfrmed but are nt essential. These inlude an iseletri eletrenepha- lgram, when the rerding is made arding t the re- mmendatins f the Amerian Clinial Neurphysilgy Siety, and demnstratin f an absent erebral irula- tin by intravenus radiistpe erebral angigraphy r by fur-vessel ntrast erebral angigraphy.4.  persistent Vegettive SttePa tients with severe bilateral hemispheri disease may shw sme imprvement frm an initially matse state, s that, after a variable interval, they appear t be awake but lie mtinless and withut evidene f awareness r higher mental ativity. This is alled a persistentvegetative state ne it has lasted ver 4 weeks and has als been variusly referred t as akineti mutism, apalli state, r ma vigil. Patients in a vegetative state frm a medial ause (eg, anxi brain injury) fr mre than 3 mnths and frm a traumati brain injury fr mre than 12 mnths are said t be in a chronic vegetative state, frm whih a few patients may regain nsiusness but remain severely disabled.5.  Minimlly Conscious StteIn this  state, patients exhibit innsistent evidene f n- siusness. There is sme degree f funtinal revery f behavirs suggesting self- r envirnmental-awareness, suh as basi verbalizatin r ntext-apprpriate gestures, emtinal respnses (eg, smiling) t emtinal but nt neutral stimuli, r purpsive respnses t envirnmental stimuli (eg, a finger mvement r eye blink apparently t mmand). Further imprvement is manifest by the rest- ratin f mmuniatin with the patient. The minimally nsius state may be temprary r permanent. Little infrmatin is available abut its natural histry r lng- term utlk, whih reflets the underlying ause. The likelihd f useful funtinal revery diminishes with time; after 12 mnths, patients are likely t remain severely disabled and withut a reliable means f mmuniatin. Prgnstiatin is diffiult. Amantadine (100200 mg rally daily) may hasten revery when given t patients in a vegetative r minimally nsius state 416 weeks after traumati brain injury.6.  Locked-In Syndrome (De-Efferented Stte)Aute  destrutive lesins (eg, infartin, hemrrhage, demyelinatin, enephalitis) invlving the ventral pns and sparing the tegmentum may lead t a mute, quadripa- reti but nsius state in whih the patient is apable f blinking and vluntary eye mvement in the vertial plane, with preserved pupillary respnses t light. Suh a patient an mistakenly be regarded as matse. Cliniians shuld regnize that lked-in individuals are fully aware f their surrundings. The prgnsis is usually pr, but revery has asinally been reprted in sme ases, inluding resumptin f independent daily life. A similar nditin may ur with severe Guillain-Barr syndrme and has a better prgnsis.Giain  JT et al. Pratie guideline update remmendatins summary: disrders f nsiusness: reprt f the Guideline Develpment, Disseminatin, and Implementatin Subm- mittee f the Amerian Aademy f Neurlgy; the Amerian Cngress f Rehabilitatin Mediine; and the Natinal Institute n Disability, Independent Living, and Rehabili- tatin Researh. Neurlgy. 2018;91:450. [PMID: 30089618]HE AD INJURYT rauma is the mst mmn ause f death in yung pe- ple, and head injury aunts fr almst half f these trauma-related deaths. Head injury severity ranges frm concussion tsevere traumatic brain injury (TBI). Cn- ussin is bradly defined as an alteratin in mental statusCMDT22_Ch24_p0978-p1053.indd  1028 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1029 CMDT 2022aused  by trauma with r withut lss f nsiusness. The term nussin is ften used synnymusly with mild TBI. Grades f TBI are traditinally defined by the Glasgw Cma Sale (GCS) measured 30 minutes after injury (Table 247).Head trauma may ause erebral injury thrugh a vari- ety f mehanisms (Table 248). Central t management is determinatin f whih patients need head imaging and bservatin. Of partiular nern is identifiatin f patients with epidural and subdural hematma, wh may present with nrmal neurlgi findings shrtly after injury ( lucid interval ) but rapidly deterirate thereafter, and in whm surgial interventin is life-saving. Clinical FindingsA.  Symptoms and SignsCmmn  symptms f nussin that develp autely inlude headahe, nausea, vmiting, nfusin, disrienta- tin, dizziness, and imbalane. A perid f amnesia enmpassing the traumati event and a variable perid f time leading up t the trauma is typial. Lss f nsius- ness may ur. Additinal symptms f phtphbia, phnphbia, diffiulty nentrating, irritability, and sleep and md disturbanes may develp ver the fllw- ing hurs t days. Examinatin is usually nrmal, althugh rientatin and attentin, shrt-term memry, and rea- tin time may be impaired. Persistent r prgressive deline in the level f nsiusness after the initial injury, r fal neurlgi findings, suggests the need fr urgent imaging and neursurgial nsultatin. Patients shuld als be examined fr signs f salp la- eratins, faial and skull frature, and nek injury. The linial signs f basilar skull frature inlude bruising Table 248. Acute cerebral sequelae of head injury (listed in alphabetical order).Sequele Clinicl Fetures ptology Acute epidural hemorrhageHeadache, confusion, somnolence, seizures, and focal defi- cits occur several hours after injury (lucid interval) and lead to coma, respiratory depression, and death unless treated by surgical evacuation.Tear in meningeal artery, vein, or dural sinus, leading to hematoma visible on CT scan. Acute subdural hemorrhageSimilar to epidural hemorrhage, but interval before onset of symptoms is longer. Neurosurgical consultation for consideration of evacuation.Hematoma from tear in veins from cortex to superior sagittal sinus or from cerebral laceration, visible on CT scan. Cerebral contusion or lacerationLoss of consciousness longer than with concussion. Focal neurologic deficits are often present. May lead to death or severe residual neurologic deficit.Bruising on side of impact (coup injury) or contralaterally (contrecoup injury). Vasogenic edema, multiple petechial hemorrhages, and mass effect. May have subarachnoid bleeding. Hernia- tion may occur in severe cases. Cerebral laceration specifically involves tearing of the cerebral tissue and pia-arachnoid overlying a contusion. Cerebral hemorrhageGenerally develops immediately after injury. Clinically resembles hypertensive hemorrhage. Surgery to relieve mass effect is sometimes necessary.Hematoma, visible on CT scan. Concussion A transient, trauma-induced alteration in mental status that may or may not involve loss of consciousness. Symptoms and signs include headache, nausea, disori- entation, irritability, amnesia, clumsiness, visual distur- bances, and focal neurologic deficit.Unknown; likely mild diffuse axonal injury and excito- toxic neuronal injury. Cerebral contusion may occur. Diffuse axonal injury Persistent loss of consciousness, coma, or persistent vege- tative state resulting from severe rotational shearing forces or deceleration.Imaging may be normal or may show tiny, scattered white matter hemorrhages. Histology reveals torn axons.Table 247. Glasgow Coma Scale.1point sEye OeningVerbl ResonseMotor Resonse 1 None None None 2 To pain Vocal but not verbalExtension 3 To voice Verbal but not conversationalFlexion 4 Spontaneous Conversational but disorientedWithdraws from pain 5 Spontaneous Oriented Localizes pain 6 Spontaneous Oriented Obeys commands1 GCS score indicating severity of traumatic brain injury (TBI): mild, 1315; moderate , 912; severe ,  8. Reproduced, with permission, from Aminoff MJ et al. Clinical Neurology , 9th ed, McGraw-Hill Education, 2015; Data from Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet . 1974;304:814.CMDT22_Ch24_p0978-p1053.indd  1029 29/06/21 8:50 PMChapTER 241030 CMDT 2022abut the  rbit ( raccoon sign ), bld in the external audi- try meatus ( Battle sign ), and leakage f erebrspinal fluid (whih an be identified by its gluse r beta- 2-transferrin ntent) frm the ear r nse. Cranial nerve palsies (invlving espeially the first, send, third, furth, fifth, seventh, and eighth nerves in any mbinatin) may als ur. The head and nek shuld be immbilized until imaging an be perfrmed.B.  Imaging and Other InvestigationsCurren t remmendatins are that head CT be perfrmed in patients with nussin and any f the fllwing: GCS sre less than 15, fal neurlgi defiit, seizure, agu- lpathy, aged 65 r lder, skull frature, persistent headahe r vmiting, retrgrade amnesia exeeding 30 minutes, intxiatin, r sft tissue injury f the head r nek. Otherwise, patients an be sent hme as lng as a respnsible aregiver an hek the patient at hurly inter- vals fr the next 24 hurs. Patients requiring imaging shuld be admitted unless the head CT is nrmal, the GCS sre is 15, there have been n seizures, there is n predis- psitin t bleeding, and they an be mnitred by a are- giver at hme. Beause injury t the spine may have ampanied head trauma, ervial spine radigraphs (three views) r CT shuld always be btained in matse patients and in patients with severe nek pain r a defiit pssibly related t rd mpressin. TreatmentHead  injury an ften be prevented by helmets, seatbelts, and ther prtetive equipment. After intraranial bleeding has been exluded linially r by head CT, treatment f mild TBI is aimed at prmt- ing reslutin f pstnussive symptms and preventing recurrent injury, whih inreases the risk f hrni neu- rbehaviral impairment and delays revery. Rarely, a reurrent nussin while a patient is still symptmati frm a first nussin may lead t fatal erebral edema (second impact syndrome ). These bservatins frm the basis f the remmendatin that patients at risk fr reur- rent nussin (eg, athletes) be held ut f the risky ativ- ity until their nussive symptms have fully reslved. In patients hspitalized with mderate r severe TBI, management ften requires a multidisiplinary apprah due t multiple nmitant injuries. Elevated intraranial pressure an result frm diffuse axnal injury r a hema- tma requiring surgial evauatin, r frm a variety f medial auses. Dempressive ranietmy may redue therwise refratry intraranial hypertensin but des nt imprve neurlgi utme. Hypthermia is assi- ated with wrsened funtinal utmes. Beause bridging veins between the brain and venus sinuses beme mre vulnerable t shear injury as the brain atrphies, a subdural hematoma may develp days r weeks fllwing head injury in elderly patients r even ur spntaneusly. Clinial presentatin an be subtle, ften with mental hanges suh as slwness, drwsiness, headahe, nfusin, r memry disturbane. Falneurlgi defiits suh as hemiparesis r hemisensry disturbane are less mmn. Surgial interventin is indi- ated if the hematma is 10 mm r mre in thikness r there is a midline shift f 5 mm r mre; if there is a deline in GCS sre f 2 r mre frm injury t hspital admis- sin; r if ne r bth pupils are fixed and dilated. Salp laeratins and depressed skull fratures shuld be treated surgially as apprpriate. Simple skull fratures require n speifi treatment. If there is any leakage f erebrspinal fluid, nservative treatment, with elevatin f the head, restritin f fluids, and administratin f aetazlamide (250 mg rally fur times daily), is ften helpful; if the leak ntinues fr mre than a few days, lumbar subarahnid drainage may be neessary. Antibit- is are given if infetin urs, based n ulture and sen- sitivity studies; vainatin against pneumus is remmended (see Table 307). Only very asinal patients require intraranial repair f the dural defet beause f persistene f the leak r reurrent meningitis. PrognosisMdera te and severe TBI may result in permanent gni- tive and mtr impairment depending n the severity and latin f the initial injury. Initial GCS and head CT find- ings have prgnsti value. Amng patients with a GCS sre f 8 r less at presentatin, mrtality apprahes 30% and nly ne-third f survivrs regain funtinal indepen- dene. Cgnitive impairment tends t affet frntal and tempral lbe funtin, ausing defiits in attentin, mem- ry, judgment, and exeutive funtin. Behaviral dysregu- latin, depressin, and disinhibitin an impair sial funtining. Ansmia, presumably due t shearing f fibers frm the nasal epithelium, is mmn. Epilepsy an develp after TBI, espeially with mre severe injury. Amng patients with severe TBI (typially lss f nsiusness fr at least 1224 hurs, intraranial hematma, depressed skull frature, r erebral ntu- sin), phenytin r levetiraetam is typially given fr 7 days t redue the inidene f early psttraumati sei- zures; this is dne exlusively t minimize aute mplia- tins resulting frm suh seizures and des nt prevent the develpment f psttraumati epilepsy. Amng patients with mild TBI, symptms f nus- sin reslve in mst patients by 1 mnth and in the vast majrity by 3 mnths. Prlnged pstnussive symp- tms are unmmn, persisting at 1 year in 1015% f patients. Risk fatrs fr prlnged pstnussive symp- tms inlude ative litigatin regarding the injury; repeated nussins; and GCS sre f 13 r less at presentatin. Headahes ften have migrainus features and may respnd t triyli antidepressants r beta-blkers (see Table 241). Opiids shuld be avided t minimize the risk f mediatin veruse headahe. Md symptms may respnd t antidepressants, anxilytis, and gnitive behaviral therapy. There appears t be an assiatin between head trauma and the later develpment f neurdegenerative disease, suh as Alzheimer disease, Parkinsn disease, r amytrphi lateral slersis (ALS). Nrmal pressure hydrephalus may als ur. Repetitive, mild headCMDT22_Ch24_p0978-p1053.indd  1030 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1031 CMDT 2022inju ry, suh as that whih urs in athletes r military persnnel, an lead t chronic traumatic encephalopathy, a distint pathlgi entity assiated with md and gnitive hanges and haraterized by the abnrmal aggregatin f tau r ther prteins either fally r glbally in the erebral rtex. Whether hrni trau- mati enephalpathy is a stati respnse t reurrent head injury r a prgressive neurdegenerative disease is nt knwn, but the severity f neurpathlgy appears t rrelate t lifetime expsure t repetitive head injury. When to Refer Patients with fal neurlgi defiits, altered n- siusness, r skull frature. Patients with late mpliatins f head injury, eg, psttraumati seizure disrder r nrmal pressure hydrephalus. When to Admit Patients with nussin and GCS sre less than 15, predispsitin t bleeding, seizure, r n respnsible aregiver at hme. Patients with abnrmal head CT.Ma riani M et al. Clinial presentatin f hrni traumati enephalpathy. Semin Neurl. 2020;40:370. [PMID: 32740900] Mish MR et al. Sprts mediine update: nussin. Emerg Med Clin Nrth Am. 2020;38:207. [PMID: 31757251]MU LTIPLE SCLEROSISE S S E N T I A L S  O F  D I A G N O S I S Episodic neurologic symptoms. Patient usually < 55 years of age at onset. Single pathologic lesion cannot explain clinical findings. Multiple foci best visualized by MRI. General ConsiderationsThis  mmn neurlgi disrder, whih prbably has an autimmune basis, has its greatest inidene in yung adults. Epidemilgi studies indiate that multiple slersis is muh mre mmn in persns f western Eurpean lineage wh live in temperate znes. N ppulatin with a high risk fr multiple slersis exists between latitudes 40 N and 40 S. A geneti susepti- bility t the disease is present. Pathlgially, fal ften perivenularareas f demyelinatin with reative glisis are fund sattered in the white matter f the brain and spinal rd and in the pti nerves. Axnal damage als urs.Clinical FindingsA.  Symptoms and SignsThe  mmn initial presentatin is weakness, numbness, tingling, r unsteadiness in a limb; spasti paraparesis; retrbulbar pti neuritis; diplpia; dysequilibrium; r a sphinter disturbane suh as urinary urgeny r hesi- tany. Symptms may disappear after a few days r weeks, althugh examinatin ften reveals a residual defiit. Several frms f the disease are regnized. In mst patients, there is an interval f mnths r years after the initial episde befre new symptms develp r the riginal nes reur (relapsing-remitting disease) . Eventually, hw- ever, relapses and usually inmplete remissins lead t inreasing disability, with weakness, spastiity, and ataxia f the limbs, impaired visin, and urinary inntinene. The findings n examinatin at this stage mmnly inlude pti atrphy; nystagmus; dysarthria; and pyramidal, sen- sry, r erebellar defiits in sme r all f the limbs. In sme f these patients, the linial urse hanges s that a steady deteriratin urs, unrelated t aute relapses (secondary progressive disease) . Less mmnly, symp- tms are steadily prgressive frm their nset, and disability develps at a relatively early stage (primary progressive disease) . The diagnsis annt be made with nfidene unless the ttal linial piture indiates invlvement f different parts of the central nervous system at different times. Fatigue is mmn in all frms f the disease. A number f fatrs (eg, infetin) may preipitate r trigger exaerbatins. Relapses are redued in pregnany but are mre likely during the 2 r 3 mnths fllwing pregnany, pssibly beause f the inreased demands and stresses that ur in the pstpartum perid.B.  ImagingMRI  f the brain and ervial rd has a majr rle in exluding ther auses f neurlgi dysfuntin and in demnstrating the presene f multiple lesins. In T1-weighted images, hypintense blak hles prbably represent areas f permanent axnal damage. Gadlinium- enhaned T1-weighted images may highlight areas f ative inflammatin with breakdwn f the bld-brain barrier, whih helps identify newer lesins. T2-weighted images prvide infrmatin abut disease burden r ttal number f lesins, whih typially appear as areas f high signal intensity. CT sans are less helpful than MRI. In patients with myelpathy alne and n linial r labratry evidene f mre widespread disease, MRI r myelgraphy is neessary t exlude a ngenital r aquired surgially treatable lesin. In patients with mixed pyramidal and erebellar defiits in the limbs, the framen magnum regin must be visualized t exlude the pssibil- ity f Arnld-Chiari malfrmatin, in whih parts f the erebellum and lwer brainstem are displaed int the ervial anal.C.  Laboratory and Other StudiesA  definitive diagnsis an never be based slely n the labratry findings. If there is linial evidene f nly aCMDT22_Ch24_p0978-p1053.indd  1031 29/06/21 8:50 PMChapTER 241032 CMDT 2022single  lesin in the entral nervus system, multiple sler- sis annt prperly be diagnsed unless it an be shwn that ther regins are affeted sublinially. Visual, brain- stem auditry, and smatsensry evked ptentials are helpful in this regard, but ther disrders may als be haraterized by multifal eletrphysilgi abnrmali- ties refleting disease f entral white matter. Certain infetins (eg, HIV , Lyme disease, syphilis), nnetive tissue diseases (eg, systemi lupus erythematsus, Sjgren syndrme), saridsis, metabli disrders (eg, vitamin B12 defiieny), and lymphma may therefre require exlusin. There may be mild lymphytsis r a slightly inreased prtein nentratin in the erebrspinal fluid, espeially sn after an aute relapse. Elevated IgG in erebrspinal fluid and disrete bands f IgG (liglnal bands) are present in many patients. The presene f suh bands is nt speifi, hwever, sine they have been fund in a variety f inflammatry neurlgi disrders and asinally in patients with vasular r neplasti disrders f the ner- vus system. Vitamin D defiieny may be assiated with an inreased risk f develping multiple slersis; randmized trials have nt shwn vitamin D supplementatin redues attak rate r prgressin in relapsing remitting disease.D . DiagnosisMultiple slersi s shuld nt be diagnsed unless there is evidene that tw r mre different regins f the entral white matter ( dissemination in space ) have been affeted at different times ( dissemination in time ); the mst widely used diagnsti algrithm is the 2017 revisin t the MDnald riteria. The diagnsis may be made in a patient with tw r mre typial attaks and bjetive evidene n linial examinatin f tw lesins (eg, pti disk atrphy and pyramidal weakness), r bjetive evi- dene f ne lesin with lear-ut histrial evidene the ther attak was typial f multiple slersis and in a dis- tint neuranatmi latin, and when n alternative explanatin fr the patients presentatin has been fund. T fulfill the riterin f disseminatin in spae in a patient with tw linial attaks but bjetive linial evi- dene f nly ne lesin, MRI shuld demnstrate at least ne lesin in at least tw f fur typial sites (periventriu- lar, rtial r juxtartial, infratentrial, r spinal); alternatively, an additinal attak lalized t a different site suffies. The riterin f disseminatin in time in a patient with nly ne attak an be fulfilled by the simul- taneus presene f gadlinium-enhaning and nnen- haning lesins at any time (inluding at initial examinatin); the presene f liglnal bands unique t the erebrspinal fluid; a new lesin n fllw-up MRI; r a send attak. Lesins in the pti nerve n MRI in patients with pti neuritis annt be used t fulfill the MDnald riteria fr disseminatin in spae r time. Pri- mary prgressive disease requires at least a year f prgres- sin, plus tw f three f the fllwing: at least ne typial brain lesin, at least tw spinal lesins, r liglnal banding in the erebrspinal fluid.In patients with a single linial event wh d nt sat- isfy riteria fr multiple slersis, a diagnsis f a clinically isolated syndrome (CIS) is made. Suh patients are at risk fr develping multiple slersis and are smetimes ffered beta-interfern r glatiramer aetate therapy, whih may delay prgressin t linially definite disease. Fllw-up MRI shuld be nsidered 612 mnths later t assess fr the presene f any new lesin. TreatmentA t least partial revery frm aute exaerbatins an rea- snably be expeted, but further relapses may ur with- ut warning. Sme disability is likely t result eventually, but abut half f all patients are withut signifiant dis- ability even 10 years after nset f symptms. Current treatments are hiefly aimed at preventing relapses, thereby reduing disability. Recovery from acute relapses may be hastened by treat- ment with corticosteroids, but the extent of recovery is unchanged. Intravenus therapy is ften given first typially methylprednislne 1 g daily fr 3 daysfllwed by ral prednisne at 6080 mg daily fr 1 week with a taper ver the ensuing 23 weeks, but randmized trials shw similar effiay whether the initial high dse is given rally r intravenusly. Lng-term treatment with rti- sterids prvides n benefit and des nt prevent further relapses. Transient exaerbatin f symptms relating t interurrent infetin r heat requires n added treatment. In patients with relapsing disease, numerus media- tins have well-established effiay at reducing the frequency of attacks (Table 249). The initial agent is h- sen after nsidering mediatin tlerane and risks, patient preferene, and disease severity. Glatiramer aetate, an interfern, r dimethyl fumarate is ften used initially due t favrable side effet prfiles and availability, althugh the effiay f early treatment with higher inten- sity therapy is being explred. In general, the mediatins mst effetive in reduing relapses have strnger immun- mdulatry effets and mre, albeit rare, serius adverse effets. Presriptin f these agents shuld be managed by a speialist. Orelizumab is the nly mediatin effetive in slwing disability prgressin in primary prgressive multiple sle- rsis and is apprved fr this indiatin by the FDA. Fr patients with ative sendary prgressive disease, ladrib- ine, relizumab, fatumumab, zanimd, and sipnimd an be used. Plasmapheresis is smetimes helpful in patients with severe relapses unrespnsive t rtisterids. Symptmati therapy fr spastiity, neurgeni bladder, r fatigue may be required. Fatigue is espeially mmn in multiple slersis, and mdafinil (200 mg rally every mrning) is an effetive and FDA-apprved therapy fr this indiatin. Dalfampridine (an extended-release fr- mulatin f 4-aminpyridine administered as 10 mg rally twie daily) is effiaius at imprving timed gait in mul- tiple slersis. Depressin and even suiidality an ur in multiple slersis and may wrsen with interfern beta-1a therapy; sreening and nventinal treatment f suh symptms are apprpriate.CMDT22_Ch24_p0978-p1053.indd  1032 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1033 CMDT 2022 When to ReferAll  patients, but espeially thse with prgressive disease despite standard therapy, shuld be referred. When to Admit Patients requiring plasma exhange fr severe relapses unrespnsive t rtisterids. During severe relapses. Patients unable t manage at hme.Fr eedman MS et al. Treatment ptimizatin in multiple slersis: Canadian MS wrking grup remmendatins. Can J Neurl Si. 2020;47:437. [PMID: 32654681] Rae-Grant A et al. Pratie guideline remmendatins summary: disease-mdifying therapies fr adults with multiple slersis: reprt f the Guideline Develpment, Disseminatin, and Implementatin Submmittee f the Amerian Aademy f Neurlgy. Neurlgy. 2018;90:777. [PMID: 29686116]NEUROMYELITIS OPTICAThis  disrder is haraterized by pti neuritis and aute myelitis with MRI hanges that extend ver at least three segments f the spinal rd. An islated myelitis r pti neuritis may als ur. Previusly knwn as Devi disease and ne regarded as a variant f multiple slersis, neur- myelitis ptia is assiated with a speifi antibdy marker (NMO-IgG) targeting the water hannel aquaprin-4 in 80% f ases, and with antibdies t myelin ligdendr- yte glyprtein (MOG-IgG) in apprximately 33% f NMO-IgG sernegative patients. MRI f the brain typially des nt shw widespread white matter invlvement, but suh hanges d nt exlude the diagnsis. Treatment is by lng-term immunsuppressin. Three mediatins are apprved by the FDA fr treatment f neurmyelitis ptia based n plaeb-ntrlled trials demnstrating a redued annual relapse rate r time t first relapse. Eulizumab is a mplement inhibitr, inebilizumab is a humanizedTable 249. Treatment of multiple sclerosis (in alphabetical order within categories).1Mediction Dose acute Eisode, Including Relse2Dexamethasone 160 mg orally daily for 35 days Methylprednisolone 1 g intravenously or orally daily for 35 days Plasmapheresis Disese-Modifying Tery (FDa roved) Alemtuzumab (Lemtrada)3,412 mg intravenously daily for 5 days; 3-day course given 1 year later Cladribine (Mavenclad)3,5,61.75 mg/kg orally divided between weeks 1 and 5, repeated once in 1 year Dimethyl fumarate (Tecfidera)3,5240 mg orally twice daily Fingolimod (Gilenya)3,4,50.5 mg orally daily Glatiramer acetate (Copaxone, Mylan, Glatopa)520 mg subcutaneously daily or 40 mg subcutaneously three times weekly Interferon -1a (Rebif)544 mcg subcutaneously three times per week Interferon -1a (Avonex)530 mcg intramuscularly once per week Interferon -1b (Betaseron, Extavia)50.25 mg subcutaneously on alternate days Mitoxantrone312 mg/m2intravenously every 3 months; maximum lifetime dose, 140 mg/m2Natalizumab  (Tysabri)3,4300 mg intravenously monthly Ocrelizumab (Ocrevus)3,4,5,6,7300 mg intravenously on day 1 and day 15, followed by 600 mg every 6 months Ofatumumab (Kesimpta)3,4,5,620 mg subcutaneously weeks 0, 1, 2, 4, and monthly thereafter Ozanimod (Zeposia)3,4,5,60.23 mg orally daily on days 14, 0.46 mg daily on days 57, and 0.92 mg daily thereafter Pegylated interferon -1a (Plegridy)5125 mg subcutaneously once every 2 weeks Siponimod (Mayzent)3,4,5,60.25 mg orally daily, titrated over 5 or 6 days to 1 or 2 mg orally daily, depending on CYP2C9 genotype Teriflunomide (Aubagio)514 mg or 7 mg orally daily1 Several of these agents require special monitoring or pretreatment; some should be avoided during pregnancy. Readers should ref er to the manufacturers guidelines.2 For corticosteroid-refractory relapses, plasmapheresis may be used.3 Relapse prevention for disease activity despite use of first-line treatment.4 High disease activity (typically with multiple gadolinium-enhancing lesions on MRI).5 Relapse prevention, first-line treatment.6 Active secondary progressive disease.7 Primary progressive disease.CMDT22_Ch24_p0978-p1053.indd  1033 29/06/21 8:50 PMChapTER 241034 CMDT 2022an ti-CD19 antibdy that depletes B ells, and satralizumab is an interleukin-6 reeptr antagnist. Use f eulizumab requires prir immunizatin against meningus. Off- label therapy is with rituximab (tw 1-g intravenus infusins spaed by 2 weeks, r fur weekly infusins f 375 mg/m2; re-dsing may ur every 6 mnths r when CD19/20-psitive r CD27-psitive lymphytes beme detetable), myphenlate mfetil (5001500 mg rally twie daily, titrated until the abslute lymphyte unt falls belw 1500/mL [1.5  109/L]), r azathiprine (2.53 mg/kg rally). Aute relapses are treated with rti- sterids at dses similar t thse utlined fr multiple slersis and with plasma exhange fr severe relapses unrespnsive t rtisterids.Cree  BAC et al; N-MOmentum Study Investigatrs. Inebili- zumab fr the treatment f neurmyelitis ptia spetrum disrder (N-MOmentum): a duble-blind, randmized plaeb-ntrlled phase 2/3 trial. Lanet. 2019;394:1352. [PMID: 31495497] Pittk SJ et al. Eulizumab in aquaprin-4-psitive neurmyeli- tis ptia spetrum disrder. N Engl J Med. 2019;381:614. [PMID: 31050279]VI TAMIN E DEFICIENCYV itamin E defiieny may prdue a disrder smewhat similar t Friedreih ataxia. There is spinerebellar degen- eratin invlving partiularly the psterir lumns f the spinal rd and leading t limb ataxia, sensry lss, absent tendn reflexes, slurring f speeh, and, in sme ases, pigmentary retinal degeneratin. The disrder may ur as a nsequene f malabsrptin r n a hereditary basis (eg, abetalipprteinemia).SP ASTICITYThe  term spastiity is mmnly used fr an upper mtr neurn defiit, but it prperly refers t a velity- dependent inrease in resistane t passive mvement that affets different musles t a different extent, is nt uni- frm in degree thrughut the range f a partiular mve- ment, and is mmnly assiated with ther features f pyramidal defiit. It is ften a majr mpliatin f strke, erebral r spinal injury, stati perinatal enephalpathy, and multiple slersis. Spastiity may be exaerbated by pressure injuries, urinary r ther infetins, and niep- tive stimuli. Physial therapy with apprpriate strething prgrams is imprtant during rehabilitatin after the develpment f an upper mtr neurn lesin and in subsequent manage- ment f the patient. The aim is t prevent jint and musle contractures and perhaps t mdulate spastiity. Mediatin management is imprtant als, but treat- ment may inrease funtinal disability when inreased extensr tne is prviding additinal supprt fr patients with weak legs. Pharmalgi treatment with balfen (510 mg twie daily rally titrated t 80 mg daily), tizani- dine (28 mg three time daily rally), diazepam (210 mg three times daily rally), r dantrlene (25 mg ne daily rally, titrated every 3 days as tlerated t a maximum f100 mg fur times daily) is ften helpful. Dantrlene is best avided in patients with pr respiratry funtin r severe myardial disease. Cannabinids are als effetive in reduing spastiity, but are assiated with side effets, inluding dizziness, drwsiness, and fatigue. Intramusular injetin f btulinum txin is used t relax targeted musles. In patients with severe spastiity that is unrespnsive t ther therapies and is assiated with marked disability, intratheal injetin f phenl r alhl may be helpful. Surgial ptins inlude implantatin f an intratheal balfen pump, rhiztmy, r neuretmy. Severe ntra- tures may be treated by surgial tendn release.MYE LOPATHIES IN AIDSA  variety f myelpathies may ur in patients with AIDS. These are disussed in Chapter 31.MYE LOPATHY OF HUMAN T-CELL LEUKEMIA VIRUS INFECTIONH uman T-ell leukemia virus (HTLV-1), a human retrvi- rus, is transmitted by breastfeeding, sexual ntat, bld transfusin, and ntaminated needles. Mst patients are asymptmati, but after a variable latent perid (whih may be as lng as several years), a myelpathy develps in sme instanes. The MRI, eletrphysilgi, and erebr- spinal fluid findings are similar t thse f multiple sler- sis, but HTLV-1 antibdies are present in serum and spinal fluid. There is n speifi treatment, but intravenus r ral rtisterids may help in the initial inflammatry phase f the disease. Prphylati measures are imprtant. Needles r syringes shuld nt be shared; infeted patients shuld nt breastfeed their infants r dnate bld, semen, r ther tissue. Infeted patients shuld use ndms t prevent sexual transmissin.SU BACUTE COMBINED DEGENERATION OF THE SPINAL CORDSubaute  mbined degeneratin f the spinal rd is due tvitamin B12deficiency , suh as urs in perniius anemia. It is haraterized by myelpathy with spastiity, weakness, prprieptive lss, and numbness due t degeneratin f the rtispinal trats and psterir l- umns. Plyneurpathy, mental hanges, r pti neurpa- thy als develp in sme patients. Megalblasti anemia may als ur, but this des notparallel the neurlgi disrder, and the frmer may be bsured if fli aid supplements have been taken. Treatment is with vitamin B12. Fr perniius anemia, a nvenient therapeuti regi- men is 1000 mg yanbalamin intramusularly daily fr 1 week, then weekly fr 1 mnth, and then mnthly fr the remainder f the patients life. Oral yanbalamin replaement is nt advised fr perniius anemia when neurlgi symptms are present. A similar syndrme is aused by rereatinal abuse f inhaled nitrus xide due t its interferene with vitamin B12metablism. Cpper defiieny, aused by malabsrptin r exess zin inges- tin, may als be respnsible.CMDT22_Ch24_p0978-p1053.indd  1034 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1035 CMDT 2022SP INAL TRAUMAE S S E N T I A L S  O F  D I A G N O S I S History of preceding trauma. Development of acute neurologic deficit. Signs of myelopathy on examination. General ConsiderationsWhile  spinal rd damage may result frm whiplash injury, severe injury usually relates t frature-dislatin ausing mpressin r angular defrmity f the rd either ervi- ally r in the lwer thrai and upper lumbar regins. Extreme hyptensin fllwing injury may als lead t rd infartin. Clinical FindingsT tal rd transetin results in immediate flaid paraly- sis and lss f sensatin belw the level f the lesin. Reflex ativity is lst fr a variable perid, and there is urinary and feal retentin. As reflex funtin returns ver the fl- lwing days and weeks, spasti paraplegia r quadriplegia develps, with hyperreflexia and extensr plantar respnses, but a flaid atrphi (lwer mtr neurn) paralysis may be fund depending n the segments f the rd that are affeted. The bladder and bwels als regain sme reflex funtin, permitting urine and fees t be expelled at intervals. As spastiity inreases, flexr r extensr spasms (r bth) f the legs beme trublesme, espeially if the patient develps bed sres r a urinary trat infetin. Paraplegia with the legs in flexin r exten- sin may eventually result. With lesser degrees f injury, patients may be left with mild limb weakness, distal sensry disturbane, r bth. Sphinter funtin may als be impaired, urinary urgeny and urge inntinene being espeially mmn. Mre partiularly, a unilateral rd lesin leads t an ipsilateral mtr disturbane with ampanying impairment f pr- prieptin and ntralateral lss f pain and temperature appreiatin belw the lesin ( Brown-Squard syndrome ). A entral rd syndrme may lead t a lwer mtr neurn defiit at the level f the lesin and lss f pain and tem- perature appreiatin belw it, with sparing f psterir lumn funtins. With mre extensive invlvement, ps- terir lumn sensatin may als be impaired and pyrami- dal weakness develps. A radiular defiit may ur at the level f the injuryr, if the auda equina is invlved, there may be evidene f disturbed funtin in several lumbsa- ral rts. TreatmentT reatment f the injury nsists f immbilizatin andif there is rd mpressinearly dempressive lamine- tmy and fusin (within 24 hurs). Early treatment with high dses f rtisterids (eg, methylprednislne,30 mg/kg by intravenus blus, fllwed by 5.4 mg/kg/h fr 23 hurs) may imprve neurlgi revery if m- mened within 8 hurs after injury, althugh the evidene is limited and sme neursurgial guidelines d nt re- mmend their use. Anatmi realignment f the spinal rd by tratin and ther rthpedi predures is imprtant. Subsequent are f the residual neurlgi defiitparaplegia r quadriplegiarequires treatment f spastiity and are f the skin, bladder, and bwels. When to ReferAll  patients with fal neurlgi defiits shuld be referred. When to Admit Patients with neurlgi defiits. Patients with spinal rd injury, mpressin, r aute epidural r subdural hematma. Patients with vertebral frature-dislatin likely t mpress the rd.Ong B  et al. Management f the patient with hrni spinal rd injury. Med Clin Nrth Am. 2020;104:263. [PMID: 32035568]SYR INGOMYELIADestruti n r degeneratin f gray and white matter adja- ent t the entral anal f the ervial spinal rd leads t avitatin and aumulatin f fluid within the spinal rd. The preise pathgenesis is unlear, but many ases are assiated with Arnold-Chiari malformation , in whih there is displaement f the erebellar tnsils, medulla, and furth ventrile int the spinal anal, smetimes with ampanying meningmyelele. In suh irumstanes, the rd avity nnets with and may merely represent a dilated entral anal. In ther ases, the ause f avitatin is less lear. There is a harateristi linial piture, with segmental atrphy, areflexia, and lss f pain and tempera- ture appreiatin in a ape distributin, wing t the destrutin f fibers rssing in frnt f the entral anal in the mid-ervial spinal rd. Thrai kyphslisis is usually present. With prgressin, invlvement f the lng mtr and sensry trats urs as well, s that a pyrami- dal and sensry defiit develps in the legs. Upward exten- sin f the avitatin (syringbulbia) leads t dysfuntin f the lwer brainstem and thus t bulbar palsy, nystagmus, and sensry impairment ver ne r bth sides f the fae. Syringmyelia, ie, rd avitatin, may als ur in assiatin with an intramedullary tumr r fllwing severe rd injury, and the avity then des nt mmuni- ate with the entral anal. In patients with Arnld-Chiari malfrmatin, CT sans reveal a small psterir fssa and enlargement f the fra- men magnum, alng with ther assiated skeletal abnr- malities at the base f the skull and upper ervial spine. MRI reveals the syrinx as well as the harateristi findings f the Arnld-Chiari malfrmatin, inluding the audal displaement f the furth ventrile and herniatin f theCMDT22_Ch24_p0978-p1053.indd  1035 29/06/21 8:50 PMChapTER 241036 CMDT 2022erebellar  tnsils thrugh the framen magnum. Fal rd enlargement is fund at myelgraphy r by MRI in patients with avitatin related t past injury r intramed- ullary neplasms. Treatment f Arnld-Chiari malfrmatin with assi- ated syringmyelia is by subipital ranietmy and upper ervial laminetmy, with the aim f dempress- ing the malfrmatin at the framen magnum. The rd avity shuld be drained and, if neessary, an utlet fr the furth ventrile an be made. In avitatin assiated with intramedullary tumr, treatment is surgial, but radiatin therapy may be neessary if mplete remval is nt ps- sible. Psttraumati syringmyelia is als treated surgi- ally if it leads t inreasing neurlgi defiits r t intlerable pain.DE GENERATIVE MOTOR NEURON DISEASESE S S E N T I A L S  O F  D I A G N O S I S Weakness. No sensory loss or sphincter disturbance. Progressive course. No identifiable underlying cause other than genetic basis in familial cases. General ConsiderationsThis gr up f degenerative disrders is haraterized lini- ally by weakness and variable wasting f affeted musles, withut ampanying sensry hanges. Mtr neurn disease in adults generally mmenes between 30 and 60 years f age. There is degeneratin f the anterir hrn ells in the spinal rd, the mtr nulei f the lwer ranial nerves, and the rtispinal and r- tibulbar pathways. The disrder is usually spradi, but familial ases may ur and several geneti mutatins r li have been identified. Cigarette smking may be ne risk fatr. ClassificationFive varieties ha ve been distinguished n linial grunds.A.  Progressive Bulbar PalsyBulbar  invlvement predminates wing t disease pr- esses affeting primarily the mtr nulei f the ranial nerves.B.  Pseudobulbar PalsyBulbar  invlvement predminates in this variety als, but it is due t bilateral rtibulbar disease and thus reflets upper mtr neurn dysfuntin. There may be a pseud- bulbar affet,  with unntrllable episdes f laughing r rying t stimuli that wuld nt nrmally have eliited suh marked reatins.C. Progressive Spinal Muscular AtrophyThis  is haraterized primarily by a lwer mtr neurn defiit in the limbs due t degeneratin f the anterir hrn ells in the spinal rd.D . Primary Lateral SclerosisThere is a p urely upper mtr neurn defiit in the limbs.E.  Amyotrophic Lateral Sclerosis ALSA mixed u pper and lwer mtr neurn defiit is fund in the limbs. This disrder is smetimes assiated with g- nitive deline (in a pattern nsistent with frnttempral dementia), a pseudbulbar affet, r parkinsnism. Apprximately 10% f ALS ases are familial and have been assiated with mutatins at several different geneti li, inluding a hexanuletide repeat n hrmsme 9 that als assiates with frnttempral dementia. Differential DiagnosisTh e spinal musular atrphies (SMAs) are inherited syndrmes aused mst ften by mutatins f the sur- vival mtr neurn 1 ( SMN1 ) gene n hrmsme 5. Different mutatins result in mre r less severe disrup- tins f the prtein, resulting in an age f nset that ranges frm infany (SMA type I), t early (type II) r late hildhd (type III), t adulthd (type IV). X-linked spinal and bulbar musular atrphy (Kennedy syndrme) is assiated with an expanded trinuletide repeat sequene n the andrgen reeptr gene and ar- ries a mre benign prgnsis than ther frms f mtr neurn disease. There are reprts f juvenile SMA due t hexsa- minidase defiieny. Pure mtr syndrmes resembling mtr neurn disease may als ur in assiatin with mnlnal gammpathy r multifal mtr neurpa- thies with ndutin blk. A mtr neurnpathy may als develp in Hdgkin disease and has a relatively benign prgnsis. Infetive anterir hrn ell diseases (pli virus r West Nile virus infetin) an generally be distinguished by the aute nset and mnphasi urse f the illness, as disussed in Chapter 32. Aute flaid myelitis fllwing infetin with entervirus may ur, espeially in hildren, withut sensry invlve- ment and resembles plimyelitis. There is n speifi treatment. Clinical FindingsA.  Symptoms and SignsDiffiu lty in swallwing, hewing, ughing, breathing, and talking (dysarthria) urs with bulbar invlvement. In prgressive bulbar palsy, there is drping f the palate; a depressed gag reflex; pling f saliva in the pharynx; a weak ugh; and a wasted, fasiulating tngue. In pseud- bulbar palsy, the tngue is ntrated and spasti and an- nt be mved rapidly frm side t side. Limb invlvement is haraterized by mtr disturbanes (weakness, stiff- ness, wasting, fasiulatins) refleting lwer r upperCMDT22_Ch24_p0978-p1053.indd  1036 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1037 CMDT 2022mt r neurn dysfuntin; there are n bjetive hanges n sensry examinatin, althugh there may be vague sen- sry mplaints. The sphinters are generally spared. Cg- nitive hanges r pseudbulbar affet may be present. The disrder is prgressive, and ALS is usually fatal within 35 years; death usually results frm pulmnary infetins. Patients with bulbar invlvement generally have the pr- est prgnsis, while patients with primary lateral slersis ften have a lnger survival despite prfund quadriparesis and spastiity.B.  Laboratory and Other StudiesEletrmygraphy  may shw signs f aute and hrni partial denervatin with reinnervatin. In patients with suspeted ALS, the diagnsis shuld nt be made with nfidene unless suh hanges are fund in at least three spinal regins (ervial, thrai, lumbsaral) r tw spinal regins and the bulbar musulature. Mtr ndu- tin velity is usually nrmal but may be slightly redued, and sensry ndutin studies are als nrmal. Bipsy f a wasted musle shws the histlgi hanges f denerva- tin but is nt neessary fr diagnsis. The serum reatine kinase may be slightly elevated but never reahes the extremely high values seen in sme f the musular dys- trphies. The erebrspinal fluid is nrmal. T diagnse SMA, mleular geneti testing fr pathgeni variants f SMN1 is available. There are abnrmal findings n retal bipsy and redued hexsaminidase A in serum and leuk- ytes in patients with juvenile SMA due t hexsaminidase defiieny. TreatmentRiluzle,  50 mg rally twie daily, whih redues the pre- synapti release f glutamate, inreased shrt-term sur- vival in ALS in randmized trials. Edaravne, a free radial savenger, slws disease prgressin in patients with mild disease. It is administered in mnthly yles as a 60 mg intravenus infusin n days 114 in the first mnth and days 110 in the subsequent mnths. Nninvasive ventilatin at least 4 hurs per day in patients with a maximal inspiratry pressure less than 60 m H2O may prlng survival in ALS. Symptmati and supprtive measures t treat spastiity (disussed earlier), drling, and dysphagia, prevent ntratures, and pre- serve mbility are imprtant. Drling is treated with ver- the-unter dengestants, antihlinergi mediatins (suh as trihexyphenidyl, amitriptyline, r atrpine), btu- linum txin injetins int the salivary glands, r use f a prtable sutin mahine. Physial and upatinal ther- apy are helpful thrughut the disease urse. Cmbina- tin dextrmethrphan/quinidine (20 mg/10 mg, ne tablet rally ne r twie daily) may relieve symptms f pseudbulbar affet. A semiliquid diet r gastrstmy tube feeding may be needed if dysphagia is severe; it is advisable t perfrm the predure befre the fred vital apaity falls belw 50% f predited t minimize the risk f m- pliatins. Trahestmy is smetimes perfrmed if respi- ratry musles are severely affeted; hwever, in the terminal stages f these disrders, realisti expetatinsand advane are planning shuld be disussed. Infrma- tin n palliative are is prvided in Chapter 5. Treatment f spinal musular atrphy takes advantage f the fat that the SMN prtein is als ended by a se- nd gene, SMN2, that usually des nt translate funtinal prtein due t aberrant spliing. Nusinersen is an antisense lignuletide that mdulates premessenger RNA spli- ing f the SMN2 gene and results in inreased prdutin f the full-length prtein; it has shwn effetiveness in bth infants and hildren with SMA. It is apprved fr use in all ages and is administered intratheally (12 mg every 14 days fr three dses, then ne after a 30-day interval, then ne every 4 mnths). Risdiplam (5 mg rally daily fr patients 2 years f age and lder weighing mre than 20 kg) is a small mleule SMN2 spliing mdifier that als results in prdutin f the full-length prtein and is apprved fr use in infants and adults. Gene therapy with intravenus delivery f an intat SMN1 gene using a viral vetr (nasemngene abeparvve) imprves ventilatr-free survival mpared t histrial ntrls and is apprved by the FDA fr use in hildren under 2 years f age with bi- alleli mutatins in SMN1 . When to ReferAll patien ts (t exlude ther treatable auses f symptms and signs) shuld be referred. When to AdmitPa tients may need t be admitted fr initiatin r titratin f nninvasive ventilatin, r fr perids f inreased requirement f nninvasive ventilatr supprt during pul- mnary infetins.Me ruri E et al; CHERISH Study Grup. Nusinersen versus sham ntrl in later-nset spinal musular atrphy. N Engl J Med. 2018;378:625. [PMID: 29443664] Nrris SP et al. Amytrphi lateral slersis: update n linial management. Curr Opin Neurl. 2020;33:641. [PMID: 32868602] pERIphERaL NEUROpaThIESPe ripheral neurpathies an be ategrized n the basis f the struture primarily affeted. The predminant path- lgi feature may be axonal degeneration (axonal or neuronal neuropathies ) r paranodal or segmental demyelination. The distintin may be pssible n the basis f neurphysilgi findings. Mtr and sensry ndutin velity an be measured in aessible seg- ments f peripheral nerves. In axnal neurpathies, n- dutin velity is nrmal r redued nly mildly and needle eletrmygraphy prvides evidene f denerva- tin in affeted musles. In demyelinating neurpathies, ndutin may be slwed nsiderably in affeted fibers, and in mre severe ases, ndutin is blked m- pletely, withut ampanying eletrmygraphi signs f denervatin.CMDT22_Ch24_p0978-p1053.indd  1037 29/06/21 8:50 PMChapTER 241038 CMDT 2022PO LYNEUROPATHIES & MONONEURITIS MULTIPLEXE S S E N T I A L S  O F  D I A G N O S I S Weakness, sensory disturbances, or both in the extremities. Pain is common. Depressed or absent tendon reflexes. May be family history of neuropathy. May be history of systemic illness or toxic exposure. General ConsiderationsDiffuse  polyneuropathies lead t a symmetri sensry, mtr, r mixed defiit, ften mst marked distally. They inlude the hereditary, metabli, and txi disrders; idi- pathi inflammatry plyneurpathy ( Guillain-Barr syn- drome ); and the peripheral neurpathies that may ur as a nnmetastati mpliatin f malignant diseases. Invlvement f mtr fibers leads t flaid weakness that is mst marked distally; dysfuntin f sensry fibers auses impaired sensry pereptin. Tendn reflexes are depressed r absent. Paresthesias, pain, and musle tender- ness may als ur. Multiple mnneurpathies ( mono- neuropathy multiplex ) suggest a pathy multifal disease press suh as vasulpathy (eg, diabetes, arteritis), an infiltrative press (eg, leprsy, saridsis), radiatin dam- age, r an immunlgi disrder (eg, brahial plexpathy). Clinical FindingsThe  ause f plyneurpathy r mnneuritis multiplex is suggested by the histry, mde f nset, and predminant linial manifestatins. Labratry wrkup inludes a m- plete bld unt, serum prtein eletrphresis with reflex t immunfixatin r immuntyping, determinatin f plasma urea and eletrlytes, liver bihemial tests, thy- rid funtin tests, vitamin B12level, tests fr rheumatid fatr and antinulear antibdy, HBsAg determinatin, a serlgi test fr syphilis, fasting bld gluse level and hemglbin A1, urinary heavy metal levels, erebrspinal fluid examinatin, and hest radigraphy. These tests shuld be rdered seletively, as guided by symptms and signs. Measurement f nerve ndutin velity an n- firm the peripheral nerve rigin f symptms and prvides a means f fllwing linial hanges, as well as indiate the likely disease press (ie, axnal r demyelinating neurpa- thy). Cutaneus nerve bipsy may help establish a preise diagnsis (eg, plyarteritis, amylidsis). In abut half f ases, n speifi ause an be established; f these, slightly less than half are subsequently fund t be familial. TreatmentT reatment is f the underlying ause, when feasible, and is disussed belw under the individual disrders. Physial therapy helps prevent ntratures, and splints anmaintain a weak extremity in a psitin f useful funtin. Anestheti extremities must be prteted frm injury. T guard against burns, patients shuld hek the temperature f water and ht surfaes with a prtin f skin having nrmal sensatin, measure water temperature with a ther- mmeter, and use ld water fr washing r lwer the temperature setting f their ht-water heaters. Shes shuld be examined frequently during the day fr grit r freign bjets in rder t prevent pressure lesins. Patients with plyneurpathies r mnneuritis multi- plex are subjet t additinal nerve injury at pressure pints and shuld therefre avid suh behavir as leaning n elbws r sitting with rssed legs fr lengthy perids. Neurpathi, burning pain may respnd t simple anal- gesis, suh as aspirin r nnsteridal anti-inflammatry agents, and t gabapentin (300 mg rally three times daily, titrated up t a maximum f 1200 mg rally three times daily as neessary) r pregabalin (50100 mg rally three times daily). Dulxetine (60 mg rally ne r twie daily), venlafaxine (start 37.5 mg rally twie daily, and titrate up t 75 mg rally tw t three times daily), r triyli antide- pressants (eg, amitriptyline 10150 mg rally at bedtime daily) may be helpful, espeially in painful diabeti neu- rpathy. Medial annabis may prvide sme relief, but lng-term safety data are laking. The use f a frame r radle t redue ntat with bedlthes may be helpful. Many patients experiene episdi stabbing pains, whih may respnd t gabapentin, pregabalin, arbamazepine (start 100 mg rally twie daily, and titrate up t 400 mg rally twie daily), r triyli antidepressants. Opiids may be neessary fr severe hyperpathia r pain indued by minimal stimuli, but their use generally shuld be avided. Symptms f autnmi dysfuntin are asinally trublesme. Treatment f pstural hyptensin is dis- ussed earlier in this hapter. Eretile dysfuntin an be treated with phsphdiesterase inhibitrs; a flaid neur- pathi bladder may respnd t parasympathmimeti mediatins suh as bethanehl hlride, 1050 mg three r fur times daily.Ada ms D et al. Patisiran, an RNAi therapeuti, fr hereditary transthyretin amylidsis. N Engl J Med. 2018;379:11. [PMID: 29972753] Bensn MD et al. Intersen treatment fr patients with heredi- tary transthyretin amylidsis. N Engl J Med. 2018;379:22. [PMID: 29972757]1.  Inerited NeurotiesA.  CharcotMarieTooth Disease HMSN Type I, IIThere  are several distint varieties f Chart-Marie-Tth disease, usually with an autsmal dminant mde f inheritane, but asinal ases ur n a spradi, reessive, r X-linked basis. Clinial presentatin may be with ft defrmities r gait disturbanes in hildhd r early adult life. Slw prgressin leads t the typial fea- tures f plyneurpathy, with distal weakness and wasting that begin in the legs, a variable amunt f distal sensry lss, and depressed r absent tendn reflexes. Tremr is a nspiuus feature in sme instanes. Hereditary motorCMDT22_Ch24_p0978-p1053.indd  1038 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1039 CMDT 2022and  sensory neuropathy (HMSN) type I is haraterized by demyelinatin n eletrdiagnsti studies and is usu- ally aused by mutatins in the peripheral myelin prtein 22 r myelin prtein zer gene. In HMSN type II , eletr- diagnsti studies shw axnal lss rather than demyelin- atin; ne-third f ases are due t mutatins in the gene mitfusin 2. A similar disrder may ur in patients with prgres- sive distal spinal musular atrphies, but there is n sen- sry lss; eletrphysilgi investigatin reveals that mtr ndutin velity is nrmal r nly slightly redued, and nerve atin ptentials are nrmal.B.  DejerineSottas Disease HMSN Type IIIThe  disrder may ur n a spradi, autsmal dmi- nant r, less mmnly, autsmal reessive basis. Onset in infany r hildhd leads t a prgressive mtr and sensry plyneurpathy with weakness, ataxia, sensry lss, and depressed r absent tendn reflexes. The periph- eral nerves may be palpably enlarged and are haraterized pathlgially by segmental demyelinatin, Shwann ell hyperplasia, and thin myelin sheaths. Eletrphysilgi- ally, there is a slwing f ndutin, and sensry atin ptentials may be unrerdable.C.  Friedreich AtaxiaThis disrder , the nly knwn autosomal recessive trinu- cleotide repeat disease, is aused by expansin f a ply- GAA lus in the gene fr frataxin n hrmsme 9, leading t symptms in hildhd r early adult life. The gait bemes ataxi, the hands beme lumsy, and ther signs f erebellar dysfuntin develp ampanied by weakness f the legs and extensr plantar respnses. Invlvement f peripheral sensry fibers leads t sensry disturbanes in the limbs and depressed tendn reflexes. There is bilateral pes avus. Pathlgially, there is a marked lss f ells in the psterir rt ganglia and degeneratin f peripheral sensry fibers. In the entral nervus system, hanges are nspiuus in the psterir and lateral lumns f the rd. Eletrphysilgially, ndutin velity in mtr fibers is nrmal r nly mildly redued, but sensry atin ptentials are small r absent. Cardia disease is the mst mmn ause f death. In the differential diagnsis fr Friedreih ataxia are ther spinerebellar ataxias, a grwing grup f at least 30 inherited disrders, eah invlving a different identified gene. These hetergeneus disrders, whih frequently (but nt exlusively) exhibit an autsmal dminant inher- itane pattern and ply-CAG expansin f the affeted gene, typially ause erebellar ataxia and varying mbi- natins f ther symptms (suh as peripheral neurpathy, phthalmparesis, dysarthria, and pyramidal and extrapy- ramidal signs).D . Refsum Disease HMSN Type IVThis  autsmal reessive disrder is due t a disturbane in phytani aid metablism. Pigmentary retinal degen- eratin is ampanied by prgressive sensrimtr ply- neurpathy and erebellar signs. Auditry dysfuntin,ardimypathy, and utaneus manifestatins may als ur. Mtr and sensry ndutin velities are redued, ften markedly, and there may be eletrmy- graphi evidene f denervatin in affeted musles. Dietary restritin f phytani aid and its preursrs may be helpful therapeutially. Plasmapheresis t redue stred phytani aid may help at the initiatin f treatment.E.  PorphyriaPe ripheral nerve invlvement may ur during aute attaks in bth variegate porphyria andacute intermit- tent porphyria. Mtr symptms usually ur first, and weakness is ften mst marked prximally and in the upper limbs rather than the lwer. Sensry symptms and signs may be prximal r distal in distributin. Autnmi invlvement is smetimes prnuned. The eletrphysi- lgi findings are in keeping with the results f neur- pathlgi studies suggesting that the neurpathy is axnal in type (see Chapter 40).F . Familial Amyloid PolyneuropathySensr y and autnmi symptms are espeially nspiu- us, whereas distal wasting and weakness ur later. The plyneurpathy is axnal and likely results frm amylid depsitin within the peripheral nerves due t mutatins in the genes ending transthyretin, aplipprtein A1, r gelslin. Transthyretin amyloidosis is the mst mmn; is assiated with ardimypathy, nephrpathy, lept- meningeal invlvement, and vitreus paity; and is treat- able with liver transplantatin, the small interfering ribnulei aid patisiran (0.3 mg/kg up t 30 mg intrave- nusly ne every 3 weeks), r the antisense lignule- tide intersen (284 mg subutaneusly weekly). Tafamidis helps transthyretin amylid ardimypathy and may slw the prgressin f the neurpathy.2.  Neuroties associted wit Systemic & Metbolic DisordersA.  Diabetes MellitusIn  this disrder, invlvement f the peripheral nervus system may lead t symmetri sensry r mixed plyneu- rpathy, asymmetri mtr radiulneurpathy r plexpa- thy (diabeti amytrphy), thraabdminal radiulpathy, autnmi neurpathy, r islated lesins f individual nerves. These may ur singly r in any mbinatin and are disussed in Chapter 27.B.  UremiaU remia may lead t a symmetri sensrimtr plyneu- rpathy that tends t affet the lwer limbs mre than the upper limbs and is mre marked distally than prxi- mally (see Chapter 22). The diagnsis an be nfirmed eletrphysilgially beause mtr and sensry n- dutin velity is mderately redued. The neurpathy imprves bth linially and eletrphysilgially with kidney transplantatin and t a lesser extent with hrni dialysis.CMDT22_Ch24_p0978-p1053.indd  1039 29/06/21 8:50 PMChapTER 241040 CMDT 2022C.  Alcoholism and Nutritional DeficiencyMan y patients with alhl use disrder have an axnal distal sensrimtr plyneurpathy that is frequently ampanied by painful ramps, musle tenderness, and painful paresthesias and is ften mre marked in the legs than in the arms. Symptms f autnmi dysfuntin may als be nspiuus. Mtr and sensry ndutin velity may be slightly redued, even in sublinial ases, but grss slwing f ndutin is unmmn. Treatment is similar t diabeti plyneurpathy but als inludes abstinene frm alhl. A similar distal sensrimtr plyneurpathy is a well-regnized feature f beriberi (thiamine defiieny). In vitamin B12defiieny, distal sen- sry plyneurpathy may develp but is usually vershad- wed by entral nervus system manifestatins (eg, myelpathy, pti neurpathy, r intelletual hanges).D . ParaproteinemiasA symmetri s ensrimtr plyneurpathy that is gradual in nset, prgressive in urse, and ften ampanied by pain and dysesthesias in the limbs may ur in patients (espeially men) with plasma cell myeloma (frmerly multiple myelma). The neurpathy is f the axnal type in lassi lyti myelma, but segmental demyelinatin (pri- mary r sendary) and axnal lss may ur in slerti myelma and lead t predminantly mtr linial mani- festatins. Bth demyelinating and axnal neurpathies are als bserved in patients with paraprteinemias withut myelma. A small fratin will develp myelma if serially fllwed. The demyelinating neurpathy in these patients may be due t the mnlnal prteins reating t a m- pnent f the nerve myelin. The neurpathy f lassi plasma ell myelma is prly respnsive t therapy. The plyneurpathy f benign monoclonal gammopathy may respnd t immunsuppressant mediatins and plasmapheresis. Plyneurpathy may als ur in assiatin with mnlnal gammpathy f unknwn signifiane, ma- rglbulinemia, and ryglbulinemia and smetimes respnds t plasmapheresis. Many patients with an IgM M-prtein will have antibdies t myelin-assiated gly- prtein (MAG); these patients may respnd t treatment with rituximab. Entrapment neurpathy, suh as arpal tunnel syndrme, is mre mmn than plyneurpathy in patients with (nnhereditary) generalized amylidsis.3.  Neuroties associted wit Infectious & Inflmmtory DisesesA.  LeprosyLeprsy is an imprtan t ause f peripheral neurpathy in ertain parts f the wrld. Sensry disturbanes are mainly due t invlvement f intrautaneus nerves. In tuberu- lid leprsy, they develp at the same time and in the same distributin as the nerve; trunks lying beneath the lesin are als invlved. In leprmatus leprsy, there is mre extensive sensry lss, and this develps earlier and t a greater extent in the lest regins f the bdy, suh as the drsal surfaes f the hands and feet, where the bailliprliferate mst atively. Mtr defiits result frm invlve- ment f superfiial nerves where their temperature is lw- est, eg, the ulnar nerve in the regin prximal t the lerann grve, the median nerve as it emerges frm beneath the frearm flexr musle t run tward the arpal tunnel, the perneal nerve at the head f the fibula, and the psterir tibial nerve in the lwer part f the leg; pathy faial musular weakness may als ur wing t invlve- ment f the superfiial branhes f the seventh ranial nerve. Mtr disturbanes in leprsy are suggestive f multiple mnneurpathy, whereas sensry hanges resemble thse f distal plyneurpathy. Examinatin, hwever, relates the distributin f sensry defiits t the temperature f the tissues; in the legs, fr example, sparing frequently urs between the tes and in the ppliteal fssae, where the temperature is higher. Treatment is with antileprti agents (see Chapter 33).B.  AIDSA  variety f neurpathies ur in HIV-infeted patients (see Chapter 31).C.  Lyme BorreliosisThe  neurlgi manifestatins f Lyme disease inlude meningitis, meningenephalitis, plyradiulneurpathy, mnneurpathy multiplex, and ranial neurpathy. Ser- lgi tests establish the underlying disrder. Lyme disease and its treatment are disussed in depth in Chapter 34.D . SarcoidosisCranial  nerve palsies (espeially faial palsy), multiple mnneurpathy and, less mmnly, symmetri plyneu- rpathy may all ur, the latter smetimes preferentially affeting either mtr r sensry fibers. Imprvement may ur with use f rtisterids.E.  PolyarteritisIn vlvement f the vasa nervrum by the vasuliti press may result in infartin f the nerve. Clinially, ne enunters an asymmetri sensrimtr plyneurpathy (mnneuritis multiplex) that pursues a waxing and waning urse. Crtisterids and yttxi agents espeially ylphsphamidemay be f benefit in severe ases (Chapter 20).F . Rheumatoid ArthritisCmpr essive r entrapment neurpathies, ishemi neu- rpathies, mild distal sensry plyneurpathy, and severe prgressive sensrimtr plyneurpathy an ur in rheumatid arthritis.4.  Neuroty associted wit Criticl IllnessPa tients in intensive are units with sepsis and multirgan failure smetimes develp plyneurpathies. This may be manifested initially by unexpeted diffiulty in weaningCMDT22_Ch24_p0978-p1053.indd  1040 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1041 CMDT 2022patients  frm a mehanial ventilatr and in mre advaned ases by wasting and weakness f the extremities and lss f tendn reflexes. Sensry abnrmalities are relatively innspiuus. The neurpathy is axnal in type. Its path- genesis is bsure, and treatment is supprtive. The prg- nsis is gd prvided patients rever frm the underlying ritial illness. A mypathy may als ur (disussed belw).5.  Toxic NeurotiesAxnal  plyneurpathy may fllw expsure t industrial agents r pestiides suh as arylamide, rganphsph- rus mpunds, hexaarbn slvents, methyl brmide, and arbn disulfide; metals suh as arseni, thallium, merury, and lead; and mediatins suh as phenytin, amidarne, perhexiline, isniazid, nitrfurantin, vin- ristine, and pyridxine in high dses. Detailed upa- tinal, envirnmental, and medial histries and regnitin f lusters f ases are imprtant in suggesting the diagnsis. Treatment is by preventing further expsure t the ausal agent. Isniazid neurpathy is prevented by pyridxine supplementatin. Diphtheriti neurpathy results frm a neurtxin released by the ausative rganism and is mmn in many areas. Palatal weakness may develp 24 weeks after infe- tin f the thrat, and infetin f the skin may similarly be fllwed by fal weakness f neighbring musles. Disturbanes f ammdatin may ur abut 45 weeks after infetin and distal sensrimtr demye- linating plyneurpathy after 13 mnths.6.  Neuroties associted wit Mlignnt DisesesA  variety f neurpathies have been assiated with nn- metastati mpliatins f malignany and were dis- ussed earlier.7.  acute Idiotic polyneuroty (Guillin-Brr Syndrome)E S S E N T I A L S  O F  D I A G N O S I S Acute or subacute progressive polyradiculoneuro- pathy. Weakness is more severe than sensory disturbances. Acute dysautonomia may be life-threatening. General ConsiderationsThis aute  r subaute plyradiulneurpathy smetimes fllws infetive illness, inulatins, r surgial pre- dures. There is an assiatin with preeding Campylo- bacter jejuni enteritis. The disrder prbably has an immunlgi basis, but the preise mehanism is unlear.Clinical FindingsA.  Symptoms and SignsThe  main mplaint is f weakness that varies widely in severity in different patients and ften has a prximal emphasis and symmetri distributin. It usually begins in the legs, spreading t a variable extent but frequently invlving the arms and ften ne r bth sides f the fae. The musles f respiratin r deglutitin may als be affeted. Sensry symptms are usually less nspiuus than mtr nes, but distal paresthesias and dysesthesias are mmn, and neurpathi r radiular pain is present in many patients. Autnmi disturbanes are als m- mn, may be severe, and are smetimes life-threatening; they inlude tahyardia, ardia irregularities, hypten- sin r hypertensin, faial flushing, abnrmalities f sweating, pulmnary dysfuntin, and impaired sphinter ntrl. The axnal subtypes f the syndrme ( acute motor axonal neuropathy [AMAN] andacute motor and sensory axonal neuropathy [AMSAN] ) are aused by antibdies t ganglisides n the axn membrane. The Miller Fisher syndrome, anther subtype, is haraterized by the linial triad f phthalmplegia, ataxia, and are- flexia, and is assiated with anti-GQ1b antibdies.B.  Laboratory FindingsThe  erebrspinal fluid harateristially ntains a high prtein nentratin with a nrmal ell unt, but these hanges may take up t 2 weeks t develp; white bld ell unts greater than 50 ells/mL (0.05  109/L) shuld prmpt nsideratin f alternative diagnses. Eletr- physilgi studies may reveal marked abnrmalities, whih d nt neessarily parallel the linial disrder in their tempral urse. Differential DiagnosisWhen  the diagnsis is made, the histry and apprpriate labratry studies shuld exlude the pssibility f pr- phyri, diphtheriti, r txi (heavy metal, hexaarbn, rganphsphate) neurpathies, and f HIV infetin. The tempral urse exludes ther peripheral neurpathies. Plimyelitis, btulism, and tik paralysis must als be nsidered as they ause weakness f aute nset. The presene f pyramidal signs, a markedly asymmetri mtr defiit, a sharp sensry level, r early sphinter invlve- ment shuld suggest a fal rd lesin. TreatmentT reatment with prednisne is ineffetive and may prlng revery time. Plasmapheresis is f value; it is best per- frmed within the first few days f illness and is partiularly useful fr linially severe r rapidly prgressive ases r thse with ventilatry impairment. IVIG (400 mg/kg/day fr 5 days) is equally helpful. Patients shuld be admitted t intensive are units if their fred vital apaity is delining, and intubatin is nsidered if the fred vital apaity reahes 15 mL/kg, the maximum inspiratryCMDT22_Ch24_p0978-p1053.indd  1041 29/06/21 8:50 PMChapTER 241042 CMDT 2022pres sure reahes 30 mm Hg, r dyspnea bemes evident. Delining xygen saturatin is a late indiatr f neur- musular respiratry failure. Respiratry tilet and hest physial therapy help prevent ateletasis. Marked hypten- sin may respnd t vlume replaement r pressr agents. Thrmbprphylaxis is imprtant. PrognosisMs t patients eventually make a gd revery, but this may take many mnths, and abut 20% f patients are left with persisting disability. Apprximately 3% f patients with aute idipathi plyneurpathy have ne r mre linially similar relapses, smetimes several years after the initial illness. When to ReferAll patients sh uld be referred. When to AdmitAll  patients shuld be hspitalized until their nditin is stable and there is n respiratry mprmise.Malek  E et al. Guillain-Barr syndrme. Semin Neurl. 2019;39:589. [PMID: 31639842]8.  Cronic Inflmmtory polyneurotyChrni  inflammatry demyelinating plyneurpathy, an aquired immunlgially mediated disrder, is linially similar t Guillain-Barr syndrme exept that it has a relapsing r steadily prgressive urse ver mnths r years and that autnmi dysfuntin is generally less mmn. It may present as an exlusively mtr disrder r with a mixed sensrimtr disturbane. In the relapsing frm, partial revery may ur after sme relapses, but in ther instanes there is n revery between exaerba- tins. Althugh remissin may ur spntaneusly with time, the disrder frequently fllws a prgressive dwn- hill urse leading t severe funtinal disability. Eletrdiagnsti studies shw marked slwing f mtr and sensry ndutin, and fal ndutin blk. Signs f partial denervatin may als be present wing t sendary axnal degeneratin. Nerve bipsy may shw hrni perivasular inflammatry infiltrates in the endneurium and epineurium, withut ampanying evidene f vasulitis. Hwever, a nrmal nerve bipsy result r the presene f nnspeifi abnrmalities des nt exlude the diagnsis. Crtisterids may arrest r reverse the dwnhill urse. Treatment is usually begun with prednisne, 6080 mg rally daily, ntinued fr 23 mnths r until a definite respnse has urred. If n respnse has urred despite 3 mnths f treatment, a higher dse may be tried. In respnsive ases, the dse is gradually tapered, but mst patients beme rtisterid-dependent, ften requiring prednisne, 20 mg daily n alternate days, n a lng-term basis. IVIG an be used in plae f, r in additin t rti- sterids, and is best used as the initial treatment in puremtr syndrmes (2 g/kg ver 25 days fllwed by 1 g/kg every 3 weeks); a weekly regimen f 0.20.4 g/kg f a 20% subutaneus immunglbulin slutin is an effetive alternative but has nt been mpared diretly t rti- sterids r IVIG. When bth IVIG and rtisterids are ineffetive, plasma exhange may be wrthwhile. Cnsis- tent with the ntin that the nditin is antibdy medi- ated, rituximab has shwn prmise. Immunsuppressant r immunmdulatry mediatins (suh as azathiprine) may be added when the respnse t ther measures is unsatisfatry r t enable maintenane dses f rti- sterids t be lwered. Symptmati treatment is als imprtant.Bunshten  C et al. Prgress in diagnsis and treatment f hrni inflammatry demyelinating plyneurpathy. Lanet Neurl. 2019;18:784. [PMID: 31076244]MO NONEUROPATHIESE S S E N T I A L S  O F  D I A G N O S I S Focal motor or sensory deficit. Deficit is in territory of an individual peripheral nerve. An individual nerve may be injured alng its urse r may be mpressed, angulated, r strethed by neighbring ana- tmi strutures, espeially at a pint where it passes thrugh a narrw spae ( entrapment neuropathy ). The relative ntributins f mehanial fatrs and ishemia t the lal damage are nt lear. With invlvement f a sen- sry r mixed nerve, pain is mmnly felt distal t the lesin. Symptms never develp with sme entrapment neurpathies, reslve rapidly and spntaneusly in thers, and beme prgressively mre disabling and distressing in yet ther ases. The preise neurlgi defiit depends n the nerve invlved. Perussin f the nerve at the site f the lesin may lead t paresthesias in its distal distributin. Entrapment neurpathy may be the sle manifestatin f sublinial plyneurpathy, and this must be brne in mind and exluded by nerve ndutin studies. Suh studies are als indispensable fr the lalizatin f the fal lesin. In patients with aute mpressin neurpathy suh as may ur in intxiated individuals ( Saturday night palsy ), n treatment is neessary. Cmplete revery gen- erally urs, usually within 2 mnths, presumably beause the underlying pathlgy is demyelinatin. Hwever, ax- nal degeneratin an ur in severe ases, and revery then takes lnger and may never be mplete. In hrni mpressive r entrapment neurpathies, avidane f aggravating fatrs and rretin f any under- lying systemi nditins are imprtant. Lal infiltratin f the regin abut the nerve with rtisterids may be f value; in additin, surgial dempressin may help ifCMDT22_Ch24_p0978-p1053.indd  1042 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1043 CMDT 2022there  is a prgressively inreasing neurlgi defiit r if eletrdiagnsti studies shw evidene f partial denerva- tin in weak musles. Peripheral nerve tumrs are unmmn, exept in neu- rfibrmatsis type 1, but als give rise t mnneurpathy. This may be distinguishable frm entrapment neurpathy nly by nting the presene f a mass alng the urse f the nerve and by demnstrating the preise site f the lesin with apprpriate eletrphysilgi studies. Treatment f symptmati lesins is by surgial remval if pssible.1.  Crl Tunnel SyndromeSee Chapter 41. 2.  prontor Teres or anterior Interosseous SyndromeThe  median nerve gives ff its mtr branh, the anterir intersseus nerve, belw the elbw as it desends between the tw heads f the prnatr teres musle. A lesin f either nerve may ur in this regin, smetimes after trauma r wing t mpressin frm, fr example, a fibrus band. With anterir intersseus nerve invlvement, there is n sensry lss, and weakness is nfined t the prnatr qua- dratus, flexr plliis lngus, and the flexr digitrum pr- fundus t the send and third digits. Weakness is mre widespread and sensry hanges ur in an apprpriate distributin when the median nerve itself is affeted. The prgnsis is variable. If imprvement des nt ur spn- taneusly, dempressive surgery may be helpful.3.  Ulnr Nerve LesionsUlnar nerve lesi ns are likely t ur in the elbw regin as the nerve runs behind the medial epindyle and desends int the ubital tunnel. In the ndylar grve, the ulnar nerve is expsed t pressure r trauma. Mre- ver, any inrease in the arrying angle f the elbw, whether ngenital, degenerative, r traumati, may ause exessive strething f the nerve when the elbw is flexed. Ulnar nerve lesins may als result frm thikening r distrtin f the anatmi strutures frming the ubital tunnel, and the resulting symptms may als be aggravated by flexin f the elbw, beause the tunnel is then nar- rwed by tightening f its rf r inward bulging f its flr. A severe lesin at either site auses sensry hanges in the fifth and medial half f the furth digits and alng the medial brder f the hand. There is weakness f the ulnar-innervated musles in the frearm and hand. With a ubital tunnel lesin, hwever, there may be relative spar- ing f the flexr arpi ulnaris musle. Eletrphysilgi evaluatin using nerve stimulatin tehniques allws mre preise lalizatin f the lesin. Initial treatment nsists f aviding pressure n the medial elbw (eg, avid resting the elbws n arm rests; pad the elbw during sleep) and preventing prlnged elbw flexin, espeially at night. Splints are available t keep the elbw frm flexing beynd 45 t 90 degrees. If nservative measures are unsuessful in relieving symp- tms and preventing further prgressin, surgial treat- ment may be neessary. This nsists f nerve transpsitinif the lesin is in the ndylar grve, r a release pre- dure if it is in the ubital tunnel. Ulnar nerve lesins may als develp at the wrist r in the palm f the hand, usually wing t repetitive trauma r t mpressin frm ganglia r benign tumrs. They an be subdivided depending n their presumed site. Cm- pressive lesins are treated surgially. If repetitive mehani- al trauma is respnsible, this is avided by upatinal adjustment r jb retraining.4.  Rdil Nerve LesionsThe  radial nerve is partiularly liable t mpressin r injury in the axilla (eg, by ruthes r by pressure when the arm hangs ver the bak f a hair). This leads t weakness r paralysis f all the musles supplied by the nerve, inluding the trieps. Sensry hanges may als ur but are ften surprisingly innspiuus, being marked nly in a small area n the bak f the hand between the thumb and index finger. Injuries t the radial nerve in the spiral grve ur harateristially during deep sleep, as in intxiated individuals, and there is then sparing f the trieps musle, whih is supplied mre prximally. The nerve may als be injured at r abve the elbw; its purely mtr psterir intersseus branh, supplying the exten- srs f the wrist and fingers, may be invlved immediately belw the elbw, but then there is sparing f the extensr arpi radialis lngus, s that the wrist an still be extended. The superfiial radial nerve may be mpressed by hand- uffs r a tight wath strap.5.  Femorl NeurotyThe  linial features f femral nerve palsy nsist f weak- ness and wasting f the quadrieps musle, with sensry impairment ver the antermedian aspet f the thigh and smetimes als f the leg t the medial mallelus, and a depressed r absent knee jerk. Islated femral neurpathy may ur in patients with diabetes r frm mpressin by retrperitneal neplasms r hematmas (eg, expanding arti aneurysm). Femral neurpathy may als result frm pressure frm the inguinal ligament when the thighs are markedly flexed and abduted, as in the lithtmy psitin.6.  Merlgi presteticThe  lateral femral utaneus nerve, a sensry nerve arising frm the L2 and L3 rts, may be mpressed r strethed in bese r diabeti patients and during pregnany. The nerve usually runs under the uter prtin f the inguinal ligament t reah the thigh, but the ligament smetimes splits t enlse it. Hyperextensin f the hip r inreased lumbar lrdsissuh as urs during pregnanyleads t nerve mpressin by the psterir fasile f the liga- ment. Hwever, entrapment f the nerve at any pint alng its urse may ause similar symptms, and several ther anatmi variatins predispse the nerve t damage when it is strethed. Pain, paresthesia, r numbness urs abut the uter aspet f the thigh, usually unilaterally, and is smetimes relieved by sitting. The pain stps at the knee, unlike the pain frm lwer lumbar siatia that radiates t the ft. Examinatin shws n abnrmalities exept inCMDT22_Ch24_p0978-p1053.indd  1043 29/06/21 8:50 PMChapTER 241044 CMDT 2022severe  ases when utaneus sensatin is impaired in the affeted area. Symptms are usually mild and mmnly settle spntaneusly. Hydrrtisne injetins medial t the antersuperir ilia spine ften relieve symptms tem- prarily, while nerve dempressin by transpsitin may prvide mre lasting relief.7.  Scitic & Common peronel (Fibulr) Nerve plsiesMisplaed  deep intramusular injetins are prbably still the mst mmn ause f siati nerve palsy. Trauma t the buttk, hip, r thigh may als be respnsible. The resulting linial defiit depends n whether the whle nerve has been affeted r nly ertain fibers. In general, the perneal (fibular) fibers f the siati nerve are mre suseptible t damage than thse destined fr the tibial nerve. A siati nerve lesin may therefre be diffiult t distinguish frm perneal (fibular) neurpathy unless there is eletrmygraphi evidene f invlvement f the shrt head f the bieps femris musle. The mmn perneal (fibular) nerve itself may be mpressed r injured in the regin f the head and nek f the fibula, eg, by sitting with rssed legs r wearing high bts. There is weakness f drsiflexin and eversin f the ft, am- panied by numbness r blunted sensatin f the anterlat- eral aspet f the alf and drsum f the ft.8.  Trsl Tunnel SyndromeThe  tibial nerve, the ther branh f the siati, supplies several musles in the lwer extremity, gives rigin t the sural nerve, and then ntinues as the psterir tibial nerve t supply the plantar flexrs f the ft and tes. It passes thrugh the tarsal tunnel behind and belw the medial mal- lelus, giving ff alaneal branhes and the medial and lat- eral plantar nerves that supply small musles f the ft and the skin n the plantar aspet f the ft and tes. Cmpres- sin f the psterir tibial nerve r its branhes between the bny flr and ligamentus rf f the tarsal tunnel leads t pain, paresthesias, and numbness ver the bttm f the ft, espeially at night, with sparing f the heel. Musle weakness may be hard t regnize linially. Cmpressive lesins f the individual plantar nerves may als ur mre distally, with linial features similar t thse f the tarsal tunnel syndrme. Treatment is surgial dempressin. When to Refer If there is unertainty abut the diagnsis. Symptms r signs are prgressing despite treatment.BE LL PALSYE S S E N T I A L S  O F  D I A G N O S I S Sudden onset of lower motor neuron facial palsy. Hyperacusis or impaired taste may occur. No other neurologic abnormalities.General ConsiderationsBell pa lsy is an idiopathic facial paresis of lower motor neu- ron type that has been attributed t an inflammatry rea- tin invlving the faial nerve near the stylmastid framen r in the bny faial anal. In sme instanes, this may be due t reativatin f herpes simplex r variella zster virus infetin in the geniulate ganglin. The disr- der is mre mmn in pregnant wmen and in persns with diabetes mellitus. Clinical FindingsThe  faial paresis (Figure 241) generally mes n abruptly, but it may wrsen ver the fllwing day r s. Pain abut the ear preedes r ampanies the weakness in many ases but usually lasts fr nly a few days. The fae itself feels stiff and pulled t ne side. There may be ipsilat- eral restritin f eye lsure and diffiulty with eating and fine faial mvements. A disturbane f taste is mmn, wing t invlvement f hrda tympani fibers, and hyper- ausis due t invlvement f fibers t the stapedius urs asinally. In ases due t herpes zster infetin, vesi- les may be bserved in the external ear anal. Differential DiagnosisLwer  mtr neurn faial palsy an be differentiated frm strke by linial examinatin. A strke r ther entral lesin will nt ause hyperausis r disturbane f taste, Figure 241. Facial palsy caused by an infection with Borrelia burgdorferi (Lyme disease). (Public Health Image Library, CDC.)CMDT22_Ch24_p0978-p1053.indd  1044 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1045 CMDT 2022generally  spares the frehead, and is ampanied by ther fal defiits. An islated faial palsy may ur in patients with HIV serpsitivity, saridsis, Lyme disease (Figure 241; als see Chapter 34), r any press ausing an inflammatry reatin in the subarahnid spae, suh as meningitis. Whenever faial palsies ur bilaterally, r a faial palsy urs in njuntin with ther neurlgi defiits, MRI brain imaging shuld be undertaken and ther investigatins nsidered. TreatmentA pprximately 60% f ases f Bell palsy rever m- pletely withut treatment, presumably beause the lesin is s mild that it leads merely t ndutin blk. Treat- ment with rtisterids (prednisne 60 mg rally daily fr 5 days fllwed by a 5-day taper, r prednislne 25 mg rally twie daily fr 10 days) inreases the hane f a mplete revery at 912 mnths by 1215%. Treat- ment with aylvir r valaylvir is nly indiated when there is evidene f herpeti vesiles in the external ear anal. It is helpful t prtet the eye with lubriating drps (r lubriating intment at night) and a path if eye lsure is nt pssible. There is n evidene that surgial predures t dempress the faial nerve are f benefit. Physial therapy may imprve faial funtin.Gagyr  I et al. Antiviral treatment f Bells palsy (idipathi faial paralysis). Chrane Database Syst Rev. 2019;9:CD001869. [PMID: 31486071]DI SCOGENIC NECK PAINE S S E N T I A L S  O F  D I A G N O S I S Neck pain, sometimes radiating to arms. Restricted neck movements. Motor, sensory, or reflex changes in arms with root involvement. Neurologic deficit in legs, gait disorder, or sphinc- ter disturbance with cord involvement. General ConsiderationsA variety  f ngenital abnrmalities may invlve the er- vial spine and lead t nek pain; these inlude hemiverte- brae, fused vertebrae, basilar impressin, and instability f the atlantaxial jint. Traumati, degenerative, infetive, and neplasti disrders may als lead t pain in the nek. When rheumatid arthritis invlves the spine, it tends t affet espeially the ervial regin, leading t pain, stiff- ness, and redued mbility; displaement f vertebrae r atlantaxial subluxatin may lead t rd mpressin that an be life-threatening if nt treated by fixatin. Furtherdetails are given in Chapter 41 and disussin here is restrited t disk disease.1.  acute Cervicl Disk protrusionAut e ervial disk prtrusin leads t pain in the nek and radiular pain in the arm, exaerbated by head mvement. With lateral herniatin f the disk, mtr, sensry, r reflex hanges may be fund in a radiular (usually C6 r C7) distributin n the affeted side (Figure 242); with mre entrally direted herniatins, the spinal rd may als be invlved, leading t spasti paraparesis and sensry distur- banes in the legs, smetimes ampanied by impaired sphinter funtin. The diagnsis is nfirmed by MRI r CT myelgraphy. In mild ases, the prgnsis is gd and mplete revery urs in a majrity f patients with nservative therapy. Evidene des nt supprt any spe- ifi interventin, and sme mbinatin f bed rest, ativ- ity restritin, immbilizatin f the nek in a llar fr several weeks, and physial therapy is generally presribed. If these measures are unsuessful r the patient has a sig- nifiant neurlgi defiit, surgial remval f the prtrud- ing disk may be neessary.2.  Cervicl SondylosisCer vial spndylsis results frm hrni ervial disk degeneratin, with herniatin f disk material, sendary alifiatin, and assiated stephyti utgrwths. One r mre f the ervial nerve rts may be mpressed, strethed, r angulated; and myelpathy may als develp as a result f mpressin, vasular insuffiieny, r reur- rent minr trauma t the rd. Patients present with nek pain and restrited head mvement, ipital headahes, radiular pain and ther sensry disturbanes in the arms, weakness f the arms r legs, r sme mbinatin f these symptms. Examinatin generally reveals that lateral flex- in and rtatin f the nek are limited. A segmental pat- tern f weakness r dermatmal sensry lss (r bth) may be fund unilaterally r bilaterally in the upper limbs, and tendn reflexes mediated by the affeted rt r rts are depressed. The C5 and C6 nerve rts are mst mmnly invlved, and examinatin frequently then reveals weak- ness f musles supplied by these rts (eg, deltids, supra- spinatus and infraspinatus, bieps, brahiradialis), pain r sensry lss abut the shulder and uter brder f the arm and frearm, and depressed bieps and brahiradialis reflexes. Spasti paraparesis may als be present if there is an assiated myelpathy, smetimes ampanied by uri- nary urgeny, inntinene, r psterir lumn r spin- thalami sensry defiits in the legs. Plain radigraphs f the ervial spine shw stephyte frmatin, narrwing f disk spaes, and enrahment n the intervertebral framina, but suh hanges are mmn in middle-aged persns and may be unrelated t the pre- senting mplaint. CT r MRI helps nfirm the diagnsis and exlude ther strutural auses f the myelpathy. Restritin f nek mvements by a ervial llar may relieve pain. Lal injetin f anesthetis r rtisterids, fr instane by a pain management speialist, may be fCMDT22_Ch24_p0978-p1053.indd  1045 29/06/21 8:50 PMChapTER 241046 CMDT 2022 Figure 242. Cutaneous innervation. The segmental or radicular (root) distribution is shown on the left side of the body and the peripheral nerve distribution on the right side. Segmental maps show differences depending on how they were constructed (single root stimulation or section; local anesthetic injection into single dorsal root ganglia). (Adapted, with permission, from Aminoff MJ, Greenberg DA, Simon RP . Clinical Neurology, 9th ed. McGraw-Hill Education, 2015.)= Iliohypogastric = Ilioinguinal = Genitofemoral Dorsal nerve of penis Perineal nerve of penisPeripheral nerve Nerve root Trigeminal (Cranial nerve V) Anterior cutaneous nerve of neck Supraclavicular nerves Axillary nerve Medial cutaneous nerve of arm Lateral cutaneous nerve of arm (branch of radial nerve) Medial cutaneous nerve of forearm Lateral cutaneous nerve of forearm Radial Median Ulnar Lateral femoral cutaneous Obturator Anterior femoral cutaneous Lateral cutaneous nerve of calf Saphenous Superficial peroneal Sural Lateral and medial plantar Deep peronealOphthalmic branch (V1) Maxillary branch (V2) Mandibular branch (V3)* * X XLateral thoracic rami Post.Mid.Ant.Anterior thoracic ramiC3 C4 C5 T2 T3 T4 T5 T6 T7 T8 T9 T10 T11 T12 L1L1 L2 L3 L4 L5 S1T2 T1 C8C6C6 C7CMDT22_Ch24_p0978-p1053.indd  1046 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1047 CMDT 2022P eripheral nerve Posterior rami of cervical nerves Supraclavicular Axillary Medial cutaneous nerve of forearmLateral cutaneous nerve of forearm Lateral femoral cutaneous Obturator Anterior femoral cutaneous Posterior femoral cutaneous Lateral cutaneous nerve of calf SaphenousSuperficial peroneal Calcaneal Lateral plantar Medial plantarGreat occipital Lesser occipital Great auricular Posterior cutaneous nerve of forearmMedial cutaneous nerve of armLateral cutaneous nerve of arm Posterior cutaneous nerve of arm MedianPosterior lumbar rami Posterior sacral rami = IliohypogastricXX Nerve root Radial Ulnar SuralT2 T2 T1T3C2 C3 C4 T4 T5 T6 T7 T8 T9 T10 T11 T12 L1 L2 C8C6 C7 S1L5 L5S3 L 3S4 S5 L4S2P osterior thoracic ramiLateral thoracic ramiC5 C6benefit . Operative treatment may be neessary t prevent further prgressin if there is a signifiant neurlgi defi- it; bwel r bladder symptms; r if rt pain is severe, persistent, and unrespnsive t nservative measures. When to Refer Pain unrespnsive t simple measures. Patients with neurlgi defiits. Patients in whm surgial treatment is under nsideratin.When to Admit Patients with prgressive r signifiant neurlgi defiit. Patients with sphinter invlvement (frm rd mpressin). Patients requiring surgial treatment.Stin AM et  al. Myelpathies due t strutural ervial and th- rai disease. Cntinuum (Minneap Minn). 2018;24:567. [PMID: 29613900]Figure 242. (Continued )CMDT22_Ch24_p0978-p1053.indd  1047 29/06/21 8:50 PMChapTER 241048 CMDT 2022BR aChIaL & LUMBaR pLEXUS LESIONS 1. Brcil plexus NeurotyBrahial  plexus neurpathy may be idipathi, smetimes urring in relatinship t a number f different nnspe- ifi illnesses r fatrs. In ther instanes, brahial plexus lesins fllw trauma r result frm ngenital anmalies, neplasti invlvement, r injury by varius physial agents. In rare instanes, the disrder urs n a familial basis. Idipathi brahial plexus neurpathy ( neuralgic amyotrophy ) harateristially begins with severe pain abut the shulder, fllwed within a few days by weak- ness, reflex hanges, and sensry disturbanes invlving espeially the C5 and C6 segments but affeting any nerve in the brahial plexus. Symptms and signs are usually unilateral but may be bilateral. Wasting f affeted musles is smetimes prfund. The disrder relates t disturbed funtin f ervial rts r part f the brahial plexus, but its preise ause is unknwn. Revery urs ver the ensuing mnths but may be inmplete. Treatment is purely symptmati, althugh emerging evidene suggests that mirsurgial neurlysis f hurglass-like nstri- tins n affeted nerves identified by magneti resnane neurgraphy r high-reslutin ultrasund imprves ut- me in patients wh have nt revered after several mnths f nservative management.2.  Cervicl Rib SyndromeC mpressin f the C8 and T1 rts r the lwer trunk f the brahial plexus by a ervial rib r band arising frm the seventh ervial vertebra leads t weakness and wasting f intrinsi hand musles, espeially thse in the thenar emi- nene, ampanied by pain and numbness in the medial tw fingers and the ulnar brder f the hand and frearm. Ele- trmygraphy, nerve ndutin studies, and smatsensry evked ptential studies may help nfirm the diagnsis. MRI may be espeially helpful in revealing the underlying mpressive struture. Plain radigraphs r CT sanning smetimes shws the ervial rib r a large transverse press f the seventh ervial vertebra, but nrmal findings d nt exlude the pssibility f a ervial band. Treatment f the disrder is by surgial exisin f the rib r band.3.  Lumboscrl plexus LesionsA  lumbsaral plexus lesin may develp in assiatin with diseases suh as diabetes, aner, r bleeding disr- ders r in relatin t injury. It asinally urs as an islated phenmenn similar t idipathi brahial plexpathy (nndiabeti lumbsaral radiulplexus neu- rpathy), and pain and weakness then tend t be mre nspiuus than sensry symptms. The distributin f symptms and signs depends n the level and pattern f neurlgi invlvement.Gstettner  C et al. Neuralgi amytrphy: a paradigm shift in diagnsis and treatment. J Neurl Neursurg Psyhiatry. 2020;91:879. [PMID: 32487526]DISORDERS OF NEUROMUSCULaR TRaNSMISSION 1. Mysteni GrvisE S S E N T I A L S  O F  D I A G N O S I S Fluctuating weakness of commonly used volun- tary muscles, producing symptoms such as diplo- pia, ptosis, and difficulty in swallowing. Activity increases weakness of affected muscles. Short-acting anticholinesterases transiently improve the weakness. General ConsiderationsM yasthenia gravis urs at all ages, sometimes in association with a thymic tumor or thyrotoxicosis , as well as in rheu- matid arthritis and lupus erythematsus. It is mst m- mn in yung wmen with HLA-DR3; if thymma is assiated, lder men are mre mmnly affeted. Onset is usually insidius, but the disrder is smetimes unmasked by a inidental infetin that leads t exa- erbatin f symptms. Exaerbatins may als ur befre the menstrual perid and during r shrtly after pregnany. Symptms are due t a variable degree f blk f neurmusular transmissin aused by autanti- bdies binding t aetylhline reeptrs; these are fund in mst patients with the disease and have a primary rle in reduing the number f funtining aetylhline reep- trs. Additinally, ellular immune ativity against the reeptr is fund. Clinical FindingsA.  Symptoms and SignsPa tients present with ptsis, diplpia, diffiulty in hewing r swallwing, respiratry diffiulties, limb weakness, r sme mbinatin f these prblems. Weakness may remain lalized t a few musle grups r may beme generalized. The external ular musles and ertain ther ranial musles, inluding the mastiatry, faial, and pha- ryngeal musles, are espeially likely t be affeted, and the respiratry and limb musles may als be invlved. Symp- tms ften flutuate in intensity during the day, and this diurnal variatin is superimpsed n a tendeny t lnger- term spntaneus relapses and remissins that may last fr weeks. Nevertheless, the disrder fllws a slwly prgres- sive urse and may have a fatal utme wing t respira- try mpliatins suh as aspiratin pneumnia. Clinial examinatin nfirms the weakness and fatiga- bility f affeted musles. In mst ases, the extraular musles are invlved, and this leads t ular palsies and ptsis, whih are mmnly asymmetri. Pupillary respnses are nrmal. The bulbar and limb musles are ften weak, but the pattern f invlvement is variable. Sus- tained ativity f affeted musles inreases the weakness,CMDT22_Ch24_p0978-p1053.indd  1048 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1049 CMDT 2022whih impr ves after a brief rest. Sensatin is nrmal, and there are usually n reflex hanges. Life-threatening exaerbatins f myasthenia (s-alled myasthenic crisis ) may lead t respiratry weakness requiring immediate admissin t the intensive are unit, where respiratry funtin an be mnitred and ventila- tr supprt is readily available.B.  Laboratory and Other StudiesAssay  f serum fr elevated levels f irulating aetylh- line reeptr antibdies is useful beause it has a sensitiv- ity f 8090% fr the diagnsis f myasthenia gravis. Certain patients withut antibdies t aetylhline reeptrs have serum antibdies t musle-speifi tyr- sine kinase (MuSK), whih shuld therefre be deter- mined; these patients are mre likely t have faial, respiratry, and prximal musle weakness than thse with antibdies t aetylhline reeptrs. Other antibd- ies assiated with myasthenia gravis inlude lw-density lipprtein reeptr-related prtein 4 (LRP4) and agrin, but tests fr these antibdies are nt widely mmerially available. Eletrphysilgi demnstratin f a derementing musle respnse t repetitive 2- r 3-Hz stimulatin f mtr nerves indiates a disturbane f neurmusular transmissin. Suh an abnrmality may even be deteted in linially strng musles with ertain prvative pre- dures. Needle eletrmygraphy f affeted musles shws a marked variatin in nfiguratin and size f individual mtr unit ptentials, and single-fiber eletrmygraphy reveals an inreased jitter, r variability, in the time interval between tw musle fiber atin ptentials frm the same mtr unit.C.  ImagingA  CT san f the hest with and withut ntrast shuld be btained t demnstrate a existing thymma. TreatmentAntih linesterase mediatins prvide symptmati ben- efit withut influening the urse f the disease. Nestig- mine, pyridstigmine, r bth an be used, the dse being determined n an individual basis. The usual dse f ne- stigmine is 7.530 mg (average, 15 mg) rally taken fur times daily; f pyridstigmine, 30180 mg (average, 60 mg) rally fur times daily. Overmediatin may temprarily inrease weakness. A wide range f mediatins (eg, ami- nglysides) may exaerbate myasthenia gravis and shuld be avided. Thymetmy shuld be perfrmed when a thymma is present. A multienter randmized trial demnstrated the benefit f thymetmy even in the absene f a radilgi- ally identifiable thymma, with imprved strength, lwer immunsuppressin requirements, and fewer hspitaliza- tins in the surgially treated grup. Thus, thymectomy should be considered in all patients younger than age 65 unless weakness is restricted to the extraocular muscles. If the disease is f reent nset and nly slwly prgressive,peratin is smetimes delayed fr a year r s, in the hpe that spntaneus remissin will ur. Treatment with rtisterids is indiated fr patients wh have respnded prly t antihlinester- ase mediatins. Sme patients experiene transient exaerbatin f weakness and even develp respiratry failure within the first 12 weeks if rtisterids are initiated at high dses (eg, prednisne 1 mg/kg/day). Therefre, in stable patients, rtisterids are intr- dued gradually in the utpatient setting. Prednisne an be started at 20 mg rally daily and inreased by 10 mg inrements weekly t a target f 1 mg/kg/day (maximum daily dse 100 mg). Fr patients hspitalized with severe myasthenia and treated with IVIG r plasma- pheresis, the higher dse an be given initially beause the mre rapid nset f atin f the frmer tw thera- pies mitigates the initial dip in strength due t rti- sterids. Crtisterids an be presribed as alternate-day r daily treatment, with alternate-day therapy ptentially mitigating side effets. One the patient has stabilized at the initial high dse, rtiste- rids an gradually be tapered t a relatively lw main- tenane level (eg, 10 mg prednisne rally daily) as imprvement urs; ttal withdrawal is diffiult, hw- ever. Treatment with azathiprine may be effetive in allwing a lwer dse f rtisterids. The usual dse is 23 mg/kg rally daily after a lwer initial dse. Other immunsuppressive agents that are used in myasthenia gravis t redue the rtisterid dse inlude myphe- nlate mfetil, rituximab, ylsprine, methtrexate, and tarlimus. Eulizumab, a mplement inhibitr, is apprved by the FDA fr aetylhline reeptr antibdy psitive myasthenia in patients wh have disease refra- try t at least tw alternate immunsuppressive thera- pies. It is administered intravenusly (900 mg weekly fr fur dses, fllwed by 1200 mg at week 5, then 1200 mg every 2 weeks). Patients must be vainated against menin- gus prir t reeiving eulizumab. In patients with majr disability, plasmapheresis r IVIG therapy may be benefiial and have similar effiay. It is als useful fr stabilizing patients befre thymetmy and fr managing aute risis. When to ReferAll patients sh uld be referred. When to Admit Patients with aute exaerbatin r respiratry invlvement. Patients requiring plasmapheresis. Fr thymetmy.Fa rmakidis C et al. Treatment f myasthenia gravis. Neurl Clin. 2018;36:311. [PMID: 29655452] Muppidi S et al; Regain Study Grup. Lng-term safety and effiay f eulizumab in generalized myasthenia gravis. Musle Nerve. 2019;60:14. [PMID: 30767274]CMDT22_Ch24_p0978-p1053.indd  1049 29/06/21 8:50 PMChapTER 241050 CMDT 20222.  Mystenic Syndrome (Lmbert-Eton Mystenic Syndrome)E S S E N T I A L S  O F  D I A G N O S I S Variable weakness, typically improving with activity. Dysautonomic symptoms may also be present. A history of malignant disease may be obtained. Clinical FindingsM yastheni syndrme may be associated with small cell carcinoma, smetimes develping befre the tumr is diag- nsed, and asinally urs with ertain autimmune diseases. There is defetive release f aetylhline in respnse t a nerve impulse, aused by P/Q-type vltage- gated alium hannel antibdies, and this leads t weak- ness, espeially f the prximal musles f the limbs. Unlike myasthenia gravis, hwever, pwer steadily increases with sustained ntratin. The diagnsis an be n- firmed eletrphysilgially, beause the musle respnse t stimulatin f its mtr nerve inreases remarkably after exerise r if the nerve is stimulated repetitively at high rates (50 Hz), even in musles that are nt linially weak. TreatmentT reatment with IVIG, plasmapheresis, and immunsup- pressive mediatin therapy (prednisne and azathiprine) may lead t linial and eletrphysilgi imprvement, in additin t therapy aimed at tumr when present. Pred- nisne is usually initiated in a daily dse f 6080 mg rally and azathiprine in a daily dse f 2 mg/kg rally. Symp- tmati therapy inludes the use f ptassium hannel antagnists; f these, amifampridine is a 3,4-diaminpyri- dine (1580 mg/day rally in three divided dses) and is apprved in the United States and Eurpe. Guanidine hydrhlride (2550 mg/kg/day rally in divided dses) is an alternative and is asinally helpful in seriusly dis- abled patients, but adverse effets f the mediatin inlude marrw suppressin. The respnse t treatment with antihlinesterase mediatins suh as pyridstig- mine r nestigmine is usually disappinting.3.  BotulismThe txin f  Clostridium botulinum prevents the release f aetylhline at neurmusular juntins and autnmi synapses. Btulism urs mst mmnly fllwing the ingestin f ntaminated hme-anned fd; utbreaks have als urred amng drug abusers due t wund infetin after injetin f ntaminated herin. The diagnsis shuld be suggested by the develpment f sud- den, flutuating, severe weakness with preserved sensa- tin in a previusly healthy persn. Symptms begin within 72 hurs fllwing ingestin f the txin and may prgress fr several days. Typially, there is diplpia, ptsis,faial weakness, dysphagia, and nasal speeh, fllwed by respiratry diffiulty and finally by weakness that appears last in the limbs. Blurring f visin (with unreative dilated pupils) is harateristi, and there may be dryness f the muth, nstipatin (paralyti ileus), and pstural hyp- tensin. The tendn reflexes are nt affeted unless the invlved musles are very weak. If the diagnsis is sus- peted, the lal health authrity shuld be ntified and a sample f serum and ntaminated fd (if available) sent t be assayed fr txin. Supprt fr the diagnsis may be btained by eletrphysilgi studies; with repetitive stimulatin f mtr nerves at fast rates, the musle respnse inreases in size prgressively. Patients shuld be hspitalized in ase respiratry assis- tane bemes neessary. Treatment is with heptavalent antitxin, in patients withut knwn allergy t hrse serum. Ptassium hannel antagnists may prvide symp- tmati relief as they d in Lambert-Eatn myastheni syndrme. Antihlinesterase mediatins are f n value. Respiratry assistane and ther supprtive measures shuld be prvided as neessary. Further details are pr- vided in Chapter 33.4.  Disorders associted wit Use of aminoglycosidesAminglyside  antibitis, eg, gentamiin, may prdue a linial disturbane similar t btulism by preventing the release f aetylhline frm nerve endings, but symptms subside rapidly as the respnsible mediatin is eliminated frm the bdy. These antibitis are partiularly dangerus in patients with preexisting disturbanes f neurmusular transmissin and are therefre best avided in patients with myasthenia gravis.MYOp aThIC DISORDERSE S S E N T I A L S  O F  D I A G N O S I S Muscle weakness without sensory loss, often in a characteristic distribution. Serum creatine kinase elevated in most cases. Age at onset, time course, and inheritance pattern may suggest underlying disorder. General ConsiderationsMy pathies an be inherited r aquired. Aquired mypa- thies ften present autely r subautely while inherited mypathies are typially insidius in nset. Patients typi- ally mplain f weakness affeting prximal musles, suh as diffiulty limbing stairs, arising frm a hair, r reahing verhead, r f head drp. Sensry symptms are absent. A detailed family histry is required. Examinatin shws weakness f prximal musles. In sme ases, there is a mre speifi pattern f weaknessCMDT22_Ch24_p0978-p1053.indd  1050 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1051 CMDT 2022(eg,  quadrieps and finger flexr weakness in inlusin bdy mysitis). Extraular musle invlvement is rarely seen, exept in ertain mithndrial disrders, ulpha- ryngeal musular dystrphy, and hyperthyridism; when present, it shuld suggest the pssibility f a neurmusular juntin disrder. Reflexes are nrmal r diminished in prprtin t the degree f weakness. Sensatin is nrmal. Initial testing shuld inlude serum reatine kinase determinatin. Cnsider testing thyrid-stimulating hr- mne, rtisl, vitamin D, and alium. Antibdies speifi t ertain inflammatry mypathies and nnetive tissue disease an be heked when these nditins are suspeted (see Chapter 20). Eletrmygraphy will reveal small mtr units and early reruitment; it is helpful in nfirming the lalizatin f weakness t the musle and suggesting a suitable site fr bipsy, as des MRI. The eletrmy- graphi findings may be nrmal in rtisterid and mithndrial mypathies. Musle bipsy establishes the diagnsis when inflammatry, mithndrial, metabli, r ertain inherited mypathies are suspeted. In ases where the family histry r pattern f weakness suggests aspeifi geneti disrder, geneti testing an be pursued diretly and bipsy may nt be needed. Seleted mmn and treatable mypathies are disussed belw.1.  Musculr DystroiesThese  inherited mypathi disrders are subdivided by mde f inheritane, age at nset, and linial features, as shwn in Table 2410. In the Duchenne type, pseudhy- pertrphy f musles frequently urs at sme stage; intel- letual disability is mmn; and there may be skeletal defrmities, musle ntratures, and ardia invlvement. A geneti defet n the shrt arm f the X hrmsme has been identified in Duhenne dystrphy. The affeted gene des fr the prtein dystrphin, whih is markedly redued r absent frm the musle f patients with the disease. Dystrphin levels are generally nrmal in the Becker variety, but the prtein is qualitatively altered. The diagnsis is usually made with geneti testing; musle bipsy is needed asinally. Duhenne musular dystr- phy an be regnized early in pregnany in abut 95% f Table 2410. Selected muscular dystrophies (listed in order of anatomic location and physiologic underpinning).1Disorder Ineritnceage t Onset (yers) Distribution prognosis Genetic assocition Duchenne type X-linked recessive 15 Pelvic, then shoulder girdle; later, limb and respiratory muscles.Rapid progression. Death within about 15 years after onset.Xp21; Dystrophin (loss of functional expression). Becker X-linked recessive 525 Pelvic, then shoulder girdle.Slow progression. May have normal life span.Xp21; Dystrophin (reduced functional expression). Limb-girdle (Erb) Autosomal recessive, dominant, or sporadic1030 Pelvic or shoulder girdle initially, with later spread to the other.Variable severity and rate of progression. Possi- ble severe disability in middle life.Multiple. Facioscapulo- humeralAutosomal dominantAny age Face and shoulder girdle initially; later, pelvic girdle and legs.Slow progression. Minor disability. Usually normal life span.4q35.2; Double homeobox protein 4. 18p11.32; Structural maintenance of chromosomes flexible hinge domain- containing protein 1. Emery-Dreifuss X-linked recessive or autosomal dominant510 Humeroperoneal or scapuloperoneal.Variable. Multiple. Distal Autosomal domi- nant or recessive4060 Onset distally in extremities; proximal involvement later.Slow progression. Multiple. Oculopharyngeal Autosomal dominantAny age Ptosis, external ophthal- moplegia, and dysphagia.Slow progression. 14q11.2q13; Poly (A)-binding protein-2. Myotonic dystrophyAutosomal dominantAny age (usually 2040)Face, neck, distal limbs. Slow progression. 19q13.32; Myotonin- protein kinase. 3q21.3; Cellular nucleic acid-binding protein.1 Not all possible genetic loci are shown.CMDT22_Ch24_p0978-p1053.indd  1051 29/06/21 8:50 PMChapTER 241052 CMDT 2022wmen  by geneti studies; in late pregnany, DNA prbes an be used n fetal tissue btained fr this purpse by amnientesis. The genes ausing sme f the ther mus- ular dystrphies are listed in Table 2410. Three antisense lignuletides are apprved by the FDA fr treatment f Duhenne musular dystrphy. Eteplirsen appears t benefit thse patients with a dystr- phin mutatin amenable t exn 51 skipping; gldirsen and viltlarsen benefit thse with a mutatin amenable t exn 53 skipping. Patients treated with these antisense lignuletides had mre funtinal dystrphin n mus- le bipsy than ntrls and a slwer rate f disease pr- gressin than mathed histrial ntrls. Prednisne (0.75 mg/kg rally daily r 10 mg/kg rally given weekly ver 2 days) r deflazart (0.9 mg/kg rally daily) imprves musle strength and funtin in bys with Duhenne dystrphy, but side effets need t be mni- tred. Althugh bth rtisterid preparatins ause similar side effets, weight gain at 1 year is less with deflazart. Prlnged bed rest must be avided, as inativ- ity ften leads t wrsening f the underlying musle dis- ease. Physial therapy and rthpedi predures may help unterat defrmities r ntratures.2.  Myotonic DystroyMy tni dystrphy, a slwly prgressive, dminantly inherited disrder, usually manifests itself in the third r furth deade but asinally appears early in hildhd. Tw types, with a different geneti basis, have been reg- nized. Mytnia leads t mplaints f musle stiffness and is evidened by the marked delay that urs befre affeted musles an relax after a ntratin. This an ften be demnstrated linially by delayed relaxatin f the hand after sustained grip r by perussin f the belly f a musle. In additin, there is weakness and wasting f the faial, sternleidmastid, and distal limb musles. Assiated linial features inlude atarats, frntal bald- ness, testiular atrphy, diabetes mellitus, ardia abnr- malities, and intelletual hanges. Eletrmygraphi sampling f affeted musles reveals mytni disharges in additin t hanges suggestive f mypathy. It is diffiult t determine whether mediatin therapy fr mytnia is safe r effetive. When mytnia is dis- abling, treatment with a sdium hannel blkersuh as phenytin (100 mg rally three times daily), prainamide (0.51 g rally fur times daily), r mexiletine (150200 mg rally three times daily)may be helpful, but the assiated side effets, partiularly fr antiarrhythmi mediatins, are ften limiting. Neither the weakness nr the urse f the disrder is influened by treatment. Cardia funtin shuld be mnitred, and paemaker plaement may be nsidered if there is evidene f heart blk.3.  Myotoni CongenitM ytnia ngenita is mmnly inherited as a dminant trait. Generalized mytnia withut weakness is usually present frm birth, but symptms may nt appear until early hildhd. Patients mplain f musle stiffness that is enhaned by ld and inativity and relieved by exerise.Musle hypertrphy, at times prnuned, is als a feature. A reessive frm with later nset is assiated with slight weakness and atrphy f distal musles. Treatment with prainamide, tainide, mexiletine, r phenytin may help the mytnia, as in mytni dystrphy.4.  Mitocondril MyotiesThe  mithndrial mypathies are a linially diverse grup f disrders that n pathlgi examinatin f skel- etal musle with the mdified Gmri stain shw hara- teristi ragged red fibers ntaining aumulatins f abnrmal mithndria. Patients may present with pr- gressive external phthalmplegia r with limb weakness that is exaerbated r indued by ativity. Other patients present with entral neurlgi dysfuntin, eg, my- lni epilepsy ( myoclonic epilepsy, ragged red fiber syndrome, or MERRF ), r the mbinatin f mypathy, enephalpathy, lati aidsis, and strke-like episdes (MELAS ). Migraine is a mmn symptm. Systemi fea- tures inlude but are nt limited t diabetes mellitus, hear- ing lss, retinpathy, ardimypathy, gastri dysmtility, and shrt stature. The serum reatine kinase is usually nr- mal. Mithndrial mypathies result frm separate abnr- malities f mithndrial DNA. Treatment is symptmati and palliative, but varius experimental apprahes are being explred.5.  acid Mltse Deficiency (pome Disese)This  is a glygen strage disease due t mutatins in the gene ending aid alpha-1,4-glusidase. Age at presenta- tin ranges frm infany t the late fifties and depends n the degree f residual enzyme ativity. The juvenile and adult-nset frms present with slwly prgressive prximal weakness that inludes respiratry failure. Cardimypathy is less mmn in the adult frm. Serum reatine kinase is mildly elevated. Musle bipsy shws glygen ntaining lyssmal vaules, but the diagnsis is suggested by deteting redued aid-1,4-alpha-glusidase ativity n a dried bld spt, and nfirmed by geneti testing. Treat- ment with rembinant alpha-glusidase (20 mg/kg intra- venusly every 2 weeks) stabilizes disease prgressin and results in imprvement in respiratry funtin.6.  Dermtomyositis, anti-Syntetse Syndromes, Immune-Medited Necrotizing Myoties, & polymyositisSee Chapter 20. 7.  Inclusion Body MyositisThis  disrder, f unknwn ause, begins insidiusly, usu- ally after middle age, with prgressive prximal weakness f first the lwer and then the upper extremities, and affeting faial and pharyngeal musles. Weakness ften begins in the quadrieps femris in the lwer limbs and the frearm flexrs in the upper limbs. Distal weakness is usu- ally mild. Serum reatine kinase levels may be nrmal r inreased. The diagnsis is nfirmed by musle bipsy.CMDT22_Ch24_p0978-p1053.indd  1052 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1053 CMDT 2022Antiytsli  5-nuletidase 1A antibdies are deteted in ne-third f ases and may be assiated with a mre severe phentype. Crtisterid and immunsuppressive therapy is smetimes ffered but is usually ineffetive, and IVIG therapy is nt remmended.8.  Endocrine MyotiesM ypathy is bserved with hypthyridism, hyperthyrid- ism, Cushing syndrme and disease, Addisn disease, vitamin D defiieny, and bth hyperparathyridism and hypparathyridism (the latter mediated by alium derangements). In hypthyridism, there may be assi- ated entrapment neurpathies, and examinatin may shw delayed relaxatin f tendn reflexes, musle enlargement, r myedema. Hyperthyridism an ause bth distal and prximal weakness and rarely a bulbar mypathy. Serum reatine kinase is nrmal exept in hypthyrid mypathy, whih an als be painful. Treatment is f the underlying endrinpathy.9.  Criticl Illness MyotyM ypathy may ur in assiatin with ritial illness, typially in patients wh reeived neurmusular blking agents and rtisterids. It is frequently disvered when patients unexpetedly require prlnged ventilatry sup- prt. There an be an assiated sensrimtr plyneu- rpathy. Serum reatine kinase may be elevated initially but has frequently returned t nrmal r is belw nrmal by the time the nditin is suspeted. Treatment is supprtive.10.  Toxic MyotiesM ypathy an ur in patients taking aminapri aid, amidarne, hlrquine, lhiine, rtisterids, yl- sprine, daptmyin, emetine, fibrates, gemitabine, nule- side reverse transriptase inhibitrs, r statin mediatins. Mypathy als urs with hrni alhlism, whereas aute reversible musle nersis may ur shrtly after aute alhl, aine, r methamphetamine intxiatin, and with prpfl infusin. Inflammatry mypathy may ur in patients taking peniillamine and an be indued by pr- grammed death-1 inhibitrs; mytnia may be indued by lfibrate, and preexisting mytnia may be exaerbated r unmasked by deplarizing musle relaxants (eg, suxameth- nium), beta-blkers (eg, prpranll), fenterl and, pssi- bly, ertain diuretis. Valpri aid an preipitate r wrsen mypathy in patients with mithndrial disrders r arni- tine palmityltransferase II defiieny. When to ReferAll  patients shuld be referred t establish the diagnsis and underlying ause.When to Admit Fr respiratry assistane. Fr rhabdmylysis.MD nald CM et al; CINRG Investigatrs. Lng-term effets f glurtiids n funtin, quality f life, and survival in patients with Duhenne musular dystrphy: a prspetive hrt study. Lanet. 2018;391:451. [PMID: 29174484] Pasnr M et al. Apprah t musle and neurmusular jun- tin disrders. Cntinuum (Minneap Minn). 2019;25:1536. [PMID: 31794459]pE RIODIC paRaLYSIS SYNDROMESPe ridi paralysis may have a familial (dminant inheri- tane) basis. The syndrmes t be desribed are channelo- pathies that manifest as abnrmal, ften ptassium-sensitive, musle-membrane exitability and lead linially t epi- sdes f flaid weakness r paralysis, smetimes in ass- iatin with abnrmalities f the plasma ptassium level. Strength is initially nrmal between attaks, but prgres- sive mypathi weakness may develp in up t ne-third f patients as they age. Hypokalemic periodic paralysis is haraterized by attaks that tend t ur n awakening, after exerise, r after a heavy meal and may last fr several days. Patients shuld avid exessive exertin. A lw- arbhydrate and lw-salt diet may help prevent attaks. An nging attak may be abrted by ptassium hlride given rally r by intravenus drip, prvided the ECG an be mnitred and kidney funtin is satisfatry. In yung Asian men, it is mmnly assiated with hyperthyrid- ism; treatment f the endrine disrder prevents reur- renes. A nnseletive beta-adrenergi blker may prevent attaks until the endrine abnrmality has been treated. Inhyperkalemic periodic paralysis, attaks als tend t ur after exerise but usually last fr less than 1 hur. They may be terminated by intravenus alium glunate (12 g) r by intravenus diuretis (fursemide, 2040 mg), gluse, r gluse and insulin. Normokalemic periodic paralysis is similar linially t the hyperkalemi variety, but the plasma ptassium level remains nrmal during attaks. Several randmized trials supprt the use f dihlrphenamide (50100 mg rally twie daily) fr pre- ventin f attaks in bth hyperkalemi and hypkalemi peridi paralysis; aetazlamide (250750 mg rally daily) is als effetive. Chlrthiazide may als be used t prevent attaks in hyperkalemi peridi paralysis. When to ReferAll patients sh uld be referred.CMDT22_Ch24_p0978-p1053.indd  1053 29/06/21 8:50 PM1054 CMDT 2022The fifth e dition of the American Psychiatric Associations Diagnostic and Statistical Manual (DSM-5) is the common language that clinicians use for psychiatric conditions. It utilizes specific criteria with which to objectively assess symptoms for use in clinical diagnosis and communication. COMMON PSYCHIATRIC DISORDERS ADJUSTMENT DISORDERSE S S E N T I A L S  O F  D I A G N O S I S Anxiety or depression in reaction to an identifi- able stress, though out of proportion to the sever- ity of the stressor. Symptoms are not at the severity of a major depressive episode or with the chronicity of gen- eralized anxiety disorder (GAD). General ConsiderationsAn individual experiences stress when adaptive ca pacity is overwhelmed by events. The event may be an insignificant one when objectively considered, and even favorable changes (eg, promotion and transfer) requiring adaptive behavior can produce stress. For everyone, stress is subjec- tively defined, and the response to stress is a function of each persons personality and physiologic endowment. Opinion differs about what events are most apt to pro- duce stress reactions. The causes of stress are different at different ageseg, in young adulthood, the sources of stress are found in the marriage or parent-child relation- ship, the employment relationship, and the struggle to achieve financial stability; in the middle years, the focus shifts to changing spousal relationships, problems with aging parents, and problems associated with having young adult offspring who themselves are encountering stressful situations; in old age, the principal concerns are apt to be retirement, loss of physical and mental capacity, major personal losses, and thoughts of death.Clinical FindingsAn  individual may react to stress by becoming anxious or depressed, by developing a physical symptom, by running away, drinking alcohol, overeating, starting an affair, or in limitless other ways. Common subjective responses are anxiety, sadness, fear, rage, guilt, and shame. Acute and reactivated stress may be manifested by restlessness, irrita- bility, fatigue, increased startle reaction, and a feeling of tension. Inability to concentrate, sleep disturbances (insomnia, bad dreams), and somatic preoccupations sometimes lead to self-medication, most commonly with alcohol or other central nervous system depressants. Emo- tional and behavioral distressing symptomatology in response to stress is called adjustment disorder , with the major symptom specified (eg, adjustment disorder with depressed mood, anxiety, mixed depression and anxiety, disturbance of conduct, mixed disturbance of emotions and conduct, or unspecified. ). Even with an identifiable stressor, if the patient meets syndromal criteria for another disorder such as major depression, then the convention would be to diagnose a major depression and not an adjustment disorder with depressed mood . Differential DiagnosisAd justment disorders are distinguished from anxiety dis- orders, mood disorders, bereavement, other stress disor- ders such as posttraumatic stress disorder (PTSD), and personality disorders exacerbated by stress and from somatic disorders with psychic overlay. Unlike many other psychiatric disorders, such as bipolar disorder or schizo- phrenia, adjustment disorders are wholly situational and usually resolve when the stressor resolves or the individual effectively adapts to the situation. Adjustment disorders may have symptoms that overlap with other disorders, such as anxiety symptoms, but they occur in reaction to an iden- tifiable life stressor such as a difficult work situation or romantic breakup. An adjustment disorder that persists and worsens can potentially evolve into another psychiatric disorder such as major depression or GAD. However, that is not the case for most patients. Patients with adjustment disorders have marked distress after a stressor and signifi- cant impairment in social or occupational functioning but25Kristin S. Raj, MD Nolan Williams, MD Charles DeBattista, DMH, MDPsychiatric DisordersCMDT22_Ch25_p1054-p1109.indd  1054 29/06/21 8:51 PM",
                  "NERVOUS SYSTEM DISORDERS979 CMDT 2022alhli  beverages, bright lights, lud nise, menstrua- tin, r use f ral ntraeptives. An unmmn variant is migraine with brainstem aura, in whih blindness r visual disturbanes thrughut bth visual fields are ampanied r fllwed by dysar- thria, dysequilibrium, tinnitus, and periral and distal paresthesias and are smetimes fllwed by transient lss r impairment f nsiusness r by a nfusinal state. This, in turn, is fllwed by a thrbbing (usually ipital) headahe, ften with nausea and vmiting. Inrecurrent painful ophthalmoplegic neuropathy (previusly phthalmplegi migraine), lateralized pain ften abut the eyeis ampanied by nausea, vmiting, and diplpia due t transient external phthalmplegia. The phthalmplegia is due t third nerve palsy, smetimes with ampanying sixth nerve invlvement, and may ut- last the rbital pain by several days r even weeks. The phthalmi divisin f the fifth nerve has als been affeted in sme patients. The nditin is rare and a diagnsis f exlusin; mre mmn auses f a painful phthalmple- gia are internal artid artery aneurysms and diabetes. TreatmentMan agement f migraine nsists f avidane f any pre- ipitating fatrs, tgether with prphylati r symptm- ati pharmalgi treatment if neessary.A.  Symptomatic TherapyDuring  aute attaks, rest in a quiet, darkened rm may be helpful until symptms subside. A simple analgesi (eg, aspirin, aetaminphen, ibuprfen, r naprxen) taken immediately ften prvides relief, but presriptin media- tin is smetimes neessary. To prevent medication overuse, use of simple analgesics should be limited to 15 days or less per month, and combination analgesics should be limited to no more than 10 days per month . 1. Ergotamines Cafergt, a mbinatin f ergtamine tartrate (1 mg) and affeine (100 mg), is ften partiularly helpful; ne r tw tablets are taken at the nset f headahe r warning symptms, fllwed by ne tablet every 30 minutes, if neessary, up t six tablets per attak and n mre than 10 days per mnth. Cafergt given retally (ne- half t ne suppsitry ntaining 2 mg f ergtamine) r dihydrergtamine mesylate (0.51 mg intravenusly r 12 mg subutaneusly r intramusularly) may be useful when vmiting preludes use f ral mediatins. Ergta- mine-ntaining preparatins shuld be avided during pregnany, in patients with ardivasular disease r its risk fatrs, and in patients taking ptent CYP 3A4 inhibitrs. 2. Serotonin agonists Triptans are 5-HT1b/1dreeptr agnists that inhibit release f vasative neurpeptides. Sumatriptan is a rapidly effetive agent fr abrting attaks when given subutaneusly by an autinjetin devie (46 mg ne subutaneusly, may repeat ne after 2 hurs if needed; maximum dse 12 mg/24 h). Nasal and ral preparatins are available but may be less effetive due t slwer absrptin. Zlmitriptan is available in ral and nasal frmulatins. The dse is 5 mg rally r in ne nstrilne; this may be repeated ne after 2 hurs. The maxi- mum dse fr bth frmulatins is 10 mg/24 h. Other triptans are available, inluding rizatriptan (510 mg rally at nset, may repeat every 2 hurs twie [maximum dse 30 mg/24 h]); naratriptan (12.5 mg rally at nset, may repeat ne after 4 hurs [maximum dse 5 mg/24 h]); almtriptan (6.2512.5 mg rally at nset, may repeat dse ne after 2 hurs [maximum dse 25 mg/24 h]); frvatrip- tan (2.5 mg rally at nset, may repeat after 2 hurs ne [maximum dse 7.5 mg/24]); and eletriptan (2040 mg rally at nset; may repeat after 2 hurs ne [maximum dse 80 mg/24 h]). Eletriptan is useful fr immediate therapy, and frvatriptan, whih has a lnger half-life, may be wrthwhile fr patients with prlnged attaks r attaks prvked by menstrual perids. Patients ften experiene greater benefit when the triptan is mbined with naprxen (500 mg rally). Triptans may ause nausea and vmiting. They shuld prbably be avided in wmen wh are pregnant, and in patients with hemiplegi r basilar migraine, a histry f strke r transient ishemi attak (TIA), r unntrlled hypertensin. In patients whse hypertensin is ntrlled, triptans are mmnly used safely, althugh autin is advised. Triptans are ntraindiated in patients with r- nary r peripheral vasular disease and Prinzmetal angina. Lasmiditan (50200 mg taken ne at headahe nset; n mre than ne dse in 24 hurs) is a 5-HT1Freeptr agnist apprved fr use in the United States that laks the vasnstritive prperties f triptans and an be given safely t patients with ardivasular risk fatrs. Dizziness and smnlene are mmn side effets, and patients shuld nt drive within 8 hurs f administratin. 3. Calcitonin generelated peptide antagonists Rimegepant sulfate (75 mg rally disslved tablet taken ne at headahe nset; maximum dse 75 mg/24 h) and ubrgepant (50 r 100 mg rally at headahe nset, may repeat after 2 hurs ne [maximum dse 200 mg/24 h]) are bth alitnin generelated peptide antagnists that ahieve pain freedm in 20% and pain relief in 60% f patients within 2 hurs. Hypersensitivity reatins may ur immediately r several days after administratin with rimegepant. 4. Other agents Prhlrperazine is effetive and may be administered retally (25 mg suppsitry), intravenusly r intramusularly (510 mg), r rally (510 mg). Intrave- nus metlpramide (1020 mg) is als partiularly use- ful in the emergeny department setting. Varius butalbital-ntaining mbinatin ral analgesis risk veruse and dependene and shuld nly be used as a last resrt. Opiid analgesis shuld be avoided beause f high rates f rebund headahe and the tendeny t develp mediatin veruse headahe. 5. Neuromodulation Sham-ntrlled trials shw that single-pulse transranial magneti stimulatin abrts migraine with aura, and nninvasive vagus nerve stimula- tin, transutaneus trigeminal nerve stimulatin, and remte eletrial stimulatin applied t the upper arm abrt migraine with r withut aura. Transranial magneti stimulatin is ntraindiated in patients with epilepsy.CMDT22_Ch24_p0978-p1053.indd  979 29/06/21 8:50 PMChapTER 24980 CMDT 2022T able 241. Pharmacologic prophylaxis of migraine (listed in alphabetical order within classes).Mediction Usul adult Orl Dily Dose Selected Side Effects nd Comments antieiletic1T opiramate 100 mg (divided twice daily) Somnolence, nausea, dyspepsia, irritability, dizziness, ataxia, nystagmus, diplopia, glaucoma, renal calculi, weight loss, hypohidrosis, hyperthermia. Valproic acid2,35001000 mg (divided twice daily)Nausea, vomiting, diarrhea, drowsiness, alopecia, weight gain, hepatotoxic- ity, thrombocytopenia, tremor, pancreatitis. Crdiovsculr Candesartan3832 mg once daily Dizziness, cough, diarrhea, fatigue. Guanfacine 1 mg once daily Dry mouth, somnolence, dizziness, constipation, erectile dysfunction. Propranolol480240 mg (divided twice to four times daily)Fatigue, dizziness, hypotension, bradycardia, depression, insomnia, nausea, vomiting, constipation. Verapamil5120240 mg (divided three times daily)Headache, hypotension, flushing, edema, constipation. May aggravate atrioventricular nodal heart block and heart failure. antideressnt6Amitriptyline 710150 mg at bedtime Sedation, dry mouth, constipation, weight gain, blurred vision, edema, hypotension, urinary retention. Venlafaxine 37.5150 mg extended release once dailyNausea, somnolence, dry mouth, dizziness, diaphoresis, sexual dysfunction, anxiety, weight loss. Monoclonl ntibodies ginst clcitonin generelted etide Eptinezumab 100 mg intravenously every 3 monthsHypersensitivity reaction during infusion, nasopharyngitis. Erenumab 70140 mg subcutaneously once monthlyInjection site reactions, constipation, muscle cramps, antibody development. Fremanezumab 225 mg subcutaneously once monthlyInjection site reactions, antibody development. Galcanezumab 120 mg subcutaneously daily  2 doses, followed by 120 mg monthlyInjection site reactions, antibody development. Oter Acupuncture  More rapid pain relief and fewer side effects than pharmacologic treatment. Botulinum toxin A Intramuscular injection Injection site reaction, hypersensitivity, muscle weakness. Riboflavin 400 mg once daily Yellow-orange discoloration of urine. Transcutaneous supraor- bital neurostimulation20 minutes daily Transient paresthesia at site of stimulation.1 Gabapentin and possibly other antiepileptics have also been used successfully.2 Avoid during pregnancy.3 Not FDA-approved for this indication.4 Other beta-adrenergic antagonists such as atenolol, metoprolol, nadolol, and timolol are similarly effective.5 Other calcium channel antagonists (eg, nimodipine, nicardipine, and diltiazem) may also help.6 Depression is commonly comorbid with migraine disorder and may warrant separate treatment.7 Other tricyclic antidepressants (eg, nortriptyline and imipramine) may help similarly.B. Preventive TherapyPreven tive treatment may be neessary if migraine head- ahes ur more frequently than two or three times a month r signifiant disability is assiated with attaks. Avid- ane f triggers and maintenane f hmestasis with reg- ular sleep, meals, and hydratin shuld nt be negleted; a headahe diary may be useful t identify triggers. Sme mre mmn agents used fr prphylaxis are listed in Table 241. The mediatin hsen first will vary with theindividual patient, depending n fatrs suh as mrbid besity, depressin, anxiety, hypertensin, and patient preferene. Several mediatins may have t be tried in turn befre headahes are brught under ntrl. One a mediatin has been fund t help, it shuld be ntinued fr several mnths. If the patient remains headahe-free, the dse may be tapered and the mediatin eventually withdrawn. Transutaneus suprarbital neurstimulatin redued the number f migraine days per mnth in aCMDT22_Ch24_p0978-p1053.indd  980 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS981 CMDT 2022sham- ntrlled randmized trial and is apprved in the United States. In chronic migraine (at least 15 days per mnth with headahes lasting 4 hurs per day r lnger), aupunture is as effetive as prphylati pharmalgi treatment, and btulinum txin type A redues headahe frequeny. Certain neurstimulatin tehniques lk prmising as preventive treatment as well as having a rle in treatment f aute attaks. These inlude single-pulse transranial magneti stimulatin, vagus nerve stimula- trs, and implantable ipital nerve stimulatin, but riti- al appraisal is neessary.2.  Tension-Tye hedceThis is the mst mm n type f primary headahe disr- der. Patients frequently mplain f periranial tenderness, pr nentratin, and ther nnspeifi symptms, in additin t headahes that are ften vise-like r tight in quality but nt pulsatile. Headahes may be exaerbated by emtinal stress, fatigue, nise, r glare. The headahes are usually generalized, may be mst intense abut the nek r bak f the head, and are nt assiated with fal neur- lgi symptms. There is diagnsti verlap with migraine. The therapeuti apprah is similar t that in migraine, exept that triptans and ergtamines are notindiated. Triyli antidepressants, suh as amitriptyline, are sup- prted fr headahe prphylaxis by randmized trial evi- dene and ften are tried first. Treatment f mrbid anxiety r depressin is imprtant. Behaviral therapies that may be effetive inlude bifeedbak and relaxatin training.3.  Cluster hedceClus ter headahe affets predminantly middle-aged men. The pathphysilgy is unlear but may relate t ativatin f ells in the ipsilateral hypthalamus, triggering the tri- geminal autnmi vasular system. There is ften n fam- ily histry f headahe r migraine. Episdes f severe unilateral perirbital pain ur daily fr several weeks and are ften ampanied by ne r mre f the fllwing: ipsilateral nasal ngestin, rhinrrhea, larimatin, red- ness f the eye, and Hrner syndrme (ptsis, pupillary meisis, and faial anhidrsis r hyphidrsis). During attaks, patients are ften restless and agitated. Episdes typially ur at night, awaken the patient, and last between 15 minutes and 3 hurs. Spntaneus remissin then urs, and the patient remains well fr weeks r mnths befre anther but f lsely spaed attaks. Buts may last fr 4 t 8 weeks and may ur up t several times per year. During a but, many patients reprt alhl trig- gers an attak; thers reprt that stress, glare, r ingestin f speifi fds asinally preipitates attaks. In a- sinal patients, remissin des nt ur. This variant has been referred t as chronic cluster headache . In lngstand- ing ases, Hrner syndrme may persist between attaks. Cluster headahe is ne f the trigeminal autonomic cephalgias, whih inlude hemirania ntinua, parx- ysmal hemirania, and shrt-lasting neuralgifrm head- ahe attaks with njuntival injetin and tearing. Similar t luster headahe, the ther trigeminalautnmi ephalgias nsist f unilateral perirbital pain assiated with ipsilateral autnmi symptms; they are distinguished frm luster headahe by different attak duratin and frequeny and their exquisite respnsiveness t indmethain. Treatment f an individual attak with ral mediatins is generally unsatisfatry, but subutaneus (6 mg) r intranasal (20 mg/spray) sumatriptan r inhalatin f 100% xygen (1215 L/min fr 15 minutes via a nn-rebreather mask) may be effetive. Zlmitriptan (5- and 10-mg nasal spray) is als effetive. Dihydrergtamine (0.51 mg intra- musularly r intravenusly) r visus lidaine (1 mg f 46% slutin intranasally) is smetimes effetive. Varius prphylati agents inlude ral mediatins suh as lithium arbnate (start at 300 mg daily, titrating arding t serum levels and treatment respnse up t a typial ttal daily dse f 9001200 mg, divided three r fur times), verapamil (start at 240 mg daily, inrease by 80 mg every 2 weeks t 960 mg daily, with rutine ECG t mnitr the PR interval), tpiramate (100400 mg daily), and ivamide (nt available in the United States). As there is ften a delay befre these mediatins are effetive, tran- sitinal therapy is ften used. Prednisne (60 mg daily fr 5 days fllwed by gradual withdrawal ver 710 days) is effetive in 7080% f patients, and subipital rtiste- rid injetin abut the greater ipital nerve is effetive in 75%. Ergtamine tartrate an be given as retal suppsit- ries (0.51 mg at night r twie daily), by muth (2 mg daily), r by subutaneus injetin (0.25 mg three times daily fr 5 days per week). Eletrial stimulatin f the vagus nerve at headahe nset suessfully abrts pain in 3050% f attaks, and twie daily prphylati stimulatin redues attak number in hrni luster headahe; this treatment is apprved in the United States. In Eurpe, sphe- npalatine ganglin stimulatin is apprved fr treatment f luster headahe based n effiay in ne randmized sham-ntrlled study. Limited evidene suggests that eletrial stimulatin f the ipital nerve by an implant- able devie may be helpful, espeially in hrni luster headahe.4.  posttrumtic hedceA variety  f nnspeifi symptms may fllw lsed head injury, regardless f whether nsiusness is lst (see Head Injury). Headahe is ften a nspiuus feature. It usually appears within a day r s fllwing injury, may wrsen ver the ensuing weeks, and then gradually sub- sides. It is usually a nstant dull ahe, with superimpsed thrbbing that may be lalized, lateralized, r generalized. Headahes are smetimes ampanied by nausea, vmit- ing, r sintillating stmas and ften respnd t simple analgesis; severe headahes may neessitate preventive treatment as utlined fr migraine.5.  primry Coug hedceSevere  head pain may be prdued by ughing (and by straining, sneezing, and laughing) but, frtunately, usually lasts fr nly a few minutes r less. Intraranial lesins, usually in the psterir fssa (eg, Arnld-ChiariCMDT22_Ch24_p0978-p1053.indd  981 29/06/21 8:50 PMChapTER 24982 CMDT 2022malfrma tin), are present in abut 10% f ases, and brain tumrs r ther spae-upying lesins may present in this way. Ardingly, CT scanning or MRI should be undertaken in all patients. The disrder is usually self-limited, althugh it may persist fr several years. Fr unknwn reasns, symptms smetimes lear mpletely after lumbar punture. Ind- methain (75150 mg daily rally) may prvide relief. Similar ativity-triggered headahe syndrmes inlude primary exertinal headahe and primary headahe ass- iated with sexual ativity.6.  hedce Due to Gint Cell (Temorl or Crnil) arteritisThis tp i is disussed in Chapter 20.7.  hedce Due to Intrcrnil Mss LesionIn traranial mass lesins f all types may ause headahe wing t displaement f vasular strutures and ther pain-sensitive tissues. While pain and latin are nnspe- ifi, headahe may be wrse upn lying dwn, awaken the patient at night, r peak in the mrning after vernight reumbeny. The key feature prompting brain imaging is a new or worsening headache in middle or later life . Other features suggesting an intraranial lesin inlude signs r symptms f infetin r malignany suh as fever, night sweats, and weight lss; immunmprmise; r histry f malignany. Signs f fal r diffuse erebral dysfuntin r f inreased intraranial pressure (eg, papilledema) als neessitate investigatin.8.  Mediction Overuse (anlgesic Rebound) hedceIn  many patients with chronic daily headaches, media- tin veruse is respnsible. Patients have hrni pain r severe headahe unrespnsive t mediatin (typially defined as n effet after having been used regularly fr mre than 3 mnths). Ergtamines, triptans, mediatins ntaining butalbital, and piids ause mediatin ver- use headahe when taken n mre than 10 days per mnth; aetaminphen, aetylsaliyli aid, and nnsteridal anti- inflammatry drugs may als be ffenders if taken n mre than 15 days per mnth. Early initiatin f a migraine preventive therapy permits withdrawal f analgesis and eventual relief f headahe.9.  hedce Due to Oter Neurologic CusesCerebr vasular disease may be assiated with headahe, but the mehanism is unlear. Headahe may ur with internal artid artery lusin r artid dissetin and after artid endarteretmy. Aute severe headahe (thunderclap ) ampanies subarahnid hemrrhage, artid r vertebral artery dissetin, erebral venus thrmbsis, ishemi r hemrrhagi strke, reversible erebral vasnstritin syndrme, hypertensive risis, psterir reversible leukenephalpathy syndrme, pitu- itary applexy, spntaneus intraranial hyptensin, vas- ulitis, and meningeal infetins; ampanying falneurlgi signs, impairment f nsiusness, and signs f meningeal irritatin indiate the need fr further inves- tigatins. Headahes are als a feature f idipathi intra- ranial hypertensin (pseudtumr erebri). Dull r thrbbing headahe is a frequent sequela f lumbar punture and may last fr several days. It is aggra- vated by the eret psture and alleviated by reumbeny. The mehanism is unlear, but the headahe is mmnly attributed t leakage f erebrspinal fluid thrugh the dural punture site. Its inidene may be redued if an atraumati needle (instead f a beveled, utting needle) is used fr the lumbar punture. When to Refer Thunderlap nset. Inreasing headahe unrespnsive t simple measures. Histry f trauma, hypertensin, fever, visual hanges. Presene f neurlgi signs r f salp tenderness. When to AdmitSuspeted  subarahnid hemrrhage r ther strutural intraranial lesin.Ceriani  CEJ et al. Nvel mediatins fr the treatment f migraine. Headahe. 2019;59:1597. [PMID: 31559638] Vukvi-Cvetkvi V et al. Neurstimulatin fr the treatment f hrni migraine and luster headahe. Ata Neurl Sand. 2019;139:4. [PMID: 30291633]F ACIAL PAIN 1. Trigeminl NeurlgiE S S E N T I A L S  O F  D I A G N O S I S Brief episodes of stabbing facial pain. Pain is in the territory of the second and third divi- sion of the trigeminal nerve. Pain exacerbated by touch. General ConsiderationsT rigeminal neuralgia (ti dulureux) is mst mmn in middle and later life. It affets wmen mre frequently than men. Pain may be due t an anmalus artery r vein impinging n the trigeminal nerve. Clinical FindingsM mentary episdes f sudden laninating faial pain mmnly arise near ne side f the muth and sht tward the ipsilateral ear, eye, r nstril. The pain may be triggered by suh fatrs as tuh, mvement, drafts, and eating. In rder t lessen the likelihd f triggering fur- ther attaks, many patients try t hld the fae still while talking. Spntaneus remissins fr several mnths rCMDT22_Ch24_p0978-p1053.indd  982 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS983 CMDT 2022lnger  may ur. As the disrder prgresses, hwever, the episdes f pain beme mre frequent, remissins beme shrter and less mmn, and a dull ahe may persist between the episdes f stabbing pain. Symptms remain nfined t the distributin f the trigeminal nerve (usu- ally the send r third divisin) n ne side nly. Differential DiagnosisThe  harateristi features f the pain in trigeminal neural- gia usually distinguish it frm ther auses f faial pain. Neurlgi examinatin shws n abnrmality exept in a few patients in whm trigeminal neuralgia is symptmati f sme underlying lesin, suh as multiple slersis r a brainstem neplasm, in whih ase the finding will depend n the nature and site f the lesin. Multiple slersis mustbe suspeted in a patient yunger than 40 years in whm trigeminal neuralgia is the presenting symptm, even if there are n ther neurlgi signs. Bilateral symptms shuld als prmpt further investigatin. Brain MRI need nly be btained when a sendary ause is suspeted; it is usually nrmal in lassi trigeminal neuralgia. TreatmentThe m ediatins mst helpful fr treatment are xarbaze- pine (althugh nt apprved by the FDA fr this india- tin) r arbamazepine, with mnitring by serial bld unts and liver bihemial tests. If these mediatins are ineffetive r annt be tlerated, phenytin shuld be tried. (Dses and side effets f these mediatins are shwn in Table 242.) Balfen (1020 mg rally three r Table 242. Medication treatment for seizures in adults (in alphabetical order within classes).Mediction Usul adult Dily Orl DoseMinimum No. of Dily DosesTime to Stedy-Stte Mediction LevelsOtiml Medic- tion Level nd Lbortory Monitoring1Selected Side Effects nd Idiosyncrtic Rections Generlized or Focl Seizures Brivaracetam2,350100 mg 2 12 days CBC, liver biochemi- cal testsSomnolence, fatigue, ataxia, vertigo, psycho- sis, leukopenia, hypersensitivity (broncho- spasm and angioedema). Cannabidiol4520 mg/kg 2 1113 days Liver biochemical tests at baseline, 1, 3, and 6 monthsSomnolence, fatigue, anorexia, weight loss, anemia, diarrhea, rash, sleep disorder, infections. Elevation in liver enzymes may occur; reduce dose in hepatic impairment. Carbamazepine24001600 mg (immediate or extended release)2 34 days 48 mcg/mL CBC, liver biochemi- cal tests, BUN/CrNystagmus, dysarthria, diplopia, ataxia, drowsiness, nausea, blood dyscrasias, hepatotoxicity, hyponatremia, Stevens-Johnson syndrome.5My  excerbte myoclonic seizures. Cenobamate2,3200400 mg 1 14 days Liver biochemical tests, potassiumMultiorgan hypersensitivity, QT shortening, somnolence, dizziness, cognitive dysfunc- tion, blurred vision. Clobazam61040 mg 2 710 days  Lethargy and somnolence, ataxia, insomnia, dysarthria, aggression, constipation, fever, Stevens-Johnson syndrome. Clorazepate322.590 mg 2 10 days  Sedation, dizziness, confusion, ataxia, depres- sion, dependency/abuse. Eslicarbazepine2,34001200 mg 1 4 days Serum sodium and chloride; liver bio- chemical testsAs for carbamazepine. Ezogabine33001200 mg 3 23 days ECG to assess QT intervalDizziness, somnolence, confusion, vertigo, nausea, ataxia, psychiatric disturbances, prolonged QT interval, retinal abnormalities.7F elbamate2,3,6,812003600 mg 3 45 days CBC and reticulo- cytes, liver bio- chemical testsAnorexia, nausea, vomiting, headache, insom- nia, weight loss, dizziness, hepatotoxicity, fatal aplastic anemia. Reserved for refractory epilepsy. (continued )CMDT22_Ch24_p0978-p1053.indd  983 29/06/21 8:50 PMChapTER 24984 CMDT 2022T able 242. Medication treatment for seizures in adults (in alphabetical order within classes).Mediction Usul adult Dily Orl DoseMinimum No. of Dily DosesTime to Stedy-Stte Mediction LevelsOtiml Medic- tion Level nd Lbortory Monitoring1Selected Side Effects nd Idiosyncrtic Rections Gabapentin39003600 mg 3 1 day  Sedation, fatigue, ataxia, nystagmus, weight loss. Lacosamide2,3100400 mg 2 3 days ECG if known cardiac conduction problems or severe cardiac diseaseVertigo, diplopia, nausea, headache, fatigue, ataxia, tremor, anaphylactoid reactions, PR prolongation, cardiac dysrhythmia, suicidality. Lamotrigine3,6,9,10100500 mg 2 45 days  Sedation, skin rash, visual disturbances, dyspepsia, ataxia. Levetiracetam3,9,1110003000 mg 2 2 days  Somnolence, ataxia, headache, behavioral changes. Oxcarbazepine2,39001800 mg 2 23 days Serum sodium As for carbamazepine. Perampanel2,3,9412 mg 1 3 weeks  Dizziness, somnolence, irritability, weight gain, falls, ataxia, dysarthria, blurred vision. Phenobarbital2,12100200 mg 1 1421 days 1040 mcg/mL CBC, liver biochemi- cal tests, BUN/CrDrowsiness, nystagmus, ataxia, skin rashes, learning difficulties, hyperactivity. Phenytoin2,12200400 mg 1 510 days 1020 mcg/mL CBC, liver biochemi- cal tests, folateNystagmus, ataxia, dysarthria, sedation, con- fusion, gingival hyperplasia, hirsutism, megaloblastic anemia, blood dyscrasias, skin rashes, fever, systemic lupus erythema- tosus, lymphadenopathy, peripheral neu- ropathy, dyskinesias. My excerbte myoclonic seizures. Pregabalin3150300 mg 2 24 days  Somnolence, dizziness, poor concentration, weight gain, thrombocytopenia, skin rashes, anaphylactoid reactions. Primidone2,127501500 mg 3 47 days 512 mcg/mL CBCSedation, nystagmus, ataxia, vertigo, nausea, skin rashes, megaloblastic anemia, irritability. Rufinamide68003200 mg 2 2 days  Somnolence, headache, dizziness, suicidality, Stevens-Johnson syndrome, leukopenia, shortened QT interval, nausea, vomiting. Tiagabine33256 mg 2 2 days  Somnolence, anxiety, dizziness, poor concen- tration, tremor, diarrhea. Topiramate2,3,6,9,12200400 mg 2 4 days Serum bicarbonate, BUN/Cr in elderly patientsSomnolence, nausea, dyspepsia, irritability, dizziness, ataxia, nystagmus, diplopia, glau- coma, renal calculi, weight loss, hypohidro- sis, hyperthermia. Valproic acid2,3,13,1415002000 mg 23 24 days 50100 mcg/mL CBC, liver biochemi- cal testsNausea, vomiting, diarrhea, drowsiness, alope- cia, weight gain, hepatotoxicity, thrombo- cytopenia, tremor, pancreatitis. Tertogenic; void in women of cildber- ing ge. Vigabatrin3,153000 mg 2 2 days  Somnolence, anorexia, nausea, vomiting, agi- tation, hostility, confusion, suicidality, neu- tropenia, Stevens-Johnson syndrome, permanent visual field loss.7Zoni samide3200600 mg 1 14 days BUN/Cr, serum bicarbonateSomnolence, ataxia, anorexia, nausea, vomiting, rash, confusion, renal calculi. Do not use in patients with sulfonamide allergy. (continued )(continued )CMDT22_Ch24_p0978-p1053.indd  984 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS985 CMDT 2022T able 242. Medication treatment for seizures in adults (in alphabetical order within classes).Mediction Usul adult Dily Orl DoseMinimum No. of Dily DosesTime to Stedy-Stte Mediction LevelsOtiml Medic- tion Level nd Lbortory Monitoring1Selected Side Effects nd Idiosyncrtic Rections absence Seizures Clonaze- pam6,11,13,16,170.040.2 mg/kg 2 710 days 2080 ng/mL CBC, liver biochemical testsDrowsiness, ataxia, irritability, behavioral changes, exacerbation of tonic-clonic seizures. Ethosuximide135001500 mg 2 510 days 40100 mcg/mL CBC, liver biochemi- cal tests, urinalysisNausea, vomiting, anorexia, headache, lethargy, unsteadiness, blood dyscrasias, systemic lupus erythematosus, urticaria, pruritus. Valproic acid2,3,13,1415002000 mg 23 24 days See above Nausea, vomiting, diarrhea, drowsiness, alopecia, weight gain, hepatotoxicity, thrombocytopenia, tremor, pancreatitis. Myoclonic Seizures Clonaze- pam6,11,13,16,170.040.2 mg/kg 2 710 days See above Drowsiness, ataxia, irritability, behavioral changes, exacerbation of tonic-clonic seizures. Levetiracetam3,9,1110003000 mg 2 2 days  Somnolence, ataxia, headache, behavioral changes. Valproic acid2,3,13,1415002000 mg 23 24 days See above Nausea, vomiting, diarrhea, drowsiness, alopecia, weight gain, hepatotoxicity, thrombocytopenia, tremor, pancreatitis. BUN, blood urea nitrogen; CBC, complete blood count; Cr, creatinine; ECG, electrocardiogram. Note that many factors influence o ptimal dose of these drugs including age, tolerance, and concomitant medication.1 Patients starting treatment with any antiepileptic drug should be monitored for new or worsening depression or suicidal thought s, especially during the first weeks of therapy. Baseline measurement of creatinine clearance is advisable in renally metabolized drugs.2 Approved as monotherapy for focal-onset seizures.3 Approved as adjunctive therapy for focal-onset seizures.4 Approved for treatment of seizures in Lennox-Gastaut and Dravet syndrome in patients 2 years and older.5 Carriers of the HLA-B*1502 allele are at higher risk for Stevens-Johnson syndrome. Patients of Asian ancestry should be tested for this allele prior to initiation of therapy.6 Approved as adjunctive therapy for Lennox-Gastaut syndrome.7 Regular ophthalmologic examination is recommended.8 Not to be used as a first-line drug; when used, blood counts should be performed regularly (every 24 weeks). Should be used on ly in selected patients because of risk of aplastic anemia and hepatic failure. It is advisable to obtain written informed consent be fore use.9 Approved as adjunctive therapy for primary generalized tonic-clonic seizures.10 Approved as monotherapy (after conversion from another drug) in focal-onset seizures.11 Approved as adjunctive therapy for myoclonic seizures.12 Approved as initial monotherapy for primary generalized tonic-clonic seizures.13 Approved as monotherapy and adjunctive therapy for absence seizures.14 Approved as adjunctive therapy for patients with multiple seizure types including absence seizures.15 Approved as monotherapy for infantile spasms.16 Approved as monotherapy for Lennox-Gastaut syndrome.17 Approved as monotherapy for myoclonic seizures.f ur times daily), tpiramate (50 mg rally twie daily), r lamtrigine (400 mg rally daily) may als be helpful, either alne r in mbinatin with ne f these ther agents. Gabapentin may als relieve pain, espeially in patients wh d nt respnd t nventinal medial therapy and thse with multiple slersis. Depending n respnse and tler- ane, up t 3600 mg daily rally is given in divided dses. Fr neuralgia refratry t medial treatment, several surgial treatment ptins are available that prvide initial pain relief in at least 80% f patients. Mirvasularsurgial dempressin with separatin f the anmalus vessel (usually nt visible n CT sans, MRI, r arteri- grams) frm the nerve rt prdues lng-term relief f symptms in rughly 75% f patients. Three less invasive tehniques are based n destrutin f nieptive tri- geminal nerve fibers, whih auses sensry lss in additin t symptm relief in half f patients: (1) radifrequeny rhiztmy prdues lng-term pain relief in 60% f patients, (2) perutaneus balln mpressin f the tri- geminal ganglin in 67%, and (3) steretati radisurgery(continued )CMDT22_Ch24_p0978-p1053.indd  985 29/06/21 8:50 PMChapTER 24986 CMDT 2022t  the trigeminal nerve rt in 45%. In elderly patients with a limited life expetany, radifrequeny rhiztmy and steretati radisurgery are smetimes preferred beause bth an be perfrmed withut general anesthesia and have few mpliatins. Surgial explratin is inapprpri- ate in patients with trigeminal neuralgia due t multiple slersis, but the less invasive tehniques are smetimes helpful.2.  atyicl Fcil pinFaial  pain withut the typial features f trigeminal neu- ralgia is generally a nstant, ften burning pain that may have a restrited distributin at its nset but sn spreads t the rest f the fae n the affeted side and smetimes invlves the ther side, the nek, r the bak f the head as well. The disrder is espeially mmn in middle-aged wmen, many f them depressed, but it is nt lear whether depressin is the ause f r a reatin t the pain. Simple analgesis shuld be given a trial, as shuld triyli antidepressants, arbamazepine, xarbazepine, and phenytin; the respnse is ften disappinting. Opiid analgesis pse a danger f additin. Attempts at surgial treatment are nt indiated.3.  Glossoryngel NeurlgiGlsspharyngeal  neuralgia is an unmmn disrder in whih pain similar in quality t that in trigeminal neural- gia urs in the thrat, abut the tnsillar fssa, and smetimes deep in the ear and at the bak f the tngue. The pain may be preipitated by swallwing, hewing, talk- ing, r yawning and is smetimes ampanied by syn- pe. In mst instanes, n underlying strutural abnrmality is present; multiple slersis is smetimes respnsible. Oxarbazepine and arbamazepine are the treatments f hie and shuld be tried befre any surgi- al predures are nsidered. Mirvasular dempres- sin is ften effetive and is generally preferred ver destrutive surgial predures suh as partial rhiztmy in medially refratry ases.4.  posteretic NeurlgiP stherpeti neuralgia develps in abut 15% f patients wh have herpes zster (shingles). This mpliatin seems espeially likely t ur in elderly r immunm- prmised persns, when the rash is severe, and when the first divisin f the trigeminal nerve is affeted. It als relates t the duratin f the rash befre treatment is insti- tuted. A histry f shingles and the presene f utaneus sarring resulting frm shingles aid in the diagnsis. Severe pain with shingles rrelates with the intensity f psther- peti symptms. Aylvir (800 mg five times daily) r valaylvir (1000 mg three times daily), when given within 72 hurs f rash nset, redues the inidene f pstherpeti neuralgia by almst half; systemi rtisterids d nothelp prevent pstherpeti neuralgia (see Chapter 6). Management f the established mpliatin is with simple analgesis. If they fail t help, a trial f a triyli antidepressant (eg, amitrip- tyline r nrtriptyline, up t 100150 mg daily rally) isften effetive. Other patients respnd t gabapentin (up t 3600 mg daily rally) r pregabalin (up t 600 mg/daily rally). Subutaneus injetin f btulinum txin A int the affeted regin prdued sustained pain relief in 87% f patients in a small plaeb-ntrlled trial. Tpial applia- tin f apsaiin ream may be helpful, as may tpial lidaine (5%). The administratin f recombinant zoster vaccine t patients ver the age f 50 years is imprtant in reduing the likelihd f herpes zster r reduing the severity f pstherpeti neuralgia shuld a reativatin ur.5.  Fcil pin Due to Oter CusesFa ial pain may be aused by temprmandibular jint dysfuntin in patients with mallusin, abnrmal bite, r faulty dentures. There may be tenderness f the mastia- try musles, and smetimes pain begins at the nset f hewing. This pattern differs frm that f jaw (mastiatry) laudiatin, a symptm f giant ell arteritis, in whih pain develps prgressively with mastiatin. Treatment f the underlying jint dysfuntin relieves symptms. A relatinship f faial pain t hewing r temperature hanges may suggest a dental disturbane. The ause is smetimes nt bvius, and diagnsis requires areful dental examinatin and radigraphs. Sinusitis and ear infetins ausing faial pain are usually regnized by a histry f respiratry trat infetin, fever, and, in sme instanes, nasal r aural disharge. There may be lalized tenderness. Radilgi evidene f sinus infetin r mas- tiditis is nfirmatry. Glauma is an imprtant ular ause f faial pain, usually lalized t the perirbital regin. On asin, pain in the jaw may be the prinipal mani- festatin f angina petris. Preipitatin by exertin and radiatin t mre typial areas suggests a ardia rigin. When to Refer Wrsening pain unrespnsive t simple measures. Cntinuing pain f unertain ause. Fr nsideratin f surgial treatment (trigeminal r glsspharyngeal neuralgia).Bendtsen  L et al. Advanes in diagnsis, lassifiatin, path- physilgy, and management f trigeminal neuralgia. Lanet Neurl. 2020;19:784. [PMID: 32822636]EP ILEPSYE S S E N T I A L S  O F  D I A G N O S I S Recurrent unprovoked seizures. Characteristic electroencephalographic changes accompany seizures. Mental status abnormalities or focal neurologic symptoms may persist for hours postictally.CMDT22_Ch24_p0978-p1053.indd  986 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS987 CMDT 2022 General ConsiderationsThe term  epilepsy dentes any disrder haraterized by recurrent unprovoked seizures. A seizure is a transient dis- turbane f erebral funtin due t an abnrmal parxys- mal neurnal disharge in the brain. Epilepsy is relatively mmn, affeting apprximately 0.5% f the ppulatin in the United States. Patients with reurrent seizures prvked by a readily reversible ause, suh as withdrawal frm alhl r drugs, hypglyemia, hyperglyemia, r uremia, are nt nsid- ered t have epilepsy. Classification of EpilepsyA rding t the Internatinal League Against Epilepsy lassifiatin system, reurrent seizures shuld be lassi- fied first by seizure type, send by epilepsy type, and third, if pssible, by epilepsy syndrme. The etilgy f reurrent seizures shuld be sught at eah stage f lassi- fiatin (see Etilgy f Epilepsy).A.  Seizure TypesThe  Internatinal League Against Epilepsy distinguishes seizures affeting nly part f the brain (fal seizures) frm thse that are generalized. 1. Focal onset seizures The initial linial and eletren- ephalgraphi manifestatins f fal (partial) seizures indiate that nly a restrited part f ne erebral hemi- sphere has been ativated. The ital manifestatins depend n the area f the brain invlved. Fal seizures are lassi- fied by mtr r nnmtr nset as well as by whether awareness is impaired. a. Motor versus nonmotor onset Seizures with mtr nset may be clonic, tonic, atonic, myoclonic, r hyperkinetic, r may manifest as automatisms repilep- tic spasms . The mst mmnly bserved fal mtr seizures nsist f lni jerking r autmatisms. Nnm- tr seizures may be manifested by sensry symptms (eg, paresthesias r tingling, gustatry, lfatry, visual r audi- try sensatins), behavir arrest, gnitive symptms (eg, speeh arrest, dj vu, jamais vu), emtinal symptms (eg, fear), r autnmi symptms r signs (eg, abnrmal epi- gastri sensatins, sweating, flushing, pupillary dilatin). Fal sensry and mtr seizures may spread (r marh) t different parts f the limb r bdy depending n their rtial representatin and were previusly alled simple partial seizures. b. Aware versus impaired awareness Awareness is defined as knwledge f self and envirnment and f events urring during a seizure. Impaired awareness may be preeded, ampanied, r fllwed by the varius mtr and nnmtr symptms mentined abve. Suh seizures were previusly alled mplex partial seizures. c. Focal to bilateral tonic-clonic Fal seizures smetimes invlve lss f awareness and evlve t bilateral tni-lni seizures, in a press previusly alled se- ndary generalizatin. 2. Generalized onset seizures Generalized seizures are thught t riginate in r rapidly spread t invlve bilateral rtial netwrks. In sme ases, the distintin between fal and generalized nset an nly be made by eletren- ephalgram (EEG). Generalized seizures are lassified int thse with mtr r nnmtr features. Awareness is typially lst with generalized seizures but may be retained partially in the briefest absene attaks and sme my- lni seizures. a. Nonmotor (absence) seizures These are harater- ized by impairment f nsiusness, smetimes with mild lni, tni, mylni, r atni mpnents (ie, redu- tin r lss f pstural tne), autnmi mpnents (eg, enuresis), r ampanying autmatisms. Onset and termi- natin f attaks are abrupt. If attaks ur during nver- satin, the patient may miss a few wrds r may break ff in midsentene fr a few sends. The impairment f external awareness is s brief that the patient is unaware f it. Absence (petit mal) seizures almst always begin in hildhd and frequently ease by the age f 20 years r are then replaed by ther frms f generalized seizure. Ele- trenephalgraphially, suh attaks are assiated with bursts f bilaterally synhrnus and symmetri 3-Hz spike-wave ativity. A nrmal bakgrund in the eletren- ephalgram and nrmal r abve-nrmal intelligene imply a gd prgnsis fr the ultimate essatin f these seizures. Atypical absence seizures may demnstrate mre marked hanges in tne, r attaks may have a mre gradual nset and terminatin than in typial absene seizures. They mmnly ur in patients with multiple seizure types, may be ampanied by develpmental delay r mental retardatin, and are assiated with slwer spike- wave disharges than thse in typial absene attaks. b. Motor seizures Types f generalized mtr seizures inlude tonic-clonic, clonic, tonic, myoclonic, myoclonic- tonic-clonic, myoclonic-atonic, atonic, and epileptic spasms. During tni-lni seizures there is sudden lss f nsiusness, the patient bemes rigid and falls t the grund, and respiratin is arrested. This tni phase, whih usually lasts fr under 1 minute, is fllwed by a lni phase in whih there is jerking f the bdy musulature that may last fr 2 r 3 minutes and is then fllwed by a stage f flaid ma. During the seizure, the tngue r lips may be bitten, urinary r feal inntinene may ur, and the patient may be injured. Immediately after the sei- zure, the patient may rever nsiusness, drift int sleep, have a further nvulsin withut revery f n- siusness between the attaks (status epilepticus), r after revering nsiusness have a further nvulsin (serial seizures). In ther ases, patients may behave in an abnrmal fashin in the immediate pstital perid, with- ut subsequent awareness r memry f events (postepi- leptic automatism) . Headahe, disrientatin, nfusin, drwsiness, nausea, sreness f the musles, r sme m- binatin f these symptms mmnly urs pstitally. Mylni seizures nsist f single r multiple mylni jerks. Atni seizures nsist f very brief (less than 2 sends) lss f musle tne and ften result in falls (epileptic drop attacks) .Epileptic spasms are sudden flexin rCMDT22_Ch24_p0978-p1053.indd  987 29/06/21 8:50 PMChapTER 24988 CMDT 2022extensin  f trunal musles; these seizures usually mani- fest during infany. 3. Unknown onset seizures In sme irumstanes, sei- zures annt be lassified beause f inmplete infrmatin r beause they d nt fit int any ategry. Generally, with additinal infrmatin frm the histry r frm vide-EEG telemetry, the seizure nset an be rretly lassified.B.  Epilepsy TypesThe  Internatinal League Against Epilepsy lassifies epi- lepsy by the seizure type. Thus, epilepsy may be focal , generalized, rcombined generalized and focal. The EEG may be helpful in failitating lassifiatin.C.  Epilepsy SyndromesEp ilepsy syndrmes are defined by nstellatins f seizure types, EEG findings, and imaging features, and ften als depend n age at nset and mrbidities. Nt every patient with epilepsy an be given a syndrmi diagnsis. Several well-knwn epilepsy syndrmes exist but are beynd the spe f this hapter. Etiology of EpilepsyIn  parallel t lassifying the seizure type, epilepsy type, and epilepsy syndrme (if appliable), the ause f the patients seizures shuld be sught. The Internatinal League Against Epilepsy lists six brad etilgi ategries; sme- times a patients seizures have mre than ne etilgy.A.  Structural Etiology1.  Pediatric age groups Cngenital abnrmalities and perinatal injuries may result in seizures presenting in infany r hildhd. 2. Mesial temporal sclerosis Hippampal slersis is a regnized ause f fal and sendarily generalized sei- zures f unertain etilgy. 3. Trauma Trauma is an imprtant ause f seizures at any age, but espeially in yung adults. Psttraumati epi- lepsy is mre likely t develp if the dura mater was pene- trated and generally bemes manifest within 2 years fllwing the injury. Seizures develping in the first week after head injury d nt neessarily imply that future attaks will ur. There is noevidene that prphylati antinvulsant mediatin treatment redues the inidene f psttraumati epilepsy. 4. Tumors and other spaceoccupying lesions Ne- plasms may lead t seizures at any age, but they are an espeially imprtant ause f seizures in middle and later life, when the inidene f neplasti disease inreases. Seizures are mmnly the initial symptms f the tumr and ften are fal in harater. They are mst likely t ur with strutural lesins invlving the frntal, parietal, r tempral regins. Tumors must be excluded by imaging studies (MRI preferred over CT) in all patients with onset of seizures after 20 years of age, focal seizures or signs, or a progressive seizure disorder.5. Vascular diseases Strke and ther vasular diseases beme inreasingly frequent auses f seizures with advaning age and are the mst mmn ause f seizures with nset at age 60 years r lder. 6. Degenerative disorders Alzheimer disease and ther degenerative disrders are a ause f seizures in later life.B.  Genetic EtiologyThis ategry enmpasses a  brad range f disrders, fr whih the age at nset ranges frm the nenatal perid t adlesene r even later in life. Mngeni disrders tend t exhibit an autsmal dminant pattern f inheritane, and where the mutatin is knwn, the respnsible gene ften endes a neurnal in hannel. A geneti etilgy may als underpin ertain epilepsies with a metabli r strutural basis.C.  Infectious EtiologyInfetius diseases must be nsider ed in all age grups as ptentially reversible auses f seizures. Seizures may ur with an aute infetive r inflammatry illness, suh as baterial meningitis r herpes enephalitis, r in patients with mre lngstanding r hrni disrders, suh as neu- rsyphilis r erebral ystiersis. In patients with AIDS, seizures may result frm entral nervus system txplas- msis, ryptal meningitis, sendary viral enephali- tis, r ther infetive mpliatins. Seizures are a mmn sequela f supratentrial brain absess, develping mst frequently in the first year after treatment.D . Metabolic EtiologyInbrn  errrs f metablism and ther inherited ndi- tins may ause epilepsy as ne f their manifestatins (eg, pyridxine defiieny, mithndrial disease); these disr- ders typially present during hildhd.E.  Immune EtiologyA utimmune diseases suh as systemi lupus erythemat- sus and autimmune limbi enephalitis may ause epi- lepsy; ften the epilepsy an be ured with immuntherapy and lifelng antiepilepti mediatin treatment is nt neessary.F . Unknown EtiologyIn  many ases, the ause f epilepsy annt be determined. Clinical FindingsA.  Symptoms and SignsN nspeifi hanges suh as headahe, md alteratins, lethargy, and mylni jerking alert sme patients t an impending seizure hurs befre it urs. These prodro- mal symptoms are distint frm the aura; the aura that may preede a generalized seizure by a few sends r minutes is itself a part f the seizure indiating fal nset frm a restrited part f the brain.CMDT22_Ch24_p0978-p1053.indd  988 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS989 CMDT 2022In  mst patients, seizures ur unpreditably at any time and withut any relatinship t psture r nging ativities. Oasinally, hwever, they ur at a partiu- lar time (eg, during sleep) r in relatin t external pre- ipitants suh as lak f sleep, missed meals, emtinal stress, menstruatin, alhl ingestin (r alhl with- drawal), r use f ertain rereatinal drugs. Fever and nnspeifi infetins may als preipitate seizures in patients with epilepsy. In a few patients, seizures are pr- vked by speifi stimuli suh as flashing lights r a flik- ering televisin set (photosensitive epilepsy), musi, r reading. Clinial examinatin between seizures shws n abnr- mality in patients with idipathi epilepsy, but in the immediate pstital perid, extensr plantar respnses may be seen. The presene f lateralized r fal signs pstitally suggests that seizures may have a fal rigin. In patients with symptmati epilepsy, the findings n exami- natin will reflet the underlying ause.B.  ImagingMRI  is indiated fr patients with fal neurlgi symp- tms r signs, fal seizures, r eletrenephalgraphi findings f a fal disturbane. It shuld als be perfrmed in patients with linial evidene f a prgressive disrder and in thse with new nset f seizures after the age f 20 years beause f the pssibility f an underlying ne- plasm. CT is generally less sensitive than MRI in deteting small strutural brain abnrmalities but may be used when MRI is ntraindiated r unavailable.C.  Laboratory StudiesInit ial investigatins after a first seizure shuld inlude mplete bld unt, serum gluse, eletrlytes, re- atinine, alium, magnesium, and liver bihemial tests t exlude varius auses f prvked seizures and t prvide a baseline fr subsequent mnitring f lng-term effets f treatment. Rutine labratry investigatins are notusually neessary after reurrent seizures in patients with knwn epilepsy. A lumbar punture may be neessary when any sign f infetin is present r in the evaluatin f new-nset seizures in the aute setting.D . ElectroencephalographyEletrenephalgraph y may supprt the linial diagnsis f epilepsy (by demnstrating parxysmal abnrmalities ntaining spikes r sharp waves), prvide a guide t prg- nsis, and help lassify the seizure disrder. Classifiatin f the disrder is imprtant fr determining the mst apprpriate antinvulsant mediatin with whih t start treatment. Fr example, absene and fal seizures with impaired awareness may be diffiult t distinguish lini- ally, but the eletrenephalgraphi findings and treat- ment f hie differ in these tw nditins. Finally, by lalizing the epileptgeni sure, the eletrenephal- graphi findings are imprtant in evaluating andidates fr surgial treatment.Differential DiagnosisThe  distintin between the varius disrders likely t be nfused with generalized seizures is usually made n the basis f the histry. The imprtane f btaining an eye- witness aunt f the attaks annt be veremphasized.A.  Differential Diagnosis of Focal Seizures1.  TIAs These are distinguished frm seizures by their lnger duratin, lak f spread, and negative (eg, weakness r numbness) rather than psitive (eg, nvulsive jerking r paresthesias) symptms. Level f nsiusness, whih is unaltered, des nt distinguish them. 2. Migraine aura Migraine aura may prdue psitive r negative symptms, tends t spread slwly frm ne part f the bdy t anther (ver minutes rather than sends), and is usually lnger in duratin (minutes t hurs). It is usually, but nt always, fllwed by a typial migraine headahe. 3. Panic attacks These may be hard t distinguish frm fal seizures unless there is evidene f an anxiety disr- der between attaks and the attaks have a lear relatin- ship t external irumstanes. 4. Rage attacks These are situatinal and lead t gal- direted aggressive behavir.B.  Differential Diagnosis of Generalized Seizures1.  Syncope Synpal episdes usually ur in relatin t pstural hange, emtinal stress, instrumentatin, pain, r straining. They are typially preeded by pallr, sweating, nausea, and malaise and lead t lss f nsiusness ampanied by flaidity; revery urs rapidly with reumbeny, and there is n pstital headahe r nfu- sin. In sme instanes, hwever, mtr ampaniments and urinary inntinene may simulate a seizure. 2. Cardiac disease Cerebral hypperfusin due t a dis- turbane f ardia rhythm shuld be suspeted in patients with knwn ardia r vasular disease r in elderly patients wh present with episdi lss f nsiusness. Prdrmal symptms are typially absent. Cardia rhythm mnitring may be neessary t establish the diagnsis; external event rerders r implantable lp rerders may be valuable if the disturbanes f nsiusness are rare. A relatinship f attaks t physial ativity and the finding f a systli murmur are suggestive f arti stensis. 3. Brainstem ischemia Lss f nsiusness is preeded r ampanied by ther brainstem signs. Basilar artery migraine and vertebrbasilar vasular disease are disussed elsewhere in this hapter. 4. Psychogenic nonepileptic seizure PNES Simulating an epilepti seizure, a PNES may ur due t a nversin disrder r malingering. Many patients als have epilepti seizures r a family histry f epilepsy. A histry f hild- hd physial r sexual abuse is mmn. Althugh a PNES tends t ur at times f emtinal stress, this may als be the ase with epilepti seizures.CMDT22_Ch24_p0978-p1053.indd  989 29/06/21 8:50 PMChapTER 24990 CMDT 2022Clini ally, the attaks superfiially resemble tni-lni seizures, but there may be bvius preparatin befre a PNES. Mrever, there is usually n tni phase; instead, there may be an asynhrnus thrashing f the limbs and the attak rarely leads t injury. Eyes are ften fribly lsed during PNES, unlike epilepti seizures, in whih they are typially pen. Cnsiusness may be nrmal r lst,  but in the latter ntext the urrene f gal-direted behavir r f shuting, swearing, et, indiates that it is feigned. Pstitally, there are n hanges in behavir r neurlgi findings. Often, linial bservatin is insuffiient t disriminate epilepti frm nnepilepti seizures and video electroen- cephalographic monitoring is required. Elevatin f serum prlatin level t at least twie the upper limit f nrmal an be seen between 10 and 20 minutes after a seizure r syn- pal event but nt after a PNES. Hwever, prlatin measure- ment has limited linial utility beause levels are nrmal after an epilepti seizure in rughly half f patients and a baseline prlatin must be drawn 6 hurs after the attak. TreatmentA.  General MeasuresF r patients with epilepsy, mediatin is presribed with the gal f preventing further attaks and is usually ntinued until there have been n seizures fr at least 2 years. Patients shuld be advised t avid situatins that uld be danger- us r life-threatening if further seizures shuld ur. Legislatin may require liniians t reprt t the state authrities any patients with seizures r ther episdi dis- turbanes f nsiusness; driving cessation for 6 months r as legislated is apprpriate fllwing an unprvked seizure. 1. Choice of medication Mediatin seletin depends n seizure type (Table 242). The dse f the seleted anti- nvulsant is gradually inreased until seizures are n- trlled r side effets prevent further inreases. If seizures ntinue despite treatment at the maximal tlerated dse, a send mediatin is added and the dse inreased depending n tlerane; the first mediatin is then gradu- ally withdrawn. In mst patients with seizures f a single type, satisfatry ntrl an be ahieved with a single antinvulsant. Treatment with tw mediatins may fur- ther redue seizure frequeny r severity but usually nly at the st f greater txiity. Treatment with mre than tw mediatins is almst always unhelpful unless the patient is having seizures f different types. Other fatrs t nsider in seleting an antinvulsant inlude likely side effets, teratgeniity, interatins with ther media- tins and ral ntraeptives, and rute f metablism. All antiepileptis are ptentially teratgeni, althugh the teratgeniity f the newer antiseizure mediatins is less lear. Nevertheless, antiepilepti mediatin must be given t pregnant wmen with epilepsy t prevent seizures, whih an pse serius risk t the fetus frm trauma, hypxia, r ther fatrs. 2. Monitoring Individual differenes in drug metablism ause a given dse f a mediatin t prdue differentbld nentratins in different patients, and this will affet the therapeuti respnse. In general, the dose of an antiepileptic agent is increased, depending on tolerance, to achieve the desired clinical response regardless of the serum drug level. When a dse is reahed that either ntrls sei- zures r is the maximum tlerated, then a steady-state trugh drug level may be btained fr future referene; reheking this level may be apprpriate during pregnany, if a breakthrugh seizure urs, a dse hange urs, r anther (ptentially interating) mediatin is added t the regimen. A labratrys therapeuti range fr a mediatin is nly a guide; many patients ahieve gd seizure ntrl with n adverse effet at serum levels that exeed the stipu- lated range, and in these ases n dse adjustment is needed. The mst mmn ause f a lwer nentratin f mediatin than expeted fr the presribed dse is sub- ptimal patient adherene. Adherene an be imprved by limiting t a minimum the number f daily dses. Reur- rent seizures r status epileptius may result if mediatins are taken erratially, and in sme irumstanes nnadher- ent patients may be better ff withut any mediatin. All antinvulsants have side effets, and many require base- line and regular labratry mnitring (Table 242). 3. Discontinuance of medication Only when adult patients have been seizure-free fr 2 years shuld with- drawal f mediatin be nsidered. Unfrtunately, there is n way f prediting whih patients an be managed su- essfully withut treatment, althugh seizure reurrene is mre likely in (1) patients with a lnger duratin f epi- lepsy prir t remissin, (2) thse with a shrter duratin f remissin, (3) thse wh initially did nt respnd t therapy, (4) thse with seizures having fal features r f multiple types, (5) thse with nset during adulthd, and (6) thse with ntinuing eletrenephalgraphi abnr- malities. Dse redutin shuld be gradual (ver weeks r mnths), and mediatins shuld be withdrawn ne at a time. If seizures reur, treatment is reinstituted with the previusly effetive regimen. 4. Surgical treatment Patients with seizures refratry t tw r mre mediatins may be andidates fr perative treatment. Surgial resetin is mst effiaius when there is a single well-defined seizure fus, partiularly in the tempral lbe. Amng well-hsen patients, up t 70% remain seizure-free after extended fllw-up. Additinal surgial tehniques fr medially refratry epilepsy apprved in the United States inlude laser interstitial ther- mal therapy, deep brain stimulatin, respnsive rtial stimulatin, and vagus nerve stimulatin.B.  Special Circumstances1.  Solitary seizures In patients wh have had nly ne seizure r a flurry f seizures ver a brief perid f several hurs, investigatin as utlined earlier shuld exlude an underlying ause requiring speifi treatment. An eletr- enephalgram shuld be btained, preferably within 24 hurs after the seizure. Prphylati antinvulsant treat- ment is generally nt required unless further attaks ur r investigatins reveal underlying pathlgy. The risk f seizure reurrene varies in different series between abutCMDT22_Ch24_p0978-p1053.indd  990 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS991 CMDT 202230%  and 70%, with higher risk f reurrene in patients with strutural brain lesins r abnrmalities n eletren- ephalgram. Epilepsy shuld notbe diagnsed n the basis f a slitary seizure. If seizures ur in the ntext f transient, nnreurrent systemi disrders suh as hypna- tremia r hypglyemia, the diagnsis f epilepsy is ina- urate, and lng-term prphylati antinvulsant treatment is unneessary. 2. Alcohol withdrawal seizures The harateristi al- hl withdrawal seizure pattern is ne r mre generalized tni-lni seizures that may ur within 48 hurs r s f withdrawal frm alhl after a perid f high r pr- lnged intake. If the seizures have nsistently fal fea- tures, the pssibility f an assiated strutural abnrmality, ften traumati in rigin, must be nsidered. Treatment with antinvulsants is generally nt required fr alhl withdrawal seizures, sine they are self-limited. Benzdiaz- epines are effetive and safe fr preventing further seizures. Status epileptius may mpliate alhl withdrawal and is managed alng nventinal lines. Further attaks will nt ur if the patient abstains frm alhl. 3. Tonicclonic status epilepticus Pr adherene t the antinvulsant regimen is the mst mmn ause; hw- ever, any disrder that an ause a single seizure may be respnsible. The mrtality rate may be as high as 20%, and amng survivrs the inidene f neurlgi and gnitive sequelae is high. The prgnsis relates t the underlying ause as well as the length f time between nset f status epileptius and the start f effetive treatment. Status epilepticus is a medical emergency. Initial management inludes maintenane f the airway and 50% dextrse (2550 mL) intravenusly in ase hypglyemia is respnsible. If seizures ntinue, an intravenus blus f lrazepam, 4 mg, is given at a rate f 2 mg/min and repeated ne after 10 minutes if neessary; alternatively, 10 mg f midazlam is given intramusularly, and again after 10 minutes if neessary. Diazepam an als be given retally as a gel (0.2 mg/kg). These measures are usually effetive in halting seizures fr a brief perid. Respiratry depressin and hyptensin may mpliate the treatment and are treated as in ther irumstanes, inluding intuba- tin and mehanial ventilatin and admissin t an inten- sive are unit. Regardless f the respnse t lrazepam r midazlam, fsphenytin r phenytin shuld be administered intrave- nusly. Fsphenytin (1820 mg phenytin equivalents [PE]/kg) is rapidly and mpletely nverted t phenytin fllwing intravenus administratin and is preferred beause it is less likely t ause reatins at the infusin site, an be given with all mmn intravenus slutins, and may be administered at a faster rate (150 mg PE/min). When fsphenytin is nt available, phenytin (1820 mg/kg) is given intravenusly at a rate f 50 mg/min. Phenytin is best injeted diretly but an als be given in saline; it pre- ipitates, hwever, if injeted int gluse-ntaining slu- tins. Beause arrhythmias may develp during rapid administratin f fsphenytin r phenytin, eletrar- digraphi mnitring is prudent. Hyptensin may ur, espeially if diazepam has als been given. Alternatively radditinally, intravenus valprate (lading dse 2040 mg/ kg ver 15 min, maximum dse 3000 mg) r levetiraetam (lading dse 60 mg/kg ver 15 min, maximum dse 4500 mg) is used fr status epileptius. Althugh neither is apprved by the FDA fr this indiatin, bth were equiva- lent t fsphenytin in a randmized trial. Due t the teratgeniity f valprate, it shuld be avided in wmen wh may be pregnant. If seizures ntinue, phenbarbital is then given in a lading dse f 1020 mg/kg intravenusly by slw r intermittent injetin (50 mg/min). Respiratry depressin and hyptensin are espeially mmn with this therapy. If these measures fail, general anesthesia with ventila- try assistane may be required; sme experts rem- mend preeding diretly t general anesthesia if nvulsins d nt ease after the initial 1820 PE/kg fsphenytin lad. Intravenus midazlam may prvide ntrl f refratry status epileptius; the suggested lading dse is 0.2 mg/kg, fllwed by 0.050.2 mg/kg/h. Prpfl (12 mg/kg as an intravenus blus, fllwed by infusin at 215 mg/kg/h depending n respnse) may als be used, as may pentbarbital (515 mg/kg intrave- nusly, fllwed by 0.54 mg/kg/h). After status epileptius is ntrlled, an ral mediatin prgram fr the lng-term management f seizures is started, and investigatins int the ause f the disrder are pursued. 4. Nonconvulsive status epilepticus In sme ases, sta- tus epileptius presents nt with nvulsins, but with a flutuating abnrmal mental status, nfusin, impaired respnsiveness, and autmatism. Eletrenephalgraphy establishes the diagnsis. The treatment apprah utlined abve applies t any type f status epileptius, althugh intravenus anesthesia is usually nt neessary. The prg- nsis is a refletin f the underlying ause rather than f ntinuing seizures. When to Refer Behaviral episdes f unertain nature. Seizures are diffiult t ntrl with mntherapy. There is a prgressive neurlgi disrder. When to Admit Status epileptius. Frequent seizures requiring rapid mediatin titratin and eletrenephalgraphi mnitring. Fr inpatient mnitring when PNES is suspeted.Ahmad  S et al. Surgial treatments f epilepsy. Semin Neurl. 2020;40:696. [PMID: 33176368] Kanner AM et al. Pratie guideline update summary: effiay and tlerability f the new antiepilepti drugs I: treatment f new-nset epilepsy. Epilepsy Curr. 2018;18:260. [PMID: 30254527] Kapur J et al; NETT and PECARN Investigatrs. Randmized trial f three antinvulsant mediatins fr status epilepti- us. N Engl J Med. 2019;381:2103. [PMID: 31774955]CMDT22_Ch24_p0978-p1053.indd  991 29/06/21 8:50 PMChapTER 24992 CMDT 2022DYSAUTO NOMIAE S S E N T I A L S  O F  D I A G N O S I S Postural hypotension or abnormal heart rate regulation. Abnormalities of sweating, intestinal motility, sex- ual function, or sphincter control. Syncope may occur. Symptoms occur in isolation or any combination. General ConsiderationsDysautn mia may ur as a result f pathlgial pr- esses in the entral r peripheral nervus system. It is manifested by a variety f symptms related t abnrmali- ties f bld pressure regulatin, thermregulatry sweat- ing, gastrintestinal funtin, sphinter ntrl, sexual funtin, respiratin, and ular funtin. The differential diagnsis depends n the time urse f autnmi dys- funtin and whether dysautnmia is an islated symp- tm r assiated with entral r peripheral neurlgi symptms and signs.A.  Causes in the Central Nervous SystemDisease at  ertain sites, regardless f its nature, may lead t dysautnmi symptms. Postural hypotension, whih is usually the mst trublesme and disabling symptm, may result frm spinal rd transetin and ther myelpathies (eg, due t tumr r syringmyelia) abve the T6 level r frm brainstem lesins suh as syringbulbia and psterir fssa tumrs. Sphincter or sexual disturbances may result frm rd lesins at any level. Certain primary degenera- tive disrders are respnsible fr dysautnmia urring in islatin (pure autonomic failure) r in assiatin with mre widespread abnrmalities (multisystem atro- phy) that may inlude parkinsnism, pyramidal symp- tms, and erebellar defiits. Pstural hyptensin is als a prminent symptm f idipathi Parkinsn disease and dementia with Lewy bdies.B.  Causes in the Peripheral Nervous SystemA  pure autnmi neurpathy may ur autely r sub- autely after a viral infetin r as a paraneplasti disr- der related usually t small ell lung aner, partiularly in assiatin with ertain antibdies, suh as anti-Hu r thse direted at neurnal nitini ganglini aetylh- line reeptrs. Dysautnmia is ften nspiuus in patients with Guillain-Barr syndrme, manifesting with marked hyptensin r hypertensin r ardia arrhyth- mias that may have a fatal utme. It may als ur with diabeti, uremi, amylidti, and varius ther metabli r txi neurpathies; in assiatin with leprsy r Cha- gas disease; and as a feature f ertain hereditary neurpa- thies with autsmal dminant r reessive inheritane r an X-linked pattern. Autnmi symptms are prminentin the rises f hepati prphyria. Small fiber neurpathies may underlie sme ases f postural orthostatic tachycar- dia syndrome (POTS) due t impaired ntratility in denervated venules and resulting prelad failure (see belw). Patients with btulism r the Lambert-Eatn myastheni syndrme may have nstipatin, urinary retentin, and a sia syndrme as a result f impaired hlinergi funtin. Clinical FindingsA.  Symptoms and SignsDysautn mi symptms inlude synpe, pstural hyp- tensin, parxysmal hypertensin, persistent tahyardia withut ther ause, faial flushing, hyphidrsis r hyper- hidrsis, vmiting, nstipatin, diarrhea, dysphagia, abdminal distentin, disturbanes f mituritin r defe- atin, eretile dysfuntin, apnei episdes, and delining night visin. In synpe, prdrmal malaise, nausea, head- ahe, diaphresis, pallr, visual disturbane, lss f ps- tural tne, and a sense f weakness and impending lss f nsiusness are fllwed by atual lss f nsiusness. It is usually ampanied by hyptensin and bradyardia and may ur in respnse t emtinal stress, pstural hyptensin, vigrus exerise in a ht envirnment, bstruted venus return t the heart, aute pain r its antiipatin, fluid lss, and a variety f ther irum- stanes. Althugh the patient is usually flaid, sme mtr ativity is nt unmmn, and urinary (and rarely feal) inntinene may als ur, thereby simulating a seizure. Revery is rapid ne the patient bemes reum- bent, but headahe, nausea, and fatigue mmnly persist.B.  Evaluation of the PatientThe e xtent and severity f autnmi dysfuntin shuld be determined, and the presene f assiated neurlgi symptms and signs asertained. Bedside testing f aut- nmi funtin inludes examinatin f pupillary rea- tivity, examinatin f the skin fr areas f exessive r redued sweating and f the hands and feet fr lr r temperature hanges, as well as assessment f bld pres- sure and heart rate in the supine psitin and 2 minutes after standing. With dysautnmia, postural hypotension is not accompanied by a compensatory rise in heart rate. Speialized tests inlude the ardivasular respnse t the Valsalva maneuver and deep respiratin, tilt-table testing, the thermregulatry sweat test, the quantitative sudmtr axn reflex test, and the quantitative diret and indiret axn reflex test. Tests f gastrintestinal mtility and urdynamis may be helpful when symptms f dysmtility, inntinene, r urinary retentin are present. The neurlgi examinatin shuld fus n deteting signs f parkinsnism, erebellar dysfuntin, disrders f neurmusular transmissin, and peripheral neurpathy. All patients shuld be tested fr vitamin B12defiieny and diabetes. Patients with aute r subaute islated dysaut- nmia shuld underg testing fr ganglini aetylhline reeptr, anti-Hu, vltage-gated ptassium hannel m- plex, and vltage-gated alium hannel antibdies. Fr thse with evidene f peripheral neurpathy, nerveCMDT22_Ch24_p0978-p1053.indd  992 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS993 CMDT 2022ndu tin studies; eletrmygraphy; and testing fr HIV , amylidsis, Sjgren syndrme, and Fabry disease are indiated. If there is evidene f entral pathlgy, imag- ing studies will exlude a treatable strutural ause. If the neurlgi examinatin is nrmal, reversible, nnneur- lgi auses f symptms must be nsidered. Islated pstural hyptensin and synpe may relate t a redued ardia utput, parxysmal ardia dysrhythmias, vlume depletin, varius mediatins, and endrine and meta- bli disrders suh as Addisn disease, hypthyridism r hyperthyridism, phehrmytma, and arinid syndrme. TreatmentThe  mst disabling symptms are usually pstural hypten- sin and synpe. Abrupt pstural hange, prlnged reumbeny, heavy meals, and ther preipitants shuld be avided. Mediatins assiated with pstural hyptensin shuld be disntinued r redued in dse. Treatment may inlude wearing waist-high elasti hsiery, salt supplementa- tin, sleeping in a semieret psitin (whih minimizes the natriuresis and diuresis that ur during reumbeny), ingestin f 500 mL water 30 minutes befre arising, and fludrrtisne (0.10.5 mg rally daily). Vasnstritr agents may be helpful and inlude middrine (2.510 mg rally three times daily), drxidpa (100600 mg rally three times daily), and ephedrine (1530 mg rally three times daily). Other agents that have been used asinally r experimentally are dihydrergtamine, yhimbine, pyr- idstigmine, and lnidine; refratry ases may respnd t erythrpietin (epetin alfa) r desmpressin. Patients must be mnitred fr reumbent hypertensin. Pstprandial hyptensin is helped by affeine. There is n satisfatry treatment fr disturbanes f sweating, but an air-nditined envirnment is helpful in aviding extreme swings in bdy temperature. When to Refer When the diagnsis is unertain. When symptms persist despite nventinal treatment.Shiba  CA et al. Management f rthstati hyptensin, pst- prandial hyptensin, and supine hypertensin. Semin Neurl. 2020;40:515. [PMID: 33058087]PO STURAL ORTHOSTATIC TACHYCARDIA SYNDROME Clinical FindingsIn PO TS, rthstati symptms (tremulusness, lighthead- edness, palpitatins, visual disturbanes, weakness, fatigue, anxiety, hyperventilatin, nausea) develp with a signifiant tahyardia (an inrease f 30 beats/min r mre r a heart rate f 120 beats/min r mre) within 10 minutes f stand- ing, in the absene f pstural hyptensin r an autnmi neurpathy. POTS is mre mmn in wmen than menand in patients between 20 and 50 years f age. Other medi- al prblems ausing a tahyardia must be exluded. Its pathphysilgy is unertain but may invlve ar- dia denditining; impaired peripheral vasnstri- tin due t peripheral sympatheti denervatin, leading t venus pling in the legs n standing and a mpen- satry tahyardia ( neuropathic POTS ); r an exagger- ated sympatheti respnse t standing, with markedly elevated levels f plasma nrepinephrine ausing the tahyardia ( hyperadrenergic POTS ). Other pssible mehanisms inlude hypvlemia, pssibly frm impaired funtin f the renin-angitensin system (volume dysregulation POTS ) and exessive mast ell ativatin leading t inapprpriate release f histamine during physial ativity. Psyhlgial mehanisms have als been invked. POTS may be assiated with jint hypermbility syndrme and mitral valve prlapse, and it may fllw pregnany, surgery, trauma, hemtherapy, vainatins, r viral infetins. TreatmentMana gement may invlve vlume repletin, a high salt diet and pius fluids, pstural and psyhphysilgi train- ing, and a graduated exerise prgram. Mediatin treat- ment may inlude a beta-blking agent (eg, prpranll 1040 mg three times daily), phenbarbital (15 mg in the mrning, 60 mg at night) r lnidine (0.2 mg twie daily) fr patients with hyperadrenergi POTS; and mid- drine (2.510 mg three times daily) r fludrrtisne (0.10.2 mg daily) if the bld pressure is lw. The lng- term prgnsis is unlear but apprximately 50% f patients rever within 3 years.TR ANSIENT ISCHEMIC ATTACKSE S S E N T I A L S  O F  D I A G N O S I S Focal neurologic deficit of acute onset. Clinical deficit resolves completely within 24 hours. Risk factors for vascular disease often present. General ConsiderationsT ransient ishemi attaks (TIAs) are haraterized by focal ischemic cerebral neurologic deficits that last frless than 24 hours (usually less than 12 hurs). Abut 30% f patients with strke have a histry f TIAs and 510% f patients with TIAs will have a strke within 90 days. The natural his- try f attaks is variable. Sme patients will have a majr strke after nly a few attaks, whereas thers may have frequent attaks fr weeks r mnths withut having a strke. The risk f strke is high in the first 3 mnths after an attak, partiularly in the first mnth and espeially within the first 48 hurs. The strke risk is greater in patients lder than 60 years, in patients with diabetes, r after TIAs that last lnger than 10 minutes and with symptms r signsCMDT22_Ch24_p0978-p1053.indd  993 29/06/21 8:50 PMChapTER 24994 CMDT 2022f  weakness, speeh impairment, r gait disturbane. In general, artid ishemi attaks are mre liable than verte- brbasilar ishemi attaks t be fllwed by strke. Urgent interventin in TIA patients redues rates f subsequent strke, and the condition should be treated with a similar sense of urgency as unstable angina. EtiologyAn  imprtant ause f transient erebral ishemia is emblizatin. In many patients with these attaks, a sure is readily apparent in the heart r a majr extraranial artery t the head, and embli smetimes are visible in the retinal arteries. An embli phenmenn explains why separate attaks may affet different parts f the territry supplied by the same majr vessel. Cardia auses f embli ishemi attaks inlude atrial fibrillatin, heart failure, infetive and nnbaterial thrmbti endardi- tis, atrial myxma, and mural thrmbi mpliating my- ardial infartin. Atrial septal defets and patent framen vale may permit venus thrmbembli t reah the brain ( paradoxical emboli ). An ulerated plaque n a majr artery t the brain may serve as a sure f embli. In the anterir irulatin, atherslerti hanges ur mst mmnly in the regin f the artid bifuratin extraranially; these hanges may ause a bruit. Ather- slersis als affets the vertebrbasilar system and the majr intraranial vessels inluding the middle and ante- rir erebral arteries. Less mmn abnrmalities f bld vessels that may ause TIAs inlude fibrmusular dysplasia, whih affets partiularly the ervial internal artid artery; athersle- rsis f the arti arh; inflammatry arterial disrders suh as giant ell arteritis, plyarteritis, and granulma- tus angiitis; and meningvasular syphilis. Critial sten- sis f a majr extraranial r intraranial artery may ause TIA, espeially in the setting f hyptensin. Hematlgi auses f TIA inlude plyythemia, sikle ell disease, hypervissity syndrmes, and the antiphsphlipid antibdy syndrme. Severe anemia may als lead t transient fal neurlgi defiits in patients with preexisting erebral arterial disease. The subclavian steal syndrome may lead t transient vertebrbasilar ishemia. Symptms develp when there is lalized stensis r lusin f ne sublavian artery prximal t the sure f the vertebral artery, s that bld is stlen frm the vertebral artery t supply the arm. A bruit in the supralaviular fssa, unequal radial pulses, and a differene f 20 mm Hg r mre between the systli bld pressures in the arms shuld suggest the diagnsis in patients with vertebrbasilar TIAs. Clinical FindingsA.  Symptoms and SignsThe  symptms f TIAs vary markedly amng patients; hw- ever, the symptms in a given individual tend t be nstant in type. Onset is abrupt and withut warning, and revery usually urs rapidly, ften within a few minutes. The spe- ifi symptms depend n the arterial distributin affeted,as utlined in the subsequent setin n strke. Of nte, TIA rarely auses f lss f nsiusness r aute nfusin but is ften errneusly blamed fr suh symptms.B.  ImagingCT  r MRI san is indiated within 24 hurs f symptm nset, in part t exlude the pssibility f a small erebral hemrrhage r a erebral tumr masquerading as a TIA. MRI with diffusin-weighted sequenes is partiularly sen- sitive fr revealing aute r subaute infartin, whih is seen in up t ne-third f ases despite reslutin f linial symptms and indiates a high risk f subsequent strke. Nninvasive imaging f the ervial vasulature shuld als be perfrmed; artid duplex ultrasngraphy is useful fr deteting signifiant stensis f the internal artid artery, and MR r CT angigraphy permits brader visualizatin f ervial and intraranial vasulature.C.  Laboratory and Other StudiesClinial  and labratry evaluatin must inlude assessment fr hypertensin, heart disease, hematlgi disrders, dia- betes mellitus, hyperlipidemia, and peripheral vasular dis- ease. It shuld inlude mplete bld unt, fasting bld gluse and serum hlesterl determinatins, and may inlude serlgi tests fr syphilis and HIV infetin. An ECG shuld be btained. Ehardigraphy with agitated saline ntrast is perfrmed if a ardiembli sure is likely, and bld ultures are btained if endarditis is suspeted. Ambulatry ECG mnitring is indiated t detet parxysmal atrial fibrillatin and, if the ause f the TIA remains elusive, extended monitoring may detet parx- ysmal atrial fibrillatin in up t 20% f patients. Differential DiagnosisFal  seizures usually ause abnrmal mtr r sensry phenmena suh as lni limb mvements, paresthesias, r tingling, rather than weakness r lss f feeling. Symp- tms generally spread (marh) up the limb and may lead t a generalized tni-lni seizure. Classi migraine is easily regnized by the visual pre- mnitry symptms, fllwed by nausea, headahe, and phtphbia, but less typial ases may be hard t distin- guish. Patients with migraine are typially yunger, m- mnly have a histry f episdes sine adlesene, and reprt that ther family members have a similar disrder. Fal neurlgi defiits may ur during perids f hypglyemia in diabeti patients reeiving insulin r ral hypglyemi agent therapy. TreatmentA.  Medical MeasuresMedial  treatment is aimed at preventing further attaks and strke. Treat diabetes mellitus, hematlgi disrders, and hypertensin, preferably with an angitensin-nverting enzyme inhibitr r angitensin reeptr blker. ACMDT22_Ch24_p0978-p1053.indd  994 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS995 CMDT 2022stati n shuld be started regardless f the urrent lw- density lipprtein level (LDL), althugh this pratie is nly supprted by randmized trial data in patients with an LDL greater than 100 mg/dL. Cigarette smking shuld be stpped, and ardia sures f emblizatin shuld be treated apprpriately. Weight redutin and regular physial ativity shuld be enuraged when apprpriate. An antiplatelet r antiagulant shuld be started as sn as imaging has established the absene f hemrrhage. 1. Hospitalization Hspitalizatin shuld be nsid- ered fr patients seen within a week f the attak, when they are at inreased risk fr early reurrene. One m- mnly used methd t assess reurrene risk is the ABCD2score; pints are assigned fr eah f the fllw- ing riteria: age 60 years r lder (1 pint), bld pressure 140/90 mm Hg r higher (1 pint), linial symptms f fal weakness (2 pints) r speeh impairment withut weakness (1 pint), duratin f 60 minutes r lnger (2 pints) r 1059 minutes (1 pint), r diabetes mellitus (1 pint). An ABCD2sre f 4 r mre pints has been suggested as a threshld fr hspital admissin. The ABCD2I(with an additinal 3 pints fr any abnrmal diffusin-weighted MRI finding r any infart [new r ld] n nnntrast CT) has been prpsed as a better preditr f subsequent strke risk. Admissin is als advisable fr patients with resend attaks, symptm- ati artid stensis, r a knwn ardia sure f embli r hyperagulable state; suh hspitalizatin failitates early interventin fr any reurrene and rapid institu- tin f sendary preventin measures. 2. Anticoagulation The hief indiatin fr antiagula- tin after TIA is atrial fibrillatin. Patients with metal heart valves, left ventriular thrmbus, and the antiphs- phlipid antibdy syndrme shuld als reeive anti- agulatin therapy. Treatment is with warfarin (target INR 2.03.0); bridging warfarin with heparin is nt neessary, but sme experts advate treatment with aspirin until the INR bemes therapeuti. Fr lng-term antiagulatin in the setting f atrial fibrillatin, apixaban (2.55 mg rally twie daily), dabigatran (150 mg rally twie daily), edxa- ban (60 mg rally daily), and rivarxaban (20 mg rally daily) are ptins. Cmbinatin antiplatelet-antiagula- tin therapy is nly indiated in patients with mehanial heart valves r thse with a separate indiatin fr anti- platelet therapy suh as a ardia stent. In patients with ardimypathy and an ejetin fratin under 35% withut atrial fibrillatin, warfarin (target INR 2.03.0) redues ishemi strke risk mpared t aspirin but results in a rughly equivalent inrease in the risk f majr hemrrhage; treatment in this ppulatin shuld there- fre be individualized. 3. Antiplatelet therapy All patients in whm antiag- ulatin is nt indiated shuld be treated with shrt-term dual antiplatelet therapy and lng-term mntherapy t redue the frequeny f TIAs and the inidene f strke. Treatment shuld be initiated within 12 hurs after the TIA r minr strke (defined by a Natinal Institutes fHealth Strke Sale f 3 r less) with an ral lading dse f lpidgrel (300600 mg) fllwed by 75 mg/day rally plus aspirin (50325 mg daily rally) fr 21 days, fllwed by mntherapy with aspirin (81 mg daily rally), aspirin mbined with extended-release dipyridamle (200 mg twie daily rally), r lpidgrel (75 mg daily rally). Cilstazl (100 mg twie daily) had similar effiay as aspirin at lng-term strke preventin in an Asian ppu- latin with less risk f hemrrhage. Cmbining lpid- grel with aspirin beynd 90 days inreases the risk f hemrrhagi mpliatins and is notremmended.B. Surgic al or Endovascular Measures1. Car otid revascularization When arterigraphy reveals a surgially aessible high-grade stensis (7099% in lumi- nal diameter) n the side apprpriate t artid ishemi attaks, perative treatment ( carotid endarterectomy ) r endovascular intervention redues the risk f ipsilateral artid strke, espeially when TIAs are f reent nset (less than 1 mnth) and when the periperative mrbidity and mrtality risk is estimated t be less than 6%. Endvasular therapy arries a slightly higher predural strke risk than endarteretmy in patients lder than 70 years and is gener- ally reserved fr yunger patients whse nek anatmy is unfavrable fr surgery. Patients with symptmati artid stensis f 5069% derive mderate benefit frm interven- tin, but surgery is nt indiated fr mild stensis (less than 50%). 2. Closure of patent foramen ovale Carefully seleted patients with patent framen vale (PFO) and right-t- left shunt benefit frm PFO lsure and antiplatelet therapy. Patients shuld be nsidered fr PFO lsure if they are between 18 and 60 years ld; have had a rypt- geni strke r TIA; and d nt have unntrlled diabe- tes, hypertensin, r a speifi indiatin fr lng-term antiagulatin. A ryptgeni strke des nt have an identified mehanism, suh as large artery atherslersis (greater than r equal t 3050% stensis f the intrara- nial r ervial arteries r a plaque greater than r equal t 4mm thik in the arti arh), knwn ardiembli sure (eg, atrial fibrillatin), small vessel arterilsler- sis (eg, launar strke smaller than 1.5 m in diameter), hyperagulable state, r dissetin. Patients with mder- ate t large interatrial shunts r assiated atrial septal aneurysms appear t benefit mst frm PFO lsure. See als Chapter 10. When to ReferAll  patients shuld be referred fr urgent investigatin andtreatment to prevent stroke. When to AdmitIf s een within a week f a TIA, patients shuld be nsid- ered fr admissin when they have an ABCD2sre f 4 pints r mre, when utpatient evaluatin is impratial, r when there are multiple attaks, artid stensis f greater than 70%, r ther nern fr early reurrene r strke.CMDT22_Ch24_p0978-p1053.indd  995 29/06/21 8:50 PMChapTER 24996 CMDT 2022Pa n Y et al. Outmes assiated with lpidgrel-aspirin use in minr strke r transient ishemi attak: a pled analysis f Clpidgrel in High-Risk Patients With Aute Nn-Disabling Cerebrvasular Events (CHANCE) and Platelet-Oriented Inhibitin in New TIA and Minr Ishemi Strke (POINT) trials. JAMA Neurl. 2019;76:1466. [PMID: 31424481]ST ROKEE S S E N T I A L S  O F  D I A G N O S I S Sudden onset of neurologic deficit of cerebrovas- cular origin. Patient often has hypertension, diabetes mellitus, tobacco use, atrial fibrillation, or atherosclerosis. Distinctive neurologic signs reflect the region of the brain involved. General ConsiderationsIn  the United States, strke is the sixth leading ause f death and a leading ause f disability. Risk fatrs fr strke inlude hypertensin, diabetes mellitus, hyperlipid- emia, igarette smking, ardia disease, HIV infetin, trigeminal herpes zster, rereatinal drug abuse, heavy alhl nsumptin, and a family histry f strke. Strkes are subdivided pathlgially int infarcts and hemorrhages. The distintin may be diffiult linially; CT sanning is essential t larify the pathlgi basis (Table 243).1.  Lcunr InfrctionLa unar infarts are small lesins (usually less than 1.5 m in diameter) that ur in the distributin f shrt penetrating arteriles in the basal ganglia, pns, erebel- lum, internal apsule, thalamus, and, less mmnly, the deep erebral white matter (Table 243). Launar infarts are assiated with prly ntrlled hypertensin r diabetes and have been fund in several linial syn- drmes, inluding ntralateral pure mtr hemiparesis r pure hemisensry defiit, ipsilateral ataxia with hemi- paresis, and dysarthria with lumsiness f the hand. The neurlgi defiit may prgress ver 2436 hurs befre stabilizing. Early mrtality and risk f strke reurrene is higher fr patients with nnlaunar than launar infarts. The prgnsis fr revery frm the defiit prdued by a lau- nar infart is usually gd, with partial r mplete reslu- tin urring ver the fllwing 46 weeks in many instanes. Treatment is as desribed fr TIA and erebral infartin.2.  Cerebrl InfrctionThrm bti r embli lusin f a majr vessel leads t erebral infartin. Causes are idential t the disrders predispsing t TIAs. The resulting defiit depends n the partiular vessel invlved and the extent f any llateralirulatin. Cerebral ishemia leads t release f exitatry and ther neurpeptides that may augment alium flux int neurns, thereby leading t ell death and inreasing the neurlgi defiit. Clinical FindingsA.  Symptoms and SignsOnset  is usually abrupt, and there may then be very little prgressin exept that due t brain swelling. Clinial evaluatin shuld always inlude examinatin f the heart fr murmurs and rhythm irregularities. Ausultating ver the artid r sublavian vessels may reveal a bruit but is nt sensitive enugh t substitute fr vasular imaging. 1. Obstruction of carotid circulation Olusin f the anterior cerebral artery distal t its juntin with the ante- rir mmuniating artery auses weakness and rtial sensry lss in the ntralateral leg and smetimes mild weakness f the arm, espeially prximally. There may be a ntralateral grasp reflex, paratni rigidity, abulia (lak f initiative), r frank nfusin. Urinary inntinene is nt unmmn, partiularly if behaviral disturbanes are nspiuus. Bilateral anterir erebral infartin is espe- ially likely t ause marked behaviral hanges and memry disturbanes. Unilateral anterir erebral artery lusin prximal t the juntin with the anterir m- muniating artery is generally well tlerated beause f the llateral supply frm the ther side. Middle cerebral artery lusin leads t ntralateral hemiplegia, hemisensry lss, and hmnymus hemian- pia (ie, bilaterally symmetri lss f visin in half f the visual fields), with the eyes deviated t the side f the lesin. If the dminant hemisphere is invlved, glbal aphasia is als present. It may be impssible t distinguish this linially frm lusin f the internal artid artery. With lusin f either f these arteries, there may als be nsiderable swelling f the hemisphere during the first 72 hurs. Fr example, an infart invlving ne erebral hemisphere may lead t suh swelling that the funtin f the ther hemisphere r the rstral brainstem is disturbed and ma results. Olusins f different branhes f the middle erebral artery ause mre limited findings. Fr example, invlvement f the superir divisin in the dmi- nant hemisphere leads t a predminantly expressive (Broca ) aphasia and t ntralateral paralysis and lss f sensatins in the arm, the fae and, t a lesser extent, the leg. Inferir branh lusin in the dminant hemisphere prdues a reeptive ( Wernicke ) aphasia and a hmny- mus visual field defet. With invlvement f the nn- dminant hemisphere, speeh and mprehensin are preserved, but there may be a left hemispatial neglet syn- drme r nstrutinal and visuspatial defiits. Olusin f the ophthalmic or central retinal artery leads t sudden painless visual lss with retinal pallr and a maular herry red spt n fundspi examinatin. Sudden, transient visin lss in ne eye ( amaurosis fugax ) is a TIA in this arterial territry. Patients with a cilioretinal artery (apprximately 25%) may have maular sparing due t llateral bld supply.CMDT22_Ch24_p0978-p1053.indd  996 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS997 CMDT 20222. Obstruction of  vertebrobasilar circulation Olusin f the posterior cerebral artery may lead t a thalami syndrme in whih ntralateral hemisensry disturbane urs, fllwed by the develpment f spntaneus pain and hyperpathia. There is ften a maular-sparing hm- nymus hemianpia and smetimes a mild, usually tem- prary, hemiparesis. Depending n the site f the lesinand the llateral irulatin, the severity f these defiits varies and ther defiits may als ur, inluding invlun- tary mvements and alexia. Olusin f the main artery beynd the rigin f its penetrating branhes may lead slely t a maular-sparing hemianpia. Vertebral artery occlusion belw the rigin f the anterir spinal and psterir inferir erebellar arteriesTable 243. Features of the major stroke subtypes.Stro ke Tye nd Subtye Clinicl Fetures Dignosis Tretment Iscemic Stroke Lacunar infarct Small (< 1.5 cm) lesions in the basal ganglia, pons, cerebel- lum, or internal capsule; less often in deep cerebral white matter; prognosis generally good; clinical features depend on location, but may worsen over first 2436 hours.MRI with diffusion-weighted sequences usually defines the area of infarction; CT is insensitive acutely but can be used to exclude hemorrhage.Antiplatelet; control risk factors (hypertension, tobacco use, hyper- cholesterolemia, and diabetes mellitus). Carotid circulation obstructionSee textsigns vary depending on occluded vessel.Noncontrast CT to exclude hemorrhage but findings may be normal during first 624 hours of an ischemic stroke; diffusion-weighted MRI is gold stan- dard for identifying acute stroke; elec- trocardiography, carotid duplex studies, echocardiography, blood glucose, com- plete blood count, and tests for hyper- lipidemia are indicated; ambulatory ECG monitoring, including extended monitoring in selected instances; CTA, MRA, or conventional angiography in selected cases; tests for hypercoagula- ble states in selected cases.03 hours in United States: intrave- nous thrombolytics (approved in Europe for up to 4.5 hours). 06 hours: endovascular mechanical embolectomy. 624 hours: endovascular mechanical embolectomy in select cases. Secondary prevention: antiplatelet agent is first-line therapy; anticoag- ulation without heparin bridge for cardioembolic strokes due to atrial fibrillation and other select cases when no contraindications exist; control risk factors as above. Vertebrobasilar occlusionSee textsigns vary based on location of occluded vessel.As for carotid circulation obstruction. As for carotid circulation obstruction. hemorrgic Stroke Spontaneous intracerebral hemorrhageCommonly associated with hypertension; also with bleed- ing disorders, amyloid angiopathy. Hypertensive hemorrhage is located commonly in the basal ganglia, pons, thalamus, cere- bellum, and less commonly the cerebral white matter.Noncontrast CT is superior to MRI for detecting bleeds of < 48 hours dura- tion; laboratory tests to identify bleeding disorder: angiography may be indicated to exclude aneurysm or AVM in younger patients without hypertension. Do notperform lumbar puncture.Lower systolic blood pressure to 140 mm Hg; cerebellar bleeds or hematomas with gross mass effect may require urgent surgical evacuation. AVM: surgical resection indicated to prevent further bleeding; other modalities to treat nonoperable AVMs available at specialized centers. Subarachnoid hemorrhagePresent with sudden onset of worst headache of life, may lead rapidly to loss of con- sciousness; signs of meningeal irritation often present; etiol- ogy usually aneurysm or AVM, but 20% have no source identified.CT to confirm diagnosis, but may be normal in rare instances; if CT negative and suspicion high, perform lumbar puncture to look for red blood cells or xanthochromia; angiography to determine source of bleed in candidates for treatment.Lower systolic blood pressure to < 140 mm Hg immediately. Aneurysm: prevent further bleeding by clipping aneurysm or coil embo- lization; nimodipine helps prevent vasospasm; once aneurysm has been obliterated intravenous fluids and induced hypertension to pre- vent vasospasm; angioplasty may also reverse symptomatic vasospasm. AVM: as above. AVMs, arteriovenous malformations; CTA, computed tomography angiography; MRA, magnetic resonance angiography.CMDT22_Ch24_p0978-p1053.indd  997 29/06/21 8:50 PMChapTER 24998 CMDT 2022may  be linially silent beause the irulatin is main- tained by the ther vertebral artery. If the remaining verte- bral artery is ngenitally small r severely atherslerti, hwever, a defiit similar t that f basilar artery lusin is seen unless there is gd llateral irulatin frm the anterir irulatin thrugh the irle f Willis. An bstrutin f the posterior inferior cerebellar artery r an bstrutin f the vertebral artery just befre it branhes t this vessel leads t the lateral medullary syndrome, haraterized by vertig and nystagmus (vestibular nuleus), ipsilateral spinthalami sensry lss invlving the fae (trigeminal nuleus and trat), dysphagia (nuleus ambiguus), limb ataxia (inferir erebellar pedunle), and Hrner syndrme (desending sympatheti fibers), m- bined with ntralateral spinthalami sensry lss invlv- ing the limbs. Olusin f both vertebral arteries r the basilar artery leads t ma with pinpint pupils, flaid quadri- plegia and sensry lss, and variable ranial nerve abnr- malities. With partial basilar artery lusin, there may be diplpia, visual lss, vertig, dysarthria, ataxia, weakness r sensry disturbanes in sme r all f the limbs, and disrete ranial nerve palsies. In patients with hemiplegia f pntine rigin, the eyes are ften deviated t the para- lyzed side, whereas in patients with a hemispheri lesin, the eyes mmnly deviate frm the hemiplegi side. When the small paramedian arteries arising frm the basi- lar artery are luded, ntralateral hemiplegia and sen- sry defiit ur in assiatin with an ipsilateral ranial nerve palsy at the level f the lesin. Olusin f any f the majr cerebellar arteries pr- dues vertig, nausea, vmiting, nystagmus, and ipsilateral limb ataxia. Cntralateral spinthalami sensry lss in the limbs may als be present. Deafness due t hlear infar- tin may fllw lusin f the anterir inferir erebellar artery, whih may als ause ipsilateral faial spintha- lami sensry lss and weakness. Massive erebellar infar- tin may lead t bstrutive hydrephalus, ma, tnsillar herniatin, and death.B.  ImagingA  CT san f the head (withut ntrast) shuld be per- frmed immediately , befre the administratin f aspirin r ther antithrmbti agents, t exlude erebral hemr- rhage (Table 243). CT is relatively insensitive t aute ishemi strke within the first 612 hurs, and subse- quent MRI with diffusin-weighted sequenes helps define the distributin and extent f infartin as well as exlude tumr r ther differential nsideratins. CT angigraphy f the head and nek shuld be perfrmed t identify large vessel lusins amenable t endvasular therapy in patients presenting within 6 hurs f strke nset and shuld be nsidered in thse presenting between 6 and 24 hurs, tgether with CT perfusin studies. Regardless f timing f presentatin, imaging f the ervial vasulature is indiated as part f a searh t identify the sure f the strke. In patients with a PFO and therwise ryptgeni strke, the intraranial vasulature must be imaged t rule ut large vessel atherslersis befre PFO lsure an be nsidered.C. Laboratory and Other StudiesIn vestigatins shuld inlude a mplete bld unt, bld gluse determinatin, and fasting lipid panel. Ser- lgi tests fr syphilis and HIV infetin may be inluded depending n the irumstanes. Sreening fr antiphs- phlipid antibdies (lupus antiagulants, antiardilipin, and anti-beta2-glyprtein antibdies); the fatr V Leiden mutatin; abnrmalities f prtein C, prtein S, r antithrmbin; r a prthrmbin gene mutatin is indiated nly if a hyperagulable disrder is suspeted (eg, a yung patient withut apparent risk fatrs fr strke) r needs t be ruled ut if PFO lsure is under nsideratin. While elevated serum hmysteine is a risk fatr fr strke, lwering hmysteine levels with vitamin supplementa- tin has nt been shwn t derease strke risk, and there- fre, rutinely heking hmysteine is notremmended. Eletrardigraphy r ntinuus ardia mnitring fr at least 24 hurs will help exlude a reent myardial infartin r a ardia arrhythmia that might be a sure f emblizatin. While atrial fibrillatin will be disvered in apprximately 10% f patients with ishemi strke during their hspitalizatin, it is estimated that an arrhythmia will be fund in an additinal 10% with prlnged ambulatry ECG mnitring after disharge; this testing is indiated in ases where atrial fibrillatin is suspeted (eg, nnlaunar strke and left atrial enlargement n ehardigraphy r lak f intraranial r artid atherslersis) but has nt been demnstrated. Ehardigraphy (with agitated saline ntrast) shuld be perfrmed in ases f nnlau- nar strke t exlude valvular disease, right-t-left shunt- ing, and ardia thrmbus. Bld ultures shuld be perfrmed if endarditis is suspeted but are nt required rutinely. Examinatin f the erebrspinal fluid is nt always neessary but may be helpful if erebral vasulitis r anther inflammatry r infetius ause f strke is sus- peted, but it shuld be delayed until after CT r MRI t exlude any risk fr herniatin due t mass effet. TreatmentMana gement is divided int aute and hrni phases: the first is aimed at minimizing disability and the send at preventing reurrent strke. A mbinatin f thrmbly- sis and endvasular therapies is available t patients wh present within 24 hurs f strke nset, determined by when the patient was last nrmal. Intravenous thrombolytic therapy with rembinant tissue plasmingen ativatr (rtPA; 0.9 mg/kg t a maxi- mum f 90 mg, with 10% given as a blus ver 1 minute and the remainder ver 1 hur) imprves the hane f revery withut signifiant disability at 90 days frm 26% t 39% if given within 3 hurs frm strke nset; it is still effetive up t 4.5 hurs frm strke nset. Treatment shuld be initiated as sn as pssible; utme is diretly related t the time frm strke nset t treatment. Intrave- nus thrmblysis is apprved in Eurpe fr use up t 4.5 hurs frm strke nset but nly fr up t 3 hurs in the United States, althugh ff-label use during the 3- t 4.5-hur windw is standard. In patients with systli pressure greater than 185 mm Hg r diastli pressure greater thanCMDT22_Ch24_p0978-p1053.indd  998 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS999 CMDT 2022110  mm Hg, the bld pressure shuld be lwered t less than 185/110 mm Hg with intravenus labetall r niar- dipine t enable rtPA administratin. Due t the risk f hemrrhage, rtPA shuld nt be used beynd 4.5 hurs, r in ther situatins where it is medially ntraindiated, althugh sme evidene suggests patients with ishemi but nt infarted tissue identified by autmated perfusin imaging r MRI may be treated up t 9 hurs after nset r upn awakening with strke symptms. Several randmized trials have demnstrated an inreased likelihd f ahieving funtinal independene after endovascular mechanical embolectomy by stent retrievers as an adjunt t intravenus rtPA. Patients with large vessel lusin (abut 20% f patients with aute ishemi strke) in whm treatment an be initiated within 6 hurs f strke nset are eligible fr embletmy, as are patients wh present between 6 hurs and 24 hurs and als have a large ishemi penumbra identified by perfu- sin CT, perfusin MRI, r diffusin-weighted MRI. Early management f a mpleted strke therwise requires general supprtive measures. Management in a stroke care unit has been shwn t imprve utmes, likely due t early rehabilitatin and preventin f medial mpliatins. During the aute stage, there may be marked brain swelling and edema, with symptms and signs f inreasing intraranial pressure, an inreasing neurlgi defiit, r herniatin syndrme. Elevated intraranial pres- sure is managed by head elevatin and smti agents suh as mannitl. Maintenane f an adequate erebral perfusin pressure helps prevent further ishemia. Early dempres- sive hemiranietmy (within 48 hurs f strke nset) fr malignant middle erebral artery infartins redues mr- tality and imprves funtinal utme. Attempts t lwer the bld pressure f hypertensive patients during the aute phase (ie, within 72 hurs) f a strke shuld generally be avoided unless the purpse is t enable the safe administra- tin f rtPA, as there is lss f erebral autregulatin, and lwering the bld pressure may further mprmise ishemi areas. Hwever, if the systli pressure exeeds 220 mm Hg, it an be lwered using intravenus labetall r niardipine with ntinuus mnitring t 170200 mm Hg, and then after 72 hurs, it an be redued further t less than 140/90 mm Hg. Bld pressure augmentatin is usu- ally nt neessary in patients with relative hyptensin but maintenane f intravenus hydratin is imprtant. Prphylati and medial measures are disussed in the setin n TIAs and shuld guide management. One hemrrhage has been exluded by CT, aspirin (325 mg rally daily) is started immediately unless the patient reeived thrmblysis, in whih ase aspirin is initiated after a fllw-up CT has ruled ut thrmblyti-assiated hemrrhage at 24 hurs. Dual antiplatelet therapy shuld be used fr 21 days in patients with minr strke (Natinal Institutes f Health Strke Sale f 3 r less). Anticoagulant mediatins are started when indiated, as disussed in the setin n TIAs. There is generally noadvantage in delay, and the mmn fear f ausing hemrrhage int a previ- usly infarted area is misplaed, sine there is a far greater risk f further emblism t the erebral irulatin if treat- ment is withheld.Physical therapy has an imprtant rle in the manage- ment f patients with impaired mtr funtin. Passive mvements at an early stage will help prevent ntratures. As peratin inreases and sme revery begins, ative mvements will imprve strength and rdinatin. In all ases, early mbilizatin and ative rehabilitatin are impr- tant. Occupational therapy may imprve mrale and mtr skills, while speech therapy may help expressive aphasia r dysarthria. Beause f the risk fr dysphagia fllwing strke, aess t fd and drink is typially restrited until an appr- priate swallwing evaluatin; the head f the bed shuld be kept elevated t prevent aspiratin. Urinary atheters shuld notbe plaed and, if plaed, remved within 2448 hurs. PrognosisThe  prgnsis fr survival after erebral infartin is better than after erebral r subarahnid hemrrhage. Patients reeiving treatment with rtPA are at least 30% mre likely t have minimal r n disability at 3 mnths than thse nt treated by this means. Thse treated with mehanial embletmy are als at least 30% mre likely t ahieve funtinal independene. Lss f nsiusness after a erebral infart implies a prer prgnsis than therwise. The extent f the infart gverns the ptential fr rehabili- tatin. Patients wh have had a erebral infart are at risk fr additinal strkes and fr myardial infarts. The prphylati measures disussed earlier redue this risk. Antiplatelet therapy redues the reurrene rate by 30% amng patients withut a ardia ause fr the strke wh are nt andidates fr artid endarteretmy. Neverthe- less, the umulative risk f reurrene f nnardiembli strke is still 37% annually. Management is fused n palliative are when meaningful revery frm massive strkes is unlikely (see Chapter 5). When to ReferAll patients sh uld be referred. When to AdmitAll  patients shuld be hspitalized, preferably in a strke are unit.Albers  GW et al; DEFUSE 3 Investigatrs. Thrmbetmy fr strke at 6 t 16 hurs with seletin by perfusin imaging. N Engl J Med. 2018;378:708. [PMID: 29364767] Ngueira RG et al; DAWN Trial Investigatrs. Thrmbetmy 6 t 24 hurs after strke with a mismath between defiit and infart. N Engl J Med. 2018;378:11. [PMID: 29129157] Pwers WJ et al. Guidelines fr the early management f patients with aute ishemi strke: 2019 update t the 2018 guide- lines fr the early management f aute ishemi strke: a guideline fr healthare prfessinals frm the Amerian Heart Assiatin/Amerian Strke Assiatin. Strke. 2019;50:e344. [PMID: 31662037]3.  Intrcerebrl hemorrgeSpn taneus, nntraumati intraerebral hemrrhage in patients with n angigraphi evidene f an assiated vasular anmaly (eg, aneurysm r angima) is usually dueCMDT22_Ch24_p0978-p1053.indd  999 29/06/21 8:50 PMChapTER 241000 CMDT 2022t  hypertensin. The pathlgi basis fr hemrrhage is prbably the presene f miraneurysms that develp n perfrating vessels in hypertensive patients. Hypertensive intraerebral hemrrhage urs mst frequently in the basal ganglia, pns, thalamus, and erebellum, and less mmnly in the erebral white matter. Hemrrhage may extend int the ventriular system r subarahnid spae, and signs f meningeal irritatin are then fund. In lder adults, erebral amylid angipathy is anther imprtant and frequent ause f hemrrhage, whih is usually lbar in distributin, smetimes reurrent, and assiated with a better immediate prgnsis than hypertensive hemr- rhage. Arterivenus malfrmatins are an imprtant ause f intraerebral hemrrhage in yunger patients. Other auses f nntraumati intraerebral hemr- rhage inlude hematlgi and bleeding disrders (eg, leukemia, thrmbytpenia, hemphilia, r disseminated intravasular agulatin), antiagulant therapy, liver disease, high alhl intake, aine and methamphet- amine abuse, herpes simplex enephalitis, vasulitis, my- amya disease, reversible erebral vasnstritin syndrme, and primary r sendary brain tumrs. There is als an assiatin with advaning age and male sex. Bleeding is primarily int the subarahnid spae when it urs frm an intraranial aneurysm, but it may be partly intraparenhymal as well. Hemrrhage an als ur int arterial and venus erebral infarts. Clinical FindingsA.  Symptoms and SignsW ith hemrrhage int the erebral hemisphere, nsius- ness is initially lst r impaired in abut ne-half f patients. Vmiting urs very frequently at the nset f bleeding, and headahe is smetimes present. Fal symp- tms and signs then develp, depending n the site f the hemrrhage. With hypertensive hemrrhage, there is gen- erally a rapidly evlving neurlgi defiit with hemiplegia r hemiparesis. A hemisensry disturbane is als present with mre deeply plaed lesins. With lesins f the puta- men, lss f njugate lateral gaze may be nspiuus. With thalami hemrrhage, there may be a lss f upward gaze, dwnward r skew deviatin f the eyes, lateral gaze palsies, and pupillary inequalities. Cerebellar hemrrhage may present with sudden nset f nausea and vmiting, dysequilibrium, ataxia f gait, limbs, r trunk; headahe; and lss f nsiusness that may terminate fatally within 48 hurs. Pntine hemrrhage auses sme mbinatin f lateral njugate gaze palsies t the side f the lesin; small reative pupils; ntralateral hemiplegia; peripheral faial weakness; and peridi respi- ratin. These signs may be bilateral with larger pntine hemrrhage, and the patient may beme lked in, with quadriplegia and preserved nsiusness.B.  ImagingCT  sanning (withut ntrast) is imprtant nt nly in nfirming that hemrrhage has urred but als in determining the size and site f the hematma. MRI isequally sensitive when magneti suseptibility weighted sequenes (eg, gradient eh) are used. If the patients n- ditin permits further interventin, CT angigraphy, MR angigraphy, r erebral angigraphy may be undertaken t determine whether an aneurysm r arterivenus mal- frmatin is present. In patients under age 55 with lbar hemrrhage and n histry f hypertensin, a ntrast- enhaned MRI may indiate a nnhypertensive ause, suh as an underlying neplasm.C.  Laboratory and Other StudiesA  mplete bld unt, platelet unt, prthrmbin and partial thrmbplastin times, liver bihemial tests, and kidney funtin tests may reveal a predispsing ause fr the hemrrhage. Lumbar puncture is contraindicated beause it may preipitate a herniatin syndrme in patients with a large hematma, and CT sanning is supe- rir in deteting intraerebral hemrrhage. TreatmentPa tients shuld be admitted t an intensive are unit fr bservatin and supprtive are. The systli bld pres- sure shuld be lwered t 140 mm Hg with intravenus labetall r niardipine, althugh randmized trials target- ing systli bld pressures f less than 140 mm Hg and less than 180 mm Hg have nt shwn a differene in ut- mes. Thrmbytpenia shuld be treated with platelet transfusin; the speifi threshld fr treatment and the gal platelet unt after transfusin vary with patient har- ateristis and prvider experiene. Cagulpathies shuld be reversed using fresh frzen plasma, prthrmbin m- plex nentrates, vitamin K, r speifi reversal agents (eg, prtamine fr heparin; idaruizumab fr dabigatran; and andexanet alfa fr apixaban, betrixaban, edxaban, and rivarxaban). Hemstati therapy with rembinant ativated fatr VII in patients withut underlying agu- lpathy has nt imprved survival r funtinal utme. Intraranial pressure may require mnitring and smti therapy. Ventriular drainage may be required in patients with intraventriular hemrrhage and aute hydrephalus. Dempressin may be helpful when a superfiial hema- tma in erebral white matter is exerting a mass effet and ausing inipient herniatin. In patients with erebellar hemrrhage wh are deterirating neurlgially r wh have brainstem mpressin r hydrephalus, prmpt surgial evauatin f the hematma is apprpriate beause spntaneus unpreditable deteriratin may therwise lead t a fatal utme and beause perative treatment may lead t mplete reslutin f the linial defiit. The treatment f underlying strutural lesins r bleeding dis- rders depends n their nature. There is n speifi treatment fr erebral amylid angipathy. When to ReferAll patients sh uld be referred. When to AdmitAll patients sh uld be hspitalized.CMDT22_Ch24_p0978-p1053.indd  1000 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1001 CMDT 2022Hst ettler IC et al. Intraerebral hemrrhage: an update n diag- nsis and treatment. Expert Rev Neurther. 2019;19:679. [PMID: 31188036]4.  Sontneous Subrcnoid hemorrgeE S S E N T I A L S  O F  D I A G N O S I S Sudden (thunderclap) severe headache. Signs of meningeal irritation usually present. Obtundation is common. Focal deficits frequently absent. General ConsiderationsBetween  5% and 10% f strkes are due t subarahnid hemrrhage. Trauma is the mst mmn ause f sub- arahnid hemrrhage, the prgnsis f whih depends n the severity f the head injury. Spntaneus (nntrau- mati) subarahnid hemrrhage frequently results frm the rupture f an arterial saccular (berry) aneurysm r frm an arteriovenous malformation. Clinical FindingsA.  Symptoms and SignsSubarahn id hemrrhage has a harateristi linial pi- ture. Its nset is with sudden ( thunderclap ) headahe f a severity never experiened previusly by the patient. This may be fllwed by nausea and vmiting and by a lss r impairment f nsiusness that an either be transient r prgress inexrably t deepening ma and death. If n- siusness is regained, the patient is ften nfused and irritable and may shw ther symptms f an altered men- tal status. Neurlgi examinatin generally reveals nuhal rigidity and ther signs f meningeal irritatin, exept in deeply matse patients. Mst aneurysms are asymptmati until they rupture, but they may ause a fal neurlgi defiit by mpress- ing adjaent strutures. Oasinal patients with aneurysms have headahes, smetimes ampanied by nausea and nek stiffness, a few hurs r days befre massive subarah- nid hemrrhage urs. This has been attributed t warn- ing leaks f a small amunt f bld frm the aneurysm. A higher risk f subarahnid hemrrhage is assiated with lder age, female sex, nn-White ethniity, hyperten- sin, tba smking, high alhl nsumptin (exeed- ing 150 g per week), previus symptms, psterir irulatin aneurysms, and larger aneurysms. Fal neur- lgi signs are usually absent but, when present, may relate either t a fal intraerebral hematma (frm arterive- nus malfrmatins) r t ishemia in the territry f the vessel with a ruptured aneurysm.B.  ImagingA  CT san (preferably with CT angigraphy) shuld be perfrmed immediately t nfirm that hemrrhage hasurred and t searh fr lues regarding its sure. It is preferable t MRI beause it is faster and mre sensitive in deteting hemrrhage in the first 24 hurs. CT findings smetimes are nrmal in patients with suspeted hemr- rhage, and the erebrspinal fluid must then be examined fr the presene f bld r xanthhrmia befre the ps- sibility f subarahnid hemrrhage is disunted. Cerebral arterigraphy is undertaken t determine the sure f bleeding. In general, bilateral artid and verte- bral arterigraphy are neessary beause aneurysms are ften multiple, while arterivenus malfrmatins may be supplied frm several sures. The predure allws an interventinal radilgist t treat an underlying aneurysm r arterivenus malfrmatin by varius tehniques. If arterigrams shw n abnrmality, the examinatin shuld be repeated after 2 weeks beause vasspasm r thrmbus may have prevented detetin f an aneurysm r ther vasular anmaly during the initial study. CT r MR angi- graphy may als be revealing but is less sensitive than nventinal arterigraphy.C.  Laboratory and Other StudiesThe  erebrspinal fluid demnstrates an elevated red bld ell unt. Subarahnid hemrrhage an be differentiated frm a traumati lumbar punture by the lak f learing f red bld ells frm the first and furth tube f erebrspi- nal fluid r by the presene f xanthhrmia, whih urs due t lysis f red bld ells and takes at least 2 hurs t develp. The abslute red bld ell unt is als helpful: in the absene f xanthhrmia, a red bld ell unt f less than 2000  106/L is very unlikely t be due t subarahnid hemrrhage. Eletrardigraphi evidene f arrhythmias r myardial ishemia has been well desribed and prbably relates t exessive sympatheti ativity. Peripheral leukytsis and transient glysuria are als mmn findings. TreatmentAll p atients shuld be hspitalized and seen by a neurl- gist. The measures utlined belw in the setin n stupr and ma are applied t matse patients. Cnsius patients are nfined t bed, advised against any exertin r straining, treated symptmatially fr headahe and anxiety, and given laxatives r stl sfteners. The systli bld pressure shuld be lwered t 140 mm Hg until the aneurysm is treated definitively. Seizure prphylaxis is nt neessary unless a nvulsin has urred (see Table 242). Patients are generally hspitalized fr at least 14 days t mnitr, prevent, and treat vasspasm. The majr aim f treatment is t prevent further hem- rrhage. The risk f further hemrrhage frm a ruptured aneurysm is greatest within a few days f the first hemr- rhage; apprximately 20% f patients will have further bleeding within 2 weeks and 40% within 6 mnths. Defini- tive treatment, ideally within 2 days f the hemrrhage, requires surgial lipping f the aneurysm r endvasular treatment by il emblizatin; the latter is smetimes feasible even fr inperable aneurysms and has a lwer mrbidity than surgery.CMDT22_Ch24_p0978-p1053.indd  1001 29/06/21 8:50 PMChapTER 241002 CMDT 2022 ComplicationsSpntaneu s subarahnid hemrrhage may result in severe mpliatins, s mnitring is neessary, usually in an intensive are unit. Hemiplegia r ther fal defiit smetimes may fllw aneurysmal bleeding after a delay f 214 days due t fal arterial spasm. The etilgy f vaso- spasm is unertain and likely multifatrial, and it sme- times leads t signifiant erebral ishemia r infartin and may further aggravate any existing inrease in intra- ranial pressure. Transranial Dppler ultrasund may be used t sreen nninvasively fr vasspasm, but nven- tinal arterigraphy is required t dument and treat vasspasm when the linial suspiin is high. Nimdipine has been shwn t redue the inidene f ishemi defiits frm arterial spasm; a dse f 60 mg every 4 hurs rally fr 21 days is given prphylatially t all patients. After surgial bliteratin f all aneurysms, symptmati vas- spasm may als be treated by intravasular vlume expan- sin and indued hypertensin; transluminal balln angiplasty f invlved intraranial vessels is als helpful. Acute hydrocephalus, whih smetimes urs due t erebrspinal fluid utflw disruptin by the subarahnid bld, shuld be suspeted if the patient deterirates lini- ally; a repeat CT san shuld be btained. Aute hydr- ephalus frequently auses intraranial hypertensin severe enugh t require temprary, and less mmnly pr- lnged r permanent, intraventriular erebrspinal fluid shunting. Cerebral salt-wasting is anther mpliatin f subarahnid hemrrhage that may develp abruptly dur- ing the first several days f hspitalizatin. The resulting hypnatremia and erebral edema may exaerbate intra- ranial hypertensin and may require arefully titrated treatment with ral sdium hlride r intravenus hyper- smti sdium slutin. Daily measurement f the serum sdium level allws fr the early detetin f this mplia- tin. Hypopituitarism may ur as a late mpliatin f subarahnid hemrrhage.Etmina n N et al. Neurvasular disease, diagnsis, and therapy: subarahnid hemrrhage and erebral vasspasm. Handb Clin Neurl. 2021;176:135. [PMID: 33272393] Lindgren A et al. Endvasular iling versus neursurgial lip- ping fr peple with aneurysmal subarahnid hemrrhage. Chrane Database Syst Rev. 2018;8:CD003085. [PMID: 30110521]5.  Intrcrnil aneurysmE S S E N T I A L S  O F  D I A G N O S I S Subarachnoid hemorrhage or focal deficit. Abnormal imaging studies. General ConsiderationsSaular  aneurysms (berry aneurysms) tend t ur at arterial bifuratins, are frequently multiple (20% f ases), and are usually asymptmati. They are assiated withplyysti kidney disease, myamya disease, familial aldsternism type 1, and artatin f the arta. Risk fatrs fr aneurysm frmatin inlude igarette smking, hypertensin, and female sex. Mst aneurysms are lated n the anterir part f the irle f Willispartiularly n the anterir r psterir mmuniating arteries, at the bifuratin f the middle erebral artery, and at the bifur- atin f the internal artid artery. Myti aneurysms resulting frm septi emblism ur in mre distal vessels and ften at the rtial surfae. The mst signifiant m- pliatin f intraranial aneurysms is a subarahnid hem- rrhage, whih is disussed in the preeding setin. Clinical FindingsA.  Symptoms and SignsAneurysms  may ause a fal neurlgi defiit by m- pressing adjaent strutures. Hwever, mst are asymp- tmati r prdue nly nnspeifi symptms until they rupture, at whih time subarahnid hemrrhage results. Its manifestatins, mpliatins, and management were utlined in the preeding setin.B.  ImagingDefinitive evaluatin is  by digital subtratin angigraphy (bilateral artid and vertebral studies), whih generally indiates the size and site f the lesin, smetimes reveals multiple aneurysms, and may shw arterial spasm if rup- ture has urred. Visualizatin by CT r MR angigraphy is nt usually adequate if perative treatment is under nsideratin beause lesins may be multiple and small lesins are smetimes missed, but these mdalities an be used t sreen patients wh have tw r mre first-degree relatives with intraranial aneurysms. TreatmentThe m ajr aim f treatment is t prevent hemorrhage. Man- agement f ruptured aneurysms was desribed in the setin n subarahnid hemrrhage. Symptmati but unruptured aneurysms merit prmpt treatment, either surgially r by endvasular tehniques. The deisin t treat r mnitr asymptmati aneurysms disvered inidentally is mpli- ated and depends n aneurysm size, latin, risk fatrs fr rupture, and treatment-related mrbidity; risk sres t guide deisin-making are available. When to ReferAll patients sh uld be referred. When to Admit All patients with a subarahnid hemrrhage. All patients fr detailed imaging. All patients underging surgial r endvasular treatment.Hak enberg KAM et al. Neurvasular disease, diagnsis, and therapy: brain aneurysms. Handb Clin Neurl. 2021;176:121. [PMID: 33272392]CMDT22_Ch24_p0978-p1053.indd  1002 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1003 CMDT 20226.  arteriovenous MlformtionsE S S E N T I A L S  O F  D I A G N O S I S Sudden onset of subarachnoid and intracerebral hemorrhage. Distinctive neurologic signs reflect the region of the brain involved. Signs of meningeal irritation in patients present- ing with subarachnoid hemorrhage. Seizures or focal deficits may occur. General ConsiderationsArteriven us malfrmatins are ngenital vasular mal- frmatins that result frm a lalized maldevelpment f part f the primitive vasular plexus and nsist f abnr- mal arterivenus mmuniatins withut intervening apillaries. They vary in size, ranging frm massive lesins that are fed by multiple vessels and invlve a large part f the brain t lesins s small that they are hard t identify at arterigraphy, surgery, r autpsy. In apprximately 10% f ases, there is an assiated arterial aneurysm, while 12% f patients presenting with aneurysms have assi- ated arterivenus malfrmatins. Clinial presentatin may relate t hemrrhage frm the malfrmatin r an assiated aneurysm r may relate t erebral ishemia due t diversin f bld by the anmalus arterivenus shunt r due t venus stagnatin. Reginal maldevelp- ment f the brain, mpressin r distrtin f adjaent erebral tissue by enlarged anmalus vessels, and prgres- sive glisis due t mehanial and ishemi fatrs may als be ntributry. Clinical FindingsMs t erebral arterivenus malfrmatins are supratent- rial, usually lying in the territry f the middle erebral artery. Up t 70% bleed at sme pint in their natural his- try, mst mmnly befre the patient reahes the age f 40 years. Arterivenus malfrmatins that have bled ne are mre likely t bleed again, at an apprximate rate f 4.5% annually. A higher risk f bleeding is als bserved if there is an assiated aneurysm, deep venus drainage, r deep brain latin; size f the malfrmatin and sex are nt assiated with risk f hemrrhage.A.  Symptoms and SignsInitial  symptms nsist f hemrrhage in 3060% f ases, reurrent seizures in 2040%, headahe in 525%, and misellaneus mplaints (inluding fal defiits) in 1015%. Hemrrhage is mmnly intraerebral as well as int the subarahnid spae and is fatal in abut 10% f ases. Seizures are mre likely with frntal r parietal arte- rivenus malfrmatins. Headahes are espeially likely when the external artid arteries are invlved in the mal- frmatin. These smetimes simulate migraine, but mremmnly are nnspeifi in harater, with nthing abut them t suggest an underlying strutural lesin. Brainstem and erebellar arterivenus malfrmatins may ause bstrutive hydrephalus. In patients presenting with subarahnid hemrrhage, examinatin may reveal an abnrmal mental status and signs f meningeal irritatin. Additinal findings may help lalize the lesin and smetimes indiate that intraranial pressure is inreased. A ranial bruit always suggests the pssibility f a erebral arterivenus malfrmatin, but bruits may als be fund with aneurysms, meningimas, aquired arterivenus fistulas, and arterivenus malfr- matins invlving the salp, alvarium, r rbit. Bruits are best heard ver the ipsilateral eye r mastid regin and are f sme help in lateralizatin but f n help in lalizatin. Absene f a bruit does not exclude the pssibility f arte- rivenus malfrmatin.B.  ImagingIn patien ts with suspeted hemrrhage, CT sanning indi- ates whether subarahnid r intraerebral bleeding has reently urred, helps lalize its sure, and may reveal the arterivenus malfrmatin. When intraranial hem- rrhage is nfirmed but the sure f hemrrhage is nt evident n the CT san, arterigraphy is neessary t exlude aneurysm r arterivenus malfrmatin. MR and CT angigraphy are nt sensitive enugh fr this purpse. Even if the findings n CT san suggest arterivenus mal- frmatin, arterigraphy is required t establish the nature f the lesin with ertainty and t determine its anatmi features s that treatment an be planned. The examinatin must generally inlude bilateral paifiatin f the inter- nal and external artid arteries and the vertebral arteries. In patients presenting withut hemrrhage, CT san r MRI usually reveals the underlying abnrmality, and MRI frequently als shws evidene f ld r reent hemr- rhage that may have been asymptmati. The nature and detailed anatmy f any fal lesin identified by these means are delineated by angigraphy, espeially if pera- tive treatment is under nsideratin. TreatmentSurgial  treatment t prevent further hemrrhage is justi- fied in patients with arterivenus malfrmatins that have bled, prvided that the lesin is aessible and the patient has a reasnable life expetany. Surgial treatment is als apprpriate if intraranial pressure is inreased and t prevent further prgressin f a fal neurlgi defiit. In patients presenting slely with seizures, antinvulsant treatment is usually suffiient (Table 242), and perative treatment is unneessary unless seizures annt be n- trlled medially. Definitive perative treatment nsists f exisin f the arterivenus malfrmatin if it is surgially aessible. Steretati radisurgery is used t treat inperable ere- bral arterivenus malfrmatins. Arterivenus malfr- matins that are inperable beause f their latin are smetimes treated slely by emblizatin; althugh the risk f hemrrhage is nt redued, neurlgi defiits mayCMDT22_Ch24_p0978-p1053.indd  1003 29/06/21 8:50 PMChapTER 241004 CMDT 2022be  stabilized r even reversed by this predure. Embliza- tin is mre mmnly perfrmed as an adjunt t surgery r radisurgery; it is als used t treat aneurysms assi- ated with the arterivenus malfrmatins. When to ReferAll patients sh uld be referred. When to Admit All patients with a subarahnid r erebral hemrrhage. All patients fr detailed imaging. All patients underging surgial r endvasular treatment.Ru tledge C et al. Brain arterivenus malfrmatins. Handb Clin Neurl. 2021;176:171. [PMID: 33272394]7.  Intrcrnil Venous TrombosisIn traranial venus thrmbsis may ur in assiatin with intraranial r maxillfaial infetins, hyperagu- lable states, plyythemia, sikle ell disease, yanti ngenital heart disease, and in pregnany r during the puerperium. Geneti fatrs are als imprtant. The disr- der is haraterized by headahe, fal r generalized n- vulsins, drwsiness, nfusin, inreased intraranial pressure, and fal neurlgi defiitsand smetimes by evidene f meningeal irritatin. The diagnsis is n- firmed by CT r MR vengraphy r angigraphy. Treatment inludes antinvulsants if seizures have urred (Table 242) andif neessarymeasures t redue intraranial pressure. Antiagulatin with dse- adjusted intravenus heparin r weight-adjusted subuta- neus lw-mleular-weight heparin, fllwed by ral warfarin antiagulatin fr 6 mnths redues mrbidity and mrtality f venus sinus thrmbsis. Dabigatran shwed similar effiay t warfarin in ne randmized trial and may be an aeptable alternative. Cnmitant intra- ranial hemrrhage related t the venus thrmbsis des nt ntraindiate heparin therapy. In ases refratry t heparin, endvasular tehniques inluding atheter- direted thrmblyti therapy (urkinase) and thrmbe- tmy are smetimes helpful but may inrease the risk fr majr hemrrhage. When to ReferAll patients sh uld be referred. When to AdmitAll patients sh uld be hspitalized.Ferr  JM et al; RE-SPECT CVT Study Grup. Safety and effiay f dabigatran etexilate vs dse-adjusted warfarin in patients with erebral venus thrmbsis: a randmized linial trial. JAMA Neurl. 2019;76:1457. [PMID: 31479105]8. Sinl Cord Vsculr DisesesE S S E N T I A L S  O F  D I A G N O S I S Sudden onset of back or limb pain and neurologic deficit in limbs. Motor, sensory, or reflex changes in limbs depend- ing on level of lesion. Imaging studies distinguish between infarct and hematoma. Infarction of the Spinal CordInf artin f the spinal rd is rare. It typially urs in the territry f the anterior spinal artery beause this vessel, whih supplies the anterir tw-thirds f the rd, is itself supplied by nly a limited number f feeders. Infartin usu- ally results frm interrupted flw in ne r mre f these feeders, eg, with arti dissetin, arti aneurysm, artgra- phy, plyarteritis, severe hyptensin, r after surgial repair f the thrai r abdminal arta. The paired psterir spinal arteries, by ntrast, are supplied by numerus arteries at different levels f the rd. Spinal rd hypperfusin may lead t a entral rd syndrme with distal weakness f lwer mtr neurn type and lss f pain and temperature appre- iatin, with preserved psterir lumn funtin. Sine the anterir spinal artery reeives numerus feeders in the ervial regin, infarts almst always ur audally. Clinial presentatin is haraterized by aute nset f flaid, areflexive paraplegia that evlves after a few days r weeks int a spasti paraplegia with extensr plantar respnses. There is an ampanying dissiated sensry lss, with impairment f appreiatin f pain and temperature but pres- ervatin f sensatins f vibratin and jint psitin. The risk f spinal rd infartin in the setting f abdminal arti surgery and thrai endvasular repair may be redued by intraperative erebrspinal fluid drainage thrugh a atheter plaed in the lumbar subarah- nid spae t redue intraspinal pressure. If signs f infar- tin are nted after surgery, bld pressure augmentatin fr 2448 hurs in additin t lumbar drainage has been nted anedtally t imprve utmes. Treatment is th- erwise symptmati. Epidural or Subdural HemorrhageEp idural r subdural hemrrhage may lead t sudden severe bak pain fllwed by an aute mpressive myelp- athy neessitating urgent spinal MRI r myelgraphy and surgial evauatin. It may ur in patients with bleeding disrders r thse wh are taking antiagulants, sme- times fllwing trauma r lumbar punture. Epidural hemrrhage may als be related t a vasular malfrmatin r tumr depsit. Spinal Dural Arteriovenous FistulaeSpi nal dural arterivenus fistulae are ngenital lesins that present with spinal subarahnid hemrrhage rCMDT22_Ch24_p0978-p1053.indd  1004 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1005 CMDT 2022my elradiulpathy. Sine mst f these malfrmatins are lated in the thralumbar regin, they lead t mtr and sensry disturbanes in the legs and t sphinter disrders. Pain in the legs r bak is ften severe. Examinatin reveals an upper, lwer, r mixed mtr defiit in the legs; sensry defiits are als present and are usually extensive, althugh asinally they are nfined t a radiular distributin. Cervial spinal dural arterivenus fistulae lead als t symptms and signs in the arms. Spinal MRI may nt detet the spinal dural arterivenus fistula, althugh mst ases shw either T2 hyperintensity in the rd r perimedullary flw vids. Myelgraphy (perfrmed with the patient prne and supine) may detet serpiginus filling defets due t enlarged vessels. Seletive spinal arterigraphy is required t nfirm the diagnsis and plan treatment. Mst lesins are extramedullary, are psterir t the rd (lying either intradurally r extradurally), and an easily be treated by ligatin f feeding vessels and exisin f the fistulus anmaly r by emblizatin predures. Delay in treatment may lead t inreased and irreversible disability r t death frm reurrent subarahnid hemrrhage. When to ReferAll patients sh uld be referred. When to AdmitAll patients sh uld be hspitalized.Gyal A et  al. Outmes fllwing surgial versus endvasular treatment f spinal dural arterivenus fistula: a systemati review and meta-analysis. J Neurl Neursurg Psyhiatry. 2019;90:1139. [PMID: 31142659]IN TRACRANIAL & SPINAL MASS LESIONS 1. primry Intrcrnil TumorsE S S E N T I A L S  O F  D I A G N O S I S Generalized or focal disturbance of cerebral func- tion, or both. Increased intracranial pressure in some patients. Neuroradiologic evidence of space-occupying lesion. General ConsiderationsRughl y ne-third f all primary intraranial neplasms (Table 244) are meningimas, ne-quarter are glimas, and the remainder are pituitary adenmas (see Chapter 26), neurfibrmas, and ther tumrs. Certain tumrs, espe- ially neurfibrmas, hemangiblastmas, and retinblas- tmas, may have a familial basis, and ngenital fatrs bear n the develpment f ranipharyngimas. Tumrs may ur at any age, but ertain glimas shw partiular age prediletins.Clinical FindingsA.  Symptoms and SignsIn traranial tumrs typially present with headahe, sei- zures, r fal neurlgi defiits. New headahes r symp- tms f elevated intraranial pressure, suh as headahes awaking a patient frm sleep r wrsening with Valsalva maneuver, ugh, r reumbeny, are suggestive f brain tumr. Intraranial tumrs may als lead t a generalized disturbane f erebral funtin with persnality hanges, intelletual deline, emtinal lability, nausea, and malaise. 1. Frontal lobe lesions Tumrs f the frntal lbe ften lead t prgressive intelletual deline, slwing f mental ativity, persnality hanges, and ntralateral grasp reflexes. They may lead t expressive aphasia if the pste- rir part f the left inferir frntal gyrus is invlved. Ans- mia may als ur as a nsequene f pressure n the lfatry nerve. Preentral lesins may ause fal mtr seizures r ntralateral pyramidal defiits. 2. Temporal lobe lesions Tumrs f the uninate regin may be manifested by seizures with lfatry r gustatry halluinatins, mtr phenmena suh as liking r smaking f the lips, and sme impairment f external awareness withut atual lss f nsiusness. Tempral lbe lesins als lead t depersnalizatin, emtinal hanges, behaviral disturbanes, sensatins f dj vu r jamais vu, mirpsia r marpsia (bjets appear smaller r larger than they are), visual field defets (rssed upper quadrantanpia), and auditry illusins r halluinatins. Left-sided lesins may lead t dysnmia and reeptive aphasia, while right-sided invlvement smetimes disturbs the pereptin f musial ntes and meldies. 3. Parietal lobe lesions Tumrs in this latin hara- teristially ause ntralateral disturbanes f sensatin and may ause sensry seizures, sensry lss r inatten- tin, r sme mbinatin f these symptms. The sensry lss is rtial in type and invlves pstural sensibility and tatile disriminatin, s that the appreiatin f shape, size, weight, and texture is impaired. Objets plaed in the hand may nt be regnized (asteregnsis). Extensive parietal lbe lesins may prdue ntralateral hyper- pathia and spntaneus pain (thalami syndrme). Invlvement f the pti radiatin leads t a ntralateral hmnymus field defet that smetimes nsists slely f lwer quadrantanpia. Lesins f the left angular gyrus ause Gerstmann syndrome (a mbinatin f alexia, agraphia, aalulia, right-left nfusin, and finger agn- sia), whereas invlvement f the left submarginal gyrus auses ideatinal apraxia. Ansgnsia (the denial, neglet, r rejetin f a paralyzed limb) is seen in patients with lesins f the nndminant (right) hemisphere. Cnstru- tinal apraxia and dressing apraxia may als ur with right-sided lesins. 4. Occipital lobe lesions Tumrs f the ipital lbe harateristially prdue ntralateral hmnymus hemianpia r a partial field defet. With left-sided r bilateral lesins, there may be visual agnsia bth fr bjets and fr lrs, while irritative lesins n either sideCMDT22_Ch24_p0978-p1053.indd  1005 29/06/21 8:50 PMChapTER 241006 CMDT 2022T able 244. Primary intracranial tumors (listed by major histology grouping and by incidence within each group).T umor Clinicl Fetures Tretment nd prognosis Tumors of Meninges Meningioma Originates from the dura mater or arachnoid; compresses rather than invades adjacent neural structures. Increasingly common with advancing age. Tumor size varies greatly. Symptoms vary with tumor siteeg, unilateral proptosis (sphenoidal ridge); anosmia and optic nerve compression (olfactory groove). Tumor is usually benign and readily detected by CT scanning; may lead to calcification and bone erosion visible on plain radiographs of skull.Treatment is surgical. Tumor may recur if removal is incomplete. Tumors of Neuroeitelil Origin Glioblastoma multiformePresents commonly with nonspecific complaints and increased intracranial pressure. As it grows, focal deficits develop. O6-methylguanine-DNA methyltransferase pro- moter methylation positivity (seen in 40% of cases) and iso- citrate dehydrogenase 1/2 mutations (seen in 10% of cases) carry better prognosis.Course is rapidly progressive, with poor prognosis (< 20% survival at 2 years). Total surgical removal is usually not possible. Radiation therapy and temozolamide may prolong survival. Tumor treatment fields added to temozolamide after completion of radiation therapy prolong survival. Astrocytoma Presentation similar to glioblastoma multiforme but course more protracted, often over several years. Cerebellar astro- cytoma may have a more benign course. Isocitrate dehy- drogenase 1/2 mutations (seen in a majority of cases) carry better prognosis in grade II and III tumors.Prognosis is variable. By the time of diagnosis, total excision is usually impossible; tumor may be radio- sensitive and temozolamide is also helpful in grade II and III tumors. In cerebellar astrocytoma, total surgical removal is often possible. Ependymoma Glioma arising from the ependyma of a ventricle, especially the fourth ventricle; leads to early signs of increased intra- cranial pressure. Arises also from central canal of cord.Tumor is best treated surgically if possible. Radiation therapy may be used for residual tumor. Oligodendroglioma Slow-growing. Usually arises in cerebral hemisphere in adults. Calcification may be visible on skull radiograph. Co-deletion of 1p/19q and isocitrate dehydrogenase 1/2 mutation required for diagnosis.Treatment is surgical and usually successful. Radiation and chemotherapy (temozolamide or procarbazine, lomustine, and vincristine) are used in grade II and III tumors. Brainstem glioma Presents during childhood with cranial nerve palsies and then with long tract signs in the limbs. Signs of increased intra- cranial pressure occur late.Tumor is inoperable; treatment is by irradiation and shunt for increased intracranial pressure. Neuronal and mixed neuronal-glial tumorsSlow-growing; usually arise in cerebral hemispheres; often associated with seizures. Some are benign (eg, dysembryo- blastic neuroepithelial tumors) and some have malignant potential (eg, ganglioglioma).Resection is not always necessary for benign tumors unless seizures are medically refractory, but is indi- cated for those with malignant potential. Medulloblastoma Seen most frequently in children. Generally arises from roof of fourth ventricle and leads to increased intracranial pressure accompanied by brainstem and cerebellar signs. May seed subarachnoid space. Wingless activated tumors carry best prognosis (> 90% 5-year survival).Treatment consists of surgery combined with radia- tion therapy and chemotherapy; 5-year survival exceeds 70%. Wingless activated tumors may require less aggressive treatment. Pineal tumor Presents with increased intracranial pressure, sometimes asso- ciated with impaired upward gaze (Parinaud syndrome) and other deficits indicative of midbrain lesion.Ventricular decompression by shunting is followed by surgical approach to tumor; irradiation is indicated if tumor is malignant. Prognosis depends on histo- pathologic findings and extent of tumor. Tumors of te Sellr Region Pituitary adenoma Functioning adenomas present with symptoms of hormone secretion; nonfunctioning adenomas present with symp- toms of local mass effect (eg, bitemporal hemianopsia, hypopituitarism) or are found incidentally.Prolactin-secreting adenomas are treated with bro- mocriptine or cabergoline. Others are surgically resected. Pituitary hormone replacement may be required. Craniopharyngioma Originates from remnants of Rathke pouch above the sella, depressing the optic chiasm. May present at any age but usually in childhood, with endocrine dysfunction and bitemporal visual field defects.Treatment is surgical, but total removal may not be possible. Radiation may be used for residual tumor. (continued )CMDT22_Ch24_p0978-p1053.indd  1006 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1007 CMDT 2022an ause unfrmed visual halluinatin s. Bilateral ipi- tal lbe invlvement auses rtial blindness in whih there is preservatin f pupillary respnses t light and lak f awareness f the defet by the patient. There may als be lss f lr pereptin, prspagnsia (inability t identify a familiar fae), simultagnsia (inability t inte- grate and interpret a mpsite sene as ppsed t its individual elements), and Balint syndrme (failure t turn the eyes t a partiular pint in spae, despite preservatin f spntaneus and reflex eye mvements). The denial f blindness r a field defet nstitutes Antn syndrme. 5. Brainstem and cerebellar lesions Brainstem lesins lead t ranial nerve palsies, ataxia, inrdinatin, nystag- mus, and pyramidal and sensry defiits in the limbs n ne r bth sides. Intrinsi brainstem tumrs, suh as gli- mas, tend t prdue an inrease in intraranial pressure nly late in their urse. Cerebellar tumrs prdue marked ataxia f the trunk if the vermis erebelli is invlved and ipsilateral appendiular defiits (ataxia, in- rdinatin, and hyptnia f the limbs) if the erebellar hemispheres are affeted. 6. Herniation syndromes If the pressure is inreased in a partiular ranial mpartment, brain tissue may herniate int a mpartment with lwer pressure. The mst familiar syndrme is herniatin f the tempral lbe unus thrugh the tentrial hiatus, whih auses mpressin f the third ranial nerve, midbrain, and psterir erebral artery. The earliest sign f this is ipsilateral pupillary dilatin, fllwed by stupr, ma, deerebrate psturing, and respiratry arrest. Anther imprtant herniatin syndrme nsists fdisplaement f the erebellar tnsils thrugh the framen magnum, whih auses medullary mpressin leading t apnea, irulatry llapse, and death. 7. False localizing signs Tumrs may lead t neurlgi signs ther than by diret mpressin r infiltratin, thereby leading t errrs f linial lalizatin. These false lalizing signs inlude third r sixth nerve palsy and bilat- eral extensr plantar respnses prdued by herniatin syndrmes, and an extensr plantar respnse urring ipsilateral t a hemispheri tumr as a result f mpressin f the ppsite erebral pedunle against the tentrium.B.  ImagingMRI  with gadlinium enhanement is the preferred methd t detet the lesin and t define its latin, shape, and size; the extent t whih nrmal anatmy is distrted; and the degree f any assiated erebral edema r mass effet. CT sanning with radintrast enhanement uld be perfrmed; hwever, it is less helpful than MRI fr small lesins r tumrs in the psterir fssa. The harateristi appearane f meningimas n MRI r CT sanning is virtually diagnsti, ie, a lesin in a typial site (parasagittal and sylvian regins, lfatry grve, sphenidal ridge, tuberulum sellae) that appears as a hmgeneus area f inreased density in nnntrast sans and enhanes uni- frmly with ntrast. Additinal MRI sequenes that may be helpful in differentiating glimas frm ther intraranial pathlgy inlude perfusin imaging, magneti resnane spetrspy, and diffusin-weighted imaging, althugh nne are speifi enugh t bviate the need fr tissueTable 244. Primary intracranial tumors (listed by major histology grouping and by incidence within each group).T umor Clinicl Fetures Tretment nd prognosis Germ cell tumors (germinomas and nongerminoma- tous germ cell tumors)Two most common locations are pineal and suprasellar regions. The pineal region presentation is as described in pineal tumors, above. Suprasellar tumors present with hypothalamic and pituitary dysfunction such as diabetes insipidus, delayed or precocious puberty, or growth hor- mone deficiency.Germinomas are treated with radiation; prognosis is good for localized tumors. Chemotherapy is added for nongerminomatous germ cell tumors. Tumors of Crnil nd Sinl Nerves Acoustic neurinoma (also referred to as acoustic neuroma)Ipsilateral hearing loss is most common initial symptom. Sub- sequent symptoms may include tinnitus, headache, vertigo, facial weakness or numbness, and long tract signs. (May be familial and bilateral when related to neurofibromatosis.) Most sensitive screening tests are MRI and brainstem audi- tory evoked potential.Treatment is excision by translabyrinthine surgery, craniectomy, or a combined approach. Outcome is usually good. Lymoms Primary cerebral lymphomaAssociated with AIDS and other immunodeficient states. Pre- sentation may be with focal deficits or with disturbances of cognition and consciousness. May be indistinguishable from cerebral toxoplasmosis.Treatment is high-dose methotrexate and corticoste- roids followed by radiation therapy. Prognosis depends on CD4 count at diagnosis. Unclssified Cerebellar hemangioblas- tomaPresents with dysequilibrium, ataxia of trunk or limbs, and signs of increased intracranial pressure. Sometimes familial. May be associated with retinal and spinal vascular lesions, polycythemia, and renal cell carcinoma.Treatment is surgical. Radiation is used for residual tumor.(continued)CMDT22_Ch24_p0978-p1053.indd  1007 29/06/21 8:50 PMChapTER 241008 CMDT 2022samp ling. Arterigraphy is largely reserved fr presurgial emblizatin f highly vasular tumrs. In patients with nrmal hrmne levels and an intrasellar mass, angigra- phy is smetimes neessary t distinguish with nfidene between a pituitary adenma and an arterial aneurysm.C.  Laboratory and Other StudiesWhen  glial neplasms are suspeted, bipsy is neessary fr definitive histlgi diagnsis and mleular analysis. The Wrld Health Organizatin lassifies glial tumrs by bth histlgy and geneti harateristis. Lumbar pun- ture is rarely neessary; the findings are seldm diagnsti, and the predure arries the risk f ausing a herniatin syndrme. Suspeted intraranial germ ell tumrs are an exeptin. If lumbar punture an be perfrmed safely, ytlgy and determinatin f alpha-fetprtein and beta- human hrini gnadtrpin shuld be perfrmed in erebrspinal fluid; tumr markers shuld be examined in serum as well. TreatmentT reatment depends n the type and site f the tumr (Table 244) and the nditin f the patient. Sme benign tumrs, espeially meningimas disvered inidentally during brain imaging fr anther purpse, may be mni- tred with serial annual imaging. Fr symptmati tumrs, mplete surgial remval may be pssible if the tumr is extra-axial (eg, meningima, austi neurma) r is nt in a ritial r inaessible regin f the brain (eg, erebel- lar hemangiblastma). Surgery als permits the diagnsis t be verified and may be benefiial in reduing intrara- nial pressure and relieving symptms even if the neplasm annt be mpletely remved. Clinial defiits are sme- times due in part t bstrutive hydrephalus, in whih ase simple surgial shunting predures ften prdue dramati benefit. In patients with malignant glimas, sur- vival rrelates t the extent f initial resetin. Radiatin therapy inreases median survival rates regardless f any preeding surgery, and its mbinatin with hemtherapy prvides additinal benefit. India- tins fr irradiatin in the treatment f patients with ther primary intraranial neplasms depend n tumr type and aessibility and the feasibility f mplete surgial remval. Lng-term neurgnitive defiits may mpliate radia- tin therapy. Temzlmide is a mmnly used ral and intravenus hemtherapeuti fr glimas. In patients with gliblastma with methylated methylguanine-DNA meth- yltransferase (MGMT) prmter, mbinatin therapy with lmustine and temzlmide imprved median survival frm 31 t 48 mnths in a randmized ntrlled trial. The additin f lw-intensity, 200 kHz frequeny alternating eletri fields (tumr treatment fields) delivered extrarani- ally at least 18 hurs daily, imprves prgressin-free sur- vival by 2.7 mnths and median survival by 4.9 mnths mpared t temzlmide alne in gliblastma. Bevai- zumab is apprved in the United States but nt in Eurpe fr use in reurrent high-grade glima. Cmbinatin therapy with prarbazine, lmustine, and vinristine imprves median survival when given with radiatin tpatients with isitrate dehydrgenasemutant astry- tma and isitrate dehydrgenasemutant, p1/19q - deleted ligdendrglima. Crtisterids help redue erebral edema and are usu- ally started befre surgery. Herniatin is treated with intra- venus dexamethasne (1020 mg as a blus, fllwed by 4 mg every 6 hurs) and intravenus mannitl (20% slutin given in a dse f 1.5 g/kg ver abut 30 minutes). Antinvulsants are als mmnly administered in standard dses (see Table 242), but are nt indiated fr prphylaxis in patients wh have n histry f seizures. Fr thse patients with diffiult t treat symptms r thse needing help with advane are planning, speialty pallia- tive are nsultatin is apprpriate (see Chapter 5). When to ReferAll patients sh uld be referred. When to Admit All patients with inreased intraranial pressure. All patients requiring bipsy, surgial treatment, r shunting predures.Bell  EH et al. Cmprehensive genmi analysis in NRG nl- gy/RTOG 9802: a phase III trial f radiatin versus radiatin plus prarbazine, lmustine (CCNU), and vinristine in high-risk lw-grade glima. J Clin Onl. 2020;38:3407. [PMID: 32706640] Desjardins A et al. Reurrent gliblastma treated with rembi- nant plivirus. N Engl J Med. 2018;379:150. [PMID: 29943666] Herrlinger U et al; Neurnlgy Wrking Grup f the German Caner Siety. Lmustine-temzlmide mbinatin therapy versus standard temzlmide therapy in patients with newly diagnsed gliblastma with methylated MGMT prmter (CeTeG/NOA-09): a randmised, pen-label, phase 3 trial. Lanet. 2019;393:678. [PMID: 30782343]2.  Metsttic Intrcrnil TumorsA.  Cerebral MetastasesMetasta ti brain tumrs present in the same way as ther erebral neplasms, ie, with inreased intraranial pres- sure, with fal r diffuse disturbane f erebral funtin, r with bth f these manifestatins. Indeed, in patients with a single erebral lesin, the metastati nature f the lesin may beme evident nly n histpathlgi exami- natin. In ther patients, there is evidene f widespread metastati disease, r an islated erebral metastasis devel- ps during treatment f the primary neplasm. The most common source of intracranial metastasis is carcinoma of the lung; ther primary sites are the breast, kidney, skin (melanma), and gastrintestinal trat. Mst erebral metastases are lated supratentrially. Labratry and radilgi studies used t evaluate patients with metastases are thse desribed fr primary neplasms. They inlude MRI and CT sanning perfrmed bth with and withut ntrast. Lumbar punture is neessary nly in patients with suspeted arinmatus meningitis. In patients with verified erebral metastasis frm an unknwnCMDT22_Ch24_p0978-p1053.indd  1008 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1009 CMDT 2022primary , investigatin is guided by symptms and signs. In wmen, mammgraphy is indiated; in men under 50, germ ell rigin is sught. Treatment f brain metastases is rapidly evlving and a multidisiplinary apprah between neursurgery, radia- tin nlgy, and nlgy is neessary. In patients with nly a single, surgially aessible erebral metastasis wh are therwise well (ie, a high level f funtining and little r n evidene f extraranial disease), it may be pssible t remve the lesin and then treat with irradiatin; the latter may als be seleted as the sle treatment. Systemi immuntherapy may als be an aeptable initial ptin in selet ases. In patients with multiple metastases r wide- spread systemi disease, steretati radisurgery, whle- brain raditherapy, r bth may help in sme instanes; systemi hemtherapy r immuntherapy may be ptins in thers, but in many, treatment is palliative nly.Fuen tes R et al. Surgery versus steretati raditherapy fr peple with single r slitary brain metastasis. Chrane Database Syst Rev. 2018;8:CD012086. [PMID: 30125049] Tsa MN et al. Whle brain raditherapy fr the treatment f newly diagnsed multiple brain metastases. Chrane Data- base Syst Rev. 2018;1:CD003869. [PMID: 29365347]B.  Leptomeningeal Metastases Carcinomatous MeningitisThe  neoplasms metastasizing most commonly to the lepto- meninges are carcinoma of the breast and lung, lymphomas, and leukemia (see Chapter 39). Leptmeningeal metastases lead t multifal neurlgi defiits, whih may be assi- ated with infiltratin f ranial and spinal nerve rts, diret invasin f the brain r spinal rd, bstrutive r mmuniating hydrephalus, r sme mbinatin f these fatrs. The diagnsis is nfirmed by examinatin f the ere- brspinal fluid. Findings may inlude elevated erebr- spinal fluid pressure, pleytsis, inreased prtein nentratin, and dereased gluse nentratin. Cyt- lgi studies may indiate that malignant ells are present; if nt, lumbar punture shuld be repeated at least twie t btain further samples fr analysis. CT sans shwing ntrast enhanement in the basal isterns r shwing hydrephalus withut any evidene f a mass lesin supprt the diagnsis. Gadlinium-enhaned MRI is mre sensitive and frequently shws enhaning fi in the leptmeninges. Myelgraphy may shw depsits n multiple nerve rts. Treatment is by irradiatin t symptmati areas, m- bined with intratheal hemtherapy in selet patients. The lng-term prgnsis is prnly abut 10% f patients survive fr 1 yearand palliative are is therefre impr- tant (see Chapter 5).3.  Intrcrnil Mss Lesions in ptients wit aIDSPrimary  cerebral lymphoma is a mmn mpliatin in patients with AIDS. This leads t disturbanes in gni- tin r nsiusness, fal mtr r sensry defiits,aphasia, seizures, and ranial neurpathies. Similar linial disturbanes may result frm cerebral toxoplasmosis , whih is als a mmn mpliatin in patients with AIDS (see Chapters 31 and 35). Neither CT nr MRI find- ings distinguish these tw disrders and serlgi tests fr txplasmsis are unreliable in AIDS patients. Toxoplasma gondii DNA deteted by plymerase hain reatin in the spinal fluid is speifi but nt sensitive fr txplasmsis, and the finding f Epstein-Barr virus DNA suggests lym- phma but is nt speifi enugh t initiate treatment. Ardingly, fr neurlgially stable patients, a trial f treatment fr txplasmsis with pyrimethamine and sul- fadiazine is remmended fr 3 weeks; the imaging studies are then repeated, and if any lesin has imprved, the regi- men is ntinued indefinitely. If any lesin des nt imprve, erebral bipsy is neessary (see als Chapter 31). Primary erebral lymphma in patients with AIDS is treated with rtisterids, high-dse methtrexate, and antiretrviral therapy. Rituximab may be used in sme patients. Whle-brain irradiatin may nt be neessary. Cryptococcal meningitis is a mmn pprtunisti infetin in patients with AIDS. Clinially, it may resemble erebral txplasmsis r lymphma, but ranial CT sans are usually nrmal (see Chapter 36).4.  primry & Metsttic Sinl TumorsA pprximately 10% f spinal tumrs are intramedullary. Ependymma is the mst mmn type f intramedullary tumr; the remainder are ther types f glima. Extramed- ullary tumrs may be extradural r intradural in latin. Amng the primary extramedullary tumrs, neurfibr- mas and meningimas are relatively mmn, benign, and may be intradural r extradural. Carinmatus metasta- ses, lymphmatus r leukemi depsits, and myelma are usually extradural; in the ase f metastases, the prstate, breast, lung, and kidney are mmn primary sites. Tumrs may lead t spinal rd dysfuntin by diret mpressin, by ishemia sendary t arterial r venus bstrutin and, in the ase f intramedullary lesins, by invasive infiltratin. Clinical FindingsA.  Symptoms and SignsSymp tms usually develp insidiusly. Pain is ften n- spiuus with extradural lesins; is harateristially aggravated by ughing r straining; may be radiular, lalized t the bak, r felt diffusely in an extremity; and may be ampanied by mtr defiits, paresthesias, r numbness, espeially in the legs. Bladder, bwel, and sexual dysfuntin may ur. When sphinter disturbanes ur, they are usually partiularly disabling. Pain, hw- ever, ften preedes speifi neurlgi symptms frm epidural metastases. Examinatin may reveal lalized spinal tenderness. A segmental lwer mtr neurn defiit r dermatmal sen- sry hanges (r bth) are smetimes fund at the level f the lesin, while an upper mtr neurn defiit and sen- sry disturbane are fund belw it.CMDT22_Ch24_p0978-p1053.indd  1009 29/06/21 8:50 PMChapTER 241010 CMDT 2022B.  ImagingMRI  with ntrast r CT myelgraphy is used t identify and lalize the lesin. The mbinatin f knwn tumr elsewhere in the bdy, bak pain, and either abnrmal plain films f the spine r neurlgi signs f rd m- pressin is an indiatin t perfrm this n an urgent basis.C.  Laboratory FindingsThe  erebrspinal fluid is ften xanthhrmi and n- tains a greatly inreased prtein nentratin with nrmal ell ntent and gluse nentratin. TreatmentIn tramedullary tumrs are treated by dempressin and surgial exisin (when feasible) and by irradiatin. The prgnsis depends n the ause and severity f rd m- pressin befre it is relieved. Treatment f epidural spinal metastases nsists f surgial dempressin, radiatin, r bth. Dexametha- sne is als given in a high dsage (eg, 1096 mg ne intravenusly, fllwed by 425 mg fur times daily fr 3 days rally r intravenusly, fllwed by rapid tapering f the dsage, depending n initial dse and respnse) t redue rd swelling and relieve pain. Radiatin alne is ften all that is required in patients with radisensitive tumrs. Surgial dempressin is reserved fr patients with tumrs that are unrespnsive t irradiatin r wh have previusly been irradiated, fr thse with spinal instability, and fr patients in whm there is sme uner- tainty abut the diagnsis. The lng-term utlk is pr, but treatment may at least delay the nset f majr disability.Lawtn  AJ et al. Assessment and management f patients with metastati spinal rd mpressin: a multidisiplinary review. J Clin Onl. 2019;37:61. [PMID: 30395488]5.  Brin abscessE S S E N T I A L S  O F  D I A G N O S I S Signs of expanding intracranial mass. Signs of primary infection or congenital heart dis- ease are sometimes present. Fever may be absent. General ConsiderationsBrain  absess presents as an intraranial spae-upying lesin and arises as a sequela f disease f the ear r nse, may be a mpliatin f infetin elsewhere in the bdy, r may result frm infetin intrdued intraranially by trauma r surgial predures. The mst mmn infe- tive rganisms are strepti, staphyli, and anaer- bes; mixed infetins als ur.Clinical FindingsA.  Symptoms and SignsHeadahe,  drwsiness, inattentin, nfusin, and seizures are early symptms, fllwed by signs f inreasing intra- ranial pressure and then a fal neurlgi defiit. There may be little r n systemi evidene f infetin.B.  Imaging and Other InvestigationsA  CT san f the head harateristially shws an area f ntrast enhanement surrunding a lw-density re. Similar abnrmalities may be fund in patients with meta- stati neplasms. MRI findings ften permit earlier reg- nitin f fal erebritis r an absess. Steretati needle aspiratin may enable a speifi etilgi rganism t be identified. Examinatin f the erebrspinal fluid des nt help in diagnsis and may preipitate a herniatin syn- drme. Peripheral leukytsis is smetimes present. TreatmentT reatment nsists f intravenus antibitis mbined with surgial drainage (aspiratin r exisin), if neessary, t redue the mass effet r smetimes t establish the diagnsis. Absesses smaller than 2 m an ften be ured medially. Brad-spetrum antibitis, seleted based n risk fatrs and likely rganisms, are used if the infeting rganism is unknwn (see Chapter 33). An initial empiri multi-antibiti regimen typially inludes eftriaxne (2 g intravenusly every 12 hurs), metrnidazle (15 mg/kg intravenus lading dse, fllwed by 7.5 mg/kg intrave- nusly every 6 hurs), and vanmyin (1 g intravenusly every 12 hurs). The regimen is altered ne ulture and sensitivity data are available. Antimirbial treatment is usually ntinued parenterally fr 68 weeks and is fl- lwed by ral treatment fr ertain infetins, suh as nardisis, atinmysis, fungal infetins, and tuberu- lsis. The patient shuld be mnitred by serial CT sans r MRI every 2 weeks and at deteriratin. Dexametha- sne (425 mg fur times daily intravenusly r rally, depending n severity, fllwed by tapering f dse, depending n respnse) may redue any assiated edema, but intravenus mannitl is smetimes required.Chw  F. Brain and spinal epidural absess. Cntinuum (Min- neap Minn). 2018;24:1327. [PMID: 30273242]NO NMETASTATIC NEUROLOGIC COMPLICATIONS OF MALIGNANT DISEASEA  variety f nnmetastati neurlgi mpliatins f malignant disease an be regnized. Metabolic encepha- lopathy due t eletrlyte abnrmalities, infetins, drug verdse, r the failure f sme vital rgan may be refleted by drwsiness, lethargy, restlessness, insmnia, agitatin, nfusin, stupr, r ma. The mental hanges are usually assiated with tremr, asterixis, and multifal mylnus. The eletrenephalgram is generally diffusely slwed. Labratry studies are neessary t detet the ause f the enephalpathy, whih must then be treated apprpriately.CMDT22_Ch24_p0978-p1053.indd  1010 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1011 CMDT 2022Im mune suppression resulting frm either the malig- nant disease r its treatment (eg, by hemtherapy) predis- pses patients t brain absess, prgressive multifal leukenephalpathy, meningitis, herpes zster infetin, and ther pprtunisti infetius diseases. Mrever, an vert r ult erebrspinal fluid fistula, as urs with sme tumrs, may als inrease the risk f infetin. MRI r CT sanning aids in the early regnitin f a brain absess, but metastati brain tumrs may have a similar appearane. Examinatin f the erebrspinal fluid is essential in the evaluatin f patients with meningitis and enephalitis but is f n help in the diagnsis f brain absess. Cerebrovascular disorders that ause neurlgi m- pliatins in patients with systemi aner inlude nnbate- rial thrmbti endarditis and septi emblizatin. Cerebral, subarahnid, r subdural hemrrhages may ur in patients with myelgenus leukemia and may be fund in assiatin with metastati tumrs, espeially melanma. Spinal subdural hemrrhage smetimes urs after lumbar punture in patients with marked thrmbytpenia. Disseminated intravascular coagulation urs mst mmnly in patients with aute prmyelyti leukemia r with sme adenarinmas and is haraterized by a flutuating enephalpathy, ften with assiated seizures, that frequently prgresses t ma r death. There may be few ampanying neurlgi signs. Venous sinus throm- bosis, whih usually presents with nvulsins and head- ahes, may als ur in patients with leukemia r lymphma. Examinatin mmnly reveals papilledema and fal r diffuse neurlgi signs. Antinvulsants, antiagulants, and mediatins t lwer the intraranial pressure may be f value. Autoimmune paraneoplastic disorders ur when the immune system reats against neurnal antigens expressed by tumr ells. The linial manifestatins depend n the autantibdy. Symptms may preede thse due t the neplasm itself. Several distint syndrmes are mmn, eah assiated with speifi antibdies and tumrs (Table 245). Identifiatin f an antibdy is nt always pssible in a suspeted autimmune paraneplasti nditin, and a searh fr an underlying neplasm shuld be undertaken. Treatment f the neplasm ffers the best hpe fr stabilizatin r imprvement f the neurlgi symptms, whih ften are nt mpletely reversible. Spe- ifi treatment f the antibdy-mediated symptms by intravenus immunglbulin (IVIG) administratin, plas- mapheresis, rtisterids, r ther immunsuppressive regimens is frequently attempted despite limited evidene f effiay. Many f the disrders listed in Table 245 an ur either as paraneplasti phenmena r in islatin; when they ur in the absene f a tumr, the respnse t immuntherapy is typially mre favrable. Autimmune disrders may als be triggered as a result f aner immuntherapy; enephalitis, meningitis, trans- verse myelitis, aute and hrni inflammatry demyelin- ating plyneurpathy, autnmi neurpathy, myasthenia gravis, and mysitis have all been desribed.Rsenfeld MR et al. P araneplasti neurlgi syndrmes. Neu- rl Clin. 2018;36:675. [PMID: 30072076]IDIOPATHIC INTRACRANIAL HYPERTENSION (Pseudotumor Cerebri)E S S E N T I A L S  O F  D I A G N O S I S Headache, worse on straining. Visual obscurations or diplopia may occur. Examination reveals papilledema. Abducens palsy is commonly present. General ConsiderationsThere are man y auses f this disrder. Thrmbsis f the transverse venus sinus as a mpliatin f titis media r hrni mastiditis is ne ause, and sagittal sinus thrm- bsis may lead t a linially similar piture. Other auses inlude hrni pulmnary disease, systemi lupus erythe- matsus, uremia, endrine disturbanes suh as hyp- parathyridism, hypthyridism, r Addisn disease, vitamin A txiity, and the use f tetrayline r ral n- traeptives. Cases have als fllwed withdrawal f rti- sterids after lng-term use. In mst instanes, hwever, n speifi ause an be fund, and the disrder remits spntaneusly after several mnths. This idipathi variety urs mst mmnly amng verweight wmen aged 2044. In all ases, sreening fr a spae-upying lesin f the brain is imprtant. Clinical FindingsA.  Symptoms and SignsSymp tms nsist f headahe, diplpia, and ther visual disturbanes due t papilledema and abduens nerve dys- funtin. Pulse-synhrnus tinnitus may als ur. Examinatin reveals papilledema and sme enlargement f the blind spts, but patients therwise lk well.B.  ImagingIn vestigatins reveal n evidene f a spae-upying lesin. CT r MRI shws small r nrmal ventriles and an empty sella turia. MR vengraphy is imprtant in sreen- ing fr thrmbsis f the intraranial venus sinuses. In sme ases, stensis f ne r mre f the venus sinuses will be bserved.C.  Laboratory FindingsLum bar punture is neessary t nfirm the presene f intraranial hypertensin, but the erebrspinal fluid is nrmal. Labratry studies help exlude sme f the ther auses mentined earlier. TreatmentU ntreated intraranial hypertensin smetimes leads t sendary pti atrphy and permanent visual lss. Aet- azlamide (250500 mg rally three times daily, inreasing slwly t a maintenane dse f up t 4000 mg daily,CMDT22_Ch24_p0978-p1053.indd  1011 29/06/21 8:50 PMChapTER 241012 CMDT 2022T able 245. Autoimmune paraneoplastic disorders and their associated antibodies and tumors (listed in alphabetical order).Syndrome Clinicl Fetures associted antibodies Tyicl associted Tumors Anti-NMDA receptor associated encephalitisParanoia, delusions, behavioral disturbance, seizure, orofacial dyskinesias, athetosis, dysau- tonomia, hypoventilationNMDA receptor1Ovarian teratoma, lung, breast, ovary, testicle Autoimmune necrotizing myopathyWeakness SRP ,1HMGCR1Lung, breast, gastrointestinal, bladder Autonomic neuropathy Postural hypotension, gastroparesisHu, ganglionic AChR1 Cerebellar degeneration Ataxia, dysarthria, nystagmus GAD65,1KLHL11, mGluR1,1NIF,1Ri, Tr, VGCC,1YoLung, breast, thymus, ovary, testicle, Hodgkin lymphoma Dermatomyositis Weakness, heliotrope skin rash TIF-1 gamma Lung, breast, ovary, gastrointes- tinal, lymphoma Lambert-Eaton myasthenic syndromeFatiguable weakness, ptosis, dip- lopia, dry mouth, constipationVGCC1Lung Limbic encephalitis/ encephalomyelitisShort-term memory loss, halluci- nations, seizures, behavioral disturbance, encephalopathyAMPA receptor,1Caspr2,1CV2/CRMP5, DPPX,1GABAAreceptor,1GABAB receptor,1GAD65,1GFAP ,1Hu, LGI1,1 Ma2, mGluR5,1NIF,1thyroglobulin1/ thyroperoxidase1Lung, breast, thymus, ovary, testicle, Hodgkin lymphoma Myasthenia gravis Fatiguable weakness, ptosis, diplopiaAChR,1LRP4,1MuSK1Thymus Myelitis Paraparesis, bowel and bladder dysfunction; sensory levelAmphiphysin,1aquaporin 4,1CRMP-5, GFAP ,1Hu, MOG,1YoLung, breast, lymphoma, leukemia, thyroid, renal Opsoclonus/myoclonus Erratic, conjugate saccadic eye movements and limb myoclonusRi Lung, breast, ovary, testicle, neuroblastoma (children) Retinopathy Vision loss Anti-recoverin, anti-retinal bipolar cell Small cell lung, melanoma Sensorimotor neuropathy Numbness with or without weak- ness; may be mild and chronic or acute and severeHu, MAG Sensory neuronopathy Pain, numbness, sensory ataxia, hearing lossHu Small cell lung Stiff person syndrome Co-contraction of antagonist and agonist musclesAmphiphysin,1GAD65,1GlyR1Small cell lung, breast, thymus, lymphoma1 Can occur in absence of tumor. AChR, acetylcholine receptor; AMPA, alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid; Caspr2, contactin associated prot ein-like 2; CRMP , collapsin response-mediator protein; DPPX, dipeptidyl-peptidase-like protein-6; GABA, gamma-aminobutyric acid; GAD, gl utamic acid decarboxylase; GFAP , glial fibrillary acidic protein; GlyR, glycine receptor; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; KLHL11, kelch-like protein 11; LGI1, leucine rich glioma inactivated; LRP4, low-density lipoprotein receptor-related protein 4; mGluR, metabotropic glutamate receptor; MAG, myelin-associated glycoprotein; MOG, myelin oligodendrocyte glycoprotein; MuSK, Muscle- specific tyrosine kinase; NIF, neuronal intermediate filament; NMDA, N-methyl-D-aspartate; SRP , signal recognition particle; TI F-1, human transcription intermediary factor-1; VGCC, voltage-gated calcium channel.divided tw  t fur times daily) redues frmatin f ere- brspinal fluid. Like aetazlamide, the antiepilepti medi- atin tpiramate (Table 242) is a arbni anhydrase inhibitr and was shwn t be similarly effetive in an pen label study; tpiramate has the added benefit f aus- ing weight lss. Fursemide (2040 mg daily) may be help- ful as adjunt therapy. Crtisterids (eg, prednisne 6080 mg daily) are smetimes presribed, but side effets and the risk f relapse n withdrawal have disuragedtheir use. Obese patients shuld be advised t lse weight. Repeated lumbar punture t lwer the intraranial pres- sure by remval f erebrspinal fluid is effetive as a temprizing measure, but pharmalgi apprahes t treatment prvide better lng-term relief. Treatment is mnitred by heking visual auity and visual fields, fun- duspi appearane, and pressure f the erebrspinal fluid. The disrder may wrsen after a perid f stability, indiating the need fr lng-term fllw-up.CMDT22_Ch24_p0978-p1053.indd  1012 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1013 CMDT 2022If  medial treatment fails t ntrl the intraranial pressure, surgial plaement f a lumbperitneal r ven- triulperitneal shunt r pti nerve sheath fenestratin shuld be undertaken t preserve visin. Venus sinus stenting is an inreasingly aepted therapeuti ptin fr dural venus sinus stensis. In additin t the abve measures, any speifi ause f intraranial hypertensin requires apprpriate treatment. Thus, hrmne therapy shuld be initiated if there is an underlying endrine disturbane. Disntinuing the use f tetrayline, ral ntraeptives, r vitamin A will allw fr reslutin f intraranial hypertensin due t these agents. If rtisterid withdrawal is respnsible, the mediatin shuld be reintrdued and then tapered mre gradually. When to ReferAll patients sh uld be referred. When to AdmitAll  patients with wrsening visin requiring shunt plae- ment r pti nerve sheath fenestratin shuld be hspitalized.Kalyvas  A et al. A systemati review f surgial treatments f idipathi intraranial hypertensin (IIH). Neursurg Rev. 2021;44:773. [PMID: 32335853] Madriz Peralta G et al. An update f idipathi intraranial hypertensin. Curr Opin Ophthalml. 2018;29:495. [PMID: 30169466]SE LECTED NEUROCUTANEOUS DISEASESBeause  the nervus system develps frm the epithelial layer f the embry, a number f ngenital diseases inlude bth neurlgi and utaneus manifestatins. Amng these disrders, three are disussed belw, and vn Hippel-Lindau disease is disussed in Chapter 26.1.  Tuberous SclerosisT uberus slersis may ur spradially r n a familial basis with autsmal dminant inheritane. Neurlgi presentatin is with seizures and prgressive psyhmtr retardatin beginning in early hildhd. The utaneus abnrmality adenma sebaeum bemes manifest usually between 5 and 10 years f age and typially nsists f red- dened ndules n the fae (heeks, naslabial flds, sides f the nse, and hin) and smetimes n the frehead and nek. Other typial utaneus lesins inlude subungual fibrmas, shagreen pathes (leathery plaques f subepider- mal fibrsis, situated usually n the trunk), and leaf-shaped hyppigmented spts. Assiated abnrmalities inlude retinal lesins and tumrs, benign rhabdmymas f the heart, lung ysts, benign tumrs in the visera, and bne ysts. The disease is slwly prgressive and leads t inreasing mental deteriratin. Antinvulsants are indiated t ntrl seizures. Everlimus, a mammalian target frapamyin (mTOR) inhibitr, is apprved in the United States and Eurpe fr medially refratry epilepsy and subepen- dymal giant ell astrytmas due t tuberus slersis.2.  NeurofibromtosisNeur fibrmatsis may ur either spradially r n a familial basis with autsmal dminant inheritane. Tw distint frms are regnized: Type 1 (Recklinghausen disease) is haraterized by multiple hyperpigmented ma- ules, Lish ndules, and neurfibrmas, and results frm mutatins in the NF1 gene n hrmsme 17. Type 2 is haraterized by bilateral eighth nerve tumrs, ften ampanied by ther intraranial r intraspinal tumrs, and is assiated with mutatins in the NF2 (merlin) gene n hrmsme 22. Neurlgi presentatin is usually with symptms and signs f tumr. Multiple neurfibrmas harateristially are present and may invlve spinal r ranial nerves, espe- ially the eighth nerve. Examinatin f the superfiial utaneus nerves usually reveals palpable mbile ndules. In sme ases, there is marked vergrwth f subutaneus tissues (plexifrm neurmas), smetimes with an underly- ing bny abnrmality. Assiated utaneus lesins inlude axillary frekling and pathes f utaneus pigmentatin (caf au lait spots ). Malignant degeneratin f neurfibr- mas asinally urs and may lead t peripheral sar- mas. Meningimas, glimas (espeially pti nerve glimas), bne ysts, phehrmytmas, slisis, and bstrutive hydrephalus may als ur. Selumetinib (25 mg/m2rally twie daily), a mitgen-ativated prtein kinase inhibitr, auses plexifrm neurfibrmas t shrink by at least 20% in tw-thirds f patients and is apprved by the FDA fr treatment f inperable plexifrm neurfibr- mas in hildren 2 years f age and lder. Studies in adults are nging.3.  Sturge-Weber SyndromeSturg e-Weber syndrme nsists f a ngenital, usually unilateral, utaneus apillary angima invlving the upper fae, leptmeningeal angimatsis, and, in many patients, hridal angima. It has n sex prediletin and usually urs spradially. The utaneus angima sme- times has a mre extensive distributin ver the head and nek and is ften quite disfiguring, espeially if there is assiated vergrwth f nnetive tissue. Fal r gener- alized seizures are the usual neurlgi presentatin and may mmene at any age. There may be ntralateral hmnymus hemianpia, hemiparesis and hemisensry disturbane, ipsilateral glauma, and mental subnrmal- ity. Skull radigraphs taken after the first 2 years f life usually reveal gyrifrm (tramline) intraranial alifia- tin, espeially in the pariet-ipital regin, due t min- eral depsitin in the rtex beneath the intraranial angima. Treatment is aimed at ntrlling seizures pharma- lgially (Table 242), but surgial treatment may be ne- essary. Ophthalmlgi advie shuld be sught nerning the management f hridal angima and f inreased intraular pressure.CMDT22_Ch24_p0978-p1053.indd  1013 29/06/21 8:50 PMChapTER 241014 CMDT 2022MO VEMENT DISORDERS 1. Essentil (Fmilil) TremorE S S E N T I A L S  O F  D I A G N O S I S Postural tremor of hands, head, or voice. Family history common. May improve temporarily with alcohol. No abnormal findings other than tremor. General ConsiderationsThe  ause f essential tremr is unertain, but it is sme- times inherited in an autsmal dminant manner. Clinical FindingsT remr may begin at any age and is enhaned by emtinal stress. The tremr usually invlves ne r bth hands, the head, r the hands and head, while the legs tend t be spared. The tremr is nt present at rest, but emerges with atin. Examinatin reveals n ther abnrmalities. Inges- tin f a small quantity f alhl mmnly prvides remarkable but shrt-lived relief by an unknwn mehanism. The tremr typially bemes mre nspiuus with time. Oasinally, it interferes with manual skills and leads t impairment f handwriting. Speeh may als be affeted if the laryngeal musles are invlved. TreatmentT reatment is ften unneessary. When it is required beause f disability, prpranll (60240 mg daily rally) may be helpful. Lng-term therapy is typial; hwever, intermittent therapy is smetimes useful in patients whse tremr bemes exaerbated in speifi preditable situa- tins. Primidne may be helpful when prpranll is inef- fetive, but patients with essential tremr are ften very sensitive t it. Therefre, the starting dse is 50 mg daily rally, and the daily dse is inreased by 50 mg every 2 weeks depending n the patients respnse; a mainte- nane dse f 125 mg three times daily rally is mmnly effetive. Oasinal patients d nt respnd t these mea- sures but are helped by alprazlam (up t 3 mg daily rally in divided dses), tpiramate (titrated up t a dse f 400 mg daily rally in divided dses ver abut 8 weeks), r gabapentin (1800 mg daily rally in divided dses). Btulinum txin A may redue tremr, but adverse effets inlude dse-dependent weakness f the injeted musles. Disabling tremr unrespnsive t medial treatment may be helped by high-frequeny thalami stimulatin (deep brain stimulatin) n ne r bth sides, arding t the laterality f symptms. Fused transranial ultra- sund thalamtmy using MRI guidane is als effetive, as is steretati radisurgery fr unilateral upper extrem- ity tremr.When to Refer When refratry t first-line treatment with prpran- ll r primidne. When additinal neurlgi signs are present (ie, parkinsnism). When to AdmitPa tients requiring surgial treatment (deep brain stimula- tr plaement) shuld be hspitalized.Ha ubenberger D et al. Essential tremr. N Engl J Med. 2018;378: 1802. [PMID: 29742376]2.  prkinson DiseseE S S E N T I A L S  O F  D I A G N O S I S Any combination of tremor, rigidity, bradykinesia, and progressive postural instability (parkinsonism). Cognitive impairment is sometimes prominent. General ConsiderationsPar kinsnism is a relatively mmn disrder that urs in all ethni grups, with an apprximately equal sex distri- butin. The mst mmn variety, idipathi Parkinsn disease, begins mst ften between 45 and 65 years f age and is a prgressive disease. EtiologyPar kinsnism may rarely ur n a familial basis, and the parkinsnian phentype may result frm mutatins f several different genes. Pstenephaliti parkinsnism is beming inreasingly rare. Expsure t ertain txins (eg, manganese dust, arbn disulfide) and severe arbn mn- xide pisning may lead t parkinsnism. Reversible parkinsnism may develp in patients reeiving neurlep- ti mediatins (see Chapter 25), reserpine, r metl- pramide. Only rarely is hemiparkinsnism the presenting feature f a prgressive spae-upying lesin. In idipathi Parkinsn disease, dpamine depletin due t degeneratin f the dpaminergi nigrstriatal sys- tem leads t an imbalane f dpamine and aetylhline, whih are neurtransmitters nrmally present in the r- pus striatum. Treatment f the mtr disturbane is direted at redressing this imbalane by blking the effet f aetylhline with antihlinergi mediatins r by the administratin f levdpa, the preursr f dpamine. Prir use f ibuprfen is assiated with a decreased risk f develping Parkinsn disease; age, family histry, male sex, nging herbiide/pestiide expsure, and signifiant prir head trauma are risk fatrs. Clinical FindingsT remor, rigidity, bradykinesia, and postural instability are the ardinal mtr features f parkinsnism and mayCMDT22_Ch24_p0978-p1053.indd  1014 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1015 CMDT 2022be  present in any mbinatin. Nnmtr manifestatins inlude affetive disrders (depressin, anxiety, and apa- thy), psyhsis, gnitive hanges, fatigue, sleep disrders, ansmia, autnmi disturbanes, sensry mplaints r pain, and sebrrhei dermatitis. Dementia r mild gni- tive impairment will eventually develp in many patients. The tremr f abut fur t six yles per send is most conspicuous at rest , is enhaned by emtinal stress, and is ften less severe during vluntary ativity. Althugh it may ultimately be present in all limbs, the tremr is mmnly nfined t ne limb r t the limbs n ne side fr mnths r years befre it bemes mre generalized. In sme patients, tremr is absent. Rigidity (an inrease in resistane t passive mvement) is respnsible fr the harateristially flexed psture seen in many patients, but the mst disabling symptms f par- kinsnism are due t bradykinesia, manifested as a slwness f vluntary mvement and a redutin in autmati mve- ments suh as swinging f the arms while walking. Curi- usly, hwever, effetive vluntary ativity may briefly be regained during an emergeny (eg, the patient is able t leap aside t avid an nming mtr vehile). Clinial diagnsis f the well-develped syndrme is usually simple. The patient has a relatively immbile fae with widened palpebral fissures, infrequent blinking, and a fixity f faial expressin. Sebrrhea f the salp and fae is mmn. There is ften mild blepharlnus, and a tremr may be present abut the muth and lips. Repetitive tap- ping (abut twie per send) ver the bridge f the nse prdues a sustained blink respnse ( Myerson sign ). Other findings may inlude saliva drling frm the muth, per- haps due t impairment f swallwing; sft and prly mdulated vie; a variable rest tremr and rigidity in sme r all f the limbs; slwness f vluntary mvements; impairment f fine r rapidly alternating mvements; and mirgraphia. There is typially n musle weakness (pr- vided that suffiient time is allwed fr pwer t be devel- ped) and n alteratin in the tendn reflexes r plantar respnses. It is diffiult fr the patient t arise frm a sitting psitin and begin walking. The gait itself is haraterized by small shuffling steps and a lss f the nrmal autmati arm swing; there may be unsteadiness n turning, diffiulty in stpping, and a tendeny t fall. Differential DiagnosisDiagn sti prblems may ur in mild ases, espeially if tremr is minimal r absent. Fr example, mild hypkinesia r slight tremr is mmnly attributed t ld age. Depres- sin, with its assiated expressinless fae, prly mdu- lated vie, and redutin in vluntary ativity, an be diffiult t distinguish frm mild parkinsnism, espeially sine the tw disrders may exist. The family histry, the harater f the tremr, and lak f ther neurlgi signs shuld distinguish essential tremr frm parkinsnism. Wilsn disease an be distinguished by its early age at nset, the presene f ther abnrmal mvements, Kayser- Fleisher rings, and hrni hepatitis, and by inreased nentratins f pper in the tissues. Huntingtn disease presenting with rigidity and bradykinesia may be mistakenfr parkinsnism unless the family histry and ampany- ing dementia are regnized. In multisystem atrphy (pre- viusly alled the Shy-Drager syndrme), autnmi insuffiieny (leading t pstural hyptensin, anhidrsis, disturbanes f sphinter ntrl, eretile dysfuntin, et) may be ampanied by parkinsnism, pyramidal defiits, lwer mtr neurn signs, r erebellar dysfuntin. In prgressive supranulear palsy, bradykinesia and rigidity are ampanied by a supranulear disrder f eye mve- ments, pseudbulbar palsy, pseud-emtinal lability (pseudbulbar affet), and axial dystnia. Creutzfeldt-Jakb disease may be ampanied by features f parkinsnism, but prgressin is rapid, dementia is usual, mylni jerk- ing is mmn, ataxia and pyramidal signs may be n- spiuus, and the MRI and eletrenephalgraphi findings are usually harateristi. In rtibasal degener- atin, asymmetri parkinsnism is ampanied by n- spiuus signs f rtial dysfuntin (eg, apraxia, sensry inattentin, dementia, aphasia). Diffuse Lewy bdy disease is haraterized by prminent visual halluinatins and gnitive impairment that begin befre r within 1 year f nset f the mtr features f parkinsnism. TreatmentT reatment is symptmati. There is great interest in devel- ping disease-mdifying therapies, but trials f several putative neurprtetive agents have shwn n benefit. Tri- als f varius gene therapies have shwn limited r n benefit.A.  Medical MeasuresMe diatin is nt required early in the urse f Parkinsn disease, but the nature f the disrder and the availability f medial treatment fr use when neessary shuld be dis- ussed with the patient. 1. Amantadine Patients with mild symptms but n dis- ability may be helped by amantadine (100 mg rally tw t three times daily [immediate release] r ne daily [extended release]). This mediatin imprves all f the linial features f parkinsnism, but its mde f atin is unlear. Side effets are unmmn but may inlude rest- lessness, nfusin, depressin, skin rashes, edema, nausea, nstipatin, anrexia, pstural hyptensin, and distur- banes f ardia rhythm. It als amelirates dyskinesias resulting frm lng-term levdpa therapy. 2. Levodopa Levdpa, whih is nverted in the bdy t dpamine, imprves all f the majr features f parkinsn- ism, inluding bradykinesia, but does not stop progression f the disrder. The mst mmn early side effets f levdpa are nausea, vmiting, and hyptensin, but ar- dia arrhythmias may als ur. Dyskinesias, restlessness, nfusin, and ther behaviral hanges tend t ur smewhat later and beme mre mmn with time. Levodopa-induced dyskinesias may take any neivable frm, inluding hrea, athetsis, dystnia, tremr, tis, and mylnus. An even later mpliatin is the wearing off effect r the on-off phenomenon, in whih abrupt but transient flutuatins in the severity f parkinsnism urCMDT22_Ch24_p0978-p1053.indd  1015 29/06/21 8:50 PMChapTER 241016 CMDT 2022un preditably but frequently during the day. The off period of marked bradykinesia has been shwn t relate in sme instanes t falling plasma levels f levdpa. During the  onphase , dyskinesias are ften nspiuus but mbility is inreased. Hwever, suh respnse flutuatins may relate t advaning disease rather than t levdpa therapy itself. Carbidpa, whih inhibits the enzyme respnsible fr the breakdwn f levdpa t dpamine, des nt rss the bld-brain barrier. When levdpa is given in mbina- tin with arbidpa, the extraerebral breakdwn f levdpa is diminished. This redues the amunt f levdpa required daily fr benefiial effets, and it lwers the inidene f nausea, vmiting, hyptensin, and ardia irregularities. Suh a mbinatin des nt prevent the develpment f respnse flutuatins and the inidene f ther side effets (dyskinesias r psyhiatri mpliatins) may atually be inreased. Sinemet, a mmerially available preparatin that n- tains arbidpa and levdpa in a fixed rati (1:10 r 1:4), is generally used. Treatment is started with a small dse eg, ne tablet f Sinemet 25/100 (ntaining 25 mg f ar- bidpa and 100 mg f levdpa) three times dailyand gradually inreased depending n the respnse. Sinemet CR is a ntrlled-release frmulatin (ntaining 25 r 50 mg f arbidpa and 100 r 200 mg f levdpa). It is mainly useful when taken at bedtime t lessen mtr dis- ability upn awakening. A frmulatin f arbidpa/ levdpa (Rytary) ntaining bth immediate- and delayed- release beads prvides a smther respnse in patients with flutuatins. The mmerially available mbinatin f levdpa with bth arbidpa and entaapne (Stalev) may als be helpful in this ntext and is disussed in the fllwing setin n COMT inhibitrs. Respnse flutua- tins are als redued by keeping the daily intake f protein at the remmended minimum and taking the main prtein meal as the last meal f the day. A ntinuus infusin f a arbidpa-levdpa enteral suspensin thrugh a peruta- neus gastrjejunstmy tube by a prtable infusin pump redues ff time in patients with advaned Parkinsn disease. Levdpa an als be taken by inhalatin (Inbrija) as a resue mediatin fr patients develping severe akine- sia (ff perids). Benefit urs abut 10 minutes after inhalatin. Side effets inlude ugh, upper respiratry trat infetin, nausea, and dislred sputum. The dyskinesias and behaviral side effets f levdpa are dse-related, but redutin in dse may eliminate any therapeuti benefit. Levdpa-indued dyskinesias may als respnd t amantadine. Levdpa therapy is ntraindiated in patients with psyhti illness r narrw-angle glauma. It shuld nt be given t patients taking mnamine xidase A inhibitrs r within 2 weeks f their withdrawal, beause hypertensive rises may result. Sudden disntinuatin f levdpa an preipitate neurlepti malignant syndrme and shuld be avided. 3. Dopamine agonists Dpamine agnists, suh as pramipexle and rpinirle, at diretly n dpamine reeptrs, and their use in parkinsnism is assiated with a lwer inidene f the respnse flutuatins anddyskinesias that ur with lng-term levdpa therapy. They are effetive in bth early and advaned stages f Par- kinsn disease. They are ften given either befre the intr- dutin f levdpa r with a lw dse f Sinemet 25/100 (arbidpa 25 mg and levdpa 100 mg, ne tablet three times daily) when dpaminergi therapy is first intrdued; the dse f Sinemet is kept nstant, while the dse f the agnist is gradually inreased. Pramipexle is started at a dsage f 0.125 mg three times daily rally, and the dse is built up gradually t between 0.5 and 1.5 mg three times daily. Rpinirle is begun at 0.25 mg three times daily rally and gradually inreased; mst patients require between 2 and 8 mg three times daily fr benefit. Extended-release, ne-daily frmu- latins f pramipexle and rpinirle have similar effiay and tlerability as the immediate release versins. Rtig- tine is a dpamine agnist absrbed transdermally frm a skin path; it is started at 2 mg ne daily and inreased weekly by 2 mg daily until ahieving an ptimal respnse, up t a maximum f 8 mg daily. Adverse effets f these varius agnists inlude fatigue, smnlene, nausea, peripheral edema, dyskinesias, nfusin, and pstural hyptensin. Less mmnly, an irresistible urge t sleep may ur, smetimes in inapprpriate and hazardus ir- umstanes. Impulse ntrl disrders invlving gambling, shpping, r sexual ativity als ur. Lal skin reatins may ur with the rtigtine path. The dopamine ago- nist withdrawal syndrome develps asinally in patients in whm a dpamine agnist is tapered. It nsists f a mbinatin f distressing physial and psyhlgial symptms that are refratry t levdpa and ther dpa- minergi mediatins and may persist fr mnths r lnger. There is n effetive treatment. The dpamine agnist shuld be reintrdued and tapered mre gradually if pssible. 4. Selective monoamine oxidase inhibitors Rasagiline, a seletive mnamine xidase B inhibitr, has a lear symp- tmati benefit in sme patients at a daily ral dse f 1 mg, taken in the mrning; it may als be used fr adjuntive therapy in patients with respnse flutuatins t levdpa. Selegiline (5 mg rally with breakfast and lunh) and safin- amide (50 mg rally daily, inreased t 100 mg daily after 14 days) are als apprved as adjuntive treatments. By inhibiting the metabli breakdwn f dpamine, these mediatins may imprve flutuatins r delining respnse t levdpa. Studies have suggested (but failed t shw nlusively) that rasagiline may slw the prgressin f Parkinsn dis- ease, and it appears t delay the need fr ther symptmati therapies. Fr these reasns, rasagiline is ften started early, partiularly fr patients wh are yung r have mild dis- ease. Hwever, the FDA has rejeted an expansin f rasa- gilines indiatin t inlude disease mdifiatin. 5. COMT inhibitors Catehlamine- O-methyltransferase (COMT) inhibitrs redue the metablism f levdpa t 3-O-methyldpa and thereby alter the plasma pharmaki- netis f levdpa, leading t mre sustained plasma levels and mre nstant dpaminergi stimulatin f the brain. Treatment with entaapne r tlapne results in reduedCMDT22_Ch24_p0978-p1053.indd  1016 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1017 CMDT 2022res pnse flutuatins, with a greater perid f respnsive- ness t administered levdpa. Tlapne is given in a dsage f 100 mg r 200 mg three times daily rally, and entaapne is given as 200 mg with eah dse f Sinemet. Opiapne, a lng-ating, peripherally seletive COMT inhibitr, is taken ne daily (50 mg) at bedtime at least 1 hur befre and after eating. The dse f Sinemet taken nurrently may have t be redued by up t ne-third t avid side effets. Diarrhea is smetimes trublesme. Beause rare ases f fulminant hepati failure have fl- lwed its use, tlapne shuld be avided in patients with preexisting liver disease. Serial liver bihemial tests shuld be perfrmed at 2-week intervals fr the first year and at lnger intervals thereafter in patients reeiving the mediatinas remmended by the manufaturer. Seri- us hepattxiity has nt been reprted with entaapne r piapne. Stalev is the mmerial preparatin f levdpa m- bined with bth arbidpa and entaapne. It is best used in patients already stabilized n equivalent dses f arbi- dpa/levdpa and entaapne. It is pried at r belw the prie f the individual ingredients (ie, arbidpa/levdpa and entaapne) and has the added nveniene f requir- ing fewer tablets t be taken daily. It is available in three strengths: Stalev 50 (12.5 mg f arbidpa, 50 mg f levdpa, and 200 mg f entaapne), Stalev 100 (25 mg f arbidpa, 100 mg f levdpa, and 200 mg f entaa- pne), and Stalev 150 (37.5 mg f arbidpa, 150 mg f levdpa, and 200 mg f entaapne). 6. Istradefylline This adensine A2Areeptr antagnist (2040 mg rally ne daily) is given t patients taking levdpa r a dpamine agnist t redue ff time; ttal ff time is typially redued by less than 1 hur per day. 7. Anticholinergic medications Antihlinergis are mre helpful in alleviating tremr and rigidity than brady- kinesia. Trihexyphenidyl and benztrpine are mmnly used frmulatins. Treatment is started with a small dse and gradually inreased until benefit urs r side effets limit further inrements. If treatment is ineffetive, the mediatin is gradually withdrawn and anther prepara- tin then tried. Hwever, these mediatins are ften prly tlerated, espeially in lder adults. Side effets limit the rutine use f these mediatins, and inlude dryness f the muth, nausea, nstipatin, palpitatins, ardia arrhythmias, urinary retentin, n- fusin, agitatin, restlessness, drwsiness, mydriasis, inreased intraular pressure, and defetive ammda- tin. Antihlinergi mediatins are ntraindiated in patients with prstati hyperplasia, narrw-angle glau- ma, r bstrutive gastrintestinal disease and are ften tlerated prly by the elderly. They are best avided whenever gnitive impairment r a predispsitin t delirium exists. 8. Antipsychotics Cnfusin and psyhti symptms may ur as a side effet f dpaminergi therapy r as a part f the underlying illness. Pimavanserin (34 mg ne daily), a sertnin(2A) agnist, is apprved by the FDA speifially fr treating the psyhsis f Parkinsn disease. This may als respnd t the atypial antipsyhti agentslzapine and quetiapine, whih have few extrapyramidal side effets and d nt blk the effets f dpaminergi mediatin. Clzapine may rarely ause marrw suppres- sin, and weekly bld unts are therefre neessary fr patients taking it. The patient is started n 6.25 mg at bedtime and the dsage inreased t 25100 mg/day as needed. In lw dses, it may als imprve iatrgeni dyskinesias. Typical antipsychotic agents and the second- generation antipsychotic agents risperidone and olanzapine may cause worsening of motor symptoms and should be avoided .B.  General MeasuresPhysial  therapy r speeh therapy helps many patients. Cgnitive impairment and psyhiatri symptms may be helped by a hlinesterase inhibitr, suh as rivastigmine (312 mg rally daily r 4.6 r 9.5 mg/24 hurs transder- mally daily). The quality f life an ften be imprved by the prvisin f simple aids t daily living, eg, rails r ban- isters plaed strategially abut the hme, speial table utlery with large handles, nnslip rubber table mats, and devies t amplify the vie.C.  Stimulation and Ablative TreatmentsHigh-frequeny  stimulatin f the subthalami nulei r glbus pallidus internus may benefit many f the mtr features f the disease but des nt affet its natural histry. Eletrial stimulatin f the brain has the advantage ver ablative thalamtmy and pallidtmy predures f being reversible and f ausing minimal r n damage t the brain, and is therefre the preferred surgial apprah t treatment. It is reserved fr patients withut gnitive impairment r psyhiatri disrder wh have a gd respnse t levdpa, but in whm dyskinesias r respnse flutuatins are prblemati. It frequently takes 36 mnths after surgery t adjust stimulatr prgramming and t ahieve ptimal results. Side effets inlude depressin, apathy, impulsivity, exeutive dysfuntin, and dereased verbal flueny in a subset f patients. Fused ultrasund thalamtmy r steretati radisurgery may help patients with medially refratry tremr-predminant parkinsnism wh are relutant t underg surgery.D . Gene TherapyIn jetins f aden-assiated viruses ending varius human genes have been made int the subthalami nuleus r putamen in varius linial trials. These apprahes may be useful in the future but remain experimental. When to ReferAll patients sh uld be referred. When to AdmitPa tients requiring surgial treatment shuld be admitted.Mith ell KT et al. Surgial treatment f Parkinsn disease. Neu- rl Clin. 2020;38:293. [PMID: 32279711]CMDT22_Ch24_p0978-p1053.indd  1017 29/06/21 8:50 PMChapTER 241018 CMDT 2022Rugha ni A et al. Cngress f Neurlgial Surgens systemati review and evidene-based guideline n subthalami nuleus and glbus pallidus internus deep brain stimulatin fr the treatment f patients with Parkinsns disease: exeutive sum- mary. Neursurgery. 2018;82:753. [PMID: 29538685]3.  huntington DiseseE S S E N T I A L S  O F  D I A G N O S I S Gradual onset and progression of chorea and dementia or behavioral change. Family history of the disorder. Responsible gene identified on chromosome 4. General ConsiderationsHunt ingtn disease is haraterized by chorea and dementia. It is inherited in an autsmal dminant manner and urs thrughut the wrld, in all ethni grups, with a prevalene rate f abut 5 per 100,000. There is an expanded and unstable CAG trinuletide repeat in the huntingtin gene at 4p16.3; lnger repeat lengths rre- spnd t an earlier age f nset and faster disease prgressin. Clinical FindingsA.  Symptoms and SignsClinial  nset is usually between 30 and 50 years f age. The disease is prgressive and usually leads t a fatal ut- me within 1520 years. The initial symptms may n- sist f either abnrmal mvements r intelletual hanges, but ultimately bth ur. The earliest mental hanges are ften behaviral, with irritability, mdiness, antisial behavir, r a psyhiatri disturbane, but a mre bvius dementia subsequently develps. The dyskinesia may ini- tially be n mre than an apparent fidgetiness r restless- ness, but eventually hreifrm mvements and sme dystni psturing ur. A parkinsnian syndrme with prgressive rigidity and akinesia (rather than hrea) smetimes urs in assiatin with dementia, espeially in ases with hildhd nset. The diagnsis is established with a widely available geneti test, althugh suh testing shuld be pursued under the guidane f a liensed geneti unselr.B.  ImagingCT  sanning r MRI usually demnstrates erebral atrphy and atrphy f the audate nuleus in established ases. Psitrn emissin tmgraphy (PET) has shwn redued striatal metabli rate. Differential DiagnosisChre a develping with n family histry f hreathetsis shuld nt be attributed t Huntingtn disease, at least nt until ther auses f hrea have been exluded liniallyand by apprpriate labratry studies. Nngeneti auses f hrea inlude strke, systemi lupus erythematsus and antiphsphlipid antibdy syndrme, paraneplasti syn- drmes, infetin with HIV , and varius mediatins. In yunger patients, self-limiting Sydenham hrea develps after grup A streptal infetins n rare asins. If a patient presents slely with prgressive intelletual fail- ure, it may nt be pssible t distinguish Huntingtn dis- ease frm ther auses f dementia unless there is a harateristi family histry r a dyskinesia develps. Huntington diseaselike (HDL) disorders resemble Huntingtn disease but are aused by ther geneti muta- tins. A linially similar autsmal dminant disrder (dentatorubral-pallidoluysian atrophy), manifested by hrea, dementia, ataxia, and mylni epilepsy, is unmmn exept in persns f Japanese anestry. Treat- ment is as fr Huntingtn disease. TreatmentThere  is n ure fr Huntingtn disease; prgressin an- nt be halted; and treatment is purely symptmati, althugh studies f antisense lignuletides inhibiting prdutin f mutant huntingtin prtein are nging. The reprted bihemial hanges suggest a relative undera- tivity f neurns ntaining GABA and aetylhline r a relative verativity f dpaminergi neurns. Tetrabena- zine, a mediatin that interferes with the vesiular strage f bigeni amines, is widely used t treat the dyskinesia. The starting dse is 12.5 mg twie r three times daily rally, inreasing by 12.5 mg every 5 days depending n respnse and tlerane; the usual maintenane dse is 25 mg three times daily. Side effets inlude depressin, pstural hyptensin, drwsiness, and parkinsnian fea- tures; tetrabenazine shuld nt be given within 14 days f taking mnamine xidase inhibitrs and is nt indiated fr the treatment f levdpa-indued dyskinesias. Reser- pine is similar in depleting entral mnamines but has mre peripheral effets and a wrse side-effet prfile, making its use prblemati in Huntingtn disease; if utilized, the dse is built up gradually t between 2 mg and 5 mg rally daily, depending n the respnse. Deutetrabenazine is als effetive in reduing hrea in Huntingtn disease and may have fewer side effets than tetrabenazine but diret mparisns are laking. The starting dse is 6 mg ne daily rally, inreased t 6 mg twie daily after 1 week and by 6-mg inrements weekly thereafter, t a maximum f 24 mg twie daily. Treatment with mediatins blking dpamine reeptrs, suh as phenthiazines r halperidl, may ntrl the dyskinesia and any behaviral distur- banes. Halperidl treatment is usually begun with a dse f 1 mg ne r twie daily rally, whih is then inreased every 3 r 4 days depending n the respnse; alternatively, atypial antipsyhti agents suh as quetiapine (inreasing frm 25 mg daily rally up t 100 mg twie daily rally as tlerated) may be tried. Amantadine in a dse f 200 mg t 400 mg daily rally is smetimes helpful fr hrea. Deep brain stimulatin has been used suessfully t treat hrea in a small number f patients. Behaviral disturbanes may respnd t lzapine. Attempts t mpensate fr the rela- tive GABA defiieny by enhaning entral GABA ativityCMDT22_Ch24_p0978-p1053.indd  1018 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1019 CMDT 2022r t mpensat e fr the relative hlinergi underativity by giving hline hlride have nt been therapeutially helpful. Offspring shuld be ffered geneti unseling. Geneti testing permits presymptmati detetin and definitive diagnsis f the disease. When to ReferAll patients sh uld be referred.T abrizi SJ et al; Phase 12a IONIS-HTTRx Study Site Teams. Targeting huntingtin expressin in patients with Huntingtns disease. N Engl J Med. 2019;380:2307. [PMID: 31059641]4.  Idiotic Torsion DystoniE S S E N T I A L S  O F  D I A G N O S I S Dystonic movements and postures. Normal birth and developmental history. No other neurologic signs. Investigations (including CT scan or MRI) reveal no cause of dystonia. General ConsiderationsIdi pathi trsin dystnia may ur spradially r n a hereditary basis, with autsmal dminant, autsmal reessive, and X-linked reessive mdes f transmissin. Symptms may begin in hildhd r later and persist thrughut life. Clinical FindingsThe  disrder is haraterized by the nset f abnrmal mvements and pstures in a patient with a nrmal birth and develpmental histry, n relevant past medial ill- ness, and n ther neurlgi signs. Investigatins (inlud- ing CT san) reveal n ause fr the abnrmal mvements. Dystni mvements f the head and nek may take the frm f trtillis, blepharspasm, faial grimaing, r fred pening r lsing f the muth. The limbs may als adpt abnrmal but harateristi pstures. The age at nset influenes bth the linial findings and the prgn- sis. With nset in hildhd, there is usually a family his- try f the disrder, symptms mmnly mmene in the legs, and prgressin is likely until there is severe dis- ability frm generalized dystnia. In ntrast, when nset is later, a psitive family histry is unlikely, initial symp- tms are ften in the arms r axial strutures, and severe disability des nt usually ur, althugh generalized dystnia may ultimately develp in sme patients. If all ases are nsidered tgether, abut ne-third f patients eventually beme s severely disabled that they are n- fined t hair r bed, while anther ne-third are affeted nly mildly.Differential DiagnosisPe rinatal anxia, birth trauma, and kerniterus are m- mn auses f dystnia, but abnrmal mvements usually then develp befre the age f 5, the early develpment f the patient is usually abnrmal, and a histry f seizures is nt unusual. Mrever, examinatin may reveal signs f mental retardatin r pyramidal defiit in additin t the mvement disrder. Dystni psturing may als ur in Wilsn disease, Huntingtn disease, r parkinsnism; as a sequela f enephalitis lethargia r previus neurlepti mediatin therapy; and in ertain ther disrders. In these ases, diagnsis is based n the histry and ampa- nying linial manifestatins. TreatmentIdi pathi trsin dystnia usually respnds prly t mediatins. A distint variety f dminantly inherited dys- tnia is remarkably respnsive t levdpa; therefre, a levdpa trial is warranted in all patients. Failing this, diaze- pam, balfen, arbamazepine, amantadine, r antihliner- gi mediatin suh as trihexyphenidyl r benztrpine (in high dsage) is asinally helpful; if nt, a trial f treatment with tetrabenazine, phenthiazines, r halperidl may be wrthwhile. In eah ase, the dse has t be individualized, depending n respnse and tlerane. Hwever, the dses f these latter mediatins that are required fr benefit lead usually t mild parkinsnism. Pallidal deep brain stimulatin is helpful fr disabling generalized dystnia and has a lwer mrbidity than steretati thalamtmy, whih is sme- times helpful in patients with predminantly unilateral limb dystnia. Ptential adverse events f deep brain stimulatin inlude erebral infetin r hemrrhage, brken leads, affetive hanges, and dysarthria. When to ReferAll patients sh uld be referred. When to AdmitPa tients requiring surgial treatment shuld be admitted.R drigues FB et al. Deep brain stimulatin fr dystnia. Chrane Database Syst Rev. 2019;1:CD012405. [PMID: 30629283]5.  Focl Torsion DystoniA  number f the dystni manifestatins that ur in idipathi trsin dystnia may als ur as islated phe- nmena. They are best regarded as fal dystnias that either ur as frmes frustes f idipathi trsin dyst- nia in patients with a psitive family histry r represent a fal manifestatin f the adult-nset frm f that disrder when there is n family histry. Medial treatment is gen- erally unsatisfatry. A trial f the mediatins used in idipathi trsin dystnia is wrthwhile, hwever, sine a few patients d shw sme respnse. In additin, with restrited dystnias suh as blepharspasm r trtillis, lal injetin f btulinum A txin int the verativeCMDT22_Ch24_p0978-p1053.indd  1019 29/06/21 8:50 PMChapTER 241020 CMDT 2022musles  may prdue wrthwhile benefit fr several weeks r mnths and an be repeated as needed. Bth blepharospasm and oromandibular dystonia may ur as an islated fal dystnia. The frmer is har- aterized by spntaneus invluntary fred lsure f the eyelids fr a variable interval. Ormandibular dystnia is manifested by invluntary ntratin f the musles abut the muth ausing, fr example, invluntary pen- ing r lsing f the muth, rving r prtruding tngue mvements, and retratin f the platysma. Cervical dys- tonia (spasmdi trtillis), usually with nset between 25 and 50 years f age, is haraterized by a tendeny fr the nek t twist t ne side. This initially urs episdi- ally, but eventually the nek is held t the side. Sme patients have a sensry trik (geste antagniste) that lessens the dystni psture, eg, tuhing the side f the fae. Spntaneus reslutin may ur in the first year r s. The disrder is therwise usually lifelng. Lal inje- tin f btulinum A txin prvides benefit in mst ases. Deep brain stimulatin f the glbus pallidus interna is an ptin if medial treatment and btulinum txin injetin are unsuessful. Writers cramp is haraterized by dystni psturing f the hand and frearm when the hand is used fr writing and smetimes when it is used fr ther tasks, eg, playing the pian r using a srewdriver r eating utensils. Media- tin treatment is usually unrewarding, and patients are ften best advised t learn t use the ther hand fr ativi- ties requiring manual dexterity. Injetins f btulinum A txin are helpful in sme instanes.Rdrigues FB  et al. Btulinum txin type A therapy fr ervial dystnia. Chrane Database Syst Rev. 2020;11:CD003633. [PMID: 33180963]6.  MyoclonusOasi nal mylni jerks may ur in anyne, espeially when drifting int sleep. General or multifocal myoclonus is mmn in patients with idipathi epilepsy and is espe- ially prminent in ertain hereditary disrders harater- ized by seizures and prgressive intelletual deline, suh as the lipid strage diseases. It is als a feature f subaute slersing panenephalitis and Creutzfeldt-Jakb disease. Generalized mylni jerking may ampany uremi and ther metabli enephalpathies, result frm therapy with levdpa r triyli antidepressants, ur in alhl r drug withdrawal states, r fllw anxi brain damage. It als urs n a hereditary r spradi basis as an islated phenmenn in therwise healthy subjets. Segmental myoclonus is a rare manifestatin f a fal spinal rd lesin. It may als be the linial expressin f epilepsia partialis continua , a disrder in whih a repeti- tive fal epilepti disharge arises in the ntralateral sensrimtr rtex, smetimes frm an underlying stru- tural lesin. An eletrenephalgram is ften helpful in larifying the epilepti nature f the disrder, and CT r MRI san may reveal the ausal lesin. Mylnus may respnd t ertain antinvulsant mediatins, espeially valpri aid r levetiraetam, r tne f the benzdiazepines, partiularly lnazepam (see Table 242). It may als respnd t piraetam (up t 16.8 g daily; nt available in the United States). Mylnus fl- lwing anxi brain damage is ften respnsive t xitrip- tan (5-hydrxytryptphan), the preursr f sertnin, and smetimes t lnazepam. Oxitriptan is given in gradually inreasing dses up t 11.5 mg daily. In patients with segmental mylnus, a lalized lesin shuld be searhed fr and treated apprpriately.7.  Wilson DiseseIn th is metabli disrder, abnrmal mvement and ps- ture may ur with r withut existing signs f liver invlvement. Psyhiatri and neurpsyhlgial mani- festatins are mmn. Wilsn disease is disussed in Chapter 16.8.  Drug-Induced abnorml MovementsPhent hiazines, butyrphennes, and metlpramide may prdue a wide variety f abnrmal mvements, inluding parkinsnism, akathisia (ie, mtr restlessness), aute dystnia, hrea, and tardive dyskinesias r dystnia; several f these are als prdued by aripiprazle. These mpliatins are disussed in Chapter 25. Chrea may als develp in patients reeiving levdpa, brmriptine, antihlinergi mediatins, phenytin, arbamazepine, lithium, amphetamines, r ral ntraeptives, and it reslves with withdrawal f the ffending substane. Simi- larly, dystnia may be prdued by levdpa, brmrip- tine, lithium, r arbamazepine; and parkinsnism by reserpine and tetrabenazine. Pstural tremr may ur with a variety f mediatins, inluding epinephrine, is- prterenl, amidarne, thephylline, affeine, lithium, thyrid hrmne, triyli antidepressants, and valpri aid.9.  Restless Legs SyndromeThis  mmn disrder, affeting 15% f peple, may ur as a primary (idipathi) disrder r in relatin t Parkinsn disease, pregnany, irn defiieny anemia, r peripheral neurpathy (espeially uremi r diabeti). It may have a hereditary basis, and several geneti li have been assiated with the disrder. Restlessness and urius sensry disturbanes lead t an irresistible urge t mve the limbs, espeially during perids f relaxatin; mve- ment f the limbs prvides relief. The urge urs exlu- sively in the evening and at night r is wrse at night than during the day. Mst patients als have periodic limb movements of sleep and ne-third have peridi limb mvements during relaxed wakefulness; bth nsist f brief invluntary flexin at the ankle, knee, and hip. Dis- turbed nturnal sleep and exessive daytime smnlene may result. Ferritin levels shuld always be measured; treatment with ral irn sulfate in patients with ferritin levels less than r equal t 75 mg/L (13.4 mml/L) shuld be attempted prir t initiatin f ther pharma- therapies. Therapy is with nnergt dpamine agnists, suh as pramipexle (0.1250.5 mg rally ne daily),CMDT22_Ch24_p0978-p1053.indd  1020 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1021 CMDT 2022rp inirle (0.254 mg rally ne daily 2 t 3 hurs befre bedtime), r rtigtine (13 mg/24 h transdermal path ne daily), r with gabapentin enaarbil (3001200 mg rally eah evening). Gabapentin (starting with 300 mg rally daily, inreasing t apprximately 1800 mg daily depending n respnse and tlerane) and pregabalin (150300 mg rally divided twie t three times daily) are related mediatins that imprve symptms. Levdpa is helpful but may lead t an augmentatin f symptms, s its use is generally reserved fr thse wh d nt respnd t ther measures. Extended-release xydne-nalxne (2.55 mg t 510 mg rally twie daily) is useful in patients with severe symptms r thse wh are refratry t first-line therapies.Win kelmann J et al. Treatment f restless legs syndrme: evidene-based review and impliatins fr linial pratie. Mv Disrd. 2018;33:1077. [PMID: 29756335]10.  Gilles De L Tourette SyndromeE S S E N T I A L S  O F  D I A G N O S I S Multiple motor and phonic tics. Symptoms begin before age 18 years. Tics occur frequently for at least 1 year. Tics vary in number, frequency, and nature over time. Clinical FindingsSimple  tis ur transiently in up t 25% f hildren, remit within weeks t mnths, and d nt require treat- ment. Turette syndrme is a mre mplex disrder. Motor tics are the initial manifestatin in 80% f ases and mst mmnly invlve the fae, whereas in the remaining 20%, the initial symptms are phonic tics; ulti- mately a mbinatin f different mtr and phni tis develp in all patients. Tis are preeded by an urge that is relieved upn perfrmane f the mvement r valiza- tin; they an be temprarily suppressed but eventually the urge bemes verwhelming. These are nted first in hildhd, generally between the ages f 2 and 15. Mtr tis ur espeially abut the fae, head, and shulders (eg, sniffing, blinking, frwning, shulder shrugging, head thrusting, et). Phni tis mmnly nsist f grunts, barks, hisses, thrat-learing, ughs, et, but smetimes als f verbal utteranes inluding prlalia (bsene speeh). There may als be ehlalia (repetitin f the speeh f thers), ehpraxia (imitatin f thers mve- ments), and palilalia (repetitin f wrds r phrases). Sme tis may be self-mutilating in nature, suh as nail- biting, hair-pulling, r biting f the lips r tngue. The disrder is hrni, but the urse may be puntuated by relapses and remissins. Obsessive-mpulsive disrder (OCD) and attentin defiit hyperativity disrder (ADHD) are mmnly assiated and may be mre dis-abling than the tis themselves. A family histry is sme- times btained. Examinatin usually reveals n abnrmalities ther than the tis. In additin t OCD, psyhiatri disturbanes may ur beause f the assiated smeti and sial embarrassment. The diagnsis f the disrder is ften delayed fr years, the tis being interpreted as psyhiatri illness r sme ther frm f abnrmal mvement. Patients are thus ften subjeted t unneessary treatment befre the disrder is regnized. The ti-like harater f the abnrmal mvements and the absene f ther neurlgi signs shuld differentiate this disrder frm ther mve- ment disrders presenting in hildhd. Wilsn disease, hwever, an simulate the nditin and shuld be exluded. TreatmentT reatment is symptmati and may need t be ntinued indefinitely. Habit reversal training r ther frms f behaviral therapy an be effetive alne r in mbinatin with pharmatherapy. Alpha-adrenergi agnists, suh as lnidine (start 0.05 mg rally at bedtime, titrating t 0.30.4 mg rally daily, divided three t fur times per day) r guanfaine (start 0.5 mg rally at bedtime, titrating t a maximum f 34 mg rally daily, divided twie daily), are first-line therapies beause f a favrable side-effet prfile mpared with typial antipsyhtis, whih are the nly FDA-apprved therapies fr the disrder. They als have the advantage f imprving the symptms f nmitant ADHD. Many speialists favr the use f tetrabenazine. The atypial antipsyhti risperidne (16 mg daily rally) is mre effetive than plaeb in ntrlling tis and mre effetive than pimzide in imprving symptms f mrbid OCD and may be tried befre the typial anti- psyhti agents. When a typial antipsyhti is required in ases f severe tis, halperidl is generally regarded as the mediatin f hie. It is started in a lw dse (0.25 mg daily rally) that is gradually inreased (by 0.25 mg every 4 r 5 days) until there is maximum benefit with a minimum f side effets r until side effets limit further inrements. A ttal daily ral dse f between 2 mg and 8 mg is usually ptimal, but higher dses are sme- times neessary. Fluphenazine (115 mg rally daily) and pimzide (110 mg rally daily) are alternatives. Typial antipsyhtis an ause signifiant weight gain and arry a risk f tardive dyskinesias and ther lng-term, ptentially irreversible mtr side effets. Small ran- dmized trials r bservatinal studies have reprted benefit frm tpiramate, nitine, tetrahydrannabinl, balfen, and lnazepam. A number f ther media- tins, inluding deutetrabenazine, valbenazine, and e- pipam, are being studied fr the treatment f tis. Injetin f btulinum txin type A at the site f the mst distressing tis is smetimes wrthwhile and has fewer side effets than systemi antipsyhti therapy. Bilateral high-frequeny deep brain stimulatin at varius sites has been helpful in sme, therwise intratable, ases. When to ReferAll patients sh uld be referred.CMDT22_Ch24_p0978-p1053.indd  1021 29/06/21 8:50 PMChapTER 241022 CMDT 2022 When to AdmitPatients  underging surgial (deep brain stimulatin) treatment shuld be admitted.M artinez-Ramirez D et al. Effiay and safety f deep brain stimu- latin in Turette syndrme: the Internatinal Turette Syn- drme Deep Brain Stimulatin Publi Database and Registry. JAMA Neurl. 2018;75:353. [PMID: 29340590] Pringsheim T et al. Pratie guideline remmendatins summary: treatment f tis in peple with Turette syndrme and hrni ti disrders. Neurlgy. 2019;92:896. [PMID: 31061208]DE MENTIAE S S E N T I A L S  O F  D I A G N O S I S Progressive intellectual decline. Not due to delirium or psychiatric disease. Age is the main risk factor, followed by family his- tory and vascular disease risk factors.General ConsiderationsDementia  is a prgressive deline in intelletual funtin that is severe enugh t mprmise sial r upatinal funtining. Mild cognitive impairment desribes a deline that has notresulted in a hange in the level f funtin. Althugh a few patients identify a preipitating event, mst experiene an insidius nset and gradual prgressin f symptms. Dementia typially begins after age 60, and the preva- lene dubles apprximately every 5 years thereafter; in persns aged 85 and lder, arund half have dementia. The prevalene f Alzheimer dementia is predited t be 15 millin by 2060 in the United States. In mst ases, the ause f dementia is aquired, either as a spradi primary neurdegenerative disease r as the result f anther disr- der, suh as strke (Table 246). Other risk fatrs fr dementia inlude family histry, diabetes mellitus, iga- rette smking, hypertensin, besity, a histry f signifi- ant head injury, and hearing lss. Vitamin D defiieny and hrni sleep deprivatin may als inrease the risk f dementia. Dementia is mre prevalent amng wmen, but this may be aunted fr by their lnger life expetany. Table 246. Common causes of age-related dementia (listed by prevalence).Disorder ptology Clinicl Fetures Alzheimer disease Plaques containing beta-amyloid pep- tide, and neurofibrillary tangles con- taining tau protein, occur throughout the neocortex. Most common age-related neurodegenerative disease; incidence doubles every 5 years after age 60.  Short-term memory impairment is early and prominent in most cases.  Variable deficits of executive function, visuospatial function, and language. Vascular dementia Multifocal ischemic change.  Stepwise or progressive accumulation of cognitive deficits in association with repeated strokes.  Symptoms depend on localization of strokes. Dementia with Lewy bodiesHistologically indistinguishable from Parkinson disease: alpha-synuclein- containing Lewy bodies occur in the brainstem, midbrain, olfactory bulb, and neocortex. Alzheimer pathology may coexist. Cognitive dysfunction, with prominent visuospatial and executive deficits.  Psychiatric disturbance, with anxiety, visual hallucinations, and fluctuating delirium.  Parkinsonian motor deficits with or after other features.  Cholinesterase inhibitors lessen delirium; poor tolerance of neuroleptics and dopaminergics. Frontotemporal dementia (FTD)Neuropathology is variable and defined by the protein found in intraneuronal aggregates. Tau protein, TAR DNA- binding protein 43 (TDP-43), or fused-in-sarcoma (FUS) protein account for most cases. Peak incidence in the sixth decade; approximately equal to Alzheimer disease as a cause of dementia in patients under 60 years old.  Familial cases result from mutations in genes for tau, progranulin, or others. Beviorl vrint FTD  Deficits in empathy, social comportment, insight, abstract thought, and executive function.  Behavior is disinhibited, impulsive, and ritualistic, with prominent apathy and increased interest in sex or sweet/fatty foods.  Relative preservation of memory.  Focal right frontal atrophy.  Association with amyotrophic lateral sclerosis. Semntic vrint rimry rogressive si  Deficits in word-finding, single-word comprehension, object and category knowledge, and face recognition.  Behaviors may be similar to behavioral variant FTD.  Focal, asymmetric temporal pole atrophy. Nonfluent/grmmtic vrint rimry rogressive si  Speech is effortful with dysarthria, phonemic errors, sound distortions, and poor grammar.  Focal extrapyramidal signs and apraxia of the right arm and leg are common; overlaps with corticobasal degeneration.  Focal left frontal atrophy.CMDT22_Ch24_p0978-p1053.indd  1022 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1023 CMDT 2022Ph ysial ativity seems t be prtetive; eduatin, nging intelletual stimulatin, and sial engagement may als be prtetive, perhaps by prmting cognitive reserve, an imprved apaity t mpensate fr insidius neurdegeneratin. Dementia is distint frm delirium and psyhiatri dis- ease. Delirium is an aute nfusinal state that ften urs in respnse t an identifiable trigger, suh as drug r alhl intxiatin r withdrawal (eg, Wernike enepha- lpathy, desribed belw), mediatin side effets (espe- ially mediatins with antihlinergi prperties, antihistamines, benzdiazepines, sleeping aids, piids, neurleptis, rtisterids, and ther sedative r psyh- trpi agents), infetin (nsider ult urinary trat infetin r pneumnia in elderly patients), metabli dis- turbane (inluding an eletrlyte abnrmality; hypglye- mia r hyperglyemia; r a nutritinal, endrine, renal, r hepati disrder), sleep deprivatin, r ther neurlgi disease (seizure, inluding a pstital state, r strke). Delirium typially invlves fluctuating levels f arusal, inluding drwsiness r agitatin, and it imprves after remval r treatment f the preipitating fatr. Patients with dementia are espeially suseptible t episdes f delirium, but regnitin f dementia is nt pssible until delirium lifts. Fr this reasn, dementia is typially diag- nsed in utpatients wh are therwise medially stable, rather than in autely ill patients in the hspital. Psyhiatri disease smetimes leads t mplaints f impaired gnitin ( pseudodementia ). Impaired attentin is usually t blame, and in sme patients with depressin r anxiety, pr fus and nentratin may even be a pri- mary mplaint. The symptms shuld imprve with appr- priate psyhiatri treatment. Md disrders are mmnly seen in patients with neurdegenerative disease and in sme ases are an early symptm. There is sme evidene that a persistent, untreated md disrder may predispse t the develpment f an age-related dementia, and psyhiatri symptms an learly exaerbate gnitive impairment in patients wh already have dementia; therefre, suspiin f dementia shuld nt distrat frm apprpriate sreening fr and treatment f depressin r anxiety. Clinical FindingsA.  Symptoms and SignsSym ptms and signs f the mmn auses f dementia are detailed in Table 246. Cliniians shuld be aware that a patients insight int a gnitive hange may be vague r absent, and llateral histry is essential t a prper evalua- tin. As patients age, primary are liniians shuld inquire peridially abut the presene f any gnitive symptms. Symptms depend n the area f the brain affeted. Short-term memory loss , invlving the repeating f ques- tins r stries and a diminished ability t reall the details f reent nversatins r events, frequently results frm pathlgi hanges in the hippampus. Word-finding dif- ficulty ften invlves diffiulty realling the names f pe- ple, plaes, r bjets, with lw-frequeny wrds affeted first, eventually resulting in speeh laden with prnuns and irumlutins. This prblem is thught t arise frmpathlgy at the temprparietal juntin f the left hemi- sphere. Prblems with artiulatin, flueny, mprehensin, r wrd meaning are anatmially distint and less m- mn. Visuospatial dysfunction may result in pr naviga- tin and getting lst in familiar plaes, impaired regnitin f previusly familiar faes and buildings, r truble dis- erning an bjet against a bakgrund. The right parietal lbe is ne f the brain areas impliated in suh symptms. Executive dysfunction may manifest by easy distratibility, impulsivity, mental inflexibility, nrete thught, slwed pressing speed, pr planning and rganizatin, r impaired judgment. Lalizatin may vary and uld inlude the frntal lbes r subrtial areas like the basal ganglia r erebral white matter. Apathy r indifferene, separate frm depressin, is mmn and may have a simi- lar anatmy as exeutive dysfuntin. Apraxia , r the lss f learned mtr behavirs, may result frm dysfuntin f the frntal r parietal lbes, espeially the left parietal lbe. The time f symptm nset must be established, but subtle, early symptms are ften apparent nly in retr- spet. Anther event, suh as an illness r hspitalizatin, may lead t new regnitin f existing symptms. Symp- tms ften aumulate ver time, and the nature of the earliest symptom is most helpful in forming the differential diagnosis. The histry shuld establish risk fatrs fr dementia, inluding family histry, ther hrni illnesses, and vasular disease risk fatrs. Finally, it is imprtant t dument the patients urrent apaity t perfrm basic and instrumental activities of daily living (see Chapter 4) and t nte the extent f deline frm the premrbid level f funtin. Indeed, it is this funtinal assessment that defines the presene and severity f dementia. The physial examinatin is imprtant t identify any ult medial illness. In additin, eye mvement abnr- malities, parkinsnism, r ther mtr abnrmalities may help identify an underlying neurlgi nditin. The wrkup shuld priritize the exlusin f nditins that are reversible r require separate therapy. Sreening fr depressin is neessary, alng with imaging and labratry wrkup, as indiated belw.B.  Neuropsychological AssessmentBrief q uantifiatin f gnitive impairment is indiated in a patient mplaining f gnitive symptms r if aregiv- ers raise similar nerns. The Folstein Mini Mental State Exam (MMSE), Montreal Cognitive Assessment (MoCA), Mini-Cg, and ther similar tests are brief, bjetive, and widely used but have imprtant limitatins: they are insen- sitive t mild gnitive impairment, they may be biased negatively by the presene f language r attentin prb- lems, and they d nt rrelate with funtinal apaity. A neurpsyhiatri evaluatin by a trained neurpsy- hlgist r psyhmetriian may be apprpriate. The gal f suh testing is t enhane lalizatin by defining the gnitive dmains that are impaired as well as t quantify the degree f impairment. There is n standard battery f tests, but a variety f metris is mmnly used t assess the symptm types highlighted abve. Assessments are mst aurate when a patient is well rested, mfrtable, and therwise medially stable.CMDT22_Ch24_p0978-p1053.indd  1023 29/06/21 8:50 PMChapTER 241024 CMDT 2022C.  ImagingBra in imaging with MRI r CT withut ntrast is indiated in any patient with a new, prgressive gnitive mplaint. The gal is t exlude ult erebrvasular disease, tumr, r ther identifiable strutural abnrmality, rather than t prvide psitive evidene f a neurdegenerative disease. Glbal r fal brain atrphy may be wrse than expeted fr age and uld suggest a partiular neurde- generative press, but suh findings are rarely speifi. PET with flurdexygluse (FDG) des nt nfirm r exlude any speifi ause f dementia but may be useful as an element f the wrkup in speifi linial irum- stanes, suh as disriminating between Alzheimer disease and frnttempral dementia in a patient with sme symp- tms f eah. PET imaging with a radilabeled ligand fr beta-amylid, ne f the pathlgi prteins in Alzheimer disease, is highly sensitive t amylid pathlgy and may prvide psitive evidene fr Alzheimer disease in a patient with gnitive deline. Hwever, after age 60 r 70, amylid plaques an aumulate in the absene f gnitive impair- ment; thus, the speifiity f a psitive amylid san dimin- ishes with age. Single-phtn emissin mputed tmgraphy ffers similar infrmatin as FDG-PET but is less sensitive. PET imaging with radilabeled ligands fr tau, a pathgeni prtein in Alzheimer disease, prgressive supranulear palsy, and sme frms f frnttempral dementia, als may help refine premrtem diagnsti auray.D . Laboratory FindingsSerum  levels f vitamin B12, free T4, and thyrid-stimulat- ing hrmne shuld be measured fr any patient with gnitive symptms. A serum rapid plasma reagin (RPR) and testing fr HIV shuld be nsidered. Other testing shuld be driven by linial suspiin, and ften inludes a mplete bld unt, serum eletrlytes, gluse, and lipid prfile. Althugh the presene f ne r tw ApE epsiln-4 alleles indiates an inreased risk f Alzheimer disease and ApE gentyping is linially available, it is f limited clinical utility. Finding an ApE epsiln-4 allele in a yung patient with dementia might raise the index f suspiin fr Alzheimer disease, but btaining a gentype in an elderly patient is unlikely t be helpful, and ding s in an asymptmati patient as a marker f risk fr Alzheimer disease is inapprpriate until a preventive therapy bemes available. Spinal fluid prtein measurements are als avail- able and may supprt the diagnsis f Alzheimer disease in the apprpriate linial ntext; levels f beta-amylid derease and tau prtein inrease in Alzheimer disease, but this testing shares sme f the same nerns as amylid PET imaging. Differential DiagnosisIn  elderly patients with gradually prgressive gnitive symptms and n ther mplaint r sign, a neurde- generative disease is likely (Table 246). Deline begin- ning befre age 60, rapid prgressin, flutuating urse, unintended weight lss, systemi mplaints, r therunexplained symptms r signs raise suspiin fr a pr- ess ther than a neurdegenerative disease. In this ase, the differential is brad and inludes infetin r inflam- matry disease (nsider a lumbar punture t sreen fr ells r antibdies in the spinal fluid), neplasm r a para- neplasti nditin, endrine r metabli disease, drugs r txins, r ther nditins. Nrmal pressure hydrephalus is a diffiult diagnsis t establish. Symp- tms inlude gait apraxia (smetimes desribed as a mag- neti gait, as if the feet are stuk t the flr), urinary inntinene, and dementia. CT sanning r MRI f the brain reveals ventriles that are enlarged in bvius dispr- prtin t sulal widening and verall brain atrphy. TreatmentA.  Nonpharmacologic ApproachesAe robic exercise (30 minutes several days per week) may redue the rate f funtinal deline and derease the demented patients aregiving needs and may redue the risk f dementia in nrmal individuals. Maintaining as ative a rle in the family and mmunity as pratially pssible is likely t be f benefit, emphasizing ativities at whih the patient feels nfident. Patients with neurde- generative diseases have a limited apaity t regain lst skills; fr instane, memry drills in a patient with Alzheimer disease are mre likely t lead t frustratin than benefit and studies shw that mputerized gnitive training des not imprve gnitin r funtin in demented patients. Vitamin E (1000 internatinal units twie daily) appears t redue the rate f funtinal deline in patients with Alzheimer disease, but des nt affet gnitin r prevent the develpment f Alzheimer disease in patients with mild gnitive impairment.B.  Cognitive SymptomsCh olinesterase inhibitors are first-line therapy fr Alzheimer disease and dementia with Lewy bdies (Table 246). They prvide mdest, symptmati treat- ment fr gnitive dysfuntin and may prlng the apaity fr independene but d notprevent disease prgressin. Cmmnly used mediatins inlude dnepezil (start at 5 mg rally daily fr 4 weeks, then inrease t 10 mg daily; a 23 mg daily dse is apprved fr mderate t severe Alzheimer disease, althugh its very mdest additinal effiay ver the 10 mg dse is vershad- wed by an inreased risk f side effets); rivastigmine (start at 1.5 mg rally twie daily, then inreasing every 2 weeks by 1.5 mg twie daily t a gal f 36 mg twie daily; r 4.6, 9.5, r 13.3 mg/24 h transdermally daily); and galantamine (start at 4 mg rally twie daily, then inreasing every 4 weeks by 4 mg twie daily t a gal f 812 mg twie daily; a ne-daily extended-release frmulatin is als available). Chlinesterase inhibitrs are notgiven fr frn- ttempral dementia beause they may wrsen behaviral symptms. Nausea and diarrhea are mmn side effets; synpe and ardia dysrhythmia are unmmn but mre serius. An ECG is ften btained befre and after starting therapy, partiularly in a patient with ardia disease r a histry f synpe.CMDT22_Ch24_p0978-p1053.indd  1024 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1025 CMDT 2022Mema ntine (start at 5 mg rally daily, then inrease by 5 mg per week up t a target f 10 mg twie daily) is apprved fr the treatment f mderate t severe Alzheimer disease. In frnttempral dementia, memantine is ineffe- tive and may wrsen gnitin. There is sme evidene that memantine may imprve gnitin and behavir amng patients with dementia with Lewy bdies. Disease-mdifying mediatins are nt yet available fr Alzheimer disease.C.  Mood and Behavioral DisturbancesSeletive  sertnin reuptake inhibitrs are generally safe and well tlerated in elderly, gnitively impaired patients, and they may be effiaius fr the treatment f depres- sin, anxiety, r agitatin. There is evidene t supprt the use f italpram (1030 mg rally daily ) for agitation; side effets inlude QT prlngatin and wrsened gnitin at the highest dse. Parxetine shuld be avided beause it has antihlinergi effets; avid all triyli antidepres- sants fr the same reasn. Other antidepressant agents, suh as buprpin r venlafaxine, may be tried. Insmnia is mmn, and trazdne (2550 mg rally at bedtime as needed) an be safe and effetive. Over-the- unter antihistamine hypntis must be avided, alng with benzdiazepines, beause f their tendeny t wrsen gnitin and preipitate delirium. Other presriptin hypntis suh as zlpidem may result in similar adverse reatins. Fr agitatin, impulsivity, and ther behavirs that interfere with safe aregiving, auses f delirium (detailed abve) shuld first be nsidered. When n reversible trigger is identified, treatment shuld be apprahed in a staged manner. Behaviral interventins, suh as rerien- tatin and distratin frm anxiety-prvking stimuli, are first-line. Ensure that the patient is kept ative during the day with bth physial exerise and mentally stimulating ativities, and that there is adequate sleep at night. Reas- sess the level f aregiving, and nsider inreasing the time spent diretly with an attendant. Next, ensure that apprpriate pharmalgi treatment f gnitin and md is ptimized. Finally, as a last resrt, when ther measures prve insuffiient and the patients behavirs raise safety nerns, nsider pharmalgi therapy. Citalpram r lw dses f an atypial antipsyhti mediatin suh as quetiapine (start 25 mg rally daily as needed, inreasing t tw t three times daily as needed) an be tried; even thugh atypial agents ause extrapyra- midal side effets less frequently than typial antipsyht- is, they shuld be used with partiular autin in a patient at risk fr falls, espeially if parkinsnian signs are already present. Regularly sheduled dsing f antipsy- htis is nt remmended, and if implemented shuld be reassessed n a frequent basis (eg, weekly), with attempts t taper ff as tlerated. There is an FDA blak bx warning against the use f all antipsyhti media- tins in elderly demented patients beause f an increased risk of death; the reasn fr the inreased mrtality is unlear. The mbinatin f dextrmethrphan and quini- dine (up t 30/10 mg rally twie daily) has shwn prmise in early linial trials.Special CircumstancesA.  Rapidly Progressive DementiaWhen  dementia develps quikly, with bvius deline ver a few weeks t a few mnths, the syndrme may be lassified as a rapidly progressive dementia. The differen- tial diagnsis fr typial dementias is still relevant, but additinal etilgies must be nsidered, inluding prin disease; infetins; txins; neplasms; and autimmune and inflammatry diseases, inluding rtisterid- respnsive (Hashimt) enephalpathy and antibdy- mediated paraneplasti and nnparaneplasti enephalitis (Table 245). Wrkup shuld begin with brain MRI with ntrast and diffusin-weighted imaging, ru- tine labratry studies (serum vitamin B12, free T4, and thyrid-stimulating hrmne levels), serum RPR, HIV antibdy, Lyme serlgy, rheumatlgi tests (erythryte sedimentatin rate, C-reative prtein, and antinulear antibdy), anti-thyrglbulin and anti-thyrperxidase antibdy levels, paraneplasti and nnparaneplasti autimmune antibdies (Table 245), and erebrspinal fluid studies (ell unt and differential; prtein and glu- se levels; prtein eletrphresis fr liglnal bands; IgG index [spinal-fluid-t-serum-gamma-glbulin level] rati; and VDRL). Depending n the linial ntext, it may be neessary t exlude Wilsn disease (24-hur urine pper level); heavy metal intxiatin (urine heavy metal panel); and infetius enephalitis due t atypial bateria, viruses, fungi, and mybateria. Creutzfeldt-Jakob disease is a relatively mmn ause f rapidly prgressive dementia (see Chapter 32). Family histry is imprtant sine mutatins in PRNP , the gene fr the prin prtein, aunt fr arund 15% f ases. Diffu- sin-weighted MRI is the mst helpful diagnsti tl, lassially revealing rtial ribbning (a gyral pattern f hyperintensity) as well as restrited diffusin in the audate and anterir putamen. An eletrenephalgram ften shws peridi mplexes. Real time quaking indued nversin (RT-QuIC), in whih patient erebrspinal fluid is mixed with rembinant prin prtein and aggre- gatin f prin prtein is deteted, is a sensitive and spe- ifi diagnsti test. Refleting the high rate f neurnal death, erebrspinal fluid levels f the intraneurnal pr- teins tau, 14-3-3, and neurn-speifi enlase are ften elevated, althugh this finding is neither sensitive nr speifi.B.  Driving and DementiaI t is remmended that anypatient with mild dementia or worse should discontinue driving. Mst states have laws regulating driving amng gnitively impaired individuals, and many require the liniian t reprt the patients diag- nsis t the publi health department r department f mtr vehiles. There is n evidene that driving lasses help patients with neurdegenerative diseases. When to ReferAll  patients with new, unexplained gnitive deline shuld be referred.CMDT22_Ch24_p0978-p1053.indd  1025 29/06/21 8:50 PMChapTER 241026 CMDT 2022 When to AdmitAdmi ssin t the hspital shuld nly ur when essen- tial in patients with dementia due t inreased risk f develping hspital-aquired delirium.Arvanitakis  Z et al. Diagnsis and management f dementia: review. JAMA. 2019;322:1589. [PMID: 31638686] Law CK et al. Physial exerise attenuates gnitive deline and redues behaviral prblems in peple with mild gnitive impairment and dementia: a systemati review. J Physither. 2020;66:9. [PMID: 31843427]WE RNICKE ENCEPHALOPATHY & KORSAKOFF SYNDROMEW ernicke encephalopathy is haraterized by nfusin, ataxia, and nystagmus leading t phthalmplegia (lateral retus musle weakness, njugate gaze palsies); peripheral neurpathy may als be present. It is due to thiamine defi- ciency and in the United States urs mst mmnly in patients with alhlism. It may als ur in patients with AIDS r hyperemesis gravidarum, and after bariatri sur- gery. In suspeted ases, thiamine (100 mg) is given intra- venusly immediately and then intramusularly n a daily basis until a satisfatry diet an be ensured after whih the same dse is given rally. Sme guidelines remmend initial dses f 200500 mg intravenusly three times daily fr the first 57 days f treatment. Intravenus gluse given before thiamine may preipitate the syndrme r wrsen the symptms. The diagnsis is nfirmed by the respnse in 1 r 2 days t treatment, whih must nt be delayed while awaiting labratry nfirmatin f thia- mine defiieny frm a bld sample btained prir t thiamine administratin. Korsakoff syndrome urs in mre severe ases; it inludes antergrade and retrgrade amnesia and smetimes nfabulatin, and may nt be regnized until after the initial delirium has lifted.ST UPOR & COMAE S S E N T I A L S  O F  D I A G N O S I S Level of consciousness is depressed. Stuporous patients respond only to repeated vig- orous stimuli. Comatose patients are unarousable and unresponsive. General ConsiderationsThe pa tient wh is stuporous is unrespnsive exept when subjeted t repeated vigrus stimuli, while the comatose patient is unarusable and unable t respnd t external events r inner needs, althugh reflex mvements and psturing may be present. Cma is a majr mpliatin f serius entral nervus system disrders. It an result frm seizures,hypthermia, metabli disturbanes, r strutural lesins ausing bilateral erebral hemispheri dysfuntin r a disturbane f the brainstem retiular ativating system. A mass lesin invlving ne erebral hemisphere may ause ma by mpressin f the brainstem. Assessment & Emergency MeasuresThe  diagnsti wrkup f the matse patient must pr- eed nmitantly with management. Supprtive therapy fr respiratin r bld pressure is initiated; in hypther- mia, all vital signs may be absent and all suh patients shuld be rewarmed befre the prgnsis is assessed. The patient an be psitined n ne side with the nek partly extended, dentures remved, and seretins leared by sutin; if neessary, the pateny f the airways is main- tained with an rpharyngeal airway. Bld is drawn fr serum gluse, eletrlyte, and alium levels; arterial bld gases; liver bihemial and kidney funtin tests; and txilgi studies as indiated. Thiamine (100 mg), fllwed by dextrse 50% (25 g), and nalxne (0.41.2 mg) are given intravenusly withut delay. Further details are then btained frm attendants f the patients medial histry, the irumstanes surrunding the nset f ma, and the time urse f subsequent events. Abrupt nset f ma suggests subarahnid hemrrhage, brainstem strke, r intraerebral hemrrhage, whereas a slwer nset and prgressin ur with ther strutural r mass lesins. Urgent nnntrast CT sanning f the head is apprpriate if it an be btained diretly frm the emer- geny department, in rder t identify intraranial hemr- rhage, brain herniatin, r ther strutural lesin that may require immediate neursurgial interventin. A metabli ause is likely with a preeding intxiated state r agitated delirium. On examinatin, attentin is paid t the behav- iral respnse t painful stimuli, the pupils and their respnse t light, the respnse t tuhing the rnea with a wisp f sterile gauze, psitin f the eyes and their mve- ment in respnse t passive mvement f the head and ie-water alri stimulatin, and the respiratry pattern.A.  Response to Painful StimuliPurp seful limb withdrawal frm painful stimuli implies that sensry pathways frm and mtr pathways t the stimulated limb are funtinally intat. Unilateral absene f respnses despite appliatin f stimuli t bth sides f the bdy in turn implies a rtispinal lesin; bilateral absene f respnsiveness suggests brainstem invlvement, bilateral pyramidal trat lesins, r psyhgeni unrespnsiveness. Dertiate (flexr) psturing may ur with lesins f the internal apsule and rstral erebral pedunle and deere- brate (extensr) psturing with dysfuntin r destrutin f the midbrain and rstral pns. Deerebrate psturing urs in the arms ampanied by flaidity r slight flexr respnses in the legs in patients with extensive brainstem damage extending dwn t the pns at the trigeminal level.B.  Ocular Findings1.  Pupils Hypthalami disease presses may lead t unilateral Hrner syndrme, while bilateral dienephaliCMDT22_Ch24_p0978-p1053.indd  1026 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1027 CMDT 2022inv lvement r destrutive pntine lesins may lead t small but reative pupils. Ipsilateral pupillary dilatin with n diret r nsensual respnse t light urs with m- pressin f the third ranial nerve, eg, with unal hernia- tin. The pupils are slightly smaller than nrmal but respnsive t light in many metabli enephalpathies; hwever, they may be fixed and dilated fllwing verds- age with atrpine r splamine, and pinpint (but respnsive) with piids. 2. Corneal reflex Tuhing the rnea with a wisp f sterile gauze r ttn shuld eliit a blink reflex. The affer- ent limb f the ar is mediated by the fifth ranial nerve; the efferent limb by the seventh nerve. A unilateral absent rneal reflex implies damage t the ipsilateral pns r a trigeminal defiit. Bilateral lss an be seen with large pn- tine lesins r in deep pharmalgi ma. 3. Eye movements Cnjugate deviatin f the eyes t the side suggests the presene f an ipsilateral hemispheri lesin, a ntralateral pntine lesin, r nging seizures frm the ntralateral hemisphere. A mesenephali lesin leads t dwnward njugate deviatin. Dysnjugate u- lar deviatin in ma implies a strutural brainstem lesin unless there was preexisting strabismus. The ulmtr respnses t passive head turning and t alri stimulatin relate t eah ther and prvide m- plementary infrmatin. In respnse t brisk rtatin f the head frm side t side and t flexin and extensin f the head, nrmally nsius patients with pen eyes d nt exhibit ntraversive njugate eye deviatin ( oculocephalic reflex ) unless there is vluntary visual fixatin r bilateral frntal pathlgy. With rtial depressin in lightly ma- tse patients, a brisk ulephali reflex is seen. With brain- stem lesins, this ulephali reflex bemes impaired r lst, depending n the site f the lesin. Theoculovestibular reflex is tested by alri stimula- tin using irrigatin with ie water. In nrmal patients, jerk nystagmus is eliited fr abut 2 r 3 minutes, with the slw mpnent tward the irrigated ear. In unnsius patients with an intat brainstem, the fast mpnent f the nystagmus disappears, s that the eyes tnially deviate tward the irrigated side fr 23 minutes befre returning t their riginal psitin. With impairment f brainstem funtin, the respnse bemes abnrmal and finally dis- appears. In metabli ma, ulephali and ulves- tibular reflex respnses are preserved, at least initially.C.  Respiratory PatternsDiseases ausing ma may lead t resp iratry abnrmali- ties. Cheyne-Stokes respiration (in whih episdes f deep breathing alternate with perids f apnea) may ur with bihemispheri r dienephali disease r in metabli disrders. Central neurogenic hyperventilation urs with lesins f the brainstem tegmentum; apneustic breathing (in whih there are prminent end-inspiratry pauses) suggests damage at the pntine level (eg, due t basilar artery lusin); and ataxic breathing (a m- pletely irregular pattern f breathing with deep and shallw breaths urring randmly) is assiated with lesins f the lwer pntine tegmentum and medulla.1. Stuor & Com Due to Structurl LesionsSupra tentorial mass lesions tend t affet brain funtin in a systemati way. There may initially be signs f hemi- spheri dysfuntin, suh as hemiparesis. As ma devel- ps and deepens, erebral funtin bemes prgressively disturbed, prduing a preditable prgressin f neur- lgi signs that suggest rstraudal deteriratin. Thus, as a supratentrial mass lesin begins t impair the dienephaln, the patient bemes drwsy, then stu- prus, and finally matse. There may be Cheyne-Stkes respiratin; small but reative pupils r an ipsilateral third nerve palsy due t unal herniatin; nrmal ulephali respnses with side-t-side head mvements but sme- times an impairment f reflex upward gaze with brisk flexin f the head; tni ipsilateral deviatin f the eyes in respnse t vestibular stimulatin with ld water; and initially a psitive respnse t pain but subsequently nly dertiate psturing. With further prgressin, midbrain failure urs. Mtr dysfuntin prgresses frm derti- ate t bilateral deerebrate psturing in respnse t pain- ful stimuli; Cheyne-Stkes respiratin is gradually replaed by sustained entral hyperventilatin; the pupils beme middle-sized and fixed; and the ulephali and ul- vestibular reflex respnses beme impaired, abnrmal, r lst. As the pns and then the medulla fail, the pupils remain unrespnsive; ulvestibular respnses are unb- tainable; respiratin is rapid and shallw; and painful stimuli may lead nly t flexr respnses in the legs. Finally, respiratin bemes irregular and stps, the pupils ften then dilating widely. In ntrast, a subtentorial (ie, brainstem) lesion may lead t an early, smetimes abrupt disturbane f n- siusness withut any rderly rstraudal prgressin f neurlgi signs. Cmpressive lesins f the brainstem, espeially erebellar hemrrhage, may be linially indis- tinguishable frm intraparenhymal presses. A strutural lesin is suspeted if the findings suggest fality. In suh irumstanes, a CT san shuld be per- frmed befre, r instead f, a lumbar punture in rder t avid any risk f erebral herniatin. Further management is f the ausal lesin and is nsidered separately under the individual disrders.2.  Stuor & Com Due to Metbolic DisturbncesPa tients with a metabli ause f ma generally have signs f pathy, diffuse, and symmetri neurlgi invlve- ment that annt be explained by lss f funtin at any single level r in a sequential manner, althugh fal r lateralized defiits may ur in hypglyemia. Pupillary reativity is usually preserved. Cmatse patients with meningitis, enephalitis, r subarahnid hemrrhage may als exhibit little in the way f fal neurlgi signs, hw- ever, and linial evidene f meningeal irritatin is sme- times very subtle in matse patients. Examinatin f the erebrspinal fluid in suh patients is essential t establish the rret diagnsis. In patients with ma due t erebral ishemia and hypxia, the absene f pupillary light reflexes 24 hursCMDT22_Ch24_p0978-p1053.indd  1027 29/06/21 8:50 PMChapTER 241028 CMDT 2022after retu rn f spntaneus irulatin indiates that there is little hane f regaining independene; absent rneal reflexes r absent r extensr mtr respnses at 72 hurs als indiate a grim prgnsis. Physial findings are less reliable preditrs f utme amng thse treated with therapeuti hypthermia, althugh absent rneal r pupillary light reflexes at 72 hurs likely indiate a pr prgnsis, as d bilaterally absent rtial smatsensry evked ptentials in respnse t median nerve stimulatin after the patient has returned t nrmthermia. Treatment f metabli enephalpathy is f the under- lying disturbane and is nsidered in ther hapters. If the ause f the enephalpathy is bsure, all mediatins exept essential nes may have t be withdrawn in ase they are respnsible fr the altered mental status.3.  Brin DetBrain  death urs when there is mplete and irreversible essatin f all brain funtin; althugh the rgans an be maintained with mehanial ventilatin fr the purpses f dnatin, in mst untries the diagnsis f brain death is equivalent to a declaration of death. T diagnse brain death, the ause f ma must be established, be mpati- ble with a knwn ause f brain death, and be irreversible. Reversible ma simulating brain death may be seen with hypthermia (temperature lwer than 32C) and verds- age with entral nervus system depressant drugs. These nditins must be exluded by warming the patient and allwing enugh time fr all sedating mediatins t be metablized (ie, at least five half-lives) r by measuring serum levels. Severe bld pressure, eletrlyte, aid-base, and endrine derangements annt be present. Finally, a neurlgi examinatin must demnstrate that the patient is matse (ie, n eye pening and n respnse t entral r peripheral pain); has lst all brain- stem reflex respnses, inluding the pupillary, rneal, ulvestibular, ulephali, rpharyngeal, and ugh reflexes; and has n respiratry drive. The respnse t pain shuld be absent r nly nsist f spinal reflex mve- ments; deerebrate r dertiate psturing is nt nsis- tent with brain death. Absene f respiratry drive is demnstrated with an apnea test (absene f spntaneus respiratry ativity at a PAco2f at least 60 mm Hg r after a rise f 20 mm Hg frm baseline). Certain anillary tests may assist the determinatin f brain death if an apnea test annt be perfrmed but are nt essential. These inlude an iseletri eletrenepha- lgram, when the rerding is made arding t the re- mmendatins f the Amerian Clinial Neurphysilgy Siety, and demnstratin f an absent erebral irula- tin by intravenus radiistpe erebral angigraphy r by fur-vessel ntrast erebral angigraphy.4.  persistent Vegettive SttePa tients with severe bilateral hemispheri disease may shw sme imprvement frm an initially matse state, s that, after a variable interval, they appear t be awake but lie mtinless and withut evidene f awareness r higher mental ativity. This is alled a persistentvegetative state ne it has lasted ver 4 weeks and has als been variusly referred t as akineti mutism, apalli state, r ma vigil. Patients in a vegetative state frm a medial ause (eg, anxi brain injury) fr mre than 3 mnths and frm a traumati brain injury fr mre than 12 mnths are said t be in a chronic vegetative state, frm whih a few patients may regain nsiusness but remain severely disabled.5.  Minimlly Conscious StteIn this  state, patients exhibit innsistent evidene f n- siusness. There is sme degree f funtinal revery f behavirs suggesting self- r envirnmental-awareness, suh as basi verbalizatin r ntext-apprpriate gestures, emtinal respnses (eg, smiling) t emtinal but nt neutral stimuli, r purpsive respnses t envirnmental stimuli (eg, a finger mvement r eye blink apparently t mmand). Further imprvement is manifest by the rest- ratin f mmuniatin with the patient. The minimally nsius state may be temprary r permanent. Little infrmatin is available abut its natural histry r lng- term utlk, whih reflets the underlying ause. The likelihd f useful funtinal revery diminishes with time; after 12 mnths, patients are likely t remain severely disabled and withut a reliable means f mmuniatin. Prgnstiatin is diffiult. Amantadine (100200 mg rally daily) may hasten revery when given t patients in a vegetative r minimally nsius state 416 weeks after traumati brain injury.6.  Locked-In Syndrome (De-Efferented Stte)Aute  destrutive lesins (eg, infartin, hemrrhage, demyelinatin, enephalitis) invlving the ventral pns and sparing the tegmentum may lead t a mute, quadripa- reti but nsius state in whih the patient is apable f blinking and vluntary eye mvement in the vertial plane, with preserved pupillary respnses t light. Suh a patient an mistakenly be regarded as matse. Cliniians shuld regnize that lked-in individuals are fully aware f their surrundings. The prgnsis is usually pr, but revery has asinally been reprted in sme ases, inluding resumptin f independent daily life. A similar nditin may ur with severe Guillain-Barr syndrme and has a better prgnsis.Giain  JT et al. Pratie guideline update remmendatins summary: disrders f nsiusness: reprt f the Guideline Develpment, Disseminatin, and Implementatin Subm- mittee f the Amerian Aademy f Neurlgy; the Amerian Cngress f Rehabilitatin Mediine; and the Natinal Institute n Disability, Independent Living, and Rehabili- tatin Researh. Neurlgy. 2018;91:450. [PMID: 30089618]HE AD INJURYT rauma is the mst mmn ause f death in yung pe- ple, and head injury aunts fr almst half f these trauma-related deaths. Head injury severity ranges frm concussion tsevere traumatic brain injury (TBI). Cn- ussin is bradly defined as an alteratin in mental statusCMDT22_Ch24_p0978-p1053.indd  1028 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1029 CMDT 2022aused  by trauma with r withut lss f nsiusness. The term nussin is ften used synnymusly with mild TBI. Grades f TBI are traditinally defined by the Glasgw Cma Sale (GCS) measured 30 minutes after injury (Table 247).Head trauma may ause erebral injury thrugh a vari- ety f mehanisms (Table 248). Central t management is determinatin f whih patients need head imaging and bservatin. Of partiular nern is identifiatin f patients with epidural and subdural hematma, wh may present with nrmal neurlgi findings shrtly after injury ( lucid interval ) but rapidly deterirate thereafter, and in whm surgial interventin is life-saving. Clinical FindingsA.  Symptoms and SignsCmmn  symptms f nussin that develp autely inlude headahe, nausea, vmiting, nfusin, disrienta- tin, dizziness, and imbalane. A perid f amnesia enmpassing the traumati event and a variable perid f time leading up t the trauma is typial. Lss f nsius- ness may ur. Additinal symptms f phtphbia, phnphbia, diffiulty nentrating, irritability, and sleep and md disturbanes may develp ver the fllw- ing hurs t days. Examinatin is usually nrmal, althugh rientatin and attentin, shrt-term memry, and rea- tin time may be impaired. Persistent r prgressive deline in the level f nsiusness after the initial injury, r fal neurlgi findings, suggests the need fr urgent imaging and neursurgial nsultatin. Patients shuld als be examined fr signs f salp la- eratins, faial and skull frature, and nek injury. The linial signs f basilar skull frature inlude bruising Table 248. Acute cerebral sequelae of head injury (listed in alphabetical order).Sequele Clinicl Fetures ptology Acute epidural hemorrhageHeadache, confusion, somnolence, seizures, and focal defi- cits occur several hours after injury (lucid interval) and lead to coma, respiratory depression, and death unless treated by surgical evacuation.Tear in meningeal artery, vein, or dural sinus, leading to hematoma visible on CT scan. Acute subdural hemorrhageSimilar to epidural hemorrhage, but interval before onset of symptoms is longer. Neurosurgical consultation for consideration of evacuation.Hematoma from tear in veins from cortex to superior sagittal sinus or from cerebral laceration, visible on CT scan. Cerebral contusion or lacerationLoss of consciousness longer than with concussion. Focal neurologic deficits are often present. May lead to death or severe residual neurologic deficit.Bruising on side of impact (coup injury) or contralaterally (contrecoup injury). Vasogenic edema, multiple petechial hemorrhages, and mass effect. May have subarachnoid bleeding. Hernia- tion may occur in severe cases. Cerebral laceration specifically involves tearing of the cerebral tissue and pia-arachnoid overlying a contusion. Cerebral hemorrhageGenerally develops immediately after injury. Clinically resembles hypertensive hemorrhage. Surgery to relieve mass effect is sometimes necessary.Hematoma, visible on CT scan. Concussion A transient, trauma-induced alteration in mental status that may or may not involve loss of consciousness. Symptoms and signs include headache, nausea, disori- entation, irritability, amnesia, clumsiness, visual distur- bances, and focal neurologic deficit.Unknown; likely mild diffuse axonal injury and excito- toxic neuronal injury. Cerebral contusion may occur. Diffuse axonal injury Persistent loss of consciousness, coma, or persistent vege- tative state resulting from severe rotational shearing forces or deceleration.Imaging may be normal or may show tiny, scattered white matter hemorrhages. Histology reveals torn axons.Table 247. Glasgow Coma Scale.1point sEye OeningVerbl ResonseMotor Resonse 1 None None None 2 To pain Vocal but not verbalExtension 3 To voice Verbal but not conversationalFlexion 4 Spontaneous Conversational but disorientedWithdraws from pain 5 Spontaneous Oriented Localizes pain 6 Spontaneous Oriented Obeys commands1 GCS score indicating severity of traumatic brain injury (TBI): mild, 1315; moderate , 912; severe ,  8. Reproduced, with permission, from Aminoff MJ et al. Clinical Neurology , 9th ed, McGraw-Hill Education, 2015; Data from Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet . 1974;304:814.CMDT22_Ch24_p0978-p1053.indd  1029 29/06/21 8:50 PMChapTER 241030 CMDT 2022abut the  rbit ( raccoon sign ), bld in the external audi- try meatus ( Battle sign ), and leakage f erebrspinal fluid (whih an be identified by its gluse r beta- 2-transferrin ntent) frm the ear r nse. Cranial nerve palsies (invlving espeially the first, send, third, furth, fifth, seventh, and eighth nerves in any mbinatin) may als ur. The head and nek shuld be immbilized until imaging an be perfrmed.B.  Imaging and Other InvestigationsCurren t remmendatins are that head CT be perfrmed in patients with nussin and any f the fllwing: GCS sre less than 15, fal neurlgi defiit, seizure, agu- lpathy, aged 65 r lder, skull frature, persistent headahe r vmiting, retrgrade amnesia exeeding 30 minutes, intxiatin, r sft tissue injury f the head r nek. Otherwise, patients an be sent hme as lng as a respnsible aregiver an hek the patient at hurly inter- vals fr the next 24 hurs. Patients requiring imaging shuld be admitted unless the head CT is nrmal, the GCS sre is 15, there have been n seizures, there is n predis- psitin t bleeding, and they an be mnitred by a are- giver at hme. Beause injury t the spine may have ampanied head trauma, ervial spine radigraphs (three views) r CT shuld always be btained in matse patients and in patients with severe nek pain r a defiit pssibly related t rd mpressin. TreatmentHead  injury an ften be prevented by helmets, seatbelts, and ther prtetive equipment. After intraranial bleeding has been exluded linially r by head CT, treatment f mild TBI is aimed at prmt- ing reslutin f pstnussive symptms and preventing recurrent injury, whih inreases the risk f hrni neu- rbehaviral impairment and delays revery. Rarely, a reurrent nussin while a patient is still symptmati frm a first nussin may lead t fatal erebral edema (second impact syndrome ). These bservatins frm the basis f the remmendatin that patients at risk fr reur- rent nussin (eg, athletes) be held ut f the risky ativ- ity until their nussive symptms have fully reslved. In patients hspitalized with mderate r severe TBI, management ften requires a multidisiplinary apprah due t multiple nmitant injuries. Elevated intraranial pressure an result frm diffuse axnal injury r a hema- tma requiring surgial evauatin, r frm a variety f medial auses. Dempressive ranietmy may redue therwise refratry intraranial hypertensin but des nt imprve neurlgi utme. Hypthermia is assi- ated with wrsened funtinal utmes. Beause bridging veins between the brain and venus sinuses beme mre vulnerable t shear injury as the brain atrphies, a subdural hematoma may develp days r weeks fllwing head injury in elderly patients r even ur spntaneusly. Clinial presentatin an be subtle, ften with mental hanges suh as slwness, drwsiness, headahe, nfusin, r memry disturbane. Falneurlgi defiits suh as hemiparesis r hemisensry disturbane are less mmn. Surgial interventin is indi- ated if the hematma is 10 mm r mre in thikness r there is a midline shift f 5 mm r mre; if there is a deline in GCS sre f 2 r mre frm injury t hspital admis- sin; r if ne r bth pupils are fixed and dilated. Salp laeratins and depressed skull fratures shuld be treated surgially as apprpriate. Simple skull fratures require n speifi treatment. If there is any leakage f erebrspinal fluid, nservative treatment, with elevatin f the head, restritin f fluids, and administratin f aetazlamide (250 mg rally fur times daily), is ften helpful; if the leak ntinues fr mre than a few days, lumbar subarahnid drainage may be neessary. Antibit- is are given if infetin urs, based n ulture and sen- sitivity studies; vainatin against pneumus is remmended (see Table 307). Only very asinal patients require intraranial repair f the dural defet beause f persistene f the leak r reurrent meningitis. PrognosisMdera te and severe TBI may result in permanent gni- tive and mtr impairment depending n the severity and latin f the initial injury. Initial GCS and head CT find- ings have prgnsti value. Amng patients with a GCS sre f 8 r less at presentatin, mrtality apprahes 30% and nly ne-third f survivrs regain funtinal indepen- dene. Cgnitive impairment tends t affet frntal and tempral lbe funtin, ausing defiits in attentin, mem- ry, judgment, and exeutive funtin. Behaviral dysregu- latin, depressin, and disinhibitin an impair sial funtining. Ansmia, presumably due t shearing f fibers frm the nasal epithelium, is mmn. Epilepsy an develp after TBI, espeially with mre severe injury. Amng patients with severe TBI (typially lss f nsiusness fr at least 1224 hurs, intraranial hematma, depressed skull frature, r erebral ntu- sin), phenytin r levetiraetam is typially given fr 7 days t redue the inidene f early psttraumati sei- zures; this is dne exlusively t minimize aute mplia- tins resulting frm suh seizures and des nt prevent the develpment f psttraumati epilepsy. Amng patients with mild TBI, symptms f nus- sin reslve in mst patients by 1 mnth and in the vast majrity by 3 mnths. Prlnged pstnussive symp- tms are unmmn, persisting at 1 year in 1015% f patients. Risk fatrs fr prlnged pstnussive symp- tms inlude ative litigatin regarding the injury; repeated nussins; and GCS sre f 13 r less at presentatin. Headahes ften have migrainus features and may respnd t triyli antidepressants r beta-blkers (see Table 241). Opiids shuld be avided t minimize the risk f mediatin veruse headahe. Md symptms may respnd t antidepressants, anxilytis, and gnitive behaviral therapy. There appears t be an assiatin between head trauma and the later develpment f neurdegenerative disease, suh as Alzheimer disease, Parkinsn disease, r amytrphi lateral slersis (ALS). Nrmal pressure hydrephalus may als ur. Repetitive, mild headCMDT22_Ch24_p0978-p1053.indd  1030 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1031 CMDT 2022inju ry, suh as that whih urs in athletes r military persnnel, an lead t chronic traumatic encephalopathy, a distint pathlgi entity assiated with md and gnitive hanges and haraterized by the abnrmal aggregatin f tau r ther prteins either fally r glbally in the erebral rtex. Whether hrni trau- mati enephalpathy is a stati respnse t reurrent head injury r a prgressive neurdegenerative disease is nt knwn, but the severity f neurpathlgy appears t rrelate t lifetime expsure t repetitive head injury. When to Refer Patients with fal neurlgi defiits, altered n- siusness, r skull frature. Patients with late mpliatins f head injury, eg, psttraumati seizure disrder r nrmal pressure hydrephalus. When to Admit Patients with nussin and GCS sre less than 15, predispsitin t bleeding, seizure, r n respnsible aregiver at hme. Patients with abnrmal head CT.Ma riani M et al. Clinial presentatin f hrni traumati enephalpathy. Semin Neurl. 2020;40:370. [PMID: 32740900] Mish MR et al. Sprts mediine update: nussin. Emerg Med Clin Nrth Am. 2020;38:207. [PMID: 31757251]MU LTIPLE SCLEROSISE S S E N T I A L S  O F  D I A G N O S I S Episodic neurologic symptoms. Patient usually < 55 years of age at onset. Single pathologic lesion cannot explain clinical findings. Multiple foci best visualized by MRI. General ConsiderationsThis  mmn neurlgi disrder, whih prbably has an autimmune basis, has its greatest inidene in yung adults. Epidemilgi studies indiate that multiple slersis is muh mre mmn in persns f western Eurpean lineage wh live in temperate znes. N ppulatin with a high risk fr multiple slersis exists between latitudes 40 N and 40 S. A geneti susepti- bility t the disease is present. Pathlgially, fal ften perivenularareas f demyelinatin with reative glisis are fund sattered in the white matter f the brain and spinal rd and in the pti nerves. Axnal damage als urs.Clinical FindingsA.  Symptoms and SignsThe  mmn initial presentatin is weakness, numbness, tingling, r unsteadiness in a limb; spasti paraparesis; retrbulbar pti neuritis; diplpia; dysequilibrium; r a sphinter disturbane suh as urinary urgeny r hesi- tany. Symptms may disappear after a few days r weeks, althugh examinatin ften reveals a residual defiit. Several frms f the disease are regnized. In mst patients, there is an interval f mnths r years after the initial episde befre new symptms develp r the riginal nes reur (relapsing-remitting disease) . Eventually, hw- ever, relapses and usually inmplete remissins lead t inreasing disability, with weakness, spastiity, and ataxia f the limbs, impaired visin, and urinary inntinene. The findings n examinatin at this stage mmnly inlude pti atrphy; nystagmus; dysarthria; and pyramidal, sen- sry, r erebellar defiits in sme r all f the limbs. In sme f these patients, the linial urse hanges s that a steady deteriratin urs, unrelated t aute relapses (secondary progressive disease) . Less mmnly, symp- tms are steadily prgressive frm their nset, and disability develps at a relatively early stage (primary progressive disease) . The diagnsis annt be made with nfidene unless the ttal linial piture indiates invlvement f different parts of the central nervous system at different times. Fatigue is mmn in all frms f the disease. A number f fatrs (eg, infetin) may preipitate r trigger exaerbatins. Relapses are redued in pregnany but are mre likely during the 2 r 3 mnths fllwing pregnany, pssibly beause f the inreased demands and stresses that ur in the pstpartum perid.B.  ImagingMRI  f the brain and ervial rd has a majr rle in exluding ther auses f neurlgi dysfuntin and in demnstrating the presene f multiple lesins. In T1-weighted images, hypintense blak hles prbably represent areas f permanent axnal damage. Gadlinium- enhaned T1-weighted images may highlight areas f ative inflammatin with breakdwn f the bld-brain barrier, whih helps identify newer lesins. T2-weighted images prvide infrmatin abut disease burden r ttal number f lesins, whih typially appear as areas f high signal intensity. CT sans are less helpful than MRI. In patients with myelpathy alne and n linial r labratry evidene f mre widespread disease, MRI r myelgraphy is neessary t exlude a ngenital r aquired surgially treatable lesin. In patients with mixed pyramidal and erebellar defiits in the limbs, the framen magnum regin must be visualized t exlude the pssibil- ity f Arnld-Chiari malfrmatin, in whih parts f the erebellum and lwer brainstem are displaed int the ervial anal.C.  Laboratory and Other StudiesA  definitive diagnsis an never be based slely n the labratry findings. If there is linial evidene f nly aCMDT22_Ch24_p0978-p1053.indd  1031 29/06/21 8:50 PMChapTER 241032 CMDT 2022single  lesin in the entral nervus system, multiple sler- sis annt prperly be diagnsed unless it an be shwn that ther regins are affeted sublinially. Visual, brain- stem auditry, and smatsensry evked ptentials are helpful in this regard, but ther disrders may als be haraterized by multifal eletrphysilgi abnrmali- ties refleting disease f entral white matter. Certain infetins (eg, HIV , Lyme disease, syphilis), nnetive tissue diseases (eg, systemi lupus erythematsus, Sjgren syndrme), saridsis, metabli disrders (eg, vitamin B12 defiieny), and lymphma may therefre require exlusin. There may be mild lymphytsis r a slightly inreased prtein nentratin in the erebrspinal fluid, espeially sn after an aute relapse. Elevated IgG in erebrspinal fluid and disrete bands f IgG (liglnal bands) are present in many patients. The presene f suh bands is nt speifi, hwever, sine they have been fund in a variety f inflammatry neurlgi disrders and asinally in patients with vasular r neplasti disrders f the ner- vus system. Vitamin D defiieny may be assiated with an inreased risk f develping multiple slersis; randmized trials have nt shwn vitamin D supplementatin redues attak rate r prgressin in relapsing remitting disease.D . DiagnosisMultiple slersi s shuld nt be diagnsed unless there is evidene that tw r mre different regins f the entral white matter ( dissemination in space ) have been affeted at different times ( dissemination in time ); the mst widely used diagnsti algrithm is the 2017 revisin t the MDnald riteria. The diagnsis may be made in a patient with tw r mre typial attaks and bjetive evidene n linial examinatin f tw lesins (eg, pti disk atrphy and pyramidal weakness), r bjetive evi- dene f ne lesin with lear-ut histrial evidene the ther attak was typial f multiple slersis and in a dis- tint neuranatmi latin, and when n alternative explanatin fr the patients presentatin has been fund. T fulfill the riterin f disseminatin in spae in a patient with tw linial attaks but bjetive linial evi- dene f nly ne lesin, MRI shuld demnstrate at least ne lesin in at least tw f fur typial sites (periventriu- lar, rtial r juxtartial, infratentrial, r spinal); alternatively, an additinal attak lalized t a different site suffies. The riterin f disseminatin in time in a patient with nly ne attak an be fulfilled by the simul- taneus presene f gadlinium-enhaning and nnen- haning lesins at any time (inluding at initial examinatin); the presene f liglnal bands unique t the erebrspinal fluid; a new lesin n fllw-up MRI; r a send attak. Lesins in the pti nerve n MRI in patients with pti neuritis annt be used t fulfill the MDnald riteria fr disseminatin in spae r time. Pri- mary prgressive disease requires at least a year f prgres- sin, plus tw f three f the fllwing: at least ne typial brain lesin, at least tw spinal lesins, r liglnal banding in the erebrspinal fluid.In patients with a single linial event wh d nt sat- isfy riteria fr multiple slersis, a diagnsis f a clinically isolated syndrome (CIS) is made. Suh patients are at risk fr develping multiple slersis and are smetimes ffered beta-interfern r glatiramer aetate therapy, whih may delay prgressin t linially definite disease. Fllw-up MRI shuld be nsidered 612 mnths later t assess fr the presene f any new lesin. TreatmentA t least partial revery frm aute exaerbatins an rea- snably be expeted, but further relapses may ur with- ut warning. Sme disability is likely t result eventually, but abut half f all patients are withut signifiant dis- ability even 10 years after nset f symptms. Current treatments are hiefly aimed at preventing relapses, thereby reduing disability. Recovery from acute relapses may be hastened by treat- ment with corticosteroids, but the extent of recovery is unchanged. Intravenus therapy is ften given first typially methylprednislne 1 g daily fr 3 daysfllwed by ral prednisne at 6080 mg daily fr 1 week with a taper ver the ensuing 23 weeks, but randmized trials shw similar effiay whether the initial high dse is given rally r intravenusly. Lng-term treatment with rti- sterids prvides n benefit and des nt prevent further relapses. Transient exaerbatin f symptms relating t interurrent infetin r heat requires n added treatment. In patients with relapsing disease, numerus media- tins have well-established effiay at reducing the frequency of attacks (Table 249). The initial agent is h- sen after nsidering mediatin tlerane and risks, patient preferene, and disease severity. Glatiramer aetate, an interfern, r dimethyl fumarate is ften used initially due t favrable side effet prfiles and availability, althugh the effiay f early treatment with higher inten- sity therapy is being explred. In general, the mediatins mst effetive in reduing relapses have strnger immun- mdulatry effets and mre, albeit rare, serius adverse effets. Presriptin f these agents shuld be managed by a speialist. Orelizumab is the nly mediatin effetive in slwing disability prgressin in primary prgressive multiple sle- rsis and is apprved fr this indiatin by the FDA. Fr patients with ative sendary prgressive disease, ladrib- ine, relizumab, fatumumab, zanimd, and sipnimd an be used. Plasmapheresis is smetimes helpful in patients with severe relapses unrespnsive t rtisterids. Symptmati therapy fr spastiity, neurgeni bladder, r fatigue may be required. Fatigue is espeially mmn in multiple slersis, and mdafinil (200 mg rally every mrning) is an effetive and FDA-apprved therapy fr this indiatin. Dalfampridine (an extended-release fr- mulatin f 4-aminpyridine administered as 10 mg rally twie daily) is effiaius at imprving timed gait in mul- tiple slersis. Depressin and even suiidality an ur in multiple slersis and may wrsen with interfern beta-1a therapy; sreening and nventinal treatment f suh symptms are apprpriate.CMDT22_Ch24_p0978-p1053.indd  1032 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1033 CMDT 2022 When to ReferAll  patients, but espeially thse with prgressive disease despite standard therapy, shuld be referred. When to Admit Patients requiring plasma exhange fr severe relapses unrespnsive t rtisterids. During severe relapses. Patients unable t manage at hme.Fr eedman MS et al. Treatment ptimizatin in multiple slersis: Canadian MS wrking grup remmendatins. Can J Neurl Si. 2020;47:437. [PMID: 32654681] Rae-Grant A et al. Pratie guideline remmendatins summary: disease-mdifying therapies fr adults with multiple slersis: reprt f the Guideline Develpment, Disseminatin, and Implementatin Submmittee f the Amerian Aademy f Neurlgy. Neurlgy. 2018;90:777. [PMID: 29686116]NEUROMYELITIS OPTICAThis  disrder is haraterized by pti neuritis and aute myelitis with MRI hanges that extend ver at least three segments f the spinal rd. An islated myelitis r pti neuritis may als ur. Previusly knwn as Devi disease and ne regarded as a variant f multiple slersis, neur- myelitis ptia is assiated with a speifi antibdy marker (NMO-IgG) targeting the water hannel aquaprin-4 in 80% f ases, and with antibdies t myelin ligdendr- yte glyprtein (MOG-IgG) in apprximately 33% f NMO-IgG sernegative patients. MRI f the brain typially des nt shw widespread white matter invlvement, but suh hanges d nt exlude the diagnsis. Treatment is by lng-term immunsuppressin. Three mediatins are apprved by the FDA fr treatment f neurmyelitis ptia based n plaeb-ntrlled trials demnstrating a redued annual relapse rate r time t first relapse. Eulizumab is a mplement inhibitr, inebilizumab is a humanizedTable 249. Treatment of multiple sclerosis (in alphabetical order within categories).1Mediction Dose acute Eisode, Including Relse2Dexamethasone 160 mg orally daily for 35 days Methylprednisolone 1 g intravenously or orally daily for 35 days Plasmapheresis Disese-Modifying Tery (FDa roved) Alemtuzumab (Lemtrada)3,412 mg intravenously daily for 5 days; 3-day course given 1 year later Cladribine (Mavenclad)3,5,61.75 mg/kg orally divided between weeks 1 and 5, repeated once in 1 year Dimethyl fumarate (Tecfidera)3,5240 mg orally twice daily Fingolimod (Gilenya)3,4,50.5 mg orally daily Glatiramer acetate (Copaxone, Mylan, Glatopa)520 mg subcutaneously daily or 40 mg subcutaneously three times weekly Interferon -1a (Rebif)544 mcg subcutaneously three times per week Interferon -1a (Avonex)530 mcg intramuscularly once per week Interferon -1b (Betaseron, Extavia)50.25 mg subcutaneously on alternate days Mitoxantrone312 mg/m2intravenously every 3 months; maximum lifetime dose, 140 mg/m2Natalizumab  (Tysabri)3,4300 mg intravenously monthly Ocrelizumab (Ocrevus)3,4,5,6,7300 mg intravenously on day 1 and day 15, followed by 600 mg every 6 months Ofatumumab (Kesimpta)3,4,5,620 mg subcutaneously weeks 0, 1, 2, 4, and monthly thereafter Ozanimod (Zeposia)3,4,5,60.23 mg orally daily on days 14, 0.46 mg daily on days 57, and 0.92 mg daily thereafter Pegylated interferon -1a (Plegridy)5125 mg subcutaneously once every 2 weeks Siponimod (Mayzent)3,4,5,60.25 mg orally daily, titrated over 5 or 6 days to 1 or 2 mg orally daily, depending on CYP2C9 genotype Teriflunomide (Aubagio)514 mg or 7 mg orally daily1 Several of these agents require special monitoring or pretreatment; some should be avoided during pregnancy. Readers should ref er to the manufacturers guidelines.2 For corticosteroid-refractory relapses, plasmapheresis may be used.3 Relapse prevention for disease activity despite use of first-line treatment.4 High disease activity (typically with multiple gadolinium-enhancing lesions on MRI).5 Relapse prevention, first-line treatment.6 Active secondary progressive disease.7 Primary progressive disease.CMDT22_Ch24_p0978-p1053.indd  1033 29/06/21 8:50 PMChapTER 241034 CMDT 2022an ti-CD19 antibdy that depletes B ells, and satralizumab is an interleukin-6 reeptr antagnist. Use f eulizumab requires prir immunizatin against meningus. Off- label therapy is with rituximab (tw 1-g intravenus infusins spaed by 2 weeks, r fur weekly infusins f 375 mg/m2; re-dsing may ur every 6 mnths r when CD19/20-psitive r CD27-psitive lymphytes beme detetable), myphenlate mfetil (5001500 mg rally twie daily, titrated until the abslute lymphyte unt falls belw 1500/mL [1.5  109/L]), r azathiprine (2.53 mg/kg rally). Aute relapses are treated with rti- sterids at dses similar t thse utlined fr multiple slersis and with plasma exhange fr severe relapses unrespnsive t rtisterids.Cree  BAC et al; N-MOmentum Study Investigatrs. Inebili- zumab fr the treatment f neurmyelitis ptia spetrum disrder (N-MOmentum): a duble-blind, randmized plaeb-ntrlled phase 2/3 trial. Lanet. 2019;394:1352. [PMID: 31495497] Pittk SJ et al. Eulizumab in aquaprin-4-psitive neurmyeli- tis ptia spetrum disrder. N Engl J Med. 2019;381:614. [PMID: 31050279]VI TAMIN E DEFICIENCYV itamin E defiieny may prdue a disrder smewhat similar t Friedreih ataxia. There is spinerebellar degen- eratin invlving partiularly the psterir lumns f the spinal rd and leading t limb ataxia, sensry lss, absent tendn reflexes, slurring f speeh, and, in sme ases, pigmentary retinal degeneratin. The disrder may ur as a nsequene f malabsrptin r n a hereditary basis (eg, abetalipprteinemia).SP ASTICITYThe  term spastiity is mmnly used fr an upper mtr neurn defiit, but it prperly refers t a velity- dependent inrease in resistane t passive mvement that affets different musles t a different extent, is nt uni- frm in degree thrughut the range f a partiular mve- ment, and is mmnly assiated with ther features f pyramidal defiit. It is ften a majr mpliatin f strke, erebral r spinal injury, stati perinatal enephalpathy, and multiple slersis. Spastiity may be exaerbated by pressure injuries, urinary r ther infetins, and niep- tive stimuli. Physial therapy with apprpriate strething prgrams is imprtant during rehabilitatin after the develpment f an upper mtr neurn lesin and in subsequent manage- ment f the patient. The aim is t prevent jint and musle contractures and perhaps t mdulate spastiity. Mediatin management is imprtant als, but treat- ment may inrease funtinal disability when inreased extensr tne is prviding additinal supprt fr patients with weak legs. Pharmalgi treatment with balfen (510 mg twie daily rally titrated t 80 mg daily), tizani- dine (28 mg three time daily rally), diazepam (210 mg three times daily rally), r dantrlene (25 mg ne daily rally, titrated every 3 days as tlerated t a maximum f100 mg fur times daily) is ften helpful. Dantrlene is best avided in patients with pr respiratry funtin r severe myardial disease. Cannabinids are als effetive in reduing spastiity, but are assiated with side effets, inluding dizziness, drwsiness, and fatigue. Intramusular injetin f btulinum txin is used t relax targeted musles. In patients with severe spastiity that is unrespnsive t ther therapies and is assiated with marked disability, intratheal injetin f phenl r alhl may be helpful. Surgial ptins inlude implantatin f an intratheal balfen pump, rhiztmy, r neuretmy. Severe ntra- tures may be treated by surgial tendn release.MYE LOPATHIES IN AIDSA  variety f myelpathies may ur in patients with AIDS. These are disussed in Chapter 31.MYE LOPATHY OF HUMAN T-CELL LEUKEMIA VIRUS INFECTIONH uman T-ell leukemia virus (HTLV-1), a human retrvi- rus, is transmitted by breastfeeding, sexual ntat, bld transfusin, and ntaminated needles. Mst patients are asymptmati, but after a variable latent perid (whih may be as lng as several years), a myelpathy develps in sme instanes. The MRI, eletrphysilgi, and erebr- spinal fluid findings are similar t thse f multiple sler- sis, but HTLV-1 antibdies are present in serum and spinal fluid. There is n speifi treatment, but intravenus r ral rtisterids may help in the initial inflammatry phase f the disease. Prphylati measures are imprtant. Needles r syringes shuld nt be shared; infeted patients shuld nt breastfeed their infants r dnate bld, semen, r ther tissue. Infeted patients shuld use ndms t prevent sexual transmissin.SU BACUTE COMBINED DEGENERATION OF THE SPINAL CORDSubaute  mbined degeneratin f the spinal rd is due tvitamin B12deficiency , suh as urs in perniius anemia. It is haraterized by myelpathy with spastiity, weakness, prprieptive lss, and numbness due t degeneratin f the rtispinal trats and psterir l- umns. Plyneurpathy, mental hanges, r pti neurpa- thy als develp in sme patients. Megalblasti anemia may als ur, but this des notparallel the neurlgi disrder, and the frmer may be bsured if fli aid supplements have been taken. Treatment is with vitamin B12. Fr perniius anemia, a nvenient therapeuti regi- men is 1000 mg yanbalamin intramusularly daily fr 1 week, then weekly fr 1 mnth, and then mnthly fr the remainder f the patients life. Oral yanbalamin replaement is nt advised fr perniius anemia when neurlgi symptms are present. A similar syndrme is aused by rereatinal abuse f inhaled nitrus xide due t its interferene with vitamin B12metablism. Cpper defiieny, aused by malabsrptin r exess zin inges- tin, may als be respnsible.CMDT22_Ch24_p0978-p1053.indd  1034 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1035 CMDT 2022SP INAL TRAUMAE S S E N T I A L S  O F  D I A G N O S I S History of preceding trauma. Development of acute neurologic deficit. Signs of myelopathy on examination. General ConsiderationsWhile  spinal rd damage may result frm whiplash injury, severe injury usually relates t frature-dislatin ausing mpressin r angular defrmity f the rd either ervi- ally r in the lwer thrai and upper lumbar regins. Extreme hyptensin fllwing injury may als lead t rd infartin. Clinical FindingsT tal rd transetin results in immediate flaid paraly- sis and lss f sensatin belw the level f the lesin. Reflex ativity is lst fr a variable perid, and there is urinary and feal retentin. As reflex funtin returns ver the fl- lwing days and weeks, spasti paraplegia r quadriplegia develps, with hyperreflexia and extensr plantar respnses, but a flaid atrphi (lwer mtr neurn) paralysis may be fund depending n the segments f the rd that are affeted. The bladder and bwels als regain sme reflex funtin, permitting urine and fees t be expelled at intervals. As spastiity inreases, flexr r extensr spasms (r bth) f the legs beme trublesme, espeially if the patient develps bed sres r a urinary trat infetin. Paraplegia with the legs in flexin r exten- sin may eventually result. With lesser degrees f injury, patients may be left with mild limb weakness, distal sensry disturbane, r bth. Sphinter funtin may als be impaired, urinary urgeny and urge inntinene being espeially mmn. Mre partiularly, a unilateral rd lesin leads t an ipsilateral mtr disturbane with ampanying impairment f pr- prieptin and ntralateral lss f pain and temperature appreiatin belw the lesin ( Brown-Squard syndrome ). A entral rd syndrme may lead t a lwer mtr neurn defiit at the level f the lesin and lss f pain and tem- perature appreiatin belw it, with sparing f psterir lumn funtins. With mre extensive invlvement, ps- terir lumn sensatin may als be impaired and pyrami- dal weakness develps. A radiular defiit may ur at the level f the injuryr, if the auda equina is invlved, there may be evidene f disturbed funtin in several lumbsa- ral rts. TreatmentT reatment f the injury nsists f immbilizatin andif there is rd mpressinearly dempressive lamine- tmy and fusin (within 24 hurs). Early treatment with high dses f rtisterids (eg, methylprednislne,30 mg/kg by intravenus blus, fllwed by 5.4 mg/kg/h fr 23 hurs) may imprve neurlgi revery if m- mened within 8 hurs after injury, althugh the evidene is limited and sme neursurgial guidelines d nt re- mmend their use. Anatmi realignment f the spinal rd by tratin and ther rthpedi predures is imprtant. Subsequent are f the residual neurlgi defiitparaplegia r quadriplegiarequires treatment f spastiity and are f the skin, bladder, and bwels. When to ReferAll  patients with fal neurlgi defiits shuld be referred. When to Admit Patients with neurlgi defiits. Patients with spinal rd injury, mpressin, r aute epidural r subdural hematma. Patients with vertebral frature-dislatin likely t mpress the rd.Ong B  et al. Management f the patient with hrni spinal rd injury. Med Clin Nrth Am. 2020;104:263. [PMID: 32035568]SYR INGOMYELIADestruti n r degeneratin f gray and white matter adja- ent t the entral anal f the ervial spinal rd leads t avitatin and aumulatin f fluid within the spinal rd. The preise pathgenesis is unlear, but many ases are assiated with Arnold-Chiari malformation , in whih there is displaement f the erebellar tnsils, medulla, and furth ventrile int the spinal anal, smetimes with ampanying meningmyelele. In suh irumstanes, the rd avity nnets with and may merely represent a dilated entral anal. In ther ases, the ause f avitatin is less lear. There is a harateristi linial piture, with segmental atrphy, areflexia, and lss f pain and tempera- ture appreiatin in a ape distributin, wing t the destrutin f fibers rssing in frnt f the entral anal in the mid-ervial spinal rd. Thrai kyphslisis is usually present. With prgressin, invlvement f the lng mtr and sensry trats urs as well, s that a pyrami- dal and sensry defiit develps in the legs. Upward exten- sin f the avitatin (syringbulbia) leads t dysfuntin f the lwer brainstem and thus t bulbar palsy, nystagmus, and sensry impairment ver ne r bth sides f the fae. Syringmyelia, ie, rd avitatin, may als ur in assiatin with an intramedullary tumr r fllwing severe rd injury, and the avity then des nt mmuni- ate with the entral anal. In patients with Arnld-Chiari malfrmatin, CT sans reveal a small psterir fssa and enlargement f the fra- men magnum, alng with ther assiated skeletal abnr- malities at the base f the skull and upper ervial spine. MRI reveals the syrinx as well as the harateristi findings f the Arnld-Chiari malfrmatin, inluding the audal displaement f the furth ventrile and herniatin f theCMDT22_Ch24_p0978-p1053.indd  1035 29/06/21 8:50 PMChapTER 241036 CMDT 2022erebellar  tnsils thrugh the framen magnum. Fal rd enlargement is fund at myelgraphy r by MRI in patients with avitatin related t past injury r intramed- ullary neplasms. Treatment f Arnld-Chiari malfrmatin with assi- ated syringmyelia is by subipital ranietmy and upper ervial laminetmy, with the aim f dempress- ing the malfrmatin at the framen magnum. The rd avity shuld be drained and, if neessary, an utlet fr the furth ventrile an be made. In avitatin assiated with intramedullary tumr, treatment is surgial, but radiatin therapy may be neessary if mplete remval is nt ps- sible. Psttraumati syringmyelia is als treated surgi- ally if it leads t inreasing neurlgi defiits r t intlerable pain.DE GENERATIVE MOTOR NEURON DISEASESE S S E N T I A L S  O F  D I A G N O S I S Weakness. No sensory loss or sphincter disturbance. Progressive course. No identifiable underlying cause other than genetic basis in familial cases. General ConsiderationsThis gr up f degenerative disrders is haraterized lini- ally by weakness and variable wasting f affeted musles, withut ampanying sensry hanges. Mtr neurn disease in adults generally mmenes between 30 and 60 years f age. There is degeneratin f the anterir hrn ells in the spinal rd, the mtr nulei f the lwer ranial nerves, and the rtispinal and r- tibulbar pathways. The disrder is usually spradi, but familial ases may ur and several geneti mutatins r li have been identified. Cigarette smking may be ne risk fatr. ClassificationFive varieties ha ve been distinguished n linial grunds.A.  Progressive Bulbar PalsyBulbar  invlvement predminates wing t disease pr- esses affeting primarily the mtr nulei f the ranial nerves.B.  Pseudobulbar PalsyBulbar  invlvement predminates in this variety als, but it is due t bilateral rtibulbar disease and thus reflets upper mtr neurn dysfuntin. There may be a pseud- bulbar affet,  with unntrllable episdes f laughing r rying t stimuli that wuld nt nrmally have eliited suh marked reatins.C. Progressive Spinal Muscular AtrophyThis  is haraterized primarily by a lwer mtr neurn defiit in the limbs due t degeneratin f the anterir hrn ells in the spinal rd.D . Primary Lateral SclerosisThere is a p urely upper mtr neurn defiit in the limbs.E.  Amyotrophic Lateral Sclerosis ALSA mixed u pper and lwer mtr neurn defiit is fund in the limbs. This disrder is smetimes assiated with g- nitive deline (in a pattern nsistent with frnttempral dementia), a pseudbulbar affet, r parkinsnism. Apprximately 10% f ALS ases are familial and have been assiated with mutatins at several different geneti li, inluding a hexanuletide repeat n hrmsme 9 that als assiates with frnttempral dementia. Differential DiagnosisTh e spinal musular atrphies (SMAs) are inherited syndrmes aused mst ften by mutatins f the sur- vival mtr neurn 1 ( SMN1 ) gene n hrmsme 5. Different mutatins result in mre r less severe disrup- tins f the prtein, resulting in an age f nset that ranges frm infany (SMA type I), t early (type II) r late hildhd (type III), t adulthd (type IV). X-linked spinal and bulbar musular atrphy (Kennedy syndrme) is assiated with an expanded trinuletide repeat sequene n the andrgen reeptr gene and ar- ries a mre benign prgnsis than ther frms f mtr neurn disease. There are reprts f juvenile SMA due t hexsa- minidase defiieny. Pure mtr syndrmes resembling mtr neurn disease may als ur in assiatin with mnlnal gammpathy r multifal mtr neurpa- thies with ndutin blk. A mtr neurnpathy may als develp in Hdgkin disease and has a relatively benign prgnsis. Infetive anterir hrn ell diseases (pli virus r West Nile virus infetin) an generally be distinguished by the aute nset and mnphasi urse f the illness, as disussed in Chapter 32. Aute flaid myelitis fllwing infetin with entervirus may ur, espeially in hildren, withut sensry invlve- ment and resembles plimyelitis. There is n speifi treatment. Clinical FindingsA.  Symptoms and SignsDiffiu lty in swallwing, hewing, ughing, breathing, and talking (dysarthria) urs with bulbar invlvement. In prgressive bulbar palsy, there is drping f the palate; a depressed gag reflex; pling f saliva in the pharynx; a weak ugh; and a wasted, fasiulating tngue. In pseud- bulbar palsy, the tngue is ntrated and spasti and an- nt be mved rapidly frm side t side. Limb invlvement is haraterized by mtr disturbanes (weakness, stiff- ness, wasting, fasiulatins) refleting lwer r upperCMDT22_Ch24_p0978-p1053.indd  1036 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1037 CMDT 2022mt r neurn dysfuntin; there are n bjetive hanges n sensry examinatin, althugh there may be vague sen- sry mplaints. The sphinters are generally spared. Cg- nitive hanges r pseudbulbar affet may be present. The disrder is prgressive, and ALS is usually fatal within 35 years; death usually results frm pulmnary infetins. Patients with bulbar invlvement generally have the pr- est prgnsis, while patients with primary lateral slersis ften have a lnger survival despite prfund quadriparesis and spastiity.B.  Laboratory and Other StudiesEletrmygraphy  may shw signs f aute and hrni partial denervatin with reinnervatin. In patients with suspeted ALS, the diagnsis shuld nt be made with nfidene unless suh hanges are fund in at least three spinal regins (ervial, thrai, lumbsaral) r tw spinal regins and the bulbar musulature. Mtr ndu- tin velity is usually nrmal but may be slightly redued, and sensry ndutin studies are als nrmal. Bipsy f a wasted musle shws the histlgi hanges f denerva- tin but is nt neessary fr diagnsis. The serum reatine kinase may be slightly elevated but never reahes the extremely high values seen in sme f the musular dys- trphies. The erebrspinal fluid is nrmal. T diagnse SMA, mleular geneti testing fr pathgeni variants f SMN1 is available. There are abnrmal findings n retal bipsy and redued hexsaminidase A in serum and leuk- ytes in patients with juvenile SMA due t hexsaminidase defiieny. TreatmentRiluzle,  50 mg rally twie daily, whih redues the pre- synapti release f glutamate, inreased shrt-term sur- vival in ALS in randmized trials. Edaravne, a free radial savenger, slws disease prgressin in patients with mild disease. It is administered in mnthly yles as a 60 mg intravenus infusin n days 114 in the first mnth and days 110 in the subsequent mnths. Nninvasive ventilatin at least 4 hurs per day in patients with a maximal inspiratry pressure less than 60 m H2O may prlng survival in ALS. Symptmati and supprtive measures t treat spastiity (disussed earlier), drling, and dysphagia, prevent ntratures, and pre- serve mbility are imprtant. Drling is treated with ver- the-unter dengestants, antihlinergi mediatins (suh as trihexyphenidyl, amitriptyline, r atrpine), btu- linum txin injetins int the salivary glands, r use f a prtable sutin mahine. Physial and upatinal ther- apy are helpful thrughut the disease urse. Cmbina- tin dextrmethrphan/quinidine (20 mg/10 mg, ne tablet rally ne r twie daily) may relieve symptms f pseudbulbar affet. A semiliquid diet r gastrstmy tube feeding may be needed if dysphagia is severe; it is advisable t perfrm the predure befre the fred vital apaity falls belw 50% f predited t minimize the risk f m- pliatins. Trahestmy is smetimes perfrmed if respi- ratry musles are severely affeted; hwever, in the terminal stages f these disrders, realisti expetatinsand advane are planning shuld be disussed. Infrma- tin n palliative are is prvided in Chapter 5. Treatment f spinal musular atrphy takes advantage f the fat that the SMN prtein is als ended by a se- nd gene, SMN2, that usually des nt translate funtinal prtein due t aberrant spliing. Nusinersen is an antisense lignuletide that mdulates premessenger RNA spli- ing f the SMN2 gene and results in inreased prdutin f the full-length prtein; it has shwn effetiveness in bth infants and hildren with SMA. It is apprved fr use in all ages and is administered intratheally (12 mg every 14 days fr three dses, then ne after a 30-day interval, then ne every 4 mnths). Risdiplam (5 mg rally daily fr patients 2 years f age and lder weighing mre than 20 kg) is a small mleule SMN2 spliing mdifier that als results in prdutin f the full-length prtein and is apprved fr use in infants and adults. Gene therapy with intravenus delivery f an intat SMN1 gene using a viral vetr (nasemngene abeparvve) imprves ventilatr-free survival mpared t histrial ntrls and is apprved by the FDA fr use in hildren under 2 years f age with bi- alleli mutatins in SMN1 . When to ReferAll patien ts (t exlude ther treatable auses f symptms and signs) shuld be referred. When to AdmitPa tients may need t be admitted fr initiatin r titratin f nninvasive ventilatin, r fr perids f inreased requirement f nninvasive ventilatr supprt during pul- mnary infetins.Me ruri E et al; CHERISH Study Grup. Nusinersen versus sham ntrl in later-nset spinal musular atrphy. N Engl J Med. 2018;378:625. [PMID: 29443664] Nrris SP et al. Amytrphi lateral slersis: update n linial management. Curr Opin Neurl. 2020;33:641. [PMID: 32868602] pERIphERaL NEUROpaThIESPe ripheral neurpathies an be ategrized n the basis f the struture primarily affeted. The predminant path- lgi feature may be axonal degeneration (axonal or neuronal neuropathies ) r paranodal or segmental demyelination. The distintin may be pssible n the basis f neurphysilgi findings. Mtr and sensry ndutin velity an be measured in aessible seg- ments f peripheral nerves. In axnal neurpathies, n- dutin velity is nrmal r redued nly mildly and needle eletrmygraphy prvides evidene f denerva- tin in affeted musles. In demyelinating neurpathies, ndutin may be slwed nsiderably in affeted fibers, and in mre severe ases, ndutin is blked m- pletely, withut ampanying eletrmygraphi signs f denervatin.CMDT22_Ch24_p0978-p1053.indd  1037 29/06/21 8:50 PMChapTER 241038 CMDT 2022PO LYNEUROPATHIES & MONONEURITIS MULTIPLEXE S S E N T I A L S  O F  D I A G N O S I S Weakness, sensory disturbances, or both in the extremities. Pain is common. Depressed or absent tendon reflexes. May be family history of neuropathy. May be history of systemic illness or toxic exposure. General ConsiderationsDiffuse  polyneuropathies lead t a symmetri sensry, mtr, r mixed defiit, ften mst marked distally. They inlude the hereditary, metabli, and txi disrders; idi- pathi inflammatry plyneurpathy ( Guillain-Barr syn- drome ); and the peripheral neurpathies that may ur as a nnmetastati mpliatin f malignant diseases. Invlvement f mtr fibers leads t flaid weakness that is mst marked distally; dysfuntin f sensry fibers auses impaired sensry pereptin. Tendn reflexes are depressed r absent. Paresthesias, pain, and musle tender- ness may als ur. Multiple mnneurpathies ( mono- neuropathy multiplex ) suggest a pathy multifal disease press suh as vasulpathy (eg, diabetes, arteritis), an infiltrative press (eg, leprsy, saridsis), radiatin dam- age, r an immunlgi disrder (eg, brahial plexpathy). Clinical FindingsThe  ause f plyneurpathy r mnneuritis multiplex is suggested by the histry, mde f nset, and predminant linial manifestatins. Labratry wrkup inludes a m- plete bld unt, serum prtein eletrphresis with reflex t immunfixatin r immuntyping, determinatin f plasma urea and eletrlytes, liver bihemial tests, thy- rid funtin tests, vitamin B12level, tests fr rheumatid fatr and antinulear antibdy, HBsAg determinatin, a serlgi test fr syphilis, fasting bld gluse level and hemglbin A1, urinary heavy metal levels, erebrspinal fluid examinatin, and hest radigraphy. These tests shuld be rdered seletively, as guided by symptms and signs. Measurement f nerve ndutin velity an n- firm the peripheral nerve rigin f symptms and prvides a means f fllwing linial hanges, as well as indiate the likely disease press (ie, axnal r demyelinating neurpa- thy). Cutaneus nerve bipsy may help establish a preise diagnsis (eg, plyarteritis, amylidsis). In abut half f ases, n speifi ause an be established; f these, slightly less than half are subsequently fund t be familial. TreatmentT reatment is f the underlying ause, when feasible, and is disussed belw under the individual disrders. Physial therapy helps prevent ntratures, and splints anmaintain a weak extremity in a psitin f useful funtin. Anestheti extremities must be prteted frm injury. T guard against burns, patients shuld hek the temperature f water and ht surfaes with a prtin f skin having nrmal sensatin, measure water temperature with a ther- mmeter, and use ld water fr washing r lwer the temperature setting f their ht-water heaters. Shes shuld be examined frequently during the day fr grit r freign bjets in rder t prevent pressure lesins. Patients with plyneurpathies r mnneuritis multi- plex are subjet t additinal nerve injury at pressure pints and shuld therefre avid suh behavir as leaning n elbws r sitting with rssed legs fr lengthy perids. Neurpathi, burning pain may respnd t simple anal- gesis, suh as aspirin r nnsteridal anti-inflammatry agents, and t gabapentin (300 mg rally three times daily, titrated up t a maximum f 1200 mg rally three times daily as neessary) r pregabalin (50100 mg rally three times daily). Dulxetine (60 mg rally ne r twie daily), venlafaxine (start 37.5 mg rally twie daily, and titrate up t 75 mg rally tw t three times daily), r triyli antide- pressants (eg, amitriptyline 10150 mg rally at bedtime daily) may be helpful, espeially in painful diabeti neu- rpathy. Medial annabis may prvide sme relief, but lng-term safety data are laking. The use f a frame r radle t redue ntat with bedlthes may be helpful. Many patients experiene episdi stabbing pains, whih may respnd t gabapentin, pregabalin, arbamazepine (start 100 mg rally twie daily, and titrate up t 400 mg rally twie daily), r triyli antidepressants. Opiids may be neessary fr severe hyperpathia r pain indued by minimal stimuli, but their use generally shuld be avided. Symptms f autnmi dysfuntin are asinally trublesme. Treatment f pstural hyptensin is dis- ussed earlier in this hapter. Eretile dysfuntin an be treated with phsphdiesterase inhibitrs; a flaid neur- pathi bladder may respnd t parasympathmimeti mediatins suh as bethanehl hlride, 1050 mg three r fur times daily.Ada ms D et al. Patisiran, an RNAi therapeuti, fr hereditary transthyretin amylidsis. N Engl J Med. 2018;379:11. [PMID: 29972753] Bensn MD et al. Intersen treatment fr patients with heredi- tary transthyretin amylidsis. N Engl J Med. 2018;379:22. [PMID: 29972757]1.  Inerited NeurotiesA.  CharcotMarieTooth Disease HMSN Type I, IIThere  are several distint varieties f Chart-Marie-Tth disease, usually with an autsmal dminant mde f inheritane, but asinal ases ur n a spradi, reessive, r X-linked basis. Clinial presentatin may be with ft defrmities r gait disturbanes in hildhd r early adult life. Slw prgressin leads t the typial fea- tures f plyneurpathy, with distal weakness and wasting that begin in the legs, a variable amunt f distal sensry lss, and depressed r absent tendn reflexes. Tremr is a nspiuus feature in sme instanes. Hereditary motorCMDT22_Ch24_p0978-p1053.indd  1038 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1039 CMDT 2022and  sensory neuropathy (HMSN) type I is haraterized by demyelinatin n eletrdiagnsti studies and is usu- ally aused by mutatins in the peripheral myelin prtein 22 r myelin prtein zer gene. In HMSN type II , eletr- diagnsti studies shw axnal lss rather than demyelin- atin; ne-third f ases are due t mutatins in the gene mitfusin 2. A similar disrder may ur in patients with prgres- sive distal spinal musular atrphies, but there is n sen- sry lss; eletrphysilgi investigatin reveals that mtr ndutin velity is nrmal r nly slightly redued, and nerve atin ptentials are nrmal.B.  DejerineSottas Disease HMSN Type IIIThe  disrder may ur n a spradi, autsmal dmi- nant r, less mmnly, autsmal reessive basis. Onset in infany r hildhd leads t a prgressive mtr and sensry plyneurpathy with weakness, ataxia, sensry lss, and depressed r absent tendn reflexes. The periph- eral nerves may be palpably enlarged and are haraterized pathlgially by segmental demyelinatin, Shwann ell hyperplasia, and thin myelin sheaths. Eletrphysilgi- ally, there is a slwing f ndutin, and sensry atin ptentials may be unrerdable.C.  Friedreich AtaxiaThis disrder , the nly knwn autosomal recessive trinu- cleotide repeat disease, is aused by expansin f a ply- GAA lus in the gene fr frataxin n hrmsme 9, leading t symptms in hildhd r early adult life. The gait bemes ataxi, the hands beme lumsy, and ther signs f erebellar dysfuntin develp ampanied by weakness f the legs and extensr plantar respnses. Invlvement f peripheral sensry fibers leads t sensry disturbanes in the limbs and depressed tendn reflexes. There is bilateral pes avus. Pathlgially, there is a marked lss f ells in the psterir rt ganglia and degeneratin f peripheral sensry fibers. In the entral nervus system, hanges are nspiuus in the psterir and lateral lumns f the rd. Eletrphysilgially, ndutin velity in mtr fibers is nrmal r nly mildly redued, but sensry atin ptentials are small r absent. Cardia disease is the mst mmn ause f death. In the differential diagnsis fr Friedreih ataxia are ther spinerebellar ataxias, a grwing grup f at least 30 inherited disrders, eah invlving a different identified gene. These hetergeneus disrders, whih frequently (but nt exlusively) exhibit an autsmal dminant inher- itane pattern and ply-CAG expansin f the affeted gene, typially ause erebellar ataxia and varying mbi- natins f ther symptms (suh as peripheral neurpathy, phthalmparesis, dysarthria, and pyramidal and extrapy- ramidal signs).D . Refsum Disease HMSN Type IVThis  autsmal reessive disrder is due t a disturbane in phytani aid metablism. Pigmentary retinal degen- eratin is ampanied by prgressive sensrimtr ply- neurpathy and erebellar signs. Auditry dysfuntin,ardimypathy, and utaneus manifestatins may als ur. Mtr and sensry ndutin velities are redued, ften markedly, and there may be eletrmy- graphi evidene f denervatin in affeted musles. Dietary restritin f phytani aid and its preursrs may be helpful therapeutially. Plasmapheresis t redue stred phytani aid may help at the initiatin f treatment.E.  PorphyriaPe ripheral nerve invlvement may ur during aute attaks in bth variegate porphyria andacute intermit- tent porphyria. Mtr symptms usually ur first, and weakness is ften mst marked prximally and in the upper limbs rather than the lwer. Sensry symptms and signs may be prximal r distal in distributin. Autnmi invlvement is smetimes prnuned. The eletrphysi- lgi findings are in keeping with the results f neur- pathlgi studies suggesting that the neurpathy is axnal in type (see Chapter 40).F . Familial Amyloid PolyneuropathySensr y and autnmi symptms are espeially nspiu- us, whereas distal wasting and weakness ur later. The plyneurpathy is axnal and likely results frm amylid depsitin within the peripheral nerves due t mutatins in the genes ending transthyretin, aplipprtein A1, r gelslin. Transthyretin amyloidosis is the mst mmn; is assiated with ardimypathy, nephrpathy, lept- meningeal invlvement, and vitreus paity; and is treat- able with liver transplantatin, the small interfering ribnulei aid patisiran (0.3 mg/kg up t 30 mg intrave- nusly ne every 3 weeks), r the antisense lignule- tide intersen (284 mg subutaneusly weekly). Tafamidis helps transthyretin amylid ardimypathy and may slw the prgressin f the neurpathy.2.  Neuroties associted wit Systemic & Metbolic DisordersA.  Diabetes MellitusIn  this disrder, invlvement f the peripheral nervus system may lead t symmetri sensry r mixed plyneu- rpathy, asymmetri mtr radiulneurpathy r plexpa- thy (diabeti amytrphy), thraabdminal radiulpathy, autnmi neurpathy, r islated lesins f individual nerves. These may ur singly r in any mbinatin and are disussed in Chapter 27.B.  UremiaU remia may lead t a symmetri sensrimtr plyneu- rpathy that tends t affet the lwer limbs mre than the upper limbs and is mre marked distally than prxi- mally (see Chapter 22). The diagnsis an be nfirmed eletrphysilgially beause mtr and sensry n- dutin velity is mderately redued. The neurpathy imprves bth linially and eletrphysilgially with kidney transplantatin and t a lesser extent with hrni dialysis.CMDT22_Ch24_p0978-p1053.indd  1039 29/06/21 8:50 PMChapTER 241040 CMDT 2022C.  Alcoholism and Nutritional DeficiencyMan y patients with alhl use disrder have an axnal distal sensrimtr plyneurpathy that is frequently ampanied by painful ramps, musle tenderness, and painful paresthesias and is ften mre marked in the legs than in the arms. Symptms f autnmi dysfuntin may als be nspiuus. Mtr and sensry ndutin velity may be slightly redued, even in sublinial ases, but grss slwing f ndutin is unmmn. Treatment is similar t diabeti plyneurpathy but als inludes abstinene frm alhl. A similar distal sensrimtr plyneurpathy is a well-regnized feature f beriberi (thiamine defiieny). In vitamin B12defiieny, distal sen- sry plyneurpathy may develp but is usually vershad- wed by entral nervus system manifestatins (eg, myelpathy, pti neurpathy, r intelletual hanges).D . ParaproteinemiasA symmetri s ensrimtr plyneurpathy that is gradual in nset, prgressive in urse, and ften ampanied by pain and dysesthesias in the limbs may ur in patients (espeially men) with plasma cell myeloma (frmerly multiple myelma). The neurpathy is f the axnal type in lassi lyti myelma, but segmental demyelinatin (pri- mary r sendary) and axnal lss may ur in slerti myelma and lead t predminantly mtr linial mani- festatins. Bth demyelinating and axnal neurpathies are als bserved in patients with paraprteinemias withut myelma. A small fratin will develp myelma if serially fllwed. The demyelinating neurpathy in these patients may be due t the mnlnal prteins reating t a m- pnent f the nerve myelin. The neurpathy f lassi plasma ell myelma is prly respnsive t therapy. The plyneurpathy f benign monoclonal gammopathy may respnd t immunsuppressant mediatins and plasmapheresis. Plyneurpathy may als ur in assiatin with mnlnal gammpathy f unknwn signifiane, ma- rglbulinemia, and ryglbulinemia and smetimes respnds t plasmapheresis. Many patients with an IgM M-prtein will have antibdies t myelin-assiated gly- prtein (MAG); these patients may respnd t treatment with rituximab. Entrapment neurpathy, suh as arpal tunnel syndrme, is mre mmn than plyneurpathy in patients with (nnhereditary) generalized amylidsis.3.  Neuroties associted wit Infectious & Inflmmtory DisesesA.  LeprosyLeprsy is an imprtan t ause f peripheral neurpathy in ertain parts f the wrld. Sensry disturbanes are mainly due t invlvement f intrautaneus nerves. In tuberu- lid leprsy, they develp at the same time and in the same distributin as the nerve; trunks lying beneath the lesin are als invlved. In leprmatus leprsy, there is mre extensive sensry lss, and this develps earlier and t a greater extent in the lest regins f the bdy, suh as the drsal surfaes f the hands and feet, where the bailliprliferate mst atively. Mtr defiits result frm invlve- ment f superfiial nerves where their temperature is lw- est, eg, the ulnar nerve in the regin prximal t the lerann grve, the median nerve as it emerges frm beneath the frearm flexr musle t run tward the arpal tunnel, the perneal nerve at the head f the fibula, and the psterir tibial nerve in the lwer part f the leg; pathy faial musular weakness may als ur wing t invlve- ment f the superfiial branhes f the seventh ranial nerve. Mtr disturbanes in leprsy are suggestive f multiple mnneurpathy, whereas sensry hanges resemble thse f distal plyneurpathy. Examinatin, hwever, relates the distributin f sensry defiits t the temperature f the tissues; in the legs, fr example, sparing frequently urs between the tes and in the ppliteal fssae, where the temperature is higher. Treatment is with antileprti agents (see Chapter 33).B.  AIDSA  variety f neurpathies ur in HIV-infeted patients (see Chapter 31).C.  Lyme BorreliosisThe  neurlgi manifestatins f Lyme disease inlude meningitis, meningenephalitis, plyradiulneurpathy, mnneurpathy multiplex, and ranial neurpathy. Ser- lgi tests establish the underlying disrder. Lyme disease and its treatment are disussed in depth in Chapter 34.D . SarcoidosisCranial  nerve palsies (espeially faial palsy), multiple mnneurpathy and, less mmnly, symmetri plyneu- rpathy may all ur, the latter smetimes preferentially affeting either mtr r sensry fibers. Imprvement may ur with use f rtisterids.E.  PolyarteritisIn vlvement f the vasa nervrum by the vasuliti press may result in infartin f the nerve. Clinially, ne enunters an asymmetri sensrimtr plyneurpathy (mnneuritis multiplex) that pursues a waxing and waning urse. Crtisterids and yttxi agents espeially ylphsphamidemay be f benefit in severe ases (Chapter 20).F . Rheumatoid ArthritisCmpr essive r entrapment neurpathies, ishemi neu- rpathies, mild distal sensry plyneurpathy, and severe prgressive sensrimtr plyneurpathy an ur in rheumatid arthritis.4.  Neuroty associted wit Criticl IllnessPa tients in intensive are units with sepsis and multirgan failure smetimes develp plyneurpathies. This may be manifested initially by unexpeted diffiulty in weaningCMDT22_Ch24_p0978-p1053.indd  1040 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1041 CMDT 2022patients  frm a mehanial ventilatr and in mre advaned ases by wasting and weakness f the extremities and lss f tendn reflexes. Sensry abnrmalities are relatively innspiuus. The neurpathy is axnal in type. Its path- genesis is bsure, and treatment is supprtive. The prg- nsis is gd prvided patients rever frm the underlying ritial illness. A mypathy may als ur (disussed belw).5.  Toxic NeurotiesAxnal  plyneurpathy may fllw expsure t industrial agents r pestiides suh as arylamide, rganphsph- rus mpunds, hexaarbn slvents, methyl brmide, and arbn disulfide; metals suh as arseni, thallium, merury, and lead; and mediatins suh as phenytin, amidarne, perhexiline, isniazid, nitrfurantin, vin- ristine, and pyridxine in high dses. Detailed upa- tinal, envirnmental, and medial histries and regnitin f lusters f ases are imprtant in suggesting the diagnsis. Treatment is by preventing further expsure t the ausal agent. Isniazid neurpathy is prevented by pyridxine supplementatin. Diphtheriti neurpathy results frm a neurtxin released by the ausative rganism and is mmn in many areas. Palatal weakness may develp 24 weeks after infe- tin f the thrat, and infetin f the skin may similarly be fllwed by fal weakness f neighbring musles. Disturbanes f ammdatin may ur abut 45 weeks after infetin and distal sensrimtr demye- linating plyneurpathy after 13 mnths.6.  Neuroties associted wit Mlignnt DisesesA  variety f neurpathies have been assiated with nn- metastati mpliatins f malignany and were dis- ussed earlier.7.  acute Idiotic polyneuroty (Guillin-Brr Syndrome)E S S E N T I A L S  O F  D I A G N O S I S Acute or subacute progressive polyradiculoneuro- pathy. Weakness is more severe than sensory disturbances. Acute dysautonomia may be life-threatening. General ConsiderationsThis aute  r subaute plyradiulneurpathy smetimes fllws infetive illness, inulatins, r surgial pre- dures. There is an assiatin with preeding Campylo- bacter jejuni enteritis. The disrder prbably has an immunlgi basis, but the preise mehanism is unlear.Clinical FindingsA.  Symptoms and SignsThe  main mplaint is f weakness that varies widely in severity in different patients and ften has a prximal emphasis and symmetri distributin. It usually begins in the legs, spreading t a variable extent but frequently invlving the arms and ften ne r bth sides f the fae. The musles f respiratin r deglutitin may als be affeted. Sensry symptms are usually less nspiuus than mtr nes, but distal paresthesias and dysesthesias are mmn, and neurpathi r radiular pain is present in many patients. Autnmi disturbanes are als m- mn, may be severe, and are smetimes life-threatening; they inlude tahyardia, ardia irregularities, hypten- sin r hypertensin, faial flushing, abnrmalities f sweating, pulmnary dysfuntin, and impaired sphinter ntrl. The axnal subtypes f the syndrme ( acute motor axonal neuropathy [AMAN] andacute motor and sensory axonal neuropathy [AMSAN] ) are aused by antibdies t ganglisides n the axn membrane. The Miller Fisher syndrome, anther subtype, is haraterized by the linial triad f phthalmplegia, ataxia, and are- flexia, and is assiated with anti-GQ1b antibdies.B.  Laboratory FindingsThe  erebrspinal fluid harateristially ntains a high prtein nentratin with a nrmal ell unt, but these hanges may take up t 2 weeks t develp; white bld ell unts greater than 50 ells/mL (0.05  109/L) shuld prmpt nsideratin f alternative diagnses. Eletr- physilgi studies may reveal marked abnrmalities, whih d nt neessarily parallel the linial disrder in their tempral urse. Differential DiagnosisWhen  the diagnsis is made, the histry and apprpriate labratry studies shuld exlude the pssibility f pr- phyri, diphtheriti, r txi (heavy metal, hexaarbn, rganphsphate) neurpathies, and f HIV infetin. The tempral urse exludes ther peripheral neurpathies. Plimyelitis, btulism, and tik paralysis must als be nsidered as they ause weakness f aute nset. The presene f pyramidal signs, a markedly asymmetri mtr defiit, a sharp sensry level, r early sphinter invlve- ment shuld suggest a fal rd lesin. TreatmentT reatment with prednisne is ineffetive and may prlng revery time. Plasmapheresis is f value; it is best per- frmed within the first few days f illness and is partiularly useful fr linially severe r rapidly prgressive ases r thse with ventilatry impairment. IVIG (400 mg/kg/day fr 5 days) is equally helpful. Patients shuld be admitted t intensive are units if their fred vital apaity is delining, and intubatin is nsidered if the fred vital apaity reahes 15 mL/kg, the maximum inspiratryCMDT22_Ch24_p0978-p1053.indd  1041 29/06/21 8:50 PMChapTER 241042 CMDT 2022pres sure reahes 30 mm Hg, r dyspnea bemes evident. Delining xygen saturatin is a late indiatr f neur- musular respiratry failure. Respiratry tilet and hest physial therapy help prevent ateletasis. Marked hypten- sin may respnd t vlume replaement r pressr agents. Thrmbprphylaxis is imprtant. PrognosisMs t patients eventually make a gd revery, but this may take many mnths, and abut 20% f patients are left with persisting disability. Apprximately 3% f patients with aute idipathi plyneurpathy have ne r mre linially similar relapses, smetimes several years after the initial illness. When to ReferAll patients sh uld be referred. When to AdmitAll  patients shuld be hspitalized until their nditin is stable and there is n respiratry mprmise.Malek  E et al. Guillain-Barr syndrme. Semin Neurl. 2019;39:589. [PMID: 31639842]8.  Cronic Inflmmtory polyneurotyChrni  inflammatry demyelinating plyneurpathy, an aquired immunlgially mediated disrder, is linially similar t Guillain-Barr syndrme exept that it has a relapsing r steadily prgressive urse ver mnths r years and that autnmi dysfuntin is generally less mmn. It may present as an exlusively mtr disrder r with a mixed sensrimtr disturbane. In the relapsing frm, partial revery may ur after sme relapses, but in ther instanes there is n revery between exaerba- tins. Althugh remissin may ur spntaneusly with time, the disrder frequently fllws a prgressive dwn- hill urse leading t severe funtinal disability. Eletrdiagnsti studies shw marked slwing f mtr and sensry ndutin, and fal ndutin blk. Signs f partial denervatin may als be present wing t sendary axnal degeneratin. Nerve bipsy may shw hrni perivasular inflammatry infiltrates in the endneurium and epineurium, withut ampanying evidene f vasulitis. Hwever, a nrmal nerve bipsy result r the presene f nnspeifi abnrmalities des nt exlude the diagnsis. Crtisterids may arrest r reverse the dwnhill urse. Treatment is usually begun with prednisne, 6080 mg rally daily, ntinued fr 23 mnths r until a definite respnse has urred. If n respnse has urred despite 3 mnths f treatment, a higher dse may be tried. In respnsive ases, the dse is gradually tapered, but mst patients beme rtisterid-dependent, ften requiring prednisne, 20 mg daily n alternate days, n a lng-term basis. IVIG an be used in plae f, r in additin t rti- sterids, and is best used as the initial treatment in puremtr syndrmes (2 g/kg ver 25 days fllwed by 1 g/kg every 3 weeks); a weekly regimen f 0.20.4 g/kg f a 20% subutaneus immunglbulin slutin is an effetive alternative but has nt been mpared diretly t rti- sterids r IVIG. When bth IVIG and rtisterids are ineffetive, plasma exhange may be wrthwhile. Cnsis- tent with the ntin that the nditin is antibdy medi- ated, rituximab has shwn prmise. Immunsuppressant r immunmdulatry mediatins (suh as azathiprine) may be added when the respnse t ther measures is unsatisfatry r t enable maintenane dses f rti- sterids t be lwered. Symptmati treatment is als imprtant.Bunshten  C et al. Prgress in diagnsis and treatment f hrni inflammatry demyelinating plyneurpathy. Lanet Neurl. 2019;18:784. [PMID: 31076244]MO NONEUROPATHIESE S S E N T I A L S  O F  D I A G N O S I S Focal motor or sensory deficit. Deficit is in territory of an individual peripheral nerve. An individual nerve may be injured alng its urse r may be mpressed, angulated, r strethed by neighbring ana- tmi strutures, espeially at a pint where it passes thrugh a narrw spae ( entrapment neuropathy ). The relative ntributins f mehanial fatrs and ishemia t the lal damage are nt lear. With invlvement f a sen- sry r mixed nerve, pain is mmnly felt distal t the lesin. Symptms never develp with sme entrapment neurpathies, reslve rapidly and spntaneusly in thers, and beme prgressively mre disabling and distressing in yet ther ases. The preise neurlgi defiit depends n the nerve invlved. Perussin f the nerve at the site f the lesin may lead t paresthesias in its distal distributin. Entrapment neurpathy may be the sle manifestatin f sublinial plyneurpathy, and this must be brne in mind and exluded by nerve ndutin studies. Suh studies are als indispensable fr the lalizatin f the fal lesin. In patients with aute mpressin neurpathy suh as may ur in intxiated individuals ( Saturday night palsy ), n treatment is neessary. Cmplete revery gen- erally urs, usually within 2 mnths, presumably beause the underlying pathlgy is demyelinatin. Hwever, ax- nal degeneratin an ur in severe ases, and revery then takes lnger and may never be mplete. In hrni mpressive r entrapment neurpathies, avidane f aggravating fatrs and rretin f any under- lying systemi nditins are imprtant. Lal infiltratin f the regin abut the nerve with rtisterids may be f value; in additin, surgial dempressin may help ifCMDT22_Ch24_p0978-p1053.indd  1042 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1043 CMDT 2022there  is a prgressively inreasing neurlgi defiit r if eletrdiagnsti studies shw evidene f partial denerva- tin in weak musles. Peripheral nerve tumrs are unmmn, exept in neu- rfibrmatsis type 1, but als give rise t mnneurpathy. This may be distinguishable frm entrapment neurpathy nly by nting the presene f a mass alng the urse f the nerve and by demnstrating the preise site f the lesin with apprpriate eletrphysilgi studies. Treatment f symptmati lesins is by surgial remval if pssible.1.  Crl Tunnel SyndromeSee Chapter 41. 2.  prontor Teres or anterior Interosseous SyndromeThe  median nerve gives ff its mtr branh, the anterir intersseus nerve, belw the elbw as it desends between the tw heads f the prnatr teres musle. A lesin f either nerve may ur in this regin, smetimes after trauma r wing t mpressin frm, fr example, a fibrus band. With anterir intersseus nerve invlvement, there is n sensry lss, and weakness is nfined t the prnatr qua- dratus, flexr plliis lngus, and the flexr digitrum pr- fundus t the send and third digits. Weakness is mre widespread and sensry hanges ur in an apprpriate distributin when the median nerve itself is affeted. The prgnsis is variable. If imprvement des nt ur spn- taneusly, dempressive surgery may be helpful.3.  Ulnr Nerve LesionsUlnar nerve lesi ns are likely t ur in the elbw regin as the nerve runs behind the medial epindyle and desends int the ubital tunnel. In the ndylar grve, the ulnar nerve is expsed t pressure r trauma. Mre- ver, any inrease in the arrying angle f the elbw, whether ngenital, degenerative, r traumati, may ause exessive strething f the nerve when the elbw is flexed. Ulnar nerve lesins may als result frm thikening r distrtin f the anatmi strutures frming the ubital tunnel, and the resulting symptms may als be aggravated by flexin f the elbw, beause the tunnel is then nar- rwed by tightening f its rf r inward bulging f its flr. A severe lesin at either site auses sensry hanges in the fifth and medial half f the furth digits and alng the medial brder f the hand. There is weakness f the ulnar-innervated musles in the frearm and hand. With a ubital tunnel lesin, hwever, there may be relative spar- ing f the flexr arpi ulnaris musle. Eletrphysilgi evaluatin using nerve stimulatin tehniques allws mre preise lalizatin f the lesin. Initial treatment nsists f aviding pressure n the medial elbw (eg, avid resting the elbws n arm rests; pad the elbw during sleep) and preventing prlnged elbw flexin, espeially at night. Splints are available t keep the elbw frm flexing beynd 45 t 90 degrees. If nservative measures are unsuessful in relieving symp- tms and preventing further prgressin, surgial treat- ment may be neessary. This nsists f nerve transpsitinif the lesin is in the ndylar grve, r a release pre- dure if it is in the ubital tunnel. Ulnar nerve lesins may als develp at the wrist r in the palm f the hand, usually wing t repetitive trauma r t mpressin frm ganglia r benign tumrs. They an be subdivided depending n their presumed site. Cm- pressive lesins are treated surgially. If repetitive mehani- al trauma is respnsible, this is avided by upatinal adjustment r jb retraining.4.  Rdil Nerve LesionsThe  radial nerve is partiularly liable t mpressin r injury in the axilla (eg, by ruthes r by pressure when the arm hangs ver the bak f a hair). This leads t weakness r paralysis f all the musles supplied by the nerve, inluding the trieps. Sensry hanges may als ur but are ften surprisingly innspiuus, being marked nly in a small area n the bak f the hand between the thumb and index finger. Injuries t the radial nerve in the spiral grve ur harateristially during deep sleep, as in intxiated individuals, and there is then sparing f the trieps musle, whih is supplied mre prximally. The nerve may als be injured at r abve the elbw; its purely mtr psterir intersseus branh, supplying the exten- srs f the wrist and fingers, may be invlved immediately belw the elbw, but then there is sparing f the extensr arpi radialis lngus, s that the wrist an still be extended. The superfiial radial nerve may be mpressed by hand- uffs r a tight wath strap.5.  Femorl NeurotyThe  linial features f femral nerve palsy nsist f weak- ness and wasting f the quadrieps musle, with sensry impairment ver the antermedian aspet f the thigh and smetimes als f the leg t the medial mallelus, and a depressed r absent knee jerk. Islated femral neurpathy may ur in patients with diabetes r frm mpressin by retrperitneal neplasms r hematmas (eg, expanding arti aneurysm). Femral neurpathy may als result frm pressure frm the inguinal ligament when the thighs are markedly flexed and abduted, as in the lithtmy psitin.6.  Merlgi presteticThe  lateral femral utaneus nerve, a sensry nerve arising frm the L2 and L3 rts, may be mpressed r strethed in bese r diabeti patients and during pregnany. The nerve usually runs under the uter prtin f the inguinal ligament t reah the thigh, but the ligament smetimes splits t enlse it. Hyperextensin f the hip r inreased lumbar lrdsissuh as urs during pregnanyleads t nerve mpressin by the psterir fasile f the liga- ment. Hwever, entrapment f the nerve at any pint alng its urse may ause similar symptms, and several ther anatmi variatins predispse the nerve t damage when it is strethed. Pain, paresthesia, r numbness urs abut the uter aspet f the thigh, usually unilaterally, and is smetimes relieved by sitting. The pain stps at the knee, unlike the pain frm lwer lumbar siatia that radiates t the ft. Examinatin shws n abnrmalities exept inCMDT22_Ch24_p0978-p1053.indd  1043 29/06/21 8:50 PMChapTER 241044 CMDT 2022severe  ases when utaneus sensatin is impaired in the affeted area. Symptms are usually mild and mmnly settle spntaneusly. Hydrrtisne injetins medial t the antersuperir ilia spine ften relieve symptms tem- prarily, while nerve dempressin by transpsitin may prvide mre lasting relief.7.  Scitic & Common peronel (Fibulr) Nerve plsiesMisplaed  deep intramusular injetins are prbably still the mst mmn ause f siati nerve palsy. Trauma t the buttk, hip, r thigh may als be respnsible. The resulting linial defiit depends n whether the whle nerve has been affeted r nly ertain fibers. In general, the perneal (fibular) fibers f the siati nerve are mre suseptible t damage than thse destined fr the tibial nerve. A siati nerve lesin may therefre be diffiult t distinguish frm perneal (fibular) neurpathy unless there is eletrmygraphi evidene f invlvement f the shrt head f the bieps femris musle. The mmn perneal (fibular) nerve itself may be mpressed r injured in the regin f the head and nek f the fibula, eg, by sitting with rssed legs r wearing high bts. There is weakness f drsiflexin and eversin f the ft, am- panied by numbness r blunted sensatin f the anterlat- eral aspet f the alf and drsum f the ft.8.  Trsl Tunnel SyndromeThe  tibial nerve, the ther branh f the siati, supplies several musles in the lwer extremity, gives rigin t the sural nerve, and then ntinues as the psterir tibial nerve t supply the plantar flexrs f the ft and tes. It passes thrugh the tarsal tunnel behind and belw the medial mal- lelus, giving ff alaneal branhes and the medial and lat- eral plantar nerves that supply small musles f the ft and the skin n the plantar aspet f the ft and tes. Cmpres- sin f the psterir tibial nerve r its branhes between the bny flr and ligamentus rf f the tarsal tunnel leads t pain, paresthesias, and numbness ver the bttm f the ft, espeially at night, with sparing f the heel. Musle weakness may be hard t regnize linially. Cmpressive lesins f the individual plantar nerves may als ur mre distally, with linial features similar t thse f the tarsal tunnel syndrme. Treatment is surgial dempressin. When to Refer If there is unertainty abut the diagnsis. Symptms r signs are prgressing despite treatment.BE LL PALSYE S S E N T I A L S  O F  D I A G N O S I S Sudden onset of lower motor neuron facial palsy. Hyperacusis or impaired taste may occur. No other neurologic abnormalities.General ConsiderationsBell pa lsy is an idiopathic facial paresis of lower motor neu- ron type that has been attributed t an inflammatry rea- tin invlving the faial nerve near the stylmastid framen r in the bny faial anal. In sme instanes, this may be due t reativatin f herpes simplex r variella zster virus infetin in the geniulate ganglin. The disr- der is mre mmn in pregnant wmen and in persns with diabetes mellitus. Clinical FindingsThe  faial paresis (Figure 241) generally mes n abruptly, but it may wrsen ver the fllwing day r s. Pain abut the ear preedes r ampanies the weakness in many ases but usually lasts fr nly a few days. The fae itself feels stiff and pulled t ne side. There may be ipsilat- eral restritin f eye lsure and diffiulty with eating and fine faial mvements. A disturbane f taste is mmn, wing t invlvement f hrda tympani fibers, and hyper- ausis due t invlvement f fibers t the stapedius urs asinally. In ases due t herpes zster infetin, vesi- les may be bserved in the external ear anal. Differential DiagnosisLwer  mtr neurn faial palsy an be differentiated frm strke by linial examinatin. A strke r ther entral lesin will nt ause hyperausis r disturbane f taste, Figure 241. Facial palsy caused by an infection with Borrelia burgdorferi (Lyme disease). (Public Health Image Library, CDC.)CMDT22_Ch24_p0978-p1053.indd  1044 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1045 CMDT 2022generally  spares the frehead, and is ampanied by ther fal defiits. An islated faial palsy may ur in patients with HIV serpsitivity, saridsis, Lyme disease (Figure 241; als see Chapter 34), r any press ausing an inflammatry reatin in the subarahnid spae, suh as meningitis. Whenever faial palsies ur bilaterally, r a faial palsy urs in njuntin with ther neurlgi defiits, MRI brain imaging shuld be undertaken and ther investigatins nsidered. TreatmentA pprximately 60% f ases f Bell palsy rever m- pletely withut treatment, presumably beause the lesin is s mild that it leads merely t ndutin blk. Treat- ment with rtisterids (prednisne 60 mg rally daily fr 5 days fllwed by a 5-day taper, r prednislne 25 mg rally twie daily fr 10 days) inreases the hane f a mplete revery at 912 mnths by 1215%. Treat- ment with aylvir r valaylvir is nly indiated when there is evidene f herpeti vesiles in the external ear anal. It is helpful t prtet the eye with lubriating drps (r lubriating intment at night) and a path if eye lsure is nt pssible. There is n evidene that surgial predures t dempress the faial nerve are f benefit. Physial therapy may imprve faial funtin.Gagyr  I et al. Antiviral treatment f Bells palsy (idipathi faial paralysis). Chrane Database Syst Rev. 2019;9:CD001869. [PMID: 31486071]DI SCOGENIC NECK PAINE S S E N T I A L S  O F  D I A G N O S I S Neck pain, sometimes radiating to arms. Restricted neck movements. Motor, sensory, or reflex changes in arms with root involvement. Neurologic deficit in legs, gait disorder, or sphinc- ter disturbance with cord involvement. General ConsiderationsA variety  f ngenital abnrmalities may invlve the er- vial spine and lead t nek pain; these inlude hemiverte- brae, fused vertebrae, basilar impressin, and instability f the atlantaxial jint. Traumati, degenerative, infetive, and neplasti disrders may als lead t pain in the nek. When rheumatid arthritis invlves the spine, it tends t affet espeially the ervial regin, leading t pain, stiff- ness, and redued mbility; displaement f vertebrae r atlantaxial subluxatin may lead t rd mpressin that an be life-threatening if nt treated by fixatin. Furtherdetails are given in Chapter 41 and disussin here is restrited t disk disease.1.  acute Cervicl Disk protrusionAut e ervial disk prtrusin leads t pain in the nek and radiular pain in the arm, exaerbated by head mvement. With lateral herniatin f the disk, mtr, sensry, r reflex hanges may be fund in a radiular (usually C6 r C7) distributin n the affeted side (Figure 242); with mre entrally direted herniatins, the spinal rd may als be invlved, leading t spasti paraparesis and sensry distur- banes in the legs, smetimes ampanied by impaired sphinter funtin. The diagnsis is nfirmed by MRI r CT myelgraphy. In mild ases, the prgnsis is gd and mplete revery urs in a majrity f patients with nservative therapy. Evidene des nt supprt any spe- ifi interventin, and sme mbinatin f bed rest, ativ- ity restritin, immbilizatin f the nek in a llar fr several weeks, and physial therapy is generally presribed. If these measures are unsuessful r the patient has a sig- nifiant neurlgi defiit, surgial remval f the prtrud- ing disk may be neessary.2.  Cervicl SondylosisCer vial spndylsis results frm hrni ervial disk degeneratin, with herniatin f disk material, sendary alifiatin, and assiated stephyti utgrwths. One r mre f the ervial nerve rts may be mpressed, strethed, r angulated; and myelpathy may als develp as a result f mpressin, vasular insuffiieny, r reur- rent minr trauma t the rd. Patients present with nek pain and restrited head mvement, ipital headahes, radiular pain and ther sensry disturbanes in the arms, weakness f the arms r legs, r sme mbinatin f these symptms. Examinatin generally reveals that lateral flex- in and rtatin f the nek are limited. A segmental pat- tern f weakness r dermatmal sensry lss (r bth) may be fund unilaterally r bilaterally in the upper limbs, and tendn reflexes mediated by the affeted rt r rts are depressed. The C5 and C6 nerve rts are mst mmnly invlved, and examinatin frequently then reveals weak- ness f musles supplied by these rts (eg, deltids, supra- spinatus and infraspinatus, bieps, brahiradialis), pain r sensry lss abut the shulder and uter brder f the arm and frearm, and depressed bieps and brahiradialis reflexes. Spasti paraparesis may als be present if there is an assiated myelpathy, smetimes ampanied by uri- nary urgeny, inntinene, r psterir lumn r spin- thalami sensry defiits in the legs. Plain radigraphs f the ervial spine shw stephyte frmatin, narrwing f disk spaes, and enrahment n the intervertebral framina, but suh hanges are mmn in middle-aged persns and may be unrelated t the pre- senting mplaint. CT r MRI helps nfirm the diagnsis and exlude ther strutural auses f the myelpathy. Restritin f nek mvements by a ervial llar may relieve pain. Lal injetin f anesthetis r rtisterids, fr instane by a pain management speialist, may be fCMDT22_Ch24_p0978-p1053.indd  1045 29/06/21 8:50 PMChapTER 241046 CMDT 2022 Figure 242. Cutaneous innervation. The segmental or radicular (root) distribution is shown on the left side of the body and the peripheral nerve distribution on the right side. Segmental maps show differences depending on how they were constructed (single root stimulation or section; local anesthetic injection into single dorsal root ganglia). (Adapted, with permission, from Aminoff MJ, Greenberg DA, Simon RP . Clinical Neurology, 9th ed. McGraw-Hill Education, 2015.)= Iliohypogastric = Ilioinguinal = Genitofemoral Dorsal nerve of penis Perineal nerve of penisPeripheral nerve Nerve root Trigeminal (Cranial nerve V) Anterior cutaneous nerve of neck Supraclavicular nerves Axillary nerve Medial cutaneous nerve of arm Lateral cutaneous nerve of arm (branch of radial nerve) Medial cutaneous nerve of forearm Lateral cutaneous nerve of forearm Radial Median Ulnar Lateral femoral cutaneous Obturator Anterior femoral cutaneous Lateral cutaneous nerve of calf Saphenous Superficial peroneal Sural Lateral and medial plantar Deep peronealOphthalmic branch (V1) Maxillary branch (V2) Mandibular branch (V3)* * X XLateral thoracic rami Post.Mid.Ant.Anterior thoracic ramiC3 C4 C5 T2 T3 T4 T5 T6 T7 T8 T9 T10 T11 T12 L1L1 L2 L3 L4 L5 S1T2 T1 C8C6C6 C7CMDT22_Ch24_p0978-p1053.indd  1046 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1047 CMDT 2022P eripheral nerve Posterior rami of cervical nerves Supraclavicular Axillary Medial cutaneous nerve of forearmLateral cutaneous nerve of forearm Lateral femoral cutaneous Obturator Anterior femoral cutaneous Posterior femoral cutaneous Lateral cutaneous nerve of calf SaphenousSuperficial peroneal Calcaneal Lateral plantar Medial plantarGreat occipital Lesser occipital Great auricular Posterior cutaneous nerve of forearmMedial cutaneous nerve of armLateral cutaneous nerve of arm Posterior cutaneous nerve of arm MedianPosterior lumbar rami Posterior sacral rami = IliohypogastricXX Nerve root Radial Ulnar SuralT2 T2 T1T3C2 C3 C4 T4 T5 T6 T7 T8 T9 T10 T11 T12 L1 L2 C8C6 C7 S1L5 L5S3 L 3S4 S5 L4S2P osterior thoracic ramiLateral thoracic ramiC5 C6benefit . Operative treatment may be neessary t prevent further prgressin if there is a signifiant neurlgi defi- it; bwel r bladder symptms; r if rt pain is severe, persistent, and unrespnsive t nservative measures. When to Refer Pain unrespnsive t simple measures. Patients with neurlgi defiits. Patients in whm surgial treatment is under nsideratin.When to Admit Patients with prgressive r signifiant neurlgi defiit. Patients with sphinter invlvement (frm rd mpressin). Patients requiring surgial treatment.Stin AM et  al. Myelpathies due t strutural ervial and th- rai disease. Cntinuum (Minneap Minn). 2018;24:567. [PMID: 29613900]Figure 242. (Continued )CMDT22_Ch24_p0978-p1053.indd  1047 29/06/21 8:50 PMChapTER 241048 CMDT 2022BR aChIaL & LUMBaR pLEXUS LESIONS 1. Brcil plexus NeurotyBrahial  plexus neurpathy may be idipathi, smetimes urring in relatinship t a number f different nnspe- ifi illnesses r fatrs. In ther instanes, brahial plexus lesins fllw trauma r result frm ngenital anmalies, neplasti invlvement, r injury by varius physial agents. In rare instanes, the disrder urs n a familial basis. Idipathi brahial plexus neurpathy ( neuralgic amyotrophy ) harateristially begins with severe pain abut the shulder, fllwed within a few days by weak- ness, reflex hanges, and sensry disturbanes invlving espeially the C5 and C6 segments but affeting any nerve in the brahial plexus. Symptms and signs are usually unilateral but may be bilateral. Wasting f affeted musles is smetimes prfund. The disrder relates t disturbed funtin f ervial rts r part f the brahial plexus, but its preise ause is unknwn. Revery urs ver the ensuing mnths but may be inmplete. Treatment is purely symptmati, althugh emerging evidene suggests that mirsurgial neurlysis f hurglass-like nstri- tins n affeted nerves identified by magneti resnane neurgraphy r high-reslutin ultrasund imprves ut- me in patients wh have nt revered after several mnths f nservative management.2.  Cervicl Rib SyndromeC mpressin f the C8 and T1 rts r the lwer trunk f the brahial plexus by a ervial rib r band arising frm the seventh ervial vertebra leads t weakness and wasting f intrinsi hand musles, espeially thse in the thenar emi- nene, ampanied by pain and numbness in the medial tw fingers and the ulnar brder f the hand and frearm. Ele- trmygraphy, nerve ndutin studies, and smatsensry evked ptential studies may help nfirm the diagnsis. MRI may be espeially helpful in revealing the underlying mpressive struture. Plain radigraphs r CT sanning smetimes shws the ervial rib r a large transverse press f the seventh ervial vertebra, but nrmal findings d nt exlude the pssibility f a ervial band. Treatment f the disrder is by surgial exisin f the rib r band.3.  Lumboscrl plexus LesionsA  lumbsaral plexus lesin may develp in assiatin with diseases suh as diabetes, aner, r bleeding disr- ders r in relatin t injury. It asinally urs as an islated phenmenn similar t idipathi brahial plexpathy (nndiabeti lumbsaral radiulplexus neu- rpathy), and pain and weakness then tend t be mre nspiuus than sensry symptms. The distributin f symptms and signs depends n the level and pattern f neurlgi invlvement.Gstettner  C et al. Neuralgi amytrphy: a paradigm shift in diagnsis and treatment. J Neurl Neursurg Psyhiatry. 2020;91:879. [PMID: 32487526]DISORDERS OF NEUROMUSCULaR TRaNSMISSION 1. Mysteni GrvisE S S E N T I A L S  O F  D I A G N O S I S Fluctuating weakness of commonly used volun- tary muscles, producing symptoms such as diplo- pia, ptosis, and difficulty in swallowing. Activity increases weakness of affected muscles. Short-acting anticholinesterases transiently improve the weakness. General ConsiderationsM yasthenia gravis urs at all ages, sometimes in association with a thymic tumor or thyrotoxicosis , as well as in rheu- matid arthritis and lupus erythematsus. It is mst m- mn in yung wmen with HLA-DR3; if thymma is assiated, lder men are mre mmnly affeted. Onset is usually insidius, but the disrder is smetimes unmasked by a inidental infetin that leads t exa- erbatin f symptms. Exaerbatins may als ur befre the menstrual perid and during r shrtly after pregnany. Symptms are due t a variable degree f blk f neurmusular transmissin aused by autanti- bdies binding t aetylhline reeptrs; these are fund in mst patients with the disease and have a primary rle in reduing the number f funtining aetylhline reep- trs. Additinally, ellular immune ativity against the reeptr is fund. Clinical FindingsA.  Symptoms and SignsPa tients present with ptsis, diplpia, diffiulty in hewing r swallwing, respiratry diffiulties, limb weakness, r sme mbinatin f these prblems. Weakness may remain lalized t a few musle grups r may beme generalized. The external ular musles and ertain ther ranial musles, inluding the mastiatry, faial, and pha- ryngeal musles, are espeially likely t be affeted, and the respiratry and limb musles may als be invlved. Symp- tms ften flutuate in intensity during the day, and this diurnal variatin is superimpsed n a tendeny t lnger- term spntaneus relapses and remissins that may last fr weeks. Nevertheless, the disrder fllws a slwly prgres- sive urse and may have a fatal utme wing t respira- try mpliatins suh as aspiratin pneumnia. Clinial examinatin nfirms the weakness and fatiga- bility f affeted musles. In mst ases, the extraular musles are invlved, and this leads t ular palsies and ptsis, whih are mmnly asymmetri. Pupillary respnses are nrmal. The bulbar and limb musles are ften weak, but the pattern f invlvement is variable. Sus- tained ativity f affeted musles inreases the weakness,CMDT22_Ch24_p0978-p1053.indd  1048 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1049 CMDT 2022whih impr ves after a brief rest. Sensatin is nrmal, and there are usually n reflex hanges. Life-threatening exaerbatins f myasthenia (s-alled myasthenic crisis ) may lead t respiratry weakness requiring immediate admissin t the intensive are unit, where respiratry funtin an be mnitred and ventila- tr supprt is readily available.B.  Laboratory and Other StudiesAssay  f serum fr elevated levels f irulating aetylh- line reeptr antibdies is useful beause it has a sensitiv- ity f 8090% fr the diagnsis f myasthenia gravis. Certain patients withut antibdies t aetylhline reeptrs have serum antibdies t musle-speifi tyr- sine kinase (MuSK), whih shuld therefre be deter- mined; these patients are mre likely t have faial, respiratry, and prximal musle weakness than thse with antibdies t aetylhline reeptrs. Other antibd- ies assiated with myasthenia gravis inlude lw-density lipprtein reeptr-related prtein 4 (LRP4) and agrin, but tests fr these antibdies are nt widely mmerially available. Eletrphysilgi demnstratin f a derementing musle respnse t repetitive 2- r 3-Hz stimulatin f mtr nerves indiates a disturbane f neurmusular transmissin. Suh an abnrmality may even be deteted in linially strng musles with ertain prvative pre- dures. Needle eletrmygraphy f affeted musles shws a marked variatin in nfiguratin and size f individual mtr unit ptentials, and single-fiber eletrmygraphy reveals an inreased jitter, r variability, in the time interval between tw musle fiber atin ptentials frm the same mtr unit.C.  ImagingA  CT san f the hest with and withut ntrast shuld be btained t demnstrate a existing thymma. TreatmentAntih linesterase mediatins prvide symptmati ben- efit withut influening the urse f the disease. Nestig- mine, pyridstigmine, r bth an be used, the dse being determined n an individual basis. The usual dse f ne- stigmine is 7.530 mg (average, 15 mg) rally taken fur times daily; f pyridstigmine, 30180 mg (average, 60 mg) rally fur times daily. Overmediatin may temprarily inrease weakness. A wide range f mediatins (eg, ami- nglysides) may exaerbate myasthenia gravis and shuld be avided. Thymetmy shuld be perfrmed when a thymma is present. A multienter randmized trial demnstrated the benefit f thymetmy even in the absene f a radilgi- ally identifiable thymma, with imprved strength, lwer immunsuppressin requirements, and fewer hspitaliza- tins in the surgially treated grup. Thus, thymectomy should be considered in all patients younger than age 65 unless weakness is restricted to the extraocular muscles. If the disease is f reent nset and nly slwly prgressive,peratin is smetimes delayed fr a year r s, in the hpe that spntaneus remissin will ur. Treatment with rtisterids is indiated fr patients wh have respnded prly t antihlinester- ase mediatins. Sme patients experiene transient exaerbatin f weakness and even develp respiratry failure within the first 12 weeks if rtisterids are initiated at high dses (eg, prednisne 1 mg/kg/day). Therefre, in stable patients, rtisterids are intr- dued gradually in the utpatient setting. Prednisne an be started at 20 mg rally daily and inreased by 10 mg inrements weekly t a target f 1 mg/kg/day (maximum daily dse 100 mg). Fr patients hspitalized with severe myasthenia and treated with IVIG r plasma- pheresis, the higher dse an be given initially beause the mre rapid nset f atin f the frmer tw thera- pies mitigates the initial dip in strength due t rti- sterids. Crtisterids an be presribed as alternate-day r daily treatment, with alternate-day therapy ptentially mitigating side effets. One the patient has stabilized at the initial high dse, rtiste- rids an gradually be tapered t a relatively lw main- tenane level (eg, 10 mg prednisne rally daily) as imprvement urs; ttal withdrawal is diffiult, hw- ever. Treatment with azathiprine may be effetive in allwing a lwer dse f rtisterids. The usual dse is 23 mg/kg rally daily after a lwer initial dse. Other immunsuppressive agents that are used in myasthenia gravis t redue the rtisterid dse inlude myphe- nlate mfetil, rituximab, ylsprine, methtrexate, and tarlimus. Eulizumab, a mplement inhibitr, is apprved by the FDA fr aetylhline reeptr antibdy psitive myasthenia in patients wh have disease refra- try t at least tw alternate immunsuppressive thera- pies. It is administered intravenusly (900 mg weekly fr fur dses, fllwed by 1200 mg at week 5, then 1200 mg every 2 weeks). Patients must be vainated against menin- gus prir t reeiving eulizumab. In patients with majr disability, plasmapheresis r IVIG therapy may be benefiial and have similar effiay. It is als useful fr stabilizing patients befre thymetmy and fr managing aute risis. When to ReferAll patients sh uld be referred. When to Admit Patients with aute exaerbatin r respiratry invlvement. Patients requiring plasmapheresis. Fr thymetmy.Fa rmakidis C et al. Treatment f myasthenia gravis. Neurl Clin. 2018;36:311. [PMID: 29655452] Muppidi S et al; Regain Study Grup. Lng-term safety and effiay f eulizumab in generalized myasthenia gravis. Musle Nerve. 2019;60:14. [PMID: 30767274]CMDT22_Ch24_p0978-p1053.indd  1049 29/06/21 8:50 PMChapTER 241050 CMDT 20222.  Mystenic Syndrome (Lmbert-Eton Mystenic Syndrome)E S S E N T I A L S  O F  D I A G N O S I S Variable weakness, typically improving with activity. Dysautonomic symptoms may also be present. A history of malignant disease may be obtained. Clinical FindingsM yastheni syndrme may be associated with small cell carcinoma, smetimes develping befre the tumr is diag- nsed, and asinally urs with ertain autimmune diseases. There is defetive release f aetylhline in respnse t a nerve impulse, aused by P/Q-type vltage- gated alium hannel antibdies, and this leads t weak- ness, espeially f the prximal musles f the limbs. Unlike myasthenia gravis, hwever, pwer steadily increases with sustained ntratin. The diagnsis an be n- firmed eletrphysilgially, beause the musle respnse t stimulatin f its mtr nerve inreases remarkably after exerise r if the nerve is stimulated repetitively at high rates (50 Hz), even in musles that are nt linially weak. TreatmentT reatment with IVIG, plasmapheresis, and immunsup- pressive mediatin therapy (prednisne and azathiprine) may lead t linial and eletrphysilgi imprvement, in additin t therapy aimed at tumr when present. Pred- nisne is usually initiated in a daily dse f 6080 mg rally and azathiprine in a daily dse f 2 mg/kg rally. Symp- tmati therapy inludes the use f ptassium hannel antagnists; f these, amifampridine is a 3,4-diaminpyri- dine (1580 mg/day rally in three divided dses) and is apprved in the United States and Eurpe. Guanidine hydrhlride (2550 mg/kg/day rally in divided dses) is an alternative and is asinally helpful in seriusly dis- abled patients, but adverse effets f the mediatin inlude marrw suppressin. The respnse t treatment with antihlinesterase mediatins suh as pyridstig- mine r nestigmine is usually disappinting.3.  BotulismThe txin f  Clostridium botulinum prevents the release f aetylhline at neurmusular juntins and autnmi synapses. Btulism urs mst mmnly fllwing the ingestin f ntaminated hme-anned fd; utbreaks have als urred amng drug abusers due t wund infetin after injetin f ntaminated herin. The diagnsis shuld be suggested by the develpment f sud- den, flutuating, severe weakness with preserved sensa- tin in a previusly healthy persn. Symptms begin within 72 hurs fllwing ingestin f the txin and may prgress fr several days. Typially, there is diplpia, ptsis,faial weakness, dysphagia, and nasal speeh, fllwed by respiratry diffiulty and finally by weakness that appears last in the limbs. Blurring f visin (with unreative dilated pupils) is harateristi, and there may be dryness f the muth, nstipatin (paralyti ileus), and pstural hyp- tensin. The tendn reflexes are nt affeted unless the invlved musles are very weak. If the diagnsis is sus- peted, the lal health authrity shuld be ntified and a sample f serum and ntaminated fd (if available) sent t be assayed fr txin. Supprt fr the diagnsis may be btained by eletrphysilgi studies; with repetitive stimulatin f mtr nerves at fast rates, the musle respnse inreases in size prgressively. Patients shuld be hspitalized in ase respiratry assis- tane bemes neessary. Treatment is with heptavalent antitxin, in patients withut knwn allergy t hrse serum. Ptassium hannel antagnists may prvide symp- tmati relief as they d in Lambert-Eatn myastheni syndrme. Antihlinesterase mediatins are f n value. Respiratry assistane and ther supprtive measures shuld be prvided as neessary. Further details are pr- vided in Chapter 33.4.  Disorders associted wit Use of aminoglycosidesAminglyside  antibitis, eg, gentamiin, may prdue a linial disturbane similar t btulism by preventing the release f aetylhline frm nerve endings, but symptms subside rapidly as the respnsible mediatin is eliminated frm the bdy. These antibitis are partiularly dangerus in patients with preexisting disturbanes f neurmusular transmissin and are therefre best avided in patients with myasthenia gravis.MYOp aThIC DISORDERSE S S E N T I A L S  O F  D I A G N O S I S Muscle weakness without sensory loss, often in a characteristic distribution. Serum creatine kinase elevated in most cases. Age at onset, time course, and inheritance pattern may suggest underlying disorder. General ConsiderationsMy pathies an be inherited r aquired. Aquired mypa- thies ften present autely r subautely while inherited mypathies are typially insidius in nset. Patients typi- ally mplain f weakness affeting prximal musles, suh as diffiulty limbing stairs, arising frm a hair, r reahing verhead, r f head drp. Sensry symptms are absent. A detailed family histry is required. Examinatin shws weakness f prximal musles. In sme ases, there is a mre speifi pattern f weaknessCMDT22_Ch24_p0978-p1053.indd  1050 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1051 CMDT 2022(eg,  quadrieps and finger flexr weakness in inlusin bdy mysitis). Extraular musle invlvement is rarely seen, exept in ertain mithndrial disrders, ulpha- ryngeal musular dystrphy, and hyperthyridism; when present, it shuld suggest the pssibility f a neurmusular juntin disrder. Reflexes are nrmal r diminished in prprtin t the degree f weakness. Sensatin is nrmal. Initial testing shuld inlude serum reatine kinase determinatin. Cnsider testing thyrid-stimulating hr- mne, rtisl, vitamin D, and alium. Antibdies speifi t ertain inflammatry mypathies and nnetive tissue disease an be heked when these nditins are suspeted (see Chapter 20). Eletrmygraphy will reveal small mtr units and early reruitment; it is helpful in nfirming the lalizatin f weakness t the musle and suggesting a suitable site fr bipsy, as des MRI. The eletrmy- graphi findings may be nrmal in rtisterid and mithndrial mypathies. Musle bipsy establishes the diagnsis when inflammatry, mithndrial, metabli, r ertain inherited mypathies are suspeted. In ases where the family histry r pattern f weakness suggests aspeifi geneti disrder, geneti testing an be pursued diretly and bipsy may nt be needed. Seleted mmn and treatable mypathies are disussed belw.1.  Musculr DystroiesThese  inherited mypathi disrders are subdivided by mde f inheritane, age at nset, and linial features, as shwn in Table 2410. In the Duchenne type, pseudhy- pertrphy f musles frequently urs at sme stage; intel- letual disability is mmn; and there may be skeletal defrmities, musle ntratures, and ardia invlvement. A geneti defet n the shrt arm f the X hrmsme has been identified in Duhenne dystrphy. The affeted gene des fr the prtein dystrphin, whih is markedly redued r absent frm the musle f patients with the disease. Dystrphin levels are generally nrmal in the Becker variety, but the prtein is qualitatively altered. The diagnsis is usually made with geneti testing; musle bipsy is needed asinally. Duhenne musular dystr- phy an be regnized early in pregnany in abut 95% f Table 2410. Selected muscular dystrophies (listed in order of anatomic location and physiologic underpinning).1Disorder Ineritnceage t Onset (yers) Distribution prognosis Genetic assocition Duchenne type X-linked recessive 15 Pelvic, then shoulder girdle; later, limb and respiratory muscles.Rapid progression. Death within about 15 years after onset.Xp21; Dystrophin (loss of functional expression). Becker X-linked recessive 525 Pelvic, then shoulder girdle.Slow progression. May have normal life span.Xp21; Dystrophin (reduced functional expression). Limb-girdle (Erb) Autosomal recessive, dominant, or sporadic1030 Pelvic or shoulder girdle initially, with later spread to the other.Variable severity and rate of progression. Possi- ble severe disability in middle life.Multiple. Facioscapulo- humeralAutosomal dominantAny age Face and shoulder girdle initially; later, pelvic girdle and legs.Slow progression. Minor disability. Usually normal life span.4q35.2; Double homeobox protein 4. 18p11.32; Structural maintenance of chromosomes flexible hinge domain- containing protein 1. Emery-Dreifuss X-linked recessive or autosomal dominant510 Humeroperoneal or scapuloperoneal.Variable. Multiple. Distal Autosomal domi- nant or recessive4060 Onset distally in extremities; proximal involvement later.Slow progression. Multiple. Oculopharyngeal Autosomal dominantAny age Ptosis, external ophthal- moplegia, and dysphagia.Slow progression. 14q11.2q13; Poly (A)-binding protein-2. Myotonic dystrophyAutosomal dominantAny age (usually 2040)Face, neck, distal limbs. Slow progression. 19q13.32; Myotonin- protein kinase. 3q21.3; Cellular nucleic acid-binding protein.1 Not all possible genetic loci are shown.CMDT22_Ch24_p0978-p1053.indd  1051 29/06/21 8:50 PMChapTER 241052 CMDT 2022wmen  by geneti studies; in late pregnany, DNA prbes an be used n fetal tissue btained fr this purpse by amnientesis. The genes ausing sme f the ther mus- ular dystrphies are listed in Table 2410. Three antisense lignuletides are apprved by the FDA fr treatment f Duhenne musular dystrphy. Eteplirsen appears t benefit thse patients with a dystr- phin mutatin amenable t exn 51 skipping; gldirsen and viltlarsen benefit thse with a mutatin amenable t exn 53 skipping. Patients treated with these antisense lignuletides had mre funtinal dystrphin n mus- le bipsy than ntrls and a slwer rate f disease pr- gressin than mathed histrial ntrls. Prednisne (0.75 mg/kg rally daily r 10 mg/kg rally given weekly ver 2 days) r deflazart (0.9 mg/kg rally daily) imprves musle strength and funtin in bys with Duhenne dystrphy, but side effets need t be mni- tred. Althugh bth rtisterid preparatins ause similar side effets, weight gain at 1 year is less with deflazart. Prlnged bed rest must be avided, as inativ- ity ften leads t wrsening f the underlying musle dis- ease. Physial therapy and rthpedi predures may help unterat defrmities r ntratures.2.  Myotonic DystroyMy tni dystrphy, a slwly prgressive, dminantly inherited disrder, usually manifests itself in the third r furth deade but asinally appears early in hildhd. Tw types, with a different geneti basis, have been reg- nized. Mytnia leads t mplaints f musle stiffness and is evidened by the marked delay that urs befre affeted musles an relax after a ntratin. This an ften be demnstrated linially by delayed relaxatin f the hand after sustained grip r by perussin f the belly f a musle. In additin, there is weakness and wasting f the faial, sternleidmastid, and distal limb musles. Assiated linial features inlude atarats, frntal bald- ness, testiular atrphy, diabetes mellitus, ardia abnr- malities, and intelletual hanges. Eletrmygraphi sampling f affeted musles reveals mytni disharges in additin t hanges suggestive f mypathy. It is diffiult t determine whether mediatin therapy fr mytnia is safe r effetive. When mytnia is dis- abling, treatment with a sdium hannel blkersuh as phenytin (100 mg rally three times daily), prainamide (0.51 g rally fur times daily), r mexiletine (150200 mg rally three times daily)may be helpful, but the assiated side effets, partiularly fr antiarrhythmi mediatins, are ften limiting. Neither the weakness nr the urse f the disrder is influened by treatment. Cardia funtin shuld be mnitred, and paemaker plaement may be nsidered if there is evidene f heart blk.3.  Myotoni CongenitM ytnia ngenita is mmnly inherited as a dminant trait. Generalized mytnia withut weakness is usually present frm birth, but symptms may nt appear until early hildhd. Patients mplain f musle stiffness that is enhaned by ld and inativity and relieved by exerise.Musle hypertrphy, at times prnuned, is als a feature. A reessive frm with later nset is assiated with slight weakness and atrphy f distal musles. Treatment with prainamide, tainide, mexiletine, r phenytin may help the mytnia, as in mytni dystrphy.4.  Mitocondril MyotiesThe  mithndrial mypathies are a linially diverse grup f disrders that n pathlgi examinatin f skel- etal musle with the mdified Gmri stain shw hara- teristi ragged red fibers ntaining aumulatins f abnrmal mithndria. Patients may present with pr- gressive external phthalmplegia r with limb weakness that is exaerbated r indued by ativity. Other patients present with entral neurlgi dysfuntin, eg, my- lni epilepsy ( myoclonic epilepsy, ragged red fiber syndrome, or MERRF ), r the mbinatin f mypathy, enephalpathy, lati aidsis, and strke-like episdes (MELAS ). Migraine is a mmn symptm. Systemi fea- tures inlude but are nt limited t diabetes mellitus, hear- ing lss, retinpathy, ardimypathy, gastri dysmtility, and shrt stature. The serum reatine kinase is usually nr- mal. Mithndrial mypathies result frm separate abnr- malities f mithndrial DNA. Treatment is symptmati and palliative, but varius experimental apprahes are being explred.5.  acid Mltse Deficiency (pome Disese)This  is a glygen strage disease due t mutatins in the gene ending aid alpha-1,4-glusidase. Age at presenta- tin ranges frm infany t the late fifties and depends n the degree f residual enzyme ativity. The juvenile and adult-nset frms present with slwly prgressive prximal weakness that inludes respiratry failure. Cardimypathy is less mmn in the adult frm. Serum reatine kinase is mildly elevated. Musle bipsy shws glygen ntaining lyssmal vaules, but the diagnsis is suggested by deteting redued aid-1,4-alpha-glusidase ativity n a dried bld spt, and nfirmed by geneti testing. Treat- ment with rembinant alpha-glusidase (20 mg/kg intra- venusly every 2 weeks) stabilizes disease prgressin and results in imprvement in respiratry funtin.6.  Dermtomyositis, anti-Syntetse Syndromes, Immune-Medited Necrotizing Myoties, & polymyositisSee Chapter 20. 7.  Inclusion Body MyositisThis  disrder, f unknwn ause, begins insidiusly, usu- ally after middle age, with prgressive prximal weakness f first the lwer and then the upper extremities, and affeting faial and pharyngeal musles. Weakness ften begins in the quadrieps femris in the lwer limbs and the frearm flexrs in the upper limbs. Distal weakness is usu- ally mild. Serum reatine kinase levels may be nrmal r inreased. The diagnsis is nfirmed by musle bipsy.CMDT22_Ch24_p0978-p1053.indd  1052 29/06/21 8:50 PMNERVOUS SYSTEM DISORDERS1053 CMDT 2022Antiytsli  5-nuletidase 1A antibdies are deteted in ne-third f ases and may be assiated with a mre severe phentype. Crtisterid and immunsuppressive therapy is smetimes ffered but is usually ineffetive, and IVIG therapy is nt remmended.8.  Endocrine MyotiesM ypathy is bserved with hypthyridism, hyperthyrid- ism, Cushing syndrme and disease, Addisn disease, vitamin D defiieny, and bth hyperparathyridism and hypparathyridism (the latter mediated by alium derangements). In hypthyridism, there may be assi- ated entrapment neurpathies, and examinatin may shw delayed relaxatin f tendn reflexes, musle enlargement, r myedema. Hyperthyridism an ause bth distal and prximal weakness and rarely a bulbar mypathy. Serum reatine kinase is nrmal exept in hypthyrid mypathy, whih an als be painful. Treatment is f the underlying endrinpathy.9.  Criticl Illness MyotyM ypathy may ur in assiatin with ritial illness, typially in patients wh reeived neurmusular blking agents and rtisterids. It is frequently disvered when patients unexpetedly require prlnged ventilatry sup- prt. There an be an assiated sensrimtr plyneu- rpathy. Serum reatine kinase may be elevated initially but has frequently returned t nrmal r is belw nrmal by the time the nditin is suspeted. Treatment is supprtive.10.  Toxic MyotiesM ypathy an ur in patients taking aminapri aid, amidarne, hlrquine, lhiine, rtisterids, yl- sprine, daptmyin, emetine, fibrates, gemitabine, nule- side reverse transriptase inhibitrs, r statin mediatins. Mypathy als urs with hrni alhlism, whereas aute reversible musle nersis may ur shrtly after aute alhl, aine, r methamphetamine intxiatin, and with prpfl infusin. Inflammatry mypathy may ur in patients taking peniillamine and an be indued by pr- grammed death-1 inhibitrs; mytnia may be indued by lfibrate, and preexisting mytnia may be exaerbated r unmasked by deplarizing musle relaxants (eg, suxameth- nium), beta-blkers (eg, prpranll), fenterl and, pssi- bly, ertain diuretis. Valpri aid an preipitate r wrsen mypathy in patients with mithndrial disrders r arni- tine palmityltransferase II defiieny. When to ReferAll  patients shuld be referred t establish the diagnsis and underlying ause.When to Admit Fr respiratry assistane. Fr rhabdmylysis.MD nald CM et al; CINRG Investigatrs. Lng-term effets f glurtiids n funtin, quality f life, and survival in patients with Duhenne musular dystrphy: a prspetive hrt study. Lanet. 2018;391:451. [PMID: 29174484] Pasnr M et al. Apprah t musle and neurmusular jun- tin disrders. Cntinuum (Minneap Minn). 2019;25:1536. [PMID: 31794459]pE RIODIC paRaLYSIS SYNDROMESPe ridi paralysis may have a familial (dminant inheri- tane) basis. The syndrmes t be desribed are channelo- pathies that manifest as abnrmal, ften ptassium-sensitive, musle-membrane exitability and lead linially t epi- sdes f flaid weakness r paralysis, smetimes in ass- iatin with abnrmalities f the plasma ptassium level. Strength is initially nrmal between attaks, but prgres- sive mypathi weakness may develp in up t ne-third f patients as they age. Hypokalemic periodic paralysis is haraterized by attaks that tend t ur n awakening, after exerise, r after a heavy meal and may last fr several days. Patients shuld avid exessive exertin. A lw- arbhydrate and lw-salt diet may help prevent attaks. An nging attak may be abrted by ptassium hlride given rally r by intravenus drip, prvided the ECG an be mnitred and kidney funtin is satisfatry. In yung Asian men, it is mmnly assiated with hyperthyrid- ism; treatment f the endrine disrder prevents reur- renes. A nnseletive beta-adrenergi blker may prevent attaks until the endrine abnrmality has been treated. Inhyperkalemic periodic paralysis, attaks als tend t ur after exerise but usually last fr less than 1 hur. They may be terminated by intravenus alium glunate (12 g) r by intravenus diuretis (fursemide, 2040 mg), gluse, r gluse and insulin. Normokalemic periodic paralysis is similar linially t the hyperkalemi variety, but the plasma ptassium level remains nrmal during attaks. Several randmized trials supprt the use f dihlrphenamide (50100 mg rally twie daily) fr pre- ventin f attaks in bth hyperkalemi and hypkalemi peridi paralysis; aetazlamide (250750 mg rally daily) is als effetive. Chlrthiazide may als be used t prevent attaks in hyperkalemi peridi paralysis. When to ReferAll patients sh uld be referred.CMDT22_Ch24_p0978-p1053.indd  1053 29/06/21 8:50 PM1054 CMDT 2022The fifth e dition of the American Psychiatric Associations Diagnostic and Statistical Manual (DSM-5) is the common language that clinicians use for psychiatric conditions. It utilizes specific criteria with which to objectively assess symptoms for use in clinical diagnosis and communication. COMMON PSYCHIATRIC DISORDERS ADJUSTMENT DISORDERSE S S E N T I A L S  O F  D I A G N O S I S Anxiety or depression in reaction to an identifi- able stress, though out of proportion to the sever- ity of the stressor. Symptoms are not at the severity of a major depressive episode or with the chronicity of gen- eralized anxiety disorder (GAD). General ConsiderationsAn individual experiences stress when adaptive ca pacity is overwhelmed by events. The event may be an insignificant one when objectively considered, and even favorable changes (eg, promotion and transfer) requiring adaptive behavior can produce stress. For everyone, stress is subjec- tively defined, and the response to stress is a function of each persons personality and physiologic endowment. Opinion differs about what events are most apt to pro- duce stress reactions. The causes of stress are different at different ageseg, in young adulthood, the sources of stress are found in the marriage or parent-child relation- ship, the employment relationship, and the struggle to achieve financial stability; in the middle years, the focus shifts to changing spousal relationships, problems with aging parents, and problems associated with having young adult offspring who themselves are encountering stressful situations; in old age, the principal concerns are apt to be retirement, loss of physical and mental capacity, major personal losses, and thoughts of death.Clinical FindingsAn  individual may react to stress by becoming anxious or depressed, by developing a physical symptom, by running away, drinking alcohol, overeating, starting an affair, or in limitless other ways. Common subjective responses are anxiety, sadness, fear, rage, guilt, and shame. Acute and reactivated stress may be manifested by restlessness, irrita- bility, fatigue, increased startle reaction, and a feeling of tension. Inability to concentrate, sleep disturbances (insomnia, bad dreams), and somatic preoccupations sometimes lead to self-medication, most commonly with alcohol or other central nervous system depressants. Emo- tional and behavioral distressing symptomatology in response to stress is called adjustment disorder , with the major symptom specified (eg, adjustment disorder with depressed mood, anxiety, mixed depression and anxiety, disturbance of conduct, mixed disturbance of emotions and conduct, or unspecified. ). Even with an identifiable stressor, if the patient meets syndromal criteria for another disorder such as major depression, then the convention would be to diagnose a major depression and not an adjustment disorder with depressed mood . Differential DiagnosisAd justment disorders are distinguished from anxiety dis- orders, mood disorders, bereavement, other stress disor- ders such as posttraumatic stress disorder (PTSD), and personality disorders exacerbated by stress and from somatic disorders with psychic overlay. Unlike many other psychiatric disorders, such as bipolar disorder or schizo- phrenia, adjustment disorders are wholly situational and usually resolve when the stressor resolves or the individual effectively adapts to the situation. Adjustment disorders may have symptoms that overlap with other disorders, such as anxiety symptoms, but they occur in reaction to an iden- tifiable life stressor such as a difficult work situation or romantic breakup. An adjustment disorder that persists and worsens can potentially evolve into another psychiatric disorder such as major depression or GAD. However, that is not the case for most patients. Patients with adjustment disorders have marked distress after a stressor and signifi- cant impairment in social or occupational functioning but25Kristin S. Raj, MD Nolan Williams, MD Charles DeBattista, DMH, MDPsychiatric DisordersCMDT22_Ch25_p1054-p1109.indd  1054 29/06/21 8:51 PM"
                ],
                [
                  "3",
                  "KIDNEY DISEASE913 CMDT 2022Thr  ar svral rasons protinuria may dvlop: (1) Functional proteinuria is a bnign procss stmming from strssors such as acut illnss, xrcis, and ortho- static protinuria.  Th lattr condition, gnrally found in popl undr 30 yars of ag, usually causs protin xcr- tion lss than 1 g/day. Th orthostatic natur of th protin- uria is confirmd by masuring an 8-hour ovrnight supin urinary protin xcrtion, which should b lss than 50 mg. (2)Overload proteinuria occurs whn th rabsorptiv capacity of tubuls is ovrwhlmd, which can rsult from xcss production of low-molcular-wight plasma pro- tins (g, Bnc Jons protins associatd with plasma cll myloma). In th cas of plasma cll myloma, protin lctrophorsis from srum or urin will xhibit a discrt, monoclonal protin spik. Othr xampls of ovrload protinuria includ myoglobinuria in rhabdomyolysis and hmoglobinuria in hmolysis. (3) Glomerular proteinuria rsults from ffacmnt of pithlial cll foot procsss and altrd glomrular prmability with an incrasd filtra- tion fraction of normal plasma protins, as in diabtic nphropathy. Protin lctrophorsis will xhibit a larg albumin spik indicativ of th incrasd prmability of albumin across th damagd GBM. (4) Tubular protein- uria occurs as a rsult of faulty rabsorption of normally filtrd protins in th proximal tubul, such as bta- 2-microglobulin. Causs may includ ATN, toxic injury (lad, aminoglycosids, and crtain antirtrovirals), drug- inducd intrstitial nphritis, and hrditary mtabolic disordrs (Wilson disas and Fanconi syndrom). Evaluation of protinuria by urin dipstick dos not actually masur protin but instad dtcts th ngativ lctrochmical charg that charactrizs albumin. As a rsult, positivly chargd Bnc Jons protins ar missd with dipstick analysis. Bnc Jons protins can b dtctd by th addition of sulfosalicylic acid to th urin spcimn or, mor commonly, dirctly masuring urin protin. It should b notd that, bcaus urin dipstick simply dtcts ngativ lctrochmical charg, alkalin urin (pH > 7.0) can caus fals-positiv rsults. Whil urin dipstick is commonly usd to scrn for pro- tinuria, quantitativ invstigation rquirs dirct valuationof urin protin xcrtion. This can b stimatd with a random urin sampl or masurd from a timd urin collction (typically 24 hours). Collction of a random urin sampl is far simplr, and th ratio of urin protin- to-cratinin concntration ([Uprotin]/[Ucratinin]) corrlats with a 24-hour urin protin collction (lss than 0.2 is normal and corrsponds to xcrtion of lss than 200 mg/ 24 hours). In a 24-hour collction, protinuria abov 150 mg is abnormal and abov 3 g is classifid as nphrotic- rang. On bnfit of a random protin-to-cratinin ratio is th minimization of rror from ovrcollction or undrcol- lction of urin in th 24-hour spcimn. A kidny biopsy may b indicatd to dtrmin th caus of abnormal pro- tinuria, particularly if accompanid by abnormal GFR or hmaturia. Th clinical squla of protinuria ar dis- cussd in th sction on Nphrotic Spctrum Glomrular Disass.B.  HematuriaH maturia is considrd clinically significant if thr ar mor than thr rd blood clls pr high-powr fild on at last two occasions. It is usually dtctd incidntally on urin dipstick or following an pisod of macroscopic hma- turia. Th diagnosis must b confirmd via microscopic xamination, as fals-positiv dipstick tsts can b causd by myoglobin, oxidizing agnts, bts and rhubarb, hydrochlo- ric acid, and bactria. Transint hmaturia is common but is lss oftn clinically significant in patints youngr than 40 yars du to lowr concrn for malignancy. Hmaturia may b du to rnal or xtrarnal causs. Extrarnal causs ar addrssd in Chaptr 23. Rnal causs account for approximatly 10% of cass and ar clas- sifid as ithr glomrular or xtraglomrular. Glomrular causs includ glomrulonphritis (g, immunoglobulin A [IgA] nphropathy), thin basmnt mmbran disas and othr hrditary disordrs (g, Alport syndrom), and sys- tmic nphritic syndroms (g, lupus nphritis). Extraglo- mrular sourcs includ cysts; calculi; intrstitial nphritis; and, most worrisom, gnitourinary noplasms from th kidny, prostat, or bladdr (s Chaptr 39). Glomerular Filtration RateTh  GFR provids a usful masur of kidny function at th lvl of th glomrulus and can ithr b masurd dirctly using biomarkrs (most commonly cratinin) or stimatd using validatd formula. Th GFR masurs th amount of plasma ultrafiltrd across th glomrular capil- laris pr unit tim and rflcts th kidnys ability to filtr fluids and substancs, including mdications; it is oftn usd to dtrmin drug dosing. Daily GFR in normal indi- viduals is variabl, with a rang of 150250 L/24 h or 100120 mL/min/1.73 m2of body surfac ara. Patints with kidny disas can hav dcrasd GFR from any procss that causs loss of functional glomruli. Howvr, thy can also hav normal or incrasd GFR, ithr from glomrular hyprfiltration or disas at a diffrnt sgmnt of th nphron, intrstitium, or vascular supply. GFR can b masurd by dtrmining th rnal clar- anc of plasma substancs that ar not bound to plasmaTable 221. Significance of specific urinary casts.T ye Significance Hyaline casts Not indicative of kidney disease Concentrated urine, febrile disease, diuretic therapy, after strenuous exercise Red cell casts Glomerulonephritis White cell casts Indicative of infection or inflammation Pyelonephritis, interstitial nephritis Renal tubular cell castsAcute tubular necrosis, interstitial nephritis Granular (muddy brown) castsNonspecific; can indicate acute tubular necrosis Broad waxy casts Indicative of stasis in enlarged collecting tubules Chronic kidney diseaseCMDT22_Ch22_p0912-p0951.indd  913 02/07/21 2:33 PMChApTEr 22914 CMDT 2022pro tins, ar frly filtrabl across th glomrulus, and ar nithr scrtd nor rabsorbd along th rnal tubuls. Th rnal claranc of a substanc is dfind as:= CU  V Pwhr  C is th claranc, U and P ar th rspctiv urin and plasma concntrations of th substanc (mg/dL), and V.is volum of urin pr unit tim (typically mL/min). In clinical practic, th claranc of ndognous cratinin (trmd creatinine clearance ) is th primary way to ma- sur GFR. Th cratinin claranc (Ccr) is approximatly 100 mL/min in halthy young womn and 120 mL/min in halthy young mn. Th cratinin claranc dclins by an avrag of 0.8 mL/min/yr aftr ag 40 yars as part of th aging procss. Cratinin is a product of muscl mtabolism producd at a rlativly constant rat and clard by rnal xcrtion. It is frly filtrd by th glomrulus and not rabsorbd by th rnal tubuls. Howvr, cratinin is not a prfct indicator of GFR for th following rasons: (1) a small amount is normally liminatd by tubular scrtion, and it progrssivly incrass as GFR dclins (thus ovrs- timating GFR); (2) with svr kidny failur, gut microor- ganisms dgrad cratinin; (3) ditary mat intak and muscl mass affct plasma cratinin lvls; (4) mdications such as aspirin, dolutgravir, probncid, and trimthoprim rduc tubular scrtion of cratinin, incrasing th plasma cratinin concntration and falsly suggsting kidny dys- function; and (5) th masurmnt assums a stabl plasma cratinin concntration ovr a 24-hour priod, so whn valus ar changing during th dvlopmnt of and rcov- ry from AKI, cratinin claranc is inaccurat. On way to masur cratinin claranc is to prform a timd urin collction and dtrmin th plasma cratinin lvl midway through th collction. An incomplt or pro- longd urin collction is a common sourc of rror. Th compltnss of th collction can b stimatd by compar- ing th amount of cratinin xcrtd in th collction to that xpctd ovr a 24-hour priod, which should b constant: Ucr V.= 15  20 mg/kg for healthy young women Ucr V.= 20  25 mg/kg for healthy young men Givn th tdious natur of timd urin collctions for masuring GFR, GFR is mor commonly stimatd (dnotd GFR) using formula that hav bn validatd using patint charactristics (such as ag, wight, rac, and sx) and plasma cratinin lvls. Th Kidny Disas Improv- ing Global Outcoms workgroup rcommnds GFR for- mula as th primary mthod for dtrmining GFR. Th prfrrd GFR formula is th 2009 CKD-Epidmiology (EPI) Collaboration cratinin quation (https://www. kidny.org/contnt/ckd-pi-cratinin-quation-2009). An altrnativ cratinin-basd GFR stimating quation is accptabl if it improvs accuracy ovr th CKD-EPI qua- tion. Svral wb-basd calculators will calculat th GFR (g, http://touchcalc.com/calculators/pi). Th Cockcroft- Gault formula is commonly usd to dtrmin drug dos- ing, but it is no longr rcommndd sinc it was dvlopdbfor th standardization of cratinin assays currntly in us.Cystatin C is anothr ndognous markr of GFR that is filtrd frly at th glomrulus, producd at a rlativly constant rat, and lss dpndnt on muscl mass. It is rabsorbd and partially mtabolizd in th rnal tubular pithlial clls. Adding th masurmnt of cystatin C to srum cratinin can improv th accuracy of th GFR. A larg mta-analysis showd that cystatin C alon or in combination with srum cratinin is a strongr prdictor of important clinical vnts, such as nd-stag kidny dis- as (ESKD) or dath, than srum cratinin alon. How- vr, bcaus cystatin C is not univrsally availabl or standardizd across assays, it rmains a complmntary biomarkr for stimating GFR. BUN is anothr indx usd in assssing kidny func- tion. It is synthsizd mainly in th livr and is th nd product of protin catabolism. Ura is frly filtrd by th glomrulus, but about 3070% is rabsorbd in th rnal tubuls. As such, it undrstimats GFR. Rnal ura rab- sorption incrass (in conjunction with incrasd sodium rabsorption) in hypovolmic patints (who, thrfor, hav an incrasd BUN). A normal BUN:cratinin ratio is approximatly 10:1, although this varis btwn individu- als. With volum dpltion, th ratio can incras to 20:1 or highr. Othr causs of incrasd BUN includ incrasd catabolism (gastrointstinal [GI] blding, cll lysis, and corticostroid usag), incrasd ditary protin, and dcrasd rnal prfusion prompting incrasd sodium (and thrfor BUN) rabsorption (g, hart failur, rnal artry stnosis) (Tabl 222). Rducd BUN lvls ar sn in livr disas and in th syndrom of inappropriat antidiurtic hormon (SIADH). In summary, cratinin and ura clarancs ovrsti- mat and undrstimat GFR, rspctivly. Bcaus ach of ths stimats bcom mor inaccurat as kidny disas advancs, a mor accurat masur of GFR as patints approach ESKD is th avrag of th cratinin and ura clarancs.KI DNEY BIOPSYIndica tions for prcutanous ndl biopsy includ (1) unxplaind AKI or CKD; (2) unxplaind protinuria or hmaturia, or both; (3) prviously idntifid and tratd Table 222. Conditions affecting BUN independently of GFR.Inceased  BUN Reduced effective circulating blood volume (prerenal azotemia) Catabolic states (gastrointestinal bleeding, corticosteroid use) High-protein diets Tetracycline Deceased BUN Liver disease Malnutrition Sickle cell anemia SIADH BUN, blood urea nitrogen; GFR, glomerular filtration rate; SIADH, syndrome of inappropriate antidiuretic hormone.CMDT22_Ch22_p0912-p0951.indd  914 02/07/21 2:33 PMKIDNEY DISEASE915 CMDT 2022lsions to guid futur thrapy; (4) sy stmic disass asso- ciatd with kidny dysfunction, such as systmic lupus rythmatosus (SLE), anti-GBM disas, and granuloma- tosis with polyangiitis; and (5) kidny transplant dysfunc- tion, to valuat for transplant rjction or othr abnormalitis. Kidny biopsis should only b prformd if th rsults will influnc th tratmnt plan or facilitat discussion about prognosis. Rlativ contraindications includ a solitary or ctopic kidny (xcption for trans- plant allografts), horssho kidny, ESKD, congnital anomalis, and multipl cysts. Absolut contraindications includ an uncorrctd blding disordr; svr uncon- trolld hyprtnsion; rnal infction or noplasm; hydro- nphrosis; or uncooprativ patints, including thos who ar unabl to li flat for th procdur. Prcutanous kidny biopsis ar gnrally saf. Th major risk is blding, which may occur up to 72 hours post biopsy. Mor than half of patints will hav at last a small hmatoma; approximatly 15% of patints will xprinc significant blding rquiring a blood transfusion. Antico- agulation should b hld for 57 days post biopsy if possibl. Th risks of nphrctomy and mortality ar about 0.06 0.08%. Whn a prcutanous ndl biopsy is tchnically not fasibl and kidny tissu is dmd clinically ssntial, a closd biopsy via intrvntional radiologic tchniqus or opn biopsy undr gnral ansthsia can b prformd.Bknkamp  A. Protinuriatak a closr look! Pdiatr Nphrol. 2020;35:533. [PMID: 31925536] Cavanaugh C t al. Urin sdimnt xamination in th diagnosis and managmnt of kidny disas: Cor Curriculum 2019. Am J Kidny Dis. 2019;73:258. [PMID: 30249419] Lvy AS t al. Masurd and stimatd glomrular filtration rat: currnt status and futur dirctions. Nat Rv Nphrol. 2020;16:51. [PMID: 31527790] ACUTE KIDNEY INJUrYE S S E N T I A L S  O F  D I A G N O S I S Rapid increase in serum creatinine. Oliguria may be present. Symptoms and signs depend on cause. General ConsiderationsAKI is dfi nd as an absolut incras in srum cratinin by 0.3 mg/dL or mor within 48 hours or a rlativ incras of at last 1.5 tims baslin that is known or prsumd to hav occurrd within 7 days. AKI is charactrizd as oligu- ric if urin production is lss than roughly 400500 mL/day. Clinically, AKI is charactrizd by an inability to maintain acid-bas, fluid, and lctrolyt balanc and to xcrt nitrognous wasts. Stage 1 is a 1.5- to 1.9-fold incras in srum cratinin or a dclin in urinary output to lss than 0.5 mL/kg/h ovr 612 hours; stage 2 is a 2.0- to 2.9-fold incras in srum cratinin or dclin in urinary output to lss than 0.5 mL/kg/h ovr 12 hours or longr; stage 3 is a3.0-fold or gratr incras in srum cratinin, an incras in srum cratinin to gratr than or qual to 4 mg/dL, a dclin in urinary output to lss than 0.3 mL/ kg/h for 24 hours or longr, anuria for 12 hours or longr, or initiation of rnal rplacmnt thrapy. In th absnc of functioning kidnys, srum cratinin concntration will typically incras by 11.5 mg/dL daily, although with crtain conditions, such as rhabdomyolysis, srum crati- nin can incras mor rapidly. On avrag, 5% of hospital admissions and 30% of intnsiv car unit (ICU) admis- sions includ a diagnosis of AKI, and AKI dvlops in 25% of hospitalizd patints. Th rats of AKI in th hospital stting hav incrasd stadily sinc th 1980s and continu to ris. Clinical FindingsA.  Symptoms and SignsAlthough  many patints will not xprinc any symptoms or xhibit any signs of AKI, th buildup of wast products can caus nonspcific symptoms and signs collctivly trmd uremia : nausa, vomiting, malais, and altrd snsorium. Mor commonly, patints xprinc symp- toms and signs of th undrlying disas causing thir AKI (g, lupus). Hyprtnsion can occur, and fluid homostasis is oftn impaird. Hypovolmia can caus stats of low blood flow to th kidnys, somtims trmd prerenal azotemia, whras hyprvolmia can rsult from intrinsic or postrnal disas. Pricardial ffusions can occur with urmia and may rsult in cardiac tamponad; a pricardial friction rub can b prsnt, signaling pricarditis. With hyprkalmia, vntricular tachycardia and othr tachyar- rhythmias can occur. Th lung xamination may rval rals in th prsnc of hyprvolmia. AKI can caus non- spcific diffus abdominal pain and ilus. Platlt dysfunc- tion with blding and clotting disordrs can occur. Th nurologic xamination somtims rvals ncphalo- pathic changs with astrixis and confusion; uncommonly sizurs may nsu.B.  Laboratory FindingsBy  dfinition, lvatd srum cratinin (and oftn BUN) lvls ar prsnt, though ths lvations do not distin- guish AKI from CKD. Mtabolic acidosis (du to dcrasd claranc of organic and inorganic acids) is oftn notd. Hyprkalmia can occur from impaird rnal potassium xcrtion or from shifting of potassium from clls into th blood as a rsult of mtabolic acidosis. With hyprkalmia, ECG can rval pakd T wavs, PR prolongation, and QRS widning. A long QT sgmnt can occur with hypo- calcmia. Hyprphosphatmia occurs whn phosphorus cannot b scrtd by damagd tubuls ithr with or with- out incrasd cll catabolism. Anmia can occur as a rsult of dcrasd rythropoitin production ovr wks, and platlt dysfunction is typical. Classification & EtiologyAKI  is commonly dividd into thr catgoris: prrnal causs (kidny hypoprfusion), intrinsic kidny disas,CMDT22_Ch22_p0912-p0951.indd  915 02/07/21 2:33 PMChApTEr 22916 CMDT 2022and  postrnal causs (obstruction to urinary outflow). Idntifying th caus is th first stp toward tratmnt (Tabl 223).A.  Prerenal CausesPrr nal causs ar th most common tiology of AKI, accounting for 4080% of cass. Prrnal azotmia is a physiologic rspons to rnal hypoprfusion. If rvrsd quickly with rstoration of rnal blood flow (g, fluid rsuscitation), rnal parnchymal damag oftn dos not occur. If hypoprfusion prsists, prrnal azotmia can lad to intrinsic kidny injury. Dcrasd rnal prfusion can occur in svral ways, such as a dcras in intravascular volum, a chang in vascular rsistanc, or low cardiac output. Causs of vol- um dpltion includ hmorrhag (g, from trauma), GI losss, xcssiv diursis, and xtravascular fluid squstra- tion (g, pancratitis, burns, and pritonitis). Changs in systmic vascular rsistanc can occur with spsis, anaphylaxis, ansthsia, and aftrload-rducing drugs. Blockad of th rnin-angiotnsin-aldostron sys- tm, such as with angiotnsin-convrting nzym (ACE) inhibitors, limits ffrnt rnal artriolar constriction out of proportion to affrnt artriolar constriction and thrby dcrass GFR. Nonstroidal anti-inflammatory drugs (NSAIDs) minimiz affrnt artriolar vasodilation by inhibiting prostaglandin-mdiatd signals. NSAIDs may hav particularly dltrious ffcts on rnal prfusion in cirrhosis and hart failur whn prostaglandins ar rcruitd to incras rnal blood flow. Epinphrin, nor- pinphrin, high-dos dopamin, ansthtic agnts, and calcinurin inhibitors also can caus rnal vasoconstric- tion. Rnal artry stnosis causs incrasd rsistanc and dcrasd rnal prfusion.Low cardiac output is a stat of low ffctiv rnal art- rial blood flow. This occurs in stats of hart failur (including cardiognic shock), pulmonary mbolism, and pricardial tamponad. Arrhythmias and valvular disor- drs can also rduc cardiac output. In th intnsiv car stting, positiv prssur vntilation will dcras vnous rturn and, in ffct, cardiac output. Whn GFR falls acutly, it is important to dtrmin whthr AKI is du to prrnal or intrinsic causs. Th his- tory, physical xamination, and laboratory data may b hlpful in distinguishing btwn ths causs. In prrnal AKI, th BUN:cratinin ratio oftn xcds 20:1 du to incrasd ura rabsorption. In oliguric patints, anothr usful indx is th fractional xcrtion of sodium (FeNa). With dcrasd GFR, th kidny rabsorbs salt and watr avidly if thr is no intrinsic tubular dysfunction. Thus, oliguric patints with prrnal AKI should hav a low frac- tional xcrtion of sodium (lss than 1%). Oliguric patints with intrinsic kidny dysfunction typically hav a high FeNa (gratr than 12%), indicating loss of tubular clls ability to rabsorb sodium. Th FeNais calculatd as follows: FeNa = claranc of Na+/GFR = claranc of Na+/Ccr:F Urine  / Serum Urine  / Serum100%E NaNa  Na cr  cr=  Th  quation was cratd and validatd to assss th diffrnc btwn oliguric ATN and prrnal AKI; its util- ity in nonoliguric patints is limitd. Furthr, bcaus diurtics act by incrasing sodium xcrtion, a high FeNa within 1224 hours aftr diurtic administration cannot b maningfully intrprtd. In contrast, a low FeNadespite rciving diurtics offrs strong vidnc of prrnal stats in oliguric patints. Givn th limitations of FeNaTable 223. Classification and differential diagnosis of acute kidney injury. peenal Azotemiapostenal AzotemiaIntinsic renal Disease Acute Tubula Necosis Acute GlomeuloneitisAcute Intestitial Neitis Etiology Poor renal perfusionObstruction of the urinary tractIschemia, nephrotoxinsImmune complex-mediated, pauci-immune, anti-GBM related, monoclonal immunoglobulinmediated, C3 glomerulopathyAllergic reaction; drug reaction; infection; autoimmune disease Serum BUN:Cr ratio > 20:1 > 20:1 < 20:1 > 20:1 < 20:1 UNa(mEq/L) < 20 Variable > 20 < 20 Variable FENa(%) < 1 Variable > 1 (when oliguric) < 1 Variable Urine osmolality (mOsm/kg)> 500 < 400 250300 Variable Variable Urinary sediment Benign or hyaline castsNormal or red cells, white cells, or crystalsGranular (muddy brown) casts, renal tubular cell castsRed cells, dysmorphic red cells, and red cell castsWhite cells, white cell casts, with or without eosinophils BUN:Cr, blood urea nitrogen:creatinine ratio; FENa, fractional excretion of sodium; GBM, glomerular basement membrane; UNa, urinary concentration of sodium.CMDT22_Ch22_p0912-p0951.indd  916 02/07/21 2:33 PMKIDNEY DISEASE917 CMDT 2022calculations,  urin microscopy is a much mor valuabl tool for dtrmining caus of AKI. Patints with prrnal azotmia typically hav bland urin sdimnts, though som hav hyalin casts. In contrast, patints with ATN oftn hav rnal tubular pithlial clls or muddy brown casts visibl. Tratmnt of prrnal AKI dpnds on th undrlying caus, but achivmnt of uvolmia, attntion to srum lctrolyts, and avoidanc of nphrotoxic drugs ar bnch- marks of thrapy. This involvs carful assssmnt of vol- um status, cardiac function, dit, and drug usag.B.  Postrenal CausesP ostrnal causs of AKI ar th last common, accounting for approximatly 510% of cass, but ar important to dtct bcaus of thir rvrsibility. Postrnal azotmia occurs whn urinary flow from both kidnys, or a singl functioning kidny, is obstructd. Obstruction lads to lvatd intraluminal prssur and rsultant kidny parn- chymal damag, with markd ffcts on rnal blood flow and tubular function. Postrnal causs of AKI includ urthral obstruction, bladdr dysfunction or obstruction, and obstruction of both urtrs or rnal plviss. In mn, bnign prostatic hyprplasia is th most common caus. Patints taking anticholinrgic drugs ar at risk for urinary rtntion. Obstruction can also b causd by bladdr, prostat, and crvical cancrs; rtropritonal fibrosis; and nurognic bladdr (g, from diabts mllitus). Lss common causs includ blood clots, bilatral urtral stons, urthral stons or stricturs, and bilatral papillary ncrosis. Patints may b anuric or polyuric and may xprinc lowr abdominal or back pain. Polyuria can occur in th stting of partial obstruction with rsultant tubular dys- function and an inability to appropriatly rabsorb salt and watr loads. Obstruction can b constant or intrmittnt and partial or complt. On xamination, th patint may hav an nlargd prostat, distndd bladdr, or mass dtctd on abdominal xamination. Laboratory xamination may initially rval high urin osmolality, low urin sodium, high BUN:cratinin ratio, and low FeNa(as tubular function may not b compromisd initially). Ths indics ar similar to a prrnal stat bcaus xtnsiv intrinsic rnal damag has not yt occurrd. Aftr svral days, howvr, th urin sodium incrass as th kidnys fail and ar unabl to concntrat th urin; this inability to concntrat th urin is calld isosthnuria. Th urin sdimnt is gnrally bland, though hmaturia may b sn if th obstruction is du to stons, blood clots, or papillary ncrosis. Patints with AKI du to suspctd postrnal causs should undrgo bladdr cathtrization and ultrasonogra- phy to assss for hydrourtr, hydronphrosis, or larg bladdr volum. Aftr rvrsal of th undrlying procss, som patints xprinc significant urinary output (calld postobstructiv diursis). In such sttings, car should b takn to avoid volum dpltion or lctrolyt drang- mnts. Prompt tratmnt of obstruction within days by cathtrs, stnts, or othr surgical procdurs can rsult in partial or complt rvrsal of AKI.C. Intrinsic Acute Kidney InjuryIn trinsic rnal disordrs account for up to 50% of all cass of AKI. Intrinsic dysfunction is considrd aftr prrnal and postrnal causs hav bn xcludd. Th potntial sits of injury ar th tubuls, intrstitium, vasculatur, and glomruli. Intrinsic AKI is discussd in gratr dtail in th following sctions. When to Refer If a patint has signs of AKI that hav not rvrsd ovr 12 wks, or if th dgr of AKI is concrning (g, doubling of cratinin) and without an immdiatly rvrsibl caus such as obstruction. If a patint has signs of urinary tract obstruction, th patint should b rfrrd to a urologist. When to AdmitTh  patint should b admittd if thr is suddn loss of kidny function rsulting in abnormalitis that cannot b handld xpditiously in an outpatint stting (g, hyprka- lmia, volum ovrload, urmia) or an acut intrvntion is ndd, such as mrgnt urologic procdurs or dialysis.Ost rmann t al. Rcommndations on acut kidny injury bio- markrs from th Acut Disas Quality Initiativ Consnsus Confrnc: a consnsus statmnt. JAMA Ntw Opn. 2020;3:2019209. [PMID: 33021646] Ronco C t al. Acut kidny injury. Lanct. 2019;394:1949. [PMID: 31777389] Srisawat N t al. Th rol of biomarkrs in acut kidny injury. Crit Car Clin. 2020;36:125. [PMID: 31733675]ACU TE TUBULAR NECROSISE S S E N T I A L S  O F  D I A G N O S I S AKI. Ischemic or toxic insult or underlying sepsis. Urine sediment with granular (muddy brown) casts and renal tubular epithelial cells is pathog- nomonic but not essential. General ConsiderationsAKI  du to tubular damag is trmd acute tubular necro- sis (ATN) and accounts for approximatly 85% of intrinsic AKI. Th two major causs of ATN ar ischmia and nph- rotoxin xposur. Ischmic ATN is charactrizd not only by inadquat GFR but also by rnal blood flow that is inadquat to maintain parnchymal cllular prfusion. Rnal tubular damag can b causd by low ffctiv art- rial blood flow to th kidnys in th stting of prolongd hypotnsion or hypoxmia, such as volum dpltion or shock. Undrlying spsis is an indpndnt risk factor for ATN, vn in th absnc of hmodynamic compromis.CMDT22_Ch22_p0912-p0951.indd  917 02/07/21 2:33 PMChApTEr 22918 CMDT 2022Pro longd priods of rnal hypoprfusion can occur with major surgical procdurs, which ar xacrbatd by vaso- dilating ansthtic agnts.A.  Exogenous NephrotoxinsExognous  nphrotoxins mor commonly caus damag than ndognous nphrotoxins. Aminoglycosides caus som dgr of ATN in up to 25% of hospitalizd patints rciving thraputic lvls of th drugs. Nonoliguric kidny injury typically occurs aftr 510 days of xposur. Prdisposing factors includ undr- lying kidny damag, volum dpltion, and advancd ag. Monitoring drug lvls is important, and troughs ar par- ticularly hlpful in prdicting rnal toxicity. Amphotericin B is typically nphrotoxic aftr a dos of 23 g. This causs a typ 1 (distal) rnal tubular acidosis with svr vasoconstriction and tubular damag, which can lad to hypokalmia and nphrognic diabts insipi- dus. Vancomycin , intravnous acyclovir , and svral cephalosporins hav also bn known to caus or b asso- ciatd with ATN. Radiographic contrast media may b dirctly nphro- toxic. Contrast nphropathy is th third lading caus of incidnt AKI in hospitalizd patints and is thought to rsult from th synrgistic combination of dirct rnal tubular pithlial cll toxicity and rnal mdullary ischmia. Th combination of prxisting diabts mllitus and CKD is associatd with th gratst risk (1550%) of contrast nphropathy. Othr risk factors includ advancd ag; vol- um dpltion; hart failur; plasma cll myloma; rpatd doss of contrast; and rcnt xposur to othr nphrotoxic agnts, including NSAIDs and ACE inhibitors. Lowr volums of contrast with low osmolality ar rcommndd in high-risk patints. Toxicity usually occurs within 2448 hours aftr th radiocontrast study. Nonionic con- trast mdia may b lss toxic, but this has not bn wll provn. Prvntion of contrast nphropathy is th goal whn using ths agnts. Th mainstay of prophylaxis is 13 mL/kg or 5001000 mL of intravnous 0.9% (normal) salin ovr 6 hours both bfor and aftr th contrast administrationcautiously in patints with prxisting cardiac dysfunction; oral intak of fluids is an accptabl altrnativ for outpatint studis. Isotonic intravnous vol- um rpltion is suprior to hypotonic intravnous solutions, and both ar suprior to oral solutions in small studis. Othr nphrotoxic agnts should b avoidd during th day bfor and aftr dy administration. Altrnativ prophylactic strat- gis involving N-actylcystin, sodium bicarbonat, manni- tol, and furosmid do not show bnfit ovr 0.9% (normal) salin administration. In fact, furosmid may lad to incrasd rats of kidny dysfunction in this stting. Calcineurin inhibitor toxicity (from tacrolimus or cyclosporin) is usually dos dpndnt. It causs distal tubular dysfunction (a typ 4 rnal tubular acidosis) and svr vasoconstriction. Rgular blood lvl monitoring is important to prvnt both acut and chronic nphrotoxic- ity. Kidny function usually improvs aftr rducing th dos or stopping th drug. Othr xognous nphrotoxins includ antinoplastics, such as cisplatin and organic solvnts, and havy mtalssuch as mrcury, cadmium, and arsnic. Hrbal mdicins ar also incrasingly rcognizd as potntially nphrotoxic.B.  Endogenous NephrotoxinsEndo gnous nphrotoxins includ pigmnt-containing products (myoglobin and hmoglobin), uric acid, and paraprotins. Pigmnt-containing products can caus dirct tubular toxicity, rsulting in ATN. Th most common typ of pig- mnt nphropathy is rhabdomyolysis, causd by rlas of myoglobin from muscl. Massiv intravascular hmolysis is sn in transfusion ractions and in crtain hmolytic anmias, and causs rlas of hmoglobin. Rvrsal of th undrlying disordr and hydration ar th mainstays of tratmnt. Hyperuricemia can occur in th stting of rapid cll turnovr and lysis. Chmothrapy for grm cll and hmatologic malignancis (lukmia and lymphoma) is th primary caus; spontanous tumor lysis syndrom can also occur, though is lss common. AKI occurs with intra- tubular prcipitation of uric acid crystals; srum uric acid lvls oftn xcd 1520 mg/dL and urin uric acid lvls ar typically gratr than 600 mg/24 h. A urin uric acid to urin cratinin ratio gratr than 1.0 idntifis individuals at risk for AKI. Allopurinol or rasburicas can b usd prophylactically, and rasburicas with or without dialysis is oftn usd for tratmnt in stablishd cass. Paraproteins sn in conjunction with plasma cll myloma can caus dirct tubular toxicity and tubular obstruction. Othr rnal complications from plasma cll myloma includ hyprcalcmia and rnal tubular dys- function, including proximal rnal tubular acidosis (s Plasma Cll Myloma blow). Clinical FindingsA.  Symptoms and SignsS Acut Kidny I njury.B.  Laboratory FindingsHyprka lmia and hyprphosphatmia ar commonly prsnt. Th BUN:cratinin ratio is usually lss than 20:1 bcaus tubular function is not intact, as dscribd in th gnral sction on AKI (Tabl 223). Urinary output can b oliguric or nonoliguric, with oliguria portnding a wors prognosis. Urin sodium concntration and FeNaar typically lvatd, indicativ of tubular dysfunction. Urin microscopy may show vidnc of acut tubular damag; th prsnc of two or mor granular casts or rnal tubular pithlial clls is strongly prdictiv of ATN but has a low ngativ prdictiv valu (s Tabl 221). Although not usually prformd in cass of ATN, kidny biopsy is som- tims hlpful in cass of diagnostic uncrtainty. TreatmentT ratmnt of ATN is aimd at hastning rcovry and avoiding complications. Prvntiv masurs should b takn to avoid volum ovrload and hyprkalmia. A pro- spctiv randomizd controlld trial did not show a bnfitCMDT22_Ch22_p0912-p0951.indd  918 02/07/21 2:33 PMKIDNEY DISEASE919 CMDT 2022of  loop diurtics on ithr rcovry from AKI or dath. Widsprad us of diurtics in critically ill patints with AKI should b usd only whn othrwis clinically indi- catd (g, in stats of volum ovrload), although unrspon- sivnss to high-dos diurtics has bn shown to prdict futur nd for acut dialysis in this population (trmd furosmid strss tst). A 2012 randomizd controlld trial did not show a bnfit on mortality from plasma ultra- filtration compard to intravnous diurtics in patints with dcompnsatd hart failur. Thus, ultrafiltration should gnrally b rsrvd for ICU patints with AKI in nd of volum rmoval who ar nonrsponsiv to diurtics, with th rcognition that this has not ultimatly improvd sur- vival in this patint population. Nutritional support should mt daily nds whil prvnting xcssiv catabolism. Ditary protin rstriction of 0.6 g/kg/day hlps prvnt mtabolic acidosis. Hypocalcmia and hyprphosphatmia can b improvd with ditary modification and phosphat- binding agnts takn with mals; xampls includ alumi- num hydroxid (500 mg orally) ovr th short trm, and calcium carbonat (5001500 mg orally), calcium actat (667 mg, two or thr tablts), svlamr carbonat (800 1600 mg orally), and lanthanum carbonat (1000 mg orally) ovr longr priods. Hypocalcmia should not b tratd in patints with rhabdomyolysis unlss thy ar symptomatic. Hyprmagnsmia can occur bcaus of rducd magn- sium xcrtion by th rnal tubuls, so magnsium-containing antacids and laxativs should b avoidd in ths patints. Dosags of all mdications must b adjustd for drugs liminatd by th kidny. Indications for dialysis in AKI from ATN or othr intrinsic disordrs includ lif-thratning lctrolyt dis- turbancs (such as hyprkalmia), volum ovrload unr- sponsiv to diursis, rfractory acidosis, and urmic complications (g, ncphalopathy, pricarditis, and si- zurs). In gravly ill patints, lss svr but worsning abnormalitis may also b indications for dialytic support. Unfortunatly, thr is no vidnc that mor intnsiv or arlir initiation of rnal rplacmnt thrapy for patints with AKI confrs any survival bnfit. Course & PrognosisTh  clinical cours of ATN is oftn dividd into thr phass: initial injury, maintnanc, and rcovry. Th maintnanc phas is xprssd as ithr oliguric (urinary output lss than 500 mL/day) or nonoliguric. Nonoliguric ATN is associatd with bttr outcoms than oliguric ATN; convrsion from oliguric to nonoliguric stats with th us of diurtics dos not altr prognosis. Whil dopamin has somtims bn usd for this purpos, numrous studis hav shown that its us in this stting is not bnficial. Avrag duration of th maintnanc phas is 13 wks, but som cass may last svral months. Cllular rpair and rmoval of tubular dbris occur during this priod. Th rcovry phas can b hraldd by diursis, du to inability of rcovring rnal tubuls to rabsorb salt and watr appro- priatly, and a solut diursis from lvatd BUN lvls. As GFR bgins to ris, BUN and srum cratinin fall. Th mortality rat associatd with AKI is 2050% in hospitalizd sttings, and up to 70% for thos in th ICUrquiring dialysis with additional comorbid illnsss. Incrasd mortality is associatd with advancd ag, svr undrlying disas, and multisystm organ failur. Lading causs of dath ar infctions, fluid and lctrolyt distur- bancs, and worsning of undrlying disas. When to Refer Whn uncrtainty xists as to th caus of or tratmnt for AKI. For fluid, lctrolyt, and acid-bas abnormalitis that ar rcalcitrant to intrvntions. Nphrology rfrral improvs outcoms in AKI. When to AdmitA  patint with symptoms or signs of AKI that rquir immdiat intrvntion, such as administration of intrav- nous fluids or dialytic thrapy, or that rquir a tam approach that cannot b coordinatd as an outpatint.Griffin  BR t al. Critical car nphrology: Cor Curriculum 2020. Am J Kidny Dis. 2020;75:435. [PMID: 31982214] Prapornratana S t al. Acut kidny injury from spsis: currnt concpts, pidmiology, pathophysiology, prvntion and tratmnt. Kidny Int. 2019;96:1083. [PMID: 31443997] STARRT-AKI Invstigators; Canadian Critical Car Trials Group; Australian and Nw Zaland Intnsiv Car Socity Clinical Trials Group; Unitd Kingdom Critical Car Rsarch Group; Canadian Nphrology Trials Ntwork; Irish Critical Car Trials Group, Bagshaw SM t al. Timing of initiation of rnal-rplacmnt thrapy in acut kidny injury. N Engl J Md. 2020;383:240. [PMID: 32668114]RH ABDOMYOLYSISE S S E N T I A L S  O F  D I A G N O S I S Associated with crush injuries to muscle, immobil- ity, drug toxicities, and hypothermia. Characterized by serum elevations in muscle enzymes, including creatine kinase, and marked electrolyte abnormalities. Release of myoglobin leads to direct renal toxicity. General ConsiderationsRhabdomyolysis  is a syndrom of acut skltal muscl ncrosis, lading to myoglobinuria and markdly lvatd cratin kinas lvls. Acut tubular ncrosis is a com- mon complication of rhabdomyolysis and is du to th filtration of xcssiv quantitis of myoglobin, which can b xacrbatd by volum dpltion. Distal tubular obstruction from pigmntd casts and intrarnal vaso- constriction can also occur. Rhabdomyolysis can rsult from crush injuris, prolongd immobility, sizurs, sub- stanc abus (g, cocain), and mdications (spcially statins). Th prsnc of kidny or livr dysfunction, dia- bts mllitus, and hypothyroidism incras th risk ofCMDT22_Ch22_p0912-p0951.indd  919 02/07/21 2:33 PMChApTEr 22920 CMDT 2022rh abdomyolysis in patints taking statins. Concurrnt us of drugs that inhibit cytochrom P450 (including protas inhibitors, rythromycin or clarithromycin, itraconazol, diltiazm, and vrapamil) with statins (xcpt pravastatin or rosuvastatin) as wll as concurrnt us of niacin and fibrat- containing thrapy can incras th risk of dvlopmnt of rhabdomyolysis. Clinical FindingsA.  Symptoms and SignsPa tints with rhabdomyolysis may hav myalgias or wak- nss or both, though it is not uncommon for thm to b asymptomatic. Urin may appar dark.B.  Laboratory FindingsRhabdomy olysis of clinical importanc commonly occurs with a srum cratin kinas gratr than 20,00050,000 intrnational units/L; on study showd that 58% of patints with AKI from rhabdomyolysis had cratin kinas lvls gratr than 16,000 intrnational units/L, whil only 11% of patints without kidny injury had cr- atin kinas valus gratr than 16,000 intrnational units/L. Oftn, thr ar lvatd srum lvls of aspartat aminotransfras (AST), alanin aminotransfras (ALT), and lactat dhydrognas (LD) (du to rlas of ths nzyms from skltal muscl). Th massiv acut lva- tions of muscl nzyms pak quickly and usually rsolv within days onc th inciting injury has bn rmovd. Th classic laboratory finding in rhabdomyolysis is a urin dipstick tst that is positiv for blood but without rd blood clls on microscopy. This fals-positiv rsult is du to dtction of myoglobin. Additionally, clinically maningful rhabdomyolysis causs injurd muscl clls to rlas intracllular componnts, lading to lctrolyt drangmnts (including hyprkalmia, hyprphosphat- mia, hypruricmia, and hypocalcmia). TreatmentTh  mainstay of tratmnt is aggrssiv volum rpltion with 0.9% normal salin (i, mor than 4 L/day) and rmoval of offnding mdications if thought to hav causd th disordr. Adjunctiv tratmnts with mannitol and alkalization of th urin hav not bn provn to chang outcoms in human trials. As patints rcovr, calcium can mov back from tissus to plasma, so arly xognous cal- cium administration for hypocalcmia is not rcommndd unlss th patint is symptomatic or th lvl bcoms xcdingly low in an unconscious patint; calcium rpl- tion can caus prcipitation of calcium phosphat givn th frquntly concurrnt hyprphosphatmia. Myopathic complications of statins usually rsolv within svral wks of discontinuing th drug. When to ReferClinically  maningful rhabdomyolysis rquirs immdiat attntion and inpatint managmnt, so affctd patints should not b rfrrd to outpatint nphrology clinics unlss to follow up aftr a hospital admission.When to AdmitPa tints whos srum cratin kinas lvls ar gratr than 15,00020,000 intrnational units/L or patints with AKI or lctrolyt drangmnts should b admittd for fluid rpltion and srial monitoring of cratin kinas and lctrolyts.Long  B t al. An vidnc-basd narrativ rviw of th mr- gncy dpartmnt valuation and managmnt of rhabdomy- olysis. Am J Emrg Md. 2019;37:518. [PMID: 30630682]IN TERSTITIAL NEPHRITISE S S E N T I A L S  O F  D I A G N O S I S Fever. Transient maculopapular rash. Acute or chronic in nature. Pyuria, white blood cell casts, and hematuria. General ConsiderationsAcut  intrstitial nphritis accounts for 1015% of cass of intrinsic rnal failur. An intrstitial inflammatory rspons with dma and possibl tubular cll damag is th typical pathologic finding. Although drugs account for ovr 70% of cass, acut intrstitial nphritis also occurs in infctious disass, autoimmun disordrs, or as idiopathic conditions. Th most common drugs implicatd ar pnicillins and cphalosporins, immun chckpoint inhibitors, sulfon- amids and sulfonamid-containing diurtics, NSAIDs, proton pump inhibitors, rifampin, and allopurinol. Infc- tious causs includ strptococcal infctions, lptospirosis, cytomgalovirus, histoplasmosis, and Rocky Mountain spottd fvr. SLE, Sjgrn syndrom, sarcoidosis, and cryoglobulinmia can also caus intrstitial nphritis, though thy ar mor classically associatd with glomrulonphritis. Clinical FindingsClinical  faturs includ fvr (mor than 80% of cass), rash (2550%), arthralgias, and priphral blood osino- philia (80%). Th classic triad of fvr, rash, and arthralgias is prsnt in only 1015% of cass. Th urin oftn contains whit clls (95%), rd clls, and whit cll casts. Protinuria is oftn prsnt, particularly in NSAID-inducd intrstitial nphritis, but is usually modst (lss than 2 g/24 h). Eosin- ophiluria is nithr vry snsitiv nor spcific for intrstitial nphritis; valuation for osinophiluria is not advisd. Although th clinical history and laboratory data oftn giv clus to th diagnosis, kidny biopsy is somtims ndd. Treatment & PrognosisAcut  intrstitial nphritis oftn carris a good prognosis, with rcovry occurring ovr wks to months. UrgntCMDT22_Ch22_p0912-p0951.indd  920 02/07/21 2:33 PMKIDNEY DISEASE921 CMDT 2022dialytic  thrapy may b ncssary in up to on-third of all rfrrd patints bfor rsolution, but patints rarly prog- rss to ESKD. Thos with prolongd oliguria and advancd ag hav a wors prognosis. Tratmnt consists of support- iv masurs and rmoval of th inciting agnt. If kidny injury prsists, a short cours of corticostroids can b considrd, although th data to support thir us ar not substantial, and thir fficacy may dpnd on th lapsd tim btwn onst of AKI and thir initiation. Short-trm, high-dos mthylprdnisolon (0.51 g/day intravnously for 14 days) or prdnison (60 mg/day orally for 12 wks) followd by a prdnison tapr can b usd in mor svr cass of drug-inducd intrstitial nphritis.Mo ldina DG t al. Tratmnt of drug-inducd acut tubuloint- rstitial nphritis: th sarch for bttr vidnc. Clin J Am Soc Nphrol. 2018;13:1785. [PMID: 30397028] Shingarv R t al. Kidny complications of immun chckpoint inhibitors: a rviw. Am J Kidny Dis. 2019;74:529. [PMID: 31303350]GLOM ERULONEPHRITISE S S E N T I A L S  O F  D I A G N O S I S Hematuria, subnephrotic proteinuria. Red cell casts pathognomonic but not required for diagnosis. Dependent edema and hypertension. AKI. General ConsiderationsAcu t glomrulonphritis is a rlativly uncommon caus of AKI, accounting for about 5% of cass. Pathologically, inflammatory glomrular lsions ar sn. Ths includ msangioprolifrativ, focal and diffus ndocapillary prolif- rativ, and crscntic lsions. Th largr th prcntag of glomruli involvd and th mor svr th lsion, th mor likly it is that th patint will hav a poor clinical outcom. Glomrulonphritids ar classifid into fiv pathophysi- ologic procsss, which can b charactrizd by srologic analysis. Markrs includ anti-GBM antibodis, antinu- trophil cytoplasmic antibodis (ANCAs), and othr immun markrs of disas. Immune complex deposition occurs whn thr is modrat ovrproduction of antign compard to antibody production. Complxs formd with markd antign xcss tnd to rmain in th circulation. Antibody xcss with larg antignantibody aggrgats usually rsults in phago- cytosis and claranc of th prcipitats by th mononuclar phagocytic systm in th livr and spln. Causs includ IgA nphropathy, infction-rlatd glomrulonphritis, lupus nphritis, and cryoglobulinmic glomrulonphritis (oftn associatd with hpatitis C virus [HCV]). Anti-GBMassociated acute glomerulonephritis is ithr confind to th kidny or associatd with pulmonary hmorrhag. Th lattr is trmd Goodpastur syndrom. Injury is rlatd to autoantibodis against typ IV collagn in th GBM. Pauci-immune acute glomerulonephritis is a form of small-vssl vasculitis associatd with ANCAs, causing kid- ny disass without dirct immun complx dposition or antibody binding. Tissu injury is blivd to b du to cll- mdiatd immun procsss. An xampl is granulomatosis with polyangiitis, a systmic ncrotizing vasculitis of small artris and vins associatd with intravascular and xtra- vascular granuloma formation. In addition to glomrulon- phritis, ths patints can hav uppr airway, pulmonary, and skin manifstations. Cytoplasmic ANCA (c-ANCA) is th common staining pattrn. Microscopic polyangiitis is anothr pauci-immun vasculitis causing acut glomrulo- nphritis, which is mor commonly associatd with pri- nuclar staining (p-ANCA). ANCA-associatd and anti-GBMassociatd acut glomrulonphritids can volv to crscntic glomrulonphritis and oftn hav poor outcoms unlss tratmnt is startd arly. Monoclonal immunoglobulinmediated glomerulo- nephritis is charactrizd by th dposition of a monoclo- nal immunoglobulin in glomruli or tubular basmnt mmbran or both. It is dtctd on immunofluorscnt or immunohistochmical staining of kidny biopsis as mono- typic immunoglobulin dposits. Srum protin lctropho- rsis and srum fr light chains ar usful diagnostic tsts to prform whn monoclonal immunoglobulinmdiatd glomrulonphritis is suspctd or confirmd. Whil many cass will occur in th stting of a monoclonal gammopa- thy, this is not always th cas. C3 glomerulopathy rsults from prdominant C3 dposition in th glomruli with or without minimal dposition of immunoglobulins. It is also idntifid by immunofluorscnc or immunohistochmistry. Th pathognsis of C3 glomrulonphropathy stms from abnormalitis in rgulation of th altrnativ pathway of complmnt. Whil chcking srum C3 lvls may b hlp- ful, normal lvls do not rul out C3 glomrulopathy. Other vascular causes of glomrulonphritis includ hyprtnsiv mrgncis and th thrombotic microangi- opathis such as hmolytic-urmic syndrom and throm- botic thrombocytopnic purpura (s Chaptr 14). Clinical FindingsA.  Symptoms and SignsPa tints with acut glomrulonphritis ar oftn hyprtn- siv and dmatous with an abnormal urinary sdimnt. Th dma is found first in body parts with low tissu tn- sion, such as th priorbital and scrotal rgions.B.  Laboratory FindingsSrum  cratinin can ris ovr days to months, dpnding on th rapidity of th undrlying procss. Th BUN:cratinin ratio is not a rliabl markr of kidny function and is mor rflctiv of th patints undrlying volum status. Dipstick and microscopic valuation rval vidnc of hmaturia and typically subnphrotic protin- uria; thr may b cllular lmnts such as dysmorphic rd clls, rd cll casts, and whit clls. Rd cll casts arCMDT22_Ch22_p0912-p0951.indd  921 02/07/21 2:33 PMChApTEr 22922 CMDT 2022spcific  for glomrulonphritis, and a dtaild sarch on urin microscopy is warrantd. Additional tsts includ srum complmnt lvls (C3, C4) that may b low in immun complx glomrulonphri- tis (xcpt for IgA nphropathy) or C3 glomrulopathy and normal in pauci-immun, anti-GBMrlatd, and mono- clonal immunoglobulinmdiatd glomrulonphritids. Othr tsts includ ASO titrs, anti-GBM antibody lvls, ANCAs, antinuclar antibody titrs, cryoglobulins, hpati- tis srologis, srum protin lctrophorsis and srum fr light chains, blood culturs, and rnal ultrasound. With fw xcptions, a kidny biopsy is ultimatly ncssary to con- firm th diagnosis, irrspctiv of laboratory data. TreatmentDpnding  on th natur and svrity of disas, tratmnt might includ high-dos corticostroids, rituximab, and cytotoxic agnts (such as cyclophosphamid). Plasma xchang can b usd in Goodpastur syndrom as a tm- porizing masur until chmothrapy can tak ffct. Tratmnt and prognosis for spcific disass ar discussd mor fully blow.Gtha  D t al. ANCA-associatd vasculitis: Cor Curriculum 2020. Am J Kidny Dis. 2020;75:124. [PMID: 31358311] Sthi S t al. Standardizd classification and rporting of glomrulonphritis. Nphrol Dial Transplant. 2019;34:193. [PMID: 30124958]COVI D-19 & THE KIDNEYE S S E N T I A L S  O F  D I A G N O S I S Broad array of clinical presentation and kidney pathology. Clinical Findings & TreatmentNar ly half of patints hospitalizd with COVID-19 prs- nt with or dvlop AKI, which is associatd with poorr prognosis. Many causs of AKI ar dscribd in patints with COVID-19, but th most common is ATN rlatd to a high inflammatory stat (trmd cytokin storm). Urinalysis may rval hmaturia, rflcting ndothlial injury and fibrin thrombi that ar commonly obsrvd on biopsy. Anothr mrging ntity is COVID-19associatd collapsing glomrulopathy, which is a typ of focal sgmntal glomrulosclrosis (s sction on Nphrotic Spctrum Glomrular Disass blow). Patints with collapsing glo- mrulopathy prsnt with nphrotic syndrom and ar typi- cally of African ancstry, highlighting a suspctd gntic prdisposition. Tratmnt of COVID-19rlatd AKI is largly supportiv; th rol of corticostroids in COVID-19 associatd collapsing glomrulopathy is undr invstigation.Cha n L t al; Mount Sinai COVID Informatics Cntr (MSCIC). AKI in hospitalizd patints with COVID-19. J Am Soc Nphrol. 2021;32:151. [PMID: 32883700]Nasr SH t al. COVID-19-associatd collapsing glomrulopathy: an mrging ntity. Kidny Int Rp. 2020;5:759. [PMID: 32368701] Ronco C t al. Managmnt of acut kidny injury in patints with COVID-19. Lanct Rspir Md. 2020;8:738. [PMID: 32416769] Shtty AA t al. COVID-19-associatd glomrular disas. J Am Soc Nphrol. 2021;32:33. [PMID: 33214201]C ARDIORENAL SYNDROMEE S S E N T I A L S  O F  D I A G N O S I S Cadiac dysfunction: acute or chronic heart failure, ischemic injury, or arrhythmias. Kidney disease: acute or chronic, depending on the type of cardiorenal syndrome. General ConsiderationsCardior nal syndrom is a pathophysiologic disordr of th hart and kidnys whrin th acut or chronic dtrio- ration of on organ rsults in th acut or chronic dtrio- ration of th othr. This syndrom is classifid into fiv typs as a mattr of convntion. Achiving uvolmia is th ovrarching thraputic goal rgardlss of typ (s Hart Failur sction in Chaptr 10). Typ 1 consists of AKI stmming from acut cardiac disas. Typ 2 is CKD du to chronic cardiac disas. Typ 3 is acut cardiac disas as a rsult of AKI. Typ 4 is chronic cardiac dcompnsation from CKD. Typ 5 con- sists of hart and kidny dysfunction du to othr acut or chronic systmic disordrs (such as spsis). Although novl agnts ar bing xamind for futur thrapis, th main- stay of tratmnt is to addrss th primary undrlying hart or kidny dysfunction.K umar U t al. Cardiornal syndrom: pathophysiology. Cardiol Clin. 2019;37:251. [PMID: 31279419] Raina R t al. An updat on th pathophysiology and tratmnt of cardiornal syndrom. Cardiol Rs. 2020;11:76. [PMID: 32256914] ChrONIC KIDNEY DISEASEE S S E N T I A L S  O F  D I A G N O S I S Decline in the GFR over months to years. Persistent proteinuria or abnormal renal morphol- ogy may be present. Hypertension in most cases. Symptoms and signs of uremia when nearing end- stage disease. Bilateral small or echogenic kidneys on ultrasound in advanced disease.CMDT22_Ch22_p0912-p0951.indd  922 02/07/21 2:33 PMKIDNEY DISEASE923 CMDT 2022 General ConsiderationsCKD affcts at last 10% of Amricans. Ma ny ar unawar of th condition bcaus thy rmain asymptomatic until th disas is nar nd stag. Th National Kidny Founda- tions staging systm hlps clinicians formulat practic plans (Tabl 224). Ovr 70% of cass of lat-stag CKD (stag 5 CKD and ESKD) in th Unitd Stats ar du to diabts mllitus or hyprtnsion/vascular disas. Glo- mrulonphritis, cystic disass, chronic tubulointrstitial disass, and othr urologic disass account for th rmaindr (Tabl 225). Gntic polymorphisms of th APOL-1 gn hav bn shown to b associatd with an incrasd risk of th dvlopmnt of CKD in prsons of African ancstry. CKD usually lads to a progrssiv dclin in kidny function vn if th inciting caus can b idntifid and tratd or rmovd. Dstruction of nphrons lads to compnsatory hyprtrophy and supranormal GFR of th rmaining nphrons in ordr to maintain ovrall homo- stasis. As a rsult, th srum cratinin may rmain rla- tivly normal vn in th fac of significant loss of rnal mass and is, thrfor, an insnsitiv markr for arly rnal damag and scarring. In addition, compnsatory hyprfiltration lads to ovrwork injury in th rmaining nphrons, which in turn causs progrssiv glomrular sclrosis and intrstitial fibrosis. Angiotnsin rcptor blockrs (ARBs) and ACE inhibitors can hlp rduc hyprfiltration injury and may slow th progrssion of protinuric CKD. Whil CKD is an indpndnt risk factor for cardiovas- cular disas (CVD), protinuric CKD confrs th highst risk. Most patints with stag 3 CKD di of undrlying CVD prior to progrssion to ESKD.Clinical FindingsA.  Symptoms and SignsStags  14 CKD ar asymptomatic. Symptoms dvlop slowly with th progrssiv dclin in GFR, ar nonsp- cific, and do not manifst until kidny disas is far advancd (GFR lss than 510 mL/min/1.73 m2). At this point, th accumulation of mtabolic wast products, or urmic toxins, rsults in th uremic syndrome . Gnral symptoms of urmia may includ fatigu, anorxia, nausa, and a mtallic tast in th mouth. Nurologic symptoms such as mmory impairmnt, insomnia, rstlss lgs, and twitching may b du to urmia. Gnralizd pruritus (without rash) may occur, as may dcrasd libido and mnstrual irrgularitis. Pricarditis, a rar complication of CKD, may prsnt with pluritic chst pain. Mdications that ar clard by th kidnys will accumulat as kidny function worsns and toxicity may nsu; an important xampl is insulin and an incrasing risk of significant hypoglycmia if doss ar not appropriatly rducd. Th most common physical finding in CKD is hypr- tnsion; this is du in part to impaird sodium xcrtion. It is oftn prsnt in arly stags of CKD and tnds to worsn with CKD progrssion. In latr stags of CKD, sodium rtntion may lad to clinically apparnt volum ovrload. Urmic signs ar sn with a profound dcras in GFR (lss than 510 mL/min/1.73 m2) and may includ a gnr- ally sallow and ill apparanc, halitosis (urmic ftor), and th urmic ncphalopathic signs of dcrasd mntal sta- tus, astrixis, myoclonus, and possibly sizurs. Symptoms and signs of urmia warrant immdiat hos- pital admission and nphrology consultation for initiation of dialysis. Th urmic syndrom is amlioratd with dialytic thrapy.Table 224. Stages of chronic kidney disease: a clinical action plan.1,2Stage 3Descition GFr (mL/min/1.73 m2) Action 1 Kidney damage with normal or GFR  90 Diagnosis and treatment of underlying etiology if possible. Treatment of comorbid conditions. Estimate progression, work to slow progression. Cardiovascular disease risk reduction.2 Kidney damage with mildly GFR 6089 3a Mildly-moderately GFR 4559 As above, and evaluating and treating complications. 3b Moderately-severely GFR 3044 4 Severely GFR 1529 Preparation for end-stage kidney disease. 5 End-stage kidney disease < 15 (or dialysis) Dialysis, transplant, or palliative care.1 Based on National Kidney Foundation, KDOQI, and KDIGO Chronic Kidney Disease Guidelines.2 Chronic kidney disease is defined as either kidney damage or GFR < 60 mL/min/1.73 m2for 3 or more months. Kidney damage is defined as pathologic abnormalities or markers of damage, including abnormalities in blood or urine tests or imaging studies.3 At all stages, persistent albuminuria confers added risk for chronic kidney disease progression and cardiovascular disease in t he following gradations: < 30 mg/day = lowest added risk, 30300 mg/day = mildly increased risk, > 3001000 mg/day = moderately increased ri sk, > 1000 mg/day = severely increased risk. GFR, glomerular filtration rate. Modified and reproduced, with permission, from Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2013 Jan;3(1) (Suppl):115 0. Copyright  2013 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.CMDT22_Ch22_p0912-p0951.indd  923 02/07/21 2:33 PMChApTEr 22924 CMDT 2022T able 225. Causes of chronic kidney disease.Glomeula  Diseases pimay glomeula diseases Focal segmental glomerulosclerosis Membranoproliferative glomerulonephritis IgA nephropathy Membranous nephropathy Alport syndrome (hereditary nephritis) Seconday glomeula diseases Diabetic nephropathy Renal amyloidosis Postinfectious glomerulonephritis HIV-associated nephropathy Collagen-vascular diseases (eg, SLE) HCV-associated membranoproliferative glomerulonephritis Tubulointestitial Neitis Drug hypersensitivity Heavy metals Analgesic nephropathy Reflux/chronic pyelonephritis Sickle cell nephropathy Idiopathic Cystic Diseases Polycystic kidney disease Medullary cystic disease Obstuctive Neoaties Prostatic disease Nephrolithiasis Retroperitoneal fibrosis/tumor Congenital/reflux Vascula Diseases Hypertensive nephrosclerosis Renal artery stenosis HCV, hepatitis C virus; SLE, systemic lupus erythematosus.Table 226. Reversible causes of kidney injury.revesible  Factos Diagnostic Clues Obstruction Post-void residual, bladder cath- eterization, renal ultrasound Extracellular fluid volume depletion or significant hypotension relative to baselineBlood pressure and pulse, including orthostatic pulse Hypercalcemia Serum electrolytes, calcium, phosphate Nephrotoxic agents Drug history Severe/urgent hypertension Blood pressure, chest radiograph Heart failure exacerbation Physical examination, chest radiograph  1 2 31 .0 0.9 0.7 0.5 0.3 0.1 1 2 3 4 5 6 7 8 9 1 01/ScrTime  (years)1 Value of serum creatinine level = 1 .0 mg/dL2 Value of serum creatinine level = 2.0 mg/dL3 Value of serum creatinine level = 5.0 mg/dL Figure 221. Decline in kidney function (expressed as the reciprocal of serum creatinine as shown here, or as estimated glomerular filtration rate [eGFR]) plotted against time to ESKD. The solid line indicates the linear decline in kidney function over time. The dotted line indicates the approximate time to ESKD.In any patint with kidny disas, it is important to idntify and corrct all possibly rvrsibl insults or xac- rbating factors (Tabl 226). Urinary obstruction, hypo- volmia, hypotnsion, nphrotoxins (such as NSAIDs, aminoglycosids, or proton pump inhibitors), svr or mrgnt hyprtnsion, and hart failur xacrbation should b xcludd.B.  Laboratory FindingsCKD is u sually dfind by an abnormal GFR prsisting for at last 3 months. Prsistnt protinuria or abnormalitis on rnal imaging (g, polycystic kidnys or a singl kidny) ar also diagnostic of CKD, vn whn GFR is normal. If multipl masurmnts of GFR ovr tim ar availabl, th rat of progrssion should b assssd (Figur 221). If th slop of th lin acutly dclins, potntially rvrsibl rnal insults should b xcludd. Anmia, hyprphospha- tmia, hypocalcmia, hyprkalmia, and mtabolic acido- sis ar common complications of advancd CKD. Th urinary sdimnt may show broad waxy casts as a rsult ofdilatd, hyprtrophic nphrons. If protinuria is prsnt, it should b quantifid as dscribd abov. This can hlp nar- row th diffrntial diagnosis of th tiology of th CKD (Tabl 225); for xampl, glomrular disass tnd to prsnt with protin xcrtion of mor than 1 g/day. Addi- tionally, highr urinary protin xcrtion is associatd with mor rapid progrssion of CKD and incrasd risk of car- diovascular mortality.CMDT22_Ch22_p0912-p0951.indd  924 02/07/21 2:33 PMKIDNEY DISEASE925 CMDT 2022C.  ImagingTh  finding of small, chognic kidnys bilatrally (lss than 910 cm) by ultrasonography suggsts th chronic scarring of advancd CKD. Larg kidnys can b sn with adult polycystic kidny disas, diabtic nphropathy, HIV-associatd nphropathy, plasma cll myloma, amy- loidosis, and obstructiv uropathy. ComplicationsTh  complications of CKD tnd to occur at rlativly pr- dictabl stags of disas as notd in Figur 222.A.  Cardiovascular ComplicationsPa tints with CKD xprinc gratr morbidity and mor- tality from CVD in comparison to th gnral population. Roughly 80% of patints with CKD di bfor raching ESKD, primarily of CVD. Of thos undrgoing dialysis, 45% will di of a cardiovascular caus. Th mchanisms for nhancd cardiovascular mortality in CKD ar complx and includ abnormal phosphorus and calcium homosta- sis, incrasd burdn of oxidativ strss, incrasd vascular ractivity, lft vntricular hyprtrophy, and coxistnt con- ditions such as hyprtnsion and diabts mllitus. 1. Hypertension Hyprtnsion is th most common complication of CKD; it tnds to b progrssiv and salt- snsitiv. Hyprrninmic stats and xognous rythro- poitin administration can xacrbat hyprtnsion. As with othr patint populations, control of hyprtn- sion should focus on both pharmacologic and nonpharma- cologic thrapy (g, dit, xrcis, wight loss, tratmnt of obstructiv slp apna). CKD rsults in disturbd sodium homostasis such that th ability of th kidny to adjust to variations in sodium and watr intak bcoms limitd as GFR dclins. A low salt dit (2 g/day) is oftn ssntial to control blood prssur and hlp avoid ovrt volum ovr- load. Diurtics ar narly always ndd to hlp control hyprtnsion (s Tabl 118); thiazids work wll in arly CKD, but loop diurtics may b mor ffctiv in thoswith a GFR lss than 30 mL/min/1.73 m2. Howvr, vol- um contraction as a rsult of vry low sodium intak (spcially with intrcurrnt illnss) or ovr-diursis in th prsnc of impaird sodium homostasis can rsult in AKI. Initial drug thrapy for protinuric patints should includ ACE inhibitors or ARBs (s Tabl 116); howvr, thr is no vidnc of supriority of ths drugs ovr othr drug classs for nonprotinuric CKD. Whn an ACE inhibitor or an ARB is initiatd or uptitratd, patints must hav srum cratinin and potassium chckd within 714 days. A ris in srum cratinin gratr than 30% from baslin mandats dos rduction or cssation of th drug. Hyprkalmia may also warrant drug cssation, xcpt in th rliabl patint who can follow a low-potas- sium dit and adhr to a potassium-binding rsin; such patints should b monitord closly. An ACE inhibitor and ARB should not b usd in combination. CKD is a common caus of rfractory hyprtnsion for which agnts from multipl classs ar oftn ndd. Currnt guidlins diffr with rspct to blood prssur goals in CKD; thos from th Joint National Commission suggst a goal of lss than 140/90 mm Hg, whil th Amrican Hart Associa- tion advocats for lss than 130/80 mm Hg. As patints with CKD ar at risk for rnal hypoprfusion and AKI with ovrtratmnt of hyprtnsion, it is prudnt to individual- iz th approach to blood prssur control to ach patint. 2. Coronary artery disease Patints with CKD ar at highr risk for dath from CVD than th gnral popula- tion. Traditional modifiabl risk factors for CVD, such as hyprtnsion, tobacco us, and hyprlipidmia, should b aggrssivly tratd. Urmic vascular calcification involv- ing disordrd phosphorus homostasis and othr mdia- tors may also b a cardiovascular risk factor in ths patints. 3. Heart failure CKD complications rsult in incrasd cardiac workload du to hyprtnsion, volum ovrload, and anmia. Patints may also hav acclratd rats of athrosclrosis and vascular calcification rsulting in vssl stiffnss. All of ths factors contribut to lft vntricularPTHGlomerular filtration  rate (mL/min/1.73 m2)PhosphorusHTN Anemia Acidosis, hyperkalemia Uremic syndromeCKD stage5 4 3 20 20 40 60 80 100 Figure 222. Complications of chronic kidney disease (CKD) by stage and glomerular filtration rate (GFR). Compli- cations arising from CKD tend to occur at the stages depicted, although there is considerable variability noted in clin- ical practice. HTN, hypertension; PTH, parathyroid hormone. (Adapted, with permission, from William Bennett, MD.)CMDT22_Ch22_p0912-p0951.indd  925 02/07/21 2:33 PMChApTEr 22926 CMDT 2022hyprtrop hy and hart failur with prsrvd jction frac- tion, which is common in CKD. Ovr tim, hart failur with dcrasd jction fraction may dvlop. Diurtic thrapy, in addition to fluid and salt rstriction, is usually ncssary; diurtic dos scalation may b ndd as kid- ny function dclins. ACE inhibitors and ARBs can b usd for patints with advancd CKD with clos monitor- ing of blood prssur as wll as for hyprkalmia and wors- ning kidny function; minralocorticoid rcptor antagonists may b usd with similar prcautions but should b discontinud whn GFR is lss than 30 mL/ min/1.73 m2. SGLT2 inhibitors hav bn shown to improv outcoms for both hart failur and CKD. 4. Atrial fibrillation Patints with advancd CKD and ESKD suffr disproportionat rats of atrial fibrillation, which approach 20% in patints rciving dialysis. Whil thos with up to CKD stag 4 should b tratd as th gn- ral population, anticoagulation for prvntion of throm- bombolic vnts bcoms challnging in thos with ESKD du to compting risks of blding and clotting as wll as a lack of data supporting its routin us. 5. Pericarditis Pricarditis rarly dvlops in urmic patints; typical findings includ pluritic chst pain and a friction rub. Cardiac tamponad can occur; thrfor, ur- mic pricarditis is a mandatory indication for hospitaliza- tion and initiation of hmodialysis.Bangalor  S t al. Managmnt of coronary disas in patints with advancd kidny disas. N Engl J Md. 2020;382:1608. [PMID: 32227756] Fay KS t al. Rsistant hyprtnsion in popl with CKD: a rviw. Am J Kidny Dis. 2021;77:110. [PMID: 32712185] Gurrot D t al. Blood prssur targts in chronic kidny disas: an updat on th vidnc. Curr Opin Nphrol Hyprtns. 2020;29:327. [PMID: 32167996] Packr M t al; EMPEROR-Rducd Trial Invstigators. Cardio- vascular and rnal outcoms with mpagliflozin in hart failur. N Engl J Md. 2020;383:1413. [PMID: 32865377] Palmr BF. Potassium bindrs for hyprkalmia in chronic kidny disasdit, rnin-angiotnsin-aldostron systm inhibitor thrapy, and hmodialysis. Mayo Clin Proc. 2020;95: 339. [PMID: 31668450]B.  Metabolic Bone DiseaseTh mtabolic b on disas of CKD rfrs to th complx disturbancs of calcium and phosphorus mtabolism, parathyroid hormon (PTH), activ vitamin D, and fibro- blast growth factor-23 (FGF-23) homostasis (s Chaptr 21 and Figur 223). A typical pattrn sn as arly as CKD stag 3 is hyprphosphatmia, hypocalcmia, and hypovitaminosis D, rsulting in scondary hyprparathy- roidism. Ths abnormalitis can contribut to vascular calcification and may b rsponsibl in part for th acclr- atd CVD and xcss mortality sn in th CKD popula- tion. Epidmiologic studis show an association btwn lvatd phosphorus lvls and incrasd risk of cardiovas- cular mortality in arly CKD through ESKD. As yt, thr ar no intrvntion trials suggsting th bst cours of tratmnt in ths patints; control of minral and PTH lvls pr currnt guidlins is discussd blow.Bon disas, or rnal ostodystrophy, in advancd CKD is common and thr ar svral typs of lsions. Rnal ostodystrophy can b diagnosd only by bon biopsy, which is rarly don. Th most common bon dis- as, ostitis fibrosa cystica, is a rsult of scondary hypr- parathyroidism and th ostoclast-stimulating ffcts of PTH. This is a high-turnovr disas with bon rsorption and subpriostal lsions; it can rsult in bon pain and proximal muscl waknss. Adynamic bon disas, or low-bon turnovr, is bcoming mor common; it may rsult iatrognically from supprssion of PTH or via spon- tanously low PTH production. Ostomalacia is charactr- izd by lack of bon minralization. In th past, ostomalacia was associatd with aluminum toxicityithr as a rsult of chronic ingstion of prscribd aluminum-containing phosphorus bindrs or from high lvls of aluminum in impur dialysat watr. Currntly, ostomalacia is mor likly to rsult from hypovitaminosis D; thr is also tho- rtical risk of ostomalacia associatd with us of bisphos- phonats in advancd CKD. All of th abov ntitis incras th risk of fracturs. Tratmnt may involv corrction of calcium, phosphorus, and 25-OH vitamin D lvls toward normal valus, and mitigation of hyprparathyroidism. Undrstanding th intrplay btwn ths abnormalitis can hlp targt thrapy (Figur 223). Dclining GFR lads to phosphorus rtntion. This rsults in hypocalcmia as phosphorus complxs with calcium, dposits in soft tissus, and stim- ulats PTH. Loss of rnal mass and low 25-OH vitamin D lvls oftn sn in CKD patints rsult in low 1,25(OH) vitamin D production by th kidny. Bcaus 1,25(OH) vitamin D is a supprssor of PTH production, hypovita- minosis D also lads to scondary hyprparathyroidism. Th first stp in tratmnt of mtabolic bon disas is control of hyprphosphatmia. This involvs ditary phos- phorus rstriction initially (s sction on ditary manag- mnt), followd by th administration of oral phosphorus bindrs if targts ar not achivd. Oral phosphorus bind- rs block absorption of ditary phosphorus in th gut and ar givn thric daily with mals. Ths should b titratd to a nar-normal srum phosphorus lvl. Calcium- containing bindrs (calcium carbonat, 650 mg/tablt, or calcium actat, 667 mg/capsul, usd at doss of on to thrGFR25(OH) Vitamin D PTH CalciumPhosphorus 1,25(OH) Vitamin D Figure 223. Mineral abnormalities of CKD. Decline in glomerular filtration rate (GFR) and loss of renal mass lead directly to increased serum phosphorus and hypo- vitaminosis D. Both of these abnormalities result in hypocalcemia and hyperparathyroidism. Many CKD patients also have nutritional 25(OH) vitamin D defi- ciency. PTH, parathyroid hormone.CMDT22_Ch22_p0912-p0951.indd  926 02/07/21 2:33 PMKIDNEY DISEASE927 CMDT 2022pills  pr mal) ar rlativly inxpnsiv but may contribut to positiv calcium balanc and vascular calcification; ovrt hyprcalcmia may also occur. Currnt guidlins suggst limiting thir us in favor of th non-calciumcontaining bindrs svlamr carbonat (8003200 mg/mal) and lanthanum carbonat (5001000 mg/mal). Nwr, iron- basd phosphorus bindrs includ frric citrat and sucro- frric oxyhydroxid and may b considrd whn othr bindrs ar not tolratd ithr du to hyprcalcmia or constipation. Thy should b avoidd in patints with iron ovrload. Aluminum hydroxid is a highly ffctiv phos- phorus bindr but can caus ostomalacia and nurologic complications whn usd long-trm; it can b usd in th acut stting for svr hyprphosphatmia or for short priods (g, 3 wks) in CKD patints. Onc srum phosphorus lvls ar controlld, activ vitamin D (1,25[OH] vitamin D, or calcitriol) or othr vita- min D analogs ar usd to trat scondary hyprparathy- roidism in advancd CKD and ESKD. Srum 25-OH vitamin D lvls should b masurd and brought to nor- mal (s Chaptr 26) prior to considring administration of activ vitamin D. Activ vitamin D (calcitriol) incrass srum calcium and phosphorus lvls; both nd to b monitord closly during calcitriol thrapy, and its dos should b dcrasd if hyprcalcmia or hyprphosphat- mia occurs. Typical calcitriol dosing is 0.25 or 0.5 mcg orally daily or vry othr day. Cinacalct targts th cal- cium-snsing rcptors of th parathyroid gland and sup- prsss PTH production. Cinacalct, 3090 mg orally onc a day, can b usd if lvatd srum phosphorus or calcium lvls prohibit th us of vitamin D analogs; it can caus srious hypocalcmia, and patints should b closly moni- tord for this complication. Optimal PTH lvls in CKD ar not known, but bcaus skltal rsistanc to PTH dvlops with urmia, rlativly high lvls ar targtd in advancd CKD to avoid adynamic bon disas. Exprt guidlins suggst goal PTH lvls nar or just abov th uppr limit of normal for modrat CKD, and at last twofold and up to ninfold th uppr limit of normal for ESKD.Ev npol P t al. Europan Consnsus Statmnt on th diag- nosis and managmnt of ostoporosis in chronic kidny disas stags G4-G5D. Nphrol Dial Transplant. 2021;36:42. [PMID: 33098421] Scialla JJ t al. Stat-of-th-art managmnt of hyprphosphat- mia in patints with CKD: an NKF-KDOQI controvrsis prspctiv. Am J Kidny Dis. 2021;77:132. [PMID: 32771650]C.  Hematologic Complications1.  Anemia Th anmia of CKD, primarily du to dcrasd rythropoitin production, oftn bcoms clini- cally significant during stag 3 CKD. CKD is also associ- atd with high lvls of hpcidin, which blocks GI iron absorption and mobilization of iron from body stors; this rsults in a functional iron dficincyth so-calld an- mia of chronic disas.  Th approach to a patint with CKD and anmia bgins with nsuring that th bon mar- row can rspond to rythropoitin. Thus, thyroid function tsts, srum vitamin B12lvls, and iron stors (frritin and iron saturation) should b chckd. Iron stors ar targtdto highr goals du to a functional blockad of iron utiliza- tion in this population. In CKD, a srum frritin blow 100200 ng/mL or iron saturation lss than 20% is suggs- tiv of iron dficincy. Iron stors may b rpltd with oral or parntral iron; iron thrapy should probably b withhld if th srum frritin is gratr than 500800 ng/mL, vn if th iron saturation is lss than 20%. Oral thrapy with fr- rous sulfat, gluconat, or fumarat, 325 mg onc daily, is th initial thrapy in pr-ESKD CKD; highr doss will rsult in incrasing hpcidin lvls. For thos who do not rspond du to poor GI absorption or lack of tolranc, intravnous iron (g, iron sucros or iron gluconat) may b ncssary. Erythropoisis-stimulating agnts (ESAs, g, rcombi- nant rythropoitin [potin alfa or bta] and darbpo- tin) ar usd to trat th anmia of CKD if othr tratabl causs ar xcludd. Thr is likly no bnfit of starting an ESA bfor hmoglobin (Hgb) valus ar lss than 9 g/dL. Th starting dos of potin alfa is 50100 units/kg onc or twic a wk, and darbpotin is startd at 0.45 mcg/kg and administrd vry 24 wks; potin bta at a starting dos of 60100 mcg is givn vry 24 wks. Ths agnts can b givn intravnously (g, to th hmodialysis patint) or subcutanously (to both th prdialysis or dialysis patint); subcutanous dosing of potin alfa is roughly 30% mor ffctiv than intravnous dosing. ESAs should b titratd to an Hgb of 1011 g/dL for optimal safty; studis show that targting a highr Hgb incrass th risk of strok and possibly othr cardiovascular vnts. Whn titrating doss, Hgb lvls should ris no mor than 1 g/dL vry 34 wks. Hyprtnsion is a common complication of tratmnt with ESAs. 2. Coagulopathy Th blding diathsis that may occur in stag 45 CKD is mainly du to platlt dysfunction, but svr anmia may also contribut. Tratmnt is rquird only in patints who ar symptom- atic. Raising th Hgb to 910 g/dL in anmic patints can rduc risk of blding via improvd clot formation. Dsmo- prssin (25 mcg intravnously vry 812 hours for two doss) is a short-livd but ffctiv tratmnt for platlt dysfunction and it is oftn usd in prparation for surgry or kidny biopsy; hyponatrmia is a potntial advrs ffct of this tratmnt. Dialysis improvs th blding tim.Locatlli  F t al. Ar all rythropoisis-stimulating agnts cratd qual? Nphrol Dial Transplant. 2020. [Epub ahad of print] [PMID: 32206785]D . HyperkalemiaPo tassium balanc gnrally rmains intact in CKD until stags 45. Howvr, hyprkalmia may occur at arlir stags whn crtain conditions ar prsnt, such as typ 4 rnal tubular acidosis (sn in patints with diabts ml- litus), high potassium dits, or mdications that dcras rnal potassium scrtion (amilorid, triamtrn, spi- ronolacton, plrnon, NSAIDs, ACE inhibitors, ARBs) or block cllular potassium uptak (bta-blockrs). Othr causs includ acidmic stats and any typ of cllular dstruction causing rlas of intracllular contnts, such as hmolysis and rhabdomyolysis.CMDT22_Ch22_p0912-p0951.indd  927 02/07/21 2:33 PMChApTEr 22928 CMDT 2022T ratmnt of acut hyprkalmia is discussd in Chaptr 21 (s Tabl 215). Cardiac monitoring is indi- catd for any ECG changs sn with hyprkalmia or a srum potassium lvl gratr than 6.06.5 mEq/L or mmol/L. Chronic hyprkalmia is bst tratd with ditary potassium rstriction (2 g/day) and minimization or limi- nation of any mdications that may impair rnal potassium xcrtion, as notd abov. Loop diurtics may b adminis- trd for thir kaliurtic ffct as long as th patint is not volum-dpltd, and oral potassium-binding rsins may b considrd.Palmr  BF t al. Clinical managmnt of hyprkalmia. Mayo Clin Proc. 2021;96:744. [PMID: 33160639]E.  AcidBase DisordersDamagd kidnys  ar unabl to xcrt th 1 mEq/kg/day of acid gnratd by mtabolism of ditary animal protins in th typical Wstrn dit. Th rsultant mtabolic acido- sis is primarily du to dcrasd GFR; proximal or distal tubular dfcts may contribut to or worsn th acidosis. Excss hydrogn ions ar buffrd by bon; th consqunt laching of calcium and phosphorus from th bon con- tributs to th mtabolic bon disas dscribd abov. Chronic acidosis can also rsult in muscl protin catabo- lism as wll as growth rtardation in childrn with CKD and may acclrat progrssion of CKD. Rduction of ditary animal protin and incrasd fruit and vgtabl intak, and th administration of oral sodium bicarbonat (in doss of 0.51.0 mEq/kg/day dividd twic daily and titratd as ndd) ar stratgis to bring srum bicarbon- at lvls toward normal. Citrat salts incras th absorp- tion of ditary aluminum and should b avoidd in CKD.Na vanthan SD t al. Effcts of tratmnt of mtabolic acidosis in CKD: a systmatic rviw and mta-analysis. Clin J Am Soc Nphrol. 2019;14:1011. [PMID: 31196951]F . Neurologic ComplicationsUrmic  ncphalopathy, rsulting from th aggrgation of urmic toxins, dos not occur until GFR falls blow 510 mL/min/1.73 m2. Symptoms bgin with difficulty in concntrating and can progrss to lthargy, confusion, si- zur, and coma. Physical findings may includ altrd mntal status, waknss, and astrixis. Ths findings improv with dialysis. Othr nurologic complications that can manifst with advancd CKD includ priphral nuropathis (stocking- glov or isolatd mononuropathis), rctil dysfunction, autonomic dysfunction, and rstlss lg syndrom. Ths may not improv with dialysis thrapy.G.  Endocrine DisordersDcrasd  libido and rctil dysfunction ar common in advancd CKD. Mn hav dcrasd tstostron lvls; womn ar oftn anovulatory. Womn with srum crati- nin lss than 1.4 mg/dL ar not at incrasd risk for poor outcoms in prgnancy; howvr, thos with srumcratinin gratr than 1.4 mg/dL may xprinc fastr progrssion of CKD with prgnancy. Ftal survival is not compromisd, howvr, unlss CKD is advancd. TreatmentA.  Slowing ProgressionT ratmnt of th undrlying caus of CKD is vital. Control of diabts should b aggrssiv in arly CKD; howvr, risk of hypoglycmia incrass in advancd CKD, and gly- cmic targts may nd to b rlaxd to avoid this dangr- ous complication. Blood prssur control is vital to slow progrssion of all forms of CKD; agnts that block th rnin-angiotnsin-aldostron systm ar particularly important in protinuric patints. Obs patints should b ncouragd to los wight. Managmnt of traditional car- diovascular risk factors is vital. Risks for AKI should b minimizd or avoidd, including long-trm us of NSAIDs. Tratmnt of mtabolic acidosis may b hlpful. Th ffi- cacy of SGLT2 inhibition for slowing progrssion of CKD in thos with and without diabts or significant protin- uria has bn dmonstratd in svral rcnt trials.Han nan M t al. Risk factors for CKD progrssion: ovrviw of findings from th CRIC study. Clin J Am Soc Nphrol. 2021;16:648. [PMID: 33177074] Hrspink HJL t al; DAPA-CKD Trial Committs and Invsti- gators. Dapagliflozin in patints with chronic kidny disas. N Engl J Md. 2020;383:1436. [PMID: 32970396] Klly JT t al. Modifiabl lifstyl factors for primary prvntion of CKD: a systmatic rviw and mta-analysis. J Am Soc Nphrol. 2021;32:239. [PMID: 32868398]B.  Dietary ManagementPa tints with CKD should b valuatd by a rnal nutri- tionist. Patint-spcific rcommndations should b mad concrning protin, salt, watr, potassium, and phosphorus intak to hlp manag CKD progrssion and complications. 1. Protein restriction Thr is incrasing intrst in plant-basd dits for th tratmnt of CKD. Rducd intak of animal protin to 0.60.8 g/kg/day may slow CKD progrssion. Howvr, significant protin rstriction is not advisabl in thos with cachxia or low srum albu- min in th absnc of th nphrotic syndrom. 2. Salt and water restriction In advancd CKD, th kid- ny is unabl to adapt to larg changs in sodium intak. Intak of gratr than 34 g/day can lad to hyprtnsion and hyprvolmia, whras intak of lss than 1 g/day can lad to volum dpltion and hypotnsion. A goal of 2 g/day of sodium is rasonabl for most patints. Daily fluid rstriction to 2 L may b ndd if volum ovrload is prsnt. 3. Potassium restriction Rstriction is ndd onc th GFR has falln blow 1020 mL/min/1.73 m2, or arlir if th patint is hyprkalmic. Patints should rciv dtaild lists dscribing potassium contnt of foods and should limit thir intak to lss than 5060 mEq/day (2 g/day). An aggrssiv bowl rgimn should b institutd for patints with hyprkalmia (mor than two bowl movmntsCMDT22_Ch22_p0912-p0951.indd  928 02/07/21 2:33 PMKIDNEY DISEASE929 CMDT 2022daily),  sinc a highr prcntag of potassium is xcrtd through th GI tract as GFR dclins. Potassium-binding rsins may b usd (s sction on Hyprkalmia). 4. Phosphorus restriction Guidlins suggst lowring lvatd srum phosphorus lvls toward normal in all stags of CKD. Ditary phosphat rstriction to 8001000 mg/day is th first stp. Procssd foods and cola bvrags ar oftn prsrvd with highly bioavailabl phosphorus and should b avoidd. Foods rich in phos- phorus such as ggs, dairy products, nuts, bans, and mat may also nd to b limitd, although car must b takn to avoid protin malnutrition. Whn GFR is lss than 2030 mL/min/1.73 m2, ditary rstriction is rarly suffi- cint to rach targt lvls, and phosphorus bindrs ar usually rquird (s sction on Mtabolic Bon Disas).Ikizlr T A t al. KDOQI clinical practic guidlin for nutrition in CKD: 2020 updat. Am J Kidny Dis. 2020;76:S1. [PMID: 32829751] Joshi S t al. Plant-basd dits for kidny disas: a guid for clinicians. Am J Kidny Dis. 2021;77:287. [PMID: 33075387]C.  Medication ManagementMan y drugs ar xcrtd by th kidny; dosags should b adjustd for GFR. Dcrasd rnal limination of insulin in advancd CKD confrs risk for hypoglycmia in tratd diabtic patints. Doss of oral hypoglycmics and insulin may nd rduction. Th risk of lactic acidosis with mt- formin is du to both dos and GFR; it should b discon- tinud whn GFR is lss than 30 mL/min/1.73 m2. Magnsium-containing mdications, such as laxativs or antacids, and phosphorus-containing mdicins (g, cathartics) should b avoidd. Activ morphin mtabo- lits can accumulat in advancd CKD; this problm is not ncountrd with othr opioid agnts. Drugs with potn- tial nphrotoxicity (NSAIDs, intravnous contrast, as wll as othrs notd in th Acut Kidny Injury sction) should b avoidd. Proton pump inhibitors should b usd only whn mdically ncssary.Shaddock  R t al. Rnal rprcussions of mdications. Prim Car. 2020;47:691. [PMID: 33121637]D . Treatment of ESKDWhn  GFR dclins to 510 mL/min/1.73 m2, rnal rplac- mnt thrapy (hmodialysis, pritonal dialysis, or kidny transplantation) is rquird to sustain lif. Patint ducation is important in undrstanding which mod of thrapy is most suitabl, as is timly prparation for tratmnt. Rfr- ral to a nphrologist has bn shown to improv mortality and thrfor should tak plac in lat stag 3 CKD or whn th GFR is dclining rapidly. Prparation for ESKD trat- mnt rquirs a tam approach with th involvmnt of diticians, social workrs, primary car clinicians, and nphrologists. For vry ldrly patints, or thos with mul- tipl dbilitating or lif-limiting comorbiditis, dialysis thrapy may not maningfully prolong lif, and th option of palliativ car should b discussd with th patint andfamily. Convrsly, for patints who ar othrwis rlativly halthy, valuation for possibl kidny transplantation should b considrd prior to initiation of dialysis. 1. Dialysis Dialysis initiation should b considrd whn GFR is nar 10 mL/min/1.73 m2and urmic symptoms ar prsnt. Othr indications for dialysis, which may occur whn GFR is 1015 mL/min/1.73 m2, ar fluid ovrload unrsponsiv to diursis and rfractory hyprkalmia. a. Hemodialysis Vascular accss for hmodialysis can b accomplishd by an artriovnous fistula (th prfrrd mthod) or prosthtic graft; cration of dialysis accss should b considrd wll bfor dialysis initiation. An indwlling cathtr is usd whn thr is no usabl vascu- lar accss. Bcaus cathtrs confr a high risk of blood- stram infction, thy should b considrd a tmporary masur. Nativ fistulas typically last longr than pros- thtic grafts but rquir a longr tim aftr surgical construction for maturation (68 wks for a fistula vrsus 2 wks for a graft). Infction, thrombosis, and anurysm formation ar complications sn mor oftn in grafts than fistulas. Staphylococcus spcis ar th most common caus of soft tissu infctions and bactrmia. Tratmnt at a hmodialysis cntr typically occurs thr tims a wk. Sssions last 35 hours, dpnding on patint siz and typ of dialysis accss. Hom hmodialysis is oftn prformd mor frquntly (36 days pr wk for shortr sssions) and rquirs a traind hlpr. Rsults of trials comparing quotidian modalitis (nocturnal and fr- qunt hom hmodialysis) to convntional in-cntr dialy- sis hav not thus far shown significant mortality diffrncs, but thr may b improvmnts in blood prssur control, minral mtabolism, and quality of lif. b. Peritoneal dialysis With pritonal dialysis, th pritonal mmbran is th dialyzr.  Thr ar diffrnt kinds of pritonal dialysis: continu- ous ambulatory pritonal dialysis (CAPD), in which th patint xchangs th dialysat four to six tims a day manually; and continuous cyclic pritonal dialysis (CCPD), which utilizs a cyclr machin to automatically prform xchangs at night. Th most common complication of pritonal dialysis is pritonitis. Pritonitis may prsnt with nausa and vom- iting, abdominal pain, diarrha or constipation, and fvr. Th normally clar dialysat bcoms cloudy; and a diagnostic pritonal fluid cll count gratr than 100 whit blood clls/mcL (0.1  109/L) with a diffrn- tial of gratr than 50% polymorphonuclar nutrophils is prsnt. Staphylococcus aureus is th most common infcting organism, but strptococci and gram-ngativ spcis may also b causativ. Empiric intrapritonal administration of ithr vancomycin or a first-gnration cphalosporin (cfazolin) plus a third-gnration cph- alosporin (cftazidim) should b institutd with th first signs of pritonitis and subsquntly tailord basd on cultur rsults. 2. Kidney transplantation Many patints with ESKD ar othrwis halthy nough to b suitabl for transplan- tation, although standard critria for rcipint slctionCMDT22_Ch22_p0912-p0951.indd  929 02/07/21 2:33 PMChApTEr 22930 CMDT 2022ar  lacking btwn transplant cntrs. Two-thirds of kidny allografts com from dcasd donors, with th rmaindr from living rlatd or unrlatd donors. Ovr 100,000 patints ar on th waiting list for a dcasd donor transplant in th Unitd Stats; th avrag wait is 37 yars, dpnding on gographic location and rcipint blood typ. 3. Medical management of ESKD As notd abov, som patints ar not candidats for kidny transplanta- tion and may not bnfit from dialysis. Vry ldrly prsons may di soon aftr dialysis initiation; thos who do not may nonthlss rapidly los functional status in th first yar of tratmnt. Th dcision to initiat dialy- sis in patints with limitd lif xpctancy should b wighd against possibl dtrioration in quality of lif. For patints with ESKD who lct not to undrgo dialysis or who withdraw from dialysis, progrssiv urmia with gradual supprssion of snsorium rsults in a painlss dath within days to months. Involvmnt of a palliativ car tam is ssntial.Fost r JG t al. Car of th rnal transplant patint. Prim Car. 2020;47:703. [PMID: 33121638] Zarantonllo D t al. Novl consrvativ managmnt of chronic kidny disas via dialysis-fr intrvntions. Curr Opin Nphrol Hyprtns. 2021;30:97. [PMID: 33186220] Prognosis in ESKDCompard  with kidny transplant rcipints and ag- matchd controls, mortality is highr for patints undrgo- ing dialysis. Thr is likly littl diffrnc in survival for wll-matchd pritonal vrsus hmodialysis patints. Survival rats on dialysis dpnd on th undrlying disas procss. Fiv-yar Kaplan-Mir survival rats vary from 37% for patints with diabts to 54% for patints with glomrulonphritis. Ovrall 5-yar survival is cur- rntly stimatd at 40%. Patints undrgoing dialysis hav an avrag lif xpctancy of 35 yars, but survival for as long as 25 yars may b achivd dpnding on comorbidi- tis. Th most common caus of dath is cardiac disas (mor than 50%). Othr causs includ infction, crbro- vascular disas, and malignancy. When to Refer A patint with stag 35 CKD should b rfrrd to a nphrologist for managmnt in conjunction with th primary car providr. A patint with othr forms of CKD such as thos with protinuria gratr than 1 g/day or polycystic kidny disas should b rfrrd to a nphrologist at arlir stags. When to Admit Admission should b considrd for dcompnsation of problms rlatd to CKD, such as worsning of acid- bas status, lctrolyt abnormalitis, and volum ovr- load, that cannot b appropriatly tratd in th outpatint stting.Admission is appropriat whn a patint nds to start dialysis and is not stabl for its outpatint initiation.Charls  C t al. Chronic kidny disas. Prim Car. 2020;47:585. [PMID: 33121630] Li PK t al. Kidny halth for vryon vrywhrfrom pr- vntion to dtction and quitabl accss to car. Clin Nphrol. 2020;93:111. [PMID: 32017699] Shlipak MG t al. Th cas for arly idntification and intrvn- tion of chronic kidny disas: conclusions from a Kidny Disas: Improving Global Outcoms (KDIGO) Controvr- sis Confrnc. Kidny Int. 2021;99:34. [PMID: 33127436] Stnvinkl P t al. A plantary halth prspctiv for kidny disas. Kidny Int. 2020;98:261. [PMID: 32709283]RE NAL ARTERY STENOSISE S S E N T I A L S  O F  D I A G N O S I S Produced by atherosclerotic occlusive disease (8090% of patients) or fibromuscular dysplasia (1015%). Hypertension. AKI in patients starting ACE inhibitor therapy if stenosis is bilateral. General ConsiderationsA pproximatly 5% of Amricans with hyprtnsion suffr from rnal artry stnosis. Athrosclrotic ischmic rnal disas accounts for most cass of rnal artry stnosis. It typically occurs among prsons ovr 45 yars of ag with additional risk factors such as CKD, diabts mllitus, and tobacco us. Fibromuscular dysplasia is a lss common caus of rnal artry stnosis that most commonly occurs in young womn. Clinical FindingsA.  Symptoms and SignsPa tints with athrosclrotic ischmic rnal disas may hav rfractory hyprtnsion, nw-onst hyprtnsion (in an oldr patint), pulmonary dma with poorly controlld blood prssur, and AKI upon starting an ACE inhibitor or ARB. Physical xamination may rval an audibl abdomi- nal bruit on th affctd sid. Unxplaind hyprtnsion in a woman youngr than 40 yars should rais suspicion for fibromuscular dysplasia.B.  Laboratory FindingsBUN and s rum cratinin may b lvatd if thr is sig- nificant rnal ischmia. Patints with bilatral rnal artry stnosis may hav hypokalmia, a finding that rflcts activation of th rnin-angiotnsin-aldostron systm in rspons to rducd blood flow (a prrnal stat).CMDT22_Ch22_p0912-p0951.indd  930 02/07/21 2:33 PMKIDNEY DISEASE931 CMDT 2022C.  ImagingA bdominal ultrasound can rval ithr asymmtric kid- ny siz if on rnal artry is affctd mor than th othr or small hyprchoic kidnys if both ar affctd. Scrning with Dopplr ultrasonography, CT angiogra- phy, or magntic rsonanc angiography (MRA) is rcom- mndd if a corrctiv procdur would b prformd whn a positiv tst rsult is found. Doppler ultrasonogra- phyis highly snsitiv and spcific (85% and 92%, rspc- tivly) and rlativly inxpnsiv but is xtrmly oprator and patint dpndnt. CT angiography consists of intravnous contrast injc- tion with digital subtraction artriography. Th snsitivi- tis from various studis rang from 77% to 98%, with spcificitis of 9094%. MRA is an xcllnt but xpnsiv way to scrn for rnal artry stnosis, particularly in thos with athroscl- rotic disas. Snsitivity is 77100% and spcificity rangs from 71% to 96%. Th imaging agnt for MRA (gadolin- ium) has bn associatd with nphrognic systmic fibro- sis, which is discussd lswhr undr Nphrognic Systmic Fibrosis. Renal angiography is th gold standard for diagnosis, but it is mor invasiv than th thr scrning tsts dis- cussd abov. Thus, it is prformd aftr a positiv scrn- ing tst. Lsions ar most commonly found in th proximal third or ostial rgion of th rnal artry. Th risk of athro- mbolic phnomna aftr angiography rangs from 5% to 10%. Fibromuscular dysplasia has a charactristic bads- on-a-string apparanc on angiography. TreatmentT ratmnt of athrosclrotic ischmic rnal disas is con- trovrsial. Options includ mdical managmnt, angio- plasty with or without stnting, and surgical bypass. Two larg randomizd trials showd that vascular intrvntion is no bttr than optimal mdical managmnt in patints with rnal artry stnosis, xcpt in slctd circumstancs (g, patints with rcurrnt pisods of flash pulmonary dma). Angioplasty might rduc th numbr of antihy- prtnsiv mdications but dos not significantly chang th progrssion of kidny dysfunction. Stnting producs significantly bttr rsults than angioplasty. Howvr, blood prssur and srum cratinin ar similar at 6 months with mdical managmnt as with ithr angioplasty and stnts. Tratmnt of fibromuscular dysplasia with prcutan- ous transluminal angioplasty is oftn curativ, which is in stark contrast to tratmnts for athrosclrotic disas.Gornik  HL t al. First intrnational consnsus on th diagnosis and managmnt of fibromuscular dysplasia. Vasc Md. 2019;24:164. [PMID: 30648921] Mannmuddhu SS t al. Rnovascular hyprtnsion. Prim Car. 2020;47:631. [PMID: 33121633] Princ M t al. Rnal rvascularization in rsistant hyprtnsion. Prog Cardiovasc Dis. 2020;63:58. [PMID: 31821813]GLOMErULAr DISEASESGlomrular  disass can b challnging to undrstand clinically bcaus th glomrulus is a histologically com- plx structur (consisting of th pithlial clls [podo- cyts], basmnt mmbran, capillary ndothlium, and msangium). Th following ar xampls of injuris that can affct any or all of th constitunts of th glomrulus: (1) ovrwork injury, as in CKD; (2) an inflammatory pro- css, such as SLE; (3) a podocyt protin mutation, as in hrditary focal sgmntal glomrulosclrosis (FSGS); or (4) a dposition disas, as in diabts or amyloidosis. Whn a glomrular disas is suspctd, a kidny biopsy may b ndd to clarify th tiology. ClassificationGlomr ular disass can b classifid in on of two clini- cal spctrath nphritic spctrum or th nphrotic spctrum (Figur 224). At th last svr nd of th nephritic spectrum , th findings of asymptomatic glo- mrular hmaturia (i, dysmorphic rd blood clls with or without som protinuria [lss than 1 g/day]) ar charactristic. Th nphritic syndrome , comprising glo- mrular hmaturia, subnphrotic protinuria (lss than 3 g/day), dma, and lvatd cratinin, falls in th mid- portion of th spctrum. Th rapidly progrssiv glo- mrulonphritids (RPGNs), with systmic symptoms, ar at th most svr and clinically urgnt nd of th spctrum. Th nephrotic spectrum is comprisd of dis- ass that prsnt primarily with protinuria of at last 0.51 g/day and a bland urin sdimnt (no clls or cl- lular casts). At th mor svr nd of th nphrotic spctrum is th nphrotic syndrome , consisting of nphrotic-rang protinuria (gratr than 3 g/day), hypoalbuminmia, dma, hyprlipidmia, and urinary oval fat bodis. Diffrntiating btwn a clinical prsn- tation within th nphritic spctrum vrsus th nphrotic spctrum is important bcaus it hlps narrow th diffr- ntial diagnosis of th undrlying glomrular disas (Tabls 227 and 228). Glomrular disass can also b classifid according to whthr thy caus rnal abnormalitis alon (primary rnal disas) or whthr th rnal abnormalitis rsult from a systmic disas (scondary rnal disas). Furthr valuation prior to kidny biopsy may includ srologic tsting for systmic disass that can rsult in glomrular damag (Figur 225).Cavana ugh C t al. Urin sdimnt xamination in th diagnosis and managmnt of kidny disas: Cor Curriculum 2019. Am J Kidny Dis. 2019;73:258. [PMID: 30249419] Flog J t al. Managmnt and tratmnt of glomrular disass (part 1): conclusions from a Kidny Disas: Improving Global Outcoms (KDIGO) Controvrsis Confrnc. Kid- ny Int. 2019;95:268. [PMID: 30665568] Rovin BH t al. Managmnt and tratmnt of glomrular dis- ass (part 2): conclusions from a Kidny Disas: Improving Global Outcoms (KDIGO) Controvrsis Confrnc. Kid- ny Int. 2019;95:281. [PMID: 30665569]CMDT22_Ch22_p0912-p0951.indd  931 02/07/21 2:33 PMChApTEr 22932 CMDT 2022NE PHRITIC SPECTRUM GLOMERULAR DISEASESE S S E N T I A L S  O F  D I A G N O S I S Asymtomatic glomeula ematuia Hematuria with dysmorphic RBCs Proteinuria < 1 g/day Neitic syndome in more severe cases  Glomerular hematuria (and RBC casts if glomerular bleeding is heavy) Proteinuria of 13 g/day Hypertension Edema Rising creatinine over days to months raidly ogessive glomeuloneiti sin most severe cases AKI with rising creatinine over days to months Glomerular hematuria (and RBC casts) Proteinuria of 13 g/day Systemic symptoms Hypertension and edema uncommonGeneral Considerations Glomrulonphritis is a trm givn to thos disass that prsnt in th nphritic spctrum and usually signifis an inflammatory procss causing rnal dysfunction. It can b acut, dvloping ovr days to wks, with or without rso- lution, or may b chronic and indolnt with progrssiv scarring. As notd abov, disass that caus a nphritic spctrum prsntation may prsnt with glomrular hma- turia and protinuria, with nphritic syndrom, or with RPGN (Figur 224). Th prsntation dpnds on th svrity of th undrlying inflammation and th pattrn of injury causd by th disas procss. Clinical FindingsA.  Symptoms and SignsNp hritic syndrom usually lads to an acut dcras in GFR and rsultant sodium rtntion. This is manifstd by hyprtnsion and dma, which is first sn in rgions of low tissu prssur such as th priorbital and scrotal aras. Havy glomrular blding from inflammation may rsult in gross hmaturia (smoky or cola-colord urin).B.  Laboratory Findings1. Serologic testing  Srologic tsts basd on th history and physical xamination hlp narrow th diffrntialAsymptomatic glomerular hematuriaNephritic syndromeNephritic Spectrum Nephrotic SpectrumMicroscop ic or macroscopic hematuria with or without proteinuria (< 1 g/day)Acute kidney injury with proteinuria of 13 g/day, hematuria, RBC casts, edema, and hypertensionAcute kidney injury with proteinuria of 13 g/day, hematuria, RBC casts, and systemic symptomsProteinuria of 300 mg/day10 g/day and bland urineProteinuria of > 3 g/day plus hypoalbuminemia, edema, hyperlipidemia, and possible oval fat bodies in urineAsymptomatic proteinuriaNephrotic syndrome Chronic glomerular disease Chronic kidney disease with or without hematuria, proteinuria, hypertension, late-stage glomerulonephritis, burned-out diseaseRapidly progressive glomerulonephritis Figure 224. Glomerular diseases present within one of the clinical spectra shown; the exact presentation is determined by the severity of the underlying disease and the pattern of injury. Nephritic diseases are characterized by the presence of an active urine sediment with glomerular hematuria and often with proteinuria. Nephrotic spec- trum diseases are proteinuric with bland urine sediments (no cells or cellular casts). All glomerular diseases may progress to a chronic, scarred state. (Adapted, with permission, from Megan Troxell, MD, PhD.)CMDT22_Ch22_p0912-p0951.indd  932 02/07/21 2:33 PMKIDNEY DISEASE933 CMDT 2022diagnosis. Ths  tsts may includ C3 and C4 complmnt lvls, antinuclar antibodis, cryoglobulins, hpatitis srologis, srum and urin protin lctrophorss, srum fr light chains, ANCAs, anti-GBM antibodis, and anti- strptolysin O (ASO) titrs (Figur 225). 2. Urinalysis Th urin dipstick is positiv for protin and blood. Urinary microscopy rvals rd blood clls that ar misshapn or dysmorphic from travrsing a damagd glo- mrular filtration barrir. Rd blood cll casts ar sn with havy glomrular blding and tubular stasis. Whn quan- tifid, protinuria is usually subnphrotic rang (lss than 3 g/day). 3. Biopsy Dfinitiv diagnosis of th undrlying glomr- ular disas cannot b mad without a kidny biopsy. Candidats for biopsy ar patints for whom tst rsults would influnc managmnt; xcptions includ thoswith advancd undrlying CKD, thos who cannot adhr to mdical thrapy, thos for whom immunosupprssiv thrapy is not appropriat, or thos for whom th prsnta- tion is classic for a particular disas (g, post-strptococcal glomrulonphritis, childhood minimal chang disas, and diabtic nphropathy). Th major risk of biopsy is blding. Contraindications includ a blding diathsis, thrombocytopnia, and uncontrolld hyprtnsion. TreatmentGn ral masurs includ tratmnt of hyprtnsion and fluid ovrload, if prsnt. Antiprotinuric thrapy with an ACE inhibitor or ARB should b considrd for thos without AKI. For thos with profound AKI, dialysis may b ndd. Th inflammatory glomrular injury may rquir immuno- supprssiv agnts (s spcific disass discussd blow).Table 227. Classification and findings in glomerulonephritis: nephritic spectrum presentations. Tyical pesentation Association/Notes Seology Postinfectious glomerulonephritisChildren: abrupt onset of nephritic syndrome and acute kidney injury but can present anywhere in nephritic spectrumStreptococci, other bacterial infec- tions (eg, staphylococci, endocardi- tis, shunt infections)Rising ASO titers, low comple- ment levels IgA nephropathy (Berger disease) and Henoch- Schnlein purpura, sys- temic IgA vasculitisClassically: gross hematuria with respiratory tract infection, but can present anywhere in nephritic spectrum; Henoch-Schnlein pur- pura with vasculitic rash and gas- trointestinal hemorrhageAbnormal IgA glycosylation in both primary (familial predisposition) and secondary disease (associated with cirrhosis, HIV, celiac disease) Henoch-Schnlein purpura in chil- dren after an inciting infectionNo serologic tests helpful; com- plement levels are normal Pauci-immune (granulo- matosis with polyangi- itis, eosinophilic granulomatosis with polyangiitis, polyarteri- tis, idiopathic crescen- tic glomerulonephritis)Classically: crescentic or RPGN, but can present anywhere in nephritic spectrum; may have respiratory tract/sinus symptoms in granulo- matosis with polyangiitisSee Figure 225 ANCAs: MPO or PR3 titers high; complement levels normal Anti-GBM glomerulone- phritis; Goodpasture syndromeClassically: crescentic or RPGN, but can present anywhere in nephritic spectrum; pulmonary hemorrhage in Goodpasture syndromeMay develop as a result of respiratory irritant exposure (chemicals or tobacco use)Anti-GBM antibody titers high; complement levels normal Cryoglobulin-associated glomerulonephritisOften acute nephritic syndrome; often with systemic vasculitis including rash and arthritisMost commonly associated with chronic hepatitis C; may occur with other chronic infections or some connective tissue diseasesCryoglobulins positive; rheuma- toid factor may be elevated; complement levels low MPGN Classically: acute nephritic syndrome, but can also have nephrotic syn- drome featuresMost patients are < 30 years old Immune complex MPGN most common C3 glomerulonephritisLow complement levels, may have findings of underlying infection or paraproteinemia Hepatitis C infection Anywhere in nephritic spectrum Can cause MPGN pattern of injury or cryoglobulinemic glomerulone- phritis; membranous nephropathy pattern of injury uncommonLow complement levels; posi- tive hepatitis C serology; rheumatoid factor may be elevated Systemic lupus erythematosusAnywhere in nephritic spectrum, depending on pattern/severity of injuryTreatment depends on clinical course and International Society of Nephrology and Renal Pathology Society classification on biopsyHigh ANA and anti-double- stranded DNA titers; low complement levels ANA, antinuclear antibodies; ANCAs: antineutrophil cytoplasmic antibodies; GBM, glomerular basement membrane; MPGN, membranop- roliferative glomerulonephritis; MPO, myeloperoxidase; PR3, proteinase 3; RPGN, rapidly progressive glomerulonephritis.CMDT22_Ch22_p0912-p0951.indd  933 02/07/21 2:33 PMChApTEr 22934 CMDT 2022 When to ReferAny  patint in whom a glomrulonphritis is suspctd should b rfrrd to a nphrologist. When to AdmitAny  suspicion of acut nphritic syndrom or RPGN warrants considration of immdiat hospitalization.Lamba  P t al. Nphritic syndrom. Prim Car. 2020;47:615. [PMID: 33121632] Popplaars F t al. Complmnt-mdiatd kidny disass. Mol Immunol. 2020;128:175. [PMID: 33137606]1.  Infection-related & postinfectious GlomeuloneitisE S S E N T I A L S  O F  D I A G N O S I S Proteinuria. Glomerular hematuria. Symptoms 13 weeks after some infections (often pharyngitis or impetigo) or during course of other infections (eg, pneumonia or endocarditis).General ConsiderationsP ostinfctious glomrulonphritis is most oftn du to infction with nphritognic group A bta-hmolytic strptococcal infctions (pharyngitis or imptigo). It can occur sporadically or in clustrs and during pidmics, with onst up to 13 wks aftr infction (avrag 710 days). Othr infctions hav bn associatd with glomrulo- nphritis including bactrmia (spcially S aureus ), bac- trial pnumonias, dp-satd abscsss, gram-ngativ infctions, infctiv ndocarditis, and shunt infctions; viral, fungal, and parasitic causs of glomrulonphritis includ hpatitis B or C, HIV , cytomgalovirus infction, infctious mononuclosis, coccidioidomycosis, malaria, mycobactria, syphilis, and toxoplasmosis. Ths ntitis rsult in glomrular injury during activ infction, and ar bttr trmd infction-rlatd glomrulonphritis rathr than postinfctious glomrulonphritis.  Clinical FindingsA.  Symptoms and SignsDisas  prsntation varis across th nphritic spctrum from asymptomatic glomrular hmaturia (spcially in pidmic cass) with minimal chang in kidny function, to nphritic syndrom with hyprtnsion, dma, andTable 228. Classification and findings in glomerulonephritis: nephrotic spectrum presentations.Disease Tyical pesentation Association/Notes Minimal change disease (nil disease; lipoid nephrosis)Child with sudden onset of full nephrotic syndromeChildren: associated with allergy or viral infection Adults: associated with Hodgkin disease, NSAIDs Membranous nephropathy Anywhere in nephrotic spectrum, but nephrotic syndrome not uncommon; particular predispo- sition to hypercoagulable statePrimary (idiopathic) may be associated with antibodies to PLA2R Secondary may be associated with non-Hodgkin lymphoma, carci- noma (gastrointestinal, renal, bronchogenic, thyroid), gold therapy, penicillamine, SLE, chronic hepatitis B or C infection Focal and segmental glomerulosclerosisAnywhere in nephrotic spectrum; children with congenital disease have nephrotic syndromeChildren: congenital disease with podocyte gene mutation, or in spec- trum of disease with minimal change disease Adults: associated with heroin abuse, HIV infection, reflux nephropa- thy, obesity, pamidronate, podocyte protein mutations, APOL1 mutations Amyloidosis Anywhere in nephrotic spectrum AL: plasma cell dyscrasia with Ig light chain overproduction and depo- sition; check SPEP and UPEP AA: serum amyloid protein A overproduction and deposition in response to chronic inflammatory disease (rheumatoid arthritis, inflammatory bowel disease, chronic infection) Diabetic nephropathy High GFR (hyperfiltration) micro- albuminuria frank proteinuria decline in GFRDiabetes diagnosis precedes diagnosis of nephropathy by years HIV-associated nephropathy Heavy proteinuria, often nephrotic syndrome, progresses to ESKD relatively quicklyUsually seen in antiviral treatment-nave patients (rare in antiretroviral therapy era), predilection for those of African descent ( APOL1 mutations) Membranoproliferative glomerulonephropathyClassically presents with acute nephritic syndrome, some may also exhibit nephrotic featuresImmune complexMPGN are idiopathic or secondary to infections, paraproteinemia, or systemic autoimmune disease; C3 glomerulopa- thies are due to alternative complement pathway dysregulation ESKD, end-stage kidney disease; GFR, glomerular filtration rate; NSAIDs, nonsteroidal anti-inflammatory drugs; PLA2R, phospholipase A2 receptor; SLE, systemic lupus erythematosus; SPEP/UPEP , serum and urine protein electrophoresis.CMDT22_Ch22_p0912-p0951.indd  934 02/07/21 2:33 PMKIDNEY DISEASE935 CMDT 2022+ + +Glomerulonephritis (GN) Serologic analysis Anti-glomerular basement membrane (GBM) antibodies Anti-GBM GNAntineutrophil cytoplasmic antibodies (ANCA) No lung hemorrhage Anti-GBM GNLung hemorrhage Goodpasture syndromeImmune complex disease markers Immune complex GNIgA IgA nephropathyAntipathogen antibodies Postinfectious or peri- infectious GNCryoglobulins Cryoglobulinemic GNAntinuclear antibodies Lupus GNComplement activation MPGN ANCA GNSystemic necrotizing vasculitis Microscopic polyangiitisRespiratory necrotizing granulomas Granulomatosis with polyangiitisAsthma and eosinophiliaNo extra- renal disease ANCA- associated crescentic GNEosinophilic granulomatosis with polyangiitis Figure 225. Serologic analysis of patients with glomerulonephritis. MPGN, membranoproliferative glomerulonephritis. (Modified, with permission, from Greenberg A et al.Primer on Kidney Diseases . Academic Press, 1994; and Jennette JC, Falk RJ. Diagnosis and management of glomerulonephritis and vasculitis presenting as a cute renal failure. Med Clin North Am. 1990;74(4):893908.  Elsevier.)CMDT22_Ch22_p0912-p0951.indd  935 02/07/21 2:33 PMChApTEr 22936 CMDT 2022prh aps gross glomrular hmaturia (smoky-colord urin); th most svr cass may rsult in oliguric AKI rquiring dialysis.B.  Laboratory FindingsSrum  complmnt lvls ar low; in postinfctious glo- mrulonphritis du to group A strptococcal infction, anti-strptolysin O (ASO) titrs can b high unlss th immun rspons has bn bluntd with prvious antibiotic tratmnt. Glomrular hmaturia and protinuria ar prs- nt. In childrn with a rcnt strptococcal infction and nphritic faturs, a diagnosis may b mad mpirically without a biopsy. Whn prformd, kidny biopsy shows a diffus prolifrativ pattrn of injury on light microscopy. Immunofluorscnc dmonstrats granular dposition of IgG and C3 in th msangium and along th capillary bas- mnt mmbran. Elctron microscopy shows larg, dns subpithlial dposits or humps.  Kidny biopsy findings in infction-rlatd glomrulonphritis ar varid and may show ovrlap with immun-complx mmbranoprolifra- tiv glomrulonphritis or C3 glomrulonphritis. TreatmentAny  activ infction should b idntifid and tratd appropriatly; othrwis, tratmnt for postinfctious glo- mrulonphritis is supportiv. Antihyprtnsivs, salt rstriction, and diurtics should b usd if ndd. Corti- costroids hav not bn shown to improv outcoms. Prognosis dpnds on th svrity of th glomrular injury and ag of th patint. Childrn ar mor likly to fully rcovr; adults ar mor pron to th dvlopmnt of svr disas (RPGN with crscnt formation) and CKD.Mo hammad D t al. Postinfctious glomrulonphritis. Pdiatr Ann. 2020;49:273. [PMID: 32520369] Satoskar AA t al. Epidmiology, pathognsis, tratmnt and outcoms of infction-associatd glomrulonphritis. Nat Rv Nphrol. 2020;16:32. [PMID: 31399725]2.  IgA NeoatyE S S E N T I A L S  O F  D I A G N O S I S Proteinuria: minimal to nephrotic range. Glomerular hematuria: microscopic is common; macroscopic (gross) after infection. Positive IgA staining on kidney biopsy. General ConsiderationsIgA  nphropathy (Brgr disas) is a primary rnal dis- as of IgA dposition in th glomrular msangium. Th inciting caus is unknown. IgA nphropathy can b a pri- mary (rnal-limitd) disas or scondary to hpatic cir- rhosis, cliac disas, and infctions such as HIV and cytomgalovirus. Suscptibility to IgA nphropathy is inhritabl.IgA nphropathy is th most common primary glo- mrular disas worldwid, particularly in Asia. It is most oftn sn in childrn and young adults, with mals affctd two to thr tims mor commonly than fmals. Clinical FindingsTh  classical prsntation of IgA nphropathy is an pisod of gross hmaturia associatd with a mucosal viral infc- tion, oftn of th uppr rspiratory tract. Th urin bcoms rd or smoky-colord 12 days aftr illnss onsta so-calld synpharyngitic prsntation in contra- distinction to th latnt priod sn in postinfctious glo- mrulonphritis. Howvr, IgA nphropathy can prsnt anywhr along th nphritic spctrum from asymptom- atic microscopic hmaturia with minimal protinuria and prsrvd GFR to RPGN (Figur 224). Rarly, nphrotic syndrom can b prsnt. Thr ar no srologic tsts that aid in this diagnosis; srum complmnts ar normal. Th typical pattrn of injury sn on kidny biopsy is a focal glomrulonphritis with msangial prolifration; immunofluorscnc dm- onstrats diffus msangial IgA and C3 dposits. TreatmentTh  disas cours of primary IgA nphropathy varis widly among patints; tratmnt approach nds to b tailord to risk for progrssion. Patints with low risk for progrssion (no hyprtnsion, normal GFR, minimal pro- tinuria) can b monitord annually. Patints at highr risk (protinuria gratr than 1.0 g/day, dcrasd GFR, or hyprtnsion or any combination of ths thr condi- tions) should b tratd with an ACE inhibitor or ARB. Thrapy should b titratd to rduc protinuria to lss than 1 g/day and to control blood prssur in th rang of 125/75 mm Hg to 130/80 mm Hg. Prior trials suggstd that corticostroids rducd protinuria whn adminis- trd to patints with GFR gratr than 50 mL/min/1.73 m2 and prsistnt protinuria gratr than 1 g/day. Howvr, mor rcnt data faild to dmonstrat slowing of GFR loss with corticostroid thrapy compard with us of ACE inhibitor or ARB alon; nthusiasm for glucocorticoid thrapy thrfor has wand. For th rar patint with IgA nphropathy and a rapidly progrssiv clinical cours with crscnt formation on biopsy, cyclophosphamid and cor- ticostroid thrapy should b considrd (s sction on ANCA-associatd vasculitis blow). Kidny transplanta- tion is an xcllnt option for patints with ESKD, but rcurrnt disas has bn documntd in 30% of patints 510 yars posttransplant. PrognosisA pproximatly on-third of patints xprinc spontan- ous clinical rmission. Progrssion to ESKD occurs in 2040% of patints. Th most unfavorabl prognostic indi- cator is protinuria gratr than 1 g/day; othr includ hyprtnsion, tubulointrstitial fibrosis, glomrulosclro- sis, or glomrular crscnts on biopsy, and abnormal GFR on prsntation.CMDT22_Ch22_p0912-p0951.indd  936 02/07/21 2:33 PMKIDNEY DISEASE937 CMDT 2022Ca mbir A t al. Nw thraputic prspctivs for IgA nphropathy in childrn. Pdiatr Nphrol. 2021;36:497. [PMID: 32040630] Raun T t al. Aftr tn yars of follow-up, no diffrnc btwn supportiv car plus immunosupprssion and supportiv car alon in IgA nphropathy. Kidny Int. 2020;98:1044. [PMID: 32450154] Trimarchi H t al. IgA nphropathy: Stat of th art: a rport from th 15th Intrnational Symposium on IgA Nphropathy clbrating th 50th annivrsary of its first dscription. Kidny Int. 2019;95:750. [PMID: 30904065]3.  henoc-Scnlein puuaH noch-Schnlin purpura is a systmic small-vssl lu- kocytoclastic vasculitis associatd with IgA subclass 1 dpo- sition in vssl walls. It is most common in childrn and is oftn associatd with an inciting infction, such as group A strptococcus or othr xposur. Thr is a mal prdomi- nanc. It classically prsnts with palpabl purpura in th lowr xtrmitis and buttock ara; arthralgias; abdominal symptoms, such as nausa, colic, and mlna; and AKI with nphritic urin sdimnt. Th rnal lsions can b idntical to thos found in IgA nphropathy, and th undrlying pathophysiology appars to b similar. Most patints with microscopic hmaturia and minimal protinuria rcovr fully ovr svral wks. Progrssiv CKD and possibly ESKD ar mor likly to dvlop in adults and in thos with both nphritic and nphrotic syndroms. Although svral tratmnt rgimns of various immunosupprssiv agnts hav bn clinically tstd, non ar provn to altr th cours of svr nphritis. Rituximab tratmnt and plasma xchang hav bn succssful for svr disas according to svral cas rports, but clinical trials ar lacking. Rapidly progrssiv disas with crscnt formation on biopsy may b tratd as in ANCA-associatd vasculitis (s sction blow). Furthr dtails about Hnoch-Schnlin purpura ar providd in Chaptr 20.Mari tati F t al. Adult-onst IgA vasculitis (Hnoch-Schnlin): updat on thrapy. Prss Md. 2020;49:104035. [PMID: 32645417]4.  pauci-Immune Glomeuloneitis (ANCA-Associated)Pa uci-immun ncrotizing glomrulonphritis is causd by th following systmic ANCA-associatd small-vssl vasculitids: granulomatosis with polyangiitis, microscopic polyangiitis, and osinophilic granulomatosis with polyan- giitis (formrly Churg-Strauss disas; s Chaptr 20). ANCA-associatd glomrulonphritis can also prsnt as a primary rnal lsion without systmic involvmnt; this is trmd idiopathic crscntic glomrulonphritis.  Th pathognsis of ths ntitis appars to involv cytokin- primd nutrophils prsnting cytoplasmic antigns on thir surfacs (protinas 3 and myloproxidas). Circu- lating ANCAs thn bind to ths antigns and activat a nutrophil rspiratory burst with consqunt vascular damag; primd nutrophils also appar to activat th altrnativ complmnt pathway. Putativ nvironmntal xposurs that may incit th initial rspons includ S aureusand silica. Immunofluorscnc of kidny biopsy spcimns dmonstrats lack of immunoglobulin or complmnt dposition, hnc th trm pauci-immun.  Rnal involv- mnt classically prsnts as an RPGN, but mor indolnt prsntations can b sn. Clinical FindingsA.  Symptoms and SignsSymp toms of a systmic inflammatory disas, including fvr, malais, and wight loss, may b prsnt and usually prcd initial prsntation by svral months. In addition to hmaturia and protinuria from glomrular inflamma- tion, som patints xhibit purpura from drmal capillary involvmnt and mononuritis multiplx from nrv artrio- lar involvmnt. Ninty prcnt of patints with granulomato- sis with polyangiitis hav uppr (spcially sinus) or lowr rspiratory tract symptoms with nodular lsions that can cavi- tat and bld. Hmoptysis is a concrning sign and usually warrants hospitalization and aggrssiv immunosupprssion.B.  Laboratory FindingsSrologically , ANCA subtyp analysis is don to dtrmin whthr antiprotinas-3 antibodis (PR3-ANCA) or anti- myloproxidas antibodis (MPO-ANCA) ar prsnt. Most patints with granulomatosis with polyangiitis ar PR3 positiv; th rmaindr ar MPO positiv or, mor rarly, do not dmonstrat circulating ANCA. Microscopic angiitis is gnrally associatd with MPO ANCA. Rnal biopsy dmonstrats ncrotizing lsions and crscnts on light microscopy; immunofluorscnc is ngativ for immun complx dposition. TreatmentT ratmnt should b institutd arly if aggrssiv disas is prsnt. Induction thrapy of high-dos corticostroids (mthylprdnisolon, 12 g/day intravnously for 3 days, followd by prdnison, 1 mg/kg orally for 1 month, with a slow tapr ovr th nxt 6 months) and cytotoxic agnts (cyclophosphamid, 0.51 g/m2intravnously pr month or 1.52 mg/kg orally for 36 months) is followd by long-trm azathioprin or mycophnolat moftil. Rituximab has bn shown to b noninfrior to cyclophosphamid for induction and is also usd in rfractory or rlapsing cass and as an altrnativ to azathioprin for maintnanc of rmission. Plasma xchang is likly hlpful in conjunction with induc- tion thrapy for cass complicatd by pulmonary hmor- rhag. Trials using th complmnt inhibitor avacopan in plac of glucocorticoids in cyclophosphamid- or rituximab- basd rgimns ar ongoing and appar promising. PrognosisW ithout tratmnt, prognosis is xtrmly poor. With aggrssiv tratmnt, complt rmission can b achivd in 75% of patints. Prognosis dpnds on th xtnt of rnal involvmnt bfor tratmnt is startd and may b wors in thos with PR3-associatd disas. ANCA titrs may b monitord to follow tratmnt fficacy; rising titrs may hrald rlaps.CMDT22_Ch22_p0912-p0951.indd  937 02/07/21 2:33 PMChApTEr 22938 CMDT 2022Gtha  D t al. ANCA-associatd vasculitis: Cor Curriculum 2020. Am J Kidny Dis. 2020;75:124. [PMID: 31358311] Smith RM t al. Rituximab as thrapy to induc rmission aftr rlaps in ANCA-associatd vasculitis. Ann Rhum Dis. 2020;79:1243. [PMID: 32581088] Walsh M t al. Plasma xchang and glucocorticoids in svr ANCA-associatd vasculitis. N Engl J Md. 2020;382:622. [PMID: 32053298]5.  Anti-Glomeula Basement Membane Glomeuloneitis & Goodastue SyndomeA utoantibodis to pitops of th GBM caus a glomrulo- nphritis (anti-GBM disas); concomitant immun attack on alvolar basmnt mmbrans rsults in pulmonary hmorrhag as wll (Goodpastur syndrom) (Figur 225). Anti-GBMassociatd glomrulonphritis accounts for 1020% of patints with acut RPGN. Th incidnc paks in th third dcad of lif during which tim mals ar prdominantly affctd and lung involvmnt is mor common, and again in th sixth and svnth dcads with lss gndr spcificity and pulmonary involvmnt. Good- pastur syndrom has bn associatd with pulmonary infction, tobacco us, and xposur to hydrocarbon sol- vnts or almtuzumab; HLA-DR2 and -B7 antigns may prdispos as wll. Clinical FindingsA.  Symptoms and SignsTh on st of disas may b prcdd by an uppr rspira- tory tract infction; hmoptysis, dyspna, and possibl rspiratory failur may nsu. Othr findings ar consistnt with an RPGN, although rar cass may prsnt with much mildr forms of th nphritic spctrum of disas (g, glo- mrular hmaturia and protinuria with minimal kidny dysfunction).B.  Laboratory FindingsChst radiographs may dmonstrat  pulmonary infiltrats if pulmonary hmorrhag is prsnt. Srum complmnt lvls ar normal. Circulating anti-GBM antibodis ar prsnt in ovr 90% of patints. A small prcntag of patints hav lvatd ANCA titrs; ths patints should b tratd with plasma xchang as for anti-GBM disas. Kidny biopsy typically shows crscnt formation with light microscopy, with linar IgG staining along th GBM with immunofluorscnc. TreatmentPa tints with pulmonary hmorrhag and strong clinical suspicion of Goodpastur syndrom should b tratd mrgntlypossibly prior to confirming th diagnosis with srology and kidny biopsy. Tratmnt is a combina- tion of plasma xchang thrapy daily for up to 2 wks to rmov circulating antibodis, and administration of corti- costroids and cyclophosphamid to prvnt formation of nw antibodis and control th inflammatory rspons. Rituximab has bn usd in a small numbr of patintswith rfractory disas. Patints with oliguric AKI or who rquir dialysis upon prsntation hav a poor prognosis. Anti-GBM antibody titrs should dcras as th clinical cours improvs.Sglm ark M t al. Anti-glomrular basmnt mmbran disas: an updat on subgroups, pathognsis and thrapis. Nphrol Dial Transplant. 2019;34(11):1826. [PMID: 30371823] Umatsu-Uchida M t al. Rituximab in tratmnt of anti-GBM antibody glomrulonphritis: a cas rport and litratur rviw. Mdicin (Baltimor). 2019;98:17801. [PMID: 31689860]6.  Membanoolifeative Glomeuloneitis & C3 GlomeuloatiesMPGN is a  rlativly rar pattrn of glomrular injury that can prsnt anywhr along th nphritic spctrum from asymptomatic glomrular hmaturia to acut nphritic syndrom with bouts of gross hmaturia to RPGN; nphrotic syndrom can also b sn. MPGN is classifid pathologically and mchanistically into immun complx and C3-rlatd disas. Etiologis of immun complx mdiatd MPGN includ chronic infction (most commonly HCV , but also bactrial and parasitic infc- tions), a paraprotinmia, or an undrlying autoimmun disas (such as lupus); it can also b idiopathic (spcially in childrn and young adults). In ths cass, th pathogn- sis is likly a chronic antignmia lading to classical complmnt pathway activation with immun complx dposition; howvr, som cass may rsult from altrna- tiv complmnt pathway dysrgulation. C3 glomrulopa- this ar causd by svral inhritd or acquird abnormalitis in th altrnativ complmnt pathway. Both typs rsult in low circulating C3 complmnt; C4 is low in immun complx disas. Light microscopy of both typs shows varying dgrs of msangial hyprcllularity, ndo- capillary prolifration and capillary wall rmodling rsulting in doubl contours of th GBM (tram track apparanc). Immunofluorscnc and lctron micros- copy provid distinguishing information. Immun complxmdiatd MPGN rvals C3 and IgG or IgM staining (or both) on immunofluorscnc; lctron microscopy dmonstrats msangial and subpithlial dposits. C3 glomrulonphritis is distinguishd by lack of immunoglobulin staining on immunofluorscnc, but can appar similar to immun complx disas with rspct to light and lctron microscopy. An additional but rar typ of C3 glomrular injury is dns dposit disas basd on thick ribbon-lik dposits sn on lctron microscopy. Togthr, dns dposit disas and C3 glomrulonphritis ar trmd C3 glomrulopathis.  Tratmnt of immun complx MPGN should b dirctd at any idntifiabl undrlying caus; idiopathic immun complx disas tratmnt is controvrsial and controlld trial data ar lacking. For thos with mild dis- as, ACE inhibitors and ARBs should b usd. For svr disas, a combination of oral cyclophosphamid or myco- phnolat moftil plus corticostroids could b considrd; rituximab is also somtims usd. Thos with RPGN and crscnts on biopsy may b tratd th sam as thos withCMDT22_Ch22_p0912-p0951.indd  938 02/07/21 2:33 PMKIDNEY DISEASE939 CMDT 2022ANCA -associatd disas providd scondary causs hav bn ruld out. Dspit thrapy, most will progrss to ESKD. Tratmnt for th C3 glomrulopathis is in volu- tion as novl thrapis to targt th dysrgulatd altrnativ complmnt cascad ar bing xplord; small, uncon- trolld sris suggst a possibl bnfit of culizumab in som patints; othrs may rspond to mycophnolat moftil. Lss favorabl prognostic findings includ dns dposit disas, arly dclin in GFR, hyprtnsion, and prsistnt nphrotic syndrom. All typs of MPGN rcur with high frquncy aftr kidny transplantation; howvr, dns dposit disas rcurs mor commonly. Plasma xchang, with or without culizumab, has bn usd with mixd rsults to trat posttransplant rcurrnc of MPGN.Fakhouri  F t al. Practical managmnt of C3 glomrulopathy and Ig-mdiatd MPGN: facts and uncrtaintis. Kidny Int. 2020;98:1135. [PMID: 32622830]7.  Cyoglobulin-Associated GlomeuloneitisEssnt ial (mixd) cryoglobulinmia is a vasculitis causd by cold-prcipitabl immunoglobulins (cryoglobulins). Th most common undrlying tiology is HCV infction; in ths cass, thr is clonal xpansion of B lymphocyts, which produc IgM rhumatoid factor. Rhumatoid fac- tor, HCV antign, and polyclonal anti-HCV IgG form complxs that dposit in vssls and incit inflamma- tion. Othr ovrt or occult infctions (g, viral, bactrial, and fungal) as wll as som autoimmun disass and lymphoprolifrativ disordrs can caus cryoglobulin- mic vasculitis. Patints xhibit purpuric and ncrotizing skin lsions in dpndnt aras, arthralgias, fvr, and hpatosplnomg- aly. Srum complmnt lvls ar low and rhumatoid fac- tor is oftn lvatd. Kidny biopsy may show svral diffrnt pattrns of injury; thr may b crscnt forma- tion, glomrular capillary thrombi, or MPGN (s abov). Tratmnt consists of aggrssivly targting th causativ infction. Puls corticostroids, plasma xchang, ritux- imab, and cytotoxic agnts hav bn usd whn thr is littl risk of xacrbating th undrlying infction or whn no infction is prsnt. S also Hpatitis C VirusAssociatd Kidny Disas.Ko lopp-Sarda MN t al. Cryoglobulinmic vasculitis: patho- physiological mchanisms and diagnosis. Curr Opin Rhu- matol. 2021;33:1. [PMID: 33186245]8.  heatitis C ViusAssociated Kidney DiseaseKidny dis as can occur in th stting of HCV infction. Th thr pattrns of kidny injury associatd with HCV ar scondary MPGN (most common), cryoglobulinmic glomrulonphritis, and mmbranous nphropathy. Th clinical prsntation is dictatd by th undrlying pattrn of injury. Many patints hav lvatd srum transami- nass and an lvatd rhumatoid factor. Hypocompl- mntmia is vry common, with C4 typically mor rducd than C3; complmnt lvls and rhumatoid factor tnd to b normal if thr is a mmbranous pattrn of injury.TreatmentV iral supprssion or radication is th cornrston of trat- mnt of HCVassociatd kidny disas (s Chaptr 16). Us of most dirct-acting antiviral agnts appars to b saf in thos with rducd GFR, with th xcption of sofosbu- vir. Thrapy with rituximab and possibly corticostroids and plasmaphrsis should b initiatd in patints with svr vasculitis prior to th initiation of antiviral thrapy.Comarm ond C t al. Tratmnt of chronic hpatitis Cassociatd cryoglobulinmia vasculitis at th ra of dirct-acting antivi- rals. Thrap Adv Gastrontrol. 2020;13:1756284820942617. [PMID: 32782479] Roth D t al. KDOQI US commntary on th 2018 KDIGO clini- cal practic guidlin for th prvntion, diagnosis, valua- tion, and tratmnt of hpatitis C. Am J Kidny Dis. 2020;75: 665. [PMID: 32279907]9.  Systemic Luus EytematosusRnal invol vmnt occurs in 3590% of patints who hav SLE, with highr stimats ncompassing subclinical dis- as. Rats of lupus nphritis ar highst in non-Whits. Th pathognsis may b dysrgulatd cllular apoptosis rsulting in autoantibodis against nuclosoms; antibody/ nuclosom complxs thn bind to componnts of th glomrulus to form immun complx glomrular disas. S Chaptr 20 for furthr discussion of SLE. Th trm lupus nphritis ncompasss many possibl pattrns of rnal injurymost cass prsnt within th nphritic spctrum (class IIV). Nonglomrular syn- droms includ tubulointrstitial nphritis and vasculitis. All patints with SLE should hav routin urinalyss to monitor for th apparanc of hmaturia or protinuria. If urinary abnormalitis ar dtctd, kidny biopsy is oftn prformd. Th Intrnational Socity of Nphrology and Rnal Pathology Socity classification of rnal glomrular lsions is class I, minimal msangial nphritis; class II, msangial prolifrativ nphritis; class III, focal (lss than 50% of glomruli affctd with capillary involvmnt) pro- lifrativ nphritis; class IV , diffus (gratr than 50% of glomruli affctd with capillary involvmnt) prolifrativ nphritis; class V , mmbranous nphropathy; and class VI, advancd sclrosis without rsidual disas activity. Classs III and IV , th most svr forms of lupus nphritis, ar furthr classifid as activ or chronic, and global or sg- mntal, which confrs additional prognostic valu. TreatmentIndivid uals with class I and class II lesions gnrally rquir no tratmnt; corticostroids or calcinurin inhibi- tors should b considrd for thos with class II lsions with nphrotic-rang protinuria. Transformation of ths typs to a mor activ lsion may occur and is usually accompanid by an incras in lupus srologic activity (g, rising titrs of antidoubl-strandd DNA antibodis and falling C3 and C4 lvls) and incrasing protinuria or fall- ing GFR. Rpat biopsy in such patints is rcommndd. Hydroxychloroquin should b considrd for all patints with lupus nphritis, rgardlss of histological class.CMDT22_Ch22_p0912-p0951.indd  939 02/07/21 2:33 PMChApTEr 22940 CMDT 2022Pa tints with xtnsiv class III lesions and all class IV lesions should rciv aggrssiv immunosupprssiv thrapy. Poor prognostic indicators in patints with class III or IV lsions includ lvatd srum cratinin, lowr complmnt lvls, mal sx, prsnc of antiphospholipid antibodis, nphrotic-rang protinuria, African dscnt (possibly in association with APOL1 risk allls), and poor rspons to thrapy. Immunosupprssiv thrapy for class V lupus nphritis is indicatd if suprimposd prolifrativ lsions xist. Class VI lsions should not b tratd. Tratmnt of class III or IV lupus nphritis consists of induction thrapy, followd by maintnanc thrapy. Induction thrapy includs corticostroids (g, mthyl- prdnisolon 1 g intravnously daily for 3 days followd by prdnison, 1 mg/kg orally daily with subsqunt tapr ovr 612 months) in combination with ithr cyclophos- phamid or mycophnolat moftil. Data suggst that Blacks and Hispanics rspond mor favorably to mycoph- nolat moftil than cyclophosphamid; in addition, myco- phnolat moftil has a mor favorabl sid-ffct profil than cyclophosphamid and should b favord whn prs- rvation of frtility is a considration. Mycophnolat moftil induction is typically givn at 23 g orally daily, thn taprd to 12 g/day for maintnanc. Cyclophospha- mid induction rgimns vary but usually involv monthly intravnous puls doss (5001000 mg/m2) for 6 months. Induction is followd by daily oral mycophnolat moftil or azathioprin maintnanc thrapy; mycophnolat moftil may b suprior to azathioprin maintnanc and causs fw advrs ffcts. Maintnanc with calcinurin inhibitors may also b considrd, but th rlaps rat is high upon discontinuation of ths agnts. With standard thrapy, rmission rats with induction vary from 80% for partial rmission to 5060% for full rmission; it may tak mor than 6 months to s ths ffcts. Rlaps is com- mon and rats of disas flar ar highr in thos who do not xprinc complt rmission; similarly, progrssion to ESKD is mor common in thos who rlaps mor fr- quntly, or in whom no rmission has bn achivd. Th us of add-on B-cll-targtd thrapy with rituximab or blimumab for class III, IV , and/or V disas may b con- sidrd. Pur class V disas is tratd with mycophnolat moftil with or without rituximab. Th lvls of various disas activity markrs (doubl- strandd DNA antibodis, srum C3, C4, CH50lvls) and th urinary protin lvls and sdimnt activity can b us- ful in monitoring rspons to tratmnt; howvr, rpat rnal biopsy yilds mor rliabl information rgarding disas activity and may b usd to guid maintnanc thrapy withdrawal. Patints with SLE who undrgo dialy- sis hav a favorabl prospct for long-trm survival; intr- stingly, systmic lupus symptoms may bcom quiscnt with th dvlopmnt of ESKD. Patints with SLE undr- going kidny transplants can hav rcurrnt rnal disas, although rats ar rlativly low.Fan ouriakis A t al. 2019 updat of th Joint Europan Lagu Against Rhumatism and Europan Dialysis and Transplant Association (EULAR/ERA-EDTA) rcommndations for th managmnt of lupus nphritis. Ann Rhum Dis. 2020;79:713. [PMID: 32220834]Furi R t al. Two-yar, randomizd, controlld trial of blimumab in lupus nphritis. N Engl J Md. 2020;383:1117. [PMID: 32937045] Parikh SV t al. Updat on lupus nphritis: Cor Curriculum 2020. Am J Kidny Dis. 2020;76:265. [PMID: 32220510]NE PHROTIC SPECTRUM GLOMERULAR DISEASESE S S E N T I A L S  O F  D I A G N O S I S Proteinuria with bland urine sediment (few if any cells or cellular casts). Nephrotic syndrome (if present) manifestations:  Nephrotic-range proteinuria (urine protein excretion > 3 g per 24 hours). Hypoalbuminemia (albumin < 3 g/dL). Peripheral edema. Hyperlipidemia. Oval fat bodies may be seen in the urine. General ConsiderationsIn Amrican  adults, th most common caus of nphrotic spctrum glomrular disas is diabts mllitus. Othr causs includ minimal chang disas, FSGS, mmbra- nous nphropathy, and amyloidosis. Any of ths ntitis can prsnt on th lss svr nd of th nphrotic spc- trum with a bland urinalysis and protinuria or on th most svr nd of th full nphrotic syndrom. Srum cratinin may b abnormal at th tim of prsntation, dpnding on th svrity and chronicity of th disas. Clinical FindingsA.  Symptoms and SignsPa tints with subnphrotic rang protinuria do not mani- fst symptoms of kidny disas. In thos with th nphrotic syndrom, priphral dma is prsntmost likly du both to sodium rtntion and hypoalbuminmia- inducd low plasma oncotic prssur. Edma may dvlop solly in dpndnt rgions, such as th lowr xtrmitis, or it may bcom gnralizd and includ priorbital dma. Dyspna du to pulmonary dma, plural ffu- sions, and diaphragmatic compromis du to ascits can occur.B.  Laboratory Findings1. Urinalysis  Protinuria occurs as a rsult of podocyto- pathy and variabl altrations of th GBM. Th urin dip- stick is a good scrning tst for albuminuria; if positiv, urinary protin xcrtion should b quantifid (s arlir Protinuria sction). A spot urin protin to urin crati- nin ratio givs a rasonabl approximation of grams of protin xcrtd pr day; a 24-hour urin sampl for pro- tin xcrtion is rarly ndd.CMDT22_Ch22_p0912-p0951.indd  940 02/07/21 2:33 PMKIDNEY DISEASE941 CMDT 2022Microscop ically, th urinary sdimnt has rlativly fw cllular lmnts or casts. Howvr, if markd hyprlipid- mia is prsnt, urinary oval fat bodis may b sn. Thy appar as grap clustrs undr light microscopy and Malts crosss undr polarizd light. 2. Blood chemistries Th nphrotic syndrom rsults in hypoalbuminmia (lss than 3 g/dL [30 g/L]). Hyprlipid- mia, du both falling oncotic prssur triggring incrasd hpatic production of lipids and to dcrasd claranc of vry low-dnsity lipoprotins causing hyprtriglycrid- mia, occurs in ovr 50% of patints with arly nphrotic syndrom, and bcoms mor frqunt and worsns in dgr as th svrity of th nphrotic syndrom incrass. An lvatd rythrocyt sdimntation rat may b sn as a rsult of incrasd lvls of fibrinogn. Havy urinary xcrtion of binding protins may rsult in dficincis of vitamin D, zinc, and coppr. Laboratory tsting to hlp lucidat th undrlying caus of th glomrular disas includs complmnt lvls, srum and urin protin lctrophorsis, srum fr light chains, antinuclar antibodis, PLA2R antibody titrs, HbA1c, and srologic tsting for hpatitis B and C, HIV , and syphilis. 3. Kidney biopsy Kidny biopsy is oftn prformd in adults with nw-onst idiopathic nphrotic syndrom if a primary rnal disas that may rquir immunosupprssiv thrapy is suspctd. Chronically and significantly dcrasd GFR indicats irrvrsibl kidny disas mitigating th usfulnss of kidny biopsy. In th stting of long-standing diabts mllitus typ 1 or 2, protinuric rnal disas is rarly biopsid unlss atypical faturs (such as significant glomrular hmaturia or cllular casts) ar also prsnt, or if thr is othr rason to suspct an additional rnal lsion. TreatmentA.  Protein LossIn  thos with subnphrotic protinuria, ditary protin rstriction may b hlpful in slowing progrssion of kidny disas (s CKD sction). In both diabtic and nondiabtic patints, anti-protin- uric thrapy should also slow progrssion of kidny dis- as. ACE inhibitors and ARBs rduc urin protin xcrtion by dcrasing glomrular capillary prssur and also hav antifibrotic ffcts. Thy can b usd in patints with rducd GFR as long as significant hyprkalmia (potassium gratr than 5.25.5 mEq/L or mmol/L) dos not occur and srum cratinin riss lss than 30% aftr drug initiation or dos titration; patints should b moni- tord closly to avoid AKI and hyprkalmia. Combination thrapy of an ARB and an ACE inhibitor incrass risk for AKI and hyprkalmia and is not rcommndd.B.  EdemaDitary  salt rstriction is ssntial for managing dma; most patints also rquir diurtic thrapy. A combination of loop and thiazid diurtics may b ndd for rfractory fluid rtntion. Both thiazid and loop diurtics ar highly protin bound; thrfor, with hypoalbuminmia and dcrasd GFR, diurtic dlivry to th kidny is rducd and largr doss oftn ar rquird.C. HyperlipidemiaH yprcholstrolmia and hyprtriglycridmia occur as notd abov. Ditary modification and xrcis should b advocatd; howvr, ffctiv lipid-lowring usually also rquirs pharmacologic tratmnt (s Chaptr 28). Thr is significant risk of rhabdomyolysis in patints with CKD who tak gmfibrozil in combination with statins; combin- ing fnofibrat or niacin with a statin is prfrrd.D . Hypercoagulable StatePa tints with nphrotic syndrom hav urinary losss of antithrombin, protin C, and protin S and incrasd plat- lt activation. Patints with srum albumin lss than 2 g/dL (20 g/L) hav considrabl risk for thrombophilia and may dvlop rnal vin thrombosis, pulmonary mbolus, and othr vnous thrombomboli; this is particularly likly with mmbranous nphropathy. Anticoagulation thrapy with warfarin is warrantd for at last 36 months in patints with vidnc of thrombosis in any location and may b rquird indfinitly for rnal vin thrombosis, pulmonary mbolus, rcurrnt thrombomboli or whn ongoing nphrotic syndrom poss a risk of thrombosis rcurrnc. When to ReferAny  patint with th nphrotic syndrom should b rfrrd immdiatly to a nphrologist for volum and blood prssur managmnt, assssmnt for kidny biopsy, and tratmnt of th undrlying disas. Protinuria of mor than 1 g/24 hours without th nphrotic syndrom also mrits nphrology rfrral, though with lss urgncy. When to AdmitPa tints with dma rfractory to outpatint thrapy or rapidly worsning kidny function that may rquir inpa- tint intrvntions should b admittd.Bknkamp  A. Protinuriatak a closr look! Pdiatr Nphrol. 2020;35:533. [PMID: 31925536] Politano SA t al. Nphrotic syndrom. Prim Car. 2020;47:597. [PMID: 33121631] Wang CS t al. Nphrotic syndrom. Pdiatr Clin North Am. 2019;66:73. [PMID: 30454752] NEphrOTIC SpECTrUM DISEASE IN prIMArY rENAL DISOrDErS MINIMAL CHANGE DISEASEE S S E N T I A L S  O F  D I A G N O S I S Nephrotic-range proteinuria. Kidney biopsy shows no changes on light microscopy. Characteristic foot-process effacement on electron microscopy.CMDT22_Ch22_p0912-p0951.indd  941 02/07/21 2:33 PMChApTEr 22942 CMDT 2022 General ConsiderationsMinimal cha ng disas is th most common caus of pro- tinuric rnal disas in childrn, accounting for about 80% of cass. It oftn rmits upon tratmnt with a cours of corticostroids. Indd, childrn with nphrotic syn- drom ar oftn tratd for minimal chang disas mpir- ically without a biopsy diagnosis. Minimal chang disas is lss common in adults, accounting for 2025% of cass of primary nphrotic syndrom in thos ovr ag 40 yars. This ntity can b idiopathic but also occurs following viral uppr rspiratory infctions (spcially in childrn), in association with noplasms such as Hodgkin disas, with drugs (lithium), and with hyprsnsitivity ractions (sp- cially to NSAIDs and b stings). Clinical FindingsA.  Symptoms and SignsPa tints prsnt with nphrotic syndrom, which confrs suscptibility to infction, tndncy toward thrombom- bolic vnts, svr hyprlipidmia, and possibly protin malnutrition. Minimal chang disas can caus AKI du to rnal tubular damag and intrstitial dma.B.  Laboratory and Histologic FindingsTh r is no hlpful srologic tsting. Biopsy should b consid- rd for childrn with nphrotic syndrom who xhibit unusual faturs (such as signs of othr systmic illnss), or who ar stroid-rsistant or rlaps upon withdrawal of corti- costroid thrapy; th lattr two conditions may indicat an undrlying focal and sgmntal glomrulosclrosis rathr than minimal chang disas. Whn kidny biopsy is pr- formd, glomruli appar normal on light microscopy and immunofluorscnc. On lctron microscopy, thr is a charactristic ffacmnt of podocyt foot procsss. Msan- gial cll prolifration may b sn in a subgroup of patints; this finding is associatd with mor hmaturia and hyprtn- sion and poor rspons to standard corticostroid tratmnt. TreatmentT ratmnt is with prdnison, 60 mg/m2/day orally; rmis- sion in stroid-rsponsiv minimal chang disas gnr- ally occurs within 48 wks. Adults oftn rquir longr courss of thrapy than childrn, rquiring up to 16 wks to achiv a rspons. Tratmnt should b continud for svral wks aftr complt rmission of protinuria, and dosing taprs should b individualizd. A significant num- br of patints will rlaps and rquir rpatd corticost- roid tratmnt. Patints with frqunt rlapss or corticostroid rsistanc may rquir cyclophosphamid, a calcinurin inhibitor (tacrolimus, cyclosporin), or ritux- imab to induc subsqunt rmissions. Progrssion to ESKD is rar. Complications most oftn aris from pro- longd corticostroid us.M djral-Thomas NR t al. Randomizd, controlld trial of tacro- limus and prdnisolon monothrapy for adults with de novo minimal chang disas: a multicntr, randomizd, controlld trial. Clin J Am Soc Nphrol. 2020;15:209. [PMID: 31953303]FOCAL SEGMENTAL GLOMERULOSCLEROSIS General ConsiderationsThis r lativly common rnal pattrn of injury rsults from damag to podocyts; such damag may b a primary/ rnal-limitd disordr or may b scondary to anothr undrlying disas stat. Primary causs fall into thr cat- goris: (1) hritabl abnormalitis in any on of svral podocyt protins, or to undrlying typ 4 collagn muta- tions; (2) polymorphisms in th APOL1 gn in thos of African ancstry; or (3) incrasd lvls of a circulating prmability factor. Scondary causs includ rnal ovr- work injury, obsity, hyprtnsion, chronic urinary rflux, HIV or SARS-CoV-2 infction, or analgsic or bisphospho- nat xposur. Gntic tsting in primary cass is bcoming mor common, spcially in th pdiatric population. Clinical FindingsIn  FSGS causd by a primary kidny disas, 80% of chil- drn and 50% of adults hav ovrt nphrotic syndrom; howvr, whn it dvlops du to a scondary caus, frank nphrotic syndrom is uncommon. Dcrasd GFR is prs- nt in 2550% of thos with FSGS at tim of diagnosis. Diagnosis rquirs kidny biopsy; thr is no hlpful srologic tst. Light microscopy shows sclrosis of sg- mnts of som, but not all, glomruli. On immunofluors- cnc, IgM and C3 ar sn in th sclrotic lsions, although it is prsumd that ths immun componnts ar simply trappd in th sclrotic glomruli and not pathog- ntic. As in minimal chang disas, lctron microscopy shows fusion of pithlial foot procsss. TreatmentT ratmnt for all forms of FSGS includs diurtics for dma, ACE inhibitors or ARBs to control protinuria and hyprtnsion, and statins or niacin for hyprlipidmia. Immunosupprssion thrapy (oral prdnison, 1 mg/kg/ day for 416 wks followd by a slow tapr) is rsrvd for nphrotic primary FSGS cass prsumd to b du to a circulating prmability factor; in thos with stroid- rsistanc or intolranc, calcinurin inhibitors and myco- phnolat moftil can b considrd. Kidny transplantation in this subgroup of FSGS patints is complicatd by a rla- tivly high rlaps rat and risk of graft loss. Thos with APOL1 -associatd and nonhrditary primary rnal dis- as may not bnfit from immunosupprssion, although robust clinical trials ar lacking. Patints with scondary FSGS do not bnfit from immunosupprssiv thrapy; tratmnt should b dirctd at th inciting caus.Ahn  W t al. Approach to diagnosis and managmnt of primary glomrular disass du to podocytopathis in adults: Cor Curriculum 2020. Am J Kidny Dis. 2020;75:955. [PMID: 32331832] Andrs HJ t al. SGLT2 inhibition rquirs rconsidration of fundamntal paradigms in chronic kidny disas, diabtic nphropathy , IgA nphropathy and podocytopathis with FSGS lsions. Nphrol Dial Transplant. 2020. [Epub ahad of print] [PMID: 33313878]CMDT22_Ch22_p0912-p0951.indd  942 02/07/21 2:33 PMKIDNEY DISEASE943 CMDT 2022Shabaka  A t al. Focal sgmntal glomrulosclrosis: stat-of- th-art and clinical prspctiv. Nphron. 2020;144:413. [PMID: 32721952]ME MBRANOUS NEPHROPATHYE S S E N T I A L S  O F  D I A G N O S I S Varying degrees of proteinuria. Most common cause of primary adult nephrotic syndrome. Significant risk for hypercoagulable state if nephrotic syndrome present. Spike and dome pattern on kidney biopsy from subepithelial deposits. Secondary causes include hepatitis B virus and carcinomas. General ConsiderationsMm branous nphropathy is th most common caus of primary nphrotic syndrom in adults, most oftn prsnting in th fifth and sixth dcads. Primary mmbranous nphropathy is an autoimmun disas with ractivity against svral possibl podocyt antigns. Scondary disas is associatd with infctions, such as hpatitis B and C, ndo- carditis, and syphilis; undrlying carcinomas (som of ths cass may also involv autoimmunity to THSD7A); autoim- mun disas, such as SLE, mixd connctiv tissu disas, and thyroiditis; and crtain drugs, such as NSAIDs and cap- topril. Th cours of primary disas is highly variabl, with spontanous rmission in approximatly 30% of patints and progrssion to ESKD ovr 310 yars in 50%. Poorr out- com is associatd with concomitant tubulointrstitial fibro- sis, mal sx, lvatd srum cratinin on prsntation, hyprtnsion, and protinuria gratr than 10 g/day. Patints with mmbranous nphropathy and nphrotic syndrom hav a highr risk of hyprcoagulabl stat with thrombosis than nphrosis from othr tiologis, including a particular prdisposition to rnal vin thrombosis. Clinical FindingsA.  Symptoms and SignsPa tints may b asymptomatic or may hav dma or frothy urin. Symptomatic vnous thrombosis may b an initial sign. Thr may b symptoms or signs of an undrlying infction or noplasm (spcially lung, stomach, brast, and colon cancrs) in scondary mmbranous nphropathy.B.  Laboratory FindingsH ypoalbuminmia and hyprlipidmia ar charactristic laboratory findings in th nphrotic syndrom. Evaluation for scondary causs including srologic tsting for SLE, syphilis, and viral hpatitids, and ag- and risk-appropri- at cancr scrning should b prformd. Elvatd titr ofcirculating PLA2R antibodis is now considrd diagnostic for primary mmbranous nphropathy and may liminat th nd for kidny biopsy. Kidny biopsy findings in mmbranous nphropathy includ incrasd capillary wall thicknss without inflammatory changs or cllular prolif- ration; whn staind with silvr mthnamin, a spik and dom pattrn rsults from projctions of xcss GBM btwn th subpithlial immun complx dposits. Immunofluorscnc shows IgG and C3 staining along capillary loops. Elctron microscopy shows a discontinu- ous pattrn of dns dposits along th subpithlial sur- fac of th basmnt mmbran. TreatmentScondary  causs must b considrd prior to considr- ation of tratmnt. Primary disas tratmnt dpnds on th risk of rnal disas progrssion. Roughly 30% of patints prsnt with subnphrotic protinuria (lss than 3 g/day) and most hav a good prognosis with consrvativ managmnt, including antiprotinuric thrapy with ACE inhibitor or ARB if blood prssur is gratr than 125/75 mm Hg. Spontanous rmission may dvlop vn in thos with havy protinuria (about 30% of cass). Thus, us of immunosupprssiv agnts should b limitd to thos at highst risk for progrssion and with salvagabl rnal function. Patints with nphrotic syndrom dspit 6 months of consrvativ managmnt and srum crati- nin lss than 3.0 mg/dL (265 mcmol/L) may lct thrapy with rituximab or with corticostroids and cyclophospha- mid for 6 months. Calcinurin inhibitors with or without corticostroids may b considrd as wll. Rduction in protinuria may tak up to 6 months, spcially with rituximab-basd rgimns. Patints with primary mmbra- nous nphropathy ar xcllnt candidats for transplant.Frvnza FC  t al; MENTOR Invstigators. Rituximab or cyclo- sporin in th tratmnt of mmbranous nphropathy. N Engl J Md. 2019;381:36. [PMID: 31269364] Safar-Bouri L t al. Mmbranous nphropathy: diagnosis, trat- mnt, and monitoring in th post-PLA2R ra. Pdiatr Nphrol. 2021;36:19. [PMID: 31811540] Trujillo H t al. Nw ways of undrstanding mmbranous nphropathy. Nphron. 2020;144:261. [PMID: 32229730] NEphrOTIC SpECTrUM DISEASE FrOM SYSTEMIC DISOrDErS DIABETIC NEPHROPATHYE S S E N T I A L S  O F  D I A G N O S I S Evidence of diabetes mellitus, typically over 10 years. Albuminuria usually precedes decline in GFR. Other end-organ damage, such as retinopathy, is common.CMDT22_Ch22_p0912-p0951.indd  943 02/07/21 2:33 PMChApTEr 22944 CMDT 2022 General ConsiderationsDiabtic nphropa thy is th most common caus of ESKD in th Unitd Stats. Th incidnc is approximatly 30% in both typ 1 and typ 2 diabts mllitus. ESKD is much mor likly to dvlop in prsons with typ 1 diabts ml- litus, in part du to fwr comorbiditis and daths bfor ESKD nsus. With th currnt pidmic of obsity and typ 2 diabts mllitus, rats of diabtic nphropathy will con- tinu to incras. Patints at highr risk includ mals, African Amricans, Nativ Amricans, and thos with a family history of kidny disas. Mortality rats ar highr for diabt- ics with kidny disas compard to thos without CKD. Clinical FindingsDiabtic  nphropathy dvlops about 10 yars aftr th onst of diabts mllitus. It may b prsnt at th tim typ 2 diabts mllitus is diagnosd. Th first stag of clas- sic diabtic nphropathy is hyprfiltration with an incras in GFR, followd by th dvlopmnt of microalbuminuria (30300 mg/day). With progrssion, albuminuria incrass to gratr than 300 mg/day and can b dtctd on a urin dipstick as ovrt protinuria; th GFR subsquntly dclins ovr tim. Yarly scrning for microalbuminuria is rcommndd for all diabtic patints to dtct disas at its arlist stag; howvr, diabtic nphropathy can, lss commonly prsnt as nonprotinuric CKD. Th most common lsion in diabtic nphropathy is diffus glomrulosclrosis, but nodular glomrulosclrosis (Kimmlstil-Wilson noduls) is pathognomonic. Th kidnys ar usually nlargd. Kidny biopsy is not rquird in most patints unlss atypical findings ar prsnt, such as suddn onst of protinuria, nphritic spctrum faturs (s abov), massiv protinuria (gratr than 10 g/day), urinary cllular casts, or rapid dclin in GFR. Patints with diabts ar pron to othr rnal disass. Ths includ papillary ncrosis, chronic intrstitial nphri- tis, and typ 4 (hyporninmic hypoaldostronmic) rnal tubular acidosis. Patints ar mor suscptibl to AKI from many insults, including intravnous contrast matrial and concomitant us of an ACE inhibitor or ARB with NSAID. TreatmentW ith th onst of microalbuminuria, aggrssiv tratmnt is ncssary. Strict glycmic control should b mphasizd arly in diabtic nphropathy, with rcognition of risk of hypoglycmia as CKD bcoms advancd (s CKD sc- tion). Rcommndd blood prssur goals should b tai- lord to th individual patint: basd on th ACCORD trial, thos with microalbuminuria (30300 mg/day) and prsrvd GFR and thos with significant CVD likly driv littl bnfit from blood prssur lowring much blow 140/90 mm Hg, although th 2017 guidlins from th Amrican Hart Association advocat tratmnt to 130/80 mm Hg or lss. Thos with ovrt protinuria (sp- cially mor than 1 g/day) bnfit from a goal of lss than 130/80 mm Hg. ACE inhibitors and ARBs in thos with microalbuminuria lowr th rat of progrssion to ovrt protinuria and slow progrssion to ESKD by rducing intraglomrular prssur and via antifibrotic ffcts; thsagnts ar not absolutly indicatd in diabtic patints without albuminuria. Diabtic patints, spcially with advancd CKD, ar at rlativly high risk for AKI and hyprkalmia with inhibition of th rnin-angiotnsin sys- tm, so monitoring for hyprkalmia or a dclin in GFR mor than 30% within ~2 wks of th initiation or uptitra- tion of this thrapy is prudnt, with dos rduction or dis- continuation of thrapy if ths complications ar ncountrd. Combination ARB and ACE inhibitor therapy is not recommended due to lack of efficacy and increased adverse events of hyperkalemia and AKI. In addition to thir cardioprotctiv ffcts, th SGLT inhibitors, includ- ing canagliflozin, mpagliflozin, and dapagliflozin, slow progrssion of diabtic nphropathy; thir us is limitd to thos with typ 2 diabts mllitus with GFR gratr than 30 mL/min/1.73 m2. Us of ths agnts may rquir rduction in diurtic dosing in thos patints rquiring natriursis. Tratmnt of othr cardiovascular risk factors and obsity is crucial. Many with diabts hav multipl comorbid conditions; thrfor, in patints with ESKD who progrss to dialysis, mortality ovr th first 5 yars is high. Patints who ar rlativly halthy, howvr, bnfit from rnal transplantation.Bakris  G. Stmming th progrssion of diabtic kidny disas: th rol of th primary car clinician. J Fam Prac. 2020;69:S81. [PMID: 33104113] D Bor IH t al. Excutiv summary of th 2020 KDIGO Diab- ts Managmnt in CKD Guidlin: vidnc-basd advancs in monitoring and tratmnt. Kidny Int. 2020;98:839. [PMID: 32653403] Li J t al. Dcision algorithm for prscribing SGLT2 inhibitors and GLP-1 rcptor agonists for diabtic kidny disas. Clin J Am Soc Nphrol. 2020;15:1678. [PMID: 32518100] Tuttl KR t al. SLGT2 inhibition for CKD and cardiovascular disas in typ 2 diabts: rport of a scintific workshop sponsord by th National Kidny Foundation. Am J Kidny Dis. 2021;77:94. [PMID: 33121838]HI V-ASSOCIATED NEPHROPATHYHI V-associatd nphropathy usually prsnts with nphrotic syndrom and dclining GFR in patints with activ HIV infction. Most who prsnt with HIV-associatd nphropathy ar of African dscnt with APOL1 risk allls (s sction on Focal Sgmntal Glomrulosclrosis). HIV- associatd nphropathy is usually associatd with low CD4 counts and AIDS, but it can also b th initial prsntation of HIV disas. Prsons living with HIV ar at risk for othr kidny disass, such as toxicity from antirtroviral mdica- tions (g, tnofovir disoproxil fumarat), vascular disas, and diabts, or an immun complxmdiatd glomrular disas (HIV-immun complx disas). Classic HIV-associatd nphropathy is charactrizd by an FSGS pattrn of injury with glomrular collaps; svr tubulointrstitial damag may also b prsnt. HIV-associatd nphropathy is lss common in th ra of HIV scrning and mor ffctiv antirtroviral thrapy. Small, uncontrolld studis hav shown that antirtroviral thrapy slows progrssion of disas. ACE inhibitors or ARBs can b usd to control blood prssur and protin- uria. Kidny biopsy is ncssary for diagnosis and to rulCMDT22_Ch22_p0912-p0951.indd  944 02/07/21 2:33 PMKIDNEY DISEASE945 CMDT 2022out  othr causs of kidny dysfunction. Patints who prog- rss to ESKD and ar othrwis halthy ar good candi- dats for kidny transplantation.H amzah L t al. Optimizing antirtroviral rgimns in chronic kid- ny disas. Curr Opin Infct Dis. 2019;32:1. [PMID: 30461453] Naickr S. HIV/AIDS and chronic kidny disas. Clin Nphrol. 2020;93:87. [PMID: 31397267]RE NAL AMYLOIDOSISAm yloidosis is a rlativly rar caus of nphrotic syndrom. It is causd by tissu dposition of an ovrproducd and abnormally foldd protin (amyloid). Svral diffrnt pro- tins can form amyloid fibrils with rnal dposition. Primary amyloidosis, or AL amyloidosis, is th most common form and is du to a plasma cll dyscrasia causing ovrproduction and dposition of monoclonal Ig light chains (s Chaptr 13). Scondary amyloidosis, or AA amyloidosis, can rarly occur in chronic inflammatory disas such as rhumatoid arthri- tis, inflammatory bowl disas, or chronic infction; in ths cass, thr is dposition of an acut phas ractant, srum amyloid A protin. Othr lss common forms of amy- loidosis may also b ncountrd. Protinuria, dcrasd GFR, and nphrotic syndrom ar prsnting symptoms and signs of rnal involvmnt in amyloidosis; vidnc of othr organ involvmnt, such as th hart, is common. Srum and urin protin lctropho- rsis should b don as scrning tsts; if a monoclonal spik is found on ithr, srum fr light chains should b quantifid and th kappa:lambda ratio assssd. Amyloid- affctd kidnys ar oftn largr than 10 cm. Pathologi- cally, glomruli ar filld with amorphous dposits that show grn birfringnc with Congo rd staining. AL amyloidosis progrsss to ESKD in an avrag of 23 yars. Fiv-yar ovrall survival is lss than 20%, with wors prognosis in thos with advancd cardiac involv- mnt. Standard tratmnt is a combination of mlphalan, corticostroids, and th protosom inhibitor bortzomib; addition of daratumumab shows promis. Mlphalan and autologous stm cll transplantation ar associatd with a high (45%) mortality rat but can induc rmission in 80% of survivors; howvr, fw patints ar ligibl for this tratmnt. In AA amyloidosis, rmission can occur if th undrlying disas is succssfully tratd. Rnal transplan- tation is an option.H ogan JJ t al. Dysprotinmia and th kidny: Cor Curriculum 2019. Am J Kidny Dis. 2019;74:822. [PMID: 31331759] Mn P t al. Monoclonal gammopathis of rnal significanc: rnal biopsy and byond. Cancrs (Basl). 2020;12:1741. [PMID: 32629844] Palladini G t al. Managmnt of AL amyloidosis in 2020. Hma- tology Am Soc Hmatol Educ Program. 2020;2020:363. [PMID: 33275753] TUBULOINTErSTITIAL DISEASEST ubulointrstitial disas may b acut or chronic. Acut disas is most commonly associatd with mdications, infctious agnts, and systmic rhumatologic disordrs.Intrstitial dma, infiltration with polymorphonuclar nutrophils, and accompanying ATN can b sn. (S Acut Kidny Injury, abov, and Tabl 229.) Chronic dis- as is associatd with insults from an acut factor or pro- grssiv insults without any obvious acut caus. Intrstitial fibrosis and tubular atrophy ar prsnt, with a mononu- clar cll prdominanc. Th chronic disordrs ar dscribd blow.CH RONIC TUBULOINTERSTITIAL DISEASESE S S E N T I A L S  O F  D I A G N O S I S Kidney size is small and contracted. Decreased urinary concentrating ability. Hyperchloremic metabolic acidosis. Reduced GFR.Table 229. Causes of acute tubulointerstitial nephritis (abbreviated list).Dug  reactions Antibiotics Beta-lactam antibiotics: methicillin, penicillin, ampicillin, cephalosporins Ciprofloxacin Erythromycin Sulfonamides (trimethoprim-sulfamethoxazole, loop and thiazide diuretics) Tetracycline Vancomycin Ethambutol Rifampin Nonsteoidal anti-inflammatoy dugs Diuetics Thiazides Furosemide Ote Allopurinol Cimetidine Phenytoin Proton pump inhibitors Systemic Infections Bacteia Streptococcus Corynebacterium diphtheriae Legionella Viuses Epstein-Barr Ote Mycoplasma Rickettsia rickettsii Leptospira icterohaemorrhagiae Toxoplasma Idioatic Tubulointerstitial nephritis-uveitisCMDT22_Ch22_p0912-p0951.indd  945 02/07/21 2:33 PMChApTEr 22946 CMDT 2022 General ConsiderationsTh  most common caus of chronic tubulointrstitial disas isobstructive uropathy , which may rsult from prolongd or rcurrnt obstruction. Th major causs ar prostat dis- as in mn; urtral calculus in a singl functioning kidny; bilatral urtral calculi; carcinoma of th crvix, colon, or bladdr; and rtropritonal tumors or fibrosis. Rflux nphropathy from vesicoureteral reflux is pri- marily a disordr of childhood and occurs whn urin passs rtrograd from th bladdr to th kidnys during voiding. It is th scond most common caus of chronic tubulointrstitial disas. It occurs as a rsult of an incom- ptnt vsicourtral sphinctr. Urin can xtravasat into th intrstitium, triggring an inflammatory rspons that lads to fibrosis ovr tim. Th inflammatory rspons is du to ithr bactria or normal urinary componnts. Analgesic nephropathy is most commonly sn in patints who ingst larg quantitis of pain mdication. Th drugs of concrn ar phnactin, paractamol, aspirin, and othr NSAIDs; actaminophn is a possibl but lss crtain culprit. Ingstion of at last 1 g/day for 3 yars of ths analgsics is considrd ncssary for kidny dys- function to dvlop, and most patints grossly undrsti- mat thir analgsic us. This disordr occurs most frquntly in individuals who ar using analgsics for chronic hadachs, muscular pains, and arthritis; fmal sx, oldr ag, and malnutrition ar risk factors for analg- sic nphropathy. Tubulointrstitial inflammation and pap- illary ncrosis ar sn on pathologic xamination. Papillary tip and innr mdullary concntrations of som analgsics ar tnfold highr than in th rnal cortx. Phnactin was onc a common caus of this disordr but is now rarly availabl. Aspirin and othr NSAIDs can caus damag through intrmdiat mtabolits, which can lad to cll ncrosis. Ths drugs also dcras mdul- lary blood flow (via inhibition of prostaglandin synthsis) and dcras glutathion lvls, which ar ncssary for dtoxification. Environmntal xposur to heavy metals such as lad, cadmium, mrcury, and bismuthoccurs infr- quntly now in th Unitd Stats but can caus tubuloint- rstitial disas. Individuals at risk for lad-inducd tubulointrstitial disas ar thos with occupational xpo- sur (g, wldrs who work with lad-basd paint) and drinkrs of alcohol distilld in automobil radiators (moonshin whisky usrs). Lad is filtrd by th glom- rulus and is transportd across th proximal convolutd tubul, whr it accumulats and causs cll damag. Fibrosd artriols and cortical scarring also lad to dam- agd kidnys. A form of chronic tubulointrstitial disas dispropor- tionatly affcting mal agricultural workrs in Cntral Amrica is an important caus of ESKD. Whil th xact pathophysiology is still unknown, th trm Mesoamerican nephropathy is applid to rflct th gographic rgion in which this disas occurs. Affctd individuals tnd to b 3050 yars of ag without diabts, hyprtnsion, or othr causs of kidny disas who work undr hot conditions, particularly in sugar can or cotton filds, and ar thus suscptibl to dhydration.Clinical FindingsA.  General FindingsPo lyuria is common bcaus tubular damag lads to nphrognic diabts insipidus, possibly from vasoprssin insnsitivity. Volum dpltion can also occur as a rsult of a salt-wasting dfct in som individuals. Patints can bcom hyprkalmic both bcaus th GFR is lowr and th distal tubuls bcom aldostron rsistant. Rnal tubular acidosis is common and dvlops through thr possibl mchanisms: (1) rducd ammonia production in th proximal tubuls, (2) inability to rab- sorb bicarbonat in th proximal tubuls, and (3) inability to scrt protons in th distal tubuls, which is ndd for urinary acidification. A typ 1 or typ 4 rnal tubular acidosis is mor commonly obsrvd in tubulointrstitial disas, xcpt in th cas of havy mtal xposur whr dirct proximal tubular damag lads to a proximal (typ 2) rnal tubular acidosis. In contrast to acut intrstitial nphritis, th urinalysis in chronic tubulointrstitial disas is oftn nonspcific; a fw clls or broad waxy casts may b sn, but urinalysis oftn is bland. Protinuria is typically lss than 2 g/day, owing to inability of th proximal tubul to rabsorb frly filtrabl protins.B.  Specific Findings1. Obstructive uropathy  In partial obstruction, patints can xhibit polyuria (from tubular damag) or oliguria (du to dcrasd GFR). Azotmia and hyprtnsion (du to incrasd rnin-angiotnsin production) ar usually prsnt. Abdominal, rctal, and gnitourinary xamina- tions may b hlpful in dtcting a distndd bladdr or larg prostat. Urinalysis may show hmaturia, pyuria, and bactriuria but is oftn bland. Abdominal ultrasound may dtct mass lsions, hydrourtr, and hydronphrosis but may ovrlook 5% of cass. CT scanning or MRI can b considrd if suspicion rmains dspit a normal ultrasound. 2. Vesicoureteral reflux Vsicourtral rflux is typically diagnosd in young childrn with a history of rcurrnt urinary tract infctions but can also dvlop aftr kidny transplantation. Rnal ultrasound or IVP can show rnal scarring and hydronphrosis. Although most damag occurs bfor ag 5 yars, progrssiv dtrioration to ESKD occurs. 3. Analgesics Patints can xhibit hmaturia, mild pro- tinuria, polyuria (from tubular damag), anmia (from GI blding or rythropoitin dficincy), and stril pyuria. Sloughd papilla can b found in th urin whn papillary ncrosis occurs and can lad to obstruction. Although clas- sically diagnosd by IVP , papillary ncrosis is mor com- monly dtctd by CT imaging. 4. Heavy metals Proximal tubular damag from lad xposur can caus dcrasd scrtion of uric acid, rsult- ing in hypruricmia and saturnin gout. Patints com- monly ar hyprtnsiv. Diagnosis is stablishd with a calcium disodium dtat (EDTA) chlation tst pr- formd on a timd urin collction. Urin xcrtion ofCMDT22_Ch22_p0912-p0951.indd  946 02/07/21 2:33 PMKIDNEY DISEASE947 CMDT 2022gratr  than 600 mg of lad following 1 g of EDTA indi- cats xcssiv lad xposur. Th proximal tubular dys- function from cadmium can caus hyprcalciuria and nphrolithiasis. 5. Mesoamerican nephropathy In addition to low-grad protinuria, hypruricmia and hypokalmia ar consis- tntly (but not univrsally) idntifid among affctd indi- viduals. Although not pathognomonic, aras of glomrular ischmia (dspit vry mild vascular disas) that accom- pany chronic tubulointrstitial injury on kidny biopsy ar highly suggstiv of Msoamrican nphropathy. 6. Balkan nephropathy Patints commonly dvlop pro- tinuria, glycosuria, acidosis, and suffr urinary concn- trating dfcts. Notably, urothlial carcinomas ar prsnt in approximatly 50% of affctd individuals at tim of diagnosis. TreatmentT ratmnt dpnds first on idntifying th disordr rsponsibl for kidny dysfunction. Th dgr of intrsti- tial fibrosis on biopsy rflcts irrvrsibl damag, which is dirctly associatd with th liklihood of ESKD progrs- sion. Tratmnt is dirctd at mdical managmnt of risk factors for disas progrssion, such as hyprtnsion and protinuria. Tubular dysfunction may rquir bicarbonat supplmntation to trat mtabolic acidosis or phosphorus and potassium rstriction. If hydronphrosis is prsnt, th obstruction should b promptly rlivd. Prolongd obstruction lads to furthr tubular damagparticularly in th distal nphron which may bcom irrvrsibl. Although surgical corrc- tion of rflux may b indicatd in slct circumstancs, this will unlikly prvnt dtrioration toward ESKD if fibrosis is xtnsiv. Patints in whom lad nphropathy is suspctd should continu chlation thrapy with EDTA if thr is minimalvidnc of irrvrsibl rnal damag, and continud xpo- sur should b avoidd. Tratmnt of analgsic nphropathy rquirs with- drawal of all analgsics. Stabilization of or improvmnt in kidny function may occur if significant intrstitial fibrosis is not prsnt. Ensuring volum rpltion during xposur to analgsics may also hav som bnficial ffcts. Patints with Msoamrican nphropathy should b counsld to rmain adquatly hydratd and, if possibl, minimiz hat xposur. NSAIDs should b avoidd du to thir hmodynamic ffcts (rducd rnal blood flow and glomrular filtration), which may xacrbat rnal injury in stats of volum dpltion and hot climats. When to Refer Patints with stag 35 CKD should b rfrrd to a nphrologist whn tubulointrstitial disass ar sus- pctd. Othr slct cass of stag 12 CKD should also b rfrrd, for xampl if rnal tubular acidosis is prsnt. Patints with urologic abnormalitis should b rfrrd to a urologist.Cor ra-Rottr R t al. Msoamrican nphropathy. Smin Nphrol. 2019;39:263. [PMID: 31054625] CYSTIC DISEASES OF ThE KIDNEYRnal cysts  ar pithlium-lind cavitis filld with fluid or smisolid matrial that dvlop primarily from rnal tubu- lar lmnts. On or mor simpl cysts ar found in 50% of individuals ovr th ag of 50 yars. Thy ar rarly symp- tomatic and hav littl clinical significanc. In contrast, gnralizd cystic disass ar associatd with cysts scat- trd throughout th cortx and mdulla of both kidnys and can progrss to ESKD (Tabl 2210). Table 2210. Clinical features of renal cystic disease. Simle renal CystsAcquied renal CystsAutosomal Domi- nant polycystic Kidney DiseaseMedullay Songe KidneyMedullay Cystic Kidney Prevalence Common Dialysis patients 1:1000 1:5000 Rare Inheritance None None Autosomal dominant None Autosomal dominant Age at onset   2040 years 4060 years Adulthood Kidney size Normal Small Large Normal Small Cyst location Cortex and medulla Cortex and medulla Cortex and medulla Collecting ducts Corticomedullary junction Hematuria Occasional Occasional Common Rare Rare Hypertension None Variable Common None None Associated complicationsNone Adenocarcinoma in cystsHepatic cysts, urinary tract infections, renal calculi, cere- bral aneurysmsRenal calculi, urinary tract infectionsPolyuria, salt wasting Kidney failure Never Always Frequently Never AlwaysCMDT22_Ch22_p0912-p0951.indd  947 02/07/21 2:33 PMChApTEr 22948 CMDT 2022SI MPLE OR SOLITARY CYSTSSimpl  cysts account for 6570% of all rnal masss. Thy ar gnrally found at th outr cortx and contain fluid that is consistnt with an ultrafiltrat of plasma. Most ar found incidntally on ultrasonographic xamination. Simpl cysts ar typically asymptomatic but can bcom infctd. Th major objctiv with simpl cysts is to diffrnti- at thm from malignancy, abscss, or polycystic kidny disas. Cystic disas can dvlop in dialysis patints and has th potntial to progrss to malignancy. Ultrasound and CT scanning ar rcommndd to valuat ths masss. Simpl cysts must mt thr sonographic critria to b considrd bnign: (1) cho fr, (2) sharply dmar- catd with smooth walls, and (3) an nhancd back wall (indicating good transmission through th cyst). Com- plx cysts can hav thick walls, calcifications, solid com- ponnts, and mixd chognicity. On CT scan, simpl cysts should hav smooth thin walls that ar sharply dmarcatd and should not nhanc with contrast mdia. Rnal cll carcinoma will nhanc but typically is of lowr dnsity than halthy parnchyma. Artriography can also b usd to valuat a mass proprativly. Rnal cll car- cinoma is hyprvascular in 80%, hypovascular in 15%, and avascular in 5% of cass. If a cyst has qustionabl imaging charactristics or is of uncrtain significanc, priodic rvaluation is rcom- mndd. Urologic consultation and surgical xploration may b considrd. Bnign cysts do not rquir any sp- cific follow-up, though changs in clinical prsntation should prompt rpat imaging.Smith AD t  al. Approach to rnal cystic masss and th rol of radiology. Radiol Clin North Am. 2020;58:897. [PMID: 32792122]AUTOS OMAL DOMINANT POLYCYSTIC KIDNEY DISEASEE S S E N T I A L S  O F  D I A G N O S I S Multiple cysts in both kidneys; number of cysts depends on patient age. Combination of hypertension and large palpable kidneys suggestive of disease. Autosomal dominant chromosomal abnormalities present in some patients. General ConsiderationsA utosomal dominant polycystic kidny disas is th most common monognic kidny disas, affcting 12.5 million individuals worldwid. ESKD dvlops by ag 60 in up to 50% of patints. Th disas has variabl pntranc but accounts for 510% of all ESKD cass globally. At last two gns account for this disordr: PKD1 on th short arm of chromosom 16 (8590% of patints) and PKD2on chromosom 4 (1015%). Patints with th PKD2 mutation hav slowr progrssion of disas and longr lif xpctancy than thos with PKD1 . Othr sporadic cass without ths mutations ar also rcognizd. Clinical FindingsA bdominal or flank pain and hmaturia (ithr microscopic or gross) ar prsnt in most patints. A history of urinary tract infctions and nphrolithiasis is common. A family history of autosomal dominant polycystic kidny disas is prsnt in 75% of cass, and mor than 50% of patints hav hyprtnsion that may prcd clinical manifstations. Patints hav larg kidnys that may b palpabl on abdomi- nal xamination. Th combination of hyprtnsion and an abdominal mass should rais suspicion for th disas. Forty to 50 prcnt hav concurrnt hpatic cysts; pancratic and splnic cysts may occur. Dspit dvlopmnt of CKD, hmoglobin is oftn normal as a rsult of cystic rythropoi- tin production. Urinalysis may show hmaturia and subn- phrotic protinuria. In patints with an stablishd family history of autosomal dominant polycystic kidny disas, ultrasonography confirms th diagnosistwo or mor cysts in patints undr ag 30 yars (snsitivity of 88.5%), two or mor cysts in ach kidny in patints agd 3059 yars (sn- sitivity of 100%), and four or mor cysts in ach kidny in patints agd 60 yars or oldr ar diagnostic for autosomal dominant polycystic kidny disas. Importantly, ths cri- tria do notapply to individuals without a known family history; patints without a known family history of polycys- tic kidny disas rquir additional diagnostic valuation including CT scanning, which rvals innumrabl cysts in cass of polycystic kidny disas (Figur 226); th prs- nc of multipl hpatic cysts can aid in stablishing th diagnosis. In som cass, gntic tsting for PKD1 andPKD2 mutations may b rquird. Figure 226. Polycystic kidney disease. CT scan showing bilateral polycystic kidneys in a 43-year-old woman who presented with newly diagnosed hyper- tension and microscopic hematuria. (Used, with permis- sion, from Michael Freckleton, MD, in Usatine RP , Smith MA, Mayeaux EJ Jr, Chumley H. The Color Atlas of Family Medicine , 2nd ed. McGraw-Hill, 2013.)CMDT22_Ch22_p0912-p0951.indd  948 02/07/21 2:33 PMKIDNEY DISEASE949 CMDT 2022 Complications & TreatmentA.  PainA bdominal or flank pain is causd by infction, blding into cysts, and nphrolithiasis. Bd rst and analgsics ar rcom- mndd. Cyst dcomprssion can hlp with chronic pain.B.  HematuriaGross  hmaturia is most commonly du to cystic ruptur into th rnal plvis, but it can also b causd by a kidny ston or urinary tract infction. Hmaturia typically rsolvs within 7 days with bd rst and hydration.C.  Renal InfectionAn  infctd rnal cyst should b suspctd in patints who hav flank pain, fvr, and lukocytosis. Importantly, urinaly- sis may b normal if th cyst dos not communicat dirctly with th urinary tract. CT scans can b hlpful bcaus an infctd cyst may hav incrasd wall thicknss. Bactrial cyst infctions ar difficult to trat. Antibiotics with cystic pntration ar th agnts of choic (g, fluoroquinolons [ciprofloxacin, 500 mg vry 12 hours, or lvofloxacin, 500 mg onc daily if GFR normal], or trimthoprim- sulfamthoxazol doubl-strngth tablt twic daily).D . NephrolithiasisU p to 20% of patints hav kidny stons, primarily cal- cium oxalat. Hydration (23 L/day) is rcommndd in ordr to prvnt prcipitation of stons.E.  HypertensionA t th tim of prsntation, 50% of patints hav hyprtn- sion, and it will dvlop in most patints during th cours of th disas. Cyst-inducd ischmia appars to caus activation of th rnin-angiotnsin systm, and cyst dcomprssion can lowr blood prssur tmporarily. Hyprtnsion should b tratd with an ACE inhibitor or an ARB as th prfrrd drug if tolratd. Intnsiv blood prssur control (goal lss than or qual to 110/75 mm Hg) is rcommndd in adults youngr than 50 yars of ag with GFR gratr than 60 mL/min/1.73m2; for all othr affctd individuals, goal blood prssur is lss than or qual to 130/85 mm Hg.F . Cerebral AneurysmsAbo ut 1015% of patints hav artrial anurysms in th circl of Willis. Scrning artriography is not rcom- mndd unlss th patint has a family history of anu- rysms, is mployd in a high-risk profssion (g, airlin pilot), or is undrgoing lctiv surgry with a high risk of dvloping modrat to svr prioprativ hyprtnsion.G.  Other ComplicationsV ascular problms includ mitral valv prolaps in up to 25% of patints, aortic anurysms, and aortic valv abnor- malitis. Colonic divrticula ar mor common in patints with polycystic kidnys.PrognosisKidny  siz, rportd as total kidny volum, is th bst prdictor of kidny function dclin in patints with auto- somal dominant polycystic kidny disas, and it can b masurd via CT or MRI using th Mayo Classification systm (www.mayo.du/rsarch/documnts/pkd-cntr- adkpkd-classification/doc-20094754). Thos at high risk according to this classification systm may bnfit from tratmnts that dlay cyst growth. Vasoprssin rcptor antagonists dcras th rat of chang in total kidny vol- um and GFR dclin, and on such mdication (tolvap- tan) is FDA approvd for th tratmnt of autosomal dominant polycystic kidny disas. Libral ingstion of watr will hav th sam physiologic ffct on vasoprssin, and patints should b ncouragd to drink at last 2 L of watr daily. Othr agnts such as octrotid, sirolimus, and tyrosin kinas inhibitors dcras th rat of cyst growth but not th dclin in kidny function and ar thus not routinly usd. Avoidanc of caffin may prvnt cyst formation du to ffcts on G-coupld protins.Cornc-L  Gall E t al. Autosomal dominant polycystic kidny disas. Lanct. 2019;393:919. [PMID: 30819518] Nobakht N t al. Advancs in autosomal dominant polycystic kidny disas: a clinical rviw. Kidny Md. 2020;2:196. [PMID: 32734239]ME DULLARY SPONGE KIDNEYMd ullary spong kidny is blivd to affct lss than 1% of th gnral population. Although prsnt at birth, it is not usually diagnosd until th fourth or fifth dcad. It is thought to occur du to disruption of th urtric bud- mtanphric msnchym intrfac, oftn rsulting from autosomal dominant mutations in gns rsponsibl for urognital dvlopmnt. Kidnys hav a markd irrgular nlargmnt of th mdullary and intrpapillary collcting ducts. This is associatd with mdullary cysts that ar dif- fus, giving a Swiss chs apparanc in ths rgions. Clinical FindingsNp hrolithiasis is th most common clinical prsntation for mdullary spong kidny. Othr prsntations may includ hmaturia (ithr gross or microscopic) or rcur- rnt urinary tract infctions. Common abnormalitis ar a dcrasd urinary concntrating ability and nphrocalci- nosis; lss common is incomplt typ 1 distal rnal tubular acidosis. Th diagnosis is stablishd clinically through laboratory data and imaging charactristics. As th pr- frrd imaging tst, CT shows cystic dilatation of th distal collcting tubuls with a striatd apparanc, and calcifica- tions in th rnal collcting systm. Similar findings on ultrasound may also support th diagnosis. TreatmentT ratmnt for mdullary spong kidny is supportiv and aimd at undrlying abnormalitis such as nphrolithiasis and acidosis. Adquat fluid intak (2 L/day) hlps rduc risk of ston formation. If hyprcalciuria is prsnt,CMDT22_Ch22_p0912-p0951.indd  949 02/07/21 2:33 PMChApTEr 22950 CMDT 2022thiazid diurtics ar  rcommndd bcaus thy dcras calcium xcrtion. Alkali thrapy is rcommndd if rnal tubular acidosis is prsnt. PrognosisRnal function is wll maintaind unlss thr ar  compli- cations from rcurrnt urinary tract infctions and nphrolithiasis.Pisani I t  al. Ultrasound to addrss mdullary spong kidny: a rtrospctiv study. BMC Nphrol. 2020;21:430. [PMID: 33046028] MULTISYSTEM DISEASES WITh VArIABLE KIDNEY INVOLVEMENT PLASMA CELL MYELOMAPlasma  cll myloma is a malignancy of plasma clls (s Chaptr 13) that can caus a varity of rnal disordrs. Injury is du to th toxic ffcts of monoclonal immuno- globulins or light chain componnts producd by plasma clls. Myloma kidny (formally calld cast nphropathy) is th most common kidny disas in plasma cll myloma and occurs whn light chains (Bnc Jons protin) in th urin caus rnal toxicity and tubular obstruction by pr- cipitating in th distal tubuls. Plasma cll myloma may also caus Fanconi syndrom, a typ 2 proximal rnal tubular acidosis charactrizd by hypophosphatmia and inappropriat glycosuria. Protinuria in myloma kidny is xclusivly tubular; hnc, urin dipstick findings ar minimal sinc glomrular protinuria is not prsnt. Hyprcalcmia and hypruricmia ar frquntly sn. Glomrular amyloidosis with nphrotic syndrom can dvlop in patints with plasma cll myloma; in ths patints, urin dipstick is positiv du to glomrular pi- thlial cll foot procss ffacmnt and albumin spilling into th Bowman capsul; hmaturia may or may not b prsnt. Othr conditions rsulting in kidny dysfunction includ plasma cll infiltration of th rnal parnchyma and hyprviscosity syndrom compromising rnal blood flow. Th prsnc of myloma-rlatd kidny disas dos not itslf prclud us of contrast dy for imaging studis; standard prcautions for th us of intravnous contrast and gadolinium in patints with rducd GFR apply to patints with myloma-rlatd kidny disas. Thrapy for AKI (s Acut Kidny Injury, abov) attributd to plasma cll myloma includs corrction of hyprcalcmia; vol- um rpltion; and chmothrapy for th undrlying malignancy, typically with bortzomib-basd agnts. Plas- maphrsis has bn proposd to rduc th burdn of circulating monoclonal protins, but rsults hav bn quivocal and its us is controvrsial.Mayszko  J t al. KDIGO Controvrsis Confrnc on onco- nphrology: kidny disas in hmatological malignancis and th burdn of cancr aftr kidny transplantation. Kidny Int. 2020;98:1407. [PMID: 33276867]SICKLE CELL DISEASEKidny  dysfunction associatd with sickl cll disas is most commonly du to sickling of rd blood clls in th rnal mdulla bcaus of low oxygn tnsion and hyprto- nicity. Congstion and stasis lad to hmorrhag, intrsti- tial inflammation, and papillary infarcts with rsultant ncrosis. Clinically, hmaturia is common, and protinuria can b prsnt as wll, portnding a poorr prognosis. Damag to rnal capillaris also lads to diminishd con- cntrating ability. Isosthnuria (urin osmolality qual to that of srum) is routin, and patints can asily bcom dhydratd. Ths abnormalitis ar also ncountrd in patints with sickl cll trait. Sickl cll glomrulopathy is lss common but inxorably progrsss to ESKD. Its pri- mary clinical manifstation is protinuria. Optimal trat- mnt rquirs adquat hydration and control of th sickl cll disas.Lim  RI t al. Amrican Socity of Hmatology 2019 guidlins for sickl cll disas: cardiopulmonary and kidny disas. Blood Adv. 2019;3:3867. [PMID: 31794601] Olaniran KO t al. Kidny function dclin among black patints with sickl cll trait and sickl cll disas: an obsr- vational cohort study. J Am Soc Nphrol. 2020;31:393. [PMID: 31810990]TU BERCULOSISRnal  tubrculosis usually rsults from hmatognous sprad and is an undrdiagnosd ntity. Up to 20% of patints with xtrapulmonary tubrculosis hav urognital involvmnt, of which th kidny is most commonly affctd. Its classic manifstation is th prsnc of micro- scopic pyuria without bactrial growth on urin cultur or stril pyuria.  Mor oftn, othr bactria ar also prsnt, and microscopic hmaturia may coxist. Urin culturs wr onc th gold standard for diagnosis, but th advnt of urin nuclic acid tsting for tubrculosis has incrasd snsitivity. Charactristic findings on imaging includ papillary ncrosis and cavitation of th rnal parnchyma. Urtral stricturs or calcifications may also b prsnt. Kidny biopsy is not usually ndd to confirm th diagnosis but rvals granulomatous inflammation and tubulointrstitial nphritis. Prompt initiation of anti- tubrculosis tratmnt is indicatd, without which pro- grssion to ESKD occurs du to chronic inflammation and obstruction.K ulchavnya E t al. Challngs in urognital tubrculosis. World J Urol. 2020;38:89. [PMID: 30997530]GO UT & THE KIDNEYTh  kidny is th primary organ for xcrtion of uric acid. Patints with proximal tubular dysfunction hav dcrasd xcrtion of uric acid and ar mor pron to gouty arthritis attacks. Dpnding on th pH and uric acid concntration, dposition can occur in th tubuls, th intrstitium, or th urinary tract. Th mor alkalin pH of th intrstitium causs urat salt dposition,CMDT22_Ch22_p0912-p0951.indd  950 02/07/21 2:33 PMKIDNEY DISEASE951 CMDT 2022wh ras th acidic nvironmnt of th tubuls and uri- nary tract causs uric acid crystal dposition at high concntrations. Thr disordrs ar commonly sn: (1) uric acid nph- rolithiasis, (2) acut uric acid nphropathy, and (3) chronic urat nphropathy. Kidny dysfunction with uric acid nphrolithiasis stms from obstructiv physiology. Acut uric acid nphropathy prsnts with dirct tubulointrsti- tial toxicity from uric acid crystals and distal tubul obstruction causd by prcipitation of uric acid crystals. Chronic urat nphropathy is causd by dposition of urat crystals in th alkalin mdium of th intrstitium; this can lad to fibrosis and atrophy. Tratmnt btwn gouty attacks involvs avoidanc of food and drugs causing hypruricmia (s Chaptr 20), aggrssiv hydration, and urat-lowring thrapy (such as with allopurinol and fbuxostat). Th thr disordrs mn- tiond abov ar sn in both ovrproducrs and undrx- crtors of uric acid. Th lattr situation may sm countrintuitiv; howvr, ths patints hav acidic urin, which nabls prcipitation of rlativly insolubl uric acid crystals. For thos with uric acid nphrolithiasis, fluid intak should xcd 3 L/day, and us of a urinary alkalinizing agnt can b considrd. Patints with hypruricmia who do not hav a history of gout or uric acid nphrolithiasis hav not bn shown to bnfit from urat-lowring thrapy.Badv SV  t al; CKD-FIX Study Invstigators. Effcts of allopu- rinol on th progrssion of chronic kidny disas. N Engl J Md. 2020;382:2504. [PMID: 32579811]NE PHROGENIC SYSTEMIC FIBROSISNp hrognic systmic fibrosis is a multisystm disordr sn only in patints with CKD (primarily with an GFR lss than 15 mL/min/1.73 m2, but rarly 1529 mL/ min/1.73 m2), AKI, and aftr kidny transplantation. His- topathologically, thr is an incras in drmal spindl cllspositiv for CD34 and procollagn I. Collagn bundls with mucin and lastic fibrs ar also notd. Nphrognic systmic fibrosis was first rcognizd in hmodialysis patints in 1997 and has bn strongly linkd to us of contrast agnts containing gadolinium. Incidnc following gadolinium injction is approximatly 14% in th highst risk (ESKD) population and lowr in patints with lss svr kidny dysfunction. Th incidnc has dcrasd ovr tim du to limiting us of gadolinium in patints with CKD and AKI and modifid gadolinium prparations. Thr is an FDA warning rgarding avoidanc of this agnt for patints with an GFR lss than 30 mL/min/1.73 m2. Clinical FindingsNp hrognic systmic fibrosis affcts svral organ sys- tms, including th skin, muscls, lungs, and cardiovascu- lar systm. Th most common manifstation is a dbilitating fibrosing skin disordr that can rang from skin-colord to rythmatous papuls, which coalsc to brawny patchs. Th skin can b thick and woody in aras and is painful out of proportion to findings on xamination. TreatmentCas  rports and sris dscrib bnfit of corticostroids, photophrsis, plasmaphrsis, and sodium thiosulfat, but thir tru fficacy is unknown. CT is prfrrd to MR imaging with gadolinium whn similar diagnostic infor- mation can b gland. If gadolinium absolutly must b usd in patints on dialysis, practic guidlins rcom- mnd using no mor than th standard dos and hmodi- alysis immdiatly aftr xposur.Ma thur M t al. Gadolinium dposition and nphrognic systmic fibrosis: a radiologists primr. Radiographics. 2020;40:153. [PMID: 31809230] Rudnick MR t al. Risks and options with gadolinium-basd con- trast agnts in patints with CKD: a rviw. Am J Kidny Dis. 2021;77:517. [PMID: 32861792]CMDT22_Ch22_p0912-p0951.indd  951 02/07/21 2:33 PM952 CMDT 2022 Mathew Sorensen, MD, MS, FACS Thomas J. Walsh, MD, MS Maahum A. Haider, MD, MPHUrologic Disorders23HE MATURIAE S S E N T I A L S  O F  D I A G N O S I S Gross hematuria requires evaluation: the upper urinary tract should be imaged, and the lower tract evaluated by cystoscopy. In microscopic hematuria, the workup should be risk stratified. General ConsiderationsAn upper tract source (kidneys and ureters) can be identified in 10% of patients with gross or microscopic hematuria. For upper tract sources, stone disease accounts for 40%, medical kidney disease (medullary sponge kidney, glomerulonephri- tis, papillary necrosis) for 20%, renal cell carcinoma for 10%, and urothelial cell carcinoma of the ureter or renal pelvis for 5%. Medication ingestion and associated medical problems may provide diagnostic clues. Analgesic use (papillary necro- sis), cyclophosphamide (chemical cystitis), antibiotics (inter- stitial nephritis), diabetes mellitus, sickle cell trait or disease (papillary necrosis), a history of stone disease, or malignancy should all be investigated. The lower tract source of gross hematuria (in the absence of infection) is most commonly from bleeding prostatic varices or urothelial carcinoma of the bladder. Microscopic hematuria in the male is most com- monly from benign prostatic hyperplasia (13%), kidney stones (6%), or urethral stricture (1.4%). The presence of hematuria in patients receiving antiplatelet or anticoagulation therapy cannot be presumed to be due to the medication; a complete evaluation is warranted consisting of upper tract imaging, cystoscopy, and urine cytology (see Chapter 39 for Bladder Cancer, Cancers of the Ureter & Renal Pelvis, Renal Cell Carcinoma, and Other Primary T umors of the Kidney). Clinical FindingsA.  Symptoms and SignsIf  gross hematuria occurs, a description of the timing (initial, terminal, total) may provide a clue to the localization ofdisease. Associated symptoms (ie, renal colic, irritative void- ing symptoms, or constitutional symptoms) should be inves- tigated. The history should be focused on risk factors for urothelial cancer (age, male sex, smoking history, history of gross hematuria, irritative lower urinary tract voiding symp- toms, history of cyclophosphamide or ifosfamide chemo- therapy, family history of urothelial carcinoma or Lynch syndrome, occupational exposure to benzene chemicals or aromatic amines, history of chronic indwelling foreign body in the urinary tract) and on nonmalignant causes. The physical examination should look for signs of systemic disease (fever, rash, lymphadenopathy, abdominal or pelvic masses) as well as signs of medical kidney disease (hyperten- sion, volume overload). The urologic evaluation may dem- onstrate an enlarged prostate, flank mass, or urethral disease. The evaluation of patients with hematuria and their risk stratification should not be influenced by whether they are taking any antiplatelet or anticoagulant agents.B.  Laboratory FindingsIn itial laboratory investigations include a urinalysis and urine culture. Microhematuria is defined as three or more red blood cells per high-power field on a microscopic evaluation of the urine. The degree of microscopic hematuria is impor- tant in risk stratification according to the 2020 American Urological Association hematuria guidelines (Figure 231). A positive dipstick reading for heme merits microscopic examination to confirm or refute the diagnosis of hematuria but is not enough to warrant workup on its own. If urinaly- sis and culture is suggestive of a urinary tract infection, follow-up urinalysis after treatment of the infection is important to ensure resolution of the hematuria. An esti- mate of kidney function should be obtained since renal insufficiency may influence the methods of further evalua- tion and management (eg, ability to obtain contrast imag- ing) of patients with hematuria. Urine cytology and other urinary-based markers are not routinely recommended in the evaluation of asymptomatic microscopic hematuria.C.  Risk StratificationFo llowing initial evaluation, clinicians should categorize patients with microscopic hematuria as low, intermediate, or high risk for a urothelial malignancy (Figure 231).CMDT22_Ch23_p0952-p0977.indd  952 29/06/21 8:49 PM",
                  "KIDNEY DISEASE913 CMDT 2022Thr  ar svral rasons protinuria may dvlop: (1) Functional proteinuria is a bnign procss stmming from strssors such as acut illnss, xrcis, and ortho- static protinuria.  Th lattr condition, gnrally found in popl undr 30 yars of ag, usually causs protin xcr- tion lss than 1 g/day. Th orthostatic natur of th protin- uria is confirmd by masuring an 8-hour ovrnight supin urinary protin xcrtion, which should b lss than 50 mg. (2)Overload proteinuria occurs whn th rabsorptiv capacity of tubuls is ovrwhlmd, which can rsult from xcss production of low-molcular-wight plasma pro- tins (g, Bnc Jons protins associatd with plasma cll myloma). In th cas of plasma cll myloma, protin lctrophorsis from srum or urin will xhibit a discrt, monoclonal protin spik. Othr xampls of ovrload protinuria includ myoglobinuria in rhabdomyolysis and hmoglobinuria in hmolysis. (3) Glomerular proteinuria rsults from ffacmnt of pithlial cll foot procsss and altrd glomrular prmability with an incrasd filtra- tion fraction of normal plasma protins, as in diabtic nphropathy. Protin lctrophorsis will xhibit a larg albumin spik indicativ of th incrasd prmability of albumin across th damagd GBM. (4) Tubular protein- uria occurs as a rsult of faulty rabsorption of normally filtrd protins in th proximal tubul, such as bta- 2-microglobulin. Causs may includ ATN, toxic injury (lad, aminoglycosids, and crtain antirtrovirals), drug- inducd intrstitial nphritis, and hrditary mtabolic disordrs (Wilson disas and Fanconi syndrom). Evaluation of protinuria by urin dipstick dos not actually masur protin but instad dtcts th ngativ lctrochmical charg that charactrizs albumin. As a rsult, positivly chargd Bnc Jons protins ar missd with dipstick analysis. Bnc Jons protins can b dtctd by th addition of sulfosalicylic acid to th urin spcimn or, mor commonly, dirctly masuring urin protin. It should b notd that, bcaus urin dipstick simply dtcts ngativ lctrochmical charg, alkalin urin (pH > 7.0) can caus fals-positiv rsults. Whil urin dipstick is commonly usd to scrn for pro- tinuria, quantitativ invstigation rquirs dirct valuationof urin protin xcrtion. This can b stimatd with a random urin sampl or masurd from a timd urin collction (typically 24 hours). Collction of a random urin sampl is far simplr, and th ratio of urin protin- to-cratinin concntration ([Uprotin]/[Ucratinin]) corrlats with a 24-hour urin protin collction (lss than 0.2 is normal and corrsponds to xcrtion of lss than 200 mg/ 24 hours). In a 24-hour collction, protinuria abov 150 mg is abnormal and abov 3 g is classifid as nphrotic- rang. On bnfit of a random protin-to-cratinin ratio is th minimization of rror from ovrcollction or undrcol- lction of urin in th 24-hour spcimn. A kidny biopsy may b indicatd to dtrmin th caus of abnormal pro- tinuria, particularly if accompanid by abnormal GFR or hmaturia. Th clinical squla of protinuria ar dis- cussd in th sction on Nphrotic Spctrum Glomrular Disass.B.  HematuriaH maturia is considrd clinically significant if thr ar mor than thr rd blood clls pr high-powr fild on at last two occasions. It is usually dtctd incidntally on urin dipstick or following an pisod of macroscopic hma- turia. Th diagnosis must b confirmd via microscopic xamination, as fals-positiv dipstick tsts can b causd by myoglobin, oxidizing agnts, bts and rhubarb, hydrochlo- ric acid, and bactria. Transint hmaturia is common but is lss oftn clinically significant in patints youngr than 40 yars du to lowr concrn for malignancy. Hmaturia may b du to rnal or xtrarnal causs. Extrarnal causs ar addrssd in Chaptr 23. Rnal causs account for approximatly 10% of cass and ar clas- sifid as ithr glomrular or xtraglomrular. Glomrular causs includ glomrulonphritis (g, immunoglobulin A [IgA] nphropathy), thin basmnt mmbran disas and othr hrditary disordrs (g, Alport syndrom), and sys- tmic nphritic syndroms (g, lupus nphritis). Extraglo- mrular sourcs includ cysts; calculi; intrstitial nphritis; and, most worrisom, gnitourinary noplasms from th kidny, prostat, or bladdr (s Chaptr 39). Glomerular Filtration RateTh  GFR provids a usful masur of kidny function at th lvl of th glomrulus and can ithr b masurd dirctly using biomarkrs (most commonly cratinin) or stimatd using validatd formula. Th GFR masurs th amount of plasma ultrafiltrd across th glomrular capil- laris pr unit tim and rflcts th kidnys ability to filtr fluids and substancs, including mdications; it is oftn usd to dtrmin drug dosing. Daily GFR in normal indi- viduals is variabl, with a rang of 150250 L/24 h or 100120 mL/min/1.73 m2of body surfac ara. Patints with kidny disas can hav dcrasd GFR from any procss that causs loss of functional glomruli. Howvr, thy can also hav normal or incrasd GFR, ithr from glomrular hyprfiltration or disas at a diffrnt sgmnt of th nphron, intrstitium, or vascular supply. GFR can b masurd by dtrmining th rnal clar- anc of plasma substancs that ar not bound to plasmaTable 221. Significance of specific urinary casts.T ye Significance Hyaline casts Not indicative of kidney disease Concentrated urine, febrile disease, diuretic therapy, after strenuous exercise Red cell casts Glomerulonephritis White cell casts Indicative of infection or inflammation Pyelonephritis, interstitial nephritis Renal tubular cell castsAcute tubular necrosis, interstitial nephritis Granular (muddy brown) castsNonspecific; can indicate acute tubular necrosis Broad waxy casts Indicative of stasis in enlarged collecting tubules Chronic kidney diseaseCMDT22_Ch22_p0912-p0951.indd  913 02/07/21 2:33 PMChApTEr 22914 CMDT 2022pro tins, ar frly filtrabl across th glomrulus, and ar nithr scrtd nor rabsorbd along th rnal tubuls. Th rnal claranc of a substanc is dfind as:= CU  V Pwhr  C is th claranc, U and P ar th rspctiv urin and plasma concntrations of th substanc (mg/dL), and V.is volum of urin pr unit tim (typically mL/min). In clinical practic, th claranc of ndognous cratinin (trmd creatinine clearance ) is th primary way to ma- sur GFR. Th cratinin claranc (Ccr) is approximatly 100 mL/min in halthy young womn and 120 mL/min in halthy young mn. Th cratinin claranc dclins by an avrag of 0.8 mL/min/yr aftr ag 40 yars as part of th aging procss. Cratinin is a product of muscl mtabolism producd at a rlativly constant rat and clard by rnal xcrtion. It is frly filtrd by th glomrulus and not rabsorbd by th rnal tubuls. Howvr, cratinin is not a prfct indicator of GFR for th following rasons: (1) a small amount is normally liminatd by tubular scrtion, and it progrssivly incrass as GFR dclins (thus ovrs- timating GFR); (2) with svr kidny failur, gut microor- ganisms dgrad cratinin; (3) ditary mat intak and muscl mass affct plasma cratinin lvls; (4) mdications such as aspirin, dolutgravir, probncid, and trimthoprim rduc tubular scrtion of cratinin, incrasing th plasma cratinin concntration and falsly suggsting kidny dys- function; and (5) th masurmnt assums a stabl plasma cratinin concntration ovr a 24-hour priod, so whn valus ar changing during th dvlopmnt of and rcov- ry from AKI, cratinin claranc is inaccurat. On way to masur cratinin claranc is to prform a timd urin collction and dtrmin th plasma cratinin lvl midway through th collction. An incomplt or pro- longd urin collction is a common sourc of rror. Th compltnss of th collction can b stimatd by compar- ing th amount of cratinin xcrtd in th collction to that xpctd ovr a 24-hour priod, which should b constant: Ucr V.= 15  20 mg/kg for healthy young women Ucr V.= 20  25 mg/kg for healthy young men Givn th tdious natur of timd urin collctions for masuring GFR, GFR is mor commonly stimatd (dnotd GFR) using formula that hav bn validatd using patint charactristics (such as ag, wight, rac, and sx) and plasma cratinin lvls. Th Kidny Disas Improv- ing Global Outcoms workgroup rcommnds GFR for- mula as th primary mthod for dtrmining GFR. Th prfrrd GFR formula is th 2009 CKD-Epidmiology (EPI) Collaboration cratinin quation (https://www. kidny.org/contnt/ckd-pi-cratinin-quation-2009). An altrnativ cratinin-basd GFR stimating quation is accptabl if it improvs accuracy ovr th CKD-EPI qua- tion. Svral wb-basd calculators will calculat th GFR (g, http://touchcalc.com/calculators/pi). Th Cockcroft- Gault formula is commonly usd to dtrmin drug dos- ing, but it is no longr rcommndd sinc it was dvlopdbfor th standardization of cratinin assays currntly in us.Cystatin C is anothr ndognous markr of GFR that is filtrd frly at th glomrulus, producd at a rlativly constant rat, and lss dpndnt on muscl mass. It is rabsorbd and partially mtabolizd in th rnal tubular pithlial clls. Adding th masurmnt of cystatin C to srum cratinin can improv th accuracy of th GFR. A larg mta-analysis showd that cystatin C alon or in combination with srum cratinin is a strongr prdictor of important clinical vnts, such as nd-stag kidny dis- as (ESKD) or dath, than srum cratinin alon. How- vr, bcaus cystatin C is not univrsally availabl or standardizd across assays, it rmains a complmntary biomarkr for stimating GFR. BUN is anothr indx usd in assssing kidny func- tion. It is synthsizd mainly in th livr and is th nd product of protin catabolism. Ura is frly filtrd by th glomrulus, but about 3070% is rabsorbd in th rnal tubuls. As such, it undrstimats GFR. Rnal ura rab- sorption incrass (in conjunction with incrasd sodium rabsorption) in hypovolmic patints (who, thrfor, hav an incrasd BUN). A normal BUN:cratinin ratio is approximatly 10:1, although this varis btwn individu- als. With volum dpltion, th ratio can incras to 20:1 or highr. Othr causs of incrasd BUN includ incrasd catabolism (gastrointstinal [GI] blding, cll lysis, and corticostroid usag), incrasd ditary protin, and dcrasd rnal prfusion prompting incrasd sodium (and thrfor BUN) rabsorption (g, hart failur, rnal artry stnosis) (Tabl 222). Rducd BUN lvls ar sn in livr disas and in th syndrom of inappropriat antidiurtic hormon (SIADH). In summary, cratinin and ura clarancs ovrsti- mat and undrstimat GFR, rspctivly. Bcaus ach of ths stimats bcom mor inaccurat as kidny disas advancs, a mor accurat masur of GFR as patints approach ESKD is th avrag of th cratinin and ura clarancs.KI DNEY BIOPSYIndica tions for prcutanous ndl biopsy includ (1) unxplaind AKI or CKD; (2) unxplaind protinuria or hmaturia, or both; (3) prviously idntifid and tratd Table 222. Conditions affecting BUN independently of GFR.Inceased  BUN Reduced effective circulating blood volume (prerenal azotemia) Catabolic states (gastrointestinal bleeding, corticosteroid use) High-protein diets Tetracycline Deceased BUN Liver disease Malnutrition Sickle cell anemia SIADH BUN, blood urea nitrogen; GFR, glomerular filtration rate; SIADH, syndrome of inappropriate antidiuretic hormone.CMDT22_Ch22_p0912-p0951.indd  914 02/07/21 2:33 PMKIDNEY DISEASE915 CMDT 2022lsions to guid futur thrapy; (4) sy stmic disass asso- ciatd with kidny dysfunction, such as systmic lupus rythmatosus (SLE), anti-GBM disas, and granuloma- tosis with polyangiitis; and (5) kidny transplant dysfunc- tion, to valuat for transplant rjction or othr abnormalitis. Kidny biopsis should only b prformd if th rsults will influnc th tratmnt plan or facilitat discussion about prognosis. Rlativ contraindications includ a solitary or ctopic kidny (xcption for trans- plant allografts), horssho kidny, ESKD, congnital anomalis, and multipl cysts. Absolut contraindications includ an uncorrctd blding disordr; svr uncon- trolld hyprtnsion; rnal infction or noplasm; hydro- nphrosis; or uncooprativ patints, including thos who ar unabl to li flat for th procdur. Prcutanous kidny biopsis ar gnrally saf. Th major risk is blding, which may occur up to 72 hours post biopsy. Mor than half of patints will hav at last a small hmatoma; approximatly 15% of patints will xprinc significant blding rquiring a blood transfusion. Antico- agulation should b hld for 57 days post biopsy if possibl. Th risks of nphrctomy and mortality ar about 0.06 0.08%. Whn a prcutanous ndl biopsy is tchnically not fasibl and kidny tissu is dmd clinically ssntial, a closd biopsy via intrvntional radiologic tchniqus or opn biopsy undr gnral ansthsia can b prformd.Bknkamp  A. Protinuriatak a closr look! Pdiatr Nphrol. 2020;35:533. [PMID: 31925536] Cavanaugh C t al. Urin sdimnt xamination in th diagnosis and managmnt of kidny disas: Cor Curriculum 2019. Am J Kidny Dis. 2019;73:258. [PMID: 30249419] Lvy AS t al. Masurd and stimatd glomrular filtration rat: currnt status and futur dirctions. Nat Rv Nphrol. 2020;16:51. [PMID: 31527790] ACUTE KIDNEY INJUrYE S S E N T I A L S  O F  D I A G N O S I S Rapid increase in serum creatinine. Oliguria may be present. Symptoms and signs depend on cause. General ConsiderationsAKI is dfi nd as an absolut incras in srum cratinin by 0.3 mg/dL or mor within 48 hours or a rlativ incras of at last 1.5 tims baslin that is known or prsumd to hav occurrd within 7 days. AKI is charactrizd as oligu- ric if urin production is lss than roughly 400500 mL/day. Clinically, AKI is charactrizd by an inability to maintain acid-bas, fluid, and lctrolyt balanc and to xcrt nitrognous wasts. Stage 1 is a 1.5- to 1.9-fold incras in srum cratinin or a dclin in urinary output to lss than 0.5 mL/kg/h ovr 612 hours; stage 2 is a 2.0- to 2.9-fold incras in srum cratinin or dclin in urinary output to lss than 0.5 mL/kg/h ovr 12 hours or longr; stage 3 is a3.0-fold or gratr incras in srum cratinin, an incras in srum cratinin to gratr than or qual to 4 mg/dL, a dclin in urinary output to lss than 0.3 mL/ kg/h for 24 hours or longr, anuria for 12 hours or longr, or initiation of rnal rplacmnt thrapy. In th absnc of functioning kidnys, srum cratinin concntration will typically incras by 11.5 mg/dL daily, although with crtain conditions, such as rhabdomyolysis, srum crati- nin can incras mor rapidly. On avrag, 5% of hospital admissions and 30% of intnsiv car unit (ICU) admis- sions includ a diagnosis of AKI, and AKI dvlops in 25% of hospitalizd patints. Th rats of AKI in th hospital stting hav incrasd stadily sinc th 1980s and continu to ris. Clinical FindingsA.  Symptoms and SignsAlthough  many patints will not xprinc any symptoms or xhibit any signs of AKI, th buildup of wast products can caus nonspcific symptoms and signs collctivly trmd uremia : nausa, vomiting, malais, and altrd snsorium. Mor commonly, patints xprinc symp- toms and signs of th undrlying disas causing thir AKI (g, lupus). Hyprtnsion can occur, and fluid homostasis is oftn impaird. Hypovolmia can caus stats of low blood flow to th kidnys, somtims trmd prerenal azotemia, whras hyprvolmia can rsult from intrinsic or postrnal disas. Pricardial ffusions can occur with urmia and may rsult in cardiac tamponad; a pricardial friction rub can b prsnt, signaling pricarditis. With hyprkalmia, vntricular tachycardia and othr tachyar- rhythmias can occur. Th lung xamination may rval rals in th prsnc of hyprvolmia. AKI can caus non- spcific diffus abdominal pain and ilus. Platlt dysfunc- tion with blding and clotting disordrs can occur. Th nurologic xamination somtims rvals ncphalo- pathic changs with astrixis and confusion; uncommonly sizurs may nsu.B.  Laboratory FindingsBy  dfinition, lvatd srum cratinin (and oftn BUN) lvls ar prsnt, though ths lvations do not distin- guish AKI from CKD. Mtabolic acidosis (du to dcrasd claranc of organic and inorganic acids) is oftn notd. Hyprkalmia can occur from impaird rnal potassium xcrtion or from shifting of potassium from clls into th blood as a rsult of mtabolic acidosis. With hyprkalmia, ECG can rval pakd T wavs, PR prolongation, and QRS widning. A long QT sgmnt can occur with hypo- calcmia. Hyprphosphatmia occurs whn phosphorus cannot b scrtd by damagd tubuls ithr with or with- out incrasd cll catabolism. Anmia can occur as a rsult of dcrasd rythropoitin production ovr wks, and platlt dysfunction is typical. Classification & EtiologyAKI  is commonly dividd into thr catgoris: prrnal causs (kidny hypoprfusion), intrinsic kidny disas,CMDT22_Ch22_p0912-p0951.indd  915 02/07/21 2:33 PMChApTEr 22916 CMDT 2022and  postrnal causs (obstruction to urinary outflow). Idntifying th caus is th first stp toward tratmnt (Tabl 223).A.  Prerenal CausesPrr nal causs ar th most common tiology of AKI, accounting for 4080% of cass. Prrnal azotmia is a physiologic rspons to rnal hypoprfusion. If rvrsd quickly with rstoration of rnal blood flow (g, fluid rsuscitation), rnal parnchymal damag oftn dos not occur. If hypoprfusion prsists, prrnal azotmia can lad to intrinsic kidny injury. Dcrasd rnal prfusion can occur in svral ways, such as a dcras in intravascular volum, a chang in vascular rsistanc, or low cardiac output. Causs of vol- um dpltion includ hmorrhag (g, from trauma), GI losss, xcssiv diursis, and xtravascular fluid squstra- tion (g, pancratitis, burns, and pritonitis). Changs in systmic vascular rsistanc can occur with spsis, anaphylaxis, ansthsia, and aftrload-rducing drugs. Blockad of th rnin-angiotnsin-aldostron sys- tm, such as with angiotnsin-convrting nzym (ACE) inhibitors, limits ffrnt rnal artriolar constriction out of proportion to affrnt artriolar constriction and thrby dcrass GFR. Nonstroidal anti-inflammatory drugs (NSAIDs) minimiz affrnt artriolar vasodilation by inhibiting prostaglandin-mdiatd signals. NSAIDs may hav particularly dltrious ffcts on rnal prfusion in cirrhosis and hart failur whn prostaglandins ar rcruitd to incras rnal blood flow. Epinphrin, nor- pinphrin, high-dos dopamin, ansthtic agnts, and calcinurin inhibitors also can caus rnal vasoconstric- tion. Rnal artry stnosis causs incrasd rsistanc and dcrasd rnal prfusion.Low cardiac output is a stat of low ffctiv rnal art- rial blood flow. This occurs in stats of hart failur (including cardiognic shock), pulmonary mbolism, and pricardial tamponad. Arrhythmias and valvular disor- drs can also rduc cardiac output. In th intnsiv car stting, positiv prssur vntilation will dcras vnous rturn and, in ffct, cardiac output. Whn GFR falls acutly, it is important to dtrmin whthr AKI is du to prrnal or intrinsic causs. Th his- tory, physical xamination, and laboratory data may b hlpful in distinguishing btwn ths causs. In prrnal AKI, th BUN:cratinin ratio oftn xcds 20:1 du to incrasd ura rabsorption. In oliguric patints, anothr usful indx is th fractional xcrtion of sodium (FeNa). With dcrasd GFR, th kidny rabsorbs salt and watr avidly if thr is no intrinsic tubular dysfunction. Thus, oliguric patints with prrnal AKI should hav a low frac- tional xcrtion of sodium (lss than 1%). Oliguric patints with intrinsic kidny dysfunction typically hav a high FeNa (gratr than 12%), indicating loss of tubular clls ability to rabsorb sodium. Th FeNais calculatd as follows: FeNa = claranc of Na+/GFR = claranc of Na+/Ccr:F Urine  / Serum Urine  / Serum100%E NaNa  Na cr  cr=  Th  quation was cratd and validatd to assss th diffrnc btwn oliguric ATN and prrnal AKI; its util- ity in nonoliguric patints is limitd. Furthr, bcaus diurtics act by incrasing sodium xcrtion, a high FeNa within 1224 hours aftr diurtic administration cannot b maningfully intrprtd. In contrast, a low FeNadespite rciving diurtics offrs strong vidnc of prrnal stats in oliguric patints. Givn th limitations of FeNaTable 223. Classification and differential diagnosis of acute kidney injury. peenal Azotemiapostenal AzotemiaIntinsic renal Disease Acute Tubula Necosis Acute GlomeuloneitisAcute Intestitial Neitis Etiology Poor renal perfusionObstruction of the urinary tractIschemia, nephrotoxinsImmune complex-mediated, pauci-immune, anti-GBM related, monoclonal immunoglobulinmediated, C3 glomerulopathyAllergic reaction; drug reaction; infection; autoimmune disease Serum BUN:Cr ratio > 20:1 > 20:1 < 20:1 > 20:1 < 20:1 UNa(mEq/L) < 20 Variable > 20 < 20 Variable FENa(%) < 1 Variable > 1 (when oliguric) < 1 Variable Urine osmolality (mOsm/kg)> 500 < 400 250300 Variable Variable Urinary sediment Benign or hyaline castsNormal or red cells, white cells, or crystalsGranular (muddy brown) casts, renal tubular cell castsRed cells, dysmorphic red cells, and red cell castsWhite cells, white cell casts, with or without eosinophils BUN:Cr, blood urea nitrogen:creatinine ratio; FENa, fractional excretion of sodium; GBM, glomerular basement membrane; UNa, urinary concentration of sodium.CMDT22_Ch22_p0912-p0951.indd  916 02/07/21 2:33 PMKIDNEY DISEASE917 CMDT 2022calculations,  urin microscopy is a much mor valuabl tool for dtrmining caus of AKI. Patints with prrnal azotmia typically hav bland urin sdimnts, though som hav hyalin casts. In contrast, patints with ATN oftn hav rnal tubular pithlial clls or muddy brown casts visibl. Tratmnt of prrnal AKI dpnds on th undrlying caus, but achivmnt of uvolmia, attntion to srum lctrolyts, and avoidanc of nphrotoxic drugs ar bnch- marks of thrapy. This involvs carful assssmnt of vol- um status, cardiac function, dit, and drug usag.B.  Postrenal CausesP ostrnal causs of AKI ar th last common, accounting for approximatly 510% of cass, but ar important to dtct bcaus of thir rvrsibility. Postrnal azotmia occurs whn urinary flow from both kidnys, or a singl functioning kidny, is obstructd. Obstruction lads to lvatd intraluminal prssur and rsultant kidny parn- chymal damag, with markd ffcts on rnal blood flow and tubular function. Postrnal causs of AKI includ urthral obstruction, bladdr dysfunction or obstruction, and obstruction of both urtrs or rnal plviss. In mn, bnign prostatic hyprplasia is th most common caus. Patints taking anticholinrgic drugs ar at risk for urinary rtntion. Obstruction can also b causd by bladdr, prostat, and crvical cancrs; rtropritonal fibrosis; and nurognic bladdr (g, from diabts mllitus). Lss common causs includ blood clots, bilatral urtral stons, urthral stons or stricturs, and bilatral papillary ncrosis. Patints may b anuric or polyuric and may xprinc lowr abdominal or back pain. Polyuria can occur in th stting of partial obstruction with rsultant tubular dys- function and an inability to appropriatly rabsorb salt and watr loads. Obstruction can b constant or intrmittnt and partial or complt. On xamination, th patint may hav an nlargd prostat, distndd bladdr, or mass dtctd on abdominal xamination. Laboratory xamination may initially rval high urin osmolality, low urin sodium, high BUN:cratinin ratio, and low FeNa(as tubular function may not b compromisd initially). Ths indics ar similar to a prrnal stat bcaus xtnsiv intrinsic rnal damag has not yt occurrd. Aftr svral days, howvr, th urin sodium incrass as th kidnys fail and ar unabl to concntrat th urin; this inability to concntrat th urin is calld isosthnuria. Th urin sdimnt is gnrally bland, though hmaturia may b sn if th obstruction is du to stons, blood clots, or papillary ncrosis. Patints with AKI du to suspctd postrnal causs should undrgo bladdr cathtrization and ultrasonogra- phy to assss for hydrourtr, hydronphrosis, or larg bladdr volum. Aftr rvrsal of th undrlying procss, som patints xprinc significant urinary output (calld postobstructiv diursis). In such sttings, car should b takn to avoid volum dpltion or lctrolyt drang- mnts. Prompt tratmnt of obstruction within days by cathtrs, stnts, or othr surgical procdurs can rsult in partial or complt rvrsal of AKI.C. Intrinsic Acute Kidney InjuryIn trinsic rnal disordrs account for up to 50% of all cass of AKI. Intrinsic dysfunction is considrd aftr prrnal and postrnal causs hav bn xcludd. Th potntial sits of injury ar th tubuls, intrstitium, vasculatur, and glomruli. Intrinsic AKI is discussd in gratr dtail in th following sctions. When to Refer If a patint has signs of AKI that hav not rvrsd ovr 12 wks, or if th dgr of AKI is concrning (g, doubling of cratinin) and without an immdiatly rvrsibl caus such as obstruction. If a patint has signs of urinary tract obstruction, th patint should b rfrrd to a urologist. When to AdmitTh  patint should b admittd if thr is suddn loss of kidny function rsulting in abnormalitis that cannot b handld xpditiously in an outpatint stting (g, hyprka- lmia, volum ovrload, urmia) or an acut intrvntion is ndd, such as mrgnt urologic procdurs or dialysis.Ost rmann t al. Rcommndations on acut kidny injury bio- markrs from th Acut Disas Quality Initiativ Consnsus Confrnc: a consnsus statmnt. JAMA Ntw Opn. 2020;3:2019209. [PMID: 33021646] Ronco C t al. Acut kidny injury. Lanct. 2019;394:1949. [PMID: 31777389] Srisawat N t al. Th rol of biomarkrs in acut kidny injury. Crit Car Clin. 2020;36:125. [PMID: 31733675]ACU TE TUBULAR NECROSISE S S E N T I A L S  O F  D I A G N O S I S AKI. Ischemic or toxic insult or underlying sepsis. Urine sediment with granular (muddy brown) casts and renal tubular epithelial cells is pathog- nomonic but not essential. General ConsiderationsAKI  du to tubular damag is trmd acute tubular necro- sis (ATN) and accounts for approximatly 85% of intrinsic AKI. Th two major causs of ATN ar ischmia and nph- rotoxin xposur. Ischmic ATN is charactrizd not only by inadquat GFR but also by rnal blood flow that is inadquat to maintain parnchymal cllular prfusion. Rnal tubular damag can b causd by low ffctiv art- rial blood flow to th kidnys in th stting of prolongd hypotnsion or hypoxmia, such as volum dpltion or shock. Undrlying spsis is an indpndnt risk factor for ATN, vn in th absnc of hmodynamic compromis.CMDT22_Ch22_p0912-p0951.indd  917 02/07/21 2:33 PMChApTEr 22918 CMDT 2022Pro longd priods of rnal hypoprfusion can occur with major surgical procdurs, which ar xacrbatd by vaso- dilating ansthtic agnts.A.  Exogenous NephrotoxinsExognous  nphrotoxins mor commonly caus damag than ndognous nphrotoxins. Aminoglycosides caus som dgr of ATN in up to 25% of hospitalizd patints rciving thraputic lvls of th drugs. Nonoliguric kidny injury typically occurs aftr 510 days of xposur. Prdisposing factors includ undr- lying kidny damag, volum dpltion, and advancd ag. Monitoring drug lvls is important, and troughs ar par- ticularly hlpful in prdicting rnal toxicity. Amphotericin B is typically nphrotoxic aftr a dos of 23 g. This causs a typ 1 (distal) rnal tubular acidosis with svr vasoconstriction and tubular damag, which can lad to hypokalmia and nphrognic diabts insipi- dus. Vancomycin , intravnous acyclovir , and svral cephalosporins hav also bn known to caus or b asso- ciatd with ATN. Radiographic contrast media may b dirctly nphro- toxic. Contrast nphropathy is th third lading caus of incidnt AKI in hospitalizd patints and is thought to rsult from th synrgistic combination of dirct rnal tubular pithlial cll toxicity and rnal mdullary ischmia. Th combination of prxisting diabts mllitus and CKD is associatd with th gratst risk (1550%) of contrast nphropathy. Othr risk factors includ advancd ag; vol- um dpltion; hart failur; plasma cll myloma; rpatd doss of contrast; and rcnt xposur to othr nphrotoxic agnts, including NSAIDs and ACE inhibitors. Lowr volums of contrast with low osmolality ar rcommndd in high-risk patints. Toxicity usually occurs within 2448 hours aftr th radiocontrast study. Nonionic con- trast mdia may b lss toxic, but this has not bn wll provn. Prvntion of contrast nphropathy is th goal whn using ths agnts. Th mainstay of prophylaxis is 13 mL/kg or 5001000 mL of intravnous 0.9% (normal) salin ovr 6 hours both bfor and aftr th contrast administrationcautiously in patints with prxisting cardiac dysfunction; oral intak of fluids is an accptabl altrnativ for outpatint studis. Isotonic intravnous vol- um rpltion is suprior to hypotonic intravnous solutions, and both ar suprior to oral solutions in small studis. Othr nphrotoxic agnts should b avoidd during th day bfor and aftr dy administration. Altrnativ prophylactic strat- gis involving N-actylcystin, sodium bicarbonat, manni- tol, and furosmid do not show bnfit ovr 0.9% (normal) salin administration. In fact, furosmid may lad to incrasd rats of kidny dysfunction in this stting. Calcineurin inhibitor toxicity (from tacrolimus or cyclosporin) is usually dos dpndnt. It causs distal tubular dysfunction (a typ 4 rnal tubular acidosis) and svr vasoconstriction. Rgular blood lvl monitoring is important to prvnt both acut and chronic nphrotoxic- ity. Kidny function usually improvs aftr rducing th dos or stopping th drug. Othr xognous nphrotoxins includ antinoplastics, such as cisplatin and organic solvnts, and havy mtalssuch as mrcury, cadmium, and arsnic. Hrbal mdicins ar also incrasingly rcognizd as potntially nphrotoxic.B.  Endogenous NephrotoxinsEndo gnous nphrotoxins includ pigmnt-containing products (myoglobin and hmoglobin), uric acid, and paraprotins. Pigmnt-containing products can caus dirct tubular toxicity, rsulting in ATN. Th most common typ of pig- mnt nphropathy is rhabdomyolysis, causd by rlas of myoglobin from muscl. Massiv intravascular hmolysis is sn in transfusion ractions and in crtain hmolytic anmias, and causs rlas of hmoglobin. Rvrsal of th undrlying disordr and hydration ar th mainstays of tratmnt. Hyperuricemia can occur in th stting of rapid cll turnovr and lysis. Chmothrapy for grm cll and hmatologic malignancis (lukmia and lymphoma) is th primary caus; spontanous tumor lysis syndrom can also occur, though is lss common. AKI occurs with intra- tubular prcipitation of uric acid crystals; srum uric acid lvls oftn xcd 1520 mg/dL and urin uric acid lvls ar typically gratr than 600 mg/24 h. A urin uric acid to urin cratinin ratio gratr than 1.0 idntifis individuals at risk for AKI. Allopurinol or rasburicas can b usd prophylactically, and rasburicas with or without dialysis is oftn usd for tratmnt in stablishd cass. Paraproteins sn in conjunction with plasma cll myloma can caus dirct tubular toxicity and tubular obstruction. Othr rnal complications from plasma cll myloma includ hyprcalcmia and rnal tubular dys- function, including proximal rnal tubular acidosis (s Plasma Cll Myloma blow). Clinical FindingsA.  Symptoms and SignsS Acut Kidny I njury.B.  Laboratory FindingsHyprka lmia and hyprphosphatmia ar commonly prsnt. Th BUN:cratinin ratio is usually lss than 20:1 bcaus tubular function is not intact, as dscribd in th gnral sction on AKI (Tabl 223). Urinary output can b oliguric or nonoliguric, with oliguria portnding a wors prognosis. Urin sodium concntration and FeNaar typically lvatd, indicativ of tubular dysfunction. Urin microscopy may show vidnc of acut tubular damag; th prsnc of two or mor granular casts or rnal tubular pithlial clls is strongly prdictiv of ATN but has a low ngativ prdictiv valu (s Tabl 221). Although not usually prformd in cass of ATN, kidny biopsy is som- tims hlpful in cass of diagnostic uncrtainty. TreatmentT ratmnt of ATN is aimd at hastning rcovry and avoiding complications. Prvntiv masurs should b takn to avoid volum ovrload and hyprkalmia. A pro- spctiv randomizd controlld trial did not show a bnfitCMDT22_Ch22_p0912-p0951.indd  918 02/07/21 2:33 PMKIDNEY DISEASE919 CMDT 2022of  loop diurtics on ithr rcovry from AKI or dath. Widsprad us of diurtics in critically ill patints with AKI should b usd only whn othrwis clinically indi- catd (g, in stats of volum ovrload), although unrspon- sivnss to high-dos diurtics has bn shown to prdict futur nd for acut dialysis in this population (trmd furosmid strss tst). A 2012 randomizd controlld trial did not show a bnfit on mortality from plasma ultra- filtration compard to intravnous diurtics in patints with dcompnsatd hart failur. Thus, ultrafiltration should gnrally b rsrvd for ICU patints with AKI in nd of volum rmoval who ar nonrsponsiv to diurtics, with th rcognition that this has not ultimatly improvd sur- vival in this patint population. Nutritional support should mt daily nds whil prvnting xcssiv catabolism. Ditary protin rstriction of 0.6 g/kg/day hlps prvnt mtabolic acidosis. Hypocalcmia and hyprphosphatmia can b improvd with ditary modification and phosphat- binding agnts takn with mals; xampls includ alumi- num hydroxid (500 mg orally) ovr th short trm, and calcium carbonat (5001500 mg orally), calcium actat (667 mg, two or thr tablts), svlamr carbonat (800 1600 mg orally), and lanthanum carbonat (1000 mg orally) ovr longr priods. Hypocalcmia should not b tratd in patints with rhabdomyolysis unlss thy ar symptomatic. Hyprmagnsmia can occur bcaus of rducd magn- sium xcrtion by th rnal tubuls, so magnsium-containing antacids and laxativs should b avoidd in ths patints. Dosags of all mdications must b adjustd for drugs liminatd by th kidny. Indications for dialysis in AKI from ATN or othr intrinsic disordrs includ lif-thratning lctrolyt dis- turbancs (such as hyprkalmia), volum ovrload unr- sponsiv to diursis, rfractory acidosis, and urmic complications (g, ncphalopathy, pricarditis, and si- zurs). In gravly ill patints, lss svr but worsning abnormalitis may also b indications for dialytic support. Unfortunatly, thr is no vidnc that mor intnsiv or arlir initiation of rnal rplacmnt thrapy for patints with AKI confrs any survival bnfit. Course & PrognosisTh  clinical cours of ATN is oftn dividd into thr phass: initial injury, maintnanc, and rcovry. Th maintnanc phas is xprssd as ithr oliguric (urinary output lss than 500 mL/day) or nonoliguric. Nonoliguric ATN is associatd with bttr outcoms than oliguric ATN; convrsion from oliguric to nonoliguric stats with th us of diurtics dos not altr prognosis. Whil dopamin has somtims bn usd for this purpos, numrous studis hav shown that its us in this stting is not bnficial. Avrag duration of th maintnanc phas is 13 wks, but som cass may last svral months. Cllular rpair and rmoval of tubular dbris occur during this priod. Th rcovry phas can b hraldd by diursis, du to inability of rcovring rnal tubuls to rabsorb salt and watr appro- priatly, and a solut diursis from lvatd BUN lvls. As GFR bgins to ris, BUN and srum cratinin fall. Th mortality rat associatd with AKI is 2050% in hospitalizd sttings, and up to 70% for thos in th ICUrquiring dialysis with additional comorbid illnsss. Incrasd mortality is associatd with advancd ag, svr undrlying disas, and multisystm organ failur. Lading causs of dath ar infctions, fluid and lctrolyt distur- bancs, and worsning of undrlying disas. When to Refer Whn uncrtainty xists as to th caus of or tratmnt for AKI. For fluid, lctrolyt, and acid-bas abnormalitis that ar rcalcitrant to intrvntions. Nphrology rfrral improvs outcoms in AKI. When to AdmitA  patint with symptoms or signs of AKI that rquir immdiat intrvntion, such as administration of intrav- nous fluids or dialytic thrapy, or that rquir a tam approach that cannot b coordinatd as an outpatint.Griffin  BR t al. Critical car nphrology: Cor Curriculum 2020. Am J Kidny Dis. 2020;75:435. [PMID: 31982214] Prapornratana S t al. Acut kidny injury from spsis: currnt concpts, pidmiology, pathophysiology, prvntion and tratmnt. Kidny Int. 2019;96:1083. [PMID: 31443997] STARRT-AKI Invstigators; Canadian Critical Car Trials Group; Australian and Nw Zaland Intnsiv Car Socity Clinical Trials Group; Unitd Kingdom Critical Car Rsarch Group; Canadian Nphrology Trials Ntwork; Irish Critical Car Trials Group, Bagshaw SM t al. Timing of initiation of rnal-rplacmnt thrapy in acut kidny injury. N Engl J Md. 2020;383:240. [PMID: 32668114]RH ABDOMYOLYSISE S S E N T I A L S  O F  D I A G N O S I S Associated with crush injuries to muscle, immobil- ity, drug toxicities, and hypothermia. Characterized by serum elevations in muscle enzymes, including creatine kinase, and marked electrolyte abnormalities. Release of myoglobin leads to direct renal toxicity. General ConsiderationsRhabdomyolysis  is a syndrom of acut skltal muscl ncrosis, lading to myoglobinuria and markdly lvatd cratin kinas lvls. Acut tubular ncrosis is a com- mon complication of rhabdomyolysis and is du to th filtration of xcssiv quantitis of myoglobin, which can b xacrbatd by volum dpltion. Distal tubular obstruction from pigmntd casts and intrarnal vaso- constriction can also occur. Rhabdomyolysis can rsult from crush injuris, prolongd immobility, sizurs, sub- stanc abus (g, cocain), and mdications (spcially statins). Th prsnc of kidny or livr dysfunction, dia- bts mllitus, and hypothyroidism incras th risk ofCMDT22_Ch22_p0912-p0951.indd  919 02/07/21 2:33 PMChApTEr 22920 CMDT 2022rh abdomyolysis in patints taking statins. Concurrnt us of drugs that inhibit cytochrom P450 (including protas inhibitors, rythromycin or clarithromycin, itraconazol, diltiazm, and vrapamil) with statins (xcpt pravastatin or rosuvastatin) as wll as concurrnt us of niacin and fibrat- containing thrapy can incras th risk of dvlopmnt of rhabdomyolysis. Clinical FindingsA.  Symptoms and SignsPa tints with rhabdomyolysis may hav myalgias or wak- nss or both, though it is not uncommon for thm to b asymptomatic. Urin may appar dark.B.  Laboratory FindingsRhabdomy olysis of clinical importanc commonly occurs with a srum cratin kinas gratr than 20,00050,000 intrnational units/L; on study showd that 58% of patints with AKI from rhabdomyolysis had cratin kinas lvls gratr than 16,000 intrnational units/L, whil only 11% of patints without kidny injury had cr- atin kinas valus gratr than 16,000 intrnational units/L. Oftn, thr ar lvatd srum lvls of aspartat aminotransfras (AST), alanin aminotransfras (ALT), and lactat dhydrognas (LD) (du to rlas of ths nzyms from skltal muscl). Th massiv acut lva- tions of muscl nzyms pak quickly and usually rsolv within days onc th inciting injury has bn rmovd. Th classic laboratory finding in rhabdomyolysis is a urin dipstick tst that is positiv for blood but without rd blood clls on microscopy. This fals-positiv rsult is du to dtction of myoglobin. Additionally, clinically maningful rhabdomyolysis causs injurd muscl clls to rlas intracllular componnts, lading to lctrolyt drangmnts (including hyprkalmia, hyprphosphat- mia, hypruricmia, and hypocalcmia). TreatmentTh  mainstay of tratmnt is aggrssiv volum rpltion with 0.9% normal salin (i, mor than 4 L/day) and rmoval of offnding mdications if thought to hav causd th disordr. Adjunctiv tratmnts with mannitol and alkalization of th urin hav not bn provn to chang outcoms in human trials. As patints rcovr, calcium can mov back from tissus to plasma, so arly xognous cal- cium administration for hypocalcmia is not rcommndd unlss th patint is symptomatic or th lvl bcoms xcdingly low in an unconscious patint; calcium rpl- tion can caus prcipitation of calcium phosphat givn th frquntly concurrnt hyprphosphatmia. Myopathic complications of statins usually rsolv within svral wks of discontinuing th drug. When to ReferClinically  maningful rhabdomyolysis rquirs immdiat attntion and inpatint managmnt, so affctd patints should not b rfrrd to outpatint nphrology clinics unlss to follow up aftr a hospital admission.When to AdmitPa tints whos srum cratin kinas lvls ar gratr than 15,00020,000 intrnational units/L or patints with AKI or lctrolyt drangmnts should b admittd for fluid rpltion and srial monitoring of cratin kinas and lctrolyts.Long  B t al. An vidnc-basd narrativ rviw of th mr- gncy dpartmnt valuation and managmnt of rhabdomy- olysis. Am J Emrg Md. 2019;37:518. [PMID: 30630682]IN TERSTITIAL NEPHRITISE S S E N T I A L S  O F  D I A G N O S I S Fever. Transient maculopapular rash. Acute or chronic in nature. Pyuria, white blood cell casts, and hematuria. General ConsiderationsAcut  intrstitial nphritis accounts for 1015% of cass of intrinsic rnal failur. An intrstitial inflammatory rspons with dma and possibl tubular cll damag is th typical pathologic finding. Although drugs account for ovr 70% of cass, acut intrstitial nphritis also occurs in infctious disass, autoimmun disordrs, or as idiopathic conditions. Th most common drugs implicatd ar pnicillins and cphalosporins, immun chckpoint inhibitors, sulfon- amids and sulfonamid-containing diurtics, NSAIDs, proton pump inhibitors, rifampin, and allopurinol. Infc- tious causs includ strptococcal infctions, lptospirosis, cytomgalovirus, histoplasmosis, and Rocky Mountain spottd fvr. SLE, Sjgrn syndrom, sarcoidosis, and cryoglobulinmia can also caus intrstitial nphritis, though thy ar mor classically associatd with glomrulonphritis. Clinical FindingsClinical  faturs includ fvr (mor than 80% of cass), rash (2550%), arthralgias, and priphral blood osino- philia (80%). Th classic triad of fvr, rash, and arthralgias is prsnt in only 1015% of cass. Th urin oftn contains whit clls (95%), rd clls, and whit cll casts. Protinuria is oftn prsnt, particularly in NSAID-inducd intrstitial nphritis, but is usually modst (lss than 2 g/24 h). Eosin- ophiluria is nithr vry snsitiv nor spcific for intrstitial nphritis; valuation for osinophiluria is not advisd. Although th clinical history and laboratory data oftn giv clus to th diagnosis, kidny biopsy is somtims ndd. Treatment & PrognosisAcut  intrstitial nphritis oftn carris a good prognosis, with rcovry occurring ovr wks to months. UrgntCMDT22_Ch22_p0912-p0951.indd  920 02/07/21 2:33 PMKIDNEY DISEASE921 CMDT 2022dialytic  thrapy may b ncssary in up to on-third of all rfrrd patints bfor rsolution, but patints rarly prog- rss to ESKD. Thos with prolongd oliguria and advancd ag hav a wors prognosis. Tratmnt consists of support- iv masurs and rmoval of th inciting agnt. If kidny injury prsists, a short cours of corticostroids can b considrd, although th data to support thir us ar not substantial, and thir fficacy may dpnd on th lapsd tim btwn onst of AKI and thir initiation. Short-trm, high-dos mthylprdnisolon (0.51 g/day intravnously for 14 days) or prdnison (60 mg/day orally for 12 wks) followd by a prdnison tapr can b usd in mor svr cass of drug-inducd intrstitial nphritis.Mo ldina DG t al. Tratmnt of drug-inducd acut tubuloint- rstitial nphritis: th sarch for bttr vidnc. Clin J Am Soc Nphrol. 2018;13:1785. [PMID: 30397028] Shingarv R t al. Kidny complications of immun chckpoint inhibitors: a rviw. Am J Kidny Dis. 2019;74:529. [PMID: 31303350]GLOM ERULONEPHRITISE S S E N T I A L S  O F  D I A G N O S I S Hematuria, subnephrotic proteinuria. Red cell casts pathognomonic but not required for diagnosis. Dependent edema and hypertension. AKI. General ConsiderationsAcu t glomrulonphritis is a rlativly uncommon caus of AKI, accounting for about 5% of cass. Pathologically, inflammatory glomrular lsions ar sn. Ths includ msangioprolifrativ, focal and diffus ndocapillary prolif- rativ, and crscntic lsions. Th largr th prcntag of glomruli involvd and th mor svr th lsion, th mor likly it is that th patint will hav a poor clinical outcom. Glomrulonphritids ar classifid into fiv pathophysi- ologic procsss, which can b charactrizd by srologic analysis. Markrs includ anti-GBM antibodis, antinu- trophil cytoplasmic antibodis (ANCAs), and othr immun markrs of disas. Immune complex deposition occurs whn thr is modrat ovrproduction of antign compard to antibody production. Complxs formd with markd antign xcss tnd to rmain in th circulation. Antibody xcss with larg antignantibody aggrgats usually rsults in phago- cytosis and claranc of th prcipitats by th mononuclar phagocytic systm in th livr and spln. Causs includ IgA nphropathy, infction-rlatd glomrulonphritis, lupus nphritis, and cryoglobulinmic glomrulonphritis (oftn associatd with hpatitis C virus [HCV]). Anti-GBMassociated acute glomerulonephritis is ithr confind to th kidny or associatd with pulmonary hmorrhag. Th lattr is trmd Goodpastur syndrom. Injury is rlatd to autoantibodis against typ IV collagn in th GBM. Pauci-immune acute glomerulonephritis is a form of small-vssl vasculitis associatd with ANCAs, causing kid- ny disass without dirct immun complx dposition or antibody binding. Tissu injury is blivd to b du to cll- mdiatd immun procsss. An xampl is granulomatosis with polyangiitis, a systmic ncrotizing vasculitis of small artris and vins associatd with intravascular and xtra- vascular granuloma formation. In addition to glomrulon- phritis, ths patints can hav uppr airway, pulmonary, and skin manifstations. Cytoplasmic ANCA (c-ANCA) is th common staining pattrn. Microscopic polyangiitis is anothr pauci-immun vasculitis causing acut glomrulo- nphritis, which is mor commonly associatd with pri- nuclar staining (p-ANCA). ANCA-associatd and anti-GBMassociatd acut glomrulonphritids can volv to crscntic glomrulonphritis and oftn hav poor outcoms unlss tratmnt is startd arly. Monoclonal immunoglobulinmediated glomerulo- nephritis is charactrizd by th dposition of a monoclo- nal immunoglobulin in glomruli or tubular basmnt mmbran or both. It is dtctd on immunofluorscnt or immunohistochmical staining of kidny biopsis as mono- typic immunoglobulin dposits. Srum protin lctropho- rsis and srum fr light chains ar usful diagnostic tsts to prform whn monoclonal immunoglobulinmdiatd glomrulonphritis is suspctd or confirmd. Whil many cass will occur in th stting of a monoclonal gammopa- thy, this is not always th cas. C3 glomerulopathy rsults from prdominant C3 dposition in th glomruli with or without minimal dposition of immunoglobulins. It is also idntifid by immunofluorscnc or immunohistochmistry. Th pathognsis of C3 glomrulonphropathy stms from abnormalitis in rgulation of th altrnativ pathway of complmnt. Whil chcking srum C3 lvls may b hlp- ful, normal lvls do not rul out C3 glomrulopathy. Other vascular causes of glomrulonphritis includ hyprtnsiv mrgncis and th thrombotic microangi- opathis such as hmolytic-urmic syndrom and throm- botic thrombocytopnic purpura (s Chaptr 14). Clinical FindingsA.  Symptoms and SignsPa tints with acut glomrulonphritis ar oftn hyprtn- siv and dmatous with an abnormal urinary sdimnt. Th dma is found first in body parts with low tissu tn- sion, such as th priorbital and scrotal rgions.B.  Laboratory FindingsSrum  cratinin can ris ovr days to months, dpnding on th rapidity of th undrlying procss. Th BUN:cratinin ratio is not a rliabl markr of kidny function and is mor rflctiv of th patints undrlying volum status. Dipstick and microscopic valuation rval vidnc of hmaturia and typically subnphrotic protin- uria; thr may b cllular lmnts such as dysmorphic rd clls, rd cll casts, and whit clls. Rd cll casts arCMDT22_Ch22_p0912-p0951.indd  921 02/07/21 2:33 PMChApTEr 22922 CMDT 2022spcific  for glomrulonphritis, and a dtaild sarch on urin microscopy is warrantd. Additional tsts includ srum complmnt lvls (C3, C4) that may b low in immun complx glomrulonphri- tis (xcpt for IgA nphropathy) or C3 glomrulopathy and normal in pauci-immun, anti-GBMrlatd, and mono- clonal immunoglobulinmdiatd glomrulonphritids. Othr tsts includ ASO titrs, anti-GBM antibody lvls, ANCAs, antinuclar antibody titrs, cryoglobulins, hpati- tis srologis, srum protin lctrophorsis and srum fr light chains, blood culturs, and rnal ultrasound. With fw xcptions, a kidny biopsy is ultimatly ncssary to con- firm th diagnosis, irrspctiv of laboratory data. TreatmentDpnding  on th natur and svrity of disas, tratmnt might includ high-dos corticostroids, rituximab, and cytotoxic agnts (such as cyclophosphamid). Plasma xchang can b usd in Goodpastur syndrom as a tm- porizing masur until chmothrapy can tak ffct. Tratmnt and prognosis for spcific disass ar discussd mor fully blow.Gtha  D t al. ANCA-associatd vasculitis: Cor Curriculum 2020. Am J Kidny Dis. 2020;75:124. [PMID: 31358311] Sthi S t al. Standardizd classification and rporting of glomrulonphritis. Nphrol Dial Transplant. 2019;34:193. [PMID: 30124958]COVI D-19 & THE KIDNEYE S S E N T I A L S  O F  D I A G N O S I S Broad array of clinical presentation and kidney pathology. Clinical Findings & TreatmentNar ly half of patints hospitalizd with COVID-19 prs- nt with or dvlop AKI, which is associatd with poorr prognosis. Many causs of AKI ar dscribd in patints with COVID-19, but th most common is ATN rlatd to a high inflammatory stat (trmd cytokin storm). Urinalysis may rval hmaturia, rflcting ndothlial injury and fibrin thrombi that ar commonly obsrvd on biopsy. Anothr mrging ntity is COVID-19associatd collapsing glomrulopathy, which is a typ of focal sgmntal glomrulosclrosis (s sction on Nphrotic Spctrum Glomrular Disass blow). Patints with collapsing glo- mrulopathy prsnt with nphrotic syndrom and ar typi- cally of African ancstry, highlighting a suspctd gntic prdisposition. Tratmnt of COVID-19rlatd AKI is largly supportiv; th rol of corticostroids in COVID-19 associatd collapsing glomrulopathy is undr invstigation.Cha n L t al; Mount Sinai COVID Informatics Cntr (MSCIC). AKI in hospitalizd patints with COVID-19. J Am Soc Nphrol. 2021;32:151. [PMID: 32883700]Nasr SH t al. COVID-19-associatd collapsing glomrulopathy: an mrging ntity. Kidny Int Rp. 2020;5:759. [PMID: 32368701] Ronco C t al. Managmnt of acut kidny injury in patints with COVID-19. Lanct Rspir Md. 2020;8:738. [PMID: 32416769] Shtty AA t al. COVID-19-associatd glomrular disas. J Am Soc Nphrol. 2021;32:33. [PMID: 33214201]C ARDIORENAL SYNDROMEE S S E N T I A L S  O F  D I A G N O S I S Cadiac dysfunction: acute or chronic heart failure, ischemic injury, or arrhythmias. Kidney disease: acute or chronic, depending on the type of cardiorenal syndrome. General ConsiderationsCardior nal syndrom is a pathophysiologic disordr of th hart and kidnys whrin th acut or chronic dtrio- ration of on organ rsults in th acut or chronic dtrio- ration of th othr. This syndrom is classifid into fiv typs as a mattr of convntion. Achiving uvolmia is th ovrarching thraputic goal rgardlss of typ (s Hart Failur sction in Chaptr 10). Typ 1 consists of AKI stmming from acut cardiac disas. Typ 2 is CKD du to chronic cardiac disas. Typ 3 is acut cardiac disas as a rsult of AKI. Typ 4 is chronic cardiac dcompnsation from CKD. Typ 5 con- sists of hart and kidny dysfunction du to othr acut or chronic systmic disordrs (such as spsis). Although novl agnts ar bing xamind for futur thrapis, th main- stay of tratmnt is to addrss th primary undrlying hart or kidny dysfunction.K umar U t al. Cardiornal syndrom: pathophysiology. Cardiol Clin. 2019;37:251. [PMID: 31279419] Raina R t al. An updat on th pathophysiology and tratmnt of cardiornal syndrom. Cardiol Rs. 2020;11:76. [PMID: 32256914] ChrONIC KIDNEY DISEASEE S S E N T I A L S  O F  D I A G N O S I S Decline in the GFR over months to years. Persistent proteinuria or abnormal renal morphol- ogy may be present. Hypertension in most cases. Symptoms and signs of uremia when nearing end- stage disease. Bilateral small or echogenic kidneys on ultrasound in advanced disease.CMDT22_Ch22_p0912-p0951.indd  922 02/07/21 2:33 PMKIDNEY DISEASE923 CMDT 2022 General ConsiderationsCKD affcts at last 10% of Amricans. Ma ny ar unawar of th condition bcaus thy rmain asymptomatic until th disas is nar nd stag. Th National Kidny Founda- tions staging systm hlps clinicians formulat practic plans (Tabl 224). Ovr 70% of cass of lat-stag CKD (stag 5 CKD and ESKD) in th Unitd Stats ar du to diabts mllitus or hyprtnsion/vascular disas. Glo- mrulonphritis, cystic disass, chronic tubulointrstitial disass, and othr urologic disass account for th rmaindr (Tabl 225). Gntic polymorphisms of th APOL-1 gn hav bn shown to b associatd with an incrasd risk of th dvlopmnt of CKD in prsons of African ancstry. CKD usually lads to a progrssiv dclin in kidny function vn if th inciting caus can b idntifid and tratd or rmovd. Dstruction of nphrons lads to compnsatory hyprtrophy and supranormal GFR of th rmaining nphrons in ordr to maintain ovrall homo- stasis. As a rsult, th srum cratinin may rmain rla- tivly normal vn in th fac of significant loss of rnal mass and is, thrfor, an insnsitiv markr for arly rnal damag and scarring. In addition, compnsatory hyprfiltration lads to ovrwork injury in th rmaining nphrons, which in turn causs progrssiv glomrular sclrosis and intrstitial fibrosis. Angiotnsin rcptor blockrs (ARBs) and ACE inhibitors can hlp rduc hyprfiltration injury and may slow th progrssion of protinuric CKD. Whil CKD is an indpndnt risk factor for cardiovas- cular disas (CVD), protinuric CKD confrs th highst risk. Most patints with stag 3 CKD di of undrlying CVD prior to progrssion to ESKD.Clinical FindingsA.  Symptoms and SignsStags  14 CKD ar asymptomatic. Symptoms dvlop slowly with th progrssiv dclin in GFR, ar nonsp- cific, and do not manifst until kidny disas is far advancd (GFR lss than 510 mL/min/1.73 m2). At this point, th accumulation of mtabolic wast products, or urmic toxins, rsults in th uremic syndrome . Gnral symptoms of urmia may includ fatigu, anorxia, nausa, and a mtallic tast in th mouth. Nurologic symptoms such as mmory impairmnt, insomnia, rstlss lgs, and twitching may b du to urmia. Gnralizd pruritus (without rash) may occur, as may dcrasd libido and mnstrual irrgularitis. Pricarditis, a rar complication of CKD, may prsnt with pluritic chst pain. Mdications that ar clard by th kidnys will accumulat as kidny function worsns and toxicity may nsu; an important xampl is insulin and an incrasing risk of significant hypoglycmia if doss ar not appropriatly rducd. Th most common physical finding in CKD is hypr- tnsion; this is du in part to impaird sodium xcrtion. It is oftn prsnt in arly stags of CKD and tnds to worsn with CKD progrssion. In latr stags of CKD, sodium rtntion may lad to clinically apparnt volum ovrload. Urmic signs ar sn with a profound dcras in GFR (lss than 510 mL/min/1.73 m2) and may includ a gnr- ally sallow and ill apparanc, halitosis (urmic ftor), and th urmic ncphalopathic signs of dcrasd mntal sta- tus, astrixis, myoclonus, and possibly sizurs. Symptoms and signs of urmia warrant immdiat hos- pital admission and nphrology consultation for initiation of dialysis. Th urmic syndrom is amlioratd with dialytic thrapy.Table 224. Stages of chronic kidney disease: a clinical action plan.1,2Stage 3Descition GFr (mL/min/1.73 m2) Action 1 Kidney damage with normal or GFR  90 Diagnosis and treatment of underlying etiology if possible. Treatment of comorbid conditions. Estimate progression, work to slow progression. Cardiovascular disease risk reduction.2 Kidney damage with mildly GFR 6089 3a Mildly-moderately GFR 4559 As above, and evaluating and treating complications. 3b Moderately-severely GFR 3044 4 Severely GFR 1529 Preparation for end-stage kidney disease. 5 End-stage kidney disease < 15 (or dialysis) Dialysis, transplant, or palliative care.1 Based on National Kidney Foundation, KDOQI, and KDIGO Chronic Kidney Disease Guidelines.2 Chronic kidney disease is defined as either kidney damage or GFR < 60 mL/min/1.73 m2for 3 or more months. Kidney damage is defined as pathologic abnormalities or markers of damage, including abnormalities in blood or urine tests or imaging studies.3 At all stages, persistent albuminuria confers added risk for chronic kidney disease progression and cardiovascular disease in t he following gradations: < 30 mg/day = lowest added risk, 30300 mg/day = mildly increased risk, > 3001000 mg/day = moderately increased ri sk, > 1000 mg/day = severely increased risk. GFR, glomerular filtration rate. Modified and reproduced, with permission, from Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2013 Jan;3(1) (Suppl):115 0. Copyright  2013 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.CMDT22_Ch22_p0912-p0951.indd  923 02/07/21 2:33 PMChApTEr 22924 CMDT 2022T able 225. Causes of chronic kidney disease.Glomeula  Diseases pimay glomeula diseases Focal segmental glomerulosclerosis Membranoproliferative glomerulonephritis IgA nephropathy Membranous nephropathy Alport syndrome (hereditary nephritis) Seconday glomeula diseases Diabetic nephropathy Renal amyloidosis Postinfectious glomerulonephritis HIV-associated nephropathy Collagen-vascular diseases (eg, SLE) HCV-associated membranoproliferative glomerulonephritis Tubulointestitial Neitis Drug hypersensitivity Heavy metals Analgesic nephropathy Reflux/chronic pyelonephritis Sickle cell nephropathy Idiopathic Cystic Diseases Polycystic kidney disease Medullary cystic disease Obstuctive Neoaties Prostatic disease Nephrolithiasis Retroperitoneal fibrosis/tumor Congenital/reflux Vascula Diseases Hypertensive nephrosclerosis Renal artery stenosis HCV, hepatitis C virus; SLE, systemic lupus erythematosus.Table 226. Reversible causes of kidney injury.revesible  Factos Diagnostic Clues Obstruction Post-void residual, bladder cath- eterization, renal ultrasound Extracellular fluid volume depletion or significant hypotension relative to baselineBlood pressure and pulse, including orthostatic pulse Hypercalcemia Serum electrolytes, calcium, phosphate Nephrotoxic agents Drug history Severe/urgent hypertension Blood pressure, chest radiograph Heart failure exacerbation Physical examination, chest radiograph  1 2 31 .0 0.9 0.7 0.5 0.3 0.1 1 2 3 4 5 6 7 8 9 1 01/ScrTime  (years)1 Value of serum creatinine level = 1 .0 mg/dL2 Value of serum creatinine level = 2.0 mg/dL3 Value of serum creatinine level = 5.0 mg/dL Figure 221. Decline in kidney function (expressed as the reciprocal of serum creatinine as shown here, or as estimated glomerular filtration rate [eGFR]) plotted against time to ESKD. The solid line indicates the linear decline in kidney function over time. The dotted line indicates the approximate time to ESKD.In any patint with kidny disas, it is important to idntify and corrct all possibly rvrsibl insults or xac- rbating factors (Tabl 226). Urinary obstruction, hypo- volmia, hypotnsion, nphrotoxins (such as NSAIDs, aminoglycosids, or proton pump inhibitors), svr or mrgnt hyprtnsion, and hart failur xacrbation should b xcludd.B.  Laboratory FindingsCKD is u sually dfind by an abnormal GFR prsisting for at last 3 months. Prsistnt protinuria or abnormalitis on rnal imaging (g, polycystic kidnys or a singl kidny) ar also diagnostic of CKD, vn whn GFR is normal. If multipl masurmnts of GFR ovr tim ar availabl, th rat of progrssion should b assssd (Figur 221). If th slop of th lin acutly dclins, potntially rvrsibl rnal insults should b xcludd. Anmia, hyprphospha- tmia, hypocalcmia, hyprkalmia, and mtabolic acido- sis ar common complications of advancd CKD. Th urinary sdimnt may show broad waxy casts as a rsult ofdilatd, hyprtrophic nphrons. If protinuria is prsnt, it should b quantifid as dscribd abov. This can hlp nar- row th diffrntial diagnosis of th tiology of th CKD (Tabl 225); for xampl, glomrular disass tnd to prsnt with protin xcrtion of mor than 1 g/day. Addi- tionally, highr urinary protin xcrtion is associatd with mor rapid progrssion of CKD and incrasd risk of car- diovascular mortality.CMDT22_Ch22_p0912-p0951.indd  924 02/07/21 2:33 PMKIDNEY DISEASE925 CMDT 2022C.  ImagingTh  finding of small, chognic kidnys bilatrally (lss than 910 cm) by ultrasonography suggsts th chronic scarring of advancd CKD. Larg kidnys can b sn with adult polycystic kidny disas, diabtic nphropathy, HIV-associatd nphropathy, plasma cll myloma, amy- loidosis, and obstructiv uropathy. ComplicationsTh  complications of CKD tnd to occur at rlativly pr- dictabl stags of disas as notd in Figur 222.A.  Cardiovascular ComplicationsPa tints with CKD xprinc gratr morbidity and mor- tality from CVD in comparison to th gnral population. Roughly 80% of patints with CKD di bfor raching ESKD, primarily of CVD. Of thos undrgoing dialysis, 45% will di of a cardiovascular caus. Th mchanisms for nhancd cardiovascular mortality in CKD ar complx and includ abnormal phosphorus and calcium homosta- sis, incrasd burdn of oxidativ strss, incrasd vascular ractivity, lft vntricular hyprtrophy, and coxistnt con- ditions such as hyprtnsion and diabts mllitus. 1. Hypertension Hyprtnsion is th most common complication of CKD; it tnds to b progrssiv and salt- snsitiv. Hyprrninmic stats and xognous rythro- poitin administration can xacrbat hyprtnsion. As with othr patint populations, control of hyprtn- sion should focus on both pharmacologic and nonpharma- cologic thrapy (g, dit, xrcis, wight loss, tratmnt of obstructiv slp apna). CKD rsults in disturbd sodium homostasis such that th ability of th kidny to adjust to variations in sodium and watr intak bcoms limitd as GFR dclins. A low salt dit (2 g/day) is oftn ssntial to control blood prssur and hlp avoid ovrt volum ovr- load. Diurtics ar narly always ndd to hlp control hyprtnsion (s Tabl 118); thiazids work wll in arly CKD, but loop diurtics may b mor ffctiv in thoswith a GFR lss than 30 mL/min/1.73 m2. Howvr, vol- um contraction as a rsult of vry low sodium intak (spcially with intrcurrnt illnss) or ovr-diursis in th prsnc of impaird sodium homostasis can rsult in AKI. Initial drug thrapy for protinuric patints should includ ACE inhibitors or ARBs (s Tabl 116); howvr, thr is no vidnc of supriority of ths drugs ovr othr drug classs for nonprotinuric CKD. Whn an ACE inhibitor or an ARB is initiatd or uptitratd, patints must hav srum cratinin and potassium chckd within 714 days. A ris in srum cratinin gratr than 30% from baslin mandats dos rduction or cssation of th drug. Hyprkalmia may also warrant drug cssation, xcpt in th rliabl patint who can follow a low-potas- sium dit and adhr to a potassium-binding rsin; such patints should b monitord closly. An ACE inhibitor and ARB should not b usd in combination. CKD is a common caus of rfractory hyprtnsion for which agnts from multipl classs ar oftn ndd. Currnt guidlins diffr with rspct to blood prssur goals in CKD; thos from th Joint National Commission suggst a goal of lss than 140/90 mm Hg, whil th Amrican Hart Associa- tion advocats for lss than 130/80 mm Hg. As patints with CKD ar at risk for rnal hypoprfusion and AKI with ovrtratmnt of hyprtnsion, it is prudnt to individual- iz th approach to blood prssur control to ach patint. 2. Coronary artery disease Patints with CKD ar at highr risk for dath from CVD than th gnral popula- tion. Traditional modifiabl risk factors for CVD, such as hyprtnsion, tobacco us, and hyprlipidmia, should b aggrssivly tratd. Urmic vascular calcification involv- ing disordrd phosphorus homostasis and othr mdia- tors may also b a cardiovascular risk factor in ths patints. 3. Heart failure CKD complications rsult in incrasd cardiac workload du to hyprtnsion, volum ovrload, and anmia. Patints may also hav acclratd rats of athrosclrosis and vascular calcification rsulting in vssl stiffnss. All of ths factors contribut to lft vntricularPTHGlomerular filtration  rate (mL/min/1.73 m2)PhosphorusHTN Anemia Acidosis, hyperkalemia Uremic syndromeCKD stage5 4 3 20 20 40 60 80 100 Figure 222. Complications of chronic kidney disease (CKD) by stage and glomerular filtration rate (GFR). Compli- cations arising from CKD tend to occur at the stages depicted, although there is considerable variability noted in clin- ical practice. HTN, hypertension; PTH, parathyroid hormone. (Adapted, with permission, from William Bennett, MD.)CMDT22_Ch22_p0912-p0951.indd  925 02/07/21 2:33 PMChApTEr 22926 CMDT 2022hyprtrop hy and hart failur with prsrvd jction frac- tion, which is common in CKD. Ovr tim, hart failur with dcrasd jction fraction may dvlop. Diurtic thrapy, in addition to fluid and salt rstriction, is usually ncssary; diurtic dos scalation may b ndd as kid- ny function dclins. ACE inhibitors and ARBs can b usd for patints with advancd CKD with clos monitor- ing of blood prssur as wll as for hyprkalmia and wors- ning kidny function; minralocorticoid rcptor antagonists may b usd with similar prcautions but should b discontinud whn GFR is lss than 30 mL/ min/1.73 m2. SGLT2 inhibitors hav bn shown to improv outcoms for both hart failur and CKD. 4. Atrial fibrillation Patints with advancd CKD and ESKD suffr disproportionat rats of atrial fibrillation, which approach 20% in patints rciving dialysis. Whil thos with up to CKD stag 4 should b tratd as th gn- ral population, anticoagulation for prvntion of throm- bombolic vnts bcoms challnging in thos with ESKD du to compting risks of blding and clotting as wll as a lack of data supporting its routin us. 5. Pericarditis Pricarditis rarly dvlops in urmic patints; typical findings includ pluritic chst pain and a friction rub. Cardiac tamponad can occur; thrfor, ur- mic pricarditis is a mandatory indication for hospitaliza- tion and initiation of hmodialysis.Bangalor  S t al. Managmnt of coronary disas in patints with advancd kidny disas. N Engl J Md. 2020;382:1608. [PMID: 32227756] Fay KS t al. Rsistant hyprtnsion in popl with CKD: a rviw. Am J Kidny Dis. 2021;77:110. [PMID: 32712185] Gurrot D t al. Blood prssur targts in chronic kidny disas: an updat on th vidnc. Curr Opin Nphrol Hyprtns. 2020;29:327. [PMID: 32167996] Packr M t al; EMPEROR-Rducd Trial Invstigators. Cardio- vascular and rnal outcoms with mpagliflozin in hart failur. N Engl J Md. 2020;383:1413. [PMID: 32865377] Palmr BF. Potassium bindrs for hyprkalmia in chronic kidny disasdit, rnin-angiotnsin-aldostron systm inhibitor thrapy, and hmodialysis. Mayo Clin Proc. 2020;95: 339. [PMID: 31668450]B.  Metabolic Bone DiseaseTh mtabolic b on disas of CKD rfrs to th complx disturbancs of calcium and phosphorus mtabolism, parathyroid hormon (PTH), activ vitamin D, and fibro- blast growth factor-23 (FGF-23) homostasis (s Chaptr 21 and Figur 223). A typical pattrn sn as arly as CKD stag 3 is hyprphosphatmia, hypocalcmia, and hypovitaminosis D, rsulting in scondary hyprparathy- roidism. Ths abnormalitis can contribut to vascular calcification and may b rsponsibl in part for th acclr- atd CVD and xcss mortality sn in th CKD popula- tion. Epidmiologic studis show an association btwn lvatd phosphorus lvls and incrasd risk of cardiovas- cular mortality in arly CKD through ESKD. As yt, thr ar no intrvntion trials suggsting th bst cours of tratmnt in ths patints; control of minral and PTH lvls pr currnt guidlins is discussd blow.Bon disas, or rnal ostodystrophy, in advancd CKD is common and thr ar svral typs of lsions. Rnal ostodystrophy can b diagnosd only by bon biopsy, which is rarly don. Th most common bon dis- as, ostitis fibrosa cystica, is a rsult of scondary hypr- parathyroidism and th ostoclast-stimulating ffcts of PTH. This is a high-turnovr disas with bon rsorption and subpriostal lsions; it can rsult in bon pain and proximal muscl waknss. Adynamic bon disas, or low-bon turnovr, is bcoming mor common; it may rsult iatrognically from supprssion of PTH or via spon- tanously low PTH production. Ostomalacia is charactr- izd by lack of bon minralization. In th past, ostomalacia was associatd with aluminum toxicityithr as a rsult of chronic ingstion of prscribd aluminum-containing phosphorus bindrs or from high lvls of aluminum in impur dialysat watr. Currntly, ostomalacia is mor likly to rsult from hypovitaminosis D; thr is also tho- rtical risk of ostomalacia associatd with us of bisphos- phonats in advancd CKD. All of th abov ntitis incras th risk of fracturs. Tratmnt may involv corrction of calcium, phosphorus, and 25-OH vitamin D lvls toward normal valus, and mitigation of hyprparathyroidism. Undrstanding th intrplay btwn ths abnormalitis can hlp targt thrapy (Figur 223). Dclining GFR lads to phosphorus rtntion. This rsults in hypocalcmia as phosphorus complxs with calcium, dposits in soft tissus, and stim- ulats PTH. Loss of rnal mass and low 25-OH vitamin D lvls oftn sn in CKD patints rsult in low 1,25(OH) vitamin D production by th kidny. Bcaus 1,25(OH) vitamin D is a supprssor of PTH production, hypovita- minosis D also lads to scondary hyprparathyroidism. Th first stp in tratmnt of mtabolic bon disas is control of hyprphosphatmia. This involvs ditary phos- phorus rstriction initially (s sction on ditary manag- mnt), followd by th administration of oral phosphorus bindrs if targts ar not achivd. Oral phosphorus bind- rs block absorption of ditary phosphorus in th gut and ar givn thric daily with mals. Ths should b titratd to a nar-normal srum phosphorus lvl. Calcium- containing bindrs (calcium carbonat, 650 mg/tablt, or calcium actat, 667 mg/capsul, usd at doss of on to thrGFR25(OH) Vitamin D PTH CalciumPhosphorus 1,25(OH) Vitamin D Figure 223. Mineral abnormalities of CKD. Decline in glomerular filtration rate (GFR) and loss of renal mass lead directly to increased serum phosphorus and hypo- vitaminosis D. Both of these abnormalities result in hypocalcemia and hyperparathyroidism. Many CKD patients also have nutritional 25(OH) vitamin D defi- ciency. PTH, parathyroid hormone.CMDT22_Ch22_p0912-p0951.indd  926 02/07/21 2:33 PMKIDNEY DISEASE927 CMDT 2022pills  pr mal) ar rlativly inxpnsiv but may contribut to positiv calcium balanc and vascular calcification; ovrt hyprcalcmia may also occur. Currnt guidlins suggst limiting thir us in favor of th non-calciumcontaining bindrs svlamr carbonat (8003200 mg/mal) and lanthanum carbonat (5001000 mg/mal). Nwr, iron- basd phosphorus bindrs includ frric citrat and sucro- frric oxyhydroxid and may b considrd whn othr bindrs ar not tolratd ithr du to hyprcalcmia or constipation. Thy should b avoidd in patints with iron ovrload. Aluminum hydroxid is a highly ffctiv phos- phorus bindr but can caus ostomalacia and nurologic complications whn usd long-trm; it can b usd in th acut stting for svr hyprphosphatmia or for short priods (g, 3 wks) in CKD patints. Onc srum phosphorus lvls ar controlld, activ vitamin D (1,25[OH] vitamin D, or calcitriol) or othr vita- min D analogs ar usd to trat scondary hyprparathy- roidism in advancd CKD and ESKD. Srum 25-OH vitamin D lvls should b masurd and brought to nor- mal (s Chaptr 26) prior to considring administration of activ vitamin D. Activ vitamin D (calcitriol) incrass srum calcium and phosphorus lvls; both nd to b monitord closly during calcitriol thrapy, and its dos should b dcrasd if hyprcalcmia or hyprphosphat- mia occurs. Typical calcitriol dosing is 0.25 or 0.5 mcg orally daily or vry othr day. Cinacalct targts th cal- cium-snsing rcptors of th parathyroid gland and sup- prsss PTH production. Cinacalct, 3090 mg orally onc a day, can b usd if lvatd srum phosphorus or calcium lvls prohibit th us of vitamin D analogs; it can caus srious hypocalcmia, and patints should b closly moni- tord for this complication. Optimal PTH lvls in CKD ar not known, but bcaus skltal rsistanc to PTH dvlops with urmia, rlativly high lvls ar targtd in advancd CKD to avoid adynamic bon disas. Exprt guidlins suggst goal PTH lvls nar or just abov th uppr limit of normal for modrat CKD, and at last twofold and up to ninfold th uppr limit of normal for ESKD.Ev npol P t al. Europan Consnsus Statmnt on th diag- nosis and managmnt of ostoporosis in chronic kidny disas stags G4-G5D. Nphrol Dial Transplant. 2021;36:42. [PMID: 33098421] Scialla JJ t al. Stat-of-th-art managmnt of hyprphosphat- mia in patints with CKD: an NKF-KDOQI controvrsis prspctiv. Am J Kidny Dis. 2021;77:132. [PMID: 32771650]C.  Hematologic Complications1.  Anemia Th anmia of CKD, primarily du to dcrasd rythropoitin production, oftn bcoms clini- cally significant during stag 3 CKD. CKD is also associ- atd with high lvls of hpcidin, which blocks GI iron absorption and mobilization of iron from body stors; this rsults in a functional iron dficincyth so-calld an- mia of chronic disas.  Th approach to a patint with CKD and anmia bgins with nsuring that th bon mar- row can rspond to rythropoitin. Thus, thyroid function tsts, srum vitamin B12lvls, and iron stors (frritin and iron saturation) should b chckd. Iron stors ar targtdto highr goals du to a functional blockad of iron utiliza- tion in this population. In CKD, a srum frritin blow 100200 ng/mL or iron saturation lss than 20% is suggs- tiv of iron dficincy. Iron stors may b rpltd with oral or parntral iron; iron thrapy should probably b withhld if th srum frritin is gratr than 500800 ng/mL, vn if th iron saturation is lss than 20%. Oral thrapy with fr- rous sulfat, gluconat, or fumarat, 325 mg onc daily, is th initial thrapy in pr-ESKD CKD; highr doss will rsult in incrasing hpcidin lvls. For thos who do not rspond du to poor GI absorption or lack of tolranc, intravnous iron (g, iron sucros or iron gluconat) may b ncssary. Erythropoisis-stimulating agnts (ESAs, g, rcombi- nant rythropoitin [potin alfa or bta] and darbpo- tin) ar usd to trat th anmia of CKD if othr tratabl causs ar xcludd. Thr is likly no bnfit of starting an ESA bfor hmoglobin (Hgb) valus ar lss than 9 g/dL. Th starting dos of potin alfa is 50100 units/kg onc or twic a wk, and darbpotin is startd at 0.45 mcg/kg and administrd vry 24 wks; potin bta at a starting dos of 60100 mcg is givn vry 24 wks. Ths agnts can b givn intravnously (g, to th hmodialysis patint) or subcutanously (to both th prdialysis or dialysis patint); subcutanous dosing of potin alfa is roughly 30% mor ffctiv than intravnous dosing. ESAs should b titratd to an Hgb of 1011 g/dL for optimal safty; studis show that targting a highr Hgb incrass th risk of strok and possibly othr cardiovascular vnts. Whn titrating doss, Hgb lvls should ris no mor than 1 g/dL vry 34 wks. Hyprtnsion is a common complication of tratmnt with ESAs. 2. Coagulopathy Th blding diathsis that may occur in stag 45 CKD is mainly du to platlt dysfunction, but svr anmia may also contribut. Tratmnt is rquird only in patints who ar symptom- atic. Raising th Hgb to 910 g/dL in anmic patints can rduc risk of blding via improvd clot formation. Dsmo- prssin (25 mcg intravnously vry 812 hours for two doss) is a short-livd but ffctiv tratmnt for platlt dysfunction and it is oftn usd in prparation for surgry or kidny biopsy; hyponatrmia is a potntial advrs ffct of this tratmnt. Dialysis improvs th blding tim.Locatlli  F t al. Ar all rythropoisis-stimulating agnts cratd qual? Nphrol Dial Transplant. 2020. [Epub ahad of print] [PMID: 32206785]D . HyperkalemiaPo tassium balanc gnrally rmains intact in CKD until stags 45. Howvr, hyprkalmia may occur at arlir stags whn crtain conditions ar prsnt, such as typ 4 rnal tubular acidosis (sn in patints with diabts ml- litus), high potassium dits, or mdications that dcras rnal potassium scrtion (amilorid, triamtrn, spi- ronolacton, plrnon, NSAIDs, ACE inhibitors, ARBs) or block cllular potassium uptak (bta-blockrs). Othr causs includ acidmic stats and any typ of cllular dstruction causing rlas of intracllular contnts, such as hmolysis and rhabdomyolysis.CMDT22_Ch22_p0912-p0951.indd  927 02/07/21 2:33 PMChApTEr 22928 CMDT 2022T ratmnt of acut hyprkalmia is discussd in Chaptr 21 (s Tabl 215). Cardiac monitoring is indi- catd for any ECG changs sn with hyprkalmia or a srum potassium lvl gratr than 6.06.5 mEq/L or mmol/L. Chronic hyprkalmia is bst tratd with ditary potassium rstriction (2 g/day) and minimization or limi- nation of any mdications that may impair rnal potassium xcrtion, as notd abov. Loop diurtics may b adminis- trd for thir kaliurtic ffct as long as th patint is not volum-dpltd, and oral potassium-binding rsins may b considrd.Palmr  BF t al. Clinical managmnt of hyprkalmia. Mayo Clin Proc. 2021;96:744. [PMID: 33160639]E.  AcidBase DisordersDamagd kidnys  ar unabl to xcrt th 1 mEq/kg/day of acid gnratd by mtabolism of ditary animal protins in th typical Wstrn dit. Th rsultant mtabolic acido- sis is primarily du to dcrasd GFR; proximal or distal tubular dfcts may contribut to or worsn th acidosis. Excss hydrogn ions ar buffrd by bon; th consqunt laching of calcium and phosphorus from th bon con- tributs to th mtabolic bon disas dscribd abov. Chronic acidosis can also rsult in muscl protin catabo- lism as wll as growth rtardation in childrn with CKD and may acclrat progrssion of CKD. Rduction of ditary animal protin and incrasd fruit and vgtabl intak, and th administration of oral sodium bicarbonat (in doss of 0.51.0 mEq/kg/day dividd twic daily and titratd as ndd) ar stratgis to bring srum bicarbon- at lvls toward normal. Citrat salts incras th absorp- tion of ditary aluminum and should b avoidd in CKD.Na vanthan SD t al. Effcts of tratmnt of mtabolic acidosis in CKD: a systmatic rviw and mta-analysis. Clin J Am Soc Nphrol. 2019;14:1011. [PMID: 31196951]F . Neurologic ComplicationsUrmic  ncphalopathy, rsulting from th aggrgation of urmic toxins, dos not occur until GFR falls blow 510 mL/min/1.73 m2. Symptoms bgin with difficulty in concntrating and can progrss to lthargy, confusion, si- zur, and coma. Physical findings may includ altrd mntal status, waknss, and astrixis. Ths findings improv with dialysis. Othr nurologic complications that can manifst with advancd CKD includ priphral nuropathis (stocking- glov or isolatd mononuropathis), rctil dysfunction, autonomic dysfunction, and rstlss lg syndrom. Ths may not improv with dialysis thrapy.G.  Endocrine DisordersDcrasd  libido and rctil dysfunction ar common in advancd CKD. Mn hav dcrasd tstostron lvls; womn ar oftn anovulatory. Womn with srum crati- nin lss than 1.4 mg/dL ar not at incrasd risk for poor outcoms in prgnancy; howvr, thos with srumcratinin gratr than 1.4 mg/dL may xprinc fastr progrssion of CKD with prgnancy. Ftal survival is not compromisd, howvr, unlss CKD is advancd. TreatmentA.  Slowing ProgressionT ratmnt of th undrlying caus of CKD is vital. Control of diabts should b aggrssiv in arly CKD; howvr, risk of hypoglycmia incrass in advancd CKD, and gly- cmic targts may nd to b rlaxd to avoid this dangr- ous complication. Blood prssur control is vital to slow progrssion of all forms of CKD; agnts that block th rnin-angiotnsin-aldostron systm ar particularly important in protinuric patints. Obs patints should b ncouragd to los wight. Managmnt of traditional car- diovascular risk factors is vital. Risks for AKI should b minimizd or avoidd, including long-trm us of NSAIDs. Tratmnt of mtabolic acidosis may b hlpful. Th ffi- cacy of SGLT2 inhibition for slowing progrssion of CKD in thos with and without diabts or significant protin- uria has bn dmonstratd in svral rcnt trials.Han nan M t al. Risk factors for CKD progrssion: ovrviw of findings from th CRIC study. Clin J Am Soc Nphrol. 2021;16:648. [PMID: 33177074] Hrspink HJL t al; DAPA-CKD Trial Committs and Invsti- gators. Dapagliflozin in patints with chronic kidny disas. N Engl J Md. 2020;383:1436. [PMID: 32970396] Klly JT t al. Modifiabl lifstyl factors for primary prvntion of CKD: a systmatic rviw and mta-analysis. J Am Soc Nphrol. 2021;32:239. [PMID: 32868398]B.  Dietary ManagementPa tints with CKD should b valuatd by a rnal nutri- tionist. Patint-spcific rcommndations should b mad concrning protin, salt, watr, potassium, and phosphorus intak to hlp manag CKD progrssion and complications. 1. Protein restriction Thr is incrasing intrst in plant-basd dits for th tratmnt of CKD. Rducd intak of animal protin to 0.60.8 g/kg/day may slow CKD progrssion. Howvr, significant protin rstriction is not advisabl in thos with cachxia or low srum albu- min in th absnc of th nphrotic syndrom. 2. Salt and water restriction In advancd CKD, th kid- ny is unabl to adapt to larg changs in sodium intak. Intak of gratr than 34 g/day can lad to hyprtnsion and hyprvolmia, whras intak of lss than 1 g/day can lad to volum dpltion and hypotnsion. A goal of 2 g/day of sodium is rasonabl for most patints. Daily fluid rstriction to 2 L may b ndd if volum ovrload is prsnt. 3. Potassium restriction Rstriction is ndd onc th GFR has falln blow 1020 mL/min/1.73 m2, or arlir if th patint is hyprkalmic. Patints should rciv dtaild lists dscribing potassium contnt of foods and should limit thir intak to lss than 5060 mEq/day (2 g/day). An aggrssiv bowl rgimn should b institutd for patints with hyprkalmia (mor than two bowl movmntsCMDT22_Ch22_p0912-p0951.indd  928 02/07/21 2:33 PMKIDNEY DISEASE929 CMDT 2022daily),  sinc a highr prcntag of potassium is xcrtd through th GI tract as GFR dclins. Potassium-binding rsins may b usd (s sction on Hyprkalmia). 4. Phosphorus restriction Guidlins suggst lowring lvatd srum phosphorus lvls toward normal in all stags of CKD. Ditary phosphat rstriction to 8001000 mg/day is th first stp. Procssd foods and cola bvrags ar oftn prsrvd with highly bioavailabl phosphorus and should b avoidd. Foods rich in phos- phorus such as ggs, dairy products, nuts, bans, and mat may also nd to b limitd, although car must b takn to avoid protin malnutrition. Whn GFR is lss than 2030 mL/min/1.73 m2, ditary rstriction is rarly suffi- cint to rach targt lvls, and phosphorus bindrs ar usually rquird (s sction on Mtabolic Bon Disas).Ikizlr T A t al. KDOQI clinical practic guidlin for nutrition in CKD: 2020 updat. Am J Kidny Dis. 2020;76:S1. [PMID: 32829751] Joshi S t al. Plant-basd dits for kidny disas: a guid for clinicians. Am J Kidny Dis. 2021;77:287. [PMID: 33075387]C.  Medication ManagementMan y drugs ar xcrtd by th kidny; dosags should b adjustd for GFR. Dcrasd rnal limination of insulin in advancd CKD confrs risk for hypoglycmia in tratd diabtic patints. Doss of oral hypoglycmics and insulin may nd rduction. Th risk of lactic acidosis with mt- formin is du to both dos and GFR; it should b discon- tinud whn GFR is lss than 30 mL/min/1.73 m2. Magnsium-containing mdications, such as laxativs or antacids, and phosphorus-containing mdicins (g, cathartics) should b avoidd. Activ morphin mtabo- lits can accumulat in advancd CKD; this problm is not ncountrd with othr opioid agnts. Drugs with potn- tial nphrotoxicity (NSAIDs, intravnous contrast, as wll as othrs notd in th Acut Kidny Injury sction) should b avoidd. Proton pump inhibitors should b usd only whn mdically ncssary.Shaddock  R t al. Rnal rprcussions of mdications. Prim Car. 2020;47:691. [PMID: 33121637]D . Treatment of ESKDWhn  GFR dclins to 510 mL/min/1.73 m2, rnal rplac- mnt thrapy (hmodialysis, pritonal dialysis, or kidny transplantation) is rquird to sustain lif. Patint ducation is important in undrstanding which mod of thrapy is most suitabl, as is timly prparation for tratmnt. Rfr- ral to a nphrologist has bn shown to improv mortality and thrfor should tak plac in lat stag 3 CKD or whn th GFR is dclining rapidly. Prparation for ESKD trat- mnt rquirs a tam approach with th involvmnt of diticians, social workrs, primary car clinicians, and nphrologists. For vry ldrly patints, or thos with mul- tipl dbilitating or lif-limiting comorbiditis, dialysis thrapy may not maningfully prolong lif, and th option of palliativ car should b discussd with th patint andfamily. Convrsly, for patints who ar othrwis rlativly halthy, valuation for possibl kidny transplantation should b considrd prior to initiation of dialysis. 1. Dialysis Dialysis initiation should b considrd whn GFR is nar 10 mL/min/1.73 m2and urmic symptoms ar prsnt. Othr indications for dialysis, which may occur whn GFR is 1015 mL/min/1.73 m2, ar fluid ovrload unrsponsiv to diursis and rfractory hyprkalmia. a. Hemodialysis Vascular accss for hmodialysis can b accomplishd by an artriovnous fistula (th prfrrd mthod) or prosthtic graft; cration of dialysis accss should b considrd wll bfor dialysis initiation. An indwlling cathtr is usd whn thr is no usabl vascu- lar accss. Bcaus cathtrs confr a high risk of blood- stram infction, thy should b considrd a tmporary masur. Nativ fistulas typically last longr than pros- thtic grafts but rquir a longr tim aftr surgical construction for maturation (68 wks for a fistula vrsus 2 wks for a graft). Infction, thrombosis, and anurysm formation ar complications sn mor oftn in grafts than fistulas. Staphylococcus spcis ar th most common caus of soft tissu infctions and bactrmia. Tratmnt at a hmodialysis cntr typically occurs thr tims a wk. Sssions last 35 hours, dpnding on patint siz and typ of dialysis accss. Hom hmodialysis is oftn prformd mor frquntly (36 days pr wk for shortr sssions) and rquirs a traind hlpr. Rsults of trials comparing quotidian modalitis (nocturnal and fr- qunt hom hmodialysis) to convntional in-cntr dialy- sis hav not thus far shown significant mortality diffrncs, but thr may b improvmnts in blood prssur control, minral mtabolism, and quality of lif. b. Peritoneal dialysis With pritonal dialysis, th pritonal mmbran is th dialyzr.  Thr ar diffrnt kinds of pritonal dialysis: continu- ous ambulatory pritonal dialysis (CAPD), in which th patint xchangs th dialysat four to six tims a day manually; and continuous cyclic pritonal dialysis (CCPD), which utilizs a cyclr machin to automatically prform xchangs at night. Th most common complication of pritonal dialysis is pritonitis. Pritonitis may prsnt with nausa and vom- iting, abdominal pain, diarrha or constipation, and fvr. Th normally clar dialysat bcoms cloudy; and a diagnostic pritonal fluid cll count gratr than 100 whit blood clls/mcL (0.1  109/L) with a diffrn- tial of gratr than 50% polymorphonuclar nutrophils is prsnt. Staphylococcus aureus is th most common infcting organism, but strptococci and gram-ngativ spcis may also b causativ. Empiric intrapritonal administration of ithr vancomycin or a first-gnration cphalosporin (cfazolin) plus a third-gnration cph- alosporin (cftazidim) should b institutd with th first signs of pritonitis and subsquntly tailord basd on cultur rsults. 2. Kidney transplantation Many patints with ESKD ar othrwis halthy nough to b suitabl for transplan- tation, although standard critria for rcipint slctionCMDT22_Ch22_p0912-p0951.indd  929 02/07/21 2:33 PMChApTEr 22930 CMDT 2022ar  lacking btwn transplant cntrs. Two-thirds of kidny allografts com from dcasd donors, with th rmaindr from living rlatd or unrlatd donors. Ovr 100,000 patints ar on th waiting list for a dcasd donor transplant in th Unitd Stats; th avrag wait is 37 yars, dpnding on gographic location and rcipint blood typ. 3. Medical management of ESKD As notd abov, som patints ar not candidats for kidny transplanta- tion and may not bnfit from dialysis. Vry ldrly prsons may di soon aftr dialysis initiation; thos who do not may nonthlss rapidly los functional status in th first yar of tratmnt. Th dcision to initiat dialy- sis in patints with limitd lif xpctancy should b wighd against possibl dtrioration in quality of lif. For patints with ESKD who lct not to undrgo dialysis or who withdraw from dialysis, progrssiv urmia with gradual supprssion of snsorium rsults in a painlss dath within days to months. Involvmnt of a palliativ car tam is ssntial.Fost r JG t al. Car of th rnal transplant patint. Prim Car. 2020;47:703. [PMID: 33121638] Zarantonllo D t al. Novl consrvativ managmnt of chronic kidny disas via dialysis-fr intrvntions. Curr Opin Nphrol Hyprtns. 2021;30:97. [PMID: 33186220] Prognosis in ESKDCompard  with kidny transplant rcipints and ag- matchd controls, mortality is highr for patints undrgo- ing dialysis. Thr is likly littl diffrnc in survival for wll-matchd pritonal vrsus hmodialysis patints. Survival rats on dialysis dpnd on th undrlying disas procss. Fiv-yar Kaplan-Mir survival rats vary from 37% for patints with diabts to 54% for patints with glomrulonphritis. Ovrall 5-yar survival is cur- rntly stimatd at 40%. Patints undrgoing dialysis hav an avrag lif xpctancy of 35 yars, but survival for as long as 25 yars may b achivd dpnding on comorbidi- tis. Th most common caus of dath is cardiac disas (mor than 50%). Othr causs includ infction, crbro- vascular disas, and malignancy. When to Refer A patint with stag 35 CKD should b rfrrd to a nphrologist for managmnt in conjunction with th primary car providr. A patint with othr forms of CKD such as thos with protinuria gratr than 1 g/day or polycystic kidny disas should b rfrrd to a nphrologist at arlir stags. When to Admit Admission should b considrd for dcompnsation of problms rlatd to CKD, such as worsning of acid- bas status, lctrolyt abnormalitis, and volum ovr- load, that cannot b appropriatly tratd in th outpatint stting.Admission is appropriat whn a patint nds to start dialysis and is not stabl for its outpatint initiation.Charls  C t al. Chronic kidny disas. Prim Car. 2020;47:585. [PMID: 33121630] Li PK t al. Kidny halth for vryon vrywhrfrom pr- vntion to dtction and quitabl accss to car. Clin Nphrol. 2020;93:111. [PMID: 32017699] Shlipak MG t al. Th cas for arly idntification and intrvn- tion of chronic kidny disas: conclusions from a Kidny Disas: Improving Global Outcoms (KDIGO) Controvr- sis Confrnc. Kidny Int. 2021;99:34. [PMID: 33127436] Stnvinkl P t al. A plantary halth prspctiv for kidny disas. Kidny Int. 2020;98:261. [PMID: 32709283]RE NAL ARTERY STENOSISE S S E N T I A L S  O F  D I A G N O S I S Produced by atherosclerotic occlusive disease (8090% of patients) or fibromuscular dysplasia (1015%). Hypertension. AKI in patients starting ACE inhibitor therapy if stenosis is bilateral. General ConsiderationsA pproximatly 5% of Amricans with hyprtnsion suffr from rnal artry stnosis. Athrosclrotic ischmic rnal disas accounts for most cass of rnal artry stnosis. It typically occurs among prsons ovr 45 yars of ag with additional risk factors such as CKD, diabts mllitus, and tobacco us. Fibromuscular dysplasia is a lss common caus of rnal artry stnosis that most commonly occurs in young womn. Clinical FindingsA.  Symptoms and SignsPa tints with athrosclrotic ischmic rnal disas may hav rfractory hyprtnsion, nw-onst hyprtnsion (in an oldr patint), pulmonary dma with poorly controlld blood prssur, and AKI upon starting an ACE inhibitor or ARB. Physical xamination may rval an audibl abdomi- nal bruit on th affctd sid. Unxplaind hyprtnsion in a woman youngr than 40 yars should rais suspicion for fibromuscular dysplasia.B.  Laboratory FindingsBUN and s rum cratinin may b lvatd if thr is sig- nificant rnal ischmia. Patints with bilatral rnal artry stnosis may hav hypokalmia, a finding that rflcts activation of th rnin-angiotnsin-aldostron systm in rspons to rducd blood flow (a prrnal stat).CMDT22_Ch22_p0912-p0951.indd  930 02/07/21 2:33 PMKIDNEY DISEASE931 CMDT 2022C.  ImagingA bdominal ultrasound can rval ithr asymmtric kid- ny siz if on rnal artry is affctd mor than th othr or small hyprchoic kidnys if both ar affctd. Scrning with Dopplr ultrasonography, CT angiogra- phy, or magntic rsonanc angiography (MRA) is rcom- mndd if a corrctiv procdur would b prformd whn a positiv tst rsult is found. Doppler ultrasonogra- phyis highly snsitiv and spcific (85% and 92%, rspc- tivly) and rlativly inxpnsiv but is xtrmly oprator and patint dpndnt. CT angiography consists of intravnous contrast injc- tion with digital subtraction artriography. Th snsitivi- tis from various studis rang from 77% to 98%, with spcificitis of 9094%. MRA is an xcllnt but xpnsiv way to scrn for rnal artry stnosis, particularly in thos with athroscl- rotic disas. Snsitivity is 77100% and spcificity rangs from 71% to 96%. Th imaging agnt for MRA (gadolin- ium) has bn associatd with nphrognic systmic fibro- sis, which is discussd lswhr undr Nphrognic Systmic Fibrosis. Renal angiography is th gold standard for diagnosis, but it is mor invasiv than th thr scrning tsts dis- cussd abov. Thus, it is prformd aftr a positiv scrn- ing tst. Lsions ar most commonly found in th proximal third or ostial rgion of th rnal artry. Th risk of athro- mbolic phnomna aftr angiography rangs from 5% to 10%. Fibromuscular dysplasia has a charactristic bads- on-a-string apparanc on angiography. TreatmentT ratmnt of athrosclrotic ischmic rnal disas is con- trovrsial. Options includ mdical managmnt, angio- plasty with or without stnting, and surgical bypass. Two larg randomizd trials showd that vascular intrvntion is no bttr than optimal mdical managmnt in patints with rnal artry stnosis, xcpt in slctd circumstancs (g, patints with rcurrnt pisods of flash pulmonary dma). Angioplasty might rduc th numbr of antihy- prtnsiv mdications but dos not significantly chang th progrssion of kidny dysfunction. Stnting producs significantly bttr rsults than angioplasty. Howvr, blood prssur and srum cratinin ar similar at 6 months with mdical managmnt as with ithr angioplasty and stnts. Tratmnt of fibromuscular dysplasia with prcutan- ous transluminal angioplasty is oftn curativ, which is in stark contrast to tratmnts for athrosclrotic disas.Gornik  HL t al. First intrnational consnsus on th diagnosis and managmnt of fibromuscular dysplasia. Vasc Md. 2019;24:164. [PMID: 30648921] Mannmuddhu SS t al. Rnovascular hyprtnsion. Prim Car. 2020;47:631. [PMID: 33121633] Princ M t al. Rnal rvascularization in rsistant hyprtnsion. Prog Cardiovasc Dis. 2020;63:58. [PMID: 31821813]GLOMErULAr DISEASESGlomrular  disass can b challnging to undrstand clinically bcaus th glomrulus is a histologically com- plx structur (consisting of th pithlial clls [podo- cyts], basmnt mmbran, capillary ndothlium, and msangium). Th following ar xampls of injuris that can affct any or all of th constitunts of th glomrulus: (1) ovrwork injury, as in CKD; (2) an inflammatory pro- css, such as SLE; (3) a podocyt protin mutation, as in hrditary focal sgmntal glomrulosclrosis (FSGS); or (4) a dposition disas, as in diabts or amyloidosis. Whn a glomrular disas is suspctd, a kidny biopsy may b ndd to clarify th tiology. ClassificationGlomr ular disass can b classifid in on of two clini- cal spctrath nphritic spctrum or th nphrotic spctrum (Figur 224). At th last svr nd of th nephritic spectrum , th findings of asymptomatic glo- mrular hmaturia (i, dysmorphic rd blood clls with or without som protinuria [lss than 1 g/day]) ar charactristic. Th nphritic syndrome , comprising glo- mrular hmaturia, subnphrotic protinuria (lss than 3 g/day), dma, and lvatd cratinin, falls in th mid- portion of th spctrum. Th rapidly progrssiv glo- mrulonphritids (RPGNs), with systmic symptoms, ar at th most svr and clinically urgnt nd of th spctrum. Th nephrotic spectrum is comprisd of dis- ass that prsnt primarily with protinuria of at last 0.51 g/day and a bland urin sdimnt (no clls or cl- lular casts). At th mor svr nd of th nphrotic spctrum is th nphrotic syndrome , consisting of nphrotic-rang protinuria (gratr than 3 g/day), hypoalbuminmia, dma, hyprlipidmia, and urinary oval fat bodis. Diffrntiating btwn a clinical prsn- tation within th nphritic spctrum vrsus th nphrotic spctrum is important bcaus it hlps narrow th diffr- ntial diagnosis of th undrlying glomrular disas (Tabls 227 and 228). Glomrular disass can also b classifid according to whthr thy caus rnal abnormalitis alon (primary rnal disas) or whthr th rnal abnormalitis rsult from a systmic disas (scondary rnal disas). Furthr valuation prior to kidny biopsy may includ srologic tsting for systmic disass that can rsult in glomrular damag (Figur 225).Cavana ugh C t al. Urin sdimnt xamination in th diagnosis and managmnt of kidny disas: Cor Curriculum 2019. Am J Kidny Dis. 2019;73:258. [PMID: 30249419] Flog J t al. Managmnt and tratmnt of glomrular disass (part 1): conclusions from a Kidny Disas: Improving Global Outcoms (KDIGO) Controvrsis Confrnc. Kid- ny Int. 2019;95:268. [PMID: 30665568] Rovin BH t al. Managmnt and tratmnt of glomrular dis- ass (part 2): conclusions from a Kidny Disas: Improving Global Outcoms (KDIGO) Controvrsis Confrnc. Kid- ny Int. 2019;95:281. [PMID: 30665569]CMDT22_Ch22_p0912-p0951.indd  931 02/07/21 2:33 PMChApTEr 22932 CMDT 2022NE PHRITIC SPECTRUM GLOMERULAR DISEASESE S S E N T I A L S  O F  D I A G N O S I S Asymtomatic glomeula ematuia Hematuria with dysmorphic RBCs Proteinuria < 1 g/day Neitic syndome in more severe cases  Glomerular hematuria (and RBC casts if glomerular bleeding is heavy) Proteinuria of 13 g/day Hypertension Edema Rising creatinine over days to months raidly ogessive glomeuloneiti sin most severe cases AKI with rising creatinine over days to months Glomerular hematuria (and RBC casts) Proteinuria of 13 g/day Systemic symptoms Hypertension and edema uncommonGeneral Considerations Glomrulonphritis is a trm givn to thos disass that prsnt in th nphritic spctrum and usually signifis an inflammatory procss causing rnal dysfunction. It can b acut, dvloping ovr days to wks, with or without rso- lution, or may b chronic and indolnt with progrssiv scarring. As notd abov, disass that caus a nphritic spctrum prsntation may prsnt with glomrular hma- turia and protinuria, with nphritic syndrom, or with RPGN (Figur 224). Th prsntation dpnds on th svrity of th undrlying inflammation and th pattrn of injury causd by th disas procss. Clinical FindingsA.  Symptoms and SignsNp hritic syndrom usually lads to an acut dcras in GFR and rsultant sodium rtntion. This is manifstd by hyprtnsion and dma, which is first sn in rgions of low tissu prssur such as th priorbital and scrotal aras. Havy glomrular blding from inflammation may rsult in gross hmaturia (smoky or cola-colord urin).B.  Laboratory Findings1. Serologic testing  Srologic tsts basd on th history and physical xamination hlp narrow th diffrntialAsymptomatic glomerular hematuriaNephritic syndromeNephritic Spectrum Nephrotic SpectrumMicroscop ic or macroscopic hematuria with or without proteinuria (< 1 g/day)Acute kidney injury with proteinuria of 13 g/day, hematuria, RBC casts, edema, and hypertensionAcute kidney injury with proteinuria of 13 g/day, hematuria, RBC casts, and systemic symptomsProteinuria of 300 mg/day10 g/day and bland urineProteinuria of > 3 g/day plus hypoalbuminemia, edema, hyperlipidemia, and possible oval fat bodies in urineAsymptomatic proteinuriaNephrotic syndrome Chronic glomerular disease Chronic kidney disease with or without hematuria, proteinuria, hypertension, late-stage glomerulonephritis, burned-out diseaseRapidly progressive glomerulonephritis Figure 224. Glomerular diseases present within one of the clinical spectra shown; the exact presentation is determined by the severity of the underlying disease and the pattern of injury. Nephritic diseases are characterized by the presence of an active urine sediment with glomerular hematuria and often with proteinuria. Nephrotic spec- trum diseases are proteinuric with bland urine sediments (no cells or cellular casts). All glomerular diseases may progress to a chronic, scarred state. (Adapted, with permission, from Megan Troxell, MD, PhD.)CMDT22_Ch22_p0912-p0951.indd  932 02/07/21 2:33 PMKIDNEY DISEASE933 CMDT 2022diagnosis. Ths  tsts may includ C3 and C4 complmnt lvls, antinuclar antibodis, cryoglobulins, hpatitis srologis, srum and urin protin lctrophorss, srum fr light chains, ANCAs, anti-GBM antibodis, and anti- strptolysin O (ASO) titrs (Figur 225). 2. Urinalysis Th urin dipstick is positiv for protin and blood. Urinary microscopy rvals rd blood clls that ar misshapn or dysmorphic from travrsing a damagd glo- mrular filtration barrir. Rd blood cll casts ar sn with havy glomrular blding and tubular stasis. Whn quan- tifid, protinuria is usually subnphrotic rang (lss than 3 g/day). 3. Biopsy Dfinitiv diagnosis of th undrlying glomr- ular disas cannot b mad without a kidny biopsy. Candidats for biopsy ar patints for whom tst rsults would influnc managmnt; xcptions includ thoswith advancd undrlying CKD, thos who cannot adhr to mdical thrapy, thos for whom immunosupprssiv thrapy is not appropriat, or thos for whom th prsnta- tion is classic for a particular disas (g, post-strptococcal glomrulonphritis, childhood minimal chang disas, and diabtic nphropathy). Th major risk of biopsy is blding. Contraindications includ a blding diathsis, thrombocytopnia, and uncontrolld hyprtnsion. TreatmentGn ral masurs includ tratmnt of hyprtnsion and fluid ovrload, if prsnt. Antiprotinuric thrapy with an ACE inhibitor or ARB should b considrd for thos without AKI. For thos with profound AKI, dialysis may b ndd. Th inflammatory glomrular injury may rquir immuno- supprssiv agnts (s spcific disass discussd blow).Table 227. Classification and findings in glomerulonephritis: nephritic spectrum presentations. Tyical pesentation Association/Notes Seology Postinfectious glomerulonephritisChildren: abrupt onset of nephritic syndrome and acute kidney injury but can present anywhere in nephritic spectrumStreptococci, other bacterial infec- tions (eg, staphylococci, endocardi- tis, shunt infections)Rising ASO titers, low comple- ment levels IgA nephropathy (Berger disease) and Henoch- Schnlein purpura, sys- temic IgA vasculitisClassically: gross hematuria with respiratory tract infection, but can present anywhere in nephritic spectrum; Henoch-Schnlein pur- pura with vasculitic rash and gas- trointestinal hemorrhageAbnormal IgA glycosylation in both primary (familial predisposition) and secondary disease (associated with cirrhosis, HIV, celiac disease) Henoch-Schnlein purpura in chil- dren after an inciting infectionNo serologic tests helpful; com- plement levels are normal Pauci-immune (granulo- matosis with polyangi- itis, eosinophilic granulomatosis with polyangiitis, polyarteri- tis, idiopathic crescen- tic glomerulonephritis)Classically: crescentic or RPGN, but can present anywhere in nephritic spectrum; may have respiratory tract/sinus symptoms in granulo- matosis with polyangiitisSee Figure 225 ANCAs: MPO or PR3 titers high; complement levels normal Anti-GBM glomerulone- phritis; Goodpasture syndromeClassically: crescentic or RPGN, but can present anywhere in nephritic spectrum; pulmonary hemorrhage in Goodpasture syndromeMay develop as a result of respiratory irritant exposure (chemicals or tobacco use)Anti-GBM antibody titers high; complement levels normal Cryoglobulin-associated glomerulonephritisOften acute nephritic syndrome; often with systemic vasculitis including rash and arthritisMost commonly associated with chronic hepatitis C; may occur with other chronic infections or some connective tissue diseasesCryoglobulins positive; rheuma- toid factor may be elevated; complement levels low MPGN Classically: acute nephritic syndrome, but can also have nephrotic syn- drome featuresMost patients are < 30 years old Immune complex MPGN most common C3 glomerulonephritisLow complement levels, may have findings of underlying infection or paraproteinemia Hepatitis C infection Anywhere in nephritic spectrum Can cause MPGN pattern of injury or cryoglobulinemic glomerulone- phritis; membranous nephropathy pattern of injury uncommonLow complement levels; posi- tive hepatitis C serology; rheumatoid factor may be elevated Systemic lupus erythematosusAnywhere in nephritic spectrum, depending on pattern/severity of injuryTreatment depends on clinical course and International Society of Nephrology and Renal Pathology Society classification on biopsyHigh ANA and anti-double- stranded DNA titers; low complement levels ANA, antinuclear antibodies; ANCAs: antineutrophil cytoplasmic antibodies; GBM, glomerular basement membrane; MPGN, membranop- roliferative glomerulonephritis; MPO, myeloperoxidase; PR3, proteinase 3; RPGN, rapidly progressive glomerulonephritis.CMDT22_Ch22_p0912-p0951.indd  933 02/07/21 2:33 PMChApTEr 22934 CMDT 2022 When to ReferAny  patint in whom a glomrulonphritis is suspctd should b rfrrd to a nphrologist. When to AdmitAny  suspicion of acut nphritic syndrom or RPGN warrants considration of immdiat hospitalization.Lamba  P t al. Nphritic syndrom. Prim Car. 2020;47:615. [PMID: 33121632] Popplaars F t al. Complmnt-mdiatd kidny disass. Mol Immunol. 2020;128:175. [PMID: 33137606]1.  Infection-related & postinfectious GlomeuloneitisE S S E N T I A L S  O F  D I A G N O S I S Proteinuria. Glomerular hematuria. Symptoms 13 weeks after some infections (often pharyngitis or impetigo) or during course of other infections (eg, pneumonia or endocarditis).General ConsiderationsP ostinfctious glomrulonphritis is most oftn du to infction with nphritognic group A bta-hmolytic strptococcal infctions (pharyngitis or imptigo). It can occur sporadically or in clustrs and during pidmics, with onst up to 13 wks aftr infction (avrag 710 days). Othr infctions hav bn associatd with glomrulo- nphritis including bactrmia (spcially S aureus ), bac- trial pnumonias, dp-satd abscsss, gram-ngativ infctions, infctiv ndocarditis, and shunt infctions; viral, fungal, and parasitic causs of glomrulonphritis includ hpatitis B or C, HIV , cytomgalovirus infction, infctious mononuclosis, coccidioidomycosis, malaria, mycobactria, syphilis, and toxoplasmosis. Ths ntitis rsult in glomrular injury during activ infction, and ar bttr trmd infction-rlatd glomrulonphritis rathr than postinfctious glomrulonphritis.  Clinical FindingsA.  Symptoms and SignsDisas  prsntation varis across th nphritic spctrum from asymptomatic glomrular hmaturia (spcially in pidmic cass) with minimal chang in kidny function, to nphritic syndrom with hyprtnsion, dma, andTable 228. Classification and findings in glomerulonephritis: nephrotic spectrum presentations.Disease Tyical pesentation Association/Notes Minimal change disease (nil disease; lipoid nephrosis)Child with sudden onset of full nephrotic syndromeChildren: associated with allergy or viral infection Adults: associated with Hodgkin disease, NSAIDs Membranous nephropathy Anywhere in nephrotic spectrum, but nephrotic syndrome not uncommon; particular predispo- sition to hypercoagulable statePrimary (idiopathic) may be associated with antibodies to PLA2R Secondary may be associated with non-Hodgkin lymphoma, carci- noma (gastrointestinal, renal, bronchogenic, thyroid), gold therapy, penicillamine, SLE, chronic hepatitis B or C infection Focal and segmental glomerulosclerosisAnywhere in nephrotic spectrum; children with congenital disease have nephrotic syndromeChildren: congenital disease with podocyte gene mutation, or in spec- trum of disease with minimal change disease Adults: associated with heroin abuse, HIV infection, reflux nephropa- thy, obesity, pamidronate, podocyte protein mutations, APOL1 mutations Amyloidosis Anywhere in nephrotic spectrum AL: plasma cell dyscrasia with Ig light chain overproduction and depo- sition; check SPEP and UPEP AA: serum amyloid protein A overproduction and deposition in response to chronic inflammatory disease (rheumatoid arthritis, inflammatory bowel disease, chronic infection) Diabetic nephropathy High GFR (hyperfiltration) micro- albuminuria frank proteinuria decline in GFRDiabetes diagnosis precedes diagnosis of nephropathy by years HIV-associated nephropathy Heavy proteinuria, often nephrotic syndrome, progresses to ESKD relatively quicklyUsually seen in antiviral treatment-nave patients (rare in antiretroviral therapy era), predilection for those of African descent ( APOL1 mutations) Membranoproliferative glomerulonephropathyClassically presents with acute nephritic syndrome, some may also exhibit nephrotic featuresImmune complexMPGN are idiopathic or secondary to infections, paraproteinemia, or systemic autoimmune disease; C3 glomerulopa- thies are due to alternative complement pathway dysregulation ESKD, end-stage kidney disease; GFR, glomerular filtration rate; NSAIDs, nonsteroidal anti-inflammatory drugs; PLA2R, phospholipase A2 receptor; SLE, systemic lupus erythematosus; SPEP/UPEP , serum and urine protein electrophoresis.CMDT22_Ch22_p0912-p0951.indd  934 02/07/21 2:33 PMKIDNEY DISEASE935 CMDT 2022+ + +Glomerulonephritis (GN) Serologic analysis Anti-glomerular basement membrane (GBM) antibodies Anti-GBM GNAntineutrophil cytoplasmic antibodies (ANCA) No lung hemorrhage Anti-GBM GNLung hemorrhage Goodpasture syndromeImmune complex disease markers Immune complex GNIgA IgA nephropathyAntipathogen antibodies Postinfectious or peri- infectious GNCryoglobulins Cryoglobulinemic GNAntinuclear antibodies Lupus GNComplement activation MPGN ANCA GNSystemic necrotizing vasculitis Microscopic polyangiitisRespiratory necrotizing granulomas Granulomatosis with polyangiitisAsthma and eosinophiliaNo extra- renal disease ANCA- associated crescentic GNEosinophilic granulomatosis with polyangiitis Figure 225. Serologic analysis of patients with glomerulonephritis. MPGN, membranoproliferative glomerulonephritis. (Modified, with permission, from Greenberg A et al.Primer on Kidney Diseases . Academic Press, 1994; and Jennette JC, Falk RJ. Diagnosis and management of glomerulonephritis and vasculitis presenting as a cute renal failure. Med Clin North Am. 1990;74(4):893908.  Elsevier.)CMDT22_Ch22_p0912-p0951.indd  935 02/07/21 2:33 PMChApTEr 22936 CMDT 2022prh aps gross glomrular hmaturia (smoky-colord urin); th most svr cass may rsult in oliguric AKI rquiring dialysis.B.  Laboratory FindingsSrum  complmnt lvls ar low; in postinfctious glo- mrulonphritis du to group A strptococcal infction, anti-strptolysin O (ASO) titrs can b high unlss th immun rspons has bn bluntd with prvious antibiotic tratmnt. Glomrular hmaturia and protinuria ar prs- nt. In childrn with a rcnt strptococcal infction and nphritic faturs, a diagnosis may b mad mpirically without a biopsy. Whn prformd, kidny biopsy shows a diffus prolifrativ pattrn of injury on light microscopy. Immunofluorscnc dmonstrats granular dposition of IgG and C3 in th msangium and along th capillary bas- mnt mmbran. Elctron microscopy shows larg, dns subpithlial dposits or humps.  Kidny biopsy findings in infction-rlatd glomrulonphritis ar varid and may show ovrlap with immun-complx mmbranoprolifra- tiv glomrulonphritis or C3 glomrulonphritis. TreatmentAny  activ infction should b idntifid and tratd appropriatly; othrwis, tratmnt for postinfctious glo- mrulonphritis is supportiv. Antihyprtnsivs, salt rstriction, and diurtics should b usd if ndd. Corti- costroids hav not bn shown to improv outcoms. Prognosis dpnds on th svrity of th glomrular injury and ag of th patint. Childrn ar mor likly to fully rcovr; adults ar mor pron to th dvlopmnt of svr disas (RPGN with crscnt formation) and CKD.Mo hammad D t al. Postinfctious glomrulonphritis. Pdiatr Ann. 2020;49:273. [PMID: 32520369] Satoskar AA t al. Epidmiology, pathognsis, tratmnt and outcoms of infction-associatd glomrulonphritis. Nat Rv Nphrol. 2020;16:32. [PMID: 31399725]2.  IgA NeoatyE S S E N T I A L S  O F  D I A G N O S I S Proteinuria: minimal to nephrotic range. Glomerular hematuria: microscopic is common; macroscopic (gross) after infection. Positive IgA staining on kidney biopsy. General ConsiderationsIgA  nphropathy (Brgr disas) is a primary rnal dis- as of IgA dposition in th glomrular msangium. Th inciting caus is unknown. IgA nphropathy can b a pri- mary (rnal-limitd) disas or scondary to hpatic cir- rhosis, cliac disas, and infctions such as HIV and cytomgalovirus. Suscptibility to IgA nphropathy is inhritabl.IgA nphropathy is th most common primary glo- mrular disas worldwid, particularly in Asia. It is most oftn sn in childrn and young adults, with mals affctd two to thr tims mor commonly than fmals. Clinical FindingsTh  classical prsntation of IgA nphropathy is an pisod of gross hmaturia associatd with a mucosal viral infc- tion, oftn of th uppr rspiratory tract. Th urin bcoms rd or smoky-colord 12 days aftr illnss onsta so-calld synpharyngitic prsntation in contra- distinction to th latnt priod sn in postinfctious glo- mrulonphritis. Howvr, IgA nphropathy can prsnt anywhr along th nphritic spctrum from asymptom- atic microscopic hmaturia with minimal protinuria and prsrvd GFR to RPGN (Figur 224). Rarly, nphrotic syndrom can b prsnt. Thr ar no srologic tsts that aid in this diagnosis; srum complmnts ar normal. Th typical pattrn of injury sn on kidny biopsy is a focal glomrulonphritis with msangial prolifration; immunofluorscnc dm- onstrats diffus msangial IgA and C3 dposits. TreatmentTh  disas cours of primary IgA nphropathy varis widly among patints; tratmnt approach nds to b tailord to risk for progrssion. Patints with low risk for progrssion (no hyprtnsion, normal GFR, minimal pro- tinuria) can b monitord annually. Patints at highr risk (protinuria gratr than 1.0 g/day, dcrasd GFR, or hyprtnsion or any combination of ths thr condi- tions) should b tratd with an ACE inhibitor or ARB. Thrapy should b titratd to rduc protinuria to lss than 1 g/day and to control blood prssur in th rang of 125/75 mm Hg to 130/80 mm Hg. Prior trials suggstd that corticostroids rducd protinuria whn adminis- trd to patints with GFR gratr than 50 mL/min/1.73 m2 and prsistnt protinuria gratr than 1 g/day. Howvr, mor rcnt data faild to dmonstrat slowing of GFR loss with corticostroid thrapy compard with us of ACE inhibitor or ARB alon; nthusiasm for glucocorticoid thrapy thrfor has wand. For th rar patint with IgA nphropathy and a rapidly progrssiv clinical cours with crscnt formation on biopsy, cyclophosphamid and cor- ticostroid thrapy should b considrd (s sction on ANCA-associatd vasculitis blow). Kidny transplanta- tion is an xcllnt option for patints with ESKD, but rcurrnt disas has bn documntd in 30% of patints 510 yars posttransplant. PrognosisA pproximatly on-third of patints xprinc spontan- ous clinical rmission. Progrssion to ESKD occurs in 2040% of patints. Th most unfavorabl prognostic indi- cator is protinuria gratr than 1 g/day; othr includ hyprtnsion, tubulointrstitial fibrosis, glomrulosclro- sis, or glomrular crscnts on biopsy, and abnormal GFR on prsntation.CMDT22_Ch22_p0912-p0951.indd  936 02/07/21 2:33 PMKIDNEY DISEASE937 CMDT 2022Ca mbir A t al. Nw thraputic prspctivs for IgA nphropathy in childrn. Pdiatr Nphrol. 2021;36:497. [PMID: 32040630] Raun T t al. Aftr tn yars of follow-up, no diffrnc btwn supportiv car plus immunosupprssion and supportiv car alon in IgA nphropathy. Kidny Int. 2020;98:1044. [PMID: 32450154] Trimarchi H t al. IgA nphropathy: Stat of th art: a rport from th 15th Intrnational Symposium on IgA Nphropathy clbrating th 50th annivrsary of its first dscription. Kidny Int. 2019;95:750. [PMID: 30904065]3.  henoc-Scnlein puuaH noch-Schnlin purpura is a systmic small-vssl lu- kocytoclastic vasculitis associatd with IgA subclass 1 dpo- sition in vssl walls. It is most common in childrn and is oftn associatd with an inciting infction, such as group A strptococcus or othr xposur. Thr is a mal prdomi- nanc. It classically prsnts with palpabl purpura in th lowr xtrmitis and buttock ara; arthralgias; abdominal symptoms, such as nausa, colic, and mlna; and AKI with nphritic urin sdimnt. Th rnal lsions can b idntical to thos found in IgA nphropathy, and th undrlying pathophysiology appars to b similar. Most patints with microscopic hmaturia and minimal protinuria rcovr fully ovr svral wks. Progrssiv CKD and possibly ESKD ar mor likly to dvlop in adults and in thos with both nphritic and nphrotic syndroms. Although svral tratmnt rgimns of various immunosupprssiv agnts hav bn clinically tstd, non ar provn to altr th cours of svr nphritis. Rituximab tratmnt and plasma xchang hav bn succssful for svr disas according to svral cas rports, but clinical trials ar lacking. Rapidly progrssiv disas with crscnt formation on biopsy may b tratd as in ANCA-associatd vasculitis (s sction blow). Furthr dtails about Hnoch-Schnlin purpura ar providd in Chaptr 20.Mari tati F t al. Adult-onst IgA vasculitis (Hnoch-Schnlin): updat on thrapy. Prss Md. 2020;49:104035. [PMID: 32645417]4.  pauci-Immune Glomeuloneitis (ANCA-Associated)Pa uci-immun ncrotizing glomrulonphritis is causd by th following systmic ANCA-associatd small-vssl vasculitids: granulomatosis with polyangiitis, microscopic polyangiitis, and osinophilic granulomatosis with polyan- giitis (formrly Churg-Strauss disas; s Chaptr 20). ANCA-associatd glomrulonphritis can also prsnt as a primary rnal lsion without systmic involvmnt; this is trmd idiopathic crscntic glomrulonphritis.  Th pathognsis of ths ntitis appars to involv cytokin- primd nutrophils prsnting cytoplasmic antigns on thir surfacs (protinas 3 and myloproxidas). Circu- lating ANCAs thn bind to ths antigns and activat a nutrophil rspiratory burst with consqunt vascular damag; primd nutrophils also appar to activat th altrnativ complmnt pathway. Putativ nvironmntal xposurs that may incit th initial rspons includ S aureusand silica. Immunofluorscnc of kidny biopsy spcimns dmonstrats lack of immunoglobulin or complmnt dposition, hnc th trm pauci-immun.  Rnal involv- mnt classically prsnts as an RPGN, but mor indolnt prsntations can b sn. Clinical FindingsA.  Symptoms and SignsSymp toms of a systmic inflammatory disas, including fvr, malais, and wight loss, may b prsnt and usually prcd initial prsntation by svral months. In addition to hmaturia and protinuria from glomrular inflamma- tion, som patints xhibit purpura from drmal capillary involvmnt and mononuritis multiplx from nrv artrio- lar involvmnt. Ninty prcnt of patints with granulomato- sis with polyangiitis hav uppr (spcially sinus) or lowr rspiratory tract symptoms with nodular lsions that can cavi- tat and bld. Hmoptysis is a concrning sign and usually warrants hospitalization and aggrssiv immunosupprssion.B.  Laboratory FindingsSrologically , ANCA subtyp analysis is don to dtrmin whthr antiprotinas-3 antibodis (PR3-ANCA) or anti- myloproxidas antibodis (MPO-ANCA) ar prsnt. Most patints with granulomatosis with polyangiitis ar PR3 positiv; th rmaindr ar MPO positiv or, mor rarly, do not dmonstrat circulating ANCA. Microscopic angiitis is gnrally associatd with MPO ANCA. Rnal biopsy dmonstrats ncrotizing lsions and crscnts on light microscopy; immunofluorscnc is ngativ for immun complx dposition. TreatmentT ratmnt should b institutd arly if aggrssiv disas is prsnt. Induction thrapy of high-dos corticostroids (mthylprdnisolon, 12 g/day intravnously for 3 days, followd by prdnison, 1 mg/kg orally for 1 month, with a slow tapr ovr th nxt 6 months) and cytotoxic agnts (cyclophosphamid, 0.51 g/m2intravnously pr month or 1.52 mg/kg orally for 36 months) is followd by long-trm azathioprin or mycophnolat moftil. Rituximab has bn shown to b noninfrior to cyclophosphamid for induction and is also usd in rfractory or rlapsing cass and as an altrnativ to azathioprin for maintnanc of rmission. Plasma xchang is likly hlpful in conjunction with induc- tion thrapy for cass complicatd by pulmonary hmor- rhag. Trials using th complmnt inhibitor avacopan in plac of glucocorticoids in cyclophosphamid- or rituximab- basd rgimns ar ongoing and appar promising. PrognosisW ithout tratmnt, prognosis is xtrmly poor. With aggrssiv tratmnt, complt rmission can b achivd in 75% of patints. Prognosis dpnds on th xtnt of rnal involvmnt bfor tratmnt is startd and may b wors in thos with PR3-associatd disas. ANCA titrs may b monitord to follow tratmnt fficacy; rising titrs may hrald rlaps.CMDT22_Ch22_p0912-p0951.indd  937 02/07/21 2:33 PMChApTEr 22938 CMDT 2022Gtha  D t al. ANCA-associatd vasculitis: Cor Curriculum 2020. Am J Kidny Dis. 2020;75:124. [PMID: 31358311] Smith RM t al. Rituximab as thrapy to induc rmission aftr rlaps in ANCA-associatd vasculitis. Ann Rhum Dis. 2020;79:1243. [PMID: 32581088] Walsh M t al. Plasma xchang and glucocorticoids in svr ANCA-associatd vasculitis. N Engl J Md. 2020;382:622. [PMID: 32053298]5.  Anti-Glomeula Basement Membane Glomeuloneitis & Goodastue SyndomeA utoantibodis to pitops of th GBM caus a glomrulo- nphritis (anti-GBM disas); concomitant immun attack on alvolar basmnt mmbrans rsults in pulmonary hmorrhag as wll (Goodpastur syndrom) (Figur 225). Anti-GBMassociatd glomrulonphritis accounts for 1020% of patints with acut RPGN. Th incidnc paks in th third dcad of lif during which tim mals ar prdominantly affctd and lung involvmnt is mor common, and again in th sixth and svnth dcads with lss gndr spcificity and pulmonary involvmnt. Good- pastur syndrom has bn associatd with pulmonary infction, tobacco us, and xposur to hydrocarbon sol- vnts or almtuzumab; HLA-DR2 and -B7 antigns may prdispos as wll. Clinical FindingsA.  Symptoms and SignsTh on st of disas may b prcdd by an uppr rspira- tory tract infction; hmoptysis, dyspna, and possibl rspiratory failur may nsu. Othr findings ar consistnt with an RPGN, although rar cass may prsnt with much mildr forms of th nphritic spctrum of disas (g, glo- mrular hmaturia and protinuria with minimal kidny dysfunction).B.  Laboratory FindingsChst radiographs may dmonstrat  pulmonary infiltrats if pulmonary hmorrhag is prsnt. Srum complmnt lvls ar normal. Circulating anti-GBM antibodis ar prsnt in ovr 90% of patints. A small prcntag of patints hav lvatd ANCA titrs; ths patints should b tratd with plasma xchang as for anti-GBM disas. Kidny biopsy typically shows crscnt formation with light microscopy, with linar IgG staining along th GBM with immunofluorscnc. TreatmentPa tints with pulmonary hmorrhag and strong clinical suspicion of Goodpastur syndrom should b tratd mrgntlypossibly prior to confirming th diagnosis with srology and kidny biopsy. Tratmnt is a combina- tion of plasma xchang thrapy daily for up to 2 wks to rmov circulating antibodis, and administration of corti- costroids and cyclophosphamid to prvnt formation of nw antibodis and control th inflammatory rspons. Rituximab has bn usd in a small numbr of patintswith rfractory disas. Patints with oliguric AKI or who rquir dialysis upon prsntation hav a poor prognosis. Anti-GBM antibody titrs should dcras as th clinical cours improvs.Sglm ark M t al. Anti-glomrular basmnt mmbran disas: an updat on subgroups, pathognsis and thrapis. Nphrol Dial Transplant. 2019;34(11):1826. [PMID: 30371823] Umatsu-Uchida M t al. Rituximab in tratmnt of anti-GBM antibody glomrulonphritis: a cas rport and litratur rviw. Mdicin (Baltimor). 2019;98:17801. [PMID: 31689860]6.  Membanoolifeative Glomeuloneitis & C3 GlomeuloatiesMPGN is a  rlativly rar pattrn of glomrular injury that can prsnt anywhr along th nphritic spctrum from asymptomatic glomrular hmaturia to acut nphritic syndrom with bouts of gross hmaturia to RPGN; nphrotic syndrom can also b sn. MPGN is classifid pathologically and mchanistically into immun complx and C3-rlatd disas. Etiologis of immun complx mdiatd MPGN includ chronic infction (most commonly HCV , but also bactrial and parasitic infc- tions), a paraprotinmia, or an undrlying autoimmun disas (such as lupus); it can also b idiopathic (spcially in childrn and young adults). In ths cass, th pathogn- sis is likly a chronic antignmia lading to classical complmnt pathway activation with immun complx dposition; howvr, som cass may rsult from altrna- tiv complmnt pathway dysrgulation. C3 glomrulopa- this ar causd by svral inhritd or acquird abnormalitis in th altrnativ complmnt pathway. Both typs rsult in low circulating C3 complmnt; C4 is low in immun complx disas. Light microscopy of both typs shows varying dgrs of msangial hyprcllularity, ndo- capillary prolifration and capillary wall rmodling rsulting in doubl contours of th GBM (tram track apparanc). Immunofluorscnc and lctron micros- copy provid distinguishing information. Immun complxmdiatd MPGN rvals C3 and IgG or IgM staining (or both) on immunofluorscnc; lctron microscopy dmonstrats msangial and subpithlial dposits. C3 glomrulonphritis is distinguishd by lack of immunoglobulin staining on immunofluorscnc, but can appar similar to immun complx disas with rspct to light and lctron microscopy. An additional but rar typ of C3 glomrular injury is dns dposit disas basd on thick ribbon-lik dposits sn on lctron microscopy. Togthr, dns dposit disas and C3 glomrulonphritis ar trmd C3 glomrulopathis.  Tratmnt of immun complx MPGN should b dirctd at any idntifiabl undrlying caus; idiopathic immun complx disas tratmnt is controvrsial and controlld trial data ar lacking. For thos with mild dis- as, ACE inhibitors and ARBs should b usd. For svr disas, a combination of oral cyclophosphamid or myco- phnolat moftil plus corticostroids could b considrd; rituximab is also somtims usd. Thos with RPGN and crscnts on biopsy may b tratd th sam as thos withCMDT22_Ch22_p0912-p0951.indd  938 02/07/21 2:33 PMKIDNEY DISEASE939 CMDT 2022ANCA -associatd disas providd scondary causs hav bn ruld out. Dspit thrapy, most will progrss to ESKD. Tratmnt for th C3 glomrulopathis is in volu- tion as novl thrapis to targt th dysrgulatd altrnativ complmnt cascad ar bing xplord; small, uncon- trolld sris suggst a possibl bnfit of culizumab in som patints; othrs may rspond to mycophnolat moftil. Lss favorabl prognostic findings includ dns dposit disas, arly dclin in GFR, hyprtnsion, and prsistnt nphrotic syndrom. All typs of MPGN rcur with high frquncy aftr kidny transplantation; howvr, dns dposit disas rcurs mor commonly. Plasma xchang, with or without culizumab, has bn usd with mixd rsults to trat posttransplant rcurrnc of MPGN.Fakhouri  F t al. Practical managmnt of C3 glomrulopathy and Ig-mdiatd MPGN: facts and uncrtaintis. Kidny Int. 2020;98:1135. [PMID: 32622830]7.  Cyoglobulin-Associated GlomeuloneitisEssnt ial (mixd) cryoglobulinmia is a vasculitis causd by cold-prcipitabl immunoglobulins (cryoglobulins). Th most common undrlying tiology is HCV infction; in ths cass, thr is clonal xpansion of B lymphocyts, which produc IgM rhumatoid factor. Rhumatoid fac- tor, HCV antign, and polyclonal anti-HCV IgG form complxs that dposit in vssls and incit inflamma- tion. Othr ovrt or occult infctions (g, viral, bactrial, and fungal) as wll as som autoimmun disass and lymphoprolifrativ disordrs can caus cryoglobulin- mic vasculitis. Patints xhibit purpuric and ncrotizing skin lsions in dpndnt aras, arthralgias, fvr, and hpatosplnomg- aly. Srum complmnt lvls ar low and rhumatoid fac- tor is oftn lvatd. Kidny biopsy may show svral diffrnt pattrns of injury; thr may b crscnt forma- tion, glomrular capillary thrombi, or MPGN (s abov). Tratmnt consists of aggrssivly targting th causativ infction. Puls corticostroids, plasma xchang, ritux- imab, and cytotoxic agnts hav bn usd whn thr is littl risk of xacrbating th undrlying infction or whn no infction is prsnt. S also Hpatitis C VirusAssociatd Kidny Disas.Ko lopp-Sarda MN t al. Cryoglobulinmic vasculitis: patho- physiological mchanisms and diagnosis. Curr Opin Rhu- matol. 2021;33:1. [PMID: 33186245]8.  heatitis C ViusAssociated Kidney DiseaseKidny dis as can occur in th stting of HCV infction. Th thr pattrns of kidny injury associatd with HCV ar scondary MPGN (most common), cryoglobulinmic glomrulonphritis, and mmbranous nphropathy. Th clinical prsntation is dictatd by th undrlying pattrn of injury. Many patints hav lvatd srum transami- nass and an lvatd rhumatoid factor. Hypocompl- mntmia is vry common, with C4 typically mor rducd than C3; complmnt lvls and rhumatoid factor tnd to b normal if thr is a mmbranous pattrn of injury.TreatmentV iral supprssion or radication is th cornrston of trat- mnt of HCVassociatd kidny disas (s Chaptr 16). Us of most dirct-acting antiviral agnts appars to b saf in thos with rducd GFR, with th xcption of sofosbu- vir. Thrapy with rituximab and possibly corticostroids and plasmaphrsis should b initiatd in patints with svr vasculitis prior to th initiation of antiviral thrapy.Comarm ond C t al. Tratmnt of chronic hpatitis Cassociatd cryoglobulinmia vasculitis at th ra of dirct-acting antivi- rals. Thrap Adv Gastrontrol. 2020;13:1756284820942617. [PMID: 32782479] Roth D t al. KDOQI US commntary on th 2018 KDIGO clini- cal practic guidlin for th prvntion, diagnosis, valua- tion, and tratmnt of hpatitis C. Am J Kidny Dis. 2020;75: 665. [PMID: 32279907]9.  Systemic Luus EytematosusRnal invol vmnt occurs in 3590% of patints who hav SLE, with highr stimats ncompassing subclinical dis- as. Rats of lupus nphritis ar highst in non-Whits. Th pathognsis may b dysrgulatd cllular apoptosis rsulting in autoantibodis against nuclosoms; antibody/ nuclosom complxs thn bind to componnts of th glomrulus to form immun complx glomrular disas. S Chaptr 20 for furthr discussion of SLE. Th trm lupus nphritis ncompasss many possibl pattrns of rnal injurymost cass prsnt within th nphritic spctrum (class IIV). Nonglomrular syn- droms includ tubulointrstitial nphritis and vasculitis. All patints with SLE should hav routin urinalyss to monitor for th apparanc of hmaturia or protinuria. If urinary abnormalitis ar dtctd, kidny biopsy is oftn prformd. Th Intrnational Socity of Nphrology and Rnal Pathology Socity classification of rnal glomrular lsions is class I, minimal msangial nphritis; class II, msangial prolifrativ nphritis; class III, focal (lss than 50% of glomruli affctd with capillary involvmnt) pro- lifrativ nphritis; class IV , diffus (gratr than 50% of glomruli affctd with capillary involvmnt) prolifrativ nphritis; class V , mmbranous nphropathy; and class VI, advancd sclrosis without rsidual disas activity. Classs III and IV , th most svr forms of lupus nphritis, ar furthr classifid as activ or chronic, and global or sg- mntal, which confrs additional prognostic valu. TreatmentIndivid uals with class I and class II lesions gnrally rquir no tratmnt; corticostroids or calcinurin inhibi- tors should b considrd for thos with class II lsions with nphrotic-rang protinuria. Transformation of ths typs to a mor activ lsion may occur and is usually accompanid by an incras in lupus srologic activity (g, rising titrs of antidoubl-strandd DNA antibodis and falling C3 and C4 lvls) and incrasing protinuria or fall- ing GFR. Rpat biopsy in such patints is rcommndd. Hydroxychloroquin should b considrd for all patints with lupus nphritis, rgardlss of histological class.CMDT22_Ch22_p0912-p0951.indd  939 02/07/21 2:33 PMChApTEr 22940 CMDT 2022Pa tints with xtnsiv class III lesions and all class IV lesions should rciv aggrssiv immunosupprssiv thrapy. Poor prognostic indicators in patints with class III or IV lsions includ lvatd srum cratinin, lowr complmnt lvls, mal sx, prsnc of antiphospholipid antibodis, nphrotic-rang protinuria, African dscnt (possibly in association with APOL1 risk allls), and poor rspons to thrapy. Immunosupprssiv thrapy for class V lupus nphritis is indicatd if suprimposd prolifrativ lsions xist. Class VI lsions should not b tratd. Tratmnt of class III or IV lupus nphritis consists of induction thrapy, followd by maintnanc thrapy. Induction thrapy includs corticostroids (g, mthyl- prdnisolon 1 g intravnously daily for 3 days followd by prdnison, 1 mg/kg orally daily with subsqunt tapr ovr 612 months) in combination with ithr cyclophos- phamid or mycophnolat moftil. Data suggst that Blacks and Hispanics rspond mor favorably to mycoph- nolat moftil than cyclophosphamid; in addition, myco- phnolat moftil has a mor favorabl sid-ffct profil than cyclophosphamid and should b favord whn prs- rvation of frtility is a considration. Mycophnolat moftil induction is typically givn at 23 g orally daily, thn taprd to 12 g/day for maintnanc. Cyclophospha- mid induction rgimns vary but usually involv monthly intravnous puls doss (5001000 mg/m2) for 6 months. Induction is followd by daily oral mycophnolat moftil or azathioprin maintnanc thrapy; mycophnolat moftil may b suprior to azathioprin maintnanc and causs fw advrs ffcts. Maintnanc with calcinurin inhibitors may also b considrd, but th rlaps rat is high upon discontinuation of ths agnts. With standard thrapy, rmission rats with induction vary from 80% for partial rmission to 5060% for full rmission; it may tak mor than 6 months to s ths ffcts. Rlaps is com- mon and rats of disas flar ar highr in thos who do not xprinc complt rmission; similarly, progrssion to ESKD is mor common in thos who rlaps mor fr- quntly, or in whom no rmission has bn achivd. Th us of add-on B-cll-targtd thrapy with rituximab or blimumab for class III, IV , and/or V disas may b con- sidrd. Pur class V disas is tratd with mycophnolat moftil with or without rituximab. Th lvls of various disas activity markrs (doubl- strandd DNA antibodis, srum C3, C4, CH50lvls) and th urinary protin lvls and sdimnt activity can b us- ful in monitoring rspons to tratmnt; howvr, rpat rnal biopsy yilds mor rliabl information rgarding disas activity and may b usd to guid maintnanc thrapy withdrawal. Patints with SLE who undrgo dialy- sis hav a favorabl prospct for long-trm survival; intr- stingly, systmic lupus symptoms may bcom quiscnt with th dvlopmnt of ESKD. Patints with SLE undr- going kidny transplants can hav rcurrnt rnal disas, although rats ar rlativly low.Fan ouriakis A t al. 2019 updat of th Joint Europan Lagu Against Rhumatism and Europan Dialysis and Transplant Association (EULAR/ERA-EDTA) rcommndations for th managmnt of lupus nphritis. Ann Rhum Dis. 2020;79:713. [PMID: 32220834]Furi R t al. Two-yar, randomizd, controlld trial of blimumab in lupus nphritis. N Engl J Md. 2020;383:1117. [PMID: 32937045] Parikh SV t al. Updat on lupus nphritis: Cor Curriculum 2020. Am J Kidny Dis. 2020;76:265. [PMID: 32220510]NE PHROTIC SPECTRUM GLOMERULAR DISEASESE S S E N T I A L S  O F  D I A G N O S I S Proteinuria with bland urine sediment (few if any cells or cellular casts). Nephrotic syndrome (if present) manifestations:  Nephrotic-range proteinuria (urine protein excretion > 3 g per 24 hours). Hypoalbuminemia (albumin < 3 g/dL). Peripheral edema. Hyperlipidemia. Oval fat bodies may be seen in the urine. General ConsiderationsIn Amrican  adults, th most common caus of nphrotic spctrum glomrular disas is diabts mllitus. Othr causs includ minimal chang disas, FSGS, mmbra- nous nphropathy, and amyloidosis. Any of ths ntitis can prsnt on th lss svr nd of th nphrotic spc- trum with a bland urinalysis and protinuria or on th most svr nd of th full nphrotic syndrom. Srum cratinin may b abnormal at th tim of prsntation, dpnding on th svrity and chronicity of th disas. Clinical FindingsA.  Symptoms and SignsPa tints with subnphrotic rang protinuria do not mani- fst symptoms of kidny disas. In thos with th nphrotic syndrom, priphral dma is prsntmost likly du both to sodium rtntion and hypoalbuminmia- inducd low plasma oncotic prssur. Edma may dvlop solly in dpndnt rgions, such as th lowr xtrmitis, or it may bcom gnralizd and includ priorbital dma. Dyspna du to pulmonary dma, plural ffu- sions, and diaphragmatic compromis du to ascits can occur.B.  Laboratory Findings1. Urinalysis  Protinuria occurs as a rsult of podocyto- pathy and variabl altrations of th GBM. Th urin dip- stick is a good scrning tst for albuminuria; if positiv, urinary protin xcrtion should b quantifid (s arlir Protinuria sction). A spot urin protin to urin crati- nin ratio givs a rasonabl approximation of grams of protin xcrtd pr day; a 24-hour urin sampl for pro- tin xcrtion is rarly ndd.CMDT22_Ch22_p0912-p0951.indd  940 02/07/21 2:33 PMKIDNEY DISEASE941 CMDT 2022Microscop ically, th urinary sdimnt has rlativly fw cllular lmnts or casts. Howvr, if markd hyprlipid- mia is prsnt, urinary oval fat bodis may b sn. Thy appar as grap clustrs undr light microscopy and Malts crosss undr polarizd light. 2. Blood chemistries Th nphrotic syndrom rsults in hypoalbuminmia (lss than 3 g/dL [30 g/L]). Hyprlipid- mia, du both falling oncotic prssur triggring incrasd hpatic production of lipids and to dcrasd claranc of vry low-dnsity lipoprotins causing hyprtriglycrid- mia, occurs in ovr 50% of patints with arly nphrotic syndrom, and bcoms mor frqunt and worsns in dgr as th svrity of th nphrotic syndrom incrass. An lvatd rythrocyt sdimntation rat may b sn as a rsult of incrasd lvls of fibrinogn. Havy urinary xcrtion of binding protins may rsult in dficincis of vitamin D, zinc, and coppr. Laboratory tsting to hlp lucidat th undrlying caus of th glomrular disas includs complmnt lvls, srum and urin protin lctrophorsis, srum fr light chains, antinuclar antibodis, PLA2R antibody titrs, HbA1c, and srologic tsting for hpatitis B and C, HIV , and syphilis. 3. Kidney biopsy Kidny biopsy is oftn prformd in adults with nw-onst idiopathic nphrotic syndrom if a primary rnal disas that may rquir immunosupprssiv thrapy is suspctd. Chronically and significantly dcrasd GFR indicats irrvrsibl kidny disas mitigating th usfulnss of kidny biopsy. In th stting of long-standing diabts mllitus typ 1 or 2, protinuric rnal disas is rarly biopsid unlss atypical faturs (such as significant glomrular hmaturia or cllular casts) ar also prsnt, or if thr is othr rason to suspct an additional rnal lsion. TreatmentA.  Protein LossIn  thos with subnphrotic protinuria, ditary protin rstriction may b hlpful in slowing progrssion of kidny disas (s CKD sction). In both diabtic and nondiabtic patints, anti-protin- uric thrapy should also slow progrssion of kidny dis- as. ACE inhibitors and ARBs rduc urin protin xcrtion by dcrasing glomrular capillary prssur and also hav antifibrotic ffcts. Thy can b usd in patints with rducd GFR as long as significant hyprkalmia (potassium gratr than 5.25.5 mEq/L or mmol/L) dos not occur and srum cratinin riss lss than 30% aftr drug initiation or dos titration; patints should b moni- tord closly to avoid AKI and hyprkalmia. Combination thrapy of an ARB and an ACE inhibitor incrass risk for AKI and hyprkalmia and is not rcommndd.B.  EdemaDitary  salt rstriction is ssntial for managing dma; most patints also rquir diurtic thrapy. A combination of loop and thiazid diurtics may b ndd for rfractory fluid rtntion. Both thiazid and loop diurtics ar highly protin bound; thrfor, with hypoalbuminmia and dcrasd GFR, diurtic dlivry to th kidny is rducd and largr doss oftn ar rquird.C. HyperlipidemiaH yprcholstrolmia and hyprtriglycridmia occur as notd abov. Ditary modification and xrcis should b advocatd; howvr, ffctiv lipid-lowring usually also rquirs pharmacologic tratmnt (s Chaptr 28). Thr is significant risk of rhabdomyolysis in patints with CKD who tak gmfibrozil in combination with statins; combin- ing fnofibrat or niacin with a statin is prfrrd.D . Hypercoagulable StatePa tints with nphrotic syndrom hav urinary losss of antithrombin, protin C, and protin S and incrasd plat- lt activation. Patints with srum albumin lss than 2 g/dL (20 g/L) hav considrabl risk for thrombophilia and may dvlop rnal vin thrombosis, pulmonary mbolus, and othr vnous thrombomboli; this is particularly likly with mmbranous nphropathy. Anticoagulation thrapy with warfarin is warrantd for at last 36 months in patints with vidnc of thrombosis in any location and may b rquird indfinitly for rnal vin thrombosis, pulmonary mbolus, rcurrnt thrombomboli or whn ongoing nphrotic syndrom poss a risk of thrombosis rcurrnc. When to ReferAny  patint with th nphrotic syndrom should b rfrrd immdiatly to a nphrologist for volum and blood prssur managmnt, assssmnt for kidny biopsy, and tratmnt of th undrlying disas. Protinuria of mor than 1 g/24 hours without th nphrotic syndrom also mrits nphrology rfrral, though with lss urgncy. When to AdmitPa tints with dma rfractory to outpatint thrapy or rapidly worsning kidny function that may rquir inpa- tint intrvntions should b admittd.Bknkamp  A. Protinuriatak a closr look! Pdiatr Nphrol. 2020;35:533. [PMID: 31925536] Politano SA t al. Nphrotic syndrom. Prim Car. 2020;47:597. [PMID: 33121631] Wang CS t al. Nphrotic syndrom. Pdiatr Clin North Am. 2019;66:73. [PMID: 30454752] NEphrOTIC SpECTrUM DISEASE IN prIMArY rENAL DISOrDErS MINIMAL CHANGE DISEASEE S S E N T I A L S  O F  D I A G N O S I S Nephrotic-range proteinuria. Kidney biopsy shows no changes on light microscopy. Characteristic foot-process effacement on electron microscopy.CMDT22_Ch22_p0912-p0951.indd  941 02/07/21 2:33 PMChApTEr 22942 CMDT 2022 General ConsiderationsMinimal cha ng disas is th most common caus of pro- tinuric rnal disas in childrn, accounting for about 80% of cass. It oftn rmits upon tratmnt with a cours of corticostroids. Indd, childrn with nphrotic syn- drom ar oftn tratd for minimal chang disas mpir- ically without a biopsy diagnosis. Minimal chang disas is lss common in adults, accounting for 2025% of cass of primary nphrotic syndrom in thos ovr ag 40 yars. This ntity can b idiopathic but also occurs following viral uppr rspiratory infctions (spcially in childrn), in association with noplasms such as Hodgkin disas, with drugs (lithium), and with hyprsnsitivity ractions (sp- cially to NSAIDs and b stings). Clinical FindingsA.  Symptoms and SignsPa tints prsnt with nphrotic syndrom, which confrs suscptibility to infction, tndncy toward thrombom- bolic vnts, svr hyprlipidmia, and possibly protin malnutrition. Minimal chang disas can caus AKI du to rnal tubular damag and intrstitial dma.B.  Laboratory and Histologic FindingsTh r is no hlpful srologic tsting. Biopsy should b consid- rd for childrn with nphrotic syndrom who xhibit unusual faturs (such as signs of othr systmic illnss), or who ar stroid-rsistant or rlaps upon withdrawal of corti- costroid thrapy; th lattr two conditions may indicat an undrlying focal and sgmntal glomrulosclrosis rathr than minimal chang disas. Whn kidny biopsy is pr- formd, glomruli appar normal on light microscopy and immunofluorscnc. On lctron microscopy, thr is a charactristic ffacmnt of podocyt foot procsss. Msan- gial cll prolifration may b sn in a subgroup of patints; this finding is associatd with mor hmaturia and hyprtn- sion and poor rspons to standard corticostroid tratmnt. TreatmentT ratmnt is with prdnison, 60 mg/m2/day orally; rmis- sion in stroid-rsponsiv minimal chang disas gnr- ally occurs within 48 wks. Adults oftn rquir longr courss of thrapy than childrn, rquiring up to 16 wks to achiv a rspons. Tratmnt should b continud for svral wks aftr complt rmission of protinuria, and dosing taprs should b individualizd. A significant num- br of patints will rlaps and rquir rpatd corticost- roid tratmnt. Patints with frqunt rlapss or corticostroid rsistanc may rquir cyclophosphamid, a calcinurin inhibitor (tacrolimus, cyclosporin), or ritux- imab to induc subsqunt rmissions. Progrssion to ESKD is rar. Complications most oftn aris from pro- longd corticostroid us.M djral-Thomas NR t al. Randomizd, controlld trial of tacro- limus and prdnisolon monothrapy for adults with de novo minimal chang disas: a multicntr, randomizd, controlld trial. Clin J Am Soc Nphrol. 2020;15:209. [PMID: 31953303]FOCAL SEGMENTAL GLOMERULOSCLEROSIS General ConsiderationsThis r lativly common rnal pattrn of injury rsults from damag to podocyts; such damag may b a primary/ rnal-limitd disordr or may b scondary to anothr undrlying disas stat. Primary causs fall into thr cat- goris: (1) hritabl abnormalitis in any on of svral podocyt protins, or to undrlying typ 4 collagn muta- tions; (2) polymorphisms in th APOL1 gn in thos of African ancstry; or (3) incrasd lvls of a circulating prmability factor. Scondary causs includ rnal ovr- work injury, obsity, hyprtnsion, chronic urinary rflux, HIV or SARS-CoV-2 infction, or analgsic or bisphospho- nat xposur. Gntic tsting in primary cass is bcoming mor common, spcially in th pdiatric population. Clinical FindingsIn  FSGS causd by a primary kidny disas, 80% of chil- drn and 50% of adults hav ovrt nphrotic syndrom; howvr, whn it dvlops du to a scondary caus, frank nphrotic syndrom is uncommon. Dcrasd GFR is prs- nt in 2550% of thos with FSGS at tim of diagnosis. Diagnosis rquirs kidny biopsy; thr is no hlpful srologic tst. Light microscopy shows sclrosis of sg- mnts of som, but not all, glomruli. On immunofluors- cnc, IgM and C3 ar sn in th sclrotic lsions, although it is prsumd that ths immun componnts ar simply trappd in th sclrotic glomruli and not pathog- ntic. As in minimal chang disas, lctron microscopy shows fusion of pithlial foot procsss. TreatmentT ratmnt for all forms of FSGS includs diurtics for dma, ACE inhibitors or ARBs to control protinuria and hyprtnsion, and statins or niacin for hyprlipidmia. Immunosupprssion thrapy (oral prdnison, 1 mg/kg/ day for 416 wks followd by a slow tapr) is rsrvd for nphrotic primary FSGS cass prsumd to b du to a circulating prmability factor; in thos with stroid- rsistanc or intolranc, calcinurin inhibitors and myco- phnolat moftil can b considrd. Kidny transplantation in this subgroup of FSGS patints is complicatd by a rla- tivly high rlaps rat and risk of graft loss. Thos with APOL1 -associatd and nonhrditary primary rnal dis- as may not bnfit from immunosupprssion, although robust clinical trials ar lacking. Patints with scondary FSGS do not bnfit from immunosupprssiv thrapy; tratmnt should b dirctd at th inciting caus.Ahn  W t al. Approach to diagnosis and managmnt of primary glomrular disass du to podocytopathis in adults: Cor Curriculum 2020. Am J Kidny Dis. 2020;75:955. [PMID: 32331832] Andrs HJ t al. SGLT2 inhibition rquirs rconsidration of fundamntal paradigms in chronic kidny disas, diabtic nphropathy , IgA nphropathy and podocytopathis with FSGS lsions. Nphrol Dial Transplant. 2020. [Epub ahad of print] [PMID: 33313878]CMDT22_Ch22_p0912-p0951.indd  942 02/07/21 2:33 PMKIDNEY DISEASE943 CMDT 2022Shabaka  A t al. Focal sgmntal glomrulosclrosis: stat-of- th-art and clinical prspctiv. Nphron. 2020;144:413. [PMID: 32721952]ME MBRANOUS NEPHROPATHYE S S E N T I A L S  O F  D I A G N O S I S Varying degrees of proteinuria. Most common cause of primary adult nephrotic syndrome. Significant risk for hypercoagulable state if nephrotic syndrome present. Spike and dome pattern on kidney biopsy from subepithelial deposits. Secondary causes include hepatitis B virus and carcinomas. General ConsiderationsMm branous nphropathy is th most common caus of primary nphrotic syndrom in adults, most oftn prsnting in th fifth and sixth dcads. Primary mmbranous nphropathy is an autoimmun disas with ractivity against svral possibl podocyt antigns. Scondary disas is associatd with infctions, such as hpatitis B and C, ndo- carditis, and syphilis; undrlying carcinomas (som of ths cass may also involv autoimmunity to THSD7A); autoim- mun disas, such as SLE, mixd connctiv tissu disas, and thyroiditis; and crtain drugs, such as NSAIDs and cap- topril. Th cours of primary disas is highly variabl, with spontanous rmission in approximatly 30% of patints and progrssion to ESKD ovr 310 yars in 50%. Poorr out- com is associatd with concomitant tubulointrstitial fibro- sis, mal sx, lvatd srum cratinin on prsntation, hyprtnsion, and protinuria gratr than 10 g/day. Patints with mmbranous nphropathy and nphrotic syndrom hav a highr risk of hyprcoagulabl stat with thrombosis than nphrosis from othr tiologis, including a particular prdisposition to rnal vin thrombosis. Clinical FindingsA.  Symptoms and SignsPa tints may b asymptomatic or may hav dma or frothy urin. Symptomatic vnous thrombosis may b an initial sign. Thr may b symptoms or signs of an undrlying infction or noplasm (spcially lung, stomach, brast, and colon cancrs) in scondary mmbranous nphropathy.B.  Laboratory FindingsH ypoalbuminmia and hyprlipidmia ar charactristic laboratory findings in th nphrotic syndrom. Evaluation for scondary causs including srologic tsting for SLE, syphilis, and viral hpatitids, and ag- and risk-appropri- at cancr scrning should b prformd. Elvatd titr ofcirculating PLA2R antibodis is now considrd diagnostic for primary mmbranous nphropathy and may liminat th nd for kidny biopsy. Kidny biopsy findings in mmbranous nphropathy includ incrasd capillary wall thicknss without inflammatory changs or cllular prolif- ration; whn staind with silvr mthnamin, a spik and dom pattrn rsults from projctions of xcss GBM btwn th subpithlial immun complx dposits. Immunofluorscnc shows IgG and C3 staining along capillary loops. Elctron microscopy shows a discontinu- ous pattrn of dns dposits along th subpithlial sur- fac of th basmnt mmbran. TreatmentScondary  causs must b considrd prior to considr- ation of tratmnt. Primary disas tratmnt dpnds on th risk of rnal disas progrssion. Roughly 30% of patints prsnt with subnphrotic protinuria (lss than 3 g/day) and most hav a good prognosis with consrvativ managmnt, including antiprotinuric thrapy with ACE inhibitor or ARB if blood prssur is gratr than 125/75 mm Hg. Spontanous rmission may dvlop vn in thos with havy protinuria (about 30% of cass). Thus, us of immunosupprssiv agnts should b limitd to thos at highst risk for progrssion and with salvagabl rnal function. Patints with nphrotic syndrom dspit 6 months of consrvativ managmnt and srum crati- nin lss than 3.0 mg/dL (265 mcmol/L) may lct thrapy with rituximab or with corticostroids and cyclophospha- mid for 6 months. Calcinurin inhibitors with or without corticostroids may b considrd as wll. Rduction in protinuria may tak up to 6 months, spcially with rituximab-basd rgimns. Patints with primary mmbra- nous nphropathy ar xcllnt candidats for transplant.Frvnza FC  t al; MENTOR Invstigators. Rituximab or cyclo- sporin in th tratmnt of mmbranous nphropathy. N Engl J Md. 2019;381:36. [PMID: 31269364] Safar-Bouri L t al. Mmbranous nphropathy: diagnosis, trat- mnt, and monitoring in th post-PLA2R ra. Pdiatr Nphrol. 2021;36:19. [PMID: 31811540] Trujillo H t al. Nw ways of undrstanding mmbranous nphropathy. Nphron. 2020;144:261. [PMID: 32229730] NEphrOTIC SpECTrUM DISEASE FrOM SYSTEMIC DISOrDErS DIABETIC NEPHROPATHYE S S E N T I A L S  O F  D I A G N O S I S Evidence of diabetes mellitus, typically over 10 years. Albuminuria usually precedes decline in GFR. Other end-organ damage, such as retinopathy, is common.CMDT22_Ch22_p0912-p0951.indd  943 02/07/21 2:33 PMChApTEr 22944 CMDT 2022 General ConsiderationsDiabtic nphropa thy is th most common caus of ESKD in th Unitd Stats. Th incidnc is approximatly 30% in both typ 1 and typ 2 diabts mllitus. ESKD is much mor likly to dvlop in prsons with typ 1 diabts ml- litus, in part du to fwr comorbiditis and daths bfor ESKD nsus. With th currnt pidmic of obsity and typ 2 diabts mllitus, rats of diabtic nphropathy will con- tinu to incras. Patints at highr risk includ mals, African Amricans, Nativ Amricans, and thos with a family history of kidny disas. Mortality rats ar highr for diabt- ics with kidny disas compard to thos without CKD. Clinical FindingsDiabtic  nphropathy dvlops about 10 yars aftr th onst of diabts mllitus. It may b prsnt at th tim typ 2 diabts mllitus is diagnosd. Th first stag of clas- sic diabtic nphropathy is hyprfiltration with an incras in GFR, followd by th dvlopmnt of microalbuminuria (30300 mg/day). With progrssion, albuminuria incrass to gratr than 300 mg/day and can b dtctd on a urin dipstick as ovrt protinuria; th GFR subsquntly dclins ovr tim. Yarly scrning for microalbuminuria is rcommndd for all diabtic patints to dtct disas at its arlist stag; howvr, diabtic nphropathy can, lss commonly prsnt as nonprotinuric CKD. Th most common lsion in diabtic nphropathy is diffus glomrulosclrosis, but nodular glomrulosclrosis (Kimmlstil-Wilson noduls) is pathognomonic. Th kidnys ar usually nlargd. Kidny biopsy is not rquird in most patints unlss atypical findings ar prsnt, such as suddn onst of protinuria, nphritic spctrum faturs (s abov), massiv protinuria (gratr than 10 g/day), urinary cllular casts, or rapid dclin in GFR. Patints with diabts ar pron to othr rnal disass. Ths includ papillary ncrosis, chronic intrstitial nphri- tis, and typ 4 (hyporninmic hypoaldostronmic) rnal tubular acidosis. Patints ar mor suscptibl to AKI from many insults, including intravnous contrast matrial and concomitant us of an ACE inhibitor or ARB with NSAID. TreatmentW ith th onst of microalbuminuria, aggrssiv tratmnt is ncssary. Strict glycmic control should b mphasizd arly in diabtic nphropathy, with rcognition of risk of hypoglycmia as CKD bcoms advancd (s CKD sc- tion). Rcommndd blood prssur goals should b tai- lord to th individual patint: basd on th ACCORD trial, thos with microalbuminuria (30300 mg/day) and prsrvd GFR and thos with significant CVD likly driv littl bnfit from blood prssur lowring much blow 140/90 mm Hg, although th 2017 guidlins from th Amrican Hart Association advocat tratmnt to 130/80 mm Hg or lss. Thos with ovrt protinuria (sp- cially mor than 1 g/day) bnfit from a goal of lss than 130/80 mm Hg. ACE inhibitors and ARBs in thos with microalbuminuria lowr th rat of progrssion to ovrt protinuria and slow progrssion to ESKD by rducing intraglomrular prssur and via antifibrotic ffcts; thsagnts ar not absolutly indicatd in diabtic patints without albuminuria. Diabtic patints, spcially with advancd CKD, ar at rlativly high risk for AKI and hyprkalmia with inhibition of th rnin-angiotnsin sys- tm, so monitoring for hyprkalmia or a dclin in GFR mor than 30% within ~2 wks of th initiation or uptitra- tion of this thrapy is prudnt, with dos rduction or dis- continuation of thrapy if ths complications ar ncountrd. Combination ARB and ACE inhibitor therapy is not recommended due to lack of efficacy and increased adverse events of hyperkalemia and AKI. In addition to thir cardioprotctiv ffcts, th SGLT inhibitors, includ- ing canagliflozin, mpagliflozin, and dapagliflozin, slow progrssion of diabtic nphropathy; thir us is limitd to thos with typ 2 diabts mllitus with GFR gratr than 30 mL/min/1.73 m2. Us of ths agnts may rquir rduction in diurtic dosing in thos patints rquiring natriursis. Tratmnt of othr cardiovascular risk factors and obsity is crucial. Many with diabts hav multipl comorbid conditions; thrfor, in patints with ESKD who progrss to dialysis, mortality ovr th first 5 yars is high. Patints who ar rlativly halthy, howvr, bnfit from rnal transplantation.Bakris  G. Stmming th progrssion of diabtic kidny disas: th rol of th primary car clinician. J Fam Prac. 2020;69:S81. [PMID: 33104113] D Bor IH t al. Excutiv summary of th 2020 KDIGO Diab- ts Managmnt in CKD Guidlin: vidnc-basd advancs in monitoring and tratmnt. Kidny Int. 2020;98:839. [PMID: 32653403] Li J t al. Dcision algorithm for prscribing SGLT2 inhibitors and GLP-1 rcptor agonists for diabtic kidny disas. Clin J Am Soc Nphrol. 2020;15:1678. [PMID: 32518100] Tuttl KR t al. SLGT2 inhibition for CKD and cardiovascular disas in typ 2 diabts: rport of a scintific workshop sponsord by th National Kidny Foundation. Am J Kidny Dis. 2021;77:94. [PMID: 33121838]HI V-ASSOCIATED NEPHROPATHYHI V-associatd nphropathy usually prsnts with nphrotic syndrom and dclining GFR in patints with activ HIV infction. Most who prsnt with HIV-associatd nphropathy ar of African dscnt with APOL1 risk allls (s sction on Focal Sgmntal Glomrulosclrosis). HIV- associatd nphropathy is usually associatd with low CD4 counts and AIDS, but it can also b th initial prsntation of HIV disas. Prsons living with HIV ar at risk for othr kidny disass, such as toxicity from antirtroviral mdica- tions (g, tnofovir disoproxil fumarat), vascular disas, and diabts, or an immun complxmdiatd glomrular disas (HIV-immun complx disas). Classic HIV-associatd nphropathy is charactrizd by an FSGS pattrn of injury with glomrular collaps; svr tubulointrstitial damag may also b prsnt. HIV-associatd nphropathy is lss common in th ra of HIV scrning and mor ffctiv antirtroviral thrapy. Small, uncontrolld studis hav shown that antirtroviral thrapy slows progrssion of disas. ACE inhibitors or ARBs can b usd to control blood prssur and protin- uria. Kidny biopsy is ncssary for diagnosis and to rulCMDT22_Ch22_p0912-p0951.indd  944 02/07/21 2:33 PMKIDNEY DISEASE945 CMDT 2022out  othr causs of kidny dysfunction. Patints who prog- rss to ESKD and ar othrwis halthy ar good candi- dats for kidny transplantation.H amzah L t al. Optimizing antirtroviral rgimns in chronic kid- ny disas. Curr Opin Infct Dis. 2019;32:1. [PMID: 30461453] Naickr S. HIV/AIDS and chronic kidny disas. Clin Nphrol. 2020;93:87. [PMID: 31397267]RE NAL AMYLOIDOSISAm yloidosis is a rlativly rar caus of nphrotic syndrom. It is causd by tissu dposition of an ovrproducd and abnormally foldd protin (amyloid). Svral diffrnt pro- tins can form amyloid fibrils with rnal dposition. Primary amyloidosis, or AL amyloidosis, is th most common form and is du to a plasma cll dyscrasia causing ovrproduction and dposition of monoclonal Ig light chains (s Chaptr 13). Scondary amyloidosis, or AA amyloidosis, can rarly occur in chronic inflammatory disas such as rhumatoid arthri- tis, inflammatory bowl disas, or chronic infction; in ths cass, thr is dposition of an acut phas ractant, srum amyloid A protin. Othr lss common forms of amy- loidosis may also b ncountrd. Protinuria, dcrasd GFR, and nphrotic syndrom ar prsnting symptoms and signs of rnal involvmnt in amyloidosis; vidnc of othr organ involvmnt, such as th hart, is common. Srum and urin protin lctropho- rsis should b don as scrning tsts; if a monoclonal spik is found on ithr, srum fr light chains should b quantifid and th kappa:lambda ratio assssd. Amyloid- affctd kidnys ar oftn largr than 10 cm. Pathologi- cally, glomruli ar filld with amorphous dposits that show grn birfringnc with Congo rd staining. AL amyloidosis progrsss to ESKD in an avrag of 23 yars. Fiv-yar ovrall survival is lss than 20%, with wors prognosis in thos with advancd cardiac involv- mnt. Standard tratmnt is a combination of mlphalan, corticostroids, and th protosom inhibitor bortzomib; addition of daratumumab shows promis. Mlphalan and autologous stm cll transplantation ar associatd with a high (45%) mortality rat but can induc rmission in 80% of survivors; howvr, fw patints ar ligibl for this tratmnt. In AA amyloidosis, rmission can occur if th undrlying disas is succssfully tratd. Rnal transplan- tation is an option.H ogan JJ t al. Dysprotinmia and th kidny: Cor Curriculum 2019. Am J Kidny Dis. 2019;74:822. [PMID: 31331759] Mn P t al. Monoclonal gammopathis of rnal significanc: rnal biopsy and byond. Cancrs (Basl). 2020;12:1741. [PMID: 32629844] Palladini G t al. Managmnt of AL amyloidosis in 2020. Hma- tology Am Soc Hmatol Educ Program. 2020;2020:363. [PMID: 33275753] TUBULOINTErSTITIAL DISEASEST ubulointrstitial disas may b acut or chronic. Acut disas is most commonly associatd with mdications, infctious agnts, and systmic rhumatologic disordrs.Intrstitial dma, infiltration with polymorphonuclar nutrophils, and accompanying ATN can b sn. (S Acut Kidny Injury, abov, and Tabl 229.) Chronic dis- as is associatd with insults from an acut factor or pro- grssiv insults without any obvious acut caus. Intrstitial fibrosis and tubular atrophy ar prsnt, with a mononu- clar cll prdominanc. Th chronic disordrs ar dscribd blow.CH RONIC TUBULOINTERSTITIAL DISEASESE S S E N T I A L S  O F  D I A G N O S I S Kidney size is small and contracted. Decreased urinary concentrating ability. Hyperchloremic metabolic acidosis. Reduced GFR.Table 229. Causes of acute tubulointerstitial nephritis (abbreviated list).Dug  reactions Antibiotics Beta-lactam antibiotics: methicillin, penicillin, ampicillin, cephalosporins Ciprofloxacin Erythromycin Sulfonamides (trimethoprim-sulfamethoxazole, loop and thiazide diuretics) Tetracycline Vancomycin Ethambutol Rifampin Nonsteoidal anti-inflammatoy dugs Diuetics Thiazides Furosemide Ote Allopurinol Cimetidine Phenytoin Proton pump inhibitors Systemic Infections Bacteia Streptococcus Corynebacterium diphtheriae Legionella Viuses Epstein-Barr Ote Mycoplasma Rickettsia rickettsii Leptospira icterohaemorrhagiae Toxoplasma Idioatic Tubulointerstitial nephritis-uveitisCMDT22_Ch22_p0912-p0951.indd  945 02/07/21 2:33 PMChApTEr 22946 CMDT 2022 General ConsiderationsTh  most common caus of chronic tubulointrstitial disas isobstructive uropathy , which may rsult from prolongd or rcurrnt obstruction. Th major causs ar prostat dis- as in mn; urtral calculus in a singl functioning kidny; bilatral urtral calculi; carcinoma of th crvix, colon, or bladdr; and rtropritonal tumors or fibrosis. Rflux nphropathy from vesicoureteral reflux is pri- marily a disordr of childhood and occurs whn urin passs rtrograd from th bladdr to th kidnys during voiding. It is th scond most common caus of chronic tubulointrstitial disas. It occurs as a rsult of an incom- ptnt vsicourtral sphinctr. Urin can xtravasat into th intrstitium, triggring an inflammatory rspons that lads to fibrosis ovr tim. Th inflammatory rspons is du to ithr bactria or normal urinary componnts. Analgesic nephropathy is most commonly sn in patints who ingst larg quantitis of pain mdication. Th drugs of concrn ar phnactin, paractamol, aspirin, and othr NSAIDs; actaminophn is a possibl but lss crtain culprit. Ingstion of at last 1 g/day for 3 yars of ths analgsics is considrd ncssary for kidny dys- function to dvlop, and most patints grossly undrsti- mat thir analgsic us. This disordr occurs most frquntly in individuals who ar using analgsics for chronic hadachs, muscular pains, and arthritis; fmal sx, oldr ag, and malnutrition ar risk factors for analg- sic nphropathy. Tubulointrstitial inflammation and pap- illary ncrosis ar sn on pathologic xamination. Papillary tip and innr mdullary concntrations of som analgsics ar tnfold highr than in th rnal cortx. Phnactin was onc a common caus of this disordr but is now rarly availabl. Aspirin and othr NSAIDs can caus damag through intrmdiat mtabolits, which can lad to cll ncrosis. Ths drugs also dcras mdul- lary blood flow (via inhibition of prostaglandin synthsis) and dcras glutathion lvls, which ar ncssary for dtoxification. Environmntal xposur to heavy metals such as lad, cadmium, mrcury, and bismuthoccurs infr- quntly now in th Unitd Stats but can caus tubuloint- rstitial disas. Individuals at risk for lad-inducd tubulointrstitial disas ar thos with occupational xpo- sur (g, wldrs who work with lad-basd paint) and drinkrs of alcohol distilld in automobil radiators (moonshin whisky usrs). Lad is filtrd by th glom- rulus and is transportd across th proximal convolutd tubul, whr it accumulats and causs cll damag. Fibrosd artriols and cortical scarring also lad to dam- agd kidnys. A form of chronic tubulointrstitial disas dispropor- tionatly affcting mal agricultural workrs in Cntral Amrica is an important caus of ESKD. Whil th xact pathophysiology is still unknown, th trm Mesoamerican nephropathy is applid to rflct th gographic rgion in which this disas occurs. Affctd individuals tnd to b 3050 yars of ag without diabts, hyprtnsion, or othr causs of kidny disas who work undr hot conditions, particularly in sugar can or cotton filds, and ar thus suscptibl to dhydration.Clinical FindingsA.  General FindingsPo lyuria is common bcaus tubular damag lads to nphrognic diabts insipidus, possibly from vasoprssin insnsitivity. Volum dpltion can also occur as a rsult of a salt-wasting dfct in som individuals. Patints can bcom hyprkalmic both bcaus th GFR is lowr and th distal tubuls bcom aldostron rsistant. Rnal tubular acidosis is common and dvlops through thr possibl mchanisms: (1) rducd ammonia production in th proximal tubuls, (2) inability to rab- sorb bicarbonat in th proximal tubuls, and (3) inability to scrt protons in th distal tubuls, which is ndd for urinary acidification. A typ 1 or typ 4 rnal tubular acidosis is mor commonly obsrvd in tubulointrstitial disas, xcpt in th cas of havy mtal xposur whr dirct proximal tubular damag lads to a proximal (typ 2) rnal tubular acidosis. In contrast to acut intrstitial nphritis, th urinalysis in chronic tubulointrstitial disas is oftn nonspcific; a fw clls or broad waxy casts may b sn, but urinalysis oftn is bland. Protinuria is typically lss than 2 g/day, owing to inability of th proximal tubul to rabsorb frly filtrabl protins.B.  Specific Findings1. Obstructive uropathy  In partial obstruction, patints can xhibit polyuria (from tubular damag) or oliguria (du to dcrasd GFR). Azotmia and hyprtnsion (du to incrasd rnin-angiotnsin production) ar usually prsnt. Abdominal, rctal, and gnitourinary xamina- tions may b hlpful in dtcting a distndd bladdr or larg prostat. Urinalysis may show hmaturia, pyuria, and bactriuria but is oftn bland. Abdominal ultrasound may dtct mass lsions, hydrourtr, and hydronphrosis but may ovrlook 5% of cass. CT scanning or MRI can b considrd if suspicion rmains dspit a normal ultrasound. 2. Vesicoureteral reflux Vsicourtral rflux is typically diagnosd in young childrn with a history of rcurrnt urinary tract infctions but can also dvlop aftr kidny transplantation. Rnal ultrasound or IVP can show rnal scarring and hydronphrosis. Although most damag occurs bfor ag 5 yars, progrssiv dtrioration to ESKD occurs. 3. Analgesics Patints can xhibit hmaturia, mild pro- tinuria, polyuria (from tubular damag), anmia (from GI blding or rythropoitin dficincy), and stril pyuria. Sloughd papilla can b found in th urin whn papillary ncrosis occurs and can lad to obstruction. Although clas- sically diagnosd by IVP , papillary ncrosis is mor com- monly dtctd by CT imaging. 4. Heavy metals Proximal tubular damag from lad xposur can caus dcrasd scrtion of uric acid, rsult- ing in hypruricmia and saturnin gout. Patints com- monly ar hyprtnsiv. Diagnosis is stablishd with a calcium disodium dtat (EDTA) chlation tst pr- formd on a timd urin collction. Urin xcrtion ofCMDT22_Ch22_p0912-p0951.indd  946 02/07/21 2:33 PMKIDNEY DISEASE947 CMDT 2022gratr  than 600 mg of lad following 1 g of EDTA indi- cats xcssiv lad xposur. Th proximal tubular dys- function from cadmium can caus hyprcalciuria and nphrolithiasis. 5. Mesoamerican nephropathy In addition to low-grad protinuria, hypruricmia and hypokalmia ar consis- tntly (but not univrsally) idntifid among affctd indi- viduals. Although not pathognomonic, aras of glomrular ischmia (dspit vry mild vascular disas) that accom- pany chronic tubulointrstitial injury on kidny biopsy ar highly suggstiv of Msoamrican nphropathy. 6. Balkan nephropathy Patints commonly dvlop pro- tinuria, glycosuria, acidosis, and suffr urinary concn- trating dfcts. Notably, urothlial carcinomas ar prsnt in approximatly 50% of affctd individuals at tim of diagnosis. TreatmentT ratmnt dpnds first on idntifying th disordr rsponsibl for kidny dysfunction. Th dgr of intrsti- tial fibrosis on biopsy rflcts irrvrsibl damag, which is dirctly associatd with th liklihood of ESKD progrs- sion. Tratmnt is dirctd at mdical managmnt of risk factors for disas progrssion, such as hyprtnsion and protinuria. Tubular dysfunction may rquir bicarbonat supplmntation to trat mtabolic acidosis or phosphorus and potassium rstriction. If hydronphrosis is prsnt, th obstruction should b promptly rlivd. Prolongd obstruction lads to furthr tubular damagparticularly in th distal nphron which may bcom irrvrsibl. Although surgical corrc- tion of rflux may b indicatd in slct circumstancs, this will unlikly prvnt dtrioration toward ESKD if fibrosis is xtnsiv. Patints in whom lad nphropathy is suspctd should continu chlation thrapy with EDTA if thr is minimalvidnc of irrvrsibl rnal damag, and continud xpo- sur should b avoidd. Tratmnt of analgsic nphropathy rquirs with- drawal of all analgsics. Stabilization of or improvmnt in kidny function may occur if significant intrstitial fibrosis is not prsnt. Ensuring volum rpltion during xposur to analgsics may also hav som bnficial ffcts. Patints with Msoamrican nphropathy should b counsld to rmain adquatly hydratd and, if possibl, minimiz hat xposur. NSAIDs should b avoidd du to thir hmodynamic ffcts (rducd rnal blood flow and glomrular filtration), which may xacrbat rnal injury in stats of volum dpltion and hot climats. When to Refer Patints with stag 35 CKD should b rfrrd to a nphrologist whn tubulointrstitial disass ar sus- pctd. Othr slct cass of stag 12 CKD should also b rfrrd, for xampl if rnal tubular acidosis is prsnt. Patints with urologic abnormalitis should b rfrrd to a urologist.Cor ra-Rottr R t al. Msoamrican nphropathy. Smin Nphrol. 2019;39:263. [PMID: 31054625] CYSTIC DISEASES OF ThE KIDNEYRnal cysts  ar pithlium-lind cavitis filld with fluid or smisolid matrial that dvlop primarily from rnal tubu- lar lmnts. On or mor simpl cysts ar found in 50% of individuals ovr th ag of 50 yars. Thy ar rarly symp- tomatic and hav littl clinical significanc. In contrast, gnralizd cystic disass ar associatd with cysts scat- trd throughout th cortx and mdulla of both kidnys and can progrss to ESKD (Tabl 2210). Table 2210. Clinical features of renal cystic disease. Simle renal CystsAcquied renal CystsAutosomal Domi- nant polycystic Kidney DiseaseMedullay Songe KidneyMedullay Cystic Kidney Prevalence Common Dialysis patients 1:1000 1:5000 Rare Inheritance None None Autosomal dominant None Autosomal dominant Age at onset   2040 years 4060 years Adulthood Kidney size Normal Small Large Normal Small Cyst location Cortex and medulla Cortex and medulla Cortex and medulla Collecting ducts Corticomedullary junction Hematuria Occasional Occasional Common Rare Rare Hypertension None Variable Common None None Associated complicationsNone Adenocarcinoma in cystsHepatic cysts, urinary tract infections, renal calculi, cere- bral aneurysmsRenal calculi, urinary tract infectionsPolyuria, salt wasting Kidney failure Never Always Frequently Never AlwaysCMDT22_Ch22_p0912-p0951.indd  947 02/07/21 2:33 PMChApTEr 22948 CMDT 2022SI MPLE OR SOLITARY CYSTSSimpl  cysts account for 6570% of all rnal masss. Thy ar gnrally found at th outr cortx and contain fluid that is consistnt with an ultrafiltrat of plasma. Most ar found incidntally on ultrasonographic xamination. Simpl cysts ar typically asymptomatic but can bcom infctd. Th major objctiv with simpl cysts is to diffrnti- at thm from malignancy, abscss, or polycystic kidny disas. Cystic disas can dvlop in dialysis patints and has th potntial to progrss to malignancy. Ultrasound and CT scanning ar rcommndd to valuat ths masss. Simpl cysts must mt thr sonographic critria to b considrd bnign: (1) cho fr, (2) sharply dmar- catd with smooth walls, and (3) an nhancd back wall (indicating good transmission through th cyst). Com- plx cysts can hav thick walls, calcifications, solid com- ponnts, and mixd chognicity. On CT scan, simpl cysts should hav smooth thin walls that ar sharply dmarcatd and should not nhanc with contrast mdia. Rnal cll carcinoma will nhanc but typically is of lowr dnsity than halthy parnchyma. Artriography can also b usd to valuat a mass proprativly. Rnal cll car- cinoma is hyprvascular in 80%, hypovascular in 15%, and avascular in 5% of cass. If a cyst has qustionabl imaging charactristics or is of uncrtain significanc, priodic rvaluation is rcom- mndd. Urologic consultation and surgical xploration may b considrd. Bnign cysts do not rquir any sp- cific follow-up, though changs in clinical prsntation should prompt rpat imaging.Smith AD t  al. Approach to rnal cystic masss and th rol of radiology. Radiol Clin North Am. 2020;58:897. [PMID: 32792122]AUTOS OMAL DOMINANT POLYCYSTIC KIDNEY DISEASEE S S E N T I A L S  O F  D I A G N O S I S Multiple cysts in both kidneys; number of cysts depends on patient age. Combination of hypertension and large palpable kidneys suggestive of disease. Autosomal dominant chromosomal abnormalities present in some patients. General ConsiderationsA utosomal dominant polycystic kidny disas is th most common monognic kidny disas, affcting 12.5 million individuals worldwid. ESKD dvlops by ag 60 in up to 50% of patints. Th disas has variabl pntranc but accounts for 510% of all ESKD cass globally. At last two gns account for this disordr: PKD1 on th short arm of chromosom 16 (8590% of patints) and PKD2on chromosom 4 (1015%). Patints with th PKD2 mutation hav slowr progrssion of disas and longr lif xpctancy than thos with PKD1 . Othr sporadic cass without ths mutations ar also rcognizd. Clinical FindingsA bdominal or flank pain and hmaturia (ithr microscopic or gross) ar prsnt in most patints. A history of urinary tract infctions and nphrolithiasis is common. A family history of autosomal dominant polycystic kidny disas is prsnt in 75% of cass, and mor than 50% of patints hav hyprtnsion that may prcd clinical manifstations. Patints hav larg kidnys that may b palpabl on abdomi- nal xamination. Th combination of hyprtnsion and an abdominal mass should rais suspicion for th disas. Forty to 50 prcnt hav concurrnt hpatic cysts; pancratic and splnic cysts may occur. Dspit dvlopmnt of CKD, hmoglobin is oftn normal as a rsult of cystic rythropoi- tin production. Urinalysis may show hmaturia and subn- phrotic protinuria. In patints with an stablishd family history of autosomal dominant polycystic kidny disas, ultrasonography confirms th diagnosistwo or mor cysts in patints undr ag 30 yars (snsitivity of 88.5%), two or mor cysts in ach kidny in patints agd 3059 yars (sn- sitivity of 100%), and four or mor cysts in ach kidny in patints agd 60 yars or oldr ar diagnostic for autosomal dominant polycystic kidny disas. Importantly, ths cri- tria do notapply to individuals without a known family history; patints without a known family history of polycys- tic kidny disas rquir additional diagnostic valuation including CT scanning, which rvals innumrabl cysts in cass of polycystic kidny disas (Figur 226); th prs- nc of multipl hpatic cysts can aid in stablishing th diagnosis. In som cass, gntic tsting for PKD1 andPKD2 mutations may b rquird. Figure 226. Polycystic kidney disease. CT scan showing bilateral polycystic kidneys in a 43-year-old woman who presented with newly diagnosed hyper- tension and microscopic hematuria. (Used, with permis- sion, from Michael Freckleton, MD, in Usatine RP , Smith MA, Mayeaux EJ Jr, Chumley H. The Color Atlas of Family Medicine , 2nd ed. McGraw-Hill, 2013.)CMDT22_Ch22_p0912-p0951.indd  948 02/07/21 2:33 PMKIDNEY DISEASE949 CMDT 2022 Complications & TreatmentA.  PainA bdominal or flank pain is causd by infction, blding into cysts, and nphrolithiasis. Bd rst and analgsics ar rcom- mndd. Cyst dcomprssion can hlp with chronic pain.B.  HematuriaGross  hmaturia is most commonly du to cystic ruptur into th rnal plvis, but it can also b causd by a kidny ston or urinary tract infction. Hmaturia typically rsolvs within 7 days with bd rst and hydration.C.  Renal InfectionAn  infctd rnal cyst should b suspctd in patints who hav flank pain, fvr, and lukocytosis. Importantly, urinaly- sis may b normal if th cyst dos not communicat dirctly with th urinary tract. CT scans can b hlpful bcaus an infctd cyst may hav incrasd wall thicknss. Bactrial cyst infctions ar difficult to trat. Antibiotics with cystic pntration ar th agnts of choic (g, fluoroquinolons [ciprofloxacin, 500 mg vry 12 hours, or lvofloxacin, 500 mg onc daily if GFR normal], or trimthoprim- sulfamthoxazol doubl-strngth tablt twic daily).D . NephrolithiasisU p to 20% of patints hav kidny stons, primarily cal- cium oxalat. Hydration (23 L/day) is rcommndd in ordr to prvnt prcipitation of stons.E.  HypertensionA t th tim of prsntation, 50% of patints hav hyprtn- sion, and it will dvlop in most patints during th cours of th disas. Cyst-inducd ischmia appars to caus activation of th rnin-angiotnsin systm, and cyst dcomprssion can lowr blood prssur tmporarily. Hyprtnsion should b tratd with an ACE inhibitor or an ARB as th prfrrd drug if tolratd. Intnsiv blood prssur control (goal lss than or qual to 110/75 mm Hg) is rcommndd in adults youngr than 50 yars of ag with GFR gratr than 60 mL/min/1.73m2; for all othr affctd individuals, goal blood prssur is lss than or qual to 130/85 mm Hg.F . Cerebral AneurysmsAbo ut 1015% of patints hav artrial anurysms in th circl of Willis. Scrning artriography is not rcom- mndd unlss th patint has a family history of anu- rysms, is mployd in a high-risk profssion (g, airlin pilot), or is undrgoing lctiv surgry with a high risk of dvloping modrat to svr prioprativ hyprtnsion.G.  Other ComplicationsV ascular problms includ mitral valv prolaps in up to 25% of patints, aortic anurysms, and aortic valv abnor- malitis. Colonic divrticula ar mor common in patints with polycystic kidnys.PrognosisKidny  siz, rportd as total kidny volum, is th bst prdictor of kidny function dclin in patints with auto- somal dominant polycystic kidny disas, and it can b masurd via CT or MRI using th Mayo Classification systm (www.mayo.du/rsarch/documnts/pkd-cntr- adkpkd-classification/doc-20094754). Thos at high risk according to this classification systm may bnfit from tratmnts that dlay cyst growth. Vasoprssin rcptor antagonists dcras th rat of chang in total kidny vol- um and GFR dclin, and on such mdication (tolvap- tan) is FDA approvd for th tratmnt of autosomal dominant polycystic kidny disas. Libral ingstion of watr will hav th sam physiologic ffct on vasoprssin, and patints should b ncouragd to drink at last 2 L of watr daily. Othr agnts such as octrotid, sirolimus, and tyrosin kinas inhibitors dcras th rat of cyst growth but not th dclin in kidny function and ar thus not routinly usd. Avoidanc of caffin may prvnt cyst formation du to ffcts on G-coupld protins.Cornc-L  Gall E t al. Autosomal dominant polycystic kidny disas. Lanct. 2019;393:919. [PMID: 30819518] Nobakht N t al. Advancs in autosomal dominant polycystic kidny disas: a clinical rviw. Kidny Md. 2020;2:196. [PMID: 32734239]ME DULLARY SPONGE KIDNEYMd ullary spong kidny is blivd to affct lss than 1% of th gnral population. Although prsnt at birth, it is not usually diagnosd until th fourth or fifth dcad. It is thought to occur du to disruption of th urtric bud- mtanphric msnchym intrfac, oftn rsulting from autosomal dominant mutations in gns rsponsibl for urognital dvlopmnt. Kidnys hav a markd irrgular nlargmnt of th mdullary and intrpapillary collcting ducts. This is associatd with mdullary cysts that ar dif- fus, giving a Swiss chs apparanc in ths rgions. Clinical FindingsNp hrolithiasis is th most common clinical prsntation for mdullary spong kidny. Othr prsntations may includ hmaturia (ithr gross or microscopic) or rcur- rnt urinary tract infctions. Common abnormalitis ar a dcrasd urinary concntrating ability and nphrocalci- nosis; lss common is incomplt typ 1 distal rnal tubular acidosis. Th diagnosis is stablishd clinically through laboratory data and imaging charactristics. As th pr- frrd imaging tst, CT shows cystic dilatation of th distal collcting tubuls with a striatd apparanc, and calcifica- tions in th rnal collcting systm. Similar findings on ultrasound may also support th diagnosis. TreatmentT ratmnt for mdullary spong kidny is supportiv and aimd at undrlying abnormalitis such as nphrolithiasis and acidosis. Adquat fluid intak (2 L/day) hlps rduc risk of ston formation. If hyprcalciuria is prsnt,CMDT22_Ch22_p0912-p0951.indd  949 02/07/21 2:33 PMChApTEr 22950 CMDT 2022thiazid diurtics ar  rcommndd bcaus thy dcras calcium xcrtion. Alkali thrapy is rcommndd if rnal tubular acidosis is prsnt. PrognosisRnal function is wll maintaind unlss thr ar  compli- cations from rcurrnt urinary tract infctions and nphrolithiasis.Pisani I t  al. Ultrasound to addrss mdullary spong kidny: a rtrospctiv study. BMC Nphrol. 2020;21:430. [PMID: 33046028] MULTISYSTEM DISEASES WITh VArIABLE KIDNEY INVOLVEMENT PLASMA CELL MYELOMAPlasma  cll myloma is a malignancy of plasma clls (s Chaptr 13) that can caus a varity of rnal disordrs. Injury is du to th toxic ffcts of monoclonal immuno- globulins or light chain componnts producd by plasma clls. Myloma kidny (formally calld cast nphropathy) is th most common kidny disas in plasma cll myloma and occurs whn light chains (Bnc Jons protin) in th urin caus rnal toxicity and tubular obstruction by pr- cipitating in th distal tubuls. Plasma cll myloma may also caus Fanconi syndrom, a typ 2 proximal rnal tubular acidosis charactrizd by hypophosphatmia and inappropriat glycosuria. Protinuria in myloma kidny is xclusivly tubular; hnc, urin dipstick findings ar minimal sinc glomrular protinuria is not prsnt. Hyprcalcmia and hypruricmia ar frquntly sn. Glomrular amyloidosis with nphrotic syndrom can dvlop in patints with plasma cll myloma; in ths patints, urin dipstick is positiv du to glomrular pi- thlial cll foot procss ffacmnt and albumin spilling into th Bowman capsul; hmaturia may or may not b prsnt. Othr conditions rsulting in kidny dysfunction includ plasma cll infiltration of th rnal parnchyma and hyprviscosity syndrom compromising rnal blood flow. Th prsnc of myloma-rlatd kidny disas dos not itslf prclud us of contrast dy for imaging studis; standard prcautions for th us of intravnous contrast and gadolinium in patints with rducd GFR apply to patints with myloma-rlatd kidny disas. Thrapy for AKI (s Acut Kidny Injury, abov) attributd to plasma cll myloma includs corrction of hyprcalcmia; vol- um rpltion; and chmothrapy for th undrlying malignancy, typically with bortzomib-basd agnts. Plas- maphrsis has bn proposd to rduc th burdn of circulating monoclonal protins, but rsults hav bn quivocal and its us is controvrsial.Mayszko  J t al. KDIGO Controvrsis Confrnc on onco- nphrology: kidny disas in hmatological malignancis and th burdn of cancr aftr kidny transplantation. Kidny Int. 2020;98:1407. [PMID: 33276867]SICKLE CELL DISEASEKidny  dysfunction associatd with sickl cll disas is most commonly du to sickling of rd blood clls in th rnal mdulla bcaus of low oxygn tnsion and hyprto- nicity. Congstion and stasis lad to hmorrhag, intrsti- tial inflammation, and papillary infarcts with rsultant ncrosis. Clinically, hmaturia is common, and protinuria can b prsnt as wll, portnding a poorr prognosis. Damag to rnal capillaris also lads to diminishd con- cntrating ability. Isosthnuria (urin osmolality qual to that of srum) is routin, and patints can asily bcom dhydratd. Ths abnormalitis ar also ncountrd in patints with sickl cll trait. Sickl cll glomrulopathy is lss common but inxorably progrsss to ESKD. Its pri- mary clinical manifstation is protinuria. Optimal trat- mnt rquirs adquat hydration and control of th sickl cll disas.Lim  RI t al. Amrican Socity of Hmatology 2019 guidlins for sickl cll disas: cardiopulmonary and kidny disas. Blood Adv. 2019;3:3867. [PMID: 31794601] Olaniran KO t al. Kidny function dclin among black patints with sickl cll trait and sickl cll disas: an obsr- vational cohort study. J Am Soc Nphrol. 2020;31:393. [PMID: 31810990]TU BERCULOSISRnal  tubrculosis usually rsults from hmatognous sprad and is an undrdiagnosd ntity. Up to 20% of patints with xtrapulmonary tubrculosis hav urognital involvmnt, of which th kidny is most commonly affctd. Its classic manifstation is th prsnc of micro- scopic pyuria without bactrial growth on urin cultur or stril pyuria.  Mor oftn, othr bactria ar also prsnt, and microscopic hmaturia may coxist. Urin culturs wr onc th gold standard for diagnosis, but th advnt of urin nuclic acid tsting for tubrculosis has incrasd snsitivity. Charactristic findings on imaging includ papillary ncrosis and cavitation of th rnal parnchyma. Urtral stricturs or calcifications may also b prsnt. Kidny biopsy is not usually ndd to confirm th diagnosis but rvals granulomatous inflammation and tubulointrstitial nphritis. Prompt initiation of anti- tubrculosis tratmnt is indicatd, without which pro- grssion to ESKD occurs du to chronic inflammation and obstruction.K ulchavnya E t al. Challngs in urognital tubrculosis. World J Urol. 2020;38:89. [PMID: 30997530]GO UT & THE KIDNEYTh  kidny is th primary organ for xcrtion of uric acid. Patints with proximal tubular dysfunction hav dcrasd xcrtion of uric acid and ar mor pron to gouty arthritis attacks. Dpnding on th pH and uric acid concntration, dposition can occur in th tubuls, th intrstitium, or th urinary tract. Th mor alkalin pH of th intrstitium causs urat salt dposition,CMDT22_Ch22_p0912-p0951.indd  950 02/07/21 2:33 PMKIDNEY DISEASE951 CMDT 2022wh ras th acidic nvironmnt of th tubuls and uri- nary tract causs uric acid crystal dposition at high concntrations. Thr disordrs ar commonly sn: (1) uric acid nph- rolithiasis, (2) acut uric acid nphropathy, and (3) chronic urat nphropathy. Kidny dysfunction with uric acid nphrolithiasis stms from obstructiv physiology. Acut uric acid nphropathy prsnts with dirct tubulointrsti- tial toxicity from uric acid crystals and distal tubul obstruction causd by prcipitation of uric acid crystals. Chronic urat nphropathy is causd by dposition of urat crystals in th alkalin mdium of th intrstitium; this can lad to fibrosis and atrophy. Tratmnt btwn gouty attacks involvs avoidanc of food and drugs causing hypruricmia (s Chaptr 20), aggrssiv hydration, and urat-lowring thrapy (such as with allopurinol and fbuxostat). Th thr disordrs mn- tiond abov ar sn in both ovrproducrs and undrx- crtors of uric acid. Th lattr situation may sm countrintuitiv; howvr, ths patints hav acidic urin, which nabls prcipitation of rlativly insolubl uric acid crystals. For thos with uric acid nphrolithiasis, fluid intak should xcd 3 L/day, and us of a urinary alkalinizing agnt can b considrd. Patints with hypruricmia who do not hav a history of gout or uric acid nphrolithiasis hav not bn shown to bnfit from urat-lowring thrapy.Badv SV  t al; CKD-FIX Study Invstigators. Effcts of allopu- rinol on th progrssion of chronic kidny disas. N Engl J Md. 2020;382:2504. [PMID: 32579811]NE PHROGENIC SYSTEMIC FIBROSISNp hrognic systmic fibrosis is a multisystm disordr sn only in patints with CKD (primarily with an GFR lss than 15 mL/min/1.73 m2, but rarly 1529 mL/ min/1.73 m2), AKI, and aftr kidny transplantation. His- topathologically, thr is an incras in drmal spindl cllspositiv for CD34 and procollagn I. Collagn bundls with mucin and lastic fibrs ar also notd. Nphrognic systmic fibrosis was first rcognizd in hmodialysis patints in 1997 and has bn strongly linkd to us of contrast agnts containing gadolinium. Incidnc following gadolinium injction is approximatly 14% in th highst risk (ESKD) population and lowr in patints with lss svr kidny dysfunction. Th incidnc has dcrasd ovr tim du to limiting us of gadolinium in patints with CKD and AKI and modifid gadolinium prparations. Thr is an FDA warning rgarding avoidanc of this agnt for patints with an GFR lss than 30 mL/min/1.73 m2. Clinical FindingsNp hrognic systmic fibrosis affcts svral organ sys- tms, including th skin, muscls, lungs, and cardiovascu- lar systm. Th most common manifstation is a dbilitating fibrosing skin disordr that can rang from skin-colord to rythmatous papuls, which coalsc to brawny patchs. Th skin can b thick and woody in aras and is painful out of proportion to findings on xamination. TreatmentCas  rports and sris dscrib bnfit of corticostroids, photophrsis, plasmaphrsis, and sodium thiosulfat, but thir tru fficacy is unknown. CT is prfrrd to MR imaging with gadolinium whn similar diagnostic infor- mation can b gland. If gadolinium absolutly must b usd in patints on dialysis, practic guidlins rcom- mnd using no mor than th standard dos and hmodi- alysis immdiatly aftr xposur.Ma thur M t al. Gadolinium dposition and nphrognic systmic fibrosis: a radiologists primr. Radiographics. 2020;40:153. [PMID: 31809230] Rudnick MR t al. Risks and options with gadolinium-basd con- trast agnts in patints with CKD: a rviw. Am J Kidny Dis. 2021;77:517. [PMID: 32861792]CMDT22_Ch22_p0912-p0951.indd  951 02/07/21 2:33 PM952 CMDT 2022 Mathew Sorensen, MD, MS, FACS Thomas J. Walsh, MD, MS Maahum A. Haider, MD, MPHUrologic Disorders23HE MATURIAE S S E N T I A L S  O F  D I A G N O S I S Gross hematuria requires evaluation: the upper urinary tract should be imaged, and the lower tract evaluated by cystoscopy. In microscopic hematuria, the workup should be risk stratified. General ConsiderationsAn upper tract source (kidneys and ureters) can be identified in 10% of patients with gross or microscopic hematuria. For upper tract sources, stone disease accounts for 40%, medical kidney disease (medullary sponge kidney, glomerulonephri- tis, papillary necrosis) for 20%, renal cell carcinoma for 10%, and urothelial cell carcinoma of the ureter or renal pelvis for 5%. Medication ingestion and associated medical problems may provide diagnostic clues. Analgesic use (papillary necro- sis), cyclophosphamide (chemical cystitis), antibiotics (inter- stitial nephritis), diabetes mellitus, sickle cell trait or disease (papillary necrosis), a history of stone disease, or malignancy should all be investigated. The lower tract source of gross hematuria (in the absence of infection) is most commonly from bleeding prostatic varices or urothelial carcinoma of the bladder. Microscopic hematuria in the male is most com- monly from benign prostatic hyperplasia (13%), kidney stones (6%), or urethral stricture (1.4%). The presence of hematuria in patients receiving antiplatelet or anticoagulation therapy cannot be presumed to be due to the medication; a complete evaluation is warranted consisting of upper tract imaging, cystoscopy, and urine cytology (see Chapter 39 for Bladder Cancer, Cancers of the Ureter & Renal Pelvis, Renal Cell Carcinoma, and Other Primary T umors of the Kidney). Clinical FindingsA.  Symptoms and SignsIf  gross hematuria occurs, a description of the timing (initial, terminal, total) may provide a clue to the localization ofdisease. Associated symptoms (ie, renal colic, irritative void- ing symptoms, or constitutional symptoms) should be inves- tigated. The history should be focused on risk factors for urothelial cancer (age, male sex, smoking history, history of gross hematuria, irritative lower urinary tract voiding symp- toms, history of cyclophosphamide or ifosfamide chemo- therapy, family history of urothelial carcinoma or Lynch syndrome, occupational exposure to benzene chemicals or aromatic amines, history of chronic indwelling foreign body in the urinary tract) and on nonmalignant causes. The physical examination should look for signs of systemic disease (fever, rash, lymphadenopathy, abdominal or pelvic masses) as well as signs of medical kidney disease (hyperten- sion, volume overload). The urologic evaluation may dem- onstrate an enlarged prostate, flank mass, or urethral disease. The evaluation of patients with hematuria and their risk stratification should not be influenced by whether they are taking any antiplatelet or anticoagulant agents.B.  Laboratory FindingsIn itial laboratory investigations include a urinalysis and urine culture. Microhematuria is defined as three or more red blood cells per high-power field on a microscopic evaluation of the urine. The degree of microscopic hematuria is impor- tant in risk stratification according to the 2020 American Urological Association hematuria guidelines (Figure 231). A positive dipstick reading for heme merits microscopic examination to confirm or refute the diagnosis of hematuria but is not enough to warrant workup on its own. If urinaly- sis and culture is suggestive of a urinary tract infection, follow-up urinalysis after treatment of the infection is important to ensure resolution of the hematuria. An esti- mate of kidney function should be obtained since renal insufficiency may influence the methods of further evalua- tion and management (eg, ability to obtain contrast imag- ing) of patients with hematuria. Urine cytology and other urinary-based markers are not routinely recommended in the evaluation of asymptomatic microscopic hematuria.C.  Risk StratificationFo llowing initial evaluation, clinicians should categorize patients with microscopic hematuria as low, intermediate, or high risk for a urothelial malignancy (Figure 231).CMDT22_Ch23_p0952-p0977.indd  952 29/06/21 8:49 PM"
                ],
                [
                  "4",
                  "Chapter 11444 CMDT 2022Elev ated BP reading (office, home or pharmacy) No hypertension6White coat  hypertension6HypertensionDedicated office visit1Mean of fice BP  180/110 mm Hg No Diabetes Diabetes31 .AOBP2 135/85 mm Hg (preferred) 2.Non-AOBP2 140/90 mm Hg (if AOBP unavailable)AOBP or non-AOBP2 1 30/80 mm HgOR Out-of-office measurement41 .ABPM (preferred) Daytime mean  135/85 mm Hg 24-hour mean  130/80 mm Hg 2.Home BP series5 Mean  135/85 mm HgORYes YesNo NoYesNo1. If AOBP is used, use the mean calculated and displayed by the device. If non-AOBP is used, take at least three readings, discard the first and calculate the mean of the remaining measurements. A history and physical examination should be performed and diagnostic tests ordered. 2.AOBP is performed with the patient unattended in a private area. Non-AOBP is performed using an electronic upper arm device with the provider in the room. 3. Diagnostic thresholds for AOBP, ABPM, and home BP in patients with diabetes have yet to be established (and may be lower than 130/80 mm Hg). 4. Serial office measurements over 35 visits can be used if ABPM or home measurement not available. 5. Home BP series: Two readings taken each morning and evening for 7 days (28 total). Discard first day readings and average the last 6 days. 6. Annual BP measurement is recommended to detect progression to hypertension.Notes: Figure 111. According to these recommendations, if AOBP measurements are not available, blood pressures recorded manually in the office may be substituted if taken as the mean of the last two readings of three consecu- tive readings. Note that the blood pressure threshold for diagnosing hypertension is higher if recorded manually in these guidelines. If home blood pressure monitoring is unavailable, office measurements recorded over three to five separate visits can be substituted. ABPM, ambulatory blood pressure measurement; AOBP , automated office blood pressure; BP , blood pressure. (Reproduced, with permission, from Leung AA et al; Hypertension Canada. Hyper- tension Canadas 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can J Cardiol. 2017;33:557. Copyright  2017 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.) Table 111. Corresponding blood pressure values across a range of blood pressure measurement methods.Mnul  Msumn in Clinic1hom Blood pssu Msumnambuloy Blood pssu Msumn (Dyim)ambuloy Blood pssu Msumn (Nigim)ambuloy Blood pssu Msumn (24-hou) 120/80 mm Hg 120/80 mm Hg 120/80 mm Hg 100/65 mm Hg 115/75 mm Hg 130/80 mm Hg 130/80 mm Hg 130/80 mm Hg 110/65 mm Hg 125/75 mm Hg 140/90 mm Hg 135/85 mm Hg 135/85 mm Hg 120/70 mm Hg 130/80 mm Hg 160/100 mm Hg 145/90 mm Hg 145/90 mm Hg 140/85 mm Hg 145/90 mm Hg1 Clinic manual blood pressures are critically dependent on technique. The use of automated devices in an unattended setting typi cally result in systolic blood pressures 913 mm Hg lower than clinic manual pressures. Data abstracted from Greenland P et al. The New 2017 ACC/AHA Guidelines up the pressure on diagnosis and treatment of hyperten sion. JAMA. 2017;318:2083.CMDT22_Ch11_p0443-p0474.indd  444 29/06/21 8:37 PMSYSteMIC hYperteNSION445 CMDT 2022I t is important to recognize that the diagnosis of hyper- tension does not automatically entail drug treatment; this decision depends on the clinical setting and evaluation of cardiovascular risk, as discussed below.Greenland  P et al. The New 2017 ACC/AHA Guidelines up the pressure on diagnosis and treatment of hypertension. JAMA. 2017;318:2083. [PMID: 29159417] Jin J. JAMA patient page. Checking blood pressure at home. JAMA. 2017;318:310. [PMID: 28719694] Leung AA et al; Hypertension Canada. Hypertension Canadas 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can J Cardiol. 2017;33:557. [PMID: 28449828] Melville S et al. Out-of-office blood pressure monitoring in 2018. JAMA. 2018;320:1805. [PMID: 30398589] Myers MG. Automated office blood pressureincorporating SPRINT into clinical practice. Am J Hypertens. 2017;30:8. [PMID: 27551025]AP PROACH TO HYPERTENSION Etiology & ClassificationA.  Primary Essential HypertensionEssential  hypertension is the term applied to the 95% of hypertensive patients in which elevated blood pressure results from complex interactions between multiple genetic and environmental factors. Blood pressure elevation above 140/90 mm Hg occurs in 1015% of White adults and 2030% of Black adults in the United States. The onset is usually between ages 25 and 50 years; it is uncommon before age 20 years. The best understood pathways under- lying hypertension include overactivation of the sympa- thetic nervous and renin-angiotensin-aldosterone systems (RAAS), blunting of the pressure-natriuresis relationship, variation in cardiovascular and renal development, and elevated intracellular sodium and calcium levels. Exacerbating factors include obesity, sleep apnea, increased salt intake, excessive alcohol use, cigarette smok- ing, polycythemia, nonsteroidal anti-inflammatory drug (NSAID) therapy, and low potassium intake. Obesity is associated with an increase in intravascular volume, ele- vated cardiac output, activation of the renin-angiotensin system, and, probably, increased sympathetic outflow. Life- style-driven weight reduction lowers blood pressure mod- estly, but the dramatic weight reduction following bariatric surgery results in improved blood pressure in most patients, and actual remission of hypertension in 2040% of cases. In patients with sleep apnea, treatment with continuous posi- tive airway pressure (CPAP) has been associated with improvements in blood pressure. Increased salt intake probably elevates blood pressure in some individuals so dietary salt restriction is recommended in patients with hypertension. Excessive use of alcohol also raises blood pressure, perhaps by increasing plasma catecholamines. Hypertension can be difficult to control in patients who consume more than 40 g of ethanol (two drinks) daily or drink in binges.  Cigarette smoking raises blood pressure by increasing plasma norepinephrine. Although the long- term effect of smoking on blood pressure is less clear, the synergistic effects of smoking and high blood pressure oncardiovascular risk are well documented. The relationship of exercise to hypertension is variable. Aerobic exercise low- ers blood pressure in previously sedentary individuals, but increasingly strenuous exercise in already active subjects has less effect. The relationship between stress and hyper- tension is not established. Polycythemia, whether primary, drug-induced, or due to diminished plasma volume, increases blood viscosity and may raise blood pressure. NSAIDs produce increases in blood pressure averaging 5 mm Hg and are best avoided in patients with borderline or elevated blood pressures. Low potassium intake is associ- ated with higher blood pressure in some patients; an intake of 90 mmol/day is recommended. The complex of abnormalities termed the metabolic syndrome (upper body obesity, insulin resistance, and hypertriglyceridemia) is associated with both the develop- ment of hypertension and an increased risk of adverse cardiovascular outcomes. Affected patients usually also have low high-density lipoprotein (HDL) cholesterol levels and elevated catecholamines and inflammatory markers such as C-reactive protein.B.  Secondary HypertensionA pproximately 5% of patients have hypertension second- ary to identifiable specific causes (Table 112). Secondary hypertension should be suspected in patients in whom hypertension develops at an early age or after the age of 50 years, and in those previously well controlled who become refractory to treatment. Hypertension resistant to maximum doses of three medications is another clue, although multiple medications are usually required to con- trol hypertension in persons with diabetes. 1. Genetic causes Hypertension can be caused by muta- tions in single genes, inherited on a Mendelian basis. Although rare, these conditions provide important insight into blood pressure regulation and possibly the genetic basis of essential hypertension. Glucocorticoid remediable aldosteronism is an autosomal dominant cause of early- onset hypertension with normal or high aldosterone and low renin levels. The syndrome of hypertension exacer- bated in pregnancy is inherited as an autosomal dominant trait. In these patients, a mutation in the mineralocorticoid receptor makes it abnormally responsive to progesterone and, paradoxically, to spironolactone. 2. Kidney disease Renal parenchymal disease is the most common cause of secondary hypertension, which results from increased intravascular volume and increased activity of the RAAS. Increased sympathetic nerve activity may also contribute. 3. Renal vascular hypertension Renal artery stenosis is present in 12% of hypertensive patients. The most com- mon cause is atherosclerosis, but fibromuscular dysplasia should be suspected in women under 50 years of age. Excessive renin release occurs due to reduction in renal perfusion pressure, while attenuation of pressure natriure- sis contributes to hypertension in patients with a single kidney or bilateral lesions. Activation of the renal sympa- thetic nerves may also be important.CMDT22_Ch11_p0443-p0474.indd  445 29/06/21 8:37 PMChapter 11446 CMDT 2022Renal vascula r hypertension should be suspected in the following circumstances: (1) the documented onset is before age 20 or after age 50 years, (2) the hypertension is resistant to three or more drugs, (3) there are epigastric or renal artery bruits, (4) there is atherosclerotic disease of the aorta or peripheral arteries (1525% of patients with symp- tomatic lower limb atherosclerotic vascular disease have renal artery stenosis), (5) there is an abrupt increase (more than 25%) in the level of serum creatinine after administra- tion of angiotensin-converting enzyme (ACE) inhibitors, or (6) episodes of pulmonary edema are associated with abrupt surges in blood pressure. (See Renal Artery Stenosis, Chapter 22.) 4. Primary hyperaldosteronism Hyperaldosteronism should be considered in people with resistant hypertension, blood pressures consistently greater than 150/100 mm Hg, hypokalemia (although this is often absent), or adrenal incidentaloma, and in those with a family history of hyper- aldosteronism. Mild hypernatremia and metabolic alkalo- sis may also occur. Hypersecretion of aldosterone is estimated to be present in 510% of hypertensive patientsand, besides noncompliance, is the most common cause of resistant hypertension. The initial screening step is the simultaneous measurement of aldosterone and renin in blood in a morning sample collected after 30 minutes qui- etly seated. Hyperaldosteronism is suggested when the plasma aldosterone concentration is elevated (normal: 116 ng/dL) in association with suppression of plasma renin activity (normal: 12.5 ng/mL/h). However, the plasma aldosterone/renin ratio (normal less than 30) is not highly specific as a screening test. This is because renin levels may approach zero, which leads to exponential increases in the plasma aldosterone/renin ratio even when aldosterone levels are normal. Hence, an elevated plasma aldosterone/renin ratio should probably not be taken as evidence of hyperaldosteronism unless the aldosterone level is actually elevated. During the workup for hyperaldosteronism, an initial plasma aldosterone/renin ratio can be measured while the patient continues taking usual medications. If under these circumstances the ratio proves normal or equivocal, medica- tions that alter renin and aldosterone levels, including ACE inhibitors, angiotensin receptor blockers (ARBs), diuretics, beta-blockers, and clonidine, should be discontinued for 2 weeks before repeating the plasma aldosterone/renin ratio; spironolactone and eplerenone should be held for 4 weeks. Slow-release verapamil and alpha-receptor blockers can be used to control blood pressure during this drug washout period. Patients with a plasma aldosterone level greater than 16 ng/dL and an aldosterone/renin ratio of 30 or more might require further evaluation for primary hyperaldosteronism. The lesion responsible for hyperaldosteronism is an adrenal adenoma or bilateral adrenal hyperplasia. 5. Cushing syndrome Hypertension occurs in about 80% of patients with spontaneous Cushing syndrome. Excess glucocorticoid may act through salt and water retention (via mineralocorticoid effects), increased angiotensinogen lev- els, or permissive effects in the regulation of vascular tone. Diagnosis and treatment of Cushing syndrome are dis- cussed in Chapter 26. 6. Pheochromocytoma Pheochromocytomas are uncom- mon; they are probably found in less than 0.1% of all patients with hypertension and in approximately two indi- viduals per million population. Chronic vasoconstriction of the arterial and venous beds leads to a reduction in plasma volume and predisposes to postural hypotension. Glucose intolerance develops in some patients. Hypertensive crisis in pheochromocytoma may be precipitated by a variety of drugs, including tricyclic antidepressants, antidopaminer- gic agents, metoclopramide, and naloxone. The diagnosis and treatment of pheochromocytoma are discussed in Chapter 26. 7. Coarctation of the aorta This uncommon cause of hypertension is discussed in Chapter 10. Evidence of radial-femoral delay should be sought in all younger patients with hypertension. 8. Hypertension associated with pregnancy Hypertension occurring de novo or worsening during pregnancy, includ- ing preeclampsia and eclampsia, is one of the most commonTable 112. Causes of secondary hypertension.endocin Conn syndrome (hyperaldosteronism) Licorice Cushing syndrome (hypercortisolism) Thyroid disease Pheochromocytoma Acromegaly Mutations in steroid gene regulatory domains Hypercalcemia rnl Parenchymal kidney disease Polycystic kidney disease Systemic sclerosis (scleroderma) Page kidney Mutations in genes encoding ion transport proteins Vscul Renal artery stenosis Coarctation auonomic Stress Neurogenic Mdicions Nonsteroidal anti-inflammatory drugs Corticosteroids Calcineurin inhibitors Stimulants Decongestants Angiogenesis inhibitors Tyrosine kinase inhibitors Estrogen Erythropoietin Alcohol, cocaine Gemcitabine Atypical antipsychotics Monoamine oxidase inhibitors O Obstructive sleep apnea PregnancyCMDT22_Ch11_p0443-p0474.indd  446 29/06/21 8:37 PMSYSteMIC hYperteNSION447 CMDT 2022cau ses of maternal and fetal morbidity and mortality (see Chapter 19). Autoantibodies with the potential to activate the angiotensin II type 1 receptor have been caus- ally implicated in preeclampsia, in resistant hypertension, and in progressive systemic sclerosis. 9. Estrogen use A small increase in blood pressure occurs in most women taking oral contraceptives. A more significant increase of 8/6 mm Hg systolic/diastolic is noted in about 5% of women, mostly in obese individuals older than age 35 who have been treated for more than 5 years. This is caused by increased hepatic synthesis of angiotensinogen. The lower dose of postmenopausal estro- gen does not generally cause hypertension but rather main- tains endothelium-mediated vasodilation. 10. Other causes of secondary hypertension Hypertension has been associated with hypercalcemia, acromegaly, hyper- thyroidism, hypothyroidism, baroreceptor denervation, com- pression of the rostral ventrolateral medulla, and increased intracranial pressure. Certain medications may cause or exac- erbate hypertensionmost importantly cyclosporine, tacroli- mus, angiogenesis inhibitors, and erythrocyte-stimulating agents (such as erythropoietin). Decongestants, NSAIDs, cocaine, and alcohol should also be considered. Over-the- counter products should not be overlooked, eg, a dietary sup- plement marketed to enhance libido was found to contain yohimbine, an alpha-2antagonist, which can produce severe rebound hypertension in patients taking clonidine. When to ReferReferra l to a hypertension specialist should be considered in cases of severe, resistant or early-/late-onset hypertension or when secondary hypertension is suggested by screening.Byrd  JB et al. Primary aldosteronism. Circulation. 2018;138:823. [PMID: 30359120] Herrmann SM et al. Renovascular hypertension. Endocrinol Metab Clin North Am. 2019;48:765. [PMID: 31655775] Complications of Untreated HypertensionM ost of the adverse outcomes in hypertension are associated with thrombosis rather than bleeding, possibly because increased vascular shear stress converts the normally antico- agulant endothelium to a prothrombotic state. The excess morbidity and mortality related to hypertension approxi- mately doubles for each 6 mm Hg increase in diastolic blood pressure. However, target-organ damage varies markedly between individuals with similar levels of office hyperten- sion; home and ambulatory pressures are superior to office readings in the prediction of end-organ damage (Table 111).A.  Hypertensive Cardiovascular DiseaseCardiac  complications are the major causes of morbidity and mortality in primary (essential) hypertension. For any level of blood pressure, left ventricular hypertrophy is asso- ciated with incremental cardiovascular risk in association with heart failure (through systolic or diastolic dysfunc- tion), ventricular arrhythmias, myocardial ischemia, and sudden death.The occurrence of heart failure is reduced by 50% with antihypertensive therapy. Hypertensive left ventricular hypertrophy regresses with therapy and is most closely related to the degree of systolic blood pressure reduction. Diuretics have produced equal or greater reductions of left ventricular mass when compared with other drug classes. Conventional beta-blockers are less effective in reducing left ventricular hypertrophy but play a specific role in patients with established coronary artery disease or impaired left ventricular function.B.  Hypertensive Cerebrovascular Disease and DementiaH ypertension is the major predisposing cause of hemor- rhagic and ischemic stroke. Cerebrovascular complications are more closely correlated with systolic than diastolic blood pressure. The incidence of these complications is markedly reduced by antihypertensive therapy. Preceding hypertension is associated with a higher incidence of sub- sequent dementia of both vascular and Alzheimer types. Home and ambulatory blood pressure may be a better predictor of cognitive decline than office readings in older people. Effective blood pressure control reduces the risk of cognitive dysfunction developing later in life.C.  Hypertensive Kidney DiseaseCh ronic hypertension is associated with injury to vascular, glomerular, and tubulointerstitial compartments within the kidney, accounting for about 25% of end-stage kidney disease. Nephrosclerosis is particularly prevalent in Blacks, in whom susceptibility is linked to APOL1 mutations and hypertension results from kidney disease rather than causing it.D . Aortic DissectionH ypertension is a contributing factor in many patients with dissection of the aorta. Its diagnosis and treatment are discussed in Chapter 12.E.  Atherosclerotic ComplicationsMost  Americans with hypertension die of complications of atherosclerosis, but antihypertensive therapy seems to have a lesser impact on atherosclerotic complications compared with heart failure, stroke, and kidney disease. Prevention of cardiovascular outcomes related to atherosclerosis proba- bly requires control of multiple risk factors, of which hypertension is only one.Seccia TM  et al. Hypertensive nephropathy. Moving from classic to emerging pathogenetic mechanisms. J Hypertens. 2017;35:205. [PMID: 27782909] Supiano MA et al. New guidelines and SPRINT results: implica- tions for geriatric hypertension. Circulation. 2019;140:976. [PMID: 31525101] Clinical FindingsThe  clinical and laboratory findings are mainly referable to involvement of the target organs: heart, brain, kidneys, eyes, and peripheral arteries.CMDT22_Ch11_p0443-p0474.indd  447 29/06/21 8:37 PMChapter 11448 CMDT 2022A.  SymptomsMild  to moderate primary (essential) hypertension is largely asymptomatic for many years. The most frequent symptom, headache, is also nonspecific. Accelerated hyper- tension is associated with somnolence, confusion, visual disturbances, and nausea and vomiting (hypertensive encephalopathy). Hypertension in patients with pheochromocytomas that secrete predominantly norepinephrine is usually sustained but may be episodic. The typical attack lasts from minutes to hours and is associated with headache, anxiety, palpitation, profuse perspiration, pallor, tremor, and nausea and vomit- ing. Blood pressure is markedly elevated, and angina or acute pulmonary edema may occur. In primary aldosteron- ism, patients may have muscular weakness, polyuria, and nocturia due to hypokalemia; hypertensive emergency is rare. Chronic hypertension often leads to left ventricular hypertrophy and diastolic dysfunction, which can present with exertional and paroxysmal nocturnal dyspnea. Cerebral involvement causes stroke due to thrombosis or hemorrhage from microaneurysms of small penetrating intracranial arteries. Hypertensive encephalopathy is probably caused by acute capillary congestion and exudation with cerebral edema and may present as posterior reversible encephalopa- thy syndrome, comprising headache, visual disturbances, altered mental state, and seizures. These symptoms usually improve rapidly with control of hypertension.B.  SignsLike  symptoms, physical findings depend on the cause of hypertension, its duration and severity, and the degree of effect on target organs. 1. Blood pressure Blood pressure is taken in both arms and, if lower extremity pulses are diminished or delayed, in the legs to exclude coarctation of the aorta. If blood pres- sure differs between right and left arms, the higher reading should be recorded as the actual blood pressure and subcla- vian stenosis suspected in the other arm. An orthostatic drop of at least 20/10 mm Hg is often present in pheochro- mocytoma. Older patients may have falsely elevated read- ings by sphygmomanometry because of noncompressible vessels. This may be suspected in the presence of Osler signa palpable brachial or radial artery when the cuff is inflated above systolic pressure. Occasionally, it may be necessary to make direct measurements of intra-arterial pressure, especially in patients with apparent severe hyper- tension who do not tolerate therapy. 2. Retinas Narrowing of arterial diameter to less than 50% of venous diameter, copper or silver wire appearance, exudates, hemorrhages, and hypertensive retinopathy are associated with a worse prognosis. The typical changes of severe hypertensive retinopathy are shown in Figure 112 (see Chapter 7). 3. Heart A left ventricular heave indicates severe hyper- trophy. Aortic regurgitation may be auscultated in up to 5% of patients, and hemodynamically insignificant aortic regurgitation can be detected by Doppler echocardiogra- phy in 1020%. A presystolic (S4) gallop due to decreasedcompliance of the left ventricle is quite common in patients in sinus rhythm. 4. Pulses Radial-femoral delay suggests coarctation of the aorta; loss of peripheral pulses occurs due to atherosclero- sis, less commonly aortic dissection, and rarely Takayasu arteritis, all of which can involve the renal arteries.C.  Laboratory FindingsRecommended  testing includes hemoglobin; serum elec- trolytes and serum creatinine; fasting blood sugar level (hypertension is a risk factor for the development of diabe- tes, and hyperglycemia can be a presenting feature of pheo- chromocytoma); plasma lipids (necessary to calculate cardiovascular risk and as a modifiable risk factor); serum uric acid (hyperuricemia is a relative contraindication to diuretic therapy); and urinalysis.D . Electrocardiography and Chest RadiographsElectrocardiographic  criteria are highly specific but not very sensitive for left ventricular hypertrophy. The strain pattern of STT wave changes is a sign of more advanced disease and is associated with a poor prognosis. A chest radiograph is not necessary in the workup for uncompli- cated hypertension.E.  EchocardiographyThe primary  role of echocardiography should be to evalu- ate patients with clinical symptoms or signs of cardiac disease.F . Diagnostic StudiesAddi tional diagnostic studies are indicated only if the clini- cal presentation or routine tests suggest secondary or com- plicated hypertension. These may include 24-hour urine free cortisol, urine or plasma metanephrines, and plasma Figure 112. Severe, chronic hypertensive retinopa- thy with hard exudates, increased vessel light reflexes, and sausage-shaped veins. (Used, with permission, from Richard E. Wyszynski, MD, in Knoop KJ, Stack LB, Storrow AB, Thurman RJ. The Atlas of Emergency Medicine , 4th ed. McGraw-Hill, 2016.)CMDT22_Ch11_p0443-p0474.indd  448 29/06/21 8:37 PMSYSteMIC hYperteNSION449 CMDT 2022aldostero ne and renin concentrations to screen for endo- crine causes of hypertension. Renal ultrasound will detect structural changes (such as polycystic kidneys, asymmetry, and hydronephrosis); echogenicity and reduced cortical volume are reliable indicators of advanced chronic kidney disease. Evaluation for renal artery stenosis should be undertaken in concert with subspecialist consultation.G.  SummarySince  most hypertension is essential or primary, few studies are necessary beyond those listed above. If conventional therapy is unsuccessful or if secondary hypertension is suspected, further studies and perhaps referral to a hyper- tension specialist are indicated. Nonpharmacologic TherapyLife style modification is recommended in all patients with elevated blood pressure. A diet rich in fruits, vegeta- bles, and low-fat dairy foods and low in saturated and total fats (DASH diet) has been shown to lower blood pressure. Increased dietary fiber lowers blood pressure. For every 7 g of dietary fiber ingested, cardiovascular risk could be lowered by 9%. The effect of diet on blood pres- sure may be mediated by shifts in the microbial species in the gut, the intestinal microbiota. Hand squeezing exer- cises three times a week can lower systolic blood pressure by 6 mm Hg. The protocol comprises four repeats of 2 minutes at 30% of maximum force (using a handheld dynamometer) with 1- to 3-minute rest intervals between squeezes. The acute increase in systolic blood pressure during vigorous exercise, known as the exercise pressor response, is around 50 mm Hg in normal individuals. In hypertensive persons, the exercise pressor response is elevated to about 75 mm Hg above resting systolic blood pressure. This exaggerated response is not reduced by antihypertensive medications, even in those with other- wise controlled hypertension, and is exacerbated by increased dietary sodium intake. Additional lifestyle changes, listed in Table 113, can prevent or mitigate hypertension or its cardiovascular consequences.Fu J et  al. Nonpharmacologic interventions for reducing blood pressure in adults with prehypertension to established hypertension. J Am Heart Assoc. 2020;9:e016804. [PMID: 32975166] Smart NA et al. An evidence-based analysis of managing hyper- tension with isometric resistance exerciseare the guidelines current? Hypertens Res. 2020;43:249. [PMID: 31758166] Who Should Be Treated With Medications?T reatment should be offered to all persons in whom blood pressure reduction, irrespective of initial blood pressure levels, will reduce cardiovascular risk with an acceptably low rate of medication-associated adverse effects. The American College of Cardiology and the American Heart Association (ACC/ AHA), Hypertension Canada (HC), and the European Soci- ety of Hypertension and European Society of Cardiology(ESH/ESC) have developed independent guidelines for the evaluation and management of hypertension. There is broad agreement that drug treatment is necessary in those with office-based blood pressures exceeding 160/100 mm Hg, irrespective of cardiac risk. Similarly, the American, Canadian, and European guidelines agree that treatment thresholds should be lower in the presence of elevated car- diovascular risk. American guidelines stand apart in recom- mending initiation of antihypertensive pharmacotherapy in those with blood pressure of 140159/9099 mm Hg, even if cardiovascular risk is not elevated. By contrast, the Cana- dian guidelines suggest lifestyle modifications in this low- cardiovascular-risk group, while the European guidelines recommend initiation of pharmacotherapy only if elevated pressure in this low-risk population persists after lifestyle modification. There is no outcomes evidence that mortal- ity or risk of cardiovascular events can be reduced by treat- ing mild hypertension (140/90160/100 mm Hg) in low-risk individuals. Table 114 compares these three sets of guidelines. Since evaluation of total cardiovascular risk (Table 115) is important in deciding who to treat with antihypertensive medications, risk calculators are essential clinical tools. The ACC has an online toolkit relevant to primary prevention (https://tools.acc.org/ascvd-risk- estimator-plus/#!/calculate/estimate/), and an associated app called ASCVD Risk Estimator Plus (downloadable at https://www.acc.org/ASCVDApp). Goals of TreatmentT raditionally, the most widely accepted goal for blood pres- sure management has been less than 140/90 mm Hg. How- ever, observational studies suggest that there does not seem to be a blood pressure level below which decrements in cardiovascular risk taper off, and a number of randomized controlled trials have suggested that treatment to bloodTable 113. The impact of lifestyle modifications.Modific- ion Invnionrsuling Dcs in Blood pssu Weight loss Target BMI 18.524.9 520 mm Hg/ 10-kg loss DASH diet Fruit, vegetables, low fat dairy814 mm Hg Sodium intake< 100 mmol/day (< 6 g salt)28 mm Hg Alcohol intakeMale  2 drinks/day Female  1 drink/day4 mm Hg Exercise Aerobic 30 min/day Dynamic 90-150 min/week Isometric (hand grip 4 rep- etitions 3 times/week)510 mm Hg Mindfulness Meditation and breathing control5 mm Hg BMI, body mass index; DASH, Dietary Approaches to Stop Hypertension.CMDT22_Ch11_p0443-p0474.indd  449 29/06/21 8:37 PMChapter 11450 CMDT 2022pres sure targets considerably below 140 mm Hg may ben- efit certain patient groups. The SPRINT study suggests that outcomes improve in nondiabetic patients with considerably elevated cardiovascu- lar risk when treatment lowers systolic pressure to less than 120 mm Hg compared to less than 140 mm Hg. On the other hand, in the HOPE3 study of largely nondiabetic patients at somewhat lower risk than those in SPRINT, reducing blood pressure by an average of 6/3 mm Hg systolic/diastolic from a baseline of 138/82 mm Hg provided no significant out- comes benefits. Therefore, it appears that blood pressure targets should be lower in people at greater estimated cardio- vascular risk. In response to the SPRINT study, the 2018 Hypertension Canada guidelines urge prescribers to consider a blood pressure goal of less than 120/80 mm Hg in patients considered at elevated risk for cardiovascular events. The 2017 ACC/AHA guidelines take a different approach by defining a 130/80 mm Hg goal as reasonable in nonelevated risk patients, strengthening this to recommended in ele- vated risk hypertensive patients. The 2018 ESH/ESC guide- lines specify a target of less than 140 mm Hg systolic for all, and less than 130 mm Hg for most if tolerated. There is a trend toward recommending similar treatment targets in the elderly; this topic is discussed in greater detail below. Some experts note that manual office measurements of around 130/80 mm Hg are likely to approximate the lower blood pressure targets specified in the SPRINT study, which used automated office blood pressure measuring devices that have been demonstrated to read as much as 16/7 mm Hg lowerTable 114. Comparison of blood pressure treatment thresholds from the 2017 ACC/AHA guidelines, the 2018 Hypertension Canada guidelines, and the 2018 ESH/ESC guidelines.Guidlins 1Cdiovscul risktsold fo pmcoy (mm hg) tg (mm hg) ACC/AHA Not increased > 140/90 < 130/80 (reasonable) Hypertension Canada Not increased > 160/100 < 140/90 (< 130/80 for diabetes) ESH/ESC Not increased > 140/902All < 140/90, most < 130/80, not < 120 ACC/AHA Increased < 130/80 < 130/80 (recommended) Hypertension Canada Increased > 140 systolic3< 120 systolic ESH/ESC Increased > 130/803120130/< 80 ACC/AHA > 65 yr Risk due to advanced age > 130/80 < 130 systolic Hypertension Canada4Increased Not specified4Not specified4ESH/ESC  > 65 yr Not increased > 140/905130140/> 806 1In all three sets of guidelines, blood pressure values are based upon nonautomated office blood pressure readings.2 Consider drug treatment if lifestyle changes fail to control blood pressure.3 Consider drug treatment if very high risk, eg, established cardiovascular disease, especially coronary disease. Note: The > 130/80 mm Hg threshold for treatment of high-risk patients in the Canadian guidelines refers to automated blood pressure readings, which are lower than nonautomated readings.4 Recommendations for persons > 75 years are not explicitly stated in the Hypertension Canada guidelines. They removed separate g oals for the elderly but consider age > 75 years to be a risk signifier triggering an approach that many would view as overly aggres sive in the extremely old.5 The European guidelines indicate a slightly more conservative treatment threshold of > 160/90 mm Hg for those > 80 years.6 This target range is also suggested in the European guidelines for patients > 80 years. ACC, American College of Cardiology; AHA, American Heart Association; ESC, European Society of Cardiology; ESH, European Societ y of Hypertension.T able 115. Cardiovascular risk factors.Mjo  isk fcos Hypertension1 Cigarette smoking Obesity (BMI  30)1 Physical inactivity Dyslipidemia1 Diabetes mellitus1 Microalbuminuria or estimated GFR < 60 mL/min/1.73 m2 Age (> 55 years for men, > 65 years for women) Family history of premature cardiovascular disease (< 55 years for men, < 65 years for women) tg-ogn dmg Heart Left ventricular hypertrophy Angina or prior myocardial infarction Prior coronary revascularization Heart failure Brain Stroke or transient ischemic attack Chronic kidney disease Peripheral arterial disease Retinopathy1 Components of the metabolic syndrome. BMI, body mass index; GFR, glomerular filtration rate. Data from Chobanian AV et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21;289(19):256072.CMDT22_Ch11_p0443-p0474.indd  450 29/06/21 8:37 PMSYSteMIC hYperteNSION451 CMDT 2022th an manual office readings. The 2018 Canadian guidelines acknowledge this disparity in measurement methods by specifying that automated office devices should be used in the monitoring of patients selected for the aggressive blood pres- sure goal of less than 120/80 mm Hg. Table 114 compares the treatment threshold and target recommendations laid out in the American, Canadian, and European guidelines. Treatment to blood pressures less than 130 mm Hg systolic seems especially important in stroke prevention. The ACCORD study examined the effect of treatment of systolic pressures to below 130135 mm Hg in patients with diabetes; the studys two by two factorial design addressed glycemic control as well as blood pressure con- trol. In the original analysis, the lower blood pressure treat- ment goal significantly increased the risk of serious adverse effects (with no additional gain in terms of heart, kidney, or retinal disease). There was, however, significant additional reduction in the risk of stroke, indicating that lower blood pressure targets might be justified in diabetic patients at high risk for cerebrovascular events. Post hoc analysis of the ACCORD study after 9 years of follow-up suggested that a beneficial effect of lower blood pressure in older high-risk persons (mostly on nonfatal myocardial infarctions) could be detected in the standard glycemic control group. Similarly, in the SPS3 trial in patients who have had a lacunar stroke, treating the systolic blood pressure to less than 130 mm Hg (mean systolic blood pressure of 127 mm Hg among treated versus mean systolic blood pressure 138 mm Hg among untreated patients) probably reduced the risk of recurrent stroke (and with an acceptably low rate of adverse effects from treatment). Blood pressure manage- ment in acute stroke is discussed below. How Low To Go?Alth ough observational studies indicate that the blood pressure-risk relationship holds up at levels considerably below 120 mm Hg, there is uncertainty about whether this is true for treated blood pressure. This question was addressed in a secondary analysis of data from the ONTARGET and TRANSCEND studies in which participants with ele- vated cardiovascular risk but no history of stroke were treated with telmisartan (plus or minus ramipril) or placebo. The risk of the composite cardiovascular endpoint was lowest at a treated systolic blood pressure range between 120 mm Hg and 140 mm Hg. Increased risk was observed at blood pres- sures below and above this range. The risk of stroke was the only exception, with incremental benefit observed below a treated systolic of 120 mm Hg. With respect to diastolic blood pressure on treatment, composite risk began to increase at levels below 70 mm Hg. This suggests that the blood pressurecardiovascular risk relationship evident in observational studies of untreated hypertension may not hold in the case of treated blood pressure and that there are grounds for a degree of caution in treating below a systolic pressure of 120 mm Hg. In seeking to simplify decision making in the treatment of hypertension, some authors have suggested that a sys- tolic blood pressure goal in the 120130 mm Hg range would be safe and effective in high-risk patients, and a systolic blood pressure of around 130 mm Hg would bereasonable in lower-risk patients, irrespective of diastolic pressures. Diastolic blood pressure will track with systolic blood pressure; the main concern about diastolic blood pressure is that treatment will lower it too much in patients who have wider pulse pressures. However, it seems that a lower diastolic blood pressure as a consequence of treat- ment does not negate the benefits of systolic blood pressure control, even though wider pulse pressures at baseline are associated with cardiovascular mortality. Treatment of Other Cardiovascular Risk FactorsData  from multiple studies indicate that statins should be part of the strategy to reduce overall cardiovascular risk. The HOPE3 study of persons at intermediate cardiovascu- lar risk showed that 10 mg of rosuvastatin reduced average low-density lipoprotein (LDL) cholesterol from 130 mg/dL to 90 mg/dL (3.362.33 mmol/L), and significantly reduced the risk of multiple cardiovascular events, including myo- cardial infarction and coronary revascularization. Low- dose aspirin (81 mg/day) is likely to be beneficial in patients older than age 50 with either target-organ damage or elevated total cardiovascular risk (greater than 2030%). Care should be taken to ensure that blood pressure is con- trolled to the recommended levels before starting aspirin to minimize the risk of intracranial hemorrhage. Data do not support the routine use of aspirin for prophylaxis in low- risk patients, including those over 65 years of age.Bhm  M et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet. 2017;389:2226. [PMID: 28390695] Ruiz-Hurtado G et al. Has the SPRINT trial introduced a new blood-pressure goal in hypertension? Nat Rev Cardiol. 2017;14:560. [PMID: 28492286] Sheppard JP et al. Benefits and harms of antihypertensive treat- ment in low-risk patients with mild hypertension. JAMA Intern Med. 2018;178:1626. [PMID: 30383082] Sobieraj P et al. Low on-treatment diastolic blood pressure and cardiovascular outcome: a post-hoc analysis using NHLBI SPRINT research materials. Sci Rep. 2019;9:13070. [PMID: 31506550] Williams B et al. 2018 Practice guidelines for the management of arterial hypertension of the European Society of Hyperten- sion (ESH) and the European Society of Cardiology (ESC). Blood Press. 2018;27:314. [PMID: 30380928]DR UG THERAPY: CURRENT ANTIHYPERTENSIVE AGENTSTh ere are many classes of antihypertensive drugs of which six (ACE inhibitors, ARBs, renin inhibitors, calcium channel blockers, diuretics, and beta-blockers) are suitable for initial therapy based on efficacy and tolerability. The specific classes of antihypertensive medications are discussed below, and guidelines for the choice of initial medications are offered.A.  Angiotensin-Converting Enzyme InhibitorsACE  inhibitors are commonly used as the initial medi- cation in mild to moderate hypertension (Table 116).CMDT22_Ch11_p0443-p0474.indd  451 29/06/21 8:37 PMChapter 11452 CMDT 2022Table 116. Antihypertensive drugs: renin and ACE inhibitors and angiotensin II receptor blockers.Dug poiy NmIniil Ol Dosg Dosg rng Cos  UniCos of 30 Dys of tmn (avg Dosg)1advs effcs Commns rnin Inibios Aliskiren Tekturna 150 mg once daily 150300 mg once daily $7.48/150 mg $224.41 Angioedema, hypotension, hyperkalemia. Contraindicated in pregnancy.Probably metabolized by CYP3A4. Absorption is inhibited by high- fat meal.Aliskiren and HCTZ Tekturna HCT 150 mg/12.5 mg once daily150 mg/12.5 mg300 mg/ 25 mg once daily$9.78/150 mg/ 12.5 mg$293.54 aCe Inibios Benazepril Lotensin 10 mg once daily 540 mg in 1 or 2 doses $0.95/20 mg $28.50 Cough, hypotension, dizziness, hyperkalemia, kidney dysfunction, angioedema; taste alteration and rash (may be more frequent with captopril); rarely, proteinuria, blood dyscrasia. Contraindicated in pregnancy.More fosinopril is excreted by the liver in patients with kidney dys- function (dose reduction may or may not be necessary). Captopril and lisinopril are active without metabolism. Captopril, enalapril, lisinopril, and quinapril are approved for heart failure.Benazepril and HCTZ Lotensin HCT 5 mg/6.25 mg once daily5 mg/6.25 mg20 mg/ 25 mg$1.07/any dose $32.21 Benazepril and amlodipineLotrel 10 mg/2.5 mg once daily10 mg/2.5 mg40 mg/ 10 mg$3.32/20 mg/ 10 mg$99.60 Captopril Capoten 25 mg twice daily 50450 mg in 2 or 3 doses$0.65/25 mg $19.50 Captopril and HCTZ Capozide 25 mg/15 mg twice daily25 mg/15 mg50 mg/ 25 mg$2.85/25 mg/ 15 mg$171.00 Enalapril Vasotec 5 mg once daily 540 mg in 1 or 2 doses $0.95/20 mg $28.50 Enalapril and HCTZ Vaseretic 5 mg/12.5 mg once daily5 mg/12.5 mg10 mg/ 25 mg$1.19/10 mg/ 25 mg$35.70 Fosinopril Monopril 10 mg once daily 1080 mg in 1 or 2 doses $0.29/20 mg $8.70 Fosinopril and HCTZ Monopril-HCT 10 mg/12.5 mg once daily10 mg/12.5 mg20 mg/ 12.5 mg$1.48/any dose $44.40 Lisinopril Prinivil, Zestril 510 mg once daily 540 mg once daily $0.08/20 mg $2.45 Lisinopril and HCTZ Prinzide or Zestoretic10 mg/12.5 mg once daily10 mg/12.5 mg20 mg/ 12.5 mg$0.14/20 mg/ 12.5 mg$4.20 Moexipril Univasc 7.5 mg once daily 7.530 mg in 1 or 2 doses $1.39/7.5 mg $41.70 Moexipril and HCTZ Uniretic 7.5 mg/12.5 mg once daily7.5 mg/12.5 mg15 mg/ 25 mg$1.70/15 mg/ 12.5 mg$51.00CMDT22_Ch11_p0443-p0474.indd  452 29/06/21 8:37 PMSYSteMIC hYperteNSION453 CMDT 2022Perindopril Aceon 4 mg once daily 416 mg in 1 or 2 doses $2.80/8 mg $84.00 Perindopril and amlodipinePrestalia 3.5 mg/2.5 mg once daily3.5 mg/2.514 mg/10 mg once daily$6.81/7 mg/5 mg $204.30 Quinapril Accupril 10 mg once daily 1080 mg in 1 or 2 doses $1.22/20 mg $36.60 Quinapril and HCTZ Accuretic 10 mg/12.5 mg once daily10 mg/12.5 mg20 mg/ 25 mg$1.22/20 mg/ 12.5 mg$36.60 Ramipril Altace 2.5 mg once daily 2.520 mg in 1 or 2 doses $1.80/5 mg $54.00 Trandolapril Mavik 1 mg once daily 18 mg once daily $1.21/4 mg $36.30 Trandolapril and verapamilTarka 2 mg/180 mg ER once daily2 mg/180 mg ER8 mg/480 mg ER$5.29/any dose $158.70 angionsin II rco Blocks Azilsartan Edarbi 40 mg once daily 4080 mg once daily $8.80/80 mg $264.00 Hyperkalemia, kidney dysfunction, rare angioedema. Combinations have additional side effects. Contraindicated in pregnancy.Losartan has a flat dose-response curve. Valsartan and irbesartan have wider dose-response ranges and longer durations of action. Addition of low-dose diuretic (separately or as combination pills) increases the response.Azilsartan and chlorthalidoneEdarbychlor 40 mg/12.5 mg once daily40 mg/12.540 mg/ 25 mg once daily$8.30/any dose $249.14 Candesartan cilexitil Atacand 16 mg once daily 832 mg once daily $3.06/16 mg $91.80 Candesartan cilexitil and HCTZAtacand HCT 16 mg/12.5 mg once daily32 mg/12.5 mg once daily$4.72/16 mg/ 12.5 mg$141.60 Eprosartan Teveten 600 mg once daily 400800 mg in 12 doses$3.43/600 mg $102.90 Irbesartan Avapro 150 mg once daily 150300 mg once daily $0.46/150 mg $13.80 Irbesartan and HCTZ Avalide 150 mg/12.5 mg once daily150300 mg irbesartan once daily$0.67/150 mg/ 12.5 mg$20.10 Losartan and HCTZ Hyzaar 50 mg/12.5 mg once daily50 mg/12.5 mg100 mg/ 25 mg tablets once daily$2.47/50 mg/ 12.5 mg/tablet$74.10 Olmesartan Benicar 20 mg once daily 2040 mg once daily $6.28/20 mg $188.40 Olmesartan and HCTZBenicar HCT 20 mg/12.5 mg once daily20 mg/12.5 mg40 mg/ 25 mg once daily$6.28/20 mg/ 12.5 mg$188.40 Olmesartan and amlodipineAzor 20 mg/5 mg once daily20 mg/5 mg40 mg/ 10 mg$3.03/20 mg/5 mg $90.90 Olmesartan and amlodipine and HCTZTribenzor 20 mg/5 mg/ 12.5 mg once daily20 mg/5 mg/12.5 mg 40 mg/10 mg/25 mg once daily$4.54/20 mg/ 5 mg/12.5 mg$136.20 Telmisartan Micardis 40 mg once daily 2080 mg once daily $4.34/40 mg $130.20 (continued )CMDT22_Ch11_p0443-p0474.indd  453 29/06/21 8:37 PMChapter 11454 CMDT 2022T elmisartan and HCTZMicardis HCT 40 mg/12.5 mg once daily40 mg/12.5 mg80 mg/ 25 mg once daily$4.83/40 mg/ 12.5 mg$144.90 Telmisartan and amlodipineTwynsta 40 mg/5 mg once daily40 mg/5 mg80 mg/ 10 mg once daily$5.20/any dose $156.00 Valsartan Diovan 80 mg once daily 80320 mg once daily $2.09/160 mg $62.70 Valsartan and HCTZ Diovan HCT 80 mg/12.5 mg once daily80320 mg valsartan once daily$4.27/160 mg/ 12.5 mg$128.10 Valsartan and amlodipineExforge 160 mg/5 mg once daily160 mg/5 mg320 mg/ 10 mg once daily$1.71/160 mg/ 10 mg$51.30 O Combinion poducs Amlodipine and val- sartan and HCTZExforge HCT 5 mg/160 mg/ 12.5 mg once daily10 mg/320 mg/25 mg up to once daily$5.70/160 mg valsartan$171.001 Average wholesale price (AWP , for AB-rated generic when available) for quantity listed. Source: IBM Micromedex Red Book (electronic version) IBM Watson Health. Greenwood Village, CO, USA. Available at https://www.mi cromedexsolutions.com, accessed March 27, 2021. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions. ACE, angiotensin-converting enzyme; ER, extended release; HCTZ, hydrochlorothiazide.Table 116. Antihypertensive drugs: renin and ACE inhibitors and angiotensin II receptor blockers.Dug poiy NmIniil Ol Dosg Dosg rng Cos  UniCos of 30 Dys of tmn (avg Dosg)1advs effcs Commns angionsin II rco Blocks (con.)(continued)CMDT22_Ch11_p0443-p0474.indd  454 29/06/21 8:37 PMSYSteMIC hYperteNSION455 CMDT 2022Their  primary mode of action is inhibition of the RAAS, but they also inhibit bradykinin degradation, stimulate the syn- thesis of vasodilating prostaglandins, and can reduce sym- pathetic nervous system activity. ACE inhibitors appear to be more effective in younger White patients. They are rela- tively less effective in Blacks and older persons and in pre- dominantly systolic hypertension. Although as single therapy they achieve adequate antihypertensive control in only about 4050% of patients, the combination of an ACE inhibitor and a diuretic or calcium channel blocker is potent. ACE inhibitors are the agents of choice in persons with type 1 diabetes with frank proteinuria or evidence of kidney dysfunction because they delay the progression to end-stage renal disease. Many authorities have expanded this indication to include persons with type 1 and type 2 diabetes mellitus with microalbuminuria who do not meet the usual criteria for antihypertensive therapy. ACE inhibitors may also delay the progression of nondiabetic kidney disease. The Heart Outcomes Prevention Evaluation (HOPE) trial demonstrated that the ACE inhibitor ramipril reduced the number of car- diovascular deaths, nonfatal myocardial infarctions, and nonfatal strokes and also reduced the incidence of new-onset heart failure, kidney dysfunction, and new-onset diabetes in a population of patients at high risk for vascular events. Although this was not specifically a hypertensive population, the benefits were associated with a modest reduction in blood pressure, and the results inferentially support the use of ACE inhibitors in similar hypertensive patients. ACE inhibi- tors are a drug of choice (usually in conjunction with a diuretic and a beta-blocker) in patients with heart failure with reduced ejection fraction and are indicated also in asymp- tomatic patients with reduced ejection fraction. How to initiate therapy A baseline metabolic panel should be drawn prior to starting medications that inter- fere with the RAAS, repeated 12 weeks after initiation of therapy to evaluate changes in creatinine and potassium. Minor dose adjustments of these medications rarely trigger significant shifts in these values. Side effects An advantage of the ACE inhibitors is their relative freedom from troublesome side effects (Table 116). Severe hypotension can occur in patients with bilateral renal artery stenosis; significant increases in creatinine may ensue but are usually reversible with the discontinuation of the ACE inhibitor. Hyperkalemia may develop in patients with kidney disease and type IV renal tubular acidosis (commonly seen in patients with diabetes) and in older adults. A chronic dry cough is common, seen in 10% of patients or more, and may require stopping the drug. Skin rashes are observed with any ACE inhibitor. Angioedema is an uncommon but potentially dangerous side effect of all agents of this class because of their inhibi- tion of kininase. Exposure of the fetus to ACE inhibitors during the second and third trimesters of pregnancy has been associated with a variety of defects due to hypoten- sion and reduced renal blood flow.B.  Angiotensin II Receptor BlockersARB s can improve cardiovascular outcomes in patients with hypertension as well as in patients with related conditions, such as heart failure and type 2 diabetes with nephropathy.ARBs have not been compared with ACE inhibitors in ran- domized controlled trials in patients with hypertension, but two trials comparing losartan with captopril in heart failure and postmyocardial infarction left ventricular dysfunction showed trends toward worse outcomes in the losartan group. By contrast, valsartan seems as effective as ACE inhibitors in these settings. Within group heterogeneity of antihyperten- sive potency and duration of action might explain such observations. The Losartan Intervention for Endpoints (LIFE) trial in nearly 9000 hypertensive patients with elec- trocardiographic evidence of left ventricular hypertrophy comparing losartan with the beta-blocker atenolol as initial therapydemonstrated a significant reduction in stroke with losartan. Of note is that in diabetic patients, death and myocardial infarction were also reduced, and there was a lower occurrence of new-onset diabetes. In a subgroup analysis from the LIFE trial, atenolol appeared to be superior to losartan in Blacks, while the opposite was the case in non- Blacks. A similar lack of efficacy of lisinopril compared to diuretics and calcium channel blockers was observed in Blacks in the Antihypertensive and Lipid-Lowering Treat- ment to Prevent Heart Attach Trial (ALLHAT), suggesting that ACE inhibitors and ARBs may not be the preferred agents in Black patients. In the treatment of hypertension, combination therapy with an ACE inhibitor and an ARB is not advised because it generally offers no advantage over monotherapy at maximum dose with addition of a comple- mentary class where necessary. Side effects Unlike ACE inhibitors, the ARBs rarely cause cough and are less likely to be associated with skin rashes or angioedema (Table 116). However, as seen with ACE inhibitors, hyperkalemia can be a problem, and patients with bilateral renal artery stenosis may exhibit hypotension and worsened kidney function. Olmesartan has been linked to a sprue-like syndrome, presenting with abdominal pain, weight loss, and nausea, which subsides upon drug discon- tinuation. There is evidence from an observational study suggesting that ARBs and ACE inhibitors are less likely to be associated with depression than calcium channel block- ers and beta-blockers.C.  Renin InhibitorsSi nce renin cleavage of angiotensinogen is the rate-limiting step in the renin-angiotensin cascade, the most efficient inac- tivation of this system would be expected with renin inhibi- tion. Conventional ACE inhibitors and ARBs probably offer incomplete blockade, even in combination. Aliskiren, a renin inhibitor, binds the proteolytic site of renin, thereby prevent- ing cleavage of angiotensinogen. Aliskiren effectively lowers blood pressure, reduces albuminuria, and limits left ventricu- lar hypertrophy, but it has yet to be established as a first-line drug based on outcomes data. The combination of aliskiren with ACE inhibitors or ARBs in persons with type 2 diabetes mellitus offers no advantage and might even increase the risk of adverse cardiac or renal consequences.D . Calcium Channel Blocking AgentsThese  agents act by causing peripheral vasodilation but with less reflex tachycardia and fluid retention than otherCMDT22_Ch11_p0443-p0474.indd  455 29/06/21 8:37 PMChapter 11456 CMDT 2022vasodilators.  They are effective as single-drug therapy in approximately 60% of patients in all demographic groups and all grades of hypertension (Table 117). For these rea- sons, they may be preferable to beta-blockers and ACE inhibitors in Blacks and older persons. Verapamil and dil- tiazem should be combined cautiously with beta-blockers because of their potential for depressing atrioventricular (AV) conduction and sinus node automaticity as well as contractility. Calcium channel blockers are equivalent to ACE inhibi- tors and thiazide diuretics in prevention of coronary heart disease, major cardiovascular events, cardiovascular death, and total mortality. A protective effect against stroke with calcium channel blockers is well established, and in two trials (ALLHAT and the Systolic Hypertension in Europe trial), these agents appeared to be more effective than diuretic-based therapy. Side effects The most common side effects of calcium channel blockers are headache, peripheral edema, brady- cardia, and constipation (especially with verapamil in older adults) (Table 117). The dihydropyridine agents nifedipine, nicardipine, isradipine, felodipine, nisoldipine, and amlodipineare more likely to produce symptoms of vasodilation, such as headache, flushing, palpitations, and peripheral edema. Edema is minimized by coadministra- tion of an ACE inhibitor or ARB. Calcium channel block- ers have negative inotropic effects and should be used cautiously in patients with cardiac dysfunction. Amlodip- ine is the only calcium channel blocker with established safety in patients with severe heart failure.E.  DiureticsThia zide diuretics (Table 118) are the antihypertensives that have been most extensively studied and most consis- tently effective in clinical trials. They lower blood pressure initially by decreasing plasma volume, but during long-term therapy, their major hemodynamic effect is reduction of peripheral vascular resistance. Most of the antihypertensive effect of these agents is achieved at lower dosages (typically, 12.5 mg of hydrochlorothiazide or equivalent), but their biochemical and metabolic effects are dose related. Chlortha- lidone has the advantage of better 24-hour blood pressure control than hydrochlorothiazide in clinical trials. Thiazides may be used at higher doses if plasma potassium is above 4.5 mmol/L. The loop diuretics (such as furosemide) may lead to electrolyte and volume depletion more readily than the thiazides and have short durations of action. Because of these adverse effects, loop diuretics should be reserved for use in patients with kidney dysfunction (serum creatinine greater than 2.5 mg/dL [208.3 mcmol/L]; estimated glo- merular filtration rate [eGFR] less than 30 mL/min/1.73 m2) in which case they are more effective than thiazides. Relative to beta-blockers and ACE inhibitors, diuretics are more potent in Blacks, older individuals, the obese, and other subgroups with increased plasma volume or low plasma renin activity (or both). They are relatively more effective in smokers than in nonsmokers. Long-term thiazide adminis- tration also mitigates the loss of bone mineral content in older women at risk for osteoporosis.Overall, diuretics administered alone control blood pressure in 50% of patients with mild to moderate hyper- tension and can be used effectively in combination with all other agents. They are also useful for lowering isolated or predominantly systolic hypertension. Side effects The adverse effects of diuretics relate primar- ily to the metabolic changes listed in Table 118. Erectile dysfunction, skin rashes, and photosensitivity are less fre- quent. Hypokalemia has been a concern but is uncommon at the recommended dosages. The risk can be minimized by limiting dietary salt or increasing dietary potassium; potassium replacement is not usually required to maintain serum K+at greater than 3.5 mmol/L. Higher serum K+ levels are prudent in patients at special risk from intracel- lular potassium depletion, such as those taking digoxin or with a history of ventricular arrhythmias in which case a potassium-sparing agent could be used. Compared with ACE inhibitors and ARBs, diuretic therapy is associated with a slightly higher incidence of mild new-onset diabe- tes. Diuretics also increase serum uric acid and may pre- cipitate gout. Increases in blood glucose, triglycerides, and LDL cholesterol may occur but are relatively minor during long-term low-dose therapy. The potential for worsening of diabetes is outweighed by the advantages of blood pres- sure control, and diuretics should not be withheld from diabetic patients.F . Aldosterone Receptor AntagonistsSp ironolactone and eplerenone are natriuretic in sodium- retaining states, such as heart failure and cirrhosis, but only very weakly so in hypertension. These drugs have reemerged in the treatment of hypertension, particularly in resistant patients and are helpful additions to most other antihyper- tensive medications. Consistent with the increasingly appreciated importance of aldosterone in essential hyper- tension, the aldosterone receptor blockers are effective at lowering blood pressure in all hypertensive patients regard- less of renin level and are also effective in Blacks. Aldoste- rone plays a central role in target-organ damage, including the development of ventricular and vascular hypertrophy and renal fibrosis. Aldosterone receptor antagonists amelio- rate these consequences of hypertension, to some extent independently of effects on blood pressure. Side effects Spironolactone can cause breast pain and gyne- comastia in men through activity at the progesterone receptor, an effect not seen with the more specific eplerenone. Hyper- kalemia is a problem with both drugs, chiefly in patients with chronic kidney disease. Hyperkalemia is more likely if the pretreatment plasma potassium exceeds 4.5 mmol/L.G.  Beta-Adrenergic Blocking AgentsT hese drugs are effective in hypertension because they decrease the heart rate and cardiac output. The beta-blockers also decrease renin release and are more efficacious in populations with elevated plasma renin activity, such as younger White patients. They neutralize the reflex tachycar- dia caused by vasodilators and are especially useful in patients with associated conditions that benefit from the cardioprotective effects of these agents.CMDT22_Ch11_p0443-p0474.indd  456 29/06/21 8:37 PMSYSteMIC hYperteNSION457 CMDT 2022Table 117. Antihypertensive drugs: calcium channel blocking agents.Dug poiy NmIniil Ol Dosg Dosg rngCos of 30 Dys of tmn (avg Dosg)1Scil pois Conciliy advs effcs Commnspil VsodilionCdic auomiciy nd Conducion Nondiydoyidin agns Diltiazem Cardizem SR 90 mg twice daily 180360 mg in 2 doses$283.20 (120 mg twice daily)++    Edema, headache, bradycardia, bloating and constipation, dizziness, AV block, heart failure, urinary frequency.Also approved for angina. Cardizem CD 180 mg ER once daily180360 mg ER once daily$46.80 (240 mg once daily) Cartia XT 180 or 240 mg ER once daily180480 mg ER once daily$46.80 (240 mg once daily) Dilacor XR 180 or 240 mg ER once daily180540 mg ER once daily$39.00 (240 mg once daily) Dilt-CD 180 or 240 mg ER once daily180480 mg ER once daily$46.80 (240 mg once daily) Diltia XT 180 or 240 mg ER once daily180540 mg ER once daily$46.80 (240 mg once daily) Taztia XT 120 or 180 mg ER once daily120540 mg ER once daily$53.40 (240 mg once daily) Tiazac 120 or 240 mg ER once daily120540 mg ER once daily$53.40 (240 mg once daily) Verapamil Calan 80 mg three times daily80480 mg in 3 divided doses$35.10 (80 mg three times daily)++    Same as diltiazem but more likely to cause constipation and heart failure.Also approved for angina and arrhythmias. Calan SR 180 mg ER once daily180480 mg ER in 1 or 2 doses$36.60 (240 mg once daily) Verelan 120 or 240 mg ER once daily240480 mg ER once daily$68.70 (240 mg once daily) Verelan PM 100 or 200 mg ER once daily100400 mg ER once daily$75.90 (200 mg once daily) (continued )CMDT22_Ch11_p0443-p0474.indd  457 29/06/21 8:37 PMChapter 11458 CMDT 2022Table 117. Antihypertensive drugs: calcium channel blocking agents.Dug poiy NmIniil Ol Dosg Dosg rngCos of 30 Dys of tmn (avg Dosg)1Scil pois Conciliy advs effcs Commnspil VsodilionCdic auomiciy nd Conducion Diydoyidins Amlodipine Norvasc 2.5 mg once daily 2.510 mg once daily$3.00 (10 mg once daily)+++ /0 /0 Edema, dizziness, palpitations, flushing, headache, hypoten- sion, tachycardia, bloating and consti- pation, urinary frequency.Amlodipine, nicar- dipine, and nife- dipine also approved for angina. Amlodipine and atorvastatinCaduet 2.5 mg/10 mg once daily10 mg/80 mg once daily$281.10 (10 mg/ 40 mg daily)+++ /0 /0 Edema (amlodipine), myopathy and hepa- totoxicity (atorvastatin). Felodipine Plendil 5 mg ER once daily 510 mg ER once daily$81.60 (10 mg ER daily)+++ /0 /0 Isradipine DynaCirc 2.5 mg twice daily 2.55 mg twice daily$120.00 (5 mg twice daily)+++ /0  Nicardipine Cardene 20 mg three times daily2040 mg three times daily$52.20 (20 mg three times daily)+++ /0  Nifedipine Adalat CC 30 mg ER once daily 3090 mg ER once daily$67.50/60 mg daily +++    Procardia XL 30 or 60 mg ER once daily30120 mg ER once daily$60.30/60 mg daily Nisoldipine Sular 17 mg daily 1734 mg daily $251.70 (34 mg once daily)+++ /0 1 Average wholesale price (AWP , for AB-rated generic when available) for quantity listed. Source: IBM Micromedex Red Book (electronic version) IBM Watson Health. Greenwood Village, CO, USA. Available at https://www.mi cromedexsolutions.com, accessed March 27, 2021. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions. AV, atrioventricular; ER, extended release; GI, gastrointestinal.(continued)CMDT22_Ch11_p0443-p0474.indd  458 29/06/21 8:37 PMSYSteMIC hYperteNSION459 CMDT 2022Table 118. Antihypertensive drugs: diuretics (in descending order of preference).Dugs poiy NmsIniil Ol Doss Dosg rng Cos  UniCos of 30 Dys of tmn1 (avg Dosg) advs effcs Commns tizids nd rld Diuics Hydrochloro- thiazide (HCTZ)Esidrix, Microzide12.5 or 25 mg once daily12.550 mg once daily$0.08/25 mg $2.40 K+,Mg2+,Ca2+,Na+, uric acid, glucose, LDL cholesterol, triglycerides; rash, erectile dysfunction.Low dosages effective in many patients with- out associated metabolic abnormalities Chlorthalidone Thalitone 12.5 or 25 mg once daily12.550 mg once daily$1.21/25 mg $36.30  Better 24-hour blood pressure control than HCTZ because of longer half-life Metolazone Zaroxolyn 1.25 or 2.5 mg once daily1.255 mg once daily$1.51/5 mg $45.30  More effective with concurrent kidney disease Indapamide Lozol 2.5 mg once daily2.55 mg once daily$0.83/2.5 mg $24.90  Does not alter serum lipid levels Bendroflume- thiazideAprinox Neo-Naclex2.5 mg once daily    Not available in United States Loo Diuics Furosemide Lasix 20 mg twice daily40320 mg in 2 or 3 doses$0.16/40 mg $9.60 Same as thiazides, but with higher risk of excessive diuresis and electrolyte imbalance. Increases calcium excretion.Short duration of action a disadvantage; should be reserved for patients with kidney disease or fluid retention. Poor antihypertensive. Ethacrynic acid Edecrin 50 mg once daily50100 mg once or twice daily$23.95/25 mg $1437.00 Bumetanide (generic) 0.25 mg twice daily0.510 mg in 2 or 3 doses$0.54/1 mg $32.40 Torsemide Demadex 5 mg once daily510 mg once daily$0.70/10 mg $21.00  Effective blood pressure medication at low dosage. (continued )CMDT22_Ch11_p0443-p0474.indd  459 29/06/21 8:37 PMChapter 11460 CMDT 2022Table 118. Antihypertensive drugs: diuretics (in descending order of preference).Dugs poiy NmsIniil Ol Doss Dosg rng Cos  UniCos of 30 Dys of tmn1 (avg Dosg) advs effcs Commns aldoson rco Blocks Spironolactone Aldactone 12.5 or 25 mg once daily12.5100 mg once daily$0.19/25 mg $5.70 Hyperkalemia, metabolic acidosis, gynecomastia.Can be useful add-on therapy in patients with refractory hypertension. Amiloride (generic) 5 mg once daily510 mg once daily$1.25/5 mg $37.50 Eplerenone Inspra 25 mg once daily25100 mg once daily$4.10/25 mg $123.00 Combinion poducs HCTZ and triamtereneDyazide, Maxzide-25 (25/37.5 mg)1 tab once daily1 or 2 tabs once daily$0.27 $8.10 Same as thiazides plus GI disturbances, hyperkalemia rather than hypokalemia, headache; triamterene can cause kidney stones and kidney dysfunction; spirono- lactone causes gynecomastia. Hyperkale- mia can occur if this combination is used in patients with advanced kidney disease or those taking ACE inhibitors.Use should be limited to patients with demonstrable need for a potassium- sparing agent. HCTZ and amiloride(generic) (50/5 mg) tab once daily1 or 2 tabs once daily$1.16 $34.80 HCTZ and spironolac- toneAldactazide (25/25 mg; 50/50 mg)1 tab (25/25 mg) once daily14 tabs once daily$1.24/ (25/25 mg)$37.201 Average wholesale price (AWP , for AB-rated generic when available) for quantity listed. Source: IBM Micromedex Red Book (electronic version) IBM Watson Health. Greenwood Village, CO, USA. Available at https://www.mi cromedexsolutions.com, accessed March 27, 2021. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions. ACE, angiotensin-converting enzyme; GI, gastrointestinal; LDL, low-density lipoprotein.(continued)CMDT22_Ch11_p0443-p0474.indd  460 29/06/21 8:37 PMSYSteMIC hYperteNSION461 CMDT 2022Th ese include individuals with angina pectoris, previous myo- cardial infarction, and stable heart failure as well as those with migraine headaches and somatic manifestations of anxiety. Although all beta-blockers appear to be similar in anti- hypertensive potency, they differ in a number of pharma- cologic properties (these differences are summarized in Table 119), including specificity to the cardiac beta- 1-receptors (cardioselectivity) and whether they also block the beta-2-receptors in the bronchi and vasculature ; at higher dosages, however, all agents are nonselective. The beta-blockers also differ in their pharmacokinetics, lipid solubilitywhich determines whether they cross the blood- brain barrier predisposing to central nervous system side effectsand route of metabolism. Metoprolol reduces mor- tality and morbidity in patients with chronic stable heart failure with reduced ejection fraction (see Chapter 10). Carvedilol and nebivolol maintain cardiac output and are beneficial in patients with left ventricular systolic dysfunc- tion. Carvedilol and nebivolol may reduce peripheral vas- cular resistance by concomitant alpha-blockade (carvedilol) and increased nitric oxide release (nebivolol). Because of the lack of efficacy in primary prevention of myocardial infarction and inferiority compared with other drugs in prevention of stroke and left ventricular hypertrophy, tra- ditional beta-blockers should not be used as first-line agents in the treatment of hypertension without specific compelling indications (such as active coronary artery disease). Vasodilating beta-blockers may emerge as alter- native first-line antihypertensives, but this possibility has yet to be rigorously tested in outcome studies. Side effects The side effects of beta-blockers include inducing or exacerbating bronchospasm in predisposed patients; sinus node dysfunction and AV conduction depres- sion (resulting in bradycardia or AV block); nasal conges- tion; Raynaud phenomenon; and central nervous system symptoms with nightmares, excitement, depression, and confusion. Fatigue, lethargy, and erectile dysfunction may occur. The traditional beta-blockers (but not the vasodilator beta-blockers carvedilol and nebivolol) have an adverse effect on lipids and glucose metabolism. Beta-blockers are used cautiously in patients with type 1 diabetes, since they can mask the symptoms of hypoglycemia and prolong these episodes by inhibiting gluconeogenesis. These drugs should also be used with caution in patients with advanced periph- eral vascular disease associated with rest pain or nonhealing ulcers, but they are generally well tolerated in patients with mild claudication. Nebivolol can be safely used in patients with stage II claudication (claudication at 200 m). In treatment of pheochromocytoma, beta-blockers should not be administered until alpha-blockade (eg, phentolamine) has been established . Otherwise, blockade of vasodilatory beta-2-adrenergic receptors will allow unopposed vasocon- strictor alpha-adrenergic receptor activation with worsening of hypertension. For the same reason, beta-blockers should not be used to treat hypertension arising from cocaine use . Great care should be exercised if the decision is made, in the absence of compelling indications, to remove beta- blockers from the treatment regimen because abrupt with- drawal can precipitate acute coronary events and severe increases in blood pressure.H. Alpha-Adrenoceptor AntagonistsPrazosin,  terazosin, and doxazosin (Table 1110) block postsynaptic alpha-receptors, relax smooth muscle, and reduce blood pressure by lowering peripheral vascular resistance. These agents are effective as single-drug therapy in some individuals, but tachyphylaxis may appear during long-term therapy. Unlike beta-blockers and diuretics, alpha-blockers have no adverse effect on serum lipid levels. In fact, alpha-blockers increase HDL cholesterol while reducing total cholesterol; whether this is beneficial in the long term has not been established. Side effects Side effects are relatively common (Table 1110). These include marked hypotension after the first dose which, therefore, should be small and given at bedtime. Post-dosing palpitations, headache, and nervous- ness may continue to occur during long-term therapy; these symptoms may be less frequent or severe with doxa- zosin because of its more gradual onset of action. In ALL- HAT, persons receiving doxazosin as initial therapy had a significant increase in heart failure hospitalizations and a higher incidence of stroke relative to those receiving diuret- ics, prompting discontinuation of this arm of the study. Cata- ractectomy in patients exposed to alpha-blockers can be complicated by the floppy iris syndrome, even after discon- tinuation of the drug, so the ophthalmologist should be alerted that the patient has been taking the drug prior to surgery. To summarize, alpha-blockers should generally not be used as initial agents to treat hypertensionexcept perhaps in men with symptomatic prostatism or nightmares linked to posttraumatic stress disorder.I.  Drugs With Central Sympatholytic ActionMet hyldopa, clonidine, guanabenz, and guanfacine (Table 1110) lower blood pressure by stimulating alpha- adrenergic receptors in the central nervous system, thus reducing efferent peripheral sympathetic outflow. There is considerable experience with methyldopa in pregnant women, and it is still used for this population. Clonidine is available in patches, which may have particular value in noncompliant patients. All of these central sympatholytic agents are effective as single therapy in some patients, but they are usually used as second- or third-line agents because of the high frequency of drug intolerance. Side effects Side effects include sedation, fatigue, dry mouth, postural hypotension, and erectile dysfunction. An important concern is rebound hypertension following withdrawal. Methyldopa also causes hepatitis and hemo- lytic anemia and should be restricted to individuals who have already tolerated long-term therapy.J.  Peripheral Sympathetic InhibitorsTh ese agents are usually used only in refractory hypertension. Reserpine remains a cost-effective antihypertensive agent (Table 1110). Its reputation for inducing mental depres- sion and its other side effectssedation, nasal stuffiness, sleep disturbances, and peptic ulcershas made it unpop- ular, though these problems are uncommon at low dosages.CMDT22_Ch11_p0443-p0474.indd  461 29/06/21 8:37 PMChapter 11462 CMDT 2022Table 119. Antihypertensive drugs: beta-adrenergic blocking agents.Dug poiy NmIniil Ol Dosg Dosg rngCos  UniCos of 30 Dys of tmn (Bsd on avg Dosg)1Scil pois Commns5B-1 Slciviy2ISa3MSa4Liid Solubiliyrnl vs hic eliminion Acebutolol Sectral 400 mg once daily2001200 mg in 1 or 2 doses$1.34/400 mg $40.20 + + + + H > R Positive ANA; rare LE syndrome; also indicated for arrhythmias. Doses > 800 mg have beta-1 and beta-2 effects. Atenolol Tenormin 25 mg once daily25100 mg once daily$0.79/50 mg $23.70 + 0 0 0 R Also indicated for angina and post-MI. Doses > 100 mg have beta-1 and beta-2 effects. Atenolol/ chlorthalidoneTenoretic 50 mg/25 mg once daily50 mg/25 mg 100 mg/25 mg once daily$1.88/50 mg/ 25 mg$56.40 + 0 0 0 R Betaxolol Kerlone 10 mg once daily1040 mg once daily$0.78/10 mg $23.40 + 0 0 + H > R Bisoprolol Zebeta 5 mg once daily520 mg once daily$1.22/10 mg $36.60 + 0 0 0 R = H Also effective for heart failure. Bisoprolol and HCTZZiac 2.5 mg/ 6.25 mg once daily2.5 mg/6.25 mg 10 mg/6.25 mg once daily$1.14/2.5/ 6.25 mg$34.20 + 0 0 0 R = H Low-dose combination approved for initial therapy. Carvedilol Coreg Coreg CR6.25 mg twice daily 20 mg ER once daily12.550 mg in 2 doses 2080 mg ER once daily$0.09/25 mg $9.91/any tablet$5.40 (25 mg twice a day) $297.300 0 0 +++ H > R Alpha:beta blocking activity 1:9; may cause ortho- static symptoms; effec- tive for heart failure. Nitric oxide potentiating vasodilatory activity. Labetalol Trandate 100 mg twice daily2002400 mg in 2 doses$0.39/200 mg $23.40 0 0/+ 0 ++ H Alpha:beta blocking activity 1:3; more orthostatic hypotension, fever, hepatotoxicity.CMDT22_Ch11_p0443-p0474.indd  462 29/06/21 8:37 PMSYSteMIC hYperteNSION463 CMDT 2022Metoprolol Lopressor Toprol-XL (SR prepara- tion)50 mg twice daily 25 mg once daily50200 mg twice daily 25400 mg once daily$0.03/50 mg $1.50/100 mg$1.80 $45.00+ 0 + +++ H Also indicated for angina and post-MI. Approved for heart failure. Doses > 100 mg have beta-1 and beta-2 effects. Metoprolol and HCTZLopressor HCT50 mg/ 12.5 mg twice daily50 mg/25 mg 200 mg/50 mg$1.77/100 mg/ 25 mg$106.20 + 0 + +++ H Nadolol Corgard 20 mg once daily20320 mg once daily$3.96/40 mg $118.80 0 0 0 0 R Nadolol and bendroflumeth- azideCorzide 40 mg/5 mg once daily40 mg/5 mg 80 mg/5 mg once daily6.14/80 mg/ 5 mg$184.20 Nebivolol Bystolic 5 mg once daily40 mg once daily $6.32/5 mg $189.60 + 0 0 ++ H Nitric oxide potentiating vasodilatory activity. Pindolol Visken 5 mg twice daily1060 mg in 2 doses$1.10/5 mg $66.00 0 ++ + + H > R In adults, 35% renal clearance. Propranolol Inderal Inderal LA InnoPran XL20 mg twice daily 80 mg ER once daily 80 mg ER once nightly40640 mg in 2 doses 120640 mg ER once daily 80120 mg ER once nightly$0.41/40 mg $2.98/120 mg $30.20/ 120 mg$24.60 $89.40 $906.000 0 ++ +++ H Also indicated for angina and post-MI. Propranolol and HCTZ(generic) 40 mg/25 mg twice daily80 mg/25 mg twice daily$1.41/80 mg/ 25 mg$84.60 0 0 ++ +++ H Timolol (generic) 5 mg twice daily1060 mg in 2 doses$1.70/10 mg $102.00 0 0 0 ++ H > R Also indicated for post-MI; 80% hepatic clearance.1 Average wholesale price (AWP , for AB-rated generic when available) for quantity listed. Source: IBM Micromedex Red Book (electronic version) IBM Watson Health. Greenwood Village, CO, USA. Available at https://www.mi cromedexsolutions.com, accessed March 27, 2021. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions.2 Agents with beta-1 selectivity are less likely to precipitate bronchospasm and decrease peripheral blood flow in low doses, but selectivity is only relative.3 Agents with ISA cause less resting bradycardia and lipid changes.4 MSA generally occurs at concentrations greater than those necessary for beta-adrenergic blockade. The clinical importance of MS A by beta-blockers has not been defined.5 Adverse effects of all beta-blockers: bronchospasm, fatigue, sleep disturbance and nightmares, bradycardia and atrioventricular block, worsening of heart failure, cold extremities, gastrointestinal disturbances, erectile dysfunction, triglycerides, high-density lipoprotein cholesterol, rare blood dyscrasias. ANA, antinuclear antibody; ER, extended release; HCTZ, hydrochlorothiazide; ISA, intrinsic sympathomimetic activity; LE, lupus erythematosus; MI, myocardial infarction; MSA, membrane-stabilizing activity; SR, sustained release; 0, no effect; +, some effect; ++, moderate effect; +++, most effect.CMDT22_Ch11_p0443-p0474.indd  463 29/06/21 8:37 PMChapter 11464 CMDT 2022Table 1110. Alpha-adrenoceptor blocking agents, sympatholytics, and vasodilators.Dug poiy Nms Iniil Dosg Dosg rng Cos  UniCos of 30 Dys of tmn (avg Dosg)1advs effcs Commns al-adnoco Blocks Doxazosin Cardura Cardura XL1 mg at bedtime 4 mg ER once daily116 mg once daily 48 mg ER once daily$0.29/4 mg $7.07/4 mg ER$8.70 (4 mg once daily) $212.10 (4 mg ER once daily)Syncope with first dose; postural hypotension, dizziness, palpitations, headache, weakness, drowsiness, sexual dys- function, anticholinergic effects, urinary inconti- nence; first-dose effects may be less with doxazosin.MayHDL and LDL cholesterol. May provide short-term relief of obstructive prostatic symptoms. Less effective in preventing car- diovascular events than diuretics.Prazosin Minipress 1 mg at bedtime 220 mg in 2 or 3 doses$0.95/5 mg $57.00 (5 mg twice daily) Terazosin Hytrin 1 mg at bedtime 120 mg in 1 or 2 doses$1.60/1, 2, 5, 10 mg$48.00 (5 mg once daily) Cnl Symolyics Clonidine Catapres Catapres TTS (transdermal patch)0.1 mg twice daily 0.1 mg/day patch weekly0.20.6 mg in 2 doses 0.10.3 mg/day patch weekly$0.21/0.1 mg $55.77/0.2 mg patch$12.60 (0.1 mg twice daily) $223.08 (0.2 mg weekly)Sedation, dry mouth, sex- ual dysfunction, head- ache, bradyarrhythmias; side effects may be less with guanfacine. Contact dermatitis with clonidine patch.Rebound hypertension may occur even after gradual withdrawal. Clonidine and chlorthalidoneClorpres 0.1 mg/15 mg one to three times daily0.1 mg/15 mg 0.3 mg/15 mg$2.77/0.1 mg/ 15 mg$166.20/0.1 mg/ 15 mg twice daily Guanfacine Tenex 1 mg once daily 13 mg once daily $0.87/1 mg $26.10 (1 mg once daily) Methyldopa Aldochlor 250 mg twice daily 5002000 mg in 2 doses$0.66/500 mg $39.60 (500 mg twice daily)Hepatitis, hemolytic ane- mia, fever.Avoid in favor of safer agents.CMDT22_Ch11_p0443-p0474.indd  464 29/06/21 8:37 PMSYSteMIC hYperteNSION465 CMDT 2022pil Nuonl angoniss Reserpine (generic) 0.05 mg once daily 0.050.25 mg once daily$1.19/0.1 mg $35.70 (0.1 mg once daily)Depression (less likely at low dosages, ie, < 0.25 mg), night terrors, nasal stuffi- ness, drowsiness, peptic disease, GI disturbances, bradycardia. Dic Vsodilos Hydralazine Apresoline 25 mg twice daily 50300 mg in 24 doses$0.15/25 mg $9.00 (25 mg twice daily)GI disturbances, tachycar- dia, headache, nasal congestion, rash, LE-like syndrome.May worsen or precipitate angina. Minoxidil (generic) 5 mg once daily 1040 mg once daily $1.28/10 mg $38.40 (10 mg once daily)Tachycardia, fluid retention, headache, hirsutism, pericardial effusion, thrombocytopenia.Should be used in combination with beta-blocker and diuretic.1 Average wholesale price (AWP , for AB-rated generic when available) for quantity listed. Source: IBM Micromedex Red Book (electronic version) IBM Watson Health. Greenwood Village, CO, USA. Available at https://www.mi cromedexsolutions.com, accessed March 27, 2021. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions. ER, extended release; GI, gastrointestinal; LE, lupus erythematosus.CMDT22_Ch11_p0443-p0474.indd  465 29/06/21 8:37 PMChapter 11466 CMDT 2022Guanethidine and guana drel inhibit catecholamine release from peripheral neurons but frequently cause orthostatic hypotension (especially in the morning or after exercise), diarrhea, and fluid retention.K.  Arteriolar DilatorsH ydralazine and minoxidil (Table 1110) relax vascular smooth muscle and produce peripheral vasodilation. When given alone, they stimulate reflex tachycardia; increase myocardial contractility; and cause headache, palpitations, and fluid retention. To counteract these effects, the agents are usually given in combination with diuretics and beta-blockers in resistant patients. Hydrala- zine produces frequent gastrointestinal disturbances and may induce a lupus-like syndrome. Minoxidil causes hir- sutism and marked fluid retention; this very potent agent is reserved for the most refractory of cases. Antihypertensive Medications & the Risk of CancerA  number of observational studies have examined the association between long-term exposure to antihyperten- sive medications and cancer. Weak associations have been suggested by some of these studies, but results have been very mixed. In the absence of large-scale prospective studies with cancer as a prespecified outcome measure, the effect of antihypertensive drugs on the risk of cancer remains uncertain. By contrast, the beneficial effect of these drugs on cardiovascular outcomes has been clearly established. Concern about increased risk of cancer should not be minimized, but at present there are no compelling data to prompt a change in prescribing patterns.Hicks  BM et al. Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ. 2018;363:k4209. [PMID: 30355745] Su KA et al. Photosensitizing antihypertensive drug use and risk of cutaneous squamous cell carcinoma. Br J Dermatol. 2018;179:1088. [PMID: 29723931] Wright CM et al. Calcium channel blockers and breast cancer incidence: an updated systematic review and meta-analysis of the evidence. Cancer Epidemiol. 2017;50:113. [PMID: 28866282] Procedures That Modulate the Activity of the Autonomic Nervous SystemBefore the adv ent of antihypertensive medications, lumbar sympathectomy was used to lower blood pressure. In a more specific and less invasive approach, the renal sympa- thetic nerves can be ablated using radiofrequency energy applied to the luminal surface of the renal arteries. How- ever, the Symplicity HTN-3 study of renal sympathetic denervation did not show any difference in blood pressure reduction compared to a sham procedure group. Subse- quently, the SPYRAL HTN-OFF MED study, using a more intensive and closely controlled ablation strategy, demon- strated clinically meaningful blood pressure reductions compared to the sham control group. Although not yetaccepted in general clinical practice, it seems probable that renal sympathetic nerve ablation will emerge as an alterna- tive or adjunctive modality in the treatment of hyperten- sion and may become useful in the management of resistant hypertension and drug intolerance.Bhm  M et al; SPYRAL HTN-OFF MED Pivotal Investigators. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395:1444. [PMID: 32234534] Hermida RC et al; Hygia Project Investigators. Bedtime hyper- tension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J. 2020;41: 4565. [PMID: 31641769] Developing an Antihypertensive RegimenHisto rically, data from large placebo-controlled trials sup- ported the overall conclusion that antihypertensive therapy with diuretics and beta-blockers had a major beneficial effect on a broad spectrum of cardiovascular outcomes, reducing the incidence of stroke by 3050% and of heart failure by 4050%, and halting progression to accelerated hypertension syndromes. The decreases in fatal and nonfa- tal coronary heart disease and cardiovascular and total mortality were less dramatic, ranging from 10% to 15%. Similar placebo-controlled data pertaining to the newer agents are generally lacking, except for stroke reduction with the calcium channel blocker nitrendipine in the Sys- tolic Hypertension in Europe trial. However, there is sub- stantial evidence that ACE inhibitors, and to a lesser extent ARBs, reduce adverse cardiovascular outcomes in other related populations (eg, patients with diabetic nephropa- thy, heart failure, or postmyocardial infarction and indi- viduals at high risk for cardiovascular events). Most large clinical trials that have compared outcomes in relatively unselected patients have failed to show a difference between newer agentssuch as ACE inhibitors, calcium channel block- ers, and ARBsand the older diuretic-based regimens with regard to survival, myocardial infarction, and stroke. Where differences have been observed, they have mostly been attrib- utable to subtle asymmetries in blood pressure control rather than to any inherent advantages of one agent over another. Recommendations for initial treatment identify ACE inhibi- tors, ARBs, and calcium channel blockers as valid choices. Because of their adverse metabolic profile, initial therapy with thiazides might best be restricted to older patients. Thiazides are acceptable as first-line therapy in Blacks because of specific efficacy in this group. As discussed above, beta-blockers are not ideal first-line drugs in the treatment of hypertension without compelling indications for their use (such as active coronary artery disease and heart failure). Vasodilator beta-blockers (such as carvedilol and nebivolol) may produce better outcomes than traditional beta-blockers; however, this possibility remains a theoretical consideration. The American Diabetes Association has advocated eve- ning dosing of one or more antihypertensive medications to restore nocturnal blood pressure dipping. The HYGIACMDT22_Ch11_p0443-p0474.indd  466 29/06/21 8:37 PMSYSteMIC hYperteNSION467 CMDT 2022trial  compared the effect of nighttime dosing of at least one antihypertensive medication with morning dosing of all antihypertensive medications in 19,000 participants with median follow-up 6.3 years, and demonstrated improved ambulatory blood pressure and nocturnal dipping, and a significant decline in major cardiovascular events in the nighttime dosing group. Participants were monitored via ambulatory blood pressure measurement, and the inci- dence of nocturnal hypotension in the HYGIA trial was very low. However, profound nocturnal hypotension might not be detected in the absence of ambulatory blood pres- sure monitoring, and ischemic optic neuropathy or other low perfusion complications would be a concern. Drugs that interrupt the renin-angiotensin cascade are more effective in young, White persons, in whom renin tends to be higher. Calcium channel blockers and diuretics are more effective in older or Black persons, in whom renin levels are generally lower. Many patients require two or more medications and even then a sub- stantial proportion fail to achieve the goal blood pres- sure. A stepped care approach to the drug treatment of hypertension is outlined in Table 1111. In diabetic patients, three or four drugs are usually required to reduce systolic blood pressure to goal. In many patients, blood pressure cannot be adequately controlled with any combination. As a result, debating the appropriate first-line agent is less relevant than determining the most appropriate combinations of agents. The mnemonic ABCD can be used to remember four classes of antihypertensive medications. These four classes can be divided into two categories: AB and CD. AB refers to drugs that block the RAAS ( ACE/ARB and beta-blockers). CD refers to those that work in other pathways ( calcium channel blockers and diuretics). Combinations of drugs between the two categories are more potent than combina- tions from within a category. Many experts recommend the use of fixed-dose combination (between two categories) antihypertensive agents as first-line therapy in patientswith substantially elevated systolic pressures (greater than 160/100 mm Hg) or difficult-to-control hypertension (which is often associated with diabetes or kidney dysfunc- tion). In light of unwanted metabolic effects, calcium chan- nel blockers might be preferable to thiazides in the younger hypertensive patient requiring a second antihypertensive drug following initiation of therapy with an ACE inhibitor or ARB. Furthermore, based on the results from the ACCOMPLISH trial, a combination of ACE inhibitor and calcium channel blocker may also prove optimal for patients at high risk for cardiovascular events. The initial use of low-dose combinations allows faster blood pressure reduction without substantially higher intolerance rates and is likely to be better accepted by patients. Data from the ALTITUDE study (in patients with type 2 diabetes and chronic kidney disease or cardiovascular disease or both) indicate that the addition of aliskiren to either ARB or ACE inhibitor was associated with worse outcomes and cannot be recommended, at least in this population. A suggested approach to treatment, tailored to patient demographics, is outlined in Table 1112. In sum, as a prelude to treatment, the patient should be informed of common side effects and the need for diligent compliance. In patients with blood pressure less than 160/90 mm Hg in whom pharmacotherapy is indicated, treatment should start with a single agent or two-drug combination at a low dose. Follow-up visits usually should be at 4- to 6-week intervals to allow for full medication effects to be established (especially with diuretics) before further titration or adjustment. If, after titration to usual doses, the patient has shown a discernible but incomplete response and a good tolerance of the initial drug, another medication should be added. See Goals of Treatment, above. As a rule of thumb, a blood pressure reduction of 10 mm Hg can be expected for each antihypertensive agent added to the regimen and titrated to the optimum dose. In those with more severe hypertension, or with comorbidi- ties (such as diabetes) that are likely to render them Table 1111. A step care approach to the initiation and titration of antihypertension medications.1,2Step  1 ACE inhibitor/ARB or3Calcium  channel blocker or Thiazide diuretic4Step  2 ACE inhibitor/ARB plus Calcium channel blocker orthiazide diuretic5Step  3 ACE inhibitor/ARB plus calcium channel blocker plus thiazide diuretic Step 4 ACE inhibitor/ARB plus calcium channel blocker plus thiazide diuretic plus spironolactone6 1Allow 2 weeks to reach full effect of each drug. Proceed through steps until target blood pressure is attained.2 Beta-blockers can be used at any stage if specifically indicated, eg, heart failure or angina.3 The European guidelines recommend starting with low-dose combination of two antihypertensive drugs in all but low-risk grade 1 hyper- tension (140159/9099 mm Hg). American guidelines suggest initiation with dual therapy for stage 2 hypertension (> 140/90 mm H g).4 Thiazide or calcium channel blocker is more effective initial therapy in older people and Blacks.5 If required, add a calcium channel blocker rather than diuretic in younger patients to avoid long-term exposure to metabolic si de effects of diuretics.6 Alternatives to spironolactone include eplerenone, amiloride, or triamterene. Watch for hyperkalemia, especially if also receiv ing ACE inhibitor/ ARB. Avoid potassium-sparing diuretics in advanced CKD. If more than three drugs are required at maximum dose, consider special ist referral. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CKD, chronic kidney disease.CMDT22_Ch11_p0443-p0474.indd  467 29/06/21 8:37 PMChapter 11468 CMDT 2022T able 1112. Choice of antihypertensive agent based on demographic considerations.1,2 Blck, all ags all Os, ag < 55 Ys all Os, ag > 55 Ys Fis-lin CCB or diuretic ACE inhibitor or ARB3or CCB or diuretic4CCB or diuretic5Scond-lin  ARB3or ACE inhibitor6or vasodilating beta-blocker6Vasodilating beta-blocker ACE inhibitor or ARB3or vasodilating beta-blocker7rsisn  ynsion Aldosterone receptor blocker Aldosterone receptor blocker Aldosterone receptor blocker addiionl oions Centrally acting alpha-agonist or peripheral alpha-antagonist8Centrally acting alpha-agonist or peripheral alpha-antagonist8Centrally acting alpha-agonist or peripheral alpha-antagonist8 1Compelling indications may alter the selection of an antihypertensive drug.2 Start with full dose of one agent, or lower doses of combination therapy. In more severe hypertension ( 140/90 mm Hg), conside r initiat- ing therapy with a fixed dose combination.3 Women of childbearing age should avoid ACE inhibitors and ARBs or discontinue as soon as pregnancy is diagnosed.4 The adverse metabolic effects of thiazide diuretics and beta-blockers should be considered in younger patients but may be less important in the older patient.5 For patients with significant kidney dysfunction, use loop diuretic instead of thiazide.6 Despite the elevated risk of angioedema and cough in Blacks, ACE inhibitors are generally well tolerated and are a useful adjun ct.7 There are theoretical advantages in the use of vasodilating beta-blockers such as carvedilol and nebivolol.8 Alpha-antagonists may precipitate or exacerbate orthostatic hypotension in older adults. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CCB, calcium channel blocker.resistan t to treatment, initiation with combination therapy is advised and more frequent follow-up is indicated. Patients who are compliant with their medications and who do not respond to conventional combination regi- mens should usually be evaluated for secondary hyperten- sion before proceeding to more complex regimens. Medication NonadherenceAdher ence to antihypertensive treatment is alarmingly poor. In one European study of antihypertensive medica- tion compliance, there was a 40% discontinuation rate at 1 year after initiation. Collaborative care, using clinicians, pharmacists, social workers, and nurses to encourage com- pliance, has had a variable and often rather modest effect on blood pressure control. Adherence is enhanced by patient education and by use of home blood pressure mea- surement. The choice of antihypertensive medication is important. Better compliance has been reported for patients whose medications could be taken once daily or as combination pills. Adherence is best with ACE inhibitors and ARBs, and worse with beta-blockers and diuretics. Consideration of Gender in HypertensionBecause  of the preponderance of male recruitment into large-scale clinical trials, the impact of gender on the evaluation and management of hypertension remains uncertain. The limited data that exist suggest a steeper relationship in women between 24-hour ambulatory and night time systolic blood pressure and the risk of cardio- vascular events. There are many gender-specific effects on the mechanisms and end organ impact of hypertension. In younger adults, men are more likely to be hypertensive than women, a relationship that reverses in later life.Regression of left ventricular hypertrophy in response to ACE inhibitors is less pronounced in women. Women are more likely to have isolated systolic hypertension, probably because they develop more active left ventricular systolic function and greater vascular stiffness than men. Fibro- muscular dysplasia of the renal artery is much more com- mon in women than men. The side effects of many antihypertensive drugs are more pronounced in women than men, including ACE inhibitorassociated cough and hyponatremia and hypokalemia in response to diuretics. Conversely, thiazides can help preserve bone density. Dependent edema due to amlodipine is more likely in women, and women are more sensitive to beta-blockers. There are no data to support a different blood pressure target in women, but this question has not been examined in dedicated clinical trials. Treatment of Hypertension in DiabetesH ypertensive patients with diabetes are at particularly high risk for cardiovascular events. Data from the ACCORD study of diabetic patients demonstrated that most of the benefits of blood pressure lowering were seen with a systolic target of less than 140 mm Hg. Although there was a reduc- tion in stroke risk at a systolic target below 120/70 mm Hg, treatment to this lower target was associated with an increased risk of serious adverse effects. US and Canadian guidelines recommend a blood pressure goal of less than 130/80 mm Hg in diabetic patients. Because of the benefi- cial effects of ACE inhibitors in diabetic nephropathy, they should be part of the initial treatment regimen. ARBs or perhaps renin inhibitors may be substituted in those intol- erant of ACE inhibitors. While the ONTARGET study showed that combinations of ACE inhibitors and ARBs in persons with atherosclerosis or type 2 diabetes withCMDT22_Ch11_p0443-p0474.indd  468 29/06/21 8:37 PMSYSteMIC hYperteNSION469 CMDT 2022end-orga n damage appeared to minimize proteinuria, this strategy slightly increased the risks of progression to dialy- sis and of death; thus, it is not recommended. Most dia- betic patients require combinations of three to five agents to achieve target blood pressure, usually including a diuretic and a calcium channel blocker or beta-blocker. Canagliflozin improves glycemic control through inhibition of the sodium-glucose co-transporter 2 (SGLT2) and, in addition, generally lowers blood pressure by 34 mm Hg. This drug was associated with improved renal outcomes and reduced cardiovascular risk in the CREDENCE trial of patients with diabetic nephropathy and can be consid- ered when additional blood pressure control is needed in patients with type 2 diabetes. In addition to rigorous blood pressure control, treatment of persons with diabe- tes should include aggressive treatment of other risk factors. Treatment of Hypertension in Chronic Kidney DiseaseH ypertension is present in 40% of patients with a GFR of 6090 mL/min/1.73 m2, and 75% of patients with a GFR less than 30 mL/min/1.73 m2. The rate of progression of chronic kidney disease is markedly slowed by treatment of hypertension. In the SPRINT trial, the reduction in cardio- vascular risk associated with lower blood pressure targets was also observed in the subgroup with a GFR of less than 60 mL/min/1.73 m2. However, an effect of lower blood pressure targets on the slowing of chronic kidney disease progression appears to be restricted to those with pro- nounced proteinuria. In the SPRINT trial, the lower blood pressure goal was associated with increased risk of acute kidney injury, but this was generally reversible and not associated with elevated biomarkers for ischemic injury. Most experts recommend a blood pressure target of less than 130/80 mm Hg in patients with chronic kidney dis- ease, with consideration of more intensive lowering if pro- teinuria greater than 1 g per 24 hours is present. Medications that interrupt the renin-angiotensin cascade can slow the progression of kidney disease and are preferred for initial therapy, especially in those with albuminuria of greater than 300 mg/g creatinine. Transition from thiazide to loop diuretic is often necessary to control volume expansion as the eGFR falls below 30 mL/min/1.73 m2. ACE inhibitors remain protective and safe in kidney disease associated with significant proteinuria and serum creatinine as high as 5 mg/dL (380 mcmol/L). However, the use of drugs blocking the RAAS cascade in patients with advanced chronic kidney disease should be supervised by a nephrol- ogist. Kidney function and electrolytes should be measured 1 week after initiating treatment and subsequently moni- tored carefully in patients with kidney disease. An increase in creatinine of 2030% is acceptable and expected; more exaggerated responses suggest the possibility of renal artery stenosis or volume contraction. Although lower blood pressure levels are associated with acute decreases in GFR, this appears not to translate into an increased risk of developing end-stage renal disease in the long term. Persis- tence with ACE inhibitor or ARB therapy as the serum potassium level exceeds 5.5 mEq/L is probably notwarranted, since other antihypertensive medications are renoprotective as long as goal blood pressures are main- tained. However, diuretics can often be helpful in control- ling mild hyperkalemia, and there are novel cation exchange polymers (such as patiromer) that sequester potassium in the gut and are more effective and better tol- erated than sodium polystyrene sulfonate. Treatment of Hypertension in BlacksSubstan tial evidence indicates that Blacks in the United States are not only more likely to become hypertensive and more susceptible to the cardiovascular and renal complica- tions of hypertensionthey also respond differently to many antihypertensive medications. The REGARDS study illustrates these differences. At systolic blood pressures less than 120 mm Hg, Black and White participants between 45 and 64 years of age had equal risk of stroke. For a 10 mm Hg increase in systolic blood pressure, the risk of stroke was threefold higher in Black participants. At levels above 140159/9099 mm Hg, the hazard ratio for stroke in Black compared to White participants between 45 and 64 years of age was 2.35. This increased susceptibility may reflect genetic differences in the cause of hypertension or the subsequent responses to it, differences in occurrence of comorbid conditions such as diabetes or obesity, or envi- ronmental factors such as diet, activity, stress, or access to health care services. In any case, as in all persons with hypertension, a multifaceted program of education and lifestyle modification is warranted. Early introduction of combination therapy has been advocated, but there are no clinical trial data to support a lower than usual blood pres- sure goal in Blacks. Because it appears that ACE inhibitors and ARBsin the absence of concomitant diureticsare less effective in Blacks than in Whites, initial therapy should generally be a diuretic or a diuretic in combination with a calcium channel blocker. However, inhibitors of the RAAS do lower blood pressure in Black patients, are useful adjuncts to the recommended diuretic and calcium chan- nel blockers, and should be used in patients with hyperten- sion and compelling indications such as heart failure and kidney disease (especially in the presence of proteinuria) (Table 1113). Black patients have an elevated risk of ACE inhibitorassociated angioedema and cough, so ARBs would be the preferred choice. Treating Hypertension in Older AdultsSeveral  studies in persons over 60 years of age have con- firmed that antihypertensive therapy prevents fatal and nonfatal myocardial infarction and reduces overall cardio- vascular mortality. The HYVET study indicated that a reasonable ultimate blood pressure goal is 150/80 mm Hg. Updated guidelines suggest that blood pressure goals should not generally be influenced by age alone. An explor- atory subgroup analysis of the SPRINT study found that people older than age 75 years showed benefit at the 120 mm Hg systolic treatment target. Importantly, these benefits were also evident in patients classified as frail. This more aggressive approach was, however, associated with greater risk of falls and worsening kidney function,CMDT22_Ch11_p0443-p0474.indd  469 29/06/21 8:37 PMChapter 11470 CMDT 2022indicating  that close monitoring is required in elderly patients treated to lower blood pressure goals. It is also important to note the exclusion criteria of the SPRINT study, which included diabetes mellitus, stroke, and ortho- static hypotension. Blood pressure treatment goals should be individual- ized in the very elderly. In the SPRINT MIND study, the lower systolic blood pressure target of 120 mm Hg was associated with a 15% reduction in the incidence of mild cognitive impairment and probable all cause dementia compared to the 140 mm Hg in the target group. Based upon this data, aggressive control of hypertension in high- risk individuals would have a significant impact on the prevalence of dementia. As discussed above, it is important to note that blood pressure measurements in the SPRINT study were made by automated devices, which are known to read lower than conventional office measurements. How to initiate antihypertensive therapy in older patients The same medications are used in older patients but at 50% lower doses. Pressure should be reduced more gradually with a safe intermediate systolic blood pressure goal of 160 mm Hg. As treatment is initiated, older patients should be carefully monitored for orthostasis, altered cog- nition, and electrolyte disturbances. The elderly are espe- cially susceptible to problems associated with polypharmacy, including drug interactions and dosing errors. Management of Supine Hypertension in Patients With Orthostatic HypotensionSup ine hypertension is common in patients with ortho- static hypotension and is associated with increased cardio- vascular risk. Treatment of orthostasis can exacerbate supine hypertension and vice versa. Life expectancy is often reduced in patients with profound autonomic ner- vous system dysfunction. In those whose life expectancy is at least several years, though, treatment of nocturnal hypertension might be considered with the use of shorter acting agents (eg, captopril, hydralazine, losartan, or quick- release nifedipine). In patients with supine hypertension, medications used to increase blood pressure during the day should not be given within 5 hours of bedtime.Follow-Up of Patients Receiving Hypertension TherapyOnc e blood pressure is controlled on a well-tolerated regi- men, follow-up visits can be infrequent and laboratory test- ing limited to those appropriate for the patient and the medications used. Y early monitoring of blood lipids is rec- ommended, and an electrocardiogram could be repeated at 2- to 4-year intervals depending on whether initial abnor- malities are present and on the presence of coronary risk factors. Patients who have had excellent blood pressure control for several years, especially if they have lost weight and initiated favorable lifestyle modifications, might be con- sidered for a trial of reduced antihypertensive medications.Carnethon  MR et al; American Heart Association Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Func- tional Genomics and Translational Biology; and Stroke Coun- cil. Cardiovascular health in African Americans: a scientific statement from the American Heart Association. Circulation. 2017;136:e393. [PMID: 29061565] Perkovic V et al; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295. [PMID: 30990260] Supiano MA et al. New guidelines and SPRINT results: implica- tions for geriatric hypertension. Circulation. 2019;140:976. [PMID: 31525101] Wenger NK et al. Hypertension across a womans life cycle. J Am Coll Cardiol. 2018;71:1797. [PMID: 29673470]RE SISTANT HYPERTENSIONResistant  hypertension is defined as the failure to reach blood pressure control in patients who are adherent to full doses of an appropriate three-drug regimen (including a diuretic). In the approach to resistant hypertension, the clinician should first confirm compliance and rule out white coat hypertension,  ideally using ambulatory or home-based measurement of blood pressure. Exacerbating factors should be considered (as outlined above). Finally, identifiable causes of resistant hypertension should be sought (Table 1114). The clinician should pay particularTable 1113. Recommended antihypertensive medications for coexisting indications.Indicion aniynsiv Mdicion Diuic B-Block aCe Inibio arBClcium Cnnl Blockaldoson angonis Heart failure       Following MI      High coronary disease risk      Diabetes      Chronic kidney disease    Recurrent stroke prevention    ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; MI, myocardial infarction.CMDT22_Ch11_p0443-p0474.indd  470 29/06/21 8:37 PMSYSteMIC hYperteNSION471 CMDT 2022at tention to the type of diuretic being used in relation to the patients kidney function. Aldosterone may play an important role in resistant hypertension and aldosterone receptor blockers can be very useful. If goal blood pressure cannot be achieved following completion of these steps, consultation with a hypertension specialist should be con- sidered. Renal sympathetic nerve ablation is a consider- ation for these patients in the absence of other options, but further trials are needed before this procedure can be rou- tinely integrated into clinical practice.W ei FF et al. Diagnosis and management of resistant hyperten- sion: state of the art. Nat Rev Nephrol. 2018;14:428. [PMID: 29700488]HY PERTENSIVE URGENCIES & EMERGENCIESH ypertensive urgencies are situations in which blood pressure must be reduced within a few hours. These include patients with asymptomatic severe hypertension (systolic blood pressure greater than 220 mm Hg or dia- stolic pressure greater than 125 mm Hg that persists after a period of observation) and those with optic disk edema, progressive target-organ complications, and severe periop- erative hypertension. Elevated blood pressure levels alonein the absence of symptoms of new or progressive target-organ damagerarely require emergency therapy. Parenteral drug therapy is not usually required; partial reduction of blood pressure with relief of symptoms is thegoal. Effective oral agents are clonidine, captopril, and slow-release nifedipine. Hypertensive emergencies require substantial reduction of blood pressure within 1 hour to avoid the risk of serious morbidity or death. Although blood pressure is usually strik- ingly elevated (diastolic pressure greater than 130 mm Hg), the correlation between pressure and end-organ damage is often poor. It is the presence of critical multiple end-organ injury that determines the seriousness of the emergency and the approach to treatment. Emergencies include hyperten- sive encephalopathy (headache, irritability, confusion, and altered mental status due to cerebrovascular spasm), hyper- tensive nephropathy (hematuria, proteinuria, and acute kidney injury due to arteriolar necrosis and intimal hyper- plasia of the interlobular arteries), intracranial hemorrhage, aortic dissection, preeclampsia-eclampsia, pulmonary edema, unstable angina, or myocardial infarction. Encepha- lopathy or nephropathy accompanying hypertensive reti- nopathy has historically been called malignant hypertension, but the therapeutic approach is identical to that used in other hypertensive emergencies. Parenteral therapy is indicated in most hypertensive emergencies, especially if encephalopathy is present. The initial goal in hypertensive emergencies is to reduce the pres- sure by no more than 25% (within minutes to 1 or 2 hours) and then toward a level of 160/100 mm Hg within 26 hours. Excessive reductions in pressure may precipitate coronary, cerebral, or renal ischemia. To avoid such declines, the use of agents that have a predictable, dose-dependent, tran- sient, and progressive antihypertensive effect is preferable (Table 1115). In that regard, the use of sublingual or oral fast-acting nifedipine preparations is best avoided. Acute ischemic stroke is often associated with marked elevation of blood pressure, which will usually fall sponta- neously. In such cases, antihypertensives should only be used if the systolic blood pressure exceeds 180200 mm Hg, and blood pressure should be reduced cautiously by 1015% (Table 1115). If thrombolytics are to be given, blood pres- sure should be maintained at less than 185/110 mm Hg during treatment and for 24 hours following treatment. Inintracerebral hemorrhage, the aim is to minimize bleeding by reducing the systolic blood pressure in most patients to 130140 mm Hg within the first 6 hours. In acute subarachnoid hemorrhage, as long as the bleeding source remains uncorrected, a compromise must be struck between preventing further bleeding and maintaining cere- bral perfusion in the face of cerebral vasospasm. In this situ- ation, blood pressure goals depend on the patients usual blood pressure. In previously normotensive patients, the tar- get should be a systolic blood pressure of 110120 mm Hg; in hypertensive patients, blood pressure should be treated to 20% below baseline pressure. In the treatment of hyper- tensive emergencies complicated by (or precipitated by) central nervous system injury, labetalol or nicardipine are good choices, since they are nonsedating and do not appear to cause significant increases in cerebral blood flow or intracranial pressure. Patients with subarachnoid hemor- rhage should receive nimodipine for 3 weeks following presentation to minimize cerebral vasospasm. In hyperten- sive emergencies arising from catecholaminergic mechanisms,Table 1114. Causes of resistant hypertension.Improper  blood pressure measurement Nonadherence Volume overload and pseudotolerance Excess sodium intake Volume retention from kidney disease Inadequate diuretic therapy Drug-induced or other causes Inadequate doses Inappropriate combinations Nonsteroidal anti-inflammatory drugs; cyclooxygenase-2 inhibitors Cocaine, amphetamines, other illicit drugs Sympathomimetics (decongestants, anorectics) Oral contraceptives Adrenal steroids Cyclosporine and tacrolimus Erythropoietin Licorice (including some chewing tobacco) Selected over-the-counter dietary supplements and medicines (eg, ephedra, ma huang, bitter orange) Associated conditions Obesity Excess alcohol intake Identifiable causes of hypertension (see Table 112) Data from Chobanian AV et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560.CMDT22_Ch11_p0443-p0474.indd  471 29/06/21 8:37 PMChapter 11472 CMDT 2022T able 1115. Treatment of hypertensive emergency depending on primary site of end-organ damage. See Table 1116 for dosages.t y of hynsiv emgncyrcommndd Dug Oions nd Combinions Dugs o avoid Myocardial ischemia and infarction Nicardipine plus esmolol1Nitroglycerin  plus labetalol Nitroglycerin plus esmolol1Hydralazine, diazoxide, minoxidil, nitroprusside Acute kidney injury Fenoldopam Nicardipine Clevidipine Aortic dissection Esmolol plus nicardipine Esmolol plus clevidipine Labetalol Esmolol plus nitroprussideHydralazine, diazoxide, minoxidil Acute pulmonary edema, LV systolic dysfunction Nicardipine plus nitroglycerin2plus a loop diuretic Clevidipine plus nitroglycerin2plus a loop diureticHydralazine, diazoxide, beta-blockers Acute pulmonary edema, diastolic dysfunction Esmolol plus low-dose nitroglycerin plus a loop diuretic Labetalol plus low-dose nitroglycerin plus a loop diuretic Ischemic stroke (systolic blood pressure > 180200 mm Hg)Nicardipine Clevidipine LabetalolNitroprusside, methyldopa, clonidine, nitroglycerin Intracerebral hemorrhage (systolic blood pressure > 140160 mm Hg)Nicardipine Clevidipine LabetalolNitroprusside, methyldopa, clonidine, nitroglycerin Hyperadrenergic states, including cocaine use Nicardipine plus a benzodiazepine Clevidipine plus a benzodiazepine Phentolamine LabetalolBeta-blockers Preeclampsia, eclampsia Labetalol NicardipineDiuretics, ACE inhibitors1 Avoid if there is LV systolic dysfunction.2 Drug of choice if LV systolic dysfunction is associated with ischemia. ACE, angiotensin-converting enzyme; LV, left ventricular.suc h as pheochromocytoma or cocaine use, beta-blockers can worsen the hypertension because of unopposed peripheral vasoconstriction; nicardipine, clevidipine, or phentolamine is preferred . Labetalol is useful in these patients if the heart rate must be controlled. Table 1115 provides guidelines for the choice of antihypertensive agent based on the site of end- organ damage. ACE inhibitors are specifically indicated for hypertensive crisis from systemic sclerosis (scleroderma). In acute aortic dissection, systolic blood pressure and heart rate should be reduced within 30 minutes to below 120 mm Hg and less than 60 beats per minute, using a combination of vasodilation and beta-blockade. Pharmacologic ManagementA.  Parenteral AgentsSodiu m nitroprusside is no longer the treatment of choice for acute hypertensive problems; in most situations, appropriatecontrol of blood pressure is best achieved using combinations of nicardipine or clevidipine plus labetalol or esmolol . (Table 1116 lists drugs, dosages, and adverse effects.) 1. Nicardipine Intravenous nicardipine is the most potent and the longest acting of the parenteral calcium channel blockers. As a primarily arterial vasodilator, it has the potential to precipitate reflex tachycardia, and for that reason it should not be used without a beta-blocker in patients with coronary artery disease. 2. Clevidipine Intravenous clevidipine is an L-type cal- cium channel blocker with a 1-minute half-life, which facilitates swift and tight control of severe hypertension. It acts on arterial resistance vessels and is devoid of venodila- tory or cardiodepressant effects. 3. Labetalol This combined beta- and alpha-blocking agent is the most potent adrenergic blocker for rapid bloodCMDT22_Ch11_p0443-p0474.indd  472 29/06/21 8:37 PMSYSteMIC hYperteNSION473 CMDT 2022Table 1116. Drugs for hypertensive emergencies and urgencies (in descending order of preference).agn acion Dosg Ons Duion advs effcs Commns hynsiv emgncis Nicardipine (Cardene)Calcium channel blocker5 mg/h intravenously; may increase by 12.5 mg/h every 15 minutes to 15 mg/h15 minutes 36 hours Hypotension, tachycardia, headache. May precipitate myocardial ischemia. Clevidipine (Cleviprex)Calcium channel blocker12 mg/h intravenously initially; double rate every 90 seconds until near goal, then by smaller amounts every 510 minutes to a maximum of 32 mg/h24 minutes 515 minutes Headache, nausea, vomiting. Lipid emulsion: contraindicated in patients with allergy to soy or egg. Labetalol (Trandate)Beta- and alpha-blocker2040 mg intravenously every 10 minutes to 300 mg; 2 mg/min infusion510 minutes 36 hours Nausea, hypotension, bronchospasm, bradycardia, heart block.Avoid in acute LV systolic dysfunction, asthma. May be continued orally. Esmolol (Brevibloc) Beta-blocker Loading dose 500 mcg/kg intravenously over 1 minute; maintenance, 25200 mcg/kg/min12 minutes 1030 minutes Bradycardia, nausea. Avoid in acute LV systolic dysfunction, asthma. Weak antihypertensive. Fenoldopam (Corlopam)Dopamine receptor agonist0.11.6 mcg/kg/min intravenously 45 minutes < 10 minutes Reflex tachycardia, hypotension, increased intraocular pressure.May protect kidney function. Enalaprilat (Vasotec)ACE inhibitor 1.25 mg intravenously every 6 hours 15 minutes 6 hours or moreExcessive hypotension. Additive with diuretics; may be contin- ued orally. Furosemide (Lasix) Diuretic 1080 mg orally or intravenously 15 minutes 4 hours Hypokalemia, hypotension. Adjunct to vasodilator. Hydralazine (Apresoline)Vasodilator 520 mg intravenously; may repeat after 20 minutes1030 minutes 26 hours Tachycardia, headache, vomiting, diarrheaAvoid in coronary artery disease, dissec- tion. Rarely used except in pregnancy. Nitroglycerin Vasodilator 0.255 mcg/kg/min intravenously 25 minutes 35 minutes Headache, nausea, hypotension, bradycardia.Tolerance may develop. Useful primar- ily with myocardial ischemia. Nitroprusside (Nitropress)Vasodilator 0.2510 mcg/kg/min intravenously Seconds 35 minutes Anxiety, increased intracranial pressure, vomiting, bowel obstruction; thiocyanate and cyanide toxicity, especially with kid- ney and liver dysfunction; hypotension. Coronary steal, decreased cerebral blood flow, increased intracranial pressure.No longer the first-line agent. hynsiv Ugncis Clonidine (Catapres)Central sympatholytic0.10.2 mg orally initially; then 0.1 mg every hour to 0.8 mg orally3060 minutes 68 hours Sedation. Rebound may occur. Captopril (Capoten) ACE inhibitor 12.525 mg orally 1530 minutes 46 hours Excessive hypotension. Nifedipine (Adalat, Procardia)Calcium channel blocker10 mg orally initially; may be repeated after 30 minutes15 minutes 26 hours Excessive hypotension, tachycardia, head- ache, angina, myocardial infarction, stroke.Response unpredictable. ACE, angiotensin-converting enzyme; CNS, central nervous system; GI, gastrointestinal; LV, left ventricular.CMDT22_Ch11_p0443-p0474.indd  473 29/06/21 8:37 PMChapter 11474 CMDT 2022pres sure reduction. Other beta-blockers are far less potent. Excessive blood pressure drops are unusual. Experience with this agent in hypertensive syndromes associated with pregnancy has been favorable. 4. Esmolol This rapidly acting beta-blocker is approved only for treatment of supraventricular tachycardia, but is often used for lowering blood pressure. It is less potent than labetalol and should be reserved for patients in whom there is particular concern about serious adverse events related to beta-blockers. 5. Fenoldopam Fenoldopam is a peripheral dopamine-1 (DA1) receptor agonist that causes a dose-dependent reduction in arterial pressure without evidence of toler- ance, rebound, withdrawal, or deterioration of kidney function. In higher dosage ranges, tachycardia may occur. This drug is natriuretic, which may simplify volume man- agement in acute kidney injury. 6. Enalaprilat This is the active form of the oral ACE inhibi- tor enalapril. The onset of action is usually within 15 minutes, but the peak effect may be delayed for up to 6 hours. Thus, enalaprilat is used primarily as an adjunctive agent. 7. Diuretics Intravenous loop diuretics can be very help- ful when the patient has signs of heart failure or fluid reten- tion, but the onset of their hypotensive response is slow, making them an adjunct rather than a primary agent for hypertensive emergencies. Low dosages should be used initially (furosemide, 20 mg, or bumetanide, 0.5 mg). They facilitate the response to vasodilators, which often stimu- late fluid retention. 8. Hydralazine Hydralazine can be given intravenously or intramuscularly, but its effect is less predictable than that of other drugs in this group. It produces reflex tachycardia and should not be given without beta-blockers in patients with possible coronary disease or aortic dissection. Hydral- azine is used primarily in pregnancy and in children, but even in these situations, it is not a first-line drug. 9. Nitroglycerin, intravenous This agent should be reserved for patients with accompanying acute coronary ischemic syndromes. 10. Nitroprusside sodium This agent is given by con- trolled intravenous infusion gradually titrated to thedesired effect. It lowers the blood pressure within seconds by direct arteriolar and venous dilation. Monitoring with an intra-arterial line avoids hypotension. Nitroprusside in combination with a beta-blockeris useful in patients with aortic dissection.B.  Oral AgentsPa tients with less severe acute hypertensive syndromes can often be treated with oral therapy. Suitable drugs will reduce the blood pressure over a period of hours. In those presenting as a consequence of noncompliance, it is usually sufficient to restore the patients previously established oral regimen. 1. Clonidine Clonidine, 0.2 mg orally initially, followed by 0.1 mg every hour to a total of 0.8 mg, will usually lower blood pressure over a period of several hours. Sedation is frequent, and rebound hypertension may occur if the drug is stopped. 2. Captopril Captopril, 12.525 mg orally, will also lower blood pressure in 1530 minutes. The response is variable and may be excessive. Captopril is the drug of choice in the management of systemic sclerosis hypertensive crisis. 3. Nifedipine The effect of fast-acting nifedipine cap- sules is unpredictable and may be excessive, resulting in hypotension and reflex tachycardia. Because myocardial infarction and stroke have been reported in this setting, the use of sublingual nifedipine is not advised. Nifedipine retard, 20 mg orally, appears to be safe and effective.C.  Subsequent TherapyWhen  the blood pressure has been brought under control, combinations of oral antihypertensive agents can be added as parenteral drugs are tapered off over a period of 23 days.Co rdonnier C et al. Intracerebral haemorrhage: current approaches to acute management. Lancet. 2018;392:1257. [PMID: 30319113] Ipek E et al. Hypertensive crisis: an update on clinical approach and management. Curr Opin Cardiol. 2017;32:397. [PMID: 28306673] Peixoto AJ. Acute severe hypertension. N Engl J Med. 2019;381:1843. [PMID: 31693807]CMDT22_Ch11_p0443-p0474.indd  474 29/06/21 8:37 PM475 CMDT 2022 ATHEROSCLEROTIC PERIPHERAL VASCULAR DISEASE OCCLUSIVE DISEASE: AORTA & ILIAC ARTERIESE S S E N T I A L S  O F  D I A G N O S I S Claudication: cramping pain or tiredness in the calf, thigh, or hip while walking. Diminished femoral pulses. Tissue loss (ulceration, gangrene) or rest pain. General ConsiderationsOlusive  atherslerti lesins develping in the extrem- ities, r peripheral artery disease (PAD), is evidene f a systemi atherslerti press. The prevalene f PAD is 30% in patients wh are 70 years ld withut ther risk fatrs, r 50 years ld with risk fatrs suh as diabetes mellitus r tba use. Pathlgi hanges f athersle- rsis may be diffuse, but flw-limiting stenses ur seg- mentally. In the lwer extremities, stenses lassially ur in three anatmi segments: the artilia segment, femral-ppliteal segment, and the infrappliteal r tibial segment f the arterial tree. Lesins in the distal arta and prximal mmn ilia arteries lassially ur in White male smkers aged 5060 years. Disease prgressin may lead t mplete lusin f ne r bth mmn ilia arteries, whih an preipitate lusin f the entire abdminal arta t the level f the renal arteries. Clinical FindingsA.  Symptoms and SignsA pprximately tw-thirds f patients with PAD are either asymptmati r d nt have lassi symptms. Intermit- tent laudiatin, whih is pain with ambulatin that urs frm insuffiient bld flw relative t demand, is typially12Warren J. Gasper, MD James C. Iannuzzi, MD, MPH Meshell D. Johnson, MDBlood Vessel & Lymphatic Disordersdesribed as severe and  ramping and primarily in the alf musles. The pain frm artilia lesins may extend int the thigh and buttks and eretile dysfuntin may ur frm bilateral mmn ilia disease. Rarely, patients m- plain nly f weakness in the legs when walking, r simply extreme limb fatigue. The symptms are relieved with rest and are reprduible when the patient walks again. Femral pulses and distal pulses are absent r very weak. Bruits may be heard ver the arta, ilia, and femral arteries.B.  Doppler and Vascular FindingsThe  rati f systli bld pressure deteted by Dppler examinatin at the ankle mpared with the brahial artery (referred t as the ankle-brahial index [ABI]) is redued t belw 0.9 (nrmal rati is 0.91.2); this differene is exag- gerated by exerise. Bth the drsalis pedis and the psterir tibial arteries are measured and the higher f the tw artery pressures is used fr alulatin. Segmental wavefrms r pulse vlume rerdings btained by strain gauge tehnl- gy thrugh bld pressure uffs demnstrate blunting f the arterial inflw thrughut the lwer extremity.C.  ImagingCT  angigraphy (CTA) and magneti resnane angigra- phy (MRA) an identify the anatmi latin f disease. Due t verlying bwel, duplex ultrasund has a limited rle in imaging the artilia segment. Imaging is required nly when symptms neessitate interventin, sine a his- try and physial examinatin with vasular testing shuld apprpriately identify the invlved levels f the arterial tree. TreatmentA.  Medical and Exercise TherapyThe  rnerstnes f PAD treatment are ardivasular risk fatr redutin and a supervised r strutured exerise prgram. Essential elements inlude smking essatin, antiplatelet therapy, lipid and bld pressure management, and weight lss. Nitine replaement therapy, buprpin, and vareniline have established benefits in smking essa- tin (see Chapter 1). Antiplatelet agents (aspirin, 81 mg rally daily, r lpidgrel, 75 mg rally daily) redue verallCMDT22_Ch12_p0475-p0501.indd  475 29/06/21 8:37 PMCHAPTER 12476 CMDT 2022ar divasular mrbidity. Lw-dse rivarxaban (2.5 mg rally twie daily) with aspirin 100 mg rally daily redues bth majr ardivasular and limb-related adverse events in symptmati patients. All patients with PAD shuld reeive high-dse statin (eg, atrvastatin 80 mg daily if tler- ated) t treat hyperhlesterlemia and inflammatin. A trial f ilstazl 100 mg rally twie a day, may imprve walking distane in apprximately tw-thirds f patients. Supervised exerise prgrams fr PAD prvide signifi- ant imprvements in pain, walking distane, and quality f life and may be mre effetive than an endvasular treatment alne. A minimum training gal is a walking sessin f 3045 minutes at least 3 days per week fr a minimum f 12 weeks. Strutured mmunity r hme- based exerise prgrams as well as alternative exerises (yling, upper-bdy ergmetry) may als be effetive.B.  Endovascular TherapyWhen  the atherslerti lesins are fal, they an be effetively treated with angiplasty and stenting. This apprah mathes the results f surgery fr single stenses but bth effetiveness and durability derease with lnger r multiple stenses.C.  Surgical InterventionA  prstheti art-femral bypass graft that bypasses the diseased artery segments is a highly effetive and durable treatment fr this disease. Patients may als be treated with a graft frm the axillary artery t the femral arteries (axill-femral bypass graft) r with a graft frm the n- tralateral femral artery (femral-femral bypass) when ilia disease is limited t ne side. The perative risk f axill-femral and femral-t-femral bypass grafts is lwer beause the abdminal avity is nt entered and the arta is nt rss-lamped, but the grafts are less durable. ComplicationsThe  mpliatins f the art-femral bypass are thse f any majr abdminal surgery in a patient ppulatin with a high prevalene f ardivasular disease. Mrtality is lw (23%), but mrbidity is higher and inludes a 510% rate f myardial infartin. While endvasular apprahes are safer and the mpliatin rate is 13%, they are less durable with extensive disease. PrognosisPa tients with islated artilia disease may have a further redutin in walking distane withut interventin, but symptms rarely prgress t rest pain r threatened limb lss. Life expetany is limited by their attendant ardi- vasular disease with a mrtality rate f 2540% at 5 years. Symptmati relief is generally exellent with super- vised exerise r after interventin. After art-femral bypass, a pateny rate f 90% at 5 years is mmn. End- vasular pateny rates and symptm relief fr patients with shrt stenses are als gd with 80% symptm free at 3 years. Reurrene rates fllwing endvasular treatment f extensive disease are 3050%.When to ReferPa tients with prgressive redutin in walking distane in spite f risk fatr mdifiatin and supervised exerise prgrams and thse with limitatins that interfere with their ativities f daily living shuld be referred fr nsul- tatin t a vasular surgen.Bnaa M P et al. Rivarxa ban in peripheral artery disease after revasularizatin. N Engl J Med. 2020;382:1994. [PMID: 32222135] MDermtt MM. Medial management f funtinal impair- ment in peripheral artery disease: a review. Prg Cardivas Dis. 2018;60:586. [PMID: 29727608] Mrs R et al. The evlving treatment f peripheral arterial disease thrugh guideline-direted remmendatins. J Clin Med. 2018;7:9. [PMID: 29315259]OCC LUSIVE DISEASE: FEMORAL & POPLITEAL ARTERIESE S S E N T I A L S  O F  D I A G N O S I S Cramping pain or tiredness in the calf with exercise. Reduced popliteal and pedal pulses. Foot pain at rest, relieved by dependency. Foot gangrene or ischemic ulcers. General ConsiderationsThe  superfiial femral artery is the peripheral artery mst mmnly luded by atherslersis. Atherslersis f the femral-ppliteal segment usually urs abut a deade after the develpment f artilia disease, has an even gender distributin, and mmnly affets Blak and Hispani patients. The disease frequently urs where the superfiial femral artery passes thrugh the abdutr magnus tendn in the distal thigh (Hunter anal). The mmn femral artery and the ppliteal artery are less ften diseased but lesins in these vessels are debilitating, resulting in shrt-distane laudiatin. Clinical FindingsA.  Symptoms and SignsSymp tms f intermittent laudiatin aused by lesins f the mmn femral artery, superfiial femral artery, and ppliteal artery are nfined t the alf. Claudiatin urs at 24 blks when there is lusin r stensis f the superfiial femral artery at the addutr anal, pr- vided gd llateral vessels frm the prfunda femris are maintained. Hwever, with nmitant disease f the prfunda femris r the ppliteal artery, muh shrter distanes may trigger symptms. With shrt-distane lau- diatin, dependent rubr f the ft with blanhing n elevatin may be present. Chrni lw bld flw states will als ause atrphi hanges in the lwer leg and ftCMDT22_Ch12_p0475-p0501.indd  476 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS477 CMDT 2022with  lss f hair, thinning f the skin and subutaneus tissues, and disuse atrphy f the musles. With segmental lusive disease f the superfiial femral artery, the m- mn femral pulsatin is nrmal, but the ppliteal and pedal pulses are redued.B.  Doppler and Vascular FindingsABI  values less than 0.9 are diagnsti f PAD and levels belw 0.4 suggest hrni limb-threatening ishemia (fr- merly ritial limb ishemia). ABI readings depend n arterial mpressin. Sine the vessels may be alified in diabetes mellitus, hrni kidney disease, and in lder adults, ABIs an be misleading. In suh patients, the te- brahial index is usually reliable with a value less than 0.7 nsidered diagnsti f PAD. Pulse vlume rerdings with uffs plaed at the high thigh, mid-thigh, alf, and ankle will delineate the levels f bstrutin with redued pressures and blunted wavefrms.C.  ImagingDuplex  ultrasngraphy, CTA, and MRA all adequately shw the anatmi latin f the bstrutive lesins and are dne nly if revasularizatin is planned. TreatmentA.  Medical and Exercise TherapyA s with artilia disease, risk fatr redutin, medial pti- mizatin with a high-dse statin, and exerise treatment are the rnerstne f therapy. Cilstazl, 100 mg rally twie a day, may imprve intermittent laudiatin symptms.B.  Surgical InterventionIn terventin is indiated if laudiatin is prgressive, ina- paitating, r interferes signifiantly with essential daily ativities r emplyment. Interventin is mandatry if there is ishemi rest pain r ishemi ulers threaten the ft. 1. Bypass surgery The mst effetive and durable treat- ment fr lesins f the superfiial femral artery is a femral- ppliteal bypass with autlgus saphenus vein. Syntheti material, usually plytetraflurethylene (PTFE), an be used, but these grafts d nt have the durability f vein bypass. 2. Endovascular surgery Endvasular tehniques, suh as angiplasty and stenting, are ften used fr lesins f the superfiial femral artery. These tehniques have lwer mrbidity than bypass surgery but als have lwer rates f durability. Endvasular therapy is mst effetive in patients underging aggressive risk fatr mdifiatin in whm lesins measure less than 10 m lng. Palitaxel-eluting stents r palitaxel-ated ballns ffer mdest imprve- ment ver bare metal stents and nnated ballns, but the effet is nt as rbust as in the rnary arteries. The 1-year pateny rate is 50% fr balln angiplasty, 70% fr drug-ated ballns, and 80% fr stents. Hwever, by 3 years, the pateny rates are signifiantly wrse fr all three tehniques and reinterventin fr restensis is mmn.After a meta-analysis f linial trial data shwed inreased mrtality at 35 years after treatment with palitaxel-ated devies, the US FDA perfrmed an independent review and remmends judiius use f the devies. Onging trials, suh as SWEDEPAD, are expeted t prvide additinal data n the risks and benefits f palitaxel devies. 3. Thromboendarterectomy Remval f the athersle- rti plaque is limited t the lesins f the mmn fem- ral and the prfunda femris arteries where bypass grafts and endvasular tehniques have a mre limited rle. ComplicationsOpen  surgial predures f the lwer extremities, partiu- larly lng bypasses with vein harvest, have a risk f wund infetin that is higher than in ther areas f the bdy. Wund infetin r serma an ur in as many as 1015% f ases. Myardial infartin rates after pen surgery are 510%, with a 14% mrtality rate. Cmplia- tin rates f endvasular surgery are 15%, making these therapies attrative despite their lwer durability. PrognosisThe p rgnsis fr mtivated patients with islated superfi- ial femral artery disease is exellent, and surgery is nt remmended fr mild r mderate laudiatin in these patients. Hwever, when laudiatin signifiantly limits daily ativity undermining quality f life and ardivasu- lar health, interventin may be warranted. All interven- tins require lse pstpredure fllw-up with repeated ultrasund surveillane s that reurrent narrwing an be treated prmptly with angiplasty r bypass t prevent mplete lusin. The reprted pateny rate f bypass grafts f the femral artery, superfiial femral artery, and ppliteal artery is 6570% at 3 years, whereas the pateny f angiplasty is less than 50% at 3 years. Beause f the extensive atherslerti disease, inlud- ing assiated rnary lesins, 5-year survival with lwer extremity PAD is 70% and dereases t 50% when there is invlvement f the tibial arteries. Hwever, with aggressive risk fatr mdifiatin, substantial imprvement in ln- gevity has been reprted. When to ReferPa tients with prgressive symptms, shrt-distane laudi- atin, rest pain, r any uleratin shuld be referred t a peripheral vasular speialist.Hiram t JS et al. Interventins fr lwer extremity peripheral artery disease. Nat Rev Cardil. 2018;15:332. [PMID: 29679023] Katsans K et al. Risk f death fllwing appliatin f pali- taxel-ated ballns and stents in the femrppliteal artery f the leg: a systemati review and meta-analysis f randm- ized ntrlled trials. J Am Heart Ass. 2018;7:e011245. [PMID: 30561254] Nrdanstig J et al. Mrtality with palitaxel-ated devies in peripheral artery disease. N Engl J Med. 2020;383:2538. [PMID: 33296560]CMDT22_Ch12_p0475-p0501.indd  477 29/06/21 8:37 PMCHAPTER 12478 CMDT 2022Rha-Singh KJ  et al; VIVA Physiians, In. Patient-level meta- analysis f 999 laudiants underging primary femrppli- teal nitinl stent implantatin. Catheter Cardivas Interv. 2017;89:1250. [PMID: 28303688]OCC LUSIVE DISEASE: TIBIAL & PEDAL ARTERIESE S S E N T I A L S  O F  D I A G N O S I S Severe pain of the forefoot that is relieved by dependency (ischemic rest pain). Pain or numbness of the foot with walking. Ulcer or gangrene, and not claudication, is a frequent initial manifestation. Pallor when the foot is elevated. General ConsiderationsO lusive presses f the tibial arteries f the lwer leg and pedal arteries in the ft ur primarily in patients with dia- betes. There ften is extensive alifiatin f the artery wall. Clinical FindingsA.  Symptoms and SignsU nless there are nmitant lesins in the artilia r femral/superfiial femral artery segments, the first man- ifestatin f leg ishemia due t tibial artery disease is fre- quently an ishemi uler r ft gangrene, rather than laudiatin. The presene f ishemi rest pain r ulers is termed chronic limb-threatening ischemia and is assi- ated with the highest rate f amputatin. Classially, ish- emi rest pain is nfined t the drsum f the ft and is relieved with dependeny: the pain des nt ur with standing, sitting, r dangling the leg ver the edge f the bed. It is severe and burning in harater, and beause it is present nly when reumbent, it may awaken the patient frm sleep. On examinatin, femral and ppliteal pulses may r may nt be present depending n disease extent, but pal- pable pedal pulses will be absent. Dependent rubr may be prminent with pallr n elevatin. The skin f the ft is generally l, atrphi, and hairless.B.  Doppler and Vascular FindingsThe  ABI is ften belw 0.4; hwever, the ABI may be falsely elevated due t alifiatin f the arterial media layer (Mnkeberg medial alifi slersis) and may nt be mpressible. Te-brahial indexes are preferred fr assess- ing perfusin and prediting wund healing.C.  ImagingDig ital subtratin angigraphy is the gld standard methd t delineate the anatmy f the tibial-pplitealsegment. MRA r CTA is less helpful fr detetin f lesins in this latin due t the small vasulature and ther tehnial issues related t image reslutin. Differential DiagnosisBeause  f the high inidene f neurpathy in these patients, it is imprtant t differentiate rest pain frm dia- beti neurpathi dysesthesia. Leg night ramps ause pain in the leg rather than the ft and shuld nt be nfused with ishemi rest pain. Dependent rubr in the presene f a te wund an ften be mistaken fr ellulitis; pallr n elevatin helps nfirm the diagnsis f rubr. TreatmentGd  ft are may prevent ulers, and mst diabeti patients will d well with a nservative regimen. Hwever, if uleratins appear and there is n signifiant healing within 23 weeks, bld flw studies (ankle-brahial index/te-brahial index) are indiated. Pr bld flw and a ft uler r nightly ishemi rest pain requires expe- ditius revasularizatin t avid a majr amputatin.A.  Bypass and Endovascular TechniquesBypass  with vein t the distal tibial r pedal arteries is an effetive therapy t treat rest pain and heal ishemi ulers f the ft. Beause the ft ften has relative sparing f vasular disease, these bypasses have had adequate pateny rates (70% at 3 years). Frtunately, in nearly all series, limb preservatin rates are muh higher than pateny rates. Endvasular treatment with plain balln angiplasty is effetive fr shrt segment lesins. The tehnial failure and relusin rates inrease drastially with lng seg- ment disease in multiple tibial arteries. Stents and drug- ated ballns have nt been suessful in the tibial vessels t date.B.  AmputationPa tients with ishemi rest pain r ulers have a 3040% 1-year risk fr majr amputatin that inreases if revasu- larizatin annt be dne. Patients with diabetes and PAD have a 4-fld risk f hrni limb-threatening ishemia mpared with nndiabeti patients with PAD and have a risk f amputatin up t 20-fld when mpared t an age- mathed ppulatin. Many patients wh have belw-the- knee r abve-the-knee amputatins due t vasular insuffiieny never regain independent ambulatry status and ften need assisted-living failities. These fatrs m- bine t demand revasularizatin whenever pssible t preserve the limb. ComplicationsThe  mpliatins f interventin are similar t thse listed fr superfiial femral artery disease with evidene that the verall ardivasular risk f interventin inreases with dereasing ABI. Patients with hrni limb-threatening ishemia require aggressive risk fatr mdifiatin. Wund infetin rates after bypass are higher if there is an pen wund in the ft.CMDT22_Ch12_p0475-p0501.indd  478 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS479 CMDT 2022 PrognosisPa tients with tibial atherslersis have extensive ather- slerti burden and a high prevalene f diabetes. Their prgnsis withut interventin is pr and mpliated by the risk f amputatin. When to ReferPa tients with diabetes and ft ulers shuld be referred fr a frmal vasular evaluatin. Interventin may nt be neessary but the severity f the disease will be quantified, whih has impliatins fr future symptm develpment. Any patient with an uler and a diabeti ft infetin shuld be evaluated fr an emergent perative inisin and drainage. Brad-spetrum intravenus antibitis shuld be given empirially; fr example, vanmyin shuld be given t ver methiillin-resistant Staphylococcus aureus (MRSA) and ertapenem r piperaillin/tazbatam shuld be given t ver gram-negative and anaerbi rganisms. Centers that have a multidisiplinary limb preservatin enter staffed with vasular surgens, pdiatrists, plasti and rthpedi surgens, prsthetis and rthti speial- ists, and diabetes speialists shuld be sught.Cnte  MS et al. Glbal vasular guidelines n the management f hrni limb-threatening ishemia. J Vas Surg. 2019;69:3. [PMID: 31159978] Farber A et al. The urrent state f ritial limb ishemia: a sys- temati review. JAMA Surg. 2016;151:1070. [PMID: 27551978]ACU TE ARTERIAL OCCLUSION OF A LIMBE S S E N T I A L S  O F  D I A G N O S I S Sudden pain in a limb with absent limb pulses. Usually some neurologic dysfunction with numb- ness, weakness, or complete paralysis. Loss of light touch sensation requires revascular- ization within 3 hours for limb viability. General ConsiderationsAu te lusin may be due t an emblus r t thrmb- sis f a diseased atherslerti segment. Embli large enugh t lude prximal arteries in the lwer extremi- ties are almst always frm the heart and are related t atrial fibrillatin. Over 50% f the embli frm the heart g t the lwer extremities, 20% t the erebrvasular iru- latin, and the remainder t the upper extremities and mesenteri and renal irulatin. Atrial fibrillatin is the mst mmn ause f ardia thrmbus frmatin; ther auses are valvular disease r thrmbus frmatin n the ventriular surfae f a large anterir myardial infart. Embli frm arterial sures suh as arterial uleratins r alified exresenes are usually small and g t the distal arterial tree (tes).The typial patient with primary thrmbsis has had a histry f laudiatin and nw has an aute lusin. If the stensis is hrni, llateral bld vessels will develp, and the resulting lusin may ause nly minimal inrease in symptms. Clinical FindingsA.  Symptoms and SignsTh e sudden nset f extremity pain, with lss r redutin in pulses, is diagnsti f aute arterial lusin. This ften will be ampanied by neurlgi dysfuntin, suh as numb- ness r paralysis in extreme ases. With ppliteal lusin, symptms may affet nly the ft. With prximal lusins, the whle leg may be affeted. Signs f severe arterial ishemia inlude pallr, lness f the extremity, and mttling. Impaired neurlgi funtin prgressing t anesthesia with paralysis indiates irreversible injury requiring amputatin.B.  Doppler and Laboratory FindingsThere  will be little r n flw fund with Dppler examina- tin f the distal vessels. Imaging, if dne, may shw an abrupt utff f ntrast with embli lusin. Bld wrk may shw myglbinemia and metabli aidsis.C.  ImagingW henever pssible, imaging shuld be dne in the perating rm beause btaining angigraphy, MRA, r CTA may delay revasularizatin and jepardize the viability f the extremity. Hwever, in ases with nly mdest symptms and where light tuh f the extremity is maintained, imaging may be helpful in planning the revasularizatin predure. TreatmentImm ediate revasularizatin is required in all ases f symptmati aute arterial thrmbsis. Evidence of neuro- logic injury, including loss of light touch sensation, indicates that collateral flow is inadequate to maintain limb viability and revascularization should be accomplished within 3 hours. Lnger delays arry a signifiant risk f irreversible tissue damage. This risk apprahes 100% at 6 hurs.A.  HeparinAs  sn as the diagnsis is made, unfratinated heparin shuld be administered (500010,000 units) intravenusly, fllwed by a heparin infusin t maintain the ativated partial thrmbplastin time (aPTT) in the therapeuti range (6085 sends) (1218 units/kg/h). This helps pre- vent lt prpagatin and may als help relieve assiated vessel spasm. Antiagulatin may imprve symptms, but revasularizatin will still be required.B.  Endovascular TechniquesPharmame hanial thrmbetmy atheters an ahieve rapid revasularizatin and are mst effetive fr the smaller arteries f the lwer leg. Catheter-direted hemi- al thrmblysis int the lt with tissue plasmingen ativatr (TPA) may be dne but ften requires 24 hurs rCMDT22_Ch12_p0475-p0501.indd  479 29/06/21 8:37 PMCHAPTER 12480 CMDT 2022lnger  t fully lyse the thrmbus. This apprah an be taken nly in patients with an intat neurlgi examina- tin withut abslute ntraindiatins, suh as bleeding diathesis, gastrintestinal bleeding, intraranial trauma, r neursurgery within the past 3 mnths. Heparin is admin- istered systemially t prevent thrmbus frmatin arund the sheath. Frequent vasular and aess site examinatins are required during the thrmblyti predure t guard against the develpment f a hematma.C.  Surgical InterventionGeneral  anesthesia is usually indiated; lal anesthesia may be used in extremely high-risk patients if the explra- tin is t be limited t the mmn femral artery. In extreme ases, it may be neessary t perfrm thrmb- embletmy frm the femral, ppliteal, and even the pedal vessels t revasularize the limb. The mbined use f devies that pulverize and aspirate lt and intrapera- tive thrmblysis with TPA imprves utmes. ComplicationsCm pliatins f revasularizatin f an autely ishemi limb an inlude severe metabli aidsis, hyperkalemia, aute kidney injury, and ardia arrest. In ases where sev- eral hurs have elapsed but revery f viable tissue may still be pssible, signifiant levels f lati aid, ptassium, and ther harmful agents suh as myglbin may be released int the irulatin during revasularizatin. Administering sdium biarbnate (150 mEq NaHCO3in 1 L f dextrse 5% in water) prir t reestablishing arterial flw is required. Surgery in the presene f thrmblyti agents and heparin arries a high risk f pstperative wund hematma. PrognosisThere  is a 1025% risk f amputatin with an aute arterial embli lusin, and a 25% r higher in-hspital mrtal- ity rate. Prgnsis fr aute thrmbti lusin f an atherslerti segment is generally better beause the l- lateral flw an maintain extremity viability. The lnger- term survival reflets the verall nditin f the patient. In high-risk patients, an aute arterial lusin is assi- ated with a dismal prgnsis.OCC LUSIVE CEREBROVASCULAR DISEASEE S S E N T I A L S  O F  D I A G N O S I S Sudden onset of weakness and numbness of an extremity or the face, aphasia, dysarthria, or uni- lateral blindness (amaurosis fugax). Bruit heard loudest in the mid neck. General ConsiderationsU nlike the ther vasular territries, symptms f ishemi erebrvasular disease are predminantly due t embli. The ishemia is reversible (transient ishemi attaks[TIAs]) when llateral flw reestablishes perfusin, but is a sign that the risk f additinal embli and a strke is high. Mst ishemi strkes are due t embli frm the heart. One-quarter f all ishemi strkes may be due t embli frm an arterial sure; apprximately 90% f these embli riginate frm the prximal internal artid artery, an area uniquely prne t the develpment f athersler- sis. Intraranial atherslerti lesins are unmmn in western ppulatins but are the mst frequent latin f erebrvasular disease in Asian ppulatins. Clinical FindingsA.  Symptoms and SignsGenerally , the symptms f a TIA last nly a few sends t minutes (but may ntinue up t 24 hurs) while a strke is defined as persistent symptms beynd 24 hurs. The mst mmn lesins assiated with artid disease invlve the anterir irulatin in the rtex with bth mtr and sensry invlvement. Embli t the retinal artery ause unilateral blindness; transient mnular blindness is termed amaursis fugax.  Psterir irula- tin symptms referable t the brainstem, erebellum, and visual regins f the brain may be due t atherslersis f the vertebral basilar systems and are muh less mmn. Signs f erebrvasular disease may inlude artid artery bruits. Hwever, there is pr rrelatin between the degree f stensis and the presene f the bruit. Further- mre, the presene f a bruit des nt rrelate with strke risk. Nnfal symptms, suh as dizziness and unsteadi- ness, seldm are related t erebrvasular atherslersis.B.  ImagingDuplex ultrasngrap hy is the imaging mdality f hie with high speifiity and sensitivity fr deteting and grad- ing the degree f stensis at the artid bifuratin (see Chapter 24). Exellent depitin f the full anatmy f the erebr- vasular irulatin frm arti arh t ranium an be btained with either MRA r CTA. Eah f the mdalities may have false-psitive r false-negative findings. Sine the deisin t intervene in ases f artid stensis depends n an aurate assessment f the degree f stensis, it is rem- mended that at least tw mdalities be used t nfirm the degree f stensis. Diagnsti erebral angigraphy is reserved fr ases where artid artery stenting (CAS) is t be dne. TreatmentSee  Chapter 24 fr a disussin f the medial manage- ment f lusive erebrvasular disease.A.  Asymptomatic PatientsLar ge studies have shwn a 5-year redutin in strke rate frm 11.5% t 5.0% with surgial treatment f asymptmati artid stensis that is greater than 60%; patients with asymptmati artid stensis may benefit frm artid interventin if their risk frm interventin is lw and their expeted survival is lnger than 5 years. Aggressive riskCMDT22_Ch12_p0475-p0501.indd  480 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS481 CMDT 2022fat r mdifiatin, inluding high-pteny statins, may be as valuable as surgial interventin in these patients; the large NIH-spnsred CREST2 study is examining this issue. Mild t mderate disease (3050% stensis) indiates the need fr nging mnitring and aggressive risk fatr mdifiatin. Patients with artid stensis that suddenly wrsens are thught t have an unstable plaque and are at partiularly high risk fr embli strke.B.  Symptomatic PatientsLa rge randmized trials have shwn that patients with TIAs r strkes frm whih they have mpletely r nearly m- pletely revered will benefit frm artid interventin if the ipsilateral artid artery has a stensis f mre than 70% (Figure 121), and they are likely t benefit if the artery has a stensis f 5069%. In these situatins, artid endartere- tmy (CEA) and, in seleted ases, CAS have been shwn t have a durable effet in preventing further events. In symp- tmati patients, interventin shuld ideally be planned within 2 weeks sine delays inrease the risk f a send event. ComplicationsThe  mst mmn mpliatin frm artid interventin is ranial nerve injury, while the mst dreaded mplia- tin is strke frm emblizatin r artid lusin. The Amerian Heart Assiatins remmendatins fr upper limits f aeptable mbined mrbidity and mrtality fr these interventins is 3% fr patients with asymptmati artid stensis, 5% fr thse with TIAs, and 7% fr patients with previus strke. Higher rates f mrbidityand mrtality negate the therapeuti benefit f artid interventin.A.  Carotid EndarterectomyIn  the 2010 CREST study the strke risk fr CEA was 2.3%. CEA als arries a 12% risk f permanent ranial nerve injury (usually the vagus nerve). There is als the risk f pstperative nek hematma, whih an ause aute air- way mprmise. Crnary artery disease is a mrbidity in mst f these patients. Myardial infartin rates after CEA are apprximately 26%.B.  Carotid Angioplasty and StentingCAS  had a strke risk f 4.1% in the 2010 CREST study; patients ver 70 years f age as well as wmen had higher strke rates with CAS than with CEA. Hwever, the risk f myardial infartin was lwer with CAS mpared t CEA (1.1% vs 2.3%). CAS is indiated fr reperative ases, prir nek radiatin, and high artid bifuratins nt therwise aessible surgially. Nnetheless, embli are mre mmn during transfemral CAS in spite f embli prtetin devies, espeially when the artid artery is trtuus and heavily alified. Transervial artid stent- ing, perfrmed thrugh a small inisin at the base f the nek, avids artery trtusity and has lwer emblizatin rates than transfemral artid stenting. PrognosisT wenty-five perent f patients presenting with artid stensis and a TIA r small strke will have further brain ishemia within 18 mnths with mst f the events ur- ring within the first 6 mnths. Histrially, patients with asymptmati artid stensis are believed t have an annual strke rate f just ver 2% but this may be lwer in the statin era. Prspetive ultrasund sreening at least annually is remmended in asymptmati patients with knwn artid stensis t identify thse wh have evidene f plaque prgressin, whih inreases strke risk. Cn- mitant rnary artery disease is mmn and is an imprtant fatr in these patients bth fr periperative risk and lng-term prgnsis. Aggressive risk fatr mdi- fiatin shuld be presribed fr patients with erebrvas- ular disease regardless f planned interventin. When to ReferAsym ptmati r symptmati patients with a artid ste- nsis f mre than 70% and patients with artid stensis f less than 70% with symptms f a TIA r strke shuld be referred t a vasular speialist fr nsultatin.Br tt TG et al; CREST Investigatrs. Lng-term results f stent- ing versus endarteretmy fr artid-artery stensis. N Engl J Med. 2016;374:1021. [PMID: 26890472] Mresli P et al. Cartid stenting versus endarteretmy fr asymptmati artid artery stensis: a systemati review and meta-analysis. Strke. 2017;48:2150. [PMID: 28679848] Paraskevas KI et al. An updated systemati review and meta- analysis f results f transervial artid artery stenting with flw reversal. J Vas Surg. 2020;72:1489. [PMID: 32422272] Figure 121. Digital subtraction angiography of a high-grade (90%) stenosis of the internal carotid artery with ulceration (arrow). (Used, with permission, from Dean SM, Satiani B, Abraham WT. Color Atlas and Synopsis of Vascular Diseases. McGraw-Hill, 2014.)CMDT22_Ch12_p0475-p0501.indd  481 29/06/21 8:37 PMCHAPTER 12482 CMDT 2022VI SCERAL ARTERY INSUFFICIENCY (Intestinal Angina)E S S E N T I A L S  O F  D I A G N O S I S Severe postprandial abdominal pain. Weight loss with a fear of eating. Acute mesenteric ischemia: severe abdominal pain yet minimal findings on physical examination. General ConsiderationsA cute mesenteric ischemia results frm lusive mesen- teri arterial disease, either embli lusin r primary thrmbsis f at least ne majr mesenteri artery. Ishemia an als result frm nonocclusive mesenteric ischemia, whih is generally seen in patients with lw flw states, suh as severe heart failure, sepsis, r hyptensin. Chronic mesenteric ischemia, als alled intestinal angina, urs when inreased flw demands during feeding are nt met resulting in abdminal pain. Beause f the rih llateral mesenteri netwrk, generally at least tw f the three majr viseral vessels (elia, superir mesenteri, inferir mesenteri arteries) are affeted befre symptms develp. Ischemic colitis, a variant f mesenteri ishemia, usually urs in the distributin f the inferir mesenteri artery. The intestinal musa is the mst sensitive t ishemia and will slugh if underperfused. Clinical FindingsA.  Symptoms and Signs1.  Acute mesenteric ischemia Viseral arterial emblism presents autely with severe abdminal pain. In ntrast, patients with primary viseral arterial thrmbsis ften give an anteedent histry nsistent with hrni mesen- teri ishemia. The key finding with aute mesenteri ishemia is severe, steady, diffuse abdminal pain with an absene f fal tenderness r distentin. This pain ut f prprtin t physial examinatin findings urs beause ishemia initially is musal and des nt impat the peritneum until transmural ishemia inflames the peritneal lining. A high white bld ell unt, lati ai- dsis, hyptensin, and abdminal distentin may aid in the diagnsis. 2. Chronic mesenteric ischemia Patients are generally ver 45 years f age and may have evidene f athersle- rsis in ther vasular beds. Symptms nsist f epigastri r periumbilial pstprandial pain lasting 13 hurs. T avid the pain, patients limit fd intake and may develp a fear f eating. Weight lss is universal. 3. Ischemic colitis Charateristi symptms are left lwer quadrant pain and tenderness, abdminal ramping, and mild diarrhea. Retal disharge will appear muus-like r bldy and shuld prmpt further evaluatin.B. Imaging and ColonoscopyCntrast-enhaned  CT is highly aurate at determining the presene f ishemi intestine. In patients with aute r hrni mesenteri ishemia, a CTA r MRA an demn- strate narrwing f the prximal viseral vessels. In aute mesenteri ishemia frm a nnlusive lw flw state, angigraphy is needed t display the typial pruned tree appearane f the distal viseral vasular bed. Ultrasund sanning f the mesenteri vessels may shw prximal bstruting lesins. In patients with ishemi litis, flexible sigmidspy shuld be perfrmed t assess the grade f ishemia that urs mst ften in watershed areas, suh as the retal sigmid and spleni flexure. TreatmentA  high suspiin f aute mesenteri ishemia ditates immediate explratin t assess bwel viability. If the bwel remains viable, arterial bypass using a prstheti nduit an be dne either frm the supra-elia arta r mmn ilia artery t the elia and the superir mesen- tery artery. In ases where bwel viability is questinable r bwel resetin will be required, the bypass an be dne with autlgus vein t avid the use f prstheti nduits in a ptentially ntaminated field. Angiplasty and stent- ing f the arteries an be used but des nt avid a surgial evaluatin f bwel viability. In hrni mesenteri ishemia, angiplasty and stenting f the prximal vessel may be benefiial depending n the anatmy f the stensis. Shuld an endvasular slutin nt be available, an art-viseral artery bypass is the pre- ferred management. The lng-term results are highly dura- ble. Viseral artery endarteretmy is reserved fr ases with multiple lesins where bypass wuld be diffiult. The mainstay f treatment f ishemi litis is mainte- nane f bld pressure and perfusin until llateral ir- ulatin bemes well established. The patient must be mnitred lsely fr evidene f perfratin neessitating resetin. PrognosisThe  mbined mrbidity and mrtality rates are 1015% frm surgial interventin in part due t malnutritin and frailty in patients preeding hrni mesenteri ishemia. Hwever, withut interventin bth nditins are uni- frmly fatal. Adequate llateral irulatin usually devel- ps in thse wh have ishemi litis, and the prgnsis fr this entity is better than hrni mesenteri ishemia. When to ReferAny  patient in whm there is a suspiin f mesenteri ishemia shuld be urgently referred fr imaging and ps- sible interventin.Alahdab F et al.  A systemati review and meta-analysis f end- vasular versus pen surgial revasularizatin fr hrni mesenteri ishemia. J Vas Surg. 2018;67:1598. [PMID: 29571626]CMDT22_Ch12_p0475-p0501.indd  482 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS483 CMDT 2022Clair  DG et al. Mesenteri ishemia. N Engl J Med. 2016;374:959. [PMID: 26962730] Lim S et al. Cntemprary management f aute mesenteri ishemia in the endvasular era. Vas Endvasular Surg. 2019;53:42. [PMID: 30360689]ACU TE MESENTERIC VEIN OCCLUSIONThe h allmarks f aute mesenteri vein lusin are pst- prandial pain and evidene f a hyperagulable state. Aute mesenteri vein lusin presents similarly t the arterial lusive syndrmes but is muh less mmn. Patients at risk inlude thse with parxysmal nturnal hemglbinuria; prtein C, prtein S, r antithrmbin defiienies; r the JAK2 mutatin. These lesins are diffi- ult t treat surgially, and thrmblysis is the mainstay f therapy. Aggressive lng-term antiagulatin is required fr these patients. NONATHEROSCLEROTIC VASCULAR DISEASE THROMBOANGIITIS OBLITERANS (Buerger Disease)E S S E N T I A L S  O F  D I A G N O S I S Typically occurs in male cigarette smokers. Distal extremities involved with severe ischemia, progressing to tissue loss. Thrombosis of the superficial veins may occur. Smoking cessation is essential to stop disease progression. General ConsiderationsBuerger  disease is a segmental, inflammatry, and thrm- bti press f the distal-mst arteries and asinally veins f the extremities. Pathlgi examinatin reveals arteritis in the affeted vessels. The ause is nt knwn but it is rarely seen in patients wh d nt smke igarettes. Arteries mst mmnly affeted are the plantar and digi- tal vessels f the ft and lwer leg. In advaned stages, the fingers and hands may beme invlved. The inidene f Buerger disease has dereased dramatially. Clinical FindingsA.  Symptoms and SignsBuerger  disease may be initially diffiult t differentiate frm rutine peripheral vasular disease, but in mst ases, the lesins are n the tes and the patient is yunger than 40 years f age. The bservatin f superfiial thrmb- phlebitis may aid the diagnsis. Beause the distal vessels are usually affeted, intermittent laudiatin is nt m- mn with Buerger disease, but rest pain, partiularly painin the distal mst extremity (ie, tes), is frequent. This pain ften prgresses t tissue lss and amputatin, unless the patient stps smking. The prgressin f the disease seems t be intermittent with aute and dramati episdes fllwed by sme perids f remissin.B.  ImagingMRA  r invasive angigraphy an demnstrate the blit- eratin f the distal arterial tree typial f Buerger disease. Differential DiagnosisIn  atherslerti peripheral vasular disease, the nset f tissue ishemia tends t be less dramati than in Buerger disease, and symptms f prximal arterial invlvement, suh as laudiatin, predminate. Symptms f Raynaud disease may be diffiult t dif- ferentiate frm Buerger disease and are ften existent in 40% f patients. Repetitive atherembli may als mimi Buerger disease and may be diffiult t differentiate. It may be neessary t image the prximal arterial tree t rule ut sures f arterial mirembli. TreatmentSmking essatin is the mainstay f therapy and will  halt the disease in mst ases. As the distal arterial tree is luded, revasularizatin is ften nt pssible. Sympa- thetmy is rarely effetive. PrognosisIf  smking essatin an be ahieved, the utlk fr Buerger disease may be better than in patients with premature periph- eral vasular disease. If smking essatin is nt ahieved, then the prgnsis is generally pr, with amputatin f bth lwer and upper extremities a pssible utme.Le  Jnur A et al; Frenh Buergers Netwrk. Lng-term utme and prgnsti fatrs f mpliatins in thrmbangiitis bliterans (Buergers disease): a multienter study f 224 patients. J Am Heart Ass. 2018;7:e010677. [PMID: 30571594] ARTERIAL ANEURYSMS ABDOMINAL AORTIC ANEURYSME S S E N T I A L S  O F  D I A G N O S I S Most aortic aneurysms are asymptomatic until rupture. 80% of abdominal aortic aneurysms measuring 5 cm are palpable; the usual threshold for treat- ment is 5.5 cm. Back or abdominal pain with aneurysmal tender- ness may precede rupture. Rupture is catastrophic: excruciating abdominal pain that radiates to the back; hypotension.CMDT22_Ch12_p0475-p0501.indd  483 29/06/21 8:37 PMCHAPTER 12484 CMDT 2022 General ConsiderationsDilatati n f the infrarenal arta is a nrmal part f aging. The arta f a healthy yung man measures apprximately 2 m. An aneurysm is nsidered present when the arti diameter exeeds 3 m, but aneurysms rarely rupture until their diameter exeeds 5 m. Abdminal arti aneurysms are fund in 2% f men ver 55 years f age; the male t female rati is 4:1. Ninety perent f abdminal athersle- rti aneurysms riginate belw the renal arteries. The aneurysms usually invlve the arti bifuratin and ften invlve the mmn ilia arteries. Inflammatry aneurysms are an unusual variant. These have an inflammatry peel (similar t the inflammatin seen with retrperitneal fibrsis) that surrunds the aneurysm and enases adjaent retrperitneal strutures, suh as the dudenum and, asinally, the ureters. Clinical FindingsA.  Symptoms and Signs1.  Asymptomatic Althugh 80% f 5-m infrarenal aneurysms are palpable n rutine physial examinatin, mst aneurysms are disvered n ultrasund r CT imag- ing as part f a sreening prgram r during the evaluatin f unrelated abdminal symptms. 2. Symptomatic a. Pain Aneurysmal expansin may be ampanied by pain that is mild t severe midabdminal dismfrt ften radiating t the lwer bak. The pain may be nstant r intermittent and is exaerbated by even gentle pressure n the aneurysm sak. Pain may als ampany inflamma- try aneurysms. Mst aneurysms have a thik layer f thrmbus lining the aneurysmal sa, but emblizatin t the lwer extremities is rarely seen. b. Rupture The sudden esape f bld int the retr- peritneal spae auses severe pain and hyptensin. Free rupture int the peritneal avity is a lethal event.B.  Laboratory FindingsIn  aute ases f a ntained rupture, the hematrit may be nrmal, sine there has been n pprtunity fr hemdilutin. Patients with aneurysms may als have rnary artery disease, artid disease, kidney impairment, and emphysema, whih are typially seen in elderly men wh smke igarettes. Preperative testing may indiate the presene f these mrbid nditins, whih inrease the risk f interventin.C.  ImagingA bdminal ultrasngraphy is the diagnsti study f hie fr initial sreening fr the presene f an aneu- rysm. In apprximately three-quarters f patients with aneurysms, urvilinear alifiatins utlining prtins f the aneurysm wall may be visible n plain radigraphs f the abdmen r bak. CT sans prvide a mre reliable assessment f aneurysm diameter and shuld be dne when the aneurysm nears the diameter threshld (5.5 m)fr treatment. Cntrast-enhaned CT sans shw the arter- ies abve and belw the aneurysm. The visualizatin f this vasulature is essential fr planning repair. CT imaging will ften demnstrate mural thrmbus within the aneurysm and is nt an indiatin fr antiagulatin. One an aneurysm is identified, rutine fllw-up with ultrasund will determine size and grwth rate. The fre- queny f imaging depends n aneurysm size ranging frm every 2 years fr aneurysms smaller than 4 m t every 6 mnths fr aneurysms at r apprahing 5 m. When an aneurysm measures apprximately 5 m, a CTA with ntrast shuld be dne t mre aurately assess the size f the aneurysm and define the anatmy. ScreeningGuidelines  remmend abdminal ultrasund sreening in men 6575 years ld with expsure t 100 r mre life- time igarettes but nflit n whether wmen with the same expsure shuld be sreened. Guidelines d nt re- mmend repeated sreening if the arta shws n enlarge- ment. While patients are mnitred, smking essatin and treatment f underlying hypertensin, hyperlipidemia, and diabetes shuld be nsidered. TreatmentA.  Elective RepairTh e risk f rupture inreases with aneurysm diameter. In gen- eral, eletive repair is indiated fr arti aneurysms 5.5 m r larger in diameter r aneurysms that demnstrate rapid expan- sin (mre than 0.5 m in 6 mnths). Symptms suh as pain r tenderness may indiate impending rupture and require urgent repair regardless f the aneurysms diameter.B.  Aneurysmal RuptureA  ruptured aneurysm is a lethal event. Apprximately half the patients exsanguinate prir t reahing a hspital. In the remainder, bleeding may be temprarily ntained in the retrperitneum (ntained rupture), allwing the patient t underg emergent surgery. Hwever, nly half f thse patients will survive. Endvasular repair is available fr ruptured aneurysm treatment in mst majr vasular en- ters, with the results ffering sme imprvement ver pen repair fr these ritially ill patients.C.  Inflammatory AneurysmThe  presene f periarti inflammatin (inflammatry aneurysm) is nt an indiatin fr surgial treatment, unless there is assiated mpressin f retrperitneal strutures, suh as the ureter r pain upn palpatin f the aneurysm. Interestingly, the inflammatin that enases an inflammatry aneurysm reedes after either endvasular r pen surgial aneurysm repair.D . Assessment of Operative RiskAneurysms  appear t be a variant f systemi athersler- sis. Patients with aneurysms have a high rate f rnary disease but a 2004 trial demnstrated minimal value inCMDT22_Ch12_p0475-p0501.indd  484 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS485 CMDT 2022addressing  stable rnary artery disease prir t aneu- rysm resetin. Hwever, in patients with signifiant symptms f rnary disease, the rnary disease shuld be treated first. Aneurysm repair shuld fllw shrtly thereafter beause there is a slightly inreased risk f aneu- rysm rupture after the rnary predures.E.  Open Surgical Resection Versus Endovascular RepairIn  pen surgial aneurysm repair, a graft is sutured t the nn-dilated vessels abve and belw the aneurysm. This invlves an abdminal inisin, extensive dissetin, and interruptin f arti bld flw. The mrtality rate is lw (25%) in enters that have a high vlume fr this pre- dure and when it is perfrmed in gd-risk patients. Older, siker patients may nt tlerate the ardipulmnary stresses f the peratin. With endvasular arti repair, a stent-graft is intrdued thrugh small inisins ver the femral arteries and psitined within the arta under flurspi guidane. The stent must be able t seal seurely against the wall f the arta abve and belw the aneurysm, thereby exluding bld frm flwing int the aneurysm sa. T suessfully treat an aneurysm, the ana- tmi requirements fr endvasular repairs are mre preise than fr pen repairs. Mst studies have fund that endvasular arti repair ffers patients redued pera- tive mrbidity and mrtality as well as shrter revery perids. Lng-term survival is equivalent between the tw tehniques. Patients wh underg endvasular repair, hwever, likely need additinal interventins and need lifelng mnitring, sine there is a 1015% inidene f ntinued aneurysm grwth after endvasular repair. ComplicationsM yocardial infarction, the mst mmn mpliatin, urs in up t 10% f patients wh underg pen aneurysm repair. The inidene f myardial infartin is substantially lwer with endvasular repair. Fr rutine infrarenal aneu- rysms, renal injury is unusual; hwever, when it des ur, r if the baseline reatinine is elevated, it is a signifiant m- pliating fatr in the pstperative perid. Respiratry mpliatins are similar t thse seen in mst majr abdminal surgery. Gastrintestinal hemrrhage, even years after arti surgeries, suggests the pssibility f graft enteric fistula, mst mmnly between the arta and the distal dudenum; the inidene f this mpliatin is higher when the initial surgery is perfrmed n an emergeny basis. PrognosisThe m rtality rate fr an pen eletive surgial resetin is 15%, and the mrtality rate fr endvasular therapy is 0.52%. Of thse wh survive surgery, apprximately 60% are alive at 5 years; myardial infartin is the leading ause f death. The lng-term survival (5 years r mre) after pen and endvasular repairs is equivalent. Mrtality rates f untreated aneurysms vary with aneu- rysm diameter. The mrtality rate amng patients with large aneurysms has been defined as fllws: 12% annual risk f rupture with an aneurysm larger than 6 m indiameter and a 25% annual risk f rupture in aneurysms f mre than 7 m diameter. In general, a patient with an arti aneurysm larger than 5.5 m has a threefld greater hane f dying f a nsequene f rupture f the aneu- rysm than f dying f the surgial resetin. At present, endvasular aneurysm repair may be less definitive than pen surgial repair and requires lse fl- lw up with an imaging predure. Devie migratin, mpnent separatin, and graft limb thrmbsis r kink- ing are mmn reasns fr repeat interventin. With mplete exlusin f bld frm the aneurysm sa, the pressure is lwered, whih auses the aneurysm t shrink. An endleak frm the tp r bttm seal znes (type 1) r thrugh a graft defet (type 3) is assiated with a per- sistent risk f rupture. Indiret leakage f bld thrugh lumbar and inferir mesenteri branhes f the aneurysm (type-2 endleak) prdues an intermediate piture with smewhat redued pressure in the sa, slw shrinkage, and lw rupture risk. Hwever, type-2 endleak warrants lse bservatin as aneurysm dilatatin an hange aneurysm mrphlgy leading t type-1 endleak and rupture. When to Refer Any patient with a 4.5-m r larger arti aneurysm shuld be referred t a vasular speialist fr bserva- tin and assessment. Urgent referrals shuld be made if the patient m- plains f pain and gentle palpatin f the aneurysm nfirms that it is the sure, regardless f the aneurys- mal size. When to Admit Patients with a tender aneurysm t palpatin r signs f arti rupture require emergent hspital admissin. Evidene f infetin after repair.O Dnnell TFX et al. Abdminal arti aneurysm sreening guidelines: United States Preventive Servies Task Fre and Siety fr Vasular Surgery. J Vas Surg. 2020;71:1457. [PMID: 32334726] Jin J. Sreening fr abdminal arti aneurysm. JAMA Patient Page. JAMA. 2019;322:2256. [PMID: 31821432] Lederle FA et al; OVER Veterans Affairs Cperative Study Grup. Open versus endvasular repair f abdminal arti aneurysm. N Engl J Med. 2019;380:2126. [PMID: 31141634] US Preventive Servies Task Fre; Owens DK et al. Sreening fr abdminal arti aneurysm: US Preventive Servies Task Fre Remmendatin Statement. JAMA. 2019;322:2211. [PMID: 31821437]TH ORACIC AORTIC ANEURYSMSE S S E N T I A L S  O F  D I A G N O S I S Widened mediastinum on chest radiograph. With rupture, sudden onset of chest pain radiating to the back.CMDT22_Ch12_p0475-p0501.indd  485 29/06/21 8:37 PMCHAPTER 12486 CMDT 2022 General ConsiderationsMs t thrai arti aneurysms are due t atherslersis; syphilis is a rare ause. Disrders f nnetive tissue and Ehlers-Danls and Marfan syndrmes als are rare auses but have imprtant therapeuti impliatins. Traumati, false aneurysms, aused by partial tearing f the arti wall with deeleratin injuries, may ur just beynd the ri- gin f the left sublavian artery. Less than 10% f arti aneurysms ur in the thrai arta. Clinical FindingsA.  Symptoms and SignsMs t thrai aneurysms are asymptmati. When symp- tms ur, they depend largely n the size and the psi- tin f the aneurysm and its rate f grwth. Substernal bak r nek pain may ur. Pressure n the trahea, esphagus, r superir vena ava an result in the fllwing symptms and signs: dyspnea, stridr r brassy ugh, dysphagia, and edema in the nek and arms as well as dis- tended nek veins. Strething f the left reurrent laryngeal nerve auses harseness. With aneurysms f the asending arta, arti regurgitatin may be present due t dilatin f the arti valve annulus. Rupture f a thrai aneurysm is atastrphi beause bleeding is rarely ntained, allwing n time fr emergent repair.B.  ImagingThe  aneurysm may be diagnsed n hest radigraph by the alified utline f the dilated arta. CT sanning with ntrast enhanement is the mdality f hie, but MRA an be used t demnstrate the anatmy and aneurysmal size and t exlude lesins that an mimi aneurysms, suh as neplasms r substernal giter. There is n lw-st alternative (eg, ultrasngraphy) fr sreening r surveil- lane. Cardia atheterizatin and ehardigraphy may be required t desribe the relatinship f the rnary vessels t an aneurysm f the asending arta. TreatmentIn diatins fr repair depend n the latin f dilatin, rate f grwth, assiated symptms, and verall nditin f the patient. Desending thrai aneurysms measuring 6 m r larger may be nsidered fr repair, sine there is a 5-year survival f 54% in these patients. Aneurysms f the desend- ing thrai arta are treated rutinely by endvasular grafting. Repair f arh aneurysms shuld be undertaken nly if there is a skilled surgial team with an aeptable rerd f utmes fr these mplex predures. The avail- ability f thrai arti endgraft tehnique using mplex branhed endvasular renstrutins fr aneurysms invlving the arh r viseral arta (ustm-made grafts with branhes t the vessels invlved in the aneurysm) des nt hange the indiatins fr aneurysm repair. Aneurysms that invlve the prximal arti arh r asending arta repre- sent partiularly hallenging prblems and may be nsid- ered fr repair when they measure 5.5 m. Open surgery is usually required, arrying substantial risk f mrbidity (inluding strke, diffuse neurlgi injury, and intelletualimpairment) beause interruptin f arh bld flw is required. ComplicationsW ith the exeptin f endvasular repair fr disrete sa- ular aneurysms f the desending thrai arta, the mrbidity and mrtality f thrai aneurysm repair is higher than fr infra-renal abdminal arti aneurysm repair. Paraplegia remains a devastating mpliatin. Mst large series reprt apprximately 410% rate f paraplegia fllwing endvasular repair f thrai arti aneurysms. The spinal arterial supply is segmental thrugh interstal branhes f the arta with variable degrees f intersegmental nnetin. Therefre, the mre extensive the aneurysm, the greater is the risk f paraplegia with repair. Prir infrarenal abdminal arti surgery, subla- vian r internal ilia artery lusin, and hyptensin all inrease the paraplegia risk. Invlvement f the arti arh als inreases the risk f strke, even when the aneurysm des nt diretly affet the artid artery. PrognosisGenerally , degenerative aneurysms f the thrai arta will enlarge (n average 0.1 m/y) and require repair t prevent death frm rupture. Saular aneurysms, partiu- larly thse distal t the left sublavian artery and the desending thrai arta, have gd results with endvas- ular repair. Resetin f aneurysms f the arti arh requires a skilled surgial team and shuld be attempted nly in lw-risk patients. Branhed r fenestrated endvas- ular grafting tehnlgy has demnstrated redued mr- bidity and mrtality. When to Refer Asending arti aneurysms larger than 4.5 m shuld be referred t a ardia surgen fr bservatin and assessment and nsidered fr repair at 5.5 m. Desending thrai arti aneurysm shuld be referred t a vasular speialist when they reah 5 m fr bser- vatin and assessment and nsidered fr repair at 6 m. When to Admit Any patient with hest r bak pain with a knwn r suspeted thrai arta aneurysm must be brught t the hspital and underg urgent imaging studies t rule ut the aneurysm as a ause f the pain.Gasper  WJ et al. Assessing the anatmi appliability f the multibranhed endvasular repair f thraabdminal arti aneurysm tehnique. J Vas Surg. 2013;57:1553. [PMID: 23395201] Uphurh GR et al. Siety fr Vasular Surgery linial pratie guidelines f thrai endvasular arti repair fr desend- ing thrai arti aneurysms. J Vas Surg. 2021;73:55S. [PMID: 32628988] Werlin EC et al. Multibranhed endvasular arti aneurysm repair in patients with and withut hrni arti dissetins. J Vas Surg. 2019;70:1419. [PMID: 31327618]CMDT22_Ch12_p0475-p0501.indd  486 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS487 CMDT 2022PE RIPHERAL ARTERY ANEURYSMSE S S E N T I A L S  O F  D I A G N O S I S Widened, prominent pulses. Acute leg or foot pain and paresthesias with loss of distal pulses. High association of popliteal aneurysms with abdominal aortic aneurysms. General ConsiderationsLike  arti aneurysms, peripheral artery aneurysms are silent until ritially symptmati. Hwever, unlike arti aneurysms, the presenting manifestatins are due t peripheral emblizatin and thrmbsis. Ppliteal artery aneurysms aunt fr 70% f peripheral arterial aneu- rysms. Ppliteal aneurysms may emblize repetitively ver time and lude distal arteries. Due t the redundant parallel arterial supply t the ft, ishemia des nt ur until a final emblus ludes flw. Primary femral artery aneurysms are muh less m- mn. Hwever, pseudaneurysms f the femral artery fllwing arterial puntures fr arterigraphy and ardia atheterizatin ur with an inidene ranging frm 0.05% t 6% f arterial puntures. Clinical FindingsA.  Symptoms and SignsThe  patient may be aware f a pulsatile mass when the aneurysm is in the grin, but ppliteal aneurysms are ften undeteted by the patient and liniian. Rarely, peripheral aneurysms may prdue symptms by mpressing the lal vein r nerve. The first symptm may be due t ish- emia f aute arterial lusin. The symptms range frm sudden-nset pain and paralysis t shrt-distane laudi- atin that slwly lessens as llateral irulatin develps. Symptms frm reurrent emblizatin t the leg are ften transient, if they ur at all. Sudden ishemia may appear in a te r part f the ft, fllwed by slw reslutin, and the true diagnsis may be elusive. The nset f reurrent episdes f pain in the ft, partiularly if ampanied by yansis, suggests emblizatin and requires investigatin f the heart and prximal arterial tree. Beause ppliteal pulses are smewhat diffiult t pal- pate even in nrmal individuals, a partiularly prminent r easily felt pulse is suggestive f aneurysm and shuld be investigated by ultrasund. Sine ppliteal aneurysms are bilateral in 60% f ases, the diagnsis f thrmbsis f a ppliteal aneurysm is ften aided by the palpatin f a pulsatile aneurysm in the ntralateral ppliteal spae. Apprximately 50% f patients with ppliteal aneurysms have an aneurysmal abdminal arta.B.  Imaging StudiesDuplex lr ultrasun d is the mst effiient investigatin t nfirm the diagnsis f peripheral aneurysm, measureits size and nfiguratin, and demnstrate mural thrm- bus. MRA r CTA is required t define the aneurysm and lal arterial anatmy fr renstrutin. Arterigraphy is nt remmended beause mural thrmbus redues the apparent diameter f the lumen n angigraphy. Patients with ppliteal aneurysms shuld underg abdminal ultra- sngraphy t determine whether an abdminal arti aneurysm is als present. TreatmentT  prevent limb lss frm thrmbsis r emblizatin, surgery is indiated when an aneurysm is assiated with any peripheral emblizatin, the aneurysm is larger than 2 m, r a mural thrmbus is present. Immediate r urgent surgery is indiated when aute emblizatin r thrmbsis has aused aute ishemia. Open surgial bypass is gener- ally indiated. Endvasular exlusin f the aneurysm an be dne but has anatmi nstraints and is reserved fr high-risk patients. Intra-arterial thrmblysis may be dne in the setting f aute ishemia, if examinatin (light tuh) remains intat, suggesting that immediate surgery is nt imperative. Aute pseudaneurysms f the femral artery due t arterial puntures an be suessfully treated using ultrasund-guided mpressin r thrmbin injetin. Open surgery with prstheti interpsitin grafting is pre- ferred fr primary aneurysms f the femral artery. PrognosisA pprximately ne-third f untreated patients will require an amputatin. The lng-term pateny f bypass grafts fr femral and ppliteal aneurysms is generally exellent but depends n the adequay f the utflw trat. Late graft lusin is less mmn than in similar surgeries fr lusive disease. When to Refer Peripheral arterial aneurysms measuring 2 m r with ultrasund evidene f thrmbus within the aneurysm shuld be referred t prevent prgressin t limb- threatening ishemia. When to Admit Patients with symptms f ishemia r any signs f emblizatin shuld be admitted and referred t a vas- ular speialist.AOR TIC DISSECTIONE S S E N T I A L S  O F  D I A G N O S I S Sudden searing chest pain with radiation to the back, abdomen, or neck in a hypertensive patient. Widened mediastinum on chest radiograph. Pulse discrepancy in the extremities. Acute aortic regurgitation may develop.CMDT22_Ch12_p0475-p0501.indd  487 29/06/21 8:37 PMCHAPTER 12488 CMDT 2022 General ConsiderationsA rti dissetin urs when a spntaneus intimal tear develps and bld dissets int the media f the arta. The tear an result frm repetitive trque applied t the asend- ing and prximal desending arta during the ardia yle; hypertensin is an imprtant mpnent f this disease press. Dissetins are lassified by the entry pint and distal extent. Type A dissection invlves the arh prximal t the left sublavian artery, and type B dissection urs in the prximal desending thrai arta typially just beynd the left sublavian artery. Dissetins may ur in the absene f hypertensin but abnrmalities f smth musle, elasti tissue, r llagen are mre mmn in these patients. Pregnany, biuspid arti valve, and artatin als are assiated with inreased risk f dissetin. Bld entering the intimal tear may extend the dissetin int the abdminal arta, the lwer extremities, the artid arteries, r less mmnly, the sublavian arteries. Bth abs- lute pressure levels and the pulse pressure are imprtant in prpagatin f dissetin. Aortic dissection is a true emer- gency and requires immediate control of blood pressure to limit the extent of the dissection. With type A dissetin, whih has the wrse prgnsis, death may ur within hurs due t rupture f the dissetin int the periardial sa r dissetin int the rnary arteries, resulting in myardial infartin. Rupture int the pleural avity is als pssible. The intimal/ medial flap f the arti wall reated by the dissetin may lude majr arti branhes, resulting in ishemia f the brain, intestines, kidney, r extremities. Clinical FindingsA.  Symptoms and SignsSe vere persistent hest pain f sudden nset radiating dwn the bak r pssibly int the anterir hest is harateristi. Radiatin f the pain int the nek may als ur. The patient is usually hypertensive. Synpe, hemiplegia, r paralysis f the lwer extremities may ur. Mesenteri ishemia r kidney injury may develp. Peripheral pulses may be diminished r unequal. A diastli murmur may develp as a result f a dis- setin in the asending arta lse t the arti valve, ausing valvular regurgitatin, heart failure, and ardia tampnade.B.  Electrocardiographic FindingsLeft  ventriular hypertrphy frm lng-standing hyperten- sin is ften present. Aute hanges suggesting myardial ishemia d nt develp unless dissetin invlves the rnary artery stium. Classially, inferir wall abnr- malities predminate sine dissetin leads t mprmise f the right rather than the left rnary artery. In sme patients, the ECG may be mpletely nrmal.C.  ImagingA  multiplanar CT san with ntrast enhanement is the immediate diagnsti imaging mdality f hie; lini- ians shuld have a lw threshld fr btaining a CT san in any hypertensive patient with hest pain and equival findings n ECG. The CT san shuld inlude bth the hest and abdmen t fully delineate the extent f thedisseted arta. MRA is an exellent imaging mdality fr hrni dissetins, but in the aute situatin, the lnger imaging time and the diffiulty f mnitring patients in the MRI sanner make the CT san preferable. Chest radi- graphs may reveal an abnrmal arti ntur r widened superir mediastinum. Althugh transesphageal ehar- digraphy (TEE) is an exellent diagnsti imaging methd, it is generally nt readily available in the aute setting. Differential DiagnosisA rti dissetin is mst mmnly misdiagnsed as my- ardial infartin r ther auses f hest pain suh as pulmnary emblizatin. Dissetins may ur with minimal pain; branh vessel lusin f the lwer extrem- ity an mimi arterial emblus. TreatmentA.  MedicalAg gressive measures t lwer bld pressure shuld ur when an arti dissetin is suspeted, even befre the diag- nsti studies have been mpleted. Treatment requires a simultaneus redutin f the systli bld pressure t 100 120 mm Hg and pulse pressure. Beta-blkers have the mst desirable effet f reduing the left ventriular ejetin fre that ntinues t weaken the arterial wall and shuld be first- line therapy. Labetall, bth an alpha- and beta-blker, lw- ers pulse pressure and ahieves rapid bld pressure ntrl. Give 20 mg ver 2 minutes by intravenus injetin. Addi- tinal dses f 4080 mg intravenusly an be given every 10 minutes (maximum dse 300 mg) until the desired bld pressure has been reahed. Alternatively, 2 mg/min may be given by intravenus infusin, titrated t desired effet. In patients wh have asthma, bradyardia, r ther nditins that neessitate the patients reatin t beta-blkers be tested, esmll is a reasnable hie beause f its shrt half-life. Give a lading dse f esmll, 0.5 mg/kg intravenusly ver 1 minute, fllwed by an infusin f 0.00250.02 mg/kg/min. Titrate the infusin t a gal heart rate f 6070 beats/min. If beta-blkade alne des nt ntrl the hypertensin, nitrprusside may be added as fllws: 50 mg f nitrprus- side in 1000 mL f 5% dextrse and water, infused at a rate f 0.5 mL/min fr a 70-kg persn (0.3 mg/kg/min); the infu- sin rate is inreased by 0.5 mL every 5 minutes until adequate ntrl f the pressure has been ahieved. In patients with asthma, while there are n data supprting the use f the al- ium hannel antagnists, diltiazem and verapamil are pten- tial alternatives t treatment with beta-blking drugs. Mrphine sulfate is the apprpriate drug t use fr pain relief. Lng-term medial are f patients shuld inlude beta- blkers in their antihypertensive regimen.B.  Surgical Intervention1.  Type A dissection Urgent surgical intervention is required for all type A dissections. If a skilled ardivasular team is nt available, the patient shuld be transferred t an appr- priate faility. The predure invlves grafting and replaing the diseased prtin f the arh and brahiephali vessels as neessary. Replaement f the arti valve may be required with reattahment f the rnary arteries.CMDT22_Ch12_p0475-p0501.indd  488 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS489 CMDT 20222. T ype B dissection with malperfusion Urgent surgery is required fr type B dissetins if there is arti branh mprmise resulting in malperfusin f the renal, vis- eral, r extremity vessels. The immediate gal f surgery is t restre flw t the ishemi tissue. Endvasular stenting f the entry tear at the level f the sublavian artery may result in bliteratin f the false lumen and restre flw int the branh vessel frm the true lumen. The results, hwever, are unpreditable and shuld nly be attempted by an experiened team. 3. Type B dissection without malperfusion Fr aute type B dissetins withut malperfusin, bld pressure ntrl is the primary treatment. Lng-term arti-speifi survival and late aneurysm frmatin rates are imprved with early thrai stent graft repair, espeially in healthy patients with high-risk anatmi features (arti diameter greater than 4 m r partial false lumen thrmbsis). Prognosis & Follow-UpThe  mrtality rate fr untreated type A dissetins is apprximately 1% per hur fr 72 hurs and ver 90% at 3 mnths. Mrtality is als extremely high fr untreated type B dissetins with malperfusin r rupture. The surgial and endvasular therapies fr these patients are tehnially demanding and require an experiened team t ahieve periperative mrtalities f less than 10%. Aneurysmal enlargement f the residual false lumen may develp despite adequate antihypertensive therapy. Y early CT sans are required t mnitr fr aneurysm develpment. Indiatins fr late aneurysm repair are determined by aneurysm size (6 m r larger), similar t undisseted thrai aneurysms. When to Admit All patients with an aute dissetin shuld be hspital- ized fr bld pressure management and bservatin. Urgent surgial repair is indiated fr all type A disse- tins and fr type B dissetins with malperfusin, rupture, r persistent symptms.Bssne E  et al. Aute arti syndrmes: diagnsis and manage- ment, an update. Eur Heart J. 2018;39:739. [PMID: 29106452] Evangelista A et al; IRAD Investigatrs. Insights frm the Interna- tinal Registry f Aute Arti Dissetin: a 20-year experiene f llabrative linial researh. Cirulatin. 2018;137:1846. [PMID: 29685932] VENOUS DISEASES VARICOSE VEINSE S S E N T I A L S  O F  D I A G N O S I S Dilated, tortuous superficial veins in the legs. Asymptomatic or there may be aching discomfort or pain. Often hereditary. Increased frequency after pregnancy.General ConsiderationsV arise veins develp in the lwer extremities. Perids f high venus pressure related t prlnged standing r heavy lifting are ntributing fatrs, but the highest ini- dene urs in wmen after pregnany. Varisities develp in ver 20% f all adults. The mbinatin f prgressive venus reflux and venus hypertensin is the hallmark f hrni venus disease. The superfiial veins are invlved, typially the great saphenus vein and its tributaries, but the shrt saphenus vein (psterir lwer leg) may als be affeted. Distentin f the vein prevents the valve leaflets frm apting, reating inmpetene and reflux f bld tward the ft. Fal venus dilatin and reflux leads t inreased pressure and distentin f the vein segment belw that valve, whih in turn auses prgressive failure f the next lwer valve. Perfrating veins that nnet the deep and superfiial systems may beme inmpetent, allwing bld t reflux int the superfiial veins frm the deep system, inreasing venus pressure and distentin. Sendary varisities an develp as a result f bstrutive hanges and valve damage in the deep venus system fllwing thrmbphlebitis, r rarely as a result f prximal venus lusin due t neplasm r fibrsis. Cngenital r aquired arterivenus fistulas r venus malfrmatins are als assiated with varisities and shuld be nsidered in yung patients with varisities. Clinical FindingsA.  Symptoms and SignsSymp tm severity is nt rrelated with the number and size f the varisities; extensive varise veins may pr- due n subjetive symptms, whereas minimal varisi- ties may prdue many symptms. Dull, ahing heaviness r a feeling f fatigue f the legs brught n by perids f standing is the mst mmn mplaint. Ithing frm venus ezema may ur either abve the ankle r diretly verlying large varisities. Dilated, trtuus veins f the thigh and alf are visible and palpable when the patient is standing. Lngstanding varise veins may prgress t hrni venus insuffiieny with assiated ankle edema, brwnish skin hyperpigmen- tatin, and hrni skin induratin r fibrsis. A bruit r thrill is never fund with primary varise veins and, when fund, alerts the liniian t the presene f an arterive- nus fistula r malfrmatin.B.  ImagingThe identifiatin  f the sure f venus reflux that feeds the symptmati veins is neessary fr effetive surgial treatment. Duplex ultrasngraphy by a tehniian experi- ened in the diagnsis and lalizatin f venus reflux is the test f hie fr planning therapy. In mst ases, reflux will arise frm the greater saphenus vein. Differential DiagnosisV arise veins due t primary superfiial venus reflux shuld be differentiated frm thse sendary t previusCMDT22_Ch12_p0475-p0501.indd  489 29/06/21 8:37 PMCHAPTER 12490 CMDT 2022r  nging bstrutin f the deep veins (pst-thrmbti syndrme). Pain r dismfrt sendary t neurpathy shuld be distinguished frm symptms assiated with existent varise veins. Similarly, vein symptms shuld be distinguished frm pain due t intermittent laudia- tin, whih urs after a preditable amunt f exerise and reslves with rest. In adlesent patients with varise veins, imaging f the deep venus system is bligatry t exlude a ngenital malfrmatin r atresia f the deep veins. Surgical treatment of varicose veins in these patients is contraindicated because the varicosities may play a signifi- cant role in venous drainage of the limb. ComplicationsSuperfiial  thrmbphlebitis f varise veins is unm- mn. The typial presentatin is aute lalized pain with tender, firm veins. The press is usually self-limiting, reslving within several weeks. The risk f deep venus thrmbsis (DVT) r emblizatin is very lw unless the thrmbphlebitis extends int the great saphenus vein in the upper medial thigh. Predispsing nditins inlude pregnany, lal trauma, r prlnged perids f sitting. In lder patients, superfiial varisities may bleed with even minr trauma. The amunt f bleeding an be alarm- ing as the pressure in the varisity is high. TreatmentA.  Nonsurgical MeasuresN nsurgial treatment is effetive. Elasti graduated m- pressin stkings (2030 mm Hg pressure) redue the venus pressure in the leg and may prevent the prgressin f disease. Gd ntrl f symptms an be ahieved when stkings are wrn daily during waking hurs and legs are elevated, espeially at night. Cmpressin stk- ings are well-suited fr elderly patients r patients wh d nt want surgery.B.  Varicose Vein SclerotherapyDiret  injetin f a slersing agent indues permanent fibrsis and bliteratin f the target veins. Chemial irri- tants (eg, glyerin) r hypertni saline are ften used fr small, less-than-4-mm retiular veins r telangietasias. Fam slertherapy is used t treat the great saphenus vein, varise veins larger than 4 mm, and perfrating veins. Slertherapy f varise veins withut treatment f underlying saphenus vein reflux is assiated with vari- sity reurrene rates ver 50% as unrreted reflux prgressively dilates adjaent veins. Cmpliatins suh as phlebitis, tissue nersis, r infetin may ur with any slersing agent.C.  Surgical Reflux TreatmentT reatment ptins fr reflux arising frm the great saphenus vein inlude surgial vein stripping (remval) r endvenus treatments using thermal devies (laser r radifrequeny atheter), yanarylate glue injetin, r fam slersant injetin. Endvenus treatments an ften be perfrmed with lal anesthesia alne and theearly suess is equal t vein stripping. Lng-term suess is highest with vein stripping and thermal treatments while the lng-term durability f yanarylate glue and fam is unknwn. One majr mpliatin f thermal treatments inludes endthermal heat-indued thrmbsis f the deep vein and may require prlnged antiagulatin. Less mmn sures f reflux inlude the small saphenus vein (fr varisities in the psterir alf) and inmpetent perfratr veins arising diretly frm the deep venus sys- tem. Crretin f reflux is perfrmed at the same time as exisin f the symptmati varise veins. When superfi- ial venus reflux is present, nmitant reflux in the deep venus system is ften sendary t vlume verlad, whih will reslve with rretin f the superfiial reflux. PrognosisSurgial  treatment f superfiial vein reflux and exisin f varise veins prvide exellent results. The 5-year suess rate (as defined as lak f pain and reurrent varisities) is 8590%. Simple exisin (phlebetmy) r injetin slertherapy withut rretin f reflux is assiated with reurrene rates ver 50%. Even after adequate treat- ment, sendary tissue hanges may persist. When to Refer Abslute indiatins fr referral fr saphenus ablatin inlude thrmbphlebitis and bleeding. Pain and smeti nerns are respnsible fr the majrity f referrals fr ablatin.Kabnik  LS et al. Classifiatin and treatment f endthermal heat-indued thrmbsis: remmendatins frm the Amerian Venus Frum and the Siety fr Vasular Sur- gery. J Vas Surg Venus Lymphat Disrd. 2021;9:6. [PMID: 33012690] DePpas E et al. Varise veins and lwer extremity venus insuffiieny. Semin Intervent Radil. 2018;35:56. [PMID: 29628617]SU PERFICIAL VENOUS THROMBOPHLEBITISE S S E N T I A L S  O F  D I A G N O S I S Red, painful induration along a superficial vein, usually at the site of a recent intravenous line. Marked swelling of the extremity may not occur. General ConsiderationsShrt-term venus a theterizatin f superfiial arm veins as well as the use f lnger-term peripherally inserted en- tral atheter (PICC) lines are the mst mmn ause f superfiial thrmbphlebitis. Intravenus atheter sites shuld be bserved daily fr signs f lal inflammatin and shuld be remved if a lal reatin develps in the vein. Serius thrmbti r septi mpliatins an ur if this pliy is nt fllwed; S aureus is the mst mmnCMDT22_Ch12_p0475-p0501.indd  490 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS491 CMDT 2022pathgen.  Other rganisms, inluding fungi, may als be respnsible. Superfiial thrmbphlebitis may ur spntaneusly, ften in pregnant r pstpartum wmen r in individuals with varise veins, r it may be assiated with trauma, as with a blw t the leg r fllwing intravenus therapy with irritating slutins. It als may be a manifestatin f systemi hyperagulability sendary t abdminal an- er suh as arinma f the panreas and may be the earli- est sign f these nditins. Superfiial thrmbphlebitis may be assiated with ult DVT in abut 20% f ases. Pulmnary embli are exeedingly rare and ur frm an assiated DVT. (See Chapters 9 and 14 fr disussin n deep venus thrmbsis.) Clinical FindingsIn  spntaneus superfiial thrmbphlebitis, the great saphenus vein is mst ften invlved. The patient usually experienes a dull pain in the regin f the invlved vein. Lal findings nsist f induratin, redness, and tender- ness alng the urse f a vein. The press may be lal- ized, r it may invlve mst f the great saphenus vein and its tributaries. The inflammatry reatin generally subsides in 12 weeks; a firm rd may remain fr a muh lnger perid. Edema f the extremity is unmmn. Lalized redness and induratin at the site f a reent intravenus line requires urgent attentin. Prximal exten- sin f the induratin and pain with hills and high fever suggest septi phlebitis and requires urgent treatment. Differential DiagnosisThe linear ra ther than irular nature f the lesin and the distributin alng the urse f a superfiial vein serve t differentiate superfiial phlebitis frm ellulitis, erythema ndsum, erythema induratum, panniulitis, and fibrsi- tis. Lymphangitis and deep thrmbphlebitis must als be nsidered. TreatmentF r spntaneus thrmbphlebitis if the press is well lalized and nt near the saphenfemral juntin, lal heat and nnsteridal anti-inflammatry mediatins are usually effetive in limiting the press. If the induratin is extensive r is prgressing tward the saphenfemral juntin (leg) r ephal-axillary juntin (arm), ligatin and divisin f the vein at the juntin f the deep and superfiial veins is indiated. Antiagulatin therapy is usually nt required fr fal presses. Prphylati dse lw-mleular-weight heparin r fndaparinux is remmended fr 5 m r ln- ger superfiial thrmbphlebitis f the lwer limb veins (Table 1414) and full antiagulatin is reserved fr dis- ease that is rapidly prgressing r if there is nern fr extensin int the deep system (Table 1416). Septi superfiial thrmbphlebitis is an intravasular absess and requires urgent treatment with heparin r fndaparinux (see Table 1416) t limit further thrmbus frmatin and remval f the ffending atheter in atheter- related infetins (see Chapter 30). Treat with antibitis(eg, vanmyin, 15 mg/kg intravenusly every 12 hurs, plus eftriaxne, 1 g intravenusly every 24 hurs). If ul- tures are psitive, therapy shuld be ntinued fr 710 days r fr 46 weeks if mpliating endarditis annt be exluded. Surgial exisin f the invlved vein may als be neessary t ntrl the infetin. PrognosisW ith spntaneus thrmbphlebitis, the urse is gener- ally benign and brief. In patients with phlebitis sendary t varise veins, reurrent episdes are likely unless r- retin f the underlying venus reflux and exisin f varisities is dne. In ntrast, the mrtality frm septi thrmbphlebitis is 20% r higher and requires aggressive treatment. Hwever, if the invlvement is lalized, the mrtality is lw and prgnsis is exellent with early treatment.Di  Nisi M et al. Treatment fr superfiial thrmbphlebitis f the leg. Chrane Database Syst Rev. 2018;2:CD004982. [PMID: 29478266]CH RONIC VENOUS INSUFFICIENCYE S S E N T I A L S  O F  D I A G N O S I S History of prior DVT or leg injury. Edema, (brawny) skin hyperpigmentation, subcu- taneous lipodermosclerosis in the lower leg. Venous ulcers: large ulcerations at or above the medial ankle. General ConsiderationsChrni  venus insuffiieny is a severe manifestatin f venus hypertensin. One f the mst mmn etilgies is prir deep venus thrmbphlebitis, althugh abut 25% f patients d nt have a knwn histry f DVT. In these ases, there may be a histry f leg trauma r surgery; besity is ften a mpliating fatr. Prgressive superfi- ial venus reflux is als a mmn ause. Other auses inlude ngenital r neplasti bstrutin f the pelvi veins r a ngenital r aquired arterivenus fistula. The basi pathlgy is aused by valve leaflets that d nt apt beause they are either thikened and sarred (pst-thrmbti syndrme) r in a dilated vein and are therefre funtinally inadequate. Prximal venus bstrutin due t hrni thrmbus r sarring m- punds the prblem. With the valves unable t stp venus bld frm returning t the ft (venus reflux), the leg develps venus hypertensin and an abnrmally high hydrstati fre is transmitted t the subutaneus veins and tissues f the lwer leg. The resulting edema results in dramati and deleterius sendary hanges. The stigmata f hrni venus insuffiieny inlude fibrsis f the sub- utaneus tissue and skin, pigmentatin f skin (hemsid- erin taken up by the dermal marphages), and, later,CMDT22_Ch12_p0475-p0501.indd  491 29/06/21 8:37 PMCHAPTER 12492 CMDT 2022uleratin,  whih is extremely slw t heal. Ithing may preipitate the frmatin f uleratin r lal wund el- lulitis. Dilatin f the superfiial veins may ur, leading t varisities. Althugh surgial treatment fr venus reflux an imprve symptms, ntrlling edema and the sendary skin hanges usually require lifelng mpres- sin therapy. Clinical FindingsA.  Symptoms and SignsPrgr essive pitting edema f the leg (partiularly the lwer leg) is the primary presenting symptm. Sendary hanges in the skin and subutaneus tissues develp ver time (Figure 122). The usual symptms are ithing, a dull dis- mfrt made wrse by perids f standing, and pain if an uleratin is present. The skin at the ankle is usually taut frm swelling, shiny, and a brwnish pigmentatin (hem- siderin) ften develps. If the nditin is lngstanding, the subutaneus tissues beme thik and fibrus. Uler- atins may ur, usually just abve the ankle, n the medial r anterir aspet f the leg. Healing results in a thin sar n a fibrti base that ften breaks dwn with minr trauma r further buts f leg swelling. Varisities may appear (Figure 123) that are assiated with inm- petent perfrating veins. Cellulitis, whih is ften diffiult t distinguish frm the hemsiderin pigmentatin, may be diagnsed by blanhing erythema with pain.B.  ImagingPa tients with pst-thrmbti syndrme r signs f hrni venus insuffiieny shuld underg duplex ultrasngra- phy t determine whether superfiial reflux is present and t evaluate the degree f deep reflux and bstrutin. Differential DiagnosisPa tients with heart failure, hrni kidney disease, r dem- pensated liver disease may have bilateral edema f the lwer extremities. Many mediatins an ause edema (eg, al- ium hannel blkers, nnsteridal anti-inflammatry agents, thiazlidinedines). Swelling frm lymphedema invlves the feet and may be unilateral, but varisities are absent. Edema frm these auses pits easily and brawny dislratin is rare. Lipedema is a disrder f adipse tissue that urs almst exlusively in wmen, is bilateral and symmetri, and is haraterized by stpping at a distint line just abve the ankles. Primary varise veins may be diffiult t differentiate frm the sendary varisities f pst-thrmbti syn- drme r venus bstrutin. Other nditins assiated with hrni ulers f the leg inlude neurpathi ulers usually frm diabetes mel- litus, arterial insuffiieny (ften manifests as painful lat- eral ankle ulers with absent pulses; medial ankle ulers, n Figure 122. Bilateral pretibial edema and erythema consistent with stasis dermatitis (sometimes mimicking cellulitis) in chronic venous insufficiency. (Used, with permission, from Dean SM, Satiani B, Abraham WT. Color Atlas and Synopsis of Vascular Diseases. McGraw-Hill, 2014.) Figure 123. Varicose veins, manifested as blue, subcutaneous, tortuous veins more than 3 mm in diam- eter. (Used, with permission, from Dean SM, Satiani B, Abraham WT. Color Atlas and Synopsis of Vascular Diseases. McGraw-Hill, 2014.)CMDT22_Ch12_p0475-p0501.indd  492 29/06/21 8:38 PMBLOOD VESSEL & LYMPHATIC DISORDERS493 CMDT 2022the  ther hand, are usually due t venus insuffiieny), autimmune diseases (eg, Felty syndrme), sikle ell ane- mia, erythema induratum (bilateral and usually n the psterir aspet f the lwer part f the leg), and fungal infetins. PreventionI rreversible tissue hanges and assiated mpliatins in the lwer legs an be redued thrugh early and aggressive antiagulatin f aute DVT t minimize the valve damages and by presribing mpressin stkings if hrni edema develps after the DVT has reslved. Treatment f aute ilifemral DVT with atheter-direted thrmblysis r mehanial thrmbetmy des nt redue pst-thrmbti syndrme and hrni venus insuffiieny. TreatmentA.  General MeasuresFitted , graduated mpressin stkings (2030 mm Hg pressure r higher) wrn frm the ft t just belw the knee during the day and evening are the mainstays f treat- ment and are usually suffiient. When they are nt, addi- tinal measures, suh as avidane f lng perids f sitting r standing, intermittent elevatins f the invlved leg, and sleeping with the legs kept abve the level f the heart, may be neessary t ntrl the swelling. Pneumati mpressin f the leg, whih an pump the fluid ut f the leg, is used in refratry ases.B.  UlcerationAs  the primary pathlgy is edema and venus hyperten- sin, healing f the uler will nt ur until the edema is ntrlled and mpressin is applied. Cirumferential nnelasti bandages n the lwer leg enhane the pumping atin f the alf musles n venus bld flw ut f the alf. A lesin an ften be treated n an ambulatry basis by means f a semi-rigid gauze bt made with Unna paste (Gelast, Medipaste) r a multi-layer mpressin dressing (eg, Prfre). Initially, the uler needs t be debrided and the bt hanged every 23 days t ntrl uler drainage. As the edema and drainage subside, pti- mal healing is ahieved when the bt is kept in plae fr 57 days. The uler, tendns, and bny prminenes must be adequately padded. Alternatively, knee-high graduated mpressin stkings with an absrbent dressing may be used, if wund drainage is minimal. Hme mpressin therapy with a pneumati mpressin devie is used in refratry ases, but many patients have severe pain with the milking atin f the pump devie. Sme patients will require admissin fr mplete bed rest and leg elevatin t ahieve uler healing. After the uler has healed, daily graduated mpressin stking therapy is mandatry t prevent uler reurrene.C.  Vein Treatment Reflux or ObstructionT reatment f superfiial vein reflux (see Varise Veins se- tin, abve) has been shwn t derease the reurrene rate f venus ulers. Where there is substantial bstrutin fthe femral and ppliteal deep venus system, superfiial varisities supply the venus return and they shuld nt be remved. Venus stents as treatment f hrni ilia deep vein stensis r bstrutin may imprve venus uler healing and redue the uler reurrene rate in severe ases. PrognosisIndivid uals with hrni venus insuffiieny ften have reurrent edema, partiularly if they d nt nsistently wear supprt stkings that have at least 2030 mm Hg mpressin. When to Refer Patients with signifiant saphenus reflux shuld be evaluated fr ablatin. Patients with ulers shuld be mnitred by an interdis- iplinary wund are team s that these hallenging wunds reeive aggressive are.Raffett  JD. Pathphysilgy f hrni venus disease and venus ulers. Surg Clin Nrth Am. 2018;98:337. [PMID: 29502775] Vedantham S et al; ATTRACT Trial Investigatrs. Pharmam- ehanial atheter-direted thrmblysis fr deep-vein thrmbsis. N Engl J Med. 2017;377:2240. [PMID: 29211671]SU PERIOR VENA CAVAL OBSTRUCTIONE S S E N T I A L S  O F  D I A G N O S I S Swelling of the neck, face, and upper extremities. Dilated veins over the upper chest and neck. General ConsiderationsP artial r mplete bstrutin f the superir vena ava is a relatively rare nditin that is usually sendary t neplas- ti r inflammatry presses in the superir mediastinum. The mst frequent auses are (1) neplasms, suh as lymph- mas, primary malignant mediastinal tumrs, r arinma f the lung with diret extensin (ver 80%); (2) hrni fibrti mediastinitis, either f unknwn rigin r sendary t tuberulsis, histplasmsis, pygeni infetins, r drugs, espeially methysergide; (3) DVT, ften by extensin f the press frm the axillary r sublavian vein int the innmi- nate vein and vena ava assiated with atheterizatin f these veins fr dialysis r fr hyperalimentatin; (4) aneu- rysm f the arti arh; and (5) nstritive periarditis. Clinical FindingsA.  Symptoms and SignsThe  nset f symptms is aute r subaute. Symptms inlude swelling f the nek and fae and upper extremities. Symptms are ften pereived as ngestin and present asCMDT22_Ch12_p0475-p0501.indd  493 29/06/21 8:38 PMCHAPTER 12494 CMDT 2022heada he, dizziness, visual disturbanes, stupr, synpe, r ugh. There is prgressive bstrutin f the venus drainage f the head, nek, and upper extremities. The uta- neus veins f the upper hest and lwer nek beme dilated, and flushing f the fae and nek develps. Brawny edema f the fae, nek, and arms urs later, and yansis f these areas then appears. Cerebral and laryngeal edema ultimately result in impaired funtin f the brain as well as respiratry insuffiieny. Bending ver r lying dwn aentuates the symptms; sitting quietly is generally pre- ferred. The manifestatins are mre severe if the bstru- tin develps rapidly and if the azygs juntin r the vena ava between that vein and the heart is bstruted.B.  Laboratory FindingsThe ven us pressure is elevated (ften mre than 20 m f water) in the arm and is nrmal in the leg. Sine lung aner is a mmn ause, brnhspy is ften perfrmed; transbrnhial bipsy, hwever, is relatively ntraindiated beause f venus hypertensin and the risk f bleeding.C.  ImagingChest  radigraphs and a CT san an define the latin and ften the nature f the bstrutive press, and n- trast vengraphy r magneti resnane vengraphy (MRV) will map ut the extent and degree f the venus bstrutin and the llateral irulatin. Brahial veng- raphy r radinulide sanning fllwing intravenus injetin f tehnetium (T-99m) pertehnetate demn- strates a blk t the flw f ntrast material int the right heart and enlarged llateral veins. These tehniques als allw estimatin f bld flw arund the lusin as well as serial evaluatin f the respnse t therapy. TreatmentCnser vative measures, suh as elevatin f the head f the bed and lifestyle mdifiatin t avid bending ver, are useful. Balln angiplasty f the bstruted aval segment mbined with stent plaement prvides prmpt relief f symptms and is the predure f hie fr all etilgies. Oasinally, antiagulatin is needed, while thrmbly- sis is rarely needed. Urgent treatment fr neplasm nsists f (1) autius use f intravenus diuretis and (2) mediastinal irradia- tin, starting within 24 hurs, with a treatment plan designed t give a high daily dse but a shrt ttal urse f therapy t rapidly shrink the lal tumr. Intensive m- bined therapy will palliate the press in up t 90% f patients. In patients with a subaute presentatin, radiatin therapy alne usually suffies. Chemtherapy is added if lymphma r small-ell arinma is diagnsed. Lng-term utme is mpliated by risk f re-lusin frm either thrmbsis r neplasm grwth. Surgial pre- dures t bypass the bstrutin are mpliated by bleed- ing frm high venus pressure. In ases where the thrmbsis is sendary t an indwelling atheter, thrm- blysis may be attempted. Clinial judgment is required sine a lng-standing lt may be fibrti and the risk f bleeding an utweigh the ptential benefit.PrognosisThe  prgnsis depends n the nature and degree f bstrutin and its speed f nset. Slwly develping frms sendary t fibrsis may be tlerated fr years. A high degree f bstrutin f rapid nset sendary t aner is ften fatal in a few days r weeks beause f inreased intraranial pressure and erebral hemrrhage, but treat- ment f the tumr with radiatin and hemtherapeuti drugs may result in signifiant palliatin. Balln angi- plasty and stenting prvide gd relief but may require re- treatment fr reurrent symptms sendary t thrmbsis r restensis. When to Refer Any patient with prgressive head and nek swelling shuld be referred t rule ut superir vena ava syndrme. When to Admit Any patient with aute edema f the head and nek r with signs and symptms f airway mprmise, suh as harseness r stridr, shuld be admitted.Kalra  M et al. Endvenus and perative treatment f superir vena ava syndrme. Surg Clin Nrth Am. 2018;98:321. [PMID: 29502774] DISEASES OF THE LYMPHATIC CHANNELS LYMPHANGITIS & LYMPHADENITISE S S E N T I A L S  O F  D I A G N O S I S Red streak from wound or cellulitis toward regional lymph nodes, which are usually enlarged and tender. Chills, fever, and malaise may be present. General ConsiderationsL ymphangitis and lymphadenitis are mmn manifesta- tins f a baterial infetin that is usually aused by hemlyti strepti r S aureus (r by bth rganisms) and bemes invasive, generally frm an infeted wund, ellulitis, r an absess. The wund may be very small r superfiial, r an established absess may be present, feed- ing bateria int the lymphatis. The invlvement f the lymphatis is ften manifested by a red streak in the skin extending in the diretin f the reginal lymph ndes. Clinical FindingsA.  Symptoms and SignsThrbb ing pain is usually present at the site f baterial invasin frm a wund, ellulitis, r absess. Malaise,CMDT22_Ch12_p0475-p0501.indd  494 29/06/21 8:38 PMBLOOD VESSEL & LYMPHATIC DISORDERS495 CMDT 2022anr exia, sweating, hills, and fever f 3840C develp quikly, ften with a rapid pulse. The red streak, when present, may be definite r may be faint and easily missed, espeially in dark-skinned patients. The invlved reginal lymph ndes may be signifiantly enlarged and are usually quite tender. The infetin may prgress rapidly, ften in a matter f hurs, and may lead t septiemia and death.B.  Laboratory FindingsLeukytsis with  a left shift is usually present. Bld ul- tures may be psitive, mst ften fr staphylal r streptal speies. Culture and sensitivity studies f the wund exudate r pus may be helpful in treatment f the mre severe r refratry infetins but are ften diffiult t interpret beause f skin ntaminants. Differential DiagnosisTh e erythema and induratin f superfiial thrmbphlebitis are lalized in and arund the thrmbsed vein. Venus thrmbsis is nt assiated with lymphadenitis, and a wund f entrane with sendary ellulitis is generally absent. Cat-srath fever (Bartonella henselae) is a ause f lymphadenitis; the ndes, thugh ften very large, are rela- tively nntender. Expsure t ats is mmn, but the patient may have frgtten abut the srath. It is extremely important to differentiate cellulitis from acute streptococcal hemolytic gangrene or a necrotizing soft tissue infection. These are deeper infetins that may be extensive and are ptentially lethal. Patients are mre seriusly ill; there may be redness due t leakage f red ells, reating a nn- blanhing erythema; subutaneus repitus, a late finding, may be palpated r ausultated; and subutaneus air may be present n radigraphy r CT san. Immediate surgial n- sultatin is needed fr wide debridement f all invlved deep tissues if a nertizing infetin is suspeted. TreatmentA.  General MeasuresPr mpt treatment shuld inlude heat (ht, mist m- presses r heating pad), elevatin when feasible, and immbilizatin f the infeted area. Analgesis may be presribed fr pain.B.  Specific MeasuresEmp iri antibiti therapy fr hemlyti strepti r S aureus (r bth rganisms) shuld always be instituted. Cephalsprins r extended-spetrum peniillins are m- mnly used (eg, ephalexin, 0.5 g rally fur times daily fr 710 days; see Table 306). Trimethprim-sulfamethxa- zle (tw duble-strength tablets rally twie daily fr 710 days) shuld be nsidered when there is nern that the pathgen is MRSA (see Tables 304 and 306).C.  Wound CareAny  wund that is the initiating site f lymphangitis shuld be treated aggressively. Any nerti tissue must be debrided and lulated pus drained.PrognosisW ith prper therapy inluding an antibiti effetive against the invading bateria, ntrl f the infetin an usually be ahieved in a few days. Delayed r inadequate therapy an lead t verwhelming infetin with septiemia. When to Admit Infetins ausing lymphangitis shuld be treated in the hspital with intravenus antibitis. Debridement may be required and prmpt surgial nsultatin is prudent.L YMPHEDEMAE S S E N T I A L S  O F  D I A G N O S I S Painless persistent edema of one or both lower extremities, primarily in young women. Pitting edema without ulceration, varicosities, or stasis pigmentation. Lymphangitis and cellulitis may occur. General ConsiderationsWhen  lymphedema is due t ngenital develpmental abnrmalities nsisting f hypplasti r hyperplasti invlvement f the prximal r distal lymphatis, it is referred t as the primary form . The bstrutin may be in the pelvi r lumbar lymph hannels and ndes when the disease is extensive and prgressive. The secondary form f lymphedema invlves inflammatry r mehani- al lymphati bstrutin frm trauma, reginal lymph nde resetin r irradiatin, r extensive invlvement f reginal ndes by malignant disease r filariasis. Lymph- edema may ur fllwing surgial remval f the lymph ndes in the grin r axillae. Sendary dilatin f the lymphatis that urs in bth frms leads t inmpe- tene f the valve system, disrupts the rderly flw alng the lymph vessels, and results in prgressive stasis f a prtein-rih fluid. Episdes f aute and hrni inflam- matin may be superimpsed, with further stasis and se- ndary fibrsis. Clinical FindingsH ypertrphy f the limb results, with markedly thikened and fibrti skin and subutaneus tissue (Figure 124) in very advaned ases. T2weighted MRI has been used t identify lymphatis and prximal bstruting masses. Lymphangigraphy and radiative istpe studies may identify fal defets in lymph flw but are f little value in planning therapy. TreatmentSine there is n  effetive ure fr lymphedema, the treat- ment strategies are designed t ntrl the prblem andCMDT22_Ch12_p0475-p0501.indd  495 29/06/21 8:38 PMCHAPTER 12496 CMDT 2022allw  nrmal ativity and funtin. Mst patients an be treated with sme f the fllwing measures: (1) The flw f lymph ut f the extremity an be aided thrugh inter- mittent elevatin f the extremity, espeially during the sleeping hurs (ft f bed elevated 1520 degrees, ahieved by plaing pillws beneath the mattress); the nstant use f graduated elasti mpressin stkings; and massage tward the trunkeither by hand r by means f pneumati pressure devies designed t milk edema ut f an extremity. Wund are enters speializ- ing in the are f patients with lymphedema may be help- ful. (2) Sendary ellulitis shuld be avided by means f gd hygiene and treatment f any trihphytsis f the tes. One an infetin starts, it shuld be treated by peri- ds f elevatin and antibiti therapy that vers Staphy- lococcus and Streptococcus rganisms (see Table 306). Infetins an be a serius and reurring prblem and are ften diffiult t ntrl. Prphylati antibitis have nt been shwn t be f benefit. (3) Intermittent urses f diureti therapy, espeially in thse with premenstrual r seasnal exaerbatins, are rarely helpful. (4) Amputatin is used nly fr the rare mpliatin f lymphangisar- ma in the extremity. PrognosisW ith aggressive treatment, inluding pneumati mpres- sin devies, gd relief f symptms an be ahieved. The lng-term utlk is ditated by the assiated nditins and avidane f reurrent ellulitis.Chen  K et al. Surgial management f pstmastetmy lymph- edema and review f the literature. Ann Plast Surg. 2021;86: S173. [PMID: 33346539] Figure 124. Lymphedema with a dorsal pedal hump and exaggerated skin folds near the ankle. (Used, with permission, from Dean SM, Satiani B, Abraham WT. Color Atlas and Synopsis of Vascular Diseases. McGraw-Hill, 2014.)SHOCKE S S E N T I A L S  O F  D I A G N O S I S Hypotension, tachycardia, oliguria, altered mental status. Peripheral hypoperfusion and impaired oxygen delivery. Four classifications: hypovolemic, cardiogenic, obstructive, or distributive. General ConsiderationsShk  urs when the rate f arterial bld flw is inad- equate t meet tissue metabli needs. This results in reginal hypxia and subsequent lati aidsis frm anaerbi metablism in peripheral tissues as well as even- tual end-rgan damage and failure. ClassificationT able 121 utlines mmn auses and mehanisms ass- iated with eah type f shk.A.  Hypovolemic ShockH ypvlemi shk results frm dereased intravasular vlume sendary t lss f bld r fluids and eletr- lytes. The etilgy may be suggested by the linial setting (eg, trauma) r by signs and symptms f bld lss (eg, gastrintestinal bleeding) r dehydratin (eg, vmiting r diarrhea). Cmpensatry vasnstritin may transiently maintain the bld pressure but unreplaed lsses f ver 15% f the intravasular vlume an result in hyptensin and prgressive tissue hypxia.B.  Cardiogenic ShockCardigeni  shk results frm ardia failure with the resultant inability f the heart t maintain adequate tissue perfusin. The linial definitin f ardigeni shk is evidene f tissue hypxia due t dereased ardia utput (ardia index less than 2.2 L/min/m2) in the presene f adequate intravasular vlume. This is mst ften aused by myardial infartin but an als be due t ardimy- pathy, myardial ntusin, valvular inmpetene r stensis, r arrhythmias. See Chapter 10.C.  Obstructive ShockPe riardial tampnade, tensin pneumthrax, and mas- sive pulmnary emblism an ause an aute derease in ardia utput resulting in shk. These are medial emer- genies requiring prmpt diagnsis and treatment.D . Distributive ShockDistributiv e r vasdilatry shk has many auses inlud- ing sepsis, anaphylaxis, traumati spinal rd injury, rCMDT22_Ch12_p0475-p0501.indd  496 29/06/21 8:38 PMBLOOD VESSEL & LYMPHATIC DISORDERS497 CMDT 2022aute  adrenal insuffiieny. The redutin in systemi vasular resistane results in inadequate ardia utput and tissue hypperfusin despite nrmal irulatry vlume. 1. Septic shock Sepsis is the mst mmn ause f dis- tributive shk and arries a mrtality rate f 2050%. TheSiety f Critial Care Mediine and the Eurpean Siety f Intensive Care Mediines 2016 definitin fr sepsis is life-threatening rgan dysfuntin aused by a dysregu- lated hst respnse t infetin frm any rganism (bate- rial, viral, r fungal). Septic shock is linially defined as sepsis with fluid-unrespnsive hyptensin (systli bld pressure less than 100 mm Hg), serum latate level higher than 2 mml/L, and a need fr vaspressrs t keep mean arterial pressure (MAP) abve 65 mm Hg. The mst m- mn ause f septi shk in hspitalized patients is infe- tin with gram-psitive r gram-negative rganisms, with a grwing inidene f infetin frm multidrug-resistant rganisms. Sepsis frm viral and fungal rganisms is inreasing but remain less than that fr baterial infetins. Risk fatrs fr septi shk inlude bateremia, extremes f age, diabetes, aner, immunsuppressin, and histry f a reent invasive predure. a. Clinical tools to identify sepsis and septic shock The Third Internatinal Cnsensus Definitins fr Sepsis and Septi Shk (SEPSIS-3) remmend using the Sequential Organ Failure Assessment (SOFA) sre t define sepsis (https://en.wikipedia.rg/wiki/SOFA_sre); an inrease f 2 r mre SOFA sre pints in a patient with infetin is diagnsti f sepsis with a predited 10% mrtality. The SEPSIS-3 grup als intrdued the quik SOFA (qSOFA) sring system (https://en.wikipedia.rg/ wiki/SOFA_sre); 1 pint eah is assigned fr hypten- sin (systli bld pressure belw 100 mm Hg), altered mental status, r tahypnea (respiratry rate mre than 22 breaths per minute). A qSOFA sre f 2 r mre in a patient with suspeted infetin suggests wrsened linial utmes and may influene triage deisins fr intensive are unit (ICU)-level are. b. Systemic inflammatory response syndrome (SIRS) Defined as a systemi respnse t a nnspeifi infetius r nninfetius insult resulting in at least tw f the fllwing findings: (1) bdy temperature higher than 38C (100.4F) r lwer than 36C (96.8F), (2) heart rate faster than 90 beats per minute, (3) respiratry rate mre than 20 breaths per minute r hyperventilatin with an arterial arbn dixide tensin (Paco2) less than 32 mm Hg, r (4) abnrmal white bld ell unt (greater than 12,000/mL r less than 4000/mL r greater than 10% immature [band] frms). Vasdilatry shk frm SIRS is ften due t burns; panreatitis; autimmune disrders, suh as vasulitis r inflammatry litis; air r amniti fluid emblus; ishemia; r trauma. SIRS is nt inluded in the 2016 frmal diagnsti riteria f sepsis. A 2018 meta- analysis demnstrated that SIRS riteria have higher sensi- tivity than qSOFA and may therefre identify patients with sepsis befre ther tests, suggesting that SIRS may be a better sreening tl fr sepsis, while qSOFA may be better used as a preditr f ICU mrtality. Studies are nging t desribe the ptimal patient ppulatins (emergeny department vs hspitalized nn-ICU patients) where SIRS and qSOFA sring systems shuld be used. 2. Neurogenic shock Neurgeni shk is aused by traumati spinal rd injury r effets f an epidural r spinal anestheti. This results in lss f sympatheti tneTable 121. Classification of shock by mechanism and common causes.Hypovolemic  shock Blood loss Traumatic hemorrhage Exsanguination Hemothorax Hemoperitoneum Fracture (femur and pelvis) Nontraumatic hemorrhage Gastrointestinal bleed AAA rupture Ectopic pregnancy rupture Volume loss Burns Skin integrity loss (toxic epidermal necrolysis) Vomiting Diarrhea Hyperosmolar states (diabetic ketoacidosis) Third spacing (eg, ascites, pancreatitis) Decreased intake Cardiogenic shock Dysrhythmia Bradycardias and blocks Tachycardias Myocardial disease Left or right ventricular infarction Dilated cardiomyopathy Mechanical Valvular Aortic regurgitation from dissection Papillary muscle rupture from ischemia Acute valvular rupture from abscess Ventricular aneurysm rupture Ventricular septum rupture Free wall ventricle rupture Obstructive shock Tension pneumothorax Pericardial disease Pericardial tamponade Constrictive pericarditis High-risk (massive) pulmonary embolism Severe pulmonary hypertension Auto PEEP from mechanical ventilation Distributive (vasodilatory) shock Anaphylactic shock Septic shock Neurogenic shock Drug-induced vasodilation Adrenal insufficiency Modified, with permission, from Stone CK, Humphries RL (editors). Current Emergency Diagnosis & Treatment , 7th ed. McGraw-Hill, 2011. AAA, abdominal aortic aneurysm; PEEP , positive end expiratory pressure.CMDT22_Ch12_p0475-p0501.indd  497 29/06/21 8:38 PMCHAPTER 12498 CMDT 2022with a redutin  in systemi vasular resistane and hyp- tensin withut a mpensatry tahyardia. Reflex vagal parasympatheti stimulatin evked by pain, gastri dila- tin, r fright may simulate neurgeni shk, prduing hyptensin, bradyardia, and synpe. 3. Endocrine shock Endrine shk an arise frm hyperthyridism, hypthyridism, r adrenal insuffi- ieny. Adrenal insuffiieny mst ften urs with abrupt essatin f lng-term rtisterid use, but it an als be preipitated by infetin, trauma, surgery, r pitu- itary injury (leading t sendary adrenal insuffiieny). In additin t hyptensin, symptms inlude weakness, nausea, abdminal pain, and nfusin. Hypthyridism an lead t myxedema ma, presenting with vasdilatin and depressed ardia utput. Shk frm hyperthyrid- ism mst ften prdues high-utput ardia failure. Clinical FindingsA.  Symptoms and SignsHyp otension is traditinally defined as a systli bld pressure f 90 mm Hg r less r a MAP f less than 6065 mm Hg but must be evaluated relative t the patients nrmal bld pressure. A drp in systli pressure f greater than 1020 mm Hg r an inrease in pulse f mre than 15 beats per minute with psitinal hange sug- gests depleted intravasular vlume. Hwever, bld pres- sure is ften nt the best indiatr f end-rgan perfusin beause mpensatry mehanisms, suh as inreased heart rate, inreased ardia ntratility, and vasnstritin an ur t prevent hyptensin. Patients with hypten- sin ften have l r mttled extremities and weak r thready peripheral pulses. Splanhni vasnstritin may lead t liguria, bwel ishemia, and liver dysfuntin, whih an ultimately result in multirgan failure. Mentatin may be nrmal r patients may beme restless, agitated, nfused, lethargi, r matse as a result f inadequate perfusin f the brain. Hypovolemic shock is evident when signs f hypper- fusin, suh as liguria, altered mental status, and l extremities, are present. Jugular venus pressure is lw, and there is a narrw pulse pressure indiative f redued strke vlume. Rapid replaement f fluids an restre tis- sue perfusin. In cardiogenic shock, there are als signs f glbal hypperfusin with liguria, altered mental status, and l extremities. Jugular venus pressure is elevated and there may be evidene f pulmnary edema with respi- ratry mprmise in the setting f left-sided heart failure. A transthoracic echocardiogram (TTE) or a transesophageal echocardiogram (TEE) is an effective diagnostic tool to dif- ferentiate hypovolemic from cardiogenic shock. In hypvle- mi shk, the left ventrile will be small beause f dereased filling, but ntratility is ften preserved. In ardigeni shk, there is a derease in left ventriular ntratility. The left ventrile may appear dilated and full beause f the inability f the left ventrile t ejet a suffi- ient strke vlume. Inobstructive shock , the entral venus pressure may be elevated but the TTE r TEE may shw redued left ventriular filling, a periardial effusin in the ase ftampnade, thikened periardium in the ase f periar- ditis, r right ventriular dysfuntin in the ase f massive pulmnary emblism. Periardientesis r periardial windw fr periardial tampnade, hest tube plaement fr tensin pneumthrax, r atheter-direted thrmb- lyti therapy fr massive pulmnary emblism an be life- saving in ases f bstrutive shk. Indistributive shock, signs inlude hyperdynami heart sunds, warm extremities initially, and a wide pulse pres- sure indiative f large strke vlume. The ehardigram may shw a hyperdynami left ventrile. Septic shock is diagnsed when there is linial evidene f infetin in the setting f persistent hyptensin and evidene f rgan hypperfusin, suh as lati aidsis, dereased urinary utput, r altered mental status despite adequate vlume resusitatin. Neurogenic shock is diagnsed when there is evidene f entral nervus system injury and persistent hyptensin despite adequate vlume resusitatin. A his- try f lng-term rtisterid use r thyrid disease an inrease the likelihd f endocrine shock.B.  Laboratory Findings and ImagingBld  speimens shuld be evaluated fr mplete bld unt, eletrlytes, gluse, arterial bld gas determina- tins, agulatin parameters, latate levels, typing and rss-mathing, and baterial ultures. An eletrardi- gram and hest radigraph shuld als be part f the initial assessment. Pint-f-are ultrasngraphy an rapidly assess glbal ardia funtin, presene f periardial effu- sin, and intravasular vlume status via inferir vena ava inspetin in ases f undifferentiated hyptensin. A TTE an mre frmally assess right- and left-sided filling pres- sures and ardia utput. TreatmentA.  General MeasuresT reatment depends n prmpt diagnsis and an aurate appraisal f initing nditins. Initial management n- sists f basi life supprt with an assessment f the patients irulatin, airway, and breathing. This may entail airway intubatin and mehanial ventilatin. Ven- tilatry failure shuld be antiipated in patients with severe metabli aidsis due t shk. Mehanial venti- latin alng with sedatin an derease respiratry musle xygen demand and allw imprved xygen delivery t hypperfused tissues. Intravenus aess and fluid resus- itatin shuld be instituted alng with ardia mnitr- ing and assessment f hemdynami parameters suh as bld pressure and heart rate. Cardia mnitring an detet myardial ishemia r malignant arrhythmias, whih an be treated by standard advaned ardia life supprt (ACLS) prtls. Unrespnsive r minimally respnsive patients shuld have their gluse heked immediately, and if their gluse levels are lw, 1 ampule f 50% dextrse intravenusly shuld be given. An arterial line shuld be plaed fr n- tinuus bld pressure measurement, and an indwelling urinary atheter shuld be inserted t mnitr urinary utput.CMDT22_Ch12_p0475-p0501.indd  498 29/06/21 8:38 PMBLOOD VESSEL & LYMPHATIC DISORDERS499 CMDT 2022B.  Hemodynamic MeasurementsEarly  nsideratin is given t plaement f a entral venus atheter (CVC) fr infusin f fluids and media- tins and fr hemdynami pressure measurements. A CVC an prvide measurements f the entral venus pressure (CVP) and the entral venus xygen saturatin (SvO2), bth f whih an be used t manage septi and ardigeni shk. Pulmnary artery atheters (PACs) allw measurement f the pulmnary artery pressure, left- sided filling pressure r the pulmnary apillary wedge pressure (PCWP), the mixed venus xygen saturatin (SvO2), and ardia utput. Multiple studies suggest that PACs d nt inrease verall mrtality r length f hspital stay but are assiated with higher use f intrpes and intravenus vasdilatrs in selet grups f ritially ill patients. The attendant risks assiated with PACs (infe- tin, arrhythmias, vein thrmbsis, and pulmnary artery rupture) an be as high as 49%; thus, the rutine use f PACs annt be remmended. Hwever, in mplex situ- atins, PACs may be useful in distinguishing between ar- digeni and septi shk, s the value f the infrmatin they might prvide must be arefully weighed in eah patient. TTE is a nninvasive alternative t the PAC. TTE an prvide infrmatin abut the pulmnary artery pres- sure and urrent ardia funtin, inluding ardia ut- put. The SvO2, whih is btained thrugh the CVC, an be used as a surrgate fr the SvO2, whih is btained thrugh the PAC. Pulse pressure variatin, as determined by arterial wavefrm analysis, r strke vlume variatin is muh mre sensitive than CVP as dynami measures f fluid respnsiveness in vlume resusitatin, but these measure- ments have nly been validated in patients wh are mehanially ventilated with tidal vlumes f 8 mL/kg, nt triggering the ventilatr, and in nrmal sinus rhythm. Pint-f-are ultrasund measurements f the inferir vena ava (IVC) an suggest intravasular vlume status and guide fluid replaement. If the patient is mehanially ventilated and the IVC dilates ~1520% with respiratins, they are likely t respnd t intravenus fluids. If the patient is spntaneusly breathing, they may be fluid- respnsive if their IVC is less than 2 m in diameter and llapses by mre than 50% with eah breath. A CVP less than 5 mm Hg suggests hypvlemia, and a CVP greater than 18 mm Hg suggests vlume verlad, ardia failure, tampnade, r pulmnary hypertensin. A ardia index lwer than 2 L/min/m2indiates a need fr intrpi supprt. A ardia index higher than 4 L/min/m2 in a hyptensive patient is nsistent with early septi shk. The systemi vasular resistane is lw (less than 800 dynes  s/m5) in sepsis and neurgeni shk and high (greater than 1500 dynes  s/m5) in hypvlemi and ardigeni shk. Treatment is direted at maintaining a CVP f 812 mm Hg, a MAP f 65 mm Hg r higher, a ardia index f 24 L/min/m2, and a SvO2greater than 70%.C.  Volume ReplacementV lume replaement is ritial in the initial management f shk. Hemorrhagic shock is treated with immediateeffrts t ahieve hemstasis and rapid infusins f bld substitutes, suh as type-speifi r type O negative paked red bld ells (PRBCs) r whle bld, whih prvides extra vlume and ltting fatrs. Eah unit f PRBC r whle bld is expeted t raise the hematrit by 3%. Hypovolemic shock sendary t dehydratin is managed with rapid bluses f istni rystallid slutins, usually in 1-L inrements. Cardiogenic shock in the absene f fluid verlad requires smaller fluid hallenges, usually in inrements f 250 mL. Septic shock usually requires large vlumes f fluid fr resusitatin (typially 30 mL/kg) as the assiated apillary leak releases fluid int the extravas- ular spae. Caution must be used in cases of large-volume resuscitation with unwarmed fluids because this can produce hypothermia, which can lead to hypothermia-induced coag- ulopathy. Warming f fluids befre administratin an avid this mpliatin. Crystallid slutin is the resusitatin fluid f hie in mst settings. Histrially, 0.9% saline was the mst widely used rystallid slutin in resusitatin. Data sug- gest that balaned rystallids, like latated Ringer slutin r Plasma-Lyte, are assiated with less kidney injury, fewer instanes f hyperhlremi metabli aidsis, and dereased verall mrtality. Cmparisns f 0.9% saline and llid (albumin) slutins in ritially ill patients fund n differene in utme exept in patients with traumati brain injury, where albumin resusitatin led t higher mrtality. Thus, the use f balaned rystallid slutins fr vlume resusitatin in shk is favred. If the patient des nt respnd t fluid resusitatin, early use f vaspressrs shuld be nsidered.D . Early Goal-Directed TherapyCmpensat ed shk an ur in the setting f nrmalized hemdynami parameters with nging glbal tissue hypxia. Traditinal endpints f resusitatin suh as bld pressure, heart rate, urinary utput, mental status, and skin perfusin an therefre be misleading. Fllwing set prtls fr the treatment f septi shk by adjusting the use f fluids, vaspressrs, and intrpes as well as by using bld transfusins t meet hemdynami targets (MAP 65 mm Hg r higher, CVP 812 mm Hg, SvO2 greater than 70%) is termed early goal-directed therapy (EGDT). Latate learane f mre than 10% an be used as a substitute fr SvO2riteria if SvO2mnitring is nt available. Tw large randmized trials published in 2014 (Pr- CESS and ARISE) demnstrated n mrtality benefit frm the institutin f the riginal algrithm fr EGDT, but this may have been due t earlier administratin f antibitis, mpnents f EGDT beming part f the usual are that liniians deliver, and the effetiveness f eduatin abut deteting and treating sepsis in a timely fashin. The Surviving Sepsis Campaigns remmendatins fr patients with sepsis r septi shk are t measure latate level; btain bld ultures prir t administratin f brad-spetrum antibitis, which should occur within 1 hour of sepsis diagnosis; and administer 30 mL/kg rystal- lid fr hyptensin r latate greater than 4 mml/L within the first 3 hurs f presentatin. SmallerCMDT22_Ch12_p0475-p0501.indd  499 29/06/21 8:38 PMCHAPTER 12500 CMDT 2022resusita tin vlumes may be apprpriate fr patients with heart failure, irrhsis, r advaned kidney disease. Vas- pressrs shuld be administered fr hyptensin nt respnsive t initial fluid resusitatin t maintain MAP 65 mm Hg r higher. Remeasure latate if initial level was high, and reassess vlume status and tissue perfusin fre- quently. A meta-analysis f hemdynami ptimizatin trials suggests that early treatment befre the develpment f rgan failure results in imprved survival, and patients wh respnd well t initial effrts demnstrate a survival advantage ver nnrespnders.E.  Medications1.  Vasoactive therapy Vaspressrs and intrpi agents are administered nly after adequate fluid resusitatin. Chie f vasative therapy depends n the presumed etilgy f shk as well as ardia utput. If there is n- tinued hyptensin with evidene f high ardia utput after adequate vlume resusitatin, then vaspressr sup- prt is needed t imprve vasmtr tne. If there is evi- dene f lw ardia utput with high filling pressures, intrpi supprt is needed t imprve ntratility. a. Distributive (vasodilatory) shock When inreased vasnstritin is required t maintain an ade- quate perfusin pressure, alpha-adrenergi atehlamine agnists (suh as nrepinephrine and phenylephrine) are generally used. Althugh nrepinephrine is bth an alpha- adrenergi and beta-adrenergi agnist, it preferentially inreases MAP ver ardia utput. The initial dse is 12 mg/min as an intravenus infusin, titrated t main- tain MAP at 65 mm Hg r higher. The usual maintenane dse is 24 mg/min intravenusly (maximum dse is 30 mg/min). Patients with refratry shk may require dsages f 1030 mg/min intravenusly. Epinephrine, als with bth alpha-adrenergi and beta-adrenergi effets, may be used in severe shk and during aute resusitatin. It is the vaspressr f hie fr anaphylati shk. Fr severe shk, give 1 mg/min as a ntinuus intravenus infusin initially and titrate t hemdynami respnse; the usual dsage range is 110 mg/min intravenusly. Dpamine has variable effets arding t dsage. At lw dses (25 mg/kg/min intravenusly), stimulatin f dpaminergi and beta-adrenergi reeptrs prdues inreased glmerular filtratin, heart rate, and ntratil- ity. At dses f 510 mg/kg/min, beta-1-adrenergi effets predminate, resulting in an inrease in heart rate and ardia ntratility. At higher dses (greater than 10 mg/ kg/min), alpha-adrenergi effets predminate, resulting in peripheral vasnstritin. The maximum dse is typi- ally 50 mg/kg/min. There is n evidene dumenting a survival benefit frm, r the superirity f, a partiular vaspressr in septi shk. Nrepinephrine is the initial vaspressr f hie in septi shk t maintain the MAP at 65 mm Hg r higher. Phenylephrine an be used fr hyperdynami septi shk if dysrhythmias r tahyardias prevent the use f agents with beta-adrenergi ativity. In meta-analyses, the use f dpamine as a first-line vaspressr in septi shk resulted in an increase in 28-day mrtality and a higher inidene farrhythmi events. Dpamine shuld nly be used as an alternative t nrepinephrine in selet patients with septi shk, inluding patients with signifiant bradyardia r lw ptential fr tahyarrhythmias. Vaspressin (antidiureti hrmne r ADH) is ften used as an adjuntive therapy t atehlamine vaspres- srs in the treatment f distributive shk. Vaspressin auses peripheral vasnstritin via V1 reeptrs lated n smth musle ells. Vaspressin als ptentiates the effets f atehlamines n the vasulature and stimulates rtisl prdutin. Intravenus infusin f vaspressin at a lw dse (0.010.04 unit/min) as a send agent t nr- epinephrine has been benefiial in septi patients with hyptensin refratry t fluid resusitatin and nven- tinal atehlamine vaspressrs. Higher dses f vas- pressin derease ardia utput and may put patients at greater risk fr splanhni and rnary artery ishemia. Studies d nt favr the use f vaspressin as first-line therapy. Angitensin II, a mpnent f the renin-angitensin- aldsterne system axis, is a ptent diret vasnstritr that ats n the arteries and veins t inrease bld pres- sure. Angitensin II (marketed as Giapreza) an be nsid- ered as an additional agent in vasdilatry shk that is refratry t atehlamines and vaspressin. The rem- mended starting dse is 20 ng/kg/min via ntinuus intra- venus infusin thrugh a entral venus line. It an be titrated every 5 minutes by inrements f up t 15 ng/kg/ min as needed t ahieve MAP gals, but nt t exeed 80 ng/kg/min during the first 3 hurs f use. Maintenane dses shuld nt exeed 40 ng/kg/min. Cnurrent venus thrmbemblism (VTE) prphylaxis is indiated as studies revealed a higher inidene f VTE with angitensin II use. b. Cardiogenic shock Given meta-analyses du- menting dereased mrtality, expert pinin suggests nr- epinephrine be the first-line vaspressr fr ardigeni shk. Dbutamine, a predminantly beta-adrenergi ag- nist, inreases ntratility and dereases afterlad. It is used fr patients with lw ardia utput and high PCWP but wh d nt have hyptensin. Dbutamine an be added t a vaspressr if there is redued myardial fun- tin (dereased ardia utput and elevated PCWP), r if there are signs f hypperfusin despite adequate vlume resusitatin and an adequate MAP . The initial dse is 0.10.5 mg/kg/min intravenus infusin, whih an be titrated every few minutes t hemdynami effet; the usual dsage range is 220 mg/kg/min intravenusly. Tahyphylaxis an ur after 48 hurs sendary t the dwn-regulatin f beta-adrenergi reeptrs. Amrinne and milrinne are phsphdiesterase inhibitrs that an be substituted fr dbutamine. These drugs inrease yli AMP levels and inrease ardia ntratility, bypassing the beta-adrenergi reeptr. Vasdilatin is a side effet f bth amrinne and milrinne. 2. Antibiotics Definitive therapy fr septi shk inludes early initiatin f empiri brad-spetrum antibitis after apprpriate ultures have been btained and within 1 hur f regnitin f septi shk. Imaging studies may prve useful t attempt lalizatin f sures f infetin.CMDT22_Ch12_p0475-p0501.indd  500 29/06/21 8:38 PMBLOOD VESSEL & LYMPHATIC DISORDERS501 CMDT 2022Surgial  management may als be neessary if nerti tis- sue r lulated infetins are present in attempts t n- trl the sure f infetin (see Table 305). 3. Corticosteroids Crtisterids are the treatment f hie in patients with shk sendary t adrenal insuf- fiieny, defined as a rtisl respnse f 9 mg/dL r less after ne injetin f 250 mg f rtitrpin. Studies supprting rtisterid use in patients with shk frm sepsis r ther etilgies are mixed. Trials where either high r lw dses f rtisterids were administered t patients in septi shk did nt nsistently shw imprved survival. The ADRENAL study demnstrated shrter time t shk reslutin (3 days vs 4 days) but n differene in 90-day mrtality. The APROCCHSS study demnstrated lwer 90-day all-ause mrtality, exept fr thse reeiving hydrrtisne plus fludrrtisne. Ntably, sme wrse utmes were bserved frm inreased rates f sendary infetins. Crtisterids an be administered in refra- try shk t derease shk duratin; the urrent rem- mended regimen is hydrrtisne 50 mg intravenusly every 6 hurs fr 57 days.F . Other Treatment ModalitiesCardia  failure may require use f transutaneus r trans- venus paing r plaement f an intra-arterial balln pump r left ventriular assist devie. Emergent revasu- larizatin by perutaneus angiplasty r rnary arterybypass surgery appears t imprve lng-term utme with inreased survival mpared with initial medial sta- bilizatin fr patients with myardial ishemia leading t ardigeni shk (see Chapter 10). Urgent renal replae- ment therapy may be indiated fr maintenane f fluid and eletrlyte balane during aute kidney injury result- ing in shk frm multiple mdalities.Annane  D et al; CRICS-TRIGGERSEP Netwrk. Hydrrti- sne plus fludrrtisne fr adults with septi shk. N Engl J Med. 2018;378:809. [PMID: 29490185] Gand S et al; Japanese Assiatin fr Aute Mediine (JAAM) Sepsis Prgnstiatin in Intensive Care Unit and Emergeny Rm (SPICE) (JAAM SPICE) Study Grup. The SIRS riteria have better perfrmane fr prediting infetin than qSOFA sres in the emergeny department. Si Rep. 2020;10:8095. [PMID: 32415144] Khanna A et al; ATHOS-3 Investigatrs. Angitensin II fr the treatment f vasdilatry shk. N Engl J Med. 2017;377:419. [PMID: 28528561] Rhdes A et al. Surviving Sepsis Campaign: internatinal guide- lines fr management f sepsis and septi shk: 2016. Crit Care Med. 2017;45:486. [PMID: 28098591] Thiele H et al. Management f ardigeni shk mpliating myardial infartin: an update 2019. Eur Heart J. 2019;40:2671. [PMID: 31274157] Venkatesh B et al; ADRENAL Trial Investigatrs and the AustralianNew Zealand Intensive Care Siety Clinial Trials Grup. Adjuntive glurtiid therapy in patients with septi shk. N Engl J Med. 2018;378:797. [PMID: 29347874]CMDT22_Ch12_p0475-p0501.indd  501 29/06/21 8:38 PM502 CMDT 2022 ANEMIAS General Approach to AnemiasAnemia is presen t in adults if the hematocrit is below 41% (hemoglobin less than 13.6 g/dL [135 g/L]) in males or below 36% (hemoglobin less than 12 g/dL [120 g/L]) in females. Congenital anemia is suggested by the patients personal and family history. The most common cause of anemia is iron deficiency. Poor diet may result in folic acid deficiency and contribute to iron deficiency, but bleeding is the most common cause of iron deficiency in adults. Physi- cal examination demonstrates pallor. Attention to physical signs of primary hematologic diseases (lymphadenopathy; hepatosplenomegaly; or bone tenderness, especially in the sternum or anterior tibia) is important. Mucosal changes such as a smooth tongue suggest megaloblastic anemia. Anemias are classified according to their pathophysiologic basis, ie, whether related to diminished production (relative or absolute reticulocytopenia) or to increased production due to accelerated loss of red blood cells (reticulocytosis) (Table 131), and according to red blood cell size (Table 132). A reticulocy- tosis occurs in one of three pathophysiologic states: acute blood loss, recent replacement of a missing erythropoietic nutrient, or reduced red blood cell survival (ie, hemolysis). A severely microcytic anemia (mean corpuscular volume [MCV] less than 70 fL) is due either to iron deficiency or thalassemia, while a severely macrocytic anemia (MCV greater than 120 fL) is almost always due to either megaloblastic anemia or to cold agglutinins in blood analyzed at room temperature. A bone marrow biopsy is generally needed to complete the evaluation of anemia when the blood laboratory evaluation fails to reveal an etiology, when there are additional cytopenias present, or when an underlying primary or secondary bone marrow pro- cess is suspected.IR ON DEFICIENCY ANEMIAE S S E N T I A L S  O F  D I A G N O S I S Iron deficiency: serum ferritin is < 12 ng/mL (27 pmol/L) or < 30 ng/mL (67 pmol/L) if also anemic.13Lloyd E. Damon, MD Charalambos Babis Andreadis, MD, MSCEBlood Disorders Caused by bleeding unless proved otherwise. Responds to iron therapy. General ConsiderationsIro n deficiency is the most common cause of anemia worldwide. The causes are listed in Table 133. Aside from circulating red blood cells, the major location of iron in the body is the storage pool as ferritin or as hemosiderin in macrophages. The average American diet contains 1015 mg of iron per day. About 10% of this amount is absorbed in the stomach, duodenum, and upper jejunum under acidic conditions. Dietary iron present as heme is efficiently absorbed (1020%) but nonheme iron less so (15%), largely because of interfer- ence by phosphates, tannins, and other food constituents. The major iron transporter from the diet across the intestinal lumen is ferroportin, which also facilitates the transport of iron to apotransferrin in macrophages for delivery to ery- throid progenitor cells in the bone marrow prepared to syn- thesize hemoglobin. Hepcidin, which is increasingly produced during inflammation, negatively regulates iron transport by promoting the degradation of ferroportin. Small amounts of ironapproximately 1 mg/dayare normally lost through exfoliation of skin and gastrointestinal mucosal cells. Menstrual blood loss plays a major role in iron metabo- lism. The average monthly menstrual blood loss is approxi- mately 50 mL but may be five times greater in some individuals. Women with heavy menstrual losses must absorb 34 mg of iron from the diet each day to maintain adequate iron stores, which is not commonly achieved. Women with menorrhagia of this degree will almost always become iron deficient without iron supplementation. In general, iron metabolism is balanced between absorp- tion of 1 mg/day and loss of 1 mg/day. Pregnancy and lacta- tion upset the iron balance, since requirements increase to 25 mg of iron per day. Normal dietary iron cannot supply these requirements, and medicinal iron is needed during pregnancy and lactation. Decreased iron absorption can also cause iron deficiency, such as in people affected by celiac disease (gluten enteropathy), and it also commonly occurs after gastric resection or jejunal bypass surgery.CMDT22_Ch13_p0502-p0547.indd  502 29/06/21 8:38 PM",
                  "Chapter 11444 CMDT 2022Elev ated BP reading (office, home or pharmacy) No hypertension6White coat  hypertension6HypertensionDedicated office visit1Mean of fice BP  180/110 mm Hg No Diabetes Diabetes31 .AOBP2 135/85 mm Hg (preferred) 2.Non-AOBP2 140/90 mm Hg (if AOBP unavailable)AOBP or non-AOBP2 1 30/80 mm HgOR Out-of-office measurement41 .ABPM (preferred) Daytime mean  135/85 mm Hg 24-hour mean  130/80 mm Hg 2.Home BP series5 Mean  135/85 mm HgORYes YesNo NoYesNo1. If AOBP is used, use the mean calculated and displayed by the device. If non-AOBP is used, take at least three readings, discard the first and calculate the mean of the remaining measurements. A history and physical examination should be performed and diagnostic tests ordered. 2.AOBP is performed with the patient unattended in a private area. Non-AOBP is performed using an electronic upper arm device with the provider in the room. 3. Diagnostic thresholds for AOBP, ABPM, and home BP in patients with diabetes have yet to be established (and may be lower than 130/80 mm Hg). 4. Serial office measurements over 35 visits can be used if ABPM or home measurement not available. 5. Home BP series: Two readings taken each morning and evening for 7 days (28 total). Discard first day readings and average the last 6 days. 6. Annual BP measurement is recommended to detect progression to hypertension.Notes: Figure 111. According to these recommendations, if AOBP measurements are not available, blood pressures recorded manually in the office may be substituted if taken as the mean of the last two readings of three consecu- tive readings. Note that the blood pressure threshold for diagnosing hypertension is higher if recorded manually in these guidelines. If home blood pressure monitoring is unavailable, office measurements recorded over three to five separate visits can be substituted. ABPM, ambulatory blood pressure measurement; AOBP , automated office blood pressure; BP , blood pressure. (Reproduced, with permission, from Leung AA et al; Hypertension Canada. Hyper- tension Canadas 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can J Cardiol. 2017;33:557. Copyright  2017 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.) Table 111. Corresponding blood pressure values across a range of blood pressure measurement methods.Mnul  Msumn in Clinic1hom Blood pssu Msumnambuloy Blood pssu Msumn (Dyim)ambuloy Blood pssu Msumn (Nigim)ambuloy Blood pssu Msumn (24-hou) 120/80 mm Hg 120/80 mm Hg 120/80 mm Hg 100/65 mm Hg 115/75 mm Hg 130/80 mm Hg 130/80 mm Hg 130/80 mm Hg 110/65 mm Hg 125/75 mm Hg 140/90 mm Hg 135/85 mm Hg 135/85 mm Hg 120/70 mm Hg 130/80 mm Hg 160/100 mm Hg 145/90 mm Hg 145/90 mm Hg 140/85 mm Hg 145/90 mm Hg1 Clinic manual blood pressures are critically dependent on technique. The use of automated devices in an unattended setting typi cally result in systolic blood pressures 913 mm Hg lower than clinic manual pressures. Data abstracted from Greenland P et al. The New 2017 ACC/AHA Guidelines up the pressure on diagnosis and treatment of hyperten sion. JAMA. 2017;318:2083.CMDT22_Ch11_p0443-p0474.indd  444 29/06/21 8:37 PMSYSteMIC hYperteNSION445 CMDT 2022I t is important to recognize that the diagnosis of hyper- tension does not automatically entail drug treatment; this decision depends on the clinical setting and evaluation of cardiovascular risk, as discussed below.Greenland  P et al. The New 2017 ACC/AHA Guidelines up the pressure on diagnosis and treatment of hypertension. JAMA. 2017;318:2083. [PMID: 29159417] Jin J. JAMA patient page. Checking blood pressure at home. JAMA. 2017;318:310. [PMID: 28719694] Leung AA et al; Hypertension Canada. Hypertension Canadas 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can J Cardiol. 2017;33:557. [PMID: 28449828] Melville S et al. Out-of-office blood pressure monitoring in 2018. JAMA. 2018;320:1805. [PMID: 30398589] Myers MG. Automated office blood pressureincorporating SPRINT into clinical practice. Am J Hypertens. 2017;30:8. [PMID: 27551025]AP PROACH TO HYPERTENSION Etiology & ClassificationA.  Primary Essential HypertensionEssential  hypertension is the term applied to the 95% of hypertensive patients in which elevated blood pressure results from complex interactions between multiple genetic and environmental factors. Blood pressure elevation above 140/90 mm Hg occurs in 1015% of White adults and 2030% of Black adults in the United States. The onset is usually between ages 25 and 50 years; it is uncommon before age 20 years. The best understood pathways under- lying hypertension include overactivation of the sympa- thetic nervous and renin-angiotensin-aldosterone systems (RAAS), blunting of the pressure-natriuresis relationship, variation in cardiovascular and renal development, and elevated intracellular sodium and calcium levels. Exacerbating factors include obesity, sleep apnea, increased salt intake, excessive alcohol use, cigarette smok- ing, polycythemia, nonsteroidal anti-inflammatory drug (NSAID) therapy, and low potassium intake. Obesity is associated with an increase in intravascular volume, ele- vated cardiac output, activation of the renin-angiotensin system, and, probably, increased sympathetic outflow. Life- style-driven weight reduction lowers blood pressure mod- estly, but the dramatic weight reduction following bariatric surgery results in improved blood pressure in most patients, and actual remission of hypertension in 2040% of cases. In patients with sleep apnea, treatment with continuous posi- tive airway pressure (CPAP) has been associated with improvements in blood pressure. Increased salt intake probably elevates blood pressure in some individuals so dietary salt restriction is recommended in patients with hypertension. Excessive use of alcohol also raises blood pressure, perhaps by increasing plasma catecholamines. Hypertension can be difficult to control in patients who consume more than 40 g of ethanol (two drinks) daily or drink in binges.  Cigarette smoking raises blood pressure by increasing plasma norepinephrine. Although the long- term effect of smoking on blood pressure is less clear, the synergistic effects of smoking and high blood pressure oncardiovascular risk are well documented. The relationship of exercise to hypertension is variable. Aerobic exercise low- ers blood pressure in previously sedentary individuals, but increasingly strenuous exercise in already active subjects has less effect. The relationship between stress and hyper- tension is not established. Polycythemia, whether primary, drug-induced, or due to diminished plasma volume, increases blood viscosity and may raise blood pressure. NSAIDs produce increases in blood pressure averaging 5 mm Hg and are best avoided in patients with borderline or elevated blood pressures. Low potassium intake is associ- ated with higher blood pressure in some patients; an intake of 90 mmol/day is recommended. The complex of abnormalities termed the metabolic syndrome (upper body obesity, insulin resistance, and hypertriglyceridemia) is associated with both the develop- ment of hypertension and an increased risk of adverse cardiovascular outcomes. Affected patients usually also have low high-density lipoprotein (HDL) cholesterol levels and elevated catecholamines and inflammatory markers such as C-reactive protein.B.  Secondary HypertensionA pproximately 5% of patients have hypertension second- ary to identifiable specific causes (Table 112). Secondary hypertension should be suspected in patients in whom hypertension develops at an early age or after the age of 50 years, and in those previously well controlled who become refractory to treatment. Hypertension resistant to maximum doses of three medications is another clue, although multiple medications are usually required to con- trol hypertension in persons with diabetes. 1. Genetic causes Hypertension can be caused by muta- tions in single genes, inherited on a Mendelian basis. Although rare, these conditions provide important insight into blood pressure regulation and possibly the genetic basis of essential hypertension. Glucocorticoid remediable aldosteronism is an autosomal dominant cause of early- onset hypertension with normal or high aldosterone and low renin levels. The syndrome of hypertension exacer- bated in pregnancy is inherited as an autosomal dominant trait. In these patients, a mutation in the mineralocorticoid receptor makes it abnormally responsive to progesterone and, paradoxically, to spironolactone. 2. Kidney disease Renal parenchymal disease is the most common cause of secondary hypertension, which results from increased intravascular volume and increased activity of the RAAS. Increased sympathetic nerve activity may also contribute. 3. Renal vascular hypertension Renal artery stenosis is present in 12% of hypertensive patients. The most com- mon cause is atherosclerosis, but fibromuscular dysplasia should be suspected in women under 50 years of age. Excessive renin release occurs due to reduction in renal perfusion pressure, while attenuation of pressure natriure- sis contributes to hypertension in patients with a single kidney or bilateral lesions. Activation of the renal sympa- thetic nerves may also be important.CMDT22_Ch11_p0443-p0474.indd  445 29/06/21 8:37 PMChapter 11446 CMDT 2022Renal vascula r hypertension should be suspected in the following circumstances: (1) the documented onset is before age 20 or after age 50 years, (2) the hypertension is resistant to three or more drugs, (3) there are epigastric or renal artery bruits, (4) there is atherosclerotic disease of the aorta or peripheral arteries (1525% of patients with symp- tomatic lower limb atherosclerotic vascular disease have renal artery stenosis), (5) there is an abrupt increase (more than 25%) in the level of serum creatinine after administra- tion of angiotensin-converting enzyme (ACE) inhibitors, or (6) episodes of pulmonary edema are associated with abrupt surges in blood pressure. (See Renal Artery Stenosis, Chapter 22.) 4. Primary hyperaldosteronism Hyperaldosteronism should be considered in people with resistant hypertension, blood pressures consistently greater than 150/100 mm Hg, hypokalemia (although this is often absent), or adrenal incidentaloma, and in those with a family history of hyper- aldosteronism. Mild hypernatremia and metabolic alkalo- sis may also occur. Hypersecretion of aldosterone is estimated to be present in 510% of hypertensive patientsand, besides noncompliance, is the most common cause of resistant hypertension. The initial screening step is the simultaneous measurement of aldosterone and renin in blood in a morning sample collected after 30 minutes qui- etly seated. Hyperaldosteronism is suggested when the plasma aldosterone concentration is elevated (normal: 116 ng/dL) in association with suppression of plasma renin activity (normal: 12.5 ng/mL/h). However, the plasma aldosterone/renin ratio (normal less than 30) is not highly specific as a screening test. This is because renin levels may approach zero, which leads to exponential increases in the plasma aldosterone/renin ratio even when aldosterone levels are normal. Hence, an elevated plasma aldosterone/renin ratio should probably not be taken as evidence of hyperaldosteronism unless the aldosterone level is actually elevated. During the workup for hyperaldosteronism, an initial plasma aldosterone/renin ratio can be measured while the patient continues taking usual medications. If under these circumstances the ratio proves normal or equivocal, medica- tions that alter renin and aldosterone levels, including ACE inhibitors, angiotensin receptor blockers (ARBs), diuretics, beta-blockers, and clonidine, should be discontinued for 2 weeks before repeating the plasma aldosterone/renin ratio; spironolactone and eplerenone should be held for 4 weeks. Slow-release verapamil and alpha-receptor blockers can be used to control blood pressure during this drug washout period. Patients with a plasma aldosterone level greater than 16 ng/dL and an aldosterone/renin ratio of 30 or more might require further evaluation for primary hyperaldosteronism. The lesion responsible for hyperaldosteronism is an adrenal adenoma or bilateral adrenal hyperplasia. 5. Cushing syndrome Hypertension occurs in about 80% of patients with spontaneous Cushing syndrome. Excess glucocorticoid may act through salt and water retention (via mineralocorticoid effects), increased angiotensinogen lev- els, or permissive effects in the regulation of vascular tone. Diagnosis and treatment of Cushing syndrome are dis- cussed in Chapter 26. 6. Pheochromocytoma Pheochromocytomas are uncom- mon; they are probably found in less than 0.1% of all patients with hypertension and in approximately two indi- viduals per million population. Chronic vasoconstriction of the arterial and venous beds leads to a reduction in plasma volume and predisposes to postural hypotension. Glucose intolerance develops in some patients. Hypertensive crisis in pheochromocytoma may be precipitated by a variety of drugs, including tricyclic antidepressants, antidopaminer- gic agents, metoclopramide, and naloxone. The diagnosis and treatment of pheochromocytoma are discussed in Chapter 26. 7. Coarctation of the aorta This uncommon cause of hypertension is discussed in Chapter 10. Evidence of radial-femoral delay should be sought in all younger patients with hypertension. 8. Hypertension associated with pregnancy Hypertension occurring de novo or worsening during pregnancy, includ- ing preeclampsia and eclampsia, is one of the most commonTable 112. Causes of secondary hypertension.endocin Conn syndrome (hyperaldosteronism) Licorice Cushing syndrome (hypercortisolism) Thyroid disease Pheochromocytoma Acromegaly Mutations in steroid gene regulatory domains Hypercalcemia rnl Parenchymal kidney disease Polycystic kidney disease Systemic sclerosis (scleroderma) Page kidney Mutations in genes encoding ion transport proteins Vscul Renal artery stenosis Coarctation auonomic Stress Neurogenic Mdicions Nonsteroidal anti-inflammatory drugs Corticosteroids Calcineurin inhibitors Stimulants Decongestants Angiogenesis inhibitors Tyrosine kinase inhibitors Estrogen Erythropoietin Alcohol, cocaine Gemcitabine Atypical antipsychotics Monoamine oxidase inhibitors O Obstructive sleep apnea PregnancyCMDT22_Ch11_p0443-p0474.indd  446 29/06/21 8:37 PMSYSteMIC hYperteNSION447 CMDT 2022cau ses of maternal and fetal morbidity and mortality (see Chapter 19). Autoantibodies with the potential to activate the angiotensin II type 1 receptor have been caus- ally implicated in preeclampsia, in resistant hypertension, and in progressive systemic sclerosis. 9. Estrogen use A small increase in blood pressure occurs in most women taking oral contraceptives. A more significant increase of 8/6 mm Hg systolic/diastolic is noted in about 5% of women, mostly in obese individuals older than age 35 who have been treated for more than 5 years. This is caused by increased hepatic synthesis of angiotensinogen. The lower dose of postmenopausal estro- gen does not generally cause hypertension but rather main- tains endothelium-mediated vasodilation. 10. Other causes of secondary hypertension Hypertension has been associated with hypercalcemia, acromegaly, hyper- thyroidism, hypothyroidism, baroreceptor denervation, com- pression of the rostral ventrolateral medulla, and increased intracranial pressure. Certain medications may cause or exac- erbate hypertensionmost importantly cyclosporine, tacroli- mus, angiogenesis inhibitors, and erythrocyte-stimulating agents (such as erythropoietin). Decongestants, NSAIDs, cocaine, and alcohol should also be considered. Over-the- counter products should not be overlooked, eg, a dietary sup- plement marketed to enhance libido was found to contain yohimbine, an alpha-2antagonist, which can produce severe rebound hypertension in patients taking clonidine. When to ReferReferra l to a hypertension specialist should be considered in cases of severe, resistant or early-/late-onset hypertension or when secondary hypertension is suggested by screening.Byrd  JB et al. Primary aldosteronism. Circulation. 2018;138:823. [PMID: 30359120] Herrmann SM et al. Renovascular hypertension. Endocrinol Metab Clin North Am. 2019;48:765. [PMID: 31655775] Complications of Untreated HypertensionM ost of the adverse outcomes in hypertension are associated with thrombosis rather than bleeding, possibly because increased vascular shear stress converts the normally antico- agulant endothelium to a prothrombotic state. The excess morbidity and mortality related to hypertension approxi- mately doubles for each 6 mm Hg increase in diastolic blood pressure. However, target-organ damage varies markedly between individuals with similar levels of office hyperten- sion; home and ambulatory pressures are superior to office readings in the prediction of end-organ damage (Table 111).A.  Hypertensive Cardiovascular DiseaseCardiac  complications are the major causes of morbidity and mortality in primary (essential) hypertension. For any level of blood pressure, left ventricular hypertrophy is asso- ciated with incremental cardiovascular risk in association with heart failure (through systolic or diastolic dysfunc- tion), ventricular arrhythmias, myocardial ischemia, and sudden death.The occurrence of heart failure is reduced by 50% with antihypertensive therapy. Hypertensive left ventricular hypertrophy regresses with therapy and is most closely related to the degree of systolic blood pressure reduction. Diuretics have produced equal or greater reductions of left ventricular mass when compared with other drug classes. Conventional beta-blockers are less effective in reducing left ventricular hypertrophy but play a specific role in patients with established coronary artery disease or impaired left ventricular function.B.  Hypertensive Cerebrovascular Disease and DementiaH ypertension is the major predisposing cause of hemor- rhagic and ischemic stroke. Cerebrovascular complications are more closely correlated with systolic than diastolic blood pressure. The incidence of these complications is markedly reduced by antihypertensive therapy. Preceding hypertension is associated with a higher incidence of sub- sequent dementia of both vascular and Alzheimer types. Home and ambulatory blood pressure may be a better predictor of cognitive decline than office readings in older people. Effective blood pressure control reduces the risk of cognitive dysfunction developing later in life.C.  Hypertensive Kidney DiseaseCh ronic hypertension is associated with injury to vascular, glomerular, and tubulointerstitial compartments within the kidney, accounting for about 25% of end-stage kidney disease. Nephrosclerosis is particularly prevalent in Blacks, in whom susceptibility is linked to APOL1 mutations and hypertension results from kidney disease rather than causing it.D . Aortic DissectionH ypertension is a contributing factor in many patients with dissection of the aorta. Its diagnosis and treatment are discussed in Chapter 12.E.  Atherosclerotic ComplicationsMost  Americans with hypertension die of complications of atherosclerosis, but antihypertensive therapy seems to have a lesser impact on atherosclerotic complications compared with heart failure, stroke, and kidney disease. Prevention of cardiovascular outcomes related to atherosclerosis proba- bly requires control of multiple risk factors, of which hypertension is only one.Seccia TM  et al. Hypertensive nephropathy. Moving from classic to emerging pathogenetic mechanisms. J Hypertens. 2017;35:205. [PMID: 27782909] Supiano MA et al. New guidelines and SPRINT results: implica- tions for geriatric hypertension. Circulation. 2019;140:976. [PMID: 31525101] Clinical FindingsThe  clinical and laboratory findings are mainly referable to involvement of the target organs: heart, brain, kidneys, eyes, and peripheral arteries.CMDT22_Ch11_p0443-p0474.indd  447 29/06/21 8:37 PMChapter 11448 CMDT 2022A.  SymptomsMild  to moderate primary (essential) hypertension is largely asymptomatic for many years. The most frequent symptom, headache, is also nonspecific. Accelerated hyper- tension is associated with somnolence, confusion, visual disturbances, and nausea and vomiting (hypertensive encephalopathy). Hypertension in patients with pheochromocytomas that secrete predominantly norepinephrine is usually sustained but may be episodic. The typical attack lasts from minutes to hours and is associated with headache, anxiety, palpitation, profuse perspiration, pallor, tremor, and nausea and vomit- ing. Blood pressure is markedly elevated, and angina or acute pulmonary edema may occur. In primary aldosteron- ism, patients may have muscular weakness, polyuria, and nocturia due to hypokalemia; hypertensive emergency is rare. Chronic hypertension often leads to left ventricular hypertrophy and diastolic dysfunction, which can present with exertional and paroxysmal nocturnal dyspnea. Cerebral involvement causes stroke due to thrombosis or hemorrhage from microaneurysms of small penetrating intracranial arteries. Hypertensive encephalopathy is probably caused by acute capillary congestion and exudation with cerebral edema and may present as posterior reversible encephalopa- thy syndrome, comprising headache, visual disturbances, altered mental state, and seizures. These symptoms usually improve rapidly with control of hypertension.B.  SignsLike  symptoms, physical findings depend on the cause of hypertension, its duration and severity, and the degree of effect on target organs. 1. Blood pressure Blood pressure is taken in both arms and, if lower extremity pulses are diminished or delayed, in the legs to exclude coarctation of the aorta. If blood pres- sure differs between right and left arms, the higher reading should be recorded as the actual blood pressure and subcla- vian stenosis suspected in the other arm. An orthostatic drop of at least 20/10 mm Hg is often present in pheochro- mocytoma. Older patients may have falsely elevated read- ings by sphygmomanometry because of noncompressible vessels. This may be suspected in the presence of Osler signa palpable brachial or radial artery when the cuff is inflated above systolic pressure. Occasionally, it may be necessary to make direct measurements of intra-arterial pressure, especially in patients with apparent severe hyper- tension who do not tolerate therapy. 2. Retinas Narrowing of arterial diameter to less than 50% of venous diameter, copper or silver wire appearance, exudates, hemorrhages, and hypertensive retinopathy are associated with a worse prognosis. The typical changes of severe hypertensive retinopathy are shown in Figure 112 (see Chapter 7). 3. Heart A left ventricular heave indicates severe hyper- trophy. Aortic regurgitation may be auscultated in up to 5% of patients, and hemodynamically insignificant aortic regurgitation can be detected by Doppler echocardiogra- phy in 1020%. A presystolic (S4) gallop due to decreasedcompliance of the left ventricle is quite common in patients in sinus rhythm. 4. Pulses Radial-femoral delay suggests coarctation of the aorta; loss of peripheral pulses occurs due to atherosclero- sis, less commonly aortic dissection, and rarely Takayasu arteritis, all of which can involve the renal arteries.C.  Laboratory FindingsRecommended  testing includes hemoglobin; serum elec- trolytes and serum creatinine; fasting blood sugar level (hypertension is a risk factor for the development of diabe- tes, and hyperglycemia can be a presenting feature of pheo- chromocytoma); plasma lipids (necessary to calculate cardiovascular risk and as a modifiable risk factor); serum uric acid (hyperuricemia is a relative contraindication to diuretic therapy); and urinalysis.D . Electrocardiography and Chest RadiographsElectrocardiographic  criteria are highly specific but not very sensitive for left ventricular hypertrophy. The strain pattern of STT wave changes is a sign of more advanced disease and is associated with a poor prognosis. A chest radiograph is not necessary in the workup for uncompli- cated hypertension.E.  EchocardiographyThe primary  role of echocardiography should be to evalu- ate patients with clinical symptoms or signs of cardiac disease.F . Diagnostic StudiesAddi tional diagnostic studies are indicated only if the clini- cal presentation or routine tests suggest secondary or com- plicated hypertension. These may include 24-hour urine free cortisol, urine or plasma metanephrines, and plasma Figure 112. Severe, chronic hypertensive retinopa- thy with hard exudates, increased vessel light reflexes, and sausage-shaped veins. (Used, with permission, from Richard E. Wyszynski, MD, in Knoop KJ, Stack LB, Storrow AB, Thurman RJ. The Atlas of Emergency Medicine , 4th ed. McGraw-Hill, 2016.)CMDT22_Ch11_p0443-p0474.indd  448 29/06/21 8:37 PMSYSteMIC hYperteNSION449 CMDT 2022aldostero ne and renin concentrations to screen for endo- crine causes of hypertension. Renal ultrasound will detect structural changes (such as polycystic kidneys, asymmetry, and hydronephrosis); echogenicity and reduced cortical volume are reliable indicators of advanced chronic kidney disease. Evaluation for renal artery stenosis should be undertaken in concert with subspecialist consultation.G.  SummarySince  most hypertension is essential or primary, few studies are necessary beyond those listed above. If conventional therapy is unsuccessful or if secondary hypertension is suspected, further studies and perhaps referral to a hyper- tension specialist are indicated. Nonpharmacologic TherapyLife style modification is recommended in all patients with elevated blood pressure. A diet rich in fruits, vegeta- bles, and low-fat dairy foods and low in saturated and total fats (DASH diet) has been shown to lower blood pressure. Increased dietary fiber lowers blood pressure. For every 7 g of dietary fiber ingested, cardiovascular risk could be lowered by 9%. The effect of diet on blood pres- sure may be mediated by shifts in the microbial species in the gut, the intestinal microbiota. Hand squeezing exer- cises three times a week can lower systolic blood pressure by 6 mm Hg. The protocol comprises four repeats of 2 minutes at 30% of maximum force (using a handheld dynamometer) with 1- to 3-minute rest intervals between squeezes. The acute increase in systolic blood pressure during vigorous exercise, known as the exercise pressor response, is around 50 mm Hg in normal individuals. In hypertensive persons, the exercise pressor response is elevated to about 75 mm Hg above resting systolic blood pressure. This exaggerated response is not reduced by antihypertensive medications, even in those with other- wise controlled hypertension, and is exacerbated by increased dietary sodium intake. Additional lifestyle changes, listed in Table 113, can prevent or mitigate hypertension or its cardiovascular consequences.Fu J et  al. Nonpharmacologic interventions for reducing blood pressure in adults with prehypertension to established hypertension. J Am Heart Assoc. 2020;9:e016804. [PMID: 32975166] Smart NA et al. An evidence-based analysis of managing hyper- tension with isometric resistance exerciseare the guidelines current? Hypertens Res. 2020;43:249. [PMID: 31758166] Who Should Be Treated With Medications?T reatment should be offered to all persons in whom blood pressure reduction, irrespective of initial blood pressure levels, will reduce cardiovascular risk with an acceptably low rate of medication-associated adverse effects. The American College of Cardiology and the American Heart Association (ACC/ AHA), Hypertension Canada (HC), and the European Soci- ety of Hypertension and European Society of Cardiology(ESH/ESC) have developed independent guidelines for the evaluation and management of hypertension. There is broad agreement that drug treatment is necessary in those with office-based blood pressures exceeding 160/100 mm Hg, irrespective of cardiac risk. Similarly, the American, Canadian, and European guidelines agree that treatment thresholds should be lower in the presence of elevated car- diovascular risk. American guidelines stand apart in recom- mending initiation of antihypertensive pharmacotherapy in those with blood pressure of 140159/9099 mm Hg, even if cardiovascular risk is not elevated. By contrast, the Cana- dian guidelines suggest lifestyle modifications in this low- cardiovascular-risk group, while the European guidelines recommend initiation of pharmacotherapy only if elevated pressure in this low-risk population persists after lifestyle modification. There is no outcomes evidence that mortal- ity or risk of cardiovascular events can be reduced by treat- ing mild hypertension (140/90160/100 mm Hg) in low-risk individuals. Table 114 compares these three sets of guidelines. Since evaluation of total cardiovascular risk (Table 115) is important in deciding who to treat with antihypertensive medications, risk calculators are essential clinical tools. The ACC has an online toolkit relevant to primary prevention (https://tools.acc.org/ascvd-risk- estimator-plus/#!/calculate/estimate/), and an associated app called ASCVD Risk Estimator Plus (downloadable at https://www.acc.org/ASCVDApp). Goals of TreatmentT raditionally, the most widely accepted goal for blood pres- sure management has been less than 140/90 mm Hg. How- ever, observational studies suggest that there does not seem to be a blood pressure level below which decrements in cardiovascular risk taper off, and a number of randomized controlled trials have suggested that treatment to bloodTable 113. The impact of lifestyle modifications.Modific- ion Invnionrsuling Dcs in Blood pssu Weight loss Target BMI 18.524.9 520 mm Hg/ 10-kg loss DASH diet Fruit, vegetables, low fat dairy814 mm Hg Sodium intake< 100 mmol/day (< 6 g salt)28 mm Hg Alcohol intakeMale  2 drinks/day Female  1 drink/day4 mm Hg Exercise Aerobic 30 min/day Dynamic 90-150 min/week Isometric (hand grip 4 rep- etitions 3 times/week)510 mm Hg Mindfulness Meditation and breathing control5 mm Hg BMI, body mass index; DASH, Dietary Approaches to Stop Hypertension.CMDT22_Ch11_p0443-p0474.indd  449 29/06/21 8:37 PMChapter 11450 CMDT 2022pres sure targets considerably below 140 mm Hg may ben- efit certain patient groups. The SPRINT study suggests that outcomes improve in nondiabetic patients with considerably elevated cardiovascu- lar risk when treatment lowers systolic pressure to less than 120 mm Hg compared to less than 140 mm Hg. On the other hand, in the HOPE3 study of largely nondiabetic patients at somewhat lower risk than those in SPRINT, reducing blood pressure by an average of 6/3 mm Hg systolic/diastolic from a baseline of 138/82 mm Hg provided no significant out- comes benefits. Therefore, it appears that blood pressure targets should be lower in people at greater estimated cardio- vascular risk. In response to the SPRINT study, the 2018 Hypertension Canada guidelines urge prescribers to consider a blood pressure goal of less than 120/80 mm Hg in patients considered at elevated risk for cardiovascular events. The 2017 ACC/AHA guidelines take a different approach by defining a 130/80 mm Hg goal as reasonable in nonelevated risk patients, strengthening this to recommended in ele- vated risk hypertensive patients. The 2018 ESH/ESC guide- lines specify a target of less than 140 mm Hg systolic for all, and less than 130 mm Hg for most if tolerated. There is a trend toward recommending similar treatment targets in the elderly; this topic is discussed in greater detail below. Some experts note that manual office measurements of around 130/80 mm Hg are likely to approximate the lower blood pressure targets specified in the SPRINT study, which used automated office blood pressure measuring devices that have been demonstrated to read as much as 16/7 mm Hg lowerTable 114. Comparison of blood pressure treatment thresholds from the 2017 ACC/AHA guidelines, the 2018 Hypertension Canada guidelines, and the 2018 ESH/ESC guidelines.Guidlins 1Cdiovscul risktsold fo pmcoy (mm hg) tg (mm hg) ACC/AHA Not increased > 140/90 < 130/80 (reasonable) Hypertension Canada Not increased > 160/100 < 140/90 (< 130/80 for diabetes) ESH/ESC Not increased > 140/902All < 140/90, most < 130/80, not < 120 ACC/AHA Increased < 130/80 < 130/80 (recommended) Hypertension Canada Increased > 140 systolic3< 120 systolic ESH/ESC Increased > 130/803120130/< 80 ACC/AHA > 65 yr Risk due to advanced age > 130/80 < 130 systolic Hypertension Canada4Increased Not specified4Not specified4ESH/ESC  > 65 yr Not increased > 140/905130140/> 806 1In all three sets of guidelines, blood pressure values are based upon nonautomated office blood pressure readings.2 Consider drug treatment if lifestyle changes fail to control blood pressure.3 Consider drug treatment if very high risk, eg, established cardiovascular disease, especially coronary disease. Note: The > 130/80 mm Hg threshold for treatment of high-risk patients in the Canadian guidelines refers to automated blood pressure readings, which are lower than nonautomated readings.4 Recommendations for persons > 75 years are not explicitly stated in the Hypertension Canada guidelines. They removed separate g oals for the elderly but consider age > 75 years to be a risk signifier triggering an approach that many would view as overly aggres sive in the extremely old.5 The European guidelines indicate a slightly more conservative treatment threshold of > 160/90 mm Hg for those > 80 years.6 This target range is also suggested in the European guidelines for patients > 80 years. ACC, American College of Cardiology; AHA, American Heart Association; ESC, European Society of Cardiology; ESH, European Societ y of Hypertension.T able 115. Cardiovascular risk factors.Mjo  isk fcos Hypertension1 Cigarette smoking Obesity (BMI  30)1 Physical inactivity Dyslipidemia1 Diabetes mellitus1 Microalbuminuria or estimated GFR < 60 mL/min/1.73 m2 Age (> 55 years for men, > 65 years for women) Family history of premature cardiovascular disease (< 55 years for men, < 65 years for women) tg-ogn dmg Heart Left ventricular hypertrophy Angina or prior myocardial infarction Prior coronary revascularization Heart failure Brain Stroke or transient ischemic attack Chronic kidney disease Peripheral arterial disease Retinopathy1 Components of the metabolic syndrome. BMI, body mass index; GFR, glomerular filtration rate. Data from Chobanian AV et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21;289(19):256072.CMDT22_Ch11_p0443-p0474.indd  450 29/06/21 8:37 PMSYSteMIC hYperteNSION451 CMDT 2022th an manual office readings. The 2018 Canadian guidelines acknowledge this disparity in measurement methods by specifying that automated office devices should be used in the monitoring of patients selected for the aggressive blood pres- sure goal of less than 120/80 mm Hg. Table 114 compares the treatment threshold and target recommendations laid out in the American, Canadian, and European guidelines. Treatment to blood pressures less than 130 mm Hg systolic seems especially important in stroke prevention. The ACCORD study examined the effect of treatment of systolic pressures to below 130135 mm Hg in patients with diabetes; the studys two by two factorial design addressed glycemic control as well as blood pressure con- trol. In the original analysis, the lower blood pressure treat- ment goal significantly increased the risk of serious adverse effects (with no additional gain in terms of heart, kidney, or retinal disease). There was, however, significant additional reduction in the risk of stroke, indicating that lower blood pressure targets might be justified in diabetic patients at high risk for cerebrovascular events. Post hoc analysis of the ACCORD study after 9 years of follow-up suggested that a beneficial effect of lower blood pressure in older high-risk persons (mostly on nonfatal myocardial infarctions) could be detected in the standard glycemic control group. Similarly, in the SPS3 trial in patients who have had a lacunar stroke, treating the systolic blood pressure to less than 130 mm Hg (mean systolic blood pressure of 127 mm Hg among treated versus mean systolic blood pressure 138 mm Hg among untreated patients) probably reduced the risk of recurrent stroke (and with an acceptably low rate of adverse effects from treatment). Blood pressure manage- ment in acute stroke is discussed below. How Low To Go?Alth ough observational studies indicate that the blood pressure-risk relationship holds up at levels considerably below 120 mm Hg, there is uncertainty about whether this is true for treated blood pressure. This question was addressed in a secondary analysis of data from the ONTARGET and TRANSCEND studies in which participants with ele- vated cardiovascular risk but no history of stroke were treated with telmisartan (plus or minus ramipril) or placebo. The risk of the composite cardiovascular endpoint was lowest at a treated systolic blood pressure range between 120 mm Hg and 140 mm Hg. Increased risk was observed at blood pres- sures below and above this range. The risk of stroke was the only exception, with incremental benefit observed below a treated systolic of 120 mm Hg. With respect to diastolic blood pressure on treatment, composite risk began to increase at levels below 70 mm Hg. This suggests that the blood pressurecardiovascular risk relationship evident in observational studies of untreated hypertension may not hold in the case of treated blood pressure and that there are grounds for a degree of caution in treating below a systolic pressure of 120 mm Hg. In seeking to simplify decision making in the treatment of hypertension, some authors have suggested that a sys- tolic blood pressure goal in the 120130 mm Hg range would be safe and effective in high-risk patients, and a systolic blood pressure of around 130 mm Hg would bereasonable in lower-risk patients, irrespective of diastolic pressures. Diastolic blood pressure will track with systolic blood pressure; the main concern about diastolic blood pressure is that treatment will lower it too much in patients who have wider pulse pressures. However, it seems that a lower diastolic blood pressure as a consequence of treat- ment does not negate the benefits of systolic blood pressure control, even though wider pulse pressures at baseline are associated with cardiovascular mortality. Treatment of Other Cardiovascular Risk FactorsData  from multiple studies indicate that statins should be part of the strategy to reduce overall cardiovascular risk. The HOPE3 study of persons at intermediate cardiovascu- lar risk showed that 10 mg of rosuvastatin reduced average low-density lipoprotein (LDL) cholesterol from 130 mg/dL to 90 mg/dL (3.362.33 mmol/L), and significantly reduced the risk of multiple cardiovascular events, including myo- cardial infarction and coronary revascularization. Low- dose aspirin (81 mg/day) is likely to be beneficial in patients older than age 50 with either target-organ damage or elevated total cardiovascular risk (greater than 2030%). Care should be taken to ensure that blood pressure is con- trolled to the recommended levels before starting aspirin to minimize the risk of intracranial hemorrhage. Data do not support the routine use of aspirin for prophylaxis in low- risk patients, including those over 65 years of age.Bhm  M et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet. 2017;389:2226. [PMID: 28390695] Ruiz-Hurtado G et al. Has the SPRINT trial introduced a new blood-pressure goal in hypertension? Nat Rev Cardiol. 2017;14:560. [PMID: 28492286] Sheppard JP et al. Benefits and harms of antihypertensive treat- ment in low-risk patients with mild hypertension. JAMA Intern Med. 2018;178:1626. [PMID: 30383082] Sobieraj P et al. Low on-treatment diastolic blood pressure and cardiovascular outcome: a post-hoc analysis using NHLBI SPRINT research materials. Sci Rep. 2019;9:13070. [PMID: 31506550] Williams B et al. 2018 Practice guidelines for the management of arterial hypertension of the European Society of Hyperten- sion (ESH) and the European Society of Cardiology (ESC). Blood Press. 2018;27:314. [PMID: 30380928]DR UG THERAPY: CURRENT ANTIHYPERTENSIVE AGENTSTh ere are many classes of antihypertensive drugs of which six (ACE inhibitors, ARBs, renin inhibitors, calcium channel blockers, diuretics, and beta-blockers) are suitable for initial therapy based on efficacy and tolerability. The specific classes of antihypertensive medications are discussed below, and guidelines for the choice of initial medications are offered.A.  Angiotensin-Converting Enzyme InhibitorsACE  inhibitors are commonly used as the initial medi- cation in mild to moderate hypertension (Table 116).CMDT22_Ch11_p0443-p0474.indd  451 29/06/21 8:37 PMChapter 11452 CMDT 2022Table 116. Antihypertensive drugs: renin and ACE inhibitors and angiotensin II receptor blockers.Dug poiy NmIniil Ol Dosg Dosg rng Cos  UniCos of 30 Dys of tmn (avg Dosg)1advs effcs Commns rnin Inibios Aliskiren Tekturna 150 mg once daily 150300 mg once daily $7.48/150 mg $224.41 Angioedema, hypotension, hyperkalemia. Contraindicated in pregnancy.Probably metabolized by CYP3A4. Absorption is inhibited by high- fat meal.Aliskiren and HCTZ Tekturna HCT 150 mg/12.5 mg once daily150 mg/12.5 mg300 mg/ 25 mg once daily$9.78/150 mg/ 12.5 mg$293.54 aCe Inibios Benazepril Lotensin 10 mg once daily 540 mg in 1 or 2 doses $0.95/20 mg $28.50 Cough, hypotension, dizziness, hyperkalemia, kidney dysfunction, angioedema; taste alteration and rash (may be more frequent with captopril); rarely, proteinuria, blood dyscrasia. Contraindicated in pregnancy.More fosinopril is excreted by the liver in patients with kidney dys- function (dose reduction may or may not be necessary). Captopril and lisinopril are active without metabolism. Captopril, enalapril, lisinopril, and quinapril are approved for heart failure.Benazepril and HCTZ Lotensin HCT 5 mg/6.25 mg once daily5 mg/6.25 mg20 mg/ 25 mg$1.07/any dose $32.21 Benazepril and amlodipineLotrel 10 mg/2.5 mg once daily10 mg/2.5 mg40 mg/ 10 mg$3.32/20 mg/ 10 mg$99.60 Captopril Capoten 25 mg twice daily 50450 mg in 2 or 3 doses$0.65/25 mg $19.50 Captopril and HCTZ Capozide 25 mg/15 mg twice daily25 mg/15 mg50 mg/ 25 mg$2.85/25 mg/ 15 mg$171.00 Enalapril Vasotec 5 mg once daily 540 mg in 1 or 2 doses $0.95/20 mg $28.50 Enalapril and HCTZ Vaseretic 5 mg/12.5 mg once daily5 mg/12.5 mg10 mg/ 25 mg$1.19/10 mg/ 25 mg$35.70 Fosinopril Monopril 10 mg once daily 1080 mg in 1 or 2 doses $0.29/20 mg $8.70 Fosinopril and HCTZ Monopril-HCT 10 mg/12.5 mg once daily10 mg/12.5 mg20 mg/ 12.5 mg$1.48/any dose $44.40 Lisinopril Prinivil, Zestril 510 mg once daily 540 mg once daily $0.08/20 mg $2.45 Lisinopril and HCTZ Prinzide or Zestoretic10 mg/12.5 mg once daily10 mg/12.5 mg20 mg/ 12.5 mg$0.14/20 mg/ 12.5 mg$4.20 Moexipril Univasc 7.5 mg once daily 7.530 mg in 1 or 2 doses $1.39/7.5 mg $41.70 Moexipril and HCTZ Uniretic 7.5 mg/12.5 mg once daily7.5 mg/12.5 mg15 mg/ 25 mg$1.70/15 mg/ 12.5 mg$51.00CMDT22_Ch11_p0443-p0474.indd  452 29/06/21 8:37 PMSYSteMIC hYperteNSION453 CMDT 2022Perindopril Aceon 4 mg once daily 416 mg in 1 or 2 doses $2.80/8 mg $84.00 Perindopril and amlodipinePrestalia 3.5 mg/2.5 mg once daily3.5 mg/2.514 mg/10 mg once daily$6.81/7 mg/5 mg $204.30 Quinapril Accupril 10 mg once daily 1080 mg in 1 or 2 doses $1.22/20 mg $36.60 Quinapril and HCTZ Accuretic 10 mg/12.5 mg once daily10 mg/12.5 mg20 mg/ 25 mg$1.22/20 mg/ 12.5 mg$36.60 Ramipril Altace 2.5 mg once daily 2.520 mg in 1 or 2 doses $1.80/5 mg $54.00 Trandolapril Mavik 1 mg once daily 18 mg once daily $1.21/4 mg $36.30 Trandolapril and verapamilTarka 2 mg/180 mg ER once daily2 mg/180 mg ER8 mg/480 mg ER$5.29/any dose $158.70 angionsin II rco Blocks Azilsartan Edarbi 40 mg once daily 4080 mg once daily $8.80/80 mg $264.00 Hyperkalemia, kidney dysfunction, rare angioedema. Combinations have additional side effects. Contraindicated in pregnancy.Losartan has a flat dose-response curve. Valsartan and irbesartan have wider dose-response ranges and longer durations of action. Addition of low-dose diuretic (separately or as combination pills) increases the response.Azilsartan and chlorthalidoneEdarbychlor 40 mg/12.5 mg once daily40 mg/12.540 mg/ 25 mg once daily$8.30/any dose $249.14 Candesartan cilexitil Atacand 16 mg once daily 832 mg once daily $3.06/16 mg $91.80 Candesartan cilexitil and HCTZAtacand HCT 16 mg/12.5 mg once daily32 mg/12.5 mg once daily$4.72/16 mg/ 12.5 mg$141.60 Eprosartan Teveten 600 mg once daily 400800 mg in 12 doses$3.43/600 mg $102.90 Irbesartan Avapro 150 mg once daily 150300 mg once daily $0.46/150 mg $13.80 Irbesartan and HCTZ Avalide 150 mg/12.5 mg once daily150300 mg irbesartan once daily$0.67/150 mg/ 12.5 mg$20.10 Losartan and HCTZ Hyzaar 50 mg/12.5 mg once daily50 mg/12.5 mg100 mg/ 25 mg tablets once daily$2.47/50 mg/ 12.5 mg/tablet$74.10 Olmesartan Benicar 20 mg once daily 2040 mg once daily $6.28/20 mg $188.40 Olmesartan and HCTZBenicar HCT 20 mg/12.5 mg once daily20 mg/12.5 mg40 mg/ 25 mg once daily$6.28/20 mg/ 12.5 mg$188.40 Olmesartan and amlodipineAzor 20 mg/5 mg once daily20 mg/5 mg40 mg/ 10 mg$3.03/20 mg/5 mg $90.90 Olmesartan and amlodipine and HCTZTribenzor 20 mg/5 mg/ 12.5 mg once daily20 mg/5 mg/12.5 mg 40 mg/10 mg/25 mg once daily$4.54/20 mg/ 5 mg/12.5 mg$136.20 Telmisartan Micardis 40 mg once daily 2080 mg once daily $4.34/40 mg $130.20 (continued )CMDT22_Ch11_p0443-p0474.indd  453 29/06/21 8:37 PMChapter 11454 CMDT 2022T elmisartan and HCTZMicardis HCT 40 mg/12.5 mg once daily40 mg/12.5 mg80 mg/ 25 mg once daily$4.83/40 mg/ 12.5 mg$144.90 Telmisartan and amlodipineTwynsta 40 mg/5 mg once daily40 mg/5 mg80 mg/ 10 mg once daily$5.20/any dose $156.00 Valsartan Diovan 80 mg once daily 80320 mg once daily $2.09/160 mg $62.70 Valsartan and HCTZ Diovan HCT 80 mg/12.5 mg once daily80320 mg valsartan once daily$4.27/160 mg/ 12.5 mg$128.10 Valsartan and amlodipineExforge 160 mg/5 mg once daily160 mg/5 mg320 mg/ 10 mg once daily$1.71/160 mg/ 10 mg$51.30 O Combinion poducs Amlodipine and val- sartan and HCTZExforge HCT 5 mg/160 mg/ 12.5 mg once daily10 mg/320 mg/25 mg up to once daily$5.70/160 mg valsartan$171.001 Average wholesale price (AWP , for AB-rated generic when available) for quantity listed. Source: IBM Micromedex Red Book (electronic version) IBM Watson Health. Greenwood Village, CO, USA. Available at https://www.mi cromedexsolutions.com, accessed March 27, 2021. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions. ACE, angiotensin-converting enzyme; ER, extended release; HCTZ, hydrochlorothiazide.Table 116. Antihypertensive drugs: renin and ACE inhibitors and angiotensin II receptor blockers.Dug poiy NmIniil Ol Dosg Dosg rng Cos  UniCos of 30 Dys of tmn (avg Dosg)1advs effcs Commns angionsin II rco Blocks (con.)(continued)CMDT22_Ch11_p0443-p0474.indd  454 29/06/21 8:37 PMSYSteMIC hYperteNSION455 CMDT 2022Their  primary mode of action is inhibition of the RAAS, but they also inhibit bradykinin degradation, stimulate the syn- thesis of vasodilating prostaglandins, and can reduce sym- pathetic nervous system activity. ACE inhibitors appear to be more effective in younger White patients. They are rela- tively less effective in Blacks and older persons and in pre- dominantly systolic hypertension. Although as single therapy they achieve adequate antihypertensive control in only about 4050% of patients, the combination of an ACE inhibitor and a diuretic or calcium channel blocker is potent. ACE inhibitors are the agents of choice in persons with type 1 diabetes with frank proteinuria or evidence of kidney dysfunction because they delay the progression to end-stage renal disease. Many authorities have expanded this indication to include persons with type 1 and type 2 diabetes mellitus with microalbuminuria who do not meet the usual criteria for antihypertensive therapy. ACE inhibitors may also delay the progression of nondiabetic kidney disease. The Heart Outcomes Prevention Evaluation (HOPE) trial demonstrated that the ACE inhibitor ramipril reduced the number of car- diovascular deaths, nonfatal myocardial infarctions, and nonfatal strokes and also reduced the incidence of new-onset heart failure, kidney dysfunction, and new-onset diabetes in a population of patients at high risk for vascular events. Although this was not specifically a hypertensive population, the benefits were associated with a modest reduction in blood pressure, and the results inferentially support the use of ACE inhibitors in similar hypertensive patients. ACE inhibi- tors are a drug of choice (usually in conjunction with a diuretic and a beta-blocker) in patients with heart failure with reduced ejection fraction and are indicated also in asymp- tomatic patients with reduced ejection fraction. How to initiate therapy A baseline metabolic panel should be drawn prior to starting medications that inter- fere with the RAAS, repeated 12 weeks after initiation of therapy to evaluate changes in creatinine and potassium. Minor dose adjustments of these medications rarely trigger significant shifts in these values. Side effects An advantage of the ACE inhibitors is their relative freedom from troublesome side effects (Table 116). Severe hypotension can occur in patients with bilateral renal artery stenosis; significant increases in creatinine may ensue but are usually reversible with the discontinuation of the ACE inhibitor. Hyperkalemia may develop in patients with kidney disease and type IV renal tubular acidosis (commonly seen in patients with diabetes) and in older adults. A chronic dry cough is common, seen in 10% of patients or more, and may require stopping the drug. Skin rashes are observed with any ACE inhibitor. Angioedema is an uncommon but potentially dangerous side effect of all agents of this class because of their inhibi- tion of kininase. Exposure of the fetus to ACE inhibitors during the second and third trimesters of pregnancy has been associated with a variety of defects due to hypoten- sion and reduced renal blood flow.B.  Angiotensin II Receptor BlockersARB s can improve cardiovascular outcomes in patients with hypertension as well as in patients with related conditions, such as heart failure and type 2 diabetes with nephropathy.ARBs have not been compared with ACE inhibitors in ran- domized controlled trials in patients with hypertension, but two trials comparing losartan with captopril in heart failure and postmyocardial infarction left ventricular dysfunction showed trends toward worse outcomes in the losartan group. By contrast, valsartan seems as effective as ACE inhibitors in these settings. Within group heterogeneity of antihyperten- sive potency and duration of action might explain such observations. The Losartan Intervention for Endpoints (LIFE) trial in nearly 9000 hypertensive patients with elec- trocardiographic evidence of left ventricular hypertrophy comparing losartan with the beta-blocker atenolol as initial therapydemonstrated a significant reduction in stroke with losartan. Of note is that in diabetic patients, death and myocardial infarction were also reduced, and there was a lower occurrence of new-onset diabetes. In a subgroup analysis from the LIFE trial, atenolol appeared to be superior to losartan in Blacks, while the opposite was the case in non- Blacks. A similar lack of efficacy of lisinopril compared to diuretics and calcium channel blockers was observed in Blacks in the Antihypertensive and Lipid-Lowering Treat- ment to Prevent Heart Attach Trial (ALLHAT), suggesting that ACE inhibitors and ARBs may not be the preferred agents in Black patients. In the treatment of hypertension, combination therapy with an ACE inhibitor and an ARB is not advised because it generally offers no advantage over monotherapy at maximum dose with addition of a comple- mentary class where necessary. Side effects Unlike ACE inhibitors, the ARBs rarely cause cough and are less likely to be associated with skin rashes or angioedema (Table 116). However, as seen with ACE inhibitors, hyperkalemia can be a problem, and patients with bilateral renal artery stenosis may exhibit hypotension and worsened kidney function. Olmesartan has been linked to a sprue-like syndrome, presenting with abdominal pain, weight loss, and nausea, which subsides upon drug discon- tinuation. There is evidence from an observational study suggesting that ARBs and ACE inhibitors are less likely to be associated with depression than calcium channel block- ers and beta-blockers.C.  Renin InhibitorsSi nce renin cleavage of angiotensinogen is the rate-limiting step in the renin-angiotensin cascade, the most efficient inac- tivation of this system would be expected with renin inhibi- tion. Conventional ACE inhibitors and ARBs probably offer incomplete blockade, even in combination. Aliskiren, a renin inhibitor, binds the proteolytic site of renin, thereby prevent- ing cleavage of angiotensinogen. Aliskiren effectively lowers blood pressure, reduces albuminuria, and limits left ventricu- lar hypertrophy, but it has yet to be established as a first-line drug based on outcomes data. The combination of aliskiren with ACE inhibitors or ARBs in persons with type 2 diabetes mellitus offers no advantage and might even increase the risk of adverse cardiac or renal consequences.D . Calcium Channel Blocking AgentsThese  agents act by causing peripheral vasodilation but with less reflex tachycardia and fluid retention than otherCMDT22_Ch11_p0443-p0474.indd  455 29/06/21 8:37 PMChapter 11456 CMDT 2022vasodilators.  They are effective as single-drug therapy in approximately 60% of patients in all demographic groups and all grades of hypertension (Table 117). For these rea- sons, they may be preferable to beta-blockers and ACE inhibitors in Blacks and older persons. Verapamil and dil- tiazem should be combined cautiously with beta-blockers because of their potential for depressing atrioventricular (AV) conduction and sinus node automaticity as well as contractility. Calcium channel blockers are equivalent to ACE inhibi- tors and thiazide diuretics in prevention of coronary heart disease, major cardiovascular events, cardiovascular death, and total mortality. A protective effect against stroke with calcium channel blockers is well established, and in two trials (ALLHAT and the Systolic Hypertension in Europe trial), these agents appeared to be more effective than diuretic-based therapy. Side effects The most common side effects of calcium channel blockers are headache, peripheral edema, brady- cardia, and constipation (especially with verapamil in older adults) (Table 117). The dihydropyridine agents nifedipine, nicardipine, isradipine, felodipine, nisoldipine, and amlodipineare more likely to produce symptoms of vasodilation, such as headache, flushing, palpitations, and peripheral edema. Edema is minimized by coadministra- tion of an ACE inhibitor or ARB. Calcium channel block- ers have negative inotropic effects and should be used cautiously in patients with cardiac dysfunction. Amlodip- ine is the only calcium channel blocker with established safety in patients with severe heart failure.E.  DiureticsThia zide diuretics (Table 118) are the antihypertensives that have been most extensively studied and most consis- tently effective in clinical trials. They lower blood pressure initially by decreasing plasma volume, but during long-term therapy, their major hemodynamic effect is reduction of peripheral vascular resistance. Most of the antihypertensive effect of these agents is achieved at lower dosages (typically, 12.5 mg of hydrochlorothiazide or equivalent), but their biochemical and metabolic effects are dose related. Chlortha- lidone has the advantage of better 24-hour blood pressure control than hydrochlorothiazide in clinical trials. Thiazides may be used at higher doses if plasma potassium is above 4.5 mmol/L. The loop diuretics (such as furosemide) may lead to electrolyte and volume depletion more readily than the thiazides and have short durations of action. Because of these adverse effects, loop diuretics should be reserved for use in patients with kidney dysfunction (serum creatinine greater than 2.5 mg/dL [208.3 mcmol/L]; estimated glo- merular filtration rate [eGFR] less than 30 mL/min/1.73 m2) in which case they are more effective than thiazides. Relative to beta-blockers and ACE inhibitors, diuretics are more potent in Blacks, older individuals, the obese, and other subgroups with increased plasma volume or low plasma renin activity (or both). They are relatively more effective in smokers than in nonsmokers. Long-term thiazide adminis- tration also mitigates the loss of bone mineral content in older women at risk for osteoporosis.Overall, diuretics administered alone control blood pressure in 50% of patients with mild to moderate hyper- tension and can be used effectively in combination with all other agents. They are also useful for lowering isolated or predominantly systolic hypertension. Side effects The adverse effects of diuretics relate primar- ily to the metabolic changes listed in Table 118. Erectile dysfunction, skin rashes, and photosensitivity are less fre- quent. Hypokalemia has been a concern but is uncommon at the recommended dosages. The risk can be minimized by limiting dietary salt or increasing dietary potassium; potassium replacement is not usually required to maintain serum K+at greater than 3.5 mmol/L. Higher serum K+ levels are prudent in patients at special risk from intracel- lular potassium depletion, such as those taking digoxin or with a history of ventricular arrhythmias in which case a potassium-sparing agent could be used. Compared with ACE inhibitors and ARBs, diuretic therapy is associated with a slightly higher incidence of mild new-onset diabe- tes. Diuretics also increase serum uric acid and may pre- cipitate gout. Increases in blood glucose, triglycerides, and LDL cholesterol may occur but are relatively minor during long-term low-dose therapy. The potential for worsening of diabetes is outweighed by the advantages of blood pres- sure control, and diuretics should not be withheld from diabetic patients.F . Aldosterone Receptor AntagonistsSp ironolactone and eplerenone are natriuretic in sodium- retaining states, such as heart failure and cirrhosis, but only very weakly so in hypertension. These drugs have reemerged in the treatment of hypertension, particularly in resistant patients and are helpful additions to most other antihyper- tensive medications. Consistent with the increasingly appreciated importance of aldosterone in essential hyper- tension, the aldosterone receptor blockers are effective at lowering blood pressure in all hypertensive patients regard- less of renin level and are also effective in Blacks. Aldoste- rone plays a central role in target-organ damage, including the development of ventricular and vascular hypertrophy and renal fibrosis. Aldosterone receptor antagonists amelio- rate these consequences of hypertension, to some extent independently of effects on blood pressure. Side effects Spironolactone can cause breast pain and gyne- comastia in men through activity at the progesterone receptor, an effect not seen with the more specific eplerenone. Hyper- kalemia is a problem with both drugs, chiefly in patients with chronic kidney disease. Hyperkalemia is more likely if the pretreatment plasma potassium exceeds 4.5 mmol/L.G.  Beta-Adrenergic Blocking AgentsT hese drugs are effective in hypertension because they decrease the heart rate and cardiac output. The beta-blockers also decrease renin release and are more efficacious in populations with elevated plasma renin activity, such as younger White patients. They neutralize the reflex tachycar- dia caused by vasodilators and are especially useful in patients with associated conditions that benefit from the cardioprotective effects of these agents.CMDT22_Ch11_p0443-p0474.indd  456 29/06/21 8:37 PMSYSteMIC hYperteNSION457 CMDT 2022Table 117. Antihypertensive drugs: calcium channel blocking agents.Dug poiy NmIniil Ol Dosg Dosg rngCos of 30 Dys of tmn (avg Dosg)1Scil pois Conciliy advs effcs Commnspil VsodilionCdic auomiciy nd Conducion Nondiydoyidin agns Diltiazem Cardizem SR 90 mg twice daily 180360 mg in 2 doses$283.20 (120 mg twice daily)++    Edema, headache, bradycardia, bloating and constipation, dizziness, AV block, heart failure, urinary frequency.Also approved for angina. Cardizem CD 180 mg ER once daily180360 mg ER once daily$46.80 (240 mg once daily) Cartia XT 180 or 240 mg ER once daily180480 mg ER once daily$46.80 (240 mg once daily) Dilacor XR 180 or 240 mg ER once daily180540 mg ER once daily$39.00 (240 mg once daily) Dilt-CD 180 or 240 mg ER once daily180480 mg ER once daily$46.80 (240 mg once daily) Diltia XT 180 or 240 mg ER once daily180540 mg ER once daily$46.80 (240 mg once daily) Taztia XT 120 or 180 mg ER once daily120540 mg ER once daily$53.40 (240 mg once daily) Tiazac 120 or 240 mg ER once daily120540 mg ER once daily$53.40 (240 mg once daily) Verapamil Calan 80 mg three times daily80480 mg in 3 divided doses$35.10 (80 mg three times daily)++    Same as diltiazem but more likely to cause constipation and heart failure.Also approved for angina and arrhythmias. Calan SR 180 mg ER once daily180480 mg ER in 1 or 2 doses$36.60 (240 mg once daily) Verelan 120 or 240 mg ER once daily240480 mg ER once daily$68.70 (240 mg once daily) Verelan PM 100 or 200 mg ER once daily100400 mg ER once daily$75.90 (200 mg once daily) (continued )CMDT22_Ch11_p0443-p0474.indd  457 29/06/21 8:37 PMChapter 11458 CMDT 2022Table 117. Antihypertensive drugs: calcium channel blocking agents.Dug poiy NmIniil Ol Dosg Dosg rngCos of 30 Dys of tmn (avg Dosg)1Scil pois Conciliy advs effcs Commnspil VsodilionCdic auomiciy nd Conducion Diydoyidins Amlodipine Norvasc 2.5 mg once daily 2.510 mg once daily$3.00 (10 mg once daily)+++ /0 /0 Edema, dizziness, palpitations, flushing, headache, hypoten- sion, tachycardia, bloating and consti- pation, urinary frequency.Amlodipine, nicar- dipine, and nife- dipine also approved for angina. Amlodipine and atorvastatinCaduet 2.5 mg/10 mg once daily10 mg/80 mg once daily$281.10 (10 mg/ 40 mg daily)+++ /0 /0 Edema (amlodipine), myopathy and hepa- totoxicity (atorvastatin). Felodipine Plendil 5 mg ER once daily 510 mg ER once daily$81.60 (10 mg ER daily)+++ /0 /0 Isradipine DynaCirc 2.5 mg twice daily 2.55 mg twice daily$120.00 (5 mg twice daily)+++ /0  Nicardipine Cardene 20 mg three times daily2040 mg three times daily$52.20 (20 mg three times daily)+++ /0  Nifedipine Adalat CC 30 mg ER once daily 3090 mg ER once daily$67.50/60 mg daily +++    Procardia XL 30 or 60 mg ER once daily30120 mg ER once daily$60.30/60 mg daily Nisoldipine Sular 17 mg daily 1734 mg daily $251.70 (34 mg once daily)+++ /0 1 Average wholesale price (AWP , for AB-rated generic when available) for quantity listed. Source: IBM Micromedex Red Book (electronic version) IBM Watson Health. Greenwood Village, CO, USA. Available at https://www.mi cromedexsolutions.com, accessed March 27, 2021. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions. AV, atrioventricular; ER, extended release; GI, gastrointestinal.(continued)CMDT22_Ch11_p0443-p0474.indd  458 29/06/21 8:37 PMSYSteMIC hYperteNSION459 CMDT 2022Table 118. Antihypertensive drugs: diuretics (in descending order of preference).Dugs poiy NmsIniil Ol Doss Dosg rng Cos  UniCos of 30 Dys of tmn1 (avg Dosg) advs effcs Commns tizids nd rld Diuics Hydrochloro- thiazide (HCTZ)Esidrix, Microzide12.5 or 25 mg once daily12.550 mg once daily$0.08/25 mg $2.40 K+,Mg2+,Ca2+,Na+, uric acid, glucose, LDL cholesterol, triglycerides; rash, erectile dysfunction.Low dosages effective in many patients with- out associated metabolic abnormalities Chlorthalidone Thalitone 12.5 or 25 mg once daily12.550 mg once daily$1.21/25 mg $36.30  Better 24-hour blood pressure control than HCTZ because of longer half-life Metolazone Zaroxolyn 1.25 or 2.5 mg once daily1.255 mg once daily$1.51/5 mg $45.30  More effective with concurrent kidney disease Indapamide Lozol 2.5 mg once daily2.55 mg once daily$0.83/2.5 mg $24.90  Does not alter serum lipid levels Bendroflume- thiazideAprinox Neo-Naclex2.5 mg once daily    Not available in United States Loo Diuics Furosemide Lasix 20 mg twice daily40320 mg in 2 or 3 doses$0.16/40 mg $9.60 Same as thiazides, but with higher risk of excessive diuresis and electrolyte imbalance. Increases calcium excretion.Short duration of action a disadvantage; should be reserved for patients with kidney disease or fluid retention. Poor antihypertensive. Ethacrynic acid Edecrin 50 mg once daily50100 mg once or twice daily$23.95/25 mg $1437.00 Bumetanide (generic) 0.25 mg twice daily0.510 mg in 2 or 3 doses$0.54/1 mg $32.40 Torsemide Demadex 5 mg once daily510 mg once daily$0.70/10 mg $21.00  Effective blood pressure medication at low dosage. (continued )CMDT22_Ch11_p0443-p0474.indd  459 29/06/21 8:37 PMChapter 11460 CMDT 2022Table 118. Antihypertensive drugs: diuretics (in descending order of preference).Dugs poiy NmsIniil Ol Doss Dosg rng Cos  UniCos of 30 Dys of tmn1 (avg Dosg) advs effcs Commns aldoson rco Blocks Spironolactone Aldactone 12.5 or 25 mg once daily12.5100 mg once daily$0.19/25 mg $5.70 Hyperkalemia, metabolic acidosis, gynecomastia.Can be useful add-on therapy in patients with refractory hypertension. Amiloride (generic) 5 mg once daily510 mg once daily$1.25/5 mg $37.50 Eplerenone Inspra 25 mg once daily25100 mg once daily$4.10/25 mg $123.00 Combinion poducs HCTZ and triamtereneDyazide, Maxzide-25 (25/37.5 mg)1 tab once daily1 or 2 tabs once daily$0.27 $8.10 Same as thiazides plus GI disturbances, hyperkalemia rather than hypokalemia, headache; triamterene can cause kidney stones and kidney dysfunction; spirono- lactone causes gynecomastia. Hyperkale- mia can occur if this combination is used in patients with advanced kidney disease or those taking ACE inhibitors.Use should be limited to patients with demonstrable need for a potassium- sparing agent. HCTZ and amiloride(generic) (50/5 mg) tab once daily1 or 2 tabs once daily$1.16 $34.80 HCTZ and spironolac- toneAldactazide (25/25 mg; 50/50 mg)1 tab (25/25 mg) once daily14 tabs once daily$1.24/ (25/25 mg)$37.201 Average wholesale price (AWP , for AB-rated generic when available) for quantity listed. Source: IBM Micromedex Red Book (electronic version) IBM Watson Health. Greenwood Village, CO, USA. Available at https://www.mi cromedexsolutions.com, accessed March 27, 2021. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions. ACE, angiotensin-converting enzyme; GI, gastrointestinal; LDL, low-density lipoprotein.(continued)CMDT22_Ch11_p0443-p0474.indd  460 29/06/21 8:37 PMSYSteMIC hYperteNSION461 CMDT 2022Th ese include individuals with angina pectoris, previous myo- cardial infarction, and stable heart failure as well as those with migraine headaches and somatic manifestations of anxiety. Although all beta-blockers appear to be similar in anti- hypertensive potency, they differ in a number of pharma- cologic properties (these differences are summarized in Table 119), including specificity to the cardiac beta- 1-receptors (cardioselectivity) and whether they also block the beta-2-receptors in the bronchi and vasculature ; at higher dosages, however, all agents are nonselective. The beta-blockers also differ in their pharmacokinetics, lipid solubilitywhich determines whether they cross the blood- brain barrier predisposing to central nervous system side effectsand route of metabolism. Metoprolol reduces mor- tality and morbidity in patients with chronic stable heart failure with reduced ejection fraction (see Chapter 10). Carvedilol and nebivolol maintain cardiac output and are beneficial in patients with left ventricular systolic dysfunc- tion. Carvedilol and nebivolol may reduce peripheral vas- cular resistance by concomitant alpha-blockade (carvedilol) and increased nitric oxide release (nebivolol). Because of the lack of efficacy in primary prevention of myocardial infarction and inferiority compared with other drugs in prevention of stroke and left ventricular hypertrophy, tra- ditional beta-blockers should not be used as first-line agents in the treatment of hypertension without specific compelling indications (such as active coronary artery disease). Vasodilating beta-blockers may emerge as alter- native first-line antihypertensives, but this possibility has yet to be rigorously tested in outcome studies. Side effects The side effects of beta-blockers include inducing or exacerbating bronchospasm in predisposed patients; sinus node dysfunction and AV conduction depres- sion (resulting in bradycardia or AV block); nasal conges- tion; Raynaud phenomenon; and central nervous system symptoms with nightmares, excitement, depression, and confusion. Fatigue, lethargy, and erectile dysfunction may occur. The traditional beta-blockers (but not the vasodilator beta-blockers carvedilol and nebivolol) have an adverse effect on lipids and glucose metabolism. Beta-blockers are used cautiously in patients with type 1 diabetes, since they can mask the symptoms of hypoglycemia and prolong these episodes by inhibiting gluconeogenesis. These drugs should also be used with caution in patients with advanced periph- eral vascular disease associated with rest pain or nonhealing ulcers, but they are generally well tolerated in patients with mild claudication. Nebivolol can be safely used in patients with stage II claudication (claudication at 200 m). In treatment of pheochromocytoma, beta-blockers should not be administered until alpha-blockade (eg, phentolamine) has been established . Otherwise, blockade of vasodilatory beta-2-adrenergic receptors will allow unopposed vasocon- strictor alpha-adrenergic receptor activation with worsening of hypertension. For the same reason, beta-blockers should not be used to treat hypertension arising from cocaine use . Great care should be exercised if the decision is made, in the absence of compelling indications, to remove beta- blockers from the treatment regimen because abrupt with- drawal can precipitate acute coronary events and severe increases in blood pressure.H. Alpha-Adrenoceptor AntagonistsPrazosin,  terazosin, and doxazosin (Table 1110) block postsynaptic alpha-receptors, relax smooth muscle, and reduce blood pressure by lowering peripheral vascular resistance. These agents are effective as single-drug therapy in some individuals, but tachyphylaxis may appear during long-term therapy. Unlike beta-blockers and diuretics, alpha-blockers have no adverse effect on serum lipid levels. In fact, alpha-blockers increase HDL cholesterol while reducing total cholesterol; whether this is beneficial in the long term has not been established. Side effects Side effects are relatively common (Table 1110). These include marked hypotension after the first dose which, therefore, should be small and given at bedtime. Post-dosing palpitations, headache, and nervous- ness may continue to occur during long-term therapy; these symptoms may be less frequent or severe with doxa- zosin because of its more gradual onset of action. In ALL- HAT, persons receiving doxazosin as initial therapy had a significant increase in heart failure hospitalizations and a higher incidence of stroke relative to those receiving diuret- ics, prompting discontinuation of this arm of the study. Cata- ractectomy in patients exposed to alpha-blockers can be complicated by the floppy iris syndrome, even after discon- tinuation of the drug, so the ophthalmologist should be alerted that the patient has been taking the drug prior to surgery. To summarize, alpha-blockers should generally not be used as initial agents to treat hypertensionexcept perhaps in men with symptomatic prostatism or nightmares linked to posttraumatic stress disorder.I.  Drugs With Central Sympatholytic ActionMet hyldopa, clonidine, guanabenz, and guanfacine (Table 1110) lower blood pressure by stimulating alpha- adrenergic receptors in the central nervous system, thus reducing efferent peripheral sympathetic outflow. There is considerable experience with methyldopa in pregnant women, and it is still used for this population. Clonidine is available in patches, which may have particular value in noncompliant patients. All of these central sympatholytic agents are effective as single therapy in some patients, but they are usually used as second- or third-line agents because of the high frequency of drug intolerance. Side effects Side effects include sedation, fatigue, dry mouth, postural hypotension, and erectile dysfunction. An important concern is rebound hypertension following withdrawal. Methyldopa also causes hepatitis and hemo- lytic anemia and should be restricted to individuals who have already tolerated long-term therapy.J.  Peripheral Sympathetic InhibitorsTh ese agents are usually used only in refractory hypertension. Reserpine remains a cost-effective antihypertensive agent (Table 1110). Its reputation for inducing mental depres- sion and its other side effectssedation, nasal stuffiness, sleep disturbances, and peptic ulcershas made it unpop- ular, though these problems are uncommon at low dosages.CMDT22_Ch11_p0443-p0474.indd  461 29/06/21 8:37 PMChapter 11462 CMDT 2022Table 119. Antihypertensive drugs: beta-adrenergic blocking agents.Dug poiy NmIniil Ol Dosg Dosg rngCos  UniCos of 30 Dys of tmn (Bsd on avg Dosg)1Scil pois Commns5B-1 Slciviy2ISa3MSa4Liid Solubiliyrnl vs hic eliminion Acebutolol Sectral 400 mg once daily2001200 mg in 1 or 2 doses$1.34/400 mg $40.20 + + + + H > R Positive ANA; rare LE syndrome; also indicated for arrhythmias. Doses > 800 mg have beta-1 and beta-2 effects. Atenolol Tenormin 25 mg once daily25100 mg once daily$0.79/50 mg $23.70 + 0 0 0 R Also indicated for angina and post-MI. Doses > 100 mg have beta-1 and beta-2 effects. Atenolol/ chlorthalidoneTenoretic 50 mg/25 mg once daily50 mg/25 mg 100 mg/25 mg once daily$1.88/50 mg/ 25 mg$56.40 + 0 0 0 R Betaxolol Kerlone 10 mg once daily1040 mg once daily$0.78/10 mg $23.40 + 0 0 + H > R Bisoprolol Zebeta 5 mg once daily520 mg once daily$1.22/10 mg $36.60 + 0 0 0 R = H Also effective for heart failure. Bisoprolol and HCTZZiac 2.5 mg/ 6.25 mg once daily2.5 mg/6.25 mg 10 mg/6.25 mg once daily$1.14/2.5/ 6.25 mg$34.20 + 0 0 0 R = H Low-dose combination approved for initial therapy. Carvedilol Coreg Coreg CR6.25 mg twice daily 20 mg ER once daily12.550 mg in 2 doses 2080 mg ER once daily$0.09/25 mg $9.91/any tablet$5.40 (25 mg twice a day) $297.300 0 0 +++ H > R Alpha:beta blocking activity 1:9; may cause ortho- static symptoms; effec- tive for heart failure. Nitric oxide potentiating vasodilatory activity. Labetalol Trandate 100 mg twice daily2002400 mg in 2 doses$0.39/200 mg $23.40 0 0/+ 0 ++ H Alpha:beta blocking activity 1:3; more orthostatic hypotension, fever, hepatotoxicity.CMDT22_Ch11_p0443-p0474.indd  462 29/06/21 8:37 PMSYSteMIC hYperteNSION463 CMDT 2022Metoprolol Lopressor Toprol-XL (SR prepara- tion)50 mg twice daily 25 mg once daily50200 mg twice daily 25400 mg once daily$0.03/50 mg $1.50/100 mg$1.80 $45.00+ 0 + +++ H Also indicated for angina and post-MI. Approved for heart failure. Doses > 100 mg have beta-1 and beta-2 effects. Metoprolol and HCTZLopressor HCT50 mg/ 12.5 mg twice daily50 mg/25 mg 200 mg/50 mg$1.77/100 mg/ 25 mg$106.20 + 0 + +++ H Nadolol Corgard 20 mg once daily20320 mg once daily$3.96/40 mg $118.80 0 0 0 0 R Nadolol and bendroflumeth- azideCorzide 40 mg/5 mg once daily40 mg/5 mg 80 mg/5 mg once daily6.14/80 mg/ 5 mg$184.20 Nebivolol Bystolic 5 mg once daily40 mg once daily $6.32/5 mg $189.60 + 0 0 ++ H Nitric oxide potentiating vasodilatory activity. Pindolol Visken 5 mg twice daily1060 mg in 2 doses$1.10/5 mg $66.00 0 ++ + + H > R In adults, 35% renal clearance. Propranolol Inderal Inderal LA InnoPran XL20 mg twice daily 80 mg ER once daily 80 mg ER once nightly40640 mg in 2 doses 120640 mg ER once daily 80120 mg ER once nightly$0.41/40 mg $2.98/120 mg $30.20/ 120 mg$24.60 $89.40 $906.000 0 ++ +++ H Also indicated for angina and post-MI. Propranolol and HCTZ(generic) 40 mg/25 mg twice daily80 mg/25 mg twice daily$1.41/80 mg/ 25 mg$84.60 0 0 ++ +++ H Timolol (generic) 5 mg twice daily1060 mg in 2 doses$1.70/10 mg $102.00 0 0 0 ++ H > R Also indicated for post-MI; 80% hepatic clearance.1 Average wholesale price (AWP , for AB-rated generic when available) for quantity listed. Source: IBM Micromedex Red Book (electronic version) IBM Watson Health. Greenwood Village, CO, USA. Available at https://www.mi cromedexsolutions.com, accessed March 27, 2021. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions.2 Agents with beta-1 selectivity are less likely to precipitate bronchospasm and decrease peripheral blood flow in low doses, but selectivity is only relative.3 Agents with ISA cause less resting bradycardia and lipid changes.4 MSA generally occurs at concentrations greater than those necessary for beta-adrenergic blockade. The clinical importance of MS A by beta-blockers has not been defined.5 Adverse effects of all beta-blockers: bronchospasm, fatigue, sleep disturbance and nightmares, bradycardia and atrioventricular block, worsening of heart failure, cold extremities, gastrointestinal disturbances, erectile dysfunction, triglycerides, high-density lipoprotein cholesterol, rare blood dyscrasias. ANA, antinuclear antibody; ER, extended release; HCTZ, hydrochlorothiazide; ISA, intrinsic sympathomimetic activity; LE, lupus erythematosus; MI, myocardial infarction; MSA, membrane-stabilizing activity; SR, sustained release; 0, no effect; +, some effect; ++, moderate effect; +++, most effect.CMDT22_Ch11_p0443-p0474.indd  463 29/06/21 8:37 PMChapter 11464 CMDT 2022Table 1110. Alpha-adrenoceptor blocking agents, sympatholytics, and vasodilators.Dug poiy Nms Iniil Dosg Dosg rng Cos  UniCos of 30 Dys of tmn (avg Dosg)1advs effcs Commns al-adnoco Blocks Doxazosin Cardura Cardura XL1 mg at bedtime 4 mg ER once daily116 mg once daily 48 mg ER once daily$0.29/4 mg $7.07/4 mg ER$8.70 (4 mg once daily) $212.10 (4 mg ER once daily)Syncope with first dose; postural hypotension, dizziness, palpitations, headache, weakness, drowsiness, sexual dys- function, anticholinergic effects, urinary inconti- nence; first-dose effects may be less with doxazosin.MayHDL and LDL cholesterol. May provide short-term relief of obstructive prostatic symptoms. Less effective in preventing car- diovascular events than diuretics.Prazosin Minipress 1 mg at bedtime 220 mg in 2 or 3 doses$0.95/5 mg $57.00 (5 mg twice daily) Terazosin Hytrin 1 mg at bedtime 120 mg in 1 or 2 doses$1.60/1, 2, 5, 10 mg$48.00 (5 mg once daily) Cnl Symolyics Clonidine Catapres Catapres TTS (transdermal patch)0.1 mg twice daily 0.1 mg/day patch weekly0.20.6 mg in 2 doses 0.10.3 mg/day patch weekly$0.21/0.1 mg $55.77/0.2 mg patch$12.60 (0.1 mg twice daily) $223.08 (0.2 mg weekly)Sedation, dry mouth, sex- ual dysfunction, head- ache, bradyarrhythmias; side effects may be less with guanfacine. Contact dermatitis with clonidine patch.Rebound hypertension may occur even after gradual withdrawal. Clonidine and chlorthalidoneClorpres 0.1 mg/15 mg one to three times daily0.1 mg/15 mg 0.3 mg/15 mg$2.77/0.1 mg/ 15 mg$166.20/0.1 mg/ 15 mg twice daily Guanfacine Tenex 1 mg once daily 13 mg once daily $0.87/1 mg $26.10 (1 mg once daily) Methyldopa Aldochlor 250 mg twice daily 5002000 mg in 2 doses$0.66/500 mg $39.60 (500 mg twice daily)Hepatitis, hemolytic ane- mia, fever.Avoid in favor of safer agents.CMDT22_Ch11_p0443-p0474.indd  464 29/06/21 8:37 PMSYSteMIC hYperteNSION465 CMDT 2022pil Nuonl angoniss Reserpine (generic) 0.05 mg once daily 0.050.25 mg once daily$1.19/0.1 mg $35.70 (0.1 mg once daily)Depression (less likely at low dosages, ie, < 0.25 mg), night terrors, nasal stuffi- ness, drowsiness, peptic disease, GI disturbances, bradycardia. Dic Vsodilos Hydralazine Apresoline 25 mg twice daily 50300 mg in 24 doses$0.15/25 mg $9.00 (25 mg twice daily)GI disturbances, tachycar- dia, headache, nasal congestion, rash, LE-like syndrome.May worsen or precipitate angina. Minoxidil (generic) 5 mg once daily 1040 mg once daily $1.28/10 mg $38.40 (10 mg once daily)Tachycardia, fluid retention, headache, hirsutism, pericardial effusion, thrombocytopenia.Should be used in combination with beta-blocker and diuretic.1 Average wholesale price (AWP , for AB-rated generic when available) for quantity listed. Source: IBM Micromedex Red Book (electronic version) IBM Watson Health. Greenwood Village, CO, USA. Available at https://www.mi cromedexsolutions.com, accessed March 27, 2021. AWP may not accurately represent the actual pharmacy cost because wide contractual variations exist among institutions. ER, extended release; GI, gastrointestinal; LE, lupus erythematosus.CMDT22_Ch11_p0443-p0474.indd  465 29/06/21 8:37 PMChapter 11466 CMDT 2022Guanethidine and guana drel inhibit catecholamine release from peripheral neurons but frequently cause orthostatic hypotension (especially in the morning or after exercise), diarrhea, and fluid retention.K.  Arteriolar DilatorsH ydralazine and minoxidil (Table 1110) relax vascular smooth muscle and produce peripheral vasodilation. When given alone, they stimulate reflex tachycardia; increase myocardial contractility; and cause headache, palpitations, and fluid retention. To counteract these effects, the agents are usually given in combination with diuretics and beta-blockers in resistant patients. Hydrala- zine produces frequent gastrointestinal disturbances and may induce a lupus-like syndrome. Minoxidil causes hir- sutism and marked fluid retention; this very potent agent is reserved for the most refractory of cases. Antihypertensive Medications & the Risk of CancerA  number of observational studies have examined the association between long-term exposure to antihyperten- sive medications and cancer. Weak associations have been suggested by some of these studies, but results have been very mixed. In the absence of large-scale prospective studies with cancer as a prespecified outcome measure, the effect of antihypertensive drugs on the risk of cancer remains uncertain. By contrast, the beneficial effect of these drugs on cardiovascular outcomes has been clearly established. Concern about increased risk of cancer should not be minimized, but at present there are no compelling data to prompt a change in prescribing patterns.Hicks  BM et al. Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ. 2018;363:k4209. [PMID: 30355745] Su KA et al. Photosensitizing antihypertensive drug use and risk of cutaneous squamous cell carcinoma. Br J Dermatol. 2018;179:1088. [PMID: 29723931] Wright CM et al. Calcium channel blockers and breast cancer incidence: an updated systematic review and meta-analysis of the evidence. Cancer Epidemiol. 2017;50:113. [PMID: 28866282] Procedures That Modulate the Activity of the Autonomic Nervous SystemBefore the adv ent of antihypertensive medications, lumbar sympathectomy was used to lower blood pressure. In a more specific and less invasive approach, the renal sympa- thetic nerves can be ablated using radiofrequency energy applied to the luminal surface of the renal arteries. How- ever, the Symplicity HTN-3 study of renal sympathetic denervation did not show any difference in blood pressure reduction compared to a sham procedure group. Subse- quently, the SPYRAL HTN-OFF MED study, using a more intensive and closely controlled ablation strategy, demon- strated clinically meaningful blood pressure reductions compared to the sham control group. Although not yetaccepted in general clinical practice, it seems probable that renal sympathetic nerve ablation will emerge as an alterna- tive or adjunctive modality in the treatment of hyperten- sion and may become useful in the management of resistant hypertension and drug intolerance.Bhm  M et al; SPYRAL HTN-OFF MED Pivotal Investigators. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395:1444. [PMID: 32234534] Hermida RC et al; Hygia Project Investigators. Bedtime hyper- tension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J. 2020;41: 4565. [PMID: 31641769] Developing an Antihypertensive RegimenHisto rically, data from large placebo-controlled trials sup- ported the overall conclusion that antihypertensive therapy with diuretics and beta-blockers had a major beneficial effect on a broad spectrum of cardiovascular outcomes, reducing the incidence of stroke by 3050% and of heart failure by 4050%, and halting progression to accelerated hypertension syndromes. The decreases in fatal and nonfa- tal coronary heart disease and cardiovascular and total mortality were less dramatic, ranging from 10% to 15%. Similar placebo-controlled data pertaining to the newer agents are generally lacking, except for stroke reduction with the calcium channel blocker nitrendipine in the Sys- tolic Hypertension in Europe trial. However, there is sub- stantial evidence that ACE inhibitors, and to a lesser extent ARBs, reduce adverse cardiovascular outcomes in other related populations (eg, patients with diabetic nephropa- thy, heart failure, or postmyocardial infarction and indi- viduals at high risk for cardiovascular events). Most large clinical trials that have compared outcomes in relatively unselected patients have failed to show a difference between newer agentssuch as ACE inhibitors, calcium channel block- ers, and ARBsand the older diuretic-based regimens with regard to survival, myocardial infarction, and stroke. Where differences have been observed, they have mostly been attrib- utable to subtle asymmetries in blood pressure control rather than to any inherent advantages of one agent over another. Recommendations for initial treatment identify ACE inhibi- tors, ARBs, and calcium channel blockers as valid choices. Because of their adverse metabolic profile, initial therapy with thiazides might best be restricted to older patients. Thiazides are acceptable as first-line therapy in Blacks because of specific efficacy in this group. As discussed above, beta-blockers are not ideal first-line drugs in the treatment of hypertension without compelling indications for their use (such as active coronary artery disease and heart failure). Vasodilator beta-blockers (such as carvedilol and nebivolol) may produce better outcomes than traditional beta-blockers; however, this possibility remains a theoretical consideration. The American Diabetes Association has advocated eve- ning dosing of one or more antihypertensive medications to restore nocturnal blood pressure dipping. The HYGIACMDT22_Ch11_p0443-p0474.indd  466 29/06/21 8:37 PMSYSteMIC hYperteNSION467 CMDT 2022trial  compared the effect of nighttime dosing of at least one antihypertensive medication with morning dosing of all antihypertensive medications in 19,000 participants with median follow-up 6.3 years, and demonstrated improved ambulatory blood pressure and nocturnal dipping, and a significant decline in major cardiovascular events in the nighttime dosing group. Participants were monitored via ambulatory blood pressure measurement, and the inci- dence of nocturnal hypotension in the HYGIA trial was very low. However, profound nocturnal hypotension might not be detected in the absence of ambulatory blood pres- sure monitoring, and ischemic optic neuropathy or other low perfusion complications would be a concern. Drugs that interrupt the renin-angiotensin cascade are more effective in young, White persons, in whom renin tends to be higher. Calcium channel blockers and diuretics are more effective in older or Black persons, in whom renin levels are generally lower. Many patients require two or more medications and even then a sub- stantial proportion fail to achieve the goal blood pres- sure. A stepped care approach to the drug treatment of hypertension is outlined in Table 1111. In diabetic patients, three or four drugs are usually required to reduce systolic blood pressure to goal. In many patients, blood pressure cannot be adequately controlled with any combination. As a result, debating the appropriate first-line agent is less relevant than determining the most appropriate combinations of agents. The mnemonic ABCD can be used to remember four classes of antihypertensive medications. These four classes can be divided into two categories: AB and CD. AB refers to drugs that block the RAAS ( ACE/ARB and beta-blockers). CD refers to those that work in other pathways ( calcium channel blockers and diuretics). Combinations of drugs between the two categories are more potent than combina- tions from within a category. Many experts recommend the use of fixed-dose combination (between two categories) antihypertensive agents as first-line therapy in patientswith substantially elevated systolic pressures (greater than 160/100 mm Hg) or difficult-to-control hypertension (which is often associated with diabetes or kidney dysfunc- tion). In light of unwanted metabolic effects, calcium chan- nel blockers might be preferable to thiazides in the younger hypertensive patient requiring a second antihypertensive drug following initiation of therapy with an ACE inhibitor or ARB. Furthermore, based on the results from the ACCOMPLISH trial, a combination of ACE inhibitor and calcium channel blocker may also prove optimal for patients at high risk for cardiovascular events. The initial use of low-dose combinations allows faster blood pressure reduction without substantially higher intolerance rates and is likely to be better accepted by patients. Data from the ALTITUDE study (in patients with type 2 diabetes and chronic kidney disease or cardiovascular disease or both) indicate that the addition of aliskiren to either ARB or ACE inhibitor was associated with worse outcomes and cannot be recommended, at least in this population. A suggested approach to treatment, tailored to patient demographics, is outlined in Table 1112. In sum, as a prelude to treatment, the patient should be informed of common side effects and the need for diligent compliance. In patients with blood pressure less than 160/90 mm Hg in whom pharmacotherapy is indicated, treatment should start with a single agent or two-drug combination at a low dose. Follow-up visits usually should be at 4- to 6-week intervals to allow for full medication effects to be established (especially with diuretics) before further titration or adjustment. If, after titration to usual doses, the patient has shown a discernible but incomplete response and a good tolerance of the initial drug, another medication should be added. See Goals of Treatment, above. As a rule of thumb, a blood pressure reduction of 10 mm Hg can be expected for each antihypertensive agent added to the regimen and titrated to the optimum dose. In those with more severe hypertension, or with comorbidi- ties (such as diabetes) that are likely to render them Table 1111. A step care approach to the initiation and titration of antihypertension medications.1,2Step  1 ACE inhibitor/ARB or3Calcium  channel blocker or Thiazide diuretic4Step  2 ACE inhibitor/ARB plus Calcium channel blocker orthiazide diuretic5Step  3 ACE inhibitor/ARB plus calcium channel blocker plus thiazide diuretic Step 4 ACE inhibitor/ARB plus calcium channel blocker plus thiazide diuretic plus spironolactone6 1Allow 2 weeks to reach full effect of each drug. Proceed through steps until target blood pressure is attained.2 Beta-blockers can be used at any stage if specifically indicated, eg, heart failure or angina.3 The European guidelines recommend starting with low-dose combination of two antihypertensive drugs in all but low-risk grade 1 hyper- tension (140159/9099 mm Hg). American guidelines suggest initiation with dual therapy for stage 2 hypertension (> 140/90 mm H g).4 Thiazide or calcium channel blocker is more effective initial therapy in older people and Blacks.5 If required, add a calcium channel blocker rather than diuretic in younger patients to avoid long-term exposure to metabolic si de effects of diuretics.6 Alternatives to spironolactone include eplerenone, amiloride, or triamterene. Watch for hyperkalemia, especially if also receiv ing ACE inhibitor/ ARB. Avoid potassium-sparing diuretics in advanced CKD. If more than three drugs are required at maximum dose, consider special ist referral. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CKD, chronic kidney disease.CMDT22_Ch11_p0443-p0474.indd  467 29/06/21 8:37 PMChapter 11468 CMDT 2022T able 1112. Choice of antihypertensive agent based on demographic considerations.1,2 Blck, all ags all Os, ag < 55 Ys all Os, ag > 55 Ys Fis-lin CCB or diuretic ACE inhibitor or ARB3or CCB or diuretic4CCB or diuretic5Scond-lin  ARB3or ACE inhibitor6or vasodilating beta-blocker6Vasodilating beta-blocker ACE inhibitor or ARB3or vasodilating beta-blocker7rsisn  ynsion Aldosterone receptor blocker Aldosterone receptor blocker Aldosterone receptor blocker addiionl oions Centrally acting alpha-agonist or peripheral alpha-antagonist8Centrally acting alpha-agonist or peripheral alpha-antagonist8Centrally acting alpha-agonist or peripheral alpha-antagonist8 1Compelling indications may alter the selection of an antihypertensive drug.2 Start with full dose of one agent, or lower doses of combination therapy. In more severe hypertension ( 140/90 mm Hg), conside r initiat- ing therapy with a fixed dose combination.3 Women of childbearing age should avoid ACE inhibitors and ARBs or discontinue as soon as pregnancy is diagnosed.4 The adverse metabolic effects of thiazide diuretics and beta-blockers should be considered in younger patients but may be less important in the older patient.5 For patients with significant kidney dysfunction, use loop diuretic instead of thiazide.6 Despite the elevated risk of angioedema and cough in Blacks, ACE inhibitors are generally well tolerated and are a useful adjun ct.7 There are theoretical advantages in the use of vasodilating beta-blockers such as carvedilol and nebivolol.8 Alpha-antagonists may precipitate or exacerbate orthostatic hypotension in older adults. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CCB, calcium channel blocker.resistan t to treatment, initiation with combination therapy is advised and more frequent follow-up is indicated. Patients who are compliant with their medications and who do not respond to conventional combination regi- mens should usually be evaluated for secondary hyperten- sion before proceeding to more complex regimens. Medication NonadherenceAdher ence to antihypertensive treatment is alarmingly poor. In one European study of antihypertensive medica- tion compliance, there was a 40% discontinuation rate at 1 year after initiation. Collaborative care, using clinicians, pharmacists, social workers, and nurses to encourage com- pliance, has had a variable and often rather modest effect on blood pressure control. Adherence is enhanced by patient education and by use of home blood pressure mea- surement. The choice of antihypertensive medication is important. Better compliance has been reported for patients whose medications could be taken once daily or as combination pills. Adherence is best with ACE inhibitors and ARBs, and worse with beta-blockers and diuretics. Consideration of Gender in HypertensionBecause  of the preponderance of male recruitment into large-scale clinical trials, the impact of gender on the evaluation and management of hypertension remains uncertain. The limited data that exist suggest a steeper relationship in women between 24-hour ambulatory and night time systolic blood pressure and the risk of cardio- vascular events. There are many gender-specific effects on the mechanisms and end organ impact of hypertension. In younger adults, men are more likely to be hypertensive than women, a relationship that reverses in later life.Regression of left ventricular hypertrophy in response to ACE inhibitors is less pronounced in women. Women are more likely to have isolated systolic hypertension, probably because they develop more active left ventricular systolic function and greater vascular stiffness than men. Fibro- muscular dysplasia of the renal artery is much more com- mon in women than men. The side effects of many antihypertensive drugs are more pronounced in women than men, including ACE inhibitorassociated cough and hyponatremia and hypokalemia in response to diuretics. Conversely, thiazides can help preserve bone density. Dependent edema due to amlodipine is more likely in women, and women are more sensitive to beta-blockers. There are no data to support a different blood pressure target in women, but this question has not been examined in dedicated clinical trials. Treatment of Hypertension in DiabetesH ypertensive patients with diabetes are at particularly high risk for cardiovascular events. Data from the ACCORD study of diabetic patients demonstrated that most of the benefits of blood pressure lowering were seen with a systolic target of less than 140 mm Hg. Although there was a reduc- tion in stroke risk at a systolic target below 120/70 mm Hg, treatment to this lower target was associated with an increased risk of serious adverse effects. US and Canadian guidelines recommend a blood pressure goal of less than 130/80 mm Hg in diabetic patients. Because of the benefi- cial effects of ACE inhibitors in diabetic nephropathy, they should be part of the initial treatment regimen. ARBs or perhaps renin inhibitors may be substituted in those intol- erant of ACE inhibitors. While the ONTARGET study showed that combinations of ACE inhibitors and ARBs in persons with atherosclerosis or type 2 diabetes withCMDT22_Ch11_p0443-p0474.indd  468 29/06/21 8:37 PMSYSteMIC hYperteNSION469 CMDT 2022end-orga n damage appeared to minimize proteinuria, this strategy slightly increased the risks of progression to dialy- sis and of death; thus, it is not recommended. Most dia- betic patients require combinations of three to five agents to achieve target blood pressure, usually including a diuretic and a calcium channel blocker or beta-blocker. Canagliflozin improves glycemic control through inhibition of the sodium-glucose co-transporter 2 (SGLT2) and, in addition, generally lowers blood pressure by 34 mm Hg. This drug was associated with improved renal outcomes and reduced cardiovascular risk in the CREDENCE trial of patients with diabetic nephropathy and can be consid- ered when additional blood pressure control is needed in patients with type 2 diabetes. In addition to rigorous blood pressure control, treatment of persons with diabe- tes should include aggressive treatment of other risk factors. Treatment of Hypertension in Chronic Kidney DiseaseH ypertension is present in 40% of patients with a GFR of 6090 mL/min/1.73 m2, and 75% of patients with a GFR less than 30 mL/min/1.73 m2. The rate of progression of chronic kidney disease is markedly slowed by treatment of hypertension. In the SPRINT trial, the reduction in cardio- vascular risk associated with lower blood pressure targets was also observed in the subgroup with a GFR of less than 60 mL/min/1.73 m2. However, an effect of lower blood pressure targets on the slowing of chronic kidney disease progression appears to be restricted to those with pro- nounced proteinuria. In the SPRINT trial, the lower blood pressure goal was associated with increased risk of acute kidney injury, but this was generally reversible and not associated with elevated biomarkers for ischemic injury. Most experts recommend a blood pressure target of less than 130/80 mm Hg in patients with chronic kidney dis- ease, with consideration of more intensive lowering if pro- teinuria greater than 1 g per 24 hours is present. Medications that interrupt the renin-angiotensin cascade can slow the progression of kidney disease and are preferred for initial therapy, especially in those with albuminuria of greater than 300 mg/g creatinine. Transition from thiazide to loop diuretic is often necessary to control volume expansion as the eGFR falls below 30 mL/min/1.73 m2. ACE inhibitors remain protective and safe in kidney disease associated with significant proteinuria and serum creatinine as high as 5 mg/dL (380 mcmol/L). However, the use of drugs blocking the RAAS cascade in patients with advanced chronic kidney disease should be supervised by a nephrol- ogist. Kidney function and electrolytes should be measured 1 week after initiating treatment and subsequently moni- tored carefully in patients with kidney disease. An increase in creatinine of 2030% is acceptable and expected; more exaggerated responses suggest the possibility of renal artery stenosis or volume contraction. Although lower blood pressure levels are associated with acute decreases in GFR, this appears not to translate into an increased risk of developing end-stage renal disease in the long term. Persis- tence with ACE inhibitor or ARB therapy as the serum potassium level exceeds 5.5 mEq/L is probably notwarranted, since other antihypertensive medications are renoprotective as long as goal blood pressures are main- tained. However, diuretics can often be helpful in control- ling mild hyperkalemia, and there are novel cation exchange polymers (such as patiromer) that sequester potassium in the gut and are more effective and better tol- erated than sodium polystyrene sulfonate. Treatment of Hypertension in BlacksSubstan tial evidence indicates that Blacks in the United States are not only more likely to become hypertensive and more susceptible to the cardiovascular and renal complica- tions of hypertensionthey also respond differently to many antihypertensive medications. The REGARDS study illustrates these differences. At systolic blood pressures less than 120 mm Hg, Black and White participants between 45 and 64 years of age had equal risk of stroke. For a 10 mm Hg increase in systolic blood pressure, the risk of stroke was threefold higher in Black participants. At levels above 140159/9099 mm Hg, the hazard ratio for stroke in Black compared to White participants between 45 and 64 years of age was 2.35. This increased susceptibility may reflect genetic differences in the cause of hypertension or the subsequent responses to it, differences in occurrence of comorbid conditions such as diabetes or obesity, or envi- ronmental factors such as diet, activity, stress, or access to health care services. In any case, as in all persons with hypertension, a multifaceted program of education and lifestyle modification is warranted. Early introduction of combination therapy has been advocated, but there are no clinical trial data to support a lower than usual blood pres- sure goal in Blacks. Because it appears that ACE inhibitors and ARBsin the absence of concomitant diureticsare less effective in Blacks than in Whites, initial therapy should generally be a diuretic or a diuretic in combination with a calcium channel blocker. However, inhibitors of the RAAS do lower blood pressure in Black patients, are useful adjuncts to the recommended diuretic and calcium chan- nel blockers, and should be used in patients with hyperten- sion and compelling indications such as heart failure and kidney disease (especially in the presence of proteinuria) (Table 1113). Black patients have an elevated risk of ACE inhibitorassociated angioedema and cough, so ARBs would be the preferred choice. Treating Hypertension in Older AdultsSeveral  studies in persons over 60 years of age have con- firmed that antihypertensive therapy prevents fatal and nonfatal myocardial infarction and reduces overall cardio- vascular mortality. The HYVET study indicated that a reasonable ultimate blood pressure goal is 150/80 mm Hg. Updated guidelines suggest that blood pressure goals should not generally be influenced by age alone. An explor- atory subgroup analysis of the SPRINT study found that people older than age 75 years showed benefit at the 120 mm Hg systolic treatment target. Importantly, these benefits were also evident in patients classified as frail. This more aggressive approach was, however, associated with greater risk of falls and worsening kidney function,CMDT22_Ch11_p0443-p0474.indd  469 29/06/21 8:37 PMChapter 11470 CMDT 2022indicating  that close monitoring is required in elderly patients treated to lower blood pressure goals. It is also important to note the exclusion criteria of the SPRINT study, which included diabetes mellitus, stroke, and ortho- static hypotension. Blood pressure treatment goals should be individual- ized in the very elderly. In the SPRINT MIND study, the lower systolic blood pressure target of 120 mm Hg was associated with a 15% reduction in the incidence of mild cognitive impairment and probable all cause dementia compared to the 140 mm Hg in the target group. Based upon this data, aggressive control of hypertension in high- risk individuals would have a significant impact on the prevalence of dementia. As discussed above, it is important to note that blood pressure measurements in the SPRINT study were made by automated devices, which are known to read lower than conventional office measurements. How to initiate antihypertensive therapy in older patients The same medications are used in older patients but at 50% lower doses. Pressure should be reduced more gradually with a safe intermediate systolic blood pressure goal of 160 mm Hg. As treatment is initiated, older patients should be carefully monitored for orthostasis, altered cog- nition, and electrolyte disturbances. The elderly are espe- cially susceptible to problems associated with polypharmacy, including drug interactions and dosing errors. Management of Supine Hypertension in Patients With Orthostatic HypotensionSup ine hypertension is common in patients with ortho- static hypotension and is associated with increased cardio- vascular risk. Treatment of orthostasis can exacerbate supine hypertension and vice versa. Life expectancy is often reduced in patients with profound autonomic ner- vous system dysfunction. In those whose life expectancy is at least several years, though, treatment of nocturnal hypertension might be considered with the use of shorter acting agents (eg, captopril, hydralazine, losartan, or quick- release nifedipine). In patients with supine hypertension, medications used to increase blood pressure during the day should not be given within 5 hours of bedtime.Follow-Up of Patients Receiving Hypertension TherapyOnc e blood pressure is controlled on a well-tolerated regi- men, follow-up visits can be infrequent and laboratory test- ing limited to those appropriate for the patient and the medications used. Y early monitoring of blood lipids is rec- ommended, and an electrocardiogram could be repeated at 2- to 4-year intervals depending on whether initial abnor- malities are present and on the presence of coronary risk factors. Patients who have had excellent blood pressure control for several years, especially if they have lost weight and initiated favorable lifestyle modifications, might be con- sidered for a trial of reduced antihypertensive medications.Carnethon  MR et al; American Heart Association Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Func- tional Genomics and Translational Biology; and Stroke Coun- cil. Cardiovascular health in African Americans: a scientific statement from the American Heart Association. Circulation. 2017;136:e393. [PMID: 29061565] Perkovic V et al; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295. [PMID: 30990260] Supiano MA et al. New guidelines and SPRINT results: implica- tions for geriatric hypertension. Circulation. 2019;140:976. [PMID: 31525101] Wenger NK et al. Hypertension across a womans life cycle. J Am Coll Cardiol. 2018;71:1797. [PMID: 29673470]RE SISTANT HYPERTENSIONResistant  hypertension is defined as the failure to reach blood pressure control in patients who are adherent to full doses of an appropriate three-drug regimen (including a diuretic). In the approach to resistant hypertension, the clinician should first confirm compliance and rule out white coat hypertension,  ideally using ambulatory or home-based measurement of blood pressure. Exacerbating factors should be considered (as outlined above). Finally, identifiable causes of resistant hypertension should be sought (Table 1114). The clinician should pay particularTable 1113. Recommended antihypertensive medications for coexisting indications.Indicion aniynsiv Mdicion Diuic B-Block aCe Inibio arBClcium Cnnl Blockaldoson angonis Heart failure       Following MI      High coronary disease risk      Diabetes      Chronic kidney disease    Recurrent stroke prevention    ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; MI, myocardial infarction.CMDT22_Ch11_p0443-p0474.indd  470 29/06/21 8:37 PMSYSteMIC hYperteNSION471 CMDT 2022at tention to the type of diuretic being used in relation to the patients kidney function. Aldosterone may play an important role in resistant hypertension and aldosterone receptor blockers can be very useful. If goal blood pressure cannot be achieved following completion of these steps, consultation with a hypertension specialist should be con- sidered. Renal sympathetic nerve ablation is a consider- ation for these patients in the absence of other options, but further trials are needed before this procedure can be rou- tinely integrated into clinical practice.W ei FF et al. Diagnosis and management of resistant hyperten- sion: state of the art. Nat Rev Nephrol. 2018;14:428. [PMID: 29700488]HY PERTENSIVE URGENCIES & EMERGENCIESH ypertensive urgencies are situations in which blood pressure must be reduced within a few hours. These include patients with asymptomatic severe hypertension (systolic blood pressure greater than 220 mm Hg or dia- stolic pressure greater than 125 mm Hg that persists after a period of observation) and those with optic disk edema, progressive target-organ complications, and severe periop- erative hypertension. Elevated blood pressure levels alonein the absence of symptoms of new or progressive target-organ damagerarely require emergency therapy. Parenteral drug therapy is not usually required; partial reduction of blood pressure with relief of symptoms is thegoal. Effective oral agents are clonidine, captopril, and slow-release nifedipine. Hypertensive emergencies require substantial reduction of blood pressure within 1 hour to avoid the risk of serious morbidity or death. Although blood pressure is usually strik- ingly elevated (diastolic pressure greater than 130 mm Hg), the correlation between pressure and end-organ damage is often poor. It is the presence of critical multiple end-organ injury that determines the seriousness of the emergency and the approach to treatment. Emergencies include hyperten- sive encephalopathy (headache, irritability, confusion, and altered mental status due to cerebrovascular spasm), hyper- tensive nephropathy (hematuria, proteinuria, and acute kidney injury due to arteriolar necrosis and intimal hyper- plasia of the interlobular arteries), intracranial hemorrhage, aortic dissection, preeclampsia-eclampsia, pulmonary edema, unstable angina, or myocardial infarction. Encepha- lopathy or nephropathy accompanying hypertensive reti- nopathy has historically been called malignant hypertension, but the therapeutic approach is identical to that used in other hypertensive emergencies. Parenteral therapy is indicated in most hypertensive emergencies, especially if encephalopathy is present. The initial goal in hypertensive emergencies is to reduce the pres- sure by no more than 25% (within minutes to 1 or 2 hours) and then toward a level of 160/100 mm Hg within 26 hours. Excessive reductions in pressure may precipitate coronary, cerebral, or renal ischemia. To avoid such declines, the use of agents that have a predictable, dose-dependent, tran- sient, and progressive antihypertensive effect is preferable (Table 1115). In that regard, the use of sublingual or oral fast-acting nifedipine preparations is best avoided. Acute ischemic stroke is often associated with marked elevation of blood pressure, which will usually fall sponta- neously. In such cases, antihypertensives should only be used if the systolic blood pressure exceeds 180200 mm Hg, and blood pressure should be reduced cautiously by 1015% (Table 1115). If thrombolytics are to be given, blood pres- sure should be maintained at less than 185/110 mm Hg during treatment and for 24 hours following treatment. Inintracerebral hemorrhage, the aim is to minimize bleeding by reducing the systolic blood pressure in most patients to 130140 mm Hg within the first 6 hours. In acute subarachnoid hemorrhage, as long as the bleeding source remains uncorrected, a compromise must be struck between preventing further bleeding and maintaining cere- bral perfusion in the face of cerebral vasospasm. In this situ- ation, blood pressure goals depend on the patients usual blood pressure. In previously normotensive patients, the tar- get should be a systolic blood pressure of 110120 mm Hg; in hypertensive patients, blood pressure should be treated to 20% below baseline pressure. In the treatment of hyper- tensive emergencies complicated by (or precipitated by) central nervous system injury, labetalol or nicardipine are good choices, since they are nonsedating and do not appear to cause significant increases in cerebral blood flow or intracranial pressure. Patients with subarachnoid hemor- rhage should receive nimodipine for 3 weeks following presentation to minimize cerebral vasospasm. In hyperten- sive emergencies arising from catecholaminergic mechanisms,Table 1114. Causes of resistant hypertension.Improper  blood pressure measurement Nonadherence Volume overload and pseudotolerance Excess sodium intake Volume retention from kidney disease Inadequate diuretic therapy Drug-induced or other causes Inadequate doses Inappropriate combinations Nonsteroidal anti-inflammatory drugs; cyclooxygenase-2 inhibitors Cocaine, amphetamines, other illicit drugs Sympathomimetics (decongestants, anorectics) Oral contraceptives Adrenal steroids Cyclosporine and tacrolimus Erythropoietin Licorice (including some chewing tobacco) Selected over-the-counter dietary supplements and medicines (eg, ephedra, ma huang, bitter orange) Associated conditions Obesity Excess alcohol intake Identifiable causes of hypertension (see Table 112) Data from Chobanian AV et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560.CMDT22_Ch11_p0443-p0474.indd  471 29/06/21 8:37 PMChapter 11472 CMDT 2022T able 1115. Treatment of hypertensive emergency depending on primary site of end-organ damage. See Table 1116 for dosages.t y of hynsiv emgncyrcommndd Dug Oions nd Combinions Dugs o avoid Myocardial ischemia and infarction Nicardipine plus esmolol1Nitroglycerin  plus labetalol Nitroglycerin plus esmolol1Hydralazine, diazoxide, minoxidil, nitroprusside Acute kidney injury Fenoldopam Nicardipine Clevidipine Aortic dissection Esmolol plus nicardipine Esmolol plus clevidipine Labetalol Esmolol plus nitroprussideHydralazine, diazoxide, minoxidil Acute pulmonary edema, LV systolic dysfunction Nicardipine plus nitroglycerin2plus a loop diuretic Clevidipine plus nitroglycerin2plus a loop diureticHydralazine, diazoxide, beta-blockers Acute pulmonary edema, diastolic dysfunction Esmolol plus low-dose nitroglycerin plus a loop diuretic Labetalol plus low-dose nitroglycerin plus a loop diuretic Ischemic stroke (systolic blood pressure > 180200 mm Hg)Nicardipine Clevidipine LabetalolNitroprusside, methyldopa, clonidine, nitroglycerin Intracerebral hemorrhage (systolic blood pressure > 140160 mm Hg)Nicardipine Clevidipine LabetalolNitroprusside, methyldopa, clonidine, nitroglycerin Hyperadrenergic states, including cocaine use Nicardipine plus a benzodiazepine Clevidipine plus a benzodiazepine Phentolamine LabetalolBeta-blockers Preeclampsia, eclampsia Labetalol NicardipineDiuretics, ACE inhibitors1 Avoid if there is LV systolic dysfunction.2 Drug of choice if LV systolic dysfunction is associated with ischemia. ACE, angiotensin-converting enzyme; LV, left ventricular.suc h as pheochromocytoma or cocaine use, beta-blockers can worsen the hypertension because of unopposed peripheral vasoconstriction; nicardipine, clevidipine, or phentolamine is preferred . Labetalol is useful in these patients if the heart rate must be controlled. Table 1115 provides guidelines for the choice of antihypertensive agent based on the site of end- organ damage. ACE inhibitors are specifically indicated for hypertensive crisis from systemic sclerosis (scleroderma). In acute aortic dissection, systolic blood pressure and heart rate should be reduced within 30 minutes to below 120 mm Hg and less than 60 beats per minute, using a combination of vasodilation and beta-blockade. Pharmacologic ManagementA.  Parenteral AgentsSodiu m nitroprusside is no longer the treatment of choice for acute hypertensive problems; in most situations, appropriatecontrol of blood pressure is best achieved using combinations of nicardipine or clevidipine plus labetalol or esmolol . (Table 1116 lists drugs, dosages, and adverse effects.) 1. Nicardipine Intravenous nicardipine is the most potent and the longest acting of the parenteral calcium channel blockers. As a primarily arterial vasodilator, it has the potential to precipitate reflex tachycardia, and for that reason it should not be used without a beta-blocker in patients with coronary artery disease. 2. Clevidipine Intravenous clevidipine is an L-type cal- cium channel blocker with a 1-minute half-life, which facilitates swift and tight control of severe hypertension. It acts on arterial resistance vessels and is devoid of venodila- tory or cardiodepressant effects. 3. Labetalol This combined beta- and alpha-blocking agent is the most potent adrenergic blocker for rapid bloodCMDT22_Ch11_p0443-p0474.indd  472 29/06/21 8:37 PMSYSteMIC hYperteNSION473 CMDT 2022Table 1116. Drugs for hypertensive emergencies and urgencies (in descending order of preference).agn acion Dosg Ons Duion advs effcs Commns hynsiv emgncis Nicardipine (Cardene)Calcium channel blocker5 mg/h intravenously; may increase by 12.5 mg/h every 15 minutes to 15 mg/h15 minutes 36 hours Hypotension, tachycardia, headache. May precipitate myocardial ischemia. Clevidipine (Cleviprex)Calcium channel blocker12 mg/h intravenously initially; double rate every 90 seconds until near goal, then by smaller amounts every 510 minutes to a maximum of 32 mg/h24 minutes 515 minutes Headache, nausea, vomiting. Lipid emulsion: contraindicated in patients with allergy to soy or egg. Labetalol (Trandate)Beta- and alpha-blocker2040 mg intravenously every 10 minutes to 300 mg; 2 mg/min infusion510 minutes 36 hours Nausea, hypotension, bronchospasm, bradycardia, heart block.Avoid in acute LV systolic dysfunction, asthma. May be continued orally. Esmolol (Brevibloc) Beta-blocker Loading dose 500 mcg/kg intravenously over 1 minute; maintenance, 25200 mcg/kg/min12 minutes 1030 minutes Bradycardia, nausea. Avoid in acute LV systolic dysfunction, asthma. Weak antihypertensive. Fenoldopam (Corlopam)Dopamine receptor agonist0.11.6 mcg/kg/min intravenously 45 minutes < 10 minutes Reflex tachycardia, hypotension, increased intraocular pressure.May protect kidney function. Enalaprilat (Vasotec)ACE inhibitor 1.25 mg intravenously every 6 hours 15 minutes 6 hours or moreExcessive hypotension. Additive with diuretics; may be contin- ued orally. Furosemide (Lasix) Diuretic 1080 mg orally or intravenously 15 minutes 4 hours Hypokalemia, hypotension. Adjunct to vasodilator. Hydralazine (Apresoline)Vasodilator 520 mg intravenously; may repeat after 20 minutes1030 minutes 26 hours Tachycardia, headache, vomiting, diarrheaAvoid in coronary artery disease, dissec- tion. Rarely used except in pregnancy. Nitroglycerin Vasodilator 0.255 mcg/kg/min intravenously 25 minutes 35 minutes Headache, nausea, hypotension, bradycardia.Tolerance may develop. Useful primar- ily with myocardial ischemia. Nitroprusside (Nitropress)Vasodilator 0.2510 mcg/kg/min intravenously Seconds 35 minutes Anxiety, increased intracranial pressure, vomiting, bowel obstruction; thiocyanate and cyanide toxicity, especially with kid- ney and liver dysfunction; hypotension. Coronary steal, decreased cerebral blood flow, increased intracranial pressure.No longer the first-line agent. hynsiv Ugncis Clonidine (Catapres)Central sympatholytic0.10.2 mg orally initially; then 0.1 mg every hour to 0.8 mg orally3060 minutes 68 hours Sedation. Rebound may occur. Captopril (Capoten) ACE inhibitor 12.525 mg orally 1530 minutes 46 hours Excessive hypotension. Nifedipine (Adalat, Procardia)Calcium channel blocker10 mg orally initially; may be repeated after 30 minutes15 minutes 26 hours Excessive hypotension, tachycardia, head- ache, angina, myocardial infarction, stroke.Response unpredictable. ACE, angiotensin-converting enzyme; CNS, central nervous system; GI, gastrointestinal; LV, left ventricular.CMDT22_Ch11_p0443-p0474.indd  473 29/06/21 8:37 PMChapter 11474 CMDT 2022pres sure reduction. Other beta-blockers are far less potent. Excessive blood pressure drops are unusual. Experience with this agent in hypertensive syndromes associated with pregnancy has been favorable. 4. Esmolol This rapidly acting beta-blocker is approved only for treatment of supraventricular tachycardia, but is often used for lowering blood pressure. It is less potent than labetalol and should be reserved for patients in whom there is particular concern about serious adverse events related to beta-blockers. 5. Fenoldopam Fenoldopam is a peripheral dopamine-1 (DA1) receptor agonist that causes a dose-dependent reduction in arterial pressure without evidence of toler- ance, rebound, withdrawal, or deterioration of kidney function. In higher dosage ranges, tachycardia may occur. This drug is natriuretic, which may simplify volume man- agement in acute kidney injury. 6. Enalaprilat This is the active form of the oral ACE inhibi- tor enalapril. The onset of action is usually within 15 minutes, but the peak effect may be delayed for up to 6 hours. Thus, enalaprilat is used primarily as an adjunctive agent. 7. Diuretics Intravenous loop diuretics can be very help- ful when the patient has signs of heart failure or fluid reten- tion, but the onset of their hypotensive response is slow, making them an adjunct rather than a primary agent for hypertensive emergencies. Low dosages should be used initially (furosemide, 20 mg, or bumetanide, 0.5 mg). They facilitate the response to vasodilators, which often stimu- late fluid retention. 8. Hydralazine Hydralazine can be given intravenously or intramuscularly, but its effect is less predictable than that of other drugs in this group. It produces reflex tachycardia and should not be given without beta-blockers in patients with possible coronary disease or aortic dissection. Hydral- azine is used primarily in pregnancy and in children, but even in these situations, it is not a first-line drug. 9. Nitroglycerin, intravenous This agent should be reserved for patients with accompanying acute coronary ischemic syndromes. 10. Nitroprusside sodium This agent is given by con- trolled intravenous infusion gradually titrated to thedesired effect. It lowers the blood pressure within seconds by direct arteriolar and venous dilation. Monitoring with an intra-arterial line avoids hypotension. Nitroprusside in combination with a beta-blockeris useful in patients with aortic dissection.B.  Oral AgentsPa tients with less severe acute hypertensive syndromes can often be treated with oral therapy. Suitable drugs will reduce the blood pressure over a period of hours. In those presenting as a consequence of noncompliance, it is usually sufficient to restore the patients previously established oral regimen. 1. Clonidine Clonidine, 0.2 mg orally initially, followed by 0.1 mg every hour to a total of 0.8 mg, will usually lower blood pressure over a period of several hours. Sedation is frequent, and rebound hypertension may occur if the drug is stopped. 2. Captopril Captopril, 12.525 mg orally, will also lower blood pressure in 1530 minutes. The response is variable and may be excessive. Captopril is the drug of choice in the management of systemic sclerosis hypertensive crisis. 3. Nifedipine The effect of fast-acting nifedipine cap- sules is unpredictable and may be excessive, resulting in hypotension and reflex tachycardia. Because myocardial infarction and stroke have been reported in this setting, the use of sublingual nifedipine is not advised. Nifedipine retard, 20 mg orally, appears to be safe and effective.C.  Subsequent TherapyWhen  the blood pressure has been brought under control, combinations of oral antihypertensive agents can be added as parenteral drugs are tapered off over a period of 23 days.Co rdonnier C et al. Intracerebral haemorrhage: current approaches to acute management. Lancet. 2018;392:1257. [PMID: 30319113] Ipek E et al. Hypertensive crisis: an update on clinical approach and management. Curr Opin Cardiol. 2017;32:397. [PMID: 28306673] Peixoto AJ. Acute severe hypertension. N Engl J Med. 2019;381:1843. [PMID: 31693807]CMDT22_Ch11_p0443-p0474.indd  474 29/06/21 8:37 PM475 CMDT 2022 ATHEROSCLEROTIC PERIPHERAL VASCULAR DISEASE OCCLUSIVE DISEASE: AORTA & ILIAC ARTERIESE S S E N T I A L S  O F  D I A G N O S I S Claudication: cramping pain or tiredness in the calf, thigh, or hip while walking. Diminished femoral pulses. Tissue loss (ulceration, gangrene) or rest pain. General ConsiderationsOlusive  atherslerti lesins develping in the extrem- ities, r peripheral artery disease (PAD), is evidene f a systemi atherslerti press. The prevalene f PAD is 30% in patients wh are 70 years ld withut ther risk fatrs, r 50 years ld with risk fatrs suh as diabetes mellitus r tba use. Pathlgi hanges f athersle- rsis may be diffuse, but flw-limiting stenses ur seg- mentally. In the lwer extremities, stenses lassially ur in three anatmi segments: the artilia segment, femral-ppliteal segment, and the infrappliteal r tibial segment f the arterial tree. Lesins in the distal arta and prximal mmn ilia arteries lassially ur in White male smkers aged 5060 years. Disease prgressin may lead t mplete lusin f ne r bth mmn ilia arteries, whih an preipitate lusin f the entire abdminal arta t the level f the renal arteries. Clinical FindingsA.  Symptoms and SignsA pprximately tw-thirds f patients with PAD are either asymptmati r d nt have lassi symptms. Intermit- tent laudiatin, whih is pain with ambulatin that urs frm insuffiient bld flw relative t demand, is typially12Warren J. Gasper, MD James C. Iannuzzi, MD, MPH Meshell D. Johnson, MDBlood Vessel & Lymphatic Disordersdesribed as severe and  ramping and primarily in the alf musles. The pain frm artilia lesins may extend int the thigh and buttks and eretile dysfuntin may ur frm bilateral mmn ilia disease. Rarely, patients m- plain nly f weakness in the legs when walking, r simply extreme limb fatigue. The symptms are relieved with rest and are reprduible when the patient walks again. Femral pulses and distal pulses are absent r very weak. Bruits may be heard ver the arta, ilia, and femral arteries.B.  Doppler and Vascular FindingsThe  rati f systli bld pressure deteted by Dppler examinatin at the ankle mpared with the brahial artery (referred t as the ankle-brahial index [ABI]) is redued t belw 0.9 (nrmal rati is 0.91.2); this differene is exag- gerated by exerise. Bth the drsalis pedis and the psterir tibial arteries are measured and the higher f the tw artery pressures is used fr alulatin. Segmental wavefrms r pulse vlume rerdings btained by strain gauge tehnl- gy thrugh bld pressure uffs demnstrate blunting f the arterial inflw thrughut the lwer extremity.C.  ImagingCT  angigraphy (CTA) and magneti resnane angigra- phy (MRA) an identify the anatmi latin f disease. Due t verlying bwel, duplex ultrasund has a limited rle in imaging the artilia segment. Imaging is required nly when symptms neessitate interventin, sine a his- try and physial examinatin with vasular testing shuld apprpriately identify the invlved levels f the arterial tree. TreatmentA.  Medical and Exercise TherapyThe  rnerstnes f PAD treatment are ardivasular risk fatr redutin and a supervised r strutured exerise prgram. Essential elements inlude smking essatin, antiplatelet therapy, lipid and bld pressure management, and weight lss. Nitine replaement therapy, buprpin, and vareniline have established benefits in smking essa- tin (see Chapter 1). Antiplatelet agents (aspirin, 81 mg rally daily, r lpidgrel, 75 mg rally daily) redue verallCMDT22_Ch12_p0475-p0501.indd  475 29/06/21 8:37 PMCHAPTER 12476 CMDT 2022ar divasular mrbidity. Lw-dse rivarxaban (2.5 mg rally twie daily) with aspirin 100 mg rally daily redues bth majr ardivasular and limb-related adverse events in symptmati patients. All patients with PAD shuld reeive high-dse statin (eg, atrvastatin 80 mg daily if tler- ated) t treat hyperhlesterlemia and inflammatin. A trial f ilstazl 100 mg rally twie a day, may imprve walking distane in apprximately tw-thirds f patients. Supervised exerise prgrams fr PAD prvide signifi- ant imprvements in pain, walking distane, and quality f life and may be mre effetive than an endvasular treatment alne. A minimum training gal is a walking sessin f 3045 minutes at least 3 days per week fr a minimum f 12 weeks. Strutured mmunity r hme- based exerise prgrams as well as alternative exerises (yling, upper-bdy ergmetry) may als be effetive.B.  Endovascular TherapyWhen  the atherslerti lesins are fal, they an be effetively treated with angiplasty and stenting. This apprah mathes the results f surgery fr single stenses but bth effetiveness and durability derease with lnger r multiple stenses.C.  Surgical InterventionA  prstheti art-femral bypass graft that bypasses the diseased artery segments is a highly effetive and durable treatment fr this disease. Patients may als be treated with a graft frm the axillary artery t the femral arteries (axill-femral bypass graft) r with a graft frm the n- tralateral femral artery (femral-femral bypass) when ilia disease is limited t ne side. The perative risk f axill-femral and femral-t-femral bypass grafts is lwer beause the abdminal avity is nt entered and the arta is nt rss-lamped, but the grafts are less durable. ComplicationsThe  mpliatins f the art-femral bypass are thse f any majr abdminal surgery in a patient ppulatin with a high prevalene f ardivasular disease. Mrtality is lw (23%), but mrbidity is higher and inludes a 510% rate f myardial infartin. While endvasular apprahes are safer and the mpliatin rate is 13%, they are less durable with extensive disease. PrognosisPa tients with islated artilia disease may have a further redutin in walking distane withut interventin, but symptms rarely prgress t rest pain r threatened limb lss. Life expetany is limited by their attendant ardi- vasular disease with a mrtality rate f 2540% at 5 years. Symptmati relief is generally exellent with super- vised exerise r after interventin. After art-femral bypass, a pateny rate f 90% at 5 years is mmn. End- vasular pateny rates and symptm relief fr patients with shrt stenses are als gd with 80% symptm free at 3 years. Reurrene rates fllwing endvasular treatment f extensive disease are 3050%.When to ReferPa tients with prgressive redutin in walking distane in spite f risk fatr mdifiatin and supervised exerise prgrams and thse with limitatins that interfere with their ativities f daily living shuld be referred fr nsul- tatin t a vasular surgen.Bnaa M P et al. Rivarxa ban in peripheral artery disease after revasularizatin. N Engl J Med. 2020;382:1994. [PMID: 32222135] MDermtt MM. Medial management f funtinal impair- ment in peripheral artery disease: a review. Prg Cardivas Dis. 2018;60:586. [PMID: 29727608] Mrs R et al. The evlving treatment f peripheral arterial disease thrugh guideline-direted remmendatins. J Clin Med. 2018;7:9. [PMID: 29315259]OCC LUSIVE DISEASE: FEMORAL & POPLITEAL ARTERIESE S S E N T I A L S  O F  D I A G N O S I S Cramping pain or tiredness in the calf with exercise. Reduced popliteal and pedal pulses. Foot pain at rest, relieved by dependency. Foot gangrene or ischemic ulcers. General ConsiderationsThe  superfiial femral artery is the peripheral artery mst mmnly luded by atherslersis. Atherslersis f the femral-ppliteal segment usually urs abut a deade after the develpment f artilia disease, has an even gender distributin, and mmnly affets Blak and Hispani patients. The disease frequently urs where the superfiial femral artery passes thrugh the abdutr magnus tendn in the distal thigh (Hunter anal). The mmn femral artery and the ppliteal artery are less ften diseased but lesins in these vessels are debilitating, resulting in shrt-distane laudiatin. Clinical FindingsA.  Symptoms and SignsSymp tms f intermittent laudiatin aused by lesins f the mmn femral artery, superfiial femral artery, and ppliteal artery are nfined t the alf. Claudiatin urs at 24 blks when there is lusin r stensis f the superfiial femral artery at the addutr anal, pr- vided gd llateral vessels frm the prfunda femris are maintained. Hwever, with nmitant disease f the prfunda femris r the ppliteal artery, muh shrter distanes may trigger symptms. With shrt-distane lau- diatin, dependent rubr f the ft with blanhing n elevatin may be present. Chrni lw bld flw states will als ause atrphi hanges in the lwer leg and ftCMDT22_Ch12_p0475-p0501.indd  476 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS477 CMDT 2022with  lss f hair, thinning f the skin and subutaneus tissues, and disuse atrphy f the musles. With segmental lusive disease f the superfiial femral artery, the m- mn femral pulsatin is nrmal, but the ppliteal and pedal pulses are redued.B.  Doppler and Vascular FindingsABI  values less than 0.9 are diagnsti f PAD and levels belw 0.4 suggest hrni limb-threatening ishemia (fr- merly ritial limb ishemia). ABI readings depend n arterial mpressin. Sine the vessels may be alified in diabetes mellitus, hrni kidney disease, and in lder adults, ABIs an be misleading. In suh patients, the te- brahial index is usually reliable with a value less than 0.7 nsidered diagnsti f PAD. Pulse vlume rerdings with uffs plaed at the high thigh, mid-thigh, alf, and ankle will delineate the levels f bstrutin with redued pressures and blunted wavefrms.C.  ImagingDuplex  ultrasngraphy, CTA, and MRA all adequately shw the anatmi latin f the bstrutive lesins and are dne nly if revasularizatin is planned. TreatmentA.  Medical and Exercise TherapyA s with artilia disease, risk fatr redutin, medial pti- mizatin with a high-dse statin, and exerise treatment are the rnerstne f therapy. Cilstazl, 100 mg rally twie a day, may imprve intermittent laudiatin symptms.B.  Surgical InterventionIn terventin is indiated if laudiatin is prgressive, ina- paitating, r interferes signifiantly with essential daily ativities r emplyment. Interventin is mandatry if there is ishemi rest pain r ishemi ulers threaten the ft. 1. Bypass surgery The mst effetive and durable treat- ment fr lesins f the superfiial femral artery is a femral- ppliteal bypass with autlgus saphenus vein. Syntheti material, usually plytetraflurethylene (PTFE), an be used, but these grafts d nt have the durability f vein bypass. 2. Endovascular surgery Endvasular tehniques, suh as angiplasty and stenting, are ften used fr lesins f the superfiial femral artery. These tehniques have lwer mrbidity than bypass surgery but als have lwer rates f durability. Endvasular therapy is mst effetive in patients underging aggressive risk fatr mdifiatin in whm lesins measure less than 10 m lng. Palitaxel-eluting stents r palitaxel-ated ballns ffer mdest imprve- ment ver bare metal stents and nnated ballns, but the effet is nt as rbust as in the rnary arteries. The 1-year pateny rate is 50% fr balln angiplasty, 70% fr drug-ated ballns, and 80% fr stents. Hwever, by 3 years, the pateny rates are signifiantly wrse fr all three tehniques and reinterventin fr restensis is mmn.After a meta-analysis f linial trial data shwed inreased mrtality at 35 years after treatment with palitaxel-ated devies, the US FDA perfrmed an independent review and remmends judiius use f the devies. Onging trials, suh as SWEDEPAD, are expeted t prvide additinal data n the risks and benefits f palitaxel devies. 3. Thromboendarterectomy Remval f the athersle- rti plaque is limited t the lesins f the mmn fem- ral and the prfunda femris arteries where bypass grafts and endvasular tehniques have a mre limited rle. ComplicationsOpen  surgial predures f the lwer extremities, partiu- larly lng bypasses with vein harvest, have a risk f wund infetin that is higher than in ther areas f the bdy. Wund infetin r serma an ur in as many as 1015% f ases. Myardial infartin rates after pen surgery are 510%, with a 14% mrtality rate. Cmplia- tin rates f endvasular surgery are 15%, making these therapies attrative despite their lwer durability. PrognosisThe p rgnsis fr mtivated patients with islated superfi- ial femral artery disease is exellent, and surgery is nt remmended fr mild r mderate laudiatin in these patients. Hwever, when laudiatin signifiantly limits daily ativity undermining quality f life and ardivasu- lar health, interventin may be warranted. All interven- tins require lse pstpredure fllw-up with repeated ultrasund surveillane s that reurrent narrwing an be treated prmptly with angiplasty r bypass t prevent mplete lusin. The reprted pateny rate f bypass grafts f the femral artery, superfiial femral artery, and ppliteal artery is 6570% at 3 years, whereas the pateny f angiplasty is less than 50% at 3 years. Beause f the extensive atherslerti disease, inlud- ing assiated rnary lesins, 5-year survival with lwer extremity PAD is 70% and dereases t 50% when there is invlvement f the tibial arteries. Hwever, with aggressive risk fatr mdifiatin, substantial imprvement in ln- gevity has been reprted. When to ReferPa tients with prgressive symptms, shrt-distane laudi- atin, rest pain, r any uleratin shuld be referred t a peripheral vasular speialist.Hiram t JS et al. Interventins fr lwer extremity peripheral artery disease. Nat Rev Cardil. 2018;15:332. [PMID: 29679023] Katsans K et al. Risk f death fllwing appliatin f pali- taxel-ated ballns and stents in the femrppliteal artery f the leg: a systemati review and meta-analysis f randm- ized ntrlled trials. J Am Heart Ass. 2018;7:e011245. [PMID: 30561254] Nrdanstig J et al. Mrtality with palitaxel-ated devies in peripheral artery disease. N Engl J Med. 2020;383:2538. [PMID: 33296560]CMDT22_Ch12_p0475-p0501.indd  477 29/06/21 8:37 PMCHAPTER 12478 CMDT 2022Rha-Singh KJ  et al; VIVA Physiians, In. Patient-level meta- analysis f 999 laudiants underging primary femrppli- teal nitinl stent implantatin. Catheter Cardivas Interv. 2017;89:1250. [PMID: 28303688]OCC LUSIVE DISEASE: TIBIAL & PEDAL ARTERIESE S S E N T I A L S  O F  D I A G N O S I S Severe pain of the forefoot that is relieved by dependency (ischemic rest pain). Pain or numbness of the foot with walking. Ulcer or gangrene, and not claudication, is a frequent initial manifestation. Pallor when the foot is elevated. General ConsiderationsO lusive presses f the tibial arteries f the lwer leg and pedal arteries in the ft ur primarily in patients with dia- betes. There ften is extensive alifiatin f the artery wall. Clinical FindingsA.  Symptoms and SignsU nless there are nmitant lesins in the artilia r femral/superfiial femral artery segments, the first man- ifestatin f leg ishemia due t tibial artery disease is fre- quently an ishemi uler r ft gangrene, rather than laudiatin. The presene f ishemi rest pain r ulers is termed chronic limb-threatening ischemia and is assi- ated with the highest rate f amputatin. Classially, ish- emi rest pain is nfined t the drsum f the ft and is relieved with dependeny: the pain des nt ur with standing, sitting, r dangling the leg ver the edge f the bed. It is severe and burning in harater, and beause it is present nly when reumbent, it may awaken the patient frm sleep. On examinatin, femral and ppliteal pulses may r may nt be present depending n disease extent, but pal- pable pedal pulses will be absent. Dependent rubr may be prminent with pallr n elevatin. The skin f the ft is generally l, atrphi, and hairless.B.  Doppler and Vascular FindingsThe  ABI is ften belw 0.4; hwever, the ABI may be falsely elevated due t alifiatin f the arterial media layer (Mnkeberg medial alifi slersis) and may nt be mpressible. Te-brahial indexes are preferred fr assess- ing perfusin and prediting wund healing.C.  ImagingDig ital subtratin angigraphy is the gld standard methd t delineate the anatmy f the tibial-pplitealsegment. MRA r CTA is less helpful fr detetin f lesins in this latin due t the small vasulature and ther tehnial issues related t image reslutin. Differential DiagnosisBeause  f the high inidene f neurpathy in these patients, it is imprtant t differentiate rest pain frm dia- beti neurpathi dysesthesia. Leg night ramps ause pain in the leg rather than the ft and shuld nt be nfused with ishemi rest pain. Dependent rubr in the presene f a te wund an ften be mistaken fr ellulitis; pallr n elevatin helps nfirm the diagnsis f rubr. TreatmentGd  ft are may prevent ulers, and mst diabeti patients will d well with a nservative regimen. Hwever, if uleratins appear and there is n signifiant healing within 23 weeks, bld flw studies (ankle-brahial index/te-brahial index) are indiated. Pr bld flw and a ft uler r nightly ishemi rest pain requires expe- ditius revasularizatin t avid a majr amputatin.A.  Bypass and Endovascular TechniquesBypass  with vein t the distal tibial r pedal arteries is an effetive therapy t treat rest pain and heal ishemi ulers f the ft. Beause the ft ften has relative sparing f vasular disease, these bypasses have had adequate pateny rates (70% at 3 years). Frtunately, in nearly all series, limb preservatin rates are muh higher than pateny rates. Endvasular treatment with plain balln angiplasty is effetive fr shrt segment lesins. The tehnial failure and relusin rates inrease drastially with lng seg- ment disease in multiple tibial arteries. Stents and drug- ated ballns have nt been suessful in the tibial vessels t date.B.  AmputationPa tients with ishemi rest pain r ulers have a 3040% 1-year risk fr majr amputatin that inreases if revasu- larizatin annt be dne. Patients with diabetes and PAD have a 4-fld risk f hrni limb-threatening ishemia mpared with nndiabeti patients with PAD and have a risk f amputatin up t 20-fld when mpared t an age- mathed ppulatin. Many patients wh have belw-the- knee r abve-the-knee amputatins due t vasular insuffiieny never regain independent ambulatry status and ften need assisted-living failities. These fatrs m- bine t demand revasularizatin whenever pssible t preserve the limb. ComplicationsThe  mpliatins f interventin are similar t thse listed fr superfiial femral artery disease with evidene that the verall ardivasular risk f interventin inreases with dereasing ABI. Patients with hrni limb-threatening ishemia require aggressive risk fatr mdifiatin. Wund infetin rates after bypass are higher if there is an pen wund in the ft.CMDT22_Ch12_p0475-p0501.indd  478 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS479 CMDT 2022 PrognosisPa tients with tibial atherslersis have extensive ather- slerti burden and a high prevalene f diabetes. Their prgnsis withut interventin is pr and mpliated by the risk f amputatin. When to ReferPa tients with diabetes and ft ulers shuld be referred fr a frmal vasular evaluatin. Interventin may nt be neessary but the severity f the disease will be quantified, whih has impliatins fr future symptm develpment. Any patient with an uler and a diabeti ft infetin shuld be evaluated fr an emergent perative inisin and drainage. Brad-spetrum intravenus antibitis shuld be given empirially; fr example, vanmyin shuld be given t ver methiillin-resistant Staphylococcus aureus (MRSA) and ertapenem r piperaillin/tazbatam shuld be given t ver gram-negative and anaerbi rganisms. Centers that have a multidisiplinary limb preservatin enter staffed with vasular surgens, pdiatrists, plasti and rthpedi surgens, prsthetis and rthti speial- ists, and diabetes speialists shuld be sught.Cnte  MS et al. Glbal vasular guidelines n the management f hrni limb-threatening ishemia. J Vas Surg. 2019;69:3. [PMID: 31159978] Farber A et al. The urrent state f ritial limb ishemia: a sys- temati review. JAMA Surg. 2016;151:1070. [PMID: 27551978]ACU TE ARTERIAL OCCLUSION OF A LIMBE S S E N T I A L S  O F  D I A G N O S I S Sudden pain in a limb with absent limb pulses. Usually some neurologic dysfunction with numb- ness, weakness, or complete paralysis. Loss of light touch sensation requires revascular- ization within 3 hours for limb viability. General ConsiderationsAu te lusin may be due t an emblus r t thrmb- sis f a diseased atherslerti segment. Embli large enugh t lude prximal arteries in the lwer extremi- ties are almst always frm the heart and are related t atrial fibrillatin. Over 50% f the embli frm the heart g t the lwer extremities, 20% t the erebrvasular iru- latin, and the remainder t the upper extremities and mesenteri and renal irulatin. Atrial fibrillatin is the mst mmn ause f ardia thrmbus frmatin; ther auses are valvular disease r thrmbus frmatin n the ventriular surfae f a large anterir myardial infart. Embli frm arterial sures suh as arterial uleratins r alified exresenes are usually small and g t the distal arterial tree (tes).The typial patient with primary thrmbsis has had a histry f laudiatin and nw has an aute lusin. If the stensis is hrni, llateral bld vessels will develp, and the resulting lusin may ause nly minimal inrease in symptms. Clinical FindingsA.  Symptoms and SignsTh e sudden nset f extremity pain, with lss r redutin in pulses, is diagnsti f aute arterial lusin. This ften will be ampanied by neurlgi dysfuntin, suh as numb- ness r paralysis in extreme ases. With ppliteal lusin, symptms may affet nly the ft. With prximal lusins, the whle leg may be affeted. Signs f severe arterial ishemia inlude pallr, lness f the extremity, and mttling. Impaired neurlgi funtin prgressing t anesthesia with paralysis indiates irreversible injury requiring amputatin.B.  Doppler and Laboratory FindingsThere  will be little r n flw fund with Dppler examina- tin f the distal vessels. Imaging, if dne, may shw an abrupt utff f ntrast with embli lusin. Bld wrk may shw myglbinemia and metabli aidsis.C.  ImagingW henever pssible, imaging shuld be dne in the perating rm beause btaining angigraphy, MRA, r CTA may delay revasularizatin and jepardize the viability f the extremity. Hwever, in ases with nly mdest symptms and where light tuh f the extremity is maintained, imaging may be helpful in planning the revasularizatin predure. TreatmentImm ediate revasularizatin is required in all ases f symptmati aute arterial thrmbsis. Evidence of neuro- logic injury, including loss of light touch sensation, indicates that collateral flow is inadequate to maintain limb viability and revascularization should be accomplished within 3 hours. Lnger delays arry a signifiant risk f irreversible tissue damage. This risk apprahes 100% at 6 hurs.A.  HeparinAs  sn as the diagnsis is made, unfratinated heparin shuld be administered (500010,000 units) intravenusly, fllwed by a heparin infusin t maintain the ativated partial thrmbplastin time (aPTT) in the therapeuti range (6085 sends) (1218 units/kg/h). This helps pre- vent lt prpagatin and may als help relieve assiated vessel spasm. Antiagulatin may imprve symptms, but revasularizatin will still be required.B.  Endovascular TechniquesPharmame hanial thrmbetmy atheters an ahieve rapid revasularizatin and are mst effetive fr the smaller arteries f the lwer leg. Catheter-direted hemi- al thrmblysis int the lt with tissue plasmingen ativatr (TPA) may be dne but ften requires 24 hurs rCMDT22_Ch12_p0475-p0501.indd  479 29/06/21 8:37 PMCHAPTER 12480 CMDT 2022lnger  t fully lyse the thrmbus. This apprah an be taken nly in patients with an intat neurlgi examina- tin withut abslute ntraindiatins, suh as bleeding diathesis, gastrintestinal bleeding, intraranial trauma, r neursurgery within the past 3 mnths. Heparin is admin- istered systemially t prevent thrmbus frmatin arund the sheath. Frequent vasular and aess site examinatins are required during the thrmblyti predure t guard against the develpment f a hematma.C.  Surgical InterventionGeneral  anesthesia is usually indiated; lal anesthesia may be used in extremely high-risk patients if the explra- tin is t be limited t the mmn femral artery. In extreme ases, it may be neessary t perfrm thrmb- embletmy frm the femral, ppliteal, and even the pedal vessels t revasularize the limb. The mbined use f devies that pulverize and aspirate lt and intrapera- tive thrmblysis with TPA imprves utmes. ComplicationsCm pliatins f revasularizatin f an autely ishemi limb an inlude severe metabli aidsis, hyperkalemia, aute kidney injury, and ardia arrest. In ases where sev- eral hurs have elapsed but revery f viable tissue may still be pssible, signifiant levels f lati aid, ptassium, and ther harmful agents suh as myglbin may be released int the irulatin during revasularizatin. Administering sdium biarbnate (150 mEq NaHCO3in 1 L f dextrse 5% in water) prir t reestablishing arterial flw is required. Surgery in the presene f thrmblyti agents and heparin arries a high risk f pstperative wund hematma. PrognosisThere  is a 1025% risk f amputatin with an aute arterial embli lusin, and a 25% r higher in-hspital mrtal- ity rate. Prgnsis fr aute thrmbti lusin f an atherslerti segment is generally better beause the l- lateral flw an maintain extremity viability. The lnger- term survival reflets the verall nditin f the patient. In high-risk patients, an aute arterial lusin is assi- ated with a dismal prgnsis.OCC LUSIVE CEREBROVASCULAR DISEASEE S S E N T I A L S  O F  D I A G N O S I S Sudden onset of weakness and numbness of an extremity or the face, aphasia, dysarthria, or uni- lateral blindness (amaurosis fugax). Bruit heard loudest in the mid neck. General ConsiderationsU nlike the ther vasular territries, symptms f ishemi erebrvasular disease are predminantly due t embli. The ishemia is reversible (transient ishemi attaks[TIAs]) when llateral flw reestablishes perfusin, but is a sign that the risk f additinal embli and a strke is high. Mst ishemi strkes are due t embli frm the heart. One-quarter f all ishemi strkes may be due t embli frm an arterial sure; apprximately 90% f these embli riginate frm the prximal internal artid artery, an area uniquely prne t the develpment f athersler- sis. Intraranial atherslerti lesins are unmmn in western ppulatins but are the mst frequent latin f erebrvasular disease in Asian ppulatins. Clinical FindingsA.  Symptoms and SignsGenerally , the symptms f a TIA last nly a few sends t minutes (but may ntinue up t 24 hurs) while a strke is defined as persistent symptms beynd 24 hurs. The mst mmn lesins assiated with artid disease invlve the anterir irulatin in the rtex with bth mtr and sensry invlvement. Embli t the retinal artery ause unilateral blindness; transient mnular blindness is termed amaursis fugax.  Psterir irula- tin symptms referable t the brainstem, erebellum, and visual regins f the brain may be due t atherslersis f the vertebral basilar systems and are muh less mmn. Signs f erebrvasular disease may inlude artid artery bruits. Hwever, there is pr rrelatin between the degree f stensis and the presene f the bruit. Further- mre, the presene f a bruit des nt rrelate with strke risk. Nnfal symptms, suh as dizziness and unsteadi- ness, seldm are related t erebrvasular atherslersis.B.  ImagingDuplex ultrasngrap hy is the imaging mdality f hie with high speifiity and sensitivity fr deteting and grad- ing the degree f stensis at the artid bifuratin (see Chapter 24). Exellent depitin f the full anatmy f the erebr- vasular irulatin frm arti arh t ranium an be btained with either MRA r CTA. Eah f the mdalities may have false-psitive r false-negative findings. Sine the deisin t intervene in ases f artid stensis depends n an aurate assessment f the degree f stensis, it is rem- mended that at least tw mdalities be used t nfirm the degree f stensis. Diagnsti erebral angigraphy is reserved fr ases where artid artery stenting (CAS) is t be dne. TreatmentSee  Chapter 24 fr a disussin f the medial manage- ment f lusive erebrvasular disease.A.  Asymptomatic PatientsLar ge studies have shwn a 5-year redutin in strke rate frm 11.5% t 5.0% with surgial treatment f asymptmati artid stensis that is greater than 60%; patients with asymptmati artid stensis may benefit frm artid interventin if their risk frm interventin is lw and their expeted survival is lnger than 5 years. Aggressive riskCMDT22_Ch12_p0475-p0501.indd  480 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS481 CMDT 2022fat r mdifiatin, inluding high-pteny statins, may be as valuable as surgial interventin in these patients; the large NIH-spnsred CREST2 study is examining this issue. Mild t mderate disease (3050% stensis) indiates the need fr nging mnitring and aggressive risk fatr mdifiatin. Patients with artid stensis that suddenly wrsens are thught t have an unstable plaque and are at partiularly high risk fr embli strke.B.  Symptomatic PatientsLa rge randmized trials have shwn that patients with TIAs r strkes frm whih they have mpletely r nearly m- pletely revered will benefit frm artid interventin if the ipsilateral artid artery has a stensis f mre than 70% (Figure 121), and they are likely t benefit if the artery has a stensis f 5069%. In these situatins, artid endartere- tmy (CEA) and, in seleted ases, CAS have been shwn t have a durable effet in preventing further events. In symp- tmati patients, interventin shuld ideally be planned within 2 weeks sine delays inrease the risk f a send event. ComplicationsThe  mst mmn mpliatin frm artid interventin is ranial nerve injury, while the mst dreaded mplia- tin is strke frm emblizatin r artid lusin. The Amerian Heart Assiatins remmendatins fr upper limits f aeptable mbined mrbidity and mrtality fr these interventins is 3% fr patients with asymptmati artid stensis, 5% fr thse with TIAs, and 7% fr patients with previus strke. Higher rates f mrbidityand mrtality negate the therapeuti benefit f artid interventin.A.  Carotid EndarterectomyIn  the 2010 CREST study the strke risk fr CEA was 2.3%. CEA als arries a 12% risk f permanent ranial nerve injury (usually the vagus nerve). There is als the risk f pstperative nek hematma, whih an ause aute air- way mprmise. Crnary artery disease is a mrbidity in mst f these patients. Myardial infartin rates after CEA are apprximately 26%.B.  Carotid Angioplasty and StentingCAS  had a strke risk f 4.1% in the 2010 CREST study; patients ver 70 years f age as well as wmen had higher strke rates with CAS than with CEA. Hwever, the risk f myardial infartin was lwer with CAS mpared t CEA (1.1% vs 2.3%). CAS is indiated fr reperative ases, prir nek radiatin, and high artid bifuratins nt therwise aessible surgially. Nnetheless, embli are mre mmn during transfemral CAS in spite f embli prtetin devies, espeially when the artid artery is trtuus and heavily alified. Transervial artid stent- ing, perfrmed thrugh a small inisin at the base f the nek, avids artery trtusity and has lwer emblizatin rates than transfemral artid stenting. PrognosisT wenty-five perent f patients presenting with artid stensis and a TIA r small strke will have further brain ishemia within 18 mnths with mst f the events ur- ring within the first 6 mnths. Histrially, patients with asymptmati artid stensis are believed t have an annual strke rate f just ver 2% but this may be lwer in the statin era. Prspetive ultrasund sreening at least annually is remmended in asymptmati patients with knwn artid stensis t identify thse wh have evidene f plaque prgressin, whih inreases strke risk. Cn- mitant rnary artery disease is mmn and is an imprtant fatr in these patients bth fr periperative risk and lng-term prgnsis. Aggressive risk fatr mdi- fiatin shuld be presribed fr patients with erebrvas- ular disease regardless f planned interventin. When to ReferAsym ptmati r symptmati patients with a artid ste- nsis f mre than 70% and patients with artid stensis f less than 70% with symptms f a TIA r strke shuld be referred t a vasular speialist fr nsultatin.Br tt TG et al; CREST Investigatrs. Lng-term results f stent- ing versus endarteretmy fr artid-artery stensis. N Engl J Med. 2016;374:1021. [PMID: 26890472] Mresli P et al. Cartid stenting versus endarteretmy fr asymptmati artid artery stensis: a systemati review and meta-analysis. Strke. 2017;48:2150. [PMID: 28679848] Paraskevas KI et al. An updated systemati review and meta- analysis f results f transervial artid artery stenting with flw reversal. J Vas Surg. 2020;72:1489. [PMID: 32422272] Figure 121. Digital subtraction angiography of a high-grade (90%) stenosis of the internal carotid artery with ulceration (arrow). (Used, with permission, from Dean SM, Satiani B, Abraham WT. Color Atlas and Synopsis of Vascular Diseases. McGraw-Hill, 2014.)CMDT22_Ch12_p0475-p0501.indd  481 29/06/21 8:37 PMCHAPTER 12482 CMDT 2022VI SCERAL ARTERY INSUFFICIENCY (Intestinal Angina)E S S E N T I A L S  O F  D I A G N O S I S Severe postprandial abdominal pain. Weight loss with a fear of eating. Acute mesenteric ischemia: severe abdominal pain yet minimal findings on physical examination. General ConsiderationsA cute mesenteric ischemia results frm lusive mesen- teri arterial disease, either embli lusin r primary thrmbsis f at least ne majr mesenteri artery. Ishemia an als result frm nonocclusive mesenteric ischemia, whih is generally seen in patients with lw flw states, suh as severe heart failure, sepsis, r hyptensin. Chronic mesenteric ischemia, als alled intestinal angina, urs when inreased flw demands during feeding are nt met resulting in abdminal pain. Beause f the rih llateral mesenteri netwrk, generally at least tw f the three majr viseral vessels (elia, superir mesenteri, inferir mesenteri arteries) are affeted befre symptms develp. Ischemic colitis, a variant f mesenteri ishemia, usually urs in the distributin f the inferir mesenteri artery. The intestinal musa is the mst sensitive t ishemia and will slugh if underperfused. Clinical FindingsA.  Symptoms and Signs1.  Acute mesenteric ischemia Viseral arterial emblism presents autely with severe abdminal pain. In ntrast, patients with primary viseral arterial thrmbsis ften give an anteedent histry nsistent with hrni mesen- teri ishemia. The key finding with aute mesenteri ishemia is severe, steady, diffuse abdminal pain with an absene f fal tenderness r distentin. This pain ut f prprtin t physial examinatin findings urs beause ishemia initially is musal and des nt impat the peritneum until transmural ishemia inflames the peritneal lining. A high white bld ell unt, lati ai- dsis, hyptensin, and abdminal distentin may aid in the diagnsis. 2. Chronic mesenteric ischemia Patients are generally ver 45 years f age and may have evidene f athersle- rsis in ther vasular beds. Symptms nsist f epigastri r periumbilial pstprandial pain lasting 13 hurs. T avid the pain, patients limit fd intake and may develp a fear f eating. Weight lss is universal. 3. Ischemic colitis Charateristi symptms are left lwer quadrant pain and tenderness, abdminal ramping, and mild diarrhea. Retal disharge will appear muus-like r bldy and shuld prmpt further evaluatin.B. Imaging and ColonoscopyCntrast-enhaned  CT is highly aurate at determining the presene f ishemi intestine. In patients with aute r hrni mesenteri ishemia, a CTA r MRA an demn- strate narrwing f the prximal viseral vessels. In aute mesenteri ishemia frm a nnlusive lw flw state, angigraphy is needed t display the typial pruned tree appearane f the distal viseral vasular bed. Ultrasund sanning f the mesenteri vessels may shw prximal bstruting lesins. In patients with ishemi litis, flexible sigmidspy shuld be perfrmed t assess the grade f ishemia that urs mst ften in watershed areas, suh as the retal sigmid and spleni flexure. TreatmentA  high suspiin f aute mesenteri ishemia ditates immediate explratin t assess bwel viability. If the bwel remains viable, arterial bypass using a prstheti nduit an be dne either frm the supra-elia arta r mmn ilia artery t the elia and the superir mesen- tery artery. In ases where bwel viability is questinable r bwel resetin will be required, the bypass an be dne with autlgus vein t avid the use f prstheti nduits in a ptentially ntaminated field. Angiplasty and stent- ing f the arteries an be used but des nt avid a surgial evaluatin f bwel viability. In hrni mesenteri ishemia, angiplasty and stenting f the prximal vessel may be benefiial depending n the anatmy f the stensis. Shuld an endvasular slutin nt be available, an art-viseral artery bypass is the pre- ferred management. The lng-term results are highly dura- ble. Viseral artery endarteretmy is reserved fr ases with multiple lesins where bypass wuld be diffiult. The mainstay f treatment f ishemi litis is mainte- nane f bld pressure and perfusin until llateral ir- ulatin bemes well established. The patient must be mnitred lsely fr evidene f perfratin neessitating resetin. PrognosisThe  mbined mrbidity and mrtality rates are 1015% frm surgial interventin in part due t malnutritin and frailty in patients preeding hrni mesenteri ishemia. Hwever, withut interventin bth nditins are uni- frmly fatal. Adequate llateral irulatin usually devel- ps in thse wh have ishemi litis, and the prgnsis fr this entity is better than hrni mesenteri ishemia. When to ReferAny  patient in whm there is a suspiin f mesenteri ishemia shuld be urgently referred fr imaging and ps- sible interventin.Alahdab F et al.  A systemati review and meta-analysis f end- vasular versus pen surgial revasularizatin fr hrni mesenteri ishemia. J Vas Surg. 2018;67:1598. [PMID: 29571626]CMDT22_Ch12_p0475-p0501.indd  482 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS483 CMDT 2022Clair  DG et al. Mesenteri ishemia. N Engl J Med. 2016;374:959. [PMID: 26962730] Lim S et al. Cntemprary management f aute mesenteri ishemia in the endvasular era. Vas Endvasular Surg. 2019;53:42. [PMID: 30360689]ACU TE MESENTERIC VEIN OCCLUSIONThe h allmarks f aute mesenteri vein lusin are pst- prandial pain and evidene f a hyperagulable state. Aute mesenteri vein lusin presents similarly t the arterial lusive syndrmes but is muh less mmn. Patients at risk inlude thse with parxysmal nturnal hemglbinuria; prtein C, prtein S, r antithrmbin defiienies; r the JAK2 mutatin. These lesins are diffi- ult t treat surgially, and thrmblysis is the mainstay f therapy. Aggressive lng-term antiagulatin is required fr these patients. NONATHEROSCLEROTIC VASCULAR DISEASE THROMBOANGIITIS OBLITERANS (Buerger Disease)E S S E N T I A L S  O F  D I A G N O S I S Typically occurs in male cigarette smokers. Distal extremities involved with severe ischemia, progressing to tissue loss. Thrombosis of the superficial veins may occur. Smoking cessation is essential to stop disease progression. General ConsiderationsBuerger  disease is a segmental, inflammatry, and thrm- bti press f the distal-mst arteries and asinally veins f the extremities. Pathlgi examinatin reveals arteritis in the affeted vessels. The ause is nt knwn but it is rarely seen in patients wh d nt smke igarettes. Arteries mst mmnly affeted are the plantar and digi- tal vessels f the ft and lwer leg. In advaned stages, the fingers and hands may beme invlved. The inidene f Buerger disease has dereased dramatially. Clinical FindingsA.  Symptoms and SignsBuerger  disease may be initially diffiult t differentiate frm rutine peripheral vasular disease, but in mst ases, the lesins are n the tes and the patient is yunger than 40 years f age. The bservatin f superfiial thrmb- phlebitis may aid the diagnsis. Beause the distal vessels are usually affeted, intermittent laudiatin is nt m- mn with Buerger disease, but rest pain, partiularly painin the distal mst extremity (ie, tes), is frequent. This pain ften prgresses t tissue lss and amputatin, unless the patient stps smking. The prgressin f the disease seems t be intermittent with aute and dramati episdes fllwed by sme perids f remissin.B.  ImagingMRA  r invasive angigraphy an demnstrate the blit- eratin f the distal arterial tree typial f Buerger disease. Differential DiagnosisIn  atherslerti peripheral vasular disease, the nset f tissue ishemia tends t be less dramati than in Buerger disease, and symptms f prximal arterial invlvement, suh as laudiatin, predminate. Symptms f Raynaud disease may be diffiult t dif- ferentiate frm Buerger disease and are ften existent in 40% f patients. Repetitive atherembli may als mimi Buerger disease and may be diffiult t differentiate. It may be neessary t image the prximal arterial tree t rule ut sures f arterial mirembli. TreatmentSmking essatin is the mainstay f therapy and will  halt the disease in mst ases. As the distal arterial tree is luded, revasularizatin is ften nt pssible. Sympa- thetmy is rarely effetive. PrognosisIf  smking essatin an be ahieved, the utlk fr Buerger disease may be better than in patients with premature periph- eral vasular disease. If smking essatin is nt ahieved, then the prgnsis is generally pr, with amputatin f bth lwer and upper extremities a pssible utme.Le  Jnur A et al; Frenh Buergers Netwrk. Lng-term utme and prgnsti fatrs f mpliatins in thrmbangiitis bliterans (Buergers disease): a multienter study f 224 patients. J Am Heart Ass. 2018;7:e010677. [PMID: 30571594] ARTERIAL ANEURYSMS ABDOMINAL AORTIC ANEURYSME S S E N T I A L S  O F  D I A G N O S I S Most aortic aneurysms are asymptomatic until rupture. 80% of abdominal aortic aneurysms measuring 5 cm are palpable; the usual threshold for treat- ment is 5.5 cm. Back or abdominal pain with aneurysmal tender- ness may precede rupture. Rupture is catastrophic: excruciating abdominal pain that radiates to the back; hypotension.CMDT22_Ch12_p0475-p0501.indd  483 29/06/21 8:37 PMCHAPTER 12484 CMDT 2022 General ConsiderationsDilatati n f the infrarenal arta is a nrmal part f aging. The arta f a healthy yung man measures apprximately 2 m. An aneurysm is nsidered present when the arti diameter exeeds 3 m, but aneurysms rarely rupture until their diameter exeeds 5 m. Abdminal arti aneurysms are fund in 2% f men ver 55 years f age; the male t female rati is 4:1. Ninety perent f abdminal athersle- rti aneurysms riginate belw the renal arteries. The aneurysms usually invlve the arti bifuratin and ften invlve the mmn ilia arteries. Inflammatry aneurysms are an unusual variant. These have an inflammatry peel (similar t the inflammatin seen with retrperitneal fibrsis) that surrunds the aneurysm and enases adjaent retrperitneal strutures, suh as the dudenum and, asinally, the ureters. Clinical FindingsA.  Symptoms and Signs1.  Asymptomatic Althugh 80% f 5-m infrarenal aneurysms are palpable n rutine physial examinatin, mst aneurysms are disvered n ultrasund r CT imag- ing as part f a sreening prgram r during the evaluatin f unrelated abdminal symptms. 2. Symptomatic a. Pain Aneurysmal expansin may be ampanied by pain that is mild t severe midabdminal dismfrt ften radiating t the lwer bak. The pain may be nstant r intermittent and is exaerbated by even gentle pressure n the aneurysm sak. Pain may als ampany inflamma- try aneurysms. Mst aneurysms have a thik layer f thrmbus lining the aneurysmal sa, but emblizatin t the lwer extremities is rarely seen. b. Rupture The sudden esape f bld int the retr- peritneal spae auses severe pain and hyptensin. Free rupture int the peritneal avity is a lethal event.B.  Laboratory FindingsIn  aute ases f a ntained rupture, the hematrit may be nrmal, sine there has been n pprtunity fr hemdilutin. Patients with aneurysms may als have rnary artery disease, artid disease, kidney impairment, and emphysema, whih are typially seen in elderly men wh smke igarettes. Preperative testing may indiate the presene f these mrbid nditins, whih inrease the risk f interventin.C.  ImagingA bdminal ultrasngraphy is the diagnsti study f hie fr initial sreening fr the presene f an aneu- rysm. In apprximately three-quarters f patients with aneurysms, urvilinear alifiatins utlining prtins f the aneurysm wall may be visible n plain radigraphs f the abdmen r bak. CT sans prvide a mre reliable assessment f aneurysm diameter and shuld be dne when the aneurysm nears the diameter threshld (5.5 m)fr treatment. Cntrast-enhaned CT sans shw the arter- ies abve and belw the aneurysm. The visualizatin f this vasulature is essential fr planning repair. CT imaging will ften demnstrate mural thrmbus within the aneurysm and is nt an indiatin fr antiagulatin. One an aneurysm is identified, rutine fllw-up with ultrasund will determine size and grwth rate. The fre- queny f imaging depends n aneurysm size ranging frm every 2 years fr aneurysms smaller than 4 m t every 6 mnths fr aneurysms at r apprahing 5 m. When an aneurysm measures apprximately 5 m, a CTA with ntrast shuld be dne t mre aurately assess the size f the aneurysm and define the anatmy. ScreeningGuidelines  remmend abdminal ultrasund sreening in men 6575 years ld with expsure t 100 r mre life- time igarettes but nflit n whether wmen with the same expsure shuld be sreened. Guidelines d nt re- mmend repeated sreening if the arta shws n enlarge- ment. While patients are mnitred, smking essatin and treatment f underlying hypertensin, hyperlipidemia, and diabetes shuld be nsidered. TreatmentA.  Elective RepairTh e risk f rupture inreases with aneurysm diameter. In gen- eral, eletive repair is indiated fr arti aneurysms 5.5 m r larger in diameter r aneurysms that demnstrate rapid expan- sin (mre than 0.5 m in 6 mnths). Symptms suh as pain r tenderness may indiate impending rupture and require urgent repair regardless f the aneurysms diameter.B.  Aneurysmal RuptureA  ruptured aneurysm is a lethal event. Apprximately half the patients exsanguinate prir t reahing a hspital. In the remainder, bleeding may be temprarily ntained in the retrperitneum (ntained rupture), allwing the patient t underg emergent surgery. Hwever, nly half f thse patients will survive. Endvasular repair is available fr ruptured aneurysm treatment in mst majr vasular en- ters, with the results ffering sme imprvement ver pen repair fr these ritially ill patients.C.  Inflammatory AneurysmThe  presene f periarti inflammatin (inflammatry aneurysm) is nt an indiatin fr surgial treatment, unless there is assiated mpressin f retrperitneal strutures, suh as the ureter r pain upn palpatin f the aneurysm. Interestingly, the inflammatin that enases an inflammatry aneurysm reedes after either endvasular r pen surgial aneurysm repair.D . Assessment of Operative RiskAneurysms  appear t be a variant f systemi athersler- sis. Patients with aneurysms have a high rate f rnary disease but a 2004 trial demnstrated minimal value inCMDT22_Ch12_p0475-p0501.indd  484 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS485 CMDT 2022addressing  stable rnary artery disease prir t aneu- rysm resetin. Hwever, in patients with signifiant symptms f rnary disease, the rnary disease shuld be treated first. Aneurysm repair shuld fllw shrtly thereafter beause there is a slightly inreased risk f aneu- rysm rupture after the rnary predures.E.  Open Surgical Resection Versus Endovascular RepairIn  pen surgial aneurysm repair, a graft is sutured t the nn-dilated vessels abve and belw the aneurysm. This invlves an abdminal inisin, extensive dissetin, and interruptin f arti bld flw. The mrtality rate is lw (25%) in enters that have a high vlume fr this pre- dure and when it is perfrmed in gd-risk patients. Older, siker patients may nt tlerate the ardipulmnary stresses f the peratin. With endvasular arti repair, a stent-graft is intrdued thrugh small inisins ver the femral arteries and psitined within the arta under flurspi guidane. The stent must be able t seal seurely against the wall f the arta abve and belw the aneurysm, thereby exluding bld frm flwing int the aneurysm sa. T suessfully treat an aneurysm, the ana- tmi requirements fr endvasular repairs are mre preise than fr pen repairs. Mst studies have fund that endvasular arti repair ffers patients redued pera- tive mrbidity and mrtality as well as shrter revery perids. Lng-term survival is equivalent between the tw tehniques. Patients wh underg endvasular repair, hwever, likely need additinal interventins and need lifelng mnitring, sine there is a 1015% inidene f ntinued aneurysm grwth after endvasular repair. ComplicationsM yocardial infarction, the mst mmn mpliatin, urs in up t 10% f patients wh underg pen aneurysm repair. The inidene f myardial infartin is substantially lwer with endvasular repair. Fr rutine infrarenal aneu- rysms, renal injury is unusual; hwever, when it des ur, r if the baseline reatinine is elevated, it is a signifiant m- pliating fatr in the pstperative perid. Respiratry mpliatins are similar t thse seen in mst majr abdminal surgery. Gastrintestinal hemrrhage, even years after arti surgeries, suggests the pssibility f graft enteric fistula, mst mmnly between the arta and the distal dudenum; the inidene f this mpliatin is higher when the initial surgery is perfrmed n an emergeny basis. PrognosisThe m rtality rate fr an pen eletive surgial resetin is 15%, and the mrtality rate fr endvasular therapy is 0.52%. Of thse wh survive surgery, apprximately 60% are alive at 5 years; myardial infartin is the leading ause f death. The lng-term survival (5 years r mre) after pen and endvasular repairs is equivalent. Mrtality rates f untreated aneurysms vary with aneu- rysm diameter. The mrtality rate amng patients with large aneurysms has been defined as fllws: 12% annual risk f rupture with an aneurysm larger than 6 m indiameter and a 25% annual risk f rupture in aneurysms f mre than 7 m diameter. In general, a patient with an arti aneurysm larger than 5.5 m has a threefld greater hane f dying f a nsequene f rupture f the aneu- rysm than f dying f the surgial resetin. At present, endvasular aneurysm repair may be less definitive than pen surgial repair and requires lse fl- lw up with an imaging predure. Devie migratin, mpnent separatin, and graft limb thrmbsis r kink- ing are mmn reasns fr repeat interventin. With mplete exlusin f bld frm the aneurysm sa, the pressure is lwered, whih auses the aneurysm t shrink. An endleak frm the tp r bttm seal znes (type 1) r thrugh a graft defet (type 3) is assiated with a per- sistent risk f rupture. Indiret leakage f bld thrugh lumbar and inferir mesenteri branhes f the aneurysm (type-2 endleak) prdues an intermediate piture with smewhat redued pressure in the sa, slw shrinkage, and lw rupture risk. Hwever, type-2 endleak warrants lse bservatin as aneurysm dilatatin an hange aneurysm mrphlgy leading t type-1 endleak and rupture. When to Refer Any patient with a 4.5-m r larger arti aneurysm shuld be referred t a vasular speialist fr bserva- tin and assessment. Urgent referrals shuld be made if the patient m- plains f pain and gentle palpatin f the aneurysm nfirms that it is the sure, regardless f the aneurys- mal size. When to Admit Patients with a tender aneurysm t palpatin r signs f arti rupture require emergent hspital admissin. Evidene f infetin after repair.O Dnnell TFX et al. Abdminal arti aneurysm sreening guidelines: United States Preventive Servies Task Fre and Siety fr Vasular Surgery. J Vas Surg. 2020;71:1457. [PMID: 32334726] Jin J. Sreening fr abdminal arti aneurysm. JAMA Patient Page. JAMA. 2019;322:2256. [PMID: 31821432] Lederle FA et al; OVER Veterans Affairs Cperative Study Grup. Open versus endvasular repair f abdminal arti aneurysm. N Engl J Med. 2019;380:2126. [PMID: 31141634] US Preventive Servies Task Fre; Owens DK et al. Sreening fr abdminal arti aneurysm: US Preventive Servies Task Fre Remmendatin Statement. JAMA. 2019;322:2211. [PMID: 31821437]TH ORACIC AORTIC ANEURYSMSE S S E N T I A L S  O F  D I A G N O S I S Widened mediastinum on chest radiograph. With rupture, sudden onset of chest pain radiating to the back.CMDT22_Ch12_p0475-p0501.indd  485 29/06/21 8:37 PMCHAPTER 12486 CMDT 2022 General ConsiderationsMs t thrai arti aneurysms are due t atherslersis; syphilis is a rare ause. Disrders f nnetive tissue and Ehlers-Danls and Marfan syndrmes als are rare auses but have imprtant therapeuti impliatins. Traumati, false aneurysms, aused by partial tearing f the arti wall with deeleratin injuries, may ur just beynd the ri- gin f the left sublavian artery. Less than 10% f arti aneurysms ur in the thrai arta. Clinical FindingsA.  Symptoms and SignsMs t thrai aneurysms are asymptmati. When symp- tms ur, they depend largely n the size and the psi- tin f the aneurysm and its rate f grwth. Substernal bak r nek pain may ur. Pressure n the trahea, esphagus, r superir vena ava an result in the fllwing symptms and signs: dyspnea, stridr r brassy ugh, dysphagia, and edema in the nek and arms as well as dis- tended nek veins. Strething f the left reurrent laryngeal nerve auses harseness. With aneurysms f the asending arta, arti regurgitatin may be present due t dilatin f the arti valve annulus. Rupture f a thrai aneurysm is atastrphi beause bleeding is rarely ntained, allwing n time fr emergent repair.B.  ImagingThe  aneurysm may be diagnsed n hest radigraph by the alified utline f the dilated arta. CT sanning with ntrast enhanement is the mdality f hie, but MRA an be used t demnstrate the anatmy and aneurysmal size and t exlude lesins that an mimi aneurysms, suh as neplasms r substernal giter. There is n lw-st alternative (eg, ultrasngraphy) fr sreening r surveil- lane. Cardia atheterizatin and ehardigraphy may be required t desribe the relatinship f the rnary vessels t an aneurysm f the asending arta. TreatmentIn diatins fr repair depend n the latin f dilatin, rate f grwth, assiated symptms, and verall nditin f the patient. Desending thrai aneurysms measuring 6 m r larger may be nsidered fr repair, sine there is a 5-year survival f 54% in these patients. Aneurysms f the desend- ing thrai arta are treated rutinely by endvasular grafting. Repair f arh aneurysms shuld be undertaken nly if there is a skilled surgial team with an aeptable rerd f utmes fr these mplex predures. The avail- ability f thrai arti endgraft tehnique using mplex branhed endvasular renstrutins fr aneurysms invlving the arh r viseral arta (ustm-made grafts with branhes t the vessels invlved in the aneurysm) des nt hange the indiatins fr aneurysm repair. Aneurysms that invlve the prximal arti arh r asending arta repre- sent partiularly hallenging prblems and may be nsid- ered fr repair when they measure 5.5 m. Open surgery is usually required, arrying substantial risk f mrbidity (inluding strke, diffuse neurlgi injury, and intelletualimpairment) beause interruptin f arh bld flw is required. ComplicationsW ith the exeptin f endvasular repair fr disrete sa- ular aneurysms f the desending thrai arta, the mrbidity and mrtality f thrai aneurysm repair is higher than fr infra-renal abdminal arti aneurysm repair. Paraplegia remains a devastating mpliatin. Mst large series reprt apprximately 410% rate f paraplegia fllwing endvasular repair f thrai arti aneurysms. The spinal arterial supply is segmental thrugh interstal branhes f the arta with variable degrees f intersegmental nnetin. Therefre, the mre extensive the aneurysm, the greater is the risk f paraplegia with repair. Prir infrarenal abdminal arti surgery, subla- vian r internal ilia artery lusin, and hyptensin all inrease the paraplegia risk. Invlvement f the arti arh als inreases the risk f strke, even when the aneurysm des nt diretly affet the artid artery. PrognosisGenerally , degenerative aneurysms f the thrai arta will enlarge (n average 0.1 m/y) and require repair t prevent death frm rupture. Saular aneurysms, partiu- larly thse distal t the left sublavian artery and the desending thrai arta, have gd results with endvas- ular repair. Resetin f aneurysms f the arti arh requires a skilled surgial team and shuld be attempted nly in lw-risk patients. Branhed r fenestrated endvas- ular grafting tehnlgy has demnstrated redued mr- bidity and mrtality. When to Refer Asending arti aneurysms larger than 4.5 m shuld be referred t a ardia surgen fr bservatin and assessment and nsidered fr repair at 5.5 m. Desending thrai arti aneurysm shuld be referred t a vasular speialist when they reah 5 m fr bser- vatin and assessment and nsidered fr repair at 6 m. When to Admit Any patient with hest r bak pain with a knwn r suspeted thrai arta aneurysm must be brught t the hspital and underg urgent imaging studies t rule ut the aneurysm as a ause f the pain.Gasper  WJ et al. Assessing the anatmi appliability f the multibranhed endvasular repair f thraabdminal arti aneurysm tehnique. J Vas Surg. 2013;57:1553. [PMID: 23395201] Uphurh GR et al. Siety fr Vasular Surgery linial pratie guidelines f thrai endvasular arti repair fr desend- ing thrai arti aneurysms. J Vas Surg. 2021;73:55S. [PMID: 32628988] Werlin EC et al. Multibranhed endvasular arti aneurysm repair in patients with and withut hrni arti dissetins. J Vas Surg. 2019;70:1419. [PMID: 31327618]CMDT22_Ch12_p0475-p0501.indd  486 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS487 CMDT 2022PE RIPHERAL ARTERY ANEURYSMSE S S E N T I A L S  O F  D I A G N O S I S Widened, prominent pulses. Acute leg or foot pain and paresthesias with loss of distal pulses. High association of popliteal aneurysms with abdominal aortic aneurysms. General ConsiderationsLike  arti aneurysms, peripheral artery aneurysms are silent until ritially symptmati. Hwever, unlike arti aneurysms, the presenting manifestatins are due t peripheral emblizatin and thrmbsis. Ppliteal artery aneurysms aunt fr 70% f peripheral arterial aneu- rysms. Ppliteal aneurysms may emblize repetitively ver time and lude distal arteries. Due t the redundant parallel arterial supply t the ft, ishemia des nt ur until a final emblus ludes flw. Primary femral artery aneurysms are muh less m- mn. Hwever, pseudaneurysms f the femral artery fllwing arterial puntures fr arterigraphy and ardia atheterizatin ur with an inidene ranging frm 0.05% t 6% f arterial puntures. Clinical FindingsA.  Symptoms and SignsThe  patient may be aware f a pulsatile mass when the aneurysm is in the grin, but ppliteal aneurysms are ften undeteted by the patient and liniian. Rarely, peripheral aneurysms may prdue symptms by mpressing the lal vein r nerve. The first symptm may be due t ish- emia f aute arterial lusin. The symptms range frm sudden-nset pain and paralysis t shrt-distane laudi- atin that slwly lessens as llateral irulatin develps. Symptms frm reurrent emblizatin t the leg are ften transient, if they ur at all. Sudden ishemia may appear in a te r part f the ft, fllwed by slw reslutin, and the true diagnsis may be elusive. The nset f reurrent episdes f pain in the ft, partiularly if ampanied by yansis, suggests emblizatin and requires investigatin f the heart and prximal arterial tree. Beause ppliteal pulses are smewhat diffiult t pal- pate even in nrmal individuals, a partiularly prminent r easily felt pulse is suggestive f aneurysm and shuld be investigated by ultrasund. Sine ppliteal aneurysms are bilateral in 60% f ases, the diagnsis f thrmbsis f a ppliteal aneurysm is ften aided by the palpatin f a pulsatile aneurysm in the ntralateral ppliteal spae. Apprximately 50% f patients with ppliteal aneurysms have an aneurysmal abdminal arta.B.  Imaging StudiesDuplex lr ultrasun d is the mst effiient investigatin t nfirm the diagnsis f peripheral aneurysm, measureits size and nfiguratin, and demnstrate mural thrm- bus. MRA r CTA is required t define the aneurysm and lal arterial anatmy fr renstrutin. Arterigraphy is nt remmended beause mural thrmbus redues the apparent diameter f the lumen n angigraphy. Patients with ppliteal aneurysms shuld underg abdminal ultra- sngraphy t determine whether an abdminal arti aneurysm is als present. TreatmentT  prevent limb lss frm thrmbsis r emblizatin, surgery is indiated when an aneurysm is assiated with any peripheral emblizatin, the aneurysm is larger than 2 m, r a mural thrmbus is present. Immediate r urgent surgery is indiated when aute emblizatin r thrmbsis has aused aute ishemia. Open surgial bypass is gener- ally indiated. Endvasular exlusin f the aneurysm an be dne but has anatmi nstraints and is reserved fr high-risk patients. Intra-arterial thrmblysis may be dne in the setting f aute ishemia, if examinatin (light tuh) remains intat, suggesting that immediate surgery is nt imperative. Aute pseudaneurysms f the femral artery due t arterial puntures an be suessfully treated using ultrasund-guided mpressin r thrmbin injetin. Open surgery with prstheti interpsitin grafting is pre- ferred fr primary aneurysms f the femral artery. PrognosisA pprximately ne-third f untreated patients will require an amputatin. The lng-term pateny f bypass grafts fr femral and ppliteal aneurysms is generally exellent but depends n the adequay f the utflw trat. Late graft lusin is less mmn than in similar surgeries fr lusive disease. When to Refer Peripheral arterial aneurysms measuring 2 m r with ultrasund evidene f thrmbus within the aneurysm shuld be referred t prevent prgressin t limb- threatening ishemia. When to Admit Patients with symptms f ishemia r any signs f emblizatin shuld be admitted and referred t a vas- ular speialist.AOR TIC DISSECTIONE S S E N T I A L S  O F  D I A G N O S I S Sudden searing chest pain with radiation to the back, abdomen, or neck in a hypertensive patient. Widened mediastinum on chest radiograph. Pulse discrepancy in the extremities. Acute aortic regurgitation may develop.CMDT22_Ch12_p0475-p0501.indd  487 29/06/21 8:37 PMCHAPTER 12488 CMDT 2022 General ConsiderationsA rti dissetin urs when a spntaneus intimal tear develps and bld dissets int the media f the arta. The tear an result frm repetitive trque applied t the asend- ing and prximal desending arta during the ardia yle; hypertensin is an imprtant mpnent f this disease press. Dissetins are lassified by the entry pint and distal extent. Type A dissection invlves the arh prximal t the left sublavian artery, and type B dissection urs in the prximal desending thrai arta typially just beynd the left sublavian artery. Dissetins may ur in the absene f hypertensin but abnrmalities f smth musle, elasti tissue, r llagen are mre mmn in these patients. Pregnany, biuspid arti valve, and artatin als are assiated with inreased risk f dissetin. Bld entering the intimal tear may extend the dissetin int the abdminal arta, the lwer extremities, the artid arteries, r less mmnly, the sublavian arteries. Bth abs- lute pressure levels and the pulse pressure are imprtant in prpagatin f dissetin. Aortic dissection is a true emer- gency and requires immediate control of blood pressure to limit the extent of the dissection. With type A dissetin, whih has the wrse prgnsis, death may ur within hurs due t rupture f the dissetin int the periardial sa r dissetin int the rnary arteries, resulting in myardial infartin. Rupture int the pleural avity is als pssible. The intimal/ medial flap f the arti wall reated by the dissetin may lude majr arti branhes, resulting in ishemia f the brain, intestines, kidney, r extremities. Clinical FindingsA.  Symptoms and SignsSe vere persistent hest pain f sudden nset radiating dwn the bak r pssibly int the anterir hest is harateristi. Radiatin f the pain int the nek may als ur. The patient is usually hypertensive. Synpe, hemiplegia, r paralysis f the lwer extremities may ur. Mesenteri ishemia r kidney injury may develp. Peripheral pulses may be diminished r unequal. A diastli murmur may develp as a result f a dis- setin in the asending arta lse t the arti valve, ausing valvular regurgitatin, heart failure, and ardia tampnade.B.  Electrocardiographic FindingsLeft  ventriular hypertrphy frm lng-standing hyperten- sin is ften present. Aute hanges suggesting myardial ishemia d nt develp unless dissetin invlves the rnary artery stium. Classially, inferir wall abnr- malities predminate sine dissetin leads t mprmise f the right rather than the left rnary artery. In sme patients, the ECG may be mpletely nrmal.C.  ImagingA  multiplanar CT san with ntrast enhanement is the immediate diagnsti imaging mdality f hie; lini- ians shuld have a lw threshld fr btaining a CT san in any hypertensive patient with hest pain and equival findings n ECG. The CT san shuld inlude bth the hest and abdmen t fully delineate the extent f thedisseted arta. MRA is an exellent imaging mdality fr hrni dissetins, but in the aute situatin, the lnger imaging time and the diffiulty f mnitring patients in the MRI sanner make the CT san preferable. Chest radi- graphs may reveal an abnrmal arti ntur r widened superir mediastinum. Althugh transesphageal ehar- digraphy (TEE) is an exellent diagnsti imaging methd, it is generally nt readily available in the aute setting. Differential DiagnosisA rti dissetin is mst mmnly misdiagnsed as my- ardial infartin r ther auses f hest pain suh as pulmnary emblizatin. Dissetins may ur with minimal pain; branh vessel lusin f the lwer extrem- ity an mimi arterial emblus. TreatmentA.  MedicalAg gressive measures t lwer bld pressure shuld ur when an arti dissetin is suspeted, even befre the diag- nsti studies have been mpleted. Treatment requires a simultaneus redutin f the systli bld pressure t 100 120 mm Hg and pulse pressure. Beta-blkers have the mst desirable effet f reduing the left ventriular ejetin fre that ntinues t weaken the arterial wall and shuld be first- line therapy. Labetall, bth an alpha- and beta-blker, lw- ers pulse pressure and ahieves rapid bld pressure ntrl. Give 20 mg ver 2 minutes by intravenus injetin. Addi- tinal dses f 4080 mg intravenusly an be given every 10 minutes (maximum dse 300 mg) until the desired bld pressure has been reahed. Alternatively, 2 mg/min may be given by intravenus infusin, titrated t desired effet. In patients wh have asthma, bradyardia, r ther nditins that neessitate the patients reatin t beta-blkers be tested, esmll is a reasnable hie beause f its shrt half-life. Give a lading dse f esmll, 0.5 mg/kg intravenusly ver 1 minute, fllwed by an infusin f 0.00250.02 mg/kg/min. Titrate the infusin t a gal heart rate f 6070 beats/min. If beta-blkade alne des nt ntrl the hypertensin, nitrprusside may be added as fllws: 50 mg f nitrprus- side in 1000 mL f 5% dextrse and water, infused at a rate f 0.5 mL/min fr a 70-kg persn (0.3 mg/kg/min); the infu- sin rate is inreased by 0.5 mL every 5 minutes until adequate ntrl f the pressure has been ahieved. In patients with asthma, while there are n data supprting the use f the al- ium hannel antagnists, diltiazem and verapamil are pten- tial alternatives t treatment with beta-blking drugs. Mrphine sulfate is the apprpriate drug t use fr pain relief. Lng-term medial are f patients shuld inlude beta- blkers in their antihypertensive regimen.B.  Surgical Intervention1.  Type A dissection Urgent surgical intervention is required for all type A dissections. If a skilled ardivasular team is nt available, the patient shuld be transferred t an appr- priate faility. The predure invlves grafting and replaing the diseased prtin f the arh and brahiephali vessels as neessary. Replaement f the arti valve may be required with reattahment f the rnary arteries.CMDT22_Ch12_p0475-p0501.indd  488 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS489 CMDT 20222. T ype B dissection with malperfusion Urgent surgery is required fr type B dissetins if there is arti branh mprmise resulting in malperfusin f the renal, vis- eral, r extremity vessels. The immediate gal f surgery is t restre flw t the ishemi tissue. Endvasular stenting f the entry tear at the level f the sublavian artery may result in bliteratin f the false lumen and restre flw int the branh vessel frm the true lumen. The results, hwever, are unpreditable and shuld nly be attempted by an experiened team. 3. Type B dissection without malperfusion Fr aute type B dissetins withut malperfusin, bld pressure ntrl is the primary treatment. Lng-term arti-speifi survival and late aneurysm frmatin rates are imprved with early thrai stent graft repair, espeially in healthy patients with high-risk anatmi features (arti diameter greater than 4 m r partial false lumen thrmbsis). Prognosis & Follow-UpThe  mrtality rate fr untreated type A dissetins is apprximately 1% per hur fr 72 hurs and ver 90% at 3 mnths. Mrtality is als extremely high fr untreated type B dissetins with malperfusin r rupture. The surgial and endvasular therapies fr these patients are tehnially demanding and require an experiened team t ahieve periperative mrtalities f less than 10%. Aneurysmal enlargement f the residual false lumen may develp despite adequate antihypertensive therapy. Y early CT sans are required t mnitr fr aneurysm develpment. Indiatins fr late aneurysm repair are determined by aneurysm size (6 m r larger), similar t undisseted thrai aneurysms. When to Admit All patients with an aute dissetin shuld be hspital- ized fr bld pressure management and bservatin. Urgent surgial repair is indiated fr all type A disse- tins and fr type B dissetins with malperfusin, rupture, r persistent symptms.Bssne E  et al. Aute arti syndrmes: diagnsis and manage- ment, an update. Eur Heart J. 2018;39:739. [PMID: 29106452] Evangelista A et al; IRAD Investigatrs. Insights frm the Interna- tinal Registry f Aute Arti Dissetin: a 20-year experiene f llabrative linial researh. Cirulatin. 2018;137:1846. [PMID: 29685932] VENOUS DISEASES VARICOSE VEINSE S S E N T I A L S  O F  D I A G N O S I S Dilated, tortuous superficial veins in the legs. Asymptomatic or there may be aching discomfort or pain. Often hereditary. Increased frequency after pregnancy.General ConsiderationsV arise veins develp in the lwer extremities. Perids f high venus pressure related t prlnged standing r heavy lifting are ntributing fatrs, but the highest ini- dene urs in wmen after pregnany. Varisities develp in ver 20% f all adults. The mbinatin f prgressive venus reflux and venus hypertensin is the hallmark f hrni venus disease. The superfiial veins are invlved, typially the great saphenus vein and its tributaries, but the shrt saphenus vein (psterir lwer leg) may als be affeted. Distentin f the vein prevents the valve leaflets frm apting, reating inmpetene and reflux f bld tward the ft. Fal venus dilatin and reflux leads t inreased pressure and distentin f the vein segment belw that valve, whih in turn auses prgressive failure f the next lwer valve. Perfrating veins that nnet the deep and superfiial systems may beme inmpetent, allwing bld t reflux int the superfiial veins frm the deep system, inreasing venus pressure and distentin. Sendary varisities an develp as a result f bstrutive hanges and valve damage in the deep venus system fllwing thrmbphlebitis, r rarely as a result f prximal venus lusin due t neplasm r fibrsis. Cngenital r aquired arterivenus fistulas r venus malfrmatins are als assiated with varisities and shuld be nsidered in yung patients with varisities. Clinical FindingsA.  Symptoms and SignsSymp tm severity is nt rrelated with the number and size f the varisities; extensive varise veins may pr- due n subjetive symptms, whereas minimal varisi- ties may prdue many symptms. Dull, ahing heaviness r a feeling f fatigue f the legs brught n by perids f standing is the mst mmn mplaint. Ithing frm venus ezema may ur either abve the ankle r diretly verlying large varisities. Dilated, trtuus veins f the thigh and alf are visible and palpable when the patient is standing. Lngstanding varise veins may prgress t hrni venus insuffiieny with assiated ankle edema, brwnish skin hyperpigmen- tatin, and hrni skin induratin r fibrsis. A bruit r thrill is never fund with primary varise veins and, when fund, alerts the liniian t the presene f an arterive- nus fistula r malfrmatin.B.  ImagingThe identifiatin  f the sure f venus reflux that feeds the symptmati veins is neessary fr effetive surgial treatment. Duplex ultrasngraphy by a tehniian experi- ened in the diagnsis and lalizatin f venus reflux is the test f hie fr planning therapy. In mst ases, reflux will arise frm the greater saphenus vein. Differential DiagnosisV arise veins due t primary superfiial venus reflux shuld be differentiated frm thse sendary t previusCMDT22_Ch12_p0475-p0501.indd  489 29/06/21 8:37 PMCHAPTER 12490 CMDT 2022r  nging bstrutin f the deep veins (pst-thrmbti syndrme). Pain r dismfrt sendary t neurpathy shuld be distinguished frm symptms assiated with existent varise veins. Similarly, vein symptms shuld be distinguished frm pain due t intermittent laudia- tin, whih urs after a preditable amunt f exerise and reslves with rest. In adlesent patients with varise veins, imaging f the deep venus system is bligatry t exlude a ngenital malfrmatin r atresia f the deep veins. Surgical treatment of varicose veins in these patients is contraindicated because the varicosities may play a signifi- cant role in venous drainage of the limb. ComplicationsSuperfiial  thrmbphlebitis f varise veins is unm- mn. The typial presentatin is aute lalized pain with tender, firm veins. The press is usually self-limiting, reslving within several weeks. The risk f deep venus thrmbsis (DVT) r emblizatin is very lw unless the thrmbphlebitis extends int the great saphenus vein in the upper medial thigh. Predispsing nditins inlude pregnany, lal trauma, r prlnged perids f sitting. In lder patients, superfiial varisities may bleed with even minr trauma. The amunt f bleeding an be alarm- ing as the pressure in the varisity is high. TreatmentA.  Nonsurgical MeasuresN nsurgial treatment is effetive. Elasti graduated m- pressin stkings (2030 mm Hg pressure) redue the venus pressure in the leg and may prevent the prgressin f disease. Gd ntrl f symptms an be ahieved when stkings are wrn daily during waking hurs and legs are elevated, espeially at night. Cmpressin stk- ings are well-suited fr elderly patients r patients wh d nt want surgery.B.  Varicose Vein SclerotherapyDiret  injetin f a slersing agent indues permanent fibrsis and bliteratin f the target veins. Chemial irri- tants (eg, glyerin) r hypertni saline are ften used fr small, less-than-4-mm retiular veins r telangietasias. Fam slertherapy is used t treat the great saphenus vein, varise veins larger than 4 mm, and perfrating veins. Slertherapy f varise veins withut treatment f underlying saphenus vein reflux is assiated with vari- sity reurrene rates ver 50% as unrreted reflux prgressively dilates adjaent veins. Cmpliatins suh as phlebitis, tissue nersis, r infetin may ur with any slersing agent.C.  Surgical Reflux TreatmentT reatment ptins fr reflux arising frm the great saphenus vein inlude surgial vein stripping (remval) r endvenus treatments using thermal devies (laser r radifrequeny atheter), yanarylate glue injetin, r fam slersant injetin. Endvenus treatments an ften be perfrmed with lal anesthesia alne and theearly suess is equal t vein stripping. Lng-term suess is highest with vein stripping and thermal treatments while the lng-term durability f yanarylate glue and fam is unknwn. One majr mpliatin f thermal treatments inludes endthermal heat-indued thrmbsis f the deep vein and may require prlnged antiagulatin. Less mmn sures f reflux inlude the small saphenus vein (fr varisities in the psterir alf) and inmpetent perfratr veins arising diretly frm the deep venus sys- tem. Crretin f reflux is perfrmed at the same time as exisin f the symptmati varise veins. When superfi- ial venus reflux is present, nmitant reflux in the deep venus system is ften sendary t vlume verlad, whih will reslve with rretin f the superfiial reflux. PrognosisSurgial  treatment f superfiial vein reflux and exisin f varise veins prvide exellent results. The 5-year suess rate (as defined as lak f pain and reurrent varisities) is 8590%. Simple exisin (phlebetmy) r injetin slertherapy withut rretin f reflux is assiated with reurrene rates ver 50%. Even after adequate treat- ment, sendary tissue hanges may persist. When to Refer Abslute indiatins fr referral fr saphenus ablatin inlude thrmbphlebitis and bleeding. Pain and smeti nerns are respnsible fr the majrity f referrals fr ablatin.Kabnik  LS et al. Classifiatin and treatment f endthermal heat-indued thrmbsis: remmendatins frm the Amerian Venus Frum and the Siety fr Vasular Sur- gery. J Vas Surg Venus Lymphat Disrd. 2021;9:6. [PMID: 33012690] DePpas E et al. Varise veins and lwer extremity venus insuffiieny. Semin Intervent Radil. 2018;35:56. [PMID: 29628617]SU PERFICIAL VENOUS THROMBOPHLEBITISE S S E N T I A L S  O F  D I A G N O S I S Red, painful induration along a superficial vein, usually at the site of a recent intravenous line. Marked swelling of the extremity may not occur. General ConsiderationsShrt-term venus a theterizatin f superfiial arm veins as well as the use f lnger-term peripherally inserted en- tral atheter (PICC) lines are the mst mmn ause f superfiial thrmbphlebitis. Intravenus atheter sites shuld be bserved daily fr signs f lal inflammatin and shuld be remved if a lal reatin develps in the vein. Serius thrmbti r septi mpliatins an ur if this pliy is nt fllwed; S aureus is the mst mmnCMDT22_Ch12_p0475-p0501.indd  490 29/06/21 8:37 PMBLOOD VESSEL & LYMPHATIC DISORDERS491 CMDT 2022pathgen.  Other rganisms, inluding fungi, may als be respnsible. Superfiial thrmbphlebitis may ur spntaneusly, ften in pregnant r pstpartum wmen r in individuals with varise veins, r it may be assiated with trauma, as with a blw t the leg r fllwing intravenus therapy with irritating slutins. It als may be a manifestatin f systemi hyperagulability sendary t abdminal an- er suh as arinma f the panreas and may be the earli- est sign f these nditins. Superfiial thrmbphlebitis may be assiated with ult DVT in abut 20% f ases. Pulmnary embli are exeedingly rare and ur frm an assiated DVT. (See Chapters 9 and 14 fr disussin n deep venus thrmbsis.) Clinical FindingsIn  spntaneus superfiial thrmbphlebitis, the great saphenus vein is mst ften invlved. The patient usually experienes a dull pain in the regin f the invlved vein. Lal findings nsist f induratin, redness, and tender- ness alng the urse f a vein. The press may be lal- ized, r it may invlve mst f the great saphenus vein and its tributaries. The inflammatry reatin generally subsides in 12 weeks; a firm rd may remain fr a muh lnger perid. Edema f the extremity is unmmn. Lalized redness and induratin at the site f a reent intravenus line requires urgent attentin. Prximal exten- sin f the induratin and pain with hills and high fever suggest septi phlebitis and requires urgent treatment. Differential DiagnosisThe linear ra ther than irular nature f the lesin and the distributin alng the urse f a superfiial vein serve t differentiate superfiial phlebitis frm ellulitis, erythema ndsum, erythema induratum, panniulitis, and fibrsi- tis. Lymphangitis and deep thrmbphlebitis must als be nsidered. TreatmentF r spntaneus thrmbphlebitis if the press is well lalized and nt near the saphenfemral juntin, lal heat and nnsteridal anti-inflammatry mediatins are usually effetive in limiting the press. If the induratin is extensive r is prgressing tward the saphenfemral juntin (leg) r ephal-axillary juntin (arm), ligatin and divisin f the vein at the juntin f the deep and superfiial veins is indiated. Antiagulatin therapy is usually nt required fr fal presses. Prphylati dse lw-mleular-weight heparin r fndaparinux is remmended fr 5 m r ln- ger superfiial thrmbphlebitis f the lwer limb veins (Table 1414) and full antiagulatin is reserved fr dis- ease that is rapidly prgressing r if there is nern fr extensin int the deep system (Table 1416). Septi superfiial thrmbphlebitis is an intravasular absess and requires urgent treatment with heparin r fndaparinux (see Table 1416) t limit further thrmbus frmatin and remval f the ffending atheter in atheter- related infetins (see Chapter 30). Treat with antibitis(eg, vanmyin, 15 mg/kg intravenusly every 12 hurs, plus eftriaxne, 1 g intravenusly every 24 hurs). If ul- tures are psitive, therapy shuld be ntinued fr 710 days r fr 46 weeks if mpliating endarditis annt be exluded. Surgial exisin f the invlved vein may als be neessary t ntrl the infetin. PrognosisW ith spntaneus thrmbphlebitis, the urse is gener- ally benign and brief. In patients with phlebitis sendary t varise veins, reurrent episdes are likely unless r- retin f the underlying venus reflux and exisin f varisities is dne. In ntrast, the mrtality frm septi thrmbphlebitis is 20% r higher and requires aggressive treatment. Hwever, if the invlvement is lalized, the mrtality is lw and prgnsis is exellent with early treatment.Di  Nisi M et al. Treatment fr superfiial thrmbphlebitis f the leg. Chrane Database Syst Rev. 2018;2:CD004982. [PMID: 29478266]CH RONIC VENOUS INSUFFICIENCYE S S E N T I A L S  O F  D I A G N O S I S History of prior DVT or leg injury. Edema, (brawny) skin hyperpigmentation, subcu- taneous lipodermosclerosis in the lower leg. Venous ulcers: large ulcerations at or above the medial ankle. General ConsiderationsChrni  venus insuffiieny is a severe manifestatin f venus hypertensin. One f the mst mmn etilgies is prir deep venus thrmbphlebitis, althugh abut 25% f patients d nt have a knwn histry f DVT. In these ases, there may be a histry f leg trauma r surgery; besity is ften a mpliating fatr. Prgressive superfi- ial venus reflux is als a mmn ause. Other auses inlude ngenital r neplasti bstrutin f the pelvi veins r a ngenital r aquired arterivenus fistula. The basi pathlgy is aused by valve leaflets that d nt apt beause they are either thikened and sarred (pst-thrmbti syndrme) r in a dilated vein and are therefre funtinally inadequate. Prximal venus bstrutin due t hrni thrmbus r sarring m- punds the prblem. With the valves unable t stp venus bld frm returning t the ft (venus reflux), the leg develps venus hypertensin and an abnrmally high hydrstati fre is transmitted t the subutaneus veins and tissues f the lwer leg. The resulting edema results in dramati and deleterius sendary hanges. The stigmata f hrni venus insuffiieny inlude fibrsis f the sub- utaneus tissue and skin, pigmentatin f skin (hemsid- erin taken up by the dermal marphages), and, later,CMDT22_Ch12_p0475-p0501.indd  491 29/06/21 8:37 PMCHAPTER 12492 CMDT 2022uleratin,  whih is extremely slw t heal. Ithing may preipitate the frmatin f uleratin r lal wund el- lulitis. Dilatin f the superfiial veins may ur, leading t varisities. Althugh surgial treatment fr venus reflux an imprve symptms, ntrlling edema and the sendary skin hanges usually require lifelng mpres- sin therapy. Clinical FindingsA.  Symptoms and SignsPrgr essive pitting edema f the leg (partiularly the lwer leg) is the primary presenting symptm. Sendary hanges in the skin and subutaneus tissues develp ver time (Figure 122). The usual symptms are ithing, a dull dis- mfrt made wrse by perids f standing, and pain if an uleratin is present. The skin at the ankle is usually taut frm swelling, shiny, and a brwnish pigmentatin (hem- siderin) ften develps. If the nditin is lngstanding, the subutaneus tissues beme thik and fibrus. Uler- atins may ur, usually just abve the ankle, n the medial r anterir aspet f the leg. Healing results in a thin sar n a fibrti base that ften breaks dwn with minr trauma r further buts f leg swelling. Varisities may appear (Figure 123) that are assiated with inm- petent perfrating veins. Cellulitis, whih is ften diffiult t distinguish frm the hemsiderin pigmentatin, may be diagnsed by blanhing erythema with pain.B.  ImagingPa tients with pst-thrmbti syndrme r signs f hrni venus insuffiieny shuld underg duplex ultrasngra- phy t determine whether superfiial reflux is present and t evaluate the degree f deep reflux and bstrutin. Differential DiagnosisPa tients with heart failure, hrni kidney disease, r dem- pensated liver disease may have bilateral edema f the lwer extremities. Many mediatins an ause edema (eg, al- ium hannel blkers, nnsteridal anti-inflammatry agents, thiazlidinedines). Swelling frm lymphedema invlves the feet and may be unilateral, but varisities are absent. Edema frm these auses pits easily and brawny dislratin is rare. Lipedema is a disrder f adipse tissue that urs almst exlusively in wmen, is bilateral and symmetri, and is haraterized by stpping at a distint line just abve the ankles. Primary varise veins may be diffiult t differentiate frm the sendary varisities f pst-thrmbti syn- drme r venus bstrutin. Other nditins assiated with hrni ulers f the leg inlude neurpathi ulers usually frm diabetes mel- litus, arterial insuffiieny (ften manifests as painful lat- eral ankle ulers with absent pulses; medial ankle ulers, n Figure 122. Bilateral pretibial edema and erythema consistent with stasis dermatitis (sometimes mimicking cellulitis) in chronic venous insufficiency. (Used, with permission, from Dean SM, Satiani B, Abraham WT. Color Atlas and Synopsis of Vascular Diseases. McGraw-Hill, 2014.) Figure 123. Varicose veins, manifested as blue, subcutaneous, tortuous veins more than 3 mm in diam- eter. (Used, with permission, from Dean SM, Satiani B, Abraham WT. Color Atlas and Synopsis of Vascular Diseases. McGraw-Hill, 2014.)CMDT22_Ch12_p0475-p0501.indd  492 29/06/21 8:38 PMBLOOD VESSEL & LYMPHATIC DISORDERS493 CMDT 2022the  ther hand, are usually due t venus insuffiieny), autimmune diseases (eg, Felty syndrme), sikle ell ane- mia, erythema induratum (bilateral and usually n the psterir aspet f the lwer part f the leg), and fungal infetins. PreventionI rreversible tissue hanges and assiated mpliatins in the lwer legs an be redued thrugh early and aggressive antiagulatin f aute DVT t minimize the valve damages and by presribing mpressin stkings if hrni edema develps after the DVT has reslved. Treatment f aute ilifemral DVT with atheter-direted thrmblysis r mehanial thrmbetmy des nt redue pst-thrmbti syndrme and hrni venus insuffiieny. TreatmentA.  General MeasuresFitted , graduated mpressin stkings (2030 mm Hg pressure r higher) wrn frm the ft t just belw the knee during the day and evening are the mainstays f treat- ment and are usually suffiient. When they are nt, addi- tinal measures, suh as avidane f lng perids f sitting r standing, intermittent elevatins f the invlved leg, and sleeping with the legs kept abve the level f the heart, may be neessary t ntrl the swelling. Pneumati mpressin f the leg, whih an pump the fluid ut f the leg, is used in refratry ases.B.  UlcerationAs  the primary pathlgy is edema and venus hyperten- sin, healing f the uler will nt ur until the edema is ntrlled and mpressin is applied. Cirumferential nnelasti bandages n the lwer leg enhane the pumping atin f the alf musles n venus bld flw ut f the alf. A lesin an ften be treated n an ambulatry basis by means f a semi-rigid gauze bt made with Unna paste (Gelast, Medipaste) r a multi-layer mpressin dressing (eg, Prfre). Initially, the uler needs t be debrided and the bt hanged every 23 days t ntrl uler drainage. As the edema and drainage subside, pti- mal healing is ahieved when the bt is kept in plae fr 57 days. The uler, tendns, and bny prminenes must be adequately padded. Alternatively, knee-high graduated mpressin stkings with an absrbent dressing may be used, if wund drainage is minimal. Hme mpressin therapy with a pneumati mpressin devie is used in refratry ases, but many patients have severe pain with the milking atin f the pump devie. Sme patients will require admissin fr mplete bed rest and leg elevatin t ahieve uler healing. After the uler has healed, daily graduated mpressin stking therapy is mandatry t prevent uler reurrene.C.  Vein Treatment Reflux or ObstructionT reatment f superfiial vein reflux (see Varise Veins se- tin, abve) has been shwn t derease the reurrene rate f venus ulers. Where there is substantial bstrutin fthe femral and ppliteal deep venus system, superfiial varisities supply the venus return and they shuld nt be remved. Venus stents as treatment f hrni ilia deep vein stensis r bstrutin may imprve venus uler healing and redue the uler reurrene rate in severe ases. PrognosisIndivid uals with hrni venus insuffiieny ften have reurrent edema, partiularly if they d nt nsistently wear supprt stkings that have at least 2030 mm Hg mpressin. When to Refer Patients with signifiant saphenus reflux shuld be evaluated fr ablatin. Patients with ulers shuld be mnitred by an interdis- iplinary wund are team s that these hallenging wunds reeive aggressive are.Raffett  JD. Pathphysilgy f hrni venus disease and venus ulers. Surg Clin Nrth Am. 2018;98:337. [PMID: 29502775] Vedantham S et al; ATTRACT Trial Investigatrs. Pharmam- ehanial atheter-direted thrmblysis fr deep-vein thrmbsis. N Engl J Med. 2017;377:2240. [PMID: 29211671]SU PERIOR VENA CAVAL OBSTRUCTIONE S S E N T I A L S  O F  D I A G N O S I S Swelling of the neck, face, and upper extremities. Dilated veins over the upper chest and neck. General ConsiderationsP artial r mplete bstrutin f the superir vena ava is a relatively rare nditin that is usually sendary t neplas- ti r inflammatry presses in the superir mediastinum. The mst frequent auses are (1) neplasms, suh as lymph- mas, primary malignant mediastinal tumrs, r arinma f the lung with diret extensin (ver 80%); (2) hrni fibrti mediastinitis, either f unknwn rigin r sendary t tuberulsis, histplasmsis, pygeni infetins, r drugs, espeially methysergide; (3) DVT, ften by extensin f the press frm the axillary r sublavian vein int the innmi- nate vein and vena ava assiated with atheterizatin f these veins fr dialysis r fr hyperalimentatin; (4) aneu- rysm f the arti arh; and (5) nstritive periarditis. Clinical FindingsA.  Symptoms and SignsThe  nset f symptms is aute r subaute. Symptms inlude swelling f the nek and fae and upper extremities. Symptms are ften pereived as ngestin and present asCMDT22_Ch12_p0475-p0501.indd  493 29/06/21 8:38 PMCHAPTER 12494 CMDT 2022heada he, dizziness, visual disturbanes, stupr, synpe, r ugh. There is prgressive bstrutin f the venus drainage f the head, nek, and upper extremities. The uta- neus veins f the upper hest and lwer nek beme dilated, and flushing f the fae and nek develps. Brawny edema f the fae, nek, and arms urs later, and yansis f these areas then appears. Cerebral and laryngeal edema ultimately result in impaired funtin f the brain as well as respiratry insuffiieny. Bending ver r lying dwn aentuates the symptms; sitting quietly is generally pre- ferred. The manifestatins are mre severe if the bstru- tin develps rapidly and if the azygs juntin r the vena ava between that vein and the heart is bstruted.B.  Laboratory FindingsThe ven us pressure is elevated (ften mre than 20 m f water) in the arm and is nrmal in the leg. Sine lung aner is a mmn ause, brnhspy is ften perfrmed; transbrnhial bipsy, hwever, is relatively ntraindiated beause f venus hypertensin and the risk f bleeding.C.  ImagingChest  radigraphs and a CT san an define the latin and ften the nature f the bstrutive press, and n- trast vengraphy r magneti resnane vengraphy (MRV) will map ut the extent and degree f the venus bstrutin and the llateral irulatin. Brahial veng- raphy r radinulide sanning fllwing intravenus injetin f tehnetium (T-99m) pertehnetate demn- strates a blk t the flw f ntrast material int the right heart and enlarged llateral veins. These tehniques als allw estimatin f bld flw arund the lusin as well as serial evaluatin f the respnse t therapy. TreatmentCnser vative measures, suh as elevatin f the head f the bed and lifestyle mdifiatin t avid bending ver, are useful. Balln angiplasty f the bstruted aval segment mbined with stent plaement prvides prmpt relief f symptms and is the predure f hie fr all etilgies. Oasinally, antiagulatin is needed, while thrmbly- sis is rarely needed. Urgent treatment fr neplasm nsists f (1) autius use f intravenus diuretis and (2) mediastinal irradia- tin, starting within 24 hurs, with a treatment plan designed t give a high daily dse but a shrt ttal urse f therapy t rapidly shrink the lal tumr. Intensive m- bined therapy will palliate the press in up t 90% f patients. In patients with a subaute presentatin, radiatin therapy alne usually suffies. Chemtherapy is added if lymphma r small-ell arinma is diagnsed. Lng-term utme is mpliated by risk f re-lusin frm either thrmbsis r neplasm grwth. Surgial pre- dures t bypass the bstrutin are mpliated by bleed- ing frm high venus pressure. In ases where the thrmbsis is sendary t an indwelling atheter, thrm- blysis may be attempted. Clinial judgment is required sine a lng-standing lt may be fibrti and the risk f bleeding an utweigh the ptential benefit.PrognosisThe  prgnsis depends n the nature and degree f bstrutin and its speed f nset. Slwly develping frms sendary t fibrsis may be tlerated fr years. A high degree f bstrutin f rapid nset sendary t aner is ften fatal in a few days r weeks beause f inreased intraranial pressure and erebral hemrrhage, but treat- ment f the tumr with radiatin and hemtherapeuti drugs may result in signifiant palliatin. Balln angi- plasty and stenting prvide gd relief but may require re- treatment fr reurrent symptms sendary t thrmbsis r restensis. When to Refer Any patient with prgressive head and nek swelling shuld be referred t rule ut superir vena ava syndrme. When to Admit Any patient with aute edema f the head and nek r with signs and symptms f airway mprmise, suh as harseness r stridr, shuld be admitted.Kalra  M et al. Endvenus and perative treatment f superir vena ava syndrme. Surg Clin Nrth Am. 2018;98:321. [PMID: 29502774] DISEASES OF THE LYMPHATIC CHANNELS LYMPHANGITIS & LYMPHADENITISE S S E N T I A L S  O F  D I A G N O S I S Red streak from wound or cellulitis toward regional lymph nodes, which are usually enlarged and tender. Chills, fever, and malaise may be present. General ConsiderationsL ymphangitis and lymphadenitis are mmn manifesta- tins f a baterial infetin that is usually aused by hemlyti strepti r S aureus (r by bth rganisms) and bemes invasive, generally frm an infeted wund, ellulitis, r an absess. The wund may be very small r superfiial, r an established absess may be present, feed- ing bateria int the lymphatis. The invlvement f the lymphatis is ften manifested by a red streak in the skin extending in the diretin f the reginal lymph ndes. Clinical FindingsA.  Symptoms and SignsThrbb ing pain is usually present at the site f baterial invasin frm a wund, ellulitis, r absess. Malaise,CMDT22_Ch12_p0475-p0501.indd  494 29/06/21 8:38 PMBLOOD VESSEL & LYMPHATIC DISORDERS495 CMDT 2022anr exia, sweating, hills, and fever f 3840C develp quikly, ften with a rapid pulse. The red streak, when present, may be definite r may be faint and easily missed, espeially in dark-skinned patients. The invlved reginal lymph ndes may be signifiantly enlarged and are usually quite tender. The infetin may prgress rapidly, ften in a matter f hurs, and may lead t septiemia and death.B.  Laboratory FindingsLeukytsis with  a left shift is usually present. Bld ul- tures may be psitive, mst ften fr staphylal r streptal speies. Culture and sensitivity studies f the wund exudate r pus may be helpful in treatment f the mre severe r refratry infetins but are ften diffiult t interpret beause f skin ntaminants. Differential DiagnosisTh e erythema and induratin f superfiial thrmbphlebitis are lalized in and arund the thrmbsed vein. Venus thrmbsis is nt assiated with lymphadenitis, and a wund f entrane with sendary ellulitis is generally absent. Cat-srath fever (Bartonella henselae) is a ause f lymphadenitis; the ndes, thugh ften very large, are rela- tively nntender. Expsure t ats is mmn, but the patient may have frgtten abut the srath. It is extremely important to differentiate cellulitis from acute streptococcal hemolytic gangrene or a necrotizing soft tissue infection. These are deeper infetins that may be extensive and are ptentially lethal. Patients are mre seriusly ill; there may be redness due t leakage f red ells, reating a nn- blanhing erythema; subutaneus repitus, a late finding, may be palpated r ausultated; and subutaneus air may be present n radigraphy r CT san. Immediate surgial n- sultatin is needed fr wide debridement f all invlved deep tissues if a nertizing infetin is suspeted. TreatmentA.  General MeasuresPr mpt treatment shuld inlude heat (ht, mist m- presses r heating pad), elevatin when feasible, and immbilizatin f the infeted area. Analgesis may be presribed fr pain.B.  Specific MeasuresEmp iri antibiti therapy fr hemlyti strepti r S aureus (r bth rganisms) shuld always be instituted. Cephalsprins r extended-spetrum peniillins are m- mnly used (eg, ephalexin, 0.5 g rally fur times daily fr 710 days; see Table 306). Trimethprim-sulfamethxa- zle (tw duble-strength tablets rally twie daily fr 710 days) shuld be nsidered when there is nern that the pathgen is MRSA (see Tables 304 and 306).C.  Wound CareAny  wund that is the initiating site f lymphangitis shuld be treated aggressively. Any nerti tissue must be debrided and lulated pus drained.PrognosisW ith prper therapy inluding an antibiti effetive against the invading bateria, ntrl f the infetin an usually be ahieved in a few days. Delayed r inadequate therapy an lead t verwhelming infetin with septiemia. When to Admit Infetins ausing lymphangitis shuld be treated in the hspital with intravenus antibitis. Debridement may be required and prmpt surgial nsultatin is prudent.L YMPHEDEMAE S S E N T I A L S  O F  D I A G N O S I S Painless persistent edema of one or both lower extremities, primarily in young women. Pitting edema without ulceration, varicosities, or stasis pigmentation. Lymphangitis and cellulitis may occur. General ConsiderationsWhen  lymphedema is due t ngenital develpmental abnrmalities nsisting f hypplasti r hyperplasti invlvement f the prximal r distal lymphatis, it is referred t as the primary form . The bstrutin may be in the pelvi r lumbar lymph hannels and ndes when the disease is extensive and prgressive. The secondary form f lymphedema invlves inflammatry r mehani- al lymphati bstrutin frm trauma, reginal lymph nde resetin r irradiatin, r extensive invlvement f reginal ndes by malignant disease r filariasis. Lymph- edema may ur fllwing surgial remval f the lymph ndes in the grin r axillae. Sendary dilatin f the lymphatis that urs in bth frms leads t inmpe- tene f the valve system, disrupts the rderly flw alng the lymph vessels, and results in prgressive stasis f a prtein-rih fluid. Episdes f aute and hrni inflam- matin may be superimpsed, with further stasis and se- ndary fibrsis. Clinical FindingsH ypertrphy f the limb results, with markedly thikened and fibrti skin and subutaneus tissue (Figure 124) in very advaned ases. T2weighted MRI has been used t identify lymphatis and prximal bstruting masses. Lymphangigraphy and radiative istpe studies may identify fal defets in lymph flw but are f little value in planning therapy. TreatmentSine there is n  effetive ure fr lymphedema, the treat- ment strategies are designed t ntrl the prblem andCMDT22_Ch12_p0475-p0501.indd  495 29/06/21 8:38 PMCHAPTER 12496 CMDT 2022allw  nrmal ativity and funtin. Mst patients an be treated with sme f the fllwing measures: (1) The flw f lymph ut f the extremity an be aided thrugh inter- mittent elevatin f the extremity, espeially during the sleeping hurs (ft f bed elevated 1520 degrees, ahieved by plaing pillws beneath the mattress); the nstant use f graduated elasti mpressin stkings; and massage tward the trunkeither by hand r by means f pneumati pressure devies designed t milk edema ut f an extremity. Wund are enters speializ- ing in the are f patients with lymphedema may be help- ful. (2) Sendary ellulitis shuld be avided by means f gd hygiene and treatment f any trihphytsis f the tes. One an infetin starts, it shuld be treated by peri- ds f elevatin and antibiti therapy that vers Staphy- lococcus and Streptococcus rganisms (see Table 306). Infetins an be a serius and reurring prblem and are ften diffiult t ntrl. Prphylati antibitis have nt been shwn t be f benefit. (3) Intermittent urses f diureti therapy, espeially in thse with premenstrual r seasnal exaerbatins, are rarely helpful. (4) Amputatin is used nly fr the rare mpliatin f lymphangisar- ma in the extremity. PrognosisW ith aggressive treatment, inluding pneumati mpres- sin devies, gd relief f symptms an be ahieved. The lng-term utlk is ditated by the assiated nditins and avidane f reurrent ellulitis.Chen  K et al. Surgial management f pstmastetmy lymph- edema and review f the literature. Ann Plast Surg. 2021;86: S173. [PMID: 33346539] Figure 124. Lymphedema with a dorsal pedal hump and exaggerated skin folds near the ankle. (Used, with permission, from Dean SM, Satiani B, Abraham WT. Color Atlas and Synopsis of Vascular Diseases. McGraw-Hill, 2014.)SHOCKE S S E N T I A L S  O F  D I A G N O S I S Hypotension, tachycardia, oliguria, altered mental status. Peripheral hypoperfusion and impaired oxygen delivery. Four classifications: hypovolemic, cardiogenic, obstructive, or distributive. General ConsiderationsShk  urs when the rate f arterial bld flw is inad- equate t meet tissue metabli needs. This results in reginal hypxia and subsequent lati aidsis frm anaerbi metablism in peripheral tissues as well as even- tual end-rgan damage and failure. ClassificationT able 121 utlines mmn auses and mehanisms ass- iated with eah type f shk.A.  Hypovolemic ShockH ypvlemi shk results frm dereased intravasular vlume sendary t lss f bld r fluids and eletr- lytes. The etilgy may be suggested by the linial setting (eg, trauma) r by signs and symptms f bld lss (eg, gastrintestinal bleeding) r dehydratin (eg, vmiting r diarrhea). Cmpensatry vasnstritin may transiently maintain the bld pressure but unreplaed lsses f ver 15% f the intravasular vlume an result in hyptensin and prgressive tissue hypxia.B.  Cardiogenic ShockCardigeni  shk results frm ardia failure with the resultant inability f the heart t maintain adequate tissue perfusin. The linial definitin f ardigeni shk is evidene f tissue hypxia due t dereased ardia utput (ardia index less than 2.2 L/min/m2) in the presene f adequate intravasular vlume. This is mst ften aused by myardial infartin but an als be due t ardimy- pathy, myardial ntusin, valvular inmpetene r stensis, r arrhythmias. See Chapter 10.C.  Obstructive ShockPe riardial tampnade, tensin pneumthrax, and mas- sive pulmnary emblism an ause an aute derease in ardia utput resulting in shk. These are medial emer- genies requiring prmpt diagnsis and treatment.D . Distributive ShockDistributiv e r vasdilatry shk has many auses inlud- ing sepsis, anaphylaxis, traumati spinal rd injury, rCMDT22_Ch12_p0475-p0501.indd  496 29/06/21 8:38 PMBLOOD VESSEL & LYMPHATIC DISORDERS497 CMDT 2022aute  adrenal insuffiieny. The redutin in systemi vasular resistane results in inadequate ardia utput and tissue hypperfusin despite nrmal irulatry vlume. 1. Septic shock Sepsis is the mst mmn ause f dis- tributive shk and arries a mrtality rate f 2050%. TheSiety f Critial Care Mediine and the Eurpean Siety f Intensive Care Mediines 2016 definitin fr sepsis is life-threatening rgan dysfuntin aused by a dysregu- lated hst respnse t infetin frm any rganism (bate- rial, viral, r fungal). Septic shock is linially defined as sepsis with fluid-unrespnsive hyptensin (systli bld pressure less than 100 mm Hg), serum latate level higher than 2 mml/L, and a need fr vaspressrs t keep mean arterial pressure (MAP) abve 65 mm Hg. The mst m- mn ause f septi shk in hspitalized patients is infe- tin with gram-psitive r gram-negative rganisms, with a grwing inidene f infetin frm multidrug-resistant rganisms. Sepsis frm viral and fungal rganisms is inreasing but remain less than that fr baterial infetins. Risk fatrs fr septi shk inlude bateremia, extremes f age, diabetes, aner, immunsuppressin, and histry f a reent invasive predure. a. Clinical tools to identify sepsis and septic shock The Third Internatinal Cnsensus Definitins fr Sepsis and Septi Shk (SEPSIS-3) remmend using the Sequential Organ Failure Assessment (SOFA) sre t define sepsis (https://en.wikipedia.rg/wiki/SOFA_sre); an inrease f 2 r mre SOFA sre pints in a patient with infetin is diagnsti f sepsis with a predited 10% mrtality. The SEPSIS-3 grup als intrdued the quik SOFA (qSOFA) sring system (https://en.wikipedia.rg/ wiki/SOFA_sre); 1 pint eah is assigned fr hypten- sin (systli bld pressure belw 100 mm Hg), altered mental status, r tahypnea (respiratry rate mre than 22 breaths per minute). A qSOFA sre f 2 r mre in a patient with suspeted infetin suggests wrsened linial utmes and may influene triage deisins fr intensive are unit (ICU)-level are. b. Systemic inflammatory response syndrome (SIRS) Defined as a systemi respnse t a nnspeifi infetius r nninfetius insult resulting in at least tw f the fllwing findings: (1) bdy temperature higher than 38C (100.4F) r lwer than 36C (96.8F), (2) heart rate faster than 90 beats per minute, (3) respiratry rate mre than 20 breaths per minute r hyperventilatin with an arterial arbn dixide tensin (Paco2) less than 32 mm Hg, r (4) abnrmal white bld ell unt (greater than 12,000/mL r less than 4000/mL r greater than 10% immature [band] frms). Vasdilatry shk frm SIRS is ften due t burns; panreatitis; autimmune disrders, suh as vasulitis r inflammatry litis; air r amniti fluid emblus; ishemia; r trauma. SIRS is nt inluded in the 2016 frmal diagnsti riteria f sepsis. A 2018 meta- analysis demnstrated that SIRS riteria have higher sensi- tivity than qSOFA and may therefre identify patients with sepsis befre ther tests, suggesting that SIRS may be a better sreening tl fr sepsis, while qSOFA may be better used as a preditr f ICU mrtality. Studies are nging t desribe the ptimal patient ppulatins (emergeny department vs hspitalized nn-ICU patients) where SIRS and qSOFA sring systems shuld be used. 2. Neurogenic shock Neurgeni shk is aused by traumati spinal rd injury r effets f an epidural r spinal anestheti. This results in lss f sympatheti tneTable 121. Classification of shock by mechanism and common causes.Hypovolemic  shock Blood loss Traumatic hemorrhage Exsanguination Hemothorax Hemoperitoneum Fracture (femur and pelvis) Nontraumatic hemorrhage Gastrointestinal bleed AAA rupture Ectopic pregnancy rupture Volume loss Burns Skin integrity loss (toxic epidermal necrolysis) Vomiting Diarrhea Hyperosmolar states (diabetic ketoacidosis) Third spacing (eg, ascites, pancreatitis) Decreased intake Cardiogenic shock Dysrhythmia Bradycardias and blocks Tachycardias Myocardial disease Left or right ventricular infarction Dilated cardiomyopathy Mechanical Valvular Aortic regurgitation from dissection Papillary muscle rupture from ischemia Acute valvular rupture from abscess Ventricular aneurysm rupture Ventricular septum rupture Free wall ventricle rupture Obstructive shock Tension pneumothorax Pericardial disease Pericardial tamponade Constrictive pericarditis High-risk (massive) pulmonary embolism Severe pulmonary hypertension Auto PEEP from mechanical ventilation Distributive (vasodilatory) shock Anaphylactic shock Septic shock Neurogenic shock Drug-induced vasodilation Adrenal insufficiency Modified, with permission, from Stone CK, Humphries RL (editors). Current Emergency Diagnosis & Treatment , 7th ed. McGraw-Hill, 2011. AAA, abdominal aortic aneurysm; PEEP , positive end expiratory pressure.CMDT22_Ch12_p0475-p0501.indd  497 29/06/21 8:38 PMCHAPTER 12498 CMDT 2022with a redutin  in systemi vasular resistane and hyp- tensin withut a mpensatry tahyardia. Reflex vagal parasympatheti stimulatin evked by pain, gastri dila- tin, r fright may simulate neurgeni shk, prduing hyptensin, bradyardia, and synpe. 3. Endocrine shock Endrine shk an arise frm hyperthyridism, hypthyridism, r adrenal insuffi- ieny. Adrenal insuffiieny mst ften urs with abrupt essatin f lng-term rtisterid use, but it an als be preipitated by infetin, trauma, surgery, r pitu- itary injury (leading t sendary adrenal insuffiieny). In additin t hyptensin, symptms inlude weakness, nausea, abdminal pain, and nfusin. Hypthyridism an lead t myxedema ma, presenting with vasdilatin and depressed ardia utput. Shk frm hyperthyrid- ism mst ften prdues high-utput ardia failure. Clinical FindingsA.  Symptoms and SignsHyp otension is traditinally defined as a systli bld pressure f 90 mm Hg r less r a MAP f less than 6065 mm Hg but must be evaluated relative t the patients nrmal bld pressure. A drp in systli pressure f greater than 1020 mm Hg r an inrease in pulse f mre than 15 beats per minute with psitinal hange sug- gests depleted intravasular vlume. Hwever, bld pres- sure is ften nt the best indiatr f end-rgan perfusin beause mpensatry mehanisms, suh as inreased heart rate, inreased ardia ntratility, and vasnstritin an ur t prevent hyptensin. Patients with hypten- sin ften have l r mttled extremities and weak r thready peripheral pulses. Splanhni vasnstritin may lead t liguria, bwel ishemia, and liver dysfuntin, whih an ultimately result in multirgan failure. Mentatin may be nrmal r patients may beme restless, agitated, nfused, lethargi, r matse as a result f inadequate perfusin f the brain. Hypovolemic shock is evident when signs f hypper- fusin, suh as liguria, altered mental status, and l extremities, are present. Jugular venus pressure is lw, and there is a narrw pulse pressure indiative f redued strke vlume. Rapid replaement f fluids an restre tis- sue perfusin. In cardiogenic shock, there are als signs f glbal hypperfusin with liguria, altered mental status, and l extremities. Jugular venus pressure is elevated and there may be evidene f pulmnary edema with respi- ratry mprmise in the setting f left-sided heart failure. A transthoracic echocardiogram (TTE) or a transesophageal echocardiogram (TEE) is an effective diagnostic tool to dif- ferentiate hypovolemic from cardiogenic shock. In hypvle- mi shk, the left ventrile will be small beause f dereased filling, but ntratility is ften preserved. In ardigeni shk, there is a derease in left ventriular ntratility. The left ventrile may appear dilated and full beause f the inability f the left ventrile t ejet a suffi- ient strke vlume. Inobstructive shock , the entral venus pressure may be elevated but the TTE r TEE may shw redued left ventriular filling, a periardial effusin in the ase ftampnade, thikened periardium in the ase f periar- ditis, r right ventriular dysfuntin in the ase f massive pulmnary emblism. Periardientesis r periardial windw fr periardial tampnade, hest tube plaement fr tensin pneumthrax, r atheter-direted thrmb- lyti therapy fr massive pulmnary emblism an be life- saving in ases f bstrutive shk. Indistributive shock, signs inlude hyperdynami heart sunds, warm extremities initially, and a wide pulse pres- sure indiative f large strke vlume. The ehardigram may shw a hyperdynami left ventrile. Septic shock is diagnsed when there is linial evidene f infetin in the setting f persistent hyptensin and evidene f rgan hypperfusin, suh as lati aidsis, dereased urinary utput, r altered mental status despite adequate vlume resusitatin. Neurogenic shock is diagnsed when there is evidene f entral nervus system injury and persistent hyptensin despite adequate vlume resusitatin. A his- try f lng-term rtisterid use r thyrid disease an inrease the likelihd f endocrine shock.B.  Laboratory Findings and ImagingBld  speimens shuld be evaluated fr mplete bld unt, eletrlytes, gluse, arterial bld gas determina- tins, agulatin parameters, latate levels, typing and rss-mathing, and baterial ultures. An eletrardi- gram and hest radigraph shuld als be part f the initial assessment. Pint-f-are ultrasngraphy an rapidly assess glbal ardia funtin, presene f periardial effu- sin, and intravasular vlume status via inferir vena ava inspetin in ases f undifferentiated hyptensin. A TTE an mre frmally assess right- and left-sided filling pres- sures and ardia utput. TreatmentA.  General MeasuresT reatment depends n prmpt diagnsis and an aurate appraisal f initing nditins. Initial management n- sists f basi life supprt with an assessment f the patients irulatin, airway, and breathing. This may entail airway intubatin and mehanial ventilatin. Ven- tilatry failure shuld be antiipated in patients with severe metabli aidsis due t shk. Mehanial venti- latin alng with sedatin an derease respiratry musle xygen demand and allw imprved xygen delivery t hypperfused tissues. Intravenus aess and fluid resus- itatin shuld be instituted alng with ardia mnitr- ing and assessment f hemdynami parameters suh as bld pressure and heart rate. Cardia mnitring an detet myardial ishemia r malignant arrhythmias, whih an be treated by standard advaned ardia life supprt (ACLS) prtls. Unrespnsive r minimally respnsive patients shuld have their gluse heked immediately, and if their gluse levels are lw, 1 ampule f 50% dextrse intravenusly shuld be given. An arterial line shuld be plaed fr n- tinuus bld pressure measurement, and an indwelling urinary atheter shuld be inserted t mnitr urinary utput.CMDT22_Ch12_p0475-p0501.indd  498 29/06/21 8:38 PMBLOOD VESSEL & LYMPHATIC DISORDERS499 CMDT 2022B.  Hemodynamic MeasurementsEarly  nsideratin is given t plaement f a entral venus atheter (CVC) fr infusin f fluids and media- tins and fr hemdynami pressure measurements. A CVC an prvide measurements f the entral venus pressure (CVP) and the entral venus xygen saturatin (SvO2), bth f whih an be used t manage septi and ardigeni shk. Pulmnary artery atheters (PACs) allw measurement f the pulmnary artery pressure, left- sided filling pressure r the pulmnary apillary wedge pressure (PCWP), the mixed venus xygen saturatin (SvO2), and ardia utput. Multiple studies suggest that PACs d nt inrease verall mrtality r length f hspital stay but are assiated with higher use f intrpes and intravenus vasdilatrs in selet grups f ritially ill patients. The attendant risks assiated with PACs (infe- tin, arrhythmias, vein thrmbsis, and pulmnary artery rupture) an be as high as 49%; thus, the rutine use f PACs annt be remmended. Hwever, in mplex situ- atins, PACs may be useful in distinguishing between ar- digeni and septi shk, s the value f the infrmatin they might prvide must be arefully weighed in eah patient. TTE is a nninvasive alternative t the PAC. TTE an prvide infrmatin abut the pulmnary artery pres- sure and urrent ardia funtin, inluding ardia ut- put. The SvO2, whih is btained thrugh the CVC, an be used as a surrgate fr the SvO2, whih is btained thrugh the PAC. Pulse pressure variatin, as determined by arterial wavefrm analysis, r strke vlume variatin is muh mre sensitive than CVP as dynami measures f fluid respnsiveness in vlume resusitatin, but these measure- ments have nly been validated in patients wh are mehanially ventilated with tidal vlumes f 8 mL/kg, nt triggering the ventilatr, and in nrmal sinus rhythm. Pint-f-are ultrasund measurements f the inferir vena ava (IVC) an suggest intravasular vlume status and guide fluid replaement. If the patient is mehanially ventilated and the IVC dilates ~1520% with respiratins, they are likely t respnd t intravenus fluids. If the patient is spntaneusly breathing, they may be fluid- respnsive if their IVC is less than 2 m in diameter and llapses by mre than 50% with eah breath. A CVP less than 5 mm Hg suggests hypvlemia, and a CVP greater than 18 mm Hg suggests vlume verlad, ardia failure, tampnade, r pulmnary hypertensin. A ardia index lwer than 2 L/min/m2indiates a need fr intrpi supprt. A ardia index higher than 4 L/min/m2 in a hyptensive patient is nsistent with early septi shk. The systemi vasular resistane is lw (less than 800 dynes  s/m5) in sepsis and neurgeni shk and high (greater than 1500 dynes  s/m5) in hypvlemi and ardigeni shk. Treatment is direted at maintaining a CVP f 812 mm Hg, a MAP f 65 mm Hg r higher, a ardia index f 24 L/min/m2, and a SvO2greater than 70%.C.  Volume ReplacementV lume replaement is ritial in the initial management f shk. Hemorrhagic shock is treated with immediateeffrts t ahieve hemstasis and rapid infusins f bld substitutes, suh as type-speifi r type O negative paked red bld ells (PRBCs) r whle bld, whih prvides extra vlume and ltting fatrs. Eah unit f PRBC r whle bld is expeted t raise the hematrit by 3%. Hypovolemic shock sendary t dehydratin is managed with rapid bluses f istni rystallid slutins, usually in 1-L inrements. Cardiogenic shock in the absene f fluid verlad requires smaller fluid hallenges, usually in inrements f 250 mL. Septic shock usually requires large vlumes f fluid fr resusitatin (typially 30 mL/kg) as the assiated apillary leak releases fluid int the extravas- ular spae. Caution must be used in cases of large-volume resuscitation with unwarmed fluids because this can produce hypothermia, which can lead to hypothermia-induced coag- ulopathy. Warming f fluids befre administratin an avid this mpliatin. Crystallid slutin is the resusitatin fluid f hie in mst settings. Histrially, 0.9% saline was the mst widely used rystallid slutin in resusitatin. Data sug- gest that balaned rystallids, like latated Ringer slutin r Plasma-Lyte, are assiated with less kidney injury, fewer instanes f hyperhlremi metabli aidsis, and dereased verall mrtality. Cmparisns f 0.9% saline and llid (albumin) slutins in ritially ill patients fund n differene in utme exept in patients with traumati brain injury, where albumin resusitatin led t higher mrtality. Thus, the use f balaned rystallid slutins fr vlume resusitatin in shk is favred. If the patient des nt respnd t fluid resusitatin, early use f vaspressrs shuld be nsidered.D . Early Goal-Directed TherapyCmpensat ed shk an ur in the setting f nrmalized hemdynami parameters with nging glbal tissue hypxia. Traditinal endpints f resusitatin suh as bld pressure, heart rate, urinary utput, mental status, and skin perfusin an therefre be misleading. Fllwing set prtls fr the treatment f septi shk by adjusting the use f fluids, vaspressrs, and intrpes as well as by using bld transfusins t meet hemdynami targets (MAP 65 mm Hg r higher, CVP 812 mm Hg, SvO2 greater than 70%) is termed early goal-directed therapy (EGDT). Latate learane f mre than 10% an be used as a substitute fr SvO2riteria if SvO2mnitring is nt available. Tw large randmized trials published in 2014 (Pr- CESS and ARISE) demnstrated n mrtality benefit frm the institutin f the riginal algrithm fr EGDT, but this may have been due t earlier administratin f antibitis, mpnents f EGDT beming part f the usual are that liniians deliver, and the effetiveness f eduatin abut deteting and treating sepsis in a timely fashin. The Surviving Sepsis Campaigns remmendatins fr patients with sepsis r septi shk are t measure latate level; btain bld ultures prir t administratin f brad-spetrum antibitis, which should occur within 1 hour of sepsis diagnosis; and administer 30 mL/kg rystal- lid fr hyptensin r latate greater than 4 mml/L within the first 3 hurs f presentatin. SmallerCMDT22_Ch12_p0475-p0501.indd  499 29/06/21 8:38 PMCHAPTER 12500 CMDT 2022resusita tin vlumes may be apprpriate fr patients with heart failure, irrhsis, r advaned kidney disease. Vas- pressrs shuld be administered fr hyptensin nt respnsive t initial fluid resusitatin t maintain MAP 65 mm Hg r higher. Remeasure latate if initial level was high, and reassess vlume status and tissue perfusin fre- quently. A meta-analysis f hemdynami ptimizatin trials suggests that early treatment befre the develpment f rgan failure results in imprved survival, and patients wh respnd well t initial effrts demnstrate a survival advantage ver nnrespnders.E.  Medications1.  Vasoactive therapy Vaspressrs and intrpi agents are administered nly after adequate fluid resusitatin. Chie f vasative therapy depends n the presumed etilgy f shk as well as ardia utput. If there is n- tinued hyptensin with evidene f high ardia utput after adequate vlume resusitatin, then vaspressr sup- prt is needed t imprve vasmtr tne. If there is evi- dene f lw ardia utput with high filling pressures, intrpi supprt is needed t imprve ntratility. a. Distributive (vasodilatory) shock When inreased vasnstritin is required t maintain an ade- quate perfusin pressure, alpha-adrenergi atehlamine agnists (suh as nrepinephrine and phenylephrine) are generally used. Althugh nrepinephrine is bth an alpha- adrenergi and beta-adrenergi agnist, it preferentially inreases MAP ver ardia utput. The initial dse is 12 mg/min as an intravenus infusin, titrated t main- tain MAP at 65 mm Hg r higher. The usual maintenane dse is 24 mg/min intravenusly (maximum dse is 30 mg/min). Patients with refratry shk may require dsages f 1030 mg/min intravenusly. Epinephrine, als with bth alpha-adrenergi and beta-adrenergi effets, may be used in severe shk and during aute resusitatin. It is the vaspressr f hie fr anaphylati shk. Fr severe shk, give 1 mg/min as a ntinuus intravenus infusin initially and titrate t hemdynami respnse; the usual dsage range is 110 mg/min intravenusly. Dpamine has variable effets arding t dsage. At lw dses (25 mg/kg/min intravenusly), stimulatin f dpaminergi and beta-adrenergi reeptrs prdues inreased glmerular filtratin, heart rate, and ntratil- ity. At dses f 510 mg/kg/min, beta-1-adrenergi effets predminate, resulting in an inrease in heart rate and ardia ntratility. At higher dses (greater than 10 mg/ kg/min), alpha-adrenergi effets predminate, resulting in peripheral vasnstritin. The maximum dse is typi- ally 50 mg/kg/min. There is n evidene dumenting a survival benefit frm, r the superirity f, a partiular vaspressr in septi shk. Nrepinephrine is the initial vaspressr f hie in septi shk t maintain the MAP at 65 mm Hg r higher. Phenylephrine an be used fr hyperdynami septi shk if dysrhythmias r tahyardias prevent the use f agents with beta-adrenergi ativity. In meta-analyses, the use f dpamine as a first-line vaspressr in septi shk resulted in an increase in 28-day mrtality and a higher inidene farrhythmi events. Dpamine shuld nly be used as an alternative t nrepinephrine in selet patients with septi shk, inluding patients with signifiant bradyardia r lw ptential fr tahyarrhythmias. Vaspressin (antidiureti hrmne r ADH) is ften used as an adjuntive therapy t atehlamine vaspres- srs in the treatment f distributive shk. Vaspressin auses peripheral vasnstritin via V1 reeptrs lated n smth musle ells. Vaspressin als ptentiates the effets f atehlamines n the vasulature and stimulates rtisl prdutin. Intravenus infusin f vaspressin at a lw dse (0.010.04 unit/min) as a send agent t nr- epinephrine has been benefiial in septi patients with hyptensin refratry t fluid resusitatin and nven- tinal atehlamine vaspressrs. Higher dses f vas- pressin derease ardia utput and may put patients at greater risk fr splanhni and rnary artery ishemia. Studies d nt favr the use f vaspressin as first-line therapy. Angitensin II, a mpnent f the renin-angitensin- aldsterne system axis, is a ptent diret vasnstritr that ats n the arteries and veins t inrease bld pres- sure. Angitensin II (marketed as Giapreza) an be nsid- ered as an additional agent in vasdilatry shk that is refratry t atehlamines and vaspressin. The rem- mended starting dse is 20 ng/kg/min via ntinuus intra- venus infusin thrugh a entral venus line. It an be titrated every 5 minutes by inrements f up t 15 ng/kg/ min as needed t ahieve MAP gals, but nt t exeed 80 ng/kg/min during the first 3 hurs f use. Maintenane dses shuld nt exeed 40 ng/kg/min. Cnurrent venus thrmbemblism (VTE) prphylaxis is indiated as studies revealed a higher inidene f VTE with angitensin II use. b. Cardiogenic shock Given meta-analyses du- menting dereased mrtality, expert pinin suggests nr- epinephrine be the first-line vaspressr fr ardigeni shk. Dbutamine, a predminantly beta-adrenergi ag- nist, inreases ntratility and dereases afterlad. It is used fr patients with lw ardia utput and high PCWP but wh d nt have hyptensin. Dbutamine an be added t a vaspressr if there is redued myardial fun- tin (dereased ardia utput and elevated PCWP), r if there are signs f hypperfusin despite adequate vlume resusitatin and an adequate MAP . The initial dse is 0.10.5 mg/kg/min intravenus infusin, whih an be titrated every few minutes t hemdynami effet; the usual dsage range is 220 mg/kg/min intravenusly. Tahyphylaxis an ur after 48 hurs sendary t the dwn-regulatin f beta-adrenergi reeptrs. Amrinne and milrinne are phsphdiesterase inhibitrs that an be substituted fr dbutamine. These drugs inrease yli AMP levels and inrease ardia ntratility, bypassing the beta-adrenergi reeptr. Vasdilatin is a side effet f bth amrinne and milrinne. 2. Antibiotics Definitive therapy fr septi shk inludes early initiatin f empiri brad-spetrum antibitis after apprpriate ultures have been btained and within 1 hur f regnitin f septi shk. Imaging studies may prve useful t attempt lalizatin f sures f infetin.CMDT22_Ch12_p0475-p0501.indd  500 29/06/21 8:38 PMBLOOD VESSEL & LYMPHATIC DISORDERS501 CMDT 2022Surgial  management may als be neessary if nerti tis- sue r lulated infetins are present in attempts t n- trl the sure f infetin (see Table 305). 3. Corticosteroids Crtisterids are the treatment f hie in patients with shk sendary t adrenal insuf- fiieny, defined as a rtisl respnse f 9 mg/dL r less after ne injetin f 250 mg f rtitrpin. Studies supprting rtisterid use in patients with shk frm sepsis r ther etilgies are mixed. Trials where either high r lw dses f rtisterids were administered t patients in septi shk did nt nsistently shw imprved survival. The ADRENAL study demnstrated shrter time t shk reslutin (3 days vs 4 days) but n differene in 90-day mrtality. The APROCCHSS study demnstrated lwer 90-day all-ause mrtality, exept fr thse reeiving hydrrtisne plus fludrrtisne. Ntably, sme wrse utmes were bserved frm inreased rates f sendary infetins. Crtisterids an be administered in refra- try shk t derease shk duratin; the urrent rem- mended regimen is hydrrtisne 50 mg intravenusly every 6 hurs fr 57 days.F . Other Treatment ModalitiesCardia  failure may require use f transutaneus r trans- venus paing r plaement f an intra-arterial balln pump r left ventriular assist devie. Emergent revasu- larizatin by perutaneus angiplasty r rnary arterybypass surgery appears t imprve lng-term utme with inreased survival mpared with initial medial sta- bilizatin fr patients with myardial ishemia leading t ardigeni shk (see Chapter 10). Urgent renal replae- ment therapy may be indiated fr maintenane f fluid and eletrlyte balane during aute kidney injury result- ing in shk frm multiple mdalities.Annane  D et al; CRICS-TRIGGERSEP Netwrk. Hydrrti- sne plus fludrrtisne fr adults with septi shk. N Engl J Med. 2018;378:809. [PMID: 29490185] Gand S et al; Japanese Assiatin fr Aute Mediine (JAAM) Sepsis Prgnstiatin in Intensive Care Unit and Emergeny Rm (SPICE) (JAAM SPICE) Study Grup. The SIRS riteria have better perfrmane fr prediting infetin than qSOFA sres in the emergeny department. Si Rep. 2020;10:8095. [PMID: 32415144] Khanna A et al; ATHOS-3 Investigatrs. Angitensin II fr the treatment f vasdilatry shk. N Engl J Med. 2017;377:419. [PMID: 28528561] Rhdes A et al. Surviving Sepsis Campaign: internatinal guide- lines fr management f sepsis and septi shk: 2016. Crit Care Med. 2017;45:486. [PMID: 28098591] Thiele H et al. Management f ardigeni shk mpliating myardial infartin: an update 2019. Eur Heart J. 2019;40:2671. [PMID: 31274157] Venkatesh B et al; ADRENAL Trial Investigatrs and the AustralianNew Zealand Intensive Care Siety Clinial Trials Grup. Adjuntive glurtiid therapy in patients with septi shk. N Engl J Med. 2018;378:797. [PMID: 29347874]CMDT22_Ch12_p0475-p0501.indd  501 29/06/21 8:38 PM502 CMDT 2022 ANEMIAS General Approach to AnemiasAnemia is presen t in adults if the hematocrit is below 41% (hemoglobin less than 13.6 g/dL [135 g/L]) in males or below 36% (hemoglobin less than 12 g/dL [120 g/L]) in females. Congenital anemia is suggested by the patients personal and family history. The most common cause of anemia is iron deficiency. Poor diet may result in folic acid deficiency and contribute to iron deficiency, but bleeding is the most common cause of iron deficiency in adults. Physi- cal examination demonstrates pallor. Attention to physical signs of primary hematologic diseases (lymphadenopathy; hepatosplenomegaly; or bone tenderness, especially in the sternum or anterior tibia) is important. Mucosal changes such as a smooth tongue suggest megaloblastic anemia. Anemias are classified according to their pathophysiologic basis, ie, whether related to diminished production (relative or absolute reticulocytopenia) or to increased production due to accelerated loss of red blood cells (reticulocytosis) (Table 131), and according to red blood cell size (Table 132). A reticulocy- tosis occurs in one of three pathophysiologic states: acute blood loss, recent replacement of a missing erythropoietic nutrient, or reduced red blood cell survival (ie, hemolysis). A severely microcytic anemia (mean corpuscular volume [MCV] less than 70 fL) is due either to iron deficiency or thalassemia, while a severely macrocytic anemia (MCV greater than 120 fL) is almost always due to either megaloblastic anemia or to cold agglutinins in blood analyzed at room temperature. A bone marrow biopsy is generally needed to complete the evaluation of anemia when the blood laboratory evaluation fails to reveal an etiology, when there are additional cytopenias present, or when an underlying primary or secondary bone marrow pro- cess is suspected.IR ON DEFICIENCY ANEMIAE S S E N T I A L S  O F  D I A G N O S I S Iron deficiency: serum ferritin is < 12 ng/mL (27 pmol/L) or < 30 ng/mL (67 pmol/L) if also anemic.13Lloyd E. Damon, MD Charalambos Babis Andreadis, MD, MSCEBlood Disorders Caused by bleeding unless proved otherwise. Responds to iron therapy. General ConsiderationsIro n deficiency is the most common cause of anemia worldwide. The causes are listed in Table 133. Aside from circulating red blood cells, the major location of iron in the body is the storage pool as ferritin or as hemosiderin in macrophages. The average American diet contains 1015 mg of iron per day. About 10% of this amount is absorbed in the stomach, duodenum, and upper jejunum under acidic conditions. Dietary iron present as heme is efficiently absorbed (1020%) but nonheme iron less so (15%), largely because of interfer- ence by phosphates, tannins, and other food constituents. The major iron transporter from the diet across the intestinal lumen is ferroportin, which also facilitates the transport of iron to apotransferrin in macrophages for delivery to ery- throid progenitor cells in the bone marrow prepared to syn- thesize hemoglobin. Hepcidin, which is increasingly produced during inflammation, negatively regulates iron transport by promoting the degradation of ferroportin. Small amounts of ironapproximately 1 mg/dayare normally lost through exfoliation of skin and gastrointestinal mucosal cells. Menstrual blood loss plays a major role in iron metabo- lism. The average monthly menstrual blood loss is approxi- mately 50 mL but may be five times greater in some individuals. Women with heavy menstrual losses must absorb 34 mg of iron from the diet each day to maintain adequate iron stores, which is not commonly achieved. Women with menorrhagia of this degree will almost always become iron deficient without iron supplementation. In general, iron metabolism is balanced between absorp- tion of 1 mg/day and loss of 1 mg/day. Pregnancy and lacta- tion upset the iron balance, since requirements increase to 25 mg of iron per day. Normal dietary iron cannot supply these requirements, and medicinal iron is needed during pregnancy and lactation. Decreased iron absorption can also cause iron deficiency, such as in people affected by celiac disease (gluten enteropathy), and it also commonly occurs after gastric resection or jejunal bypass surgery.CMDT22_Ch13_p0502-p0547.indd  502 29/06/21 8:38 PM"
                ]
              ],
              "shape": {
                "columns": 2,
                "rows": 5
              }
            },
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>string_values</th>\n",
              "      <th>spacy_doc</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>CANCER1613 CMDT 2022Office  of Disease Prevent...</td>\n",
              "      <td>(CANCER1613, CMDT, 2022Office,  , of, Disease,...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>DIABETES MELLITUS &amp; HYPOGLYCEMIA1213 CMDT 2022...</td>\n",
              "      <td>(DIABETES, MELLITUS, &amp;, HYPOGLYCEMIA1213, CMDT...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>NERVOUS SYSTEM DISORDERS979 CMDT 2022alhli...</td>\n",
              "      <td>(NERVOUS, SYSTEM, DISORDERS979, CMDT, 2022al...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>KIDNEY DISEASE913 CMDT 2022Thr  ar svral ...</td>\n",
              "      <td>(KIDNEY, DISEASE913, CMDT, 2022Thr,  , ar, ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>Chapter 11444 CMDT 2022Elev ated BP reading (o...</td>\n",
              "      <td>(Chapter, 11444, CMDT, 2022Elev, ated, BP, rea...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>"
            ],
            "text/plain": [
              "                                       string_values  \\\n",
              "0  CANCER1613 CMDT 2022Office  of Disease Prevent...   \n",
              "1  DIABETES MELLITUS & HYPOGLYCEMIA1213 CMDT 2022...   \n",
              "2  NERVOUS SYSTEM DISORDERS979 CMDT 2022alhli...   \n",
              "3  KIDNEY DISEASE913 CMDT 2022Thr  ar svral ...   \n",
              "4  Chapter 11444 CMDT 2022Elev ated BP reading (o...   \n",
              "\n",
              "                                           spacy_doc  \n",
              "0  (CANCER1613, CMDT, 2022Office,  , of, Disease,...  \n",
              "1  (DIABETES, MELLITUS, &, HYPOGLYCEMIA1213, CMDT...  \n",
              "2  (NERVOUS, SYSTEM, DISORDERS979, CMDT, 2022al...  \n",
              "3  (KIDNEY, DISEASE913, CMDT, 2022Thr,  , ar, ...  \n",
              "4  (Chapter, 11444, CMDT, 2022Elev, ated, BP, rea...  "
            ]
          },
          "execution_count": 75,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "df.head()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 84,
      "metadata": {},
      "outputs": [],
      "source": [
        "\n",
        "doc_adj = [token.text.lower() for doc in df.spacy_doc for token in doc if token.pos_=='ADJ']\n",
        "doc_noun = [token.text.lower() for doc in df.spacy_doc for token in doc if token.pos_=='NOUN']"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 88,
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "[('\\ue040f', 282),\n",
              " ('high', 259),\n",
              " ('severe', 222),\n",
              " ('common', 200),\n",
              " ('less', 186),\n",
              " ('retinal', 184),\n",
              " ('such', 183),\n",
              " ('due', 183),\n",
              " ('other', 176),\n",
              " ('daily', 172),\n",
              " ('primary', 158),\n",
              " ('first', 153),\n",
              " ('present', 151),\n",
              " ('chronic', 146),\n",
              " ('-', 141),\n",
              " ('r\\ue03bnal', 140),\n",
              " ('low', 135),\n",
              " ('visual', 130),\n",
              " ('small', 129),\n",
              " ('clinical', 128),\n",
              " ('peripheral', 116),\n",
              " ('renal', 104),\n",
              " ('initial', 103),\n",
              " ('greater', 100),\n",
              " ('higher', 98),\n",
              " ('most', 96),\n",
              " ('acute', 95),\n",
              " ('su\\ue034h', 94),\n",
              " ('early', 91),\n",
              " ('urinary', 91),\n",
              " ('surgical', 87),\n",
              " ('lower', 87),\n",
              " ('similar', 86),\n",
              " ('advanced', 85),\n",
              " ('available', 81),\n",
              " ('multiple', 80),\n",
              " ('colorectal', 79),\n",
              " ('systemic', 79),\n",
              " ('many', 79),\n",
              " ('normal', 77),\n",
              " ('metastatic', 76),\n",
              " ('helpful', 76),\n",
              " ('oral', 74),\n",
              " ('gastric', 73),\n",
              " ('single', 73),\n",
              " ('large', 71),\n",
              " ('optic', 70),\n",
              " ('likely', 68),\n",
              " ('mild', 68),\n",
              " ('several', 68),\n",
              " ('long', 66),\n",
              " ('tubular', 66),\n",
              " ('upper', 65),\n",
              " ('arterial', 65),\n",
              " ('cardiovascular', 62),\n",
              " ('corneal', 61),\n",
              " ('important', 60),\n",
              " ('rare', 60),\n",
              " ('malignant', 60),\n",
              " ('free', 60),\n",
              " ('elevated', 59),\n",
              " ('central', 59),\n",
              " ('significant', 59),\n",
              " ('intraocular', 59),\n",
              " ('local', 58),\n",
              " ('bilateral', 58),\n",
              " ('few', 57),\n",
              " ('new', 56),\n",
              " ('pancreatic', 54),\n",
              " ('topical', 54),\n",
              " ('useful', 53),\n",
              " ('spinal', 53),\n",
              " ('antihypertensive', 53),\n",
              " ('anti', 52),\n",
              " ('diabetic', 51),\n",
              " ('further', 51),\n",
              " ('positive', 50),\n",
              " ('able', 50),\n",
              " ('ocular', 50),\n",
              " ('older', 50),\n",
              " ('adjuvant', 49),\n",
              " ('abdominal', 49),\n",
              " ('more', 49),\n",
              " ('hypertensive', 49),\n",
              " ('fluid', 48),\n",
              " ('effective', 48),\n",
              " ('cardiac', 48),\n",
              " ('anterior', 48),\n",
              " ('poor', 47),\n",
              " ('pleural', 46),\n",
              " ('different', 46),\n",
              " ('least', 46),\n",
              " ('macular', 46),\n",
              " ('adverse', 45),\n",
              " ('pulmonary', 44),\n",
              " ('specific', 44),\n",
              " ('deep', 44),\n",
              " ('systolic', 44),\n",
              " ('neuropathy', 43),\n",
              " ('secondary', 43),\n",
              " ('ne\\ue034essary', 43),\n",
              " ('sudden', 42),\n",
              " ('distal', 41),\n",
              " ('major', 40),\n",
              " ('third', 40),\n",
              " ('\\ue03ab\\ue048ut', 40),\n",
              " ('n\\ue040rmal', 40),\n",
              " ('inflammatory', 39),\n",
              " ('sensitive', 39),\n",
              " ('frequent', 39),\n",
              " ('extensive', 38),\n",
              " ('left', 38),\n",
              " ('vascular', 38),\n",
              " ('\\ue03and', 38),\n",
              " ('m\\ue040st', 38),\n",
              " ('red', 37),\n",
              " ('essential', 37),\n",
              " ('overall', 37),\n",
              " ('benign', 37),\n",
              " ('focal', 37),\n",
              " ('vas\\ue034ular', 37),\n",
              " ('necessary', 36),\n",
              " ('white', 35),\n",
              " ('ischemic', 35),\n",
              " ('glom\\ue03brular', 35),\n",
              " ('limited', 34),\n",
              " ('various', 34),\n",
              " ('hepatocellular', 34),\n",
              " ('partial', 34),\n",
              " ('rapid', 33),\n",
              " ('medical', 33),\n",
              " ('minimal', 33),\n",
              " ('\\ue034ardia\\ue034', 33),\n",
              " ('ing', 32),\n",
              " ('uric', 32),\n",
              " ('posterior', 32),\n",
              " ('larger', 31),\n",
              " ('progressive', 31),\n",
              " ('resistant', 31),\n",
              " ('young', 31),\n",
              " ('active', 31),\n",
              " ('pmnervous', 31),\n",
              " ('pr\\ue040ximal', 31),\n",
              " ('gastrointestinal', 30),\n",
              " ('rash', 30),\n",
              " ('median', 30),\n",
              " ('possible', 30),\n",
              " ('palliative', 30),\n",
              " ('intravenous', 30),\n",
              " ('neurologic', 30),\n",
              " ('t\\ue048', 30),\n",
              " ('cerebral', 30),\n",
              " ('diagnostic', 29),\n",
              " ('non', 29),\n",
              " ('physical', 29),\n",
              " ('complete', 29),\n",
              " ('adequate', 29),\n",
              " ('radical', 29),\n",
              " ('open', 29),\n",
              " ('hepatic', 29),\n",
              " ('vitreous', 29),\n",
              " ('distant', 28),\n",
              " ('mental', 28),\n",
              " ('better', 28),\n",
              " ('asymptomatic', 28),\n",
              " ('patient', 28),\n",
              " ('\\ue034erebr\\ue040spinal', 28),\n",
              " ('n\\ue03bphrotic', 28),\n",
              " ('ipsilateral', 27),\n",
              " ('subsequent', 27),\n",
              " ('same', 27),\n",
              " ('additional', 27),\n",
              " ('proximal', 27),\n",
              " ('ophthalmic', 27),\n",
              " ('fem\\ue040ral', 27),\n",
              " ('neoadjuvant', 26),\n",
              " ('negative', 26),\n",
              " ('familial', 26),\n",
              " ('relative', 26),\n",
              " ('aggressive', 26),\n",
              " ('good', 26),\n",
              " ('intestinal', 26),\n",
              " ('elderly', 26),\n",
              " ('esophageal', 26),\n",
              " ('variable', 26),\n",
              " ('intracranial', 26),\n",
              " ('weekly', 25),\n",
              " ('invasive', 25),\n",
              " ('smaller', 25),\n",
              " ('standard', 25),\n",
              " ('general', 25),\n",
              " ('intensive', 25),\n",
              " ('trigeminal', 25),\n",
              " ('usual', 25),\n",
              " ('t\\ue040', 25),\n",
              " ('\\ue034entral', 25),\n",
              " ('end\\ue040vas\\ue034ular', 25),\n",
              " ('total', 24),\n",
              " ('rectal', 24),\n",
              " ('maximum', 24),\n",
              " ('symptomatic', 24),\n",
              " ('external', 24),\n",
              " ('cystic', 24),\n",
              " ('absent', 24),\n",
              " ('underlying', 24),\n",
              " ('\\ue034ranial', 24),\n",
              " ('lar', 23),\n",
              " ('cutaneous', 23),\n",
              " ('persistent', 23),\n",
              " ('superior', 23),\n",
              " ('unilateral', 23),\n",
              " ('viral', 23),\n",
              " ('preferred', 23),\n",
              " ('genetic', 23),\n",
              " ('immediate', 23),\n",
              " ('urgent', 23),\n",
              " ('\\ue03av\\ue03ail\\ue03able', 23),\n",
              " ('intra\\ue034ranial', 23),\n",
              " ('ventricular', 22),\n",
              " ('regional', 22),\n",
              " ('recurrent', 22),\n",
              " ('short', 22),\n",
              " ('hereditary', 22),\n",
              " ('gross', 22),\n",
              " ('permanent', 22),\n",
              " ('reversible', 22),\n",
              " ('impaired', 22),\n",
              " ('idiopathic', 22),\n",
              " ('imp\\ue040rtant', 22),\n",
              " ('pupillary', 22),\n",
              " ('a\\ue034ute', 22),\n",
              " ('pr\\ue040gressive', 22),\n",
              " ('p\\ue040lyneur\\ue040pathy', 22),\n",
              " ('dry', 21),\n",
              " ('last', 21),\n",
              " ('full', 21),\n",
              " ('meta', 21),\n",
              " ('transient', 21),\n",
              " ('venous', 20),\n",
              " ('abnormal', 20),\n",
              " ('younger', 20),\n",
              " ('biliary', 20),\n",
              " ('painful', 20),\n",
              " ('nal', 20),\n",
              " ('individual', 20),\n",
              " ('atrial', 20),\n",
              " ('medial', 20),\n",
              " ('diuretic', 20),\n",
              " ('anal', 19),\n",
              " ('glomerular', 19),\n",
              " ('postoperative', 19),\n",
              " ('little', 19),\n",
              " ('hyper-', 19),\n",
              " ('myocardial', 19),\n",
              " ('sure', 19),\n",
              " ('s\\ue03bv\\ue03bral', 19),\n",
              " ('l\\ue03bss', 19),\n",
              " ('coronary', 19),\n",
              " ('foreign', 19),\n",
              " ('testicular', 18),\n",
              " ('therapeutic', 18),\n",
              " ('hot', 18),\n",
              " ('moderate', 18),\n",
              " ('second', 18),\n",
              " ('cranial', 18),\n",
              " ('intra-', 18),\n",
              " ('late', 18),\n",
              " ('dominant', 18),\n",
              " ('neur\\ue040pathy', 18),\n",
              " ('superfi\\ue034ial', 18),\n",
              " ('polycystic', 18),\n",
              " ('intermediate', 17),\n",
              " ('like', 17),\n",
              " ('cytotoxic', 17),\n",
              " ('light', 17),\n",
              " ('uncommon', 17),\n",
              " ('average', 17),\n",
              " ('eral', 17),\n",
              " ('mal', 17),\n",
              " ('dependent', 17),\n",
              " ('papillary', 17),\n",
              " ('urothelial', 17),\n",
              " ('nervous', 17),\n",
              " ('p\\ue040ssible', 17),\n",
              " ('lateral', 17),\n",
              " ('syst\\ue03bmic', 17),\n",
              " ('nephrotic', 17),\n",
              " ('current', 16),\n",
              " ('histologic', 16),\n",
              " ('34', 16),\n",
              " ('obstructive', 16),\n",
              " ('direct', 16),\n",
              " ('pre-', 16),\n",
              " ('solid', 16),\n",
              " ('worse', 16),\n",
              " ('fewer', 16),\n",
              " ('wide', 16),\n",
              " ('prostatic', 16),\n",
              " ('internal', 16),\n",
              " ('side', 16),\n",
              " ('safe', 16),\n",
              " ('simple', 16),\n",
              " ('t\\ue03able', 16),\n",
              " ('glu\\ue03c\\ue048se', 16),\n",
              " ('\\ue040ral', 16),\n",
              " ('resp\\ue040nsible', 16),\n",
              " ('abd\\ue040minal', 16),\n",
              " ('reflex', 16),\n",
              " ('int\\ue03brstitial', 16),\n",
              " ('retinopathy', 16),\n",
              " ('certain', 15),\n",
              " ('appropriate', 15),\n",
              " ('squamous', 15),\n",
              " ('epithelial', 15),\n",
              " ('right', 15),\n",
              " ('heavy', 15),\n",
              " ('improved', 15),\n",
              " ('optimal', 15),\n",
              " ('adenomatous', 15),\n",
              " ('functional', 15),\n",
              " ('abrupt', 15),\n",
              " ('toxic', 15),\n",
              " ('fatal', 15),\n",
              " ('dietary', 15),\n",
              " ('middle', 15),\n",
              " ('residual', 15),\n",
              " ('l\\ue048wer', 15),\n",
              " ('depressed', 15),\n",
              " ('capillary', 15),\n",
              " ('unresp\\ue040nsive', 15),\n",
              " ('medi\\ue034al', 15),\n",
              " ('marked', 15),\n",
              " ('giant', 15),\n",
              " ('\\ue034ervi\\ue034al', 15),\n",
              " ('fun\\ue034ti\\ue040nal', 15),\n",
              " ('tibial', 15),\n",
              " ('diab\\ue03btic', 15),\n",
              " ('aortic', 15),\n",
              " ('excessive', 15),\n",
              " ('human', 14),\n",
              " ('main', 14),\n",
              " ('sive', 14),\n",
              " ('untreated', 14),\n",
              " ('preoperative', 14),\n",
              " ('annual', 14),\n",
              " ('vein', 14),\n",
              " ('typical', 14),\n",
              " ('equal', 14),\n",
              " ('systematic', 14),\n",
              " ('segmental', 14),\n",
              " ('neu-', 14),\n",
              " ('bacterial', 14),\n",
              " ('autosomal', 14),\n",
              " ('\\ue040ther', 14),\n",
              " ('n\\ue040', 14),\n",
              " ('ven\\ue040us', 14),\n",
              " ('di\\ue03btary', 14),\n",
              " ('adrenal', 13),\n",
              " ('palpable', 13),\n",
              " ('visible', 13),\n",
              " ('mediastinal', 13),\n",
              " ('curative', 13),\n",
              " ('differential', 13),\n",
              " ('difficult', 13),\n",
              " ('intrinsic', 13),\n",
              " ('healthy', 13),\n",
              " ('fecal', 13),\n",
              " ('mixed', 13),\n",
              " ('vertebral', 13),\n",
              " ('sensory', 13),\n",
              " ('ba\\ue034k', 13),\n",
              " ('fa\\ue034ial', 13),\n",
              " ('palsy', 13),\n",
              " ('ax\\ue040nal', 13),\n",
              " ('pati\\ue03bnt', 13),\n",
              " ('n\\ue03bphropathy', 13),\n",
              " ('s\\ue03bcondary', 13),\n",
              " ('nephritic', 13),\n",
              " ('routine', 12),\n",
              " ('immune', 12),\n",
              " ('respiratory', 12),\n",
              " ('select', 12),\n",
              " ('irreversible', 12),\n",
              " ('post', 12),\n",
              " ('feasible', 12),\n",
              " ('unresectable', 12),\n",
              " ('antiviral', 12),\n",
              " ('false', 12),\n",
              " ('longer', 12),\n",
              " ('localized', 12),\n",
              " ('superficial', 12),\n",
              " ('serious', 12),\n",
              " ('gradual', 12),\n",
              " ('slow', 12),\n",
              " ('widespread', 12),\n",
              " ('apparent', 12),\n",
              " ('inadequate', 12),\n",
              " ('microscopic', 12),\n",
              " ('sub-', 12),\n",
              " ('abn\\ue040rmal', 12),\n",
              " ('ass\\ue040\\ue034iated', 12),\n",
              " ('my\\ue040\\ue034ardial', 12),\n",
              " ('bra\\ue034hial', 12),\n",
              " ('incr\\ue03bas\\ue03bd', 12),\n",
              " ('intrav\\ue03bnous', 12),\n",
              " ('m\\ue03bmbranous', 12),\n",
              " ('pmdisorders', 12),\n",
              " ('stromal', 11),\n",
              " ('definitive', 11),\n",
              " ('helical', 11),\n",
              " ('meta-', 11),\n",
              " ('prior', 11),\n",
              " ('usu-', 11),\n",
              " ('stable', 11),\n",
              " ('conventional', 11),\n",
              " ('intrahepatic', 11),\n",
              " ('latter', 11),\n",
              " ('insu-', 11),\n",
              " ('equivalent', 11),\n",
              " ('serial', 11),\n",
              " ('intermittent', 11),\n",
              " ('affected', 11),\n",
              " ('regular', 11),\n",
              " ('pelvic', 11),\n",
              " ('european', 11),\n",
              " ('epidural', 11),\n",
              " ('sexual', 11),\n",
              " ('beneficial', 11),\n",
              " ('ambulatory', 11),\n",
              " ('autonomic', 11),\n",
              " ('\\ue048ften', 11),\n",
              " ('effe\\ue034tive', 11),\n",
              " ('in\\ue034lude', 11),\n",
              " ('additi\\ue040n', 11),\n",
              " ('disturban\\ue034es', 11),\n",
              " ('resp\\ue040nsive', 11),\n",
              " ('\\ue034\\ue040mm\\ue040nly', 11),\n",
              " ('pulm\\ue040nary', 11),\n",
              " ('effe\\ue034ts', 11),\n",
              " ('weak', 11),\n",
              " ('gbm', 11),\n",
              " ('preservative', 11),\n",
              " ('allergic', 11),\n",
              " ('orbital', 11),\n",
              " ('liposomal', 10),\n",
              " ('clear', 10),\n",
              " ('corticosteroid', 10),\n",
              " ('sided', 10),\n",
              " ('cognitive', 10),\n",
              " ('unusual', 10),\n",
              " ('best', 10),\n",
              " ('absolute', 10),\n",
              " ('solitary', 10),\n",
              " ('symp-', 10),\n",
              " ('prognostic', 10),\n",
              " ('male', 10),\n",
              " ('sixth', 10),\n",
              " ('peritoneal', 10),\n",
              " ('slight', 10),\n",
              " ('profound', 10),\n",
              " ('mesenteric', 10),\n",
              " ('prolonged', 10),\n",
              " ('black', 10),\n",
              " ('potent', 10),\n",
              " ('fat', 10),\n",
              " ('refractory', 10),\n",
              " ('ill', 10),\n",
              " ('in\\ue03cre\\ue03ased', 10),\n",
              " ('d\\ue048', 10),\n",
              " ('\\ue03able', 10),\n",
              " ('\\ue046g', 10),\n",
              " ('separate', 10),\n",
              " ('repetitive', 10),\n",
              " ('\\ue040ften', 10),\n",
              " ('adjunctive', 10),\n",
              " ('generalized', 10),\n",
              " ('idi\\ue040pathi\\ue034', 10),\n",
              " ('is\\ue040lated', 10),\n",
              " ('p\\ue040stural', 10),\n",
              " ('l\\ue040w', 10),\n",
              " ('\\ue034\\ue040llateral', 10),\n",
              " ('als\\ue040', 10),\n",
              " ('mus\\ue034ular', 10),\n",
              " ('h\\ue03blpful', 10),\n",
              " ('th\\ue03bs\\ue03b', 10),\n",
              " ('ur\\ue03bmic', 10),\n",
              " ('atopic', 10),\n",
              " ('ml', 10),\n",
              " ('monocular', 10),\n",
              " ('cervical', 9),\n",
              " ('electrolyte', 9),\n",
              " ('erectile', 9),\n",
              " ('nonspecific', 9),\n",
              " ('curable', 9),\n",
              " ('blind', 9),\n",
              " ('inter-', 9),\n",
              " ('key', 9),\n",
              " ('great', 9),\n",
              " ('radia-', 9),\n",
              " ('excellent', 9)]"
            ]
          },
          "execution_count": 88,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "Counter(doc_adj).most_common(500)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 87,
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/plain": [
              "[('patients', 1302),\n",
              " ('%', 1154),\n",
              " ('t\\ue040', 1050),\n",
              " ('\\ue040f', 999),\n",
              " ('disease', 653),\n",
              " ('risk', 576),\n",
              " ('treatment', 534),\n",
              " ('mg', 489),\n",
              " ('f\\ue040r', 476),\n",
              " ('cancer', 446),\n",
              " ('insulin', 437),\n",
              " ('pmid', 426),\n",
              " ('therapy', 422),\n",
              " ('pressure', 372),\n",
              " ('blood', 337),\n",
              " ('p\\ue03atients', 334),\n",
              " ('pain', 267),\n",
              " ('type', 261),\n",
              " ('patient', 223),\n",
              " ('years', 223),\n",
              " ('\\ue048f', 209),\n",
              " ('g', 208),\n",
              " ('b\\ue03b', 207),\n",
              " ('levels', 206),\n",
              " ('days', 198),\n",
              " ('nerve', 198),\n",
              " ('use', 195),\n",
              " ('age', 193),\n",
              " ('kidney', 191),\n",
              " ('\\ue048r', 186),\n",
              " ('survival', 183),\n",
              " ('s', 178),\n",
              " ('day', 175),\n",
              " ('loss', 171),\n",
              " ('t', 170),\n",
              " ('hours', 170),\n",
              " ('stage', 169),\n",
              " ('surgery', 168),\n",
              " ('hypertension', 166),\n",
              " ('t\\ue048', 166),\n",
              " ('pati\\ue03bnts', 165),\n",
              " ('tumors', 164),\n",
              " ('artery', 163),\n",
              " ('diagnosis', 160),\n",
              " ('times', 158),\n",
              " ('\\ue03and', 155),\n",
              " ('\\ue040r', 151),\n",
              " ('tumor', 149),\n",
              " ('cell', 148),\n",
              " ('agents', 147),\n",
              " ('signs', 145),\n",
              " ('weeks', 144),\n",
              " ('', 138),\n",
              " ('cancers', 136),\n",
              " ('dose', 136),\n",
              " ('inhibitors', 136),\n",
              " ('fr\\ue040m', 136),\n",
              " ('cases', 134),\n",
              " ('injury', 134),\n",
              " ('tion', 133),\n",
              " ('symptoms', 133),\n",
              " ('seizures', 133),\n",
              " ('chemotherapy', 129),\n",
              " ('drugs', 126),\n",
              " ('term', 125),\n",
              " ('\\ue034an', 123),\n",
              " ('nausea', 120),\n",
              " ('side', 119),\n",
              " ('eye', 118),\n",
              " ('rate', 117),\n",
              " ('studies', 117),\n",
              " ('\\ue046g', 116),\n",
              " ('o', 115),\n",
              " ('weight', 114),\n",
              " ('syndrome', 112),\n",
              " ('n', 112),\n",
              " ('\\ue040n', 112),\n",
              " ('prostate', 110),\n",
              " ('level', 109),\n",
              " ('carcinoma', 108),\n",
              " ('liver', 107),\n",
              " ('02/07/21', 103),\n",
              " ('brain', 103),\n",
              " ('infection', 99),\n",
              " ('weakness', 98),\n",
              " ('system', 96),\n",
              " ('resection', 96),\n",
              " ('diabetes', 95),\n",
              " ('dis\\ue03bas\\ue03b', 94),\n",
              " ('months', 93),\n",
              " ('\\ue040\\ue034\\ue034ur', 93),\n",
              " ('men', 92),\n",
              " ('combination', 91),\n",
              " ('serum', 91),\n",
              " ('results', 91),\n",
              " ('l', 91),\n",
              " ('aneurysm', 91),\n",
              " ('year', 90),\n",
              " ('metastases', 90),\n",
              " ('effects', 90),\n",
              " ('management', 89),\n",
              " ('life', 88),\n",
              " ('beta', 88),\n",
              " ('edema', 87),\n",
              " ('drug', 87),\n",
              " ('heart', 86),\n",
              " ('fluid', 86),\n",
              " ('imaging', 86),\n",
              " ('radiation', 85),\n",
              " ('time', 83),\n",
              " ('plasma', 83),\n",
              " ('table', 82),\n",
              " ('vision', 82),\n",
              " ('lesions', 82),\n",
              " ('chapter', 82),\n",
              " ('29/06/21', 81),\n",
              " ('lung', 80),\n",
              " ('study', 80),\n",
              " ('factors', 79),\n",
              " ('aneurysms', 79),\n",
              " ('hem\\ue040rrhage', 79),\n",
              " ('dl', 78),\n",
              " ('f\\ue048r', 78),\n",
              " ('glaucoma', 78),\n",
              " ('failure', 77),\n",
              " ('dysfunction', 77),\n",
              " ('findings', 77),\n",
              " ('obstruction', 76),\n",
              " ('rates', 76),\n",
              " ('history', 76),\n",
              " ('\\ue03are', 76),\n",
              " ('findingsa.', 75),\n",
              " ('minutes', 74),\n",
              " ('p\\ue03atient', 74),\n",
              " ('adults', 73),\n",
              " ('ment', 73),\n",
              " ('head', 73),\n",
              " ('skin', 72),\n",
              " ('lesi\\ue040n', 72),\n",
              " ('trial', 71),\n",
              " ('onset', 70),\n",
              " ('et', 68),\n",
              " ('benefit', 68),\n",
              " ('inhibitor', 68),\n",
              " ('h\\ue040urs', 68),\n",
              " ('diarrhea', 67),\n",
              " ('ing', 67),\n",
              " ('vein', 67),\n",
              " ('tests', 66),\n",
              " ('th\\ue03b', 66),\n",
              " ('function', 65),\n",
              " ('cm', 65),\n",
              " ('line', 65),\n",
              " ('drop', 65),\n",
              " ('calcium', 64),\n",
              " ('screening', 64),\n",
              " ('biopsy', 63),\n",
              " ('blockers', 63),\n",
              " ('tissue', 62),\n",
              " ('status', 61),\n",
              " ('di\\ue03abetes', 61),\n",
              " ('dise\\ue03ase', 61),\n",
              " ('agent', 59),\n",
              " ('guidelines', 59),\n",
              " ('family', 59),\n",
              " ('prognosis', 58),\n",
              " ('complications', 58),\n",
              " ('death', 57),\n",
              " ('site', 57),\n",
              " ('trials', 57),\n",
              " ('control', 57),\n",
              " ('response', 57),\n",
              " ('solution', 57),\n",
              " ('analysis', 56),\n",
              " ('pmchapter', 56),\n",
              " ('d\\ue048se', 56),\n",
              " ('\\ue034ar\\ue040tid', 56),\n",
              " ('cause', 55),\n",
              " ('incidence', 55),\n",
              " ('eg', 55),\n",
              " ('colon', 54),\n",
              " ('receptor', 54),\n",
              " ('fatigue', 54),\n",
              " ('vomiting', 54),\n",
              " ('lymph', 54),\n",
              " ('progression', 54),\n",
              " ('test', 54),\n",
              " ('grade', 53),\n",
              " ('testing', 53),\n",
              " ('review', 53),\n",
              " ('anemia', 53),\n",
              " ('mm', 53),\n",
              " ('effect', 52),\n",
              " ('gene', 51),\n",
              " ('occlusion', 51),\n",
              " ('du\\ue03b', 51),\n",
              " ('tract', 50),\n",
              " ('medications', 50),\n",
              " ('di\\ue03abeti\\ue03c', 50),\n",
              " ('dis\\ue040rders', 50)]"
            ]
          },
          "execution_count": 87,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "Counter(doc_noun).most_common(200)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 57,
      "metadata": {},
      "outputs": [],
      "source": [
        "adj_list = list(set(doc_adj))"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 43,
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "5060\n"
          ]
        }
      ],
      "source": [
        "print(len(adj_list))"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 59,
      "metadata": {},
      "outputs": [],
      "source": [
        "stop_words = [\"patient\", \"may\", \"disease\", \"cause\", \"treatment\", \"also\", \"symptom\", \"usually\", \"sign\",\n",
        "                \"diagnosis\", \"result\", \"pain\", \"include\", \"pressure\", \"lung\", \"pulmonary\", \"respiratory\",\n",
        "                \"chest\", \"fluid\", \"complication\", \"change\", \"blood\", \"infection\", \"therapy\", \"prevent\",\n",
        "                \"acute\", \"care\", \"child\", \"level\", \"air\", \"use\", \"severe\", \"help\", \"used\", \"exercise\",\n",
        "                \"normal\", \"incidence\", \"pneumonia\",\"tissue\", \"show\", \"chronic\", \"failure\", \"cast\", \"increased\",\n",
        "                \"monitor\", \"hypoxemia\", \"produce\", \"edema\", \"increase\", \"space\", \"occurs\", \"cough\", \"alveolar\", \n",
        "                \"heart\", \"pathophysiology\", \"sputum\", \"provide\", \"decreased\", \"pneumothorax\", \"test\", \"special\",\n",
        "                \"tube\", \"condition\", \"common\", \"surgery\",\"secretion\", \"fibrosis\", \"disorder\", \"pa\", \"area\", \"form\",\n",
        "                \"cell\", \"skin\", \"drainage\", \"tb\", \"year\", \"commonly\", \"check\", \"teach\", \"rest\", \"watch\", \"encourage\", \n",
        "                \"underlying\", \"consideration\", \"et\", \"early\", \"hour\", \"family\", \"need\", \"effusion\", \"body\", \"drug\", \"support\", \n",
        "                \"rate\", \"syndrome\", \"requires\", \"inflammation\", \"abg\", \"side\", \"infant\", \"however\", \"upper\", \"cor\", \"pulmonale\",\n",
        "                 \"ventilator\", \"mechanical\", \"breath\", \"maintain\" , \"foot\", \"day\", \"bed\", \"parent\", \"especially\", \"fever\", \"culture\",\n",
        "                'system', 'within', 'factor', 'amount', 'death', 'movement', 'progress', 'volume', 'one', 'stage', 'report',\n",
        "                'avoid', 'respiration', 'trauma', 'occur', 'atelectasis', 'hand', 'includes', 'weight', 'tendon', 'hypertension', \n",
        "                'le', 'time', 'lead', 'damage', 'causing', 'require', 'activity', 'injury', 'risk', 'mm', 'measure', 'examination',\n",
        "                'nerve', 'stress', 'make', 'al', 'see', 'decrease', 'age', 'hg''case', 'month', 'coughing', 'develops', 'formation', \n",
        "                'without', 'site', 'every', 'reduce', 'relieve', 'effect','percussion', 'ordered', 'develop', 'affect', 'loss', 'flow',\n",
        "                'lesion', 'technique', 'exposure', 'gas', 'finding', 'procedure', 'begin', 'wall', 'immediately', 'type', 'response', \n",
        "                'position', 'needed', 'administer', 'control', 'ass', 'increasing', 'although', 'tell', 'output', 'give', 'analysis',\n",
        "                'history', 'often' ,'week', 'home', 'perform','function', 'typically', 'frequently', 'adult', 'indicate', 'administration',\n",
        "                'explain', 'using', 'suggest', 'called', 'center', 'head', 'people', 'resulting', 'including', 'period', 'feature', 'case','pmid','tion','eg','pmchapter','med'\n",
        "                   ]"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 60,
      "metadata": {},
      "outputs": [],
      "source": [
        "new_stopwords = adj_list+stop_words"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 61,
      "metadata": {},
      "outputs": [],
      "source": [
        "stpwrd = stopwords.words('english')"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 62,
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            " adjective words = 5060\n",
            " topic domain stop words = 222\n",
            " marge adj_list & stop_words =  5282\n",
            " english stop words = 198\n"
          ]
        }
      ],
      "source": [
        "print(f' adjective words = {len(adj_list)}')\n",
        "print(f' topic domain stop words = {len(stop_words)}')\n",
        "print(f' marge adj_list & stop_words =  {len(new_stopwords)}')\n",
        "print(f' english stop words = {len(stpwrd)}')"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 63,
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "after marge all of the stop words = 5480\n"
          ]
        }
      ],
      "source": [
        "stpwrd.extend(new_stopwords)\n",
        "\n",
        "print(f'after marge all of the stop words = {len(stpwrd)}')"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 65,
      "metadata": {},
      "outputs": [],
      "source": [
        "wordnet_lemmatizer = WordNetLemmatizer()\n",
        "def text_preprocessing(articles):\n",
        "    tokens = word_tokenize(articles)                                            # Tokenize the article: tokens\n",
        "    lower_tokens= [t.lower() for t in tokens]                                   # Convert the tokens into lowercase: lower_tokens\n",
        "    alpha_only = [t for t in lower_tokens if t.isalpha()]                       # Retain alphabetic words: alpha_only\n",
        "    no_stops = [t for t in alpha_only if t not in stopwords.words('english')]   # Remove all stop words: no_stops\n",
        "    lemmatized = [wordnet_lemmatizer.lemmatize(t) for t in no_stops]           # Lemmatize all tokens into a new list: lemmatized\n",
        "    no_stops = [t for t in lemmatized if t not in stpwrd ]                     # Remove all stop words: no_stops\n",
        "    return no_stops\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 66,
      "metadata": {},
      "outputs": [],
      "source": [
        "bow1 = text_preprocessing(article1)\n",
        "bow2 = text_preprocessing(article2)\n",
        "bow3 = text_preprocessing(article3)\n",
        "bow4 = text_preprocessing(article4)\n",
        "bow5 = text_preprocessing(article5)\n",
        "bow6 = text_preprocessing(article6)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 68,
      "metadata": {},
      "outputs": [
        {
          "name": "stdout",
          "output_type": "stream",
          "text": [
            "Counter({'kidney': 74, 'study': 71, 'given': 49, 'three': 38, 'unit': 37, 'benefit': 35, 'diabetes': 34, 'glucose': 34, 'dka': 32, 'g': 29, 'b': 25, 'pen': 25, 'egfr': 24, 'per': 23, 'either': 22, 'diet': 22, 'pmdiabetes': 21, 'required': 20, 'ldl': 20, 'nph': 20, 'islet': 19, 'mody': 19, 'united': 19, 'event': 19, 'even': 18, 'gene': 16, 'urine': 16, 'plasma': 16, 'whether': 14, 'hypoglycemia': 14, 'lin': 13, 'n': 12, 'inhibitor': 11, 'l': 11, 'cholesterol': 11, 'illness': 10, 'hg': 10, 'laboratory': 10, 'receptor': 10, 'two': 10, 'meal': 10, 'metformin': 10, 'mcg': 10, 'lipid': 9, 'medication': 9, 'ace': 9, 'e': 9, 'size': 9, 'dispensed': 9, 'agent': 9, 'despite': 8, 'action': 8, 'hdl': 8, 'dos': 8, 'unless': 8, 'prefilled': 8, 'infused': 8, 'nordisk': 8, 'vessel': 8, 'shift': 8, 'degree': 7, 'binding': 7, 'thus': 7, 'designed': 7, 'v': 7, 'seen': 7, 'fiber': 7, 'index': 7, 'state': 7, 'subcutaneously': 7, 'delivers': 7, 'lysine': 7, 'lispro': 7, 'novo': 7, 'mix': 7, 'needle': 7, 'instituted': 7, 'si': 7, 'guideline': 7, 'life': 6, 'prevention': 6, 'sample': 6, 'minimed': 6, 'lipoprotein': 6, 'slightly': 6, 'ingested': 6, 'minute': 6, 'analog': 6, 'agonist': 6, 'dinner': 6, 'titer': 6, 'men': 6, 'glargine': 6, 'delivery': 6, 'sensitivity': 6, 'acidosis': 6, 'relief': 6, 'cvd': 6, 'insensitivity': 5, 'identified': 5, 'inhibit': 5, 'pancreatitis': 5, 'intensively': 5, 'ukpds': 5, 'findingsa': 5, 'keep': 5, 'suggests': 5, 'kg': 5, 'strip': 5, 'f': 5, 'te': 5, 'abnormality': 5, 'rise': 5, 'review': 5, 'fda': 5, 'five': 5, 'peak': 5, 'rapidly': 5, 'glulisine': 5, 'syrinx': 5, 'csii': 5, 'still': 5, 'identify': 5, 'icu': 5, 'icma': 5, 'suggested': 4, 'ct': 4, 'requiring': 4, 'er': 4, 'dcct': 4, 'end': 4, 'ada': 4, 'newly': 4, 'diuresis': 4, 'figure': 4, 'plus': 4, 'highly': 4, 'set': 4, 'sweetener': 4, 'otherwise': 4, 'tablet': 4, 'pioglitazone': 4, 'lowering': 4, 'syringe': 4, 'giving': 4, 'bind': 4, 'ure': 4, 'hypersensitivity': 4, 'nine': 4, 'r': 4, 'table': 4, 'detemir': 4, 'degludec': 4, 'supply': 4, 'preparation': 4, 'lilly': 4, 'us': 4, 'management': 4, 'night': 4, 'bedtime': 4, 'issue': 4, 'value': 4, 'severity': 4, 'mri': 4, 'ketone': 4, 'ria': 4, 'proinsulin': 4, 'measurement': 4, 'pnets': 4, 'mortality': 4, 'resistance': 3, 'six': 3, 'atp': 3, 'defect': 3, 'puberty': 3, 'reverse': 3, 'diabetesthe': 3, 'ci': 3, 'subsequently': 3, 'persist': 3, 'suffered': 3, 'lens': 3, 'gresses': 3, 'quently': 3, 'tubule': 3, 'c': 3, 'fasting': 3, 'testing': 3, 'expense': 3, 'line': 3, 'http': 3, 'tend': 3, 'fruit': 3, 'primarily': 3, 'bile': 3, 'user': 3, 'flushing': 3, 'gliclazide': 3, 'noted': 3, 'repaglinide': 3, 'nateglinide': 3, 'breakfast': 3, 'release': 3, 'xr': 3, 'exenatide': 3, 'liraglutide': 3, 'delivering': 3, 'semaglutide': 3, 'take': 3, 'empagliflozin': 3, 'symlin': 3, 'reserve': 3, 'cyp': 3, 'suspended': 3, 'find': 3, 'tends': 3, 'tide': 3, 'exendin': 3, 'linked': 3, 'seek': 3, 'gliptin': 3, 'ii': 3, 'density': 3, 'eight': 3, 'fiasp': 3, 'reversed': 3, 'humalog': 3, 'sanofi': 3, 'persists': 3, 'tive': 3, 'led': 3, 'depend': 3, 'jama': 3, 'ica': 3, 'distinguish': 3, 'get': 3, 'tively': 3, 'antibody': 3, 'ent': 3, 'noninsulin': 3, 'efficacy': 3, 'based': 3, 'ckd': 3, 'igg': 3, 'tie': 3, 'penis': 3, 'preexisting': 3, 'bicarbonate': 3, 'signsthe': 3, 'ketoacidosis': 3, 'replenish': 3, 'distress': 3, 'drink': 3, 'suppressed': 3, 'vldl': 3, 'obesity': 2, 'prevents': 2, 'dna': 2, 'wolfram': 2, 'ized': 2, 'perk': 2, 'alpelisib': 2, 'hemochromatosis': 2, 'trial': 2, 'dia': 2, 'betes': 2, 'gfr': 2, 'unlike': 2, 'believed': 2, 'inhibiting': 2, 'suggesting': 2, 'shown': 2, 'depending': 2, 'fruity': 2, 'pruritus': 2, 'eruptive': 2, 'wherein': 2, 'presented': 2, 'tolerance': 2, 'permission': 2, 'mb': 2, 'bedridden': 2, 'hemoglobin': 2, 'referred': 2, 'el': 2, 'criterion': 2, 'asting': 2, 'mmol': 2, 'exists': 2, 'finger': 2, 'monitoring': 2, 'wirelessly': 2, 'insight': 2, 'freestyle': 2, 'libre': 2, 'treatmenta': 2, 'curve': 2, 'represents': 2, 'listed': 2, 'beta': 2, 'tolbutamide': 2, 'tolazamide': 2, 'acetohexamide': 2, 'chlorpropamide': 2, 'press': 2, 'dailyup': 2, 'glucotrol': 2, 'meglitinide': 2, 'mitiglinide': 2, 'glucophage': 2, 'dulaglutide': 2, 'filled': 2, 'byetta': 2, 'diluent': 2, 'reaction': 2, 'lixisenatide': 2, 'alogliptin': 2, 'taking': 2, 'sitagliptin': 2, 'canagliflozin': 2, 'bromocriptine': 2, 'colesevelam': 2, 'start': 2, 'nausea': 2, 'intestine': 2, 'ever': 2, 'iii': 2, 'iv': 2, 'gut': 2, 'suppresses': 2, 'drinking': 2, 'glutide': 2, 'express': 2, 'p': 2, 'hip': 2, 'technosphere': 2, 'formulated': 2, 'lyumjev': 2, 'protamine': 2, 'novolog': 2, 'aventis': 2, 'concentration': 2, 'npl': 2, 'length': 2, 'insulet': 2, 'deliver': 2, 'iaa': 2, 'education': 2, 'friend': 2, 'evening': 2, 'specificity': 2, 'carbohydrate': 2, 'lada': 2, 'rent': 2, 'another': 2, 'combination': 2, 'reached': 2, 'cost': 2, 'ar': 2, 'gain': 2, 'bladder': 2, 'consensus': 2, 'ther': 2, 'blunted': 2, 'target': 2, 'aim': 2, 'pregnancy': 2, 'refuse': 2, 'ige': 2, 'extent': 2, 'bmj': 2, 'iris': 2, 'feeling': 2, 'preventing': 2, 'terized': 2, 'inserted': 2, 'aspirin': 2, 'bleeding': 2, 'burden': 2, 'stiffness': 2, 'j': 2, 'iwgdf': 2, 'rev': 2, 'curr': 2, 'getting': 2, 'abetic': 2, 'hyperglycemia': 2, 'sepsis': 2, 'ensues': 2, 'alcohol': 2, 'depleted': 2, 'tients': 2, 'flux': 2, 'sodium': 2, 'kcl': 2, 'clin': 2, 'anion': 2, 'gap': 2, 'rule': 2, 'prognosisthe': 2, 'jbds': 2, 'gen': 2, 'oglycemia': 2, 'upon': 2, 'ingesting': 2, 'occult': 2, 'insulinoma': 2, 'obtain': 2, 'send': 2, 'conclude': 2, 'feeding': 2, 'among': 2, 'hypercholesterolemia': 2, 'apolipoprotein': 2, 'homozygote': 2, 'extremely': 2, 'childhood': 2, 'triglyceride': 2, 'particle': 2, 'hypertriglyceridemia': 2, 'hyperlipidemia': 2, 'atherosclerosis': 2, 'lancet': 2, 'west': 1, 'mellitust': 1, 'ype': 1, 'whenever': 1, 'wnt': 1, 'wrestler': 1, 'glucokinase': 1, 'account': 1, 'mitochondrial': 1, 'leprechaunism': 1, 'exocrine': 1, 'endocrinopathies': 1, 'klinefelter': 1, 'turner': 1, 'others': 1, 'sometimes': 1, 'hnf': 1, 'homeobox': 1, 'mutation': 1, 'trna': 1, 'leu': 1, 'uur': 1, 'inherited': 1, 'midd': 1, 'insipidus': 1, 'tus': 1, 'moad': 1, 'dus': 1, 'thy': 1, 'nent': 1, 'niacin': 1, 'sirolimus': 1, 'acromegaly': 1, 'cushing': 1, 'glucagonoma': 1, 'cirrhosis': 1, 'dystrophy': 1, 'lipodystrophy': 1, 'phenytoin': 1, 'pentamidine': 1, 'calcineurin': 1, 'somatostatinoma': 1, 'hemosiderosis': 1, 'tify': 1, 'erides': 1, 'utility': 1, 'controlfindings': 1, 'resulted': 1, 'definitely': 1, 'edic': 1, 'kingdom': 1, 'tightly': 1, 'trialsa': 1, 'diabetesat': 1, 'lived': 1, 'studied': 1, 'lifestyle': 1, 'interfering': 1, 'urination': 1, 'diverted': 1, 'consciousness': 1, 'presenting': 1, 'obstetrical': 1, 'delivered': 1, 'lb': 1, 'clinistix': 1, 'acanthosis': 1, 'nigricans': 1, 'nape': 1, 'neck': 1, 'velvety': 1, 'appearance': 1, 'umesh': 1, 'masharani': 1, 'mrcp': 1, 'uk': 1, 'vides': 1, 'thereby': 1, 'advantage': 1, 'diagnose': 1, 'load': 1, 'text': 1, 'confirmed': 1, 'repeat': 1, 'speed': 1, 'style': 1, 'link': 1, 'pling': 1, 'expired': 1, 'meter': 1, 'ingly': 1, 'inserting': 1, 'wire': 1, 'drift': 1, 'birth': 1, 'render': 1, 'dieta': 1, 'substituting': 1, 'nut': 1, 'bined': 1, 'list': 1, 'w': 1, 'il': 1, 'sit': 1, 'nutrient': 1, 'indexblood': 1, 'food': 1, 'reference': 1, 'sweetening': 1, 'bulking': 1, 'hsh': 1, 'treating': 1, 'hyperglycemiathe': 1, 'stimulate': 1, 'divide': 1, 'yet': 1, 'tiveness': 1, 'let': 1, 'dymelor': 1, 'diabinese': 1, 'amaryl': 1, 'xl': 1, 'micronase': 1, 'glynase': 1, 'tolinase': 1, 'orinase': 1, 'japan': 1, 'prandin': 1, 'hoursd': 1, 'starlix': 1, 'biguanides': 1, 'thiazolidinediones': 1, 'actos': 1, 'rosiglitazone': 1, 'avandia': 1, 'acarbose': 1, 'precose': 1, 'miglitol': 1, 'glyset': 1, 'voglibose': 1, 'trulicity': 1, 'syringeusual': 1, 'ering': 1, 'neously': 1, 'bydureon': 1, 'powder': 1, 'suspend': 1, 'provided': 1, 'inject': 1, 'victoza': 1, 'adlyxin': 1, 'lyxumia': 1, 'dosesinitial': 1, 'ozempic': 1, 'rybelsus': 1, 'water': 1, 'wait': 1, 'eat': 1, 'nesina': 1, 'linagliptin': 1, 'tradjenta': 1, 'saxagliptin': 1, 'onglyza': 1, 'januvia': 1, 'vildagliptin': 1, 'galvus': 1, 'limit': 1, 'invokana': 1, 'dapagliflozin': 1, 'farxiga': 1, 'jardiance': 1, 'ertugliflozin': 1, 'steglatro': 1, 'cycloset': 1, 'welchol': 1, 'pramlintide': 1, 'vial': 1, 'containing': 1, 'increment': 1, 'initiation': 1, 'aspartate': 1, 'aminotransferase': 1, 'estimated': 1, 'filtration': 1, 'est': 1, 'lized': 1, 'glinide': 1, 'tein': 1, 'upset': 1, 'egfrs': 1, 'interferes': 1, 'sensitize': 1, 'stent': 1, 'safety': 1, 'concern': 1, 'record': 1, 'lifted': 1, 'alt': 1, 'absorption': 1, 'digest': 1, 'undigested': 1, 'return': 1, 'subset': 1, 'design': 1, 'withdrew': 1, 'died': 1, 'versus': 1, 'advised': 1, 'experience': 1, 'existing': 1, 'ney': 1, 'gip': 1, 'teneligliptin': 1, 'issued': 1, 'freely': 1, 'filtered': 1, 'sglt': 1, 'ries': 1, 'nyha': 1, 'grene': 1, 'labeled': 1, 'iapp': 1, 'dizziness': 1, 'recommended': 1, 'actoplusmet': 1, 'oseni': 1, 'insulininsulin': 1, 'differ': 1, 'preserve': 1, 'summary': 1, 'bioavailability': 1, 'administered': 1, 'niacinamide': 1, 'treprostinil': 1, 'citrate': 1, 'interfere': 1, 'hagedorn': 1, 'isophane': 1, 'admelog': 1, 'apidra': 1, 'afrezza': 1, 'ryzodeg': 1, 'lantus': 1, 'toujeo': 1, 'basaglar': 1, 'levemir': 1, 'tresiba': 1, 'origin': 1, 'pensed': 1, 'ration': 1, 'neither': 1, 'tended': 1, 'self': 1, 'predinner': 1, 'dexterity': 1, 'method': 1, 'reused': 1, 'sterility': 1, 'reuse': 1, 'injector': 1, 'owen': 1, 'rying': 1, 'bd': 1, 'kinked': 1, 'ily': 1, 'interrupted': 1, 'closed': 1, 'loop': 1, 'devised': 1, 'iq': 1, 'vide': 1, 'referee': 1, 'whistle': 1, 'transplan': 1, 'eligibility': 1, 'pendent': 1, 'suppress': 1, 'sl': 1, 'obes': 1, 'dk': 1, 'diabetesa': 1, 'distinguishing': 1, 'diabetesan': 1, 'training': 1, 'since': 1, 'probably': 1, 'obligation': 1, 'provides': 1, 'lie': 1, 'nurse': 1, 'prevented': 1, 'hygiene': 1, 'bring': 1, 'serve': 1, 'medicationst': 1, 'setting': 1, 'marker': 1, 'glutamic': 1, 'decarboxylase': 1, 'phosphatase': 1, 'zinc': 1, 'transporter': 1, 'example': 1, 'regimen': 1, 'man': 1, 'assumes': 1, 'consuming': 1, 'approximately': 1, 'drate': 1, 'lunch': 1, 'raised': 1, 'cose': 1, 'must': 1, 'dawn': 1, 'phenomenon': 1, 'somogyi': 1, 'surge': 1, 'shifting': 1, 'sleeve': 1, 'bmi': 1, 'depends': 1, 'split': 1, 'ity': 1, 'controla': 1, 'onstrated': 1, 'regarding': 1, 'microvascular': 1, 'macrovascular': 1, 'decision': 1, 'seven': 1, 'class': 1, 'insulinsif': 1, 'reache': 1, 'except': 1, 'taken': 1, 'know': 1, 'eskd': 1, 'doubling': 1, 'creatinine': 1, 'promote': 1, 'retention': 1, 'fracture': 1, 'cancer': 1, 'vomiting': 1, 'tract': 1, 'dehydration': 1, 'algorithm': 1, 'recommendation': 1, 'panel': 1, 'association': 1, 'hunger': 1, 'tiredness': 1, 'seizure': 1, 'keeping': 1, 'rin': 1, 'blunts': 1, 'group': 1, 'achieved': 1, 'polypharmacy': 1, 'frail': 1, 'expectancypremeal': 1, 'hospitalized': 1, 'fructosamine': 1, 'reliance': 1, 'placed': 1, 'kit': 1, 'ister': 1, 'turned': 1, 'immunopathology': 1, 'iga': 1, 'igd': 1, 'sensitized': 1, 'disfiguring': 1, 'blindness': 1, 'justified': 1, 'jerk': 1, 'dulled': 1, 'feel': 1, 'arthropathy': 1, 'swelling': 1, 'surprisingly': 1, 'reserved': 1, 'distribute': 1, 'ulcer': 1, 'metatarsal': 1, 'arrow': 1, 'dean': 1, 'sm': 1, 'satiani': 1, 'abraham': 1, 'wt': 1, 'color': 1, 'atlas': 1, 'synopsis': 1, 'ive': 1, 'blister': 1, 'burning': 1, 'tyline': 1, 'sleep': 1, 'lessened': 1, 'tried': 1, 'rubbed': 1, 'cachexia': 1, 'trunk': 1, 'pupil': 1, 'neuritis': 1, 'fullness': 1, 'reflux': 1, 'lessness': 1, 'lessen': 1, 'usefulness': 1, 'distended': 1, 'severing': 1, 'persisting': 1, 'resting': 1, 'dil': 1, 'pellet': 1, 'ring': 1, 'kept': 1, 'fitted': 1, 'tilting': 1, 'etdrs': 1, 'edly': 1, 'turbulent': 1, 'gangrene': 1, 'membrane': 1, 'knee': 1, 'leg': 1, 'glistening': 1, 'shin': 1, 'bone': 1, 'tightening': 1, 'tunnel': 1, 'dupuytren': 1, 'ture': 1, 'dish': 1, 'sity': 1, 'engl': 1, 'rj': 1, 'shen': 1, 'ji': 1, 'situationsa': 1, 'hospitalh': 1, 'lenging': 1, 'vice': 1, 'ting': 1, 'view': 1, 'ie': 1, 'patientsee': 1, 'stillbirth': 1, 'severely': 1, 'utilizing': 1, 'nless': 1, 'di': 1, 'ketoacidosise': 1, 'tenderness': 1, 'findingst': 1, 'coma': 1, 'accident': 1, 'uremia': 1, 'leftover': 1, 'might': 1, 'contain': 1, 'elevate': 1, 'keto': 1, 'freezing': 1, 'na': 1, 'niques': 1, 'ter': 1, 'sheet': 1, 'replacementin': 1, 'tely': 1, 'plishes': 1, 'tered': 1, 'potassiumt': 1, 'beginning': 1, 'ecg': 1, 'u': 1, 'bicarbonatethe': 1, 'note': 1, 'liter': 1, 'hyperchloremic': 1, 'revers': 1, 'transition': 1, 'tently': 1, 'lightly': 1, 'hyp': 1, 'erglycemic': 1, 'statee': 1, 'osmolality': 1, 'considerationsth': 1, 'pathogenesisa': 1, 'signsonset': 1, 'tures': 1, 'findingssevere': 1, 'h': 1, 'replacementfluid': 1, 'id': 1, 'insulinless': 1, 'potassiumw': 1, 'ith': 1, 'driving': 1, 'istered': 1, 'phosphateif': 1, 'ten': 1, 'sip': 1, 'lac': 1, 'acidosise': 1, 'hyperventilation': 1, 'represent': 1, 'epinephrine': 1, 'melas': 1, 'ety': 1, 'ethylene': 1, 'ues': 1, 'treatmentaggressiv': 1, 'the': 1, 'tumorse': 1, 'confusion': 1, 'vision': 1, 'anxiety': 1, 'convulsion': 1, 'recovery': 1, 'ninety': 1, 'prerequisite': 1, 'epilepsy': 1, 'whipple': 1, 'slurred': 1, 'field': 1, 'findingsb': 1, 'surreptitious': 1, 'bound': 1, 'act': 1, 'absence': 1, 'testsif': 1, 'sent': 1, 'energy': 1, 'screen': 1, 'assay': 1, 'hospital': 1, 'protocol': 1, 'vised': 1, 'place': 1, 'cannula': 1, 'permit': 1, 'walking': 1, 'obtained': 1, 'frequency': 1, 'fingersticks': 1, 'manifestation': 1, 'neuroglycopenia': 1, 'hydroxybutyrate': 1, 'elapsed': 1, 'followed': 1, 'intravenously': 1, 'simply': 1, 'would': 1, 'collected': 1, 'fluoride': 1, 'ice': 1, 'glycolysis': 1, 'separated': 1, 'receipt': 1, 'arrange': 1, 'tory': 1, 'run': 1, 'localization': 1, 'tumorsafter': 1, 'series': 1, 'subtypes': 1, 'lys': 1, 'hynic': 1, 'nh': 1, 'effluent': 1, 'identifies': 1, 'treatmentthe': 1, 'blindly': 1, 'behind': 1, 'prefer': 1, 'sunitinib': 1, 'nislet': 1, 'hypoglycemiathese': 1, 'stprandial': 1, 'try': 1, 'digested': 1, 'diabetesthis': 1, 'refined': 1, 'hypoglycemiap': 1, 'hla': 1, 'actitious': 1, 'hypoglycemiaf': 1, 'hypoglycemiaa': 1, 'quinine': 1, 'inhibits': 1, 'depleting': 1, 'nad': 1, 'nadh': 1, 'esis': 1, 'dilute': 1, 'gin': 1, 'ensuring': 1, 'blaha': 1, 'md': 1, 'mphthe': 1, 'hypothesis': 1, 'stating': 1, 'development': 1, 'ascvd': 1, 'widely': 1, 'throughout': 1, 'community': 1, 'reduction': 1, 'woman': 1, 'documented': 1, 'lowered': 1, 'data': 1, 'generally': 1, 'tent': 1, 'differing': 1, 'assist': 1, 'cians': 1, 'selecting': 1, 'predominantly': 1, 'developing': 1, 'pathogenesis': 1, 'million': 1, 'involve': 1, 'metabolism': 1, 'tions': 1, 'proprotein': 1, 'convertase': 1, 'protein': 1, 'regulates': 1, 'breakdown': 1, 'transplantation': 1, 'plasmapheresis': 1, 'correct': 1, 'appears': 1, 'confer': 1, 'lifetime': 1, 'heterozygote': 1, 'person': 1, 'caused': 1, 'lipase': 1, 'enables': 1, 'chylomicron': 1, 'chylomicronemiasyndrome': 1, 'hepatosplenomegaly': 1, 'lism': 1, 'named': 1, 'electrophoresed': 1, 'dysbetalipoproteinemia': 1, 'yk': 1, 'chylomicronemia': 1, 'characterized': 1, 'trend': 1, 'cardiovasc': 1, 'hegele': 1, 'ra': 1, 'dyslipidaemias': 1, 'phenotype': 1, 'society': 1, 'task': 1, 'force': 1, 'statement': 1, 'endocrinol': 1, 'khera': 1, 'av': 1, 'matter': 1, 'circulation': 1, 'mortensen': 1, 'infarction': 1, 'vention': 1, 'cohort': 1, 'sniderman': 1, 'ad': 1, 'narrative': 1, 'cardiol': 1, 'li': 1, 'pid': 1, 'fraction': 1, 'diseasein': 1, 'carried': 1, 'molecule': 1, 'sum': 1, 'component': 1, 'pm': 1})\n"
          ]
        }
      ],
      "source": [
        "print(Counter(bow2))"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 55,
      "metadata": {},
      "outputs": [],
      "source": [
        "corpus1 = \" \".join(no_stops01)\n",
        "corpus2 = \" \".join(no_stops02)\n",
        "corpus3 = \" \".join(no_stops03)\n",
        "corpus4 = \" \".join(no_stops04)\n",
        "corpus5 = \" \".join(no_stops05)\n",
        "corpus6 = \" \".join(no_stops06)\n",
        "\n",
        "df01 = pd.DataFrame([corpus1], columns=['string_values'])\n",
        "new_row1 = pd.DataFrame({'string_values':[corpus2]})\n",
        "new_row2 = pd.DataFrame({'string_values':[corpus3]})\n",
        "new_row3 = pd.DataFrame({'string_values':[corpus4]})\n",
        "new_row4 = pd.DataFrame({'string_values':[corpus5]})\n",
        "new_row5 = pd.DataFrame({'string_values':[corpus6]})\n",
        "\n",
        "df01 = pd.concat([df01, new_row1], ignore_index=True)\n",
        "df01 = pd.concat([df01, new_row2], ignore_index=True)\n",
        "df01 = pd.concat([df01, new_row3], ignore_index=True)\n",
        "df01 = pd.concat([df01, new_row4], ignore_index=True)\n",
        "df01 = pd.concat([df01, new_row5], ignore_index=True)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 56,
      "metadata": {},
      "outputs": [],
      "source": [
        "df = pd.DataFrame([article1], columns=['string_values'])  \n",
        "new_row1 = pd.DataFrame({'string_values':[article2]})\n",
        "new_row2 = pd.DataFrame({'string_values':[article3]})\n",
        "new_row3 = pd.DataFrame({'string_values':[article4]})\n",
        "new_row4 = pd.DataFrame({'string_values':[article5]})\n",
        "new_row5 = pd.DataFrame({'string_values':[article6]})\n",
        "\n",
        "df = pd.concat([df, new_row1], ignore_index=True)\n",
        "df = pd.concat([df, new_row2], ignore_index=True)\n",
        "df = pd.concat([df, new_row3], ignore_index=True)\n",
        "df = pd.concat([df, new_row4], ignore_index=True)\n",
        "df = pd.concat([df, new_row5], ignore_index=True)\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 58,
      "metadata": {},
      "outputs": [
        {
          "data": {
            "text/html": [
              "<div>\n",
              "<style scoped>\n",
              "    .dataframe tbody tr th:only-of-type {\n",
              "        vertical-align: middle;\n",
              "    }\n",
              "\n",
              "    .dataframe tbody tr th {\n",
              "        vertical-align: top;\n",
              "    }\n",
              "\n",
              "    .dataframe thead th {\n",
              "        text-align: right;\n",
              "    }\n",
              "</style>\n",
              "<table border=\"1\" class=\"dataframe\">\n",
              "  <thead>\n",
              "    <tr style=\"text-align: right;\">\n",
              "      <th></th>\n",
              "      <th>string_values</th>\n",
              "    </tr>\n",
              "  </thead>\n",
              "  <tbody>\n",
              "    <tr>\n",
              "      <th>0</th>\n",
              "      <td>prevention health promotion tobacco tobacco ht...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>1</th>\n",
              "      <td>diabetes life islet west diabetes mellitust yp...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>2</th>\n",
              "      <td>beverage brainstem aura blindness field thria ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>3</th>\n",
              "      <td>kidney proteinuria found overload proteinuria ...</td>\n",
              "    </tr>\n",
              "    <tr>\n",
              "      <th>4</th>\n",
              "      <td>chapter ated bp reading office pharmacy coat o...</td>\n",
              "    </tr>\n",
              "  </tbody>\n",
              "</table>\n",
              "</div>"
            ],
            "text/plain": [
              "                                       string_values\n",
              "0  prevention health promotion tobacco tobacco ht...\n",
              "1  diabetes life islet west diabetes mellitust yp...\n",
              "2  beverage brainstem aura blindness field thria ...\n",
              "3  kidney proteinuria found overload proteinuria ...\n",
              "4  chapter ated bp reading office pharmacy coat o..."
            ]
          },
          "execution_count": 58,
          "metadata": {},
          "output_type": "execute_result"
        }
      ],
      "source": [
        "df01.head()"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 59,
      "metadata": {},
      "outputs": [],
      "source": [
        "df01.to_csv('Current Medical Diagnosis1.csv', index=False)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": 60,
      "metadata": {},
      "outputs": [],
      "source": [
        "import pickle\n",
        "with open('Current medical diagnosis1.ob', 'wb') as fp:\n",
        "    pickle.dump(stpwrd, fp)"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {},
      "outputs": [],
      "source": []
    }
  ],
  "metadata": {
    "accelerator": "GPU",
    "colab": {
      "gpuType": "T4",
      "provenance": []
    },
    "kernelspec": {
      "display_name": "diagnosis",
      "language": "python",
      "name": "python3"
    },
    "language_info": {
      "codemirror_mode": {
        "name": "ipython",
        "version": 3
      },
      "file_extension": ".py",
      "mimetype": "text/x-python",
      "name": "python",
      "nbconvert_exporter": "python",
      "pygments_lexer": "ipython3",
      "version": "3.12.0"
    }
  },
  "nbformat": 4,
  "nbformat_minor": 0
}
